data_6prq_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6prq _Structure_validation_residue.Date_analyzed 2019-09-13 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.452 HD22 ' HG2' ' A' ' 136' ' ' ARG . 0.2 OUTLIER . . . . . 0 N--CA 1.481 1.101 0 CA-C-O 119.818 -0.134 . . . . 73.22 111.093 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.642 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 61.5 t -60.77 125.59 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 123.037 0.535 . . . . 74.23 111.057 175.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -71.36 -66.97 0.55 Allowed 'General case' 0 C--N 1.346 0.45 0 CA-C-N 115.544 -0.753 . . . . 74.15 109.763 177.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 20.4 p-80 178.19 177.36 0.42 Allowed 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 124.634 1.174 . . . . 72.21 109.724 -176.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 43.9 t -71.34 136.84 24.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.078 0 C-N-CA 123.497 0.719 . . . . 72.32 110.157 177.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.8 t . . . . . 0 N--CA 1.473 0.679 0 C-N-CA 124.384 1.074 . . . . 74.22 109.448 178.17 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.418 ' HB3' ' HE ' ' A' ' 120' ' ' ARG . 5.9 m-20 . . . . . 0 N--CA 1.478 0.937 0 N-CA-C 109.545 -0.539 . . . . 71.1 109.545 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.488 HD11 ' HA2' ' A' ' 165' ' ' GLY . 12.3 mt -100.76 132.45 46.16 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 107.601 -1.259 . . . . 74.54 107.601 167.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . 0.418 ' HE ' ' HB3' ' A' ' 118' ' ' ASP . 21.4 mmt85 -127.84 133.49 49.38 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 107.851 -1.166 . . . . 74.34 107.851 -177.255 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -154.01 145.3 22.97 Favored 'General case' 0 N--CA 1.47 0.552 0 O-C-N 123.441 0.463 . . . . 73.11 109.756 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.659 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 41.3 mt-10 -112.09 148.36 34.1 Favored 'General case' 0 C--O 1.246 0.885 0 C-N-CA 123.59 0.756 . . . . 75.43 109.721 174.557 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.642 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.7 pt? -145.88 130.04 8.68 Favored Pre-proline 0 C--O 1.222 -0.376 0 CA-C-N 115.443 -0.799 . . . . 62.14 111.065 -176.735 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.18 117.49 4.28 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 121.819 1.679 . . . . 75.24 110.152 163.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.465 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 21.3 tp -110.59 139.8 45.5 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 123.624 0.77 . . . . 72.13 109.237 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.637 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 4.7 m -76.63 149.33 36.54 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 109.015 -0.735 . . . . 74.05 109.015 170.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.411 HD11 ' O ' ' A' ' 183' ' ' HIS . 44.4 mt -57.06 -44.58 83.18 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 122.267 1.032 . . . . 73.34 109.868 177.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -57.26 -37.7 72.75 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 113.383 -1.735 . . . . 63.52 111.439 176.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.637 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 42.1 mm-40 -77.58 -27.36 51.36 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 122.644 0.378 . . . . 74.24 111.758 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.464 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -58.75 -36.32 74.16 Favored 'General case' 0 C--O 1.243 0.741 0 C-N-CA 123.203 0.601 . . . . 64.43 111.446 167.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.408 ' CZ ' ' HB3' ' A' ' 216' ' ' GLU . 70.9 t80 -74.0 -51.84 14.67 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.151 -0.931 . . . . 73.44 112.427 171.15 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 34.3 m80 -63.83 -49.15 73.96 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 123.358 0.411 . . . . 73.55 112.04 -167.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 48.44 52.76 18.25 Favored Glycine 0 CA--C 1.534 1.28 0 O-C-N 124.118 0.886 . . . . 55.02 114.125 178.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -102.67 -168.61 26.45 Favored Glycine 0 C--N 1.347 1.139 0 CA-C-O 120.044 -0.309 . . . . 64.22 112.481 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.427 ' HB3' ' OG ' ' A' ' 146' ' ' SER . 2.1 mp0 -77.36 113.97 15.69 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 109.556 -0.535 . . . . 74.21 109.556 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.452 ' HG2' HD22 ' A' ' 98' ' ' LEU . 2.4 mpt_? -124.36 150.61 45.33 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 124.106 0.963 . . . . 74.11 108.681 173.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.8 p -76.35 129.74 36.89 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.093 0 CA-C-O 121.256 0.551 . . . . 72.42 111.266 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.502 HG23 HD22 ' A' ' 174' ' ' LEU . 7.9 p -111.27 141.0 27.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 C-N-CA 124.66 1.184 . . . . 71.43 108.81 170.577 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -125.72 100.68 6.53 Favored 'General case' 0 C--O 1.238 0.498 0 N-CA-C 107.819 -1.178 . . . . 74.22 107.819 178.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.7 m -123.84 108.03 19.97 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 C-N-CA 124.288 1.035 . . . . 73.3 110.436 -175.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 66.19 25.29 10.68 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 124.633 1.173 . . . . 71.01 111.766 179.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.83 4.96 78.41 Favored Glycine 0 C--N 1.353 1.482 0 CA-C-N 116.035 -0.53 . . . . 65.35 112.909 -176.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 30.9 tpt180 -94.02 115.41 27.74 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 108.687 -0.857 . . . . 73.23 108.687 177.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 75.3 ttt180 -97.74 115.58 28.28 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.729 -0.841 . . . . 71.54 108.729 177.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.437 HG11 ' SD ' ' A' ' 164' ' ' MET . 16.1 t -130.51 154.59 40.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 108.059 -1.089 . . . . 75.41 108.059 173.748 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.427 ' OG ' ' HB3' ' A' ' 135' ' ' GLU . 48.3 t -92.19 109.0 20.36 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.289 -1.004 . . . . 60.5 108.289 171.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 9.9 p -97.77 129.6 47.71 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 C-N-CA 123.702 0.801 . . . . 74.12 109.743 -178.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 29.1 ttt180 -107.96 97.47 7.17 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 107.719 -1.215 . . . . 73.02 107.719 173.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.562 ' HB ' HD12 ' A' ' 159' ' ' ILE . 26.1 pt -78.51 141.4 60.82 Favored Pre-proline 0 CA--C 1.552 1.053 0 N-CA-C 109.286 -0.635 . . . . 70.01 109.286 177.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -70.06 134.19 26.76 Favored 'Trans proline' 0 C--N 1.372 1.78 0 C-N-CA 122.299 1.999 . . . . 74.23 112.526 -173.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.401 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 71.5 Cg_exo -54.31 138.85 73.38 Favored 'Trans proline' 0 C--N 1.371 1.752 0 C-N-CA 123.121 2.547 . . . . 75.12 112.02 168.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 105.78 36.93 2.67 Favored Glycine 0 N--CA 1.463 0.493 0 N-CA-C 111.589 -0.604 . . . . 54.22 111.589 -173.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.582 HG23 HD11 ' A' ' 159' ' ' ILE . 2.4 p -112.71 155.93 13.83 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.251 0 N-CA-C 109.099 -0.704 . . . . 73.23 109.099 -177.194 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.427 ' HD2' ' O ' ' A' ' 188' ' ' LEU . 38.7 mtp180 -142.38 173.16 11.78 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 125.177 1.391 . . . . 74.12 110.742 -168.46 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.4 tp10 -58.39 121.1 10.02 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 123.758 0.823 . . . . 74.41 110.997 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.25 7.68 88.13 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-N 116.252 -0.431 . . . . 62.1 113.48 -178.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.449 ' HB3' HG21 ' A' ' 153' ' ' VAL . 38.6 t -77.8 125.55 29.51 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 109.45 -0.574 . . . . 74.01 109.45 179.134 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.469 HG12 HD23 ' A' ' 175' ' ' LEU . 8.5 t -98.5 120.26 47.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-N 114.609 -1.178 . . . . 72.12 108.75 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.582 HD11 HG23 ' A' ' 153' ' ' VAL . 49.1 mt -107.21 120.43 58.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.92 0.888 . . . . 73.21 111.136 -172.508 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 25.8 ttm180 -92.58 114.13 26.6 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 123.2 0.6 . . . . 73.4 111.068 177.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -113.46 96.07 38.55 Favored Pre-proline 0 CA--C 1.559 1.313 0 N-CA-C 109.279 -0.637 . . . . 74.1 109.279 173.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -62.24 148.66 92.84 Favored 'Trans proline' 0 C--N 1.388 2.609 0 C-N-CA 123.646 2.898 . . . . 74.13 113.588 -177.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 85.5 -12.85 57.88 Favored Glycine 0 C--N 1.349 1.272 0 O-C-N 123.813 0.696 . . . . 75.23 113.34 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.437 ' SD ' HG11 ' A' ' 145' ' ' VAL . 36.4 mmm -92.33 -28.58 16.85 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.411 1.084 . . . . 75.41 111.912 -170.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . 0.488 ' HA2' HD11 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.344 1.025 0 N-CA-C 111.158 -0.777 . . . . 61.24 111.158 176.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo . . . . . 0 CA--C 1.537 0.667 0 N-CA-C 111.307 -0.305 . . . . 75.03 111.307 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -105.34 152.18 17.22 Favored Glycine 0 CA--C 1.504 -0.652 0 N-CA-C 109.806 -1.317 . . . . 75.12 109.806 171.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -112.96 168.81 9.39 Favored 'General case' 0 C--O 1.241 0.628 0 CA-C-O 121.503 0.668 . . . . 71.51 110.488 -173.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.502 HD22 HG23 ' A' ' 138' ' ' VAL . 12.4 tp -118.62 115.39 24.44 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 107.722 -1.214 . . . . 73.13 107.722 175.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.469 HD23 HG12 ' A' ' 158' ' ' VAL . 53.6 mt -88.38 100.22 12.86 Favored 'General case' 0 C--O 1.241 0.653 0 O-C-N 123.958 0.786 . . . . 74.43 110.305 177.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 81.5 mt -88.29 102.99 15.39 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.013 -0.994 . . . . 71.12 110.57 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.659 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 48.2 t -86.66 104.81 14.28 Favored 'Isoleucine or valine' 0 C--O 1.241 0.605 0 N-CA-C 108.307 -0.998 . . . . 53.31 108.307 173.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.465 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 9.6 m -82.04 150.82 4.33 Favored 'Isoleucine or valine' 0 C--O 1.245 0.821 0 CA-C-O 121.325 0.583 . . . . 64.11 110.838 -177.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 24.0 mmm-85 -126.99 97.11 4.83 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.242 -1.392 . . . . 73.52 107.242 -175.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.464 HD22 ' HB3' ' A' ' 125' ' ' LEU . 46.1 mt -66.4 147.09 53.8 Favored 'General case' 0 C--O 1.242 0.683 0 CA-C-O 120.536 0.208 . . . . 75.21 110.656 -176.449 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.435 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 37.6 mt -54.8 152.19 13.72 Favored Pre-proline 0 CA--C 1.556 1.19 0 O-C-N 124.09 0.869 . . . . 73.45 111.829 -173.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -58.29 -8.7 5.43 Favored 'Trans proline' 0 C--N 1.383 2.376 0 C-N-CA 123.377 2.718 . . . . 73.42 113.363 172.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . 0.411 ' O ' HD11 ' A' ' 127' ' ' LEU . 6.3 t60 -93.59 107.97 30.65 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 124.79 1.236 . . . . 73.33 108.614 168.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -99.52 163.69 0.55 Allowed 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 123.314 2.676 . . . . 74.02 112.427 165.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -156.64 -45.67 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 N-CA-C 109.02 -0.733 . . . . 71.02 109.02 168.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . 0.445 ' CE2' HD13 ' A' ' 193' ' ' LEU . 5.6 m-85 -100.66 122.54 43.49 Favored 'General case' 0 C--O 1.238 0.454 0 C-N-CA 123.585 0.754 . . . . 72.42 110.699 -177.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 12.0 mtp180 -99.75 108.72 21.11 Favored 'General case' 0 C--O 1.237 0.441 0 C-N-CA 124.612 1.165 . . . . 73.35 108.624 170.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.427 ' O ' ' HD2' ' A' ' 154' ' ' ARG . 60.2 tp -84.54 110.67 18.87 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.932 -0.766 . . . . 73.35 108.932 170.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 24.0 mm-40 -104.11 97.05 7.07 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 107.325 -1.361 . . . . 73.42 107.325 172.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 67.64 -89.06 0.18 Allowed Glycine 0 CA--C 1.531 1.044 0 O-C-N 123.757 0.66 . . . . 73.43 112.807 -175.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 50.3 tt0 -120.74 -18.12 7.78 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 125.103 1.361 . . . . 75.24 109.779 -176.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . 0.42 ' O ' HD12 ' A' ' 188' ' ' LEU . 44.5 m-20 -96.07 160.04 14.65 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.382 1.073 . . . . 74.55 111.383 -173.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.602 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 96.3 mt -119.21 154.97 32.54 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.202 1.001 . . . . 73.41 112.298 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 74.0 m-85 -139.0 120.72 15.28 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 106.248 -1.76 . . . . 74.44 106.248 170.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . 0.437 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -141.7 140.06 33.07 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 108.178 -1.045 . . . . 64.43 108.178 176.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 19.1 m -77.15 129.98 36.71 Favored 'General case' 0 CA--C 1.539 0.548 0 O-C-N 123.347 0.405 . . . . 65.15 110.323 -175.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.412 HD11 ' HB3' ' A' ' 212' ' ' ALA . 51.2 tp -114.42 111.79 21.99 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 123.951 0.9 . . . . 74.22 108.785 176.694 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -101.64 107.73 19.06 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.127 -0.694 . . . . 72.12 109.127 178.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . 0.494 HG13 HG12 ' A' ' 223' ' ' VAL . 5.9 m -108.52 145.69 32.1 Favored Pre-proline 0 N--CA 1.478 0.963 0 C-N-CA 123.755 0.822 . . . . 72.14 109.472 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -70.83 149.67 60.45 Favored 'Trans proline' 0 C--N 1.366 1.481 0 C-N-CA 121.699 1.599 . . . . 73.03 110.664 173.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . 0.434 ' HA ' HG22 ' A' ' 255' ' ' ILE . . . -56.11 -43.53 99.29 Favored Pre-proline 0 CA--C 1.561 1.389 0 CA-C-O 118.374 -0.822 . . . . 71.32 113.112 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -46.21 -51.51 8.52 Favored 'Trans proline' 0 C--N 1.394 2.952 0 C-N-CA 122.921 2.414 . . . . 73.42 114.274 169.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 5.7 mt -69.15 -38.57 78.21 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 C-N-CA 122.335 0.254 . . . . 74.14 111.117 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.18 -41.55 88.75 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.239 0.616 . . . . 74.45 112.234 -179.193 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 33.1 m -82.84 -38.64 15.0 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 CA-C-N 115.891 -0.595 . . . . 74.02 111.53 -174.665 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.6 m -77.0 -24.79 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 CA-C-O 120.82 0.343 . . . . 73.3 110.849 177.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 76.68 52.84 5.71 Favored Glycine 0 C--N 1.346 1.112 0 CA-C-N 115.376 -0.829 . . . . 70.3 112.366 -175.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.42 -160.35 27.51 Favored Glycine 0 C--N 1.359 1.817 0 N-CA-C 112.123 -0.391 . . . . 70.43 112.123 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 21.2 ptmt -119.91 142.9 48.28 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 123.023 0.529 . . . . 72.34 109.727 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . 0.406 HG21 HG12 ' A' ' 199' ' ' VAL . 75.6 t -128.7 135.11 63.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 C-N-CA 124.351 1.06 . . . . 74.43 108.631 177.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . 0.588 ' HG2' ' HG2' ' A' ' 220' ' ' GLU . 99.3 mtt180 -77.95 112.56 14.97 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 109.198 -0.668 . . . . 75.55 109.198 171.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.412 ' HB3' HD11 ' A' ' 197' ' ' LEU . . . -99.14 129.27 45.38 Favored 'General case' 0 C--O 1.242 0.686 0 N-CA-C 108.436 -0.949 . . . . 64.4 108.436 175.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 213' ' ' MET . . . . . 0.413 ' SD ' ' N ' ' A' ' 214' ' ' THR . 1.3 tpp -69.72 130.29 41.93 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.837 -0.62 . . . . 74.54 109.79 175.054 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 214' ' ' THR . . . . . 0.417 HG23 HG13 ' A' ' 219' ' ' VAL . 7.7 t -134.07 163.67 29.06 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.507 1.123 . . . . 75.43 110.142 173.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 79.4 mt -71.68 -8.87 56.79 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 124.004 0.922 . . . . 73.41 113.183 -172.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . 0.408 ' HB3' ' CZ ' ' A' ' 131' ' ' PHE . 10.3 pt-20 -97.39 -18.34 19.16 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.433 0.693 . . . . 74.2 111.767 173.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.74 -146.36 15.74 Favored Glycine 0 C--N 1.349 1.253 0 CA-C-O 119.556 -0.58 . . . . 53.43 112.181 -176.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -91.17 131.15 1.42 Allowed 'Trans proline' 0 CA--C 1.559 1.736 0 C-N-CA 122.796 2.331 . . . . 72.3 112.777 170.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . 0.417 HG13 HG23 ' A' ' 214' ' ' THR . 20.5 m -110.13 147.25 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 108.996 -0.742 . . . . 74.0 108.996 163.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . 0.588 ' HG2' ' HG2' ' A' ' 211' ' ' ARG . 42.8 mt-10 -114.37 104.33 11.96 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 108.781 -0.822 . . . . 73.12 108.781 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 2.8 p -95.68 120.25 44.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 124.033 0.933 . . . . 74.44 110.373 -177.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.12 103.57 12.65 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 107.689 -1.226 . . . . 70.51 107.689 173.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.494 HG12 HG13 ' A' ' 199' ' ' VAL . 14.6 m -65.96 143.89 98.61 Favored Pre-proline 0 CA--C 1.553 1.059 0 C-N-CA 123.229 0.612 . . . . 75.44 110.168 -179.014 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -55.58 138.79 81.71 Favored 'Trans proline' 0 C--N 1.376 1.994 0 C-N-CA 122.625 2.216 . . . . 64.44 112.209 176.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.11 122.34 11.42 Favored 'Trans proline' 0 C--N 1.369 1.624 0 C-N-CA 122.181 1.921 . . . . 72.32 110.129 172.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . 0.491 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 96.0 mtt180 63.39 41.25 7.77 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 124.418 1.074 . . . . 74.43 110.996 -175.591 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.4 t -65.15 168.89 6.13 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 122.858 0.463 . . . . 53.11 111.009 177.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.2 mp0 -118.09 146.72 43.92 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 123.889 0.876 . . . . 74.41 109.165 -176.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -75.02 135.91 41.25 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.745 -0.835 . . . . 53.31 108.745 173.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 106.11 -7.91 41.36 Favored Glycine 0 C--N 1.34 0.762 0 N-CA-C 112.153 -0.379 . . . . 75.45 112.153 -175.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 62.0 mtp180 -79.92 160.99 25.79 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.284 0.634 . . . . 75.12 111.079 179.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.487 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 10.5 mptt -119.05 112.91 20.15 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 124.065 0.946 . . . . 74.32 108.503 176.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . 0.495 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 39.6 mt -89.69 110.08 21.0 Favored 'General case' 0 C--N 1.358 0.958 0 N-CA-C 108.868 -0.79 . . . . 73.0 108.868 -178.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 41.4 ttp180 -83.81 102.51 12.38 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 114.923 -1.035 . . . . 64.52 111.046 -169.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 26.5 mt -95.74 98.01 10.13 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 108.513 -0.921 . . . . 74.31 108.513 174.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . 0.43 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 26.7 mtpp -80.79 143.87 32.53 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.96 0.41 . . . . 71.14 111.316 -174.403 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 75.94 24.12 70.21 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.148 -0.933 . . . . 74.24 111.809 -174.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 48.4 mmtm -128.94 10.25 5.91 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.366 1.066 . . . . 74.2 110.442 177.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -84.67 -158.21 28.34 Favored Glycine 0 C--N 1.359 1.838 0 O-C-N 123.13 0.269 . . . . 53.15 113.052 175.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.528 ' CD1' HD23 ' A' ' 193' ' ' LEU . 10.5 m-85 -98.02 166.14 14.02 Favored Pre-proline 0 N--CA 1.48 1.044 0 C-N-CA 123.131 0.573 . . . . 70.12 110.565 172.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -61.01 160.45 25.82 Favored 'Trans proline' 0 C--N 1.384 2.409 0 C-N-CA 122.829 2.353 . . . . 75.34 112.113 172.201 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 175.76 -171.21 44.29 Favored Glycine 0 CA--C 1.527 0.791 0 CA-C-N 116.147 -0.479 . . . . 73.32 113.515 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -57.31 -38.73 93.92 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.975 3.116 . . . . 74.05 113.29 -179.155 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -92.33 21.84 4.94 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 123.389 0.676 . . . . 74.12 111.937 -179.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 91.66 -102.66 2.95 Favored Glycine 0 C--N 1.347 1.194 0 N-CA-C 111.746 -0.541 . . . . 75.34 111.746 178.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 51.6 ttt180 -121.52 140.02 52.74 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 122.933 0.493 . . . . 73.12 109.675 174.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -81.06 -157.2 16.4 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 124.014 0.821 . . . . 71.33 113.076 -179.039 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . 0.43 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 3.5 p30 -146.62 154.25 41.27 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 123.032 0.533 . . . . 71.41 110.722 -174.604 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.602 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 26.2 tp -98.58 128.27 44.83 Favored 'General case' 0 C--O 1.22 -0.468 0 C-N-CA 124.338 1.055 . . . . 74.42 110.384 -174.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . 0.487 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 63.1 m-85 -102.63 107.43 18.34 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 123.57 0.748 . . . . 74.42 109.505 173.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.495 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 77.2 mt -87.07 111.11 20.58 Favored 'General case' 0 C--O 1.233 0.233 0 C-N-CA 123.701 0.8 . . . . 74.34 112.52 178.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.405 ' HG2' ' HE3' ' A' ' 232' ' ' LYS . 1.6 tm-20 -80.42 90.37 5.63 Favored 'General case' 0 CA--C 1.552 1.025 0 N-CA-C 108.457 -0.942 . . . . 73.54 108.457 -176.546 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.4 ' O ' ' HD2' ' A' ' 254' ' ' ARG . 46.0 t -53.29 128.34 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 125.991 1.716 . . . . 74.15 112.882 -177.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . 0.4 ' HD2' ' O ' ' A' ' 253' ' ' VAL . 23.5 mmm180 -126.8 98.57 5.41 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 107.255 -1.387 . . . . 74.22 107.255 173.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.434 HG22 ' HA ' ' A' ' 201' ' ' ALA . 63.6 mt -76.53 102.43 3.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 108.861 -0.792 . . . . 74.34 108.861 177.161 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 8.9 t . . . . . 0 C--O 1.253 1.263 0 C-N-CA 124.357 1.063 . . . . 72.02 110.173 -171.424 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.603 HD21 ' HG3' ' A' ' 136' ' ' ARG . 0.2 OUTLIER . . . . . 0 N--CA 1.482 1.164 0 CA-C-O 119.653 -0.213 . . . . 74.22 110.913 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.629 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 43.9 t -58.04 119.82 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 C-N-CA 122.988 0.515 . . . . 50.43 111.238 177.576 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -67.22 -71.4 0.2 Allowed 'General case' 0 C--O 1.238 0.485 0 O-C-N 124.275 0.984 . . . . 73.11 109.31 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.0 m80 -168.0 176.12 6.33 Favored 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 124.665 1.186 . . . . 72.33 109.757 -178.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 99.5 t -61.38 136.51 24.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.025 0 C-N-CA 124.094 0.958 . . . . 73.22 110.47 171.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 42.6 p . . . . . 0 CA--C 1.551 0.992 0 N-CA-C 109.122 -0.696 . . . . 75.1 109.122 170.231 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 . . . . . 0 N--CA 1.47 0.54 0 N-CA-C 108.686 -0.857 . . . . 74.33 108.686 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.486 HD22 ' HB ' ' A' ' 140' ' ' VAL . 44.5 tp -128.79 134.98 48.56 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 107.759 -1.2 . . . . 72.33 107.759 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . 0.405 ' HD3' ' HB2' ' A' ' 175' ' ' LEU . 9.8 mmt85 -115.43 134.97 54.59 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 109.438 -0.579 . . . . 74.03 109.438 -178.017 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -150.6 154.54 37.7 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 123.329 0.652 . . . . 73.03 109.38 173.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -119.78 151.35 38.94 Favored 'General case' 0 C--O 1.245 0.851 0 C-N-CA 123.134 0.574 . . . . 72.42 110.169 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.629 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.4 pt? -144.95 143.13 19.72 Favored Pre-proline 0 N--CA 1.471 0.59 0 CA-C-N 115.424 -0.807 . . . . 74.13 111.286 -178.388 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.43 113.95 3.87 Favored 'Trans proline' 0 C--N 1.37 1.68 0 C-N-CA 121.377 1.384 . . . . 55.55 109.119 160.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.472 HD22 HG12 ' A' ' 178' ' ' VAL . 20.0 tp -104.97 148.44 26.72 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 108.463 -0.94 . . . . 74.3 108.463 178.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.686 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 4.1 m -82.15 157.54 23.99 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 109.919 -0.401 . . . . 74.11 109.919 175.274 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.437 HD23 ' HB3' ' A' ' 180' ' ' LEU . 77.5 mt -59.16 -48.68 80.72 Favored 'General case' 0 N--CA 1.482 1.145 0 CA-C-O 122.342 1.068 . . . . 72.5 109.529 172.331 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.53 -34.46 64.7 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 113.621 -1.627 . . . . 74.41 111.963 174.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.49 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 17.0 mm-40 -85.63 -17.69 35.39 Favored 'General case' 0 N--CA 1.481 1.083 0 C-N-CA 123.398 0.679 . . . . 73.11 112.416 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.688 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -58.23 -43.41 87.75 Favored 'General case' 0 C--O 1.249 1.05 0 CA-C-O 121.382 0.611 . . . . 74.45 109.697 163.155 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -71.32 -60.31 2.3 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 114.842 -1.072 . . . . 74.14 111.62 174.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -69.05 -47.16 66.04 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 123.588 0.755 . . . . 72.1 112.252 -169.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 71.76 -86.25 0.45 Allowed Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.816 -0.914 . . . . 74.23 110.816 -170.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.0 -179.57 51.3 Favored Glycine 0 C--N 1.345 1.08 0 N-CA-C 114.528 0.571 . . . . 70.34 114.528 174.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 14.8 mp0 -98.61 115.27 28.27 Favored 'General case' 0 N--CA 1.471 0.584 0 N-CA-C 107.301 -1.37 . . . . 71.2 107.301 175.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.603 ' HG3' HD21 ' A' ' 98' ' ' LEU . 39.3 mmt-85 -132.15 138.51 48.07 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.711 1.204 . . . . 71.35 108.287 -173.278 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.426 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 27.8 m -73.61 123.01 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 121.343 0.592 . . . . 70.21 111.295 -176.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 13.4 p -105.43 141.36 20.94 Favored 'Isoleucine or valine' 0 C--O 1.252 1.23 0 C-N-CA 125.092 1.357 . . . . 74.22 110.195 178.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 13.2 tp10 -120.29 103.36 9.17 Favored 'General case' 0 C--O 1.243 0.75 0 C-N-CA 124.033 0.933 . . . . 74.02 109.001 174.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.496 HG22 HD22 ' A' ' 174' ' ' LEU . 2.9 m -143.87 123.56 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 123.939 0.896 . . . . 70.2 110.693 -173.189 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.03 19.9 11.95 Favored 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 124.322 1.049 . . . . 63.34 112.137 173.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 83.62 17.5 65.93 Favored Glycine 0 C--N 1.347 1.161 0 CA-C-N 116.366 -0.379 . . . . 73.01 112.345 -177.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.2 mmm180 -108.12 118.17 36.04 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 108.317 -0.994 . . . . 74.41 108.317 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 49.9 ttt180 -94.94 108.2 20.25 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 108.406 -0.961 . . . . 64.34 108.406 173.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 72.2 t -135.82 146.74 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 108.674 -0.861 . . . . 74.35 108.674 -178.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.426 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 67.0 p -90.17 107.63 19.25 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.563 -1.273 . . . . 74.33 107.563 167.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.9 p -97.68 140.92 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-O 121.322 0.582 . . . . 73.44 111.012 -172.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 14.4 ttp180 -104.13 103.39 13.17 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 107.741 -1.207 . . . . 75.5 107.741 177.241 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.447 ' HB ' HD12 ' A' ' 159' ' ' ILE . 36.5 pt -92.1 112.78 56.67 Favored Pre-proline 0 CA--C 1.555 1.137 0 N-CA-C 109.553 -0.536 . . . . 74.24 109.553 179.067 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.436 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 96.2 Cg_exo -47.82 131.01 20.1 Favored 'Trans proline' 0 C--N 1.39 2.727 0 C-N-CA 123.947 3.098 . . . . 70.14 114.676 -173.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 23.2 Cg_exo -67.19 135.52 37.44 Favored 'Trans proline' 0 C--N 1.379 2.162 0 C-N-CA 123.472 2.781 . . . . 71.34 112.269 -177.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . 0.646 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 120.51 41.88 0.52 Allowed Glycine 0 C--N 1.349 1.272 0 N-CA-C 111.908 -0.477 . . . . 54.32 111.908 -175.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.688 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.6 p -115.33 162.89 13.08 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.533 0 C-N-CA 123.915 0.886 . . . . 75.21 109.76 -173.17 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 43.9 mtp180 -143.26 168.99 18.49 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 125.228 1.411 . . . . 73.22 110.09 -170.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -54.94 120.59 7.1 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.759 0.824 . . . . 75.2 111.022 170.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.87 3.65 90.39 Favored Glycine 0 C--N 1.349 1.288 0 O-C-N 123.647 0.592 . . . . 70.54 113.903 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 40.3 t -81.99 131.89 35.25 Favored 'General case' 0 C--O 1.248 0.983 0 N-CA-C 109.303 -0.628 . . . . 71.41 109.303 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 9.0 p -97.42 135.74 30.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.986 0 CA-C-N 115.103 -0.953 . . . . 73.3 109.24 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.497 HD11 HG23 ' A' ' 153' ' ' VAL . 28.1 mt -112.61 123.07 67.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 123.9 0.88 . . . . 75.45 110.707 -175.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.415 HH21 HD12 ' A' ' 175' ' ' LEU . 35.3 ttm180 -92.53 118.84 31.4 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 117.924 0.329 . . . . 72.23 110.26 174.504 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.464 HG22 ' HB3' ' A' ' 174' ' ' LEU . 4.5 m -113.0 125.65 29.47 Favored Pre-proline 0 CA--C 1.551 1.0 0 N-CA-C 108.004 -1.109 . . . . 75.23 108.004 171.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -79.26 148.72 21.46 Favored 'Trans proline' 0 C--N 1.367 1.532 0 C-N-CA 122.132 1.888 . . . . 72.44 113.081 -174.185 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 74.37 23.24 76.13 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 115.141 0.816 . . . . 73.25 115.141 173.057 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 50.7 tpp -102.91 -45.92 4.83 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 117.811 0.806 . . . . 70.44 110.7 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.349 1.299 0 CA-C-N 116.093 -0.503 . . . . 74.33 112.52 -177.85 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo . . . . . 0 CA--C 1.541 0.837 0 N-CA-C 111.015 -0.417 . . . . 75.15 111.015 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -108.68 168.29 13.47 Favored Glycine 0 N--CA 1.462 0.369 0 N-CA-C 111.185 -0.766 . . . . 74.22 111.185 175.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -118.92 169.88 9.5 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 123.61 0.764 . . . . 74.31 111.656 -165.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.496 HD22 HG22 ' A' ' 140' ' ' VAL . 37.0 tp -124.62 116.47 22.46 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-N 114.608 -1.178 . . . . 64.43 108.234 169.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.415 HD12 HH21 ' A' ' 160' ' ' ARG . 41.3 mt -92.19 100.93 13.45 Favored 'General case' 0 C--O 1.243 0.76 0 CA-C-N 114.248 -1.342 . . . . 74.23 109.868 175.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 85.2 mt -90.85 107.39 19.16 Favored 'General case' 0 CA--C 1.538 0.494 0 CA-C-N 114.462 -1.245 . . . . 74.33 111.177 178.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 34.9 t -86.67 106.11 15.51 Favored 'Isoleucine or valine' 0 C--O 1.249 1.05 0 N-CA-C 108.459 -0.941 . . . . 71.32 108.459 175.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.472 HG12 HD22 ' A' ' 125' ' ' LEU . 19.0 m -81.57 149.77 4.77 Favored 'Isoleucine or valine' 0 C--O 1.24 0.6 0 CA-C-O 121.811 0.815 . . . . 75.11 112.203 -179.268 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 25.0 mmm-85 -123.75 105.66 9.86 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 107.38 -1.341 . . . . 72.53 107.38 174.607 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.437 ' HB3' HD23 ' A' ' 127' ' ' LEU . 30.2 mt -67.73 142.66 56.21 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 118.191 0.45 . . . . 74.42 111.186 -178.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.686 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 41.3 mt -55.22 142.35 58.61 Favored Pre-proline 0 CA--C 1.555 1.153 0 O-C-N 124.029 0.831 . . . . 74.0 111.791 -175.051 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.31 63.98 7.86 Favored 'Trans proline' 0 C--N 1.378 2.105 0 C-N-CA 123.389 2.726 . . . . 73.34 113.113 -177.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 3.7 p80 -149.61 50.18 0.75 Allowed Pre-proline 0 CA--C 1.564 1.5 0 C-N-CA 124.043 0.937 . . . . 70.35 108.84 169.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -62.63 122.97 11.52 Favored 'Trans proline' 0 C--N 1.385 2.459 0 C-N-CA 121.814 1.676 . . . . 75.42 111.808 -166.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.3 p -122.54 -42.57 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 N-CA-C 107.894 -1.15 . . . . 73.31 107.894 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -101.1 123.45 45.27 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.765 -1.107 . . . . 74.42 109.09 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 91.5 mtm180 -119.0 119.71 35.09 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.606 1.162 . . . . 73.33 108.085 -179.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 66.1 tp -105.0 139.02 40.31 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.848 0.859 . . . . 72.43 110.936 -174.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 -134.53 108.03 7.86 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 124.415 1.086 . . . . 72.55 108.104 164.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 73.16 -82.48 0.65 Allowed Glycine 0 C--N 1.35 1.332 0 O-C-N 123.529 0.518 . . . . 70.02 112.914 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -134.84 -15.64 2.03 Favored 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 123.772 0.829 . . . . 74.43 110.748 177.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 52.9 m-20 -91.0 143.78 26.35 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.345 0.658 . . . . 62.35 112.396 -174.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.565 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 87.3 mt -112.7 161.21 17.12 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 125.112 1.365 . . . . 75.33 111.215 -174.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -141.0 121.83 14.41 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 107.325 -1.361 . . . . 73.53 107.325 174.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . 0.42 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -148.96 136.23 20.12 Favored 'General case' 0 N--CA 1.468 0.453 0 N-CA-C 108.891 -0.781 . . . . 71.12 108.891 -178.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 196' ' ' THR . . . . . 0.556 ' HA ' ' HB2' ' A' ' 252' ' ' GLU . 12.1 m -81.28 123.14 28.25 Favored 'General case' 0 CA--C 1.542 0.665 0 O-C-N 123.478 0.486 . . . . 72.5 110.616 -175.678 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.48 HD21 HD12 ' A' ' 251' ' ' LEU . 48.2 tp -108.71 113.28 26.11 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.825 0.85 . . . . 73.31 109.484 -179.699 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -87.23 113.11 22.68 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 108.43 -0.952 . . . . 65.25 108.43 172.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 4.2 p -118.37 124.9 28.22 Favored Pre-proline 0 CA--C 1.551 1.005 0 C-N-CA 124.035 0.934 . . . . 75.02 109.347 178.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -61.73 146.27 96.79 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 122.507 2.138 . . . . 74.33 112.287 175.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . 0.409 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -54.55 -42.98 97.49 Favored Pre-proline 0 CA--C 1.56 1.338 0 CA-C-O 117.346 -1.311 . . . . 64.34 113.965 -176.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . 0.409 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 7.1 Cg_endo -48.84 -47.6 20.68 Favored 'Trans proline' 0 C--N 1.402 3.344 0 C-N-CA 122.647 2.231 . . . . 71.5 112.821 172.189 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 15.7 mt -70.01 -38.15 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 122.725 0.41 . . . . 71.34 110.843 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.2 -41.47 98.39 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 123.307 0.643 . . . . 72.31 111.778 -177.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.7 m -80.21 -40.07 19.75 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 CA-C-N 116.108 -0.496 . . . . 71.45 111.715 -176.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.0 m -79.88 -24.02 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 CA-C-N 117.842 0.292 . . . . 74.42 111.194 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.498 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 73.22 61.38 3.46 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.855 -0.611 . . . . 74.13 112.317 -174.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.55 -142.22 9.77 Favored Glycine 0 C--N 1.356 1.672 0 N-CA-C 111.799 -0.52 . . . . 71.22 111.799 -178.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -131.36 144.78 51.48 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 123.812 0.845 . . . . 74.04 110.216 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 11.8 m -134.35 169.77 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.508 1.123 . . . . 75.11 109.171 175.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . 0.454 ' HD3' ' H ' ' A' ' 211' ' ' ARG . 0.0 OUTLIER -104.03 133.7 48.54 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.536 -0.756 . . . . 72.45 109.079 176.163 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -117.81 114.87 23.91 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 108.597 -0.89 . . . . 72.11 108.597 172.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 3.9 tpt -70.56 105.13 3.0 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.966 -0.561 . . . . 61.54 109.687 177.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 5.8 t -115.69 169.37 9.25 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.486 0.714 . . . . 74.3 111.255 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 46.4 mt -75.4 -3.06 31.5 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.254 1.022 . . . . 73.33 112.535 -170.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -106.1 -6.27 18.77 Favored 'General case' 0 N--CA 1.484 1.234 0 C-N-CA 124.029 0.931 . . . . 74.24 111.566 175.218 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 116.62 155.99 10.54 Favored Glycine 0 C--N 1.348 1.214 0 CA-C-O 118.583 -1.12 . . . . 60.22 111.634 -175.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -59.76 126.91 21.79 Favored 'Trans proline' 0 C--N 1.379 2.184 0 C-N-CA 123.096 2.531 . . . . 71.25 113.078 -168.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 35.1 m -108.47 166.49 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 C-N-CA 123.296 0.639 . . . . 71.52 110.184 -179.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -113.22 113.26 25.08 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 108.11 -1.07 . . . . 72.13 108.11 -177.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.469 HG21 HD13 ' A' ' 235' ' ' LEU . 5.2 t -95.92 115.99 36.53 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-N 115.664 -0.698 . . . . 61.42 109.303 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -85.61 101.25 12.55 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.585 -1.265 . . . . 74.12 107.585 170.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.498 HG23 ' HA2' ' A' ' 207' ' ' GLY . 9.0 m -74.71 146.56 83.38 Favored Pre-proline 0 CA--C 1.559 1.323 0 N-CA-C 109.509 -0.552 . . . . 73.12 109.509 -176.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -60.79 136.18 64.72 Favored 'Trans proline' 0 C--N 1.376 2.021 0 C-N-CA 122.769 2.312 . . . . 71.44 112.027 177.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_exo -54.88 122.57 11.89 Favored 'Trans proline' 0 C--N 1.377 2.037 0 C-N-CA 122.244 1.963 . . . . 70.22 110.572 169.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 68.6 mtm180 62.57 49.99 3.74 Favored 'General case' 0 CA--C 1.551 1.002 0 O-C-N 124.333 1.021 . . . . 74.44 110.576 -177.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.5 t -72.87 170.21 15.19 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.007 0.523 . . . . 74.11 110.52 177.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . 0.56 ' H ' ' HD2' ' A' ' 231' ' ' ARG . 2.0 mp0 -121.35 147.05 46.21 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.269 0.628 . . . . 72.42 109.987 -178.424 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -76.34 123.3 25.74 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.209 1.004 . . . . 54.53 109.483 175.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 113.91 -10.65 22.98 Favored Glycine 0 N--CA 1.472 1.085 0 N-CA-C 111.924 -0.47 . . . . 62.52 111.924 -171.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . 0.56 ' HD2' ' H ' ' A' ' 228' ' ' GLN . 20.9 mtt180 -69.98 161.61 29.7 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.516 0.726 . . . . 75.21 111.402 173.042 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.3 mptp? -119.99 111.3 17.74 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 107.825 -1.176 . . . . 73.22 107.825 176.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . 0.553 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 60.0 mt -85.63 107.51 17.57 Favored 'General case' 0 C--N 1.356 0.868 0 N-CA-C 108.613 -0.884 . . . . 73.34 108.613 -178.349 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 38.4 ttm180 -84.4 105.92 15.6 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.248 -0.887 . . . . 75.12 109.993 -171.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.563 ' HB3' ' HG3' ' A' ' 238' ' ' LYS . 58.2 mt -98.07 99.13 10.37 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 108.652 -0.87 . . . . 74.14 108.652 172.586 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -75.88 144.64 41.05 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 122.489 0.316 . . . . 75.32 111.159 -177.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 72.92 28.13 67.43 Favored Glycine 0 C--N 1.353 1.481 0 O-C-N 123.755 0.659 . . . . 65.02 113.042 -175.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . 0.563 ' HG3' ' HB3' ' A' ' 235' ' ' LEU . 4.1 mmtm -119.8 -10.59 9.5 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 124.138 0.975 . . . . 71.52 111.512 -178.304 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . 0.422 ' O ' ' HD2' ' A' ' 246' ' ' ARG . . . -81.93 -154.01 12.51 Favored Glycine 0 C--N 1.339 0.719 0 O-C-N 123.414 0.446 . . . . 63.35 113.279 -179.156 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.646 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 6.1 m-85 -94.68 158.69 34.93 Favored Pre-proline 0 CA--C 1.548 0.867 0 C-N-CA 123.576 0.75 . . . . 75.5 109.811 177.033 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.66 129.32 26.64 Favored 'Trans proline' 0 C--N 1.387 2.556 0 C-N-CA 123.361 2.707 . . . . 75.55 113.482 -178.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -158.18 -169.09 21.34 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.626 -0.716 . . . . 63.23 112.278 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.35 -17.99 59.3 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 123.133 2.555 . . . . 72.31 113.414 -177.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -98.42 21.23 11.4 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 123.868 0.867 . . . . 70.52 111.233 178.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 88.74 -82.97 1.48 Allowed Glycine 0 C--N 1.347 1.176 0 N-CA-C 110.122 -1.191 . . . . 73.11 110.122 -174.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.422 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 22.5 mtm180 -127.09 158.77 36.12 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 107.324 -1.362 . . . . 75.52 107.324 165.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.08 -156.96 4.76 Favored Glycine 0 C--N 1.344 1.002 0 O-C-N 123.483 0.489 . . . . 64.41 114.142 -174.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 35.0 m-20 -117.8 151.15 37.9 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 108.871 -0.788 . . . . 72.44 108.871 -176.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.565 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 18.3 tp -105.19 114.57 28.83 Favored 'General case' 0 CA--C 1.531 0.233 0 N-CA-C 108.71 -0.848 . . . . 73.04 108.71 171.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -96.18 106.86 19.11 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 123.109 0.564 . . . . 74.41 109.984 175.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.553 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 73.4 mt -88.0 120.96 29.85 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 124.162 0.985 . . . . 70.41 112.789 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.556 ' HB2' ' HA ' ' A' ' 196' ' ' THR . 26.0 mt-10 -79.11 91.3 4.9 Favored 'General case' 0 C--O 1.24 0.574 0 C-N-CA 123.774 0.83 . . . . 74.25 109.279 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 48.0 t -52.37 114.81 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.655 1.182 . . . . 74.23 112.108 178.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 49.7 mmm-85 -117.09 93.68 4.28 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 106.933 -1.506 . . . . 72.31 106.933 173.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 72.2 mt -74.55 110.73 9.33 Favored 'Isoleucine or valine' 0 C--N 1.343 0.31 0 N-CA-C 108.274 -1.01 . . . . 75.5 108.274 177.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 4.5 t . . . . . 0 CA--C 1.557 1.226 0 C-N-CA 123.982 0.913 . . . . 74.31 109.539 -177.205 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.45 ' HB2' ' HB3' ' A' ' 136' ' ' ARG . 1.2 tm? . . . . . 0 C--O 1.24 0.578 0 N-CA-C 106.685 -1.598 . . . . 73.12 106.685 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.408 ' O ' ' HB3' ' A' ' 123' ' ' LEU . 86.0 t -68.3 134.82 29.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 N-CA-C 108.84 -0.8 . . . . 74.34 108.84 177.334 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -150.25 56.45 0.94 Allowed 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 107.999 -1.111 . . . . 71.01 107.999 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -65.7 109.4 2.41 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-N 113.995 -1.457 . . . . 72.04 108.659 176.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 39.8 t -59.55 121.77 8.05 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.765 0 O-C-N 124.287 0.992 . . . . 74.54 109.384 -178.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.9 t . . . . . 0 N--CA 1.471 0.579 0 C-N-CA 123.896 0.878 . . . . 74.3 109.487 -173.391 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 . . . . . 0 N--CA 1.472 0.673 0 N-CA-C 108.472 -0.936 . . . . 71.12 108.472 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.05 144.48 26.28 Favored 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 107.015 -1.476 . . . . 73.1 107.015 178.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -130.59 129.36 42.67 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 108.108 -1.071 . . . . 74.42 108.108 176.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -150.79 150.23 30.72 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-N 115.75 -0.659 . . . . 62.42 109.571 -179.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -120.24 148.0 44.24 Favored 'General case' 0 C--O 1.245 0.84 0 N-CA-C 109.11 -0.7 . . . . 74.13 109.11 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.408 ' HB3' ' O ' ' A' ' 99' ' ' VAL . 1.3 pt? -145.32 147.58 34.44 Favored Pre-proline 0 N--CA 1.467 0.404 0 C-N-CA 122.8 0.44 . . . . 72.45 111.76 179.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -78.04 114.21 3.55 Favored 'Trans proline' 0 C--N 1.366 1.448 0 C-N-CA 121.751 1.634 . . . . 72.12 109.935 159.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.433 HD21 HG11 ' A' ' 178' ' ' VAL . 34.7 tp -106.75 157.24 17.88 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 108.791 -0.818 . . . . 72.1 108.791 177.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.704 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 14.4 m -89.36 151.69 21.93 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 122.99 0.516 . . . . 75.04 110.344 177.519 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.562 HD22 ' HB3' ' A' ' 180' ' ' LEU . 68.9 mt -58.1 -50.57 73.01 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.725 0.81 . . . . 62.3 109.389 174.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -53.78 -39.07 65.11 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 113.95 -1.477 . . . . 74.13 111.673 178.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.532 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 28.4 mm-40 -86.06 -18.07 33.45 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 122.999 0.52 . . . . 73.23 111.269 -176.484 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.599 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -64.41 -36.93 85.77 Favored 'General case' 0 C--O 1.242 0.673 0 C-N-CA 123.447 0.699 . . . . 70.01 109.886 167.353 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.443 ' HA ' ' HE1' ' A' ' 240' ' ' PHE . 27.6 t80 -71.94 -55.92 6.61 Favored 'General case' 0 CA--C 1.551 0.982 0 CA-C-N 114.999 -1.001 . . . . 61.12 110.574 172.053 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -67.97 -44.89 75.65 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 112.24 0.459 . . . . 72.12 112.24 -171.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.81 -111.62 4.27 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 111.275 -0.73 . . . . 72.25 111.275 -173.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.41 -175.87 54.54 Favored Glycine 0 C--N 1.347 1.163 0 N-CA-C 114.232 0.453 . . . . 51.05 114.232 171.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.429 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 2.0 mp0 -87.4 143.96 26.98 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 109.283 -0.636 . . . . 62.33 109.283 178.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.45 ' HB3' ' HB2' ' A' ' 98' ' ' LEU . 0.6 OUTLIER -156.79 147.84 21.98 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 109.546 -0.539 . . . . 74.25 109.546 -178.268 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 32.1 m -82.14 125.38 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 CA-C-O 121.51 0.671 . . . . 73.12 111.206 -174.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 41.1 t -120.7 144.77 28.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 125.035 1.334 . . . . 73.3 109.442 -176.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -126.15 97.79 5.22 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.041 0.536 . . . . 63.12 109.584 169.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.0 m -107.54 132.62 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 N-CA-C 108.922 -0.77 . . . . 73.22 108.922 173.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.46 23.02 13.35 Favored 'General case' 0 CA--C 1.554 1.118 0 C-N-CA 123.964 0.905 . . . . 75.01 111.694 -176.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.23 0.07 88.67 Favored Glycine 0 C--N 1.357 1.703 0 CA-C-N 116.038 -0.528 . . . . 74.51 113.468 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -103.34 123.27 46.48 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.696 0.798 . . . . 65.24 110.036 -175.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.2 ttp-105 -88.2 105.93 17.86 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.344 0.658 . . . . 73.55 110.797 -174.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 38.5 t -124.42 134.41 66.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.351 1.061 . . . . 73.51 108.828 178.021 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 37.2 m -83.81 120.9 26.61 Favored 'General case' 0 CA--C 1.546 0.803 0 N-CA-C 109.682 -0.488 . . . . 73.3 109.682 176.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.483 ' HB ' ' HE3' ' A' ' 164' ' ' MET . 8.1 p -99.77 148.73 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 123.317 0.647 . . . . 73.42 110.687 -178.387 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.3 ttt85 -110.02 96.39 6.2 Favored 'General case' 0 C--O 1.237 0.43 0 N-CA-C 107.324 -1.361 . . . . 72.04 107.324 160.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.487 ' HB ' HD13 ' A' ' 159' ' ' ILE . 37.9 pt -78.05 125.98 84.44 Favored Pre-proline 0 C--O 1.243 0.724 0 N-CA-C 108.617 -0.883 . . . . 62.31 108.617 173.144 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.404 ' HD2' HG22 ' A' ' 159' ' ' ILE . 97.7 Cg_exo -48.68 127.18 15.89 Favored 'Trans proline' 0 C--N 1.384 2.406 0 C-N-CA 123.04 2.494 . . . . 63.22 113.37 -178.266 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.554 ' HB2' ' HZ ' ' A' ' 240' ' ' PHE . 57.1 Cg_endo -69.36 143.85 54.16 Favored 'Trans proline' 0 C--N 1.376 2.007 0 C-N-CA 122.251 1.967 . . . . 75.44 110.355 175.02 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.44 27.37 5.56 Favored Glycine 0 C--N 1.337 0.586 0 N-CA-C 110.927 -0.869 . . . . 63.01 110.927 -171.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.599 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.2 p -93.67 157.32 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 N-CA-C 108.168 -1.049 . . . . 72.25 108.168 -176.603 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.4 mtp180 -147.11 169.23 19.72 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 124.141 0.976 . . . . 75.41 109.751 -166.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -51.99 123.86 11.42 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.539 0.736 . . . . 74.52 111.624 174.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 85.55 -7.64 75.56 Favored Glycine 0 C--N 1.349 1.302 0 CA-C-O 119.419 -0.656 . . . . 32.02 114.111 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.4 m -69.53 122.64 19.44 Favored 'General case' 0 C--N 1.351 0.633 0 CA-C-N 117.336 0.568 . . . . 74.31 110.553 -178.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.5 t -98.93 123.17 51.39 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 N-CA-C 108.486 -0.931 . . . . 72.44 108.486 179.302 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.546 HD12 HG23 ' A' ' 153' ' ' VAL . 43.5 mt -102.49 115.69 44.85 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.593 0 C-N-CA 123.926 0.89 . . . . 72.22 110.537 -169.075 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.402 ' HG3' ' HB2' ' A' ' 173' ' ' ASP . 30.3 ttm180 -89.69 115.86 27.38 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.07 0.548 . . . . 72.42 110.493 175.237 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.44 ' O ' ' HA ' ' A' ' 173' ' ' ASP . 15.0 m -119.16 116.11 34.12 Favored Pre-proline 0 CA--C 1.555 1.172 0 C-N-CA 123.363 0.665 . . . . 75.43 109.578 176.32 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 11.2 Cg_exo -72.47 148.51 48.41 Favored 'Trans proline' 0 C--N 1.368 1.594 0 C-N-CA 122.479 2.119 . . . . 73.42 111.998 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.65 18.27 28.36 Favored Glycine 0 C--N 1.341 0.825 0 N-CA-C 115.673 1.029 . . . . 73.2 115.673 172.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.483 ' HE3' ' HB ' ' A' ' 147' ' ' VAL . 54.2 mtt -121.6 -57.45 1.82 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 118.449 1.125 . . . . 71.3 112.128 176.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.35 1.329 0 O-C-N 123.372 0.42 . . . . 73.24 113.047 -174.51 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo . . . . . 0 CA--C 1.547 1.155 0 CA-C-O 119.956 -0.102 . . . . 74.21 112.167 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -95.41 159.21 22.44 Favored Glycine 0 C--N 1.348 1.212 0 O-C-N 123.385 0.428 . . . . 73.1 112.406 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.44 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 9.4 p-10 -96.46 151.54 19.47 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 123.012 0.525 . . . . 74.42 112.036 -167.475 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 11.2 tp -113.88 124.27 51.8 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 107.472 -1.307 . . . . 74.45 107.472 163.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.401 ' HA ' ' O ' ' A' ' 159' ' ' ILE . 37.3 mt -99.28 100.63 11.74 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.583 1.153 . . . . 74.53 110.098 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 93.0 mt -95.8 102.74 14.57 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.93 0.892 . . . . 73.12 110.917 177.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 6.5 p -86.16 111.91 21.9 Favored 'Isoleucine or valine' 0 C--O 1.244 0.81 0 CA-C-O 121.635 0.731 . . . . 62.43 109.209 172.388 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.433 HG11 HD21 ' A' ' 125' ' ' LEU . 6.2 m -86.98 149.35 4.14 Favored 'Isoleucine or valine' 0 C--O 1.241 0.607 0 CA-C-N 115.638 -0.71 . . . . 73.12 111.49 -178.365 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -124.31 104.57 8.87 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 106.914 -1.513 . . . . 73.34 106.914 176.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.562 ' HB3' HD22 ' A' ' 127' ' ' LEU . 32.4 mt -68.09 143.36 55.5 Favored 'General case' 0 CA--C 1.54 0.59 0 O-C-N 123.098 0.249 . . . . 71.21 111.243 -175.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.704 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 54.8 mt -53.86 147.83 22.42 Favored Pre-proline 0 CA--C 1.553 1.063 0 C-N-CA 123.852 0.861 . . . . 74.52 111.661 -173.265 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.19 37.24 0.62 Allowed 'Trans proline' 0 C--N 1.368 1.557 0 C-N-CA 123.32 2.68 . . . . 71.24 114.394 -175.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -121.06 65.55 13.93 Favored Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 123.544 0.738 . . . . 65.51 109.371 170.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -68.28 123.7 10.87 Favored 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 121.485 1.456 . . . . 75.04 111.231 -169.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.7 p -134.61 -38.81 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 N-CA-C 108.499 -0.926 . . . . 74.24 108.499 178.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . 0.42 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 5.5 m-85 -114.82 141.92 47.24 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 121.902 0.858 . . . . 74.54 112.259 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.543 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 43.8 mtt85 -128.54 154.0 46.62 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 113.472 -1.695 . . . . 73.2 106.838 171.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.44 HD11 HD23 ' A' ' 193' ' ' LEU . 42.5 tp -132.7 138.41 47.25 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 109.051 -0.722 . . . . 72.24 109.051 179.534 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -142.32 117.69 10.22 Favored 'General case' 0 C--O 1.241 0.645 0 N-CA-C 109.101 -0.703 . . . . 73.45 109.101 173.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 68.16 -86.82 0.18 Allowed Glycine 0 C--N 1.349 1.279 0 O-C-N 123.864 0.727 . . . . 75.41 112.986 -177.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 4.5 pm0 -135.41 -14.85 1.94 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.25 1.02 . . . . 74.31 111.206 -174.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -111.19 156.42 21.45 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-O 121.16 0.505 . . . . 74.12 111.36 -174.075 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.44 HD23 HD11 ' A' ' 188' ' ' LEU . 79.5 mt -109.09 170.78 7.83 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.334 1.054 . . . . 71.34 109.593 -168.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . 0.543 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 71.4 m-85 -142.45 122.58 13.75 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 107.51 -1.293 . . . . 74.52 107.51 177.502 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . 0.458 ' HB2' HD23 ' A' ' 251' ' ' LEU . . . -134.99 152.45 51.75 Favored 'General case' 0 CA--C 1.508 -0.657 0 N-CA-C 109.522 -0.547 . . . . 73.21 109.522 177.127 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 4.9 m -98.77 119.09 36.93 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 108.969 -0.752 . . . . 75.24 108.969 177.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.469 HD21 HD12 ' A' ' 251' ' ' LEU . 61.4 tp -105.31 111.84 24.73 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.347 1.059 . . . . 71.13 109.716 -174.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -94.43 104.85 16.81 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 109.333 -0.617 . . . . 74.51 109.333 176.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . 0.542 HG12 HG13 ' A' ' 223' ' ' VAL . 14.6 m -101.52 140.87 21.6 Favored Pre-proline 0 N--CA 1.476 0.825 0 N-CA-C 109.378 -0.601 . . . . 74.43 109.378 177.036 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.19 151.21 84.13 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 121.999 1.799 . . . . 73.21 110.986 171.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -56.69 -44.95 99.97 Favored Pre-proline 0 CA--C 1.546 0.791 0 CA-C-O 118.327 -0.844 . . . . 75.14 113.051 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . 0.415 ' O ' HG21 ' A' ' 206' ' ' VAL . 69.7 Cg_exo -46.69 -55.64 3.64 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 122.484 2.123 . . . . 64.42 113.495 170.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.2 mt -65.57 -37.25 79.56 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 122.736 0.414 . . . . 74.25 111.613 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -56.27 -58.33 8.43 Favored 'General case' 0 CA--C 1.547 0.828 0 CA-C-O 121.261 0.553 . . . . 73.43 111.087 178.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.6 m -69.79 -40.06 78.62 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.969 0 CA-C-N 115.212 -0.904 . . . . 74.34 112.461 -173.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . 0.415 HG21 ' O ' ' A' ' 202' ' ' PRO . 18.3 m -78.17 -27.0 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 122.259 0.224 . . . . 74.12 110.977 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.54 ' HA2' HG22 ' A' ' 223' ' ' VAL . . . 77.52 63.66 2.2 Favored Glycine 0 C--N 1.341 0.835 0 CA-C-N 115.919 -0.582 . . . . 73.41 113.171 -176.4 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -91.89 -147.12 19.82 Favored Glycine 0 C--N 1.354 1.578 0 N-CA-C 111.694 -0.563 . . . . 75.21 111.694 177.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -138.18 135.5 35.7 Favored 'General case' 0 C--O 1.24 0.593 0 C-N-CA 123.154 0.582 . . . . 73.41 110.462 178.051 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 61.3 t -120.68 134.64 63.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.131 0.972 . . . . 70.23 108.964 -179.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.68 114.81 17.92 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.502 -0.555 . . . . 75.41 109.502 171.533 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.63 146.0 28.3 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 108.71 -0.848 . . . . 64.35 108.71 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 55.4 mmm -83.81 148.59 26.92 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 110.13 -0.322 . . . . 72.32 110.13 174.411 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 214' ' ' THR . . . . . 0.42 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 9.3 t -140.03 167.59 21.77 Favored 'General case' 0 C--O 1.242 0.691 0 C-N-CA 124.0 0.92 . . . . 72.54 109.873 173.581 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 63.7 mt -74.31 -0.56 17.46 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 123.882 0.873 . . . . 75.32 112.138 -173.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.65 -4.07 9.78 Favored 'General case' 0 N--CA 1.485 1.292 0 N-CA-C 112.747 0.647 . . . . 74.23 112.747 176.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 153.89 -160.74 29.55 Favored Glycine 0 N--CA 1.478 1.465 0 CA-C-O 119.679 -0.512 . . . . 62.41 112.859 178.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -94.26 132.54 0.71 Allowed 'Trans proline' 0 CA--C 1.559 1.726 0 C-N-CA 123.473 2.782 . . . . 72.11 112.596 168.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 34.3 m -111.38 151.97 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.64 0.776 . . . . 73.44 110.32 173.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -114.58 115.14 26.69 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-O 121.139 0.495 . . . . 73.44 110.099 171.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.506 ' HB ' HD11 ' A' ' 235' ' ' LEU . 2.6 p -104.66 121.44 56.48 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 123.359 0.664 . . . . 74.34 110.968 179.408 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.98 105.62 15.0 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 109.22 -0.659 . . . . 75.52 109.22 173.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.542 HG13 HG12 ' A' ' 199' ' ' VAL . 11.0 m -71.2 135.61 84.65 Favored Pre-proline 0 CA--C 1.556 1.189 0 N-CA-C 108.839 -0.8 . . . . 72.32 108.839 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . 0.427 ' HB2' HH12 ' A' ' 231' ' ' ARG . 31.5 Cg_exo -61.28 144.12 98.52 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 122.373 2.048 . . . . 71.15 112.581 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -51.24 128.35 25.04 Favored 'Trans proline' 0 C--N 1.38 2.222 0 C-N-CA 122.904 2.403 . . . . 74.43 112.046 173.008 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 42.1 mtp180 67.87 60.98 0.43 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 125.032 1.333 . . . . 75.12 110.369 -175.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -85.3 139.62 31.46 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 114.852 -1.067 . . . . 72.22 111.29 178.355 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 23.1 mp0 -112.2 158.84 19.19 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 123.768 0.827 . . . . 75.4 109.392 176.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -71.07 140.47 50.71 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 116.013 -0.54 . . . . 72.54 109.673 174.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 96.97 -3.7 62.5 Favored Glycine 0 CA--C 1.521 0.443 0 CA-C-O 119.448 -0.64 . . . . 52.12 112.996 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . 0.427 HH12 ' HB2' ' A' ' 224' ' ' PRO . 90.1 mtt180 -69.41 156.11 39.37 Favored 'General case' 0 N--CA 1.478 0.972 0 CA-C-N 117.649 0.724 . . . . 75.44 110.733 172.585 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 13.2 mptt -125.44 123.23 38.81 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 123.404 0.682 . . . . 74.4 109.726 177.31 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 46.6 mt -112.6 109.98 19.87 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 108.554 -0.906 . . . . 71.12 108.554 -175.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . 0.427 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 57.3 ttp85 -99.23 104.31 16.24 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 116.072 -0.513 . . . . 75.41 111.145 -168.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.506 HD11 ' HB ' ' A' ' 221' ' ' VAL . 37.0 mt -89.9 100.52 13.32 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 124.091 0.956 . . . . 75.02 110.145 -176.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . 0.417 ' HE2' ' HB3' ' A' ' 236' ' ' LYS . 42.4 mtpt -66.37 151.53 46.94 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 116.378 -0.374 . . . . 74.11 111.534 177.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.65 20.2 73.76 Favored Glycine 0 C--N 1.348 1.203 0 CA-C-N 115.325 -0.852 . . . . 64.21 112.845 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.0 mmtt -137.59 16.44 2.92 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.801 0.84 . . . . 73.31 111.266 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -99.11 -160.72 29.42 Favored Glycine 0 C--N 1.347 1.161 0 O-C-N 123.654 0.596 . . . . 73.42 112.038 170.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.554 ' HZ ' ' HB2' ' A' ' 151' ' ' PRO . 13.3 t80 -83.43 127.14 69.56 Favored Pre-proline 0 CA--C 1.552 1.043 0 CA-C-N 116.74 0.27 . . . . 71.3 110.945 -176.531 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . 0.589 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 13.5 Cg_exo -70.87 126.33 12.47 Favored 'Trans proline' 0 C--N 1.376 1.979 0 C-N-CA 122.269 1.979 . . . . 74.53 111.732 173.474 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -158.69 -146.13 4.45 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-O 119.149 -0.806 . . . . 50.03 112.583 -176.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -65.38 -24.54 57.25 Favored 'Trans proline' 0 C--N 1.376 2.01 0 C-N-CA 123.375 2.717 . . . . 73.32 112.866 -177.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.45 22.54 3.9 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 124.041 0.937 . . . . 70.24 111.113 178.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 81.18 -98.63 1.87 Allowed Glycine 0 C--N 1.345 1.042 0 N-CA-C 110.469 -1.053 . . . . 64.34 110.469 -176.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.589 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 23.2 ttm180 -128.62 146.53 50.83 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 109.146 -0.687 . . . . 75.35 109.146 166.148 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -85.61 -155.34 24.99 Favored Glycine 0 C--O 1.253 1.338 0 O-C-N 123.694 0.621 . . . . 64.42 112.424 175.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -140.27 160.52 39.78 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.835 0.854 . . . . 62.24 109.961 -174.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.428 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 15.6 tp -99.51 122.39 42.51 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 123.919 0.887 . . . . 74.41 110.329 178.1 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -101.57 104.47 15.35 Favored 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 108.433 -0.951 . . . . 72.31 108.433 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.536 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 74.5 mt -85.72 149.93 24.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.987 0.915 . . . . 72.32 112.328 -178.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -114.47 96.01 5.55 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.539 -0.912 . . . . 70.51 108.539 176.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 69.1 t -52.15 125.82 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 123.582 0.753 . . . . 72.24 111.683 176.776 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 27.3 mmm-85 -136.17 101.5 4.72 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 125.257 1.423 . . . . 74.1 107.259 179.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 65.1 mt -80.97 125.39 39.45 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 CA-C-N 116.342 -0.39 . . . . 75.55 110.053 -175.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 10.0 t . . . . . 0 CA--C 1.55 0.966 0 C-N-CA 124.402 1.081 . . . . 74.13 109.653 -179.766 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.632 ' HB2' ' HG2' ' A' ' 136' ' ' ARG . 22.0 tp . . . . . 0 N--CA 1.471 0.623 0 N-CA-C 109.294 -0.632 . . . . 74.2 109.294 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.429 ' HA ' ' CB ' ' A' ' 123' ' ' LEU . 12.5 p -65.48 137.06 25.65 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 115.345 -0.843 . . . . 63.41 110.042 172.245 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.82 -50.14 8.96 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.215 -0.661 . . . . 73.14 109.215 174.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 49.0 p-80 -170.16 163.97 9.11 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 114.896 -1.047 . . . . 71.41 109.964 -175.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 1.8 p -95.38 162.09 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.086 0 N-CA-C 109.642 -0.503 . . . . 71.44 109.642 174.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 71.7 p . . . . . 0 N--CA 1.479 1.022 0 C-N-CA 124.792 1.237 . . . . 75.34 109.362 -171.972 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 120.886 0.374 . . . . 75.44 110.418 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 31.6 tp -122.64 146.2 47.67 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 107.662 -1.236 . . . . 74.35 107.662 -170.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 64.6 ttt-85 -141.72 143.87 33.76 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.737 -0.838 . . . . 72.44 108.737 -176.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . 0.439 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -149.06 118.81 7.03 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 109.079 -0.711 . . . . 73.25 109.079 175.656 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -94.03 139.38 31.02 Favored 'General case' 0 C--O 1.247 0.959 0 N-CA-C 109.305 -0.628 . . . . 74.42 109.305 174.132 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.429 ' CB ' ' HA ' ' A' ' 99' ' ' VAL . 1.8 pt? -144.87 132.37 10.37 Favored Pre-proline 0 CA--C 1.541 0.622 0 C-N-CA 123.099 0.56 . . . . 73.34 111.41 -166.21 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.425 ' HA ' ' HB2' ' A' ' 179' ' ' ARG . 18.7 Cg_exo -68.82 115.08 3.77 Favored 'Trans proline' 0 C--N 1.375 1.973 0 C-N-CA 122.654 2.236 . . . . 75.22 112.194 177.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.434 ' HB3' HD21 ' A' ' 180' ' ' LEU . 16.9 tp -109.2 166.84 10.55 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.512 1.125 . . . . 74.44 108.202 174.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.575 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 25.9 m -103.32 156.64 17.59 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 109.671 -0.492 . . . . 73.44 109.671 173.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.463 HD23 ' HB3' ' A' ' 180' ' ' LEU . 87.5 mt -56.02 -50.5 70.74 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-O 121.671 0.748 . . . . 75.51 110.069 171.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -57.48 -34.18 68.77 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 114.517 -1.22 . . . . 71.13 111.987 176.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.575 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 31.3 mm-40 -74.12 -31.49 62.79 Favored 'General case' 0 N--CA 1.482 1.169 0 C-N-CA 123.171 0.588 . . . . 74.41 111.56 176.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.447 ' HB2' ' O ' ' A' ' 153' ' ' VAL . . . -59.33 -37.91 79.02 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.442 0.697 . . . . 70.33 111.471 169.511 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.548 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 46.8 t80 -71.61 -47.73 52.7 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 115.79 -0.641 . . . . 75.51 112.174 173.16 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 31.8 m80 -63.09 -53.71 49.39 Favored 'General case' 0 N--CA 1.483 1.187 0 O-C-N 123.702 0.626 . . . . 64.44 111.004 -173.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 59.41 149.76 0.01 OUTLIER Glycine 0 CA--C 1.537 1.431 0 CA-C-N 115.772 -0.649 . . . . 74.51 113.297 -168.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 170.37 -179.06 42.74 Favored Glycine 0 CA--C 1.505 -0.551 0 C-N-CA 119.968 -1.11 . . . . 54.4 114.666 177.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -89.78 138.36 31.55 Favored 'General case' 0 C--O 1.24 0.596 0 CA-C-N 113.445 -1.377 . . . . 75.13 107.886 177.153 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.632 ' HG2' ' HB2' ' A' ' 98' ' ' LEU . 19.7 tpp180 -154.05 158.19 40.16 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 108.622 -0.881 . . . . 74.04 108.622 178.347 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.4 p -80.14 126.16 39.29 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.21 0 CA-C-O 121.544 0.687 . . . . 71.21 111.689 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 8.9 p -107.71 123.24 62.96 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 C-N-CA 124.732 1.213 . . . . 73.51 108.883 171.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -118.94 98.73 6.33 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 108.508 -0.923 . . . . 72.44 108.508 177.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 14.3 m -122.69 134.73 65.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 124.245 1.018 . . . . 73.34 109.785 -176.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.21 29.79 19.42 Favored 'General case' 0 CA--C 1.551 1.012 0 C-N-CA 124.18 0.992 . . . . 71.3 110.38 -173.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.28 6.39 79.91 Favored Glycine 0 C--N 1.358 1.797 0 CA-C-N 115.364 -0.835 . . . . 62.13 113.806 -177.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -99.31 115.08 28.35 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 109.103 -0.703 . . . . 73.53 109.103 -176.267 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -95.41 116.04 28.25 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 123.709 0.803 . . . . 74.43 110.144 -175.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.668 HG23 ' SD ' ' A' ' 164' ' ' MET . 7.5 m -142.79 156.99 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 125.368 1.467 . . . . 74.24 108.539 176.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 38.9 t -88.37 127.02 35.48 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 109.864 -0.421 . . . . 73.35 109.864 174.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.7 p -99.91 144.88 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 123.699 0.8 . . . . 75.33 109.567 171.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.6 ttt180 -109.43 116.22 31.41 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.593 -0.891 . . . . 74.41 108.593 168.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.1 pt -121.1 132.04 24.31 Favored Pre-proline 0 CA--C 1.549 0.927 0 N-CA-C 108.93 -0.767 . . . . 72.3 108.93 171.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -76.45 166.61 27.13 Favored 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 122.8 2.333 . . . . 73.13 113.531 -170.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -68.89 154.62 70.65 Favored 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.109 1.873 . . . . 65.41 110.468 165.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 90.41 44.35 4.66 Favored Glycine 0 C--O 1.239 0.44 0 N-CA-C 111.548 -0.621 . . . . 75.14 111.548 -173.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.447 ' O ' ' HB2' ' A' ' 130' ' ' ALA . 2.7 p -116.3 156.26 17.52 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.102 0 N-CA-C 108.197 -1.038 . . . . 75.15 108.197 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.2 mtp180 -138.76 166.17 25.1 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 123.967 0.907 . . . . 72.12 110.916 -164.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -57.97 127.55 32.61 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 122.957 0.503 . . . . 61.4 110.823 170.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 77.19 6.67 86.45 Favored Glycine 0 C--N 1.349 1.261 0 O-C-N 123.717 0.636 . . . . 71.04 113.379 -178.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.4 ' O ' ' HA ' ' A' ' 177' ' ' VAL . 41.2 t -69.56 122.45 19.09 Favored 'General case' 0 C--N 1.358 0.953 0 C-N-CA 122.942 0.497 . . . . 71.41 109.7 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.436 HG22 HD22 ' A' ' 175' ' ' LEU . 7.3 p -103.01 119.94 52.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 O-C-N 124.475 1.109 . . . . 74.31 109.608 -176.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 17.6 mt -115.74 116.82 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 123.864 0.865 . . . . 71.55 109.86 -173.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 44.1 ttp180 -75.8 120.3 20.97 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 118.36 0.527 . . . . 75.03 110.141 175.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.643 ' HB ' ' HB3' ' A' ' 174' ' ' LEU . 84.2 t -112.16 113.88 51.42 Favored Pre-proline 0 CA--C 1.552 1.027 0 C-N-CA 124.249 1.019 . . . . 72.4 109.636 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -76.95 157.4 34.61 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.664 2.242 . . . . 73.51 113.233 178.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . 0.575 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . 105.76 -25.94 22.63 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 115.365 0.906 . . . . 75.5 115.365 173.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.668 ' SD ' HG23 ' A' ' 145' ' ' VAL . 4.1 mpp? -111.0 -45.89 3.4 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-N 118.893 1.347 . . . . 74.23 112.431 -175.001 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.343 0.936 0 C-N-CA 121.441 -0.409 . . . . 75.31 112.624 179.313 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo . . . . . 0 CA--C 1.543 0.962 0 N-CA-C 110.241 -0.715 . . . . 74.52 110.241 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . 0.575 ' HA3' ' H ' ' A' ' 163' ' ' GLY . . . 103.91 119.97 4.7 Favored Glycine 0 C--N 1.34 0.778 0 N-CA-C 112.301 -0.319 . . . . 60.31 112.301 -176.329 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -134.6 107.5 7.53 Favored 'General case' 0 C--N 1.333 -0.141 0 C-N-CA 124.524 1.129 . . . . 73.02 108.153 172.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.643 ' HB3' ' HB ' ' A' ' 161' ' ' VAL . 27.4 tp -121.33 105.89 10.95 Favored 'General case' 0 C--O 1.226 -0.132 0 N-CA-C 107.2 -1.407 . . . . 75.22 107.2 168.003 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.436 HD22 HG22 ' A' ' 158' ' ' VAL . 59.8 mt -84.76 99.39 10.83 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.017 -0.538 . . . . 70.12 110.483 -176.015 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.439 ' HA ' ' O ' ' A' ' 121' ' ' ALA . 59.8 mt -84.35 102.81 13.0 Favored 'General case' 0 C--N 1.344 0.351 0 CA-C-N 115.569 -0.741 . . . . 74.44 109.393 176.101 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 157' ' ' SER . 42.7 t -95.98 95.05 4.54 Favored 'Isoleucine or valine' 0 C--O 1.242 0.665 0 CA-C-N 114.61 -1.177 . . . . 74.24 107.962 179.343 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.445 HG21 HG22 ' A' ' 153' ' ' VAL . 5.6 m -75.3 147.63 8.14 Favored 'Isoleucine or valine' 0 C--O 1.245 0.831 0 CA-C-O 121.521 0.676 . . . . 75.24 110.898 -171.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . 0.425 ' HB2' ' HA ' ' A' ' 124' ' ' PRO . 34.3 mmt180 -121.35 94.93 4.49 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 108.119 -1.067 . . . . 74.53 108.119 -176.238 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.463 ' HB3' HD23 ' A' ' 127' ' ' LEU . 50.1 mt -67.34 147.12 53.36 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 110.269 -0.271 . . . . 75.13 110.269 -176.343 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.55 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 20.3 mt -56.59 123.41 56.95 Favored Pre-proline 0 CA--C 1.552 1.054 0 CA-C-O 119.307 -0.378 . . . . 73.13 110.362 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 17.2 Cg_exo -66.82 85.27 0.3 Allowed 'Trans proline' 0 C--N 1.379 2.143 0 C-N-CA 123.508 2.805 . . . . 75.21 113.356 -172.423 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -162.44 77.25 2.01 Favored Pre-proline 0 CA--C 1.558 1.281 0 N-CA-C 108.094 -1.076 . . . . 71.05 108.094 171.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -63.33 123.46 12.17 Favored 'Trans proline' 0 C--N 1.377 2.031 0 C-N-CA 122.002 1.801 . . . . 74.22 111.924 -171.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.8 p -134.56 -46.78 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 N-CA-C 107.517 -1.29 . . . . 62.2 107.517 174.135 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . 0.531 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 4.3 m-85 -103.55 123.77 47.55 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.22 -0.9 . . . . 73.44 110.61 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 15.0 mtm180 -120.82 104.75 10.11 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.905 -1.517 . . . . 75.41 106.905 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 44.3 tp -83.6 138.55 33.31 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 108.996 -0.742 . . . . 73.15 108.996 174.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -141.59 104.93 4.65 Favored 'General case' 0 C--O 1.243 0.747 0 N-CA-C 107.393 -1.336 . . . . 74.55 107.393 176.273 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 74.84 -88.17 0.76 Allowed Glycine 0 C--N 1.348 1.221 0 CA-C-N 115.738 -0.665 . . . . 61.34 111.654 -174.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -136.59 -6.36 1.96 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 123.625 0.77 . . . . 71.1 110.854 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -98.53 149.55 22.62 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.369 0.668 . . . . 71.24 111.202 -177.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.591 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.7 mt -109.58 151.17 27.16 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.486 1.114 . . . . 74.54 109.207 -177.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -140.41 120.17 13.42 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 107.372 -1.344 . . . . 73.41 107.372 178.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . 0.439 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -143.24 140.66 30.78 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.742 0.817 . . . . 63.42 108.939 -177.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 20.5 m -83.39 127.98 34.13 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-O 121.194 0.521 . . . . 63.53 110.208 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . . . . . . . . . 65.1 tp -112.3 120.66 42.5 Favored 'General case' 0 C--O 1.22 -0.479 0 C-N-CA 125.216 1.406 . . . . 74.21 108.941 176.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -99.35 123.08 43.33 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.402 -0.962 . . . . 74.32 108.402 170.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 4.6 m -110.2 147.78 36.99 Favored Pre-proline 0 C--O 1.245 0.849 0 C-N-CA 123.039 0.536 . . . . 74.41 109.883 -177.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -60.22 134.1 53.7 Favored 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 122.367 2.045 . . . . 72.14 110.877 168.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -53.96 -43.35 96.57 Favored Pre-proline 0 CA--C 1.564 1.493 0 C-N-CA 124.325 1.05 . . . . 71.4 113.541 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_exo -55.13 -46.48 32.71 Favored 'Trans proline' 0 C--N 1.395 3.024 0 C-N-CA 122.473 2.116 . . . . 74.45 112.97 171.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 7.1 mt -63.28 -38.24 81.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 123.344 0.657 . . . . 74.14 111.072 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.91 -43.62 98.29 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 123.099 0.56 . . . . 64.55 111.889 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . 0.527 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 35.8 m -80.81 -38.96 17.59 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 CA-C-N 116.154 -0.476 . . . . 71.12 112.178 -175.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.0 m -79.53 -35.78 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 CA-C-N 118.12 0.418 . . . . 74.43 110.573 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 89.81 80.02 1.34 Allowed Glycine 0 C--N 1.348 1.22 0 CA-C-N 115.613 -0.721 . . . . 75.01 112.229 -175.11 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -117.54 -160.42 11.71 Favored Glycine 0 C--N 1.357 1.732 0 N-CA-C 112.164 -0.374 . . . . 44.41 112.164 175.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . 0.568 ' HB2' ' HZ2' ' A' ' 209' ' ' LYS . 10.5 mtmp? -115.98 137.44 52.11 Favored 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 123.47 0.708 . . . . 75.44 110.373 -179.187 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 28.2 t -118.82 152.06 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.745 1.218 . . . . 55.15 108.749 176.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -81.13 119.2 23.27 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 108.434 -0.95 . . . . 75.22 108.434 171.58 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -102.16 122.94 45.12 Favored 'General case' 0 C--O 1.239 0.511 0 N-CA-C 108.125 -1.065 . . . . 75.3 108.125 175.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 54.7 mmm -77.21 113.4 14.92 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.193 0.52 . . . . 72.33 110.288 178.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 214' ' ' THR . . . . . 0.531 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 9.1 t -109.83 167.96 9.77 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-N 114.692 -1.14 . . . . 64.15 109.766 171.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 72.1 mt -71.12 -7.5 47.0 Favored 'General case' 0 CA--C 1.546 0.821 0 CA-C-N 114.701 -1.136 . . . . 73.24 111.735 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -90.57 -19.79 23.34 Favored 'General case' 0 CA--C 1.558 1.26 0 C-N-CA 124.211 1.004 . . . . 74.02 110.951 172.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 137.24 -154.36 22.33 Favored Glycine 0 C--N 1.347 1.163 0 N-CA-C 110.901 -0.88 . . . . 64.43 110.901 -174.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -89.19 129.06 1.92 Allowed 'Trans proline' 0 CA--C 1.55 1.295 0 C-N-CA 122.649 2.232 . . . . 61.32 111.923 170.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.0 m -109.82 167.91 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 123.775 0.83 . . . . 74.32 111.197 174.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -105.69 115.79 30.85 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 123.598 0.759 . . . . 64.32 109.906 177.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 2.7 p -116.55 125.44 73.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 123.974 0.91 . . . . 71.31 109.566 174.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -92.31 121.83 34.18 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.124 -0.695 . . . . 71.42 109.124 175.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 10.0 m -81.7 145.43 54.33 Favored Pre-proline 0 CA--C 1.553 1.06 0 N-CA-C 108.989 -0.745 . . . . 75.52 108.989 177.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -61.99 141.92 90.94 Favored 'Trans proline' 0 C--N 1.371 1.713 0 C-N-CA 122.13 1.887 . . . . 74.24 111.914 173.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -60.04 122.21 11.03 Favored 'Trans proline' 0 C--N 1.368 1.592 0 C-N-CA 122.784 2.322 . . . . 75.54 112.257 174.358 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . 0.527 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 62.3 mtp180 65.85 39.33 4.7 Favored 'General case' 0 N--CA 1.482 1.172 0 C-N-CA 124.732 1.213 . . . . 73.3 111.427 -176.294 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 7.1 t -70.9 174.41 6.17 Favored 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 122.941 0.496 . . . . 75.13 111.272 -179.098 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.2 mp0 -123.55 143.65 50.07 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 123.859 0.863 . . . . 73.32 109.54 -176.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.08 123.28 21.18 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.785 0.834 . . . . 63.31 110.098 175.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 112.87 12.24 12.88 Favored Glycine 0 C--N 1.34 0.788 0 CA-C-N 116.244 -0.434 . . . . 74.3 112.605 -176.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . 0.404 ' O ' ' HA ' ' A' ' 252' ' ' GLU . 84.8 mtt180 -91.17 154.51 19.28 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 109.292 -0.633 . . . . 74.01 109.292 167.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.418 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.1 OUTLIER -104.27 111.45 24.08 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 123.615 0.766 . . . . 71.52 109.03 172.568 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . 0.476 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 67.8 mt -87.63 104.78 16.84 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 108.333 -0.988 . . . . 75.14 108.333 -177.363 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 40.5 ttm105 -76.58 110.39 11.1 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-N 115.313 -0.858 . . . . 75.21 111.755 -172.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.427 HD12 HD23 ' A' ' 249' ' ' LEU . 20.9 mt -91.97 106.12 18.21 Favored 'General case' 0 C--O 1.239 0.551 0 N-CA-C 107.897 -1.149 . . . . 71.22 107.897 169.338 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 93.3 mttt -66.57 132.89 49.18 Favored 'General case' 0 CA--C 1.538 0.506 0 CA-C-N 114.578 -1.192 . . . . 75.33 111.828 -167.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 79.91 -1.11 80.61 Favored Glycine 0 C--N 1.348 1.228 0 O-C-N 123.834 0.709 . . . . 64.01 114.649 173.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -84.57 -3.78 58.63 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.496 0.554 . . . . 71.41 112.496 -176.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.91 -179.31 48.92 Favored Glycine 0 C--N 1.346 1.136 0 N-CA-C 112.446 -0.262 . . . . 71.24 112.446 174.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.548 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 73.9 m-85 -86.38 155.86 56.93 Favored Pre-proline 0 N--CA 1.476 0.847 0 C-N-CA 123.197 0.599 . . . . 75.32 112.296 -173.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -60.97 140.5 90.5 Favored 'Trans proline' 0 C--N 1.384 2.444 0 C-N-CA 122.778 2.318 . . . . 73.25 112.772 178.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -150.82 -162.01 10.37 Favored Glycine 0 CA--C 1.533 1.179 0 N-CA-C 110.458 -1.057 . . . . 72.13 110.458 175.044 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -69.7 -20.68 34.81 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.803 2.335 . . . . 74.11 113.043 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.79 3.18 55.33 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.673 0.789 . . . . 74.24 112.083 -175.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.37 -105.97 1.62 Allowed Glycine 0 C--N 1.35 1.314 0 N-CA-C 110.619 -0.993 . . . . 64.31 110.619 -176.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 50.6 mtm-85 -126.58 152.28 46.82 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 108.045 -1.095 . . . . 74.51 108.045 167.395 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -78.03 -158.28 10.79 Favored Glycine 0 C--N 1.343 0.936 0 O-C-N 123.362 0.414 . . . . 72.21 112.152 174.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 38.6 m-20 -136.65 170.1 16.62 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 109.323 -0.621 . . . . 62.34 109.323 -175.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.591 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 23.9 tp -103.27 124.44 48.64 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.202 -0.666 . . . . 75.21 109.202 171.35 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . 0.418 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 48.3 m-85 -107.89 104.35 13.81 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.293 0.637 . . . . 65.23 109.405 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.476 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 85.2 mt -89.11 113.75 24.93 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.802 0.841 . . . . 73.11 112.414 -178.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' A' ' 231' ' ' ARG . 39.2 tt0 -78.85 91.66 4.78 Favored 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 108.777 -0.823 . . . . 74.11 108.777 176.838 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.1 p -54.11 130.98 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.353 1.061 . . . . 74.14 111.066 176.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 13.2 mmt180 -131.02 99.01 4.75 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 125.12 1.368 . . . . 72.02 107.548 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 63.5 mt -76.58 124.76 35.48 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 C-N-CA 123.822 0.849 . . . . 72.35 109.269 -175.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 9.4 t . . . . . 0 C--O 1.25 1.086 0 C-N-CA 123.552 0.741 . . . . 72.5 109.781 -175.62 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.443 HD22 HD11 ' A' ' 123' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.484 1.226 0 CA-C-O 121.254 0.549 . . . . 62.23 110.108 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.537 ' HA ' ' HB2' ' A' ' 123' ' ' LEU . 11.4 p -84.08 143.46 11.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 C-N-CA 124.702 1.201 . . . . 72.42 110.624 171.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -77.82 -87.07 0.05 Allowed 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 108.439 -0.949 . . . . 73.53 108.439 169.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.4 m80 -168.78 179.54 4.16 Favored 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 125.026 1.33 . . . . 74.12 109.72 177.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 93.4 t -62.23 140.16 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 C-N-CA 123.654 0.782 . . . . 72.4 111.146 178.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 37.4 p . . . . . 0 CA--C 1.547 0.833 0 C-N-CA 123.163 0.585 . . . . 73.21 109.443 172.487 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.8 t70 . . . . . 0 CA--C 1.538 0.51 0 CA-C-O 120.638 0.256 . . . . 73.31 110.576 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.537 HD11 ' HA2' ' A' ' 165' ' ' GLY . 12.4 mt -125.59 142.46 51.5 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 107.26 -1.385 . . . . 74.04 107.26 160.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . 0.58 ' HG2' ' HB2' ' A' ' 175' ' ' LEU . 41.0 mtm180 -141.91 145.78 34.97 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 107.694 -1.224 . . . . 75.25 107.694 178.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -151.46 118.42 5.85 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 108.516 -0.92 . . . . 71.24 108.516 175.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -88.85 132.45 34.66 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 108.086 -1.079 . . . . 74.55 108.086 173.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.537 ' HB2' ' HA ' ' A' ' 99' ' ' VAL . 2.2 pt? -142.71 146.65 39.0 Favored Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 122.778 0.431 . . . . 72.51 111.683 -168.564 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -75.97 121.6 6.3 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.689 2.259 . . . . 62.41 111.182 173.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.437 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 14.2 tp -120.16 168.94 10.7 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.216 1.006 . . . . 74.32 108.793 174.69 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.642 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 11.5 m -107.06 155.98 19.25 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.136 0.574 . . . . 74.12 109.776 174.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 80.5 mt -50.49 -52.41 38.57 Favored 'General case' 0 N--CA 1.487 1.41 0 C-N-CA 124.127 0.971 . . . . 70.31 110.216 173.29 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.552 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -54.91 -39.52 68.89 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 113.506 -1.679 . . . . 71.44 112.103 177.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.642 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 16.0 mm-40 -76.88 -26.31 54.06 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 123.099 0.56 . . . . 73.22 112.107 -176.354 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.519 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -61.12 -44.56 97.16 Favored 'General case' 0 C--O 1.252 1.219 0 CA-C-O 121.62 0.724 . . . . 72.3 111.129 169.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -67.69 -46.31 72.65 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 114.029 -1.441 . . . . 73.53 112.747 176.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.2 m80 -69.2 -47.43 64.86 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 122.775 0.43 . . . . 74.34 110.759 -176.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.69 -148.24 50.99 Favored Glycine 0 C--N 1.344 1.022 0 N-CA-C 111.229 -0.749 . . . . 72.23 111.229 -169.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 117.26 172.72 16.21 Favored Glycine 0 N--CA 1.472 1.039 0 CA-C-N 117.224 0.512 . . . . 73.14 113.471 172.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 13.7 mp0 -90.11 114.42 26.34 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 107.744 -1.206 . . . . 61.13 107.744 179.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 4.9 mmp_? -116.75 163.19 16.51 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 123.855 0.862 . . . . 74.51 110.306 -177.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.6 p -88.48 124.07 41.24 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 CA-C-O 121.241 0.543 . . . . 75.33 110.241 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.434 ' HA ' HG12 ' A' ' 99' ' ' VAL . 12.0 p -114.24 145.87 19.5 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.694 0 C-N-CA 123.816 0.846 . . . . 64.44 109.962 178.463 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -125.91 109.06 12.05 Favored 'General case' 0 C--O 1.242 0.682 0 N-CA-C 108.668 -0.864 . . . . 74.45 108.668 174.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.9 m -130.43 117.52 39.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 123.678 0.791 . . . . 74.1 111.068 -176.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.05 23.39 13.79 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.835 1.254 . . . . 75.5 112.257 176.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.12 12.71 57.25 Favored Glycine 0 C--N 1.343 0.944 0 CA-C-O 120.032 -0.315 . . . . 60.25 112.995 -178.309 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.1 mpt_? -103.3 116.87 33.27 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.203 -0.665 . . . . 74.42 109.203 177.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 62.5 ttp85 -94.32 105.17 17.15 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 108.14 -1.059 . . . . 74.42 108.14 172.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 8.9 m -142.11 157.07 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 C-N-CA 124.338 1.055 . . . . 65.34 109.575 -175.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 54.3 p -90.94 120.08 31.66 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 122.889 0.476 . . . . 63.54 110.217 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.22 141.35 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.348 0.659 . . . . 63.32 109.425 177.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -107.04 103.42 12.83 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 108.298 -1.001 . . . . 71.34 108.298 174.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.476 ' HB ' HD11 ' A' ' 159' ' ' ILE . 37.8 pt -106.98 107.27 60.22 Favored Pre-proline 0 CA--C 1.548 0.873 0 N-CA-C 108.677 -0.861 . . . . 73.4 108.677 170.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.96 162.08 43.11 Favored 'Trans proline' 0 C--N 1.38 2.235 0 C-N-CA 122.972 2.448 . . . . 71.11 113.389 -171.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -59.85 114.77 2.22 Favored 'Trans proline' 0 C--N 1.376 2.017 0 C-N-CA 122.482 2.121 . . . . 74.21 110.448 169.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . 0.421 ' HA2' ' CD2' ' A' ' 240' ' ' PHE . . . 140.62 61.35 0.04 OUTLIER Glycine 0 C--N 1.341 0.811 0 N-CA-C 111.811 -0.515 . . . . 73.2 111.811 -173.724 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.564 HG23 HD13 ' A' ' 159' ' ' ILE . 3.2 p -150.9 163.14 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.301 0 C-N-CA 122.505 0.322 . . . . 74.43 110.162 -178.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 44.8 mtp180 -146.8 177.02 9.43 Favored 'General case' 0 N--CA 1.484 1.234 0 C-N-CA 124.987 1.315 . . . . 75.42 110.113 -171.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.2 tp10 -51.72 118.2 3.22 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 125.053 1.341 . . . . 71.14 111.51 170.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 79.0 1.28 84.91 Favored Glycine 0 C--N 1.351 1.373 0 CA-C-O 119.382 -0.677 . . . . 73.51 113.866 176.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.4 m -73.78 136.49 43.59 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-N 117.352 0.576 . . . . 72.52 110.953 -176.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.404 HG12 HD22 ' A' ' 175' ' ' LEU . 13.2 t -101.06 122.97 53.77 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-N 114.646 -1.161 . . . . 61.12 108.894 -174.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.564 HD13 HG23 ' A' ' 153' ' ' VAL . 16.6 mt -106.4 107.35 22.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 N-CA-C 109.035 -0.728 . . . . 74.21 109.035 -175.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.494 ' HA ' HD21 ' A' ' 175' ' ' LEU . 58.4 ttt-85 -81.7 109.13 15.83 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 110.03 -0.359 . . . . 73.24 110.03 176.202 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.426 HG22 ' O ' ' A' ' 174' ' ' LEU . 19.5 m -101.72 97.81 8.56 Favored Pre-proline 0 CA--C 1.559 1.319 0 N-CA-C 108.647 -0.872 . . . . 74.13 108.647 172.069 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -74.55 155.98 45.07 Favored 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 123.053 2.502 . . . . 62.55 113.189 -176.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 73.27 24.73 74.78 Favored Glycine 0 C--N 1.345 1.076 0 CA-C-N 115.488 -0.778 . . . . 72.51 112.586 -178.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 6.7 tpt -125.68 -56.89 1.47 Allowed 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 124.01 0.924 . . . . 74.35 111.573 -166.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . 0.537 ' HA2' HD11 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.353 1.491 0 O-C-N 123.725 0.641 . . . . 73.01 112.14 -175.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo . . . . . 0 CA--C 1.54 0.818 0 CA-C-O 120.713 0.214 . . . . 73.21 112.539 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -98.87 178.69 31.05 Favored Glycine 0 C--O 1.222 -0.625 0 N-CA-C 110.565 -1.014 . . . . 74.13 110.565 166.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -146.56 157.14 43.68 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 118.12 0.96 . . . . 71.51 111.259 -171.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.426 ' O ' HG22 ' A' ' 161' ' ' VAL . 27.0 tp -114.57 115.59 27.42 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 114.655 -1.157 . . . . 74.14 108.684 176.297 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.58 ' HB2' ' HG2' ' A' ' 120' ' ' ARG . 93.8 mt -90.35 99.46 12.48 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.297 1.039 . . . . 65.12 110.254 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 45.6 mt -87.07 104.59 16.48 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 122.81 0.444 . . . . 72.15 110.51 175.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.5 t -89.39 95.78 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 107.803 -1.184 . . . . 72.53 107.803 176.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.437 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 8.1 m -82.08 144.11 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 109.769 -0.456 . . . . 75.3 109.769 -174.695 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 5.2 mmm180 -122.28 105.55 10.31 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 106.118 -1.808 . . . . 75.1 106.118 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 36.6 mt -69.61 147.88 50.11 Favored 'General case' 0 N--CA 1.473 0.706 0 O-C-N 123.373 0.421 . . . . 70.21 111.175 -172.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.454 HD11 HG22 ' A' ' 126' ' ' THR . 36.5 mt -55.73 121.04 36.95 Favored Pre-proline 0 C--N 1.357 0.905 0 O-C-N 123.641 0.588 . . . . 73.54 109.748 177.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -65.98 88.02 0.24 Allowed 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 122.969 2.446 . . . . 61.41 112.306 -178.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 13.3 p80 -156.99 62.9 2.88 Favored Pre-proline 0 CA--C 1.55 0.958 0 N-CA-C 107.794 -1.187 . . . . 74.1 107.794 169.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -56.14 122.06 11.1 Favored 'Trans proline' 0 C--N 1.382 2.339 0 C-N-CA 122.089 1.859 . . . . 74.24 112.639 -170.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.83 -45.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 N-CA-C 107.704 -1.221 . . . . 64.0 107.704 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . 0.418 ' CE2' HD12 ' A' ' 193' ' ' LEU . 4.9 m-85 -107.41 131.98 53.68 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 123.93 0.892 . . . . 72.41 110.384 178.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 69.0 mtp180 -117.81 131.12 56.61 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.765 1.226 . . . . 74.41 108.635 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 58.6 tp -109.9 130.84 55.48 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 121.004 0.43 . . . . 74.25 110.182 177.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -129.87 101.79 6.02 Favored 'General case' 0 C--O 1.24 0.572 0 N-CA-C 107.417 -1.327 . . . . 64.33 107.417 172.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 69.67 -82.65 0.29 Allowed Glycine 0 CA--C 1.53 1.008 0 O-C-N 123.793 0.683 . . . . 62.11 112.607 -176.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -134.2 -22.18 1.79 Allowed 'General case' 0 CA--C 1.552 1.053 0 C-N-CA 124.733 1.213 . . . . 73.12 109.554 -177.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 41.3 m-20 -81.41 149.73 28.69 Favored 'General case' 0 C--N 1.358 0.967 0 C-N-CA 123.809 0.844 . . . . 72.43 111.385 -178.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.546 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.8 mt -109.58 155.04 21.92 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 124.639 1.176 . . . . 75.11 110.491 174.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -140.02 119.02 12.6 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 105.605 -1.998 . . . . 75.32 105.605 172.34 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -135.5 134.41 39.49 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 109.184 -0.672 . . . . 71.4 109.184 -178.235 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 196' ' ' THR . . . . . 0.431 ' HA ' ' HB3' ' A' ' 252' ' ' GLU . 24.0 m -70.91 123.64 22.49 Favored 'General case' 0 CA--C 1.541 0.612 0 O-C-N 123.654 0.596 . . . . 74.54 110.064 -179.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.463 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 61.3 tp -105.95 111.34 23.95 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 108.767 -0.827 . . . . 72.2 108.767 -178.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -85.04 116.74 23.6 Favored 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.492 -0.929 . . . . 61.25 108.492 176.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 2.2 m -122.86 141.64 35.95 Favored Pre-proline 0 N--CA 1.479 0.986 0 N-CA-C 108.996 -0.742 . . . . 73.11 108.996 177.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -72.7 147.1 44.44 Favored 'Trans proline' 0 C--N 1.366 1.485 0 C-N-CA 121.539 1.493 . . . . 71.32 110.521 169.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -58.31 -40.97 86.87 Favored Pre-proline 0 CA--C 1.558 1.26 0 C-N-CA 123.689 0.796 . . . . 62.32 112.419 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -45.68 -54.84 4.07 Favored 'Trans proline' 0 C--N 1.392 2.844 0 C-N-CA 122.524 2.15 . . . . 70.31 114.164 167.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 11.7 mt -65.58 -36.29 77.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 C-N-CA 122.237 0.215 . . . . 75.13 111.429 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.53 -44.27 93.23 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.16 0.584 . . . . 74.34 111.944 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.7 m -80.16 -41.15 20.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 CA-C-N 116.063 -0.517 . . . . 53.34 111.569 -176.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.3 m -78.88 -21.18 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 122.549 0.34 . . . . 74.04 111.148 -178.649 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.506 ' HA2' HG21 ' A' ' 223' ' ' VAL . . . 71.2 65.32 2.48 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 115.764 -0.653 . . . . 74.32 112.439 -176.484 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -93.85 -155.55 31.87 Favored Glycine 0 C--N 1.353 1.505 0 CA-C-N 116.94 0.37 . . . . 65.4 112.535 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.22 134.87 54.62 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.326 1.05 . . . . 75.52 108.438 178.332 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 46.6 t -117.97 125.77 74.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 124.078 0.951 . . . . 73.35 108.593 -178.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -79.6 109.14 13.71 Favored 'General case' 0 CA--C 1.542 0.659 0 N-CA-C 109.137 -0.69 . . . . 72.03 109.137 177.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.95 129.92 48.35 Favored 'General case' 0 C--O 1.238 0.483 0 C-N-CA 123.417 0.687 . . . . 70.1 109.148 179.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.2 116.75 18.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.004 -0.544 . . . . 70.5 109.899 174.593 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 9.9 t -109.67 163.56 13.36 Favored 'General case' 0 C--O 1.242 0.685 0 O-C-N 123.901 0.75 . . . . 74.43 109.402 172.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . 0.552 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 90.2 mt -71.53 -2.58 17.37 Favored 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 115.507 -0.77 . . . . 73.31 112.61 -172.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -112.26 -11.72 13.69 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.565 0.746 . . . . 63.21 112.111 175.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 153.71 -156.34 26.73 Favored Glycine 0 C--N 1.349 1.267 0 CA-C-O 119.546 -0.585 . . . . 61.32 112.799 -179.047 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -94.28 133.53 0.76 Allowed 'Trans proline' 0 CA--C 1.556 1.592 0 C-N-CA 123.001 2.467 . . . . 74.14 112.846 174.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 27.1 m -114.56 157.5 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 123.585 0.754 . . . . 73.34 109.639 170.351 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -114.47 113.9 25.09 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 108.999 -0.741 . . . . 72.22 108.999 177.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.454 HG23 HD12 ' A' ' 235' ' ' LEU . 6.3 t -95.79 117.19 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 C-N-CA 123.99 0.916 . . . . 75.04 110.026 -177.328 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.99 100.57 11.14 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 108.977 -0.749 . . . . 74.21 108.977 176.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.506 HG21 ' HA2' ' A' ' 207' ' ' GLY . 20.0 m -79.43 137.45 55.65 Favored Pre-proline 0 CA--C 1.551 1.019 0 N-CA-C 109.415 -0.587 . . . . 74.22 109.415 179.415 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -63.31 144.9 92.39 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.537 2.158 . . . . 64.41 112.498 176.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -55.77 120.41 8.2 Favored 'Trans proline' 0 C--N 1.381 2.258 0 C-N-CA 123.081 2.521 . . . . 74.03 112.043 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 67.3 mtt180 64.76 54.61 1.34 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.382 1.073 . . . . 74.32 110.388 -175.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.3 t -75.49 167.36 22.04 Favored 'General case' 0 CA--C 1.545 0.781 0 CA-C-N 115.372 -0.831 . . . . 72.11 109.159 173.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -128.15 146.28 50.76 Favored 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 123.217 0.607 . . . . 74.12 109.614 -177.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -68.13 127.9 34.6 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 115.318 -0.855 . . . . 74.35 109.27 175.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.29 0.31 23.69 Favored Glycine 0 N--CA 1.471 1.032 0 CA-C-O 119.497 -0.613 . . . . 73.4 112.841 -173.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 25.0 mtp180 -84.4 154.89 22.55 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 117.414 0.607 . . . . 74.23 109.865 170.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.64 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.0 OUTLIER -120.59 101.67 7.91 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 108.497 -0.927 . . . . 75.33 108.497 176.269 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 37.2 mt -83.37 113.98 21.11 Favored 'General case' 0 C--N 1.352 0.686 0 N-CA-C 108.964 -0.754 . . . . 73.12 108.964 -173.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 -87.24 106.68 18.07 Favored 'General case' 0 C--O 1.239 0.507 0 C-N-CA 123.782 0.833 . . . . 75.32 110.839 -167.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.464 ' HB2' ' HB3' ' A' ' 249' ' ' LEU . 15.7 mt -94.06 104.28 16.32 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 108.112 -1.07 . . . . 75.15 108.112 174.091 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -74.65 141.47 44.61 Favored 'General case' 0 C--O 1.242 0.683 0 CA-C-N 115.763 -0.653 . . . . 73.13 112.025 -170.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 66.59 32.99 83.16 Favored Glycine 0 C--N 1.349 1.271 0 O-C-N 124.12 0.888 . . . . 71.22 113.253 178.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 41.1 mmtm -116.13 -2.68 12.15 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.663 0.785 . . . . 74.21 111.166 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . 0.445 ' O ' ' HD2' ' A' ' 246' ' ' ARG . . . -82.03 -156.16 17.28 Favored Glycine 0 C--N 1.347 1.177 0 O-C-N 123.657 0.598 . . . . 71.01 114.181 -178.164 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.421 ' CD2' ' HA2' ' A' ' 152' ' ' GLY . 35.0 m-85 -88.34 160.29 45.64 Favored Pre-proline 0 N--CA 1.482 1.159 0 C-N-CA 123.204 0.601 . . . . 64.34 110.56 176.176 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -57.09 152.5 44.15 Favored 'Trans proline' 0 C--N 1.382 2.313 0 C-N-CA 123.031 2.487 . . . . 73.43 113.971 178.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 176.94 -167.71 39.2 Favored Glycine 0 C--N 1.341 0.853 0 CA-C-N 115.27 -0.877 . . . . 74.34 112.11 176.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.27 -15.3 35.15 Favored 'Trans proline' 0 C--N 1.382 2.291 0 C-N-CA 122.983 2.456 . . . . 74.54 112.619 -176.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -96.77 24.12 6.39 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.175 0.99 . . . . 60.21 110.692 174.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 77.8 -89.62 1.06 Allowed Glycine 0 C--N 1.345 1.063 0 N-CA-C 110.943 -0.863 . . . . 70.42 110.943 -175.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.445 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 23.1 mtm180 -128.09 155.89 43.67 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 108.728 -0.841 . . . . 75.14 108.728 169.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -70.9 -160.78 3.72 Favored Glycine 0 C--N 1.348 1.231 0 O-C-N 123.727 0.642 . . . . 71.23 114.397 -176.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -129.21 138.33 51.64 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 122.888 0.475 . . . . 74.52 109.772 -173.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.546 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 30.6 tp -97.27 115.96 28.59 Favored 'General case' 0 C--O 1.214 -0.788 0 C-N-CA 123.624 0.77 . . . . 75.13 110.017 -178.308 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . 0.64 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 97.3 m-85 -101.65 106.95 18.06 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 123.497 0.719 . . . . 74.24 109.356 179.1 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.514 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 78.3 mt -87.08 118.72 26.65 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.372 -0.831 . . . . 73.52 113.115 -175.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.431 ' HB3' ' HA ' ' A' ' 196' ' ' THR . 10.5 tp10 -79.76 91.71 5.34 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 108.578 -0.897 . . . . 74.21 108.578 -178.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 59.7 t -52.5 118.38 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 123.99 0.916 . . . . 74.03 110.875 177.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 30.7 mmm180 -123.48 94.79 4.35 Favored 'General case' 0 C--O 1.24 0.569 0 C-N-CA 124.635 1.174 . . . . 74.11 107.95 176.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 63.4 mt -76.62 114.25 16.69 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 115.716 -0.674 . . . . 71.31 109.299 177.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 6.4 t . . . . . 0 C--O 1.248 1.014 0 C-N-CA 124.619 1.168 . . . . 75.42 108.944 -179.559 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.7 tp . . . . . 0 C--O 1.236 0.358 0 N-CA-C 107.599 -1.26 . . . . 74.41 107.599 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.568 ' HB ' ' HB3' ' A' ' 123' ' ' LEU 0.269 2.4 p 36.57 -95.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 C-N-CA 126.337 1.855 . . . . 75.52 113.713 176.956 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.418 ' H ' HG13 ' A' ' 99' ' ' VAL . . . 57.31 8.32 0.57 Allowed 'General case' 0 N--CA 1.493 1.683 0 C-N-CA 124.963 1.305 . . . . 62.25 113.14 -176.725 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 35.7 t-80 -103.81 71.91 1.08 Allowed 'General case' 0 C--O 1.243 0.756 0 N-CA-C 107.374 -1.343 . . . . 74.11 107.374 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 81.0 t -72.53 137.18 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 CA-C-N 114.375 -1.284 . . . . 72.42 109.702 -179.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 72.2 p . . . . . 0 N--CA 1.476 0.838 0 C-N-CA 124.504 1.122 . . . . 74.13 112.724 -173.842 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.3 p30 . . . . . 0 N--CA 1.468 0.432 0 N-CA-C 106.811 -1.552 . . . . 71.14 106.811 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 1.3 tt -99.83 143.34 30.17 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 106.427 -1.694 . . . . 73.43 106.427 177.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 12.7 tpp85 -119.0 125.23 48.9 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 118.778 0.717 . . . . 73.54 110.591 -173.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -147.85 149.95 33.25 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.341 0.656 . . . . 71.34 109.794 178.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.663 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 41.8 mt-10 -127.83 149.4 50.29 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.52 0.728 . . . . 71.43 109.418 -179.074 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.568 ' HB3' ' HB ' ' A' ' 99' ' ' VAL . 1.5 pt? -143.93 147.1 36.93 Favored Pre-proline 0 N--CA 1.474 0.741 0 O-C-N 123.505 0.503 . . . . 70.4 111.323 -176.623 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -76.79 113.93 3.74 Favored 'Trans proline' 0 C--N 1.371 1.738 0 C-N-CA 121.426 1.418 . . . . 73.44 109.688 162.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.437 HD23 HG11 ' A' ' 178' ' ' VAL . 18.6 tp -108.28 158.8 17.15 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.758 0.823 . . . . 74.43 108.839 178.456 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.58 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 6.9 m -95.52 156.26 16.4 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 123.397 0.679 . . . . 73.44 109.191 175.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 82.0 mt -58.34 -49.33 77.58 Favored 'General case' 0 N--CA 1.488 1.436 0 CA-C-O 122.348 1.071 . . . . 74.23 109.455 174.302 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.404 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.9 mp0 -57.01 -38.16 72.7 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 113.276 -1.784 . . . . 74.14 111.475 177.155 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 31.5 mm-40 -80.02 -21.16 43.86 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.231 0.612 . . . . 74.01 112.469 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.502 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -61.63 -40.33 94.47 Favored 'General case' 0 C--O 1.256 1.417 0 CA-C-O 121.665 0.745 . . . . 44.34 110.696 167.321 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.489 ' HA ' ' CE1' ' A' ' 240' ' ' PHE . 69.0 t80 -70.31 -48.35 56.98 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 113.964 -1.471 . . . . 75.01 112.774 172.611 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -71.55 -47.32 55.78 Favored 'General case' 0 N--CA 1.485 1.277 0 N-CA-C 112.067 0.395 . . . . 74.14 112.067 -172.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.32 -115.89 8.19 Favored Glycine 0 CA--C 1.533 1.204 0 N-CA-C 111.121 -0.791 . . . . 72.01 111.121 -175.643 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.8 174.55 39.71 Favored Glycine 0 C--N 1.346 1.124 0 N-CA-C 115.175 0.83 . . . . 70.52 115.175 167.613 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -87.61 118.26 26.98 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.346 1.059 . . . . 65.25 108.221 178.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -130.44 138.88 50.53 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 124.368 1.067 . . . . 74.43 108.543 -176.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 7.2 p -83.12 139.93 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 N-CA-C 108.697 -0.853 . . . . 75.24 108.697 174.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.431 HG22 HG13 ' A' ' 99' ' ' VAL . 7.1 p -143.04 153.09 16.89 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 C-N-CA 124.011 0.924 . . . . 74.53 109.324 -178.275 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -116.38 100.27 7.77 Favored 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 107.782 -1.192 . . . . 73.2 107.782 170.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 9.0 t -103.65 111.54 33.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 N-CA-C 108.753 -0.832 . . . . 71.34 108.753 -172.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.93 26.0 15.33 Favored 'General case' 0 N--CA 1.479 1.017 0 O-C-N 124.493 1.121 . . . . 72.43 111.658 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 91.75 13.63 57.77 Favored Glycine 0 C--N 1.355 1.585 0 CA-C-N 115.807 -0.633 . . . . 74.4 113.315 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 25.8 ttt180 -116.7 116.23 27.13 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 122.986 0.514 . . . . 72.23 110.134 177.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -87.5 114.09 23.8 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 122.838 0.455 . . . . 75.51 110.196 -178.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.6 p -148.13 152.79 12.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 C-N-CA 124.835 1.254 . . . . 72.02 109.089 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 43.7 m -82.86 122.19 27.91 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 122.835 0.454 . . . . 75.13 110.258 175.15 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.407 HG22 HG22 ' A' ' 149' ' ' ILE . 13.7 p -98.59 123.99 51.48 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 C-N-CA 123.646 0.778 . . . . 75.03 109.594 175.366 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 30.9 ttt85 -108.05 98.25 7.84 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 107.849 -1.167 . . . . 74.41 107.849 174.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.407 HG22 HG22 ' A' ' 147' ' ' VAL . 35.3 pt -96.32 131.4 28.64 Favored Pre-proline 0 N--CA 1.479 0.984 0 N-CA-C 109.673 -0.492 . . . . 75.32 109.673 178.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -67.71 145.32 69.04 Favored 'Trans proline' 0 C--N 1.375 1.94 0 C-N-CA 122.852 2.368 . . . . 73.54 112.982 -174.154 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.468 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 32.1 Cg_exo -63.68 125.12 14.85 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 123.045 2.497 . . . . 74.33 110.596 171.186 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 131.44 41.25 0.21 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 111.827 -0.509 . . . . 71.31 111.827 -173.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.502 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -118.58 154.21 20.77 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 N-CA-C 108.775 -0.824 . . . . 74.32 108.775 -177.484 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 40.9 mtp180 -144.66 166.85 24.01 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 124.943 1.297 . . . . 73.22 109.055 -165.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -52.75 123.18 10.65 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 123.61 0.764 . . . . 71.21 111.943 176.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 80.62 -4.61 68.17 Favored Glycine 0 C--N 1.348 1.202 0 CA-C-N 115.896 -0.593 . . . . 64.13 113.629 179.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 32.4 t -68.82 127.52 33.38 Favored 'General case' 0 C--O 1.248 1.016 0 C-N-CA 123.665 0.786 . . . . 61.1 110.134 -176.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.429 HG11 HD22 ' A' ' 175' ' ' LEU . 8.7 t -97.89 119.46 45.94 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-N 114.303 -1.317 . . . . 63.4 108.627 -176.449 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.501 HD12 HG23 ' A' ' 153' ' ' VAL . 17.2 mt -102.94 117.07 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 123.664 0.786 . . . . 75.4 110.054 -170.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 22.3 ttm180 -84.02 117.39 23.37 Favored 'General case' 0 C--O 1.239 0.512 0 C-N-CA 123.53 0.732 . . . . 64.41 110.414 172.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.84 101.39 53.02 Favored Pre-proline 0 CA--C 1.559 1.29 0 N-CA-C 108.293 -1.003 . . . . 70.54 108.293 169.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -64.92 149.66 89.2 Favored 'Trans proline' 0 C--N 1.384 2.407 0 C-N-CA 123.55 2.833 . . . . 60.44 113.428 -172.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 71.3 24.2 77.22 Favored Glycine 0 C--N 1.348 1.216 0 O-C-N 123.594 0.559 . . . . 62.43 113.795 175.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 2.9 tpt -100.52 -51.86 3.5 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.149 0.98 . . . . 64.42 109.998 -177.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.351 1.391 0 CA-C-N 115.403 -0.817 . . . . 71.32 112.092 -179.511 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo . . . . . 0 CA--C 1.554 1.523 0 CA-C-O 121.173 0.405 . . . . 64.15 112.507 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -100.6 150.5 18.82 Favored Glycine 0 C--N 1.342 0.866 0 N-CA-C 108.988 -1.645 . . . . 61.31 108.988 174.193 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -113.09 -179.89 3.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 118.049 0.924 . . . . 74.23 111.498 -164.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 15.6 tp -121.98 128.63 51.69 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 107.82 -1.178 . . . . 72.11 107.82 167.3 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.429 HD22 HG11 ' A' ' 158' ' ' VAL . 76.6 mt -99.76 101.99 13.31 Favored 'General case' 0 C--O 1.243 0.746 0 C-N-CA 125.085 1.354 . . . . 75.4 110.28 178.342 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.404 HD12 HG21 ' A' ' 149' ' ' ILE . 86.4 mt -91.28 109.46 20.73 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 123.612 0.765 . . . . 74.53 111.114 175.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.663 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 21.5 t -90.2 105.22 16.0 Favored 'Isoleucine or valine' 0 C--O 1.247 0.938 0 N-CA-C 108.115 -1.068 . . . . 71.11 108.115 173.286 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.437 HG11 HD23 ' A' ' 125' ' ' LEU . 6.1 m -82.4 151.34 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 CA-C-O 121.223 0.535 . . . . 73.12 111.615 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 38.2 mmt180 -124.07 98.95 6.01 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 107.67 -1.233 . . . . 74.34 107.67 176.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 57.5 mt -67.46 144.64 55.61 Favored 'General case' 0 C--O 1.241 0.628 0 O-C-N 123.139 0.274 . . . . 72.04 110.685 -178.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.58 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 44.1 mt -59.83 147.03 80.11 Favored Pre-proline 0 CA--C 1.558 1.284 0 O-C-N 124.366 1.041 . . . . 74.11 110.967 -176.436 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -75.46 58.09 5.06 Favored 'Trans proline' 0 C--N 1.375 1.96 0 C-N-CA 123.991 3.127 . . . . 75.35 113.845 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -142.28 51.82 2.17 Favored Pre-proline 0 CA--C 1.562 1.434 0 C-N-CA 123.035 0.534 . . . . 54.04 109.831 171.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -64.21 123.56 12.05 Favored 'Trans proline' 0 C--N 1.388 2.632 0 C-N-CA 122.43 2.087 . . . . 74.21 111.905 -168.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -128.22 -37.49 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 123.81 0.844 . . . . 74.52 109.363 -177.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . 0.43 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 6.0 m-85 -107.39 124.37 49.74 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 114.814 -1.085 . . . . 73.33 110.338 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.644 ' HB3' ' HB2' ' A' ' 194' ' ' TYR . 19.6 tpp180 -105.02 139.08 40.24 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 106.934 -1.506 . . . . 65.13 106.934 172.073 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 51.1 tp -123.41 122.62 38.74 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 122.897 0.479 . . . . 63.43 109.86 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -144.9 127.86 16.47 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 122.39 0.276 . . . . 74.13 110.322 169.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 63.94 33.83 88.28 Favored Glycine 0 C--N 1.356 1.648 0 O-C-N 123.91 0.756 . . . . 75.25 114.246 177.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 73.96 -5.24 2.08 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 125.714 1.606 . . . . 75.22 112.659 -175.567 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -93.33 149.98 20.82 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.479 0.711 . . . . 73.01 109.579 178.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.644 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 93.1 mt -108.92 163.57 13.17 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 124.281 1.033 . . . . 70.21 109.94 -176.409 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . 0.644 ' HB2' ' HB3' ' A' ' 187' ' ' ARG . 85.1 m-85 -143.38 121.52 12.18 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 106.803 -1.554 . . . . 74.51 106.803 178.01 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -147.25 164.32 33.58 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.444 0.697 . . . . 75.54 109.921 -176.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 17.5 m -106.2 125.45 51.01 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.51 -0.768 . . . . 63.12 109.17 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.525 ' HB2' HD21 ' A' ' 251' ' ' LEU . 65.5 tp -112.44 115.65 29.03 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.541 0.736 . . . . 74.43 109.631 177.419 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -78.7 131.03 36.46 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 108.138 -1.06 . . . . 65.44 108.138 169.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' A' ' 255' ' ' ILE . 90.9 t -129.78 121.15 19.86 Favored Pre-proline 0 N--CA 1.474 0.728 0 N-CA-C 107.682 -1.229 . . . . 75.2 107.682 178.626 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -65.83 147.66 85.57 Favored 'Trans proline' 0 C--N 1.369 1.657 0 C-N-CA 122.143 1.895 . . . . 74.13 110.888 176.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . 0.441 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -53.5 -42.5 92.24 Favored Pre-proline 0 N--CA 1.48 1.065 0 C-N-CA 124.483 1.113 . . . . 65.11 113.569 -177.323 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . 0.441 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 10.8 Cg_endo -52.42 -51.29 11.46 Favored 'Trans proline' 0 C--N 1.397 3.107 0 C-N-CA 122.144 1.896 . . . . 74.34 112.64 172.219 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 7.0 mt -66.49 -37.11 78.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 123.211 0.604 . . . . 72.21 111.641 -179.065 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.3 -42.97 99.11 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 122.926 0.49 . . . . 74.53 111.929 -178.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.2 m -82.62 -35.59 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.87 0 CA-C-N 115.931 -0.577 . . . . 75.32 111.987 -175.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 12.4 m -87.23 -18.92 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 CA-C-N 118.043 0.383 . . . . 74.22 111.658 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.41 ' HA2' HG21 ' A' ' 223' ' ' VAL . . . 77.87 55.04 4.28 Favored Glycine 0 C--N 1.344 1.022 0 CA-C-N 115.857 -0.61 . . . . 75.24 113.218 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -84.87 -169.66 46.17 Favored Glycine 0 C--N 1.349 1.252 0 CA-C-O 121.783 0.657 . . . . 71.11 112.585 -177.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . 0.431 ' HD2' ' N ' ' A' ' 209' ' ' LYS . 0.0 OUTLIER -115.61 120.18 38.58 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 107.771 -1.196 . . . . 74.15 107.771 -173.667 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . 0.437 HG11 HG23 ' A' ' 199' ' ' VAL . 7.3 p -124.42 144.07 35.57 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 124.37 1.068 . . . . 75.22 109.343 -178.304 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.22 138.06 34.74 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.297 -0.631 . . . . 72.13 109.297 176.134 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -107.69 131.56 54.28 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 108.446 -0.946 . . . . 63.5 108.446 169.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.49 104.55 9.16 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.988 -1.116 . . . . 74.32 107.988 179.375 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 214' ' ' THR . . . . . 0.43 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 14.8 t -112.41 168.15 9.87 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.161 0.584 . . . . 72.24 110.543 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . 0.404 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 65.2 mt -70.03 -7.3 39.93 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 123.562 0.745 . . . . 71.23 111.788 -179.094 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -97.28 -18.07 19.42 Favored 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.679 1.192 . . . . 70.32 111.382 175.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 133.06 -147.83 19.11 Favored Glycine 0 N--CA 1.475 1.284 0 CA-C-O 119.188 -0.784 . . . . 70.23 111.82 -178.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -85.84 126.73 2.98 Favored 'Trans proline' 0 CA--C 1.559 1.757 0 C-N-CA 122.878 2.386 . . . . 73.34 112.021 172.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 26.1 m -109.68 156.1 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 122.918 0.487 . . . . 63.35 110.944 172.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 24.9 mm-40 -95.09 109.89 21.89 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 123.572 0.749 . . . . 72.12 109.827 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.473 HG22 HD11 ' A' ' 235' ' ' LEU . 8.7 t -104.25 117.52 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.663 0.785 . . . . 73.24 109.057 172.525 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -98.62 102.42 14.15 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 108.279 -1.008 . . . . 71.34 108.279 174.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.41 HG21 ' HA2' ' A' ' 207' ' ' GLY . 11.9 m -75.97 143.52 74.35 Favored Pre-proline 0 CA--C 1.551 1.011 0 N-CA-C 109.638 -0.504 . . . . 75.33 109.638 -176.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -64.46 140.68 70.62 Favored 'Trans proline' 0 C--N 1.368 1.587 0 C-N-CA 122.777 2.318 . . . . 70.04 112.34 174.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.9 129.38 34.63 Favored 'Trans proline' 0 C--N 1.376 1.992 0 C-N-CA 122.713 2.275 . . . . 53.31 111.337 171.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 64.3 mtm180 65.85 34.89 6.98 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 125.116 1.367 . . . . 74.43 110.988 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 5.7 t -66.64 164.55 16.6 Favored 'General case' 0 CA--C 1.549 0.919 0 N-CA-C 109.938 -0.393 . . . . 74.12 109.938 176.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -120.46 150.95 40.0 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.731 0.813 . . . . 75.52 109.697 -176.019 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -68.28 141.92 55.72 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.13 0.972 . . . . 60.23 110.727 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 91.11 -3.83 80.64 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-O 119.467 -0.629 . . . . 72.41 112.542 -176.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 41.1 mtp180 -72.01 161.3 31.12 Favored 'General case' 0 C--N 1.362 1.125 0 CA-C-O 122.16 0.981 . . . . 74.22 110.64 177.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -107.62 107.73 18.67 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 113.892 -1.503 . . . . 71.13 108.043 -173.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . 0.447 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 45.9 mt -100.38 98.31 8.96 Favored 'General case' 0 C--N 1.349 0.576 0 N-CA-C 107.328 -1.36 . . . . 73.03 107.328 175.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . 0.492 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 20.0 ttm180 -100.92 115.86 31.43 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.154 0.502 . . . . 74.12 110.698 -171.457 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.473 HD11 HG22 ' A' ' 221' ' ' VAL . 23.4 mt -96.06 117.75 31.3 Favored 'General case' 0 C--O 1.241 0.631 0 C-N-CA 124.159 0.983 . . . . 74.05 109.508 -176.02 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 49.8 mtmt -72.46 133.66 44.95 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.597 0.759 . . . . 74.31 111.151 -175.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 70.69 33.81 66.82 Favored Glycine 0 C--N 1.345 1.03 0 O-C-N 124.214 0.946 . . . . 64.14 112.954 176.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 72.7 mmtt -123.17 5.49 9.19 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.246 0.618 . . . . 72.13 111.958 178.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -85.51 -147.94 10.18 Favored Glycine 0 C--N 1.35 1.328 0 O-C-N 123.532 0.52 . . . . 72.03 112.952 177.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.489 ' CE1' ' HA ' ' A' ' 131' ' ' PHE . 16.2 m-85 -95.95 145.18 29.1 Favored Pre-proline 0 N--CA 1.478 0.931 0 C-N-CA 123.05 0.54 . . . . 75.14 111.589 173.435 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.72 156.53 39.82 Favored 'Trans proline' 0 C--N 1.375 1.968 0 C-N-CA 123.308 2.672 . . . . 72.34 112.468 173.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 173.92 -163.17 34.09 Favored Glycine 0 CA--C 1.535 1.335 0 CA-C-N 115.317 -0.856 . . . . 74.24 111.921 177.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.43 -16.49 43.31 Favored 'Trans proline' 0 C--N 1.379 2.179 0 C-N-CA 123.274 2.649 . . . . 62.33 112.912 -175.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -97.1 22.62 8.27 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.794 0.837 . . . . 63.05 111.222 177.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 79.93 -138.31 19.88 Favored Glycine 0 C--N 1.352 1.441 0 N-CA-C 110.699 -0.961 . . . . 51.31 110.699 -174.222 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 56.4 ttt180 -110.53 142.19 42.65 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 117.509 0.654 . . . . 72.03 109.648 171.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -77.76 -158.24 10.24 Favored Glycine 0 C--N 1.342 0.903 0 O-C-N 123.684 0.615 . . . . 64.12 112.945 177.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -128.52 170.58 13.02 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.803 0.841 . . . . 73.2 109.746 -172.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.644 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 15.7 tp -111.79 113.66 26.15 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.784 0.834 . . . . 73.31 109.806 171.424 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . 0.474 ' HB3' ' O ' ' A' ' 193' ' ' LEU . 2.9 t80 -88.42 108.06 19.18 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 107.567 -1.272 . . . . 74.14 107.567 174.202 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.525 HD21 ' HB2' ' A' ' 197' ' ' LEU . 52.3 mt -91.16 145.42 24.69 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 123.522 0.729 . . . . 73.34 110.744 170.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -107.63 101.95 11.23 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 107.161 -1.422 . . . . 75.24 107.161 167.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.3 p -62.38 128.25 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 CA-C-O 121.326 0.584 . . . . 72.34 110.115 177.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 9.9 mmm180 -125.72 94.33 4.09 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 107.195 -1.409 . . . . 75.42 107.195 -177.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.442 ' HA ' ' O ' ' A' ' 199' ' ' VAL . 67.2 mt -76.55 139.89 18.09 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 CA-C-N 115.364 -0.835 . . . . 73.12 110.379 -173.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.5 t . . . . . 0 CA--C 1.554 1.108 0 C-N-CA 123.781 0.832 . . . . 74.53 109.244 -175.429 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.6 tp . . . . . 0 N--CA 1.48 1.025 0 CA-C-O 121.523 0.678 . . . . 74.23 110.237 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 12.9 p 176.86 146.32 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-N 114.218 -1.356 . . . . 73.34 109.282 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -88.08 -78.53 0.32 Allowed 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 108.37 -0.974 . . . . 71.42 108.37 167.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 10.3 m170 -159.32 165.42 33.42 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 124.163 0.985 . . . . 64.3 109.92 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 84.2 t -64.02 136.35 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 O-C-N 124.052 0.845 . . . . 73.24 109.637 174.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 32.6 p . . . . . 0 CA--C 1.549 0.94 0 C-N-CA 123.716 0.806 . . . . 75.43 109.363 173.927 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 . . . . . 0 C--O 1.241 0.65 0 N-CA-C 108.878 -0.786 . . . . 73.23 108.878 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 30.3 mt -96.4 156.22 16.43 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 123.469 0.708 . . . . 74.11 109.19 -178.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.2 146.28 44.68 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.519 -1.289 . . . . 74.15 107.519 174.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -158.36 136.82 10.98 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 123.528 0.731 . . . . 71.32 109.787 -178.042 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -100.97 142.62 32.19 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.485 0.714 . . . . 72.34 109.718 -178.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -146.45 143.09 18.25 Favored Pre-proline 0 CA--C 1.552 1.049 0 C-N-CA 123.077 0.551 . . . . 71.23 110.565 174.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_exo -77.4 118.26 4.57 Favored 'Trans proline' 0 C--N 1.376 2.004 0 C-N-CA 122.97 2.447 . . . . 72.35 111.327 172.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.424 ' HG ' ' HB2' ' A' ' 129' ' ' GLU . 14.8 tp -108.62 155.59 20.51 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 123.75 0.82 . . . . 74.34 109.678 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.597 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 20.7 m -93.56 157.48 16.17 Favored 'General case' 0 CA--C 1.55 0.945 0 N-CA-C 109.363 -0.606 . . . . 74.11 109.363 174.235 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.477 HD12 ' O ' ' A' ' 183' ' ' HIS . 32.6 mt -58.22 -48.18 81.16 Favored 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 123.944 0.898 . . . . 74.25 110.382 178.786 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -54.25 -36.49 63.62 Favored 'General case' 0 C--O 1.218 -0.584 0 CA-C-N 113.796 -1.547 . . . . 73.44 110.736 176.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.597 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 7.5 mm-40 -79.6 -23.04 42.95 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.48 0.712 . . . . 74.14 111.411 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.738 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -63.0 -36.32 83.16 Favored 'General case' 0 C--O 1.244 0.793 0 CA-C-O 121.42 0.628 . . . . 74.41 110.304 167.334 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -81.31 -33.54 32.51 Favored 'General case' 0 CA--C 1.554 1.097 0 CA-C-N 114.709 -1.132 . . . . 75.22 111.972 176.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . 0.465 ' HB2' ' HA ' ' A' ' 129' ' ' GLU . 24.6 m80 -84.13 -40.96 17.58 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 112.631 0.604 . . . . 63.53 112.631 -173.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 72.16 -129.55 15.23 Favored Glycine 0 CA--C 1.536 1.389 0 N-CA-C 110.834 -0.907 . . . . 74.11 110.834 -166.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 134.97 140.2 4.19 Favored Glycine 0 N--CA 1.477 1.401 0 CA-C-N 117.805 0.802 . . . . 64.21 114.145 169.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -86.54 113.6 22.59 Favored 'General case' 0 C--N 1.357 0.91 0 N-CA-C 108.486 -0.931 . . . . 75.14 108.486 167.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -141.81 170.11 16.32 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.901 1.281 . . . . 73.12 108.314 175.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.507 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 14.7 p -95.18 143.3 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 118.639 0.654 . . . . 75.3 111.276 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 12.2 p -114.94 138.24 45.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 C-N-CA 123.833 0.853 . . . . 70.45 109.553 172.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -125.51 105.12 8.81 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 108.678 -0.86 . . . . 63.24 108.678 173.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.2 m -129.59 133.72 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 124.187 0.995 . . . . 74.02 110.042 -177.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.96 22.82 13.67 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 124.534 1.134 . . . . 73.44 111.313 -176.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.64 -6.7 79.6 Favored Glycine 0 C--N 1.354 1.538 0 CA-C-N 115.734 -0.666 . . . . 74.51 113.124 -176.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 53.4 ttt85 -94.81 119.67 33.77 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 123.632 0.773 . . . . 74.23 110.396 -175.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 20.6 ttp180 -105.07 109.63 21.69 Favored 'General case' 0 CA--C 1.552 1.024 0 C-N-CA 123.998 0.919 . . . . 74.44 110.797 -174.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 13.7 m -133.24 155.54 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 C-N-CA 124.708 1.203 . . . . 65.2 108.795 174.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.507 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 60.1 p -76.8 126.8 31.59 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 118.235 0.471 . . . . 55.41 110.684 -179.567 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.94 120.35 48.14 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.741 0 CA-C-O 121.827 0.822 . . . . 73.1 110.48 176.164 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 49.8 ttt180 -109.13 95.13 5.43 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 108.74 -0.837 . . . . 73.21 108.74 176.313 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 28.4 pt -93.66 119.78 66.8 Favored Pre-proline 0 CA--C 1.547 0.852 0 N-CA-C 107.913 -1.143 . . . . 73.34 107.913 171.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -76.64 163.17 32.08 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.352 2.035 . . . . 74.11 112.507 -177.403 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -54.76 142.68 73.17 Favored 'Trans proline' 0 C--N 1.375 1.963 0 C-N-CA 123.005 2.47 . . . . 72.34 112.372 171.188 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 108.66 38.31 1.92 Allowed Glycine 0 C--N 1.339 0.721 0 CA-C-N 116.773 -0.194 . . . . 72.33 113.037 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.738 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -108.66 163.07 6.23 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.359 0 N-CA-C 108.7 -0.852 . . . . 75.44 108.7 177.005 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.51 ' HB2' ' HB2' ' A' ' 157' ' ' SER . 25.1 mtp-105 -141.8 164.28 30.63 Favored 'General case' 0 N--CA 1.492 1.635 0 C-N-CA 123.963 0.905 . . . . 73.13 111.071 -165.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.1 tp10 -54.53 116.72 2.82 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.444 1.098 . . . . 71.1 111.226 165.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.27 4.68 90.11 Favored Glycine 0 C--N 1.357 1.706 0 CA-C-N 116.04 -0.527 . . . . 70.34 113.166 178.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.51 ' HB2' ' HB2' ' A' ' 154' ' ' ARG . 30.1 t -79.21 124.2 28.13 Favored 'General case' 0 C--O 1.25 1.11 0 N-CA-C 109.026 -0.731 . . . . 74.13 109.026 -179.686 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.42 HG11 HD23 ' A' ' 175' ' ' LEU . 20.0 t -99.05 120.68 48.71 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 CA-C-N 114.298 -1.319 . . . . 72.4 107.886 -177.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.48 HD11 HG23 ' A' ' 153' ' ' VAL . 13.0 mt -101.86 122.01 53.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 123.533 0.733 . . . . 72.2 110.15 -168.697 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 74.2 ttt180 -86.31 103.25 14.72 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 123.317 0.647 . . . . 74.34 109.908 177.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.441 HG22 ' O ' ' A' ' 174' ' ' LEU . 16.4 m -107.59 104.92 54.65 Favored Pre-proline 0 CA--C 1.564 1.5 0 C-N-CA 122.608 0.363 . . . . 74.11 110.027 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -67.41 140.69 53.47 Favored 'Trans proline' 0 C--N 1.375 1.954 0 C-N-CA 122.82 2.346 . . . . 74.45 113.332 -173.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 105.04 -9.97 47.32 Favored Glycine 0 C--N 1.349 1.282 0 N-CA-C 114.868 0.707 . . . . 61.44 114.868 170.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.4 mpt? -81.9 -61.35 1.94 Allowed 'General case' 0 N--CA 1.482 1.135 0 CA-C-N 117.815 0.807 . . . . 74.41 110.157 176.096 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.345 1.073 0 CA-C-N 115.345 -0.843 . . . . 74.35 111.785 176.709 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo . . . . . 0 CA--C 1.541 0.866 0 N-CA-C 111.683 -0.16 . . . . 70.41 111.683 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -80.97 -132.26 1.2 Allowed Glycine 0 C--N 1.34 0.764 0 N-CA-C 111.498 -0.641 . . . . 74.03 111.498 175.177 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -163.81 177.79 8.35 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.205 0.526 . . . . 71.42 110.885 -175.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.441 ' O ' HG22 ' A' ' 161' ' ' VAL . 15.0 tp -129.32 122.57 29.83 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 108.571 -0.9 . . . . 75.21 108.571 173.527 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.42 HD23 HG11 ' A' ' 158' ' ' VAL . 49.8 mt -88.11 99.41 12.17 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.139 -0.937 . . . . 73.32 110.927 179.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 74.9 mt -87.44 105.34 17.22 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 123.011 0.524 . . . . 74.33 110.748 175.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.8 t -85.49 104.45 13.37 Favored 'Isoleucine or valine' 0 C--O 1.242 0.697 0 N-CA-C 108.23 -1.026 . . . . 73.12 108.23 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.447 HG21 HG22 ' A' ' 153' ' ' VAL . 25.3 m -83.95 144.79 9.25 Favored 'Isoleucine or valine' 0 C--O 1.251 1.136 0 CA-C-O 121.481 0.657 . . . . 74.11 110.367 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 13.5 mmm180 -118.53 99.3 6.72 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 107.068 -1.456 . . . . 74.42 107.068 -178.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.418 HD21 ' HB3' ' A' ' 125' ' ' LEU . 29.5 mt -67.56 146.1 54.24 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 118.314 0.507 . . . . 73.41 110.303 177.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.454 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 73.1 mt -55.27 154.51 11.06 Favored Pre-proline 0 CA--C 1.553 1.063 0 O-C-N 124.489 1.118 . . . . 74.04 112.839 -170.337 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -66.81 0.38 3.72 Favored 'Trans proline' 0 C--N 1.381 2.287 0 C-N-CA 123.081 2.52 . . . . 74.41 112.808 171.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . 0.477 ' O ' HD12 ' A' ' 127' ' ' LEU . 14.7 t60 -95.55 99.21 4.41 Favored Pre-proline 0 CA--C 1.541 0.611 0 C-N-CA 124.974 1.31 . . . . 72.43 107.582 162.721 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -103.64 123.67 0.07 OUTLIER 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 123.135 2.557 . . . . 72.04 112.413 168.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -120.68 -43.58 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 107.74 -1.207 . . . . 72.44 107.74 171.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -113.64 126.31 55.12 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 114.674 -1.148 . . . . 73.43 110.144 176.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 36.5 ttp85 -119.41 127.04 52.74 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 108.51 -0.922 . . . . 71.44 108.51 172.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.414 HD11 ' O ' ' A' ' 192' ' ' ASP . 56.0 tp -90.18 132.53 35.42 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 108.359 -0.978 . . . . 75.22 108.359 170.461 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -144.48 130.1 19.07 Favored 'General case' 0 C--O 1.241 0.642 0 N-CA-C 109.621 -0.511 . . . . 74.12 109.621 173.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 70.95 -75.78 0.59 Allowed Glycine 0 C--N 1.35 1.346 0 O-C-N 124.003 0.814 . . . . 63.52 111.871 -175.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . 0.493 ' HB2' ' O ' ' A' ' 240' ' ' PHE . 3.7 pt20 -157.6 -10.49 0.08 Allowed 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 124.118 0.967 . . . . 61.41 110.846 174.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . 0.414 ' O ' HD11 ' A' ' 188' ' ' LEU . 80.3 m-20 -96.31 162.96 13.28 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 123.014 0.526 . . . . 62.12 110.942 -175.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.481 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.2 mt -106.9 155.91 19.25 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 107.704 -1.221 . . . . 73.15 107.704 -178.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -137.15 121.8 18.53 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 108.642 -0.873 . . . . 70.24 108.642 -175.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . 0.471 ' HB2' HD22 ' A' ' 251' ' ' LEU . . . -142.63 162.12 36.29 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.697 0.799 . . . . 72.12 110.221 -178.603 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 196' ' ' THR . . . . . 0.504 ' HA ' ' HB3' ' A' ' 252' ' ' GLU . 36.0 m -109.08 119.37 39.34 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 109.018 -0.734 . . . . 71.23 109.018 174.794 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.502 HD22 HD13 ' A' ' 251' ' ' LEU . 55.1 tp -106.84 110.13 22.21 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 109.17 -0.678 . . . . 71.32 109.17 178.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -89.83 127.56 36.0 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 107.804 -1.184 . . . . 70.2 107.804 172.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . 0.499 HG13 HG13 ' A' ' 210' ' ' VAL . 15.4 m -119.99 139.83 28.87 Favored Pre-proline 0 C--O 1.244 0.78 0 N-CA-C 109.097 -0.705 . . . . 71.03 109.097 -178.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -60.05 143.99 99.51 Favored 'Trans proline' 0 C--N 1.367 1.522 0 C-N-CA 122.073 1.849 . . . . 75.14 111.085 174.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -53.44 -45.69 98.41 Favored Pre-proline 0 CA--C 1.555 1.165 0 CA-C-O 118.359 -0.829 . . . . 75.13 113.046 177.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -55.62 -42.33 68.8 Favored 'Trans proline' 0 C--N 1.39 2.755 0 C-N-CA 122.106 1.871 . . . . 74.34 113.261 172.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 4.0 mt -65.84 -43.6 93.12 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 C-N-CA 122.63 0.372 . . . . 74.43 111.256 176.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -58.56 -44.72 89.79 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 123.057 0.543 . . . . 74.11 111.451 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . 0.473 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 33.4 m -77.39 -40.28 28.83 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 CA-C-N 115.745 -0.661 . . . . 74.55 112.081 -175.542 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.0 m -81.13 -20.72 11.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 119.1 0.863 . . . . 63.24 111.188 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.585 ' HA2' HG22 ' A' ' 223' ' ' VAL . . . 80.09 48.45 6.48 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-N 115.985 -0.552 . . . . 73.32 112.179 -175.837 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.27 -174.0 49.41 Favored Glycine 0 C--N 1.351 1.375 0 CA-C-O 121.37 0.428 . . . . 61.23 112.945 -177.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 222' ' ' ALA . 20.5 pttm -114.17 134.71 54.72 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.385 1.074 . . . . 74.31 109.797 -176.106 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . 0.499 HG13 HG13 ' A' ' 199' ' ' VAL . 7.6 p -133.71 157.23 42.13 Favored 'Isoleucine or valine' 0 C--O 1.241 0.608 0 C-N-CA 124.552 1.141 . . . . 75.24 108.494 -175.317 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 59.2 mmt-85 -91.55 128.93 37.57 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 109.489 -0.56 . . . . 73.43 109.489 178.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -102.72 122.09 43.76 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 108.643 -0.873 . . . . 75.35 108.643 171.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 5.6 tpt -74.04 104.66 4.95 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.732 0.813 . . . . 74.3 109.574 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 10.1 t -110.82 170.76 7.88 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 123.452 0.701 . . . . 65.31 110.623 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 62.4 mt -73.89 -2.2 22.83 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.022 0.929 . . . . 73.14 112.481 -175.233 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -114.82 -0.22 13.57 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 123.743 0.817 . . . . 73.24 112.17 174.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 133.25 -154.15 21.08 Favored Glycine 0 N--CA 1.48 1.597 0 CA-C-O 119.269 -0.74 . . . . 73.22 112.818 177.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -89.9 134.12 2.18 Favored 'Trans proline' 0 CA--C 1.554 1.49 0 C-N-CA 122.92 2.413 . . . . 74.11 112.259 172.083 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.1 m -113.79 158.15 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 CA-C-O 121.014 0.435 . . . . 73.11 111.74 175.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -96.75 104.54 16.54 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 114.966 -1.015 . . . . 74.12 108.429 -177.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.409 ' HB ' HD12 ' A' ' 235' ' ' LEU . 2.8 p -118.84 113.51 41.84 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 CA-C-O 121.437 0.637 . . . . 74.44 109.928 177.461 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 209' ' ' LYS . . . -97.28 118.69 34.3 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 108.759 -0.83 . . . . 75.34 108.759 178.061 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.585 HG22 ' HA2' ' A' ' 207' ' ' GLY . 18.2 m -72.96 148.04 88.96 Favored Pre-proline 0 CA--C 1.555 1.152 0 N-CA-C 109.523 -0.547 . . . . 75.14 109.523 176.029 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.0 151.98 73.31 Favored 'Trans proline' 0 CA--C 1.559 1.753 0 C-N-CA 122.173 1.915 . . . . 74.01 112.019 173.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -52.07 119.68 6.09 Favored 'Trans proline' 0 C--N 1.383 2.365 0 C-N-CA 123.646 2.898 . . . . 75.51 112.801 177.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . 0.473 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 48.6 mtm180 54.34 58.11 5.25 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 124.488 1.115 . . . . 72.55 110.668 -174.612 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 10.7 t -66.22 169.29 7.33 Favored 'General case' 0 CA--C 1.545 0.761 0 CA-C-N 115.539 -0.755 . . . . 63.13 109.506 173.079 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.8 mp0 -121.33 144.13 48.81 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 123.035 0.534 . . . . 74.11 109.83 -175.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -67.2 119.67 12.48 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-N 115.212 -0.904 . . . . 63.02 108.822 173.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.33 -12.06 19.26 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-O 119.65 -0.528 . . . . 71.45 112.315 -174.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 58.2 mtp180 -74.14 160.9 30.58 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 117.2 0.5 . . . . 74.14 110.604 174.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.411 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.3 mppt? -128.55 120.57 26.97 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.77 0.428 . . . . 74.11 110.676 -175.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . 0.452 HD12 HG13 ' A' ' 223' ' ' VAL . 59.6 mt -97.59 112.88 24.56 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 108.697 -0.853 . . . . 73.54 108.697 -178.248 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . 0.523 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 39.5 ttt85 -98.6 104.61 16.67 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 116.014 -0.539 . . . . 73.53 110.015 -172.211 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.469 HD11 HD23 ' A' ' 249' ' ' LEU . 27.3 mt -91.63 107.2 19.04 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.671 0.788 . . . . 74.14 109.156 -177.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 6.8 mtpm? -77.25 144.1 38.45 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 112.273 0.471 . . . . 71.51 112.273 -173.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 85.38 35.92 11.45 Favored Glycine 0 C--N 1.349 1.266 0 O-C-N 123.769 0.668 . . . . 74.22 112.323 -177.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 34.9 mmtm -125.61 -41.16 2.02 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 122.86 0.464 . . . . 74.22 112.184 -176.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -83.85 -178.04 51.69 Favored Glycine 0 C--N 1.337 0.62 0 C-N-CA 121.609 -0.329 . . . . 73.21 112.28 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.493 ' O ' ' HB2' ' A' ' 191' ' ' GLN . 72.5 m-85 -94.93 157.91 35.88 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 123.307 0.643 . . . . 75.11 111.77 -174.122 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -52.42 150.48 20.5 Favored 'Trans proline' 0 C--N 1.381 2.283 0 C-N-CA 123.254 2.636 . . . . 75.31 114.002 175.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 179.01 -159.54 24.5 Favored Glycine 0 CA--C 1.535 1.293 0 CA-C-O 119.516 -0.602 . . . . 71.5 113.099 -176.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -62.92 -34.34 71.85 Favored 'Trans proline' 0 C--N 1.375 1.925 0 C-N-CA 123.925 3.083 . . . . 72.52 114.217 -171.163 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.89 22.81 4.0 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.342 0.657 . . . . 73.01 111.289 178.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.97 -96.56 2.14 Favored Glycine 0 C--N 1.347 1.191 0 N-CA-C 111.192 -0.763 . . . . 63.43 111.192 179.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 42.1 ttt-85 -115.65 144.69 43.55 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 123.558 0.743 . . . . 75.43 109.09 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -80.26 168.99 52.37 Favored Glycine 0 C--O 1.253 1.297 0 O-C-N 123.604 0.565 . . . . 62.44 112.899 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 55.4 m-20 -139.57 171.97 13.48 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.342 1.057 . . . . 74.53 108.915 -173.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.523 ' O ' ' HA ' ' A' ' 234' ' ' ARG . 15.5 tp -98.44 128.92 45.02 Favored 'General case' 0 C--O 1.21 -0.974 0 C-N-CA 123.101 0.56 . . . . 73.3 109.761 177.129 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 53.8 t80 -111.47 102.62 10.97 Favored 'General case' 0 CA--C 1.551 1.01 0 N-CA-C 107.49 -1.3 . . . . 71.22 107.49 -178.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.502 HD13 HD22 ' A' ' 197' ' ' LEU . 90.3 mt -87.54 150.61 23.61 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.996 0.919 . . . . 74.44 112.688 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.504 ' HB3' ' HA ' ' A' ' 196' ' ' THR . 14.0 tp10 -105.62 98.09 7.83 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 123.494 0.717 . . . . 74.41 109.314 173.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 80.3 t -56.98 112.5 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 123.205 0.602 . . . . 61.33 111.019 174.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 49.3 mmm-85 -119.07 96.06 5.07 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 125.033 1.333 . . . . 75.15 108.069 177.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 58.8 mt -75.5 128.18 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 N-CA-C 109.561 -0.533 . . . . 75.43 109.561 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.249 1.028 0 C-N-CA 124.574 1.15 . . . . 75.34 107.911 -176.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.618 ' HB2' ' HB3' ' A' ' 136' ' ' ARG . 33.4 tp . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 109.379 -0.6 . . . . 75.43 109.379 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.424 HG22 HD21 ' A' ' 123' ' ' LEU . 24.0 t -89.6 150.93 3.57 Favored 'Isoleucine or valine' 0 C--O 1.239 0.502 0 C-N-CA 124.454 1.102 . . . . 73.54 109.14 172.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -77.23 -51.06 11.57 Favored 'General case' 0 CA--C 1.54 0.579 0 O-C-N 123.713 0.633 . . . . 64.21 109.484 175.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 46.5 p-80 -179.2 177.13 0.8 Allowed 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 124.864 1.266 . . . . 71.24 109.535 -175.126 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.501 HG13 HD11 ' A' ' 119' ' ' LEU . 29.5 m -78.51 155.12 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 C-N-CA 122.683 0.393 . . . . 72.33 111.366 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.0 t . . . . . 0 CA--C 1.546 0.799 0 CA-C-O 122.402 1.096 . . . . 71.42 109.226 179.354 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 . . . . . 0 C--O 1.241 0.655 0 N-CA-C 108.452 -0.944 . . . . 72.14 108.452 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.501 HD11 HG13 ' A' ' 102' ' ' VAL . 4.5 mm? -96.19 159.69 14.82 Favored 'General case' 0 N--CA 1.464 0.25 0 C-N-CA 124.129 0.972 . . . . 73.31 109.418 176.008 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 23.1 ptt180 -141.95 121.12 12.99 Favored 'General case' 0 C--O 1.241 0.649 0 N-CA-C 109.322 -0.622 . . . . 75.24 109.322 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -145.69 129.43 17.17 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 124.232 1.013 . . . . 73.31 109.446 -173.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.728 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 43.5 mt-10 -105.05 138.54 41.09 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 123.721 0.808 . . . . 71.5 109.228 178.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.471 HD22 HG13 ' A' ' 178' ' ' VAL . 1.8 pt? -135.64 141.52 37.47 Favored Pre-proline 0 N--CA 1.474 0.747 0 N-CA-C 110.033 -0.358 . . . . 75.41 110.033 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -73.38 113.27 3.73 Favored 'Trans proline' 0 C--N 1.368 1.586 0 C-N-CA 122.217 1.944 . . . . 64.53 109.924 171.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.544 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 11.9 tp -122.67 147.73 46.11 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 106.27 -1.752 . . . . 74.33 106.27 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 8.9 t -107.24 172.95 6.54 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 119.455 1.025 . . . . 74.1 110.491 175.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.458 HD21 HD12 ' A' ' 180' ' ' LEU . 31.4 mt -55.38 -46.17 76.52 Favored 'General case' 0 N--CA 1.47 0.533 0 O-C-N 124.561 1.163 . . . . 71.12 109.949 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -51.66 -40.79 60.66 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 113.969 -1.469 . . . . 72.12 111.263 177.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.502 ' HB2' ' HG ' ' A' ' 125' ' ' LEU . 22.8 mm-40 -83.31 -24.02 32.33 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.195 0.598 . . . . 74.43 111.193 -178.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.412 ' HA ' ' CG1' ' A' ' 153' ' ' VAL . . . -59.78 -32.97 71.1 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 123.117 0.567 . . . . 75.53 111.645 167.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.3 t80 -77.72 -53.53 7.43 Favored 'General case' 0 C--N 1.351 0.636 0 CA-C-N 116.167 -0.47 . . . . 72.45 111.062 171.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -60.36 -45.85 92.04 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 123.552 0.532 . . . . 72.32 111.728 -172.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 59.53 -125.28 38.91 Favored Glycine 0 C--N 1.349 1.257 0 O-C-N 123.881 0.738 . . . . 65.51 111.378 -178.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.01 169.83 29.66 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 114.009 0.364 . . . . 64.44 114.009 166.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.414 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.6 mp0 -88.08 126.82 35.31 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 107.443 -1.318 . . . . 73.41 107.443 172.38 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.618 ' HB3' ' HB2' ' A' ' 98' ' ' LEU . 6.6 tpt180 -154.83 134.0 12.42 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 108.87 -0.789 . . . . 75.43 108.87 -177.221 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.677 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 10.9 p -74.75 143.38 13.47 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 C-N-CA 123.103 0.561 . . . . 64.22 112.477 -168.287 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.437 HG13 ' HB3' ' A' ' 98' ' ' LEU . 5.0 m -128.66 161.56 37.35 Favored 'Isoleucine or valine' 0 C--O 1.247 0.956 0 C-N-CA 124.458 1.103 . . . . 63.0 110.258 178.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 46.4 mm-40 -111.09 111.32 22.34 Favored 'General case' 0 C--O 1.238 0.499 0 C-N-CA 123.954 0.902 . . . . 71.54 109.419 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.437 HG21 HD23 ' A' ' 174' ' ' LEU . 45.2 t -138.27 119.89 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 123.503 0.721 . . . . 74.25 110.628 178.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 64.05 21.78 12.7 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 124.785 1.234 . . . . 63.13 112.94 171.105 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.19 14.12 77.49 Favored Glycine 0 C--N 1.349 1.251 0 CA-C-N 116.702 -0.226 . . . . 74.0 112.729 -176.159 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? -110.78 118.5 36.31 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.422 1.089 . . . . 74.25 108.152 176.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 54.2 ttp180 -87.1 106.33 17.79 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 107.694 -1.224 . . . . 73.32 107.694 174.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 8.1 m -136.01 135.78 50.13 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 123.541 0.737 . . . . 72.42 110.429 -172.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.677 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 35.9 t -83.51 128.28 34.39 Favored 'General case' 0 C--O 1.241 0.616 0 C-N-CA 123.371 0.668 . . . . 71.21 109.679 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.523 HG12 HG13 ' A' ' 161' ' ' VAL . 99.0 t -99.65 125.98 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 123.577 0.751 . . . . 74.4 110.469 177.482 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . 0.414 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 74.4 ttt180 -99.08 104.23 16.22 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 123.844 0.857 . . . . 74.03 109.483 172.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.498 HG23 HG21 ' A' ' 159' ' ' ILE . 28.3 pt -107.54 118.11 54.14 Favored Pre-proline 0 CA--C 1.55 0.969 0 N-CA-C 108.598 -0.89 . . . . 72.51 108.598 169.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -67.09 152.15 80.48 Favored 'Trans proline' 0 C--N 1.379 2.14 0 C-N-CA 122.668 2.245 . . . . 75.31 113.107 -175.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_exo -49.2 113.7 1.02 Allowed 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 123.609 2.873 . . . . 73.43 112.662 170.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 129.94 65.37 0.1 Allowed Glycine 0 C--N 1.342 0.911 0 CA-C-N 116.319 -0.401 . . . . 75.34 112.208 177.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.5 HG23 HD13 ' A' ' 159' ' ' ILE . 3.9 p -129.72 159.96 41.22 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.51 0 C-N-CA 123.15 0.58 . . . . 74.4 109.529 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 29.9 mtp-105 -136.79 168.31 19.78 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 123.8 0.84 . . . . 73.32 111.292 -164.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -57.1 121.64 10.52 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.403 1.081 . . . . 73.44 111.333 171.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.62 9.9 86.66 Favored Glycine 0 C--N 1.35 1.339 0 O-C-N 123.832 0.708 . . . . 73.25 113.21 178.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 30.3 t -73.39 122.89 22.79 Favored 'General case' 0 C--N 1.356 0.881 0 C-N-CA 123.165 0.586 . . . . 64.54 109.468 -177.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.435 HG12 HD21 ' A' ' 175' ' ' LEU . 11.3 t -99.46 116.25 42.19 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 O-C-N 124.399 1.062 . . . . 73.33 108.485 -178.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.5 HD13 HG23 ' A' ' 153' ' ' VAL . 18.1 mt -107.66 113.42 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 123.665 0.786 . . . . 73.54 110.247 -170.79 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 26.8 ttm180 -89.59 113.28 24.69 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 123.346 0.658 . . . . 74.04 110.878 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.523 HG13 HG12 ' A' ' 147' ' ' VAL . 22.5 m -109.48 99.48 37.34 Favored Pre-proline 0 CA--C 1.564 1.51 0 N-CA-C 109.603 -0.517 . . . . 74.24 109.603 176.333 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -69.62 150.31 68.87 Favored 'Trans proline' 0 C--N 1.377 2.058 0 C-N-CA 123.298 2.665 . . . . 74.3 113.501 -172.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.32 10.37 86.26 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-N 115.383 -0.826 . . . . 75.12 113.656 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.455 ' HE3' HG22 ' A' ' 147' ' ' VAL . 58.4 mtp -114.82 -20.48 10.58 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.365 0.666 . . . . 71.24 112.419 -173.473 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.342 0.867 0 CA-C-O 119.755 -0.469 . . . . 74.35 112.067 177.061 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo . . . . . 0 CA--C 1.544 0.976 0 N-CA-C 111.56 -0.208 . . . . 74.52 111.56 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -90.98 160.23 27.17 Favored Glycine 0 C--N 1.334 0.46 0 N-CA-C 110.063 -1.215 . . . . 52.41 110.063 170.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -120.03 176.95 5.18 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.012 0.525 . . . . 74.35 110.446 -174.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.437 HD23 HG21 ' A' ' 140' ' ' VAL . 19.5 tp -128.06 115.95 19.25 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 115.34 -0.846 . . . . 74.11 109.304 172.424 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.435 HD21 HG12 ' A' ' 158' ' ' VAL . 88.9 mt -87.87 105.69 17.6 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 125.164 1.386 . . . . 74.22 110.852 179.28 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 36.6 mt -95.91 108.06 20.39 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 123.079 0.551 . . . . 74.51 111.037 177.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.728 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 19.7 t -90.78 99.9 10.32 Favored 'Isoleucine or valine' 0 C--O 1.242 0.71 0 N-CA-C 107.957 -1.127 . . . . 75.14 107.957 174.054 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.471 HG13 HD22 ' A' ' 123' ' ' LEU . 4.3 m -82.21 141.48 14.97 Favored 'Isoleucine or valine' 0 C--O 1.245 0.833 0 N-CA-C 109.054 -0.721 . . . . 75.33 109.054 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 16.1 mmm-85 -119.54 104.98 10.78 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.669 -1.234 . . . . 75.15 107.669 -175.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.544 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 61.2 mt -68.87 147.43 51.71 Favored 'General case' 0 CA--C 1.545 0.763 0 O-C-N 123.506 0.504 . . . . 75.31 111.009 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.448 ' HB2' ' HB3' ' A' ' 183' ' ' HIS . 27.7 mt -63.64 168.78 4.96 Favored Pre-proline 0 CA--C 1.56 1.33 0 C-N-CA 124.07 0.948 . . . . 71.42 111.098 -174.361 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -75.76 43.01 1.02 Allowed 'Trans proline' 0 C--N 1.381 2.243 0 C-N-CA 122.885 2.39 . . . . 71.45 111.601 162.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . 0.448 ' HB3' ' HB2' ' A' ' 181' ' ' LEU . 8.2 t60 -125.27 95.48 41.23 Favored Pre-proline 0 CA--C 1.532 0.281 0 N-CA-C 105.88 -1.896 . . . . 73.45 105.88 -178.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -100.75 123.76 0.11 Allowed 'Trans proline' 0 CA--C 1.554 1.525 0 C-N-CA 122.636 2.224 . . . . 63.5 113.052 176.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.431 HG13 HD13 ' A' ' 127' ' ' LEU . 4.1 p -144.75 -42.04 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 N-CA-C 108.855 -0.794 . . . . 72.11 108.855 175.135 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -126.96 154.93 43.91 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.387 1.075 . . . . 73.24 110.208 174.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 18.6 ttp85 -156.25 142.8 18.55 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 123.221 0.608 . . . . 65.12 109.564 178.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.435 HD11 ' HD1' ' A' ' 240' ' ' PHE . 56.6 tp -104.63 140.61 37.78 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.762 0.825 . . . . 74.44 110.27 178.186 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -139.64 111.49 7.35 Favored 'General case' 0 C--O 1.246 0.877 0 N-CA-C 107.191 -1.411 . . . . 75.03 107.191 168.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 74.66 -80.93 0.88 Allowed Glycine 0 C--N 1.347 1.171 0 O-C-N 123.558 0.536 . . . . 64.2 112.611 177.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . 0.405 ' HB3' ' HA3' ' A' ' 242' ' ' GLY . 9.3 pt20 -138.39 -23.04 1.0 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 124.068 0.947 . . . . 53.23 110.168 176.302 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . 0.411 ' O ' HD12 ' A' ' 188' ' ' LEU . 0.6 OUTLIER -89.6 157.59 17.98 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 123.832 0.853 . . . . 64.25 110.884 -173.046 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.578 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.7 mt -108.62 166.88 10.46 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 124.75 1.22 . . . . 73.33 109.508 -177.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -142.78 122.1 13.07 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 107.135 -1.432 . . . . 74.33 107.135 -178.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . 0.407 ' HB1' HD21 ' A' ' 251' ' ' LEU . . . -148.19 152.18 36.8 Favored 'General case' 0 CA--C 1.518 -0.285 0 C-N-CA 123.823 0.849 . . . . 75.12 110.459 -174.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 7.4 m -100.94 120.87 40.8 Favored 'General case' 0 CA--C 1.541 0.604 0 O-C-N 124.025 0.828 . . . . 74.41 109.389 176.294 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.505 HD22 HD12 ' A' ' 251' ' ' LEU . 66.0 tp -107.53 111.89 24.37 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.839 0.856 . . . . 75.54 109.467 -179.346 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -95.28 119.14 33.27 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.399 0.68 . . . . 75.41 109.259 176.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . 0.513 HG12 HG13 ' A' ' 223' ' ' VAL . 6.0 m -122.99 139.97 32.53 Favored Pre-proline 0 N--CA 1.475 0.8 0 C-N-CA 123.37 0.668 . . . . 73.23 109.267 -178.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_exo -59.31 144.37 99.42 Favored 'Trans proline' 0 C--N 1.372 1.793 0 C-N-CA 122.745 2.297 . . . . 64.52 111.81 171.411 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . 0.411 ' HA ' HG22 ' A' ' 255' ' ' ILE . . . -55.67 -44.63 99.76 Favored Pre-proline 0 CA--C 1.554 1.12 0 CA-C-O 117.963 -1.018 . . . . 53.51 111.991 177.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -48.61 -51.3 10.58 Favored 'Trans proline' 0 C--N 1.399 3.232 0 C-N-CA 122.537 2.158 . . . . 73.1 112.865 169.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 4.3 mt -62.44 -38.84 82.33 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.078 0 C-N-CA 123.202 0.601 . . . . 72.24 111.03 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.45 -44.41 96.47 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.17 0.588 . . . . 61.05 112.06 -178.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.3 m -78.55 -39.39 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-N 116.004 -0.543 . . . . 73.4 111.426 -174.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.1 m -82.9 -20.8 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 122.434 0.294 . . . . 74.44 111.284 -179.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.426 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 72.6 68.16 1.66 Allowed Glycine 0 C--N 1.343 0.932 0 N-CA-C 111.324 -0.711 . . . . 60.54 111.324 -175.531 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -92.87 -164.49 37.85 Favored Glycine 0 C--N 1.352 1.472 0 N-CA-C 111.482 -0.647 . . . . 74.11 111.482 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -115.11 139.17 50.12 Favored 'General case' 0 C--O 1.241 0.647 0 C-N-CA 123.554 0.742 . . . . 73.32 109.146 -178.05 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . 0.531 HG21 HG11 ' A' ' 221' ' ' VAL . 6.6 m -134.39 149.22 29.77 Favored 'Isoleucine or valine' 0 C--O 1.24 0.589 0 C-N-CA 123.876 0.87 . . . . 63.52 109.073 177.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . 0.412 ' H ' ' HD2' ' A' ' 211' ' ' ARG . 0.2 OUTLIER -104.87 125.9 51.38 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 108.116 -1.068 . . . . 74.11 108.116 174.874 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.446 ' HB3' HD13 ' A' ' 197' ' ' LEU . . . -99.89 129.2 45.95 Favored 'General case' 0 C--O 1.245 0.843 0 N-CA-C 108.792 -0.818 . . . . 75.31 108.792 -175.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 6.1 tpt -71.47 102.6 2.71 Favored 'General case' 0 CA--C 1.537 0.452 0 O-C-N 124.198 0.936 . . . . 73.21 109.4 -178.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 214' ' ' THR . . . . . 0.426 HG22 HG13 ' A' ' 219' ' ' VAL . 10.0 t -110.95 166.75 10.78 Favored 'General case' 0 C--O 1.238 0.451 0 CA-C-O 121.62 0.724 . . . . 72.33 110.694 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . 0.458 HD11 ' O ' ' A' ' 127' ' ' LEU . 25.9 mt -66.59 -19.04 65.68 Favored 'General case' 0 CA--C 1.545 0.765 0 CA-C-N 114.634 -1.166 . . . . 73.51 110.88 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -87.48 -21.7 25.35 Favored 'General case' 0 CA--C 1.558 1.263 0 C-N-CA 125.609 1.564 . . . . 63.12 111.797 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 139.39 -146.91 18.71 Favored Glycine 0 C--N 1.352 1.431 0 CA-C-O 119.157 -0.802 . . . . 71.42 111.583 -169.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -93.51 133.79 0.94 Allowed 'Trans proline' 0 CA--C 1.557 1.666 0 C-N-CA 122.373 2.049 . . . . 73.03 112.276 165.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . 0.426 HG13 HG22 ' A' ' 214' ' ' THR . 16.5 m -108.97 143.25 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 C-N-CA 122.934 0.494 . . . . 64.1 110.453 171.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -91.37 108.9 20.21 Favored 'General case' 0 CA--C 1.542 0.649 0 CA-C-O 121.524 0.678 . . . . 73.55 109.598 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.531 HG11 HG21 ' A' ' 210' ' ' VAL . 2.6 p -119.19 127.15 75.85 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.761 0 C-N-CA 123.55 0.74 . . . . 72.1 110.557 173.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -96.88 120.21 36.79 Favored 'General case' 0 C--O 1.238 0.453 0 C-N-CA 123.982 0.913 . . . . 71.31 109.215 177.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.513 HG13 HG12 ' A' ' 199' ' ' VAL . 11.5 m -82.65 141.85 45.26 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 109.631 -0.507 . . . . 63.14 109.631 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -63.74 141.07 77.37 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 122.752 2.302 . . . . 74.12 112.202 175.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -62.12 125.31 16.13 Favored 'Trans proline' 0 C--N 1.37 1.693 0 C-N-CA 122.513 2.142 . . . . 73.31 111.076 173.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 56.6 mtm180 64.77 50.21 2.08 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 124.951 1.407 . . . . 74.34 109.993 -172.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.0 t -79.5 169.7 17.66 Favored 'General case' 0 CA--C 1.546 0.804 0 CA-C-N 115.862 -0.608 . . . . 63.42 109.619 172.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . 0.524 ' H ' ' HD3' ' A' ' 231' ' ' ARG . 26.3 mp0 -125.04 142.09 51.71 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 123.808 0.843 . . . . 73.35 109.373 -172.605 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.66 119.39 13.83 Favored 'General case' 0 C--N 1.348 0.515 0 C-N-CA 123.469 0.708 . . . . 74.43 109.221 175.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.75 -7.08 22.17 Favored Glycine 0 C--N 1.34 0.793 0 CA-C-N 116.156 -0.475 . . . . 73.51 111.999 -171.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . 0.524 ' HD3' ' H ' ' A' ' 228' ' ' GLN . 75.2 mtp180 -81.94 160.94 23.24 Favored 'General case' 0 C--N 1.354 0.761 0 C-N-CA 122.766 0.426 . . . . 73.1 110.416 173.479 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.436 ' HG2' ' CE1' ' A' ' 250' ' ' TYR . 2.7 mppt? -122.23 135.59 54.78 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.267 0.627 . . . . 74.41 110.35 -175.727 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 61.8 mt -112.19 104.74 12.95 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 107.697 -1.223 . . . . 72.51 107.697 175.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . 0.543 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 50.3 ttt180 -94.14 109.04 20.84 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 115.682 -0.69 . . . . 74.13 109.622 -173.341 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.469 HD13 HD21 ' A' ' 249' ' ' LEU . 18.5 mt -85.95 128.11 34.77 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 122.838 0.455 . . . . 74.43 110.219 -175.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 50.0 mtmt -71.04 122.14 19.5 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.449 1.1 . . . . 73.11 111.762 -167.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.58 16.98 70.37 Favored Glycine 0 C--N 1.351 1.385 0 O-C-N 123.793 0.683 . . . . 55.11 114.02 172.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -94.9 7.28 46.51 Favored 'General case' 0 N--CA 1.48 1.049 0 N-CA-C 112.49 0.552 . . . . 75.32 112.49 -174.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -95.62 -170.84 35.9 Favored Glycine 0 C--N 1.34 0.789 0 O-C-N 123.553 0.533 . . . . 62.2 112.347 175.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.435 ' HD1' HD11 ' A' ' 188' ' ' LEU . 60.3 m-85 -85.95 159.88 53.57 Favored Pre-proline 0 CA--C 1.544 0.733 0 C-N-CA 123.578 0.751 . . . . 75.11 111.107 -176.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -52.97 127.94 26.94 Favored 'Trans proline' 0 C--N 1.391 2.812 0 C-N-CA 122.713 2.276 . . . . 71.4 112.221 176.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . 0.405 ' HA3' ' HB3' ' A' ' 191' ' ' GLN . . . -157.0 -164.36 13.49 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-O 119.03 -0.872 . . . . 74.34 111.945 -177.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.39 -30.34 91.02 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 123.569 2.846 . . . . 75.31 114.153 -173.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -93.61 22.97 4.96 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 123.428 0.691 . . . . 73.43 111.329 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 87.87 -73.92 2.26 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 110.104 -1.198 . . . . 74.31 110.104 -174.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 50.0 mtm180 -127.02 162.52 25.82 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 124.16 0.984 . . . . 73.44 108.674 167.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -89.38 -156.86 32.34 Favored Glycine 0 C--N 1.342 0.876 0 O-C-N 123.671 0.607 . . . . 72.03 112.398 176.476 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -135.86 171.59 14.24 Favored 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 109.182 -0.673 . . . . 72.41 109.182 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.578 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 12.8 tp -106.81 117.4 33.96 Favored 'General case' 0 C--O 1.213 -0.848 0 C-N-CA 123.268 0.627 . . . . 71.11 111.171 176.11 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . 0.468 ' HB3' ' O ' ' A' ' 193' ' ' LEU . 1.9 t80 -89.68 103.98 16.58 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 107.979 -1.119 . . . . 73.52 107.979 173.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.505 HD12 HD22 ' A' ' 197' ' ' LEU . 76.2 mt -88.77 148.03 24.15 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 123.261 0.625 . . . . 74.15 110.921 172.515 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -109.34 97.49 7.07 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 108.768 -0.827 . . . . 74.32 108.768 175.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 57.3 t -53.68 113.94 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 123.28 0.632 . . . . 70.33 110.802 173.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 27.7 mmt85 -123.64 94.3 4.2 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 107.185 -1.413 . . . . 73.42 107.185 178.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.411 HG22 ' HA ' ' A' ' 201' ' ' ALA . 76.6 mt -77.82 114.76 18.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 123.718 0.807 . . . . 65.24 110.318 -176.551 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 4.2 t . . . . . 0 CA--C 1.562 1.428 0 C-N-CA 123.633 0.773 . . . . 64.23 109.527 176.051 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.415 HD21 HD11 ' A' ' 125' ' ' LEU . 30.5 tp . . . . . 0 C--O 1.241 0.658 0 CA-C-O 119.806 -0.14 . . . . 63.35 111.121 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.443 ' HA ' ' CB ' ' A' ' 123' ' ' LEU . 14.8 p -67.3 120.62 14.94 Favored 'Isoleucine or valine' 0 C--N 1.36 1.051 0 CA-C-O 121.54 0.686 . . . . 74.24 110.26 175.462 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -85.67 -60.71 1.94 Allowed 'General case' 0 C--O 1.24 0.564 0 CA-C-N 114.933 -1.031 . . . . 71.22 110.456 -175.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 26.6 t-80 -165.94 157.81 14.22 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 115.793 -0.64 . . . . 75.53 111.217 -171.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 25.9 t -64.42 145.14 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 125.148 1.379 . . . . 73.11 111.028 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.652 HG22 ' HG3' ' A' ' 122' ' ' GLU . 41.6 p . . . . . 0 CA--C 1.547 0.847 0 C-N-CA 123.517 0.727 . . . . 74.44 111.377 177.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.243 0.746 0 N-CA-C 108.061 -1.088 . . . . 65.21 108.061 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.452 HD23 HG12 ' A' ' 140' ' ' VAL . 0.5 OUTLIER -95.77 135.88 36.9 Favored 'General case' 0 C--N 1.345 0.402 0 N-CA-C 106.283 -1.747 . . . . 52.21 106.283 175.015 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 56.7 mtp180 -142.65 126.52 17.17 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 108.304 -0.998 . . . . 74.02 108.304 -175.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -148.78 133.27 17.65 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.335 0.654 . . . . 73.42 110.157 -178.465 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.652 ' HG3' HG22 ' A' ' 103' ' ' THR . 44.8 mt-10 -92.89 144.99 24.72 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 122.929 0.491 . . . . 62.41 109.993 173.061 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.443 ' CB ' ' HA ' ' A' ' 99' ' ' VAL . 1.7 pt? -146.68 132.18 9.23 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.365 -0.834 . . . . 75.24 110.533 -177.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -72.09 114.96 4.13 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 121.814 1.676 . . . . 75.31 111.221 175.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.427 ' HB3' HD23 ' A' ' 180' ' ' LEU . 22.0 tp -108.93 167.26 10.22 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.539 1.136 . . . . 70.14 108.065 176.334 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.482 HG22 HD11 ' A' ' 181' ' ' LEU . 7.8 m -103.46 159.8 15.27 Favored 'General case' 0 N--CA 1.476 0.865 0 O-C-N 121.624 -0.672 . . . . 72.33 109.513 171.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.531 HD21 ' HB3' ' A' ' 180' ' ' LEU . 81.2 mt -52.12 -52.77 49.5 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-O 121.311 0.577 . . . . 73.51 109.625 169.441 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.573 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.7 mp0 -55.64 -39.74 71.26 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 114.588 -1.187 . . . . 71.14 112.146 177.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -77.7 -21.17 52.4 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 122.765 0.426 . . . . 72.13 111.845 -178.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.457 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -68.55 -36.08 78.3 Favored 'General case' 0 C--O 1.248 0.99 0 C-N-CA 123.628 0.771 . . . . 73.54 110.64 168.531 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.471 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 69.2 t80 -64.44 -49.05 73.0 Favored 'General case' 0 C--N 1.346 0.448 0 CA-C-N 115.232 -0.894 . . . . 75.1 110.537 170.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -72.94 -28.82 62.67 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 112.855 0.687 . . . . 70.43 112.855 -173.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 67.3 -96.18 0.32 Allowed Glycine 0 C--N 1.351 1.376 0 N-CA-C 111.415 -0.674 . . . . 54.11 111.415 -174.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.38 150.55 25.46 Favored Glycine 0 C--N 1.349 1.29 0 N-CA-C 114.78 0.672 . . . . 72.35 114.78 167.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -85.59 125.57 33.22 Favored 'General case' 0 N--CA 1.473 0.684 0 N-CA-C 108.116 -1.068 . . . . 73.13 108.116 169.633 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 21.9 mmt180 -129.22 152.66 48.55 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.255 1.022 . . . . 74.54 108.742 -168.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 22.3 m -85.24 127.11 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.212 0 N-CA-C 110.053 -0.351 . . . . 75.21 110.053 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 85.7 t -123.73 122.78 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 123.086 0.554 . . . . 70.33 109.884 175.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -124.8 96.53 4.91 Favored 'General case' 0 N--CA 1.476 0.87 0 CA-C-O 121.99 0.9 . . . . 73.54 109.24 172.063 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.452 HG12 HD23 ' A' ' 119' ' ' LEU . 74.0 t -130.59 133.11 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 123.786 0.834 . . . . 71.54 109.64 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.33 28.35 17.84 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 124.621 1.168 . . . . 60.1 111.157 -178.639 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.12 -9.3 66.98 Favored Glycine 0 C--N 1.35 1.321 0 CA-C-N 115.548 -0.751 . . . . 62.03 113.447 -177.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.2 tpp180 -91.08 115.67 28.19 Favored 'General case' 0 C--N 1.344 0.339 0 N-CA-C 109.424 -0.584 . . . . 75.21 109.424 -176.143 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 59.0 ttp180 -103.72 111.4 23.88 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 108.636 -0.875 . . . . 74.14 108.636 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.581 HG11 ' HE1' ' A' ' 164' ' ' MET . 2.5 p -145.89 141.86 21.74 Favored 'Isoleucine or valine' 0 C--O 1.243 0.731 0 C-N-CA 125.011 1.324 . . . . 71.43 108.325 178.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 32.4 p -77.69 134.14 38.19 Favored 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 116.384 -0.371 . . . . 74.24 110.016 178.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.553 ' HB ' ' HE3' ' A' ' 164' ' ' MET . 9.0 p -98.74 136.11 31.03 Favored 'Isoleucine or valine' 0 C--N 1.341 0.2 0 N-CA-C 109.126 -0.694 . . . . 72.45 109.126 175.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.1 ttt85 -108.19 95.45 5.68 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 107.559 -1.275 . . . . 75.33 107.559 168.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.465 ' HB ' HD11 ' A' ' 159' ' ' ILE . 36.5 pt -87.03 113.62 54.46 Favored Pre-proline 0 CA--C 1.552 1.021 0 N-CA-C 107.777 -1.194 . . . . 75.11 107.777 171.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 149' ' ' ILE . 33.1 Cg_exo -61.45 137.41 69.64 Favored 'Trans proline' 0 C--N 1.381 2.251 0 C-N-CA 122.683 2.255 . . . . 75.12 112.85 -173.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.425 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 83.7 Cg_exo -50.62 120.07 5.98 Favored 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 123.281 2.654 . . . . 74.32 112.132 172.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 126.03 52.57 0.16 Allowed Glycine 0 C--N 1.341 0.826 0 N-CA-C 110.861 -0.896 . . . . 63.21 110.861 -174.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.523 HG23 HD13 ' A' ' 159' ' ' ILE . 1.9 p -126.05 161.87 30.71 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.197 0 C-N-CA 123.94 0.896 . . . . 71.13 109.247 -176.548 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -140.94 165.9 26.26 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 124.869 1.267 . . . . 73.23 111.576 -165.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -57.12 122.85 13.38 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.948 0.899 . . . . 74.12 110.008 169.118 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.86 7.88 86.44 Favored Glycine 0 C--N 1.343 0.931 0 CA-C-O 119.4 -0.667 . . . . 64.3 113.824 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.5 t -78.77 123.33 27.08 Favored 'General case' 0 C--O 1.244 0.794 0 N-CA-C 109.415 -0.587 . . . . 71.32 109.415 177.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.414 HG23 HD23 ' A' ' 175' ' ' LEU . 7.6 p -100.49 120.78 50.42 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.126 0 CA-C-N 115.063 -0.971 . . . . 74.35 109.569 -179.233 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.523 HD13 HG23 ' A' ' 153' ' ' VAL . 20.1 mt -106.73 116.82 51.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.963 0.905 . . . . 72.25 110.32 -167.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.473 ' HG3' ' HB2' ' A' ' 173' ' ' ASP . 29.6 ttm180 -89.3 113.12 24.35 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.653 0.781 . . . . 72.13 111.245 -179.305 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 18.4 m -115.41 103.27 54.3 Favored Pre-proline 0 CA--C 1.561 1.374 0 CA-C-O 121.498 0.666 . . . . 75.4 110.581 178.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -65.5 145.65 83.04 Favored 'Trans proline' 0 C--N 1.381 2.258 0 C-N-CA 122.716 2.278 . . . . 75.22 112.992 -177.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 94.07 -23.25 32.22 Favored Glycine 0 C--N 1.345 1.03 0 CA-C-N 115.742 -0.663 . . . . 71.13 113.962 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.581 ' HE1' HG11 ' A' ' 145' ' ' VAL . 68.8 mtp -95.13 -23.66 17.2 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 112.927 0.714 . . . . 71.4 112.927 -169.548 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.346 1.105 0 N-CA-C 113.8 0.28 . . . . 71.22 113.8 -177.274 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo . . . . . 0 CA--C 1.537 0.649 0 N-CA-C 111.544 -0.214 . . . . 74.31 111.544 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -84.96 166.73 41.17 Favored Glycine 0 CA--C 1.509 -0.331 0 CA-C-N 116.169 -0.469 . . . . 53.51 111.946 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.473 ' HB2' ' HG3' ' A' ' 160' ' ' ARG . 8.2 p-10 -116.77 145.65 43.36 Favored 'General case' 0 C--O 1.245 0.824 0 C-N-CA 123.846 0.859 . . . . 64.21 109.28 -177.443 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 17.7 tp -106.39 122.37 46.12 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.824 -1.176 . . . . 75.2 107.824 176.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.414 HD23 HG23 ' A' ' 158' ' ' VAL . 77.1 mt -98.8 98.91 9.96 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 125.279 1.432 . . . . 74.13 110.282 -177.543 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 52.8 mt -92.57 107.39 19.18 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 123.411 0.684 . . . . 74.34 111.405 178.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.644 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 34.7 t -88.66 104.22 14.57 Favored 'Isoleucine or valine' 0 C--O 1.245 0.836 0 N-CA-C 108.465 -0.939 . . . . 74.42 108.465 173.551 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 9.7 m -82.0 147.59 5.99 Favored 'Isoleucine or valine' 0 C--O 1.242 0.686 0 CA-C-O 121.499 0.666 . . . . 75.32 110.318 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 24.3 mmm-85 -120.63 96.32 5.08 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 107.418 -1.327 . . . . 74.43 107.418 -179.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.531 ' HB3' HD21 ' A' ' 127' ' ' LEU . 31.0 mt -69.26 136.53 52.07 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 122.626 0.371 . . . . 73.13 110.368 -174.677 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.482 HD11 HG22 ' A' ' 126' ' ' THR . 53.7 mt -53.67 125.49 46.0 Favored Pre-proline 0 CA--C 1.554 1.122 0 CA-C-O 118.543 -0.742 . . . . 74.24 110.319 -177.189 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 24.0 Cg_exo -64.18 85.23 0.15 Allowed 'Trans proline' 0 C--N 1.379 2.139 0 C-N-CA 123.109 2.539 . . . . 74.13 113.471 -174.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -154.23 54.82 1.15 Allowed Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 123.758 0.823 . . . . 74.35 109.054 171.147 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -61.21 122.92 11.87 Favored 'Trans proline' 0 C--N 1.381 2.273 0 C-N-CA 122.54 2.16 . . . . 72.4 112.143 -165.055 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.29 -44.57 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 N-CA-C 107.824 -1.176 . . . . 70.11 107.824 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . 0.446 ' HE2' HD13 ' A' ' 193' ' ' LEU . 3.6 m-85 -104.81 123.75 48.22 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.209 -0.905 . . . . 72.44 109.353 176.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.509 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 4.3 mmm180 -115.68 150.94 35.97 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 106.082 -1.821 . . . . 70.42 106.082 178.422 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.408 HD12 ' O ' ' A' ' 192' ' ' ASP . 63.9 tp -130.76 132.02 45.06 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 122.833 0.453 . . . . 71.33 109.832 -176.357 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -143.5 116.76 9.0 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 108.417 -0.957 . . . . 74.34 108.417 168.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 55.42 52.85 44.93 Favored Glycine 0 C--N 1.355 1.584 0 O-C-N 123.953 0.783 . . . . 64.55 114.04 176.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . 0.4 ' OE1' ' HD2' ' A' ' 243' ' ' PRO . 38.5 mt-30 72.5 -5.94 1.71 Allowed 'General case' 0 N--CA 1.496 1.866 0 C-N-CA 125.024 1.329 . . . . 75.11 113.168 177.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . 0.408 ' O ' HD12 ' A' ' 188' ' ' LEU . 23.1 t70 -98.98 145.09 27.42 Favored 'General case' 0 C--N 1.348 0.503 0 N-CA-C 109.483 -0.562 . . . . 73.43 109.483 -176.64 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.604 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.7 mt -105.72 152.97 22.5 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.691 0.796 . . . . 72.43 109.232 -174.098 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . 0.509 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 98.3 m-85 -140.84 120.82 13.63 Favored 'General case' 0 C--O 1.223 -0.308 0 N-CA-C 107.649 -1.241 . . . . 75.12 107.649 -174.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -147.47 169.46 19.5 Favored 'General case' 0 C--O 1.24 0.595 0 C-N-CA 123.637 0.775 . . . . 74.44 110.287 -175.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 16.6 m -116.25 126.99 54.35 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.757 -0.656 . . . . 73.3 109.447 175.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . . . . . . . . . 67.0 tp -107.39 119.46 39.46 Favored 'General case' 0 C--O 1.214 -0.804 0 C-N-CA 124.47 1.108 . . . . 71.52 108.696 176.071 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -97.31 136.79 37.29 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.257 -1.016 . . . . 73.52 108.257 167.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . 0.499 HG13 HG12 ' A' ' 210' ' ' VAL . 13.3 m -130.26 142.82 46.78 Favored Pre-proline 0 N--CA 1.476 0.833 0 N-CA-C 109.1 -0.704 . . . . 73.43 109.1 179.235 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -61.94 140.06 82.85 Favored 'Trans proline' 0 C--N 1.372 1.79 0 C-N-CA 121.942 1.761 . . . . 71.01 110.772 172.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . 0.414 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -52.78 -42.2 88.24 Favored Pre-proline 0 CA--C 1.558 1.263 0 CA-C-O 117.542 -1.218 . . . . 75.22 113.041 178.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . 0.459 ' O ' HG21 ' A' ' 206' ' ' VAL . 8.8 Cg_endo -49.78 -52.69 8.37 Favored 'Trans proline' 0 C--N 1.408 3.671 0 C-N-CA 122.851 2.367 . . . . 72.35 112.267 169.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 3.4 mt -60.98 -41.66 89.94 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 122.836 0.454 . . . . 74.51 111.271 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.49 -42.53 98.55 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.163 0.585 . . . . 53.21 112.187 -175.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 28.1 m -81.2 -35.51 14.25 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 CA-C-N 115.959 -0.564 . . . . 75.21 111.894 -173.06 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . 0.459 HG21 ' O ' ' A' ' 202' ' ' PRO . 20.8 m -88.0 -19.21 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 O-C-N 122.118 -0.364 . . . . 74.04 111.635 178.614 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.415 ' HA2' HG22 ' A' ' 223' ' ' VAL . . . 76.37 66.67 1.81 Allowed Glycine 0 C--N 1.342 0.894 0 O-C-N 123.484 0.49 . . . . 75.33 112.181 -177.449 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.02 -168.45 42.89 Favored Glycine 0 C--N 1.348 1.203 0 N-CA-C 111.854 -0.498 . . . . 73.33 111.854 175.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -125.79 119.34 27.63 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 107.997 -1.112 . . . . 74.41 107.997 -179.323 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . 0.499 HG12 HG13 ' A' ' 199' ' ' VAL . 7.9 p -116.43 147.88 19.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.547 0 C-N-CA 124.143 0.977 . . . . 74.12 109.439 -174.1 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -76.24 123.66 26.25 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 116.026 -0.534 . . . . 75.44 109.579 172.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.13 130.14 47.15 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 108.052 -1.092 . . . . 74.34 108.052 173.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 56.3 mmm -76.55 141.01 41.32 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.131 0.491 . . . . 64.34 110.776 178.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 214' ' ' THR . . . . . 0.414 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 5.7 t -143.68 166.91 23.53 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-N 114.563 -1.199 . . . . 73.35 110.159 177.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . 0.573 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 65.1 mt -66.51 -19.84 65.88 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 124.306 1.042 . . . . 73.31 110.953 176.046 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -82.97 -18.25 40.61 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 124.859 1.263 . . . . 75.34 111.022 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 134.26 -147.49 19.11 Favored Glycine 0 C--N 1.352 1.433 0 N-CA-C 111.226 -0.75 . . . . 72.1 111.226 -174.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -93.11 129.37 0.76 Allowed 'Trans proline' 0 CA--C 1.56 1.787 0 C-N-CA 122.432 2.088 . . . . 73.12 112.775 165.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.7 m -109.15 166.71 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 C-N-CA 123.595 0.758 . . . . 73.21 109.56 169.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -113.94 116.47 29.3 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 109.867 -0.42 . . . . 74.51 109.867 178.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.4 p -108.78 136.82 43.38 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.681 0 C-N-CA 123.459 0.704 . . . . 74.41 110.175 173.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -95.12 115.73 27.81 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 124.025 0.93 . . . . 51.01 109.491 176.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.461 HG11 HG11 ' A' ' 199' ' ' VAL . 14.2 m -82.06 142.05 47.57 Favored Pre-proline 0 CA--C 1.548 0.893 0 N-CA-C 109.376 -0.601 . . . . 73.31 109.376 176.16 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_exo -61.0 141.12 93.47 Favored 'Trans proline' 0 C--N 1.368 1.558 0 C-N-CA 122.451 2.1 . . . . 75.12 112.746 172.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_exo -56.4 119.79 7.23 Favored 'Trans proline' 0 C--N 1.373 1.833 0 C-N-CA 122.588 2.192 . . . . 74.45 111.783 169.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . 0.415 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 53.7 mtm180 60.75 51.64 4.75 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.676 1.19 . . . . 74.45 110.759 -174.082 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 227' ' ' THR . . . . . 0.469 ' OG1' ' HD2' ' A' ' 231' ' ' ARG . 12.1 t -73.17 172.68 10.64 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-N 114.955 -1.02 . . . . 74.34 110.257 174.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -126.49 141.81 51.75 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 123.149 0.58 . . . . 74.34 109.455 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -63.96 119.69 10.56 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.759 0.824 . . . . 74.4 109.836 175.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.98 4.78 20.75 Favored Glycine 0 C--O 1.241 0.57 0 C-N-CA 123.69 0.662 . . . . 73.41 112.314 -176.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . 0.469 ' HD2' ' OG1' ' A' ' 227' ' ' THR . 92.3 mtt180 -79.54 159.01 27.06 Favored 'General case' 0 C--N 1.358 0.942 0 CA-C-O 121.707 0.765 . . . . 73.0 109.551 170.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.453 ' HG3' ' HE2' ' A' ' 250' ' ' TYR . 10.1 mptt -108.34 99.13 8.57 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 114.32 -1.309 . . . . 74.11 108.452 -176.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . 0.449 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 62.6 mt -90.11 96.48 10.69 Favored 'General case' 0 C--N 1.349 0.545 0 N-CA-C 106.231 -1.766 . . . . 75.1 106.231 176.518 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . 0.483 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 39.1 ttp180 -96.11 101.36 13.01 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 114.915 -1.039 . . . . 73.31 110.015 -167.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.478 HD12 HD21 ' A' ' 249' ' ' LEU . 43.3 mt -81.08 105.92 12.67 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.934 0.894 . . . . 73.02 108.806 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt -74.61 144.18 44.02 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.171 0.588 . . . . 74.41 112.267 -171.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 71.11 19.99 77.65 Favored Glycine 0 C--N 1.349 1.275 0 O-C-N 123.764 0.665 . . . . 52.02 113.934 178.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . 0.488 ' HZ1' ' HB3' ' A' ' 238' ' ' LYS . 1.4 mmmp? -106.65 -12.43 15.56 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.792 0.437 . . . . 71.43 111.173 -179.356 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.17 -175.51 49.82 Favored Glycine 0 C--N 1.348 1.217 0 O-C-N 123.409 0.443 . . . . 72.31 112.138 173.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.471 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 87.5 m-85 -77.4 149.26 78.5 Favored Pre-proline 0 N--CA 1.475 0.809 0 N-CA-C 112.252 0.464 . . . . 74.04 112.252 -172.027 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . 0.558 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 53.3 Cg_endo -65.52 160.58 42.28 Favored 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 122.838 2.359 . . . . 64.45 113.562 -175.548 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 164.7 -151.74 20.97 Favored Glycine 0 C--N 1.346 1.097 0 CA-C-O 118.929 -0.928 . . . . 70.34 112.044 -178.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . 0.4 ' HD2' ' OE1' ' A' ' 191' ' ' GLN . 37.6 Cg_endo -61.33 -32.53 89.77 Favored 'Trans proline' 0 C--N 1.377 2.047 0 C-N-CA 123.264 2.643 . . . . 73.34 113.198 -176.513 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -84.52 18.63 2.22 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 123.485 0.714 . . . . 71.31 111.77 178.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 78.77 -78.12 1.7 Allowed Glycine 0 C--N 1.347 1.175 0 N-CA-C 110.039 -1.224 . . . . 74.32 110.039 -172.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.558 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 62.2 mtm180 -128.47 169.51 14.24 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 124.081 0.953 . . . . 64.42 108.579 166.245 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -82.78 -163.66 34.07 Favored Glycine 0 C--N 1.337 0.626 0 N-CA-C 111.697 -0.561 . . . . 41.11 111.697 172.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -130.78 170.73 13.98 Favored 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 109.238 -0.653 . . . . 72.43 109.238 -178.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.604 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 17.5 tp -115.87 120.65 39.9 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.868 0.867 . . . . 73.31 110.663 175.365 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . 0.453 ' HE2' ' HG3' ' A' ' 232' ' ' LYS . 10.7 t80 -89.31 107.93 19.34 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.613 1.165 . . . . 75.15 108.693 175.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.449 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 87.8 mt -94.14 117.86 30.71 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.904 -0.406 . . . . 73.02 109.904 167.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -88.29 93.56 9.55 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 107.327 -1.36 . . . . 74.52 107.327 171.412 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 3.3 p -60.05 133.82 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 O-C-N 123.725 0.641 . . . . 73.43 110.645 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 48.6 mmm-85 -135.26 102.01 5.03 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 125.049 1.34 . . . . 75.14 107.529 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 63.0 mt -76.54 116.93 20.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.359 -0.837 . . . . 75.11 109.768 -175.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.0 t . . . . . 0 CA--C 1.553 1.087 0 C-N-CA 124.829 1.252 . . . . 70.32 109.214 -178.635 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.419 HD21 ' H ' ' A' ' 99' ' ' VAL . 2.0 pt? . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 119.973 -0.06 . . . . 74.31 111.084 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.694 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 13.6 p -64.45 146.7 12.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 C-N-CA 123.584 0.754 . . . . 72.12 111.894 -179.098 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.44 ' HB3' ' HD3' ' A' ' 124' ' ' PRO . . . -83.22 -58.35 2.88 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 109.479 -0.563 . . . . 63.45 109.479 173.16 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 40.0 t-80 -175.59 159.58 2.38 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 123.697 0.799 . . . . 73.43 109.857 -175.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -66.44 136.68 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.346 0.658 . . . . 73.24 110.277 171.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 12.6 t . . . . . 0 CA--C 1.543 0.708 0 N-CA-C 109.308 -0.627 . . . . 74.43 109.308 179.041 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 20.8 t70 . . . . . 0 N--CA 1.477 0.903 0 CA-C-O 120.879 0.371 . . . . 72.35 110.034 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.494 HD11 HD13 ' A' ' 174' ' ' LEU . 0.2 OUTLIER -138.16 137.41 37.61 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 106.392 -1.707 . . . . 75.54 106.392 177.46 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . 0.477 ' HD3' ' HB2' ' A' ' 175' ' ' LEU . 19.4 mmt85 -125.58 138.59 53.95 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 109.065 -0.717 . . . . 73.22 109.065 -178.57 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . 0.411 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -159.11 126.74 4.91 Favored 'General case' 0 CA--C 1.536 0.417 0 O-C-N 123.703 0.627 . . . . 74.25 109.447 175.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -105.73 150.55 25.41 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 109.607 -0.516 . . . . 71.55 109.607 175.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.694 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.4 pt? -145.87 147.08 31.13 Favored Pre-proline 0 N--CA 1.473 0.72 0 C-N-CA 123.033 0.533 . . . . 72.41 111.925 -170.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.44 ' HD3' ' HB3' ' A' ' 100' ' ' ALA . 91.5 Cg_endo -81.76 113.41 2.51 Favored 'Trans proline' 0 C--N 1.376 1.993 0 C-N-CA 121.769 1.646 . . . . 74.32 111.082 171.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.422 ' HB3' HD21 ' A' ' 180' ' ' LEU . 19.2 tp -111.06 167.71 10.05 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.043 -1.095 . . . . 63.31 108.043 175.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.562 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 8.8 m -101.09 155.07 18.21 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 109.922 -0.399 . . . . 74.15 109.922 174.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.411 HD23 ' HB3' ' A' ' 180' ' ' LEU . 85.6 mt -51.96 -51.93 53.75 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 122.304 1.049 . . . . 73.4 109.766 171.14 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -56.83 -40.14 75.5 Favored 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 113.386 -1.734 . . . . 74.14 111.735 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.427 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 23.8 mm-40 -79.87 -18.27 51.13 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 123.358 0.663 . . . . 73.32 112.195 -179.025 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.618 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -63.25 -41.57 99.09 Favored 'General case' 0 C--O 1.249 1.036 0 C-N-CA 122.863 0.465 . . . . 74.02 110.583 165.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -67.93 -54.45 18.6 Favored 'General case' 0 C--N 1.354 0.787 0 CA-C-N 115.664 -0.698 . . . . 74.31 110.932 172.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.5 m80 -69.88 -30.03 67.39 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 123.941 0.776 . . . . 72.42 112.158 -170.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.08 -149.34 51.71 Favored Glycine 0 C--N 1.346 1.124 0 N-CA-C 111.334 -0.706 . . . . 75.11 111.334 -171.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 136.92 136.94 3.57 Favored Glycine 0 C--N 1.346 1.095 0 CA-C-N 116.73 0.265 . . . . 74.41 112.673 170.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -80.21 127.0 31.83 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.408 0.683 . . . . 75.23 109.191 174.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.2 mpt_? -136.26 168.13 19.99 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.527 0.731 . . . . 75.2 109.101 177.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.5 p -85.85 129.61 37.78 Favored 'Isoleucine or valine' 0 C--O 1.246 0.878 0 CA-C-O 121.311 0.577 . . . . 74.32 110.66 174.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.478 HG23 HD22 ' A' ' 174' ' ' LEU . 14.6 p -98.65 142.33 14.9 Favored 'Isoleucine or valine' 0 C--O 1.242 0.704 0 C-N-CA 124.215 1.006 . . . . 74.42 109.43 175.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . 0.433 ' H ' HG13 ' A' ' 99' ' ' VAL . 42.7 mm-40 -121.76 100.68 7.13 Favored 'General case' 0 C--O 1.24 0.563 0 C-N-CA 124.61 1.164 . . . . 74.41 108.142 179.042 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.404 HG13 HG22 ' A' ' 138' ' ' VAL . 3.2 m -124.05 107.53 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.79 0 C-N-CA 123.352 0.661 . . . . 72.43 111.063 -176.569 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.87 24.24 11.29 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 124.747 1.219 . . . . 70.33 111.909 176.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 91.12 3.49 69.9 Favored Glycine 0 C--N 1.346 1.116 0 CA-C-N 116.031 -0.531 . . . . 75.53 113.371 -177.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 64.0 mtp85 -95.98 119.62 34.81 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.024 -0.732 . . . . 72.22 109.024 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 33.9 ttt85 -98.82 116.63 31.49 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.483 0.713 . . . . 74.5 109.952 -178.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 46.3 t -136.53 145.53 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.778 0.831 . . . . 73.13 108.918 179.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 21.2 m -79.03 110.99 14.78 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 109.072 -0.714 . . . . 74.4 109.072 171.08 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.0 p -98.28 137.41 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 CA-C-O 121.762 0.791 . . . . 74.34 110.597 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 77.6 ttt180 -103.82 117.78 35.16 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 114.485 -1.234 . . . . 74.32 108.342 175.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 33.4 pt -122.86 127.0 25.89 Favored Pre-proline 0 N--CA 1.477 0.919 0 N-CA-C 109.01 -0.737 . . . . 74.41 109.01 169.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -81.86 159.97 18.63 Favored 'Trans proline' 0 C--N 1.375 1.959 0 C-N-CA 122.909 2.406 . . . . 73.24 114.523 -167.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -68.1 114.92 3.57 Favored 'Trans proline' 0 C--N 1.381 2.289 0 C-N-CA 123.331 2.687 . . . . 53.44 110.618 174.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . 0.632 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 133.9 49.7 0.08 OUTLIER Glycine 0 N--CA 1.469 0.844 0 N-CA-C 111.299 -0.72 . . . . 45.24 111.299 -173.712 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.618 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.4 p -125.99 165.61 23.56 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.403 0 N-CA-C 108.35 -0.981 . . . . 62.45 108.35 -176.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 51.3 mtp180 -145.69 166.7 25.07 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 124.519 1.127 . . . . 72.43 110.375 -165.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -55.49 123.89 15.43 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 124.005 0.922 . . . . 75.11 111.112 169.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.75 5.42 74.31 Favored Glycine 0 C--N 1.35 1.337 0 O-C-N 123.752 0.657 . . . . 75.01 113.601 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 31.2 t -73.45 126.01 29.23 Favored 'General case' 0 C--O 1.243 0.715 0 N-CA-C 109.828 -0.434 . . . . 72.1 109.828 -177.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.443 HG23 HD21 ' A' ' 175' ' ' LEU . 7.4 p -99.43 120.05 48.26 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 CA-C-N 114.756 -1.111 . . . . 74.4 109.911 -174.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.49 HD11 HG23 ' A' ' 153' ' ' VAL . 24.9 mt -106.95 115.53 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 124.004 0.922 . . . . 74.34 110.081 -171.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.519 ' HA ' HD23 ' A' ' 175' ' ' LEU . 69.3 ttt180 -83.53 119.1 24.28 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.504 0.722 . . . . 73.23 111.024 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.589 HG21 ' HG3' ' A' ' 164' ' ' MET . 16.6 m -124.37 104.76 31.38 Favored Pre-proline 0 CA--C 1.571 1.77 0 CA-C-O 120.764 0.316 . . . . 74.35 110.209 174.745 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.17 156.59 64.42 Favored 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.865 2.376 . . . . 73.41 113.7 -178.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.56 23.15 65.55 Favored Glycine 0 C--N 1.348 1.247 0 CA-C-N 115.336 -0.847 . . . . 73.24 113.808 176.472 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.589 ' HG3' HG21 ' A' ' 161' ' ' VAL . 16.4 mmt -106.81 -62.08 1.45 Allowed 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.079 0.952 . . . . 72.41 111.271 178.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.539 0 N-CA-C 111.591 -0.603 . . . . 63.51 111.591 178.414 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo . . . . . 0 CA--C 1.538 0.701 0 N-CA-C 110.653 -0.556 . . . . 75.21 110.653 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -110.08 148.41 17.4 Favored Glycine 0 CA--C 1.503 -0.693 0 N-CA-C 111.334 -0.706 . . . . 52.12 111.334 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 -109.0 130.54 55.48 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 123.215 0.606 . . . . 75.25 109.53 -165.017 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.494 HD13 HD11 ' A' ' 119' ' ' LEU . 17.4 tp -100.6 115.12 29.42 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 107.145 -1.428 . . . . 75.53 107.145 173.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.519 HD23 ' HA ' ' A' ' 160' ' ' ARG . 65.0 mt -92.23 100.73 13.28 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-N 114.46 -1.246 . . . . 65.32 109.794 -179.162 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.411 ' HA ' ' O ' ' A' ' 121' ' ' ALA . 83.2 mt -86.63 102.49 14.23 Favored 'General case' 0 C--N 1.346 0.418 0 CA-C-N 114.773 -1.103 . . . . 74.31 110.061 176.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 47.2 t -90.0 99.4 9.4 Favored 'Isoleucine or valine' 0 C--O 1.243 0.714 0 N-CA-C 108.397 -0.964 . . . . 65.54 108.397 176.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 4.9 m -79.49 148.12 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 N-CA-C 109.493 -0.558 . . . . 75.34 109.493 -177.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 40.0 mmm-85 -126.63 99.2 5.69 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 105.85 -1.908 . . . . 74.44 105.85 -175.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.422 HD21 ' HB3' ' A' ' 125' ' ' LEU . 38.2 mt -68.65 148.34 50.58 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 122.339 0.256 . . . . 74.01 110.954 -173.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.562 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 39.1 mt -55.76 130.52 72.01 Favored Pre-proline 0 CA--C 1.552 1.04 0 CA-C-O 118.844 -0.598 . . . . 74.5 110.737 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -67.91 84.47 0.42 Allowed 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 123.279 2.653 . . . . 74.22 112.079 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 8.6 p80 -154.58 50.62 0.55 Allowed Pre-proline 0 CA--C 1.558 1.274 0 N-CA-C 107.87 -1.159 . . . . 72.12 107.87 169.347 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -62.69 126.42 18.21 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 122.713 2.275 . . . . 73.14 112.261 -163.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -137.74 -45.1 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 108.686 -0.857 . . . . 74.41 108.686 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . 0.413 ' CD2' HD11 ' A' ' 193' ' ' LEU . 6.5 m-85 -103.82 123.61 47.42 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.932 0.893 . . . . 74.21 110.269 -177.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.6 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 92.3 mtt180 -119.15 109.18 15.58 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.623 1.169 . . . . 75.1 107.887 -176.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.485 HD23 ' CD2' ' A' ' 240' ' ' PHE . 62.0 tp -85.09 142.56 29.45 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 122.659 0.383 . . . . 73.3 110.378 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -142.45 115.61 8.88 Favored 'General case' 0 C--O 1.243 0.736 0 N-CA-C 107.782 -1.192 . . . . 73.33 107.782 164.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 67.46 -95.37 0.31 Allowed Glycine 0 C--N 1.346 1.139 0 CA-C-N 115.725 -0.67 . . . . 75.05 111.514 -173.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 -123.84 -23.27 4.7 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.034 0.934 . . . . 72.42 110.247 177.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -93.83 153.34 18.33 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.411 0.624 . . . . 74.11 111.038 -171.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.616 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 73.6 mt -113.36 167.08 10.87 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.198 -0.91 . . . . 73.14 112.581 -170.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . 0.6 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 97.4 m-85 -135.28 121.57 20.32 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 105.873 -1.899 . . . . 74.51 105.873 172.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . 0.433 ' HB2' HD13 ' A' ' 249' ' ' LEU . . . -152.75 140.1 19.56 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 108.573 -0.899 . . . . 72.45 108.573 176.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.02 141.71 40.21 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 123.566 0.541 . . . . 73.4 110.128 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.544 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 57.5 tp -110.03 113.73 26.67 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.027 -0.988 . . . . 72.35 109.07 179.29 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -85.71 101.9 13.16 Favored 'General case' 0 C--O 1.24 0.566 0 N-CA-C 108.149 -1.056 . . . . 72.12 108.149 176.228 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . 0.427 HG11 HG12 ' A' ' 253' ' ' VAL . 4.3 p -116.82 127.44 26.72 Favored Pre-proline 0 CA--C 1.548 0.881 0 N-CA-C 109.332 -0.618 . . . . 63.11 109.332 -178.237 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -58.71 144.71 97.71 Favored 'Trans proline' 0 C--N 1.379 2.169 0 C-N-CA 122.461 2.107 . . . . 72.22 111.948 172.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -54.49 -42.93 97.07 Favored Pre-proline 0 CA--C 1.564 1.506 0 CA-C-O 118.106 -0.949 . . . . 63.25 112.117 175.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_exo -46.12 -53.24 6.07 Favored 'Trans proline' 0 C--N 1.397 3.106 0 C-N-CA 122.684 2.256 . . . . 74.13 114.126 167.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . 0.456 HG23 HG23 ' A' ' 223' ' ' VAL . 12.8 mt -65.96 -37.02 78.89 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 O-C-N 123.169 0.293 . . . . 71.31 110.923 -178.111 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.13 -43.86 97.23 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 123.306 0.642 . . . . 63.33 111.599 -177.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 32.6 m -76.79 -37.97 28.9 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 115.951 -0.568 . . . . 72.0 111.262 -176.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.4 m -83.44 -23.87 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 N-CA-C 111.763 0.283 . . . . 73.22 111.763 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.458 ' HA2' HG21 ' A' ' 223' ' ' VAL . . . 72.19 64.05 2.77 Favored Glycine 0 C--N 1.341 0.84 0 CA-C-N 116.227 -0.442 . . . . 71.12 112.183 -172.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -94.53 -154.19 30.78 Favored Glycine 0 C--N 1.355 1.625 0 CA-C-O 121.428 0.46 . . . . 52.32 112.378 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 14.7 mmmm -121.76 128.97 52.33 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 123.781 0.832 . . . . 75.32 109.104 -174.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 39.5 t -116.18 129.98 71.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 N-CA-C 108.91 -0.774 . . . . 75.03 108.91 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -78.24 106.09 9.91 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 107.861 -1.163 . . . . 75.41 107.861 168.064 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -98.83 133.42 43.15 Favored 'General case' 0 C--N 1.343 0.31 0 C-N-CA 123.822 0.849 . . . . 64.42 108.922 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -74.94 144.24 43.32 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 122.651 0.38 . . . . 71.23 110.402 173.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 7.5 t -148.27 167.43 25.16 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 124.353 1.061 . . . . 75.4 109.77 172.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 45.8 mt -71.58 -15.12 62.26 Favored 'General case' 0 CA--C 1.552 1.046 0 CA-C-N 115.178 -0.919 . . . . 75.04 110.796 176.363 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -80.73 -20.73 42.16 Favored 'General case' 0 CA--C 1.564 1.503 0 C-N-CA 124.747 1.219 . . . . 71.51 109.888 174.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 135.03 -151.26 20.4 Favored Glycine 0 C--N 1.361 1.932 0 CA-C-O 119.628 -0.54 . . . . 62.43 112.41 -177.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -91.84 124.54 0.78 Allowed 'Trans proline' 0 C--N 1.368 1.591 0 C-N-CA 123.33 2.687 . . . . 70.1 111.807 170.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 22.7 m -116.98 160.71 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 C-N-CA 123.604 0.762 . . . . 62.04 110.771 179.389 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -115.28 110.39 19.35 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 109.001 -0.74 . . . . 62.51 109.001 178.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.498 HG21 HD22 ' A' ' 235' ' ' LEU . 5.9 p -97.09 138.29 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 123.37 0.668 . . . . 71.24 110.512 177.082 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -93.81 111.7 23.44 Favored 'General case' 0 C--O 1.239 0.533 0 C-N-CA 123.698 0.799 . . . . 73.32 109.009 173.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.458 HG21 ' HA2' ' A' ' 207' ' ' GLY . 13.8 m -86.47 140.66 34.0 Favored Pre-proline 0 CA--C 1.55 0.964 0 N-CA-C 108.91 -0.774 . . . . 71.11 108.91 177.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -62.12 143.38 94.62 Favored 'Trans proline' 0 CA--C 1.56 1.818 0 C-N-CA 122.501 2.134 . . . . 74.52 112.318 177.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.9 123.76 12.47 Favored 'Trans proline' 0 C--N 1.378 2.104 0 C-N-CA 122.408 2.072 . . . . 73.01 110.669 174.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 44.2 mtm105 64.07 48.88 2.87 Favored 'General case' 0 N--CA 1.475 0.824 0 O-C-N 124.233 0.958 . . . . 75.35 110.343 -173.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.8 t -71.16 170.63 12.55 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.319 0.58 . . . . 72.2 111.103 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.9 mp0 -121.91 139.39 53.71 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.221 1.008 . . . . 73.01 108.574 -176.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -76.62 127.69 33.28 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.288 0.635 . . . . 75.41 109.94 179.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.38 -4.71 23.36 Favored Glycine 0 C--N 1.339 0.746 0 N-CA-C 111.512 -0.635 . . . . 51.44 111.512 -173.077 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . 0.439 ' O ' ' HA ' ' A' ' 252' ' ' GLU . 60.6 mtt-85 -71.51 160.1 33.32 Favored 'General case' 0 C--N 1.36 1.042 0 C-N-CA 122.917 0.487 . . . . 74.1 110.762 173.669 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.451 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.1 OUTLIER -123.43 100.43 6.82 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.088 0.955 . . . . 74.42 108.774 179.69 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . 0.43 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 86.3 mt -84.89 104.85 15.2 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 108.92 -0.77 . . . . 74.22 108.92 -176.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 14.6 ttp180 -82.31 101.95 10.89 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 114.784 -1.098 . . . . 74.31 110.367 -171.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.514 ' HB3' ' HG3' ' A' ' 238' ' ' LYS . 48.9 mt -89.62 101.61 14.3 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 115.131 -0.94 . . . . 65.24 108.555 171.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 47.0 mtpt -73.06 149.15 43.41 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.354 0.662 . . . . 74.52 110.574 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 67.72 28.88 73.48 Favored Glycine 0 C--N 1.345 1.05 0 O-C-N 123.369 0.418 . . . . 74.55 113.413 -178.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . 0.514 ' HG3' ' HB3' ' A' ' 235' ' ' LEU . 0.0 OUTLIER -127.55 -8.38 5.69 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 124.165 0.986 . . . . 72.44 111.145 -176.973 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . 0.433 ' HA2' HD13 ' A' ' 193' ' ' LEU . . . -84.71 -163.97 37.42 Favored Glycine 0 C--N 1.344 0.977 0 CA-C-N 115.919 -0.582 . . . . 75.21 113.174 176.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.632 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 1.5 m-85 -85.99 158.88 55.39 Favored Pre-proline 0 N--CA 1.48 1.053 0 N-CA-C 109.341 -0.615 . . . . 73.22 109.341 179.014 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -47.53 129.55 16.83 Favored 'Trans proline' 0 C--N 1.382 2.32 0 C-N-CA 123.077 2.518 . . . . 73.22 113.598 174.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -165.34 -162.8 17.3 Favored Glycine 0 CA--C 1.535 1.282 0 CA-C-O 118.986 -0.897 . . . . 63.43 112.203 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_exo -47.05 -41.1 26.55 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 124.616 3.544 . . . . 71.43 115.378 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -87.47 21.0 2.63 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 123.965 0.906 . . . . 74.24 112.145 -177.456 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.15 -81.82 1.5 Allowed Glycine 0 C--N 1.346 1.102 0 N-CA-C 110.568 -1.013 . . . . 65.2 110.568 -173.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -113.2 135.41 53.85 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.624 -1.25 . . . . 74.5 107.624 169.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.48 -157.21 5.28 Favored Glycine 0 C--N 1.345 1.045 0 N-CA-C 115.152 0.821 . . . . 73.3 115.152 -169.165 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -111.27 164.58 12.74 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 123.155 0.582 . . . . 75.42 110.374 -175.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.616 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 20.0 tp -128.04 116.26 19.75 Favored 'General case' 0 C--O 1.218 -0.602 0 C-N-CA 124.644 1.178 . . . . 75.42 109.342 169.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . 0.451 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 10.6 m-85 -97.46 107.36 19.86 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 109.243 -0.651 . . . . 72.45 109.243 175.298 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.544 ' HB3' ' HB2' ' A' ' 197' ' ' LEU . 85.8 mt -86.58 115.4 24.04 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 124.004 0.922 . . . . 75.11 112.042 178.236 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.439 ' HA ' ' O ' ' A' ' 231' ' ' ARG . 36.4 tt0 -77.74 93.91 4.37 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 108.348 -0.982 . . . . 63.34 108.348 175.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.427 HG12 HG11 ' A' ' 199' ' ' VAL . 91.9 t -48.71 116.49 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 C-N-CA 124.705 1.202 . . . . 73.21 111.286 176.738 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 26.5 mmm180 -120.75 94.8 4.47 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 107.416 -1.328 . . . . 75.22 107.416 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 60.3 mt -77.69 106.98 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-N 115.379 -0.828 . . . . 74.2 109.366 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 CA--C 1.552 1.034 0 C-N-CA 124.034 0.934 . . . . 62.33 108.942 -179.701 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 111.289 0.107 . . . . 74.22 111.289 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 7.4 p -61.15 125.25 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 O-C-N 123.79 0.681 . . . . 64.52 110.946 -175.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -74.25 -75.92 0.15 Allowed 'General case' 0 C--N 1.346 0.427 0 N-CA-C 108.483 -0.932 . . . . 72.03 108.483 174.191 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -162.91 153.23 16.34 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 124.866 1.266 . . . . 74.11 108.416 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 8.4 p -67.74 121.03 16.13 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.916 0 CA-C-O 121.063 0.459 . . . . 73.31 109.798 172.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.571 HG22 ' HG3' ' A' ' 122' ' ' GLU . 11.4 t . . . . . 0 CA--C 1.549 0.906 0 C-N-CA 123.699 0.799 . . . . 61.13 111.86 -174.066 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 . . . . . 0 C--O 1.241 0.646 0 CA-C-O 121.973 0.892 . . . . 52.21 111.442 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.677 HD13 ' HA2' ' A' ' 165' ' ' GLY . 24.5 mt -94.36 155.26 17.07 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 106.681 -1.6 . . . . 70.24 106.681 159.284 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . 0.512 ' HE ' HD13 ' A' ' 175' ' ' LEU . 29.6 ttm180 -144.47 114.66 7.47 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 109.66 -0.496 . . . . 74.43 109.66 -174.147 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -126.8 126.46 43.42 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 123.523 0.729 . . . . 54.34 110.195 -177.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.571 ' HG3' HG22 ' A' ' 103' ' ' THR . 24.4 mt-10 -92.09 136.74 32.93 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 108.505 -0.924 . . . . 74.41 108.505 169.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -145.13 147.26 33.72 Favored Pre-proline 0 N--CA 1.468 0.44 0 C-N-CA 123.191 0.596 . . . . 74.43 110.578 -170.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.86 154.48 67.3 Favored 'Trans proline' 0 C--N 1.369 1.617 0 C-N-CA 121.877 1.718 . . . . 71.53 111.646 170.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 22.2 tp -149.5 150.34 32.15 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.811 0.844 . . . . 73.23 109.067 174.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.589 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 69.2 m -84.59 151.98 24.16 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 123.326 0.651 . . . . 72.42 109.487 172.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.495 HD11 ' O ' ' A' ' 183' ' ' HIS . 45.1 mt -58.19 -48.05 81.53 Favored 'General case' 0 N--CA 1.483 1.194 0 CA-C-O 121.881 0.848 . . . . 74.44 110.204 176.236 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.63 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.7 mp0 -57.88 -31.79 67.06 Favored 'General case' 0 N--CA 1.484 1.259 0 CA-C-N 114.328 -1.306 . . . . 74.12 111.97 178.06 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 38.0 mm-40 -88.95 -16.69 31.17 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 112.109 0.411 . . . . 63.14 112.109 178.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.67 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -63.26 -31.65 72.85 Favored 'General case' 0 C--O 1.25 1.12 0 CA-C-O 121.168 0.508 . . . . 74.45 110.152 162.853 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.546 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 17.1 t80 -71.87 -60.37 2.27 Favored 'General case' 0 C--N 1.351 0.642 0 CA-C-N 115.326 -0.852 . . . . 74.3 110.877 168.238 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -71.89 -28.62 63.64 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 113.605 0.965 . . . . 75.55 113.605 -168.233 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 74.09 -87.46 0.68 Allowed Glycine 0 CA--C 1.532 1.123 0 N-CA-C 110.738 -0.945 . . . . 63.51 110.738 -167.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 84.01 126.65 1.34 Allowed Glycine 0 C--N 1.352 1.449 0 C-N-CA 122.844 0.259 . . . . 43.34 113.129 174.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.429 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.7 mp0 -78.28 114.56 17.28 Favored 'General case' 0 C--N 1.345 0.392 0 N-CA-C 108.431 -0.952 . . . . 74.5 108.431 176.509 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 7.3 mpt_? -131.36 153.38 49.7 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 123.084 0.554 . . . . 74.22 109.884 176.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 14.7 p -72.89 140.9 17.13 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.083 0 C-N-CA 123.308 0.643 . . . . 73.3 111.779 -173.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 7.9 p -136.43 124.57 35.15 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 C-N-CA 125.239 1.416 . . . . 73.12 108.553 -179.425 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -116.57 96.44 5.51 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 107.358 -1.349 . . . . 71.15 107.358 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.487 HG12 HD12 ' A' ' 119' ' ' LEU . 90.0 t -130.73 131.49 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 122.992 0.517 . . . . 73.44 109.714 -178.531 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.02 30.08 19.6 Favored 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 124.962 1.305 . . . . 64.31 112.021 -179.278 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 92.07 -1.15 73.47 Favored Glycine 0 C--N 1.344 1.025 0 CA-C-N 115.336 -0.847 . . . . 75.23 114.137 173.741 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.84 119.15 38.64 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-N 118.284 1.042 . . . . 75.12 110.691 -179.312 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 63.2 ttp85 -92.66 106.66 18.6 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.139 0.975 . . . . 73.42 108.489 172.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 61.7 t -133.5 149.77 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 108.238 -1.023 . . . . 74.31 108.238 178.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 34.9 p -81.02 120.97 25.47 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 109.132 -0.692 . . . . 73.31 109.132 172.597 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.4 p -96.83 131.12 44.37 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 CA-C-O 121.19 0.519 . . . . 74.41 110.647 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . 0.429 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 40.6 ttp180 -104.28 102.06 11.76 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 107.746 -1.205 . . . . 75.53 107.746 175.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.663 ' HB ' HD12 ' A' ' 159' ' ' ILE . 30.8 pt -91.96 130.82 37.07 Favored Pre-proline 0 CA--C 1.549 0.941 0 N-CA-C 108.965 -0.754 . . . . 74.24 108.965 176.226 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -63.63 135.99 51.82 Favored 'Trans proline' 0 C--N 1.383 2.37 0 C-N-CA 122.88 2.387 . . . . 73.34 112.847 -171.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.402 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 76.0 Cg_exo -54.49 141.59 72.88 Favored 'Trans proline' 0 C--N 1.379 2.159 0 C-N-CA 123.427 2.751 . . . . 73.03 112.381 169.6 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 104.18 24.66 7.45 Favored Glycine 0 C--N 1.338 0.675 0 N-CA-C 111.645 -0.582 . . . . 71.43 111.645 -176.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.67 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.4 p -95.06 158.74 2.93 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.917 0 N-CA-C 108.504 -0.924 . . . . 72.31 108.504 -177.268 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.486 ' HA ' HD12 ' A' ' 180' ' ' LEU . 27.0 mtm180 -149.62 176.15 10.91 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 124.426 1.09 . . . . 75.14 110.135 -170.621 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -52.93 124.86 15.3 Favored 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 124.017 0.927 . . . . 62.52 111.744 173.148 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.85 10.03 83.44 Favored Glycine 0 C--N 1.347 1.182 0 O-C-N 123.534 0.521 . . . . 72.54 113.809 177.36 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.444 ' HB3' HG21 ' A' ' 153' ' ' VAL . 33.0 t -76.97 122.35 24.77 Favored 'General case' 0 C--O 1.246 0.879 0 N-CA-C 109.391 -0.596 . . . . 74.33 109.391 179.342 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.471 HG22 HD22 ' A' ' 175' ' ' LEU . 7.1 p -94.14 121.88 45.14 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.964 0 C-N-CA 123.77 0.828 . . . . 73.42 109.689 -179.335 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.663 HD12 ' HB ' ' A' ' 149' ' ' ILE . 46.3 mt -110.52 118.16 56.51 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 124.273 1.029 . . . . 74.52 109.999 -172.475 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 60.0 ttp85 -95.78 109.96 22.19 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 122.863 0.465 . . . . 75.44 110.408 -178.169 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 10.7 m -109.48 101.57 46.44 Favored Pre-proline 0 CA--C 1.569 1.7 0 C-N-CA 122.933 0.493 . . . . 63.23 110.125 -178.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . 0.49 ' HA ' ' HB3' ' A' ' 173' ' ' ASP . 33.2 Cg_exo -64.1 147.61 91.48 Favored 'Trans proline' 0 C--N 1.384 2.403 0 C-N-CA 123.554 2.836 . . . . 62.02 114.314 -172.675 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.18 5.08 89.36 Favored Glycine 0 C--N 1.348 1.249 0 CA-C-N 115.058 -0.974 . . . . 72.14 114.447 175.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 46.9 tpp -96.43 -36.14 10.92 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.092 0.557 . . . . 73.52 110.95 -177.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . 0.677 ' HA2' HD13 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.349 1.26 0 CA-C-N 115.635 -0.711 . . . . 72.03 114.3 -175.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo . . . . . 0 CA--C 1.549 1.261 0 CA-C-O 120.996 0.332 . . . . 61.01 111.77 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -101.09 160.42 18.6 Favored Glycine 0 C--N 1.34 0.763 0 N-CA-C 111.075 -0.81 . . . . 62.35 111.075 176.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.49 ' HB3' ' HA ' ' A' ' 162' ' ' PRO . 0.9 OUTLIER -124.94 179.59 4.96 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.696 0.798 . . . . 74.25 110.966 -167.021 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 21.2 tp -127.74 118.91 24.66 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.146 0.578 . . . . 75.24 109.686 175.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.512 HD13 ' HE ' ' A' ' 120' ' ' ARG . 86.0 mt -86.19 99.32 11.45 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 124.608 1.163 . . . . 63.15 110.391 177.606 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 76.5 mt -89.82 102.61 15.31 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.704 0.802 . . . . 73.53 110.576 174.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.447 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 29.3 t -90.9 102.79 13.79 Favored 'Isoleucine or valine' 0 C--O 1.244 0.777 0 N-CA-C 108.313 -0.995 . . . . 63.02 108.313 175.597 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 5.5 m -79.75 150.47 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 CA-C-O 121.65 0.738 . . . . 75.5 111.479 -173.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 19.6 mmt85 -122.26 98.47 5.95 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 114.482 -1.235 . . . . 73.24 107.811 -178.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.486 HD12 ' HA ' ' A' ' 154' ' ' ARG . 21.5 mt -68.34 151.49 46.81 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.207 0.603 . . . . 73.42 112.443 -177.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.589 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 60.6 mt -53.69 138.58 51.95 Favored Pre-proline 0 CA--C 1.559 1.322 0 O-C-N 124.091 0.869 . . . . 74.0 111.324 -179.304 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -57.32 -13.08 11.94 Favored 'Trans proline' 0 C--N 1.383 2.375 0 C-N-CA 124.239 3.293 . . . . 74.12 115.584 -173.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . 0.495 ' O ' HD11 ' A' ' 127' ' ' LEU . 1.0 OUTLIER -87.52 114.33 58.3 Favored Pre-proline 0 CA--C 1.548 0.889 0 N-CA-C 108.708 -0.849 . . . . 75.14 108.708 173.247 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -92.62 126.67 0.75 Allowed 'Trans proline' 0 C--N 1.377 2.066 0 C-N-CA 122.568 2.179 . . . . 74.31 112.287 173.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.9 p -127.29 -41.8 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 N-CA-C 109.565 -0.531 . . . . 61.13 109.565 174.302 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . 0.417 ' HE2' HD13 ' A' ' 193' ' ' LEU . 6.5 m-85 -107.52 125.2 50.98 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 115.896 -0.593 . . . . 74.31 110.691 -178.074 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.57 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 6.2 mpt_? -112.38 103.97 12.11 Favored 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 107.237 -1.394 . . . . 72.12 107.237 175.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 42.1 tp -92.72 136.51 33.17 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.115 0.566 . . . . 71.14 109.8 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -143.68 134.05 24.64 Favored 'General case' 0 C--O 1.241 0.657 0 N-CA-C 109.225 -0.657 . . . . 75.35 109.225 165.586 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 68.28 -81.88 0.2 Allowed Glycine 0 C--N 1.352 1.426 0 O-C-N 123.913 0.758 . . . . 71.22 113.087 -178.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 24.1 pt20 -144.34 -17.57 0.56 Allowed 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 123.645 0.778 . . . . 65.51 110.755 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -109.86 158.27 18.35 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-O 121.269 0.557 . . . . 75.25 111.683 -170.049 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.468 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 77.4 mt -111.34 163.38 14.04 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.005 1.322 . . . . 74.44 111.779 -168.67 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . 0.57 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 82.5 m-85 -139.52 124.16 18.37 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 114.563 -1.199 . . . . 74.51 108.516 170.032 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -135.84 171.43 14.47 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 122.836 0.454 . . . . 65.32 110.157 175.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 7.8 m -102.48 134.42 45.84 Favored 'General case' 0 CA--C 1.544 0.712 0 N-CA-C 109.389 -0.597 . . . . 71.31 109.389 178.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.597 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 42.7 tp -109.98 114.09 27.34 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.382 1.073 . . . . 62.32 110.133 -177.384 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -94.11 103.71 15.75 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.414 0.686 . . . . 74.01 109.746 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . 0.546 HG11 HG12 ' A' ' 223' ' ' VAL . 3.5 m -113.2 142.44 27.42 Favored Pre-proline 0 N--CA 1.479 1.012 0 C-N-CA 122.981 0.513 . . . . 74.3 109.668 176.666 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -68.96 155.49 68.33 Favored 'Trans proline' 0 C--N 1.365 1.439 0 C-N-CA 122.33 2.02 . . . . 74.11 111.38 167.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . 0.404 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -60.04 -45.85 98.02 Favored Pre-proline 0 N--CA 1.479 0.979 0 CA-C-O 118.737 -0.649 . . . . 73.21 112.215 177.518 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . 0.41 ' O ' HG23 ' A' ' 206' ' ' VAL . 9.8 Cg_endo -49.77 -45.76 30.49 Favored 'Trans proline' 0 C--N 1.391 2.781 0 C-N-CA 122.568 2.179 . . . . 60.42 113.348 171.479 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . 0.49 ' HA ' ' HA3' ' A' ' 207' ' ' GLY . 3.5 mt -67.64 -43.94 86.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 O-C-N 121.967 -0.458 . . . . 72.51 111.569 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -52.51 -43.96 65.42 Favored 'General case' 0 CA--C 1.538 0.489 0 O-C-N 124.446 1.091 . . . . 55.24 111.177 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . 0.631 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 28.8 m -88.91 -58.46 3.46 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.262 0 N-CA-C 113.015 0.746 . . . . 74.53 113.015 -176.555 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . 0.511 HG13 HG22 ' A' ' 205' ' ' VAL . 18.6 m -104.43 -25.28 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 113.328 0.862 . . . . 74.22 113.328 -172.124 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.49 ' HA3' ' HA ' ' A' ' 203' ' ' ILE . . . -74.96 -70.82 1.21 Allowed Glycine 0 C--N 1.346 1.123 0 C-N-CA 121.565 -0.35 . . . . 64.35 112.289 -168.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 92.15 -2.06 74.6 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-O 119.2 -0.778 . . . . 74.34 114.131 170.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 40.8 mtmt -139.33 138.93 37.09 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 108.352 -0.981 . . . . 74.01 108.352 178.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . 0.501 HG11 HG13 ' A' ' 199' ' ' VAL . 7.3 p -160.58 145.98 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 C-N-CA 123.897 0.879 . . . . 75.01 108.71 -178.771 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . 0.462 ' HA ' ' HA ' ' A' ' 220' ' ' GLU . 69.0 mtt180 -93.56 123.88 37.17 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 122.759 0.424 . . . . 74.24 109.951 177.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.458 ' HB2' HD11 ' A' ' 197' ' ' LEU . . . -101.18 165.02 11.51 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 124.237 1.015 . . . . 73.35 109.146 173.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 66.2 mmm -103.34 146.75 28.0 Favored 'General case' 0 C--O 1.239 0.551 0 CA-C-O 121.162 0.506 . . . . 74.33 110.419 175.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 214' ' ' THR . . . . . 0.413 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.3 t -138.6 169.08 18.43 Favored 'General case' 0 C--O 1.238 0.467 0 CA-C-N 114.726 -1.125 . . . . 70.43 109.709 173.721 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . 0.63 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 81.9 mt -70.92 -3.3 18.53 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 114.844 -1.071 . . . . 70.31 113.223 -174.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 1.8 pp20? -121.0 -1.45 9.85 Favored 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.274 0.629 . . . . 73.1 112.52 178.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.16 -158.51 27.71 Favored Glycine 0 N--CA 1.475 1.278 0 CA-C-O 119.719 -0.489 . . . . 44.25 113.443 176.043 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -90.76 129.47 1.43 Allowed 'Trans proline' 0 C--N 1.367 1.52 0 C-N-CA 123.223 2.616 . . . . 62.22 112.412 174.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . 0.401 HG12 ' HE3' ' A' ' 238' ' ' LYS . 31.5 m -109.66 151.43 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 123.819 0.848 . . . . 71.32 109.434 171.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . 0.462 ' HA ' ' HA ' ' A' ' 211' ' ' ARG . 32.9 tt0 -114.58 114.62 25.97 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.647 -0.501 . . . . 64.32 109.647 173.055 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.419 HG22 HD21 ' A' ' 235' ' ' LEU . 4.5 p -100.56 144.32 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 C-N-CA 124.703 1.201 . . . . 61.21 110.744 178.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -95.96 113.02 24.6 Favored 'General case' 0 C--O 1.24 0.561 0 N-CA-C 109.159 -0.682 . . . . 73.34 109.159 173.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.546 HG12 HG11 ' A' ' 199' ' ' VAL . 14.1 m -84.53 138.6 38.4 Favored Pre-proline 0 N--CA 1.481 1.097 0 N-CA-C 108.86 -0.792 . . . . 74.33 108.86 176.36 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -54.3 140.68 72.51 Favored 'Trans proline' 0 C--N 1.379 2.136 0 C-N-CA 122.625 2.217 . . . . 72.53 112.622 177.283 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -54.17 112.74 1.07 Allowed 'Trans proline' 0 C--N 1.379 2.181 0 C-N-CA 122.881 2.388 . . . . 75.13 111.282 174.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . 0.631 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 60.6 mtp180 63.27 58.43 1.4 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.531 1.133 . . . . 74.52 110.634 -171.164 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.8 t -71.15 171.82 10.31 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.334 -0.848 . . . . 74.54 110.431 175.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.5 mp0 -121.18 146.35 46.87 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.711 0.804 . . . . 75.51 109.225 -175.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -72.52 113.73 9.87 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 123.218 0.607 . . . . 65.22 110.292 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.6 4.88 19.23 Favored Glycine 0 C--N 1.339 0.712 0 CA-C-N 115.73 -0.668 . . . . 72.21 112.399 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 61.3 mtp180 -76.17 153.25 36.32 Favored 'General case' 0 N--CA 1.477 0.918 0 CA-C-N 117.345 0.573 . . . . 73.44 109.962 172.092 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.482 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 0.2 OUTLIER -111.71 119.27 38.08 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 123.727 0.811 . . . . 73.23 108.934 -179.746 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 70.2 mt -106.02 114.49 28.66 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 122.85 0.46 . . . . 74.31 109.827 -178.022 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . 0.562 ' HG3' ' HB3' ' A' ' 248' ' ' ASP . 39.7 ttp180 -82.48 104.22 12.61 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 124.863 1.265 . . . . 74.41 111.354 -171.23 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.493 ' HB2' ' HB3' ' A' ' 249' ' ' LEU . 38.2 mt -89.48 97.63 11.3 Favored 'General case' 0 C--O 1.239 0.531 0 C-N-CA 123.231 0.612 . . . . 71.55 109.594 172.618 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -72.81 134.95 45.12 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 114.766 -1.106 . . . . 64.51 110.119 -178.323 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 85.26 24.65 43.02 Favored Glycine 0 C--N 1.34 0.77 0 O-C-N 123.493 0.496 . . . . 74.44 113.247 178.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . 0.401 ' HE3' HG12 ' A' ' 219' ' ' VAL . 70.3 mmtt -124.52 -6.88 7.5 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 123.223 0.609 . . . . 75.43 112.353 176.627 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -85.32 -161.67 34.74 Favored Glycine 0 C--N 1.345 1.082 0 O-C-N 123.53 0.518 . . . . 60.42 112.506 175.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.546 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 92.2 m-85 -97.24 147.0 32.32 Favored Pre-proline 0 N--CA 1.481 1.082 0 C-N-CA 123.524 0.729 . . . . 75.25 111.282 175.434 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . 0.41 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 36.2 Cg_endo -64.43 132.52 33.75 Favored 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 122.257 1.971 . . . . 75.33 111.315 171.452 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -156.83 -148.64 5.15 Favored Glycine 0 CA--C 1.532 1.152 0 CA-C-O 119.01 -0.883 . . . . 73.5 111.595 -176.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -51.63 -53.96 6.15 Favored 'Trans proline' 0 C--N 1.377 2.055 0 C-N-CA 123.953 3.102 . . . . 73.13 114.999 -177.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -83.67 -24.46 31.32 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 122.608 0.363 . . . . 72.2 111.778 -177.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 141.86 -155.4 25.4 Favored Glycine 0 N--CA 1.47 0.92 0 N-CA-C 110.091 -1.204 . . . . 74.24 110.091 -177.088 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.41 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 22.1 ttm180 -65.13 134.73 54.39 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 118.511 1.155 . . . . 73.13 109.351 171.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -75.05 -170.85 27.49 Favored Glycine 0 C--O 1.249 1.052 0 CA-C-O 121.974 0.763 . . . . 73.12 114.686 -170.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . 0.562 ' HB3' ' HG3' ' A' ' 234' ' ' ARG . 12.1 m-20 -129.33 136.9 50.61 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 114.268 -0.966 . . . . 74.42 109.565 -169.555 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.493 ' HB3' ' HB2' ' A' ' 235' ' ' LEU . 20.7 tp -97.01 111.74 23.82 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.889 -0.411 . . . . 74.13 109.889 179.559 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -91.85 106.63 18.61 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.222 0.534 . . . . 74.12 109.813 177.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.597 ' HB3' ' HB2' ' A' ' 197' ' ' LEU . 85.9 mt -87.53 120.01 28.41 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 124.245 1.018 . . . . 70.34 112.379 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -80.61 93.86 6.2 Favored 'General case' 0 CA--C 1.539 0.535 0 N-CA-C 108.093 -1.077 . . . . 75.44 108.093 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 60.3 t -48.96 123.68 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.561 1.144 . . . . 73.01 111.184 175.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 38.5 mmm-85 -128.69 100.94 5.92 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 107.219 -1.4 . . . . 75.01 107.219 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 56.5 mt -83.34 117.84 29.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 115.149 -0.932 . . . . 70.3 110.05 -177.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.8 t . . . . . 0 CA--C 1.556 1.187 0 C-N-CA 124.23 1.012 . . . . 72.34 108.603 174.53 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.65 HD21 ' HG3' ' A' ' 136' ' ' ARG . 20.4 tp . . . . . 0 N--CA 1.474 0.737 0 N-CA-C 110.236 -0.283 . . . . 61.32 110.236 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.572 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 10.0 p -60.76 126.79 19.26 Favored 'Isoleucine or valine' 0 C--N 1.36 1.063 0 O-C-N 123.465 0.478 . . . . 73.01 111.025 175.579 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -83.31 -65.9 0.95 Allowed 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.493 -0.776 . . . . 73.12 109.699 -179.104 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -150.13 147.45 27.77 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 114.987 -1.006 . . . . 74.1 110.258 -169.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 92.9 t -78.81 124.59 37.4 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 N-CA-C 109.259 -0.645 . . . . 74.31 109.259 169.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 70.1 p . . . . . 0 CA--C 1.55 0.956 0 C-N-CA 123.359 0.664 . . . . 73.05 109.471 176.042 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 16.2 t70 . . . . . 0 N--CA 1.475 0.818 0 N-CA-C 108.591 -0.892 . . . . 74.5 108.591 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 28.6 tp -101.61 142.07 33.53 Favored 'General case' 0 C--O 1.22 -0.453 0 N-CA-C 107.356 -1.35 . . . . 72.33 107.356 -178.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 37.3 ttp-105 -143.28 132.93 23.73 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 108.513 -0.921 . . . . 72.23 108.513 -178.091 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -144.75 138.41 27.16 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 123.953 0.901 . . . . 75.54 109.052 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -103.26 148.98 25.15 Favored 'General case' 0 C--O 1.252 1.191 0 CA-C-O 120.935 0.398 . . . . 72.15 110.101 176.344 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.572 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.6 pt? -146.95 130.93 8.44 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.674 -0.694 . . . . 73.24 111.967 -170.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.97 120.64 7.63 Favored 'Trans proline' 0 C--N 1.378 2.084 0 C-N-CA 122.49 2.127 . . . . 74.54 111.477 174.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 18.0 tp -120.42 152.79 37.45 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.542 1.137 . . . . 70.04 109.165 179.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.497 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 22.4 m -86.25 155.41 20.7 Favored 'General case' 0 CA--C 1.551 0.993 0 N-CA-C 109.365 -0.606 . . . . 63.15 109.365 172.009 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 28.6 mt -55.34 -49.23 72.76 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-O 121.923 0.868 . . . . 73.13 109.934 175.113 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.605 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.3 mp0 -55.96 -35.44 66.69 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 113.943 -1.48 . . . . 73.32 111.544 177.665 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.497 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 35.7 mm-40 -83.11 -19.57 36.5 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 122.993 0.517 . . . . 73.33 112.077 -179.474 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.538 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -65.27 -31.66 72.92 Favored 'General case' 0 C--O 1.246 0.919 0 CA-C-O 121.169 0.509 . . . . 72.44 110.162 165.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.438 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 6.6 t80 -77.28 -47.36 20.29 Favored 'General case' 0 CA--C 1.546 0.789 0 CA-C-N 115.366 -0.834 . . . . 71.51 112.279 170.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -76.75 -30.19 56.46 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 112.54 0.57 . . . . 75.43 112.54 -171.224 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 67.92 -107.08 1.91 Allowed Glycine 0 CA--C 1.533 1.218 0 N-CA-C 111.564 -0.614 . . . . 65.01 111.564 -173.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.33 162.43 36.39 Favored Glycine 0 C--N 1.353 1.496 0 N-CA-C 114.904 0.722 . . . . 63.14 114.904 168.621 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.468 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 1.6 mp0 -96.03 114.17 25.86 Favored 'General case' 0 C--N 1.357 0.917 0 N-CA-C 108.856 -0.794 . . . . 75.21 108.856 179.185 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.65 ' HG3' HD21 ' A' ' 98' ' ' LEU . 4.6 mmp_? -130.37 139.25 50.66 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.836 0.854 . . . . 51.35 109.372 -174.78 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 17.9 m -74.55 128.23 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 CA-C-O 121.638 0.732 . . . . 75.4 111.614 -172.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.426 HG12 HG11 ' A' ' 99' ' ' VAL . 21.7 t -119.87 129.65 75.16 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 C-N-CA 125.292 1.437 . . . . 75.22 109.168 -177.531 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -121.8 97.74 5.63 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 108.746 -0.835 . . . . 73.32 108.746 177.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.443 HG22 HD22 ' A' ' 174' ' ' LEU . 27.9 m -137.82 142.87 35.02 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.885 0 C-N-CA 125.09 1.356 . . . . 72.13 108.336 -177.304 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.55 19.2 11.47 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 124.081 0.953 . . . . 73.1 112.665 176.48 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.08 22.87 75.82 Favored Glycine 0 C--N 1.352 1.463 0 CA-C-N 116.393 -0.367 . . . . 64.3 112.359 -174.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -120.79 135.65 55.1 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.366 1.067 . . . . 75.31 108.861 -178.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 41.1 ttt180 -111.41 106.24 15.09 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.005 -0.739 . . . . 74.22 109.005 175.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 29.2 t -132.59 126.89 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 N-CA-C 108.461 -0.94 . . . . 64.14 108.461 -178.33 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 72.6 p -71.53 122.87 21.24 Favored 'General case' 0 CA--C 1.54 0.592 0 N-CA-C 109.084 -0.71 . . . . 71.13 109.084 171.651 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.468 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 7.3 p -96.79 140.72 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 109.769 -0.456 . . . . 73.33 109.769 -177.742 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.9 ttp180 -109.35 99.96 9.13 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 107.395 -1.335 . . . . 70.13 107.395 171.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.551 ' HB ' HD13 ' A' ' 159' ' ' ILE . 35.8 pt -89.27 127.53 54.8 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 108.467 -0.938 . . . . 72.34 108.467 175.128 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.09 135.86 33.2 Favored 'Trans proline' 0 C--N 1.376 2.008 0 C-N-CA 122.477 2.118 . . . . 75.32 113.061 -173.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_exo -46.25 119.92 3.37 Favored 'Trans proline' 0 C--N 1.376 2.012 0 C-N-CA 123.937 3.091 . . . . 73.45 112.75 167.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 123.48 58.17 0.19 Allowed Glycine 0 N--CA 1.465 0.625 0 N-CA-C 110.635 -0.986 . . . . 74.5 110.635 -175.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.538 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.0 p -134.17 161.48 40.7 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.319 0 C-N-CA 123.698 0.799 . . . . 75.34 109.397 -178.162 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 14.5 mtp180 -141.35 170.94 14.78 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 126.05 1.74 . . . . 72.24 109.747 -169.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -55.24 126.54 25.33 Favored 'General case' 0 CA--C 1.551 1.015 0 CA-C-N 116.027 -0.533 . . . . 71.35 110.695 164.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.38 2.7 74.97 Favored Glycine 0 C--N 1.346 1.126 0 CA-C-O 119.781 -0.455 . . . . 60.13 113.891 179.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 42.1 t -77.76 130.96 37.39 Favored 'General case' 0 C--O 1.247 0.932 0 N-CA-C 109.677 -0.49 . . . . 74.52 109.677 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.416 HG13 HD23 ' A' ' 175' ' ' LEU . 15.3 t -106.78 121.52 59.62 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-N 114.743 -1.117 . . . . 75.02 109.275 -168.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.551 HD13 ' HB ' ' A' ' 149' ' ' ILE . 23.6 mt -109.73 113.93 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 123.65 0.78 . . . . 74.55 110.686 -171.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.404 ' HA ' HD22 ' A' ' 175' ' ' LEU . 48.6 ttm-85 -83.19 119.42 24.52 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.22 0.608 . . . . 72.51 110.119 177.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.517 ' O ' ' HA ' ' A' ' 173' ' ' ASP . 5.1 m -123.94 132.14 24.28 Favored Pre-proline 0 N--CA 1.481 1.106 0 C-N-CA 123.138 0.575 . . . . 75.23 109.822 -178.362 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.92 157.26 43.22 Favored 'Trans proline' 0 C--N 1.374 1.899 0 C-N-CA 122.54 2.16 . . . . 73.34 113.889 -175.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.52 24.14 63.56 Favored Glycine 0 C--N 1.35 1.31 0 CA-C-N 115.128 -0.942 . . . . 73.34 115.389 171.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.415 ' SD ' HD21 ' A' ' 174' ' ' LEU . 62.3 mtt -124.66 -61.09 1.34 Allowed 'General case' 0 N--CA 1.493 1.708 0 CA-C-N 119.075 1.437 . . . . 73.23 112.919 -179.137 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.693 0 C-N-CA 121.699 -0.286 . . . . 75.12 113.605 -176.223 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo . . . . . 0 CA--C 1.547 1.16 0 N-CA-C 111.031 -0.411 . . . . 73.13 111.031 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . 85.11 109.28 0.67 Allowed Glycine 0 C--O 1.22 -0.757 0 CA-C-O 119.22 -0.767 . . . . 72.21 112.762 178.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.517 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 47.3 m-20 -144.98 134.52 23.24 Favored 'General case' 0 N--CA 1.481 1.119 0 CA-C-N 117.899 0.849 . . . . 72.52 111.489 172.398 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.443 HD22 HG22 ' A' ' 140' ' ' VAL . 28.1 tp -112.16 126.6 55.38 Favored 'General case' 0 C--N 1.347 0.477 0 N-CA-C 108.459 -0.941 . . . . 74.22 108.459 171.082 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.416 HD23 HG13 ' A' ' 158' ' ' VAL . 29.9 mt -93.99 100.73 12.82 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.539 1.135 . . . . 73.52 110.163 176.661 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 62.9 mt -87.11 104.45 16.36 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.532 0.733 . . . . 74.23 111.272 176.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 23.4 t -90.08 100.3 10.77 Favored 'Isoleucine or valine' 0 C--O 1.243 0.748 0 N-CA-C 108.101 -1.074 . . . . 74.12 108.101 175.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 3.2 m -78.25 149.88 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-O 121.624 0.726 . . . . 74.11 111.32 -174.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 33.0 mmt180 -119.22 95.29 4.74 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.497 -1.229 . . . . 75.24 107.963 -177.321 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 39.6 mt -67.99 147.91 51.77 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 110.192 -0.299 . . . . 61.1 110.192 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.415 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 47.5 mt -54.2 146.83 29.15 Favored Pre-proline 0 CA--C 1.562 1.415 0 C-N-CA 124.111 0.964 . . . . 73.33 111.417 -174.33 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -61.51 77.11 0.09 OUTLIER 'Trans proline' 0 C--N 1.379 2.173 0 C-N-CA 123.176 2.584 . . . . 73.03 111.447 171.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 8.2 t60 170.78 87.69 0.04 OUTLIER Pre-proline 0 CA--C 1.547 0.859 0 C-N-CA 126.242 1.817 . . . . 74.44 107.287 -166.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -98.76 125.27 0.17 Allowed 'Trans proline' 0 CA--C 1.564 1.994 0 C-N-CA 123.316 2.678 . . . . 74.43 113.188 172.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -122.64 -42.0 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.632 -0.668 . . . . 71.43 109.413 174.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . 0.402 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 4.7 m-85 -98.08 128.36 44.56 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.19 -0.914 . . . . 75.13 110.304 -178.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 10.4 mtt180 -112.63 103.98 12.04 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 106.218 -1.771 . . . . 72.41 106.218 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.418 HD13 ' O ' ' A' ' 192' ' ' ASP . 42.7 tp -81.44 110.84 17.24 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-O 121.259 0.552 . . . . 74.22 109.576 176.585 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.11 99.49 10.5 Favored 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 106.393 -1.706 . . . . 72.21 106.393 171.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 62.7 -94.9 0.11 Allowed Glycine 0 C--N 1.349 1.294 0 O-C-N 124.018 0.823 . . . . 65.4 113.352 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . 0.535 HE22 ' HB3' ' A' ' 244' ' ' ALA . 8.7 pt20 -108.46 -19.2 13.53 Favored 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 123.742 0.817 . . . . 73.33 110.849 178.042 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . 0.418 ' O ' HD13 ' A' ' 188' ' ' LEU . 29.0 m-20 -97.0 155.03 16.95 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 123.876 0.87 . . . . 75.02 111.63 -172.541 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.459 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 82.6 mt -109.53 154.33 22.86 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 124.206 1.003 . . . . 74.45 109.484 -177.55 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -137.17 121.83 18.55 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 107.502 -1.296 . . . . 74.25 107.502 171.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -134.03 141.51 47.24 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 108.632 -0.877 . . . . 55.45 108.632 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 3.5 m -82.3 122.46 27.98 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 109.747 -0.464 . . . . 65.12 109.747 -178.706 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.441 HD12 ' HB2' ' A' ' 212' ' ' ALA . 57.2 tp -107.75 112.2 24.76 Favored 'General case' 0 C--O 1.216 -0.69 0 C-N-CA 124.335 1.054 . . . . 70.51 109.116 -178.706 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -93.52 108.23 19.96 Favored 'General case' 0 N--CA 1.474 0.755 0 CA-C-O 121.338 0.59 . . . . 72.22 109.617 177.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . 0.459 HG22 HG22 ' A' ' 210' ' ' VAL . 65.2 t -101.37 126.0 35.93 Favored Pre-proline 0 N--CA 1.474 0.74 0 C-N-CA 124.148 0.979 . . . . 75.2 109.344 -176.659 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_exo -57.18 139.29 89.59 Favored 'Trans proline' 0 C--N 1.369 1.622 0 C-N-CA 122.624 2.216 . . . . 62.21 111.503 171.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -55.31 -41.83 92.79 Favored Pre-proline 0 N--CA 1.482 1.136 0 N-CA-C 113.673 0.99 . . . . 74.32 113.673 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo -47.58 -52.91 7.25 Favored 'Trans proline' 0 C--N 1.386 2.519 0 C-N-CA 122.166 1.911 . . . . 73.15 113.621 168.013 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . 0.538 HG21 HG12 ' A' ' 210' ' ' VAL . 9.3 mt -67.73 -33.33 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 123.035 0.534 . . . . 65.53 111.689 -179.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -68.39 -42.24 79.34 Favored 'General case' 0 C--O 1.245 0.861 0 C-N-CA 123.122 0.569 . . . . 70.11 111.855 -177.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.2 m -77.44 -40.78 29.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 CA-C-N 115.729 -0.669 . . . . 72.24 110.968 -177.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.1 m -79.16 -30.38 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 CA-C-O 120.841 0.353 . . . . 75.22 111.437 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.511 ' HA2' HG22 ' A' ' 223' ' ' VAL . . . 79.87 67.37 1.58 Allowed Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.683 -0.689 . . . . 74.14 112.513 -175.323 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -97.92 -148.99 24.56 Favored Glycine 0 C--N 1.35 1.347 0 CA-C-N 116.688 0.244 . . . . 43.0 112.546 176.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . 0.675 ' HD3' ' HB2' ' A' ' 220' ' ' GLU . 4.7 ttmp? -125.54 131.44 52.77 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.517 0.727 . . . . 74.21 109.081 -178.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . 0.538 HG12 HG21 ' A' ' 203' ' ' ILE . 5.7 m -120.87 135.76 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.357 -0.979 . . . . 75.34 108.357 172.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . 0.531 ' HD3' ' HB2' ' A' ' 218' ' ' PRO . 35.0 ttm105 -96.26 117.15 30.2 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 121.279 0.561 . . . . 74.33 109.699 178.766 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.441 ' HB2' HD12 ' A' ' 197' ' ' LEU . . . -99.78 155.4 17.66 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.027 0.931 . . . . 75.24 109.681 178.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 58.1 mmm -92.4 128.21 38.17 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 109.82 -0.437 . . . . 72.22 109.82 172.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 214' ' ' THR . . . . . 0.402 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.0 t -114.42 173.01 6.67 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-N 115.277 -0.874 . . . . 73.1 109.172 167.357 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . 0.605 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 73.1 mt -75.28 -2.99 30.72 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-N 115.449 -0.796 . . . . 75.52 112.614 -172.794 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.65 7.76 11.12 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 123.541 0.736 . . . . 72.22 112.122 179.219 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 137.01 -161.16 25.11 Favored Glycine 0 N--CA 1.476 1.362 0 CA-C-O 119.817 -0.435 . . . . 73.2 112.91 178.143 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . 0.531 ' HB2' ' HD3' ' A' ' 211' ' ' ARG . 98.5 Cg_endo -94.35 125.17 0.45 Allowed 'Trans proline' 0 C--N 1.37 1.681 0 C-N-CA 123.499 2.799 . . . . 62.01 112.763 176.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.7 m -108.85 146.28 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 123.322 0.649 . . . . 75.11 110.52 175.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . 0.675 ' HB2' ' HD3' ' A' ' 209' ' ' LYS . 9.9 pt-20 -113.73 104.66 12.43 Favored 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 108.996 -0.742 . . . . 75.11 108.996 -177.251 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.5 p -97.61 135.54 31.65 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 CA-C-N 115.656 -0.702 . . . . 74.32 110.832 -179.084 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -93.93 117.63 30.37 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-N 115.269 -0.878 . . . . 63.54 109.418 176.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.511 HG22 ' HA2' ' A' ' 207' ' ' GLY . 21.4 m -84.22 140.06 39.34 Favored Pre-proline 0 CA--C 1.553 1.096 0 N-CA-C 109.615 -0.513 . . . . 72.54 109.615 176.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -64.37 144.23 85.13 Favored 'Trans proline' 0 C--N 1.378 2.081 0 C-N-CA 122.583 2.189 . . . . 71.31 112.065 173.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -56.52 126.89 23.77 Favored 'Trans proline' 0 C--N 1.371 1.73 0 C-N-CA 122.746 2.297 . . . . 74.13 111.76 171.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 50.9 mtt180 65.64 44.28 3.02 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 124.445 1.098 . . . . 74.42 110.592 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 5.5 t -77.43 168.84 19.35 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 122.874 0.469 . . . . 65.44 110.046 177.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -130.72 152.06 50.48 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 122.893 0.477 . . . . 71.22 109.782 -178.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.61 134.06 48.32 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.752 0.821 . . . . 74.14 111.166 178.454 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.2 -8.11 20.91 Favored Glycine 0 C--N 1.341 0.854 0 CA-C-O 119.562 -0.576 . . . . 73.44 112.755 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -78.84 159.31 27.88 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-N 117.45 0.625 . . . . 73.45 109.483 175.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.571 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 12.9 mptt -118.57 102.6 9.01 Favored 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 123.748 0.819 . . . . 74.14 109.37 177.41 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . 0.434 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 83.3 mt -78.92 104.61 9.67 Favored 'General case' 0 C--N 1.355 0.805 0 N-CA-C 108.463 -0.94 . . . . 74.35 108.463 -176.116 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 22.3 ttp85 -79.65 121.49 25.36 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 115.261 -0.881 . . . . 75.03 110.446 -169.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 34.4 mt -105.94 120.09 40.87 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.733 0.813 . . . . 73.34 109.93 175.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -70.55 128.32 35.74 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 124.327 1.051 . . . . 74.43 112.237 -169.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 81.56 7.48 88.13 Favored Glycine 0 C--N 1.349 1.267 0 O-C-N 123.718 0.636 . . . . 74.52 114.453 171.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 38.2 mmtm -85.16 -23.33 28.42 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 117.192 0.496 . . . . 74.31 112.237 -178.141 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -81.62 173.74 53.97 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 111.861 -0.495 . . . . 75.34 111.861 176.229 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.438 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 88.2 m-85 -81.15 150.82 68.96 Favored Pre-proline 0 N--CA 1.477 0.894 0 N-CA-C 112.739 0.644 . . . . 73.21 112.739 -172.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -55.61 132.15 50.37 Favored 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.066 2.511 . . . . 75.54 111.226 170.151 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -160.81 -150.8 6.0 Favored Glycine 0 CA--C 1.532 1.154 0 CA-C-O 119.595 -0.558 . . . . 63.13 112.05 -174.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -65.77 -27.56 52.02 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 123.168 2.579 . . . . 73.21 113.287 -174.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . 0.535 ' HB3' HE22 ' A' ' 191' ' ' GLN . . . -109.51 21.79 16.57 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 123.667 0.787 . . . . 64.25 111.052 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.08 -151.6 33.61 Favored Glycine 0 C--N 1.347 1.171 0 N-CA-C 110.489 -1.045 . . . . 72.52 110.489 -170.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -61.83 138.9 58.39 Favored 'General case' 0 N--CA 1.477 0.924 0 CA-C-N 117.979 0.889 . . . . 74.22 110.162 174.124 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -78.54 -158.87 12.57 Favored Glycine 0 C--O 1.247 0.94 0 CA-C-N 115.969 -0.56 . . . . 33.13 112.146 172.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 -144.35 156.02 44.05 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.011 0.524 . . . . 75.52 109.938 -173.167 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.459 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 20.6 tp -97.67 109.84 22.52 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.462 0.649 . . . . 72.01 110.039 179.037 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . 0.571 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 97.5 m-85 -91.33 106.96 18.87 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-N 115.108 -0.951 . . . . 72.4 109.942 176.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.457 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 72.5 mt -89.25 112.76 23.89 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 123.939 0.895 . . . . 75.15 112.486 -179.289 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -78.62 91.37 4.61 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.945 -0.761 . . . . 74.42 108.945 178.259 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.1 p -55.54 125.9 11.64 Favored 'Isoleucine or valine' 0 C--N 1.353 0.732 0 CA-C-N 115.043 -0.98 . . . . 74.15 110.324 175.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 44.8 mmm-85 -131.15 109.83 10.73 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 106.536 -1.653 . . . . 75.41 106.536 175.587 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 66.3 mt -83.67 121.21 36.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.454 0 CA-C-N 115.966 -0.561 . . . . 71.15 111.799 -171.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 21.5 m . . . . . 0 CA--C 1.558 1.284 0 C-N-CA 124.586 1.154 . . . . 74.31 108.992 175.158 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.446 ' HB3' HD11 ' A' ' 123' ' ' LEU . 86.5 mt . . . . . 0 N--CA 1.472 0.644 0 N-CA-C 109.543 -0.54 . . . . 73.42 109.543 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.488 ' HB ' HG23 ' A' ' 138' ' ' VAL . 6.4 t -82.9 119.64 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 115.092 -0.958 . . . . 70.33 109.468 178.641 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -75.35 -51.43 13.19 Favored 'General case' 0 N--CA 1.478 0.936 0 O-C-N 124.352 1.032 . . . . 75.23 110.579 177.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -165.79 178.15 6.75 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 125.094 1.358 . . . . 74.42 109.338 -172.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.466 HG12 ' HB1' ' A' ' 121' ' ' ALA . 19.0 m -92.04 156.39 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 112.151 0.426 . . . . 71.35 112.151 179.43 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 60.9 p . . . . . 0 C--O 1.238 0.473 0 CA-C-N 115.11 -0.95 . . . . 71.42 109.268 172.775 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.459 ' HB3' ' CZ ' ' A' ' 120' ' ' ARG . 5.9 m-20 . . . . . 0 C--O 1.24 0.595 0 N-CA-C 108.667 -0.864 . . . . 63.24 108.667 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.505 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 14.1 tp -131.63 131.48 43.24 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 107.42 -1.326 . . . . 74.13 107.42 179.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . 0.702 ' HG3' ' HB2' ' A' ' 175' ' ' LEU . 0.0 OUTLIER -134.41 133.93 41.09 Favored 'General case' 0 N--CA 1.482 1.135 0 N-CA-C 109.173 -0.677 . . . . 73.53 109.173 -177.172 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . 0.466 ' HB1' HG12 ' A' ' 102' ' ' VAL . . . -146.46 164.17 33.33 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 124.079 0.952 . . . . 74.13 110.479 -176.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.641 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 46.3 mt-10 -126.42 151.01 48.29 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.079 0.951 . . . . 75.5 108.685 173.728 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.446 HD11 ' HB3' ' A' ' 98' ' ' LEU . 1.4 pt? -145.88 135.3 11.44 Favored Pre-proline 0 N--CA 1.477 0.897 0 C-N-CA 122.967 0.507 . . . . 74.42 110.171 -178.187 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -71.21 113.08 3.48 Favored 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 121.648 1.566 . . . . 73.0 109.583 167.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.418 HD22 HG11 ' A' ' 178' ' ' VAL . 17.2 tp -108.29 157.81 18.03 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 108.264 -1.013 . . . . 74.01 108.264 178.385 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.497 HG21 HD12 ' A' ' 181' ' ' LEU . 3.4 m -95.41 161.0 14.26 Favored 'General case' 0 CA--C 1.544 0.736 0 N-CA-C 109.4 -0.593 . . . . 72.44 109.4 173.629 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.457 HD22 ' HB3' ' A' ' 180' ' ' LEU . 67.7 mt -61.33 -46.17 91.36 Favored 'General case' 0 N--CA 1.476 0.836 0 CA-C-O 121.42 0.629 . . . . 72.41 110.104 175.674 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -60.15 -34.83 74.11 Favored 'General case' 0 N--CA 1.484 1.252 0 CA-C-N 114.636 -1.165 . . . . 73.11 111.871 176.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -72.94 -33.57 66.01 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 123.308 0.643 . . . . 74.11 110.472 177.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.461 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -62.68 -36.68 83.68 Favored 'General case' 0 C--O 1.246 0.891 0 C-N-CA 123.955 0.902 . . . . 72.01 111.883 171.347 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.493 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 31.7 t80 -66.87 -61.28 2.03 Favored 'General case' 0 N--CA 1.472 0.671 0 O-C-N 123.961 0.788 . . . . 74.11 111.72 175.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 40.7 m80 -77.68 -26.32 50.16 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 115.54 -0.754 . . . . 75.34 112.645 -170.088 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 62.68 -121.72 25.87 Favored Glycine 0 C--N 1.349 1.295 0 O-C-N 123.374 0.421 . . . . 53.43 112.281 -175.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 89.59 172.63 45.52 Favored Glycine 0 C--N 1.345 1.059 0 N-CA-C 114.288 0.475 . . . . 75.43 114.288 173.53 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 23.4 mp0 -84.17 136.66 33.88 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 123.512 0.725 . . . . 65.44 109.392 176.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.32 148.12 30.05 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 106.947 -1.501 . . . . 74.53 106.947 170.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.402 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 34.7 m -77.41 127.68 38.19 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-O 121.786 0.803 . . . . 70.0 111.643 -173.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.488 HG23 ' HB ' ' A' ' 99' ' ' VAL . 6.7 p -97.54 128.36 48.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.905 -1.146 . . . . 75.53 107.905 170.524 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . 0.435 ' HA ' ' O ' ' A' ' 143' ' ' ARG . 42.4 tt0 -123.27 95.06 4.45 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 107.908 -1.145 . . . . 75.25 107.908 -179.6 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.478 ' O ' ' HG2' ' A' ' 143' ' ' ARG . 15.3 m -136.92 138.16 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 124.714 1.206 . . . . 72.4 108.653 -173.418 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.86 20.41 10.63 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 123.741 0.816 . . . . 64.23 111.864 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.55 1.73 87.52 Favored Glycine 0 C--N 1.349 1.274 0 CA-C-O 119.549 -0.584 . . . . 73.22 113.754 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.478 ' HG2' ' O ' ' A' ' 140' ' ' VAL . 8.5 ptm180 -99.98 127.21 46.22 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 118.066 0.933 . . . . 75.32 109.253 176.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -114.16 113.77 25.14 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 124.073 0.949 . . . . 74.11 108.645 178.032 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 4.1 p -148.71 146.39 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 123.456 0.702 . . . . 75.33 109.912 -178.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.402 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 19.7 m -70.03 112.95 6.78 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.025 0.53 . . . . 75.25 110.931 178.775 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 14.2 p -98.99 137.31 26.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.042 0.537 . . . . 72.33 110.021 175.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 59.1 ttp180 -104.75 122.76 46.38 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 107.455 -1.313 . . . . 75.4 107.455 171.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.659 ' HB ' HD13 ' A' ' 159' ' ' ILE . 28.0 pt -107.46 127.47 27.78 Favored Pre-proline 0 CA--C 1.552 1.024 0 N-CA-C 108.172 -1.047 . . . . 72.43 108.172 172.393 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -53.61 130.85 40.84 Favored 'Trans proline' 0 C--N 1.387 2.594 0 C-N-CA 123.29 2.66 . . . . 74.04 113.914 -171.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -59.81 109.96 0.67 Allowed 'Trans proline' 0 C--N 1.378 2.085 0 C-N-CA 122.486 2.124 . . . . 75.02 109.952 170.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . 0.414 ' HA2' ' CD2' ' A' ' 240' ' ' PHE . . . 139.19 28.48 0.23 Allowed Glycine 0 N--CA 1.468 0.776 0 CA-C-N 116.291 -0.413 . . . . 74.31 112.306 -169.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.536 HG23 HD12 ' A' ' 159' ' ' ILE . 2.1 p -104.94 157.36 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.269 0 N-CA-C 109.815 -0.439 . . . . 74.23 109.815 -173.607 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -139.64 163.95 31.2 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 124.951 1.301 . . . . 74.43 110.635 -165.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 20.3 tp10 -47.32 117.9 1.95 Allowed 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 124.479 1.112 . . . . 71.31 112.779 169.506 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.83 7.58 86.25 Favored Glycine 0 C--N 1.353 1.514 0 CA-C-N 115.573 -0.74 . . . . 72.3 113.978 178.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 33.6 t -76.55 129.51 36.57 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 117.311 0.556 . . . . 74.1 109.861 -178.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.405 HG23 HD22 ' A' ' 175' ' ' LEU . 7.1 p -96.56 131.43 43.35 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.093 0 CA-C-N 115.363 -0.835 . . . . 71.3 109.758 -177.391 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.659 HD13 ' HB ' ' A' ' 149' ' ' ILE . 23.1 mt -116.98 115.8 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 123.675 0.79 . . . . 74.13 110.693 -173.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 18.1 ttm180 -86.78 117.76 25.74 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.059 0.544 . . . . 72.53 110.369 -179.184 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.438 ' HA ' ' HD3' ' A' ' 162' ' ' PRO . 9.0 m -120.29 107.19 39.57 Favored Pre-proline 0 CA--C 1.563 1.446 0 N-CA-C 109.621 -0.511 . . . . 74.45 109.621 178.054 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . 0.438 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 7.9 Cg_exo -72.41 152.87 55.38 Favored 'Trans proline' 0 C--N 1.376 2.014 0 C-N-CA 123.105 2.537 . . . . 73.41 112.834 -174.282 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 72.36 24.7 75.9 Favored Glycine 0 C--N 1.35 1.339 0 O-C-N 123.61 0.569 . . . . 73.31 113.126 179.019 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 48.7 tpp -111.08 -37.53 5.32 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.101 0.56 . . . . 61.11 110.6 -178.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.151 0 CA-C-N 116.106 -0.497 . . . . 72.53 113.467 174.926 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo . . . . . 0 CA--C 1.539 0.756 0 N-CA-C 110.995 -0.425 . . . . 64.23 110.995 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -76.12 151.6 40.7 Favored Glycine 0 C--N 1.336 0.579 0 N-CA-C 111.796 -0.522 . . . . 72.23 111.796 174.203 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -103.72 172.74 6.64 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.761 0.825 . . . . 74.21 109.154 178.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 37.5 tp -129.85 114.37 15.82 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 109.336 -0.616 . . . . 75.3 109.336 170.464 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.702 ' HB2' ' HG3' ' A' ' 120' ' ' ARG . 32.4 mt -85.56 102.39 13.49 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 114.903 -1.044 . . . . 75.2 110.837 176.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.441 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 79.0 mt -91.59 102.55 15.2 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.087 0.955 . . . . 72.12 111.71 179.137 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.641 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 43.3 t -86.48 103.83 13.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 N-CA-C 108.678 -0.86 . . . . 75.24 108.678 174.115 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.418 HG11 HD22 ' A' ' 125' ' ' LEU . 9.4 m -80.01 151.97 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-O 121.683 0.754 . . . . 75.02 112.124 -177.755 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 7.0 mmm180 -124.69 97.44 5.29 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 125.404 1.482 . . . . 73.43 107.598 178.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.457 ' HB3' HD22 ' A' ' 127' ' ' LEU . 54.9 mt -67.15 134.18 51.27 Favored 'General case' 0 CA--C 1.546 0.793 0 O-C-N 123.156 0.285 . . . . 74.44 110.902 -178.47 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.497 HD12 HG21 ' A' ' 126' ' ' THR . 37.1 mt -55.1 146.49 39.44 Favored Pre-proline 0 C--N 1.364 1.222 0 C-N-CA 124.197 0.999 . . . . 74.15 111.379 -174.505 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_exo -70.13 79.07 1.08 Allowed 'Trans proline' 0 C--N 1.376 2.0 0 C-N-CA 123.196 2.597 . . . . 74.24 113.043 -176.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 7.9 p80 -161.31 57.71 0.86 Allowed Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 124.152 0.981 . . . . 74.01 109.457 173.322 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -66.5 122.52 9.97 Favored 'Trans proline' 0 C--N 1.376 2.009 0 C-N-CA 121.976 1.784 . . . . 55.42 112.019 -168.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 195' ' ' ALA . 2.9 p -134.92 -41.07 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 C-N-CA 123.364 0.666 . . . . 74.42 109.322 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . 0.446 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 8.8 m-85 -109.89 124.36 51.23 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 122.917 0.487 . . . . 75.12 110.925 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.45 114.79 25.51 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.069 1.348 . . . . 73.12 107.824 175.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 54.9 tp -86.43 144.78 27.13 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 122.897 0.479 . . . . 74.53 110.441 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -142.98 99.87 3.54 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 106.073 -1.825 . . . . 64.44 106.073 177.311 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 65.26 -88.6 0.1 OUTLIER Glycine 0 C--N 1.344 1.003 0 N-CA-C 112.088 -0.405 . . . . 72.14 112.088 -172.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -130.66 -10.69 3.97 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 123.92 0.888 . . . . 73.15 110.58 175.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -85.87 150.41 24.55 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.71 0.804 . . . . 72.01 111.489 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.644 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 95.9 mt -114.91 161.12 18.7 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 124.25 1.02 . . . . 75.02 111.588 -177.856 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 250' ' ' TYR . 89.1 m-85 -140.89 118.41 11.54 Favored 'General case' 0 C--O 1.233 0.227 0 N-CA-C 107.091 -1.448 . . . . 75.01 107.091 173.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . 0.455 ' HA ' ' O ' ' A' ' 185' ' ' VAL . . . -141.23 128.7 21.27 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.82 -0.437 . . . . 72.3 109.82 -176.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 14.2 m -76.8 114.92 16.1 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-O 121.163 0.506 . . . . 72.45 110.915 -173.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.504 HD23 HD12 ' A' ' 251' ' ' LEU . 69.3 tp -106.58 113.06 26.34 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.329 1.052 . . . . 74.31 109.689 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -84.51 129.49 34.85 Favored 'General case' 0 C--O 1.242 0.701 0 N-CA-C 109.061 -0.718 . . . . 74.32 109.061 169.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 12.1 m -125.84 141.78 40.33 Favored Pre-proline 0 N--CA 1.48 1.042 0 N-CA-C 108.25 -1.019 . . . . 75.12 108.25 176.238 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -64.67 141.17 71.45 Favored 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 121.693 1.595 . . . . 75.32 110.698 170.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . 0.431 ' HA ' HG22 ' A' ' 255' ' ' ILE . . . -55.83 -41.86 93.1 Favored Pre-proline 0 CA--C 1.558 1.288 0 C-N-CA 123.878 0.871 . . . . 75.12 113.308 -178.312 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -49.04 -47.77 20.56 Favored 'Trans proline' 0 C--N 1.39 2.744 0 C-N-CA 122.434 2.09 . . . . 74.14 114.081 169.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . 0.485 ' HA ' ' HA3' ' A' ' 207' ' ' GLY . 5.6 mt -66.46 -44.37 90.51 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 CA-C-N 117.822 0.283 . . . . 73.44 111.252 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -50.69 -43.85 57.78 Favored 'General case' 0 CA--C 1.538 0.514 0 O-C-N 124.546 1.154 . . . . 60.42 111.51 -178.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . 0.647 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 29.6 m -89.34 -59.61 2.74 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.404 0 N-CA-C 113.226 0.824 . . . . 74.44 113.226 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 27.3 m -102.39 -24.61 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 N-CA-C 113.537 0.94 . . . . 71.43 113.537 -171.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.485 ' HA3' ' HA ' ' A' ' 203' ' ' ILE . . . -75.0 -76.01 0.78 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 121.181 -0.533 . . . . 74.54 111.993 -173.411 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 94.69 -0.36 65.05 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-O 119.155 -0.803 . . . . 75.42 114.02 172.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . 0.453 ' O ' HD11 ' A' ' 203' ' ' ILE . 48.6 mtmt -138.11 132.89 32.71 Favored 'General case' 0 N--CA 1.481 1.082 0 CA-C-N 118.165 0.982 . . . . 73.24 108.838 178.553 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 7.7 p -153.65 141.64 13.44 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 C-N-CA 124.124 0.97 . . . . 75.24 108.758 -174.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 16.6 ptp180 -77.5 148.92 35.06 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 110.172 -0.307 . . . . 74.51 110.172 175.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.417 ' HB3' HD13 ' A' ' 197' ' ' LEU . . . -140.1 159.86 41.24 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.33 0.652 . . . . 71.22 109.82 174.342 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -106.28 143.7 34.03 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-N 115.599 -0.728 . . . . 65.42 110.702 179.259 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 214' ' ' THR . . . . . 0.446 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 8.9 t -133.4 165.43 24.86 Favored 'General case' 0 C--O 1.24 0.566 0 C-N-CA 124.102 0.961 . . . . 64.41 109.489 171.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 81.4 mt -64.44 -14.82 58.89 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.268 1.027 . . . . 74.21 111.789 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -95.86 -21.39 18.11 Favored 'General case' 0 CA--C 1.558 1.281 0 C-N-CA 123.443 0.697 . . . . 71.24 111.787 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.13 -151.66 23.84 Favored Glycine 0 N--CA 1.478 1.438 0 CA-C-O 119.26 -0.744 . . . . 64.23 112.67 -176.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -91.76 133.26 1.37 Allowed 'Trans proline' 0 CA--C 1.559 1.752 0 C-N-CA 123.115 2.543 . . . . 53.43 113.695 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . 0.495 HG12 ' HZ1' ' A' ' 238' ' ' LYS . 36.0 m -114.89 159.36 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 123.939 0.896 . . . . 74.34 110.495 171.565 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -114.08 113.43 24.72 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 123.859 0.863 . . . . 71.54 109.069 175.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.417 HG23 HD11 ' A' ' 235' ' ' LEU . 20.5 t -95.14 126.24 47.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 123.661 0.785 . . . . 75.42 109.548 -178.615 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -106.5 99.44 9.02 Favored 'General case' 0 C--O 1.24 0.582 0 N-CA-C 107.003 -1.481 . . . . 71.24 107.003 173.311 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.475 HG12 HD13 ' A' ' 233' ' ' LEU . 3.3 m -79.09 132.23 64.06 Favored Pre-proline 0 CA--C 1.553 1.065 0 N-CA-C 108.031 -1.1 . . . . 73.24 108.031 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -56.37 129.61 35.69 Favored 'Trans proline' 0 C--N 1.375 1.956 0 C-N-CA 122.133 1.889 . . . . 74.11 111.665 176.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -42.35 124.27 3.05 Favored 'Trans proline' 0 C--N 1.385 2.462 0 C-N-CA 124.69 3.593 . . . . 65.41 114.361 -173.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . 0.647 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 52.8 mtm180 64.09 73.44 0.43 Allowed 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 124.333 1.053 . . . . 75.3 111.046 -173.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 227' ' ' THR . . . . . 0.425 HG22 HD11 ' A' ' 255' ' ' ILE . 8.2 t -88.59 171.99 9.63 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 123.647 0.779 . . . . 73.23 110.457 175.446 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -127.9 140.2 52.15 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 123.741 0.816 . . . . 73.13 109.249 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.53 128.8 37.78 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.228 0.611 . . . . 45.44 109.863 177.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.24 -4.07 22.05 Favored Glycine 0 C--N 1.339 0.729 0 O-C-N 123.342 0.401 . . . . 74.21 113.276 -170.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . 0.42 ' O ' HG12 ' A' ' 253' ' ' VAL . 69.5 mtp180 -93.59 162.48 13.94 Favored 'General case' 0 N--CA 1.477 0.902 0 CA-C-N 117.39 0.595 . . . . 75.3 111.553 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.782 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 3.2 mptp? -118.35 104.6 10.89 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 108.946 -0.761 . . . . 72.24 108.946 -176.679 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . 0.554 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 23.4 mt -84.42 115.33 22.48 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.52 0.728 . . . . 71.3 109.898 -172.227 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . 0.417 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 58.5 ttt180 -86.67 110.21 19.71 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 123.497 0.719 . . . . 74.04 111.631 -170.476 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.487 HD13 HD23 ' A' ' 249' ' ' LEU . 15.5 mt -99.95 104.0 15.59 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.024 -1.102 . . . . 73.34 108.024 170.474 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 56.0 mttp -74.66 138.86 43.15 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.942 0.497 . . . . 73.11 111.712 -171.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . 0.43 ' O ' ' HD3' ' A' ' 246' ' ' ARG . . . 80.05 6.84 88.98 Favored Glycine 0 C--N 1.348 1.243 0 O-C-N 123.903 0.752 . . . . 63.42 113.486 178.207 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . 0.495 ' HZ1' HG12 ' A' ' 219' ' ' VAL . 33.5 mmtp -106.96 8.59 30.58 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-N 117.263 0.532 . . . . 75.1 111.831 179.092 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -97.35 -178.5 34.2 Favored Glycine 0 C--N 1.344 1.023 0 O-C-N 123.481 0.488 . . . . 63.14 112.03 170.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.526 ' CE1' HD21 ' A' ' 193' ' ' LEU . 25.7 m-85 -76.28 163.1 68.51 Favored Pre-proline 0 CA--C 1.549 0.93 0 C-N-CA 124.257 1.023 . . . . 74.13 112.588 -174.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -52.47 129.05 30.21 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 123.248 2.632 . . . . 75.11 112.804 173.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -156.33 -162.26 11.31 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.091 -0.838 . . . . 75.34 112.043 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -61.39 -30.98 88.14 Favored 'Trans proline' 0 C--N 1.377 2.047 0 C-N-CA 123.465 2.777 . . . . 73.51 112.916 -175.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -90.95 22.13 3.82 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.961 0.905 . . . . 74.23 111.438 179.473 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 82.27 -70.82 3.08 Favored Glycine 0 C--N 1.35 1.307 0 N-CA-C 111.104 -0.798 . . . . 73.11 111.104 -175.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.43 ' HD3' ' O ' ' A' ' 237' ' ' GLY . 78.2 mtt180 -116.32 161.47 18.97 Favored 'General case' 0 C--O 1.243 0.749 0 C-N-CA 124.459 1.103 . . . . 75.31 108.578 172.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -96.13 -158.3 31.93 Favored Glycine 0 C--O 1.243 0.704 0 CA-C-N 115.699 -0.682 . . . . 73.22 112.308 177.38 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -132.35 155.63 48.07 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 109.641 -0.504 . . . . 71.21 109.641 -175.671 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.644 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 14.3 tp -103.25 129.02 50.1 Favored 'General case' 0 C--O 1.214 -0.812 0 C-N-CA 123.648 0.779 . . . . 72.41 109.12 171.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . 0.782 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 92.7 m-85 -115.36 107.64 15.48 Favored 'General case' 0 N--CA 1.477 0.906 0 N-CA-C 108.907 -0.775 . . . . 74.24 108.907 176.693 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.554 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 42.1 mt -87.5 126.15 34.74 Favored 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 123.568 0.747 . . . . 72.42 111.876 -173.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -78.91 90.84 4.74 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 107.366 -1.346 . . . . 75.12 107.366 176.03 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.42 HG12 ' O ' ' A' ' 231' ' ' ARG . 2.8 p -63.29 124.12 17.35 Favored 'Isoleucine or valine' 0 C--O 1.239 0.55 0 CA-C-O 121.802 0.81 . . . . 73.22 110.472 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 29.7 mmm180 -124.25 95.34 4.51 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 107.574 -1.269 . . . . 73.44 107.574 -178.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.431 HG22 ' HA ' ' A' ' 201' ' ' ALA . 69.1 mt -75.83 107.14 6.34 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 115.204 -0.907 . . . . 63.34 109.394 -177.725 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.2 t . . . . . 0 CA--C 1.549 0.928 0 C-N-CA 124.539 1.136 . . . . 72.5 109.139 -179.317 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.643 ' HG ' ' HG2' ' A' ' 136' ' ' ARG . 68.2 mt . . . . . 0 N--CA 1.481 1.097 0 N-CA-C 110.449 -0.204 . . . . 75.51 110.449 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.448 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 11.8 p -56.28 134.62 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 O-C-N 123.858 0.724 . . . . 61.31 111.531 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.96 -60.73 2.19 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 108.746 -0.835 . . . . 71.13 108.746 174.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 31.2 m80 -162.94 159.48 23.66 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 124.98 1.312 . . . . 74.34 108.82 -177.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.456 ' HA ' ' HB2' ' A' ' 121' ' ' ALA . 13.0 p -78.0 127.7 38.44 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.007 0 CA-C-O 121.025 0.44 . . . . 74.43 110.451 178.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.467 HG21 ' HA ' ' A' ' 121' ' ' ALA . 43.8 p . . . . . 0 N--CA 1.475 0.799 0 C-N-CA 123.537 0.735 . . . . 74.13 110.474 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.0 p30 . . . . . 0 C--O 1.243 0.741 0 N-CA-C 107.734 -1.21 . . . . 75.44 107.734 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.47 HD11 HG22 ' A' ' 140' ' ' VAL . 39.7 mt -95.04 139.02 31.98 Favored 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 107.402 -1.332 . . . . 74.24 107.402 -176.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -146.3 135.8 23.03 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.379 -0.971 . . . . 71.01 108.379 178.403 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . 0.467 ' HA ' HG21 ' A' ' 103' ' ' THR . . . -156.95 139.2 14.67 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.189 -0.671 . . . . 75.53 109.189 -171.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -96.7 148.02 23.31 Favored 'General case' 0 C--O 1.244 0.764 0 N-CA-C 109.38 -0.6 . . . . 71.53 109.38 173.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.611 HD12 ' HB3' ' A' ' 98' ' ' LEU . 1.6 pt? -144.12 132.18 10.84 Favored Pre-proline 0 N--CA 1.473 0.71 0 CA-C-N 115.991 -0.55 . . . . 75.31 110.83 -171.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.418 ' HA ' ' HB2' ' A' ' 179' ' ' ARG . 55.6 Cg_endo -68.5 117.2 4.82 Favored 'Trans proline' 0 C--N 1.374 1.895 0 C-N-CA 121.963 1.775 . . . . 75.52 110.932 174.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.43 HD23 HG11 ' A' ' 178' ' ' VAL . 16.0 tp -119.8 150.56 40.22 Favored 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 108.828 -0.804 . . . . 73.2 108.828 178.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.511 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 10.5 m -89.16 158.28 17.97 Favored 'General case' 0 CA--C 1.547 0.854 0 N-CA-C 109.31 -0.626 . . . . 65.34 109.31 175.345 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.46 HD13 ' O ' ' A' ' 183' ' ' HIS . 55.9 mt -54.56 -51.32 65.6 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 123.886 0.875 . . . . 75.12 111.062 177.317 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.441 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 2.1 mp0 -55.67 -37.59 68.5 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 114.325 -1.307 . . . . 74.34 111.024 176.834 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.511 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 10.3 mm-40 -79.18 -18.12 53.64 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.557 0.743 . . . . 64.31 111.313 -177.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.624 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -66.12 -42.37 89.27 Favored 'General case' 0 C--O 1.252 1.221 0 CA-C-O 121.004 0.43 . . . . 72.03 110.951 165.785 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -65.02 -48.88 72.32 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 115.824 -0.626 . . . . 73.31 111.318 172.507 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.6 m80 -73.82 -48.07 34.02 Favored 'General case' 0 N--CA 1.481 1.116 0 O-C-N 123.773 0.671 . . . . 70.03 111.839 -171.444 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 58.51 -109.54 2.03 Favored Glycine 0 CA--C 1.533 1.176 0 N-CA-C 111.351 -0.7 . . . . 72.51 111.351 -172.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.21 -162.89 50.13 Favored Glycine 0 C--N 1.346 1.106 0 N-CA-C 114.983 0.753 . . . . 74.24 114.983 166.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -79.06 135.97 37.03 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 124.424 1.09 . . . . 73.42 110.989 -174.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.643 ' HG2' ' HG ' ' A' ' 98' ' ' LEU . 13.8 tpt180 -156.86 167.97 28.87 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.137 0.975 . . . . 73.33 109.215 175.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.0 p -110.25 136.72 45.36 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 CA-C-O 121.148 0.499 . . . . 73.42 110.613 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 15.5 m -121.23 137.81 53.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 C-N-CA 124.011 0.925 . . . . 71.44 108.864 172.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -126.47 98.44 5.42 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-O 121.894 0.854 . . . . 74.31 109.228 171.368 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.47 HG22 HD11 ' A' ' 119' ' ' LEU . 10.6 m -130.24 139.41 51.47 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 124.517 1.127 . . . . 74.0 108.63 -179.161 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.54 24.77 14.17 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 124.256 1.023 . . . . 75.13 111.465 -176.234 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.11 -3.9 74.18 Favored Glycine 0 C--N 1.351 1.406 0 CA-C-N 115.809 -0.632 . . . . 74.11 113.038 -177.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -97.17 116.37 29.26 Favored 'General case' 0 C--N 1.346 0.456 0 C-N-CA 123.409 0.684 . . . . 75.12 109.425 -176.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 44.1 ttm180 -101.45 106.12 17.21 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 108.598 -0.89 . . . . 73.55 108.598 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 38.5 t -127.74 142.85 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 124.025 0.93 . . . . 73.53 109.223 -177.311 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 9.6 p -77.28 114.5 16.17 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 123.28 0.632 . . . . 75.14 110.041 175.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.8 p -98.88 136.43 29.93 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 C-N-CA 123.808 0.843 . . . . 73.01 110.345 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 59.6 ttp180 -111.2 95.44 5.53 Favored 'General case' 0 C--O 1.242 0.705 0 N-CA-C 108.227 -1.027 . . . . 72.52 108.227 168.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.432 ' HB ' HD11 ' A' ' 159' ' ' ILE . 34.9 pt -82.48 128.5 66.62 Favored Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 108.492 -0.929 . . . . 72.3 108.492 175.067 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -68.98 147.19 67.35 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.41 2.073 . . . . 74.31 113.059 -168.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -64.32 111.91 1.76 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 122.362 2.041 . . . . 75.13 110.636 172.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . 0.758 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 142.23 30.45 0.13 Allowed Glycine 0 C--N 1.354 1.578 0 C-N-CA 121.435 -0.412 . . . . 74.4 114.051 -174.632 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.624 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.0 p -106.26 164.57 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.683 0 C-N-CA 123.506 0.722 . . . . 74.0 109.891 -176.166 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.409 HH11 HD21 ' A' ' 188' ' ' LEU . 52.9 mtm-85 -144.56 167.19 23.1 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 125.106 1.363 . . . . 71.43 108.979 -172.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . 0.448 ' HB2' ' HB2' ' A' ' 180' ' ' LEU . 13.3 tp10 -54.82 122.48 10.86 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 123.329 0.651 . . . . 75.42 110.14 168.218 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 89.12 -11.6 68.94 Favored Glycine 0 C--N 1.344 0.983 0 CA-C-O 119.632 -0.538 . . . . 75.22 113.395 179.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.423 ' HB3' HG21 ' A' ' 153' ' ' VAL . 35.0 t -70.86 129.53 39.31 Favored 'General case' 0 C--O 1.245 0.863 0 CA-C-N 117.206 0.503 . . . . 71.2 109.756 -178.015 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.451 HG12 HD23 ' A' ' 175' ' ' LEU . 18.6 t -104.01 119.37 52.64 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 CA-C-N 114.386 -1.279 . . . . 70.44 109.073 -173.068 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.536 HD13 HG23 ' A' ' 153' ' ' VAL . 23.4 mt -103.13 117.45 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 C-N-CA 123.803 0.841 . . . . 71.42 110.023 -171.095 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 55.9 ttt85 -90.52 111.64 23.01 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 123.686 0.794 . . . . 71.11 110.226 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.3 m -120.31 102.37 45.79 Favored Pre-proline 0 CA--C 1.568 1.665 0 C-N-CA 122.618 0.367 . . . . 74.13 110.611 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -63.56 150.99 87.11 Favored 'Trans proline' 0 C--N 1.375 1.93 0 C-N-CA 122.938 2.425 . . . . 72.35 113.175 -177.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 106.11 -26.11 21.57 Favored Glycine 0 CA--C 1.535 1.329 0 CA-C-O 119.038 -0.868 . . . . 72.44 114.777 177.024 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -81.24 -55.15 4.92 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-N 118.674 1.237 . . . . 74.35 111.23 -178.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.348 1.219 0 CA-C-N 115.993 -0.549 . . . . 74.01 113.755 -177.792 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo . . . . . 0 CA--C 1.55 1.288 0 N-CA-C 111.489 -0.235 . . . . 74.52 111.489 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -65.49 -171.54 3.38 Favored Glycine 0 C--N 1.346 1.106 0 CA-C-N 115.866 -0.606 . . . . 64.44 113.943 -177.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 10.5 p-10 -108.58 172.9 6.57 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 123.828 0.851 . . . . 54.14 112.129 -168.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.44 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 19.2 tp -120.41 116.76 26.11 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 114.44 -1.255 . . . . 70.25 107.867 172.205 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.451 HD23 HG12 ' A' ' 158' ' ' VAL . 65.3 mt -88.11 100.03 12.64 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.982 0.913 . . . . 74.13 110.901 177.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 70.8 mt -91.46 104.9 17.36 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 123.222 0.609 . . . . 72.41 111.044 176.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.416 HG21 HG11 ' A' ' 158' ' ' VAL . 12.4 t -91.58 101.11 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 108.399 -0.963 . . . . 75.43 108.399 177.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.43 HG11 HD23 ' A' ' 125' ' ' LEU . 3.7 m -76.84 150.12 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 CA-C-O 121.612 0.72 . . . . 74.24 112.16 -172.814 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . 0.418 ' HB2' ' HA ' ' A' ' 124' ' ' PRO . 42.8 mmt180 -116.18 91.55 3.63 Favored 'General case' 0 C--O 1.238 0.448 0 C-N-CA 125.352 1.461 . . . . 75.45 107.686 -179.41 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.448 ' HB2' ' HB2' ' A' ' 155' ' ' GLU . 21.3 mt -69.9 148.77 48.58 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 120.716 0.293 . . . . 72.45 110.28 175.431 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.1 mt -54.74 144.41 45.8 Favored Pre-proline 0 CA--C 1.556 1.195 0 C-N-CA 123.927 0.891 . . . . 65.45 112.131 -175.319 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.453 ' O ' ' HD3' ' A' ' 184' ' ' PRO . 23.9 Cg_exo -65.62 1.4 2.21 Favored 'Trans proline' 0 C--N 1.385 2.474 0 C-N-CA 123.529 2.819 . . . . 61.5 113.347 175.52 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . 0.46 ' O ' HD13 ' A' ' 127' ' ' LEU . 8.4 t60 -91.36 98.31 1.7 Allowed Pre-proline 0 CA--C 1.549 0.93 0 N-CA-C 107.546 -1.279 . . . . 71.1 107.546 159.34 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 182' ' ' PRO . 60.6 Cg_endo -102.16 124.7 0.09 OUTLIER 'Trans proline' 0 C--N 1.37 1.665 0 C-N-CA 122.913 2.408 . . . . 73.53 111.729 168.22 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -114.28 -42.2 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 CA-C-O 121.348 0.594 . . . . 73.24 109.728 177.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . 0.469 ' HD2' HD21 ' A' ' 193' ' ' LEU . 5.5 m-85 -101.54 125.44 48.19 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 115.562 -0.745 . . . . 74.4 109.96 -177.384 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 37.2 ttp-105 -98.74 111.98 24.19 Favored 'General case' 0 C--O 1.243 0.758 0 N-CA-C 107.167 -1.419 . . . . 63.42 107.167 169.597 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.409 HD21 HH11 ' A' ' 154' ' ' ARG . 54.2 tp -83.45 116.99 22.77 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 108.443 -0.947 . . . . 72.15 108.443 172.482 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -126.76 99.21 5.67 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 124.488 1.115 . . . . 74.33 108.253 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 55.87 56.49 23.65 Favored Glycine 0 C--N 1.353 1.475 0 CA-C-O 119.504 -0.609 . . . . 63.15 113.76 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 69.13 -6.16 0.96 Allowed 'General case' 0 N--CA 1.504 2.25 0 C-N-CA 125.281 1.432 . . . . 75.43 113.15 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -97.82 150.12 21.61 Favored 'General case' 0 C--N 1.35 0.616 0 C-N-CA 124.864 1.266 . . . . 74.02 108.756 -178.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.607 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 94.9 mt -111.43 148.98 31.92 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 121.616 0.722 . . . . 74.25 112.418 -176.246 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -132.96 121.33 22.64 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 114.062 -1.427 . . . . 75.44 107.728 171.182 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -132.9 170.51 15.22 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 124.294 1.038 . . . . 64.12 109.071 177.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 54.9 m -109.96 133.38 53.24 Favored 'General case' 0 CA--C 1.537 0.449 0 N-CA-C 109.034 -0.728 . . . . 73.15 109.034 172.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . . . . . . . . . 52.5 tp -112.51 112.11 23.42 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 108.466 -0.938 . . . . 74.15 108.466 175.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -90.77 102.46 15.22 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 108.824 -0.806 . . . . 72.3 108.824 175.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 7.7 p -109.3 131.88 21.59 Favored Pre-proline 0 CA--C 1.548 0.882 0 CA-C-N 114.98 -1.009 . . . . 72.21 109.291 -176.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -56.32 145.34 78.57 Favored 'Trans proline' 0 C--N 1.373 1.847 0 C-N-CA 122.785 2.323 . . . . 74.01 113.181 174.051 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . 0.454 ' HA ' HG22 ' A' ' 255' ' ' ILE . . . -54.73 -45.86 99.52 Favored Pre-proline 0 CA--C 1.563 1.465 0 C-N-CA 124.112 0.965 . . . . 74.54 113.4 176.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . 0.416 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 26.0 Cg_endo -58.76 -44.18 38.25 Favored 'Trans proline' 0 C--N 1.392 2.826 0 C-N-CA 122.014 1.809 . . . . 72.55 111.941 175.692 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.5 mt -63.68 -37.62 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 C-N-CA 123.105 0.562 . . . . 64.42 110.931 178.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -61.89 -46.76 87.97 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.436 0.695 . . . . 75.24 112.011 -177.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.3 m -77.08 -36.91 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 N-CA-C 112.235 0.457 . . . . 71.11 112.235 -177.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m -80.57 -25.24 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 CA-C-O 120.838 0.351 . . . . 75.22 110.978 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.487 ' HA2' HG22 ' A' ' 223' ' ' VAL . . . 72.93 69.4 1.4 Allowed Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.421 -0.809 . . . . 62.32 112.244 -173.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -96.08 -149.17 25.28 Favored Glycine 0 C--N 1.352 1.452 0 CA-C-O 121.312 0.395 . . . . 75.13 113.117 -178.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 53.1 tttp -125.82 125.93 43.69 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 124.845 1.258 . . . . 73.03 108.792 -172.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . 0.496 HG23 HG12 ' A' ' 221' ' ' VAL . 11.4 m -130.5 163.2 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.203 1.001 . . . . 72.21 108.598 173.474 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 39.0 ptt85 -104.57 148.16 26.82 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 109.665 -0.495 . . . . 74.34 109.665 176.08 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -120.45 135.23 55.12 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 108.852 -0.795 . . . . 62.1 108.852 174.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 5.0 tpt -87.02 107.57 18.48 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 108.906 -0.776 . . . . 74.3 108.906 178.368 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 214' ' ' THR . . . . . 0.419 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 14.6 t -110.33 168.62 9.31 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 121.075 0.464 . . . . 73.0 109.78 174.287 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . 0.441 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 61.9 mt -74.55 -9.91 59.03 Favored 'General case' 0 CA--C 1.542 0.653 0 CA-C-N 115.667 -0.697 . . . . 70.11 112.519 -173.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -86.36 -21.75 27.03 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.598 0.759 . . . . 73.05 110.625 173.429 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 139.96 -169.73 24.57 Favored Glycine 0 C--N 1.345 1.032 0 N-CA-C 111.281 -0.728 . . . . 74.31 111.281 -173.645 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -76.01 126.85 9.6 Favored 'Trans proline' 0 C--N 1.363 1.336 0 C-N-CA 122.42 2.08 . . . . 74.11 112.015 176.049 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 33.4 m -110.25 163.53 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 123.549 0.74 . . . . 74.34 109.268 171.592 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -114.04 127.24 55.85 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.41 -0.589 . . . . 74.23 109.41 174.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.517 ' HB ' HD12 ' A' ' 235' ' ' LEU . 3.2 p -120.76 118.44 56.44 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 C-N-CA 123.818 0.847 . . . . 73.25 110.007 175.194 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.37 113.5 24.81 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 108.24 -1.022 . . . . 70.41 108.24 174.338 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.487 HG22 ' HA2' ' A' ' 207' ' ' GLY . 10.4 m -73.31 139.71 78.96 Favored Pre-proline 0 CA--C 1.553 1.096 0 N-CA-C 108.751 -0.833 . . . . 74.25 108.751 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 223' ' ' VAL . 3.0 Cg_exo -74.52 145.39 33.37 Favored 'Trans proline' 0 CA--C 1.557 1.674 0 C-N-CA 122.143 1.895 . . . . 53.42 111.309 178.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_exo -54.32 130.36 39.43 Favored 'Trans proline' 0 C--N 1.38 2.235 0 C-N-CA 123.325 2.683 . . . . 74.45 113.247 -179.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 61.69 61.28 1.47 Allowed 'General case' 0 N--CA 1.477 0.892 0 O-C-N 124.639 1.212 . . . . 73.33 111.201 -176.212 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.9 t -87.81 172.04 9.94 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 109.56 -0.533 . . . . 74.22 109.56 172.37 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . 0.448 HE21 ' HD2' ' A' ' 231' ' ' ARG . 1.9 mp0 -130.66 153.25 49.15 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 108.72 -0.845 . . . . 73.03 108.72 -178.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -72.36 139.69 48.02 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 122.779 0.432 . . . . 74.32 110.028 176.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 101.75 -6.84 55.01 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 116.052 -0.522 . . . . 70.11 112.395 -178.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . 0.448 ' HD2' HE21 ' A' ' 228' ' ' GLN . 58.6 mtp180 -82.48 160.72 22.6 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.006 0.522 . . . . 71.02 110.251 179.081 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.486 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 11.9 mptt -118.3 116.97 27.85 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.828 0.851 . . . . 73.22 109.73 -178.293 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 73.6 mt -92.0 107.42 19.2 Favored 'General case' 0 C--O 1.24 0.603 0 N-CA-C 107.265 -1.383 . . . . 73.34 107.265 175.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . 0.436 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 66.5 ttt180 -88.56 103.14 15.62 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.362 -0.835 . . . . 75.11 110.313 -166.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.517 HD12 ' HB ' ' A' ' 221' ' ' VAL . 33.3 mt -93.28 97.58 10.71 Favored 'General case' 0 C--N 1.348 0.508 0 N-CA-C 108.706 -0.85 . . . . 72.25 108.706 178.076 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . 0.544 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 10.3 mtmp? -81.38 144.38 31.48 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.332 -0.849 . . . . 62.15 111.525 -172.524 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 76.46 18.39 79.16 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.499 -0.773 . . . . 75.41 112.817 -172.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 73.1 mmtt -121.05 7.11 10.3 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.278 0.631 . . . . 75.42 111.934 -178.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . 0.4 ' HA2' ' CD1' ' A' ' 193' ' ' LEU . . . -92.22 -169.44 40.73 Favored Glycine 0 C--N 1.338 0.681 0 O-C-N 123.578 0.549 . . . . 61.33 112.131 174.679 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.758 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 3.9 m-85 -76.77 144.23 72.64 Favored Pre-proline 0 CA--C 1.547 0.849 0 C-N-CA 122.302 0.241 . . . . 71.2 110.614 -175.634 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.89 127.73 21.22 Favored 'Trans proline' 0 C--N 1.377 2.055 0 C-N-CA 122.885 2.39 . . . . 72.31 111.646 176.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -164.36 -154.09 7.71 Favored Glycine 0 CA--C 1.537 1.458 0 CA-C-O 119.448 -0.64 . . . . 71.3 113.298 -174.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -60.67 -24.28 78.17 Favored 'Trans proline' 0 C--N 1.379 2.166 0 C-N-CA 124.263 3.309 . . . . 74.43 114.164 -178.111 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.0 23.01 5.21 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 123.453 0.701 . . . . 74.32 111.461 176.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 74.33 -78.54 0.97 Allowed Glycine 0 C--N 1.348 1.206 0 N-CA-C 110.938 -0.865 . . . . 75.43 110.938 -173.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 12.8 ttt85 -129.65 141.74 50.86 Favored 'General case' 0 CA--C 1.546 0.8 0 N-CA-C 108.348 -0.982 . . . . 72.24 108.348 172.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.74 -156.78 5.28 Favored Glycine 0 N--CA 1.475 1.252 0 N-CA-C 113.805 0.282 . . . . 74.22 113.805 -178.032 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . 0.544 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 0.7 OUTLIER -148.44 156.46 42.51 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 123.125 0.57 . . . . 65.22 111.281 179.39 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.607 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 28.5 tp -110.42 133.63 53.09 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.73 1.212 . . . . 74.13 111.196 -172.137 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -106.21 107.2 18.09 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.147 0.979 . . . . 73.34 109.402 174.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.486 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 84.8 mt -87.56 115.57 25.08 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.1 0.56 . . . . 73.11 111.839 176.546 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -79.89 93.74 5.72 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 108.472 -0.936 . . . . 74.32 108.472 179.056 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 59.6 t -48.18 121.0 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.553 1.141 . . . . 73.31 110.659 174.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 25.6 mmm180 -128.9 95.45 4.09 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.194 -1.41 . . . . 74.14 107.194 177.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.454 HG22 ' HA ' ' A' ' 201' ' ' ALA . 66.5 mt -75.32 120.38 24.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-N 114.898 -1.046 . . . . 73.22 109.407 -176.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.556 1.189 0 C-N-CA 123.637 0.775 . . . . 74.14 109.315 -173.697 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.491 HD23 HH11 ' A' ' 136' ' ' ARG . 55.1 tp . . . . . 0 N--CA 1.478 0.961 0 N-CA-C 109.928 -0.397 . . . . 73.33 109.928 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.552 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 8.1 p -87.54 158.81 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 C-N-CA 123.216 0.606 . . . . 70.52 110.093 168.598 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -88.82 -89.62 0.14 Allowed 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 123.278 0.631 . . . . 71.03 109.896 170.241 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -160.74 176.52 11.41 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 125.106 1.363 . . . . 72.21 108.915 -174.443 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 9.1 p -68.68 125.62 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 CA-C-O 121.224 0.535 . . . . 74.31 110.557 178.186 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 81.9 p . . . . . 0 CA--C 1.547 0.833 0 C-N-CA 124.122 0.969 . . . . 74.15 109.826 175.45 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 . . . . . 0 C--O 1.241 0.649 0 CA-C-O 121.518 0.675 . . . . 62.41 110.603 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.518 HD12 ' HA2' ' A' ' 165' ' ' GLY . 14.5 mt -104.53 155.11 19.1 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.179 -1.415 . . . . 75.23 107.179 162.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 10.8 ttm180 -145.11 118.26 8.89 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 108.87 -0.789 . . . . 73.35 108.87 -175.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -141.37 141.61 33.8 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 123.702 0.801 . . . . 61.32 109.724 -176.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.705 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 39.4 mt-10 -116.95 149.82 39.55 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.066 0.546 . . . . 73.04 110.811 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.552 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.6 pt? -145.85 144.89 23.29 Favored Pre-proline 0 N--CA 1.471 0.599 0 CA-C-N 115.392 -0.822 . . . . 72.23 110.873 -179.44 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -77.55 115.3 3.86 Favored 'Trans proline' 0 C--N 1.371 1.739 0 C-N-CA 121.825 1.683 . . . . 75.14 110.711 168.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.548 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 15.7 tp -107.37 154.1 21.8 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.532 0.733 . . . . 65.55 109.407 179.36 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.579 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 11.5 m -87.74 160.97 17.86 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.137 0.575 . . . . 65.52 109.527 175.455 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.446 HD11 HG11 ' A' ' 185' ' ' VAL . 30.2 mt -63.07 -48.96 76.42 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 123.884 0.874 . . . . 74.2 110.562 178.58 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -57.28 -31.59 65.76 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 114.777 -1.101 . . . . 72.5 110.937 176.621 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.579 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 8.8 mm-40 -83.82 -23.99 31.17 Favored 'General case' 0 C--O 1.212 -0.869 0 C-N-CA 122.996 0.519 . . . . 73.45 111.054 -179.091 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.667 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -60.62 -35.21 75.6 Favored 'General case' 0 C--O 1.248 1.015 0 CA-C-O 121.804 0.811 . . . . 70.51 110.3 165.536 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.517 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 55.3 t80 -72.03 -47.42 51.9 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.419 -1.264 . . . . 71.21 111.82 172.213 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.3 m80 -83.96 -16.82 42.71 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 113.283 0.846 . . . . 71.24 113.283 -171.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 89.75 -117.72 5.06 Favored Glycine 0 CA--C 1.535 1.326 0 N-CA-C 111.987 -0.445 . . . . 72.44 111.987 -170.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 148.91 94.01 0.12 Allowed Glycine 0 C--N 1.353 1.488 0 CA-C-N 117.828 0.814 . . . . 73.44 113.571 175.12 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -85.21 123.06 30.28 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 123.273 0.629 . . . . 72.43 109.397 175.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.556 ' NH2' HD13 ' A' ' 176' ' ' LEU . 16.9 ptt-85 -148.65 168.45 22.81 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.204 0.602 . . . . 73.23 111.526 -170.157 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 23.1 m -89.84 106.23 16.93 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 CA-C-N 115.022 -0.99 . . . . 75.43 108.624 169.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.494 HG22 HG13 ' A' ' 99' ' ' VAL . 7.4 p -98.89 123.1 51.3 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 123.153 0.581 . . . . 63.11 109.789 -179.38 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -119.03 98.73 6.32 Favored 'General case' 0 C--O 1.241 0.614 0 C-N-CA 124.256 1.023 . . . . 73.41 109.186 -178.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.405 HG21 HD22 ' A' ' 174' ' ' LEU . 8.6 m -131.8 121.45 47.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 124.457 1.103 . . . . 75.0 109.919 -173.605 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.25 22.84 13.55 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 124.533 1.133 . . . . 74.12 111.954 -178.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 88.8 2.39 78.64 Favored Glycine 0 C--N 1.345 1.067 0 CA-C-O 119.815 -0.436 . . . . 72.23 113.388 -177.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -92.8 113.92 26.33 Favored 'General case' 0 C--N 1.348 0.515 0 N-CA-C 108.625 -0.88 . . . . 74.41 108.625 175.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 59.9 ttp180 -106.22 110.85 23.22 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 108.116 -1.068 . . . . 74.5 108.116 176.1 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 5.7 m -141.38 155.72 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 124.52 1.128 . . . . 74.14 109.078 -177.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 47.4 t -87.21 115.5 24.65 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.128 -0.693 . . . . 65.22 109.128 177.312 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.2 p -99.33 136.66 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-O 121.095 0.474 . . . . 53.13 110.718 179.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.5 ttp180 -110.29 98.76 7.92 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 107.743 -1.206 . . . . 74.34 107.743 172.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.479 ' HB ' HD11 ' A' ' 159' ' ' ILE . 28.9 pt -89.88 131.24 39.99 Favored Pre-proline 0 N--CA 1.475 0.809 0 N-CA-C 108.684 -0.858 . . . . 74.25 108.684 177.27 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -72.01 157.7 53.98 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.45 2.1 . . . . 72.33 112.828 -172.1 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -68.5 148.17 72.39 Favored 'Trans proline' 0 C--N 1.375 1.959 0 C-N-CA 122.283 1.988 . . . . 74.12 111.356 172.204 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 100.04 41.49 2.83 Favored Glycine 0 C--N 1.34 0.786 0 N-CA-C 110.988 -0.845 . . . . 65.13 110.988 -176.504 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.667 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -111.37 160.74 10.47 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.267 0 N-CA-C 108.265 -1.013 . . . . 72.43 108.265 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.408 ' HD3' ' HB3' ' A' ' 188' ' ' LEU . 74.8 mtm180 -148.47 176.74 10.05 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 123.909 0.884 . . . . 72.01 111.735 -166.118 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -55.61 115.74 2.51 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 114.214 -1.357 . . . . 50.22 111.072 170.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 75.89 10.22 85.06 Favored Glycine 0 C--N 1.345 1.053 0 O-C-N 123.601 0.563 . . . . 63.11 113.683 178.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 37.5 t -75.13 125.97 30.05 Favored 'General case' 0 C--O 1.245 0.819 0 C-N-CA 122.97 0.508 . . . . 71.05 109.906 -178.797 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.421 HG13 HD23 ' A' ' 175' ' ' LEU . 21.2 t -95.83 121.57 46.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 C-N-CA 124.719 1.208 . . . . 74.45 109.457 -175.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.533 HD13 HG23 ' A' ' 153' ' ' VAL . 27.3 mt -107.28 111.21 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 123.46 0.704 . . . . 71.14 109.634 -174.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.406 ' HA ' HD22 ' A' ' 175' ' ' LEU . 25.1 ttp180 -84.83 117.76 24.07 Favored 'General case' 0 CA--C 1.538 0.493 0 O-C-N 123.655 0.597 . . . . 74.21 109.989 179.192 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.5 m -114.86 96.47 44.67 Favored Pre-proline 0 CA--C 1.561 1.394 0 CA-C-O 121.431 0.634 . . . . 71.24 109.419 175.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -63.22 136.61 56.68 Favored 'Trans proline' 0 C--N 1.379 2.153 0 C-N-CA 123.391 2.727 . . . . 74.35 113.224 -175.616 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.59 -17.14 59.43 Favored Glycine 0 C--N 1.345 1.064 0 N-CA-C 114.39 0.516 . . . . 52.12 114.39 174.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 10.4 mtm -100.69 -6.29 25.31 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 117.718 0.759 . . . . 65.1 112.187 -174.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . 0.518 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.351 1.391 0 N-CA-C 111.813 -0.515 . . . . 75.52 111.813 175.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo . . . . . 0 CA--C 1.541 0.852 0 CA-C-O 121.047 0.353 . . . . 74.43 111.688 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -98.63 151.93 19.64 Favored Glycine 0 N--CA 1.452 -0.294 0 N-CA-C 110.123 -1.191 . . . . 74.12 110.123 171.039 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -116.49 167.83 10.71 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 124.422 1.089 . . . . 74.44 109.751 -173.598 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.485 HD23 HG21 ' A' ' 138' ' ' VAL . 11.8 tp -120.22 129.64 54.17 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.167 -1.049 . . . . 75.05 108.167 176.479 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.421 HD23 HG13 ' A' ' 158' ' ' VAL . 83.1 mt -103.79 98.6 8.43 Favored 'General case' 0 C--O 1.233 0.212 0 C-N-CA 124.345 1.058 . . . . 64.4 109.636 -175.39 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.556 HD13 ' NH2' ' A' ' 136' ' ' ARG . 45.4 mt -92.88 101.23 13.59 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.357 -0.838 . . . . 72.43 109.649 178.827 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.705 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 25.5 t -90.71 107.65 18.78 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 N-CA-C 108.422 -0.955 . . . . 74.21 108.422 179.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.548 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 3.2 m -87.43 148.93 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 109.463 -0.569 . . . . 73.42 109.463 -177.733 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 10.0 mmm-85 -123.51 104.17 8.9 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 107.466 -1.309 . . . . 74.22 107.466 -174.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 27.4 mt -69.15 151.55 46.22 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-O 121.213 0.53 . . . . 74.15 111.3 -178.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 52.9 mt -54.56 150.7 16.59 Favored Pre-proline 0 CA--C 1.561 1.397 0 CA-C-N 114.608 -1.178 . . . . 74.44 112.383 -177.172 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -61.1 -8.05 9.26 Favored 'Trans proline' 0 C--N 1.385 2.489 0 C-N-CA 123.144 2.562 . . . . 74.02 113.459 177.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . 0.434 ' O ' HD13 ' A' ' 127' ' ' LEU . 5.2 t60 -93.44 104.83 13.53 Favored Pre-proline 0 CA--C 1.544 0.743 0 C-N-CA 124.436 1.094 . . . . 72.32 108.726 164.011 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -101.16 128.82 0.13 Allowed 'Trans proline' 0 CA--C 1.559 1.746 0 C-N-CA 123.379 2.72 . . . . 72.2 112.486 165.69 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . 0.446 HG11 HD11 ' A' ' 127' ' ' LEU . 2.6 p -113.85 -46.21 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 122.899 0.48 . . . . 74.04 109.998 172.802 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -98.98 122.68 42.55 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.031 0.443 . . . . 74.31 110.774 -174.195 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.621 ' HB3' ' HB2' ' A' ' 194' ' ' TYR . 28.7 ttm180 -97.88 109.13 21.94 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 107.6 -1.259 . . . . 75.21 107.6 170.536 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.408 ' HB3' ' HD3' ' A' ' 154' ' ' ARG . 50.1 tp -89.56 112.62 23.87 Favored 'General case' 0 CA--C 1.543 0.702 0 N-CA-C 108.597 -0.89 . . . . 63.4 108.597 173.515 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -108.97 102.13 11.16 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 108.291 -1.003 . . . . 74.4 108.291 176.162 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 72.16 -87.41 0.49 Allowed Glycine 0 C--N 1.347 1.166 0 O-C-N 123.704 0.627 . . . . 71.4 111.765 -174.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 5.0 pm0 -134.01 -4.94 2.75 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 124.17 0.988 . . . . 73.33 110.574 178.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 56.5 m-20 -93.66 151.4 19.68 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.598 0.759 . . . . 72.31 111.198 -177.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.424 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 88.8 mt -107.44 147.07 30.9 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 124.372 1.069 . . . . 72.3 109.429 -178.493 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . 0.621 ' HB2' ' HB3' ' A' ' 187' ' ' ARG . 89.4 m-85 -133.46 121.07 21.69 Favored 'General case' 0 C--O 1.232 0.182 0 N-CA-C 107.389 -1.337 . . . . 75.31 107.389 175.233 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -134.76 170.88 15.16 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 123.916 0.886 . . . . 73.43 108.892 178.126 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 87.1 m -109.55 124.2 50.71 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.64 -0.709 . . . . 72.41 109.288 175.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.41 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 57.6 tp -107.06 111.75 24.36 Favored 'General case' 0 C--O 1.225 -0.201 0 C-N-CA 124.154 0.982 . . . . 74.52 109.106 177.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -87.45 125.53 34.34 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 107.758 -1.201 . . . . 75.13 107.758 172.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . 0.459 HG13 HG23 ' A' ' 210' ' ' VAL . 15.4 m -120.15 135.19 24.23 Favored Pre-proline 0 N--CA 1.475 0.82 0 N-CA-C 108.901 -0.777 . . . . 75.23 108.901 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -57.69 140.21 92.79 Favored 'Trans proline' 0 C--N 1.367 1.549 0 C-N-CA 122.314 2.01 . . . . 72.01 111.624 169.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -50.24 -44.21 80.33 Favored Pre-proline 0 CA--C 1.567 1.621 0 CA-C-O 118.057 -0.973 . . . . 65.4 113.069 179.384 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo -47.59 -52.61 7.75 Favored 'Trans proline' 0 C--N 1.404 3.485 0 C-N-CA 122.816 2.344 . . . . 74.31 112.754 168.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 11.8 mt -68.34 -33.4 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 C-N-CA 123.079 0.552 . . . . 75.32 111.7 -176.316 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.61 -47.97 83.51 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.329 0.651 . . . . 74.04 110.863 178.227 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . 0.461 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 32.8 m -81.78 -35.57 13.66 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.898 0 CA-C-N 115.695 -0.684 . . . . 70.14 112.362 -174.587 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.2 m -84.61 -22.97 7.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 CA-C-N 118.24 0.473 . . . . 71.51 111.245 -179.039 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 71.7 56.7 6.42 Favored Glycine 0 C--N 1.343 0.939 0 CA-C-N 115.823 -0.626 . . . . 72.02 112.31 -174.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -84.75 -152.96 17.98 Favored Glycine 0 C--N 1.355 1.624 0 N-CA-C 111.979 -0.449 . . . . 72.12 111.979 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -111.79 140.54 46.34 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.106 -0.702 . . . . 73.35 109.106 177.29 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . 0.459 HG23 HG13 ' A' ' 199' ' ' VAL . 41.1 t -125.66 149.47 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 108.066 -1.087 . . . . 71.15 108.066 168.635 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . 0.42 ' HD2' ' HG2' ' A' ' 220' ' ' GLU . 0.2 OUTLIER -90.06 125.27 35.35 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 108.268 -1.012 . . . . 74.41 108.268 166.946 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -100.43 129.11 46.35 Favored 'General case' 0 C--O 1.248 0.999 0 N-CA-C 108.59 -0.893 . . . . 72.14 108.59 178.537 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 213' ' ' MET . . . . . 0.497 ' HA ' ' HE1' ' A' ' 213' ' ' MET . 4.2 tpt -76.25 105.16 7.14 Favored 'General case' 0 CA--C 1.537 0.471 0 O-C-N 123.697 0.623 . . . . 72.53 109.435 178.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 9.2 t -117.26 169.68 9.28 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 123.418 0.687 . . . . 71.01 110.524 177.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 63.3 mt -76.1 -5.6 47.31 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 123.957 0.903 . . . . 73.31 111.423 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -88.12 -20.38 25.73 Favored 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 124.077 0.951 . . . . 73.34 110.348 172.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 130.64 -149.87 19.15 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-O 119.073 -0.848 . . . . 65.02 111.108 -174.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -86.83 120.38 1.67 Allowed 'Trans proline' 0 CA--C 1.553 1.428 0 C-N-CA 122.211 1.941 . . . . 73.41 111.604 169.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 20.0 m -108.24 155.39 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 108.968 -0.753 . . . . 63.21 108.968 173.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . 0.42 ' HG2' ' HD2' ' A' ' 211' ' ' ARG . 33.4 mt-10 -109.46 107.36 17.47 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 108.788 -0.819 . . . . 74.22 108.788 -175.305 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.2 p -96.38 132.54 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 123.739 0.816 . . . . 63.42 110.342 177.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -90.69 105.41 17.8 Favored 'General case' 0 C--O 1.24 0.588 0 C-N-CA 123.648 0.779 . . . . 44.51 108.961 173.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.11 133.51 93.63 Favored Pre-proline 0 CA--C 1.557 1.24 0 C-N-CA 124.038 0.935 . . . . 62.2 110.063 177.578 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_exo -65.04 140.69 66.88 Favored 'Trans proline' 0 C--N 1.379 2.144 0 C-N-CA 122.89 2.393 . . . . 75.42 111.539 172.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -58.98 124.41 15.63 Favored 'Trans proline' 0 C--N 1.376 2.008 0 C-N-CA 122.724 2.283 . . . . 75.24 111.418 178.147 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . 0.461 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 85.3 mtm180 60.41 76.74 0.35 Allowed 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 124.423 1.089 . . . . 74.03 110.865 -177.533 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 7.5 t -103.71 173.81 6.14 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 123.365 0.666 . . . . 71.31 109.594 174.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -131.44 155.53 47.18 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 123.655 0.782 . . . . 72.35 109.019 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.11 130.23 42.12 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.297 0.639 . . . . 74.12 110.279 177.191 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.03 -11.5 22.48 Favored Glycine 0 C--N 1.337 0.588 0 C-N-CA 123.505 0.574 . . . . 74.32 112.129 -176.087 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 73.3 mtp180 -81.7 155.58 25.48 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 122.818 0.447 . . . . 74.11 110.481 178.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 0.5 OUTLIER -118.53 125.29 49.55 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.776 0.83 . . . . 74.44 109.762 -179.115 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 28.1 mt -100.79 111.55 23.79 Favored 'General case' 0 C--N 1.353 0.759 0 N-CA-C 108.127 -1.064 . . . . 73.02 108.127 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . 0.411 ' HG3' ' HB3' ' A' ' 248' ' ' ASP . 57.4 ttm-85 -82.91 105.4 13.88 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.9 0.88 . . . . 74.44 110.894 -170.268 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.498 HD12 HD23 ' A' ' 249' ' ' LEU . 30.0 mt -87.03 97.46 10.73 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 107.782 -1.192 . . . . 62.13 107.782 171.103 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -71.76 138.2 48.25 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 114.831 -1.077 . . . . 75.44 111.634 -169.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 75.89 4.08 76.05 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 123.801 0.688 . . . . 63.4 113.991 177.219 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . 0.613 ' HE2' ' HA ' ' A' ' 238' ' ' LYS . 9.6 mmpt? -94.17 -3.13 51.47 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.253 0.621 . . . . 73.13 111.955 -177.484 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.27 -170.68 47.2 Favored Glycine 0 C--N 1.343 0.967 0 N-CA-C 111.941 -0.463 . . . . 53.51 111.941 171.236 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.517 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 97.3 m-85 -83.6 154.9 65.68 Favored Pre-proline 0 N--CA 1.477 0.917 0 C-N-CA 122.822 0.449 . . . . 61.35 111.687 -177.148 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . 0.443 ' HA ' ' O ' ' A' ' 245' ' ' GLY . 26.3 Cg_exo -64.5 127.05 18.06 Favored 'Trans proline' 0 C--N 1.375 1.962 0 C-N-CA 122.144 1.896 . . . . 73.02 110.468 166.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -165.22 -156.9 9.4 Favored Glycine 0 C--N 1.342 0.916 0 CA-C-O 119.219 -0.767 . . . . 75.24 112.329 -177.063 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -59.43 -10.78 11.83 Favored 'Trans proline' 0 N--CA 1.504 2.14 0 C-N-CA 124.017 3.145 . . . . 73.52 115.257 -178.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -109.49 19.14 19.62 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.287 0.635 . . . . 64.52 111.06 176.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 241' ' ' PRO . . . 77.45 -76.49 1.68 Allowed Glycine 0 C--N 1.345 1.067 0 N-CA-C 110.993 -0.843 . . . . 72.45 110.993 -173.34 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 55.5 mtm180 -123.77 155.88 37.1 Favored 'General case' 0 N--CA 1.476 0.875 0 N-CA-C 107.801 -1.185 . . . . 75.12 107.801 170.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -90.74 -177.89 43.85 Favored Glycine 0 C--N 1.338 0.682 0 O-C-N 123.34 0.4 . . . . 50.12 113.245 176.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . 0.411 ' HB3' ' HG3' ' A' ' 234' ' ' ARG . 60.9 m-20 -136.01 142.5 44.48 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.82 0.848 . . . . 75.23 109.189 -175.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.498 HD23 HD12 ' A' ' 235' ' ' LEU . 19.3 tp -97.53 112.97 24.6 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 109.346 -0.613 . . . . 74.24 109.346 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -90.29 105.86 18.1 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 108.754 -0.832 . . . . 75.02 108.754 176.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.512 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 93.6 mt -87.92 110.77 20.8 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.376 0.67 . . . . 73.43 112.01 176.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -79.06 92.98 5.06 Favored 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 109.117 -0.697 . . . . 75.25 109.117 -178.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 70.6 t -48.04 117.66 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 C-N-CA 124.911 1.284 . . . . 75.15 110.997 173.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 26.3 mmm180 -128.98 101.24 5.97 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 106.435 -1.691 . . . . 74.45 106.435 174.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 60.4 mt -77.17 117.51 22.24 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 CA-C-N 115.582 -0.735 . . . . 75.44 110.94 -172.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 3.3 t . . . . . 0 CA--C 1.559 1.326 0 C-N-CA 124.092 0.957 . . . . 72.21 109.211 177.725 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.634 ' HG ' ' HG2' ' A' ' 136' ' ' ARG . 89.0 mt . . . . . 0 N--CA 1.478 0.926 0 N-CA-C 109.844 -0.428 . . . . 63.21 109.844 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.427 HG21 ' HB3' ' A' ' 123' ' ' LEU . 30.0 t -58.89 131.13 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 C-N-CA 123.574 0.749 . . . . 71.24 111.798 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -70.67 -52.52 20.6 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.322 -0.853 . . . . 73.45 109.732 176.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -179.96 174.99 0.85 Allowed 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.556 1.142 . . . . 75.35 109.266 -178.124 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 88.7 t -65.19 132.16 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 N-CA-C 108.762 -0.829 . . . . 72.21 108.762 171.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.429 HG21 ' HA ' ' A' ' 121' ' ' ALA . 24.5 p . . . . . 0 CA--C 1.547 0.842 0 CA-C-O 121.557 0.694 . . . . 72.22 110.962 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 . . . . . 0 CA--C 1.54 0.574 0 CA-C-O 120.974 0.416 . . . . 73.31 110.816 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.474 HD21 HD13 ' A' ' 174' ' ' LEU . 4.9 tt -136.89 149.07 47.43 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 106.611 -1.626 . . . . 54.32 106.611 -179.312 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . 0.442 ' N ' HD23 ' A' ' 119' ' ' LEU . 0.1 OUTLIER -138.11 148.69 45.23 Favored 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 119.335 0.97 . . . . 71.24 110.351 179.533 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . 0.429 ' HA ' HG21 ' A' ' 103' ' ' THR . . . -156.89 163.26 39.37 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.525 1.13 . . . . 71.23 108.709 -177.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -126.45 151.56 47.59 Favored 'General case' 0 C--O 1.248 0.99 0 CA-C-O 121.063 0.459 . . . . 74.42 110.224 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.427 ' HB3' HG21 ' A' ' 99' ' ' VAL . 1.6 pt? -140.41 135.02 15.65 Favored Pre-proline 0 N--CA 1.468 0.451 0 CA-C-N 115.681 -0.691 . . . . 74.41 111.593 -174.6 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -66.09 114.55 3.05 Favored 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 121.781 1.654 . . . . 75.4 110.351 161.152 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.434 HD23 HG13 ' A' ' 178' ' ' VAL . 16.1 tp -115.48 166.29 12.05 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.313 1.045 . . . . 74.11 108.222 175.443 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 17.6 m -108.74 161.53 15.02 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.208 0.603 . . . . 73.51 109.46 174.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.464 HD11 ' O ' ' A' ' 183' ' ' HIS . 30.8 mt -55.97 -51.94 65.94 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.808 0.843 . . . . 75.44 109.7 173.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.568 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.9 mp0 -57.36 -38.38 74.07 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 114.408 -1.269 . . . . 72.4 111.667 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -76.83 -21.86 54.42 Favored 'General case' 0 N--CA 1.479 1.025 0 C-N-CA 123.362 0.665 . . . . 70.21 111.672 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.58 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -71.85 -25.82 62.12 Favored 'General case' 0 C--O 1.249 1.073 0 C-N-CA 123.704 0.802 . . . . 51.44 110.94 170.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.516 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 36.9 t80 -82.39 -47.39 12.36 Favored 'General case' 0 C--N 1.35 0.602 0 CA-C-N 115.477 -0.783 . . . . 75.25 111.736 171.601 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -74.32 -47.46 34.43 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 123.237 0.335 . . . . 74.43 111.338 -172.093 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.16 -153.09 52.63 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 111.183 -0.767 . . . . 74.24 111.183 -168.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 119.46 -175.96 15.96 Favored Glycine 0 C--N 1.343 0.953 0 N-CA-C 114.379 0.511 . . . . 53.22 114.379 171.149 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.614 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.7 mp0 -90.74 136.28 33.17 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.993 0.917 . . . . 74.14 109.372 -177.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.634 ' HG2' ' HG ' ' A' ' 98' ' ' LEU . 0.2 OUTLIER -153.11 150.89 29.57 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 110.375 -0.231 . . . . 75.2 110.375 176.059 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 25.3 m -75.87 136.82 24.03 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 123.251 0.62 . . . . 71.1 111.836 -173.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.422 HG23 ' HB ' ' A' ' 99' ' ' VAL . 5.8 p -142.86 135.9 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 C-N-CA 124.212 1.005 . . . . 74.54 111.297 178.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -100.37 98.39 9.04 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 109.483 -0.562 . . . . 75.42 109.483 169.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.0 m -108.36 124.87 65.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 N-CA-C 108.895 -0.78 . . . . 72.33 108.895 171.61 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.09 21.83 13.09 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 124.324 1.05 . . . . 61.51 111.436 -174.086 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.28 -1.78 86.38 Favored Glycine 0 C--N 1.356 1.656 0 CA-C-N 115.835 -0.62 . . . . 61.42 113.238 -178.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.3 mmt85 -94.3 117.11 29.62 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 123.207 0.603 . . . . 73.44 109.905 -178.295 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 43.1 ttm180 -84.9 115.94 23.05 Favored 'General case' 0 C--N 1.352 0.705 0 N-CA-C 109.756 -0.461 . . . . 74.31 109.756 175.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 12.2 m -136.68 155.27 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 C-N-CA 125.136 1.375 . . . . 74.33 108.708 177.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 60.8 p -86.81 114.98 23.93 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 109.139 -0.689 . . . . 73.52 109.139 174.134 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.0 p -96.15 124.67 48.96 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 CA-C-O 121.172 0.51 . . . . 73.35 109.924 176.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . 0.614 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 13.7 ttp180 -99.03 104.94 17.01 Favored 'General case' 0 C--O 1.244 0.799 0 N-CA-C 108.841 -0.8 . . . . 71.03 108.841 175.511 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 32.7 pt -95.63 131.3 29.71 Favored Pre-proline 0 CA--C 1.548 0.878 0 N-CA-C 108.737 -0.838 . . . . 74.1 108.737 174.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -71.39 146.1 49.57 Favored 'Trans proline' 0 C--N 1.371 1.728 0 C-N-CA 122.554 2.169 . . . . 73.11 112.923 -174.697 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.64 142.5 89.84 Favored 'Trans proline' 0 C--N 1.378 2.108 0 C-N-CA 122.881 2.387 . . . . 75.13 111.425 172.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.71 52.39 0.75 Allowed Glycine 0 C--N 1.339 0.709 0 N-CA-C 110.7 -0.96 . . . . 75.42 110.7 -173.246 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.58 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.3 p -130.65 162.12 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 108.165 -1.05 . . . . 72.01 108.165 179.581 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.589 ' HA ' HD13 ' A' ' 180' ' ' LEU . 0.0 OUTLIER -162.37 173.67 13.81 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 124.925 1.29 . . . . 73.44 110.379 -179.352 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.4 tp10 -47.3 118.38 2.15 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 124.601 1.16 . . . . 73.33 112.711 -176.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 100.5 -24.86 30.47 Favored Glycine 0 C--N 1.349 1.296 0 CA-C-O 119.153 -0.804 . . . . 74.3 113.562 178.797 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.569 ' HB2' HG21 ' A' ' 153' ' ' VAL . 43.6 m -60.09 125.7 24.68 Favored 'General case' 0 C--O 1.248 0.998 0 C-N-CA 123.34 0.656 . . . . 64.23 111.127 -174.493 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.432 HG23 HD23 ' A' ' 175' ' ' LEU . 14.8 p -100.57 123.21 53.37 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.095 0 CA-C-N 114.801 -1.091 . . . . 75.31 109.071 -179.027 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.457 HD12 HG23 ' A' ' 153' ' ' VAL . 25.9 mt -105.38 112.97 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.329 1.052 . . . . 74.43 109.545 -170.166 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 34.6 ttt-85 -92.75 105.32 17.48 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 122.822 0.449 . . . . 75.02 110.256 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.431 HG22 ' HB3' ' A' ' 174' ' ' LEU . 10.5 m -97.79 112.38 61.41 Favored Pre-proline 0 CA--C 1.561 1.396 0 N-CA-C 108.072 -1.084 . . . . 72.35 108.072 176.209 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 7.6 Cg_exo -73.65 156.22 49.26 Favored 'Trans proline' 0 C--N 1.374 1.875 0 C-N-CA 123.132 2.555 . . . . 75.21 113.213 -171.598 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 66.09 24.44 71.79 Favored Glycine 0 C--N 1.347 1.188 0 O-C-N 123.715 0.635 . . . . 64.43 114.14 177.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.6 tpt -101.8 -63.21 1.17 Allowed 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.293 0.637 . . . . 74.41 111.288 -170.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.514 0 N-CA-C 111.412 -0.675 . . . . 53.04 111.412 178.863 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo . . . . . 0 CA--C 1.544 0.992 0 CA-C-O 120.859 0.275 . . . . 73.14 112.108 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -99.89 -137.09 9.64 Favored Glycine 0 C--N 1.342 0.916 0 N-CA-C 111.156 -0.778 . . . . 71.33 111.156 176.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -167.38 165.55 14.92 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 117.377 0.588 . . . . 75.14 111.245 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.474 HD13 HD21 ' A' ' 119' ' ' LEU . 35.5 tp -124.98 122.63 37.86 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 114.822 -1.081 . . . . 74.23 108.191 166.844 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.432 HD23 HG23 ' A' ' 158' ' ' VAL . 30.2 mt -95.17 101.42 13.16 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.542 1.137 . . . . 61.31 110.188 178.535 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 56.5 mt -93.5 105.42 17.47 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.56 0.744 . . . . 72.04 111.653 178.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 15.4 t -88.66 108.36 18.77 Favored 'Isoleucine or valine' 0 C--O 1.246 0.876 0 N-CA-C 108.977 -0.749 . . . . 73.11 108.977 176.286 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.434 HG13 HD23 ' A' ' 125' ' ' LEU . 25.5 m -77.69 148.3 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 N-CA-C 112.991 0.738 . . . . 72.24 112.991 -176.779 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -124.08 96.89 5.11 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 113.91 -1.495 . . . . 75.33 107.613 175.321 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.589 HD13 ' HA ' ' A' ' 154' ' ' ARG . 35.1 mt -69.09 147.74 51.02 Favored 'General case' 0 C--O 1.241 0.624 0 O-C-N 123.132 0.27 . . . . 72.42 110.725 -179.246 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.402 ' HA ' ' HD3' ' A' ' 182' ' ' PRO . 40.8 mt -54.13 128.55 57.51 Favored Pre-proline 0 CA--C 1.551 0.988 0 O-C-N 124.354 1.034 . . . . 73.44 110.055 177.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 31.7 Cg_exo -60.27 82.04 0.07 OUTLIER 'Trans proline' 0 C--N 1.377 2.034 0 C-N-CA 123.792 2.994 . . . . 65.32 113.563 -176.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . 0.464 ' O ' HD11 ' A' ' 127' ' ' LEU . 2.3 p80 -170.05 109.08 0.45 Allowed Pre-proline 0 CA--C 1.551 0.986 0 N-CA-C 106.652 -1.61 . . . . 73.31 106.652 171.521 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -89.52 127.31 1.63 Allowed 'Trans proline' 0 C--N 1.36 1.159 0 C-N-CA 122.096 1.864 . . . . 72.24 112.622 178.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 5.2 p -137.21 -47.78 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 109.515 -0.55 . . . . 73.21 109.515 168.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -109.84 123.55 49.76 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 121.436 0.636 . . . . 72.44 111.731 -176.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.461 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 0.1 OUTLIER -113.47 162.5 16.06 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.672 1.589 . . . . 75.43 109.351 -179.461 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.408 HD11 ' O ' ' A' ' 192' ' ' ASP . 43.2 tp -130.49 136.71 49.25 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 123.665 0.786 . . . . 64.54 109.958 179.832 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . 0.466 ' HB3' ' CE1' ' A' ' 194' ' ' TYR . 10.0 tp10 -142.07 109.94 5.82 Favored 'General case' 0 C--O 1.242 0.683 0 C-N-CA 124.184 0.994 . . . . 73.43 108.345 176.147 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 72.22 -83.33 0.53 Allowed Glycine 0 C--N 1.347 1.153 0 N-CA-C 111.447 -0.661 . . . . 64.4 111.447 -174.468 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . 0.533 ' NE2' ' HB1' ' A' ' 244' ' ' ALA . 29.7 pt20 -141.74 -8.26 0.95 Allowed 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.85 0.86 . . . . 72.23 110.017 178.206 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . 0.408 ' O ' HD11 ' A' ' 188' ' ' LEU . 17.1 m-20 -93.88 156.35 16.69 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.447 0.699 . . . . 75.21 111.169 -171.406 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.475 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 90.4 mt -104.59 150.89 24.26 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 124.816 1.246 . . . . 65.23 108.913 -177.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . 0.466 ' CE1' ' HB3' ' A' ' 189' ' ' GLU . 77.4 m-85 -138.26 128.39 25.75 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 107.167 -1.42 . . . . 74.12 107.167 -177.687 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -154.18 171.27 19.44 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 123.842 0.857 . . . . 64.31 109.197 -176.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 14.6 m -120.41 135.28 55.09 Favored 'General case' 0 C--O 1.238 0.5 0 N-CA-C 108.867 -0.79 . . . . 74.11 108.867 176.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.546 HD22 HD11 ' A' ' 233' ' ' LEU . 70.1 tp -123.63 114.18 19.66 Favored 'General case' 0 C--O 1.217 -0.62 0 C-N-CA 124.112 0.965 . . . . 73.2 109.542 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -84.78 119.78 25.69 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 108.266 -1.012 . . . . 75.52 108.266 171.032 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 84.2 t -110.22 126.4 29.02 Favored Pre-proline 0 N--CA 1.469 0.486 0 N-CA-C 108.632 -0.877 . . . . 72.01 108.632 -178.543 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -54.56 133.33 56.2 Favored 'Trans proline' 0 C--N 1.375 1.958 0 C-N-CA 122.767 2.311 . . . . 71.15 110.903 172.4 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -51.68 -45.37 91.52 Favored Pre-proline 0 CA--C 1.556 1.191 0 C-N-CA 124.568 1.147 . . . . 71.21 113.685 -175.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -53.41 -45.53 40.35 Favored 'Trans proline' 0 C--N 1.39 2.751 0 C-N-CA 121.841 1.694 . . . . 74.23 113.666 173.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . 0.441 HG21 HG11 ' A' ' 210' ' ' VAL . 8.7 mt -67.62 -37.71 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 C-N-CA 122.386 0.274 . . . . 75.15 111.276 178.437 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -67.19 -34.53 77.7 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 122.977 0.511 . . . . 54.42 112.319 -176.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.3 m -83.77 -39.17 14.74 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 CA-C-N 116.159 -0.473 . . . . 70.24 111.052 -177.593 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m -82.68 -24.81 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-N 118.12 0.418 . . . . 73.0 110.939 179.676 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 79.02 67.54 1.58 Allowed Glycine 0 C--N 1.341 0.813 0 CA-C-N 116.084 -0.507 . . . . 72.51 112.493 -177.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -101.46 -147.23 19.95 Favored Glycine 0 C--N 1.35 1.31 0 CA-C-N 116.854 0.327 . . . . 64.24 112.337 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 59.1 pttt -127.64 138.19 52.76 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 124.319 1.048 . . . . 73.11 109.43 -177.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . 0.441 HG11 HG21 ' A' ' 203' ' ' ILE . 17.9 m -126.28 143.74 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.117 0.967 . . . . 73.34 109.179 175.31 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 10.0 mpt_? -85.36 107.16 17.23 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 108.958 -0.756 . . . . 74.43 108.958 174.253 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.6 117.59 35.22 Favored 'General case' 0 CA--C 1.517 -0.31 0 N-CA-C 107.62 -1.252 . . . . 64.24 107.62 174.39 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 213' ' ' MET . . . . . 0.543 ' HA ' ' HA ' ' A' ' 218' ' ' PRO . 1.2 ppp? -79.38 138.23 37.59 Favored 'General case' 0 C--O 1.243 0.754 0 N-CA-C 109.29 -0.633 . . . . 74.22 109.29 179.003 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 214' ' ' THR . . . . . 0.521 HG21 ' HG2' ' A' ' 216' ' ' GLU . 4.5 t -128.9 174.95 9.04 Favored 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 124.155 0.982 . . . . 75.54 108.805 177.344 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . 0.568 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 73.9 mt -72.99 -3.34 25.46 Favored 'General case' 0 CA--C 1.549 0.929 0 N-CA-C 113.613 0.968 . . . . 74.32 113.613 -169.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . 0.521 ' HG2' HG21 ' A' ' 214' ' ' THR . 14.3 pt-20 -104.8 -4.62 22.07 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 123.806 0.842 . . . . 70.05 111.183 175.487 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 129.28 -174.09 19.35 Favored Glycine 0 C--N 1.344 0.982 0 N-CA-C 110.686 -0.966 . . . . 63.23 110.686 -172.073 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . 0.543 ' HA ' ' HA ' ' A' ' 213' ' ' MET . 2.2 Cg_endo -81.84 133.38 7.96 Favored 'Trans proline' 0 CA--C 1.55 1.283 0 C-N-CA 122.52 2.147 . . . . 70.45 112.13 179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 34.5 m -110.27 165.15 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.076 0 C-N-CA 123.077 0.551 . . . . 74.11 111.915 171.371 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -111.41 113.03 25.19 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 124.058 0.943 . . . . 74.23 109.011 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.471 HG22 HD11 ' A' ' 235' ' ' LEU . 21.8 t -97.19 117.65 42.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 123.439 0.696 . . . . 74.3 110.36 178.731 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -87.57 105.53 17.39 Favored 'General case' 0 C--O 1.239 0.519 0 N-CA-C 107.442 -1.318 . . . . 64.04 107.442 171.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 6.2 m -80.95 142.38 51.96 Favored Pre-proline 0 CA--C 1.553 1.085 0 N-CA-C 109.383 -0.599 . . . . 61.31 109.383 -177.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -62.62 144.28 93.98 Favored 'Trans proline' 0 C--N 1.371 1.725 0 C-N-CA 123.003 2.469 . . . . 75.43 112.977 177.022 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.04 122.99 10.94 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.411 2.074 . . . . 73.3 111.306 174.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 73.5 mtt180 67.99 36.38 3.39 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.693 1.197 . . . . 73.51 110.822 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 227' ' ' THR . . . . . 0.476 HG23 HD13 ' A' ' 255' ' ' ILE . 9.3 t -67.53 172.06 5.49 Favored 'General case' 0 CA--C 1.551 1.017 0 CA-C-N 115.865 -0.607 . . . . 74.42 110.86 -178.585 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.2 mp0 -117.51 138.03 52.16 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.645 0.778 . . . . 61.04 109.623 -174.314 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -66.66 114.64 5.73 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.365 0.666 . . . . 62.41 110.046 176.317 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.79 3.71 19.86 Favored Glycine 0 C--N 1.336 0.549 0 CA-C-N 115.897 -0.592 . . . . 70.11 112.251 -176.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . 0.41 ' O ' HG11 ' A' ' 253' ' ' VAL . 57.3 mtp180 -78.39 161.83 26.87 Favored 'General case' 0 C--O 1.243 0.725 0 CA-C-O 121.684 0.754 . . . . 74.53 110.838 173.129 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.426 ' HD2' ' N ' ' A' ' 232' ' ' LYS . 0.1 OUTLIER -99.96 100.7 11.64 Favored 'General case' 0 C--O 1.24 0.565 0 CA-C-N 114.235 -1.348 . . . . 74.01 108.367 -178.447 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . 0.552 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 33.3 mt -84.53 97.71 9.72 Favored 'General case' 0 C--N 1.351 0.646 0 N-CA-C 105.217 -2.142 . . . . 74.43 105.217 173.826 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . 0.469 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 51.6 ttp85 -96.13 103.64 15.54 Favored 'General case' 0 C--O 1.24 0.593 0 CA-C-N 114.781 -1.099 . . . . 73.11 109.437 -165.854 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.513 HD13 HD22 ' A' ' 249' ' ' LEU . 20.2 mt -85.02 97.83 10.06 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.589 -1.263 . . . . 75.21 107.589 177.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . 0.548 ' HB2' ' HZ2' ' A' ' 236' ' ' LYS . 10.4 mtmp? -69.43 135.97 50.96 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 114.639 -1.164 . . . . 73.11 111.479 -169.67 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 80.17 13.82 81.39 Favored Glycine 0 C--N 1.347 1.194 0 O-C-N 123.577 0.548 . . . . 74.03 113.354 177.395 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . 0.664 ' HE2' ' HA ' ' A' ' 238' ' ' LYS . 9.3 mmpt? -96.98 -18.79 19.21 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 122.877 0.471 . . . . 72.3 112.222 -178.318 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . 0.461 ' HA2' ' HG ' ' A' ' 193' ' ' LEU . . . -82.75 169.64 49.02 Favored Glycine 0 C--N 1.338 0.689 0 N-CA-C 112.028 -0.429 . . . . 63.04 112.028 176.688 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.516 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 98.0 m-85 -66.06 154.91 88.69 Favored Pre-proline 0 N--CA 1.479 0.994 0 C-N-CA 123.45 0.7 . . . . 74.22 111.933 -172.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -66.55 128.13 18.55 Favored 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 121.948 1.765 . . . . 64.35 110.289 165.163 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -151.5 -159.02 8.65 Favored Glycine 0 N--CA 1.465 0.632 0 CA-C-O 119.714 -0.492 . . . . 65.3 112.732 -178.591 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -65.95 -13.02 37.92 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.375 2.716 . . . . 73.04 114.324 -170.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . 0.533 ' HB1' ' NE2' ' A' ' 191' ' ' GLN . . . -116.9 25.03 10.81 Favored 'General case' 0 N--CA 1.482 1.126 0 C-N-CA 122.86 0.464 . . . . 62.43 110.684 178.767 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 102.87 -101.92 2.17 Favored Glycine 0 C--N 1.348 1.206 0 CA-C-O 119.764 -0.465 . . . . 62.1 112.149 174.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 9.5 ttm180 -124.43 155.31 39.09 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 108.573 -0.899 . . . . 74.33 108.573 173.092 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -94.74 -173.48 38.01 Favored Glycine 0 C--N 1.335 0.511 0 CA-C-O 121.271 0.373 . . . . 64.34 113.114 -177.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -135.95 168.06 20.04 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 108.062 -1.088 . . . . 71.25 108.062 -177.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.513 HD22 HD13 ' A' ' 235' ' ' LEU . 16.7 tp -104.96 124.16 49.03 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 122.786 0.434 . . . . 72.2 110.366 173.037 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . 0.423 ' HB3' ' HA ' ' A' ' 194' ' ' TYR . 11.6 t80 -89.3 108.53 19.68 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 124.62 1.168 . . . . 74.32 108.077 171.232 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.552 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 65.7 mt -96.89 120.83 37.97 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.793 -0.447 . . . . 75.53 109.793 164.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -83.55 94.41 8.05 Favored 'General case' 0 C--O 1.237 0.41 0 N-CA-C 108.012 -1.107 . . . . 72.32 108.012 168.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.41 HG11 ' O ' ' A' ' 231' ' ' ARG . 2.3 p -59.48 126.9 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 CA-C-O 121.291 0.567 . . . . 71.21 110.203 177.513 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 10.2 mmm180 -127.19 94.74 4.09 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 107.299 -1.371 . . . . 75.23 107.299 -177.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.476 HD13 HG23 ' A' ' 227' ' ' THR . 64.6 mt -74.77 120.04 23.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 115.193 -0.912 . . . . 73.1 109.74 -172.54 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.4 t . . . . . 0 CA--C 1.557 1.214 0 C-N-CA 125.161 1.384 . . . . 73.4 108.506 -174.129 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.524 HD12 HD12 ' A' ' 149' ' ' ILE . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.476 0 N-CA-C 107.038 -1.468 . . . . 75.44 107.038 . . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.466 HG23 ' HB2' ' A' ' 121' ' ' ALA . 2.9 p -173.88 131.39 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-N 113.72 -1.582 . . . . 72.44 109.006 -176.12 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.454 ' HB3' ' HD3' ' A' ' 124' ' ' PRO . . . -94.09 -46.85 6.94 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 123.264 0.626 . . . . 62.25 110.072 174.441 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 2.1 p80 -163.45 151.72 13.59 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 115.653 -0.703 . . . . 75.11 111.18 -178.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 93.5 t -73.79 126.57 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.021 0.929 . . . . 71.2 109.168 175.009 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 10.1 t . . . . . 0 CA--C 1.547 0.838 0 CA-C-O 122.357 1.075 . . . . 74.31 110.127 -178.277 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.0 t70 . . . . . 0 N--CA 1.472 0.638 0 N-CA-C 109.299 -0.63 . . . . 60.53 109.299 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.482 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 33.4 tp -136.35 121.33 18.8 Favored 'General case' 0 C--O 1.215 -0.755 0 N-CA-C 106.595 -1.631 . . . . 74.43 106.595 -175.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -121.34 131.88 54.45 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.603 -0.517 . . . . 74.32 109.603 -171.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . 0.466 ' HB2' HG23 ' A' ' 99' ' ' VAL . . . -153.12 146.81 25.14 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.294 0.637 . . . . 71.15 109.701 -177.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -126.16 152.98 45.25 Favored 'General case' 0 C--O 1.244 0.768 0 CA-C-O 121.081 0.467 . . . . 72.24 110.49 177.062 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -145.5 148.58 37.6 Favored Pre-proline 0 N--CA 1.471 0.583 0 CA-C-N 114.933 -1.031 . . . . 72.33 110.362 -177.119 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.473 ' HA ' ' HB2' ' A' ' 179' ' ' ARG . 4.0 Cg_exo -73.86 115.31 4.28 Favored 'Trans proline' 0 C--N 1.37 1.695 0 C-N-CA 121.561 1.507 . . . . 73.43 110.151 167.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.406 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 23.8 tp -105.84 148.47 27.52 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 108.378 -0.971 . . . . 74.02 108.378 175.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.767 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 24.7 m -76.38 147.23 38.18 Favored 'General case' 0 CA--C 1.547 0.853 0 N-CA-C 109.963 -0.384 . . . . 62.35 109.963 173.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.505 HD21 ' HB3' ' A' ' 180' ' ' LEU . 96.6 mt -52.73 -51.42 60.57 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 121.822 0.82 . . . . 65.22 110.48 172.786 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.59 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -55.76 -28.83 58.01 Favored 'General case' 0 CA--C 1.551 1.003 0 CA-C-N 113.947 -1.479 . . . . 61.33 112.451 177.211 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.689 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 22.1 mm-40 -86.24 -21.44 27.41 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 118.18 0.446 . . . . 73.3 111.679 178.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.599 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -61.13 -34.67 75.36 Favored 'General case' 0 C--O 1.239 0.546 0 CA-C-O 121.268 0.556 . . . . 72.34 110.059 164.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.637 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 57.8 t80 -76.42 -50.84 13.1 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 114.823 -1.08 . . . . 75.21 112.887 172.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -75.27 -49.21 19.97 Favored 'General case' 0 N--CA 1.486 1.33 0 C-N-CA 122.338 0.255 . . . . 74.24 111.651 -170.364 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.15 -161.61 44.33 Favored Glycine 0 CA--C 1.535 1.331 0 CA-C-O 119.905 -0.386 . . . . 71.54 112.153 -173.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 128.63 -169.66 20.08 Favored Glycine 0 N--CA 1.476 1.305 0 CA-C-N 117.307 0.554 . . . . 52.32 114.272 171.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -94.61 121.34 36.07 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 124.156 0.982 . . . . 74.24 108.592 -178.129 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -130.66 167.32 18.96 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.759 0.823 . . . . 73.53 108.977 172.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 13.0 p -90.53 142.14 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 108.736 -0.839 . . . . 75.33 108.736 179.152 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.464 HG21 HG21 ' A' ' 140' ' ' VAL . 8.8 p -131.05 136.59 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 N-CA-C 108.863 -0.792 . . . . 71.53 108.863 177.522 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . 0.46 ' HA ' ' O ' ' A' ' 143' ' ' ARG . 36.6 tt0 -126.6 97.83 5.17 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.854 -0.425 . . . . 72.25 109.854 172.483 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.464 HG21 HG21 ' A' ' 138' ' ' VAL . 22.9 t -122.13 138.26 52.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 108.208 -1.034 . . . . 73.41 108.208 174.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 64.52 21.58 12.48 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 124.712 1.205 . . . . 72.13 111.341 -176.61 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.59 13.71 82.9 Favored Glycine 0 C--N 1.352 1.452 0 CA-C-N 116.056 -0.52 . . . . 64.22 113.631 -179.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.46 ' O ' ' HA ' ' A' ' 139' ' ' GLU . 72.5 mtt180 -108.71 117.67 34.79 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.29 0.636 . . . . 74.34 109.468 179.217 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 21.7 ttm180 -105.35 105.35 15.35 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 109.842 -0.429 . . . . 75.44 109.842 -176.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 61.1 t -129.92 141.98 45.01 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.53 1.132 . . . . 63.53 108.291 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 72.0 p -72.2 111.12 7.14 Favored 'General case' 0 CA--C 1.546 0.817 0 N-CA-C 109.022 -0.733 . . . . 74.44 109.022 174.212 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.2 p -96.82 147.4 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 C-N-CA 123.884 0.874 . . . . 72.24 109.327 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -109.03 127.45 54.11 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 107.888 -1.152 . . . . 73.42 107.888 171.281 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.524 HD12 HD12 ' A' ' 98' ' ' LEU . 38.1 pt -120.62 124.73 27.45 Favored Pre-proline 0 CA--C 1.547 0.858 0 N-CA-C 107.873 -1.158 . . . . 72.44 107.873 170.016 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -72.13 153.5 57.12 Favored 'Trans proline' 0 C--N 1.373 1.847 0 C-N-CA 122.346 2.031 . . . . 71.34 113.021 -173.061 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -65.59 147.68 86.63 Favored 'Trans proline' 0 C--N 1.373 1.852 0 C-N-CA 122.282 1.988 . . . . 72.11 111.428 170.041 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 101.42 53.38 1.0 Allowed Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.123 -1.191 . . . . 75.11 110.123 -171.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.599 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -128.49 161.04 38.02 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.299 0 N-CA-C 108.191 -1.041 . . . . 70.42 108.191 -179.459 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -146.16 171.39 15.0 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 124.206 1.002 . . . . 74.34 110.502 -165.562 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -56.59 125.74 23.54 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 123.416 0.686 . . . . 73.22 110.426 169.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.83 -6.0 56.21 Favored Glycine 0 C--N 1.347 1.151 0 CA-C-O 119.362 -0.688 . . . . 72.21 113.921 179.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 47.8 t -67.06 129.11 38.82 Favored 'General case' 0 C--N 1.359 0.987 0 C-N-CA 123.404 0.682 . . . . 75.41 109.548 -178.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.426 HG13 HD21 ' A' ' 175' ' ' LEU . 13.7 t -104.98 118.25 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 O-C-N 124.83 1.331 . . . . 74.11 109.102 -171.218 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.497 HD11 HG23 ' A' ' 153' ' ' VAL . 28.1 mt -104.51 111.31 33.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 123.878 0.871 . . . . 74.42 109.71 -171.311 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 54.9 ttt180 -81.35 117.89 22.2 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.573 0.749 . . . . 70.44 110.643 177.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.635 HG22 ' HB3' ' A' ' 174' ' ' LEU . 2.9 m -118.04 117.14 35.51 Favored Pre-proline 0 CA--C 1.557 1.224 0 N-CA-C 109.093 -0.706 . . . . 73.3 109.093 170.687 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -81.26 149.69 17.2 Favored 'Trans proline' 0 C--N 1.377 2.042 0 C-N-CA 122.473 2.116 . . . . 73.11 112.663 -177.538 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 82.1 24.71 54.26 Favored Glycine 0 C--N 1.349 1.286 0 CA-C-N 115.925 -0.579 . . . . 75.13 113.649 177.383 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 54.9 tpp -109.8 -57.68 2.15 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.545 0.738 . . . . 72.23 110.68 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 1.657 0 N-CA-C 111.665 -0.574 . . . . 73.22 111.665 -179.755 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo . . . . . 0 CA--C 1.543 0.935 0 N-CA-C 111.52 -0.223 . . . . 74.22 111.52 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -94.67 144.89 17.43 Favored Glycine 0 C--N 1.338 0.658 0 N-CA-C 112.096 -0.402 . . . . 74.45 112.096 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . 0.412 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 63.9 m-20 -106.39 116.47 31.99 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 123.035 0.534 . . . . 74.12 110.207 -169.561 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.635 ' HB3' HG22 ' A' ' 161' ' ' VAL . 47.3 tp -89.85 109.68 20.66 Favored 'General case' 0 C--O 1.235 0.338 0 N-CA-C 107.36 -1.348 . . . . 74.11 107.36 171.428 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.426 HD21 HG13 ' A' ' 158' ' ' VAL . 70.0 mt -89.88 98.91 12.04 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.085 1.354 . . . . 72.04 109.538 -179.416 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 84.0 mt -90.22 102.86 15.58 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 124.075 0.95 . . . . 71.02 110.876 179.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 35.1 t -86.91 105.25 14.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 N-CA-C 108.161 -1.051 . . . . 72.53 108.161 175.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 7.8 m -83.48 148.99 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 CA-C-O 121.551 0.691 . . . . 72.42 111.336 -178.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . 0.473 ' HB2' ' HA ' ' A' ' 124' ' ' PRO . 35.3 mmt180 -119.04 100.15 7.17 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 107.236 -1.394 . . . . 74.13 107.236 -178.492 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.505 ' HB3' HD21 ' A' ' 127' ' ' LEU . 41.7 mt -67.47 145.86 54.56 Favored 'General case' 0 C--O 1.239 0.514 0 O-C-N 122.938 0.149 . . . . 72.45 110.771 -176.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.767 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 26.5 mt -55.98 138.92 71.76 Favored Pre-proline 0 CA--C 1.548 0.897 0 O-C-N 123.603 0.564 . . . . 72.44 111.211 -177.034 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.8 67.55 4.79 Favored 'Trans proline' 0 C--N 1.377 2.036 0 C-N-CA 123.368 2.712 . . . . 73.25 113.668 -174.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 8.8 p80 -155.47 82.3 3.84 Favored Pre-proline 0 CA--C 1.557 1.247 0 N-CA-C 108.18 -1.044 . . . . 74.32 108.18 172.055 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -62.88 126.16 17.51 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 121.726 1.617 . . . . 74.3 111.548 -175.085 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.8 p -136.75 -48.14 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 108.103 -1.073 . . . . 74.4 108.103 174.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . 0.484 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 4.2 m-85 -113.16 137.16 51.88 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.759 0.824 . . . . 73.43 110.554 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.569 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 2.7 mpt_? -125.09 154.39 41.46 Favored 'General case' 0 CA--C 1.537 0.446 0 N-CA-C 106.836 -1.542 . . . . 74.44 106.836 175.626 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 48.4 tp -134.43 137.9 44.37 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.305 -0.628 . . . . 71.02 109.305 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -142.07 115.89 9.23 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 107.592 -1.262 . . . . 71.1 107.592 169.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 66.71 -95.48 0.27 Allowed Glycine 0 C--N 1.346 1.13 0 O-C-N 123.779 0.674 . . . . 73.23 111.918 -175.282 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . 0.433 ' OE1' ' HD2' ' A' ' 243' ' ' PRO . 1.9 mp0 -120.63 -19.51 7.42 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.673 0.789 . . . . 74.4 110.267 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -83.03 144.01 30.23 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.438 0.695 . . . . 64.02 112.005 -171.421 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.504 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.6 mt -106.64 155.72 19.36 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 124.917 1.287 . . . . 74.24 108.239 177.379 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . 0.569 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 73.9 m-85 -139.9 121.84 15.59 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 107.117 -1.438 . . . . 74.34 107.117 -179.083 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -139.9 141.87 36.52 Favored 'General case' 0 CA--C 1.51 -0.58 0 N-CA-C 109.342 -0.614 . . . . 74.24 109.342 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 25.7 m -91.35 118.07 30.21 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 108.779 -0.823 . . . . 75.31 108.779 178.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.458 HD11 ' HB3' ' A' ' 212' ' ' ALA . 65.0 tp -105.94 113.3 26.76 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.714 0.805 . . . . 71.1 109.357 -178.154 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -89.54 111.55 22.49 Favored 'General case' 0 C--O 1.244 0.776 0 N-CA-C 108.879 -0.786 . . . . 61.54 108.879 172.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . 0.404 HG21 HG11 ' A' ' 210' ' ' VAL . 60.5 t -97.44 119.18 63.38 Favored Pre-proline 0 CA--C 1.536 0.414 0 N-CA-C 108.269 -1.011 . . . . 72.45 108.269 179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -56.52 135.13 68.62 Favored 'Trans proline' 0 C--N 1.371 1.731 0 C-N-CA 122.439 2.093 . . . . 74.54 110.95 176.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -50.33 -43.86 79.99 Favored Pre-proline 0 CA--C 1.564 1.482 0 C-N-CA 124.803 1.241 . . . . 53.21 113.519 -174.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . 0.405 ' O ' HG22 ' A' ' 206' ' ' VAL . 92.1 Cg_exo -49.35 -54.7 5.04 Favored 'Trans proline' 0 C--N 1.397 3.094 0 C-N-CA 122.395 2.064 . . . . 75.1 113.075 169.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 12.6 mt -66.03 -35.65 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 122.6 0.36 . . . . 74.33 110.956 -178.328 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -58.27 -44.13 88.26 Favored 'General case' 0 N--CA 1.464 0.26 0 C-N-CA 123.503 0.721 . . . . 75.21 110.885 -178.07 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 31.5 m -89.75 -57.69 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.157 0 N-CA-C 112.701 0.63 . . . . 72.41 112.701 -177.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . 0.405 HG22 ' O ' ' A' ' 202' ' ' PRO . 33.2 m -94.86 -27.01 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 118.768 0.713 . . . . 72.24 112.388 -173.299 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -86.53 -146.89 10.24 Favored Glycine 0 C--N 1.342 0.906 0 N-CA-C 112.29 -0.324 . . . . 64.4 112.29 -171.183 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 169.05 10.4 0.02 OUTLIER Glycine 0 C--N 1.339 0.732 0 CA-C-O 118.933 -0.926 . . . . 73.33 115.184 -179.222 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 53.5 mttp -138.48 119.42 14.33 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 118.255 1.027 . . . . 64.13 108.538 -179.206 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . 0.404 HG11 HG21 ' A' ' 199' ' ' VAL . 6.2 p -140.54 137.05 36.31 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 108.054 -1.091 . . . . 73.21 108.054 177.317 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 7.6 mpt_? -98.56 126.88 44.28 Favored 'General case' 0 C--O 1.24 0.555 0 N-CA-C 108.672 -0.862 . . . . 74.42 108.672 -177.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.458 ' HB3' HD11 ' A' ' 197' ' ' LEU . . . -102.2 138.42 39.16 Favored 'General case' 0 C--O 1.244 0.808 0 C-N-CA 123.537 0.735 . . . . 72.33 110.076 -176.102 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 213' ' ' MET . . . . . 0.412 ' HA ' ' HE1' ' A' ' 213' ' ' MET . 3.0 tpt -74.69 109.18 7.96 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.379 -0.828 . . . . 73.15 109.378 175.026 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 214' ' ' THR . . . . . 0.484 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 8.8 t -111.61 166.81 10.84 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 123.011 0.524 . . . . 61.54 110.162 174.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . 0.59 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 64.6 mt -72.38 -5.53 37.09 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 123.8 0.84 . . . . 74.45 111.86 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -96.16 -20.61 18.48 Favored 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.405 1.082 . . . . 73.25 111.126 177.121 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 136.41 -146.41 18.37 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 119.211 -0.772 . . . . 61.01 111.298 -171.239 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -86.06 127.78 3.07 Favored 'Trans proline' 0 CA--C 1.556 1.618 0 C-N-CA 122.541 2.16 . . . . 71.22 112.729 170.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 17.2 m -109.34 150.9 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 N-CA-C 108.974 -0.75 . . . . 71.21 108.974 164.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -111.35 108.76 18.46 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 107.874 -1.158 . . . . 72.32 107.874 178.048 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 2.8 p -104.43 133.81 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 C-N-CA 123.187 0.595 . . . . 73.51 110.31 177.225 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.19 125.57 35.12 Favored 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 115.625 -0.716 . . . . 74.54 109.779 177.457 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.41 HG11 HD13 ' A' ' 233' ' ' LEU . 28.1 m -97.4 141.12 22.54 Favored Pre-proline 0 N--CA 1.479 1.018 0 N-CA-C 108.485 -0.931 . . . . 75.01 108.485 173.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -60.62 139.89 88.24 Favored 'Trans proline' 0 C--N 1.37 1.698 0 C-N-CA 122.171 1.914 . . . . 71.1 111.971 176.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -53.31 112.39 0.92 Allowed 'Trans proline' 0 C--N 1.381 2.253 0 C-N-CA 122.629 2.219 . . . . 75.23 110.781 172.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 70.2 mtp180 66.13 72.4 0.39 Allowed 'General case' 0 CA--C 1.548 0.884 0 O-C-N 124.597 1.186 . . . . 75.02 110.428 -164.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 12.1 t -81.6 173.87 11.95 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.638 0.775 . . . . 72.4 109.299 169.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -132.24 147.38 52.41 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 123.814 0.846 . . . . 71.2 109.302 -176.437 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.08 117.6 11.86 Favored 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 123.316 0.647 . . . . 73.24 109.583 174.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.25 3.16 22.97 Favored Glycine 0 C--N 1.344 1.023 0 CA-C-N 116.133 -0.485 . . . . 71.45 113.108 -174.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 19.2 mtp-105 -83.63 160.65 21.33 Favored 'General case' 0 N--CA 1.479 1.015 0 CA-C-N 117.286 0.543 . . . . 75.42 111.223 175.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -116.05 120.83 40.36 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.549 1.139 . . . . 74.25 109.523 -176.224 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . 0.41 HD13 HG11 ' A' ' 223' ' ' VAL . 33.1 mt -110.54 100.02 8.91 Favored 'General case' 0 C--O 1.237 0.416 0 N-CA-C 107.2 -1.407 . . . . 74.23 107.2 174.548 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 44.4 ttp180 -95.65 104.13 16.04 Favored 'General case' 0 CA--C 1.542 0.636 0 CA-C-N 115.566 -0.743 . . . . 75.01 109.859 -170.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.461 HD12 HD22 ' A' ' 249' ' ' LEU . 16.5 mt -81.04 119.07 23.06 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 123.17 0.588 . . . . 74.42 110.131 -177.118 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 34.2 mtmm -66.65 120.67 13.85 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 125.085 1.354 . . . . 75.45 112.514 -168.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 65.84 33.95 87.27 Favored Glycine 0 C--N 1.351 1.405 0 O-C-N 123.983 0.802 . . . . 63.14 114.053 170.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 28.5 mmtp -116.01 2.11 13.4 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 123.474 0.71 . . . . 74.51 111.635 179.104 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -88.72 -177.58 46.66 Favored Glycine 0 C--N 1.345 1.082 0 N-CA-C 111.434 -0.666 . . . . 65.21 111.434 167.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.637 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 95.2 m-85 -74.68 151.82 87.04 Favored Pre-proline 0 N--CA 1.479 1.016 0 C-N-CA 122.545 0.338 . . . . 73.54 111.119 -177.141 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -77.58 165.68 26.77 Favored 'Trans proline' 0 C--N 1.372 1.788 0 C-N-CA 122.036 1.824 . . . . 73.32 111.631 178.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 161.07 -157.39 28.92 Favored Glycine 0 CA--C 1.528 0.876 0 CA-C-O 119.545 -0.586 . . . . 63.04 113.106 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . 0.433 ' HD2' ' OE1' ' A' ' 191' ' ' GLN . 77.1 Cg_exo -54.35 -23.24 29.83 Favored 'Trans proline' 0 C--N 1.375 1.945 0 C-N-CA 124.174 3.249 . . . . 71.31 114.315 175.582 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -90.42 19.42 5.24 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 123.362 0.665 . . . . 63.11 111.484 176.233 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 71.26 -94.18 0.54 Allowed Glycine 0 C--N 1.352 1.452 0 N-CA-C 110.893 -0.883 . . . . 74.43 110.893 -174.568 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -119.7 146.2 45.82 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 124.7 1.2 . . . . 75.35 107.847 166.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -80.44 -173.16 46.12 Favored Glycine 0 C--O 1.24 0.483 0 O-C-N 123.766 0.666 . . . . 73.1 111.751 173.021 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -137.94 163.05 32.46 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.278 0.631 . . . . 73.11 109.327 -176.37 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.504 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 18.3 tp -99.63 109.58 22.07 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 109.46 -0.57 . . . . 74.42 109.46 172.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -87.86 105.42 17.4 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 107.083 -1.451 . . . . 72.04 107.083 175.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.41 HD22 ' HB2' ' A' ' 197' ' ' LEU . 78.4 mt -87.49 145.98 26.01 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 123.02 0.528 . . . . 75.45 111.575 172.678 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -110.83 98.18 7.39 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 107.924 -1.139 . . . . 74.44 107.924 174.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 61.3 t -56.94 126.56 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 123.227 0.611 . . . . 75.05 110.737 176.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 23.2 mmt180 -132.86 97.11 3.95 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 106.968 -1.493 . . . . 75.11 106.968 178.339 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 62.4 mt -74.59 122.57 28.28 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 N-CA-C 109.274 -0.639 . . . . 71.44 109.274 -177.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.3 t . . . . . 0 CA--C 1.565 1.525 0 C-N-CA 124.719 1.207 . . . . 64.05 108.779 -177.392 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.44 ' HB3' HD13 ' A' ' 123' ' ' LEU . 14.8 mt . . . . . 0 N--CA 1.482 1.148 0 CA-C-O 119.612 -0.232 . . . . 75.41 111.082 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.759 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 24.6 m -58.62 159.16 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 N-CA-C 114.252 1.205 . . . . 71.43 114.252 -173.796 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -108.08 -43.2 4.46 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 113.428 -1.714 . . . . 74.54 109.127 178.053 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 2.9 p80 -177.9 169.74 1.97 Allowed 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 124.08 0.952 . . . . 74.35 110.445 -178.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 85.7 t -64.98 116.33 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 108.287 -1.005 . . . . 73.43 108.287 166.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.526 ' HB ' ' HB2' ' A' ' 122' ' ' GLU . 10.2 t . . . . . 0 N--CA 1.473 0.695 0 O-C-N 123.381 0.426 . . . . 75.12 111.539 -174.109 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.472 0.653 0 N-CA-C 108.642 -0.873 . . . . 72.24 108.642 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 50.3 tp -108.18 127.06 53.49 Favored 'General case' 0 C--O 1.217 -0.638 0 N-CA-C 106.994 -1.484 . . . . 74.33 106.994 173.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 45.3 mtp85 -120.76 108.95 14.58 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.621 -0.511 . . . . 75.54 109.621 -170.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -130.69 139.55 50.32 Favored 'General case' 0 N--CA 1.478 0.944 0 C-N-CA 123.436 0.694 . . . . 72.33 110.578 -174.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . 0.526 ' HB2' ' HB ' ' A' ' 103' ' ' THR . 34.8 tt0 -104.38 146.53 28.7 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.266 0.626 . . . . 74.34 110.294 178.436 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.759 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.8 pt? -145.7 146.32 28.79 Favored Pre-proline 0 N--CA 1.467 0.415 0 C-N-CA 124.077 0.951 . . . . 64.32 110.379 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -78.36 121.91 5.42 Favored 'Trans proline' 0 C--N 1.366 1.457 0 C-N-CA 121.977 1.785 . . . . 73.11 110.581 167.539 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.529 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 14.2 tp -111.86 162.04 15.72 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.582 0.753 . . . . 75.3 109.218 175.161 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 19.5 m -101.86 158.03 16.42 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 109.174 -0.676 . . . . 75.02 109.174 175.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.454 HD12 ' O ' ' A' ' 183' ' ' HIS . 65.1 mt -55.81 -52.19 64.87 Favored 'General case' 0 N--CA 1.486 1.352 0 CA-C-O 121.717 0.77 . . . . 73.22 111.248 179.06 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.413 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 10.9 mp0 -54.26 -33.24 58.1 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 114.495 -1.23 . . . . 65.2 111.708 175.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.4 mm-40 -85.96 -18.61 32.16 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 123.306 0.642 . . . . 75.22 111.98 -176.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.639 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -60.23 -41.34 92.9 Favored 'General case' 0 C--O 1.247 0.947 0 CA-C-O 121.805 0.812 . . . . 72.42 110.41 162.345 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.466 ' HA ' ' CE2' ' A' ' 240' ' ' PHE . 66.1 t80 -73.15 -43.2 61.91 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 114.365 -1.289 . . . . 72.4 112.812 175.003 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.8 m80 -83.94 -49.25 9.16 Favored 'General case' 0 N--CA 1.493 1.692 0 N-CA-C 112.439 0.533 . . . . 71.13 112.439 -172.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.06 -110.61 3.46 Favored Glycine 0 CA--C 1.531 1.063 0 N-CA-C 111.412 -0.675 . . . . 64.13 111.412 -173.597 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 90.0 172.99 45.13 Favored Glycine 0 C--N 1.35 1.318 0 C-N-CA 123.079 0.371 . . . . 61.14 113.923 168.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.624 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 2.1 mp0 -86.34 125.72 33.83 Favored 'General case' 0 C--N 1.351 0.671 0 N-CA-C 108.975 -0.75 . . . . 75.11 108.975 178.071 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 33.2 ttt85 -156.15 138.05 14.41 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 108.139 -1.06 . . . . 73.34 108.139 175.434 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.725 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 12.6 p -72.51 142.64 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 112.85 0.685 . . . . 73.33 112.85 -167.327 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 34.6 m -124.26 152.39 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 124.262 1.025 . . . . 75.35 109.781 174.121 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -124.5 104.31 8.66 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 107.179 -1.415 . . . . 63.13 107.179 171.14 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 7.1 p -150.9 139.12 14.43 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.965 0 C-N-CA 123.593 0.757 . . . . 72.24 109.885 -176.368 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.17 20.56 11.07 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 125.26 1.424 . . . . 74.43 112.768 -176.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.19 26.65 57.33 Favored Glycine 0 C--N 1.346 1.085 0 CA-C-N 116.538 -0.301 . . . . 63.24 112.385 -176.057 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.3 mmt180 -127.16 117.57 22.63 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.61 0.764 . . . . 74.03 110.277 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 43.1 ttp180 -98.5 104.57 16.62 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 108.321 -0.992 . . . . 72.13 108.321 173.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.2 m -146.81 137.47 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 123.672 0.789 . . . . 72.54 109.853 -177.197 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.725 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 35.7 p -73.34 118.19 15.99 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.413 0.685 . . . . 64.12 110.146 177.173 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.9 p -100.08 139.07 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 122.933 0.493 . . . . 64.02 110.129 -178.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . 0.624 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 24.8 ttp180 -106.9 106.47 17.01 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 108.344 -0.984 . . . . 75.23 108.344 173.585 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.494 ' HB ' HD12 ' A' ' 159' ' ' ILE . 34.2 pt -96.73 128.33 36.29 Favored Pre-proline 0 CA--C 1.546 0.794 0 N-CA-C 107.828 -1.175 . . . . 75.13 107.828 175.084 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -71.14 151.35 61.12 Favored 'Trans proline' 0 C--N 1.373 1.822 0 C-N-CA 122.331 2.021 . . . . 72.43 113.59 -167.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.427 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 43.4 Cg_exo -60.54 110.52 0.82 Allowed 'Trans proline' 0 C--N 1.378 2.105 0 C-N-CA 122.779 2.319 . . . . 70.41 109.939 169.755 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 131.37 59.64 0.09 OUTLIER Glycine 0 C--N 1.341 0.811 0 N-CA-C 111.01 -0.836 . . . . 73.51 111.01 -170.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.639 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -140.24 162.82 24.26 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.203 0 N-CA-C 108.453 -0.943 . . . . 72.05 108.453 177.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.537 ' HD2' ' HB3' ' A' ' 188' ' ' LEU . 38.5 mtp180 -146.67 176.52 9.79 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 124.405 1.082 . . . . 72.44 110.869 -171.006 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -56.74 117.81 4.27 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 124.537 1.135 . . . . 75.42 111.694 173.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.24 7.75 87.67 Favored Glycine 0 C--N 1.342 0.869 0 CA-C-N 115.372 -0.831 . . . . 72.52 113.645 179.128 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 33.8 t -78.76 136.32 37.35 Favored 'General case' 0 C--N 1.35 0.599 0 CA-C-O 121.145 0.498 . . . . 62.11 109.799 -178.105 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 8.2 t -103.47 119.29 51.81 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 CA-C-N 114.531 -1.213 . . . . 74.44 109.329 -172.099 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.567 HD11 HG23 ' A' ' 153' ' ' VAL . 26.4 mt -103.05 115.55 45.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.811 0.844 . . . . 75.12 110.417 -171.214 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 32.2 ttt85 -85.06 107.32 17.1 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.603 0.761 . . . . 74.41 109.813 177.098 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.433 HG22 ' O ' ' A' ' 174' ' ' LEU . 25.4 m -112.88 111.59 51.01 Favored Pre-proline 0 CA--C 1.56 1.356 0 C-N-CA 122.648 0.379 . . . . 70.42 110.404 178.119 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -65.97 148.74 86.17 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 123.286 2.657 . . . . 74.42 114.01 -173.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 70.75 23.9 77.44 Favored Glycine 0 C--N 1.352 1.433 0 CA-C-N 116.025 -0.534 . . . . 74.1 114.218 173.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 52.9 mmm -120.16 -30.64 4.6 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.876 0.87 . . . . 75.2 111.554 -172.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.346 1.104 0 O-C-N 123.146 0.279 . . . . 73.43 113.069 -179.462 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo . . . . . 0 CA--C 1.535 0.561 0 CA-C-O 119.686 -0.214 . . . . 75.33 111.698 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -97.65 150.12 19.4 Favored Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.788 -0.925 . . . . 75.04 110.788 175.014 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -106.88 160.05 15.79 Favored 'General case' 0 C--O 1.238 0.45 0 C-N-CA 123.622 0.769 . . . . 54.01 109.691 -178.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.433 ' O ' HG22 ' A' ' 161' ' ' VAL . 13.8 tp -115.04 114.7 25.72 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 108.204 -1.035 . . . . 73.12 108.204 -179.713 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 57.0 mt -84.72 101.69 12.4 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.673 1.189 . . . . 74.31 111.237 176.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.431 ' HB3' HD21 ' A' ' 123' ' ' LEU . 42.5 mt -90.93 105.65 17.97 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 114.95 -1.023 . . . . 74.31 111.32 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 27.3 t -85.55 99.67 7.77 Favored 'Isoleucine or valine' 0 C--O 1.242 0.685 0 N-CA-C 107.959 -1.126 . . . . 72.44 107.959 172.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.529 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 17.4 m -82.25 148.88 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 121.216 0.531 . . . . 74.3 110.235 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 39.4 mmm-85 -121.2 103.95 9.38 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.798 -1.186 . . . . 72.21 107.798 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.451 ' HB3' HD21 ' A' ' 127' ' ' LEU . 30.6 mt -67.97 149.08 50.19 Favored 'General case' 0 C--O 1.242 0.667 0 N-CA-C 109.256 -0.646 . . . . 71.41 109.256 177.339 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 40.2 mt -53.85 137.56 54.79 Favored Pre-proline 0 CA--C 1.552 1.045 0 O-C-N 123.674 0.609 . . . . 75.42 110.311 -178.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -58.78 -5.13 2.35 Favored 'Trans proline' 0 C--N 1.378 2.119 0 C-N-CA 123.141 2.56 . . . . 75.25 114.073 -177.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . 0.454 ' O ' HD12 ' A' ' 127' ' ' LEU . 6.2 t60 -83.72 107.76 11.36 Favored Pre-proline 0 CA--C 1.548 0.893 0 C-N-CA 124.654 1.182 . . . . 75.15 108.526 162.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -96.67 163.48 1.12 Allowed 'Trans proline' 0 C--N 1.369 1.631 0 C-N-CA 122.916 2.411 . . . . 74.45 111.922 168.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.66 -42.98 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 122.999 0.52 . . . . 72.2 109.769 169.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . 0.466 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 5.6 m-85 -101.92 123.97 46.74 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 115.783 -0.644 . . . . 70.45 110.795 -176.903 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -109.64 123.38 49.38 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 125.136 1.375 . . . . 73.3 108.092 179.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.537 ' HB3' ' HD2' ' A' ' 154' ' ' ARG . 22.4 tp -95.58 113.11 24.73 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-O 121.445 0.641 . . . . 65.43 111.174 -173.158 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -83.93 170.37 14.08 Favored 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 125.533 1.533 . . . . 72.04 107.826 162.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . -42.77 86.74 0.01 OUTLIER Glycine 0 C--N 1.362 2.004 0 CA-C-N 118.761 0.71 . . . . 60.42 114.357 175.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 67.18 -4.82 0.78 Allowed 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 127.658 2.383 . . . . 72.21 113.554 -175.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . 0.496 ' O ' HD13 ' A' ' 188' ' ' LEU . 27.2 t70 -105.52 156.13 18.52 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 124.899 1.28 . . . . 64.44 109.989 -174.463 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.553 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 78.4 mt -113.62 157.7 21.78 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 124.047 0.939 . . . . 72.11 112.177 -172.686 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 46.8 m-85 -139.61 122.25 16.33 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 114.419 -1.264 . . . . 74.2 108.378 174.164 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -142.61 171.1 14.51 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.144 0.978 . . . . 73.52 109.504 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 16.2 m -109.41 128.43 55.13 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 109.779 -0.452 . . . . 74.23 109.779 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.452 HD23 HD13 ' A' ' 251' ' ' LEU . 62.3 tp -114.75 115.0 26.35 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.222 1.009 . . . . 62.45 109.713 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . 0.433 ' HA ' ' HB2' ' A' ' 254' ' ' ARG . 10.3 m-20 -99.68 106.35 18.27 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.655 -0.498 . . . . 75.24 109.655 178.489 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . 0.436 HG11 HG21 ' A' ' 210' ' ' VAL . 6.4 m -107.72 147.36 35.23 Favored Pre-proline 0 N--CA 1.481 1.097 0 C-N-CA 123.232 0.613 . . . . 74.22 109.563 178.179 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.32 148.8 55.87 Favored 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 122.149 1.899 . . . . 64.2 110.565 167.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -54.14 -44.38 98.4 Favored Pre-proline 0 CA--C 1.56 1.346 0 CA-C-O 117.468 -1.253 . . . . 61.42 112.893 176.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -43.66 -52.98 4.78 Favored 'Trans proline' 0 C--N 1.403 3.396 0 C-N-CA 123.029 2.486 . . . . 75.45 113.895 171.032 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . 0.521 HG21 HG11 ' A' ' 210' ' ' VAL . 6.3 mt -71.05 -38.06 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 CA-C-N 116.62 -0.263 . . . . 73.4 110.781 -177.639 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -61.01 -38.71 87.05 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 123.321 0.648 . . . . 65.34 112.078 -178.211 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . 0.402 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 34.8 m -84.45 -38.44 13.62 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 CA-C-N 116.173 -0.467 . . . . 73.24 111.759 -176.318 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.1 m -78.2 -27.51 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 CA-C-N 118.121 0.418 . . . . 65.52 111.201 179.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . 0.464 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 79.56 53.52 4.32 Favored Glycine 0 C--N 1.339 0.72 0 CA-C-N 115.554 -0.748 . . . . 73.25 112.849 -175.773 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.8 -152.6 11.53 Favored Glycine 0 C--N 1.354 1.555 0 N-CA-C 111.762 -0.535 . . . . 75.23 111.762 178.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 57.9 mttp -125.27 139.13 53.98 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 123.371 0.668 . . . . 74.44 109.842 176.265 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . 0.521 HG11 HG21 ' A' ' 203' ' ' ILE . 13.6 m -123.71 134.63 65.9 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 CA-C-N 114.737 -1.119 . . . . 70.04 108.322 173.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 39.7 ttp-105 -81.64 113.48 19.68 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 108.835 -0.802 . . . . 72.4 108.835 175.564 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.411 ' HB2' HD12 ' A' ' 197' ' ' LEU . . . -101.19 165.6 11.21 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.374 -0.973 . . . . 72.21 108.374 175.338 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 1.9 mtp -106.4 154.14 21.23 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.593 0.711 . . . . 74.31 110.762 173.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 214' ' ' THR . . . . . 0.466 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.8 t -144.53 173.38 11.86 Favored 'General case' 0 C--O 1.242 0.705 0 CA-C-N 113.641 -1.618 . . . . 75.22 108.365 171.715 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . 0.413 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 49.9 mt -73.7 -10.53 59.78 Favored 'General case' 0 CA--C 1.553 1.069 0 CA-C-N 115.946 -0.57 . . . . 74.34 111.092 -179.723 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -86.87 -18.98 29.59 Favored 'General case' 0 CA--C 1.551 1.011 0 C-N-CA 124.58 1.152 . . . . 54.02 110.819 173.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 134.26 -157.91 23.12 Favored Glycine 0 C--N 1.353 1.48 0 CA-C-O 119.53 -0.595 . . . . 61.12 111.786 -176.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -84.4 130.96 4.7 Favored 'Trans proline' 0 C--N 1.366 1.46 0 C-N-CA 122.5 2.134 . . . . 74.31 112.227 175.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 35.1 m -113.08 161.9 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 124.22 1.008 . . . . 74.31 111.292 178.219 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -106.25 121.23 43.78 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 108.627 -0.879 . . . . 74.41 108.627 173.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 20.2 t -103.26 115.45 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 109.312 -0.625 . . . . 72.43 109.312 176.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -84.59 100.66 11.56 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 107.689 -1.226 . . . . 74.41 107.689 170.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.464 HG23 ' HA2' ' A' ' 207' ' ' GLY . 12.3 m -76.26 141.1 69.89 Favored Pre-proline 0 CA--C 1.549 0.913 0 N-CA-C 108.927 -0.768 . . . . 72.41 108.927 -178.653 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_exo -64.46 136.02 48.68 Favored 'Trans proline' 0 C--N 1.367 1.531 0 C-N-CA 122.622 2.215 . . . . 75.15 112.092 177.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -58.34 117.6 4.34 Favored 'Trans proline' 0 C--N 1.371 1.716 0 C-N-CA 122.611 2.207 . . . . 72.22 111.23 174.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . 0.402 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 93.1 mtt180 64.96 51.74 1.68 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 124.636 1.174 . . . . 73.42 110.826 -175.449 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.6 t -77.61 172.35 13.52 Favored 'General case' 0 CA--C 1.545 0.788 0 CA-C-N 115.248 -0.887 . . . . 74.52 109.555 170.556 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 28.1 mp0 -122.5 145.46 48.29 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 123.398 0.679 . . . . 74.4 110.036 -174.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.57 121.86 18.65 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.734 -0.839 . . . . 75.5 108.734 172.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.69 -7.7 19.87 Favored Glycine 0 N--CA 1.469 0.893 0 CA-C-N 116.087 -0.506 . . . . 52.54 112.324 -171.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 70.5 mtp180 -83.28 160.1 21.79 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 122.842 0.457 . . . . 73.21 110.347 173.319 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.575 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 3.4 mppt? -125.13 113.4 17.66 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.966 0.906 . . . . 73.11 109.527 177.443 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 38.3 mt -89.89 125.71 35.45 Favored 'General case' 0 C--N 1.354 0.802 0 N-CA-C 108.451 -0.944 . . . . 74.22 108.451 -177.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . 0.509 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 37.2 ttp180 -106.26 112.17 25.07 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-O 121.056 0.455 . . . . 73.44 111.22 -168.781 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.429 HD12 HD23 ' A' ' 249' ' ' LEU . 44.7 mt -86.61 127.12 34.9 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-N 115.347 -0.842 . . . . 73.3 110.11 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 35.1 mtmm -70.18 124.64 24.62 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 124.763 1.225 . . . . 73.31 111.809 -172.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 70.8 13.92 72.43 Favored Glycine 0 C--N 1.348 1.216 0 N-CA-C 114.954 0.742 . . . . 74.33 114.954 170.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -87.74 -9.96 52.5 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.226 0.61 . . . . 72.12 111.982 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -87.6 179.57 47.66 Favored Glycine 0 C--N 1.342 0.896 0 O-C-N 123.407 0.442 . . . . 70.13 112.799 177.08 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.466 ' CE2' ' HA ' ' A' ' 131' ' ' PHE . 14.4 m-85 -69.07 144.45 95.48 Favored Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 123.565 0.746 . . . . 75.44 110.99 -177.154 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 23.0 Cg_exo -66.65 130.35 23.25 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.632 2.222 . . . . 74.24 112.304 172.411 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -161.21 -151.53 6.29 Favored Glycine 0 CA--C 1.538 1.507 0 CA-C-O 119.271 -0.738 . . . . 72.12 111.99 178.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -56.18 -23.62 46.02 Favored 'Trans proline' 0 C--N 1.377 2.048 0 C-N-CA 123.996 3.131 . . . . 65.32 115.865 -174.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -101.15 22.6 12.09 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 123.298 0.639 . . . . 71.52 111.586 -179.397 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.16 -93.31 1.82 Allowed Glycine 0 C--N 1.341 0.846 0 N-CA-C 110.075 -1.21 . . . . 72.24 110.075 -172.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.467 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 46.6 mtm180 -122.14 153.68 38.41 Favored 'General case' 0 N--CA 1.478 0.935 0 N-CA-C 108.484 -0.932 . . . . 74.21 108.484 170.218 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -84.61 -162.46 34.94 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.789 -0.641 . . . . 64.13 112.186 178.365 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 42.7 m-20 -138.95 173.65 11.35 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.424 0.689 . . . . 72.22 109.853 -173.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.553 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 16.6 tp -119.82 115.85 24.68 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.397 0.679 . . . . 72.42 111.583 176.2 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . 0.412 ' CZ ' ' HD3' ' A' ' 234' ' ' ARG . 20.5 m-85 -88.95 107.44 19.02 Favored 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 123.561 0.744 . . . . 74.35 109.997 171.259 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.575 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 38.2 mt -89.93 118.72 29.7 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 125.041 1.336 . . . . 74.34 112.178 176.081 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -77.57 96.56 4.81 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 108.965 -0.754 . . . . 73.2 108.965 178.261 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 45.2 t -49.85 115.1 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 124.201 1.001 . . . . 70.03 111.354 173.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . 0.433 ' HB2' ' HA ' ' A' ' 198' ' ' ASP . 30.5 mmm180 -118.21 93.2 4.04 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 106.905 -1.517 . . . . 75.35 106.905 174.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 71.2 mt -76.48 122.94 31.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 N-CA-C 109.216 -0.661 . . . . 75.04 109.216 176.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.557 1.244 0 CA-C-O 117.446 -1.264 . . . . 73.41 107.941 -178.597 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.457 HD13 ' HG3' ' A' ' 136' ' ' ARG . 60.7 tp . . . . . 0 CA--C 1.535 0.384 0 N-CA-C 105.994 -1.854 . . . . 74.4 105.994 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 12.4 p -107.26 154.99 8.07 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 C-N-CA 124.445 1.098 . . . . 72.1 109.306 165.636 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -141.57 1.93 1.58 Allowed 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 124.366 1.066 . . . . 75.1 110.518 173.318 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 9.2 t-80 -109.06 103.33 12.33 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.898 1.279 . . . . 72.14 109.545 -177.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 82.6 t -83.98 136.21 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 N-CA-C 108.597 -0.89 . . . . 71.33 108.597 173.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 43.1 p . . . . . 0 N--CA 1.472 0.671 0 C-N-CA 123.459 0.704 . . . . 71.3 111.912 -172.092 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 . . . . . 0 N--CA 1.47 0.558 0 N-CA-C 108.69 -0.856 . . . . 71.41 108.69 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.437 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 2.5 tt -94.36 138.61 32.12 Favored 'General case' 0 C--O 1.215 -0.722 0 N-CA-C 105.993 -1.854 . . . . 72.44 105.993 179.822 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -128.49 139.91 52.09 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 109.586 -0.524 . . . . 74.44 109.586 -169.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -153.83 149.77 27.73 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 123.889 0.876 . . . . 71.41 110.313 -177.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 72.6 tt0 -127.75 135.29 49.93 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.536 1.134 . . . . 74.05 109.375 -174.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -140.84 142.41 28.04 Favored Pre-proline 0 N--CA 1.478 0.973 0 C-N-CA 122.785 0.434 . . . . 72.42 110.865 -175.149 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_exo -73.6 113.34 3.76 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 121.889 1.726 . . . . 73.42 109.851 166.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.434 HD23 HG12 ' A' ' 178' ' ' VAL . 17.9 tp -109.54 165.79 11.39 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.299 1.039 . . . . 71.35 108.932 179.401 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.606 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 8.6 m -95.39 156.6 16.25 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.23 0.612 . . . . 63.14 109.903 176.266 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.633 HD21 ' HB3' ' A' ' 180' ' ' LEU . 51.9 mt -56.7 -50.35 72.43 Favored 'General case' 0 N--CA 1.487 1.405 0 CA-C-O 122.21 1.005 . . . . 71.54 109.353 174.083 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.489 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -58.51 -38.07 76.93 Favored 'General case' 0 CA--C 1.546 0.813 0 CA-C-N 113.614 -1.63 . . . . 73.45 111.802 178.823 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.428 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 12.0 mm-40 -77.94 -23.25 48.61 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 122.844 0.458 . . . . 75.35 111.831 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.606 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -66.23 -32.0 73.16 Favored 'General case' 0 C--O 1.252 1.201 0 CA-C-O 121.712 0.768 . . . . 63.43 111.156 168.505 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.458 ' HA ' ' CE2' ' A' ' 240' ' ' PHE . 36.9 t80 -75.73 -47.92 24.03 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 114.746 -1.115 . . . . 75.33 111.892 172.798 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -75.23 -48.17 24.7 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 122.59 0.356 . . . . 74.53 111.626 -170.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 63.58 -130.14 40.03 Favored Glycine 0 CA--C 1.532 1.124 0 O-C-N 123.666 0.604 . . . . 54.14 111.861 -175.204 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 94.76 -172.94 31.67 Favored Glycine 0 C--N 1.35 1.332 0 N-CA-C 114.245 0.458 . . . . 35.51 114.245 171.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 7.6 mp0 -88.93 125.96 35.18 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.152 0.981 . . . . 74.54 109.965 -176.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . 0.457 ' HG3' HD13 ' A' ' 98' ' ' LEU . 33.3 mmt180 -137.78 168.49 19.57 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 124.883 1.273 . . . . 72.24 108.325 171.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.0 p -90.23 144.79 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 108.676 -0.861 . . . . 75.21 108.676 178.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 7.8 p -134.23 138.2 50.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 123.249 0.62 . . . . 74.34 109.457 179.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -124.69 106.15 9.86 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 108.14 -1.059 . . . . 75.21 108.14 169.185 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.5 m -125.09 117.81 51.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 C-N-CA 124.461 1.105 . . . . 75.41 109.592 -178.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 64.43 20.47 12.17 Favored 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 124.598 1.159 . . . . 74.24 111.771 179.579 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.69 -6.9 74.23 Favored Glycine 0 C--N 1.357 1.704 0 O-C-N 123.225 0.328 . . . . 73.02 113.478 -178.302 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 6.3 tpm_? -91.6 117.41 29.71 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 108.92 -0.77 . . . . 65.35 108.92 176.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 52.5 ttp180 -99.66 122.07 42.14 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 123.583 0.753 . . . . 75.34 109.516 179.181 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 19.0 t -133.19 156.99 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 N-CA-C 108.3 -1.0 . . . . 74.54 108.3 176.148 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 24.3 p -85.35 113.71 21.87 Favored 'General case' 0 CA--C 1.547 0.838 0 N-CA-C 108.325 -0.991 . . . . 75.25 108.325 165.511 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.563 ' HB ' ' HE3' ' A' ' 164' ' ' MET . 7.2 p -98.02 123.52 50.54 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 CA-C-O 121.641 0.734 . . . . 72.42 111.402 -176.259 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -97.94 104.77 16.83 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 107.76 -1.2 . . . . 74.23 107.76 167.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 38.7 pt -97.32 103.63 16.61 Favored Pre-proline 0 CA--C 1.55 0.967 0 N-CA-C 108.154 -1.054 . . . . 75.14 108.154 167.19 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -61.09 151.21 80.16 Favored 'Trans proline' 0 C--N 1.383 2.366 0 C-N-CA 122.613 2.209 . . . . 74.32 112.788 -178.116 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -49.28 151.37 6.62 Favored 'Trans proline' 0 C--N 1.378 2.081 0 C-N-CA 123.829 3.019 . . . . 71.54 114.153 176.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 108.73 23.36 6.55 Favored Glycine 0 N--CA 1.478 1.438 0 C-N-CA 121.465 -0.398 . . . . 51.51 113.238 174.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.608 HG21 HD13 ' A' ' 159' ' ' ILE . 2.5 p -99.65 162.84 2.95 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.192 0 N-CA-C 107.831 -1.174 . . . . 73.21 107.831 179.464 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.583 ' HA ' HD13 ' A' ' 180' ' ' LEU . 0.0 OUTLIER -158.87 177.69 10.88 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.618 1.167 . . . . 74.53 111.91 -172.02 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.3 tp10 -51.58 115.5 1.65 Allowed 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 124.76 1.224 . . . . 74.11 111.722 178.09 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 80.68 10.43 85.18 Favored Glycine 0 C--N 1.356 1.64 0 CA-C-N 115.775 -0.648 . . . . 61.51 113.591 177.652 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.4 t -85.77 123.76 31.51 Favored 'General case' 0 C--O 1.245 0.822 0 C-N-CA 123.097 0.559 . . . . 74.24 109.58 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.414 HG21 ' HB ' ' A' ' 177' ' ' VAL . 3.4 t -99.6 122.4 51.38 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 124.129 0.972 . . . . 75.44 108.659 -176.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.608 HD13 HG21 ' A' ' 153' ' ' VAL . 13.5 mt -103.11 119.68 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 124.046 0.938 . . . . 74.42 109.33 -169.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 34.3 ttt180 -97.43 103.67 15.63 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 122.693 0.397 . . . . 72.44 110.361 -177.115 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 12.1 m -102.39 118.91 57.75 Favored Pre-proline 0 CA--C 1.559 1.293 0 N-CA-C 109.451 -0.574 . . . . 72.25 109.451 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.47 152.25 43.36 Favored 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.635 2.224 . . . . 71.34 113.684 -173.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 79.74 24.48 60.19 Favored Glycine 0 C--N 1.349 1.267 0 N-CA-C 115.0 0.76 . . . . 61.52 115.0 168.147 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.563 ' HE3' ' HB ' ' A' ' 147' ' ' VAL . 39.6 mtt -105.18 -62.91 1.29 Allowed 'General case' 0 N--CA 1.488 1.465 0 CA-C-N 118.285 1.042 . . . . 74.22 112.093 176.061 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.349 1.294 0 CA-C-N 115.933 -0.576 . . . . 64.22 112.937 -177.295 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_exo . . . . . 0 CA--C 1.541 0.857 0 N-CA-C 110.966 -0.436 . . . . 74.3 110.966 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -101.78 153.3 18.74 Favored Glycine 0 CA--C 1.502 -0.773 0 N-CA-C 110.621 -0.992 . . . . 72.33 110.621 174.634 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -112.69 178.59 4.24 Favored 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 123.473 0.709 . . . . 74.41 111.511 -168.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.437 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 34.9 tp -130.16 112.92 13.86 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 114.579 -1.191 . . . . 74.1 108.615 168.419 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 72.9 mt -85.09 100.86 11.98 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.138 1.375 . . . . 72.32 111.238 177.118 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 70.7 mt -95.38 101.64 13.38 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 122.69 0.396 . . . . 70.55 110.666 174.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.414 ' HB ' HG21 ' A' ' 158' ' ' VAL . 2.5 p -87.03 108.65 18.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 N-CA-C 109.158 -0.682 . . . . 74.14 109.158 172.576 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.434 HG12 HD23 ' A' ' 125' ' ' LEU . 4.0 m -87.35 149.37 4.11 Favored 'Isoleucine or valine' 0 C--O 1.245 0.851 0 CA-C-N 115.946 -0.57 . . . . 74.3 110.665 -177.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 13.1 mmm-85 -124.97 101.31 6.99 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 107.491 -1.299 . . . . 64.32 107.491 -178.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.633 ' HB3' HD21 ' A' ' 127' ' ' LEU . 25.3 mt -69.46 148.61 49.3 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 112.082 0.401 . . . . 65.14 112.082 -172.115 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.606 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 39.8 mt -57.5 138.25 81.57 Favored Pre-proline 0 CA--C 1.559 1.295 0 C-N-CA 123.283 0.633 . . . . 73.03 110.752 179.488 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.44 83.79 1.0 Allowed 'Trans proline' 0 C--N 1.374 1.875 0 C-N-CA 123.188 2.592 . . . . 75.14 112.584 -177.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -165.19 54.03 0.34 Allowed Pre-proline 0 CA--C 1.559 1.306 0 C-N-CA 124.12 0.968 . . . . 73.43 109.314 170.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.61 124.4 15.71 Favored 'Trans proline' 0 C--N 1.389 2.668 0 C-N-CA 122.627 2.218 . . . . 75.23 112.723 -169.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.4 p -130.84 -44.42 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 124.182 0.993 . . . . 75.41 109.561 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . 0.408 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 6.4 m-85 -105.01 120.29 41.11 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.218 0.532 . . . . 73.31 111.347 -176.048 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.694 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 23.5 mtp180 -104.17 162.7 12.95 Favored 'General case' 0 N--CA 1.467 0.425 0 C-N-CA 124.18 0.992 . . . . 75.42 109.337 173.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 57.2 tp -132.42 127.53 35.56 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 123.493 0.717 . . . . 64.04 109.743 179.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -139.52 102.52 4.48 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 125.034 1.333 . . . . 73.45 108.122 176.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 56.59 58.41 14.53 Favored Glycine 0 C--N 1.353 1.479 0 O-C-N 123.951 0.782 . . . . 75.34 114.04 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . 0.56 ' NE2' ' HD2' ' A' ' 243' ' ' PRO . 52.6 mt-30 74.09 -15.81 0.57 Allowed 'General case' 0 N--CA 1.505 2.322 0 C-N-CA 125.407 1.483 . . . . 75.14 112.305 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -97.41 152.44 18.95 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.333 1.053 . . . . 65.21 108.362 -175.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.418 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 78.4 mt -110.33 168.47 9.42 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 122.024 0.916 . . . . 72.31 111.512 -173.187 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . 0.694 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 35.6 m-85 -134.14 132.29 39.68 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 114.085 -1.416 . . . . 64.15 108.062 171.182 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . 0.401 ' HB3' HD11 ' A' ' 249' ' ' LEU . . . -154.02 168.28 26.95 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.909 0.884 . . . . 73.1 109.308 174.18 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 35.5 m -105.75 128.51 53.74 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 115.702 -0.681 . . . . 71.24 109.672 178.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.484 HD11 ' HB1' ' A' ' 212' ' ' ALA . 59.9 tp -107.76 113.65 27.05 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.733 -0.84 . . . . 75.23 108.733 173.382 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -94.9 119.82 34.08 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.373 -0.973 . . . . 72.43 108.373 175.496 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . 0.462 HG12 HG22 ' A' ' 253' ' ' VAL . 7.5 p -134.52 134.77 22.68 Favored Pre-proline 0 N--CA 1.479 1.018 0 C-N-CA 124.284 1.033 . . . . 64.42 109.37 -173.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.58 149.14 91.05 Favored 'Trans proline' 0 C--N 1.372 1.782 0 C-N-CA 122.715 2.277 . . . . 72.24 113.092 175.693 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . 0.491 ' HA ' HG22 ' A' ' 255' ' ' ILE . . . -60.75 -43.19 91.16 Favored Pre-proline 0 N--CA 1.478 0.972 0 N-CA-C 113.171 0.804 . . . . 75.53 113.171 176.445 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . 0.419 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 10.6 Cg_endo -53.73 -44.36 49.84 Favored 'Trans proline' 0 C--N 1.392 2.854 0 C-N-CA 121.759 1.639 . . . . 75.52 112.294 172.025 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.7 mt -67.44 -36.22 75.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 122.821 0.449 . . . . 73.53 111.189 177.618 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -64.57 -41.42 96.3 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 123.201 0.6 . . . . 73.22 111.802 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.7 m -79.89 -42.28 22.14 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 CA-C-N 116.003 -0.544 . . . . 72.34 111.362 -177.017 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 10.1 m -80.1 -20.02 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 122.471 0.308 . . . . 73.24 111.054 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 68.92 65.92 2.45 Favored Glycine 0 C--N 1.343 0.962 0 CA-C-N 115.687 -0.688 . . . . 55.33 112.461 -176.26 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.83 -145.92 15.4 Favored Glycine 0 C--N 1.357 1.7 0 N-CA-C 111.233 -0.747 . . . . 63.2 111.233 175.316 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 24.4 pttm -133.0 149.82 52.2 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 122.853 0.461 . . . . 71.51 109.88 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 2.8 m -145.09 134.37 18.04 Favored 'Isoleucine or valine' 0 C--O 1.239 0.528 0 N-CA-C 107.539 -1.282 . . . . 73.02 107.539 176.246 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 31.7 ptt180 -79.43 137.77 37.38 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 109.472 -0.566 . . . . 75.33 109.472 176.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.484 ' HB1' HD11 ' A' ' 197' ' ' LEU . . . -108.19 134.65 50.75 Favored 'General case' 0 C--O 1.245 0.845 0 C-N-CA 123.311 0.644 . . . . 74.45 109.408 174.218 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 4.8 tpt -75.85 106.26 7.33 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 108.837 -0.801 . . . . 74.22 108.837 173.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 214' ' ' THR . . . . . 0.408 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 11.2 t -110.68 165.85 11.49 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 109.703 -0.48 . . . . 64.31 109.703 174.553 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . 0.489 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 59.7 mt -69.69 -17.7 63.5 Favored 'General case' 0 CA--C 1.551 0.99 0 CA-C-N 115.686 -0.688 . . . . 74.33 111.162 178.348 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -79.21 -19.42 50.83 Favored 'General case' 0 CA--C 1.556 1.209 0 C-N-CA 123.934 0.894 . . . . 70.21 110.948 174.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 131.77 -148.53 19.06 Favored Glycine 0 C--N 1.346 1.088 0 N-CA-C 111.378 -0.689 . . . . 75.14 111.378 -176.079 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -85.86 126.85 2.99 Favored 'Trans proline' 0 CA--C 1.557 1.64 0 C-N-CA 122.376 2.05 . . . . 74.42 112.473 172.118 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . 0.518 HG12 ' HD2' ' A' ' 238' ' ' LYS . 34.9 m -111.56 155.47 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 N-CA-C 109.132 -0.692 . . . . 71.22 109.132 169.575 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -114.36 111.8 22.04 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.944 -0.761 . . . . 72.44 108.944 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.432 HG23 HD11 ' A' ' 235' ' ' LEU . 8.5 t -96.27 115.75 36.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.381 0 C-N-CA 123.593 0.757 . . . . 71.22 109.704 -178.594 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.59 101.28 13.97 Favored 'General case' 0 C--O 1.239 0.529 0 N-CA-C 106.673 -1.603 . . . . 63.03 106.673 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 19.0 m -75.21 141.47 74.13 Favored Pre-proline 0 CA--C 1.551 1.018 0 C-N-CA 122.546 0.338 . . . . 74.04 110.546 -173.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -60.07 133.27 49.15 Favored 'Trans proline' 0 C--N 1.378 2.092 0 C-N-CA 122.679 2.253 . . . . 74.22 111.828 176.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -56.0 124.57 16.58 Favored 'Trans proline' 0 C--N 1.377 2.077 0 C-N-CA 122.692 2.261 . . . . 72.2 110.92 173.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 60.58 51.98 4.8 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 124.593 1.157 . . . . 74.33 110.77 -173.271 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.2 t -78.61 165.77 23.3 Favored 'General case' 0 CA--C 1.544 0.741 0 N-CA-C 109.229 -0.656 . . . . 73.43 109.229 170.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.7 mp0 -119.51 147.32 44.58 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 108.707 -0.849 . . . . 75.32 108.707 -174.628 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.01 143.62 52.51 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.554 0.742 . . . . 74.12 110.844 178.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 89.46 0.04 80.03 Favored Glycine 0 C--N 1.343 0.966 0 O-C-N 123.442 0.464 . . . . 62.55 113.342 -179.065 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . 0.46 ' O ' HG12 ' A' ' 253' ' ' VAL . 80.8 mtp180 -80.26 163.48 23.95 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-N 117.455 0.627 . . . . 74.43 109.855 174.426 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.8 mptp? -112.97 107.31 15.81 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 108.69 -0.856 . . . . 75.34 108.69 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 56.9 mt -85.2 116.34 23.5 Favored 'General case' 0 C--N 1.355 0.824 0 N-CA-C 107.92 -1.141 . . . . 75.2 107.92 178.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 19.6 ttm-85 -95.79 114.76 26.53 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 124.097 0.959 . . . . 74.25 109.433 -164.229 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.432 HD11 HG23 ' A' ' 221' ' ' VAL . 25.0 mt -106.77 106.07 16.41 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.081 0.552 . . . . 74.31 109.698 176.573 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . 0.539 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 44.8 mttp -62.7 148.98 44.91 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 123.651 0.781 . . . . 73.11 111.718 176.539 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.51 35.44 81.41 Favored Glycine 0 C--N 1.355 1.636 0 O-C-N 123.971 0.794 . . . . 64.22 113.228 176.009 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . 0.518 ' HD2' HG12 ' A' ' 219' ' ' VAL . 15.9 mmtm -123.82 -23.08 4.75 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 123.774 0.83 . . . . 74.32 112.116 -176.159 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -81.38 -155.66 14.05 Favored Glycine 0 C--N 1.341 0.844 0 O-C-N 123.592 0.557 . . . . 74.04 112.68 178.203 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.458 ' CE2' ' HA ' ' A' ' 131' ' ' PHE . 75.3 m-85 -96.26 143.68 26.54 Favored Pre-proline 0 N--CA 1.474 0.754 0 O-C-N 122.346 -0.502 . . . . 71.03 111.802 178.186 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . 0.566 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 27.9 Cg_exo -62.22 168.21 9.71 Favored 'Trans proline' 0 C--N 1.378 2.095 0 C-N-CA 123.245 2.63 . . . . 72.13 112.868 176.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 163.22 -159.08 31.58 Favored Glycine 0 CA--C 1.534 1.226 0 CA-C-O 119.586 -0.564 . . . . 60.35 112.959 -177.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . 0.56 ' HD2' ' NE2' ' A' ' 191' ' ' GLN . 39.8 Cg_exo -60.44 -24.04 76.73 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 123.768 2.979 . . . . 74.24 113.363 177.601 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.44 18.56 7.08 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.668 0.787 . . . . 74.34 111.507 178.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.34 -98.84 1.79 Allowed Glycine 0 C--N 1.349 1.266 0 N-CA-C 110.746 -0.942 . . . . 64.14 110.746 -174.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.566 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 51.9 ttt180 -129.32 149.69 51.0 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.362 0.665 . . . . 75.53 109.845 166.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -75.31 -171.21 28.99 Favored Glycine 0 C--N 1.348 1.234 0 O-C-N 123.592 0.558 . . . . 74.33 112.882 176.387 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . 0.539 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 1.6 p-10 -145.16 169.56 17.93 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 123.89 0.876 . . . . 72.01 110.526 -174.307 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.418 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 22.9 tp -110.61 126.39 54.41 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 124.121 0.968 . . . . 73.31 112.095 -171.075 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 15.1 m-85 -88.84 107.06 18.78 Favored 'General case' 0 C--N 1.357 0.918 0 C-N-CA 123.7 0.8 . . . . 71.24 109.308 168.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.479 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 73.5 mt -88.57 121.93 31.48 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 123.783 0.833 . . . . 73.1 111.628 171.325 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -82.35 92.83 7.05 Favored 'General case' 0 C--O 1.235 0.313 0 N-CA-C 108.032 -1.099 . . . . 71.0 108.032 174.351 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.462 HG22 HG12 ' A' ' 199' ' ' VAL . 2.4 p -58.61 114.29 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 C-N-CA 123.395 0.678 . . . . 45.14 110.484 177.586 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 21.3 mmm-85 -116.08 95.2 4.98 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 107.802 -1.184 . . . . 73.41 107.802 -177.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.491 HG22 ' HA ' ' A' ' 201' ' ' ALA . 75.2 mt -76.03 102.57 3.05 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 114.991 -1.004 . . . . 74.21 110.41 -174.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 CA--C 1.564 1.512 0 C-N-CA 124.337 1.055 . . . . 71.35 109.258 175.985 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.488 ' HA ' HD13 ' A' ' 123' ' ' LEU . 3.5 mm? . . . . . 0 CA--C 1.537 0.453 0 N-CA-C 107.402 -1.333 . . . . 74.22 107.402 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 7.1 p -60.1 -27.94 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 C-N-CA 123.092 0.557 . . . . 74.1 111.391 -178.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . 64.86 35.85 8.21 Favored 'General case' 0 C--N 1.355 0.818 0 O-C-N 124.541 1.151 . . . . 74.23 110.905 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 66.5 t-80 -75.35 91.07 2.68 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 114.755 -1.112 . . . . 75.04 108.088 178.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 46.3 t -57.2 145.72 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 C-N-CA 124.582 1.153 . . . . 75.43 111.297 -173.391 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.5 t . . . . . 0 C--O 1.242 0.665 0 C-N-CA 123.172 0.589 . . . . 75.34 109.836 177.885 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 . . . . . 0 N--CA 1.474 0.751 0 CA-C-O 120.919 0.39 . . . . 72.4 110.158 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.532 HD11 ' HA2' ' A' ' 165' ' ' GLY . 11.6 mt -124.05 151.41 43.83 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 108.129 -1.063 . . . . 72.41 108.129 168.524 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . 0.499 ' HG2' ' HB2' ' A' ' 175' ' ' LEU . 17.3 mtp180 -142.6 151.01 41.07 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.571 0.748 . . . . 74.14 109.376 177.587 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . 0.481 ' HB2' HD21 ' A' ' 176' ' ' LEU . . . -151.63 120.11 6.44 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 123.615 0.766 . . . . 75.04 109.412 177.003 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 37.8 mm-40 -84.05 143.18 29.91 Favored 'General case' 0 C--O 1.242 0.708 0 N-CA-C 109.111 -0.699 . . . . 73.34 109.111 175.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.488 HD13 ' HA ' ' A' ' 98' ' ' LEU . 0.7 OUTLIER -145.21 145.25 26.06 Favored Pre-proline 0 N--CA 1.475 0.781 0 C-N-CA 122.38 0.272 . . . . 74.2 110.923 174.707 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -81.64 114.51 2.69 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 121.864 1.709 . . . . 74.52 110.638 165.173 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.4 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 15.1 tp -106.79 138.8 42.29 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 123.863 0.865 . . . . 73.4 109.354 -178.71 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' THR . . . . . 0.766 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 20.8 m -78.78 158.76 28.15 Favored 'General case' 0 CA--C 1.548 0.901 0 N-CA-C 109.605 -0.517 . . . . 75.04 109.605 172.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.417 HD12 ' O ' ' A' ' 183' ' ' HIS . 31.6 mt -61.52 -47.11 87.09 Favored 'General case' 0 N--CA 1.483 1.177 0 CA-C-O 121.909 0.861 . . . . 75.33 110.004 178.287 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -56.81 -32.76 66.03 Favored 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 114.12 -1.4 . . . . 74.41 111.172 175.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.766 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 29.6 mm-40 -76.97 -32.08 57.0 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 122.977 0.511 . . . . 73.24 111.385 178.514 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' ALA . . . . . 0.498 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -55.6 -35.1 65.46 Favored 'General case' 0 C--O 1.245 0.824 0 C-N-CA 122.999 0.519 . . . . 64.01 111.564 167.326 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' PHE . . . . . 0.555 ' HA ' ' HE2' ' A' ' 240' ' ' PHE . 69.2 t80 -75.17 -47.62 27.55 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.447 -0.797 . . . . 72.51 112.877 171.306 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -68.95 -48.51 63.02 Favored 'General case' 0 N--CA 1.485 1.306 0 N-CA-C 112.115 0.413 . . . . 75.2 112.115 -170.092 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 57.52 -122.14 28.17 Favored Glycine 0 CA--C 1.534 1.272 0 O-C-N 123.869 0.731 . . . . 74.22 111.984 -172.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.27 -173.67 55.14 Favored Glycine 0 C--N 1.35 1.32 0 N-CA-C 114.358 0.503 . . . . 72.14 114.358 168.491 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' GLU . . . . . 0.54 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 1.3 mp0 -83.38 112.12 19.63 Favored 'General case' 0 C--N 1.356 0.856 0 N-CA-C 109.56 -0.533 . . . . 70.23 109.56 -178.552 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 10.3 mmm180 -123.07 156.47 34.84 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.291 1.036 . . . . 73.25 108.462 178.194 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.1 m -77.05 133.32 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 C-N-CA 122.46 0.304 . . . . 71.5 111.356 -176.718 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 144' ' ' ARG . 38.6 t -125.13 134.05 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.685 1.194 . . . . 73.21 108.798 172.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -125.67 97.17 5.05 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.058 0.943 . . . . 74.32 109.366 171.637 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 53.2 t -122.84 122.31 65.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 C-N-CA 123.548 0.739 . . . . 64.35 109.803 178.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.56 28.41 18.09 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 124.93 1.292 . . . . 75.43 112.381 175.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 98.37 -13.61 62.84 Favored Glycine 0 C--N 1.349 1.294 0 CA-C-N 116.107 -0.497 . . . . 63.24 113.594 178.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.98 118.0 30.35 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 117.508 0.654 . . . . 74.21 110.569 -179.716 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.401 ' HA ' ' O ' ' A' ' 138' ' ' VAL . 38.0 ttp180 -95.49 106.15 18.2 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 124.499 1.12 . . . . 63.45 108.41 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.9 t -128.33 131.21 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.19 0.996 . . . . 74.11 109.491 -179.197 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 70.0 m -72.25 115.19 11.2 Favored 'General case' 0 C--O 1.242 0.677 0 N-CA-C 108.635 -0.876 . . . . 71.34 108.635 170.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 7.1 p -96.81 143.67 11.93 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 123.044 0.538 . . . . 74.55 110.295 -178.637 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 31.2 ttm180 -107.89 100.26 9.64 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 107.585 -1.265 . . . . 72.13 107.585 171.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.426 ' HB ' HD13 ' A' ' 159' ' ' ILE . 27.7 pt -92.91 130.91 34.8 Favored Pre-proline 0 CA--C 1.548 0.881 0 N-CA-C 108.393 -0.966 . . . . 73.2 108.393 172.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -66.7 131.04 24.79 Favored 'Trans proline' 0 C--N 1.376 2.002 0 C-N-CA 122.617 2.211 . . . . 64.01 113.121 -172.164 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_exo -53.02 117.61 3.93 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.303 2.669 . . . . 75.3 111.824 167.037 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 124.46 54.26 0.18 Allowed Glycine 0 CA--C 1.506 -0.489 0 N-CA-C 110.758 -0.937 . . . . 71.42 110.758 -173.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.498 HG11 ' HA ' ' A' ' 130' ' ' ALA . 3.1 p -126.85 156.62 38.11 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.301 0 C-N-CA 123.456 0.703 . . . . 75.31 109.542 -175.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 55.4 mtp180 -138.26 176.09 9.0 Favored 'General case' 0 N--CA 1.491 1.599 0 C-N-CA 124.61 1.164 . . . . 75.12 111.284 -168.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -55.55 121.56 9.32 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 124.272 1.029 . . . . 74.33 111.04 171.367 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.14 7.86 84.8 Favored Glycine 0 C--N 1.348 1.204 0 O-C-N 123.589 0.556 . . . . 64.23 113.842 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 70.8 m -72.37 126.32 29.55 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 117.287 0.543 . . . . 75.41 109.818 176.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.444 HG12 HD21 ' A' ' 175' ' ' LEU . 32.7 t -100.47 123.03 53.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-N 114.045 -1.434 . . . . 71.24 108.265 -175.313 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.472 HD12 HG23 ' A' ' 153' ' ' VAL . 25.4 mt -110.57 118.6 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 123.414 0.686 . . . . 75.32 110.153 -172.452 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 33.2 ttm-85 -85.12 130.29 34.64 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.663 0.785 . . . . 72.12 110.619 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.616 HG22 ' HB3' ' A' ' 174' ' ' LEU . 4.2 m -124.49 125.96 25.52 Favored Pre-proline 0 CA--C 1.551 0.984 0 N-CA-C 108.691 -0.855 . . . . 64.33 108.691 166.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.34 147.17 28.81 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 122.614 2.209 . . . . 71.02 113.424 -173.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 70.62 24.89 76.52 Favored Glycine 0 C--N 1.351 1.415 0 CA-C-N 115.733 -0.667 . . . . 52.04 114.348 170.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 44.3 tpp -104.99 -37.64 6.89 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.152 0.581 . . . . 75.54 109.904 177.205 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' GLY . . . . . 0.532 ' HA2' HD11 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.347 1.167 0 CA-C-N 115.483 -0.781 . . . . 32.54 112.942 -177.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo . . . . . 0 CA--C 1.537 0.67 0 N-CA-C 110.425 -0.644 . . . . 63.23 110.425 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -95.5 172.66 30.4 Favored Glycine 0 C--O 1.237 0.338 0 N-CA-C 110.768 -0.933 . . . . 72.41 110.768 173.091 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -120.22 159.48 24.85 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 123.447 0.699 . . . . 71.55 110.689 -170.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' LEU . . . . . 0.616 ' HB3' HG22 ' A' ' 161' ' ' VAL . 43.1 tp -109.74 120.43 42.46 Favored 'General case' 0 C--O 1.242 0.698 0 N-CA-C 107.092 -1.447 . . . . 74.51 107.092 169.519 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' LEU . . . . . 0.499 ' HB2' ' HG2' ' A' ' 120' ' ' ARG . 52.5 mt -100.36 100.29 11.06 Favored 'General case' 0 C--O 1.241 0.616 0 O-C-N 124.495 1.122 . . . . 74.43 109.326 -178.003 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.481 HD21 ' HB2' ' A' ' 121' ' ' ALA . 26.7 mt -86.92 101.28 13.25 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 114.562 -1.199 . . . . 63.04 109.098 -179.394 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 23.1 t -93.47 105.98 17.46 Favored 'Isoleucine or valine' 0 C--O 1.244 0.812 0 N-CA-C 108.451 -0.944 . . . . 75.34 108.451 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.459 HG22 HG22 ' A' ' 153' ' ' VAL . 13.7 m -82.44 147.95 5.62 Favored 'Isoleucine or valine' 0 C--O 1.241 0.643 0 CA-C-N 115.593 -0.73 . . . . 73.15 110.271 -178.435 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 17.0 mmt180 -123.72 105.53 9.77 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 107.675 -1.231 . . . . 70.35 107.675 178.665 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 180' ' ' LEU . . . . . 0.4 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 33.9 mt -67.22 148.81 51.27 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 117.725 0.239 . . . . 73.23 110.381 179.521 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 181' ' ' LEU . . . . . 0.556 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 29.5 mt -57.46 157.44 13.33 Favored Pre-proline 0 CA--C 1.556 1.179 0 C-N-CA 123.78 0.832 . . . . 75.32 112.486 -171.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -57.19 -12.79 10.83 Favored 'Trans proline' 0 C--N 1.386 2.524 0 C-N-CA 123.019 2.48 . . . . 65.23 113.336 174.136 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 183' ' ' HIS . . . . . 0.417 ' O ' HD12 ' A' ' 127' ' ' LEU . 28.3 t60 -99.09 101.12 11.52 Favored Pre-proline 0 CA--C 1.545 0.763 0 C-N-CA 124.364 1.066 . . . . 64.4 108.528 166.235 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -102.44 128.41 0.1 Allowed 'Trans proline' 0 CA--C 1.557 1.665 0 C-N-CA 123.387 2.725 . . . . 73.04 112.396 162.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.9 p -116.93 -44.82 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 N-CA-C 109.135 -0.691 . . . . 74.25 109.135 172.138 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -100.28 123.84 45.0 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.576 -0.738 . . . . 73.31 111.438 -177.054 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 187' ' ' ARG . . . . . 0.705 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 80.2 mtt180 -109.46 160.85 15.87 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-N 114.084 -1.416 . . . . 75.43 108.118 175.42 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 188' ' ' LEU . . . . . 0.47 HD13 ' HD1' ' A' ' 240' ' ' PHE . 51.7 tp -130.78 142.64 50.41 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 108.913 -0.773 . . . . 72.2 108.913 178.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -140.85 99.95 3.72 Favored 'General case' 0 C--O 1.242 0.697 0 N-CA-C 107.411 -1.329 . . . . 74.21 107.411 175.168 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 70.18 -78.64 0.42 Allowed Glycine 0 CA--C 1.531 1.047 0 O-C-N 123.881 0.738 . . . . 73.43 112.216 -175.325 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -138.34 -14.38 1.31 Allowed 'General case' 0 CA--C 1.558 1.26 0 C-N-CA 123.866 0.867 . . . . 74.44 110.448 -176.503 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . 0.443 ' O ' HD11 ' A' ' 188' ' ' LEU . 9.2 m-20 -86.16 153.86 21.75 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 124.177 0.991 . . . . 72.52 112.103 -178.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 193' ' ' LEU . . . . . 0.516 ' HG ' ' HA2' ' A' ' 239' ' ' GLY . 85.0 mt -107.35 160.76 15.38 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 124.264 1.026 . . . . 72.32 108.519 175.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 194' ' ' TYR . . . . . 0.705 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 64.7 m-85 -136.63 121.55 18.79 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.584 -1.265 . . . . 73.42 107.584 177.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -144.14 148.29 34.86 Favored 'General case' 0 C--O 1.239 0.542 0 O-C-N 124.308 1.005 . . . . 42.32 109.197 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 49.4 m -88.37 127.18 35.49 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.258 -0.883 . . . . 74.12 109.165 173.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 197' ' ' LEU . . . . . 0.475 HD22 HD12 ' A' ' 251' ' ' LEU . 66.3 tp -105.9 110.5 22.81 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 108.215 -1.031 . . . . 73.2 108.215 178.101 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -92.35 112.02 23.81 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 108.71 -0.848 . . . . 74.23 108.71 178.061 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 2.8 p -119.51 127.22 26.56 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 124.023 0.929 . . . . 75.22 108.946 -177.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 200' ' ' PRO . . . . . 0.433 ' HD2' HD12 ' A' ' 203' ' ' ILE . 51.7 Cg_exo -56.65 142.28 91.03 Favored 'Trans proline' 0 C--N 1.376 2.02 0 C-N-CA 122.729 2.286 . . . . 73.24 111.786 174.285 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 201' ' ' ALA . . . . . 0.478 ' HA ' HG22 ' A' ' 255' ' ' ILE . . . -55.8 -42.48 96.31 Favored Pre-proline 0 CA--C 1.557 1.222 0 CA-C-O 118.252 -0.88 . . . . 74.31 112.478 176.627 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 202' ' ' PRO . . . . . 0.484 ' O ' HG21 ' A' ' 206' ' ' VAL . 63.3 Cg_exo -46.75 -55.35 3.9 Favored 'Trans proline' 0 C--N 1.394 2.967 0 C-N-CA 122.972 2.448 . . . . 75.02 114.005 167.022 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 203' ' ' ILE . . . . . 0.433 HD12 ' HD2' ' A' ' 200' ' ' PRO . 21.1 mt -61.7 -41.7 91.48 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 122.907 0.483 . . . . 75.1 111.122 -179.503 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.36 -35.39 78.98 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 115.063 -0.971 . . . . 71.52 111.832 -175.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 205' ' ' VAL . . . . . 0.514 HG21 HG13 ' A' ' 206' ' ' VAL . 25.9 m -89.35 -55.52 6.21 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 N-CA-C 112.798 0.666 . . . . 73.02 112.798 178.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . 0.514 HG13 HG21 ' A' ' 205' ' ' VAL . 18.4 m -95.13 -38.3 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 CA-C-N 118.337 0.517 . . . . 74.5 112.074 -171.504 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -91.17 -115.93 1.95 Allowed Glycine 0 C--N 1.34 0.765 0 CA-C-N 116.606 -0.27 . . . . 75.25 112.657 -164.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 142.36 14.31 0.37 Allowed Glycine 0 C--N 1.335 0.521 0 CA-C-O 119.655 -0.525 . . . . 72.52 113.732 177.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 209' ' ' LYS . . . . . 0.409 ' O ' HD11 ' A' ' 203' ' ' ILE . 15.4 tppt? -117.51 118.22 31.59 Favored 'General case' 0 C--N 1.349 0.553 0 CA-C-N 117.762 0.781 . . . . 73.14 109.453 -173.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 210' ' ' VAL . . . . . 0.421 HG23 ' HB ' ' A' ' 221' ' ' VAL . 2.9 m -145.34 146.21 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.831 0 N-CA-C 108.596 -0.89 . . . . 73.2 108.596 170.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 56.4 mtm-85 -107.16 124.31 49.52 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.648 -0.871 . . . . 70.05 108.648 174.253 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 212' ' ' ALA . . . . . 0.454 ' HB1' HD13 ' A' ' 197' ' ' LEU . . . -103.09 137.91 40.64 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.298 0.639 . . . . 54.44 109.559 178.185 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 44.1 mmm -82.98 119.91 25.04 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 122.37 0.268 . . . . 71.03 110.489 174.506 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 3.5 t -118.04 169.88 9.3 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.411 1.085 . . . . 71.2 109.816 171.026 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 83.1 mt -73.96 -10.48 59.68 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 123.735 0.814 . . . . 73.55 112.688 -172.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -93.87 -13.33 27.33 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.602 0.761 . . . . 62.33 111.366 175.041 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 140.16 -157.87 25.64 Favored Glycine 0 C--N 1.347 1.183 0 CA-C-O 119.521 -0.599 . . . . 51.23 111.611 -177.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -85.59 135.83 5.18 Favored 'Trans proline' 0 CA--C 1.551 1.343 0 C-N-CA 122.469 2.113 . . . . 62.31 112.244 172.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.9 m -113.08 159.92 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 123.38 0.672 . . . . 75.21 110.26 168.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -111.35 109.59 19.66 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 107.669 -1.234 . . . . 73.33 107.669 179.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . 0.467 HG22 HD12 ' A' ' 235' ' ' LEU . 12.7 t -96.16 125.24 49.07 Favored 'Isoleucine or valine' 0 C--O 1.243 0.754 0 C-N-CA 123.535 0.734 . . . . 74.21 109.582 177.471 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -88.67 103.59 16.07 Favored 'General case' 0 C--O 1.24 0.598 0 N-CA-C 108.767 -0.827 . . . . 72.51 108.767 170.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 17.0 m -80.04 136.01 54.43 Favored Pre-proline 0 N--CA 1.477 0.887 0 N-CA-C 107.879 -1.156 . . . . 74.41 107.879 172.068 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -61.47 129.44 28.13 Favored 'Trans proline' 0 CA--C 1.555 1.543 0 C-N-CA 122.0 1.8 . . . . 74.44 111.83 176.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -52.02 128.42 26.87 Favored 'Trans proline' 0 C--N 1.372 1.791 0 C-N-CA 122.655 2.236 . . . . 74.42 111.993 172.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 226' ' ' ARG . . . . . 0.416 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 17.5 mtp180 65.31 42.61 3.84 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 125.252 1.421 . . . . 75.42 111.949 -173.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 227' ' ' THR . . . . . 0.452 HG22 HD11 ' A' ' 255' ' ' ILE . 8.5 t -78.36 177.45 8.46 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.115 0.566 . . . . 65.52 110.462 174.584 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . 0.507 HE21 ' HD2' ' A' ' 231' ' ' ARG . 1.8 mp0 -126.85 154.08 44.83 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 123.412 0.685 . . . . 73.2 109.371 -178.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -71.61 149.43 45.61 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.236 0.614 . . . . 74.4 110.572 176.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 88.25 -4.13 85.42 Favored Glycine 0 CA--C 1.527 0.807 0 CA-C-O 119.705 -0.497 . . . . 72.54 112.853 -178.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 231' ' ' ARG . . . . . 0.507 ' HD2' HE21 ' A' ' 228' ' ' GLN . 83.3 mtp180 -77.88 162.34 26.92 Favored 'General case' 0 C--N 1.36 1.063 0 CA-C-O 121.224 0.535 . . . . 75.22 111.153 177.641 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 232' ' ' LYS . . . . . 0.475 ' HG2' ' CZ ' ' A' ' 250' ' ' TYR . 10.6 mptt -118.35 122.06 41.92 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.89 0.876 . . . . 74.55 110.311 -173.302 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 64.4 mt -110.54 117.33 33.24 Favored 'General case' 0 C--N 1.348 0.506 0 N-CA-C 107.784 -1.191 . . . . 74.31 107.784 173.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 44.1 ttp180 -112.78 111.44 22.22 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 109.29 -0.633 . . . . 74.45 109.29 -168.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.467 HD12 HG22 ' A' ' 221' ' ' VAL . 14.7 mt -96.8 120.84 37.89 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 123.581 0.752 . . . . 74.1 109.82 -174.212 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 51.1 mttp -71.14 147.04 48.78 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.256 0.622 . . . . 74.34 112.32 -177.514 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.73 15.81 69.28 Favored Glycine 0 C--N 1.352 1.453 0 O-C-N 124.054 0.846 . . . . 55.34 114.401 173.486 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 238' ' ' LYS . . . . . 0.43 ' HG3' ' HB2' ' A' ' 235' ' ' LEU . 1.3 mmpm? -101.35 -17.43 16.52 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 123.548 0.739 . . . . 74.43 111.708 -175.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 239' ' ' GLY . . . . . 0.516 ' HA2' ' HG ' ' A' ' 193' ' ' LEU . . . -74.97 -148.13 1.66 Allowed Glycine 0 C--N 1.346 1.084 0 O-C-N 123.847 0.717 . . . . 74.12 113.709 -176.679 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 240' ' ' PHE . . . . . 0.555 ' HE2' ' HA ' ' A' ' 131' ' ' PHE . 39.9 m-85 -97.32 155.53 37.26 Favored Pre-proline 0 N--CA 1.475 0.786 0 CA-C-O 119.158 -0.448 . . . . 70.21 111.576 174.557 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -55.12 146.92 56.65 Favored 'Trans proline' 0 C--N 1.385 2.466 0 C-N-CA 122.906 2.404 . . . . 72.23 112.751 179.495 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -178.98 -165.71 33.78 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.669 -0.696 . . . . 72.42 112.15 -178.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -58.05 -27.6 80.19 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.375 2.717 . . . . 74.11 114.49 -179.606 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.07 22.82 5.44 Favored 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 123.556 0.742 . . . . 64.44 111.718 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.13 -86.01 1.56 Allowed Glycine 0 C--N 1.348 1.218 0 N-CA-C 110.097 -1.201 . . . . 54.14 110.097 -174.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 246' ' ' ARG . . . . . 0.475 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 18.6 mtm180 -126.94 164.54 21.24 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 108.355 -0.98 . . . . 71.14 108.355 163.238 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -77.85 -153.87 6.5 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.541 -0.754 . . . . 71.15 113.71 -177.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -120.5 164.5 16.33 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.154 0.581 . . . . 62.51 110.262 -177.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 249' ' ' LEU . . . . . 0.495 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 15.8 tp -109.98 111.15 22.37 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.037 0.935 . . . . 73.12 108.913 168.293 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 250' ' ' TYR . . . . . 0.475 ' CZ ' ' HG2' ' A' ' 232' ' ' LYS . 17.9 t80 -90.68 104.57 17.14 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 107.914 -1.143 . . . . 75.31 107.914 178.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 251' ' ' LEU . . . . . 0.475 HD12 HD22 ' A' ' 197' ' ' LEU . 63.7 mt -89.19 148.8 23.43 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.292 1.037 . . . . 73.22 111.583 179.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -110.14 97.12 6.68 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 107.922 -1.14 . . . . 65.23 107.922 173.145 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 60.2 t -52.24 117.09 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 123.663 0.785 . . . . 73.11 110.104 174.531 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 12.8 mmm180 -124.73 93.12 3.81 Favored 'General case' 0 C--O 1.238 0.463 0 N-CA-C 107.708 -1.219 . . . . 73.22 107.708 178.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.478 HG22 ' HA ' ' A' ' 201' ' ' ALA . 60.1 mt -75.64 104.82 4.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-N 115.103 -0.953 . . . . 73.44 109.267 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.554 1.116 0 C-N-CA 124.047 0.939 . . . . 75.03 109.728 -178.001 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.14 0 CA-C-O 120.452 0.167 . . . . 71.14 110.662 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.34 -63.97 1.29 Allowed 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.487 0.715 . . . . 75.52 110.639 -178.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.452 HD22 ' HG2' ' A' ' 136' ' ' ARG . 0.2 OUTLIER -103.84 -38.35 7.07 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.856 0.863 . . . . 73.22 111.093 -178.529 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.642 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 61.5 t -60.77 125.59 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 123.037 0.535 . . . . 74.23 111.057 175.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -71.36 -66.97 0.55 Allowed 'General case' 0 C--N 1.346 0.45 0 CA-C-N 115.544 -0.753 . . . . 74.15 109.763 177.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 20.4 p-80 178.19 177.36 0.42 Allowed 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 124.634 1.174 . . . . 72.21 109.724 -176.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 43.9 t -71.34 136.84 24.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.078 0 C-N-CA 123.497 0.719 . . . . 72.32 110.157 177.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.8 t -135.73 165.65 25.09 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.384 1.074 . . . . 74.22 109.448 178.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.2 t -115.55 138.34 51.15 Favored 'General case' 0 C--O 1.239 0.517 0 N-CA-C 108.417 -0.957 . . . . 73.41 108.417 175.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 63.61 48.37 78.24 Favored Glycine 0 C--N 1.35 1.359 0 N-CA-C 111.75 -0.54 . . . . 74.03 111.75 -174.088 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 32.0 p -60.28 -56.09 25.75 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.276 1.03 . . . . 61.41 111.913 -173.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 165.79 154.61 8.25 Favored Glycine 0 C--O 1.244 0.744 0 N-CA-C 111.088 -0.805 . . . . 64.14 111.088 179.087 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . 0.494 ' HA3' HG22 ' A' ' 158' ' ' VAL . . . 61.9 47.64 88.81 Favored Glycine 0 C--N 1.348 1.203 0 O-C-N 124.065 0.509 . . . . 43.45 112.989 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 69.5 m -71.99 87.44 1.04 Allowed 'General case' 0 CA--C 1.546 0.826 0 CA-C-O 121.502 0.667 . . . . 74.32 109.857 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 171.5 27.72 0.02 OUTLIER Glycine 0 C--N 1.336 0.561 0 CA-C-N 114.612 -1.176 . . . . 62.42 110.632 -178.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -105.47 107.13 2.76 Favored Glycine 0 C--N 1.354 1.557 0 N-CA-C 111.361 -0.696 . . . . 74.32 111.361 178.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 29.1 m -65.92 106.08 1.48 Allowed 'General case' 0 C--N 1.35 0.61 0 C-N-CA 123.562 0.745 . . . . 72.43 110.483 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -160.74 -135.19 1.78 Allowed Glycine 0 C--N 1.339 0.71 0 CA-C-N 116.081 -0.509 . . . . 73.31 111.845 -178.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.438 ' O ' ' HA2' ' A' ' 172' ' ' GLY . . . 71.22 -85.33 0.41 Allowed Glycine 0 C--N 1.336 0.557 0 CA-C-O 119.612 -0.549 . . . . 71.33 112.153 -177.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 79.0 p 47.6 40.39 11.57 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 125.129 1.372 . . . . 71.52 110.933 -174.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 158.53 -133.66 3.53 Favored Glycine 0 C--N 1.336 0.563 0 N-CA-C 109.333 -1.507 . . . . 62.13 109.333 -171.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -96.35 120.35 36.49 Favored 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 108.566 -0.901 . . . . 73.0 108.566 178.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.418 ' HB3' ' HE ' ' A' ' 120' ' ' ARG . 5.9 m-20 -79.39 121.19 24.84 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.545 -0.539 . . . . 71.1 109.545 174.21 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.488 HD11 ' HA2' ' A' ' 165' ' ' GLY . 12.3 mt -100.76 132.45 46.16 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 107.601 -1.259 . . . . 74.54 107.601 167.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . 0.418 ' HE ' ' HB3' ' A' ' 118' ' ' ASP . 21.4 mmt85 -127.84 133.49 49.38 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 107.851 -1.166 . . . . 74.34 107.851 -177.255 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -154.01 145.3 22.97 Favored 'General case' 0 N--CA 1.47 0.552 0 O-C-N 123.441 0.463 . . . . 73.11 109.756 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.659 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 41.3 mt-10 -112.09 148.36 34.1 Favored 'General case' 0 C--O 1.246 0.885 0 C-N-CA 123.59 0.756 . . . . 75.43 109.721 174.557 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.642 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.7 pt? -145.88 130.04 8.68 Favored Pre-proline 0 C--O 1.222 -0.376 0 CA-C-N 115.443 -0.799 . . . . 62.14 111.065 -176.735 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.18 117.49 4.28 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 121.819 1.679 . . . . 75.24 110.152 163.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.465 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 21.3 tp -110.59 139.8 45.5 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 123.624 0.77 . . . . 72.13 109.237 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.637 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 4.7 m -76.63 149.33 36.54 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 109.015 -0.735 . . . . 74.05 109.015 170.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.411 HD11 ' O ' ' A' ' 183' ' ' HIS . 44.4 mt -57.06 -44.58 83.18 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 122.267 1.032 . . . . 73.34 109.868 177.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -57.26 -37.7 72.75 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 113.383 -1.735 . . . . 63.52 111.439 176.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.637 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 42.1 mm-40 -77.58 -27.36 51.36 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 122.644 0.378 . . . . 74.24 111.758 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.464 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -58.75 -36.32 74.16 Favored 'General case' 0 C--O 1.243 0.741 0 C-N-CA 123.203 0.601 . . . . 64.43 111.446 167.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.408 ' CZ ' ' HB3' ' A' ' 216' ' ' GLU . 70.9 t80 -74.0 -51.84 14.67 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.151 -0.931 . . . . 73.44 112.427 171.15 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 34.3 m80 -63.83 -49.15 73.96 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 123.358 0.411 . . . . 73.55 112.04 -167.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 48.44 52.76 18.25 Favored Glycine 0 CA--C 1.534 1.28 0 O-C-N 124.118 0.886 . . . . 55.02 114.125 178.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -102.67 -168.61 26.45 Favored Glycine 0 C--N 1.347 1.139 0 CA-C-O 120.044 -0.309 . . . . 64.22 112.481 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.427 ' HB3' ' OG ' ' A' ' 146' ' ' SER . 2.1 mp0 -77.36 113.97 15.69 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 109.556 -0.535 . . . . 74.21 109.556 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.452 ' HG2' HD22 ' A' ' 98' ' ' LEU . 2.4 mpt_? -124.36 150.61 45.33 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 124.106 0.963 . . . . 74.11 108.681 173.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.8 p -76.35 129.74 36.89 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.093 0 CA-C-O 121.256 0.551 . . . . 72.42 111.266 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.502 HG23 HD22 ' A' ' 174' ' ' LEU . 7.9 p -111.27 141.0 27.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 C-N-CA 124.66 1.184 . . . . 71.43 108.81 170.577 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -125.72 100.68 6.53 Favored 'General case' 0 C--O 1.238 0.498 0 N-CA-C 107.819 -1.178 . . . . 74.22 107.819 178.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.7 m -123.84 108.03 19.97 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 C-N-CA 124.288 1.035 . . . . 73.3 110.436 -175.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 66.19 25.29 10.68 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 124.633 1.173 . . . . 71.01 111.766 179.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.83 4.96 78.41 Favored Glycine 0 C--N 1.353 1.482 0 CA-C-N 116.035 -0.53 . . . . 65.35 112.909 -176.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 30.9 tpt180 -94.02 115.41 27.74 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 108.687 -0.857 . . . . 73.23 108.687 177.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 75.3 ttt180 -97.74 115.58 28.28 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.729 -0.841 . . . . 71.54 108.729 177.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.437 HG11 ' SD ' ' A' ' 164' ' ' MET . 16.1 t -130.51 154.59 40.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 108.059 -1.089 . . . . 75.41 108.059 173.748 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.427 ' OG ' ' HB3' ' A' ' 135' ' ' GLU . 48.3 t -92.19 109.0 20.36 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.289 -1.004 . . . . 60.5 108.289 171.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 9.9 p -97.77 129.6 47.71 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 C-N-CA 123.702 0.801 . . . . 74.12 109.743 -178.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 29.1 ttt180 -107.96 97.47 7.17 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 107.719 -1.215 . . . . 73.02 107.719 173.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.562 ' HB ' HD12 ' A' ' 159' ' ' ILE . 26.1 pt -78.51 141.4 60.82 Favored Pre-proline 0 CA--C 1.552 1.053 0 N-CA-C 109.286 -0.635 . . . . 70.01 109.286 177.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -70.06 134.19 26.76 Favored 'Trans proline' 0 C--N 1.372 1.78 0 C-N-CA 122.299 1.999 . . . . 74.23 112.526 -173.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.401 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 71.5 Cg_exo -54.31 138.85 73.38 Favored 'Trans proline' 0 C--N 1.371 1.752 0 C-N-CA 123.121 2.547 . . . . 75.12 112.02 168.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 105.78 36.93 2.67 Favored Glycine 0 N--CA 1.463 0.493 0 N-CA-C 111.589 -0.604 . . . . 54.22 111.589 -173.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.582 HG23 HD11 ' A' ' 159' ' ' ILE . 2.4 p -112.71 155.93 13.83 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.251 0 N-CA-C 109.099 -0.704 . . . . 73.23 109.099 -177.194 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.427 ' HD2' ' O ' ' A' ' 188' ' ' LEU . 38.7 mtp180 -142.38 173.16 11.78 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 125.177 1.391 . . . . 74.12 110.742 -168.46 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.4 tp10 -58.39 121.1 10.02 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 123.758 0.823 . . . . 74.41 110.997 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.25 7.68 88.13 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-N 116.252 -0.431 . . . . 62.1 113.48 -178.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.449 ' HB3' HG21 ' A' ' 153' ' ' VAL . 38.6 t -77.8 125.55 29.51 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 109.45 -0.574 . . . . 74.01 109.45 179.134 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.494 HG22 ' HA3' ' A' ' 108' ' ' GLY . 8.5 t -98.5 120.26 47.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-N 114.609 -1.178 . . . . 72.12 108.75 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.582 HD11 HG23 ' A' ' 153' ' ' VAL . 49.1 mt -107.21 120.43 58.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.92 0.888 . . . . 73.21 111.136 -172.508 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 25.8 ttm180 -92.58 114.13 26.6 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 123.2 0.6 . . . . 73.4 111.068 177.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -113.46 96.07 38.55 Favored Pre-proline 0 CA--C 1.559 1.313 0 N-CA-C 109.279 -0.637 . . . . 74.1 109.279 173.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -62.24 148.66 92.84 Favored 'Trans proline' 0 C--N 1.388 2.609 0 C-N-CA 123.646 2.898 . . . . 74.13 113.588 -177.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 85.5 -12.85 57.88 Favored Glycine 0 C--N 1.349 1.272 0 O-C-N 123.813 0.696 . . . . 75.23 113.34 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.437 ' SD ' HG11 ' A' ' 145' ' ' VAL . 36.4 mmm -92.33 -28.58 16.85 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.411 1.084 . . . . 75.41 111.912 -170.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . 0.488 ' HA2' HD11 ' A' ' 119' ' ' LEU . . . -82.64 -94.76 0.55 Allowed Glycine 0 C--N 1.344 1.025 0 N-CA-C 111.158 -0.777 . . . . 61.24 111.158 176.276 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.442 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -59.12 98.63 0.11 Allowed Glycine 0 C--N 1.345 1.042 0 C-N-CA 123.625 0.631 . . . . 61.23 112.894 172.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.7 mm-40 -75.97 104.93 6.74 Favored 'General case' 0 C--O 1.241 0.649 0 C-N-CA 124.296 1.038 . . . . 73.5 108.645 177.087 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 164.57 -163.18 36.05 Favored Glycine 0 C--N 1.338 0.65 0 O-C-N 123.314 0.384 . . . . 72.42 112.335 -179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.447 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 60.8 t30 -74.76 -46.27 5.24 Favored Pre-proline 0 CA--C 1.558 1.274 0 CA-C-O 118.2 -0.905 . . . . 74.44 111.261 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.447 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 16.4 Cg_exo -70.39 106.23 1.74 Allowed 'Trans proline' 0 C--N 1.39 2.742 0 C-N-CA 121.527 1.485 . . . . 74.2 109.849 167.438 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.28 123.02 9.54 Favored 'Trans proline' 0 C--N 1.375 1.927 0 C-N-CA 121.985 1.79 . . . . 75.03 111.307 -171.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.442 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -105.34 152.18 17.22 Favored Glycine 0 CA--C 1.504 -0.652 0 N-CA-C 109.806 -1.317 . . . . 75.12 109.806 171.516 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -112.96 168.81 9.39 Favored 'General case' 0 C--O 1.241 0.628 0 CA-C-O 121.503 0.668 . . . . 71.51 110.488 -173.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.502 HD22 HG23 ' A' ' 138' ' ' VAL . 12.4 tp -118.62 115.39 24.44 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 107.722 -1.214 . . . . 73.13 107.722 175.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.469 HD23 HG12 ' A' ' 158' ' ' VAL . 53.6 mt -88.38 100.22 12.86 Favored 'General case' 0 C--O 1.241 0.653 0 O-C-N 123.958 0.786 . . . . 74.43 110.305 177.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 81.5 mt -88.29 102.99 15.39 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.013 -0.994 . . . . 71.12 110.57 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.659 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 48.2 t -86.66 104.81 14.28 Favored 'Isoleucine or valine' 0 C--O 1.241 0.605 0 N-CA-C 108.307 -0.998 . . . . 53.31 108.307 173.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.465 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 9.6 m -82.04 150.82 4.33 Favored 'Isoleucine or valine' 0 C--O 1.245 0.821 0 CA-C-O 121.325 0.583 . . . . 64.11 110.838 -177.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 24.0 mmm-85 -126.99 97.11 4.83 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.242 -1.392 . . . . 73.52 107.242 -175.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.464 HD22 ' HB3' ' A' ' 125' ' ' LEU . 46.1 mt -66.4 147.09 53.8 Favored 'General case' 0 C--O 1.242 0.683 0 CA-C-O 120.536 0.208 . . . . 75.21 110.656 -176.449 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.435 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 37.6 mt -54.8 152.19 13.72 Favored Pre-proline 0 CA--C 1.556 1.19 0 O-C-N 124.09 0.869 . . . . 73.45 111.829 -173.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -58.29 -8.7 5.43 Favored 'Trans proline' 0 C--N 1.383 2.376 0 C-N-CA 123.377 2.718 . . . . 73.42 113.363 172.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . 0.411 ' O ' HD11 ' A' ' 127' ' ' LEU . 6.3 t60 -93.59 107.97 30.65 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 124.79 1.236 . . . . 73.33 108.614 168.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -99.52 163.69 0.55 Allowed 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 123.314 2.676 . . . . 74.02 112.427 165.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -156.64 -45.67 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 N-CA-C 109.02 -0.733 . . . . 71.02 109.02 168.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . 0.445 ' CE2' HD13 ' A' ' 193' ' ' LEU . 5.6 m-85 -100.66 122.54 43.49 Favored 'General case' 0 C--O 1.238 0.454 0 C-N-CA 123.585 0.754 . . . . 72.42 110.699 -177.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 12.0 mtp180 -99.75 108.72 21.11 Favored 'General case' 0 C--O 1.237 0.441 0 C-N-CA 124.612 1.165 . . . . 73.35 108.624 170.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.427 ' O ' ' HD2' ' A' ' 154' ' ' ARG . 60.2 tp -84.54 110.67 18.87 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.932 -0.766 . . . . 73.35 108.932 170.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 24.0 mm-40 -104.11 97.05 7.07 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 107.325 -1.361 . . . . 73.42 107.325 172.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 67.64 -89.06 0.18 Allowed Glycine 0 CA--C 1.531 1.044 0 O-C-N 123.757 0.66 . . . . 73.43 112.807 -175.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 50.3 tt0 -120.74 -18.12 7.78 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 125.103 1.361 . . . . 75.24 109.779 -176.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . 0.42 ' O ' HD12 ' A' ' 188' ' ' LEU . 44.5 m-20 -96.07 160.04 14.65 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.382 1.073 . . . . 74.55 111.383 -173.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.602 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 96.3 mt -119.21 154.97 32.54 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.202 1.001 . . . . 73.41 112.298 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 74.0 m-85 -139.0 120.72 15.28 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 106.248 -1.76 . . . . 74.44 106.248 170.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . 0.437 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -141.7 140.06 33.07 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 108.178 -1.045 . . . . 64.43 108.178 176.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 19.1 m -77.15 129.98 36.71 Favored 'General case' 0 CA--C 1.539 0.548 0 O-C-N 123.347 0.405 . . . . 65.15 110.323 -175.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.412 HD11 ' HB3' ' A' ' 212' ' ' ALA . 51.2 tp -114.42 111.79 21.99 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 123.951 0.9 . . . . 74.22 108.785 176.694 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -101.64 107.73 19.06 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.127 -0.694 . . . . 72.12 109.127 178.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . 0.494 HG13 HG12 ' A' ' 223' ' ' VAL . 5.9 m -108.52 145.69 32.1 Favored Pre-proline 0 N--CA 1.478 0.963 0 C-N-CA 123.755 0.822 . . . . 72.14 109.472 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -70.83 149.67 60.45 Favored 'Trans proline' 0 C--N 1.366 1.481 0 C-N-CA 121.699 1.599 . . . . 73.03 110.664 173.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . 0.434 ' HA ' HG22 ' A' ' 255' ' ' ILE . . . -56.11 -43.53 99.29 Favored Pre-proline 0 CA--C 1.561 1.389 0 CA-C-O 118.374 -0.822 . . . . 71.32 113.112 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -46.21 -51.51 8.52 Favored 'Trans proline' 0 C--N 1.394 2.952 0 C-N-CA 122.921 2.414 . . . . 73.42 114.274 169.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 5.7 mt -69.15 -38.57 78.21 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 C-N-CA 122.335 0.254 . . . . 74.14 111.117 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.18 -41.55 88.75 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.239 0.616 . . . . 74.45 112.234 -179.193 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 33.1 m -82.84 -38.64 15.0 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 CA-C-N 115.891 -0.595 . . . . 74.02 111.53 -174.665 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.6 m -77.0 -24.79 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 CA-C-O 120.82 0.343 . . . . 73.3 110.849 177.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 76.68 52.84 5.71 Favored Glycine 0 C--N 1.346 1.112 0 CA-C-N 115.376 -0.829 . . . . 70.3 112.366 -175.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.42 -160.35 27.51 Favored Glycine 0 C--N 1.359 1.817 0 N-CA-C 112.123 -0.391 . . . . 70.43 112.123 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 21.2 ptmt -119.91 142.9 48.28 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 123.023 0.529 . . . . 72.34 109.727 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . 0.406 HG21 HG12 ' A' ' 199' ' ' VAL . 75.6 t -128.7 135.11 63.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 C-N-CA 124.351 1.06 . . . . 74.43 108.631 177.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . 0.588 ' HG2' ' HG2' ' A' ' 220' ' ' GLU . 99.3 mtt180 -77.95 112.56 14.97 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 109.198 -0.668 . . . . 75.55 109.198 171.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.412 ' HB3' HD11 ' A' ' 197' ' ' LEU . . . -99.14 129.27 45.38 Favored 'General case' 0 C--O 1.242 0.686 0 N-CA-C 108.436 -0.949 . . . . 64.4 108.436 175.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 213' ' ' MET . . . . . 0.413 ' SD ' ' N ' ' A' ' 214' ' ' THR . 1.3 tpp -69.72 130.29 41.93 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.837 -0.62 . . . . 74.54 109.79 175.054 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 214' ' ' THR . . . . . 0.417 HG23 HG13 ' A' ' 219' ' ' VAL . 7.7 t -134.07 163.67 29.06 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.507 1.123 . . . . 75.43 110.142 173.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 79.4 mt -71.68 -8.87 56.79 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 124.004 0.922 . . . . 73.41 113.183 -172.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . 0.408 ' HB3' ' CZ ' ' A' ' 131' ' ' PHE . 10.3 pt-20 -97.39 -18.34 19.16 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.433 0.693 . . . . 74.2 111.767 173.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.74 -146.36 15.74 Favored Glycine 0 C--N 1.349 1.253 0 CA-C-O 119.556 -0.58 . . . . 53.43 112.181 -176.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -91.17 131.15 1.42 Allowed 'Trans proline' 0 CA--C 1.559 1.736 0 C-N-CA 122.796 2.331 . . . . 72.3 112.777 170.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . 0.417 HG13 HG23 ' A' ' 214' ' ' THR . 20.5 m -110.13 147.25 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 108.996 -0.742 . . . . 74.0 108.996 163.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . 0.588 ' HG2' ' HG2' ' A' ' 211' ' ' ARG . 42.8 mt-10 -114.37 104.33 11.96 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 108.781 -0.822 . . . . 73.12 108.781 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 2.8 p -95.68 120.25 44.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 124.033 0.933 . . . . 74.44 110.373 -177.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.12 103.57 12.65 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 107.689 -1.226 . . . . 70.51 107.689 173.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.494 HG12 HG13 ' A' ' 199' ' ' VAL . 14.6 m -65.96 143.89 98.61 Favored Pre-proline 0 CA--C 1.553 1.059 0 C-N-CA 123.229 0.612 . . . . 75.44 110.168 -179.014 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -55.58 138.79 81.71 Favored 'Trans proline' 0 C--N 1.376 1.994 0 C-N-CA 122.625 2.216 . . . . 64.44 112.209 176.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.11 122.34 11.42 Favored 'Trans proline' 0 C--N 1.369 1.624 0 C-N-CA 122.181 1.921 . . . . 72.32 110.129 172.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . 0.491 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 96.0 mtt180 63.39 41.25 7.77 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 124.418 1.074 . . . . 74.43 110.996 -175.591 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.4 t -65.15 168.89 6.13 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 122.858 0.463 . . . . 53.11 111.009 177.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.2 mp0 -118.09 146.72 43.92 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 123.889 0.876 . . . . 74.41 109.165 -176.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -75.02 135.91 41.25 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.745 -0.835 . . . . 53.31 108.745 173.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 106.11 -7.91 41.36 Favored Glycine 0 C--N 1.34 0.762 0 N-CA-C 112.153 -0.379 . . . . 75.45 112.153 -175.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 62.0 mtp180 -79.92 160.99 25.79 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.284 0.634 . . . . 75.12 111.079 179.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.487 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 10.5 mptt -119.05 112.91 20.15 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 124.065 0.946 . . . . 74.32 108.503 176.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . 0.495 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 39.6 mt -89.69 110.08 21.0 Favored 'General case' 0 C--N 1.358 0.958 0 N-CA-C 108.868 -0.79 . . . . 73.0 108.868 -178.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 41.4 ttp180 -83.81 102.51 12.38 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 114.923 -1.035 . . . . 64.52 111.046 -169.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 26.5 mt -95.74 98.01 10.13 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 108.513 -0.921 . . . . 74.31 108.513 174.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . 0.43 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 26.7 mtpp -80.79 143.87 32.53 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.96 0.41 . . . . 71.14 111.316 -174.403 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 75.94 24.12 70.21 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.148 -0.933 . . . . 74.24 111.809 -174.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 48.4 mmtm -128.94 10.25 5.91 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.366 1.066 . . . . 74.2 110.442 177.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -84.67 -158.21 28.34 Favored Glycine 0 C--N 1.359 1.838 0 O-C-N 123.13 0.269 . . . . 53.15 113.052 175.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.528 ' CD1' HD23 ' A' ' 193' ' ' LEU . 10.5 m-85 -98.02 166.14 14.02 Favored Pre-proline 0 N--CA 1.48 1.044 0 C-N-CA 123.131 0.573 . . . . 70.12 110.565 172.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -61.01 160.45 25.82 Favored 'Trans proline' 0 C--N 1.384 2.409 0 C-N-CA 122.829 2.353 . . . . 75.34 112.113 172.201 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 175.76 -171.21 44.29 Favored Glycine 0 CA--C 1.527 0.791 0 CA-C-N 116.147 -0.479 . . . . 73.32 113.515 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -57.31 -38.73 93.92 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.975 3.116 . . . . 74.05 113.29 -179.155 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -92.33 21.84 4.94 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 123.389 0.676 . . . . 74.12 111.937 -179.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 91.66 -102.66 2.95 Favored Glycine 0 C--N 1.347 1.194 0 N-CA-C 111.746 -0.541 . . . . 75.34 111.746 178.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 51.6 ttt180 -121.52 140.02 52.74 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 122.933 0.493 . . . . 73.12 109.675 174.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -81.06 -157.2 16.4 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 124.014 0.821 . . . . 71.33 113.076 -179.039 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . 0.43 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 3.5 p30 -146.62 154.25 41.27 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 123.032 0.533 . . . . 71.41 110.722 -174.604 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.602 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 26.2 tp -98.58 128.27 44.83 Favored 'General case' 0 C--O 1.22 -0.468 0 C-N-CA 124.338 1.055 . . . . 74.42 110.384 -174.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . 0.487 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 63.1 m-85 -102.63 107.43 18.34 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 123.57 0.748 . . . . 74.42 109.505 173.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.495 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 77.2 mt -87.07 111.11 20.58 Favored 'General case' 0 C--O 1.233 0.233 0 C-N-CA 123.701 0.8 . . . . 74.34 112.52 178.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.405 ' HG2' ' HE3' ' A' ' 232' ' ' LYS . 1.6 tm-20 -80.42 90.37 5.63 Favored 'General case' 0 CA--C 1.552 1.025 0 N-CA-C 108.457 -0.942 . . . . 73.54 108.457 -176.546 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.4 ' O ' ' HD2' ' A' ' 254' ' ' ARG . 46.0 t -53.29 128.34 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 125.991 1.716 . . . . 74.15 112.882 -177.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . 0.4 ' HD2' ' O ' ' A' ' 253' ' ' VAL . 23.5 mmm180 -126.8 98.57 5.41 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 107.255 -1.387 . . . . 74.22 107.255 173.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.434 HG22 ' HA ' ' A' ' 201' ' ' ALA . 63.6 mt -76.53 102.43 3.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 108.861 -0.792 . . . . 74.34 108.861 177.161 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 8.9 t . . . . . 0 C--O 1.253 1.263 0 C-N-CA 124.357 1.063 . . . . 72.02 110.173 -171.424 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.822 0 N-CA-C 109.421 -0.585 . . . . 62.43 109.421 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.74 -54.38 11.98 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 123.537 0.735 . . . . 62.31 111.175 -175.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.603 HD21 ' HG3' ' A' ' 136' ' ' ARG . 0.2 OUTLIER -139.79 -49.91 0.48 Allowed 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 115.782 -0.645 . . . . 74.22 110.913 -177.991 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.629 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 43.9 t -58.04 119.82 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 C-N-CA 122.988 0.515 . . . . 50.43 111.238 177.576 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -67.22 -71.4 0.2 Allowed 'General case' 0 C--O 1.238 0.485 0 O-C-N 124.275 0.984 . . . . 73.11 109.31 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.0 m80 -168.0 176.12 6.33 Favored 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 124.665 1.186 . . . . 72.33 109.757 -178.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 99.5 t -61.38 136.51 24.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.025 0 C-N-CA 124.094 0.958 . . . . 73.22 110.47 171.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 42.6 p -68.11 110.79 4.13 Favored 'General case' 0 CA--C 1.551 0.992 0 N-CA-C 109.122 -0.696 . . . . 75.1 109.122 170.231 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 13.7 p -65.55 116.6 6.97 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.83 0.852 . . . . 75.1 110.046 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 87.76 40.48 6.71 Favored Glycine 0 C--N 1.345 1.043 0 N-CA-C 110.955 -0.858 . . . . 71.33 110.955 -169.424 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 25.9 p -62.35 111.57 2.06 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 124.063 0.945 . . . . 74.02 111.321 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -146.94 -170.3 15.19 Favored Glycine 0 C--N 1.345 1.061 0 CA-C-N 116.338 -0.392 . . . . 70.22 112.855 -176.073 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 131.61 -61.4 0.66 Allowed Glycine 0 C--N 1.346 1.113 0 N-CA-C 111.591 -0.604 . . . . 52.11 111.591 178.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 25.8 t -168.88 -175.21 2.3 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 124.187 0.995 . . . . 73.31 109.196 -175.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -77.77 161.94 50.04 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.833 -0.507 . . . . 74.02 111.833 172.473 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -115.97 -63.6 0.36 Allowed Glycine 0 N--CA 1.473 1.159 0 N-CA-C 111.745 -0.542 . . . . 73.12 111.745 178.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 23.7 t -70.79 -175.46 1.1 Allowed 'General case' 0 CA--C 1.558 1.269 0 C-N-CA 123.726 0.811 . . . . 75.23 110.866 178.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -57.84 -38.68 89.54 Favored Glycine 0 C--N 1.355 1.621 0 N-CA-C 113.853 0.301 . . . . 75.31 113.853 -177.424 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 174.25 -57.49 0.13 Allowed Glycine 0 C--N 1.34 0.798 0 N-CA-C 110.457 -1.057 . . . . 75.24 110.457 178.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 16.6 p -83.14 137.35 34.11 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 123.911 0.884 . . . . 71.31 110.152 174.571 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 96.07 129.64 6.07 Favored Glycine 0 C--N 1.345 1.073 0 N-CA-C 110.559 -1.017 . . . . 63.11 110.559 -174.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.3 ptp180 -72.72 145.31 47.23 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 117.161 0.481 . . . . 74.31 111.057 -173.464 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -87.51 149.96 24.05 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 108.686 -0.857 . . . . 74.33 108.686 165.462 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.486 HD22 ' HB ' ' A' ' 140' ' ' VAL . 44.5 tp -128.79 134.98 48.56 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 107.759 -1.2 . . . . 72.33 107.759 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . 0.405 ' HD3' ' HB2' ' A' ' 175' ' ' LEU . 9.8 mmt85 -115.43 134.97 54.59 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 109.438 -0.579 . . . . 74.03 109.438 -178.017 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -150.6 154.54 37.7 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 123.329 0.652 . . . . 73.03 109.38 173.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -119.78 151.35 38.94 Favored 'General case' 0 C--O 1.245 0.851 0 C-N-CA 123.134 0.574 . . . . 72.42 110.169 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.629 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.4 pt? -144.95 143.13 19.72 Favored Pre-proline 0 N--CA 1.471 0.59 0 CA-C-N 115.424 -0.807 . . . . 74.13 111.286 -178.388 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.43 113.95 3.87 Favored 'Trans proline' 0 C--N 1.37 1.68 0 C-N-CA 121.377 1.384 . . . . 55.55 109.119 160.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.472 HD22 HG12 ' A' ' 178' ' ' VAL . 20.0 tp -104.97 148.44 26.72 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 108.463 -0.94 . . . . 74.3 108.463 178.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.686 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 4.1 m -82.15 157.54 23.99 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 109.919 -0.401 . . . . 74.11 109.919 175.274 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.437 HD23 ' HB3' ' A' ' 180' ' ' LEU . 77.5 mt -59.16 -48.68 80.72 Favored 'General case' 0 N--CA 1.482 1.145 0 CA-C-O 122.342 1.068 . . . . 72.5 109.529 172.331 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.53 -34.46 64.7 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 113.621 -1.627 . . . . 74.41 111.963 174.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.49 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 17.0 mm-40 -85.63 -17.69 35.39 Favored 'General case' 0 N--CA 1.481 1.083 0 C-N-CA 123.398 0.679 . . . . 73.11 112.416 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.688 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -58.23 -43.41 87.75 Favored 'General case' 0 C--O 1.249 1.05 0 CA-C-O 121.382 0.611 . . . . 74.45 109.697 163.155 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -71.32 -60.31 2.3 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 114.842 -1.072 . . . . 74.14 111.62 174.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -69.05 -47.16 66.04 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 123.588 0.755 . . . . 72.1 112.252 -169.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 71.76 -86.25 0.45 Allowed Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.816 -0.914 . . . . 74.23 110.816 -170.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.0 -179.57 51.3 Favored Glycine 0 C--N 1.345 1.08 0 N-CA-C 114.528 0.571 . . . . 70.34 114.528 174.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 14.8 mp0 -98.61 115.27 28.27 Favored 'General case' 0 N--CA 1.471 0.584 0 N-CA-C 107.301 -1.37 . . . . 71.2 107.301 175.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.603 ' HG3' HD21 ' A' ' 98' ' ' LEU . 39.3 mmt-85 -132.15 138.51 48.07 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.711 1.204 . . . . 71.35 108.287 -173.278 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.426 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 27.8 m -73.61 123.01 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 121.343 0.592 . . . . 70.21 111.295 -176.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 13.4 p -105.43 141.36 20.94 Favored 'Isoleucine or valine' 0 C--O 1.252 1.23 0 C-N-CA 125.092 1.357 . . . . 74.22 110.195 178.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 13.2 tp10 -120.29 103.36 9.17 Favored 'General case' 0 C--O 1.243 0.75 0 C-N-CA 124.033 0.933 . . . . 74.02 109.001 174.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.496 HG22 HD22 ' A' ' 174' ' ' LEU . 2.9 m -143.87 123.56 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 123.939 0.896 . . . . 70.2 110.693 -173.189 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.03 19.9 11.95 Favored 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 124.322 1.049 . . . . 63.34 112.137 173.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 83.62 17.5 65.93 Favored Glycine 0 C--N 1.347 1.161 0 CA-C-N 116.366 -0.379 . . . . 73.01 112.345 -177.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.2 mmm180 -108.12 118.17 36.04 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 108.317 -0.994 . . . . 74.41 108.317 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 49.9 ttt180 -94.94 108.2 20.25 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 108.406 -0.961 . . . . 64.34 108.406 173.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 72.2 t -135.82 146.74 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 108.674 -0.861 . . . . 74.35 108.674 -178.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.426 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 67.0 p -90.17 107.63 19.25 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.563 -1.273 . . . . 74.33 107.563 167.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.9 p -97.68 140.92 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-O 121.322 0.582 . . . . 73.44 111.012 -172.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 14.4 ttp180 -104.13 103.39 13.17 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 107.741 -1.207 . . . . 75.5 107.741 177.241 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.447 ' HB ' HD12 ' A' ' 159' ' ' ILE . 36.5 pt -92.1 112.78 56.67 Favored Pre-proline 0 CA--C 1.555 1.137 0 N-CA-C 109.553 -0.536 . . . . 74.24 109.553 179.067 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.436 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 96.2 Cg_exo -47.82 131.01 20.1 Favored 'Trans proline' 0 C--N 1.39 2.727 0 C-N-CA 123.947 3.098 . . . . 70.14 114.676 -173.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 23.2 Cg_exo -67.19 135.52 37.44 Favored 'Trans proline' 0 C--N 1.379 2.162 0 C-N-CA 123.472 2.781 . . . . 71.34 112.269 -177.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . 0.646 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 120.51 41.88 0.52 Allowed Glycine 0 C--N 1.349 1.272 0 N-CA-C 111.908 -0.477 . . . . 54.32 111.908 -175.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.688 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.6 p -115.33 162.89 13.08 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.533 0 C-N-CA 123.915 0.886 . . . . 75.21 109.76 -173.17 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 43.9 mtp180 -143.26 168.99 18.49 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 125.228 1.411 . . . . 73.22 110.09 -170.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -54.94 120.59 7.1 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.759 0.824 . . . . 75.2 111.022 170.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.87 3.65 90.39 Favored Glycine 0 C--N 1.349 1.288 0 O-C-N 123.647 0.592 . . . . 70.54 113.903 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 40.3 t -81.99 131.89 35.25 Favored 'General case' 0 C--O 1.248 0.983 0 N-CA-C 109.303 -0.628 . . . . 71.41 109.303 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 9.0 p -97.42 135.74 30.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.986 0 CA-C-N 115.103 -0.953 . . . . 73.3 109.24 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.497 HD11 HG23 ' A' ' 153' ' ' VAL . 28.1 mt -112.61 123.07 67.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 123.9 0.88 . . . . 75.45 110.707 -175.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.415 HH21 HD12 ' A' ' 175' ' ' LEU . 35.3 ttm180 -92.53 118.84 31.4 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 117.924 0.329 . . . . 72.23 110.26 174.504 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.464 HG22 ' HB3' ' A' ' 174' ' ' LEU . 4.5 m -113.0 125.65 29.47 Favored Pre-proline 0 CA--C 1.551 1.0 0 N-CA-C 108.004 -1.109 . . . . 75.23 108.004 171.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -79.26 148.72 21.46 Favored 'Trans proline' 0 C--N 1.367 1.532 0 C-N-CA 122.132 1.888 . . . . 72.44 113.081 -174.185 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 74.37 23.24 76.13 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 115.141 0.816 . . . . 73.25 115.141 173.057 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 50.7 tpp -102.91 -45.92 4.83 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 117.811 0.806 . . . . 70.44 110.7 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -74.57 -88.21 0.22 Allowed Glycine 0 C--N 1.349 1.299 0 CA-C-N 116.093 -0.503 . . . . 74.33 112.52 -177.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.579 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -58.71 99.36 0.12 Allowed Glycine 0 C--N 1.347 1.165 0 C-N-CA 123.567 0.603 . . . . 45.2 112.536 173.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.4 mm-40 -87.31 104.31 16.29 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 123.785 0.834 . . . . 64.4 109.105 178.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 156.38 -164.44 32.48 Favored Glycine 0 C--N 1.339 0.723 0 N-CA-C 111.472 -0.651 . . . . 73.4 111.472 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -60.38 -45.25 97.46 Favored Pre-proline 0 CA--C 1.561 1.368 0 CA-C-O 118.178 -0.915 . . . . 74.45 112.014 177.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -74.81 106.71 2.32 Favored 'Trans proline' 0 C--N 1.39 2.728 0 C-N-CA 121.885 1.724 . . . . 75.14 110.341 168.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -77.56 126.07 8.0 Favored 'Trans proline' 0 C--N 1.375 1.954 0 C-N-CA 121.494 1.463 . . . . 75.15 111.015 -175.042 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.579 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -108.68 168.29 13.47 Favored Glycine 0 N--CA 1.462 0.369 0 N-CA-C 111.185 -0.766 . . . . 74.22 111.185 175.662 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -118.92 169.88 9.5 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 123.61 0.764 . . . . 74.31 111.656 -165.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.496 HD22 HG22 ' A' ' 140' ' ' VAL . 37.0 tp -124.62 116.47 22.46 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-N 114.608 -1.178 . . . . 64.43 108.234 169.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.415 HD12 HH21 ' A' ' 160' ' ' ARG . 41.3 mt -92.19 100.93 13.45 Favored 'General case' 0 C--O 1.243 0.76 0 CA-C-N 114.248 -1.342 . . . . 74.23 109.868 175.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 85.2 mt -90.85 107.39 19.16 Favored 'General case' 0 CA--C 1.538 0.494 0 CA-C-N 114.462 -1.245 . . . . 74.33 111.177 178.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 34.9 t -86.67 106.11 15.51 Favored 'Isoleucine or valine' 0 C--O 1.249 1.05 0 N-CA-C 108.459 -0.941 . . . . 71.32 108.459 175.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.472 HG12 HD22 ' A' ' 125' ' ' LEU . 19.0 m -81.57 149.77 4.77 Favored 'Isoleucine or valine' 0 C--O 1.24 0.6 0 CA-C-O 121.811 0.815 . . . . 75.11 112.203 -179.268 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 25.0 mmm-85 -123.75 105.66 9.86 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 107.38 -1.341 . . . . 72.53 107.38 174.607 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.437 ' HB3' HD23 ' A' ' 127' ' ' LEU . 30.2 mt -67.73 142.66 56.21 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 118.191 0.45 . . . . 74.42 111.186 -178.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.686 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 41.3 mt -55.22 142.35 58.61 Favored Pre-proline 0 CA--C 1.555 1.153 0 O-C-N 124.029 0.831 . . . . 74.0 111.791 -175.051 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.31 63.98 7.86 Favored 'Trans proline' 0 C--N 1.378 2.105 0 C-N-CA 123.389 2.726 . . . . 73.34 113.113 -177.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 3.7 p80 -149.61 50.18 0.75 Allowed Pre-proline 0 CA--C 1.564 1.5 0 C-N-CA 124.043 0.937 . . . . 70.35 108.84 169.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -62.63 122.97 11.52 Favored 'Trans proline' 0 C--N 1.385 2.459 0 C-N-CA 121.814 1.676 . . . . 75.42 111.808 -166.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.3 p -122.54 -42.57 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 N-CA-C 107.894 -1.15 . . . . 73.31 107.894 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -101.1 123.45 45.27 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.765 -1.107 . . . . 74.42 109.09 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 91.5 mtm180 -119.0 119.71 35.09 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.606 1.162 . . . . 73.33 108.085 -179.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 66.1 tp -105.0 139.02 40.31 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.848 0.859 . . . . 72.43 110.936 -174.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 -134.53 108.03 7.86 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 124.415 1.086 . . . . 72.55 108.104 164.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 73.16 -82.48 0.65 Allowed Glycine 0 C--N 1.35 1.332 0 O-C-N 123.529 0.518 . . . . 70.02 112.914 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -134.84 -15.64 2.03 Favored 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 123.772 0.829 . . . . 74.43 110.748 177.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 52.9 m-20 -91.0 143.78 26.35 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.345 0.658 . . . . 62.35 112.396 -174.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.565 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 87.3 mt -112.7 161.21 17.12 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 125.112 1.365 . . . . 75.33 111.215 -174.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -141.0 121.83 14.41 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 107.325 -1.361 . . . . 73.53 107.325 174.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . 0.42 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -148.96 136.23 20.12 Favored 'General case' 0 N--CA 1.468 0.453 0 N-CA-C 108.891 -0.781 . . . . 71.12 108.891 -178.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 196' ' ' THR . . . . . 0.556 ' HA ' ' HB2' ' A' ' 252' ' ' GLU . 12.1 m -81.28 123.14 28.25 Favored 'General case' 0 CA--C 1.542 0.665 0 O-C-N 123.478 0.486 . . . . 72.5 110.616 -175.678 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.48 HD21 HD12 ' A' ' 251' ' ' LEU . 48.2 tp -108.71 113.28 26.11 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.825 0.85 . . . . 73.31 109.484 -179.699 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -87.23 113.11 22.68 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 108.43 -0.952 . . . . 65.25 108.43 172.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 4.2 p -118.37 124.9 28.22 Favored Pre-proline 0 CA--C 1.551 1.005 0 C-N-CA 124.035 0.934 . . . . 75.02 109.347 178.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -61.73 146.27 96.79 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 122.507 2.138 . . . . 74.33 112.287 175.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . 0.409 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -54.55 -42.98 97.49 Favored Pre-proline 0 CA--C 1.56 1.338 0 CA-C-O 117.346 -1.311 . . . . 64.34 113.965 -176.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . 0.409 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 7.1 Cg_endo -48.84 -47.6 20.68 Favored 'Trans proline' 0 C--N 1.402 3.344 0 C-N-CA 122.647 2.231 . . . . 71.5 112.821 172.189 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 15.7 mt -70.01 -38.15 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 122.725 0.41 . . . . 71.34 110.843 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.2 -41.47 98.39 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 123.307 0.643 . . . . 72.31 111.778 -177.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.7 m -80.21 -40.07 19.75 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 CA-C-N 116.108 -0.496 . . . . 71.45 111.715 -176.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.0 m -79.88 -24.02 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 CA-C-N 117.842 0.292 . . . . 74.42 111.194 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.498 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 73.22 61.38 3.46 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.855 -0.611 . . . . 74.13 112.317 -174.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.55 -142.22 9.77 Favored Glycine 0 C--N 1.356 1.672 0 N-CA-C 111.799 -0.52 . . . . 71.22 111.799 -178.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -131.36 144.78 51.48 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 123.812 0.845 . . . . 74.04 110.216 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 11.8 m -134.35 169.77 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.508 1.123 . . . . 75.11 109.171 175.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . 0.454 ' HD3' ' H ' ' A' ' 211' ' ' ARG . 0.0 OUTLIER -104.03 133.7 48.54 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.536 -0.756 . . . . 72.45 109.079 176.163 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -117.81 114.87 23.91 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 108.597 -0.89 . . . . 72.11 108.597 172.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 3.9 tpt -70.56 105.13 3.0 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.966 -0.561 . . . . 61.54 109.687 177.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 5.8 t -115.69 169.37 9.25 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.486 0.714 . . . . 74.3 111.255 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 46.4 mt -75.4 -3.06 31.5 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.254 1.022 . . . . 73.33 112.535 -170.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -106.1 -6.27 18.77 Favored 'General case' 0 N--CA 1.484 1.234 0 C-N-CA 124.029 0.931 . . . . 74.24 111.566 175.218 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 116.62 155.99 10.54 Favored Glycine 0 C--N 1.348 1.214 0 CA-C-O 118.583 -1.12 . . . . 60.22 111.634 -175.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -59.76 126.91 21.79 Favored 'Trans proline' 0 C--N 1.379 2.184 0 C-N-CA 123.096 2.531 . . . . 71.25 113.078 -168.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 35.1 m -108.47 166.49 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 C-N-CA 123.296 0.639 . . . . 71.52 110.184 -179.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -113.22 113.26 25.08 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 108.11 -1.07 . . . . 72.13 108.11 -177.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.469 HG21 HD13 ' A' ' 235' ' ' LEU . 5.2 t -95.92 115.99 36.53 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-N 115.664 -0.698 . . . . 61.42 109.303 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -85.61 101.25 12.55 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.585 -1.265 . . . . 74.12 107.585 170.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.498 HG23 ' HA2' ' A' ' 207' ' ' GLY . 9.0 m -74.71 146.56 83.38 Favored Pre-proline 0 CA--C 1.559 1.323 0 N-CA-C 109.509 -0.552 . . . . 73.12 109.509 -176.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -60.79 136.18 64.72 Favored 'Trans proline' 0 C--N 1.376 2.021 0 C-N-CA 122.769 2.312 . . . . 71.44 112.027 177.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_exo -54.88 122.57 11.89 Favored 'Trans proline' 0 C--N 1.377 2.037 0 C-N-CA 122.244 1.963 . . . . 70.22 110.572 169.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 68.6 mtm180 62.57 49.99 3.74 Favored 'General case' 0 CA--C 1.551 1.002 0 O-C-N 124.333 1.021 . . . . 74.44 110.576 -177.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.5 t -72.87 170.21 15.19 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.007 0.523 . . . . 74.11 110.52 177.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . 0.56 ' H ' ' HD2' ' A' ' 231' ' ' ARG . 2.0 mp0 -121.35 147.05 46.21 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.269 0.628 . . . . 72.42 109.987 -178.424 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -76.34 123.3 25.74 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.209 1.004 . . . . 54.53 109.483 175.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 113.91 -10.65 22.98 Favored Glycine 0 N--CA 1.472 1.085 0 N-CA-C 111.924 -0.47 . . . . 62.52 111.924 -171.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . 0.56 ' HD2' ' H ' ' A' ' 228' ' ' GLN . 20.9 mtt180 -69.98 161.61 29.7 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.516 0.726 . . . . 75.21 111.402 173.042 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.3 mptp? -119.99 111.3 17.74 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 107.825 -1.176 . . . . 73.22 107.825 176.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . 0.553 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 60.0 mt -85.63 107.51 17.57 Favored 'General case' 0 C--N 1.356 0.868 0 N-CA-C 108.613 -0.884 . . . . 73.34 108.613 -178.349 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 38.4 ttm180 -84.4 105.92 15.6 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.248 -0.887 . . . . 75.12 109.993 -171.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.563 ' HB3' ' HG3' ' A' ' 238' ' ' LYS . 58.2 mt -98.07 99.13 10.37 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 108.652 -0.87 . . . . 74.14 108.652 172.586 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -75.88 144.64 41.05 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 122.489 0.316 . . . . 75.32 111.159 -177.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 72.92 28.13 67.43 Favored Glycine 0 C--N 1.353 1.481 0 O-C-N 123.755 0.659 . . . . 65.02 113.042 -175.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . 0.563 ' HG3' ' HB3' ' A' ' 235' ' ' LEU . 4.1 mmtm -119.8 -10.59 9.5 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 124.138 0.975 . . . . 71.52 111.512 -178.304 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . 0.422 ' O ' ' HD2' ' A' ' 246' ' ' ARG . . . -81.93 -154.01 12.51 Favored Glycine 0 C--N 1.339 0.719 0 O-C-N 123.414 0.446 . . . . 63.35 113.279 -179.156 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.646 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 6.1 m-85 -94.68 158.69 34.93 Favored Pre-proline 0 CA--C 1.548 0.867 0 C-N-CA 123.576 0.75 . . . . 75.5 109.811 177.033 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.66 129.32 26.64 Favored 'Trans proline' 0 C--N 1.387 2.556 0 C-N-CA 123.361 2.707 . . . . 75.55 113.482 -178.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -158.18 -169.09 21.34 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.626 -0.716 . . . . 63.23 112.278 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.35 -17.99 59.3 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 123.133 2.555 . . . . 72.31 113.414 -177.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -98.42 21.23 11.4 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 123.868 0.867 . . . . 70.52 111.233 178.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 88.74 -82.97 1.48 Allowed Glycine 0 C--N 1.347 1.176 0 N-CA-C 110.122 -1.191 . . . . 73.11 110.122 -174.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.422 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 22.5 mtm180 -127.09 158.77 36.12 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 107.324 -1.362 . . . . 75.52 107.324 165.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.08 -156.96 4.76 Favored Glycine 0 C--N 1.344 1.002 0 O-C-N 123.483 0.489 . . . . 64.41 114.142 -174.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 35.0 m-20 -117.8 151.15 37.9 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 108.871 -0.788 . . . . 72.44 108.871 -176.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.565 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 18.3 tp -105.19 114.57 28.83 Favored 'General case' 0 CA--C 1.531 0.233 0 N-CA-C 108.71 -0.848 . . . . 73.04 108.71 171.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -96.18 106.86 19.11 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 123.109 0.564 . . . . 74.41 109.984 175.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.553 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 73.4 mt -88.0 120.96 29.85 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 124.162 0.985 . . . . 70.41 112.789 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.556 ' HB2' ' HA ' ' A' ' 196' ' ' THR . 26.0 mt-10 -79.11 91.3 4.9 Favored 'General case' 0 C--O 1.24 0.574 0 C-N-CA 123.774 0.83 . . . . 74.25 109.279 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 48.0 t -52.37 114.81 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.655 1.182 . . . . 74.23 112.108 178.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 49.7 mmm-85 -117.09 93.68 4.28 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 106.933 -1.506 . . . . 72.31 106.933 173.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 72.2 mt -74.55 110.73 9.33 Favored 'Isoleucine or valine' 0 C--N 1.343 0.31 0 N-CA-C 108.274 -1.01 . . . . 75.5 108.274 177.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 4.5 t . . . . . 0 CA--C 1.557 1.226 0 C-N-CA 123.982 0.913 . . . . 74.31 109.539 -177.205 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.229 0 N-CA-C 110.361 -0.237 . . . . 74.23 110.361 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -62.42 -32.33 73.16 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.49 0.716 . . . . 75.42 111.36 178.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.45 ' HB2' ' HB3' ' A' ' 136' ' ' ARG . 1.2 tm? -112.43 111.02 21.57 Favored 'General case' 0 C--O 1.24 0.578 0 N-CA-C 106.685 -1.598 . . . . 73.12 106.685 169.345 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.408 ' O ' ' HB3' ' A' ' 123' ' ' LEU . 86.0 t -68.3 134.82 29.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 N-CA-C 108.84 -0.8 . . . . 74.34 108.84 177.334 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -150.25 56.45 0.94 Allowed 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 107.999 -1.111 . . . . 71.01 107.999 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -65.7 109.4 2.41 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-N 113.995 -1.457 . . . . 72.04 108.659 176.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 39.8 t -59.55 121.77 8.05 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.765 0 O-C-N 124.287 0.992 . . . . 74.54 109.384 -178.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.9 t -151.21 149.73 29.76 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.896 0.878 . . . . 74.3 109.487 -173.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.5 m -95.81 67.5 2.75 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.019 -0.734 . . . . 72.21 109.019 177.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -92.66 160.22 25.29 Favored Glycine 0 C--N 1.347 1.178 0 CA-C-N 115.052 -0.977 . . . . 73.41 113.954 -172.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 17.4 m -94.0 162.45 13.88 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 124.053 0.941 . . . . 71.14 111.608 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 99.13 116.8 3.82 Favored Glycine 0 C--N 1.349 1.277 0 N-CA-C 111.551 -0.62 . . . . 73.13 111.551 177.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -115.65 164.1 12.23 Favored Glycine 0 C--N 1.346 1.089 0 CA-C-N 116.952 0.376 . . . . 73.31 112.694 -176.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 34.9 t -91.36 -43.27 9.86 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.821 0.848 . . . . 72.22 109.543 175.047 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 141.8 -91.77 0.18 Allowed Glycine 0 C--O 1.239 0.434 0 CA-C-N 115.105 -0.952 . . . . 75.55 110.876 -177.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 60.11 -150.18 40.64 Favored Glycine 0 C--N 1.35 1.342 0 O-C-N 124.158 0.564 . . . . 72.04 112.846 179.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 24.5 p -175.96 135.87 0.29 Allowed 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.295 1.038 . . . . 74.53 109.237 172.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 70.17 -152.12 50.72 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 123.659 0.599 . . . . 75.41 113.106 177.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 168.85 177.43 39.7 Favored Glycine 0 C--O 1.24 0.506 0 N-CA-C 110.502 -1.039 . . . . 74.35 110.502 -177.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' SER . . . . . 0.42 ' HB3' ' HA2' ' A' ' 172' ' ' GLY . 34.6 t -137.31 98.44 3.72 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 117.5 0.65 . . . . 62.11 110.335 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 63.5 -124.19 30.88 Favored Glycine 0 C--N 1.346 1.094 0 CA-C-N 115.295 -0.866 . . . . 53.2 112.848 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -79.22 119.41 22.26 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 122.718 0.407 . . . . 75.53 109.963 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -92.72 133.72 35.74 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 108.472 -0.936 . . . . 71.12 108.472 172.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.05 144.48 26.28 Favored 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 107.015 -1.476 . . . . 73.1 107.015 178.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -130.59 129.36 42.67 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 108.108 -1.071 . . . . 74.42 108.108 176.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -150.79 150.23 30.72 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-N 115.75 -0.659 . . . . 62.42 109.571 -179.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -120.24 148.0 44.24 Favored 'General case' 0 C--O 1.245 0.84 0 N-CA-C 109.11 -0.7 . . . . 74.13 109.11 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.408 ' HB3' ' O ' ' A' ' 99' ' ' VAL . 1.3 pt? -145.32 147.58 34.44 Favored Pre-proline 0 N--CA 1.467 0.404 0 C-N-CA 122.8 0.44 . . . . 72.45 111.76 179.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -78.04 114.21 3.55 Favored 'Trans proline' 0 C--N 1.366 1.448 0 C-N-CA 121.751 1.634 . . . . 72.12 109.935 159.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.433 HD21 HG11 ' A' ' 178' ' ' VAL . 34.7 tp -106.75 157.24 17.88 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 108.791 -0.818 . . . . 72.1 108.791 177.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.704 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 14.4 m -89.36 151.69 21.93 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 122.99 0.516 . . . . 75.04 110.344 177.519 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.562 HD22 ' HB3' ' A' ' 180' ' ' LEU . 68.9 mt -58.1 -50.57 73.01 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.725 0.81 . . . . 62.3 109.389 174.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -53.78 -39.07 65.11 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 113.95 -1.477 . . . . 74.13 111.673 178.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.532 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 28.4 mm-40 -86.06 -18.07 33.45 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 122.999 0.52 . . . . 73.23 111.269 -176.484 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.599 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -64.41 -36.93 85.77 Favored 'General case' 0 C--O 1.242 0.673 0 C-N-CA 123.447 0.699 . . . . 70.01 109.886 167.353 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.443 ' HA ' ' HE1' ' A' ' 240' ' ' PHE . 27.6 t80 -71.94 -55.92 6.61 Favored 'General case' 0 CA--C 1.551 0.982 0 CA-C-N 114.999 -1.001 . . . . 61.12 110.574 172.053 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -67.97 -44.89 75.65 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 112.24 0.459 . . . . 72.12 112.24 -171.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.81 -111.62 4.27 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 111.275 -0.73 . . . . 72.25 111.275 -173.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.41 -175.87 54.54 Favored Glycine 0 C--N 1.347 1.163 0 N-CA-C 114.232 0.453 . . . . 51.05 114.232 171.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.429 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 2.0 mp0 -87.4 143.96 26.98 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 109.283 -0.636 . . . . 62.33 109.283 178.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.45 ' HB3' ' HB2' ' A' ' 98' ' ' LEU . 0.6 OUTLIER -156.79 147.84 21.98 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 109.546 -0.539 . . . . 74.25 109.546 -178.268 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 32.1 m -82.14 125.38 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 CA-C-O 121.51 0.671 . . . . 73.12 111.206 -174.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 41.1 t -120.7 144.77 28.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 125.035 1.334 . . . . 73.3 109.442 -176.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -126.15 97.79 5.22 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.041 0.536 . . . . 63.12 109.584 169.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.0 m -107.54 132.62 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 N-CA-C 108.922 -0.77 . . . . 73.22 108.922 173.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.46 23.02 13.35 Favored 'General case' 0 CA--C 1.554 1.118 0 C-N-CA 123.964 0.905 . . . . 75.01 111.694 -176.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.23 0.07 88.67 Favored Glycine 0 C--N 1.357 1.703 0 CA-C-N 116.038 -0.528 . . . . 74.51 113.468 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -103.34 123.27 46.48 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.696 0.798 . . . . 65.24 110.036 -175.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.2 ttp-105 -88.2 105.93 17.86 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.344 0.658 . . . . 73.55 110.797 -174.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 38.5 t -124.42 134.41 66.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.351 1.061 . . . . 73.51 108.828 178.021 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 37.2 m -83.81 120.9 26.61 Favored 'General case' 0 CA--C 1.546 0.803 0 N-CA-C 109.682 -0.488 . . . . 73.3 109.682 176.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.483 ' HB ' ' HE3' ' A' ' 164' ' ' MET . 8.1 p -99.77 148.73 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 123.317 0.647 . . . . 73.42 110.687 -178.387 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.3 ttt85 -110.02 96.39 6.2 Favored 'General case' 0 C--O 1.237 0.43 0 N-CA-C 107.324 -1.361 . . . . 72.04 107.324 160.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.487 ' HB ' HD13 ' A' ' 159' ' ' ILE . 37.9 pt -78.05 125.98 84.44 Favored Pre-proline 0 C--O 1.243 0.724 0 N-CA-C 108.617 -0.883 . . . . 62.31 108.617 173.144 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.404 ' HD2' HG22 ' A' ' 159' ' ' ILE . 97.7 Cg_exo -48.68 127.18 15.89 Favored 'Trans proline' 0 C--N 1.384 2.406 0 C-N-CA 123.04 2.494 . . . . 63.22 113.37 -178.266 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.554 ' HB2' ' HZ ' ' A' ' 240' ' ' PHE . 57.1 Cg_endo -69.36 143.85 54.16 Favored 'Trans proline' 0 C--N 1.376 2.007 0 C-N-CA 122.251 1.967 . . . . 75.44 110.355 175.02 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.44 27.37 5.56 Favored Glycine 0 C--N 1.337 0.586 0 N-CA-C 110.927 -0.869 . . . . 63.01 110.927 -171.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.599 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.2 p -93.67 157.32 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 N-CA-C 108.168 -1.049 . . . . 72.25 108.168 -176.603 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.4 mtp180 -147.11 169.23 19.72 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 124.141 0.976 . . . . 75.41 109.751 -166.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -51.99 123.86 11.42 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.539 0.736 . . . . 74.52 111.624 174.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 85.55 -7.64 75.56 Favored Glycine 0 C--N 1.349 1.302 0 CA-C-O 119.419 -0.656 . . . . 32.02 114.111 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.4 m -69.53 122.64 19.44 Favored 'General case' 0 C--N 1.351 0.633 0 CA-C-N 117.336 0.568 . . . . 74.31 110.553 -178.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.5 t -98.93 123.17 51.39 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 N-CA-C 108.486 -0.931 . . . . 72.44 108.486 179.302 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.546 HD12 HG23 ' A' ' 153' ' ' VAL . 43.5 mt -102.49 115.69 44.85 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.593 0 C-N-CA 123.926 0.89 . . . . 72.22 110.537 -169.075 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.402 ' HG3' ' HB2' ' A' ' 173' ' ' ASP . 30.3 ttm180 -89.69 115.86 27.38 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.07 0.548 . . . . 72.42 110.493 175.237 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.44 ' O ' ' HA ' ' A' ' 173' ' ' ASP . 15.0 m -119.16 116.11 34.12 Favored Pre-proline 0 CA--C 1.555 1.172 0 C-N-CA 123.363 0.665 . . . . 75.43 109.578 176.32 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 11.2 Cg_exo -72.47 148.51 48.41 Favored 'Trans proline' 0 C--N 1.368 1.594 0 C-N-CA 122.479 2.119 . . . . 73.42 111.998 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.65 18.27 28.36 Favored Glycine 0 C--N 1.341 0.825 0 N-CA-C 115.673 1.029 . . . . 73.2 115.673 172.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.483 ' HE3' ' HB ' ' A' ' 147' ' ' VAL . 54.2 mtt -121.6 -57.45 1.82 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 118.449 1.125 . . . . 71.3 112.128 176.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -61.36 -88.79 0.03 OUTLIER Glycine 0 C--N 1.35 1.329 0 O-C-N 123.372 0.42 . . . . 73.24 113.047 -174.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.537 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -68.99 92.93 0.31 Allowed Glycine 0 C--N 1.338 0.648 0 O-C-N 123.648 0.264 . . . . 54.14 112.631 176.047 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.0 mm-40 -92.2 128.97 38.25 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 123.182 0.593 . . . . 75.14 109.733 171.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 174.82 -59.65 0.12 Allowed Glycine 0 C--N 1.337 0.626 0 N-CA-C 110.945 -0.862 . . . . 61.32 110.945 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -162.62 -51.63 0.01 OUTLIER Pre-proline 0 CA--C 1.561 1.401 0 C-N-CA 124.402 1.081 . . . . 71.0 109.498 176.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -81.44 122.76 4.15 Favored 'Trans proline' 0 C--N 1.395 2.997 0 C-N-CA 121.775 1.65 . . . . 63.23 111.089 171.103 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -61.81 121.91 10.21 Favored 'Trans proline' 0 C--N 1.378 2.116 0 C-N-CA 122.627 2.218 . . . . 74.21 112.167 -176.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.537 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -95.41 159.21 22.44 Favored Glycine 0 C--N 1.348 1.212 0 O-C-N 123.385 0.428 . . . . 73.1 112.406 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.44 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 9.4 p-10 -96.46 151.54 19.47 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 123.012 0.525 . . . . 74.42 112.036 -167.475 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 11.2 tp -113.88 124.27 51.8 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 107.472 -1.307 . . . . 74.45 107.472 163.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.401 ' HA ' ' O ' ' A' ' 159' ' ' ILE . 37.3 mt -99.28 100.63 11.74 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.583 1.153 . . . . 74.53 110.098 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 93.0 mt -95.8 102.74 14.57 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.93 0.892 . . . . 73.12 110.917 177.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 6.5 p -86.16 111.91 21.9 Favored 'Isoleucine or valine' 0 C--O 1.244 0.81 0 CA-C-O 121.635 0.731 . . . . 62.43 109.209 172.388 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.433 HG11 HD21 ' A' ' 125' ' ' LEU . 6.2 m -86.98 149.35 4.14 Favored 'Isoleucine or valine' 0 C--O 1.241 0.607 0 CA-C-N 115.638 -0.71 . . . . 73.12 111.49 -178.365 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -124.31 104.57 8.87 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 106.914 -1.513 . . . . 73.34 106.914 176.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.562 ' HB3' HD22 ' A' ' 127' ' ' LEU . 32.4 mt -68.09 143.36 55.5 Favored 'General case' 0 CA--C 1.54 0.59 0 O-C-N 123.098 0.249 . . . . 71.21 111.243 -175.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.704 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 54.8 mt -53.86 147.83 22.42 Favored Pre-proline 0 CA--C 1.553 1.063 0 C-N-CA 123.852 0.861 . . . . 74.52 111.661 -173.265 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.19 37.24 0.62 Allowed 'Trans proline' 0 C--N 1.368 1.557 0 C-N-CA 123.32 2.68 . . . . 71.24 114.394 -175.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -121.06 65.55 13.93 Favored Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 123.544 0.738 . . . . 65.51 109.371 170.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -68.28 123.7 10.87 Favored 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 121.485 1.456 . . . . 75.04 111.231 -169.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.7 p -134.61 -38.81 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 N-CA-C 108.499 -0.926 . . . . 74.24 108.499 178.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . 0.42 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 5.5 m-85 -114.82 141.92 47.24 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 121.902 0.858 . . . . 74.54 112.259 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.543 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 43.8 mtt85 -128.54 154.0 46.62 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 113.472 -1.695 . . . . 73.2 106.838 171.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.44 HD11 HD23 ' A' ' 193' ' ' LEU . 42.5 tp -132.7 138.41 47.25 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 109.051 -0.722 . . . . 72.24 109.051 179.534 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -142.32 117.69 10.22 Favored 'General case' 0 C--O 1.241 0.645 0 N-CA-C 109.101 -0.703 . . . . 73.45 109.101 173.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 68.16 -86.82 0.18 Allowed Glycine 0 C--N 1.349 1.279 0 O-C-N 123.864 0.727 . . . . 75.41 112.986 -177.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 4.5 pm0 -135.41 -14.85 1.94 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.25 1.02 . . . . 74.31 111.206 -174.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -111.19 156.42 21.45 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-O 121.16 0.505 . . . . 74.12 111.36 -174.075 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.44 HD23 HD11 ' A' ' 188' ' ' LEU . 79.5 mt -109.09 170.78 7.83 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.334 1.054 . . . . 71.34 109.593 -168.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . 0.543 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 71.4 m-85 -142.45 122.58 13.75 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 107.51 -1.293 . . . . 74.52 107.51 177.502 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . 0.458 ' HB2' HD23 ' A' ' 251' ' ' LEU . . . -134.99 152.45 51.75 Favored 'General case' 0 CA--C 1.508 -0.657 0 N-CA-C 109.522 -0.547 . . . . 73.21 109.522 177.127 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 4.9 m -98.77 119.09 36.93 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 108.969 -0.752 . . . . 75.24 108.969 177.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.469 HD21 HD12 ' A' ' 251' ' ' LEU . 61.4 tp -105.31 111.84 24.73 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.347 1.059 . . . . 71.13 109.716 -174.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -94.43 104.85 16.81 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 109.333 -0.617 . . . . 74.51 109.333 176.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . 0.542 HG12 HG13 ' A' ' 223' ' ' VAL . 14.6 m -101.52 140.87 21.6 Favored Pre-proline 0 N--CA 1.476 0.825 0 N-CA-C 109.378 -0.601 . . . . 74.43 109.378 177.036 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.19 151.21 84.13 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 121.999 1.799 . . . . 73.21 110.986 171.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -56.69 -44.95 99.97 Favored Pre-proline 0 CA--C 1.546 0.791 0 CA-C-O 118.327 -0.844 . . . . 75.14 113.051 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . 0.415 ' O ' HG21 ' A' ' 206' ' ' VAL . 69.7 Cg_exo -46.69 -55.64 3.64 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 122.484 2.123 . . . . 64.42 113.495 170.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.2 mt -65.57 -37.25 79.56 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 122.736 0.414 . . . . 74.25 111.613 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -56.27 -58.33 8.43 Favored 'General case' 0 CA--C 1.547 0.828 0 CA-C-O 121.261 0.553 . . . . 73.43 111.087 178.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.6 m -69.79 -40.06 78.62 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.969 0 CA-C-N 115.212 -0.904 . . . . 74.34 112.461 -173.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . 0.415 HG21 ' O ' ' A' ' 202' ' ' PRO . 18.3 m -78.17 -27.0 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 122.259 0.224 . . . . 74.12 110.977 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.54 ' HA2' HG22 ' A' ' 223' ' ' VAL . . . 77.52 63.66 2.2 Favored Glycine 0 C--N 1.341 0.835 0 CA-C-N 115.919 -0.582 . . . . 73.41 113.171 -176.4 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -91.89 -147.12 19.82 Favored Glycine 0 C--N 1.354 1.578 0 N-CA-C 111.694 -0.563 . . . . 75.21 111.694 177.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -138.18 135.5 35.7 Favored 'General case' 0 C--O 1.24 0.593 0 C-N-CA 123.154 0.582 . . . . 73.41 110.462 178.051 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 61.3 t -120.68 134.64 63.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.131 0.972 . . . . 70.23 108.964 -179.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.68 114.81 17.92 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.502 -0.555 . . . . 75.41 109.502 171.533 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.63 146.0 28.3 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 108.71 -0.848 . . . . 64.35 108.71 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 55.4 mmm -83.81 148.59 26.92 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 110.13 -0.322 . . . . 72.32 110.13 174.411 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 214' ' ' THR . . . . . 0.42 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 9.3 t -140.03 167.59 21.77 Favored 'General case' 0 C--O 1.242 0.691 0 C-N-CA 124.0 0.92 . . . . 72.54 109.873 173.581 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 63.7 mt -74.31 -0.56 17.46 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 123.882 0.873 . . . . 75.32 112.138 -173.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.65 -4.07 9.78 Favored 'General case' 0 N--CA 1.485 1.292 0 N-CA-C 112.747 0.647 . . . . 74.23 112.747 176.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 153.89 -160.74 29.55 Favored Glycine 0 N--CA 1.478 1.465 0 CA-C-O 119.679 -0.512 . . . . 62.41 112.859 178.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -94.26 132.54 0.71 Allowed 'Trans proline' 0 CA--C 1.559 1.726 0 C-N-CA 123.473 2.782 . . . . 72.11 112.596 168.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 34.3 m -111.38 151.97 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.64 0.776 . . . . 73.44 110.32 173.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -114.58 115.14 26.69 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-O 121.139 0.495 . . . . 73.44 110.099 171.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.506 ' HB ' HD11 ' A' ' 235' ' ' LEU . 2.6 p -104.66 121.44 56.48 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 123.359 0.664 . . . . 74.34 110.968 179.408 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.98 105.62 15.0 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 109.22 -0.659 . . . . 75.52 109.22 173.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.542 HG13 HG12 ' A' ' 199' ' ' VAL . 11.0 m -71.2 135.61 84.65 Favored Pre-proline 0 CA--C 1.556 1.189 0 N-CA-C 108.839 -0.8 . . . . 72.32 108.839 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . 0.427 ' HB2' HH12 ' A' ' 231' ' ' ARG . 31.5 Cg_exo -61.28 144.12 98.52 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 122.373 2.048 . . . . 71.15 112.581 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -51.24 128.35 25.04 Favored 'Trans proline' 0 C--N 1.38 2.222 0 C-N-CA 122.904 2.403 . . . . 74.43 112.046 173.008 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 42.1 mtp180 67.87 60.98 0.43 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 125.032 1.333 . . . . 75.12 110.369 -175.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -85.3 139.62 31.46 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 114.852 -1.067 . . . . 72.22 111.29 178.355 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 23.1 mp0 -112.2 158.84 19.19 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 123.768 0.827 . . . . 75.4 109.392 176.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -71.07 140.47 50.71 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 116.013 -0.54 . . . . 72.54 109.673 174.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 96.97 -3.7 62.5 Favored Glycine 0 CA--C 1.521 0.443 0 CA-C-O 119.448 -0.64 . . . . 52.12 112.996 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . 0.427 HH12 ' HB2' ' A' ' 224' ' ' PRO . 90.1 mtt180 -69.41 156.11 39.37 Favored 'General case' 0 N--CA 1.478 0.972 0 CA-C-N 117.649 0.724 . . . . 75.44 110.733 172.585 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 13.2 mptt -125.44 123.23 38.81 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 123.404 0.682 . . . . 74.4 109.726 177.31 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 46.6 mt -112.6 109.98 19.87 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 108.554 -0.906 . . . . 71.12 108.554 -175.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . 0.427 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 57.3 ttp85 -99.23 104.31 16.24 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 116.072 -0.513 . . . . 75.41 111.145 -168.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.506 HD11 ' HB ' ' A' ' 221' ' ' VAL . 37.0 mt -89.9 100.52 13.32 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 124.091 0.956 . . . . 75.02 110.145 -176.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . 0.417 ' HE2' ' HB3' ' A' ' 236' ' ' LYS . 42.4 mtpt -66.37 151.53 46.94 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 116.378 -0.374 . . . . 74.11 111.534 177.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.65 20.2 73.76 Favored Glycine 0 C--N 1.348 1.203 0 CA-C-N 115.325 -0.852 . . . . 64.21 112.845 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.0 mmtt -137.59 16.44 2.92 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.801 0.84 . . . . 73.31 111.266 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -99.11 -160.72 29.42 Favored Glycine 0 C--N 1.347 1.161 0 O-C-N 123.654 0.596 . . . . 73.42 112.038 170.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.554 ' HZ ' ' HB2' ' A' ' 151' ' ' PRO . 13.3 t80 -83.43 127.14 69.56 Favored Pre-proline 0 CA--C 1.552 1.043 0 CA-C-N 116.74 0.27 . . . . 71.3 110.945 -176.531 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . 0.589 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 13.5 Cg_exo -70.87 126.33 12.47 Favored 'Trans proline' 0 C--N 1.376 1.979 0 C-N-CA 122.269 1.979 . . . . 74.53 111.732 173.474 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -158.69 -146.13 4.45 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-O 119.149 -0.806 . . . . 50.03 112.583 -176.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -65.38 -24.54 57.25 Favored 'Trans proline' 0 C--N 1.376 2.01 0 C-N-CA 123.375 2.717 . . . . 73.32 112.866 -177.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.45 22.54 3.9 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 124.041 0.937 . . . . 70.24 111.113 178.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 81.18 -98.63 1.87 Allowed Glycine 0 C--N 1.345 1.042 0 N-CA-C 110.469 -1.053 . . . . 64.34 110.469 -176.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.589 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 23.2 ttm180 -128.62 146.53 50.83 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 109.146 -0.687 . . . . 75.35 109.146 166.148 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -85.61 -155.34 24.99 Favored Glycine 0 C--O 1.253 1.338 0 O-C-N 123.694 0.621 . . . . 64.42 112.424 175.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -140.27 160.52 39.78 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.835 0.854 . . . . 62.24 109.961 -174.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.428 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 15.6 tp -99.51 122.39 42.51 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 123.919 0.887 . . . . 74.41 110.329 178.1 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -101.57 104.47 15.35 Favored 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 108.433 -0.951 . . . . 72.31 108.433 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.536 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 74.5 mt -85.72 149.93 24.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.987 0.915 . . . . 72.32 112.328 -178.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -114.47 96.01 5.55 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.539 -0.912 . . . . 70.51 108.539 176.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 69.1 t -52.15 125.82 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 123.582 0.753 . . . . 72.24 111.683 176.776 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 27.3 mmm-85 -136.17 101.5 4.72 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 125.257 1.423 . . . . 74.1 107.259 179.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 65.1 mt -80.97 125.39 39.45 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 CA-C-N 116.342 -0.39 . . . . 75.55 110.053 -175.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 10.0 t . . . . . 0 CA--C 1.55 0.966 0 C-N-CA 124.402 1.081 . . . . 74.13 109.653 -179.766 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.192 0 N-CA-C 110.22 -0.289 . . . . 75.14 110.22 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -157.35 -71.91 0.1 Allowed 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 123.033 0.533 . . . . 73.11 110.09 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.632 ' HB2' ' HG2' ' A' ' 136' ' ' ARG . 22.0 tp -80.58 -50.45 9.97 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.294 -0.632 . . . . 74.2 109.294 177.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.429 ' HA ' ' CB ' ' A' ' 123' ' ' LEU . 12.5 p -65.48 137.06 25.65 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 115.345 -0.843 . . . . 63.41 110.042 172.245 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.82 -50.14 8.96 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.215 -0.661 . . . . 73.14 109.215 174.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 49.0 p-80 -170.16 163.97 9.11 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 114.896 -1.047 . . . . 71.41 109.964 -175.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 1.8 p -95.38 162.09 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.086 0 N-CA-C 109.642 -0.503 . . . . 71.44 109.642 174.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 71.7 p -140.16 -176.66 4.68 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 124.792 1.237 . . . . 75.34 109.362 -171.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 44.7 t -75.75 166.41 23.58 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 124.05 0.94 . . . . 71.3 112.251 -175.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -94.4 174.64 33.83 Favored Glycine 0 C--N 1.353 1.481 0 CA-C-N 115.513 -0.767 . . . . 64.43 112.103 176.175 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 34.9 t -75.64 167.62 21.55 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 124.139 0.976 . . . . 54.22 111.839 -174.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -109.38 132.67 11.19 Favored Glycine 0 C--N 1.344 1.003 0 CA-C-N 115.721 -0.672 . . . . 71.53 111.748 -179.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.79 47.99 23.63 Favored Glycine 0 C--N 1.348 1.233 0 O-C-N 123.964 0.449 . . . . 55.45 112.582 179.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 21.1 m -76.17 76.89 2.99 Favored 'General case' 0 CA--C 1.554 1.098 0 C-N-CA 123.608 0.763 . . . . 75.05 110.367 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -87.29 -60.67 1.63 Allowed Glycine 0 C--N 1.348 1.243 0 CA-C-N 115.628 -0.715 . . . . 73.15 113.016 -176.54 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -85.63 56.78 4.9 Favored Glycine 0 C--N 1.344 1.022 0 N-CA-C 112.039 -0.424 . . . . 70.21 112.039 -179.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 35.3 p -160.86 138.38 9.29 Favored 'General case' 0 C--O 1.239 0.55 0 C-N-CA 124.425 1.09 . . . . 75.03 108.612 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -134.91 172.09 22.14 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 111.266 -0.734 . . . . 65.22 111.266 178.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 162.64 -159.1 31.39 Favored Glycine 0 C--N 1.336 0.58 0 N-CA-C 111.967 -0.453 . . . . 70.42 111.967 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 17.3 m -89.33 14.34 11.37 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 123.973 0.909 . . . . 75.11 112.443 -175.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 146.33 -142.46 10.51 Favored Glycine 0 C--N 1.35 1.36 0 N-CA-C 112.328 -0.309 . . . . 74.43 112.328 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.33 138.63 41.91 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 124.479 1.112 . . . . 75.43 110.487 -174.44 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.627 ' HB3' ' HB2' ' A' ' 167' ' ' GLN . 6.7 p-10 -70.36 146.56 50.38 Favored 'General case' 0 N--CA 1.486 1.361 0 CA-C-O 120.886 0.374 . . . . 75.44 110.418 170.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 31.6 tp -122.64 146.2 47.67 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 107.662 -1.236 . . . . 74.35 107.662 -170.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 64.6 ttt-85 -141.72 143.87 33.76 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.737 -0.838 . . . . 72.44 108.737 -176.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . 0.439 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -149.06 118.81 7.03 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 109.079 -0.711 . . . . 73.25 109.079 175.656 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -94.03 139.38 31.02 Favored 'General case' 0 C--O 1.247 0.959 0 N-CA-C 109.305 -0.628 . . . . 74.42 109.305 174.132 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.429 ' CB ' ' HA ' ' A' ' 99' ' ' VAL . 1.8 pt? -144.87 132.37 10.37 Favored Pre-proline 0 CA--C 1.541 0.622 0 C-N-CA 123.099 0.56 . . . . 73.34 111.41 -166.21 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.425 ' HA ' ' HB2' ' A' ' 179' ' ' ARG . 18.7 Cg_exo -68.82 115.08 3.77 Favored 'Trans proline' 0 C--N 1.375 1.973 0 C-N-CA 122.654 2.236 . . . . 75.22 112.194 177.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.434 ' HB3' HD21 ' A' ' 180' ' ' LEU . 16.9 tp -109.2 166.84 10.55 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.512 1.125 . . . . 74.44 108.202 174.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.575 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 25.9 m -103.32 156.64 17.59 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 109.671 -0.492 . . . . 73.44 109.671 173.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.463 HD23 ' HB3' ' A' ' 180' ' ' LEU . 87.5 mt -56.02 -50.5 70.74 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-O 121.671 0.748 . . . . 75.51 110.069 171.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -57.48 -34.18 68.77 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 114.517 -1.22 . . . . 71.13 111.987 176.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.575 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 31.3 mm-40 -74.12 -31.49 62.79 Favored 'General case' 0 N--CA 1.482 1.169 0 C-N-CA 123.171 0.588 . . . . 74.41 111.56 176.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.447 ' HB2' ' O ' ' A' ' 153' ' ' VAL . . . -59.33 -37.91 79.02 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.442 0.697 . . . . 70.33 111.471 169.511 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.548 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 46.8 t80 -71.61 -47.73 52.7 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 115.79 -0.641 . . . . 75.51 112.174 173.16 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 31.8 m80 -63.09 -53.71 49.39 Favored 'General case' 0 N--CA 1.483 1.187 0 O-C-N 123.702 0.626 . . . . 64.44 111.004 -173.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 59.41 149.76 0.01 OUTLIER Glycine 0 CA--C 1.537 1.431 0 CA-C-N 115.772 -0.649 . . . . 74.51 113.297 -168.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 170.37 -179.06 42.74 Favored Glycine 0 CA--C 1.505 -0.551 0 C-N-CA 119.968 -1.11 . . . . 54.4 114.666 177.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -89.78 138.36 31.55 Favored 'General case' 0 C--O 1.24 0.596 0 CA-C-N 113.445 -1.377 . . . . 75.13 107.886 177.153 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.632 ' HG2' ' HB2' ' A' ' 98' ' ' LEU . 19.7 tpp180 -154.05 158.19 40.16 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 108.622 -0.881 . . . . 74.04 108.622 178.347 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.4 p -80.14 126.16 39.29 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.21 0 CA-C-O 121.544 0.687 . . . . 71.21 111.689 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 8.9 p -107.71 123.24 62.96 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 C-N-CA 124.732 1.213 . . . . 73.51 108.883 171.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -118.94 98.73 6.33 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 108.508 -0.923 . . . . 72.44 108.508 177.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 14.3 m -122.69 134.73 65.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 124.245 1.018 . . . . 73.34 109.785 -176.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.21 29.79 19.42 Favored 'General case' 0 CA--C 1.551 1.012 0 C-N-CA 124.18 0.992 . . . . 71.3 110.38 -173.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.28 6.39 79.91 Favored Glycine 0 C--N 1.358 1.797 0 CA-C-N 115.364 -0.835 . . . . 62.13 113.806 -177.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -99.31 115.08 28.35 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 109.103 -0.703 . . . . 73.53 109.103 -176.267 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -95.41 116.04 28.25 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 123.709 0.803 . . . . 74.43 110.144 -175.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.668 HG23 ' SD ' ' A' ' 164' ' ' MET . 7.5 m -142.79 156.99 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 125.368 1.467 . . . . 74.24 108.539 176.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 38.9 t -88.37 127.02 35.48 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 109.864 -0.421 . . . . 73.35 109.864 174.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.7 p -99.91 144.88 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 123.699 0.8 . . . . 75.33 109.567 171.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.6 ttt180 -109.43 116.22 31.41 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.593 -0.891 . . . . 74.41 108.593 168.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 35.1 pt -121.1 132.04 24.31 Favored Pre-proline 0 CA--C 1.549 0.927 0 N-CA-C 108.93 -0.767 . . . . 72.3 108.93 171.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -76.45 166.61 27.13 Favored 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 122.8 2.333 . . . . 73.13 113.531 -170.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -68.89 154.62 70.65 Favored 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.109 1.873 . . . . 65.41 110.468 165.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 90.41 44.35 4.66 Favored Glycine 0 C--O 1.239 0.44 0 N-CA-C 111.548 -0.621 . . . . 75.14 111.548 -173.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.447 ' O ' ' HB2' ' A' ' 130' ' ' ALA . 2.7 p -116.3 156.26 17.52 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.102 0 N-CA-C 108.197 -1.038 . . . . 75.15 108.197 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.2 mtp180 -138.76 166.17 25.1 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 123.967 0.907 . . . . 72.12 110.916 -164.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -57.97 127.55 32.61 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 122.957 0.503 . . . . 61.4 110.823 170.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 77.19 6.67 86.45 Favored Glycine 0 C--N 1.349 1.261 0 O-C-N 123.717 0.636 . . . . 71.04 113.379 -178.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.4 ' O ' ' HA ' ' A' ' 177' ' ' VAL . 41.2 t -69.56 122.45 19.09 Favored 'General case' 0 C--N 1.358 0.953 0 C-N-CA 122.942 0.497 . . . . 71.41 109.7 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.436 HG22 HD22 ' A' ' 175' ' ' LEU . 7.3 p -103.01 119.94 52.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 O-C-N 124.475 1.109 . . . . 74.31 109.608 -176.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 17.6 mt -115.74 116.82 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 123.864 0.865 . . . . 71.55 109.86 -173.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 44.1 ttp180 -75.8 120.3 20.97 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 118.36 0.527 . . . . 75.03 110.141 175.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.643 ' HB ' ' HB3' ' A' ' 174' ' ' LEU . 84.2 t -112.16 113.88 51.42 Favored Pre-proline 0 CA--C 1.552 1.027 0 C-N-CA 124.249 1.019 . . . . 72.4 109.636 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -76.95 157.4 34.61 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.664 2.242 . . . . 73.51 113.233 178.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . 0.575 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . 105.76 -25.94 22.63 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 115.365 0.906 . . . . 75.5 115.365 173.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.668 ' SD ' HG23 ' A' ' 145' ' ' VAL . 4.1 mpp? -111.0 -45.89 3.4 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-N 118.893 1.347 . . . . 74.23 112.431 -175.001 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -76.47 -165.88 21.99 Favored Glycine 0 C--N 1.343 0.936 0 C-N-CA 121.441 -0.409 . . . . 75.31 112.624 179.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -111.85 -66.45 0.51 Allowed Glycine 0 C--N 1.339 0.727 0 N-CA-C 112.14 -0.384 . . . . 73.43 112.14 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.627 ' HB2' ' HB3' ' A' ' 118' ' ' ASP . 11.8 mm-40 -58.7 175.38 0.26 Allowed 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 124.917 1.287 . . . . 64.01 113.1 -177.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 129.11 -174.68 19.12 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 115.341 -0.845 . . . . 74.22 112.013 171.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -80.79 -46.11 1.24 Allowed Pre-proline 0 CA--C 1.56 1.346 0 N-CA-C 109.496 -0.557 . . . . 75.11 109.496 169.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -89.2 163.87 5.67 Favored 'Trans proline' 0 C--N 1.388 2.623 0 C-N-CA 121.561 1.508 . . . . 62.42 110.263 162.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -63.22 124.94 14.74 Favored 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 121.481 1.454 . . . . 74.52 110.241 169.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.575 ' HA3' ' H ' ' A' ' 163' ' ' GLY . . . 103.91 119.97 4.7 Favored Glycine 0 C--N 1.34 0.778 0 N-CA-C 112.301 -0.319 . . . . 60.31 112.301 -176.329 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -134.6 107.5 7.53 Favored 'General case' 0 C--N 1.333 -0.141 0 C-N-CA 124.524 1.129 . . . . 73.02 108.153 172.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.643 ' HB3' ' HB ' ' A' ' 161' ' ' VAL . 27.4 tp -121.33 105.89 10.95 Favored 'General case' 0 C--O 1.226 -0.132 0 N-CA-C 107.2 -1.407 . . . . 75.22 107.2 168.003 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.436 HD22 HG22 ' A' ' 158' ' ' VAL . 59.8 mt -84.76 99.39 10.83 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.017 -0.538 . . . . 70.12 110.483 -176.015 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.439 ' HA ' ' O ' ' A' ' 121' ' ' ALA . 59.8 mt -84.35 102.81 13.0 Favored 'General case' 0 C--N 1.344 0.351 0 CA-C-N 115.569 -0.741 . . . . 74.44 109.393 176.101 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 157' ' ' SER . 42.7 t -95.98 95.05 4.54 Favored 'Isoleucine or valine' 0 C--O 1.242 0.665 0 CA-C-N 114.61 -1.177 . . . . 74.24 107.962 179.343 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.445 HG21 HG22 ' A' ' 153' ' ' VAL . 5.6 m -75.3 147.63 8.14 Favored 'Isoleucine or valine' 0 C--O 1.245 0.831 0 CA-C-O 121.521 0.676 . . . . 75.24 110.898 -171.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . 0.425 ' HB2' ' HA ' ' A' ' 124' ' ' PRO . 34.3 mmt180 -121.35 94.93 4.49 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 108.119 -1.067 . . . . 74.53 108.119 -176.238 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.463 ' HB3' HD23 ' A' ' 127' ' ' LEU . 50.1 mt -67.34 147.12 53.36 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 110.269 -0.271 . . . . 75.13 110.269 -176.343 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.55 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 20.3 mt -56.59 123.41 56.95 Favored Pre-proline 0 CA--C 1.552 1.054 0 CA-C-O 119.307 -0.378 . . . . 73.13 110.362 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 17.2 Cg_exo -66.82 85.27 0.3 Allowed 'Trans proline' 0 C--N 1.379 2.143 0 C-N-CA 123.508 2.805 . . . . 75.21 113.356 -172.423 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -162.44 77.25 2.01 Favored Pre-proline 0 CA--C 1.558 1.281 0 N-CA-C 108.094 -1.076 . . . . 71.05 108.094 171.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -63.33 123.46 12.17 Favored 'Trans proline' 0 C--N 1.377 2.031 0 C-N-CA 122.002 1.801 . . . . 74.22 111.924 -171.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.8 p -134.56 -46.78 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 N-CA-C 107.517 -1.29 . . . . 62.2 107.517 174.135 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . 0.531 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 4.3 m-85 -103.55 123.77 47.55 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.22 -0.9 . . . . 73.44 110.61 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 15.0 mtm180 -120.82 104.75 10.11 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.905 -1.517 . . . . 75.41 106.905 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 44.3 tp -83.6 138.55 33.31 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 108.996 -0.742 . . . . 73.15 108.996 174.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -141.59 104.93 4.65 Favored 'General case' 0 C--O 1.243 0.747 0 N-CA-C 107.393 -1.336 . . . . 74.55 107.393 176.273 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 74.84 -88.17 0.76 Allowed Glycine 0 C--N 1.348 1.221 0 CA-C-N 115.738 -0.665 . . . . 61.34 111.654 -174.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -136.59 -6.36 1.96 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 123.625 0.77 . . . . 71.1 110.854 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -98.53 149.55 22.62 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.369 0.668 . . . . 71.24 111.202 -177.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.591 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.7 mt -109.58 151.17 27.16 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.486 1.114 . . . . 74.54 109.207 -177.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -140.41 120.17 13.42 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 107.372 -1.344 . . . . 73.41 107.372 178.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . 0.439 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -143.24 140.66 30.78 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.742 0.817 . . . . 63.42 108.939 -177.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 20.5 m -83.39 127.98 34.13 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-O 121.194 0.521 . . . . 63.53 110.208 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . . . . . . . . . 65.1 tp -112.3 120.66 42.5 Favored 'General case' 0 C--O 1.22 -0.479 0 C-N-CA 125.216 1.406 . . . . 74.21 108.941 176.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -99.35 123.08 43.33 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.402 -0.962 . . . . 74.32 108.402 170.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 4.6 m -110.2 147.78 36.99 Favored Pre-proline 0 C--O 1.245 0.849 0 C-N-CA 123.039 0.536 . . . . 74.41 109.883 -177.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -60.22 134.1 53.7 Favored 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 122.367 2.045 . . . . 72.14 110.877 168.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -53.96 -43.35 96.57 Favored Pre-proline 0 CA--C 1.564 1.493 0 C-N-CA 124.325 1.05 . . . . 71.4 113.541 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_exo -55.13 -46.48 32.71 Favored 'Trans proline' 0 C--N 1.395 3.024 0 C-N-CA 122.473 2.116 . . . . 74.45 112.97 171.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 7.1 mt -63.28 -38.24 81.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 123.344 0.657 . . . . 74.14 111.072 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.91 -43.62 98.29 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 123.099 0.56 . . . . 64.55 111.889 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . 0.527 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 35.8 m -80.81 -38.96 17.59 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 CA-C-N 116.154 -0.476 . . . . 71.12 112.178 -175.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.0 m -79.53 -35.78 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 CA-C-N 118.12 0.418 . . . . 74.43 110.573 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 89.81 80.02 1.34 Allowed Glycine 0 C--N 1.348 1.22 0 CA-C-N 115.613 -0.721 . . . . 75.01 112.229 -175.11 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -117.54 -160.42 11.71 Favored Glycine 0 C--N 1.357 1.732 0 N-CA-C 112.164 -0.374 . . . . 44.41 112.164 175.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . 0.568 ' HB2' ' HZ2' ' A' ' 209' ' ' LYS . 10.5 mtmp? -115.98 137.44 52.11 Favored 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 123.47 0.708 . . . . 75.44 110.373 -179.187 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 28.2 t -118.82 152.06 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.745 1.218 . . . . 55.15 108.749 176.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -81.13 119.2 23.27 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 108.434 -0.95 . . . . 75.22 108.434 171.58 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -102.16 122.94 45.12 Favored 'General case' 0 C--O 1.239 0.511 0 N-CA-C 108.125 -1.065 . . . . 75.3 108.125 175.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 54.7 mmm -77.21 113.4 14.92 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.193 0.52 . . . . 72.33 110.288 178.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 214' ' ' THR . . . . . 0.531 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 9.1 t -109.83 167.96 9.77 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-N 114.692 -1.14 . . . . 64.15 109.766 171.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 72.1 mt -71.12 -7.5 47.0 Favored 'General case' 0 CA--C 1.546 0.821 0 CA-C-N 114.701 -1.136 . . . . 73.24 111.735 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -90.57 -19.79 23.34 Favored 'General case' 0 CA--C 1.558 1.26 0 C-N-CA 124.211 1.004 . . . . 74.02 110.951 172.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 137.24 -154.36 22.33 Favored Glycine 0 C--N 1.347 1.163 0 N-CA-C 110.901 -0.88 . . . . 64.43 110.901 -174.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -89.19 129.06 1.92 Allowed 'Trans proline' 0 CA--C 1.55 1.295 0 C-N-CA 122.649 2.232 . . . . 61.32 111.923 170.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.0 m -109.82 167.91 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 123.775 0.83 . . . . 74.32 111.197 174.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -105.69 115.79 30.85 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 123.598 0.759 . . . . 64.32 109.906 177.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 2.7 p -116.55 125.44 73.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 123.974 0.91 . . . . 71.31 109.566 174.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -92.31 121.83 34.18 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.124 -0.695 . . . . 71.42 109.124 175.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 10.0 m -81.7 145.43 54.33 Favored Pre-proline 0 CA--C 1.553 1.06 0 N-CA-C 108.989 -0.745 . . . . 75.52 108.989 177.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -61.99 141.92 90.94 Favored 'Trans proline' 0 C--N 1.371 1.713 0 C-N-CA 122.13 1.887 . . . . 74.24 111.914 173.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -60.04 122.21 11.03 Favored 'Trans proline' 0 C--N 1.368 1.592 0 C-N-CA 122.784 2.322 . . . . 75.54 112.257 174.358 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . 0.527 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 62.3 mtp180 65.85 39.33 4.7 Favored 'General case' 0 N--CA 1.482 1.172 0 C-N-CA 124.732 1.213 . . . . 73.3 111.427 -176.294 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 7.1 t -70.9 174.41 6.17 Favored 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 122.941 0.496 . . . . 75.13 111.272 -179.098 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.2 mp0 -123.55 143.65 50.07 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 123.859 0.863 . . . . 73.32 109.54 -176.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.08 123.28 21.18 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.785 0.834 . . . . 63.31 110.098 175.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 112.87 12.24 12.88 Favored Glycine 0 C--N 1.34 0.788 0 CA-C-N 116.244 -0.434 . . . . 74.3 112.605 -176.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . 0.404 ' O ' ' HA ' ' A' ' 252' ' ' GLU . 84.8 mtt180 -91.17 154.51 19.28 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 109.292 -0.633 . . . . 74.01 109.292 167.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.418 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.1 OUTLIER -104.27 111.45 24.08 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 123.615 0.766 . . . . 71.52 109.03 172.568 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . 0.476 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 67.8 mt -87.63 104.78 16.84 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 108.333 -0.988 . . . . 75.14 108.333 -177.363 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 40.5 ttm105 -76.58 110.39 11.1 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-N 115.313 -0.858 . . . . 75.21 111.755 -172.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.427 HD12 HD23 ' A' ' 249' ' ' LEU . 20.9 mt -91.97 106.12 18.21 Favored 'General case' 0 C--O 1.239 0.551 0 N-CA-C 107.897 -1.149 . . . . 71.22 107.897 169.338 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 93.3 mttt -66.57 132.89 49.18 Favored 'General case' 0 CA--C 1.538 0.506 0 CA-C-N 114.578 -1.192 . . . . 75.33 111.828 -167.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 79.91 -1.11 80.61 Favored Glycine 0 C--N 1.348 1.228 0 O-C-N 123.834 0.709 . . . . 64.01 114.649 173.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -84.57 -3.78 58.63 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.496 0.554 . . . . 71.41 112.496 -176.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.91 -179.31 48.92 Favored Glycine 0 C--N 1.346 1.136 0 N-CA-C 112.446 -0.262 . . . . 71.24 112.446 174.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.548 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 73.9 m-85 -86.38 155.86 56.93 Favored Pre-proline 0 N--CA 1.476 0.847 0 C-N-CA 123.197 0.599 . . . . 75.32 112.296 -173.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -60.97 140.5 90.5 Favored 'Trans proline' 0 C--N 1.384 2.444 0 C-N-CA 122.778 2.318 . . . . 73.25 112.772 178.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -150.82 -162.01 10.37 Favored Glycine 0 CA--C 1.533 1.179 0 N-CA-C 110.458 -1.057 . . . . 72.13 110.458 175.044 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -69.7 -20.68 34.81 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.803 2.335 . . . . 74.11 113.043 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.79 3.18 55.33 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.673 0.789 . . . . 74.24 112.083 -175.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.37 -105.97 1.62 Allowed Glycine 0 C--N 1.35 1.314 0 N-CA-C 110.619 -0.993 . . . . 64.31 110.619 -176.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 50.6 mtm-85 -126.58 152.28 46.82 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 108.045 -1.095 . . . . 74.51 108.045 167.395 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -78.03 -158.28 10.79 Favored Glycine 0 C--N 1.343 0.936 0 O-C-N 123.362 0.414 . . . . 72.21 112.152 174.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 38.6 m-20 -136.65 170.1 16.62 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 109.323 -0.621 . . . . 62.34 109.323 -175.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.591 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 23.9 tp -103.27 124.44 48.64 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.202 -0.666 . . . . 75.21 109.202 171.35 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . 0.418 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 48.3 m-85 -107.89 104.35 13.81 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.293 0.637 . . . . 65.23 109.405 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.476 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 85.2 mt -89.11 113.75 24.93 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.802 0.841 . . . . 73.11 112.414 -178.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' A' ' 231' ' ' ARG . 39.2 tt0 -78.85 91.66 4.78 Favored 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 108.777 -0.823 . . . . 74.11 108.777 176.838 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.1 p -54.11 130.98 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.353 1.061 . . . . 74.14 111.066 176.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 13.2 mmt180 -131.02 99.01 4.75 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 125.12 1.368 . . . . 72.02 107.548 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 63.5 mt -76.58 124.76 35.48 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 C-N-CA 123.822 0.849 . . . . 72.35 109.269 -175.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 9.4 t . . . . . 0 C--O 1.25 1.086 0 C-N-CA 123.552 0.741 . . . . 72.5 109.781 -175.62 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.44 ' HB1' HG13 ' A' ' 99' ' ' VAL . . . . . . . . 0 N--CA 1.484 1.238 0 N-CA-C 109.959 -0.385 . . . . 73.53 109.959 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -149.25 -84.77 0.09 Allowed 'General case' 0 N--CA 1.48 1.06 0 C-N-CA 122.508 0.323 . . . . 73.43 110.71 -179.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.443 HD22 HD11 ' A' ' 123' ' ' LEU . 0.0 OUTLIER -82.9 -24.21 33.23 Favored 'General case' 0 N--CA 1.484 1.226 0 CA-C-O 121.254 0.549 . . . . 62.23 110.108 178.237 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.537 ' HA ' ' HB2' ' A' ' 123' ' ' LEU . 11.4 p -84.08 143.46 11.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 C-N-CA 124.702 1.201 . . . . 72.42 110.624 171.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -77.82 -87.07 0.05 Allowed 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 108.439 -0.949 . . . . 73.53 108.439 169.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.4 m80 -168.78 179.54 4.16 Favored 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 125.026 1.33 . . . . 74.12 109.72 177.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 93.4 t -62.23 140.16 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 C-N-CA 123.654 0.782 . . . . 72.4 111.146 178.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 37.4 p -66.57 110.21 3.09 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 123.163 0.585 . . . . 73.21 109.443 172.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 48.0 t -58.2 98.55 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 124.745 1.218 . . . . 73.42 112.109 -175.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -173.35 -175.19 40.93 Favored Glycine 0 C--N 1.342 0.867 0 CA-C-N 115.764 -0.653 . . . . 51.43 111.592 178.415 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 32.2 p -77.65 -66.13 0.88 Allowed 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.335 0.654 . . . . 72.25 109.793 177.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -161.5 154.16 25.08 Favored Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.665 -0.574 . . . . 72.44 111.665 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -109.76 -89.48 1.99 Allowed Glycine 0 C--N 1.345 1.035 0 C-N-CA 123.335 0.493 . . . . 75.11 112.478 -177.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 13.0 t -154.1 34.76 0.43 Allowed 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 121.403 0.62 . . . . 73.02 110.105 -174.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -79.95 156.12 39.66 Favored Glycine 0 C--N 1.342 0.912 0 CA-C-N 115.62 -0.718 . . . . 74.52 112.656 176.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 101.74 43.36 2.13 Favored Glycine 0 C--N 1.338 0.675 0 C-N-CA 123.642 0.639 . . . . 74.51 113.15 176.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 39.6 m -76.01 110.34 10.4 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 122.721 0.408 . . . . 71.01 110.386 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 77.75 -73.28 2.11 Favored Glycine 0 C--N 1.344 1.021 0 N-CA-C 110.676 -0.97 . . . . 61.12 110.676 -174.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.527 ' HA3' ' HG2' ' A' ' 171' ' ' PRO . . . -76.97 98.45 1.32 Allowed Glycine 0 C--N 1.344 0.994 0 N-CA-C 110.645 -0.982 . . . . 75.3 110.645 170.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 14.3 p -76.13 92.8 3.26 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 123.4 0.68 . . . . 74.23 110.87 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -127.24 -177.08 14.71 Favored Glycine 0 C--N 1.342 0.878 0 CA-C-N 115.268 -0.878 . . . . 72.15 111.071 172.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.569 ' HB3' ' HA2' ' A' ' 166' ' ' GLY . 20.0 tpp180 -63.1 124.64 21.65 Favored 'General case' 0 C--O 1.248 1.006 0 C-N-CA 122.9 0.48 . . . . 73.52 110.921 -176.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -61.24 125.33 23.35 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 114.361 -1.29 . . . . 73.31 110.576 171.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.537 HD11 ' HA2' ' A' ' 165' ' ' GLY . 12.4 mt -125.59 142.46 51.5 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 107.26 -1.385 . . . . 74.04 107.26 160.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . 0.58 ' HG2' ' HB2' ' A' ' 175' ' ' LEU . 41.0 mtm180 -141.91 145.78 34.97 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 107.694 -1.224 . . . . 75.25 107.694 178.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -151.46 118.42 5.85 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 108.516 -0.92 . . . . 71.24 108.516 175.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -88.85 132.45 34.66 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 108.086 -1.079 . . . . 74.55 108.086 173.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.537 ' HB2' ' HA ' ' A' ' 99' ' ' VAL . 2.2 pt? -142.71 146.65 39.0 Favored Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 122.778 0.431 . . . . 72.51 111.683 -168.564 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -75.97 121.6 6.3 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.689 2.259 . . . . 62.41 111.182 173.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.437 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 14.2 tp -120.16 168.94 10.7 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.216 1.006 . . . . 74.32 108.793 174.69 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.642 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 11.5 m -107.06 155.98 19.25 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.136 0.574 . . . . 74.12 109.776 174.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 80.5 mt -50.49 -52.41 38.57 Favored 'General case' 0 N--CA 1.487 1.41 0 C-N-CA 124.127 0.971 . . . . 70.31 110.216 173.29 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.552 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -54.91 -39.52 68.89 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 113.506 -1.679 . . . . 71.44 112.103 177.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.642 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 16.0 mm-40 -76.88 -26.31 54.06 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 123.099 0.56 . . . . 73.22 112.107 -176.354 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.519 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -61.12 -44.56 97.16 Favored 'General case' 0 C--O 1.252 1.219 0 CA-C-O 121.62 0.724 . . . . 72.3 111.129 169.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -67.69 -46.31 72.65 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 114.029 -1.441 . . . . 73.53 112.747 176.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.2 m80 -69.2 -47.43 64.86 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 122.775 0.43 . . . . 74.34 110.759 -176.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.69 -148.24 50.99 Favored Glycine 0 C--N 1.344 1.022 0 N-CA-C 111.229 -0.749 . . . . 72.23 111.229 -169.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 117.26 172.72 16.21 Favored Glycine 0 N--CA 1.472 1.039 0 CA-C-N 117.224 0.512 . . . . 73.14 113.471 172.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 13.7 mp0 -90.11 114.42 26.34 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 107.744 -1.206 . . . . 61.13 107.744 179.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 4.9 mmp_? -116.75 163.19 16.51 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 123.855 0.862 . . . . 74.51 110.306 -177.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.6 p -88.48 124.07 41.24 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 CA-C-O 121.241 0.543 . . . . 75.33 110.241 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.434 ' HA ' HG12 ' A' ' 99' ' ' VAL . 12.0 p -114.24 145.87 19.5 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.694 0 C-N-CA 123.816 0.846 . . . . 64.44 109.962 178.463 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -125.91 109.06 12.05 Favored 'General case' 0 C--O 1.242 0.682 0 N-CA-C 108.668 -0.864 . . . . 74.45 108.668 174.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.9 m -130.43 117.52 39.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 123.678 0.791 . . . . 74.1 111.068 -176.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.05 23.39 13.79 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.835 1.254 . . . . 75.5 112.257 176.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.12 12.71 57.25 Favored Glycine 0 C--N 1.343 0.944 0 CA-C-O 120.032 -0.315 . . . . 60.25 112.995 -178.309 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.1 mpt_? -103.3 116.87 33.27 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.203 -0.665 . . . . 74.42 109.203 177.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 62.5 ttp85 -94.32 105.17 17.15 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 108.14 -1.059 . . . . 74.42 108.14 172.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 8.9 m -142.11 157.07 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 C-N-CA 124.338 1.055 . . . . 65.34 109.575 -175.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 54.3 p -90.94 120.08 31.66 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 122.889 0.476 . . . . 63.54 110.217 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.22 141.35 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.348 0.659 . . . . 63.32 109.425 177.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -107.04 103.42 12.83 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 108.298 -1.001 . . . . 71.34 108.298 174.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.476 ' HB ' HD11 ' A' ' 159' ' ' ILE . 37.8 pt -106.98 107.27 60.22 Favored Pre-proline 0 CA--C 1.548 0.873 0 N-CA-C 108.677 -0.861 . . . . 73.4 108.677 170.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.96 162.08 43.11 Favored 'Trans proline' 0 C--N 1.38 2.235 0 C-N-CA 122.972 2.448 . . . . 71.11 113.389 -171.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -59.85 114.77 2.22 Favored 'Trans proline' 0 C--N 1.376 2.017 0 C-N-CA 122.482 2.121 . . . . 74.21 110.448 169.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . 0.421 ' HA2' ' CD2' ' A' ' 240' ' ' PHE . . . 140.62 61.35 0.04 OUTLIER Glycine 0 C--N 1.341 0.811 0 N-CA-C 111.811 -0.515 . . . . 73.2 111.811 -173.724 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.564 HG23 HD13 ' A' ' 159' ' ' ILE . 3.2 p -150.9 163.14 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.301 0 C-N-CA 122.505 0.322 . . . . 74.43 110.162 -178.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 44.8 mtp180 -146.8 177.02 9.43 Favored 'General case' 0 N--CA 1.484 1.234 0 C-N-CA 124.987 1.315 . . . . 75.42 110.113 -171.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.2 tp10 -51.72 118.2 3.22 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 125.053 1.341 . . . . 71.14 111.51 170.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 79.0 1.28 84.91 Favored Glycine 0 C--N 1.351 1.373 0 CA-C-O 119.382 -0.677 . . . . 73.51 113.866 176.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.4 m -73.78 136.49 43.59 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-N 117.352 0.576 . . . . 72.52 110.953 -176.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.404 HG12 HD22 ' A' ' 175' ' ' LEU . 13.2 t -101.06 122.97 53.77 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-N 114.646 -1.161 . . . . 61.12 108.894 -174.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.564 HD13 HG23 ' A' ' 153' ' ' VAL . 16.6 mt -106.4 107.35 22.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 N-CA-C 109.035 -0.728 . . . . 74.21 109.035 -175.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.494 ' HA ' HD21 ' A' ' 175' ' ' LEU . 58.4 ttt-85 -81.7 109.13 15.83 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 110.03 -0.359 . . . . 73.24 110.03 176.202 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.426 HG22 ' O ' ' A' ' 174' ' ' LEU . 19.5 m -101.72 97.81 8.56 Favored Pre-proline 0 CA--C 1.559 1.319 0 N-CA-C 108.647 -0.872 . . . . 74.13 108.647 172.069 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -74.55 155.98 45.07 Favored 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 123.053 2.502 . . . . 62.55 113.189 -176.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 73.27 24.73 74.78 Favored Glycine 0 C--N 1.345 1.076 0 CA-C-N 115.488 -0.778 . . . . 72.51 112.586 -178.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 6.7 tpt -125.68 -56.89 1.47 Allowed 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 124.01 0.924 . . . . 74.35 111.573 -166.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . 0.537 ' HA2' HD11 ' A' ' 119' ' ' LEU . . . -70.43 -79.96 0.32 Allowed Glycine 0 C--N 1.353 1.491 0 O-C-N 123.725 0.641 . . . . 73.01 112.14 -175.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.569 ' HA2' ' HB3' ' A' ' 117' ' ' ARG . . . -60.5 116.96 9.96 Favored Glycine 0 C--N 1.338 0.69 0 O-C-N 123.98 0.459 . . . . 50.42 113.688 169.493 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.6 mm-40 -81.51 146.57 30.12 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 124.049 0.94 . . . . 73.14 109.846 177.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 118.3 -177.63 16.55 Favored Glycine 0 N--CA 1.465 0.577 0 CA-C-N 116.536 -0.302 . . . . 64.13 112.478 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -65.16 -43.51 66.29 Favored Pre-proline 0 CA--C 1.554 1.114 0 CA-C-O 118.367 -0.825 . . . . 75.25 112.183 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.43 118.69 5.77 Favored 'Trans proline' 0 C--N 1.393 2.891 0 C-N-CA 121.424 1.416 . . . . 71.42 110.157 167.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . 0.527 ' HG2' ' HA3' ' A' ' 114' ' ' GLY . 62.6 Cg_endo -73.8 125.2 9.78 Favored 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 121.731 1.621 . . . . 73.21 112.539 -175.087 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.418 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -98.87 178.69 31.05 Favored Glycine 0 C--O 1.222 -0.625 0 N-CA-C 110.565 -1.014 . . . . 74.13 110.565 166.67 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -146.56 157.14 43.68 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 118.12 0.96 . . . . 71.51 111.259 -171.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.426 ' O ' HG22 ' A' ' 161' ' ' VAL . 27.0 tp -114.57 115.59 27.42 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 114.655 -1.157 . . . . 74.14 108.684 176.297 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.58 ' HB2' ' HG2' ' A' ' 120' ' ' ARG . 93.8 mt -90.35 99.46 12.48 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.297 1.039 . . . . 65.12 110.254 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 45.6 mt -87.07 104.59 16.48 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 122.81 0.444 . . . . 72.15 110.51 175.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.5 t -89.39 95.78 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 107.803 -1.184 . . . . 72.53 107.803 176.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.437 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 8.1 m -82.08 144.11 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 109.769 -0.456 . . . . 75.3 109.769 -174.695 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 5.2 mmm180 -122.28 105.55 10.31 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 106.118 -1.808 . . . . 75.1 106.118 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 36.6 mt -69.61 147.88 50.11 Favored 'General case' 0 N--CA 1.473 0.706 0 O-C-N 123.373 0.421 . . . . 70.21 111.175 -172.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.454 HD11 HG22 ' A' ' 126' ' ' THR . 36.5 mt -55.73 121.04 36.95 Favored Pre-proline 0 C--N 1.357 0.905 0 O-C-N 123.641 0.588 . . . . 73.54 109.748 177.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -65.98 88.02 0.24 Allowed 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 122.969 2.446 . . . . 61.41 112.306 -178.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 13.3 p80 -156.99 62.9 2.88 Favored Pre-proline 0 CA--C 1.55 0.958 0 N-CA-C 107.794 -1.187 . . . . 74.1 107.794 169.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -56.14 122.06 11.1 Favored 'Trans proline' 0 C--N 1.382 2.339 0 C-N-CA 122.089 1.859 . . . . 74.24 112.639 -170.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.83 -45.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 N-CA-C 107.704 -1.221 . . . . 64.0 107.704 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . 0.418 ' CE2' HD12 ' A' ' 193' ' ' LEU . 4.9 m-85 -107.41 131.98 53.68 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 123.93 0.892 . . . . 72.41 110.384 178.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 69.0 mtp180 -117.81 131.12 56.61 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.765 1.226 . . . . 74.41 108.635 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 58.6 tp -109.9 130.84 55.48 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 121.004 0.43 . . . . 74.25 110.182 177.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -129.87 101.79 6.02 Favored 'General case' 0 C--O 1.24 0.572 0 N-CA-C 107.417 -1.327 . . . . 64.33 107.417 172.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 69.67 -82.65 0.29 Allowed Glycine 0 CA--C 1.53 1.008 0 O-C-N 123.793 0.683 . . . . 62.11 112.607 -176.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 49.8 tt0 -134.2 -22.18 1.79 Allowed 'General case' 0 CA--C 1.552 1.053 0 C-N-CA 124.733 1.213 . . . . 73.12 109.554 -177.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 41.3 m-20 -81.41 149.73 28.69 Favored 'General case' 0 C--N 1.358 0.967 0 C-N-CA 123.809 0.844 . . . . 72.43 111.385 -178.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.546 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.8 mt -109.58 155.04 21.92 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 124.639 1.176 . . . . 75.11 110.491 174.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -140.02 119.02 12.6 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 105.605 -1.998 . . . . 75.32 105.605 172.34 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -135.5 134.41 39.49 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 109.184 -0.672 . . . . 71.4 109.184 -178.235 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 196' ' ' THR . . . . . 0.431 ' HA ' ' HB3' ' A' ' 252' ' ' GLU . 24.0 m -70.91 123.64 22.49 Favored 'General case' 0 CA--C 1.541 0.612 0 O-C-N 123.654 0.596 . . . . 74.54 110.064 -179.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.463 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 61.3 tp -105.95 111.34 23.95 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 108.767 -0.827 . . . . 72.2 108.767 -178.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -85.04 116.74 23.6 Favored 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.492 -0.929 . . . . 61.25 108.492 176.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 2.2 m -122.86 141.64 35.95 Favored Pre-proline 0 N--CA 1.479 0.986 0 N-CA-C 108.996 -0.742 . . . . 73.11 108.996 177.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -72.7 147.1 44.44 Favored 'Trans proline' 0 C--N 1.366 1.485 0 C-N-CA 121.539 1.493 . . . . 71.32 110.521 169.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -58.31 -40.97 86.87 Favored Pre-proline 0 CA--C 1.558 1.26 0 C-N-CA 123.689 0.796 . . . . 62.32 112.419 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -45.68 -54.84 4.07 Favored 'Trans proline' 0 C--N 1.392 2.844 0 C-N-CA 122.524 2.15 . . . . 70.31 114.164 167.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 11.7 mt -65.58 -36.29 77.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 C-N-CA 122.237 0.215 . . . . 75.13 111.429 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.53 -44.27 93.23 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.16 0.584 . . . . 74.34 111.944 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.7 m -80.16 -41.15 20.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 CA-C-N 116.063 -0.517 . . . . 53.34 111.569 -176.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.3 m -78.88 -21.18 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 122.549 0.34 . . . . 74.04 111.148 -178.649 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.506 ' HA2' HG21 ' A' ' 223' ' ' VAL . . . 71.2 65.32 2.48 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 115.764 -0.653 . . . . 74.32 112.439 -176.484 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -93.85 -155.55 31.87 Favored Glycine 0 C--N 1.353 1.505 0 CA-C-N 116.94 0.37 . . . . 65.4 112.535 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.22 134.87 54.62 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.326 1.05 . . . . 75.52 108.438 178.332 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 46.6 t -117.97 125.77 74.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 124.078 0.951 . . . . 73.35 108.593 -178.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -79.6 109.14 13.71 Favored 'General case' 0 CA--C 1.542 0.659 0 N-CA-C 109.137 -0.69 . . . . 72.03 109.137 177.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.95 129.92 48.35 Favored 'General case' 0 C--O 1.238 0.483 0 C-N-CA 123.417 0.687 . . . . 70.1 109.148 179.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.2 116.75 18.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.004 -0.544 . . . . 70.5 109.899 174.593 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 9.9 t -109.67 163.56 13.36 Favored 'General case' 0 C--O 1.242 0.685 0 O-C-N 123.901 0.75 . . . . 74.43 109.402 172.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . 0.552 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 90.2 mt -71.53 -2.58 17.37 Favored 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 115.507 -0.77 . . . . 73.31 112.61 -172.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -112.26 -11.72 13.69 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.565 0.746 . . . . 63.21 112.111 175.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 153.71 -156.34 26.73 Favored Glycine 0 C--N 1.349 1.267 0 CA-C-O 119.546 -0.585 . . . . 61.32 112.799 -179.047 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -94.28 133.53 0.76 Allowed 'Trans proline' 0 CA--C 1.556 1.592 0 C-N-CA 123.001 2.467 . . . . 74.14 112.846 174.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 27.1 m -114.56 157.5 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 123.585 0.754 . . . . 73.34 109.639 170.351 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -114.47 113.9 25.09 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 108.999 -0.741 . . . . 72.22 108.999 177.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.454 HG23 HD12 ' A' ' 235' ' ' LEU . 6.3 t -95.79 117.19 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 C-N-CA 123.99 0.916 . . . . 75.04 110.026 -177.328 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.99 100.57 11.14 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 108.977 -0.749 . . . . 74.21 108.977 176.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.506 HG21 ' HA2' ' A' ' 207' ' ' GLY . 20.0 m -79.43 137.45 55.65 Favored Pre-proline 0 CA--C 1.551 1.019 0 N-CA-C 109.415 -0.587 . . . . 74.22 109.415 179.415 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -63.31 144.9 92.39 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.537 2.158 . . . . 64.41 112.498 176.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -55.77 120.41 8.2 Favored 'Trans proline' 0 C--N 1.381 2.258 0 C-N-CA 123.081 2.521 . . . . 74.03 112.043 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 67.3 mtt180 64.76 54.61 1.34 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.382 1.073 . . . . 74.32 110.388 -175.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.3 t -75.49 167.36 22.04 Favored 'General case' 0 CA--C 1.545 0.781 0 CA-C-N 115.372 -0.831 . . . . 72.11 109.159 173.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -128.15 146.28 50.76 Favored 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 123.217 0.607 . . . . 74.12 109.614 -177.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -68.13 127.9 34.6 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 115.318 -0.855 . . . . 74.35 109.27 175.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.29 0.31 23.69 Favored Glycine 0 N--CA 1.471 1.032 0 CA-C-O 119.497 -0.613 . . . . 73.4 112.841 -173.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 25.0 mtp180 -84.4 154.89 22.55 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 117.414 0.607 . . . . 74.23 109.865 170.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.64 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.0 OUTLIER -120.59 101.67 7.91 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 108.497 -0.927 . . . . 75.33 108.497 176.269 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 37.2 mt -83.37 113.98 21.11 Favored 'General case' 0 C--N 1.352 0.686 0 N-CA-C 108.964 -0.754 . . . . 73.12 108.964 -173.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 -87.24 106.68 18.07 Favored 'General case' 0 C--O 1.239 0.507 0 C-N-CA 123.782 0.833 . . . . 75.32 110.839 -167.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.464 ' HB2' ' HB3' ' A' ' 249' ' ' LEU . 15.7 mt -94.06 104.28 16.32 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 108.112 -1.07 . . . . 75.15 108.112 174.091 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -74.65 141.47 44.61 Favored 'General case' 0 C--O 1.242 0.683 0 CA-C-N 115.763 -0.653 . . . . 73.13 112.025 -170.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 66.59 32.99 83.16 Favored Glycine 0 C--N 1.349 1.271 0 O-C-N 124.12 0.888 . . . . 71.22 113.253 178.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 41.1 mmtm -116.13 -2.68 12.15 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.663 0.785 . . . . 74.21 111.166 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . 0.445 ' O ' ' HD2' ' A' ' 246' ' ' ARG . . . -82.03 -156.16 17.28 Favored Glycine 0 C--N 1.347 1.177 0 O-C-N 123.657 0.598 . . . . 71.01 114.181 -178.164 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.421 ' CD2' ' HA2' ' A' ' 152' ' ' GLY . 35.0 m-85 -88.34 160.29 45.64 Favored Pre-proline 0 N--CA 1.482 1.159 0 C-N-CA 123.204 0.601 . . . . 64.34 110.56 176.176 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -57.09 152.5 44.15 Favored 'Trans proline' 0 C--N 1.382 2.313 0 C-N-CA 123.031 2.487 . . . . 73.43 113.971 178.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 176.94 -167.71 39.2 Favored Glycine 0 C--N 1.341 0.853 0 CA-C-N 115.27 -0.877 . . . . 74.34 112.11 176.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.27 -15.3 35.15 Favored 'Trans proline' 0 C--N 1.382 2.291 0 C-N-CA 122.983 2.456 . . . . 74.54 112.619 -176.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -96.77 24.12 6.39 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.175 0.99 . . . . 60.21 110.692 174.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 77.8 -89.62 1.06 Allowed Glycine 0 C--N 1.345 1.063 0 N-CA-C 110.943 -0.863 . . . . 70.42 110.943 -175.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.445 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 23.1 mtm180 -128.09 155.89 43.67 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 108.728 -0.841 . . . . 75.14 108.728 169.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -70.9 -160.78 3.72 Favored Glycine 0 C--N 1.348 1.231 0 O-C-N 123.727 0.642 . . . . 71.23 114.397 -176.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -129.21 138.33 51.64 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 122.888 0.475 . . . . 74.52 109.772 -173.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.546 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 30.6 tp -97.27 115.96 28.59 Favored 'General case' 0 C--O 1.214 -0.788 0 C-N-CA 123.624 0.77 . . . . 75.13 110.017 -178.308 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . 0.64 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 97.3 m-85 -101.65 106.95 18.06 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 123.497 0.719 . . . . 74.24 109.356 179.1 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.514 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 78.3 mt -87.08 118.72 26.65 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.372 -0.831 . . . . 73.52 113.115 -175.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.431 ' HB3' ' HA ' ' A' ' 196' ' ' THR . 10.5 tp10 -79.76 91.71 5.34 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 108.578 -0.897 . . . . 74.21 108.578 -178.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 59.7 t -52.5 118.38 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 123.99 0.916 . . . . 74.03 110.875 177.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 30.7 mmm180 -123.48 94.79 4.35 Favored 'General case' 0 C--O 1.24 0.569 0 C-N-CA 124.635 1.174 . . . . 74.11 107.95 176.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 63.4 mt -76.62 114.25 16.69 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 115.716 -0.674 . . . . 71.31 109.299 177.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 6.4 t . . . . . 0 C--O 1.248 1.014 0 C-N-CA 124.619 1.168 . . . . 75.42 108.944 -179.559 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.072 0 N-CA-C 109.406 -0.59 . . . . 62.44 109.406 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -63.1 -63.77 1.1 Allowed 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 123.622 0.769 . . . . 74.02 110.467 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.7 tp -128.46 149.03 50.75 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.599 -1.26 . . . . 74.41 107.599 160.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.568 ' HB ' ' HB3' ' A' ' 123' ' ' LEU 0.269 2.4 p 36.57 -95.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 C-N-CA 126.337 1.855 . . . . 75.52 113.713 176.956 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.418 ' H ' HG13 ' A' ' 99' ' ' VAL . . . 57.31 8.32 0.57 Allowed 'General case' 0 N--CA 1.493 1.683 0 C-N-CA 124.963 1.305 . . . . 62.25 113.14 -176.725 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 35.7 t-80 -103.81 71.91 1.08 Allowed 'General case' 0 C--O 1.243 0.756 0 N-CA-C 107.374 -1.343 . . . . 74.11 107.374 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 81.0 t -72.53 137.18 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 CA-C-N 114.375 -1.284 . . . . 72.42 109.702 -179.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 72.2 p -79.97 14.49 1.79 Allowed 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 124.504 1.122 . . . . 74.13 112.724 -173.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 28.6 m 65.2 12.61 8.15 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 124.879 1.272 . . . . 71.53 111.877 -174.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -113.74 150.63 18.53 Favored Glycine 0 C--N 1.349 1.294 0 CA-C-N 115.953 -0.567 . . . . 75.02 112.499 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 34.8 t -163.97 97.86 0.84 Allowed 'General case' 0 C--O 1.247 0.925 0 C-N-CA 124.286 1.034 . . . . 64.4 108.971 178.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -86.32 -162.85 37.45 Favored Glycine 0 C--N 1.344 0.995 0 CA-C-N 116.675 -0.238 . . . . 75.23 113.07 -175.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -113.61 93.58 0.67 Allowed Glycine 0 C--N 1.34 0.795 0 N-CA-C 110.983 -0.847 . . . . 62.22 110.983 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.626 ' HB2' ' HB3' ' A' ' 118' ' ' ASP . 38.2 t -57.53 112.7 1.51 Allowed 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.705 1.202 . . . . 73.2 111.419 177.472 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -136.48 -128.62 2.73 Favored Glycine 0 C--N 1.338 0.657 0 N-CA-C 110.695 -0.962 . . . . 73.51 110.695 178.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 68.08 -83.82 0.17 Allowed Glycine 0 C--N 1.354 1.54 0 C-N-CA 123.107 0.384 . . . . 74.24 112.491 175.095 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.5 t -144.02 99.33 3.37 Favored 'General case' 0 C--O 1.242 0.671 0 N-CA-C 108.525 -0.917 . . . . 75.23 108.525 172.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 88.93 141.53 8.14 Favored Glycine 0 CA--C 1.527 0.806 0 CA-C-N 115.744 -0.662 . . . . 73.51 112.234 178.081 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 121.64 -84.5 0.37 Allowed Glycine 0 C--O 1.238 0.378 0 N-CA-C 110.339 -1.105 . . . . 74.5 110.339 -176.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 76.0 p 44.74 61.98 2.25 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 125.296 1.438 . . . . 74.12 110.998 -173.172 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.99 -176.24 45.81 Favored Glycine 0 N--CA 1.461 0.3 0 CA-C-N 114.076 -1.42 . . . . 75.02 110.168 -178.523 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 5.4 ptm180 -75.46 120.39 20.83 Favored 'General case' 0 C--O 1.247 0.937 0 CA-C-N 117.851 0.826 . . . . 75.05 109.957 179.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.626 ' HB3' ' HB2' ' A' ' 109' ' ' SER . 4.3 p30 -81.26 135.35 35.72 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 106.811 -1.552 . . . . 71.14 106.811 162.296 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 1.3 tt -99.83 143.34 30.17 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 106.427 -1.694 . . . . 73.43 106.427 177.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 12.7 tpp85 -119.0 125.23 48.9 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 118.778 0.717 . . . . 73.54 110.591 -173.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -147.85 149.95 33.25 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.341 0.656 . . . . 71.34 109.794 178.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.663 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 41.8 mt-10 -127.83 149.4 50.29 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.52 0.728 . . . . 71.43 109.418 -179.074 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.568 ' HB3' ' HB ' ' A' ' 99' ' ' VAL . 1.5 pt? -143.93 147.1 36.93 Favored Pre-proline 0 N--CA 1.474 0.741 0 O-C-N 123.505 0.503 . . . . 70.4 111.323 -176.623 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -76.79 113.93 3.74 Favored 'Trans proline' 0 C--N 1.371 1.738 0 C-N-CA 121.426 1.418 . . . . 73.44 109.688 162.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.437 HD23 HG11 ' A' ' 178' ' ' VAL . 18.6 tp -108.28 158.8 17.15 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.758 0.823 . . . . 74.43 108.839 178.456 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.58 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 6.9 m -95.52 156.26 16.4 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 123.397 0.679 . . . . 73.44 109.191 175.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 82.0 mt -58.34 -49.33 77.58 Favored 'General case' 0 N--CA 1.488 1.436 0 CA-C-O 122.348 1.071 . . . . 74.23 109.455 174.302 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.404 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.9 mp0 -57.01 -38.16 72.7 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 113.276 -1.784 . . . . 74.14 111.475 177.155 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 31.5 mm-40 -80.02 -21.16 43.86 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.231 0.612 . . . . 74.01 112.469 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.502 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -61.63 -40.33 94.47 Favored 'General case' 0 C--O 1.256 1.417 0 CA-C-O 121.665 0.745 . . . . 44.34 110.696 167.321 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.489 ' HA ' ' CE1' ' A' ' 240' ' ' PHE . 69.0 t80 -70.31 -48.35 56.98 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 113.964 -1.471 . . . . 75.01 112.774 172.611 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -71.55 -47.32 55.78 Favored 'General case' 0 N--CA 1.485 1.277 0 N-CA-C 112.067 0.395 . . . . 74.14 112.067 -172.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.32 -115.89 8.19 Favored Glycine 0 CA--C 1.533 1.204 0 N-CA-C 111.121 -0.791 . . . . 72.01 111.121 -175.643 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.8 174.55 39.71 Favored Glycine 0 C--N 1.346 1.124 0 N-CA-C 115.175 0.83 . . . . 70.52 115.175 167.613 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -87.61 118.26 26.98 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.346 1.059 . . . . 65.25 108.221 178.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -130.44 138.88 50.53 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 124.368 1.067 . . . . 74.43 108.543 -176.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 7.2 p -83.12 139.93 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 N-CA-C 108.697 -0.853 . . . . 75.24 108.697 174.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.431 HG22 HG13 ' A' ' 99' ' ' VAL . 7.1 p -143.04 153.09 16.89 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 C-N-CA 124.011 0.924 . . . . 74.53 109.324 -178.275 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -116.38 100.27 7.77 Favored 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 107.782 -1.192 . . . . 73.2 107.782 170.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 9.0 t -103.65 111.54 33.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 N-CA-C 108.753 -0.832 . . . . 71.34 108.753 -172.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.93 26.0 15.33 Favored 'General case' 0 N--CA 1.479 1.017 0 O-C-N 124.493 1.121 . . . . 72.43 111.658 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 91.75 13.63 57.77 Favored Glycine 0 C--N 1.355 1.585 0 CA-C-N 115.807 -0.633 . . . . 74.4 113.315 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 25.8 ttt180 -116.7 116.23 27.13 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 122.986 0.514 . . . . 72.23 110.134 177.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -87.5 114.09 23.8 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 122.838 0.455 . . . . 75.51 110.196 -178.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.6 p -148.13 152.79 12.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 C-N-CA 124.835 1.254 . . . . 72.02 109.089 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 43.7 m -82.86 122.19 27.91 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 122.835 0.454 . . . . 75.13 110.258 175.15 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.407 HG22 HG22 ' A' ' 149' ' ' ILE . 13.7 p -98.59 123.99 51.48 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 C-N-CA 123.646 0.778 . . . . 75.03 109.594 175.366 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 30.9 ttt85 -108.05 98.25 7.84 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 107.849 -1.167 . . . . 74.41 107.849 174.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.407 HG22 HG22 ' A' ' 147' ' ' VAL . 35.3 pt -96.32 131.4 28.64 Favored Pre-proline 0 N--CA 1.479 0.984 0 N-CA-C 109.673 -0.492 . . . . 75.32 109.673 178.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -67.71 145.32 69.04 Favored 'Trans proline' 0 C--N 1.375 1.94 0 C-N-CA 122.852 2.368 . . . . 73.54 112.982 -174.154 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.468 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 32.1 Cg_exo -63.68 125.12 14.85 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 123.045 2.497 . . . . 74.33 110.596 171.186 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 131.44 41.25 0.21 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 111.827 -0.509 . . . . 71.31 111.827 -173.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.502 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -118.58 154.21 20.77 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 N-CA-C 108.775 -0.824 . . . . 74.32 108.775 -177.484 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 40.9 mtp180 -144.66 166.85 24.01 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 124.943 1.297 . . . . 73.22 109.055 -165.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -52.75 123.18 10.65 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 123.61 0.764 . . . . 71.21 111.943 176.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 80.62 -4.61 68.17 Favored Glycine 0 C--N 1.348 1.202 0 CA-C-N 115.896 -0.593 . . . . 64.13 113.629 179.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 32.4 t -68.82 127.52 33.38 Favored 'General case' 0 C--O 1.248 1.016 0 C-N-CA 123.665 0.786 . . . . 61.1 110.134 -176.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.429 HG11 HD22 ' A' ' 175' ' ' LEU . 8.7 t -97.89 119.46 45.94 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-N 114.303 -1.317 . . . . 63.4 108.627 -176.449 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.501 HD12 HG23 ' A' ' 153' ' ' VAL . 17.2 mt -102.94 117.07 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 123.664 0.786 . . . . 75.4 110.054 -170.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 22.3 ttm180 -84.02 117.39 23.37 Favored 'General case' 0 C--O 1.239 0.512 0 C-N-CA 123.53 0.732 . . . . 64.41 110.414 172.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.84 101.39 53.02 Favored Pre-proline 0 CA--C 1.559 1.29 0 N-CA-C 108.293 -1.003 . . . . 70.54 108.293 169.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -64.92 149.66 89.2 Favored 'Trans proline' 0 C--N 1.384 2.407 0 C-N-CA 123.55 2.833 . . . . 60.44 113.428 -172.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 71.3 24.2 77.22 Favored Glycine 0 C--N 1.348 1.216 0 O-C-N 123.594 0.559 . . . . 62.43 113.795 175.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 2.9 tpt -100.52 -51.86 3.5 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.149 0.98 . . . . 64.42 109.998 -177.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -82.84 -89.16 0.7 Allowed Glycine 0 C--N 1.351 1.391 0 CA-C-N 115.403 -0.817 . . . . 71.32 112.092 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -65.36 91.76 0.13 Allowed Glycine 0 C--N 1.354 1.538 0 C-N-CA 123.04 0.352 . . . . 41.12 113.15 179.472 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.1 mm-40 -70.26 146.1 50.87 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 123.289 0.636 . . . . 64.24 111.145 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 123.25 -168.07 15.47 Favored Glycine 0 N--CA 1.476 1.361 0 CA-C-O 119.733 -0.482 . . . . 74.13 112.874 176.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.414 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 93.0 m-20 -53.25 -47.62 95.36 Favored Pre-proline 0 CA--C 1.567 1.624 0 C-N-CA 124.062 0.945 . . . . 73.45 112.69 -178.3 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.414 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 2.0 Cg_endo -85.08 113.44 1.51 Allowed 'Trans proline' 0 C--N 1.388 2.614 0 C-N-CA 122.572 2.181 . . . . 72.42 110.355 168.409 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -80.35 123.7 5.05 Favored 'Trans proline' 0 C--N 1.371 1.725 0 C-N-CA 121.745 1.63 . . . . 64.15 112.507 -175.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -100.6 150.5 18.82 Favored Glycine 0 C--N 1.342 0.866 0 N-CA-C 108.988 -1.645 . . . . 61.31 108.988 174.193 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -113.09 -179.89 3.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 118.049 0.924 . . . . 74.23 111.498 -164.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 15.6 tp -121.98 128.63 51.69 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 107.82 -1.178 . . . . 72.11 107.82 167.3 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.429 HD22 HG11 ' A' ' 158' ' ' VAL . 76.6 mt -99.76 101.99 13.31 Favored 'General case' 0 C--O 1.243 0.746 0 C-N-CA 125.085 1.354 . . . . 75.4 110.28 178.342 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.404 HD12 HG21 ' A' ' 149' ' ' ILE . 86.4 mt -91.28 109.46 20.73 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 123.612 0.765 . . . . 74.53 111.114 175.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.663 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 21.5 t -90.2 105.22 16.0 Favored 'Isoleucine or valine' 0 C--O 1.247 0.938 0 N-CA-C 108.115 -1.068 . . . . 71.11 108.115 173.286 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.437 HG11 HD23 ' A' ' 125' ' ' LEU . 6.1 m -82.4 151.34 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 CA-C-O 121.223 0.535 . . . . 73.12 111.615 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 38.2 mmt180 -124.07 98.95 6.01 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 107.67 -1.233 . . . . 74.34 107.67 176.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 57.5 mt -67.46 144.64 55.61 Favored 'General case' 0 C--O 1.241 0.628 0 O-C-N 123.139 0.274 . . . . 72.04 110.685 -178.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.58 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 44.1 mt -59.83 147.03 80.11 Favored Pre-proline 0 CA--C 1.558 1.284 0 O-C-N 124.366 1.041 . . . . 74.11 110.967 -176.436 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -75.46 58.09 5.06 Favored 'Trans proline' 0 C--N 1.375 1.96 0 C-N-CA 123.991 3.127 . . . . 75.35 113.845 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -142.28 51.82 2.17 Favored Pre-proline 0 CA--C 1.562 1.434 0 C-N-CA 123.035 0.534 . . . . 54.04 109.831 171.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -64.21 123.56 12.05 Favored 'Trans proline' 0 C--N 1.388 2.632 0 C-N-CA 122.43 2.087 . . . . 74.21 111.905 -168.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -128.22 -37.49 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 123.81 0.844 . . . . 74.52 109.363 -177.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . 0.43 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 6.0 m-85 -107.39 124.37 49.74 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 114.814 -1.085 . . . . 73.33 110.338 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.644 ' HB3' ' HB2' ' A' ' 194' ' ' TYR . 19.6 tpp180 -105.02 139.08 40.24 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 106.934 -1.506 . . . . 65.13 106.934 172.073 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 51.1 tp -123.41 122.62 38.74 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 122.897 0.479 . . . . 63.43 109.86 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -144.9 127.86 16.47 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 122.39 0.276 . . . . 74.13 110.322 169.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 63.94 33.83 88.28 Favored Glycine 0 C--N 1.356 1.648 0 O-C-N 123.91 0.756 . . . . 75.25 114.246 177.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 73.96 -5.24 2.08 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 125.714 1.606 . . . . 75.22 112.659 -175.567 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -93.33 149.98 20.82 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.479 0.711 . . . . 73.01 109.579 178.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.644 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 93.1 mt -108.92 163.57 13.17 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 124.281 1.033 . . . . 70.21 109.94 -176.409 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . 0.644 ' HB2' ' HB3' ' A' ' 187' ' ' ARG . 85.1 m-85 -143.38 121.52 12.18 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 106.803 -1.554 . . . . 74.51 106.803 178.01 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -147.25 164.32 33.58 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.444 0.697 . . . . 75.54 109.921 -176.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 17.5 m -106.2 125.45 51.01 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.51 -0.768 . . . . 63.12 109.17 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.525 ' HB2' HD21 ' A' ' 251' ' ' LEU . 65.5 tp -112.44 115.65 29.03 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.541 0.736 . . . . 74.43 109.631 177.419 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -78.7 131.03 36.46 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 108.138 -1.06 . . . . 65.44 108.138 169.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' A' ' 255' ' ' ILE . 90.9 t -129.78 121.15 19.86 Favored Pre-proline 0 N--CA 1.474 0.728 0 N-CA-C 107.682 -1.229 . . . . 75.2 107.682 178.626 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -65.83 147.66 85.57 Favored 'Trans proline' 0 C--N 1.369 1.657 0 C-N-CA 122.143 1.895 . . . . 74.13 110.888 176.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . 0.441 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -53.5 -42.5 92.24 Favored Pre-proline 0 N--CA 1.48 1.065 0 C-N-CA 124.483 1.113 . . . . 65.11 113.569 -177.323 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . 0.441 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 10.8 Cg_endo -52.42 -51.29 11.46 Favored 'Trans proline' 0 C--N 1.397 3.107 0 C-N-CA 122.144 1.896 . . . . 74.34 112.64 172.219 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 7.0 mt -66.49 -37.11 78.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 123.211 0.604 . . . . 72.21 111.641 -179.065 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.3 -42.97 99.11 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 122.926 0.49 . . . . 74.53 111.929 -178.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.2 m -82.62 -35.59 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.87 0 CA-C-N 115.931 -0.577 . . . . 75.32 111.987 -175.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 12.4 m -87.23 -18.92 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 CA-C-N 118.043 0.383 . . . . 74.22 111.658 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.41 ' HA2' HG21 ' A' ' 223' ' ' VAL . . . 77.87 55.04 4.28 Favored Glycine 0 C--N 1.344 1.022 0 CA-C-N 115.857 -0.61 . . . . 75.24 113.218 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -84.87 -169.66 46.17 Favored Glycine 0 C--N 1.349 1.252 0 CA-C-O 121.783 0.657 . . . . 71.11 112.585 -177.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . 0.431 ' HD2' ' N ' ' A' ' 209' ' ' LYS . 0.0 OUTLIER -115.61 120.18 38.58 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 107.771 -1.196 . . . . 74.15 107.771 -173.667 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . 0.437 HG11 HG23 ' A' ' 199' ' ' VAL . 7.3 p -124.42 144.07 35.57 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 124.37 1.068 . . . . 75.22 109.343 -178.304 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.22 138.06 34.74 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.297 -0.631 . . . . 72.13 109.297 176.134 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -107.69 131.56 54.28 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 108.446 -0.946 . . . . 63.5 108.446 169.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.49 104.55 9.16 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.988 -1.116 . . . . 74.32 107.988 179.375 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 214' ' ' THR . . . . . 0.43 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 14.8 t -112.41 168.15 9.87 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.161 0.584 . . . . 72.24 110.543 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . 0.404 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 65.2 mt -70.03 -7.3 39.93 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 123.562 0.745 . . . . 71.23 111.788 -179.094 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -97.28 -18.07 19.42 Favored 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.679 1.192 . . . . 70.32 111.382 175.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 133.06 -147.83 19.11 Favored Glycine 0 N--CA 1.475 1.284 0 CA-C-O 119.188 -0.784 . . . . 70.23 111.82 -178.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -85.84 126.73 2.98 Favored 'Trans proline' 0 CA--C 1.559 1.757 0 C-N-CA 122.878 2.386 . . . . 73.34 112.021 172.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 26.1 m -109.68 156.1 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 122.918 0.487 . . . . 63.35 110.944 172.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 24.9 mm-40 -95.09 109.89 21.89 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 123.572 0.749 . . . . 72.12 109.827 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.473 HG22 HD11 ' A' ' 235' ' ' LEU . 8.7 t -104.25 117.52 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.663 0.785 . . . . 73.24 109.057 172.525 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -98.62 102.42 14.15 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 108.279 -1.008 . . . . 71.34 108.279 174.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.41 HG21 ' HA2' ' A' ' 207' ' ' GLY . 11.9 m -75.97 143.52 74.35 Favored Pre-proline 0 CA--C 1.551 1.011 0 N-CA-C 109.638 -0.504 . . . . 75.33 109.638 -176.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -64.46 140.68 70.62 Favored 'Trans proline' 0 C--N 1.368 1.587 0 C-N-CA 122.777 2.318 . . . . 70.04 112.34 174.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.9 129.38 34.63 Favored 'Trans proline' 0 C--N 1.376 1.992 0 C-N-CA 122.713 2.275 . . . . 53.31 111.337 171.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 64.3 mtm180 65.85 34.89 6.98 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 125.116 1.367 . . . . 74.43 110.988 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 5.7 t -66.64 164.55 16.6 Favored 'General case' 0 CA--C 1.549 0.919 0 N-CA-C 109.938 -0.393 . . . . 74.12 109.938 176.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -120.46 150.95 40.0 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.731 0.813 . . . . 75.52 109.697 -176.019 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -68.28 141.92 55.72 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.13 0.972 . . . . 60.23 110.727 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 91.11 -3.83 80.64 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-O 119.467 -0.629 . . . . 72.41 112.542 -176.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 41.1 mtp180 -72.01 161.3 31.12 Favored 'General case' 0 C--N 1.362 1.125 0 CA-C-O 122.16 0.981 . . . . 74.22 110.64 177.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -107.62 107.73 18.67 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 113.892 -1.503 . . . . 71.13 108.043 -173.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . 0.447 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 45.9 mt -100.38 98.31 8.96 Favored 'General case' 0 C--N 1.349 0.576 0 N-CA-C 107.328 -1.36 . . . . 73.03 107.328 175.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . 0.492 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 20.0 ttm180 -100.92 115.86 31.43 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.154 0.502 . . . . 74.12 110.698 -171.457 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.473 HD11 HG22 ' A' ' 221' ' ' VAL . 23.4 mt -96.06 117.75 31.3 Favored 'General case' 0 C--O 1.241 0.631 0 C-N-CA 124.159 0.983 . . . . 74.05 109.508 -176.02 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 49.8 mtmt -72.46 133.66 44.95 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.597 0.759 . . . . 74.31 111.151 -175.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 70.69 33.81 66.82 Favored Glycine 0 C--N 1.345 1.03 0 O-C-N 124.214 0.946 . . . . 64.14 112.954 176.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 72.7 mmtt -123.17 5.49 9.19 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.246 0.618 . . . . 72.13 111.958 178.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -85.51 -147.94 10.18 Favored Glycine 0 C--N 1.35 1.328 0 O-C-N 123.532 0.52 . . . . 72.03 112.952 177.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.489 ' CE1' ' HA ' ' A' ' 131' ' ' PHE . 16.2 m-85 -95.95 145.18 29.1 Favored Pre-proline 0 N--CA 1.478 0.931 0 C-N-CA 123.05 0.54 . . . . 75.14 111.589 173.435 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.72 156.53 39.82 Favored 'Trans proline' 0 C--N 1.375 1.968 0 C-N-CA 123.308 2.672 . . . . 72.34 112.468 173.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 173.92 -163.17 34.09 Favored Glycine 0 CA--C 1.535 1.335 0 CA-C-N 115.317 -0.856 . . . . 74.24 111.921 177.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.43 -16.49 43.31 Favored 'Trans proline' 0 C--N 1.379 2.179 0 C-N-CA 123.274 2.649 . . . . 62.33 112.912 -175.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -97.1 22.62 8.27 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.794 0.837 . . . . 63.05 111.222 177.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 79.93 -138.31 19.88 Favored Glycine 0 C--N 1.352 1.441 0 N-CA-C 110.699 -0.961 . . . . 51.31 110.699 -174.222 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 56.4 ttt180 -110.53 142.19 42.65 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 117.509 0.654 . . . . 72.03 109.648 171.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -77.76 -158.24 10.24 Favored Glycine 0 C--N 1.342 0.903 0 O-C-N 123.684 0.615 . . . . 64.12 112.945 177.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -128.52 170.58 13.02 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.803 0.841 . . . . 73.2 109.746 -172.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.644 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 15.7 tp -111.79 113.66 26.15 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.784 0.834 . . . . 73.31 109.806 171.424 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . 0.474 ' HB3' ' O ' ' A' ' 193' ' ' LEU . 2.9 t80 -88.42 108.06 19.18 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 107.567 -1.272 . . . . 74.14 107.567 174.202 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.525 HD21 ' HB2' ' A' ' 197' ' ' LEU . 52.3 mt -91.16 145.42 24.69 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 123.522 0.729 . . . . 73.34 110.744 170.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -107.63 101.95 11.23 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 107.161 -1.422 . . . . 75.24 107.161 167.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.3 p -62.38 128.25 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 CA-C-O 121.326 0.584 . . . . 72.34 110.115 177.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 9.9 mmm180 -125.72 94.33 4.09 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 107.195 -1.409 . . . . 75.42 107.195 -177.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.442 ' HA ' ' O ' ' A' ' 199' ' ' VAL . 67.2 mt -76.55 139.89 18.09 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 CA-C-N 115.364 -0.835 . . . . 73.12 110.379 -173.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.5 t . . . . . 0 CA--C 1.554 1.108 0 C-N-CA 123.781 0.832 . . . . 74.53 109.244 -175.429 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.173 0 N-CA-C 110.349 -0.241 . . . . 72.23 110.349 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -99.81 -68.19 0.82 Allowed 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 122.736 0.415 . . . . 73.22 110.809 179.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.6 tp -120.52 62.78 0.85 Allowed 'General case' 0 N--CA 1.48 1.025 0 CA-C-O 121.523 0.678 . . . . 74.23 110.237 -173.181 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 12.9 p 176.86 146.32 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-N 114.218 -1.356 . . . . 73.34 109.282 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -88.08 -78.53 0.32 Allowed 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 108.37 -0.974 . . . . 71.42 108.37 167.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 10.3 m170 -159.32 165.42 33.42 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 124.163 0.985 . . . . 64.3 109.92 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 84.2 t -64.02 136.35 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 O-C-N 124.052 0.845 . . . . 73.24 109.637 174.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 32.6 p -67.69 86.84 0.21 Allowed 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 123.716 0.806 . . . . 75.43 109.363 173.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.1 m -68.25 140.02 56.01 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.879 -1.055 . . . . 74.41 111.733 -171.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 134.07 155.81 7.7 Favored Glycine 0 C--N 1.345 1.061 0 O-C-N 123.736 0.647 . . . . 63.31 111.809 176.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 19.0 t -74.35 97.28 3.0 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.171 -0.677 . . . . 74.42 109.171 176.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 157.26 -172.15 34.68 Favored Glycine 0 C--N 1.342 0.884 0 CA-C-N 115.417 -0.811 . . . . 64.42 111.476 -176.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.14 143.3 5.9 Favored Glycine 0 C--N 1.342 0.898 0 CA-C-O 120.125 -0.264 . . . . 74.21 112.543 179.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 41.5 m -78.55 80.51 4.93 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 123.428 0.691 . . . . 72.3 109.842 177.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -177.88 150.59 10.03 Favored Glycine 0 C--N 1.343 0.946 0 CA-C-N 115.558 -0.746 . . . . 61.42 111.497 178.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 88.47 122.57 1.94 Allowed Glycine 0 C--N 1.343 0.949 0 O-C-N 123.64 0.259 . . . . 60.01 113.303 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 62.4 m -149.97 115.51 5.52 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 123.323 0.649 . . . . 75.2 109.944 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 63.88 -124.9 31.64 Favored Glycine 0 C--N 1.353 1.486 0 O-C-N 123.913 0.758 . . . . 75.41 113.327 175.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -75.95 75.5 1.5 Allowed Glycine 0 C--N 1.346 1.122 0 N-CA-C 111.939 -0.465 . . . . 72.4 111.939 177.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 56.3 m -146.44 138.05 24.64 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.19 0.996 . . . . 64.02 109.261 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -75.75 157.72 49.29 Favored Glycine 0 C--N 1.351 1.361 0 CA-C-O 119.436 -0.647 . . . . 70.43 111.727 175.272 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 72.8 mtp180 -61.95 114.51 3.42 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 122.694 0.398 . . . . 74.44 111.118 -177.066 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -91.14 150.3 21.44 Favored 'General case' 0 C--O 1.241 0.65 0 N-CA-C 108.878 -0.786 . . . . 73.23 108.878 175.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 30.3 mt -96.4 156.22 16.43 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 123.469 0.708 . . . . 74.11 109.19 -178.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.2 146.28 44.68 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.519 -1.289 . . . . 74.15 107.519 174.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -158.36 136.82 10.98 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 123.528 0.731 . . . . 71.32 109.787 -178.042 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -100.97 142.62 32.19 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.485 0.714 . . . . 72.34 109.718 -178.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -146.45 143.09 18.25 Favored Pre-proline 0 CA--C 1.552 1.049 0 C-N-CA 123.077 0.551 . . . . 71.23 110.565 174.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_exo -77.4 118.26 4.57 Favored 'Trans proline' 0 C--N 1.376 2.004 0 C-N-CA 122.97 2.447 . . . . 72.35 111.327 172.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.424 ' HG ' ' HB2' ' A' ' 129' ' ' GLU . 14.8 tp -108.62 155.59 20.51 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 123.75 0.82 . . . . 74.34 109.678 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.597 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 20.7 m -93.56 157.48 16.17 Favored 'General case' 0 CA--C 1.55 0.945 0 N-CA-C 109.363 -0.606 . . . . 74.11 109.363 174.235 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.477 HD12 ' O ' ' A' ' 183' ' ' HIS . 32.6 mt -58.22 -48.18 81.16 Favored 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 123.944 0.898 . . . . 74.25 110.382 178.786 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -54.25 -36.49 63.62 Favored 'General case' 0 C--O 1.218 -0.584 0 CA-C-N 113.796 -1.547 . . . . 73.44 110.736 176.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.597 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 7.5 mm-40 -79.6 -23.04 42.95 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.48 0.712 . . . . 74.14 111.411 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.738 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -63.0 -36.32 83.16 Favored 'General case' 0 C--O 1.244 0.793 0 CA-C-O 121.42 0.628 . . . . 74.41 110.304 167.334 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -81.31 -33.54 32.51 Favored 'General case' 0 CA--C 1.554 1.097 0 CA-C-N 114.709 -1.132 . . . . 75.22 111.972 176.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . 0.465 ' HB2' ' HA ' ' A' ' 129' ' ' GLU . 24.6 m80 -84.13 -40.96 17.58 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 112.631 0.604 . . . . 63.53 112.631 -173.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 72.16 -129.55 15.23 Favored Glycine 0 CA--C 1.536 1.389 0 N-CA-C 110.834 -0.907 . . . . 74.11 110.834 -166.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 134.97 140.2 4.19 Favored Glycine 0 N--CA 1.477 1.401 0 CA-C-N 117.805 0.802 . . . . 64.21 114.145 169.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -86.54 113.6 22.59 Favored 'General case' 0 C--N 1.357 0.91 0 N-CA-C 108.486 -0.931 . . . . 75.14 108.486 167.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -141.81 170.11 16.32 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.901 1.281 . . . . 73.12 108.314 175.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.507 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 14.7 p -95.18 143.3 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 118.639 0.654 . . . . 75.3 111.276 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 12.2 p -114.94 138.24 45.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 C-N-CA 123.833 0.853 . . . . 70.45 109.553 172.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -125.51 105.12 8.81 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 108.678 -0.86 . . . . 63.24 108.678 173.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.2 m -129.59 133.72 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 124.187 0.995 . . . . 74.02 110.042 -177.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.96 22.82 13.67 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 124.534 1.134 . . . . 73.44 111.313 -176.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.64 -6.7 79.6 Favored Glycine 0 C--N 1.354 1.538 0 CA-C-N 115.734 -0.666 . . . . 74.51 113.124 -176.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 53.4 ttt85 -94.81 119.67 33.77 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 123.632 0.773 . . . . 74.23 110.396 -175.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 20.6 ttp180 -105.07 109.63 21.69 Favored 'General case' 0 CA--C 1.552 1.024 0 C-N-CA 123.998 0.919 . . . . 74.44 110.797 -174.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 13.7 m -133.24 155.54 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 C-N-CA 124.708 1.203 . . . . 65.2 108.795 174.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.507 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 60.1 p -76.8 126.8 31.59 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 118.235 0.471 . . . . 55.41 110.684 -179.567 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.94 120.35 48.14 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.741 0 CA-C-O 121.827 0.822 . . . . 73.1 110.48 176.164 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 49.8 ttt180 -109.13 95.13 5.43 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 108.74 -0.837 . . . . 73.21 108.74 176.313 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 28.4 pt -93.66 119.78 66.8 Favored Pre-proline 0 CA--C 1.547 0.852 0 N-CA-C 107.913 -1.143 . . . . 73.34 107.913 171.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -76.64 163.17 32.08 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.352 2.035 . . . . 74.11 112.507 -177.403 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -54.76 142.68 73.17 Favored 'Trans proline' 0 C--N 1.375 1.963 0 C-N-CA 123.005 2.47 . . . . 72.34 112.372 171.188 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 108.66 38.31 1.92 Allowed Glycine 0 C--N 1.339 0.721 0 CA-C-N 116.773 -0.194 . . . . 72.33 113.037 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.738 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -108.66 163.07 6.23 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.359 0 N-CA-C 108.7 -0.852 . . . . 75.44 108.7 177.005 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.51 ' HB2' ' HB2' ' A' ' 157' ' ' SER . 25.1 mtp-105 -141.8 164.28 30.63 Favored 'General case' 0 N--CA 1.492 1.635 0 C-N-CA 123.963 0.905 . . . . 73.13 111.071 -165.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.1 tp10 -54.53 116.72 2.82 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.444 1.098 . . . . 71.1 111.226 165.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.27 4.68 90.11 Favored Glycine 0 C--N 1.357 1.706 0 CA-C-N 116.04 -0.527 . . . . 70.34 113.166 178.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.51 ' HB2' ' HB2' ' A' ' 154' ' ' ARG . 30.1 t -79.21 124.2 28.13 Favored 'General case' 0 C--O 1.25 1.11 0 N-CA-C 109.026 -0.731 . . . . 74.13 109.026 -179.686 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.42 HG11 HD23 ' A' ' 175' ' ' LEU . 20.0 t -99.05 120.68 48.71 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 CA-C-N 114.298 -1.319 . . . . 72.4 107.886 -177.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.48 HD11 HG23 ' A' ' 153' ' ' VAL . 13.0 mt -101.86 122.01 53.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 123.533 0.733 . . . . 72.2 110.15 -168.697 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 74.2 ttt180 -86.31 103.25 14.72 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 123.317 0.647 . . . . 74.34 109.908 177.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.441 HG22 ' O ' ' A' ' 174' ' ' LEU . 16.4 m -107.59 104.92 54.65 Favored Pre-proline 0 CA--C 1.564 1.5 0 C-N-CA 122.608 0.363 . . . . 74.11 110.027 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -67.41 140.69 53.47 Favored 'Trans proline' 0 C--N 1.375 1.954 0 C-N-CA 122.82 2.346 . . . . 74.45 113.332 -173.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 105.04 -9.97 47.32 Favored Glycine 0 C--N 1.349 1.282 0 N-CA-C 114.868 0.707 . . . . 61.44 114.868 170.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.4 mpt? -81.9 -61.35 1.94 Allowed 'General case' 0 N--CA 1.482 1.135 0 CA-C-N 117.815 0.807 . . . . 74.41 110.157 176.096 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -87.8 171.41 41.16 Favored Glycine 0 C--N 1.345 1.073 0 CA-C-N 115.345 -0.843 . . . . 74.35 111.785 176.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 60.72 51.52 58.14 Favored Glycine 0 C--N 1.343 0.965 0 O-C-N 124.238 0.611 . . . . 73.34 112.611 176.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.6 mm-40 -76.56 104.88 7.3 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 120.982 0.42 . . . . 72.33 110.434 -176.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -176.93 -146.2 6.02 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.572 -1.011 . . . . 71.31 110.572 -178.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -73.06 -46.28 8.25 Favored Pre-proline 0 CA--C 1.56 1.35 0 CA-C-O 118.7 -0.667 . . . . 63.02 111.033 176.188 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -94.58 107.42 0.14 Allowed 'Trans proline' 0 C--N 1.393 2.871 0 C-N-CA 122.284 1.989 . . . . 61.14 111.573 167.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -65.34 127.84 19.07 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 122.585 2.19 . . . . 70.41 111.683 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -80.97 -132.26 1.2 Allowed Glycine 0 C--N 1.34 0.764 0 N-CA-C 111.498 -0.641 . . . . 74.03 111.498 175.177 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -163.81 177.79 8.35 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.205 0.526 . . . . 71.42 110.885 -175.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.441 ' O ' HG22 ' A' ' 161' ' ' VAL . 15.0 tp -129.32 122.57 29.83 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 108.571 -0.9 . . . . 75.21 108.571 173.527 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.42 HD23 HG11 ' A' ' 158' ' ' VAL . 49.8 mt -88.11 99.41 12.17 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.139 -0.937 . . . . 73.32 110.927 179.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 74.9 mt -87.44 105.34 17.22 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 123.011 0.524 . . . . 74.33 110.748 175.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.8 t -85.49 104.45 13.37 Favored 'Isoleucine or valine' 0 C--O 1.242 0.697 0 N-CA-C 108.23 -1.026 . . . . 73.12 108.23 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.447 HG21 HG22 ' A' ' 153' ' ' VAL . 25.3 m -83.95 144.79 9.25 Favored 'Isoleucine or valine' 0 C--O 1.251 1.136 0 CA-C-O 121.481 0.657 . . . . 74.11 110.367 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 13.5 mmm180 -118.53 99.3 6.72 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 107.068 -1.456 . . . . 74.42 107.068 -178.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.418 HD21 ' HB3' ' A' ' 125' ' ' LEU . 29.5 mt -67.56 146.1 54.24 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 118.314 0.507 . . . . 73.41 110.303 177.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.454 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 73.1 mt -55.27 154.51 11.06 Favored Pre-proline 0 CA--C 1.553 1.063 0 O-C-N 124.489 1.118 . . . . 74.04 112.839 -170.337 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -66.81 0.38 3.72 Favored 'Trans proline' 0 C--N 1.381 2.287 0 C-N-CA 123.081 2.52 . . . . 74.41 112.808 171.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . 0.477 ' O ' HD12 ' A' ' 127' ' ' LEU . 14.7 t60 -95.55 99.21 4.41 Favored Pre-proline 0 CA--C 1.541 0.611 0 C-N-CA 124.974 1.31 . . . . 72.43 107.582 162.721 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -103.64 123.67 0.07 OUTLIER 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 123.135 2.557 . . . . 72.04 112.413 168.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -120.68 -43.58 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 107.74 -1.207 . . . . 72.44 107.74 171.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -113.64 126.31 55.12 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 114.674 -1.148 . . . . 73.43 110.144 176.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 36.5 ttp85 -119.41 127.04 52.74 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 108.51 -0.922 . . . . 71.44 108.51 172.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.414 HD11 ' O ' ' A' ' 192' ' ' ASP . 56.0 tp -90.18 132.53 35.42 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 108.359 -0.978 . . . . 75.22 108.359 170.461 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -144.48 130.1 19.07 Favored 'General case' 0 C--O 1.241 0.642 0 N-CA-C 109.621 -0.511 . . . . 74.12 109.621 173.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 70.95 -75.78 0.59 Allowed Glycine 0 C--N 1.35 1.346 0 O-C-N 124.003 0.814 . . . . 63.52 111.871 -175.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . 0.493 ' HB2' ' O ' ' A' ' 240' ' ' PHE . 3.7 pt20 -157.6 -10.49 0.08 Allowed 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 124.118 0.967 . . . . 61.41 110.846 174.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . 0.414 ' O ' HD11 ' A' ' 188' ' ' LEU . 80.3 m-20 -96.31 162.96 13.28 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 123.014 0.526 . . . . 62.12 110.942 -175.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.481 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.2 mt -106.9 155.91 19.25 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 107.704 -1.221 . . . . 73.15 107.704 -178.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -137.15 121.8 18.53 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 108.642 -0.873 . . . . 70.24 108.642 -175.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . 0.471 ' HB2' HD22 ' A' ' 251' ' ' LEU . . . -142.63 162.12 36.29 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.697 0.799 . . . . 72.12 110.221 -178.603 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 196' ' ' THR . . . . . 0.504 ' HA ' ' HB3' ' A' ' 252' ' ' GLU . 36.0 m -109.08 119.37 39.34 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 109.018 -0.734 . . . . 71.23 109.018 174.794 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.502 HD22 HD13 ' A' ' 251' ' ' LEU . 55.1 tp -106.84 110.13 22.21 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 109.17 -0.678 . . . . 71.32 109.17 178.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -89.83 127.56 36.0 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 107.804 -1.184 . . . . 70.2 107.804 172.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . 0.499 HG13 HG13 ' A' ' 210' ' ' VAL . 15.4 m -119.99 139.83 28.87 Favored Pre-proline 0 C--O 1.244 0.78 0 N-CA-C 109.097 -0.705 . . . . 71.03 109.097 -178.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -60.05 143.99 99.51 Favored 'Trans proline' 0 C--N 1.367 1.522 0 C-N-CA 122.073 1.849 . . . . 75.14 111.085 174.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -53.44 -45.69 98.41 Favored Pre-proline 0 CA--C 1.555 1.165 0 CA-C-O 118.359 -0.829 . . . . 75.13 113.046 177.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -55.62 -42.33 68.8 Favored 'Trans proline' 0 C--N 1.39 2.755 0 C-N-CA 122.106 1.871 . . . . 74.34 113.261 172.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 4.0 mt -65.84 -43.6 93.12 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 C-N-CA 122.63 0.372 . . . . 74.43 111.256 176.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -58.56 -44.72 89.79 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 123.057 0.543 . . . . 74.11 111.451 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . 0.473 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 33.4 m -77.39 -40.28 28.83 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 CA-C-N 115.745 -0.661 . . . . 74.55 112.081 -175.542 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.0 m -81.13 -20.72 11.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 119.1 0.863 . . . . 63.24 111.188 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.585 ' HA2' HG22 ' A' ' 223' ' ' VAL . . . 80.09 48.45 6.48 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-N 115.985 -0.552 . . . . 73.32 112.179 -175.837 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.27 -174.0 49.41 Favored Glycine 0 C--N 1.351 1.375 0 CA-C-O 121.37 0.428 . . . . 61.23 112.945 -177.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 222' ' ' ALA . 20.5 pttm -114.17 134.71 54.72 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.385 1.074 . . . . 74.31 109.797 -176.106 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . 0.499 HG13 HG13 ' A' ' 199' ' ' VAL . 7.6 p -133.71 157.23 42.13 Favored 'Isoleucine or valine' 0 C--O 1.241 0.608 0 C-N-CA 124.552 1.141 . . . . 75.24 108.494 -175.317 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 59.2 mmt-85 -91.55 128.93 37.57 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 109.489 -0.56 . . . . 73.43 109.489 178.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -102.72 122.09 43.76 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 108.643 -0.873 . . . . 75.35 108.643 171.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 5.6 tpt -74.04 104.66 4.95 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.732 0.813 . . . . 74.3 109.574 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 10.1 t -110.82 170.76 7.88 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 123.452 0.701 . . . . 65.31 110.623 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 62.4 mt -73.89 -2.2 22.83 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.022 0.929 . . . . 73.14 112.481 -175.233 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -114.82 -0.22 13.57 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 123.743 0.817 . . . . 73.24 112.17 174.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 133.25 -154.15 21.08 Favored Glycine 0 N--CA 1.48 1.597 0 CA-C-O 119.269 -0.74 . . . . 73.22 112.818 177.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -89.9 134.12 2.18 Favored 'Trans proline' 0 CA--C 1.554 1.49 0 C-N-CA 122.92 2.413 . . . . 74.11 112.259 172.083 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.1 m -113.79 158.15 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 CA-C-O 121.014 0.435 . . . . 73.11 111.74 175.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -96.75 104.54 16.54 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 114.966 -1.015 . . . . 74.12 108.429 -177.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.409 ' HB ' HD12 ' A' ' 235' ' ' LEU . 2.8 p -118.84 113.51 41.84 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 CA-C-O 121.437 0.637 . . . . 74.44 109.928 177.461 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 209' ' ' LYS . . . -97.28 118.69 34.3 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 108.759 -0.83 . . . . 75.34 108.759 178.061 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.585 HG22 ' HA2' ' A' ' 207' ' ' GLY . 18.2 m -72.96 148.04 88.96 Favored Pre-proline 0 CA--C 1.555 1.152 0 N-CA-C 109.523 -0.547 . . . . 75.14 109.523 176.029 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.0 151.98 73.31 Favored 'Trans proline' 0 CA--C 1.559 1.753 0 C-N-CA 122.173 1.915 . . . . 74.01 112.019 173.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -52.07 119.68 6.09 Favored 'Trans proline' 0 C--N 1.383 2.365 0 C-N-CA 123.646 2.898 . . . . 75.51 112.801 177.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . 0.473 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 48.6 mtm180 54.34 58.11 5.25 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 124.488 1.115 . . . . 72.55 110.668 -174.612 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 10.7 t -66.22 169.29 7.33 Favored 'General case' 0 CA--C 1.545 0.761 0 CA-C-N 115.539 -0.755 . . . . 63.13 109.506 173.079 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.8 mp0 -121.33 144.13 48.81 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 123.035 0.534 . . . . 74.11 109.83 -175.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -67.2 119.67 12.48 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-N 115.212 -0.904 . . . . 63.02 108.822 173.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.33 -12.06 19.26 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-O 119.65 -0.528 . . . . 71.45 112.315 -174.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 58.2 mtp180 -74.14 160.9 30.58 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 117.2 0.5 . . . . 74.14 110.604 174.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.411 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.3 mppt? -128.55 120.57 26.97 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.77 0.428 . . . . 74.11 110.676 -175.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . 0.452 HD12 HG13 ' A' ' 223' ' ' VAL . 59.6 mt -97.59 112.88 24.56 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 108.697 -0.853 . . . . 73.54 108.697 -178.248 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . 0.523 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 39.5 ttt85 -98.6 104.61 16.67 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 116.014 -0.539 . . . . 73.53 110.015 -172.211 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.469 HD11 HD23 ' A' ' 249' ' ' LEU . 27.3 mt -91.63 107.2 19.04 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.671 0.788 . . . . 74.14 109.156 -177.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 6.8 mtpm? -77.25 144.1 38.45 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 112.273 0.471 . . . . 71.51 112.273 -173.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 85.38 35.92 11.45 Favored Glycine 0 C--N 1.349 1.266 0 O-C-N 123.769 0.668 . . . . 74.22 112.323 -177.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 34.9 mmtm -125.61 -41.16 2.02 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 122.86 0.464 . . . . 74.22 112.184 -176.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -83.85 -178.04 51.69 Favored Glycine 0 C--N 1.337 0.62 0 C-N-CA 121.609 -0.329 . . . . 73.21 112.28 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.493 ' O ' ' HB2' ' A' ' 191' ' ' GLN . 72.5 m-85 -94.93 157.91 35.88 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 123.307 0.643 . . . . 75.11 111.77 -174.122 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -52.42 150.48 20.5 Favored 'Trans proline' 0 C--N 1.381 2.283 0 C-N-CA 123.254 2.636 . . . . 75.31 114.002 175.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 179.01 -159.54 24.5 Favored Glycine 0 CA--C 1.535 1.293 0 CA-C-O 119.516 -0.602 . . . . 71.5 113.099 -176.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -62.92 -34.34 71.85 Favored 'Trans proline' 0 C--N 1.375 1.925 0 C-N-CA 123.925 3.083 . . . . 72.52 114.217 -171.163 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.89 22.81 4.0 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.342 0.657 . . . . 73.01 111.289 178.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.97 -96.56 2.14 Favored Glycine 0 C--N 1.347 1.191 0 N-CA-C 111.192 -0.763 . . . . 63.43 111.192 179.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 42.1 ttt-85 -115.65 144.69 43.55 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 123.558 0.743 . . . . 75.43 109.09 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -80.26 168.99 52.37 Favored Glycine 0 C--O 1.253 1.297 0 O-C-N 123.604 0.565 . . . . 62.44 112.899 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 55.4 m-20 -139.57 171.97 13.48 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.342 1.057 . . . . 74.53 108.915 -173.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.523 ' O ' ' HA ' ' A' ' 234' ' ' ARG . 15.5 tp -98.44 128.92 45.02 Favored 'General case' 0 C--O 1.21 -0.974 0 C-N-CA 123.101 0.56 . . . . 73.3 109.761 177.129 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 53.8 t80 -111.47 102.62 10.97 Favored 'General case' 0 CA--C 1.551 1.01 0 N-CA-C 107.49 -1.3 . . . . 71.22 107.49 -178.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.502 HD13 HD22 ' A' ' 197' ' ' LEU . 90.3 mt -87.54 150.61 23.61 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.996 0.919 . . . . 74.44 112.688 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.504 ' HB3' ' HA ' ' A' ' 196' ' ' THR . 14.0 tp10 -105.62 98.09 7.83 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 123.494 0.717 . . . . 74.41 109.314 173.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 80.3 t -56.98 112.5 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 123.205 0.602 . . . . 61.33 111.019 174.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 49.3 mmm-85 -119.07 96.06 5.07 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 125.033 1.333 . . . . 75.15 108.069 177.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 58.8 mt -75.5 128.18 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 N-CA-C 109.561 -0.533 . . . . 75.43 109.561 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.249 1.028 0 C-N-CA 124.574 1.15 . . . . 75.34 107.911 -176.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 110.653 -0.128 . . . . 73.41 110.653 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -156.19 -53.53 0.08 Allowed 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 122.936 0.495 . . . . 74.51 110.67 179.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.618 ' HB2' ' HB3' ' A' ' 136' ' ' ARG . 33.4 tp -83.31 -74.89 0.34 Allowed 'General case' 0 N--CA 1.476 0.868 0 N-CA-C 109.379 -0.6 . . . . 75.43 109.379 -179.521 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.424 HG22 HD21 ' A' ' 123' ' ' LEU . 24.0 t -89.6 150.93 3.57 Favored 'Isoleucine or valine' 0 C--O 1.239 0.502 0 C-N-CA 124.454 1.102 . . . . 73.54 109.14 172.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -77.23 -51.06 11.57 Favored 'General case' 0 CA--C 1.54 0.579 0 O-C-N 123.713 0.633 . . . . 64.21 109.484 175.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 46.5 p-80 -179.2 177.13 0.8 Allowed 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 124.864 1.266 . . . . 71.24 109.535 -175.126 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.501 HG13 HD11 ' A' ' 119' ' ' LEU . 29.5 m -78.51 155.12 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 C-N-CA 122.683 0.393 . . . . 72.33 111.366 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.0 t -131.96 51.25 2.16 Favored 'General case' 0 CA--C 1.546 0.799 0 CA-C-O 122.402 1.096 . . . . 71.42 109.226 179.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 30.2 t -73.74 97.3 2.68 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 114.806 -1.088 . . . . 72.22 109.785 178.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -139.67 -115.3 1.25 Allowed Glycine 0 C--N 1.343 0.931 0 N-CA-C 110.545 -1.022 . . . . 53.42 110.545 178.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 61.4 m -79.27 177.74 8.6 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 117.331 0.566 . . . . 73.33 110.3 172.352 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 78.13 54.07 4.58 Favored Glycine 0 C--N 1.346 1.096 0 N-CA-C 110.849 -0.9 . . . . 62.13 110.849 -171.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.65 167.95 31.05 Favored Glycine 0 C--N 1.346 1.108 0 CA-C-N 115.19 -0.505 . . . . 60.23 112.206 -176.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 52.3 p -86.53 -22.32 26.41 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 123.579 0.751 . . . . 73.53 111.173 177.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 86.57 66.72 1.37 Allowed Glycine 0 C--N 1.352 1.441 0 N-CA-C 110.154 -1.178 . . . . 75.33 110.154 -172.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -162.01 64.32 0.26 Allowed Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.934 -0.867 . . . . 74.53 110.934 -176.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 31.0 t -55.35 -30.72 60.82 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.565 1.146 . . . . 71.3 111.966 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 81.3 -13.31 34.11 Favored Glycine 0 C--N 1.35 1.319 0 N-CA-C 114.678 0.631 . . . . 71.24 114.678 171.438 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -94.1 0.75 66.87 Favored Glycine 0 C--N 1.352 1.438 0 CA-C-N 117.438 0.619 . . . . 55.33 113.092 -176.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 70.5 p -141.51 -165.23 1.94 Allowed 'General case' 0 C--O 1.243 0.746 0 C-N-CA 124.04 0.936 . . . . 72.44 109.158 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -72.78 -115.89 0.06 OUTLIER Glycine 0 C--N 1.349 1.255 0 N-CA-C 110.537 -1.025 . . . . 60.13 110.537 169.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 65.4 mtt85 -91.57 118.12 30.33 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 117.892 0.846 . . . . 73.43 109.102 168.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -87.6 128.34 35.27 Favored 'General case' 0 C--O 1.241 0.655 0 N-CA-C 108.452 -0.944 . . . . 72.14 108.452 171.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.501 HD11 HG13 ' A' ' 102' ' ' VAL . 4.5 mm? -96.19 159.69 14.82 Favored 'General case' 0 N--CA 1.464 0.25 0 C-N-CA 124.129 0.972 . . . . 73.31 109.418 176.008 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 23.1 ptt180 -141.95 121.12 12.99 Favored 'General case' 0 C--O 1.241 0.649 0 N-CA-C 109.322 -0.622 . . . . 75.24 109.322 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -145.69 129.43 17.17 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 124.232 1.013 . . . . 73.31 109.446 -173.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.728 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 43.5 mt-10 -105.05 138.54 41.09 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 123.721 0.808 . . . . 71.5 109.228 178.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.471 HD22 HG13 ' A' ' 178' ' ' VAL . 1.8 pt? -135.64 141.52 37.47 Favored Pre-proline 0 N--CA 1.474 0.747 0 N-CA-C 110.033 -0.358 . . . . 75.41 110.033 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -73.38 113.27 3.73 Favored 'Trans proline' 0 C--N 1.368 1.586 0 C-N-CA 122.217 1.944 . . . . 64.53 109.924 171.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.544 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 11.9 tp -122.67 147.73 46.11 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 106.27 -1.752 . . . . 74.33 106.27 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 8.9 t -107.24 172.95 6.54 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 119.455 1.025 . . . . 74.1 110.491 175.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.458 HD21 HD12 ' A' ' 180' ' ' LEU . 31.4 mt -55.38 -46.17 76.52 Favored 'General case' 0 N--CA 1.47 0.533 0 O-C-N 124.561 1.163 . . . . 71.12 109.949 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -51.66 -40.79 60.66 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 113.969 -1.469 . . . . 72.12 111.263 177.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.502 ' HB2' ' HG ' ' A' ' 125' ' ' LEU . 22.8 mm-40 -83.31 -24.02 32.33 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.195 0.598 . . . . 74.43 111.193 -178.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.412 ' HA ' ' CG1' ' A' ' 153' ' ' VAL . . . -59.78 -32.97 71.1 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 123.117 0.567 . . . . 75.53 111.645 167.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.3 t80 -77.72 -53.53 7.43 Favored 'General case' 0 C--N 1.351 0.636 0 CA-C-N 116.167 -0.47 . . . . 72.45 111.062 171.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -60.36 -45.85 92.04 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 123.552 0.532 . . . . 72.32 111.728 -172.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 59.53 -125.28 38.91 Favored Glycine 0 C--N 1.349 1.257 0 O-C-N 123.881 0.738 . . . . 65.51 111.378 -178.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.01 169.83 29.66 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 114.009 0.364 . . . . 64.44 114.009 166.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.414 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.6 mp0 -88.08 126.82 35.31 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 107.443 -1.318 . . . . 73.41 107.443 172.38 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.618 ' HB3' ' HB2' ' A' ' 98' ' ' LEU . 6.6 tpt180 -154.83 134.0 12.42 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 108.87 -0.789 . . . . 75.43 108.87 -177.221 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.677 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 10.9 p -74.75 143.38 13.47 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 C-N-CA 123.103 0.561 . . . . 64.22 112.477 -168.287 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.437 HG13 ' HB3' ' A' ' 98' ' ' LEU . 5.0 m -128.66 161.56 37.35 Favored 'Isoleucine or valine' 0 C--O 1.247 0.956 0 C-N-CA 124.458 1.103 . . . . 63.0 110.258 178.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 46.4 mm-40 -111.09 111.32 22.34 Favored 'General case' 0 C--O 1.238 0.499 0 C-N-CA 123.954 0.902 . . . . 71.54 109.419 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.437 HG21 HD23 ' A' ' 174' ' ' LEU . 45.2 t -138.27 119.89 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 123.503 0.721 . . . . 74.25 110.628 178.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 64.05 21.78 12.7 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 124.785 1.234 . . . . 63.13 112.94 171.105 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.19 14.12 77.49 Favored Glycine 0 C--N 1.349 1.251 0 CA-C-N 116.702 -0.226 . . . . 74.0 112.729 -176.159 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? -110.78 118.5 36.31 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.422 1.089 . . . . 74.25 108.152 176.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 54.2 ttp180 -87.1 106.33 17.79 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 107.694 -1.224 . . . . 73.32 107.694 174.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 8.1 m -136.01 135.78 50.13 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 123.541 0.737 . . . . 72.42 110.429 -172.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.677 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 35.9 t -83.51 128.28 34.39 Favored 'General case' 0 C--O 1.241 0.616 0 C-N-CA 123.371 0.668 . . . . 71.21 109.679 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.523 HG12 HG13 ' A' ' 161' ' ' VAL . 99.0 t -99.65 125.98 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 123.577 0.751 . . . . 74.4 110.469 177.482 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . 0.414 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 74.4 ttt180 -99.08 104.23 16.22 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 123.844 0.857 . . . . 74.03 109.483 172.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.498 HG23 HG21 ' A' ' 159' ' ' ILE . 28.3 pt -107.54 118.11 54.14 Favored Pre-proline 0 CA--C 1.55 0.969 0 N-CA-C 108.598 -0.89 . . . . 72.51 108.598 169.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -67.09 152.15 80.48 Favored 'Trans proline' 0 C--N 1.379 2.14 0 C-N-CA 122.668 2.245 . . . . 75.31 113.107 -175.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_exo -49.2 113.7 1.02 Allowed 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 123.609 2.873 . . . . 73.43 112.662 170.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 129.94 65.37 0.1 Allowed Glycine 0 C--N 1.342 0.911 0 CA-C-N 116.319 -0.401 . . . . 75.34 112.208 177.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.5 HG23 HD13 ' A' ' 159' ' ' ILE . 3.9 p -129.72 159.96 41.22 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.51 0 C-N-CA 123.15 0.58 . . . . 74.4 109.529 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 29.9 mtp-105 -136.79 168.31 19.78 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 123.8 0.84 . . . . 73.32 111.292 -164.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -57.1 121.64 10.52 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.403 1.081 . . . . 73.44 111.333 171.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.62 9.9 86.66 Favored Glycine 0 C--N 1.35 1.339 0 O-C-N 123.832 0.708 . . . . 73.25 113.21 178.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 30.3 t -73.39 122.89 22.79 Favored 'General case' 0 C--N 1.356 0.881 0 C-N-CA 123.165 0.586 . . . . 64.54 109.468 -177.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.435 HG12 HD21 ' A' ' 175' ' ' LEU . 11.3 t -99.46 116.25 42.19 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 O-C-N 124.399 1.062 . . . . 73.33 108.485 -178.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.5 HD13 HG23 ' A' ' 153' ' ' VAL . 18.1 mt -107.66 113.42 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 123.665 0.786 . . . . 73.54 110.247 -170.79 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 26.8 ttm180 -89.59 113.28 24.69 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 123.346 0.658 . . . . 74.04 110.878 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.523 HG13 HG12 ' A' ' 147' ' ' VAL . 22.5 m -109.48 99.48 37.34 Favored Pre-proline 0 CA--C 1.564 1.51 0 N-CA-C 109.603 -0.517 . . . . 74.24 109.603 176.333 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -69.62 150.31 68.87 Favored 'Trans proline' 0 C--N 1.377 2.058 0 C-N-CA 123.298 2.665 . . . . 74.3 113.501 -172.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.32 10.37 86.26 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-N 115.383 -0.826 . . . . 75.12 113.656 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.455 ' HE3' HG22 ' A' ' 147' ' ' VAL . 58.4 mtp -114.82 -20.48 10.58 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.365 0.666 . . . . 71.24 112.419 -173.473 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -86.81 -104.38 0.81 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.755 -0.469 . . . . 74.35 112.067 177.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -65.92 105.56 1.3 Allowed Glycine 0 C--N 1.349 1.281 0 N-CA-C 111.46 -0.656 . . . . 75.31 111.46 176.231 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.6 mm-40 -79.0 134.39 36.79 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.512 0.725 . . . . 72.05 110.332 -176.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 145.25 -164.13 28.02 Favored Glycine 0 C--N 1.341 0.809 0 CA-C-N 115.967 -0.56 . . . . 72.12 111.854 -176.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -67.08 -52.46 30.63 Favored Pre-proline 0 CA--C 1.565 1.546 0 CA-C-O 118.015 -0.993 . . . . 53.21 110.316 -178.724 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -75.33 106.27 2.24 Favored 'Trans proline' 0 C--N 1.396 3.041 0 CA-C-N 121.375 1.527 . . . . 75.12 110.229 170.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.45 124.81 9.66 Favored 'Trans proline' 0 C--N 1.372 1.799 0 C-N-CA 121.343 1.362 . . . . 74.52 111.56 -171.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -90.98 160.23 27.17 Favored Glycine 0 C--N 1.334 0.46 0 N-CA-C 110.063 -1.215 . . . . 52.41 110.063 170.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -120.03 176.95 5.18 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.012 0.525 . . . . 74.35 110.446 -174.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.437 HD23 HG21 ' A' ' 140' ' ' VAL . 19.5 tp -128.06 115.95 19.25 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 115.34 -0.846 . . . . 74.11 109.304 172.424 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.435 HD21 HG12 ' A' ' 158' ' ' VAL . 88.9 mt -87.87 105.69 17.6 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 125.164 1.386 . . . . 74.22 110.852 179.28 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 36.6 mt -95.91 108.06 20.39 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 123.079 0.551 . . . . 74.51 111.037 177.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.728 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 19.7 t -90.78 99.9 10.32 Favored 'Isoleucine or valine' 0 C--O 1.242 0.71 0 N-CA-C 107.957 -1.127 . . . . 75.14 107.957 174.054 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.471 HG13 HD22 ' A' ' 123' ' ' LEU . 4.3 m -82.21 141.48 14.97 Favored 'Isoleucine or valine' 0 C--O 1.245 0.833 0 N-CA-C 109.054 -0.721 . . . . 75.33 109.054 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 16.1 mmm-85 -119.54 104.98 10.78 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.669 -1.234 . . . . 75.15 107.669 -175.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.544 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 61.2 mt -68.87 147.43 51.71 Favored 'General case' 0 CA--C 1.545 0.763 0 O-C-N 123.506 0.504 . . . . 75.31 111.009 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.448 ' HB2' ' HB3' ' A' ' 183' ' ' HIS . 27.7 mt -63.64 168.78 4.96 Favored Pre-proline 0 CA--C 1.56 1.33 0 C-N-CA 124.07 0.948 . . . . 71.42 111.098 -174.361 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -75.76 43.01 1.02 Allowed 'Trans proline' 0 C--N 1.381 2.243 0 C-N-CA 122.885 2.39 . . . . 71.45 111.601 162.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . 0.448 ' HB3' ' HB2' ' A' ' 181' ' ' LEU . 8.2 t60 -125.27 95.48 41.23 Favored Pre-proline 0 CA--C 1.532 0.281 0 N-CA-C 105.88 -1.896 . . . . 73.45 105.88 -178.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -100.75 123.76 0.11 Allowed 'Trans proline' 0 CA--C 1.554 1.525 0 C-N-CA 122.636 2.224 . . . . 63.5 113.052 176.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.431 HG13 HD13 ' A' ' 127' ' ' LEU . 4.1 p -144.75 -42.04 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 N-CA-C 108.855 -0.794 . . . . 72.11 108.855 175.135 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -126.96 154.93 43.91 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.387 1.075 . . . . 73.24 110.208 174.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 18.6 ttp85 -156.25 142.8 18.55 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 123.221 0.608 . . . . 65.12 109.564 178.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.435 HD11 ' HD1' ' A' ' 240' ' ' PHE . 56.6 tp -104.63 140.61 37.78 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.762 0.825 . . . . 74.44 110.27 178.186 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -139.64 111.49 7.35 Favored 'General case' 0 C--O 1.246 0.877 0 N-CA-C 107.191 -1.411 . . . . 75.03 107.191 168.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 74.66 -80.93 0.88 Allowed Glycine 0 C--N 1.347 1.171 0 O-C-N 123.558 0.536 . . . . 64.2 112.611 177.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . 0.405 ' HB3' ' HA3' ' A' ' 242' ' ' GLY . 9.3 pt20 -138.39 -23.04 1.0 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 124.068 0.947 . . . . 53.23 110.168 176.302 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . 0.411 ' O ' HD12 ' A' ' 188' ' ' LEU . 0.6 OUTLIER -89.6 157.59 17.98 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 123.832 0.853 . . . . 64.25 110.884 -173.046 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.578 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.7 mt -108.62 166.88 10.46 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 124.75 1.22 . . . . 73.33 109.508 -177.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -142.78 122.1 13.07 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 107.135 -1.432 . . . . 74.33 107.135 -178.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . 0.407 ' HB1' HD21 ' A' ' 251' ' ' LEU . . . -148.19 152.18 36.8 Favored 'General case' 0 CA--C 1.518 -0.285 0 C-N-CA 123.823 0.849 . . . . 75.12 110.459 -174.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 7.4 m -100.94 120.87 40.8 Favored 'General case' 0 CA--C 1.541 0.604 0 O-C-N 124.025 0.828 . . . . 74.41 109.389 176.294 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.505 HD22 HD12 ' A' ' 251' ' ' LEU . 66.0 tp -107.53 111.89 24.37 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.839 0.856 . . . . 75.54 109.467 -179.346 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -95.28 119.14 33.27 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.399 0.68 . . . . 75.41 109.259 176.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . 0.513 HG12 HG13 ' A' ' 223' ' ' VAL . 6.0 m -122.99 139.97 32.53 Favored Pre-proline 0 N--CA 1.475 0.8 0 C-N-CA 123.37 0.668 . . . . 73.23 109.267 -178.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_exo -59.31 144.37 99.42 Favored 'Trans proline' 0 C--N 1.372 1.793 0 C-N-CA 122.745 2.297 . . . . 64.52 111.81 171.411 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . 0.411 ' HA ' HG22 ' A' ' 255' ' ' ILE . . . -55.67 -44.63 99.76 Favored Pre-proline 0 CA--C 1.554 1.12 0 CA-C-O 117.963 -1.018 . . . . 53.51 111.991 177.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -48.61 -51.3 10.58 Favored 'Trans proline' 0 C--N 1.399 3.232 0 C-N-CA 122.537 2.158 . . . . 73.1 112.865 169.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 4.3 mt -62.44 -38.84 82.33 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.078 0 C-N-CA 123.202 0.601 . . . . 72.24 111.03 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.45 -44.41 96.47 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.17 0.588 . . . . 61.05 112.06 -178.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.3 m -78.55 -39.39 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-N 116.004 -0.543 . . . . 73.4 111.426 -174.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.1 m -82.9 -20.8 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 122.434 0.294 . . . . 74.44 111.284 -179.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.426 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 72.6 68.16 1.66 Allowed Glycine 0 C--N 1.343 0.932 0 N-CA-C 111.324 -0.711 . . . . 60.54 111.324 -175.531 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -92.87 -164.49 37.85 Favored Glycine 0 C--N 1.352 1.472 0 N-CA-C 111.482 -0.647 . . . . 74.11 111.482 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -115.11 139.17 50.12 Favored 'General case' 0 C--O 1.241 0.647 0 C-N-CA 123.554 0.742 . . . . 73.32 109.146 -178.05 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . 0.531 HG21 HG11 ' A' ' 221' ' ' VAL . 6.6 m -134.39 149.22 29.77 Favored 'Isoleucine or valine' 0 C--O 1.24 0.589 0 C-N-CA 123.876 0.87 . . . . 63.52 109.073 177.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . 0.412 ' H ' ' HD2' ' A' ' 211' ' ' ARG . 0.2 OUTLIER -104.87 125.9 51.38 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 108.116 -1.068 . . . . 74.11 108.116 174.874 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.446 ' HB3' HD13 ' A' ' 197' ' ' LEU . . . -99.89 129.2 45.95 Favored 'General case' 0 C--O 1.245 0.843 0 N-CA-C 108.792 -0.818 . . . . 75.31 108.792 -175.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 6.1 tpt -71.47 102.6 2.71 Favored 'General case' 0 CA--C 1.537 0.452 0 O-C-N 124.198 0.936 . . . . 73.21 109.4 -178.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 214' ' ' THR . . . . . 0.426 HG22 HG13 ' A' ' 219' ' ' VAL . 10.0 t -110.95 166.75 10.78 Favored 'General case' 0 C--O 1.238 0.451 0 CA-C-O 121.62 0.724 . . . . 72.33 110.694 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . 0.458 HD11 ' O ' ' A' ' 127' ' ' LEU . 25.9 mt -66.59 -19.04 65.68 Favored 'General case' 0 CA--C 1.545 0.765 0 CA-C-N 114.634 -1.166 . . . . 73.51 110.88 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -87.48 -21.7 25.35 Favored 'General case' 0 CA--C 1.558 1.263 0 C-N-CA 125.609 1.564 . . . . 63.12 111.797 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 139.39 -146.91 18.71 Favored Glycine 0 C--N 1.352 1.431 0 CA-C-O 119.157 -0.802 . . . . 71.42 111.583 -169.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -93.51 133.79 0.94 Allowed 'Trans proline' 0 CA--C 1.557 1.666 0 C-N-CA 122.373 2.049 . . . . 73.03 112.276 165.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . 0.426 HG13 HG22 ' A' ' 214' ' ' THR . 16.5 m -108.97 143.25 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 C-N-CA 122.934 0.494 . . . . 64.1 110.453 171.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -91.37 108.9 20.21 Favored 'General case' 0 CA--C 1.542 0.649 0 CA-C-O 121.524 0.678 . . . . 73.55 109.598 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.531 HG11 HG21 ' A' ' 210' ' ' VAL . 2.6 p -119.19 127.15 75.85 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.761 0 C-N-CA 123.55 0.74 . . . . 72.1 110.557 173.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -96.88 120.21 36.79 Favored 'General case' 0 C--O 1.238 0.453 0 C-N-CA 123.982 0.913 . . . . 71.31 109.215 177.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.513 HG13 HG12 ' A' ' 199' ' ' VAL . 11.5 m -82.65 141.85 45.26 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 109.631 -0.507 . . . . 63.14 109.631 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -63.74 141.07 77.37 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 122.752 2.302 . . . . 74.12 112.202 175.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -62.12 125.31 16.13 Favored 'Trans proline' 0 C--N 1.37 1.693 0 C-N-CA 122.513 2.142 . . . . 73.31 111.076 173.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 56.6 mtm180 64.77 50.21 2.08 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 124.951 1.407 . . . . 74.34 109.993 -172.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.0 t -79.5 169.7 17.66 Favored 'General case' 0 CA--C 1.546 0.804 0 CA-C-N 115.862 -0.608 . . . . 63.42 109.619 172.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . 0.524 ' H ' ' HD3' ' A' ' 231' ' ' ARG . 26.3 mp0 -125.04 142.09 51.71 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 123.808 0.843 . . . . 73.35 109.373 -172.605 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.66 119.39 13.83 Favored 'General case' 0 C--N 1.348 0.515 0 C-N-CA 123.469 0.708 . . . . 74.43 109.221 175.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.75 -7.08 22.17 Favored Glycine 0 C--N 1.34 0.793 0 CA-C-N 116.156 -0.475 . . . . 73.51 111.999 -171.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . 0.524 ' HD3' ' H ' ' A' ' 228' ' ' GLN . 75.2 mtp180 -81.94 160.94 23.24 Favored 'General case' 0 C--N 1.354 0.761 0 C-N-CA 122.766 0.426 . . . . 73.1 110.416 173.479 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.436 ' HG2' ' CE1' ' A' ' 250' ' ' TYR . 2.7 mppt? -122.23 135.59 54.78 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.267 0.627 . . . . 74.41 110.35 -175.727 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 61.8 mt -112.19 104.74 12.95 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 107.697 -1.223 . . . . 72.51 107.697 175.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . 0.543 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 50.3 ttt180 -94.14 109.04 20.84 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 115.682 -0.69 . . . . 74.13 109.622 -173.341 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.469 HD13 HD21 ' A' ' 249' ' ' LEU . 18.5 mt -85.95 128.11 34.77 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 122.838 0.455 . . . . 74.43 110.219 -175.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 50.0 mtmt -71.04 122.14 19.5 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.449 1.1 . . . . 73.11 111.762 -167.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.58 16.98 70.37 Favored Glycine 0 C--N 1.351 1.385 0 O-C-N 123.793 0.683 . . . . 55.11 114.02 172.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -94.9 7.28 46.51 Favored 'General case' 0 N--CA 1.48 1.049 0 N-CA-C 112.49 0.552 . . . . 75.32 112.49 -174.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -95.62 -170.84 35.9 Favored Glycine 0 C--N 1.34 0.789 0 O-C-N 123.553 0.533 . . . . 62.2 112.347 175.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.435 ' HD1' HD11 ' A' ' 188' ' ' LEU . 60.3 m-85 -85.95 159.88 53.57 Favored Pre-proline 0 CA--C 1.544 0.733 0 C-N-CA 123.578 0.751 . . . . 75.11 111.107 -176.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -52.97 127.94 26.94 Favored 'Trans proline' 0 C--N 1.391 2.812 0 C-N-CA 122.713 2.276 . . . . 71.4 112.221 176.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . 0.405 ' HA3' ' HB3' ' A' ' 191' ' ' GLN . . . -157.0 -164.36 13.49 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-O 119.03 -0.872 . . . . 74.34 111.945 -177.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.39 -30.34 91.02 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 123.569 2.846 . . . . 75.31 114.153 -173.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -93.61 22.97 4.96 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 123.428 0.691 . . . . 73.43 111.329 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 87.87 -73.92 2.26 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 110.104 -1.198 . . . . 74.31 110.104 -174.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 50.0 mtm180 -127.02 162.52 25.82 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 124.16 0.984 . . . . 73.44 108.674 167.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -89.38 -156.86 32.34 Favored Glycine 0 C--N 1.342 0.876 0 O-C-N 123.671 0.607 . . . . 72.03 112.398 176.476 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -135.86 171.59 14.24 Favored 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 109.182 -0.673 . . . . 72.41 109.182 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.578 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 12.8 tp -106.81 117.4 33.96 Favored 'General case' 0 C--O 1.213 -0.848 0 C-N-CA 123.268 0.627 . . . . 71.11 111.171 176.11 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . 0.468 ' HB3' ' O ' ' A' ' 193' ' ' LEU . 1.9 t80 -89.68 103.98 16.58 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 107.979 -1.119 . . . . 73.52 107.979 173.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.505 HD12 HD22 ' A' ' 197' ' ' LEU . 76.2 mt -88.77 148.03 24.15 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 123.261 0.625 . . . . 74.15 110.921 172.515 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -109.34 97.49 7.07 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 108.768 -0.827 . . . . 74.32 108.768 175.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 57.3 t -53.68 113.94 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 123.28 0.632 . . . . 70.33 110.802 173.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 27.7 mmt85 -123.64 94.3 4.2 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 107.185 -1.413 . . . . 73.42 107.185 178.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.411 HG22 ' HA ' ' A' ' 201' ' ' ALA . 76.6 mt -77.82 114.76 18.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 123.718 0.807 . . . . 65.24 110.318 -176.551 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 4.2 t . . . . . 0 CA--C 1.562 1.428 0 C-N-CA 123.633 0.773 . . . . 64.23 109.527 176.051 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.527 ' HB3' ' HG2' ' A' ' 139' ' ' GLU . . . . . . . . 0 N--CA 1.481 1.121 0 N-CA-C 110.343 -0.243 . . . . 73.24 110.343 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -82.14 -61.54 1.88 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 123.42 0.688 . . . . 73.21 111.348 -174.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.415 HD21 HD11 ' A' ' 125' ' ' LEU . 30.5 tp -83.82 -55.43 4.26 Favored 'General case' 0 C--O 1.241 0.658 0 C-N-CA 122.882 0.473 . . . . 63.35 111.121 -170.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.443 ' HA ' ' CB ' ' A' ' 123' ' ' LEU . 14.8 p -67.3 120.62 14.94 Favored 'Isoleucine or valine' 0 C--N 1.36 1.051 0 CA-C-O 121.54 0.686 . . . . 74.24 110.26 175.462 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -85.67 -60.71 1.94 Allowed 'General case' 0 C--O 1.24 0.564 0 CA-C-N 114.933 -1.031 . . . . 71.22 110.456 -175.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 26.6 t-80 -165.94 157.81 14.22 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 115.793 -0.64 . . . . 75.53 111.217 -171.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 25.9 t -64.42 145.14 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 125.148 1.379 . . . . 73.11 111.028 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.652 HG22 ' HG3' ' A' ' 122' ' ' GLU . 41.6 p -63.66 -45.99 87.65 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 123.517 0.727 . . . . 74.44 111.377 177.237 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 46.0 t -99.74 -75.71 0.56 Allowed 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 123.95 0.9 . . . . 65.22 109.887 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 160.4 -60.59 0.3 Allowed Glycine 0 C--N 1.345 1.047 0 N-CA-C 110.385 -1.086 . . . . 70.14 110.385 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 57.6 p -89.27 70.27 8.21 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 123.687 0.795 . . . . 71.52 110.21 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 85.63 -81.97 1.7 Allowed Glycine 0 C--N 1.347 1.17 0 CA-C-N 115.696 -0.683 . . . . 52.14 111.443 -176.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 162.39 156.71 8.59 Favored Glycine 0 C--O 1.243 0.659 0 CA-C-O 119.589 -0.561 . . . . 74.12 111.834 179.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 40.9 m -57.09 109.75 0.71 Allowed 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 123.499 0.72 . . . . 74.2 111.582 -176.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -67.69 135.58 30.89 Favored Glycine 0 C--N 1.343 0.955 0 CA-C-N 115.386 -0.825 . . . . 62.33 112.709 -177.443 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 140.24 38.76 0.09 OUTLIER Glycine 0 C--N 1.335 0.519 0 N-CA-C 111.842 -0.503 . . . . 73.14 111.842 -179.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 35.3 t -158.08 -61.69 0.08 Allowed 'General case' 0 CA--C 1.541 0.631 0 N-CA-C 109.519 -0.548 . . . . 64.24 109.519 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -70.63 -54.28 10.52 Favored Glycine 0 C--N 1.344 1.024 0 CA-C-N 115.708 -0.678 . . . . 73.33 112.809 -178.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.71 -49.78 3.9 Favored Glycine 0 C--N 1.343 0.947 0 N-CA-C 114.183 0.433 . . . . 75.31 114.183 172.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.2 t -74.94 119.92 19.78 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 122.86 0.464 . . . . 65.11 110.312 -176.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 62.54 -132.68 44.54 Favored Glycine 0 C--N 1.352 1.468 0 O-C-N 123.846 0.716 . . . . 74.11 111.849 -177.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.558 ' H ' ' HA3' ' A' ' 166' ' ' GLY . 4.4 tpm_? -90.53 122.53 33.44 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 123.165 0.586 . . . . 72.25 109.558 168.562 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -60.58 109.26 0.98 Allowed 'General case' 0 C--O 1.243 0.746 0 N-CA-C 108.061 -1.088 . . . . 65.21 108.061 165.373 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.452 HD23 HG12 ' A' ' 140' ' ' VAL . 0.5 OUTLIER -95.77 135.88 36.9 Favored 'General case' 0 C--N 1.345 0.402 0 N-CA-C 106.283 -1.747 . . . . 52.21 106.283 175.015 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 56.7 mtp180 -142.65 126.52 17.17 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 108.304 -0.998 . . . . 74.02 108.304 -175.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -148.78 133.27 17.65 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.335 0.654 . . . . 73.42 110.157 -178.465 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.652 ' HG3' HG22 ' A' ' 103' ' ' THR . 44.8 mt-10 -92.89 144.99 24.72 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 122.929 0.491 . . . . 62.41 109.993 173.061 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.443 ' CB ' ' HA ' ' A' ' 99' ' ' VAL . 1.7 pt? -146.68 132.18 9.23 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.365 -0.834 . . . . 75.24 110.533 -177.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -72.09 114.96 4.13 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 121.814 1.676 . . . . 75.31 111.221 175.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.427 ' HB3' HD23 ' A' ' 180' ' ' LEU . 22.0 tp -108.93 167.26 10.22 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.539 1.136 . . . . 70.14 108.065 176.334 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.482 HG22 HD11 ' A' ' 181' ' ' LEU . 7.8 m -103.46 159.8 15.27 Favored 'General case' 0 N--CA 1.476 0.865 0 O-C-N 121.624 -0.672 . . . . 72.33 109.513 171.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.531 HD21 ' HB3' ' A' ' 180' ' ' LEU . 81.2 mt -52.12 -52.77 49.5 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-O 121.311 0.577 . . . . 73.51 109.625 169.441 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.573 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.7 mp0 -55.64 -39.74 71.26 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 114.588 -1.187 . . . . 71.14 112.146 177.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -77.7 -21.17 52.4 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 122.765 0.426 . . . . 72.13 111.845 -178.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.457 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -68.55 -36.08 78.3 Favored 'General case' 0 C--O 1.248 0.99 0 C-N-CA 123.628 0.771 . . . . 73.54 110.64 168.531 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.471 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 69.2 t80 -64.44 -49.05 73.0 Favored 'General case' 0 C--N 1.346 0.448 0 CA-C-N 115.232 -0.894 . . . . 75.1 110.537 170.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -72.94 -28.82 62.67 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 112.855 0.687 . . . . 70.43 112.855 -173.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 67.3 -96.18 0.32 Allowed Glycine 0 C--N 1.351 1.376 0 N-CA-C 111.415 -0.674 . . . . 54.11 111.415 -174.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.38 150.55 25.46 Favored Glycine 0 C--N 1.349 1.29 0 N-CA-C 114.78 0.672 . . . . 72.35 114.78 167.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -85.59 125.57 33.22 Favored 'General case' 0 N--CA 1.473 0.684 0 N-CA-C 108.116 -1.068 . . . . 73.13 108.116 169.633 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 21.9 mmt180 -129.22 152.66 48.55 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.255 1.022 . . . . 74.54 108.742 -168.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 22.3 m -85.24 127.11 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.212 0 N-CA-C 110.053 -0.351 . . . . 75.21 110.053 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 85.7 t -123.73 122.78 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 123.086 0.554 . . . . 70.33 109.884 175.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . 0.527 ' HG2' ' HB3' ' A' ' 96' ' ' ALA . 11.7 pt-20 -124.8 96.53 4.91 Favored 'General case' 0 N--CA 1.476 0.87 0 CA-C-O 121.99 0.9 . . . . 73.54 109.24 172.063 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.452 HG12 HD23 ' A' ' 119' ' ' LEU . 74.0 t -130.59 133.11 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 123.786 0.834 . . . . 71.54 109.64 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.33 28.35 17.84 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 124.621 1.168 . . . . 60.1 111.157 -178.639 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.12 -9.3 66.98 Favored Glycine 0 C--N 1.35 1.321 0 CA-C-N 115.548 -0.751 . . . . 62.03 113.447 -177.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.2 tpp180 -91.08 115.67 28.19 Favored 'General case' 0 C--N 1.344 0.339 0 N-CA-C 109.424 -0.584 . . . . 75.21 109.424 -176.143 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 59.0 ttp180 -103.72 111.4 23.88 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 108.636 -0.875 . . . . 74.14 108.636 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.581 HG11 ' HE1' ' A' ' 164' ' ' MET . 2.5 p -145.89 141.86 21.74 Favored 'Isoleucine or valine' 0 C--O 1.243 0.731 0 C-N-CA 125.011 1.324 . . . . 71.43 108.325 178.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 32.4 p -77.69 134.14 38.19 Favored 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 116.384 -0.371 . . . . 74.24 110.016 178.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.553 ' HB ' ' HE3' ' A' ' 164' ' ' MET . 9.0 p -98.74 136.11 31.03 Favored 'Isoleucine or valine' 0 C--N 1.341 0.2 0 N-CA-C 109.126 -0.694 . . . . 72.45 109.126 175.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.1 ttt85 -108.19 95.45 5.68 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 107.559 -1.275 . . . . 75.33 107.559 168.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.465 ' HB ' HD11 ' A' ' 159' ' ' ILE . 36.5 pt -87.03 113.62 54.46 Favored Pre-proline 0 CA--C 1.552 1.021 0 N-CA-C 107.777 -1.194 . . . . 75.11 107.777 171.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 149' ' ' ILE . 33.1 Cg_exo -61.45 137.41 69.64 Favored 'Trans proline' 0 C--N 1.381 2.251 0 C-N-CA 122.683 2.255 . . . . 75.12 112.85 -173.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.425 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 83.7 Cg_exo -50.62 120.07 5.98 Favored 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 123.281 2.654 . . . . 74.32 112.132 172.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 126.03 52.57 0.16 Allowed Glycine 0 C--N 1.341 0.826 0 N-CA-C 110.861 -0.896 . . . . 63.21 110.861 -174.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.523 HG23 HD13 ' A' ' 159' ' ' ILE . 1.9 p -126.05 161.87 30.71 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.197 0 C-N-CA 123.94 0.896 . . . . 71.13 109.247 -176.548 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -140.94 165.9 26.26 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 124.869 1.267 . . . . 73.23 111.576 -165.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -57.12 122.85 13.38 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.948 0.899 . . . . 74.12 110.008 169.118 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.86 7.88 86.44 Favored Glycine 0 C--N 1.343 0.931 0 CA-C-O 119.4 -0.667 . . . . 64.3 113.824 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.5 t -78.77 123.33 27.08 Favored 'General case' 0 C--O 1.244 0.794 0 N-CA-C 109.415 -0.587 . . . . 71.32 109.415 177.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.414 HG23 HD23 ' A' ' 175' ' ' LEU . 7.6 p -100.49 120.78 50.42 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.126 0 CA-C-N 115.063 -0.971 . . . . 74.35 109.569 -179.233 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.523 HD13 HG23 ' A' ' 153' ' ' VAL . 20.1 mt -106.73 116.82 51.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.963 0.905 . . . . 72.25 110.32 -167.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.473 ' HG3' ' HB2' ' A' ' 173' ' ' ASP . 29.6 ttm180 -89.3 113.12 24.35 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.653 0.781 . . . . 72.13 111.245 -179.305 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 18.4 m -115.41 103.27 54.3 Favored Pre-proline 0 CA--C 1.561 1.374 0 CA-C-O 121.498 0.666 . . . . 75.4 110.581 178.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -65.5 145.65 83.04 Favored 'Trans proline' 0 C--N 1.381 2.258 0 C-N-CA 122.716 2.278 . . . . 75.22 112.992 -177.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 94.07 -23.25 32.22 Favored Glycine 0 C--N 1.345 1.03 0 CA-C-N 115.742 -0.663 . . . . 71.13 113.962 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.581 ' HE1' HG11 ' A' ' 145' ' ' VAL . 68.8 mtp -95.13 -23.66 17.2 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 112.927 0.714 . . . . 71.4 112.927 -169.548 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -78.18 -112.82 0.19 Allowed Glycine 0 C--N 1.346 1.105 0 N-CA-C 113.8 0.28 . . . . 71.22 113.8 -177.274 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.558 ' HA3' ' H ' ' A' ' 117' ' ' ARG . . . -68.97 105.66 1.55 Allowed Glycine 0 C--N 1.341 0.853 0 C-N-CA 122.836 0.255 . . . . 73.23 112.828 178.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -68.2 151.44 46.96 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.354 0.662 . . . . 74.43 110.578 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 138.32 -169.61 24.2 Favored Glycine 0 N--CA 1.466 0.688 0 CA-C-N 115.798 -0.637 . . . . 73.41 111.772 -176.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 41.1 t30 -64.58 -49.21 71.79 Favored Pre-proline 0 CA--C 1.553 1.07 0 CA-C-O 117.696 -1.145 . . . . 73.25 111.239 177.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -78.72 104.46 1.81 Allowed 'Trans proline' 0 C--N 1.396 3.047 0 C-N-CA 121.596 1.531 . . . . 74.43 110.525 168.139 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -65.9 125.24 13.87 Favored 'Trans proline' 0 C--N 1.381 2.28 0 C-N-CA 122.285 1.99 . . . . 74.31 111.544 -174.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -84.96 166.73 41.17 Favored Glycine 0 CA--C 1.509 -0.331 0 CA-C-N 116.169 -0.469 . . . . 53.51 111.946 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.473 ' HB2' ' HG3' ' A' ' 160' ' ' ARG . 8.2 p-10 -116.77 145.65 43.36 Favored 'General case' 0 C--O 1.245 0.824 0 C-N-CA 123.846 0.859 . . . . 64.21 109.28 -177.443 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 17.7 tp -106.39 122.37 46.12 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.824 -1.176 . . . . 75.2 107.824 176.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.414 HD23 HG23 ' A' ' 158' ' ' VAL . 77.1 mt -98.8 98.91 9.96 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 125.279 1.432 . . . . 74.13 110.282 -177.543 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 52.8 mt -92.57 107.39 19.18 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 123.411 0.684 . . . . 74.34 111.405 178.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.644 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 34.7 t -88.66 104.22 14.57 Favored 'Isoleucine or valine' 0 C--O 1.245 0.836 0 N-CA-C 108.465 -0.939 . . . . 74.42 108.465 173.551 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 9.7 m -82.0 147.59 5.99 Favored 'Isoleucine or valine' 0 C--O 1.242 0.686 0 CA-C-O 121.499 0.666 . . . . 75.32 110.318 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 24.3 mmm-85 -120.63 96.32 5.08 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 107.418 -1.327 . . . . 74.43 107.418 -179.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.531 ' HB3' HD21 ' A' ' 127' ' ' LEU . 31.0 mt -69.26 136.53 52.07 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 122.626 0.371 . . . . 73.13 110.368 -174.677 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.482 HD11 HG22 ' A' ' 126' ' ' THR . 53.7 mt -53.67 125.49 46.0 Favored Pre-proline 0 CA--C 1.554 1.122 0 CA-C-O 118.543 -0.742 . . . . 74.24 110.319 -177.189 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 24.0 Cg_exo -64.18 85.23 0.15 Allowed 'Trans proline' 0 C--N 1.379 2.139 0 C-N-CA 123.109 2.539 . . . . 74.13 113.471 -174.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -154.23 54.82 1.15 Allowed Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 123.758 0.823 . . . . 74.35 109.054 171.147 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -61.21 122.92 11.87 Favored 'Trans proline' 0 C--N 1.381 2.273 0 C-N-CA 122.54 2.16 . . . . 72.4 112.143 -165.055 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.29 -44.57 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 N-CA-C 107.824 -1.176 . . . . 70.11 107.824 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . 0.446 ' HE2' HD13 ' A' ' 193' ' ' LEU . 3.6 m-85 -104.81 123.75 48.22 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.209 -0.905 . . . . 72.44 109.353 176.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.509 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 4.3 mmm180 -115.68 150.94 35.97 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 106.082 -1.821 . . . . 70.42 106.082 178.422 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.408 HD12 ' O ' ' A' ' 192' ' ' ASP . 63.9 tp -130.76 132.02 45.06 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 122.833 0.453 . . . . 71.33 109.832 -176.357 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -143.5 116.76 9.0 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 108.417 -0.957 . . . . 74.34 108.417 168.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 55.42 52.85 44.93 Favored Glycine 0 C--N 1.355 1.584 0 O-C-N 123.953 0.783 . . . . 64.55 114.04 176.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . 0.4 ' OE1' ' HD2' ' A' ' 243' ' ' PRO . 38.5 mt-30 72.5 -5.94 1.71 Allowed 'General case' 0 N--CA 1.496 1.866 0 C-N-CA 125.024 1.329 . . . . 75.11 113.168 177.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . 0.408 ' O ' HD12 ' A' ' 188' ' ' LEU . 23.1 t70 -98.98 145.09 27.42 Favored 'General case' 0 C--N 1.348 0.503 0 N-CA-C 109.483 -0.562 . . . . 73.43 109.483 -176.64 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.604 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.7 mt -105.72 152.97 22.5 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.691 0.796 . . . . 72.43 109.232 -174.098 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . 0.509 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 98.3 m-85 -140.84 120.82 13.63 Favored 'General case' 0 C--O 1.223 -0.308 0 N-CA-C 107.649 -1.241 . . . . 75.12 107.649 -174.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -147.47 169.46 19.5 Favored 'General case' 0 C--O 1.24 0.595 0 C-N-CA 123.637 0.775 . . . . 74.44 110.287 -175.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 16.6 m -116.25 126.99 54.35 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.757 -0.656 . . . . 73.3 109.447 175.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . . . . . . . . . 67.0 tp -107.39 119.46 39.46 Favored 'General case' 0 C--O 1.214 -0.804 0 C-N-CA 124.47 1.108 . . . . 71.52 108.696 176.071 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -97.31 136.79 37.29 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.257 -1.016 . . . . 73.52 108.257 167.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . 0.499 HG13 HG12 ' A' ' 210' ' ' VAL . 13.3 m -130.26 142.82 46.78 Favored Pre-proline 0 N--CA 1.476 0.833 0 N-CA-C 109.1 -0.704 . . . . 73.43 109.1 179.235 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -61.94 140.06 82.85 Favored 'Trans proline' 0 C--N 1.372 1.79 0 C-N-CA 121.942 1.761 . . . . 71.01 110.772 172.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . 0.414 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -52.78 -42.2 88.24 Favored Pre-proline 0 CA--C 1.558 1.263 0 CA-C-O 117.542 -1.218 . . . . 75.22 113.041 178.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . 0.459 ' O ' HG21 ' A' ' 206' ' ' VAL . 8.8 Cg_endo -49.78 -52.69 8.37 Favored 'Trans proline' 0 C--N 1.408 3.671 0 C-N-CA 122.851 2.367 . . . . 72.35 112.267 169.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 3.4 mt -60.98 -41.66 89.94 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 122.836 0.454 . . . . 74.51 111.271 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.49 -42.53 98.55 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.163 0.585 . . . . 53.21 112.187 -175.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 28.1 m -81.2 -35.51 14.25 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 CA-C-N 115.959 -0.564 . . . . 75.21 111.894 -173.06 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . 0.459 HG21 ' O ' ' A' ' 202' ' ' PRO . 20.8 m -88.0 -19.21 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 O-C-N 122.118 -0.364 . . . . 74.04 111.635 178.614 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.415 ' HA2' HG22 ' A' ' 223' ' ' VAL . . . 76.37 66.67 1.81 Allowed Glycine 0 C--N 1.342 0.894 0 O-C-N 123.484 0.49 . . . . 75.33 112.181 -177.449 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.02 -168.45 42.89 Favored Glycine 0 C--N 1.348 1.203 0 N-CA-C 111.854 -0.498 . . . . 73.33 111.854 175.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -125.79 119.34 27.63 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 107.997 -1.112 . . . . 74.41 107.997 -179.323 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . 0.499 HG12 HG13 ' A' ' 199' ' ' VAL . 7.9 p -116.43 147.88 19.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.547 0 C-N-CA 124.143 0.977 . . . . 74.12 109.439 -174.1 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -76.24 123.66 26.25 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 116.026 -0.534 . . . . 75.44 109.579 172.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.13 130.14 47.15 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 108.052 -1.092 . . . . 74.34 108.052 173.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 56.3 mmm -76.55 141.01 41.32 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.131 0.491 . . . . 64.34 110.776 178.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 214' ' ' THR . . . . . 0.414 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 5.7 t -143.68 166.91 23.53 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-N 114.563 -1.199 . . . . 73.35 110.159 177.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . 0.573 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 65.1 mt -66.51 -19.84 65.88 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 124.306 1.042 . . . . 73.31 110.953 176.046 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -82.97 -18.25 40.61 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 124.859 1.263 . . . . 75.34 111.022 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 134.26 -147.49 19.11 Favored Glycine 0 C--N 1.352 1.433 0 N-CA-C 111.226 -0.75 . . . . 72.1 111.226 -174.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -93.11 129.37 0.76 Allowed 'Trans proline' 0 CA--C 1.56 1.787 0 C-N-CA 122.432 2.088 . . . . 73.12 112.775 165.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.7 m -109.15 166.71 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 C-N-CA 123.595 0.758 . . . . 73.21 109.56 169.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -113.94 116.47 29.3 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 109.867 -0.42 . . . . 74.51 109.867 178.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.4 p -108.78 136.82 43.38 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.681 0 C-N-CA 123.459 0.704 . . . . 74.41 110.175 173.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -95.12 115.73 27.81 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 124.025 0.93 . . . . 51.01 109.491 176.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.461 HG11 HG11 ' A' ' 199' ' ' VAL . 14.2 m -82.06 142.05 47.57 Favored Pre-proline 0 CA--C 1.548 0.893 0 N-CA-C 109.376 -0.601 . . . . 73.31 109.376 176.16 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_exo -61.0 141.12 93.47 Favored 'Trans proline' 0 C--N 1.368 1.558 0 C-N-CA 122.451 2.1 . . . . 75.12 112.746 172.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_exo -56.4 119.79 7.23 Favored 'Trans proline' 0 C--N 1.373 1.833 0 C-N-CA 122.588 2.192 . . . . 74.45 111.783 169.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . 0.415 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 53.7 mtm180 60.75 51.64 4.75 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.676 1.19 . . . . 74.45 110.759 -174.082 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 227' ' ' THR . . . . . 0.469 ' OG1' ' HD2' ' A' ' 231' ' ' ARG . 12.1 t -73.17 172.68 10.64 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-N 114.955 -1.02 . . . . 74.34 110.257 174.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -126.49 141.81 51.75 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 123.149 0.58 . . . . 74.34 109.455 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -63.96 119.69 10.56 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.759 0.824 . . . . 74.4 109.836 175.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.98 4.78 20.75 Favored Glycine 0 C--O 1.241 0.57 0 C-N-CA 123.69 0.662 . . . . 73.41 112.314 -176.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . 0.469 ' HD2' ' OG1' ' A' ' 227' ' ' THR . 92.3 mtt180 -79.54 159.01 27.06 Favored 'General case' 0 C--N 1.358 0.942 0 CA-C-O 121.707 0.765 . . . . 73.0 109.551 170.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.453 ' HG3' ' HE2' ' A' ' 250' ' ' TYR . 10.1 mptt -108.34 99.13 8.57 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 114.32 -1.309 . . . . 74.11 108.452 -176.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . 0.449 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 62.6 mt -90.11 96.48 10.69 Favored 'General case' 0 C--N 1.349 0.545 0 N-CA-C 106.231 -1.766 . . . . 75.1 106.231 176.518 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . 0.483 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 39.1 ttp180 -96.11 101.36 13.01 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 114.915 -1.039 . . . . 73.31 110.015 -167.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.478 HD12 HD21 ' A' ' 249' ' ' LEU . 43.3 mt -81.08 105.92 12.67 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.934 0.894 . . . . 73.02 108.806 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt -74.61 144.18 44.02 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.171 0.588 . . . . 74.41 112.267 -171.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 71.11 19.99 77.65 Favored Glycine 0 C--N 1.349 1.275 0 O-C-N 123.764 0.665 . . . . 52.02 113.934 178.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . 0.488 ' HZ1' ' HB3' ' A' ' 238' ' ' LYS . 1.4 mmmp? -106.65 -12.43 15.56 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.792 0.437 . . . . 71.43 111.173 -179.356 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.17 -175.51 49.82 Favored Glycine 0 C--N 1.348 1.217 0 O-C-N 123.409 0.443 . . . . 72.31 112.138 173.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.471 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 87.5 m-85 -77.4 149.26 78.5 Favored Pre-proline 0 N--CA 1.475 0.809 0 N-CA-C 112.252 0.464 . . . . 74.04 112.252 -172.027 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . 0.558 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 53.3 Cg_endo -65.52 160.58 42.28 Favored 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 122.838 2.359 . . . . 64.45 113.562 -175.548 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 164.7 -151.74 20.97 Favored Glycine 0 C--N 1.346 1.097 0 CA-C-O 118.929 -0.928 . . . . 70.34 112.044 -178.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . 0.4 ' HD2' ' OE1' ' A' ' 191' ' ' GLN . 37.6 Cg_endo -61.33 -32.53 89.77 Favored 'Trans proline' 0 C--N 1.377 2.047 0 C-N-CA 123.264 2.643 . . . . 73.34 113.198 -176.513 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -84.52 18.63 2.22 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 123.485 0.714 . . . . 71.31 111.77 178.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 78.77 -78.12 1.7 Allowed Glycine 0 C--N 1.347 1.175 0 N-CA-C 110.039 -1.224 . . . . 74.32 110.039 -172.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.558 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 62.2 mtm180 -128.47 169.51 14.24 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 124.081 0.953 . . . . 64.42 108.579 166.245 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -82.78 -163.66 34.07 Favored Glycine 0 C--N 1.337 0.626 0 N-CA-C 111.697 -0.561 . . . . 41.11 111.697 172.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -130.78 170.73 13.98 Favored 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 109.238 -0.653 . . . . 72.43 109.238 -178.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.604 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 17.5 tp -115.87 120.65 39.9 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.868 0.867 . . . . 73.31 110.663 175.365 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . 0.453 ' HE2' ' HG3' ' A' ' 232' ' ' LYS . 10.7 t80 -89.31 107.93 19.34 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.613 1.165 . . . . 75.15 108.693 175.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.449 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 87.8 mt -94.14 117.86 30.71 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.904 -0.406 . . . . 73.02 109.904 167.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -88.29 93.56 9.55 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 107.327 -1.36 . . . . 74.52 107.327 171.412 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 3.3 p -60.05 133.82 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 O-C-N 123.725 0.641 . . . . 73.43 110.645 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 48.6 mmm-85 -135.26 102.01 5.03 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 125.049 1.34 . . . . 75.14 107.529 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 63.0 mt -76.54 116.93 20.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.359 -0.837 . . . . 75.11 109.768 -175.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.0 t . . . . . 0 CA--C 1.553 1.087 0 C-N-CA 124.829 1.252 . . . . 70.32 109.214 -178.635 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.155 0 N-CA-C 110.121 -0.325 . . . . 74.41 110.121 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.458 ' HB1' ' HB3' ' A' ' 136' ' ' ARG . . . -106.47 -18.86 13.85 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 123.006 0.523 . . . . 74.33 112.277 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.419 HD21 ' H ' ' A' ' 99' ' ' VAL . 2.0 pt? -140.27 -50.2 0.47 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 117.529 0.15 . . . . 74.31 111.084 178.078 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.694 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 13.6 p -64.45 146.7 12.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 C-N-CA 123.584 0.754 . . . . 72.12 111.894 -179.098 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.44 ' HB3' ' HD3' ' A' ' 124' ' ' PRO . . . -83.22 -58.35 2.88 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 109.479 -0.563 . . . . 63.45 109.479 173.16 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 40.0 t-80 -175.59 159.58 2.38 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 123.697 0.799 . . . . 73.43 109.857 -175.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -66.44 136.68 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.346 0.658 . . . . 73.24 110.277 171.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 12.6 t -127.95 154.73 45.25 Favored 'General case' 0 CA--C 1.543 0.708 0 N-CA-C 109.308 -0.627 . . . . 74.43 109.308 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 28.6 m -89.55 95.07 10.11 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 123.186 0.594 . . . . 75.13 109.789 -175.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . 0.581 ' HA3' ' HG3' ' A' ' 120' ' ' ARG . . . -92.77 -176.22 41.26 Favored Glycine 0 C--N 1.348 1.244 0 CA-C-N 116.483 -0.326 . . . . 61.32 113.172 -177.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 23.3 m -72.6 113.27 9.45 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 123.064 0.546 . . . . 73.05 110.693 -179.399 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.59 129.0 36.09 Favored Glycine 0 C--N 1.346 1.095 0 N-CA-C 110.821 -0.912 . . . . 74.22 110.821 170.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -73.37 75.39 1.0 Allowed Glycine 0 C--N 1.349 1.305 0 CA-C-N 117.011 0.406 . . . . 71.31 113.363 -177.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 37.2 t -77.43 -54.37 6.52 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 123.768 0.827 . . . . 73.42 109.402 -179.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -92.77 4.64 75.85 Favored Glycine 0 C--N 1.346 1.129 0 CA-C-N 115.585 -0.734 . . . . 35.35 111.929 171.568 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -80.82 154.4 35.71 Favored Glycine 0 C--N 1.351 1.388 0 C-N-CA 123.286 0.47 . . . . 55.34 112.035 177.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 15.5 m -75.83 103.43 5.91 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 123.264 0.625 . . . . 71.22 109.511 177.206 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 127.63 165.24 11.83 Favored Glycine 0 C--N 1.344 1.012 0 N-CA-C 112.182 -0.367 . . . . 74.32 112.182 -177.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 154.09 7.34 0.09 OUTLIER Glycine 0 N--CA 1.473 1.137 0 CA-C-O 120.058 -0.301 . . . . 54.51 113.08 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 47.2 t -71.59 -50.41 31.17 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.712 0.805 . . . . 74.12 109.958 177.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -96.61 148.27 18.94 Favored Glycine 0 C--N 1.34 0.795 0 N-CA-C 110.968 -0.853 . . . . 74.02 110.968 173.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 43.3 ttm105 -65.77 127.9 33.83 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.514 0.726 . . . . 74.2 111.428 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -72.47 147.34 46.17 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.535 0.734 . . . . 72.35 110.034 172.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.494 HD11 HD13 ' A' ' 174' ' ' LEU . 0.2 OUTLIER -138.16 137.41 37.61 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 106.392 -1.707 . . . . 75.54 106.392 177.46 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . 0.581 ' HG3' ' HA3' ' A' ' 105' ' ' GLY . 19.4 mmt85 -125.58 138.59 53.95 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 109.065 -0.717 . . . . 73.22 109.065 -178.57 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . 0.411 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -159.11 126.74 4.91 Favored 'General case' 0 CA--C 1.536 0.417 0 O-C-N 123.703 0.627 . . . . 74.25 109.447 175.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -105.73 150.55 25.41 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 109.607 -0.516 . . . . 71.55 109.607 175.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.694 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.4 pt? -145.87 147.08 31.13 Favored Pre-proline 0 N--CA 1.473 0.72 0 C-N-CA 123.033 0.533 . . . . 72.41 111.925 -170.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.44 ' HD3' ' HB3' ' A' ' 100' ' ' ALA . 91.5 Cg_endo -81.76 113.41 2.51 Favored 'Trans proline' 0 C--N 1.376 1.993 0 C-N-CA 121.769 1.646 . . . . 74.32 111.082 171.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.422 ' HB3' HD21 ' A' ' 180' ' ' LEU . 19.2 tp -111.06 167.71 10.05 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.043 -1.095 . . . . 63.31 108.043 175.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.562 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 8.8 m -101.09 155.07 18.21 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 109.922 -0.399 . . . . 74.15 109.922 174.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.411 HD23 ' HB3' ' A' ' 180' ' ' LEU . 85.6 mt -51.96 -51.93 53.75 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 122.304 1.049 . . . . 73.4 109.766 171.14 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -56.83 -40.14 75.5 Favored 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 113.386 -1.734 . . . . 74.14 111.735 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.427 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 23.8 mm-40 -79.87 -18.27 51.13 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 123.358 0.663 . . . . 73.32 112.195 -179.025 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.618 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -63.25 -41.57 99.09 Favored 'General case' 0 C--O 1.249 1.036 0 C-N-CA 122.863 0.465 . . . . 74.02 110.583 165.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -67.93 -54.45 18.6 Favored 'General case' 0 C--N 1.354 0.787 0 CA-C-N 115.664 -0.698 . . . . 74.31 110.932 172.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.5 m80 -69.88 -30.03 67.39 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 123.941 0.776 . . . . 72.42 112.158 -170.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.08 -149.34 51.71 Favored Glycine 0 C--N 1.346 1.124 0 N-CA-C 111.334 -0.706 . . . . 75.11 111.334 -171.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 136.92 136.94 3.57 Favored Glycine 0 C--N 1.346 1.095 0 CA-C-N 116.73 0.265 . . . . 74.41 112.673 170.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -80.21 127.0 31.83 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.408 0.683 . . . . 75.23 109.191 174.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.458 ' HB3' ' HB1' ' A' ' 97' ' ' ALA . 8.2 mpt_? -136.26 168.13 19.99 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.527 0.731 . . . . 75.2 109.101 177.412 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.5 p -85.85 129.61 37.78 Favored 'Isoleucine or valine' 0 C--O 1.246 0.878 0 CA-C-O 121.311 0.577 . . . . 74.32 110.66 174.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.478 HG23 HD22 ' A' ' 174' ' ' LEU . 14.6 p -98.65 142.33 14.9 Favored 'Isoleucine or valine' 0 C--O 1.242 0.704 0 C-N-CA 124.215 1.006 . . . . 74.42 109.43 175.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . 0.433 ' H ' HG13 ' A' ' 99' ' ' VAL . 42.7 mm-40 -121.76 100.68 7.13 Favored 'General case' 0 C--O 1.24 0.563 0 C-N-CA 124.61 1.164 . . . . 74.41 108.142 179.042 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.404 HG13 HG22 ' A' ' 138' ' ' VAL . 3.2 m -124.05 107.53 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.79 0 C-N-CA 123.352 0.661 . . . . 72.43 111.063 -176.569 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.87 24.24 11.29 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 124.747 1.219 . . . . 70.33 111.909 176.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 91.12 3.49 69.9 Favored Glycine 0 C--N 1.346 1.116 0 CA-C-N 116.031 -0.531 . . . . 75.53 113.371 -177.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 64.0 mtp85 -95.98 119.62 34.81 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.024 -0.732 . . . . 72.22 109.024 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 33.9 ttt85 -98.82 116.63 31.49 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.483 0.713 . . . . 74.5 109.952 -178.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 46.3 t -136.53 145.53 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.778 0.831 . . . . 73.13 108.918 179.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 21.2 m -79.03 110.99 14.78 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 109.072 -0.714 . . . . 74.4 109.072 171.08 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.0 p -98.28 137.41 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 CA-C-O 121.762 0.791 . . . . 74.34 110.597 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 77.6 ttt180 -103.82 117.78 35.16 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 114.485 -1.234 . . . . 74.32 108.342 175.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 33.4 pt -122.86 127.0 25.89 Favored Pre-proline 0 N--CA 1.477 0.919 0 N-CA-C 109.01 -0.737 . . . . 74.41 109.01 169.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -81.86 159.97 18.63 Favored 'Trans proline' 0 C--N 1.375 1.959 0 C-N-CA 122.909 2.406 . . . . 73.24 114.523 -167.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -68.1 114.92 3.57 Favored 'Trans proline' 0 C--N 1.381 2.289 0 C-N-CA 123.331 2.687 . . . . 53.44 110.618 174.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . 0.632 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 133.9 49.7 0.08 OUTLIER Glycine 0 N--CA 1.469 0.844 0 N-CA-C 111.299 -0.72 . . . . 45.24 111.299 -173.712 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.618 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.4 p -125.99 165.61 23.56 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.403 0 N-CA-C 108.35 -0.981 . . . . 62.45 108.35 -176.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 51.3 mtp180 -145.69 166.7 25.07 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 124.519 1.127 . . . . 72.43 110.375 -165.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -55.49 123.89 15.43 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 124.005 0.922 . . . . 75.11 111.112 169.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.75 5.42 74.31 Favored Glycine 0 C--N 1.35 1.337 0 O-C-N 123.752 0.657 . . . . 75.01 113.601 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 31.2 t -73.45 126.01 29.23 Favored 'General case' 0 C--O 1.243 0.715 0 N-CA-C 109.828 -0.434 . . . . 72.1 109.828 -177.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.443 HG23 HD21 ' A' ' 175' ' ' LEU . 7.4 p -99.43 120.05 48.26 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 CA-C-N 114.756 -1.111 . . . . 74.4 109.911 -174.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.49 HD11 HG23 ' A' ' 153' ' ' VAL . 24.9 mt -106.95 115.53 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 124.004 0.922 . . . . 74.34 110.081 -171.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.519 ' HA ' HD23 ' A' ' 175' ' ' LEU . 69.3 ttt180 -83.53 119.1 24.28 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.504 0.722 . . . . 73.23 111.024 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.589 HG21 ' HG3' ' A' ' 164' ' ' MET . 16.6 m -124.37 104.76 31.38 Favored Pre-proline 0 CA--C 1.571 1.77 0 CA-C-O 120.764 0.316 . . . . 74.35 110.209 174.745 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.17 156.59 64.42 Favored 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.865 2.376 . . . . 73.41 113.7 -178.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.56 23.15 65.55 Favored Glycine 0 C--N 1.348 1.247 0 CA-C-N 115.336 -0.847 . . . . 73.24 113.808 176.472 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.589 ' HG3' HG21 ' A' ' 161' ' ' VAL . 16.4 mmt -106.81 -62.08 1.45 Allowed 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.079 0.952 . . . . 72.41 111.271 178.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -65.56 -74.48 0.5 Allowed Glycine 0 C--N 1.354 1.539 0 N-CA-C 111.591 -0.603 . . . . 63.51 111.591 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.715 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -72.67 116.41 5.69 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 111.803 -0.519 . . . . 72.32 111.803 166.635 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.3 mm-40 -88.94 158.7 17.96 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 124.258 1.023 . . . . 62.25 110.916 177.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 76.8 -123.9 6.83 Favored Glycine 0 C--N 1.342 0.907 0 CA-C-N 115.502 -0.772 . . . . 75.11 113.378 172.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -76.22 -48.9 3.25 Favored Pre-proline 0 CA--C 1.551 0.99 0 CA-C-O 117.76 -1.114 . . . . 75.41 112.006 -173.391 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -79.3 105.2 1.86 Allowed 'Trans proline' 0 C--N 1.393 2.881 0 C-N-CA 121.683 1.589 . . . . 74.14 110.809 172.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -77.57 125.09 7.36 Favored 'Trans proline' 0 C--N 1.379 2.159 0 C-N-CA 122.104 1.869 . . . . 75.21 110.653 -175.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.715 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -110.08 148.41 17.4 Favored Glycine 0 CA--C 1.503 -0.693 0 N-CA-C 111.334 -0.706 . . . . 52.12 111.334 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 -109.0 130.54 55.48 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 123.215 0.606 . . . . 75.25 109.53 -165.017 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.494 HD13 HD11 ' A' ' 119' ' ' LEU . 17.4 tp -100.6 115.12 29.42 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 107.145 -1.428 . . . . 75.53 107.145 173.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.519 HD23 ' HA ' ' A' ' 160' ' ' ARG . 65.0 mt -92.23 100.73 13.28 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-N 114.46 -1.246 . . . . 65.32 109.794 -179.162 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.411 ' HA ' ' O ' ' A' ' 121' ' ' ALA . 83.2 mt -86.63 102.49 14.23 Favored 'General case' 0 C--N 1.346 0.418 0 CA-C-N 114.773 -1.103 . . . . 74.31 110.061 176.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 47.2 t -90.0 99.4 9.4 Favored 'Isoleucine or valine' 0 C--O 1.243 0.714 0 N-CA-C 108.397 -0.964 . . . . 65.54 108.397 176.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 4.9 m -79.49 148.12 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 N-CA-C 109.493 -0.558 . . . . 75.34 109.493 -177.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 40.0 mmm-85 -126.63 99.2 5.69 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 105.85 -1.908 . . . . 74.44 105.85 -175.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.422 HD21 ' HB3' ' A' ' 125' ' ' LEU . 38.2 mt -68.65 148.34 50.58 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 122.339 0.256 . . . . 74.01 110.954 -173.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.562 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 39.1 mt -55.76 130.52 72.01 Favored Pre-proline 0 CA--C 1.552 1.04 0 CA-C-O 118.844 -0.598 . . . . 74.5 110.737 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -67.91 84.47 0.42 Allowed 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 123.279 2.653 . . . . 74.22 112.079 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 8.6 p80 -154.58 50.62 0.55 Allowed Pre-proline 0 CA--C 1.558 1.274 0 N-CA-C 107.87 -1.159 . . . . 72.12 107.87 169.347 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -62.69 126.42 18.21 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 122.713 2.275 . . . . 73.14 112.261 -163.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -137.74 -45.1 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 108.686 -0.857 . . . . 74.41 108.686 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . 0.413 ' CD2' HD11 ' A' ' 193' ' ' LEU . 6.5 m-85 -103.82 123.61 47.42 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.932 0.893 . . . . 74.21 110.269 -177.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.6 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 92.3 mtt180 -119.15 109.18 15.58 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.623 1.169 . . . . 75.1 107.887 -176.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.485 HD23 ' CD2' ' A' ' 240' ' ' PHE . 62.0 tp -85.09 142.56 29.45 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 122.659 0.383 . . . . 73.3 110.378 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -142.45 115.61 8.88 Favored 'General case' 0 C--O 1.243 0.736 0 N-CA-C 107.782 -1.192 . . . . 73.33 107.782 164.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 67.46 -95.37 0.31 Allowed Glycine 0 C--N 1.346 1.139 0 CA-C-N 115.725 -0.67 . . . . 75.05 111.514 -173.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 -123.84 -23.27 4.7 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.034 0.934 . . . . 72.42 110.247 177.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -93.83 153.34 18.33 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.411 0.624 . . . . 74.11 111.038 -171.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.616 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 73.6 mt -113.36 167.08 10.87 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.198 -0.91 . . . . 73.14 112.581 -170.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . 0.6 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 97.4 m-85 -135.28 121.57 20.32 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 105.873 -1.899 . . . . 74.51 105.873 172.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . 0.433 ' HB2' HD13 ' A' ' 249' ' ' LEU . . . -152.75 140.1 19.56 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 108.573 -0.899 . . . . 72.45 108.573 176.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.02 141.71 40.21 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 123.566 0.541 . . . . 73.4 110.128 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.544 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 57.5 tp -110.03 113.73 26.67 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.027 -0.988 . . . . 72.35 109.07 179.29 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -85.71 101.9 13.16 Favored 'General case' 0 C--O 1.24 0.566 0 N-CA-C 108.149 -1.056 . . . . 72.12 108.149 176.228 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . 0.427 HG11 HG12 ' A' ' 253' ' ' VAL . 4.3 p -116.82 127.44 26.72 Favored Pre-proline 0 CA--C 1.548 0.881 0 N-CA-C 109.332 -0.618 . . . . 63.11 109.332 -178.237 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -58.71 144.71 97.71 Favored 'Trans proline' 0 C--N 1.379 2.169 0 C-N-CA 122.461 2.107 . . . . 72.22 111.948 172.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -54.49 -42.93 97.07 Favored Pre-proline 0 CA--C 1.564 1.506 0 CA-C-O 118.106 -0.949 . . . . 63.25 112.117 175.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_exo -46.12 -53.24 6.07 Favored 'Trans proline' 0 C--N 1.397 3.106 0 C-N-CA 122.684 2.256 . . . . 74.13 114.126 167.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . 0.456 HG23 HG23 ' A' ' 223' ' ' VAL . 12.8 mt -65.96 -37.02 78.89 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 O-C-N 123.169 0.293 . . . . 71.31 110.923 -178.111 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.13 -43.86 97.23 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 123.306 0.642 . . . . 63.33 111.599 -177.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 32.6 m -76.79 -37.97 28.9 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 115.951 -0.568 . . . . 72.0 111.262 -176.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.4 m -83.44 -23.87 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 N-CA-C 111.763 0.283 . . . . 73.22 111.763 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.458 ' HA2' HG21 ' A' ' 223' ' ' VAL . . . 72.19 64.05 2.77 Favored Glycine 0 C--N 1.341 0.84 0 CA-C-N 116.227 -0.442 . . . . 71.12 112.183 -172.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -94.53 -154.19 30.78 Favored Glycine 0 C--N 1.355 1.625 0 CA-C-O 121.428 0.46 . . . . 52.32 112.378 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 14.7 mmmm -121.76 128.97 52.33 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 123.781 0.832 . . . . 75.32 109.104 -174.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 39.5 t -116.18 129.98 71.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 N-CA-C 108.91 -0.774 . . . . 75.03 108.91 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -78.24 106.09 9.91 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 107.861 -1.163 . . . . 75.41 107.861 168.064 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -98.83 133.42 43.15 Favored 'General case' 0 C--N 1.343 0.31 0 C-N-CA 123.822 0.849 . . . . 64.42 108.922 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -74.94 144.24 43.32 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 122.651 0.38 . . . . 71.23 110.402 173.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 7.5 t -148.27 167.43 25.16 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 124.353 1.061 . . . . 75.4 109.77 172.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 45.8 mt -71.58 -15.12 62.26 Favored 'General case' 0 CA--C 1.552 1.046 0 CA-C-N 115.178 -0.919 . . . . 75.04 110.796 176.363 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -80.73 -20.73 42.16 Favored 'General case' 0 CA--C 1.564 1.503 0 C-N-CA 124.747 1.219 . . . . 71.51 109.888 174.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 135.03 -151.26 20.4 Favored Glycine 0 C--N 1.361 1.932 0 CA-C-O 119.628 -0.54 . . . . 62.43 112.41 -177.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -91.84 124.54 0.78 Allowed 'Trans proline' 0 C--N 1.368 1.591 0 C-N-CA 123.33 2.687 . . . . 70.1 111.807 170.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 22.7 m -116.98 160.71 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 C-N-CA 123.604 0.762 . . . . 62.04 110.771 179.389 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -115.28 110.39 19.35 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 109.001 -0.74 . . . . 62.51 109.001 178.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.498 HG21 HD22 ' A' ' 235' ' ' LEU . 5.9 p -97.09 138.29 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 123.37 0.668 . . . . 71.24 110.512 177.082 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -93.81 111.7 23.44 Favored 'General case' 0 C--O 1.239 0.533 0 C-N-CA 123.698 0.799 . . . . 73.32 109.009 173.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.458 HG21 ' HA2' ' A' ' 207' ' ' GLY . 13.8 m -86.47 140.66 34.0 Favored Pre-proline 0 CA--C 1.55 0.964 0 N-CA-C 108.91 -0.774 . . . . 71.11 108.91 177.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -62.12 143.38 94.62 Favored 'Trans proline' 0 CA--C 1.56 1.818 0 C-N-CA 122.501 2.134 . . . . 74.52 112.318 177.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.9 123.76 12.47 Favored 'Trans proline' 0 C--N 1.378 2.104 0 C-N-CA 122.408 2.072 . . . . 73.01 110.669 174.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 44.2 mtm105 64.07 48.88 2.87 Favored 'General case' 0 N--CA 1.475 0.824 0 O-C-N 124.233 0.958 . . . . 75.35 110.343 -173.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.8 t -71.16 170.63 12.55 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.319 0.58 . . . . 72.2 111.103 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.9 mp0 -121.91 139.39 53.71 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.221 1.008 . . . . 73.01 108.574 -176.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -76.62 127.69 33.28 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.288 0.635 . . . . 75.41 109.94 179.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.38 -4.71 23.36 Favored Glycine 0 C--N 1.339 0.746 0 N-CA-C 111.512 -0.635 . . . . 51.44 111.512 -173.077 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . 0.439 ' O ' ' HA ' ' A' ' 252' ' ' GLU . 60.6 mtt-85 -71.51 160.1 33.32 Favored 'General case' 0 C--N 1.36 1.042 0 C-N-CA 122.917 0.487 . . . . 74.1 110.762 173.669 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.451 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.1 OUTLIER -123.43 100.43 6.82 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.088 0.955 . . . . 74.42 108.774 179.69 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . 0.43 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 86.3 mt -84.89 104.85 15.2 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 108.92 -0.77 . . . . 74.22 108.92 -176.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 14.6 ttp180 -82.31 101.95 10.89 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 114.784 -1.098 . . . . 74.31 110.367 -171.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.514 ' HB3' ' HG3' ' A' ' 238' ' ' LYS . 48.9 mt -89.62 101.61 14.3 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 115.131 -0.94 . . . . 65.24 108.555 171.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 47.0 mtpt -73.06 149.15 43.41 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.354 0.662 . . . . 74.52 110.574 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 67.72 28.88 73.48 Favored Glycine 0 C--N 1.345 1.05 0 O-C-N 123.369 0.418 . . . . 74.55 113.413 -178.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . 0.514 ' HG3' ' HB3' ' A' ' 235' ' ' LEU . 0.0 OUTLIER -127.55 -8.38 5.69 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 124.165 0.986 . . . . 72.44 111.145 -176.973 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . 0.433 ' HA2' HD13 ' A' ' 193' ' ' LEU . . . -84.71 -163.97 37.42 Favored Glycine 0 C--N 1.344 0.977 0 CA-C-N 115.919 -0.582 . . . . 75.21 113.174 176.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.632 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 1.5 m-85 -85.99 158.88 55.39 Favored Pre-proline 0 N--CA 1.48 1.053 0 N-CA-C 109.341 -0.615 . . . . 73.22 109.341 179.014 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -47.53 129.55 16.83 Favored 'Trans proline' 0 C--N 1.382 2.32 0 C-N-CA 123.077 2.518 . . . . 73.22 113.598 174.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -165.34 -162.8 17.3 Favored Glycine 0 CA--C 1.535 1.282 0 CA-C-O 118.986 -0.897 . . . . 63.43 112.203 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_exo -47.05 -41.1 26.55 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 124.616 3.544 . . . . 71.43 115.378 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -87.47 21.0 2.63 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 123.965 0.906 . . . . 74.24 112.145 -177.456 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.15 -81.82 1.5 Allowed Glycine 0 C--N 1.346 1.102 0 N-CA-C 110.568 -1.013 . . . . 65.2 110.568 -173.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -113.2 135.41 53.85 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.624 -1.25 . . . . 74.5 107.624 169.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.48 -157.21 5.28 Favored Glycine 0 C--N 1.345 1.045 0 N-CA-C 115.152 0.821 . . . . 73.3 115.152 -169.165 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -111.27 164.58 12.74 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 123.155 0.582 . . . . 75.42 110.374 -175.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.616 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 20.0 tp -128.04 116.26 19.75 Favored 'General case' 0 C--O 1.218 -0.602 0 C-N-CA 124.644 1.178 . . . . 75.42 109.342 169.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . 0.451 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 10.6 m-85 -97.46 107.36 19.86 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 109.243 -0.651 . . . . 72.45 109.243 175.298 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.544 ' HB3' ' HB2' ' A' ' 197' ' ' LEU . 85.8 mt -86.58 115.4 24.04 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 124.004 0.922 . . . . 75.11 112.042 178.236 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.439 ' HA ' ' O ' ' A' ' 231' ' ' ARG . 36.4 tt0 -77.74 93.91 4.37 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 108.348 -0.982 . . . . 63.34 108.348 175.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.427 HG12 HG11 ' A' ' 199' ' ' VAL . 91.9 t -48.71 116.49 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 C-N-CA 124.705 1.202 . . . . 73.21 111.286 176.738 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 26.5 mmm180 -120.75 94.8 4.47 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 107.416 -1.328 . . . . 75.22 107.416 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 60.3 mt -77.69 106.98 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-N 115.379 -0.828 . . . . 74.2 109.366 -178.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 CA--C 1.552 1.034 0 C-N-CA 124.034 0.934 . . . . 62.33 108.942 -179.701 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.414 ' HB2' ' O ' ' A' ' 99' ' ' VAL . . . . . . . . 0 N--CA 1.477 0.878 0 N-CA-C 109.671 -0.492 . . . . 71.32 109.671 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.549 ' HB2' ' HB3' ' A' ' 136' ' ' ARG . . . -84.66 -67.08 0.82 Allowed 'General case' 0 CA--C 1.546 0.79 0 O-C-N 123.384 0.427 . . . . 71.04 110.497 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -100.69 -37.63 8.66 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 122.776 0.43 . . . . 74.22 111.289 174.673 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.414 ' O ' ' HB2' ' A' ' 96' ' ' ALA . 7.4 p -61.15 125.25 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 O-C-N 123.79 0.681 . . . . 64.52 110.946 -175.22 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -74.25 -75.92 0.15 Allowed 'General case' 0 C--N 1.346 0.427 0 N-CA-C 108.483 -0.932 . . . . 72.03 108.483 174.191 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -162.91 153.23 16.34 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 124.866 1.266 . . . . 74.11 108.416 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 8.4 p -67.74 121.03 16.13 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.916 0 CA-C-O 121.063 0.459 . . . . 73.31 109.798 172.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.571 HG22 ' HG3' ' A' ' 122' ' ' GLU . 11.4 t -96.46 -27.88 14.68 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 123.699 0.799 . . . . 61.13 111.86 -174.066 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 42.3 m -149.9 173.14 14.12 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 123.935 0.894 . . . . 72.55 109.821 -177.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -169.96 62.48 0.18 Allowed Glycine 0 C--N 1.338 0.67 0 N-CA-C 111.057 -0.817 . . . . 74.31 111.057 177.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 32.7 t -148.72 119.52 7.57 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.272 0.629 . . . . 74.43 109.606 -174.32 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.76 75.13 2.29 Favored Glycine 0 C--N 1.348 1.239 0 O-C-N 123.439 0.462 . . . . 44.04 112.868 -177.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -83.81 167.64 44.44 Favored Glycine 0 C--N 1.342 0.894 0 N-CA-C 112.167 -0.373 . . . . 72.24 112.167 175.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 28.4 m 61.74 35.41 16.86 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 123.581 0.752 . . . . 73.43 110.683 -173.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -70.38 -33.0 68.14 Favored Glycine 0 C--N 1.351 1.379 0 CA-C-N 114.921 -1.036 . . . . 75.13 112.03 175.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 66.68 -96.71 0.31 Allowed Glycine 0 C--N 1.349 1.25 0 O-C-N 123.621 0.248 . . . . 74.32 113.653 173.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 39.3 p -70.37 -30.05 66.87 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 124.011 0.924 . . . . 72.01 111.397 -177.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -164.27 -126.02 0.8 Allowed Glycine 0 C--N 1.338 0.651 0 N-CA-C 111.015 -0.834 . . . . 73.55 111.015 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 171.96 146.64 5.4 Favored Glycine 0 C--N 1.339 0.748 0 N-CA-C 111.29 -0.724 . . . . 71.43 111.29 177.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 62.6 p -100.19 -170.28 1.85 Allowed 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 123.766 0.826 . . . . 73.45 110.817 -176.726 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -55.34 122.68 27.28 Favored Glycine 0 C--N 1.361 1.952 0 N-CA-C 110.568 -1.013 . . . . 72.21 110.568 170.257 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 40.4 ttm180 -61.72 131.22 49.21 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.011 0.524 . . . . 75.44 111.875 -167.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -77.1 152.33 35.03 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 115.228 -0.896 . . . . 52.21 111.442 -178.132 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.677 HD13 ' HA2' ' A' ' 165' ' ' GLY . 24.5 mt -94.36 155.26 17.07 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 106.681 -1.6 . . . . 70.24 106.681 159.284 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . 0.512 ' HE ' HD13 ' A' ' 175' ' ' LEU . 29.6 ttm180 -144.47 114.66 7.47 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 109.66 -0.496 . . . . 74.43 109.66 -174.147 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -126.8 126.46 43.42 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 123.523 0.729 . . . . 54.34 110.195 -177.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.571 ' HG3' HG22 ' A' ' 103' ' ' THR . 24.4 mt-10 -92.09 136.74 32.93 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 108.505 -0.924 . . . . 74.41 108.505 169.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -145.13 147.26 33.72 Favored Pre-proline 0 N--CA 1.468 0.44 0 C-N-CA 123.191 0.596 . . . . 74.43 110.578 -170.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.86 154.48 67.3 Favored 'Trans proline' 0 C--N 1.369 1.617 0 C-N-CA 121.877 1.718 . . . . 71.53 111.646 170.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 22.2 tp -149.5 150.34 32.15 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.811 0.844 . . . . 73.23 109.067 174.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.589 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 69.2 m -84.59 151.98 24.16 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 123.326 0.651 . . . . 72.42 109.487 172.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.495 HD11 ' O ' ' A' ' 183' ' ' HIS . 45.1 mt -58.19 -48.05 81.53 Favored 'General case' 0 N--CA 1.483 1.194 0 CA-C-O 121.881 0.848 . . . . 74.44 110.204 176.236 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.63 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.7 mp0 -57.88 -31.79 67.06 Favored 'General case' 0 N--CA 1.484 1.259 0 CA-C-N 114.328 -1.306 . . . . 74.12 111.97 178.06 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 38.0 mm-40 -88.95 -16.69 31.17 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 112.109 0.411 . . . . 63.14 112.109 178.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.67 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -63.26 -31.65 72.85 Favored 'General case' 0 C--O 1.25 1.12 0 CA-C-O 121.168 0.508 . . . . 74.45 110.152 162.853 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.546 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 17.1 t80 -71.87 -60.37 2.27 Favored 'General case' 0 C--N 1.351 0.642 0 CA-C-N 115.326 -0.852 . . . . 74.3 110.877 168.238 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -71.89 -28.62 63.64 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 113.605 0.965 . . . . 75.55 113.605 -168.233 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 74.09 -87.46 0.68 Allowed Glycine 0 CA--C 1.532 1.123 0 N-CA-C 110.738 -0.945 . . . . 63.51 110.738 -167.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 84.01 126.65 1.34 Allowed Glycine 0 C--N 1.352 1.449 0 C-N-CA 122.844 0.259 . . . . 43.34 113.129 174.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.429 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.7 mp0 -78.28 114.56 17.28 Favored 'General case' 0 C--N 1.345 0.392 0 N-CA-C 108.431 -0.952 . . . . 74.5 108.431 176.509 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.549 ' HB3' ' HB2' ' A' ' 97' ' ' ALA . 7.3 mpt_? -131.36 153.38 49.7 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 123.084 0.554 . . . . 74.22 109.884 176.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 14.7 p -72.89 140.9 17.13 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.083 0 C-N-CA 123.308 0.643 . . . . 73.3 111.779 -173.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 7.9 p -136.43 124.57 35.15 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 C-N-CA 125.239 1.416 . . . . 73.12 108.553 -179.425 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -116.57 96.44 5.51 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 107.358 -1.349 . . . . 71.15 107.358 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.487 HG12 HD12 ' A' ' 119' ' ' LEU . 90.0 t -130.73 131.49 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 122.992 0.517 . . . . 73.44 109.714 -178.531 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.02 30.08 19.6 Favored 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 124.962 1.305 . . . . 64.31 112.021 -179.278 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 92.07 -1.15 73.47 Favored Glycine 0 C--N 1.344 1.025 0 CA-C-N 115.336 -0.847 . . . . 75.23 114.137 173.741 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.84 119.15 38.64 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-N 118.284 1.042 . . . . 75.12 110.691 -179.312 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 63.2 ttp85 -92.66 106.66 18.6 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.139 0.975 . . . . 73.42 108.489 172.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 61.7 t -133.5 149.77 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 108.238 -1.023 . . . . 74.31 108.238 178.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 34.9 p -81.02 120.97 25.47 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 109.132 -0.692 . . . . 73.31 109.132 172.597 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.4 p -96.83 131.12 44.37 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 CA-C-O 121.19 0.519 . . . . 74.41 110.647 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . 0.429 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 40.6 ttp180 -104.28 102.06 11.76 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 107.746 -1.205 . . . . 75.53 107.746 175.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.663 ' HB ' HD12 ' A' ' 159' ' ' ILE . 30.8 pt -91.96 130.82 37.07 Favored Pre-proline 0 CA--C 1.549 0.941 0 N-CA-C 108.965 -0.754 . . . . 74.24 108.965 176.226 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -63.63 135.99 51.82 Favored 'Trans proline' 0 C--N 1.383 2.37 0 C-N-CA 122.88 2.387 . . . . 73.34 112.847 -171.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.402 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 76.0 Cg_exo -54.49 141.59 72.88 Favored 'Trans proline' 0 C--N 1.379 2.159 0 C-N-CA 123.427 2.751 . . . . 73.03 112.381 169.6 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 104.18 24.66 7.45 Favored Glycine 0 C--N 1.338 0.675 0 N-CA-C 111.645 -0.582 . . . . 71.43 111.645 -176.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.67 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.4 p -95.06 158.74 2.93 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.917 0 N-CA-C 108.504 -0.924 . . . . 72.31 108.504 -177.268 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.486 ' HA ' HD12 ' A' ' 180' ' ' LEU . 27.0 mtm180 -149.62 176.15 10.91 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 124.426 1.09 . . . . 75.14 110.135 -170.621 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -52.93 124.86 15.3 Favored 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 124.017 0.927 . . . . 62.52 111.744 173.148 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.85 10.03 83.44 Favored Glycine 0 C--N 1.347 1.182 0 O-C-N 123.534 0.521 . . . . 72.54 113.809 177.36 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.444 ' HB3' HG21 ' A' ' 153' ' ' VAL . 33.0 t -76.97 122.35 24.77 Favored 'General case' 0 C--O 1.246 0.879 0 N-CA-C 109.391 -0.596 . . . . 74.33 109.391 179.342 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.471 HG22 HD22 ' A' ' 175' ' ' LEU . 7.1 p -94.14 121.88 45.14 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.964 0 C-N-CA 123.77 0.828 . . . . 73.42 109.689 -179.335 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.663 HD12 ' HB ' ' A' ' 149' ' ' ILE . 46.3 mt -110.52 118.16 56.51 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 124.273 1.029 . . . . 74.52 109.999 -172.475 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 60.0 ttp85 -95.78 109.96 22.19 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 122.863 0.465 . . . . 75.44 110.408 -178.169 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 10.7 m -109.48 101.57 46.44 Favored Pre-proline 0 CA--C 1.569 1.7 0 C-N-CA 122.933 0.493 . . . . 63.23 110.125 -178.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . 0.49 ' HA ' ' HB3' ' A' ' 173' ' ' ASP . 33.2 Cg_exo -64.1 147.61 91.48 Favored 'Trans proline' 0 C--N 1.384 2.403 0 C-N-CA 123.554 2.836 . . . . 62.02 114.314 -172.675 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.18 5.08 89.36 Favored Glycine 0 C--N 1.348 1.249 0 CA-C-N 115.058 -0.974 . . . . 72.14 114.447 175.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 46.9 tpp -96.43 -36.14 10.92 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.092 0.557 . . . . 73.52 110.95 -177.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . 0.677 ' HA2' HD13 ' A' ' 119' ' ' LEU . . . -83.45 -105.96 0.52 Allowed Glycine 0 C--N 1.349 1.26 0 CA-C-N 115.635 -0.711 . . . . 72.03 114.3 -175.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.408 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -64.67 93.99 0.16 Allowed Glycine 0 C--N 1.348 1.247 0 C-N-CA 123.351 0.501 . . . . 62.35 113.125 179.24 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -67.79 117.28 9.47 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 123.662 0.785 . . . . 73.34 110.173 178.014 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 165.11 -172.06 40.64 Favored Glycine 0 C--N 1.34 0.773 0 O-C-N 123.601 0.563 . . . . 75.34 112.983 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -61.5 -40.4 70.84 Favored Pre-proline 0 CA--C 1.56 1.343 0 C-N-CA 123.739 0.816 . . . . 75.13 111.867 174.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -82.01 104.52 1.41 Allowed 'Trans proline' 0 C--N 1.393 2.918 0 C-N-CA 122.064 1.843 . . . . 73.03 109.73 162.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -71.74 125.29 10.95 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 121.937 1.758 . . . . 61.01 111.77 -174.448 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.408 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -101.09 160.42 18.6 Favored Glycine 0 C--N 1.34 0.763 0 N-CA-C 111.075 -0.81 . . . . 62.35 111.075 176.837 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.49 ' HB3' ' HA ' ' A' ' 162' ' ' PRO . 0.9 OUTLIER -124.94 179.59 4.96 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.696 0.798 . . . . 74.25 110.966 -167.021 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 21.2 tp -127.74 118.91 24.66 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.146 0.578 . . . . 75.24 109.686 175.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.512 HD13 ' HE ' ' A' ' 120' ' ' ARG . 86.0 mt -86.19 99.32 11.45 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 124.608 1.163 . . . . 63.15 110.391 177.606 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 76.5 mt -89.82 102.61 15.31 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.704 0.802 . . . . 73.53 110.576 174.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.447 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 29.3 t -90.9 102.79 13.79 Favored 'Isoleucine or valine' 0 C--O 1.244 0.777 0 N-CA-C 108.313 -0.995 . . . . 63.02 108.313 175.597 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 5.5 m -79.75 150.47 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 CA-C-O 121.65 0.738 . . . . 75.5 111.479 -173.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 19.6 mmt85 -122.26 98.47 5.95 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 114.482 -1.235 . . . . 73.24 107.811 -178.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.486 HD12 ' HA ' ' A' ' 154' ' ' ARG . 21.5 mt -68.34 151.49 46.81 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.207 0.603 . . . . 73.42 112.443 -177.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.589 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 60.6 mt -53.69 138.58 51.95 Favored Pre-proline 0 CA--C 1.559 1.322 0 O-C-N 124.091 0.869 . . . . 74.0 111.324 -179.304 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -57.32 -13.08 11.94 Favored 'Trans proline' 0 C--N 1.383 2.375 0 C-N-CA 124.239 3.293 . . . . 74.12 115.584 -173.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . 0.495 ' O ' HD11 ' A' ' 127' ' ' LEU . 1.0 OUTLIER -87.52 114.33 58.3 Favored Pre-proline 0 CA--C 1.548 0.889 0 N-CA-C 108.708 -0.849 . . . . 75.14 108.708 173.247 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -92.62 126.67 0.75 Allowed 'Trans proline' 0 C--N 1.377 2.066 0 C-N-CA 122.568 2.179 . . . . 74.31 112.287 173.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.9 p -127.29 -41.8 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 N-CA-C 109.565 -0.531 . . . . 61.13 109.565 174.302 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . 0.417 ' HE2' HD13 ' A' ' 193' ' ' LEU . 6.5 m-85 -107.52 125.2 50.98 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 115.896 -0.593 . . . . 74.31 110.691 -178.074 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.57 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 6.2 mpt_? -112.38 103.97 12.11 Favored 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 107.237 -1.394 . . . . 72.12 107.237 175.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 42.1 tp -92.72 136.51 33.17 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.115 0.566 . . . . 71.14 109.8 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -143.68 134.05 24.64 Favored 'General case' 0 C--O 1.241 0.657 0 N-CA-C 109.225 -0.657 . . . . 75.35 109.225 165.586 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 68.28 -81.88 0.2 Allowed Glycine 0 C--N 1.352 1.426 0 O-C-N 123.913 0.758 . . . . 71.22 113.087 -178.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 24.1 pt20 -144.34 -17.57 0.56 Allowed 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 123.645 0.778 . . . . 65.51 110.755 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -109.86 158.27 18.35 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-O 121.269 0.557 . . . . 75.25 111.683 -170.049 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.468 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 77.4 mt -111.34 163.38 14.04 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.005 1.322 . . . . 74.44 111.779 -168.67 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . 0.57 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 82.5 m-85 -139.52 124.16 18.37 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 114.563 -1.199 . . . . 74.51 108.516 170.032 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -135.84 171.43 14.47 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 122.836 0.454 . . . . 65.32 110.157 175.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 7.8 m -102.48 134.42 45.84 Favored 'General case' 0 CA--C 1.544 0.712 0 N-CA-C 109.389 -0.597 . . . . 71.31 109.389 178.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.597 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 42.7 tp -109.98 114.09 27.34 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.382 1.073 . . . . 62.32 110.133 -177.384 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -94.11 103.71 15.75 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.414 0.686 . . . . 74.01 109.746 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . 0.546 HG11 HG12 ' A' ' 223' ' ' VAL . 3.5 m -113.2 142.44 27.42 Favored Pre-proline 0 N--CA 1.479 1.012 0 C-N-CA 122.981 0.513 . . . . 74.3 109.668 176.666 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -68.96 155.49 68.33 Favored 'Trans proline' 0 C--N 1.365 1.439 0 C-N-CA 122.33 2.02 . . . . 74.11 111.38 167.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . 0.404 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -60.04 -45.85 98.02 Favored Pre-proline 0 N--CA 1.479 0.979 0 CA-C-O 118.737 -0.649 . . . . 73.21 112.215 177.518 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . 0.41 ' O ' HG23 ' A' ' 206' ' ' VAL . 9.8 Cg_endo -49.77 -45.76 30.49 Favored 'Trans proline' 0 C--N 1.391 2.781 0 C-N-CA 122.568 2.179 . . . . 60.42 113.348 171.479 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . 0.49 ' HA ' ' HA3' ' A' ' 207' ' ' GLY . 3.5 mt -67.64 -43.94 86.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 O-C-N 121.967 -0.458 . . . . 72.51 111.569 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -52.51 -43.96 65.42 Favored 'General case' 0 CA--C 1.538 0.489 0 O-C-N 124.446 1.091 . . . . 55.24 111.177 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . 0.631 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 28.8 m -88.91 -58.46 3.46 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.262 0 N-CA-C 113.015 0.746 . . . . 74.53 113.015 -176.555 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . 0.511 HG13 HG22 ' A' ' 205' ' ' VAL . 18.6 m -104.43 -25.28 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 113.328 0.862 . . . . 74.22 113.328 -172.124 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.49 ' HA3' ' HA ' ' A' ' 203' ' ' ILE . . . -74.96 -70.82 1.21 Allowed Glycine 0 C--N 1.346 1.123 0 C-N-CA 121.565 -0.35 . . . . 64.35 112.289 -168.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 92.15 -2.06 74.6 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-O 119.2 -0.778 . . . . 74.34 114.131 170.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 40.8 mtmt -139.33 138.93 37.09 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 108.352 -0.981 . . . . 74.01 108.352 178.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . 0.501 HG11 HG13 ' A' ' 199' ' ' VAL . 7.3 p -160.58 145.98 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 C-N-CA 123.897 0.879 . . . . 75.01 108.71 -178.771 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . 0.462 ' HA ' ' HA ' ' A' ' 220' ' ' GLU . 69.0 mtt180 -93.56 123.88 37.17 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 122.759 0.424 . . . . 74.24 109.951 177.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.458 ' HB2' HD11 ' A' ' 197' ' ' LEU . . . -101.18 165.02 11.51 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 124.237 1.015 . . . . 73.35 109.146 173.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 66.2 mmm -103.34 146.75 28.0 Favored 'General case' 0 C--O 1.239 0.551 0 CA-C-O 121.162 0.506 . . . . 74.33 110.419 175.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 214' ' ' THR . . . . . 0.413 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.3 t -138.6 169.08 18.43 Favored 'General case' 0 C--O 1.238 0.467 0 CA-C-N 114.726 -1.125 . . . . 70.43 109.709 173.721 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . 0.63 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 81.9 mt -70.92 -3.3 18.53 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 114.844 -1.071 . . . . 70.31 113.223 -174.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 1.8 pp20? -121.0 -1.45 9.85 Favored 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.274 0.629 . . . . 73.1 112.52 178.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.16 -158.51 27.71 Favored Glycine 0 N--CA 1.475 1.278 0 CA-C-O 119.719 -0.489 . . . . 44.25 113.443 176.043 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -90.76 129.47 1.43 Allowed 'Trans proline' 0 C--N 1.367 1.52 0 C-N-CA 123.223 2.616 . . . . 62.22 112.412 174.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . 0.401 HG12 ' HE3' ' A' ' 238' ' ' LYS . 31.5 m -109.66 151.43 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 123.819 0.848 . . . . 71.32 109.434 171.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . 0.462 ' HA ' ' HA ' ' A' ' 211' ' ' ARG . 32.9 tt0 -114.58 114.62 25.97 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.647 -0.501 . . . . 64.32 109.647 173.055 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.419 HG22 HD21 ' A' ' 235' ' ' LEU . 4.5 p -100.56 144.32 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 C-N-CA 124.703 1.201 . . . . 61.21 110.744 178.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -95.96 113.02 24.6 Favored 'General case' 0 C--O 1.24 0.561 0 N-CA-C 109.159 -0.682 . . . . 73.34 109.159 173.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.546 HG12 HG11 ' A' ' 199' ' ' VAL . 14.1 m -84.53 138.6 38.4 Favored Pre-proline 0 N--CA 1.481 1.097 0 N-CA-C 108.86 -0.792 . . . . 74.33 108.86 176.36 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -54.3 140.68 72.51 Favored 'Trans proline' 0 C--N 1.379 2.136 0 C-N-CA 122.625 2.217 . . . . 72.53 112.622 177.283 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -54.17 112.74 1.07 Allowed 'Trans proline' 0 C--N 1.379 2.181 0 C-N-CA 122.881 2.388 . . . . 75.13 111.282 174.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . 0.631 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 60.6 mtp180 63.27 58.43 1.4 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.531 1.133 . . . . 74.52 110.634 -171.164 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.8 t -71.15 171.82 10.31 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.334 -0.848 . . . . 74.54 110.431 175.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.5 mp0 -121.18 146.35 46.87 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.711 0.804 . . . . 75.51 109.225 -175.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -72.52 113.73 9.87 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 123.218 0.607 . . . . 65.22 110.292 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.6 4.88 19.23 Favored Glycine 0 C--N 1.339 0.712 0 CA-C-N 115.73 -0.668 . . . . 72.21 112.399 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 61.3 mtp180 -76.17 153.25 36.32 Favored 'General case' 0 N--CA 1.477 0.918 0 CA-C-N 117.345 0.573 . . . . 73.44 109.962 172.092 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.482 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 0.2 OUTLIER -111.71 119.27 38.08 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 123.727 0.811 . . . . 73.23 108.934 -179.746 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 70.2 mt -106.02 114.49 28.66 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 122.85 0.46 . . . . 74.31 109.827 -178.022 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . 0.562 ' HG3' ' HB3' ' A' ' 248' ' ' ASP . 39.7 ttp180 -82.48 104.22 12.61 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 124.863 1.265 . . . . 74.41 111.354 -171.23 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.493 ' HB2' ' HB3' ' A' ' 249' ' ' LEU . 38.2 mt -89.48 97.63 11.3 Favored 'General case' 0 C--O 1.239 0.531 0 C-N-CA 123.231 0.612 . . . . 71.55 109.594 172.618 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -72.81 134.95 45.12 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 114.766 -1.106 . . . . 64.51 110.119 -178.323 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 85.26 24.65 43.02 Favored Glycine 0 C--N 1.34 0.77 0 O-C-N 123.493 0.496 . . . . 74.44 113.247 178.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . 0.401 ' HE3' HG12 ' A' ' 219' ' ' VAL . 70.3 mmtt -124.52 -6.88 7.5 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 123.223 0.609 . . . . 75.43 112.353 176.627 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -85.32 -161.67 34.74 Favored Glycine 0 C--N 1.345 1.082 0 O-C-N 123.53 0.518 . . . . 60.42 112.506 175.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.546 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 92.2 m-85 -97.24 147.0 32.32 Favored Pre-proline 0 N--CA 1.481 1.082 0 C-N-CA 123.524 0.729 . . . . 75.25 111.282 175.434 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . 0.41 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 36.2 Cg_endo -64.43 132.52 33.75 Favored 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 122.257 1.971 . . . . 75.33 111.315 171.452 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -156.83 -148.64 5.15 Favored Glycine 0 CA--C 1.532 1.152 0 CA-C-O 119.01 -0.883 . . . . 73.5 111.595 -176.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -51.63 -53.96 6.15 Favored 'Trans proline' 0 C--N 1.377 2.055 0 C-N-CA 123.953 3.102 . . . . 73.13 114.999 -177.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -83.67 -24.46 31.32 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 122.608 0.363 . . . . 72.2 111.778 -177.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 141.86 -155.4 25.4 Favored Glycine 0 N--CA 1.47 0.92 0 N-CA-C 110.091 -1.204 . . . . 74.24 110.091 -177.088 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.41 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 22.1 ttm180 -65.13 134.73 54.39 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 118.511 1.155 . . . . 73.13 109.351 171.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -75.05 -170.85 27.49 Favored Glycine 0 C--O 1.249 1.052 0 CA-C-O 121.974 0.763 . . . . 73.12 114.686 -170.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . 0.562 ' HB3' ' HG3' ' A' ' 234' ' ' ARG . 12.1 m-20 -129.33 136.9 50.61 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 114.268 -0.966 . . . . 74.42 109.565 -169.555 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.493 ' HB3' ' HB2' ' A' ' 235' ' ' LEU . 20.7 tp -97.01 111.74 23.82 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.889 -0.411 . . . . 74.13 109.889 179.559 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -91.85 106.63 18.61 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.222 0.534 . . . . 74.12 109.813 177.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.597 ' HB3' ' HB2' ' A' ' 197' ' ' LEU . 85.9 mt -87.53 120.01 28.41 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 124.245 1.018 . . . . 70.34 112.379 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -80.61 93.86 6.2 Favored 'General case' 0 CA--C 1.539 0.535 0 N-CA-C 108.093 -1.077 . . . . 75.44 108.093 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 60.3 t -48.96 123.68 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.561 1.144 . . . . 73.01 111.184 175.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 38.5 mmm-85 -128.69 100.94 5.92 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 107.219 -1.4 . . . . 75.01 107.219 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 56.5 mt -83.34 117.84 29.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 115.149 -0.932 . . . . 70.3 110.05 -177.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.8 t . . . . . 0 CA--C 1.556 1.187 0 C-N-CA 124.23 1.012 . . . . 72.34 108.603 174.53 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 109.968 -0.382 . . . . 64.54 109.968 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -177.48 -68.85 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.944 0 C-N-CA 124.839 1.255 . . . . 73.23 107.971 176.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.65 HD21 ' HG3' ' A' ' 136' ' ' ARG . 20.4 tp -92.46 -55.14 3.51 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 115.488 -0.778 . . . . 61.32 110.236 -176.797 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.572 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 10.0 p -60.76 126.79 19.26 Favored 'Isoleucine or valine' 0 C--N 1.36 1.063 0 O-C-N 123.465 0.478 . . . . 73.01 111.025 175.579 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -83.31 -65.9 0.95 Allowed 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.493 -0.776 . . . . 73.12 109.699 -179.104 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -150.13 147.45 27.77 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 114.987 -1.006 . . . . 74.1 110.258 -169.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 92.9 t -78.81 124.59 37.4 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 N-CA-C 109.259 -0.645 . . . . 74.31 109.259 169.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 70.1 p -76.53 93.4 3.55 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 123.359 0.664 . . . . 73.05 109.471 176.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.7 m -72.72 86.15 1.22 Allowed 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 123.52 0.728 . . . . 63.02 109.226 178.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -154.56 120.3 1.01 Allowed Glycine 0 C--N 1.34 0.788 0 CA-C-N 115.027 -0.988 . . . . 70.33 110.779 -177.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 39.8 t -73.04 161.69 30.36 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 123.609 0.763 . . . . 74.43 111.994 -174.173 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -122.23 57.14 0.63 Allowed Glycine 0 C--N 1.338 0.691 0 CA-C-N 114.888 -1.051 . . . . 72.52 110.647 175.337 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -68.39 -21.86 74.47 Favored Glycine 0 C--N 1.354 1.578 0 O-C-N 124.02 0.482 . . . . 74.44 113.791 -179.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 19.4 m -63.09 90.79 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.024 0 C-N-CA 123.796 0.839 . . . . 74.34 110.551 177.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 158.04 -42.33 0.51 Allowed Glycine 0 C--N 1.338 0.659 0 CA-C-N 115.483 -0.78 . . . . 54.23 111.23 -175.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 85.47 -48.92 4.1 Favored Glycine 0 C--N 1.354 1.571 0 C-N-CA 122.78 0.229 . . . . 74.21 112.543 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 36.7 m -71.19 108.2 4.58 Favored 'General case' 0 CA--C 1.553 1.089 0 C-N-CA 124.006 0.923 . . . . 75.2 110.407 177.209 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -140.65 178.78 19.77 Favored Glycine 0 C--N 1.343 0.925 0 N-CA-C 111.417 -0.673 . . . . 52.41 111.417 176.777 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -133.39 -173.02 13.12 Favored Glycine 0 C--N 1.346 1.109 0 CA-C-N 117.235 0.518 . . . . 61.22 113.432 -178.332 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 15.9 m -65.1 -56.18 14.48 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 124.22 1.008 . . . . 73.42 111.162 -178.683 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -83.14 117.59 4.45 Favored Glycine 0 C--N 1.344 1.01 0 N-CA-C 111.588 -0.605 . . . . 73.11 111.588 176.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 27.7 ptt180 -73.29 154.39 40.17 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 123.452 0.701 . . . . 73.21 112.337 -177.065 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.672 ' HB2' ' HB2' ' A' ' 167' ' ' GLN . 16.2 t70 -72.27 133.61 45.14 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 108.591 -0.892 . . . . 74.5 108.591 170.119 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 28.6 tp -101.61 142.07 33.53 Favored 'General case' 0 C--O 1.22 -0.453 0 N-CA-C 107.356 -1.35 . . . . 72.33 107.356 -178.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 37.3 ttp-105 -143.28 132.93 23.73 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 108.513 -0.921 . . . . 72.23 108.513 -178.091 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -144.75 138.41 27.16 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 123.953 0.901 . . . . 75.54 109.052 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -103.26 148.98 25.15 Favored 'General case' 0 C--O 1.252 1.191 0 CA-C-O 120.935 0.398 . . . . 72.15 110.101 176.344 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.572 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.6 pt? -146.95 130.93 8.44 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.674 -0.694 . . . . 73.24 111.967 -170.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.97 120.64 7.63 Favored 'Trans proline' 0 C--N 1.378 2.084 0 C-N-CA 122.49 2.127 . . . . 74.54 111.477 174.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 18.0 tp -120.42 152.79 37.45 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.542 1.137 . . . . 70.04 109.165 179.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.497 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 22.4 m -86.25 155.41 20.7 Favored 'General case' 0 CA--C 1.551 0.993 0 N-CA-C 109.365 -0.606 . . . . 63.15 109.365 172.009 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 28.6 mt -55.34 -49.23 72.76 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-O 121.923 0.868 . . . . 73.13 109.934 175.113 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.605 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.3 mp0 -55.96 -35.44 66.69 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 113.943 -1.48 . . . . 73.32 111.544 177.665 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.497 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 35.7 mm-40 -83.11 -19.57 36.5 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 122.993 0.517 . . . . 73.33 112.077 -179.474 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.538 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -65.27 -31.66 72.92 Favored 'General case' 0 C--O 1.246 0.919 0 CA-C-O 121.169 0.509 . . . . 72.44 110.162 165.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.438 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 6.6 t80 -77.28 -47.36 20.29 Favored 'General case' 0 CA--C 1.546 0.789 0 CA-C-N 115.366 -0.834 . . . . 71.51 112.279 170.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -76.75 -30.19 56.46 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 112.54 0.57 . . . . 75.43 112.54 -171.224 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 67.92 -107.08 1.91 Allowed Glycine 0 CA--C 1.533 1.218 0 N-CA-C 111.564 -0.614 . . . . 65.01 111.564 -173.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.33 162.43 36.39 Favored Glycine 0 C--N 1.353 1.496 0 N-CA-C 114.904 0.722 . . . . 63.14 114.904 168.621 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.468 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 1.6 mp0 -96.03 114.17 25.86 Favored 'General case' 0 C--N 1.357 0.917 0 N-CA-C 108.856 -0.794 . . . . 75.21 108.856 179.185 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.65 ' HG3' HD21 ' A' ' 98' ' ' LEU . 4.6 mmp_? -130.37 139.25 50.66 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.836 0.854 . . . . 51.35 109.372 -174.78 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 17.9 m -74.55 128.23 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 CA-C-O 121.638 0.732 . . . . 75.4 111.614 -172.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.426 HG12 HG11 ' A' ' 99' ' ' VAL . 21.7 t -119.87 129.65 75.16 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 C-N-CA 125.292 1.437 . . . . 75.22 109.168 -177.531 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -121.8 97.74 5.63 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 108.746 -0.835 . . . . 73.32 108.746 177.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.443 HG22 HD22 ' A' ' 174' ' ' LEU . 27.9 m -137.82 142.87 35.02 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.885 0 C-N-CA 125.09 1.356 . . . . 72.13 108.336 -177.304 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.55 19.2 11.47 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 124.081 0.953 . . . . 73.1 112.665 176.48 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.08 22.87 75.82 Favored Glycine 0 C--N 1.352 1.463 0 CA-C-N 116.393 -0.367 . . . . 64.3 112.359 -174.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -120.79 135.65 55.1 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.366 1.067 . . . . 75.31 108.861 -178.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 41.1 ttt180 -111.41 106.24 15.09 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.005 -0.739 . . . . 74.22 109.005 175.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 29.2 t -132.59 126.89 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 N-CA-C 108.461 -0.94 . . . . 64.14 108.461 -178.33 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 72.6 p -71.53 122.87 21.24 Favored 'General case' 0 CA--C 1.54 0.592 0 N-CA-C 109.084 -0.71 . . . . 71.13 109.084 171.651 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.468 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 7.3 p -96.79 140.72 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 109.769 -0.456 . . . . 73.33 109.769 -177.742 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.9 ttp180 -109.35 99.96 9.13 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 107.395 -1.335 . . . . 70.13 107.395 171.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.551 ' HB ' HD13 ' A' ' 159' ' ' ILE . 35.8 pt -89.27 127.53 54.8 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 108.467 -0.938 . . . . 72.34 108.467 175.128 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.09 135.86 33.2 Favored 'Trans proline' 0 C--N 1.376 2.008 0 C-N-CA 122.477 2.118 . . . . 75.32 113.061 -173.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_exo -46.25 119.92 3.37 Favored 'Trans proline' 0 C--N 1.376 2.012 0 C-N-CA 123.937 3.091 . . . . 73.45 112.75 167.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 123.48 58.17 0.19 Allowed Glycine 0 N--CA 1.465 0.625 0 N-CA-C 110.635 -0.986 . . . . 74.5 110.635 -175.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.538 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.0 p -134.17 161.48 40.7 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.319 0 C-N-CA 123.698 0.799 . . . . 75.34 109.397 -178.162 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 14.5 mtp180 -141.35 170.94 14.78 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 126.05 1.74 . . . . 72.24 109.747 -169.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -55.24 126.54 25.33 Favored 'General case' 0 CA--C 1.551 1.015 0 CA-C-N 116.027 -0.533 . . . . 71.35 110.695 164.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.38 2.7 74.97 Favored Glycine 0 C--N 1.346 1.126 0 CA-C-O 119.781 -0.455 . . . . 60.13 113.891 179.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 42.1 t -77.76 130.96 37.39 Favored 'General case' 0 C--O 1.247 0.932 0 N-CA-C 109.677 -0.49 . . . . 74.52 109.677 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.416 HG13 HD23 ' A' ' 175' ' ' LEU . 15.3 t -106.78 121.52 59.62 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-N 114.743 -1.117 . . . . 75.02 109.275 -168.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.551 HD13 ' HB ' ' A' ' 149' ' ' ILE . 23.6 mt -109.73 113.93 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 123.65 0.78 . . . . 74.55 110.686 -171.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.404 ' HA ' HD22 ' A' ' 175' ' ' LEU . 48.6 ttm-85 -83.19 119.42 24.52 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.22 0.608 . . . . 72.51 110.119 177.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.517 ' O ' ' HA ' ' A' ' 173' ' ' ASP . 5.1 m -123.94 132.14 24.28 Favored Pre-proline 0 N--CA 1.481 1.106 0 C-N-CA 123.138 0.575 . . . . 75.23 109.822 -178.362 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.92 157.26 43.22 Favored 'Trans proline' 0 C--N 1.374 1.899 0 C-N-CA 122.54 2.16 . . . . 73.34 113.889 -175.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.52 24.14 63.56 Favored Glycine 0 C--N 1.35 1.31 0 CA-C-N 115.128 -0.942 . . . . 73.34 115.389 171.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.415 ' SD ' HD21 ' A' ' 174' ' ' LEU . 62.3 mtt -124.66 -61.09 1.34 Allowed 'General case' 0 N--CA 1.493 1.708 0 CA-C-N 119.075 1.437 . . . . 73.23 112.919 -179.137 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -86.43 -115.88 0.95 Allowed Glycine 0 N--CA 1.481 1.693 0 C-N-CA 121.699 -0.286 . . . . 75.12 113.605 -176.223 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -154.08 -58.73 0.01 OUTLIER Glycine 0 C--N 1.35 1.306 0 CA-C-O 119.749 -0.473 . . . . 72.33 112.412 174.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.672 ' HB2' ' HB2' ' A' ' 118' ' ' ASP . 13.1 mm-40 -72.42 150.68 43.14 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 112.047 0.388 . . . . 72.15 112.047 -177.043 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 148.2 -153.33 25.2 Favored Glycine 0 C--N 1.348 1.214 0 CA-C-N 114.854 -1.066 . . . . 73.31 111.461 177.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -88.15 -45.82 0.47 Allowed Pre-proline 0 CA--C 1.562 1.44 0 CA-C-O 118.858 -0.591 . . . . 74.22 110.098 172.465 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -90.54 165.87 4.24 Favored 'Trans proline' 0 C--N 1.386 2.51 0 C-N-CA 122.155 1.903 . . . . 72.21 112.014 165.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -68.28 126.33 14.16 Favored 'Trans proline' 0 C--N 1.373 1.858 0 C-N-CA 122.067 1.845 . . . . 73.13 111.031 170.048 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . 85.11 109.28 0.67 Allowed Glycine 0 C--O 1.22 -0.757 0 CA-C-O 119.22 -0.767 . . . . 72.21 112.762 178.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.517 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 47.3 m-20 -144.98 134.52 23.24 Favored 'General case' 0 N--CA 1.481 1.119 0 CA-C-N 117.899 0.849 . . . . 72.52 111.489 172.398 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.443 HD22 HG22 ' A' ' 140' ' ' VAL . 28.1 tp -112.16 126.6 55.38 Favored 'General case' 0 C--N 1.347 0.477 0 N-CA-C 108.459 -0.941 . . . . 74.22 108.459 171.082 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.416 HD23 HG13 ' A' ' 158' ' ' VAL . 29.9 mt -93.99 100.73 12.82 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.539 1.135 . . . . 73.52 110.163 176.661 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 62.9 mt -87.11 104.45 16.36 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.532 0.733 . . . . 74.23 111.272 176.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 23.4 t -90.08 100.3 10.77 Favored 'Isoleucine or valine' 0 C--O 1.243 0.748 0 N-CA-C 108.101 -1.074 . . . . 74.12 108.101 175.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 3.2 m -78.25 149.88 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-O 121.624 0.726 . . . . 74.11 111.32 -174.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 33.0 mmt180 -119.22 95.29 4.74 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.497 -1.229 . . . . 75.24 107.963 -177.321 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 39.6 mt -67.99 147.91 51.77 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 110.192 -0.299 . . . . 61.1 110.192 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.415 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 47.5 mt -54.2 146.83 29.15 Favored Pre-proline 0 CA--C 1.562 1.415 0 C-N-CA 124.111 0.964 . . . . 73.33 111.417 -174.33 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -61.51 77.11 0.09 OUTLIER 'Trans proline' 0 C--N 1.379 2.173 0 C-N-CA 123.176 2.584 . . . . 73.03 111.447 171.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 8.2 t60 170.78 87.69 0.04 OUTLIER Pre-proline 0 CA--C 1.547 0.859 0 C-N-CA 126.242 1.817 . . . . 74.44 107.287 -166.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -98.76 125.27 0.17 Allowed 'Trans proline' 0 CA--C 1.564 1.994 0 C-N-CA 123.316 2.678 . . . . 74.43 113.188 172.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -122.64 -42.0 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.632 -0.668 . . . . 71.43 109.413 174.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . 0.402 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 4.7 m-85 -98.08 128.36 44.56 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.19 -0.914 . . . . 75.13 110.304 -178.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 10.4 mtt180 -112.63 103.98 12.04 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 106.218 -1.771 . . . . 72.41 106.218 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.418 HD13 ' O ' ' A' ' 192' ' ' ASP . 42.7 tp -81.44 110.84 17.24 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-O 121.259 0.552 . . . . 74.22 109.576 176.585 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.11 99.49 10.5 Favored 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 106.393 -1.706 . . . . 72.21 106.393 171.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 62.7 -94.9 0.11 Allowed Glycine 0 C--N 1.349 1.294 0 O-C-N 124.018 0.823 . . . . 65.4 113.352 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . 0.535 HE22 ' HB3' ' A' ' 244' ' ' ALA . 8.7 pt20 -108.46 -19.2 13.53 Favored 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 123.742 0.817 . . . . 73.33 110.849 178.042 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . 0.418 ' O ' HD13 ' A' ' 188' ' ' LEU . 29.0 m-20 -97.0 155.03 16.95 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 123.876 0.87 . . . . 75.02 111.63 -172.541 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.459 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 82.6 mt -109.53 154.33 22.86 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 124.206 1.003 . . . . 74.45 109.484 -177.55 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -137.17 121.83 18.55 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 107.502 -1.296 . . . . 74.25 107.502 171.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -134.03 141.51 47.24 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 108.632 -0.877 . . . . 55.45 108.632 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 3.5 m -82.3 122.46 27.98 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 109.747 -0.464 . . . . 65.12 109.747 -178.706 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.441 HD12 ' HB2' ' A' ' 212' ' ' ALA . 57.2 tp -107.75 112.2 24.76 Favored 'General case' 0 C--O 1.216 -0.69 0 C-N-CA 124.335 1.054 . . . . 70.51 109.116 -178.706 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -93.52 108.23 19.96 Favored 'General case' 0 N--CA 1.474 0.755 0 CA-C-O 121.338 0.59 . . . . 72.22 109.617 177.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . 0.459 HG22 HG22 ' A' ' 210' ' ' VAL . 65.2 t -101.37 126.0 35.93 Favored Pre-proline 0 N--CA 1.474 0.74 0 C-N-CA 124.148 0.979 . . . . 75.2 109.344 -176.659 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_exo -57.18 139.29 89.59 Favored 'Trans proline' 0 C--N 1.369 1.622 0 C-N-CA 122.624 2.216 . . . . 62.21 111.503 171.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -55.31 -41.83 92.79 Favored Pre-proline 0 N--CA 1.482 1.136 0 N-CA-C 113.673 0.99 . . . . 74.32 113.673 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo -47.58 -52.91 7.25 Favored 'Trans proline' 0 C--N 1.386 2.519 0 C-N-CA 122.166 1.911 . . . . 73.15 113.621 168.013 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . 0.538 HG21 HG12 ' A' ' 210' ' ' VAL . 9.3 mt -67.73 -33.33 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 123.035 0.534 . . . . 65.53 111.689 -179.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -68.39 -42.24 79.34 Favored 'General case' 0 C--O 1.245 0.861 0 C-N-CA 123.122 0.569 . . . . 70.11 111.855 -177.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.2 m -77.44 -40.78 29.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 CA-C-N 115.729 -0.669 . . . . 72.24 110.968 -177.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.1 m -79.16 -30.38 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 CA-C-O 120.841 0.353 . . . . 75.22 111.437 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.511 ' HA2' HG22 ' A' ' 223' ' ' VAL . . . 79.87 67.37 1.58 Allowed Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.683 -0.689 . . . . 74.14 112.513 -175.323 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -97.92 -148.99 24.56 Favored Glycine 0 C--N 1.35 1.347 0 CA-C-N 116.688 0.244 . . . . 43.0 112.546 176.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . 0.675 ' HD3' ' HB2' ' A' ' 220' ' ' GLU . 4.7 ttmp? -125.54 131.44 52.77 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.517 0.727 . . . . 74.21 109.081 -178.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . 0.538 HG12 HG21 ' A' ' 203' ' ' ILE . 5.7 m -120.87 135.76 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.357 -0.979 . . . . 75.34 108.357 172.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . 0.531 ' HD3' ' HB2' ' A' ' 218' ' ' PRO . 35.0 ttm105 -96.26 117.15 30.2 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 121.279 0.561 . . . . 74.33 109.699 178.766 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.441 ' HB2' HD12 ' A' ' 197' ' ' LEU . . . -99.78 155.4 17.66 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.027 0.931 . . . . 75.24 109.681 178.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 58.1 mmm -92.4 128.21 38.17 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 109.82 -0.437 . . . . 72.22 109.82 172.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 214' ' ' THR . . . . . 0.402 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.0 t -114.42 173.01 6.67 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-N 115.277 -0.874 . . . . 73.1 109.172 167.357 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . 0.605 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 73.1 mt -75.28 -2.99 30.72 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-N 115.449 -0.796 . . . . 75.52 112.614 -172.794 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.65 7.76 11.12 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 123.541 0.736 . . . . 72.22 112.122 179.219 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 137.01 -161.16 25.11 Favored Glycine 0 N--CA 1.476 1.362 0 CA-C-O 119.817 -0.435 . . . . 73.2 112.91 178.143 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . 0.531 ' HB2' ' HD3' ' A' ' 211' ' ' ARG . 98.5 Cg_endo -94.35 125.17 0.45 Allowed 'Trans proline' 0 C--N 1.37 1.681 0 C-N-CA 123.499 2.799 . . . . 62.01 112.763 176.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.7 m -108.85 146.28 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 123.322 0.649 . . . . 75.11 110.52 175.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . 0.675 ' HB2' ' HD3' ' A' ' 209' ' ' LYS . 9.9 pt-20 -113.73 104.66 12.43 Favored 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 108.996 -0.742 . . . . 75.11 108.996 -177.251 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.5 p -97.61 135.54 31.65 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 CA-C-N 115.656 -0.702 . . . . 74.32 110.832 -179.084 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -93.93 117.63 30.37 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-N 115.269 -0.878 . . . . 63.54 109.418 176.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.511 HG22 ' HA2' ' A' ' 207' ' ' GLY . 21.4 m -84.22 140.06 39.34 Favored Pre-proline 0 CA--C 1.553 1.096 0 N-CA-C 109.615 -0.513 . . . . 72.54 109.615 176.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -64.37 144.23 85.13 Favored 'Trans proline' 0 C--N 1.378 2.081 0 C-N-CA 122.583 2.189 . . . . 71.31 112.065 173.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -56.52 126.89 23.77 Favored 'Trans proline' 0 C--N 1.371 1.73 0 C-N-CA 122.746 2.297 . . . . 74.13 111.76 171.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 50.9 mtt180 65.64 44.28 3.02 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 124.445 1.098 . . . . 74.42 110.592 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 5.5 t -77.43 168.84 19.35 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 122.874 0.469 . . . . 65.44 110.046 177.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -130.72 152.06 50.48 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 122.893 0.477 . . . . 71.22 109.782 -178.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.61 134.06 48.32 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.752 0.821 . . . . 74.14 111.166 178.454 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.2 -8.11 20.91 Favored Glycine 0 C--N 1.341 0.854 0 CA-C-O 119.562 -0.576 . . . . 73.44 112.755 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -78.84 159.31 27.88 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-N 117.45 0.625 . . . . 73.45 109.483 175.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.571 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 12.9 mptt -118.57 102.6 9.01 Favored 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 123.748 0.819 . . . . 74.14 109.37 177.41 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . 0.434 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 83.3 mt -78.92 104.61 9.67 Favored 'General case' 0 C--N 1.355 0.805 0 N-CA-C 108.463 -0.94 . . . . 74.35 108.463 -176.116 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 22.3 ttp85 -79.65 121.49 25.36 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 115.261 -0.881 . . . . 75.03 110.446 -169.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 34.4 mt -105.94 120.09 40.87 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.733 0.813 . . . . 73.34 109.93 175.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -70.55 128.32 35.74 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 124.327 1.051 . . . . 74.43 112.237 -169.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 81.56 7.48 88.13 Favored Glycine 0 C--N 1.349 1.267 0 O-C-N 123.718 0.636 . . . . 74.52 114.453 171.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 38.2 mmtm -85.16 -23.33 28.42 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 117.192 0.496 . . . . 74.31 112.237 -178.141 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -81.62 173.74 53.97 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 111.861 -0.495 . . . . 75.34 111.861 176.229 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.438 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 88.2 m-85 -81.15 150.82 68.96 Favored Pre-proline 0 N--CA 1.477 0.894 0 N-CA-C 112.739 0.644 . . . . 73.21 112.739 -172.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -55.61 132.15 50.37 Favored 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.066 2.511 . . . . 75.54 111.226 170.151 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -160.81 -150.8 6.0 Favored Glycine 0 CA--C 1.532 1.154 0 CA-C-O 119.595 -0.558 . . . . 63.13 112.05 -174.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -65.77 -27.56 52.02 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 123.168 2.579 . . . . 73.21 113.287 -174.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . 0.535 ' HB3' HE22 ' A' ' 191' ' ' GLN . . . -109.51 21.79 16.57 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 123.667 0.787 . . . . 64.25 111.052 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.08 -151.6 33.61 Favored Glycine 0 C--N 1.347 1.171 0 N-CA-C 110.489 -1.045 . . . . 72.52 110.489 -170.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -61.83 138.9 58.39 Favored 'General case' 0 N--CA 1.477 0.924 0 CA-C-N 117.979 0.889 . . . . 74.22 110.162 174.124 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -78.54 -158.87 12.57 Favored Glycine 0 C--O 1.247 0.94 0 CA-C-N 115.969 -0.56 . . . . 33.13 112.146 172.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 -144.35 156.02 44.05 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.011 0.524 . . . . 75.52 109.938 -173.167 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.459 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 20.6 tp -97.67 109.84 22.52 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.462 0.649 . . . . 72.01 110.039 179.037 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . 0.571 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 97.5 m-85 -91.33 106.96 18.87 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-N 115.108 -0.951 . . . . 72.4 109.942 176.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.457 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 72.5 mt -89.25 112.76 23.89 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 123.939 0.895 . . . . 75.15 112.486 -179.289 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -78.62 91.37 4.61 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.945 -0.761 . . . . 74.42 108.945 178.259 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.1 p -55.54 125.9 11.64 Favored 'Isoleucine or valine' 0 C--N 1.353 0.732 0 CA-C-N 115.043 -0.98 . . . . 74.15 110.324 175.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 44.8 mmm-85 -131.15 109.83 10.73 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 106.536 -1.653 . . . . 75.41 106.536 175.587 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 66.3 mt -83.67 121.21 36.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.454 0 CA-C-N 115.966 -0.561 . . . . 71.15 111.799 -171.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 21.5 m . . . . . 0 CA--C 1.558 1.284 0 C-N-CA 124.586 1.154 . . . . 74.31 108.992 175.158 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . 0.505 ' HB3' ' O ' ' A' ' 99' ' ' VAL . . . . . . . . 0 N--CA 1.477 0.909 0 N-CA-C 109.788 -0.449 . . . . 64.45 109.788 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.16 -79.08 0.13 Allowed 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 122.693 0.397 . . . . 55.24 110.836 -176.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.446 ' HB3' HD11 ' A' ' 123' ' ' LEU . 86.5 mt -91.17 -56.4 3.17 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.437 0.695 . . . . 73.42 109.543 -178.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.505 ' O ' ' HB3' ' A' ' 96' ' ' ALA . 6.4 t -82.9 119.64 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 115.092 -0.958 . . . . 70.33 109.468 178.641 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -75.35 -51.43 13.19 Favored 'General case' 0 N--CA 1.478 0.936 0 O-C-N 124.352 1.032 . . . . 75.23 110.579 177.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -165.79 178.15 6.75 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 125.094 1.358 . . . . 74.42 109.338 -172.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.466 HG12 ' HB1' ' A' ' 121' ' ' ALA . 19.0 m -92.04 156.39 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 112.151 0.426 . . . . 71.35 112.151 179.43 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 60.9 p -72.89 -53.59 10.95 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-N 115.11 -0.95 . . . . 71.42 109.268 172.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.5 t -171.33 151.7 3.16 Favored 'General case' 0 C--O 1.245 0.864 0 CA-C-N 114.572 -1.195 . . . . 74.2 109.364 177.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -93.89 161.2 24.54 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-N 116.003 -0.544 . . . . 53.53 112.039 173.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' SER . . . . . 0.688 ' HB2' ' HB2' ' A' ' 118' ' ' ASP . 41.0 m -131.14 169.64 15.62 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 124.015 0.926 . . . . 72.31 108.654 173.152 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -171.39 111.49 0.4 Allowed Glycine 0 C--N 1.34 0.782 0 N-CA-C 112.11 -0.396 . . . . 63.3 112.11 -175.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -85.32 98.63 2.27 Favored Glycine 0 C--N 1.34 0.78 0 N-CA-C 111.869 -0.492 . . . . 53.24 111.869 -178.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.0 m -57.56 -34.08 68.81 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 123.694 0.797 . . . . 74.01 111.441 176.511 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -148.19 168.24 28.95 Favored Glycine 0 C--N 1.338 0.644 0 CA-C-N 114.75 -1.114 . . . . 73.4 110.724 172.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 83.72 -59.46 4.96 Favored Glycine 0 C--N 1.344 1.001 0 N-CA-C 111.375 -0.69 . . . . 73.25 111.375 -174.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 33.2 t -72.83 113.86 10.33 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 123.138 0.575 . . . . 64.11 110.683 178.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -115.5 -14.28 8.28 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-N 116.194 -0.457 . . . . 74.11 112.896 178.341 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -83.96 -52.39 3.67 Favored Glycine 0 C--N 1.351 1.39 0 CA-C-N 116.695 0.248 . . . . 71.1 112.767 -177.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 44.9 m -107.85 141.6 39.19 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 123.673 0.789 . . . . 71.32 109.746 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -78.02 -93.43 0.27 Allowed Glycine 0 C--N 1.347 1.173 0 N-CA-C 111.644 -0.582 . . . . 74.12 111.644 177.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.551 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 9.9 mpt_? -96.33 122.37 39.14 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 108.39 -0.967 . . . . 72.05 108.39 168.436 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.688 ' HB2' ' HB2' ' A' ' 106' ' ' SER . 5.9 m-20 -73.36 147.92 43.91 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 108.667 -0.864 . . . . 63.24 108.667 173.759 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.505 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 14.1 tp -131.63 131.48 43.24 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 107.42 -1.326 . . . . 74.13 107.42 179.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . 0.702 ' HG3' ' HB2' ' A' ' 175' ' ' LEU . 0.0 OUTLIER -134.41 133.93 41.09 Favored 'General case' 0 N--CA 1.482 1.135 0 N-CA-C 109.173 -0.677 . . . . 73.53 109.173 -177.172 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . 0.466 ' HB1' HG12 ' A' ' 102' ' ' VAL . . . -146.46 164.17 33.33 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 124.079 0.952 . . . . 74.13 110.479 -176.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.641 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 46.3 mt-10 -126.42 151.01 48.29 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.079 0.951 . . . . 75.5 108.685 173.728 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.446 HD11 ' HB3' ' A' ' 98' ' ' LEU . 1.4 pt? -145.88 135.3 11.44 Favored Pre-proline 0 N--CA 1.477 0.897 0 C-N-CA 122.967 0.507 . . . . 74.42 110.171 -178.187 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -71.21 113.08 3.48 Favored 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 121.648 1.566 . . . . 73.0 109.583 167.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.418 HD22 HG11 ' A' ' 178' ' ' VAL . 17.2 tp -108.29 157.81 18.03 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 108.264 -1.013 . . . . 74.01 108.264 178.385 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.497 HG21 HD12 ' A' ' 181' ' ' LEU . 3.4 m -95.41 161.0 14.26 Favored 'General case' 0 CA--C 1.544 0.736 0 N-CA-C 109.4 -0.593 . . . . 72.44 109.4 173.629 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.457 HD22 ' HB3' ' A' ' 180' ' ' LEU . 67.7 mt -61.33 -46.17 91.36 Favored 'General case' 0 N--CA 1.476 0.836 0 CA-C-O 121.42 0.629 . . . . 72.41 110.104 175.674 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -60.15 -34.83 74.11 Favored 'General case' 0 N--CA 1.484 1.252 0 CA-C-N 114.636 -1.165 . . . . 73.11 111.871 176.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -72.94 -33.57 66.01 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 123.308 0.643 . . . . 74.11 110.472 177.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.461 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -62.68 -36.68 83.68 Favored 'General case' 0 C--O 1.246 0.891 0 C-N-CA 123.955 0.902 . . . . 72.01 111.883 171.347 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.493 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 31.7 t80 -66.87 -61.28 2.03 Favored 'General case' 0 N--CA 1.472 0.671 0 O-C-N 123.961 0.788 . . . . 74.11 111.72 175.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 40.7 m80 -77.68 -26.32 50.16 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 115.54 -0.754 . . . . 75.34 112.645 -170.088 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 62.68 -121.72 25.87 Favored Glycine 0 C--N 1.349 1.295 0 O-C-N 123.374 0.421 . . . . 53.43 112.281 -175.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 89.59 172.63 45.52 Favored Glycine 0 C--N 1.345 1.059 0 N-CA-C 114.288 0.475 . . . . 75.43 114.288 173.53 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 23.4 mp0 -84.17 136.66 33.88 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 123.512 0.725 . . . . 65.44 109.392 176.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.32 148.12 30.05 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 106.947 -1.501 . . . . 74.53 106.947 170.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.402 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 34.7 m -77.41 127.68 38.19 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-O 121.786 0.803 . . . . 70.0 111.643 -173.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.488 HG23 ' HB ' ' A' ' 99' ' ' VAL . 6.7 p -97.54 128.36 48.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.905 -1.146 . . . . 75.53 107.905 170.524 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . 0.435 ' HA ' ' O ' ' A' ' 143' ' ' ARG . 42.4 tt0 -123.27 95.06 4.45 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 107.908 -1.145 . . . . 75.25 107.908 -179.6 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.478 ' O ' ' HG2' ' A' ' 143' ' ' ARG . 15.3 m -136.92 138.16 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 124.714 1.206 . . . . 72.4 108.653 -173.418 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.86 20.41 10.63 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 123.741 0.816 . . . . 64.23 111.864 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.55 1.73 87.52 Favored Glycine 0 C--N 1.349 1.274 0 CA-C-O 119.549 -0.584 . . . . 73.22 113.754 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.478 ' HG2' ' O ' ' A' ' 140' ' ' VAL . 8.5 ptm180 -99.98 127.21 46.22 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 118.066 0.933 . . . . 75.32 109.253 176.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -114.16 113.77 25.14 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 124.073 0.949 . . . . 74.11 108.645 178.032 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 4.1 p -148.71 146.39 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 123.456 0.702 . . . . 75.33 109.912 -178.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.402 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 19.7 m -70.03 112.95 6.78 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.025 0.53 . . . . 75.25 110.931 178.775 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 14.2 p -98.99 137.31 26.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.042 0.537 . . . . 72.33 110.021 175.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 59.1 ttp180 -104.75 122.76 46.38 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 107.455 -1.313 . . . . 75.4 107.455 171.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.659 ' HB ' HD13 ' A' ' 159' ' ' ILE . 28.0 pt -107.46 127.47 27.78 Favored Pre-proline 0 CA--C 1.552 1.024 0 N-CA-C 108.172 -1.047 . . . . 72.43 108.172 172.393 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -53.61 130.85 40.84 Favored 'Trans proline' 0 C--N 1.387 2.594 0 C-N-CA 123.29 2.66 . . . . 74.04 113.914 -171.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -59.81 109.96 0.67 Allowed 'Trans proline' 0 C--N 1.378 2.085 0 C-N-CA 122.486 2.124 . . . . 75.02 109.952 170.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . 0.414 ' HA2' ' CD2' ' A' ' 240' ' ' PHE . . . 139.19 28.48 0.23 Allowed Glycine 0 N--CA 1.468 0.776 0 CA-C-N 116.291 -0.413 . . . . 74.31 112.306 -169.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.536 HG23 HD12 ' A' ' 159' ' ' ILE . 2.1 p -104.94 157.36 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.269 0 N-CA-C 109.815 -0.439 . . . . 74.23 109.815 -173.607 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -139.64 163.95 31.2 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 124.951 1.301 . . . . 74.43 110.635 -165.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 20.3 tp10 -47.32 117.9 1.95 Allowed 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 124.479 1.112 . . . . 71.31 112.779 169.506 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.83 7.58 86.25 Favored Glycine 0 C--N 1.353 1.514 0 CA-C-N 115.573 -0.74 . . . . 72.3 113.978 178.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 33.6 t -76.55 129.51 36.57 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 117.311 0.556 . . . . 74.1 109.861 -178.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.405 HG23 HD22 ' A' ' 175' ' ' LEU . 7.1 p -96.56 131.43 43.35 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.093 0 CA-C-N 115.363 -0.835 . . . . 71.3 109.758 -177.391 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.659 HD13 ' HB ' ' A' ' 149' ' ' ILE . 23.1 mt -116.98 115.8 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 123.675 0.79 . . . . 74.13 110.693 -173.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 18.1 ttm180 -86.78 117.76 25.74 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.059 0.544 . . . . 72.53 110.369 -179.184 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.438 ' HA ' ' HD3' ' A' ' 162' ' ' PRO . 9.0 m -120.29 107.19 39.57 Favored Pre-proline 0 CA--C 1.563 1.446 0 N-CA-C 109.621 -0.511 . . . . 74.45 109.621 178.054 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . 0.438 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 7.9 Cg_exo -72.41 152.87 55.38 Favored 'Trans proline' 0 C--N 1.376 2.014 0 C-N-CA 123.105 2.537 . . . . 73.41 112.834 -174.282 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 72.36 24.7 75.9 Favored Glycine 0 C--N 1.35 1.339 0 O-C-N 123.61 0.569 . . . . 73.31 113.126 179.019 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 48.7 tpp -111.08 -37.53 5.32 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.101 0.56 . . . . 61.11 110.6 -178.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -76.72 -140.0 1.05 Allowed Glycine 0 CA--C 1.532 1.151 0 CA-C-N 116.106 -0.497 . . . . 72.53 113.467 174.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.551 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -68.07 111.53 4.09 Favored Glycine 0 C--N 1.344 0.977 0 C-N-CA 122.945 0.307 . . . . 65.12 113.453 -176.026 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.541 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -88.09 163.1 16.4 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 123.761 0.825 . . . . 74.3 110.767 176.805 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 156.79 -78.25 0.19 Allowed Glycine 0 C--N 1.338 0.678 0 N-CA-C 109.587 -1.405 . . . . 72.05 109.587 179.354 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -135.89 -57.1 0.02 OUTLIER Pre-proline 0 CA--C 1.562 1.431 0 CA-C-O 118.427 -0.797 . . . . 75.35 109.713 170.265 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -76.48 111.75 3.32 Favored 'Trans proline' 0 C--N 1.39 2.752 0 CA-C-N 121.327 1.51 . . . . 75.11 110.302 167.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -74.7 126.39 10.13 Favored 'Trans proline' 0 C--N 1.372 1.785 0 C-N-CA 122.228 1.952 . . . . 64.23 110.995 -176.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -76.12 151.6 40.7 Favored Glycine 0 C--N 1.336 0.579 0 N-CA-C 111.796 -0.522 . . . . 72.23 111.796 174.203 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -103.72 172.74 6.64 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.761 0.825 . . . . 74.21 109.154 178.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 37.5 tp -129.85 114.37 15.82 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 109.336 -0.616 . . . . 75.3 109.336 170.464 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.702 ' HB2' ' HG3' ' A' ' 120' ' ' ARG . 32.4 mt -85.56 102.39 13.49 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 114.903 -1.044 . . . . 75.2 110.837 176.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.441 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 79.0 mt -91.59 102.55 15.2 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.087 0.955 . . . . 72.12 111.71 179.137 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.641 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 43.3 t -86.48 103.83 13.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 N-CA-C 108.678 -0.86 . . . . 75.24 108.678 174.115 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.418 HG11 HD22 ' A' ' 125' ' ' LEU . 9.4 m -80.01 151.97 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-O 121.683 0.754 . . . . 75.02 112.124 -177.755 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 7.0 mmm180 -124.69 97.44 5.29 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 125.404 1.482 . . . . 73.43 107.598 178.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.457 ' HB3' HD22 ' A' ' 127' ' ' LEU . 54.9 mt -67.15 134.18 51.27 Favored 'General case' 0 CA--C 1.546 0.793 0 O-C-N 123.156 0.285 . . . . 74.44 110.902 -178.47 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.497 HD12 HG21 ' A' ' 126' ' ' THR . 37.1 mt -55.1 146.49 39.44 Favored Pre-proline 0 C--N 1.364 1.222 0 C-N-CA 124.197 0.999 . . . . 74.15 111.379 -174.505 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_exo -70.13 79.07 1.08 Allowed 'Trans proline' 0 C--N 1.376 2.0 0 C-N-CA 123.196 2.597 . . . . 74.24 113.043 -176.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 7.9 p80 -161.31 57.71 0.86 Allowed Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 124.152 0.981 . . . . 74.01 109.457 173.322 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -66.5 122.52 9.97 Favored 'Trans proline' 0 C--N 1.376 2.009 0 C-N-CA 121.976 1.784 . . . . 55.42 112.019 -168.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 195' ' ' ALA . 2.9 p -134.92 -41.07 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 C-N-CA 123.364 0.666 . . . . 74.42 109.322 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . 0.446 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 8.8 m-85 -109.89 124.36 51.23 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 122.917 0.487 . . . . 75.12 110.925 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.45 114.79 25.51 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.069 1.348 . . . . 73.12 107.824 175.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 54.9 tp -86.43 144.78 27.13 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 122.897 0.479 . . . . 74.53 110.441 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -142.98 99.87 3.54 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 106.073 -1.825 . . . . 64.44 106.073 177.311 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 65.26 -88.6 0.1 OUTLIER Glycine 0 C--N 1.344 1.003 0 N-CA-C 112.088 -0.405 . . . . 72.14 112.088 -172.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -130.66 -10.69 3.97 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 123.92 0.888 . . . . 73.15 110.58 175.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -85.87 150.41 24.55 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.71 0.804 . . . . 72.01 111.489 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.644 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 95.9 mt -114.91 161.12 18.7 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 124.25 1.02 . . . . 75.02 111.588 -177.856 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 250' ' ' TYR . 89.1 m-85 -140.89 118.41 11.54 Favored 'General case' 0 C--O 1.233 0.227 0 N-CA-C 107.091 -1.448 . . . . 75.01 107.091 173.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . 0.455 ' HA ' ' O ' ' A' ' 185' ' ' VAL . . . -141.23 128.7 21.27 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.82 -0.437 . . . . 72.3 109.82 -176.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 14.2 m -76.8 114.92 16.1 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-O 121.163 0.506 . . . . 72.45 110.915 -173.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.504 HD23 HD12 ' A' ' 251' ' ' LEU . 69.3 tp -106.58 113.06 26.34 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.329 1.052 . . . . 74.31 109.689 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -84.51 129.49 34.85 Favored 'General case' 0 C--O 1.242 0.701 0 N-CA-C 109.061 -0.718 . . . . 74.32 109.061 169.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 12.1 m -125.84 141.78 40.33 Favored Pre-proline 0 N--CA 1.48 1.042 0 N-CA-C 108.25 -1.019 . . . . 75.12 108.25 176.238 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -64.67 141.17 71.45 Favored 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 121.693 1.595 . . . . 75.32 110.698 170.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . 0.431 ' HA ' HG22 ' A' ' 255' ' ' ILE . . . -55.83 -41.86 93.1 Favored Pre-proline 0 CA--C 1.558 1.288 0 C-N-CA 123.878 0.871 . . . . 75.12 113.308 -178.312 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -49.04 -47.77 20.56 Favored 'Trans proline' 0 C--N 1.39 2.744 0 C-N-CA 122.434 2.09 . . . . 74.14 114.081 169.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . 0.485 ' HA ' ' HA3' ' A' ' 207' ' ' GLY . 5.6 mt -66.46 -44.37 90.51 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 CA-C-N 117.822 0.283 . . . . 73.44 111.252 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -50.69 -43.85 57.78 Favored 'General case' 0 CA--C 1.538 0.514 0 O-C-N 124.546 1.154 . . . . 60.42 111.51 -178.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . 0.647 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 29.6 m -89.34 -59.61 2.74 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.404 0 N-CA-C 113.226 0.824 . . . . 74.44 113.226 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 27.3 m -102.39 -24.61 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 N-CA-C 113.537 0.94 . . . . 71.43 113.537 -171.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.485 ' HA3' ' HA ' ' A' ' 203' ' ' ILE . . . -75.0 -76.01 0.78 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 121.181 -0.533 . . . . 74.54 111.993 -173.411 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 94.69 -0.36 65.05 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-O 119.155 -0.803 . . . . 75.42 114.02 172.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . 0.453 ' O ' HD11 ' A' ' 203' ' ' ILE . 48.6 mtmt -138.11 132.89 32.71 Favored 'General case' 0 N--CA 1.481 1.082 0 CA-C-N 118.165 0.982 . . . . 73.24 108.838 178.553 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 7.7 p -153.65 141.64 13.44 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 C-N-CA 124.124 0.97 . . . . 75.24 108.758 -174.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 16.6 ptp180 -77.5 148.92 35.06 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 110.172 -0.307 . . . . 74.51 110.172 175.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.417 ' HB3' HD13 ' A' ' 197' ' ' LEU . . . -140.1 159.86 41.24 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.33 0.652 . . . . 71.22 109.82 174.342 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -106.28 143.7 34.03 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-N 115.599 -0.728 . . . . 65.42 110.702 179.259 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 214' ' ' THR . . . . . 0.446 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 8.9 t -133.4 165.43 24.86 Favored 'General case' 0 C--O 1.24 0.566 0 C-N-CA 124.102 0.961 . . . . 64.41 109.489 171.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 81.4 mt -64.44 -14.82 58.89 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.268 1.027 . . . . 74.21 111.789 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -95.86 -21.39 18.11 Favored 'General case' 0 CA--C 1.558 1.281 0 C-N-CA 123.443 0.697 . . . . 71.24 111.787 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.13 -151.66 23.84 Favored Glycine 0 N--CA 1.478 1.438 0 CA-C-O 119.26 -0.744 . . . . 64.23 112.67 -176.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -91.76 133.26 1.37 Allowed 'Trans proline' 0 CA--C 1.559 1.752 0 C-N-CA 123.115 2.543 . . . . 53.43 113.695 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . 0.495 HG12 ' HZ1' ' A' ' 238' ' ' LYS . 36.0 m -114.89 159.36 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 123.939 0.896 . . . . 74.34 110.495 171.565 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -114.08 113.43 24.72 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 123.859 0.863 . . . . 71.54 109.069 175.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.417 HG23 HD11 ' A' ' 235' ' ' LEU . 20.5 t -95.14 126.24 47.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 123.661 0.785 . . . . 75.42 109.548 -178.615 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -106.5 99.44 9.02 Favored 'General case' 0 C--O 1.24 0.582 0 N-CA-C 107.003 -1.481 . . . . 71.24 107.003 173.311 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.475 HG12 HD13 ' A' ' 233' ' ' LEU . 3.3 m -79.09 132.23 64.06 Favored Pre-proline 0 CA--C 1.553 1.065 0 N-CA-C 108.031 -1.1 . . . . 73.24 108.031 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -56.37 129.61 35.69 Favored 'Trans proline' 0 C--N 1.375 1.956 0 C-N-CA 122.133 1.889 . . . . 74.11 111.665 176.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -42.35 124.27 3.05 Favored 'Trans proline' 0 C--N 1.385 2.462 0 C-N-CA 124.69 3.593 . . . . 65.41 114.361 -173.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . 0.647 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 52.8 mtm180 64.09 73.44 0.43 Allowed 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 124.333 1.053 . . . . 75.3 111.046 -173.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 227' ' ' THR . . . . . 0.425 HG22 HD11 ' A' ' 255' ' ' ILE . 8.2 t -88.59 171.99 9.63 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 123.647 0.779 . . . . 73.23 110.457 175.446 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -127.9 140.2 52.15 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 123.741 0.816 . . . . 73.13 109.249 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.53 128.8 37.78 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.228 0.611 . . . . 45.44 109.863 177.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.24 -4.07 22.05 Favored Glycine 0 C--N 1.339 0.729 0 O-C-N 123.342 0.401 . . . . 74.21 113.276 -170.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . 0.42 ' O ' HG12 ' A' ' 253' ' ' VAL . 69.5 mtp180 -93.59 162.48 13.94 Favored 'General case' 0 N--CA 1.477 0.902 0 CA-C-N 117.39 0.595 . . . . 75.3 111.553 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.782 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 3.2 mptp? -118.35 104.6 10.89 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 108.946 -0.761 . . . . 72.24 108.946 -176.679 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . 0.554 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 23.4 mt -84.42 115.33 22.48 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.52 0.728 . . . . 71.3 109.898 -172.227 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . 0.417 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 58.5 ttt180 -86.67 110.21 19.71 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 123.497 0.719 . . . . 74.04 111.631 -170.476 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.487 HD13 HD23 ' A' ' 249' ' ' LEU . 15.5 mt -99.95 104.0 15.59 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.024 -1.102 . . . . 73.34 108.024 170.474 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 56.0 mttp -74.66 138.86 43.15 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.942 0.497 . . . . 73.11 111.712 -171.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . 0.43 ' O ' ' HD3' ' A' ' 246' ' ' ARG . . . 80.05 6.84 88.98 Favored Glycine 0 C--N 1.348 1.243 0 O-C-N 123.903 0.752 . . . . 63.42 113.486 178.207 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . 0.495 ' HZ1' HG12 ' A' ' 219' ' ' VAL . 33.5 mmtp -106.96 8.59 30.58 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-N 117.263 0.532 . . . . 75.1 111.831 179.092 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -97.35 -178.5 34.2 Favored Glycine 0 C--N 1.344 1.023 0 O-C-N 123.481 0.488 . . . . 63.14 112.03 170.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.526 ' CE1' HD21 ' A' ' 193' ' ' LEU . 25.7 m-85 -76.28 163.1 68.51 Favored Pre-proline 0 CA--C 1.549 0.93 0 C-N-CA 124.257 1.023 . . . . 74.13 112.588 -174.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -52.47 129.05 30.21 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 123.248 2.632 . . . . 75.11 112.804 173.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -156.33 -162.26 11.31 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.091 -0.838 . . . . 75.34 112.043 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -61.39 -30.98 88.14 Favored 'Trans proline' 0 C--N 1.377 2.047 0 C-N-CA 123.465 2.777 . . . . 73.51 112.916 -175.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -90.95 22.13 3.82 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.961 0.905 . . . . 74.23 111.438 179.473 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 82.27 -70.82 3.08 Favored Glycine 0 C--N 1.35 1.307 0 N-CA-C 111.104 -0.798 . . . . 73.11 111.104 -175.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.43 ' HD3' ' O ' ' A' ' 237' ' ' GLY . 78.2 mtt180 -116.32 161.47 18.97 Favored 'General case' 0 C--O 1.243 0.749 0 C-N-CA 124.459 1.103 . . . . 75.31 108.578 172.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -96.13 -158.3 31.93 Favored Glycine 0 C--O 1.243 0.704 0 CA-C-N 115.699 -0.682 . . . . 73.22 112.308 177.38 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -132.35 155.63 48.07 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 109.641 -0.504 . . . . 71.21 109.641 -175.671 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.644 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 14.3 tp -103.25 129.02 50.1 Favored 'General case' 0 C--O 1.214 -0.812 0 C-N-CA 123.648 0.779 . . . . 72.41 109.12 171.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . 0.782 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 92.7 m-85 -115.36 107.64 15.48 Favored 'General case' 0 N--CA 1.477 0.906 0 N-CA-C 108.907 -0.775 . . . . 74.24 108.907 176.693 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.554 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 42.1 mt -87.5 126.15 34.74 Favored 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 123.568 0.747 . . . . 72.42 111.876 -173.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -78.91 90.84 4.74 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 107.366 -1.346 . . . . 75.12 107.366 176.03 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.42 HG12 ' O ' ' A' ' 231' ' ' ARG . 2.8 p -63.29 124.12 17.35 Favored 'Isoleucine or valine' 0 C--O 1.239 0.55 0 CA-C-O 121.802 0.81 . . . . 73.22 110.472 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 29.7 mmm180 -124.25 95.34 4.51 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 107.574 -1.269 . . . . 73.44 107.574 -178.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.431 HG22 ' HA ' ' A' ' 201' ' ' ALA . 69.1 mt -75.83 107.14 6.34 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 115.204 -0.907 . . . . 63.34 109.394 -177.725 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.2 t . . . . . 0 CA--C 1.549 0.928 0 C-N-CA 124.539 1.136 . . . . 72.5 109.139 -179.317 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.378 0 N-CA-C 110.403 -0.221 . . . . 74.44 110.403 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -117.15 -77.89 0.57 Allowed 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 122.998 0.519 . . . . 74.11 109.917 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.643 ' HG ' ' HG2' ' A' ' 136' ' ' ARG . 68.2 mt -85.38 -57.08 3.21 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 122.694 0.398 . . . . 75.51 110.449 177.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.448 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 11.8 p -56.28 134.62 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 O-C-N 123.858 0.724 . . . . 61.31 111.531 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.96 -60.73 2.19 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 108.746 -0.835 . . . . 71.13 108.746 174.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 31.2 m80 -162.94 159.48 23.66 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 124.98 1.312 . . . . 74.34 108.82 -177.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.456 ' HA ' ' HB2' ' A' ' 121' ' ' ALA . 13.0 p -78.0 127.7 38.44 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.007 0 CA-C-O 121.025 0.44 . . . . 74.43 110.451 178.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.467 HG21 ' HA ' ' A' ' 121' ' ' ALA . 43.8 p -82.57 150.4 26.92 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.537 0.735 . . . . 74.13 110.474 -179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 29.1 t -68.02 145.69 54.25 Favored 'General case' 0 CA--C 1.551 0.99 0 C-N-CA 123.402 0.681 . . . . 72.33 109.51 175.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . 0.491 ' HA3' ' HD2' ' A' ' 120' ' ' ARG . . . -151.85 131.73 3.54 Favored Glycine 0 C--N 1.344 1.019 0 C-N-CA 121.457 -0.401 . . . . 65.12 113.038 -174.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 35.1 p -63.58 147.86 50.36 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.867 0.867 . . . . 75.45 111.144 178.319 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 171.38 -30.45 0.12 Allowed Glycine 0 C--N 1.342 0.881 0 CA-C-N 115.974 -0.557 . . . . 74.11 112.258 -177.381 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.56 -165.63 26.14 Favored Glycine 0 C--N 1.346 1.09 0 C-N-CA 123.19 0.424 . . . . 61.12 112.738 177.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.464 ' HA ' ' HB3' ' A' ' 115' ' ' SER . 69.8 p -132.62 121.65 23.51 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 123.509 0.724 . . . . 70.13 110.109 178.398 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -65.6 -38.83 95.05 Favored Glycine 0 C--N 1.355 1.591 0 O-C-N 123.661 0.601 . . . . 75.21 111.683 174.346 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -97.43 -158.74 30.85 Favored Glycine 0 C--N 1.352 1.44 0 N-CA-C 111.425 -0.67 . . . . 75.1 111.425 169.324 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 25.7 m -75.97 -33.74 59.78 Favored 'General case' 0 N--CA 1.479 0.986 0 C-N-CA 123.713 0.805 . . . . 72.14 110.869 174.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -149.25 -32.39 0.05 OUTLIER Glycine 0 C--N 1.343 0.938 0 N-CA-C 111.144 -0.782 . . . . 60.53 111.144 179.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -66.92 88.4 0.14 Allowed Glycine 0 C--N 1.353 1.508 0 N-CA-C 111.424 -0.67 . . . . 74.43 111.424 172.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' SER . . . . . 0.464 ' HB3' ' HA ' ' A' ' 109' ' ' SER . 19.5 p -112.79 124.92 53.67 Favored 'General case' 0 C--O 1.238 0.487 0 C-N-CA 123.907 0.883 . . . . 63.03 109.22 179.316 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -81.88 66.17 3.9 Favored Glycine 0 C--N 1.344 1.019 0 N-CA-C 110.72 -0.952 . . . . 64.43 110.72 172.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 11.7 mmm180 -71.65 147.72 47.22 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 124.107 0.963 . . . . 75.3 110.746 -177.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -72.97 150.47 42.46 Favored 'General case' 0 C--O 1.243 0.741 0 N-CA-C 107.734 -1.21 . . . . 75.44 107.734 170.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.47 HD11 HG22 ' A' ' 140' ' ' VAL . 39.7 mt -95.04 139.02 31.98 Favored 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 107.402 -1.332 . . . . 74.24 107.402 -176.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . 0.491 ' HD2' ' HA3' ' A' ' 105' ' ' GLY . 17.8 ptp180 -146.3 135.8 23.03 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.379 -0.971 . . . . 71.01 108.379 178.403 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . 0.467 ' HA ' HG21 ' A' ' 103' ' ' THR . . . -156.95 139.2 14.67 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.189 -0.671 . . . . 75.53 109.189 -171.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -96.7 148.02 23.31 Favored 'General case' 0 C--O 1.244 0.764 0 N-CA-C 109.38 -0.6 . . . . 71.53 109.38 173.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.611 HD12 ' HB3' ' A' ' 98' ' ' LEU . 1.6 pt? -144.12 132.18 10.84 Favored Pre-proline 0 N--CA 1.473 0.71 0 CA-C-N 115.991 -0.55 . . . . 75.31 110.83 -171.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.418 ' HA ' ' HB2' ' A' ' 179' ' ' ARG . 55.6 Cg_endo -68.5 117.2 4.82 Favored 'Trans proline' 0 C--N 1.374 1.895 0 C-N-CA 121.963 1.775 . . . . 75.52 110.932 174.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.43 HD23 HG11 ' A' ' 178' ' ' VAL . 16.0 tp -119.8 150.56 40.22 Favored 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 108.828 -0.804 . . . . 73.2 108.828 178.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.511 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 10.5 m -89.16 158.28 17.97 Favored 'General case' 0 CA--C 1.547 0.854 0 N-CA-C 109.31 -0.626 . . . . 65.34 109.31 175.345 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.46 HD13 ' O ' ' A' ' 183' ' ' HIS . 55.9 mt -54.56 -51.32 65.6 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 123.886 0.875 . . . . 75.12 111.062 177.317 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.441 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 2.1 mp0 -55.67 -37.59 68.5 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 114.325 -1.307 . . . . 74.34 111.024 176.834 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.511 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 10.3 mm-40 -79.18 -18.12 53.64 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.557 0.743 . . . . 64.31 111.313 -177.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.624 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -66.12 -42.37 89.27 Favored 'General case' 0 C--O 1.252 1.221 0 CA-C-O 121.004 0.43 . . . . 72.03 110.951 165.785 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -65.02 -48.88 72.32 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 115.824 -0.626 . . . . 73.31 111.318 172.507 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.6 m80 -73.82 -48.07 34.02 Favored 'General case' 0 N--CA 1.481 1.116 0 O-C-N 123.773 0.671 . . . . 70.03 111.839 -171.444 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 58.51 -109.54 2.03 Favored Glycine 0 CA--C 1.533 1.176 0 N-CA-C 111.351 -0.7 . . . . 72.51 111.351 -172.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.21 -162.89 50.13 Favored Glycine 0 C--N 1.346 1.106 0 N-CA-C 114.983 0.753 . . . . 74.24 114.983 166.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -79.06 135.97 37.03 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 124.424 1.09 . . . . 73.42 110.989 -174.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.643 ' HG2' ' HG ' ' A' ' 98' ' ' LEU . 13.8 tpt180 -156.86 167.97 28.87 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.137 0.975 . . . . 73.33 109.215 175.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.0 p -110.25 136.72 45.36 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 CA-C-O 121.148 0.499 . . . . 73.42 110.613 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 15.5 m -121.23 137.81 53.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 C-N-CA 124.011 0.925 . . . . 71.44 108.864 172.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -126.47 98.44 5.42 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-O 121.894 0.854 . . . . 74.31 109.228 171.368 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.47 HG22 HD11 ' A' ' 119' ' ' LEU . 10.6 m -130.24 139.41 51.47 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 124.517 1.127 . . . . 74.0 108.63 -179.161 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.54 24.77 14.17 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 124.256 1.023 . . . . 75.13 111.465 -176.234 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.11 -3.9 74.18 Favored Glycine 0 C--N 1.351 1.406 0 CA-C-N 115.809 -0.632 . . . . 74.11 113.038 -177.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -97.17 116.37 29.26 Favored 'General case' 0 C--N 1.346 0.456 0 C-N-CA 123.409 0.684 . . . . 75.12 109.425 -176.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 44.1 ttm180 -101.45 106.12 17.21 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 108.598 -0.89 . . . . 73.55 108.598 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 38.5 t -127.74 142.85 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 124.025 0.93 . . . . 73.53 109.223 -177.311 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 9.6 p -77.28 114.5 16.17 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 123.28 0.632 . . . . 75.14 110.041 175.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.8 p -98.88 136.43 29.93 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 C-N-CA 123.808 0.843 . . . . 73.01 110.345 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 59.6 ttp180 -111.2 95.44 5.53 Favored 'General case' 0 C--O 1.242 0.705 0 N-CA-C 108.227 -1.027 . . . . 72.52 108.227 168.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.432 ' HB ' HD11 ' A' ' 159' ' ' ILE . 34.9 pt -82.48 128.5 66.62 Favored Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 108.492 -0.929 . . . . 72.3 108.492 175.067 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -68.98 147.19 67.35 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.41 2.073 . . . . 74.31 113.059 -168.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -64.32 111.91 1.76 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 122.362 2.041 . . . . 75.13 110.636 172.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . 0.758 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 142.23 30.45 0.13 Allowed Glycine 0 C--N 1.354 1.578 0 C-N-CA 121.435 -0.412 . . . . 74.4 114.051 -174.632 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.624 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.0 p -106.26 164.57 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.683 0 C-N-CA 123.506 0.722 . . . . 74.0 109.891 -176.166 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.409 HH11 HD21 ' A' ' 188' ' ' LEU . 52.9 mtm-85 -144.56 167.19 23.1 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 125.106 1.363 . . . . 71.43 108.979 -172.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . 0.448 ' HB2' ' HB2' ' A' ' 180' ' ' LEU . 13.3 tp10 -54.82 122.48 10.86 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 123.329 0.651 . . . . 75.42 110.14 168.218 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 89.12 -11.6 68.94 Favored Glycine 0 C--N 1.344 0.983 0 CA-C-O 119.632 -0.538 . . . . 75.22 113.395 179.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.423 ' HB3' HG21 ' A' ' 153' ' ' VAL . 35.0 t -70.86 129.53 39.31 Favored 'General case' 0 C--O 1.245 0.863 0 CA-C-N 117.206 0.503 . . . . 71.2 109.756 -178.015 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.451 HG12 HD23 ' A' ' 175' ' ' LEU . 18.6 t -104.01 119.37 52.64 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 CA-C-N 114.386 -1.279 . . . . 70.44 109.073 -173.068 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.536 HD13 HG23 ' A' ' 153' ' ' VAL . 23.4 mt -103.13 117.45 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 C-N-CA 123.803 0.841 . . . . 71.42 110.023 -171.095 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 55.9 ttt85 -90.52 111.64 23.01 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 123.686 0.794 . . . . 71.11 110.226 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.3 m -120.31 102.37 45.79 Favored Pre-proline 0 CA--C 1.568 1.665 0 C-N-CA 122.618 0.367 . . . . 74.13 110.611 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -63.56 150.99 87.11 Favored 'Trans proline' 0 C--N 1.375 1.93 0 C-N-CA 122.938 2.425 . . . . 72.35 113.175 -177.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 106.11 -26.11 21.57 Favored Glycine 0 CA--C 1.535 1.329 0 CA-C-O 119.038 -0.868 . . . . 72.44 114.777 177.024 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -81.24 -55.15 4.92 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-N 118.674 1.237 . . . . 74.35 111.23 -178.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -70.61 -179.51 27.98 Favored Glycine 0 C--N 1.348 1.219 0 CA-C-N 115.993 -0.549 . . . . 74.01 113.755 -177.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -95.59 -50.46 1.99 Allowed Glycine 0 C--N 1.343 0.96 0 CA-C-O 119.487 -0.618 . . . . 72.0 113.578 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.582 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -38.4 127.44 1.41 Allowed 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 115.66 1.726 . . . . 70.22 115.66 -161.981 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 91.35 165.88 40.04 Favored Glycine 0 C--N 1.353 1.513 0 O-C-N 124.42 1.075 . . . . 73.34 111.944 -178.101 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -65.8 -43.38 59.24 Favored Pre-proline 0 CA--C 1.559 1.324 0 CA-C-O 118.682 -0.675 . . . . 75.42 110.326 173.644 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -67.46 143.5 63.49 Favored 'Trans proline' 0 C--N 1.388 2.648 0 C-N-CA 121.25 1.3 . . . . 75.14 110.248 161.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -64.34 126.81 17.72 Favored 'Trans proline' 0 C--N 1.371 1.741 0 C-N-CA 122.007 1.805 . . . . 74.52 111.489 -176.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -65.49 -171.54 3.38 Favored Glycine 0 C--N 1.346 1.106 0 CA-C-N 115.866 -0.606 . . . . 64.44 113.943 -177.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 10.5 p-10 -108.58 172.9 6.57 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 123.828 0.851 . . . . 54.14 112.129 -168.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.44 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 19.2 tp -120.41 116.76 26.11 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 114.44 -1.255 . . . . 70.25 107.867 172.205 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.451 HD23 HG12 ' A' ' 158' ' ' VAL . 65.3 mt -88.11 100.03 12.64 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.982 0.913 . . . . 74.13 110.901 177.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 70.8 mt -91.46 104.9 17.36 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 123.222 0.609 . . . . 72.41 111.044 176.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.416 HG21 HG11 ' A' ' 158' ' ' VAL . 12.4 t -91.58 101.11 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 108.399 -0.963 . . . . 75.43 108.399 177.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.43 HG11 HD23 ' A' ' 125' ' ' LEU . 3.7 m -76.84 150.12 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 CA-C-O 121.612 0.72 . . . . 74.24 112.16 -172.814 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . 0.418 ' HB2' ' HA ' ' A' ' 124' ' ' PRO . 42.8 mmt180 -116.18 91.55 3.63 Favored 'General case' 0 C--O 1.238 0.448 0 C-N-CA 125.352 1.461 . . . . 75.45 107.686 -179.41 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.448 ' HB2' ' HB2' ' A' ' 155' ' ' GLU . 21.3 mt -69.9 148.77 48.58 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 120.716 0.293 . . . . 72.45 110.28 175.431 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.1 mt -54.74 144.41 45.8 Favored Pre-proline 0 CA--C 1.556 1.195 0 C-N-CA 123.927 0.891 . . . . 65.45 112.131 -175.319 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.453 ' O ' ' HD3' ' A' ' 184' ' ' PRO . 23.9 Cg_exo -65.62 1.4 2.21 Favored 'Trans proline' 0 C--N 1.385 2.474 0 C-N-CA 123.529 2.819 . . . . 61.5 113.347 175.52 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . 0.46 ' O ' HD13 ' A' ' 127' ' ' LEU . 8.4 t60 -91.36 98.31 1.7 Allowed Pre-proline 0 CA--C 1.549 0.93 0 N-CA-C 107.546 -1.279 . . . . 71.1 107.546 159.34 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 182' ' ' PRO . 60.6 Cg_endo -102.16 124.7 0.09 OUTLIER 'Trans proline' 0 C--N 1.37 1.665 0 C-N-CA 122.913 2.408 . . . . 73.53 111.729 168.22 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -114.28 -42.2 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 CA-C-O 121.348 0.594 . . . . 73.24 109.728 177.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . 0.469 ' HD2' HD21 ' A' ' 193' ' ' LEU . 5.5 m-85 -101.54 125.44 48.19 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 115.562 -0.745 . . . . 74.4 109.96 -177.384 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 37.2 ttp-105 -98.74 111.98 24.19 Favored 'General case' 0 C--O 1.243 0.758 0 N-CA-C 107.167 -1.419 . . . . 63.42 107.167 169.597 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.409 HD21 HH11 ' A' ' 154' ' ' ARG . 54.2 tp -83.45 116.99 22.77 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 108.443 -0.947 . . . . 72.15 108.443 172.482 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -126.76 99.21 5.67 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 124.488 1.115 . . . . 74.33 108.253 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 55.87 56.49 23.65 Favored Glycine 0 C--N 1.353 1.475 0 CA-C-O 119.504 -0.609 . . . . 63.15 113.76 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 69.13 -6.16 0.96 Allowed 'General case' 0 N--CA 1.504 2.25 0 C-N-CA 125.281 1.432 . . . . 75.43 113.15 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -97.82 150.12 21.61 Favored 'General case' 0 C--N 1.35 0.616 0 C-N-CA 124.864 1.266 . . . . 74.02 108.756 -178.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.607 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 94.9 mt -111.43 148.98 31.92 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 121.616 0.722 . . . . 74.25 112.418 -176.246 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -132.96 121.33 22.64 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 114.062 -1.427 . . . . 75.44 107.728 171.182 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -132.9 170.51 15.22 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 124.294 1.038 . . . . 64.12 109.071 177.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 54.9 m -109.96 133.38 53.24 Favored 'General case' 0 CA--C 1.537 0.449 0 N-CA-C 109.034 -0.728 . . . . 73.15 109.034 172.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . . . . . . . . . 52.5 tp -112.51 112.11 23.42 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 108.466 -0.938 . . . . 74.15 108.466 175.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -90.77 102.46 15.22 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 108.824 -0.806 . . . . 72.3 108.824 175.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 7.7 p -109.3 131.88 21.59 Favored Pre-proline 0 CA--C 1.548 0.882 0 CA-C-N 114.98 -1.009 . . . . 72.21 109.291 -176.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -56.32 145.34 78.57 Favored 'Trans proline' 0 C--N 1.373 1.847 0 C-N-CA 122.785 2.323 . . . . 74.01 113.181 174.051 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . 0.454 ' HA ' HG22 ' A' ' 255' ' ' ILE . . . -54.73 -45.86 99.52 Favored Pre-proline 0 CA--C 1.563 1.465 0 C-N-CA 124.112 0.965 . . . . 74.54 113.4 176.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . 0.416 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 26.0 Cg_endo -58.76 -44.18 38.25 Favored 'Trans proline' 0 C--N 1.392 2.826 0 C-N-CA 122.014 1.809 . . . . 72.55 111.941 175.692 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.5 mt -63.68 -37.62 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 C-N-CA 123.105 0.562 . . . . 64.42 110.931 178.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -61.89 -46.76 87.97 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.436 0.695 . . . . 75.24 112.011 -177.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.3 m -77.08 -36.91 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 N-CA-C 112.235 0.457 . . . . 71.11 112.235 -177.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m -80.57 -25.24 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 CA-C-O 120.838 0.351 . . . . 75.22 110.978 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.487 ' HA2' HG22 ' A' ' 223' ' ' VAL . . . 72.93 69.4 1.4 Allowed Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.421 -0.809 . . . . 62.32 112.244 -173.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -96.08 -149.17 25.28 Favored Glycine 0 C--N 1.352 1.452 0 CA-C-O 121.312 0.395 . . . . 75.13 113.117 -178.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 53.1 tttp -125.82 125.93 43.69 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 124.845 1.258 . . . . 73.03 108.792 -172.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . 0.496 HG23 HG12 ' A' ' 221' ' ' VAL . 11.4 m -130.5 163.2 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.203 1.001 . . . . 72.21 108.598 173.474 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 39.0 ptt85 -104.57 148.16 26.82 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 109.665 -0.495 . . . . 74.34 109.665 176.08 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -120.45 135.23 55.12 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 108.852 -0.795 . . . . 62.1 108.852 174.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 5.0 tpt -87.02 107.57 18.48 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 108.906 -0.776 . . . . 74.3 108.906 178.368 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 214' ' ' THR . . . . . 0.419 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 14.6 t -110.33 168.62 9.31 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 121.075 0.464 . . . . 73.0 109.78 174.287 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . 0.441 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 61.9 mt -74.55 -9.91 59.03 Favored 'General case' 0 CA--C 1.542 0.653 0 CA-C-N 115.667 -0.697 . . . . 70.11 112.519 -173.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -86.36 -21.75 27.03 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.598 0.759 . . . . 73.05 110.625 173.429 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 139.96 -169.73 24.57 Favored Glycine 0 C--N 1.345 1.032 0 N-CA-C 111.281 -0.728 . . . . 74.31 111.281 -173.645 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -76.01 126.85 9.6 Favored 'Trans proline' 0 C--N 1.363 1.336 0 C-N-CA 122.42 2.08 . . . . 74.11 112.015 176.049 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 33.4 m -110.25 163.53 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 123.549 0.74 . . . . 74.34 109.268 171.592 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -114.04 127.24 55.85 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.41 -0.589 . . . . 74.23 109.41 174.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.517 ' HB ' HD12 ' A' ' 235' ' ' LEU . 3.2 p -120.76 118.44 56.44 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 C-N-CA 123.818 0.847 . . . . 73.25 110.007 175.194 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.37 113.5 24.81 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 108.24 -1.022 . . . . 70.41 108.24 174.338 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.487 HG22 ' HA2' ' A' ' 207' ' ' GLY . 10.4 m -73.31 139.71 78.96 Favored Pre-proline 0 CA--C 1.553 1.096 0 N-CA-C 108.751 -0.833 . . . . 74.25 108.751 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 223' ' ' VAL . 3.0 Cg_exo -74.52 145.39 33.37 Favored 'Trans proline' 0 CA--C 1.557 1.674 0 C-N-CA 122.143 1.895 . . . . 53.42 111.309 178.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_exo -54.32 130.36 39.43 Favored 'Trans proline' 0 C--N 1.38 2.235 0 C-N-CA 123.325 2.683 . . . . 74.45 113.247 -179.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 61.69 61.28 1.47 Allowed 'General case' 0 N--CA 1.477 0.892 0 O-C-N 124.639 1.212 . . . . 73.33 111.201 -176.212 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.9 t -87.81 172.04 9.94 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 109.56 -0.533 . . . . 74.22 109.56 172.37 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . 0.448 HE21 ' HD2' ' A' ' 231' ' ' ARG . 1.9 mp0 -130.66 153.25 49.15 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 108.72 -0.845 . . . . 73.03 108.72 -178.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -72.36 139.69 48.02 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 122.779 0.432 . . . . 74.32 110.028 176.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 101.75 -6.84 55.01 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 116.052 -0.522 . . . . 70.11 112.395 -178.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . 0.448 ' HD2' HE21 ' A' ' 228' ' ' GLN . 58.6 mtp180 -82.48 160.72 22.6 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.006 0.522 . . . . 71.02 110.251 179.081 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.486 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 11.9 mptt -118.3 116.97 27.85 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.828 0.851 . . . . 73.22 109.73 -178.293 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 73.6 mt -92.0 107.42 19.2 Favored 'General case' 0 C--O 1.24 0.603 0 N-CA-C 107.265 -1.383 . . . . 73.34 107.265 175.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . 0.436 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 66.5 ttt180 -88.56 103.14 15.62 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.362 -0.835 . . . . 75.11 110.313 -166.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.517 HD12 ' HB ' ' A' ' 221' ' ' VAL . 33.3 mt -93.28 97.58 10.71 Favored 'General case' 0 C--N 1.348 0.508 0 N-CA-C 108.706 -0.85 . . . . 72.25 108.706 178.076 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . 0.544 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 10.3 mtmp? -81.38 144.38 31.48 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.332 -0.849 . . . . 62.15 111.525 -172.524 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 76.46 18.39 79.16 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.499 -0.773 . . . . 75.41 112.817 -172.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 73.1 mmtt -121.05 7.11 10.3 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.278 0.631 . . . . 75.42 111.934 -178.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . 0.4 ' HA2' ' CD1' ' A' ' 193' ' ' LEU . . . -92.22 -169.44 40.73 Favored Glycine 0 C--N 1.338 0.681 0 O-C-N 123.578 0.549 . . . . 61.33 112.131 174.679 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.758 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 3.9 m-85 -76.77 144.23 72.64 Favored Pre-proline 0 CA--C 1.547 0.849 0 C-N-CA 122.302 0.241 . . . . 71.2 110.614 -175.634 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.89 127.73 21.22 Favored 'Trans proline' 0 C--N 1.377 2.055 0 C-N-CA 122.885 2.39 . . . . 72.31 111.646 176.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -164.36 -154.09 7.71 Favored Glycine 0 CA--C 1.537 1.458 0 CA-C-O 119.448 -0.64 . . . . 71.3 113.298 -174.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -60.67 -24.28 78.17 Favored 'Trans proline' 0 C--N 1.379 2.166 0 C-N-CA 124.263 3.309 . . . . 74.43 114.164 -178.111 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.0 23.01 5.21 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 123.453 0.701 . . . . 74.32 111.461 176.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 74.33 -78.54 0.97 Allowed Glycine 0 C--N 1.348 1.206 0 N-CA-C 110.938 -0.865 . . . . 75.43 110.938 -173.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 12.8 ttt85 -129.65 141.74 50.86 Favored 'General case' 0 CA--C 1.546 0.8 0 N-CA-C 108.348 -0.982 . . . . 72.24 108.348 172.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.74 -156.78 5.28 Favored Glycine 0 N--CA 1.475 1.252 0 N-CA-C 113.805 0.282 . . . . 74.22 113.805 -178.032 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . 0.544 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 0.7 OUTLIER -148.44 156.46 42.51 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 123.125 0.57 . . . . 65.22 111.281 179.39 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.607 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 28.5 tp -110.42 133.63 53.09 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.73 1.212 . . . . 74.13 111.196 -172.137 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -106.21 107.2 18.09 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.147 0.979 . . . . 73.34 109.402 174.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.486 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 84.8 mt -87.56 115.57 25.08 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.1 0.56 . . . . 73.11 111.839 176.546 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -79.89 93.74 5.72 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 108.472 -0.936 . . . . 74.32 108.472 179.056 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 59.6 t -48.18 121.0 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.553 1.141 . . . . 73.31 110.659 174.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 25.6 mmm180 -128.9 95.45 4.09 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.194 -1.41 . . . . 74.14 107.194 177.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.454 HG22 ' HA ' ' A' ' 201' ' ' ALA . 66.5 mt -75.32 120.38 24.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-N 114.898 -1.046 . . . . 73.22 109.407 -176.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.556 1.189 0 C-N-CA 123.637 0.775 . . . . 74.14 109.315 -173.697 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.076 0 N-CA-C 109.827 -0.435 . . . . 74.22 109.827 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -160.78 -64.44 0.06 Allowed 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 122.808 0.443 . . . . 73.43 110.409 -177.459 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.491 HD23 HH11 ' A' ' 136' ' ' ARG . 55.1 tp -81.47 -52.15 7.55 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 123.236 0.614 . . . . 73.33 109.928 -178.281 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.552 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 8.1 p -87.54 158.81 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 C-N-CA 123.216 0.606 . . . . 70.52 110.093 168.598 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -88.82 -89.62 0.14 Allowed 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 123.278 0.631 . . . . 71.03 109.896 170.241 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -160.74 176.52 11.41 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 125.106 1.363 . . . . 72.21 108.915 -174.443 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 9.1 p -68.68 125.62 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 CA-C-O 121.224 0.535 . . . . 74.31 110.557 178.186 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 81.9 p -71.23 107.35 4.19 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 124.122 0.969 . . . . 74.15 109.826 175.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 43.0 t -73.56 82.73 1.51 Allowed 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.404 0.681 . . . . 72.13 110.216 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -165.33 136.81 4.37 Favored Glycine 0 C--N 1.342 0.907 0 N-CA-C 111.407 -0.677 . . . . 75.13 111.407 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 50.6 m -70.56 141.58 51.84 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 123.839 0.856 . . . . 72.41 111.305 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -137.31 111.47 0.84 Allowed Glycine 0 C--N 1.346 1.117 0 N-CA-C 111.897 -0.481 . . . . 74.5 111.897 -175.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.89 58.2 3.66 Favored Glycine 0 C--N 1.346 1.12 0 C-N-CA 123.134 0.397 . . . . 43.41 112.596 -178.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 25.8 m -79.65 90.1 5.16 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 123.528 0.731 . . . . 63.12 109.858 179.018 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 80.0 -73.95 2.37 Favored Glycine 0 C--N 1.346 1.134 0 CA-C-N 115.46 -0.791 . . . . 65.24 111.709 -177.237 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 64.31 19.07 63.81 Favored Glycine 0 C--N 1.351 1.402 0 O-C-N 123.861 0.389 . . . . 63.25 113.892 179.229 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 18.0 p -69.8 109.03 4.2 Favored 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 123.61 0.764 . . . . 74.42 110.904 -177.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.84 -115.18 4.44 Favored Glycine 0 C--N 1.348 1.245 0 CA-C-N 115.932 -0.576 . . . . 73.5 112.233 -177.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -161.68 153.84 24.67 Favored Glycine 0 C--N 1.342 0.89 0 N-CA-C 112.343 -0.303 . . . . 72.2 112.343 -179.369 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 60.4 m -149.29 178.74 8.5 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 124.699 1.2 . . . . 75.04 109.627 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -63.46 149.93 49.82 Favored Glycine 0 C--N 1.353 1.474 0 N-CA-C 111.729 -0.549 . . . . 73.0 111.729 173.384 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . 0.484 ' HB3' ' HA3' ' A' ' 166' ' ' GLY . 59.6 ttt180 -59.85 120.58 9.85 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.881 0.872 . . . . 72.34 111.176 -174.802 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -88.12 147.73 24.78 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-O 121.518 0.675 . . . . 62.41 110.603 -179.459 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.518 HD12 ' HA2' ' A' ' 165' ' ' GLY . 14.5 mt -104.53 155.11 19.1 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.179 -1.415 . . . . 75.23 107.179 162.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 10.8 ttm180 -145.11 118.26 8.89 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 108.87 -0.789 . . . . 73.35 108.87 -175.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -141.37 141.61 33.8 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 123.702 0.801 . . . . 61.32 109.724 -176.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.705 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 39.4 mt-10 -116.95 149.82 39.55 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.066 0.546 . . . . 73.04 110.811 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.552 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.6 pt? -145.85 144.89 23.29 Favored Pre-proline 0 N--CA 1.471 0.599 0 CA-C-N 115.392 -0.822 . . . . 72.23 110.873 -179.44 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -77.55 115.3 3.86 Favored 'Trans proline' 0 C--N 1.371 1.739 0 C-N-CA 121.825 1.683 . . . . 75.14 110.711 168.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.548 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 15.7 tp -107.37 154.1 21.8 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.532 0.733 . . . . 65.55 109.407 179.36 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.579 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 11.5 m -87.74 160.97 17.86 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.137 0.575 . . . . 65.52 109.527 175.455 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.446 HD11 HG11 ' A' ' 185' ' ' VAL . 30.2 mt -63.07 -48.96 76.42 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 123.884 0.874 . . . . 74.2 110.562 178.58 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -57.28 -31.59 65.76 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 114.777 -1.101 . . . . 72.5 110.937 176.621 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.579 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 8.8 mm-40 -83.82 -23.99 31.17 Favored 'General case' 0 C--O 1.212 -0.869 0 C-N-CA 122.996 0.519 . . . . 73.45 111.054 -179.091 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.667 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -60.62 -35.21 75.6 Favored 'General case' 0 C--O 1.248 1.015 0 CA-C-O 121.804 0.811 . . . . 70.51 110.3 165.536 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.517 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 55.3 t80 -72.03 -47.42 51.9 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.419 -1.264 . . . . 71.21 111.82 172.213 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.3 m80 -83.96 -16.82 42.71 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 113.283 0.846 . . . . 71.24 113.283 -171.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 89.75 -117.72 5.06 Favored Glycine 0 CA--C 1.535 1.326 0 N-CA-C 111.987 -0.445 . . . . 72.44 111.987 -170.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 148.91 94.01 0.12 Allowed Glycine 0 C--N 1.353 1.488 0 CA-C-N 117.828 0.814 . . . . 73.44 113.571 175.12 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -85.21 123.06 30.28 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 123.273 0.629 . . . . 72.43 109.397 175.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.556 ' NH2' HD13 ' A' ' 176' ' ' LEU . 16.9 ptt-85 -148.65 168.45 22.81 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.204 0.602 . . . . 73.23 111.526 -170.157 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 23.1 m -89.84 106.23 16.93 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 CA-C-N 115.022 -0.99 . . . . 75.43 108.624 169.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.494 HG22 HG13 ' A' ' 99' ' ' VAL . 7.4 p -98.89 123.1 51.3 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 123.153 0.581 . . . . 63.11 109.789 -179.38 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -119.03 98.73 6.32 Favored 'General case' 0 C--O 1.241 0.614 0 C-N-CA 124.256 1.023 . . . . 73.41 109.186 -178.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.405 HG21 HD22 ' A' ' 174' ' ' LEU . 8.6 m -131.8 121.45 47.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 124.457 1.103 . . . . 75.0 109.919 -173.605 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.25 22.84 13.55 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 124.533 1.133 . . . . 74.12 111.954 -178.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 88.8 2.39 78.64 Favored Glycine 0 C--N 1.345 1.067 0 CA-C-O 119.815 -0.436 . . . . 72.23 113.388 -177.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -92.8 113.92 26.33 Favored 'General case' 0 C--N 1.348 0.515 0 N-CA-C 108.625 -0.88 . . . . 74.41 108.625 175.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 59.9 ttp180 -106.22 110.85 23.22 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 108.116 -1.068 . . . . 74.5 108.116 176.1 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 5.7 m -141.38 155.72 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 124.52 1.128 . . . . 74.14 109.078 -177.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 47.4 t -87.21 115.5 24.65 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.128 -0.693 . . . . 65.22 109.128 177.312 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.2 p -99.33 136.66 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-O 121.095 0.474 . . . . 53.13 110.718 179.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.5 ttp180 -110.29 98.76 7.92 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 107.743 -1.206 . . . . 74.34 107.743 172.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.479 ' HB ' HD11 ' A' ' 159' ' ' ILE . 28.9 pt -89.88 131.24 39.99 Favored Pre-proline 0 N--CA 1.475 0.809 0 N-CA-C 108.684 -0.858 . . . . 74.25 108.684 177.27 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -72.01 157.7 53.98 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.45 2.1 . . . . 72.33 112.828 -172.1 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -68.5 148.17 72.39 Favored 'Trans proline' 0 C--N 1.375 1.959 0 C-N-CA 122.283 1.988 . . . . 74.12 111.356 172.204 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 100.04 41.49 2.83 Favored Glycine 0 C--N 1.34 0.786 0 N-CA-C 110.988 -0.845 . . . . 65.13 110.988 -176.504 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.667 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -111.37 160.74 10.47 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.267 0 N-CA-C 108.265 -1.013 . . . . 72.43 108.265 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.408 ' HD3' ' HB3' ' A' ' 188' ' ' LEU . 74.8 mtm180 -148.47 176.74 10.05 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 123.909 0.884 . . . . 72.01 111.735 -166.118 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -55.61 115.74 2.51 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 114.214 -1.357 . . . . 50.22 111.072 170.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 75.89 10.22 85.06 Favored Glycine 0 C--N 1.345 1.053 0 O-C-N 123.601 0.563 . . . . 63.11 113.683 178.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 37.5 t -75.13 125.97 30.05 Favored 'General case' 0 C--O 1.245 0.819 0 C-N-CA 122.97 0.508 . . . . 71.05 109.906 -178.797 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.421 HG13 HD23 ' A' ' 175' ' ' LEU . 21.2 t -95.83 121.57 46.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 C-N-CA 124.719 1.208 . . . . 74.45 109.457 -175.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.533 HD13 HG23 ' A' ' 153' ' ' VAL . 27.3 mt -107.28 111.21 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 123.46 0.704 . . . . 71.14 109.634 -174.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.406 ' HA ' HD22 ' A' ' 175' ' ' LEU . 25.1 ttp180 -84.83 117.76 24.07 Favored 'General case' 0 CA--C 1.538 0.493 0 O-C-N 123.655 0.597 . . . . 74.21 109.989 179.192 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.5 m -114.86 96.47 44.67 Favored Pre-proline 0 CA--C 1.561 1.394 0 CA-C-O 121.431 0.634 . . . . 71.24 109.419 175.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -63.22 136.61 56.68 Favored 'Trans proline' 0 C--N 1.379 2.153 0 C-N-CA 123.391 2.727 . . . . 74.35 113.224 -175.616 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.59 -17.14 59.43 Favored Glycine 0 C--N 1.345 1.064 0 N-CA-C 114.39 0.516 . . . . 52.12 114.39 174.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 10.4 mtm -100.69 -6.29 25.31 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 117.718 0.759 . . . . 65.1 112.187 -174.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . 0.518 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . -88.33 -115.19 1.25 Allowed Glycine 0 C--N 1.351 1.391 0 N-CA-C 111.813 -0.515 . . . . 75.52 111.813 175.285 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.484 ' HA3' ' HB3' ' A' ' 117' ' ' ARG . . . -67.71 129.91 27.85 Favored Glycine 0 C--N 1.347 1.169 0 N-CA-C 112.012 -0.435 . . . . 73.22 112.012 178.373 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.0 mm-40 -89.65 154.18 20.16 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.477 0.711 . . . . 64.4 110.986 -177.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 137.68 -166.89 24.98 Favored Glycine 0 N--CA 1.472 1.041 0 N-CA-C 111.788 -0.525 . . . . 72.23 111.788 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -71.51 -42.18 10.73 Favored Pre-proline 0 CA--C 1.56 1.361 0 CA-C-O 118.331 -0.843 . . . . 65.15 110.805 174.085 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -69.57 116.26 4.46 Favored 'Trans proline' 0 C--N 1.394 2.953 0 C-N-CA 122.015 1.81 . . . . 73.22 110.401 164.32 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -71.08 125.08 11.11 Favored 'Trans proline' 0 C--N 1.375 1.957 0 C-N-CA 121.546 1.497 . . . . 74.43 111.688 177.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -98.63 151.93 19.64 Favored Glycine 0 N--CA 1.452 -0.294 0 N-CA-C 110.123 -1.191 . . . . 74.12 110.123 171.039 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -116.49 167.83 10.71 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 124.422 1.089 . . . . 74.44 109.751 -173.598 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.485 HD23 HG21 ' A' ' 138' ' ' VAL . 11.8 tp -120.22 129.64 54.17 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.167 -1.049 . . . . 75.05 108.167 176.479 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.421 HD23 HG13 ' A' ' 158' ' ' VAL . 83.1 mt -103.79 98.6 8.43 Favored 'General case' 0 C--O 1.233 0.212 0 C-N-CA 124.345 1.058 . . . . 64.4 109.636 -175.39 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.556 HD13 ' NH2' ' A' ' 136' ' ' ARG . 45.4 mt -92.88 101.23 13.59 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.357 -0.838 . . . . 72.43 109.649 178.827 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.705 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 25.5 t -90.71 107.65 18.78 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 N-CA-C 108.422 -0.955 . . . . 74.21 108.422 179.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.548 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 3.2 m -87.43 148.93 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 109.463 -0.569 . . . . 73.42 109.463 -177.733 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 10.0 mmm-85 -123.51 104.17 8.9 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 107.466 -1.309 . . . . 74.22 107.466 -174.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 27.4 mt -69.15 151.55 46.22 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-O 121.213 0.53 . . . . 74.15 111.3 -178.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 52.9 mt -54.56 150.7 16.59 Favored Pre-proline 0 CA--C 1.561 1.397 0 CA-C-N 114.608 -1.178 . . . . 74.44 112.383 -177.172 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -61.1 -8.05 9.26 Favored 'Trans proline' 0 C--N 1.385 2.489 0 C-N-CA 123.144 2.562 . . . . 74.02 113.459 177.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . 0.434 ' O ' HD13 ' A' ' 127' ' ' LEU . 5.2 t60 -93.44 104.83 13.53 Favored Pre-proline 0 CA--C 1.544 0.743 0 C-N-CA 124.436 1.094 . . . . 72.32 108.726 164.011 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -101.16 128.82 0.13 Allowed 'Trans proline' 0 CA--C 1.559 1.746 0 C-N-CA 123.379 2.72 . . . . 72.2 112.486 165.69 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . 0.446 HG11 HD11 ' A' ' 127' ' ' LEU . 2.6 p -113.85 -46.21 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 122.899 0.48 . . . . 74.04 109.998 172.802 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -98.98 122.68 42.55 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.031 0.443 . . . . 74.31 110.774 -174.195 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.621 ' HB3' ' HB2' ' A' ' 194' ' ' TYR . 28.7 ttm180 -97.88 109.13 21.94 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 107.6 -1.259 . . . . 75.21 107.6 170.536 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.408 ' HB3' ' HD3' ' A' ' 154' ' ' ARG . 50.1 tp -89.56 112.62 23.87 Favored 'General case' 0 CA--C 1.543 0.702 0 N-CA-C 108.597 -0.89 . . . . 63.4 108.597 173.515 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -108.97 102.13 11.16 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 108.291 -1.003 . . . . 74.4 108.291 176.162 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 72.16 -87.41 0.49 Allowed Glycine 0 C--N 1.347 1.166 0 O-C-N 123.704 0.627 . . . . 71.4 111.765 -174.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 5.0 pm0 -134.01 -4.94 2.75 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 124.17 0.988 . . . . 73.33 110.574 178.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 56.5 m-20 -93.66 151.4 19.68 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.598 0.759 . . . . 72.31 111.198 -177.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.424 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 88.8 mt -107.44 147.07 30.9 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 124.372 1.069 . . . . 72.3 109.429 -178.493 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . 0.621 ' HB2' ' HB3' ' A' ' 187' ' ' ARG . 89.4 m-85 -133.46 121.07 21.69 Favored 'General case' 0 C--O 1.232 0.182 0 N-CA-C 107.389 -1.337 . . . . 75.31 107.389 175.233 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -134.76 170.88 15.16 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 123.916 0.886 . . . . 73.43 108.892 178.126 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 87.1 m -109.55 124.2 50.71 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.64 -0.709 . . . . 72.41 109.288 175.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.41 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 57.6 tp -107.06 111.75 24.36 Favored 'General case' 0 C--O 1.225 -0.201 0 C-N-CA 124.154 0.982 . . . . 74.52 109.106 177.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -87.45 125.53 34.34 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 107.758 -1.201 . . . . 75.13 107.758 172.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . 0.459 HG13 HG23 ' A' ' 210' ' ' VAL . 15.4 m -120.15 135.19 24.23 Favored Pre-proline 0 N--CA 1.475 0.82 0 N-CA-C 108.901 -0.777 . . . . 75.23 108.901 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -57.69 140.21 92.79 Favored 'Trans proline' 0 C--N 1.367 1.549 0 C-N-CA 122.314 2.01 . . . . 72.01 111.624 169.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -50.24 -44.21 80.33 Favored Pre-proline 0 CA--C 1.567 1.621 0 CA-C-O 118.057 -0.973 . . . . 65.4 113.069 179.384 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo -47.59 -52.61 7.75 Favored 'Trans proline' 0 C--N 1.404 3.485 0 C-N-CA 122.816 2.344 . . . . 74.31 112.754 168.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 11.8 mt -68.34 -33.4 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 C-N-CA 123.079 0.552 . . . . 75.32 111.7 -176.316 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.61 -47.97 83.51 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.329 0.651 . . . . 74.04 110.863 178.227 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . 0.461 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 32.8 m -81.78 -35.57 13.66 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.898 0 CA-C-N 115.695 -0.684 . . . . 70.14 112.362 -174.587 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.2 m -84.61 -22.97 7.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 CA-C-N 118.24 0.473 . . . . 71.51 111.245 -179.039 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 71.7 56.7 6.42 Favored Glycine 0 C--N 1.343 0.939 0 CA-C-N 115.823 -0.626 . . . . 72.02 112.31 -174.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -84.75 -152.96 17.98 Favored Glycine 0 C--N 1.355 1.624 0 N-CA-C 111.979 -0.449 . . . . 72.12 111.979 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -111.79 140.54 46.34 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.106 -0.702 . . . . 73.35 109.106 177.29 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . 0.459 HG23 HG13 ' A' ' 199' ' ' VAL . 41.1 t -125.66 149.47 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 108.066 -1.087 . . . . 71.15 108.066 168.635 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . 0.42 ' HD2' ' HG2' ' A' ' 220' ' ' GLU . 0.2 OUTLIER -90.06 125.27 35.35 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 108.268 -1.012 . . . . 74.41 108.268 166.946 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -100.43 129.11 46.35 Favored 'General case' 0 C--O 1.248 0.999 0 N-CA-C 108.59 -0.893 . . . . 72.14 108.59 178.537 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 213' ' ' MET . . . . . 0.497 ' HA ' ' HE1' ' A' ' 213' ' ' MET . 4.2 tpt -76.25 105.16 7.14 Favored 'General case' 0 CA--C 1.537 0.471 0 O-C-N 123.697 0.623 . . . . 72.53 109.435 178.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 9.2 t -117.26 169.68 9.28 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 123.418 0.687 . . . . 71.01 110.524 177.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 63.3 mt -76.1 -5.6 47.31 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 123.957 0.903 . . . . 73.31 111.423 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -88.12 -20.38 25.73 Favored 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 124.077 0.951 . . . . 73.34 110.348 172.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 130.64 -149.87 19.15 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-O 119.073 -0.848 . . . . 65.02 111.108 -174.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -86.83 120.38 1.67 Allowed 'Trans proline' 0 CA--C 1.553 1.428 0 C-N-CA 122.211 1.941 . . . . 73.41 111.604 169.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 20.0 m -108.24 155.39 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 108.968 -0.753 . . . . 63.21 108.968 173.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . 0.42 ' HG2' ' HD2' ' A' ' 211' ' ' ARG . 33.4 mt-10 -109.46 107.36 17.47 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 108.788 -0.819 . . . . 74.22 108.788 -175.305 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.2 p -96.38 132.54 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 123.739 0.816 . . . . 63.42 110.342 177.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -90.69 105.41 17.8 Favored 'General case' 0 C--O 1.24 0.588 0 C-N-CA 123.648 0.779 . . . . 44.51 108.961 173.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.11 133.51 93.63 Favored Pre-proline 0 CA--C 1.557 1.24 0 C-N-CA 124.038 0.935 . . . . 62.2 110.063 177.578 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_exo -65.04 140.69 66.88 Favored 'Trans proline' 0 C--N 1.379 2.144 0 C-N-CA 122.89 2.393 . . . . 75.42 111.539 172.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -58.98 124.41 15.63 Favored 'Trans proline' 0 C--N 1.376 2.008 0 C-N-CA 122.724 2.283 . . . . 75.24 111.418 178.147 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . 0.461 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 85.3 mtm180 60.41 76.74 0.35 Allowed 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 124.423 1.089 . . . . 74.03 110.865 -177.533 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 7.5 t -103.71 173.81 6.14 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 123.365 0.666 . . . . 71.31 109.594 174.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -131.44 155.53 47.18 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 123.655 0.782 . . . . 72.35 109.019 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.11 130.23 42.12 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.297 0.639 . . . . 74.12 110.279 177.191 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.03 -11.5 22.48 Favored Glycine 0 C--N 1.337 0.588 0 C-N-CA 123.505 0.574 . . . . 74.32 112.129 -176.087 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 73.3 mtp180 -81.7 155.58 25.48 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 122.818 0.447 . . . . 74.11 110.481 178.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 0.5 OUTLIER -118.53 125.29 49.55 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.776 0.83 . . . . 74.44 109.762 -179.115 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 28.1 mt -100.79 111.55 23.79 Favored 'General case' 0 C--N 1.353 0.759 0 N-CA-C 108.127 -1.064 . . . . 73.02 108.127 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . 0.411 ' HG3' ' HB3' ' A' ' 248' ' ' ASP . 57.4 ttm-85 -82.91 105.4 13.88 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.9 0.88 . . . . 74.44 110.894 -170.268 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.498 HD12 HD23 ' A' ' 249' ' ' LEU . 30.0 mt -87.03 97.46 10.73 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 107.782 -1.192 . . . . 62.13 107.782 171.103 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -71.76 138.2 48.25 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 114.831 -1.077 . . . . 75.44 111.634 -169.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 75.89 4.08 76.05 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 123.801 0.688 . . . . 63.4 113.991 177.219 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . 0.613 ' HE2' ' HA ' ' A' ' 238' ' ' LYS . 9.6 mmpt? -94.17 -3.13 51.47 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.253 0.621 . . . . 73.13 111.955 -177.484 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.27 -170.68 47.2 Favored Glycine 0 C--N 1.343 0.967 0 N-CA-C 111.941 -0.463 . . . . 53.51 111.941 171.236 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.517 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 97.3 m-85 -83.6 154.9 65.68 Favored Pre-proline 0 N--CA 1.477 0.917 0 C-N-CA 122.822 0.449 . . . . 61.35 111.687 -177.148 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . 0.443 ' HA ' ' O ' ' A' ' 245' ' ' GLY . 26.3 Cg_exo -64.5 127.05 18.06 Favored 'Trans proline' 0 C--N 1.375 1.962 0 C-N-CA 122.144 1.896 . . . . 73.02 110.468 166.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -165.22 -156.9 9.4 Favored Glycine 0 C--N 1.342 0.916 0 CA-C-O 119.219 -0.767 . . . . 75.24 112.329 -177.063 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -59.43 -10.78 11.83 Favored 'Trans proline' 0 N--CA 1.504 2.14 0 C-N-CA 124.017 3.145 . . . . 73.52 115.257 -178.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -109.49 19.14 19.62 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.287 0.635 . . . . 64.52 111.06 176.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 241' ' ' PRO . . . 77.45 -76.49 1.68 Allowed Glycine 0 C--N 1.345 1.067 0 N-CA-C 110.993 -0.843 . . . . 72.45 110.993 -173.34 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 55.5 mtm180 -123.77 155.88 37.1 Favored 'General case' 0 N--CA 1.476 0.875 0 N-CA-C 107.801 -1.185 . . . . 75.12 107.801 170.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -90.74 -177.89 43.85 Favored Glycine 0 C--N 1.338 0.682 0 O-C-N 123.34 0.4 . . . . 50.12 113.245 176.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . 0.411 ' HB3' ' HG3' ' A' ' 234' ' ' ARG . 60.9 m-20 -136.01 142.5 44.48 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.82 0.848 . . . . 75.23 109.189 -175.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.498 HD23 HD12 ' A' ' 235' ' ' LEU . 19.3 tp -97.53 112.97 24.6 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 109.346 -0.613 . . . . 74.24 109.346 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -90.29 105.86 18.1 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 108.754 -0.832 . . . . 75.02 108.754 176.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.512 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 93.6 mt -87.92 110.77 20.8 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.376 0.67 . . . . 73.43 112.01 176.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -79.06 92.98 5.06 Favored 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 109.117 -0.697 . . . . 75.25 109.117 -178.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 70.6 t -48.04 117.66 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 C-N-CA 124.911 1.284 . . . . 75.15 110.997 173.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 26.3 mmm180 -128.98 101.24 5.97 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 106.435 -1.691 . . . . 74.45 106.435 174.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 60.4 mt -77.17 117.51 22.24 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 CA-C-N 115.582 -0.735 . . . . 75.44 110.94 -172.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 3.3 t . . . . . 0 CA--C 1.559 1.326 0 C-N-CA 124.092 0.957 . . . . 72.21 109.211 177.725 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.578 0 N-CA-C 108.742 -0.836 . . . . 75.31 108.742 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.74 -54.34 6.2 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.213 0.605 . . . . 61.51 111.531 -171.468 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.634 ' HG ' ' HG2' ' A' ' 136' ' ' ARG . 89.0 mt -82.86 -71.93 0.47 Allowed 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 109.844 -0.428 . . . . 63.21 109.844 177.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.427 HG21 ' HB3' ' A' ' 123' ' ' LEU . 30.0 t -58.89 131.13 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 C-N-CA 123.574 0.749 . . . . 71.24 111.798 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -70.67 -52.52 20.6 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.322 -0.853 . . . . 73.45 109.732 176.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -179.96 174.99 0.85 Allowed 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.556 1.142 . . . . 75.35 109.266 -178.124 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 88.7 t -65.19 132.16 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 N-CA-C 108.762 -0.829 . . . . 72.21 108.762 171.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.429 HG21 ' HA ' ' A' ' 121' ' ' ALA . 24.5 p -63.48 90.61 0.05 OUTLIER 'General case' 0 CA--C 1.547 0.842 0 CA-C-O 121.557 0.694 . . . . 72.22 110.962 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.0 p -76.57 91.67 3.41 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 114.741 -1.118 . . . . 63.54 109.154 176.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -172.37 159.7 30.73 Favored Glycine 0 C--N 1.339 0.696 0 CA-C-N 115.265 -0.88 . . . . 65.1 112.132 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 49.8 m -121.93 142.75 49.96 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.045 0.938 . . . . 60.32 109.285 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 178.39 -114.3 0.45 Allowed Glycine 0 C--N 1.339 0.716 0 N-CA-C 111.584 -0.606 . . . . 64.1 111.584 -179.309 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -107.73 107.94 2.67 Favored Glycine 0 C--N 1.341 0.814 0 N-CA-C 112.12 -0.392 . . . . 73.21 112.12 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 42.6 p -75.25 158.78 32.39 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 123.269 0.627 . . . . 72.35 110.135 175.157 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -68.41 149.82 50.22 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 123.196 0.31 . . . . 72.44 112.441 176.736 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -88.01 17.34 47.07 Favored Glycine 0 C--N 1.344 0.982 0 CA-C-O 119.975 -0.347 . . . . 74.52 113.076 178.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 41.3 t -84.0 -71.13 0.52 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.816 0.846 . . . . 75.53 109.599 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 65.68 -97.89 0.31 Allowed Glycine 0 C--N 1.351 1.393 0 O-C-N 123.475 0.485 . . . . 64.52 112.317 -178.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.74 -169.59 50.16 Favored Glycine 0 C--N 1.35 1.31 0 O-C-N 123.72 0.306 . . . . 62.21 112.782 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 25.2 m -77.59 147.27 35.75 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 123.223 0.609 . . . . 54.11 109.463 173.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 91.87 139.23 8.56 Favored Glycine 0 C--N 1.347 1.174 0 N-CA-C 112.032 -0.427 . . . . 61.31 112.032 -178.684 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 2.2 tmm_? -76.59 118.85 19.66 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.379 -0.6 . . . . 75.42 109.379 -176.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -89.1 146.23 24.95 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 123.717 0.807 . . . . 73.31 110.816 -179.062 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.474 HD21 HD13 ' A' ' 174' ' ' LEU . 4.9 tt -136.89 149.07 47.43 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 106.611 -1.626 . . . . 54.32 106.611 -179.312 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . 0.442 ' N ' HD23 ' A' ' 119' ' ' LEU . 0.1 OUTLIER -138.11 148.69 45.23 Favored 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 119.335 0.97 . . . . 71.24 110.351 179.533 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . 0.429 ' HA ' HG21 ' A' ' 103' ' ' THR . . . -156.89 163.26 39.37 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.525 1.13 . . . . 71.23 108.709 -177.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -126.45 151.56 47.59 Favored 'General case' 0 C--O 1.248 0.99 0 CA-C-O 121.063 0.459 . . . . 74.42 110.224 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.427 ' HB3' HG21 ' A' ' 99' ' ' VAL . 1.6 pt? -140.41 135.02 15.65 Favored Pre-proline 0 N--CA 1.468 0.451 0 CA-C-N 115.681 -0.691 . . . . 74.41 111.593 -174.6 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -66.09 114.55 3.05 Favored 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 121.781 1.654 . . . . 75.4 110.351 161.152 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.434 HD23 HG13 ' A' ' 178' ' ' VAL . 16.1 tp -115.48 166.29 12.05 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.313 1.045 . . . . 74.11 108.222 175.443 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 17.6 m -108.74 161.53 15.02 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.208 0.603 . . . . 73.51 109.46 174.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.464 HD11 ' O ' ' A' ' 183' ' ' HIS . 30.8 mt -55.97 -51.94 65.94 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.808 0.843 . . . . 75.44 109.7 173.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.568 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.9 mp0 -57.36 -38.38 74.07 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 114.408 -1.269 . . . . 72.4 111.667 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -76.83 -21.86 54.42 Favored 'General case' 0 N--CA 1.479 1.025 0 C-N-CA 123.362 0.665 . . . . 70.21 111.672 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.58 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -71.85 -25.82 62.12 Favored 'General case' 0 C--O 1.249 1.073 0 C-N-CA 123.704 0.802 . . . . 51.44 110.94 170.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.516 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 36.9 t80 -82.39 -47.39 12.36 Favored 'General case' 0 C--N 1.35 0.602 0 CA-C-N 115.477 -0.783 . . . . 75.25 111.736 171.601 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -74.32 -47.46 34.43 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 123.237 0.335 . . . . 74.43 111.338 -172.093 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.16 -153.09 52.63 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 111.183 -0.767 . . . . 74.24 111.183 -168.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 119.46 -175.96 15.96 Favored Glycine 0 C--N 1.343 0.953 0 N-CA-C 114.379 0.511 . . . . 53.22 114.379 171.149 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.614 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.7 mp0 -90.74 136.28 33.17 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.993 0.917 . . . . 74.14 109.372 -177.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.634 ' HG2' ' HG ' ' A' ' 98' ' ' LEU . 0.2 OUTLIER -153.11 150.89 29.57 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 110.375 -0.231 . . . . 75.2 110.375 176.059 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 25.3 m -75.87 136.82 24.03 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 123.251 0.62 . . . . 71.1 111.836 -173.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.422 HG23 ' HB ' ' A' ' 99' ' ' VAL . 5.8 p -142.86 135.9 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 C-N-CA 124.212 1.005 . . . . 74.54 111.297 178.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -100.37 98.39 9.04 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 109.483 -0.562 . . . . 75.42 109.483 169.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.0 m -108.36 124.87 65.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 N-CA-C 108.895 -0.78 . . . . 72.33 108.895 171.61 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.09 21.83 13.09 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 124.324 1.05 . . . . 61.51 111.436 -174.086 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.28 -1.78 86.38 Favored Glycine 0 C--N 1.356 1.656 0 CA-C-N 115.835 -0.62 . . . . 61.42 113.238 -178.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.3 mmt85 -94.3 117.11 29.62 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 123.207 0.603 . . . . 73.44 109.905 -178.295 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 43.1 ttm180 -84.9 115.94 23.05 Favored 'General case' 0 C--N 1.352 0.705 0 N-CA-C 109.756 -0.461 . . . . 74.31 109.756 175.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 12.2 m -136.68 155.27 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 C-N-CA 125.136 1.375 . . . . 74.33 108.708 177.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 60.8 p -86.81 114.98 23.93 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 109.139 -0.689 . . . . 73.52 109.139 174.134 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.0 p -96.15 124.67 48.96 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 CA-C-O 121.172 0.51 . . . . 73.35 109.924 176.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . 0.614 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 13.7 ttp180 -99.03 104.94 17.01 Favored 'General case' 0 C--O 1.244 0.799 0 N-CA-C 108.841 -0.8 . . . . 71.03 108.841 175.511 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 32.7 pt -95.63 131.3 29.71 Favored Pre-proline 0 CA--C 1.548 0.878 0 N-CA-C 108.737 -0.838 . . . . 74.1 108.737 174.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -71.39 146.1 49.57 Favored 'Trans proline' 0 C--N 1.371 1.728 0 C-N-CA 122.554 2.169 . . . . 73.11 112.923 -174.697 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.64 142.5 89.84 Favored 'Trans proline' 0 C--N 1.378 2.108 0 C-N-CA 122.881 2.387 . . . . 75.13 111.425 172.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.71 52.39 0.75 Allowed Glycine 0 C--N 1.339 0.709 0 N-CA-C 110.7 -0.96 . . . . 75.42 110.7 -173.246 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.58 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.3 p -130.65 162.12 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 108.165 -1.05 . . . . 72.01 108.165 179.581 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.589 ' HA ' HD13 ' A' ' 180' ' ' LEU . 0.0 OUTLIER -162.37 173.67 13.81 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 124.925 1.29 . . . . 73.44 110.379 -179.352 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.4 tp10 -47.3 118.38 2.15 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 124.601 1.16 . . . . 73.33 112.711 -176.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 100.5 -24.86 30.47 Favored Glycine 0 C--N 1.349 1.296 0 CA-C-O 119.153 -0.804 . . . . 74.3 113.562 178.797 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.569 ' HB2' HG21 ' A' ' 153' ' ' VAL . 43.6 m -60.09 125.7 24.68 Favored 'General case' 0 C--O 1.248 0.998 0 C-N-CA 123.34 0.656 . . . . 64.23 111.127 -174.493 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.432 HG23 HD23 ' A' ' 175' ' ' LEU . 14.8 p -100.57 123.21 53.37 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.095 0 CA-C-N 114.801 -1.091 . . . . 75.31 109.071 -179.027 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.457 HD12 HG23 ' A' ' 153' ' ' VAL . 25.9 mt -105.38 112.97 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.329 1.052 . . . . 74.43 109.545 -170.166 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 34.6 ttt-85 -92.75 105.32 17.48 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 122.822 0.449 . . . . 75.02 110.256 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.431 HG22 ' HB3' ' A' ' 174' ' ' LEU . 10.5 m -97.79 112.38 61.41 Favored Pre-proline 0 CA--C 1.561 1.396 0 N-CA-C 108.072 -1.084 . . . . 72.35 108.072 176.209 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 7.6 Cg_exo -73.65 156.22 49.26 Favored 'Trans proline' 0 C--N 1.374 1.875 0 C-N-CA 123.132 2.555 . . . . 75.21 113.213 -171.598 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 66.09 24.44 71.79 Favored Glycine 0 C--N 1.347 1.188 0 O-C-N 123.715 0.635 . . . . 64.43 114.14 177.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.6 tpt -101.8 -63.21 1.17 Allowed 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.293 0.637 . . . . 74.41 111.288 -170.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -68.48 -62.8 3.89 Favored Glycine 0 C--N 1.353 1.514 0 N-CA-C 111.412 -0.675 . . . . 53.04 111.412 178.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.531 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -69.72 99.77 0.7 Allowed Glycine 0 C--N 1.341 0.822 0 CA-C-N 115.121 -0.54 . . . . 72.32 111.87 173.048 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -89.25 169.51 11.38 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.579 0.752 . . . . 75.5 110.56 176.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 89.57 -143.28 17.13 Favored Glycine 0 C--O 1.242 0.622 0 N-CA-C 111.344 -0.703 . . . . 71.23 111.344 -174.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 29.5 p-10 -92.23 -13.56 0.19 Allowed Pre-proline 0 CA--C 1.563 1.453 0 N-CA-C 114.8 1.407 . . . . 74.42 114.8 175.447 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -91.53 101.75 0.23 Allowed 'Trans proline' 0 C--N 1.398 3.145 0 CA-C-N 123.099 2.142 . . . . 73.23 110.997 165.714 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -73.22 126.72 11.33 Favored 'Trans proline' 0 C--N 1.371 1.749 0 C-N-CA 122.421 2.081 . . . . 73.14 112.108 -176.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.531 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -99.89 -137.09 9.64 Favored Glycine 0 C--N 1.342 0.916 0 N-CA-C 111.156 -0.778 . . . . 71.33 111.156 176.761 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -167.38 165.55 14.92 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 117.377 0.588 . . . . 75.14 111.245 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.474 HD13 HD21 ' A' ' 119' ' ' LEU . 35.5 tp -124.98 122.63 37.86 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 114.822 -1.081 . . . . 74.23 108.191 166.844 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.432 HD23 HG23 ' A' ' 158' ' ' VAL . 30.2 mt -95.17 101.42 13.16 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.542 1.137 . . . . 61.31 110.188 178.535 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 56.5 mt -93.5 105.42 17.47 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.56 0.744 . . . . 72.04 111.653 178.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 15.4 t -88.66 108.36 18.77 Favored 'Isoleucine or valine' 0 C--O 1.246 0.876 0 N-CA-C 108.977 -0.749 . . . . 73.11 108.977 176.286 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.434 HG13 HD23 ' A' ' 125' ' ' LEU . 25.5 m -77.69 148.3 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 N-CA-C 112.991 0.738 . . . . 72.24 112.991 -176.779 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -124.08 96.89 5.11 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 113.91 -1.495 . . . . 75.33 107.613 175.321 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.589 HD13 ' HA ' ' A' ' 154' ' ' ARG . 35.1 mt -69.09 147.74 51.02 Favored 'General case' 0 C--O 1.241 0.624 0 O-C-N 123.132 0.27 . . . . 72.42 110.725 -179.246 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.402 ' HA ' ' HD3' ' A' ' 182' ' ' PRO . 40.8 mt -54.13 128.55 57.51 Favored Pre-proline 0 CA--C 1.551 0.988 0 O-C-N 124.354 1.034 . . . . 73.44 110.055 177.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 31.7 Cg_exo -60.27 82.04 0.07 OUTLIER 'Trans proline' 0 C--N 1.377 2.034 0 C-N-CA 123.792 2.994 . . . . 65.32 113.563 -176.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . 0.464 ' O ' HD11 ' A' ' 127' ' ' LEU . 2.3 p80 -170.05 109.08 0.45 Allowed Pre-proline 0 CA--C 1.551 0.986 0 N-CA-C 106.652 -1.61 . . . . 73.31 106.652 171.521 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -89.52 127.31 1.63 Allowed 'Trans proline' 0 C--N 1.36 1.159 0 C-N-CA 122.096 1.864 . . . . 72.24 112.622 178.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 5.2 p -137.21 -47.78 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 109.515 -0.55 . . . . 73.21 109.515 168.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -109.84 123.55 49.76 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 121.436 0.636 . . . . 72.44 111.731 -176.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.461 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 0.1 OUTLIER -113.47 162.5 16.06 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.672 1.589 . . . . 75.43 109.351 -179.461 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.408 HD11 ' O ' ' A' ' 192' ' ' ASP . 43.2 tp -130.49 136.71 49.25 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 123.665 0.786 . . . . 64.54 109.958 179.832 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . 0.466 ' HB3' ' CE1' ' A' ' 194' ' ' TYR . 10.0 tp10 -142.07 109.94 5.82 Favored 'General case' 0 C--O 1.242 0.683 0 C-N-CA 124.184 0.994 . . . . 73.43 108.345 176.147 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 72.22 -83.33 0.53 Allowed Glycine 0 C--N 1.347 1.153 0 N-CA-C 111.447 -0.661 . . . . 64.4 111.447 -174.468 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . 0.533 ' NE2' ' HB1' ' A' ' 244' ' ' ALA . 29.7 pt20 -141.74 -8.26 0.95 Allowed 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.85 0.86 . . . . 72.23 110.017 178.206 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . 0.408 ' O ' HD11 ' A' ' 188' ' ' LEU . 17.1 m-20 -93.88 156.35 16.69 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.447 0.699 . . . . 75.21 111.169 -171.406 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.475 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 90.4 mt -104.59 150.89 24.26 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 124.816 1.246 . . . . 65.23 108.913 -177.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . 0.466 ' CE1' ' HB3' ' A' ' 189' ' ' GLU . 77.4 m-85 -138.26 128.39 25.75 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 107.167 -1.42 . . . . 74.12 107.167 -177.687 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -154.18 171.27 19.44 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 123.842 0.857 . . . . 64.31 109.197 -176.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 14.6 m -120.41 135.28 55.09 Favored 'General case' 0 C--O 1.238 0.5 0 N-CA-C 108.867 -0.79 . . . . 74.11 108.867 176.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.546 HD22 HD11 ' A' ' 233' ' ' LEU . 70.1 tp -123.63 114.18 19.66 Favored 'General case' 0 C--O 1.217 -0.62 0 C-N-CA 124.112 0.965 . . . . 73.2 109.542 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -84.78 119.78 25.69 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 108.266 -1.012 . . . . 75.52 108.266 171.032 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 84.2 t -110.22 126.4 29.02 Favored Pre-proline 0 N--CA 1.469 0.486 0 N-CA-C 108.632 -0.877 . . . . 72.01 108.632 -178.543 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -54.56 133.33 56.2 Favored 'Trans proline' 0 C--N 1.375 1.958 0 C-N-CA 122.767 2.311 . . . . 71.15 110.903 172.4 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -51.68 -45.37 91.52 Favored Pre-proline 0 CA--C 1.556 1.191 0 C-N-CA 124.568 1.147 . . . . 71.21 113.685 -175.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -53.41 -45.53 40.35 Favored 'Trans proline' 0 C--N 1.39 2.751 0 C-N-CA 121.841 1.694 . . . . 74.23 113.666 173.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . 0.441 HG21 HG11 ' A' ' 210' ' ' VAL . 8.7 mt -67.62 -37.71 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 C-N-CA 122.386 0.274 . . . . 75.15 111.276 178.437 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -67.19 -34.53 77.7 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 122.977 0.511 . . . . 54.42 112.319 -176.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.3 m -83.77 -39.17 14.74 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 CA-C-N 116.159 -0.473 . . . . 70.24 111.052 -177.593 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m -82.68 -24.81 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-N 118.12 0.418 . . . . 73.0 110.939 179.676 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 79.02 67.54 1.58 Allowed Glycine 0 C--N 1.341 0.813 0 CA-C-N 116.084 -0.507 . . . . 72.51 112.493 -177.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -101.46 -147.23 19.95 Favored Glycine 0 C--N 1.35 1.31 0 CA-C-N 116.854 0.327 . . . . 64.24 112.337 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 59.1 pttt -127.64 138.19 52.76 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 124.319 1.048 . . . . 73.11 109.43 -177.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . 0.441 HG11 HG21 ' A' ' 203' ' ' ILE . 17.9 m -126.28 143.74 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.117 0.967 . . . . 73.34 109.179 175.31 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 10.0 mpt_? -85.36 107.16 17.23 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 108.958 -0.756 . . . . 74.43 108.958 174.253 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.6 117.59 35.22 Favored 'General case' 0 CA--C 1.517 -0.31 0 N-CA-C 107.62 -1.252 . . . . 64.24 107.62 174.39 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 213' ' ' MET . . . . . 0.543 ' HA ' ' HA ' ' A' ' 218' ' ' PRO . 1.2 ppp? -79.38 138.23 37.59 Favored 'General case' 0 C--O 1.243 0.754 0 N-CA-C 109.29 -0.633 . . . . 74.22 109.29 179.003 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 214' ' ' THR . . . . . 0.521 HG21 ' HG2' ' A' ' 216' ' ' GLU . 4.5 t -128.9 174.95 9.04 Favored 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 124.155 0.982 . . . . 75.54 108.805 177.344 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . 0.568 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 73.9 mt -72.99 -3.34 25.46 Favored 'General case' 0 CA--C 1.549 0.929 0 N-CA-C 113.613 0.968 . . . . 74.32 113.613 -169.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . 0.521 ' HG2' HG21 ' A' ' 214' ' ' THR . 14.3 pt-20 -104.8 -4.62 22.07 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 123.806 0.842 . . . . 70.05 111.183 175.487 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 129.28 -174.09 19.35 Favored Glycine 0 C--N 1.344 0.982 0 N-CA-C 110.686 -0.966 . . . . 63.23 110.686 -172.073 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . 0.543 ' HA ' ' HA ' ' A' ' 213' ' ' MET . 2.2 Cg_endo -81.84 133.38 7.96 Favored 'Trans proline' 0 CA--C 1.55 1.283 0 C-N-CA 122.52 2.147 . . . . 70.45 112.13 179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 34.5 m -110.27 165.15 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.076 0 C-N-CA 123.077 0.551 . . . . 74.11 111.915 171.371 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -111.41 113.03 25.19 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 124.058 0.943 . . . . 74.23 109.011 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.471 HG22 HD11 ' A' ' 235' ' ' LEU . 21.8 t -97.19 117.65 42.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 123.439 0.696 . . . . 74.3 110.36 178.731 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -87.57 105.53 17.39 Favored 'General case' 0 C--O 1.239 0.519 0 N-CA-C 107.442 -1.318 . . . . 64.04 107.442 171.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 6.2 m -80.95 142.38 51.96 Favored Pre-proline 0 CA--C 1.553 1.085 0 N-CA-C 109.383 -0.599 . . . . 61.31 109.383 -177.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -62.62 144.28 93.98 Favored 'Trans proline' 0 C--N 1.371 1.725 0 C-N-CA 123.003 2.469 . . . . 75.43 112.977 177.022 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.04 122.99 10.94 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.411 2.074 . . . . 73.3 111.306 174.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 73.5 mtt180 67.99 36.38 3.39 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.693 1.197 . . . . 73.51 110.822 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 227' ' ' THR . . . . . 0.476 HG23 HD13 ' A' ' 255' ' ' ILE . 9.3 t -67.53 172.06 5.49 Favored 'General case' 0 CA--C 1.551 1.017 0 CA-C-N 115.865 -0.607 . . . . 74.42 110.86 -178.585 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.2 mp0 -117.51 138.03 52.16 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.645 0.778 . . . . 61.04 109.623 -174.314 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -66.66 114.64 5.73 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.365 0.666 . . . . 62.41 110.046 176.317 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.79 3.71 19.86 Favored Glycine 0 C--N 1.336 0.549 0 CA-C-N 115.897 -0.592 . . . . 70.11 112.251 -176.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . 0.41 ' O ' HG11 ' A' ' 253' ' ' VAL . 57.3 mtp180 -78.39 161.83 26.87 Favored 'General case' 0 C--O 1.243 0.725 0 CA-C-O 121.684 0.754 . . . . 74.53 110.838 173.129 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.426 ' HD2' ' N ' ' A' ' 232' ' ' LYS . 0.1 OUTLIER -99.96 100.7 11.64 Favored 'General case' 0 C--O 1.24 0.565 0 CA-C-N 114.235 -1.348 . . . . 74.01 108.367 -178.447 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . 0.552 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 33.3 mt -84.53 97.71 9.72 Favored 'General case' 0 C--N 1.351 0.646 0 N-CA-C 105.217 -2.142 . . . . 74.43 105.217 173.826 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . 0.469 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 51.6 ttp85 -96.13 103.64 15.54 Favored 'General case' 0 C--O 1.24 0.593 0 CA-C-N 114.781 -1.099 . . . . 73.11 109.437 -165.854 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.513 HD13 HD22 ' A' ' 249' ' ' LEU . 20.2 mt -85.02 97.83 10.06 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.589 -1.263 . . . . 75.21 107.589 177.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . 0.548 ' HB2' ' HZ2' ' A' ' 236' ' ' LYS . 10.4 mtmp? -69.43 135.97 50.96 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 114.639 -1.164 . . . . 73.11 111.479 -169.67 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 80.17 13.82 81.39 Favored Glycine 0 C--N 1.347 1.194 0 O-C-N 123.577 0.548 . . . . 74.03 113.354 177.395 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . 0.664 ' HE2' ' HA ' ' A' ' 238' ' ' LYS . 9.3 mmpt? -96.98 -18.79 19.21 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 122.877 0.471 . . . . 72.3 112.222 -178.318 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . 0.461 ' HA2' ' HG ' ' A' ' 193' ' ' LEU . . . -82.75 169.64 49.02 Favored Glycine 0 C--N 1.338 0.689 0 N-CA-C 112.028 -0.429 . . . . 63.04 112.028 176.688 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.516 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 98.0 m-85 -66.06 154.91 88.69 Favored Pre-proline 0 N--CA 1.479 0.994 0 C-N-CA 123.45 0.7 . . . . 74.22 111.933 -172.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -66.55 128.13 18.55 Favored 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 121.948 1.765 . . . . 64.35 110.289 165.163 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -151.5 -159.02 8.65 Favored Glycine 0 N--CA 1.465 0.632 0 CA-C-O 119.714 -0.492 . . . . 65.3 112.732 -178.591 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -65.95 -13.02 37.92 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.375 2.716 . . . . 73.04 114.324 -170.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . 0.533 ' HB1' ' NE2' ' A' ' 191' ' ' GLN . . . -116.9 25.03 10.81 Favored 'General case' 0 N--CA 1.482 1.126 0 C-N-CA 122.86 0.464 . . . . 62.43 110.684 178.767 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 102.87 -101.92 2.17 Favored Glycine 0 C--N 1.348 1.206 0 CA-C-O 119.764 -0.465 . . . . 62.1 112.149 174.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 9.5 ttm180 -124.43 155.31 39.09 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 108.573 -0.899 . . . . 74.33 108.573 173.092 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -94.74 -173.48 38.01 Favored Glycine 0 C--N 1.335 0.511 0 CA-C-O 121.271 0.373 . . . . 64.34 113.114 -177.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -135.95 168.06 20.04 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 108.062 -1.088 . . . . 71.25 108.062 -177.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.513 HD22 HD13 ' A' ' 235' ' ' LEU . 16.7 tp -104.96 124.16 49.03 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 122.786 0.434 . . . . 72.2 110.366 173.037 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . 0.423 ' HB3' ' HA ' ' A' ' 194' ' ' TYR . 11.6 t80 -89.3 108.53 19.68 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 124.62 1.168 . . . . 74.32 108.077 171.232 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.552 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 65.7 mt -96.89 120.83 37.97 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.793 -0.447 . . . . 75.53 109.793 164.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -83.55 94.41 8.05 Favored 'General case' 0 C--O 1.237 0.41 0 N-CA-C 108.012 -1.107 . . . . 72.32 108.012 168.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.41 HG11 ' O ' ' A' ' 231' ' ' ARG . 2.3 p -59.48 126.9 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 CA-C-O 121.291 0.567 . . . . 71.21 110.203 177.513 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 10.2 mmm180 -127.19 94.74 4.09 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 107.299 -1.371 . . . . 75.23 107.299 -177.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.476 HD13 HG23 ' A' ' 227' ' ' THR . 64.6 mt -74.77 120.04 23.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 115.193 -0.912 . . . . 73.1 109.74 -172.54 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.4 t . . . . . 0 CA--C 1.557 1.214 0 C-N-CA 125.161 1.384 . . . . 73.4 108.506 -174.129 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.955 0 N-CA-C 110.17 -0.307 . . . . 52.3 110.17 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.528 ' HB3' HG13 ' A' ' 137' ' ' VAL . . . -73.41 -98.25 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.078 0 C-N-CA 124.049 0.94 . . . . 74.15 109.867 174.032 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.524 HD12 HD12 ' A' ' 149' ' ' ILE . 0.9 OUTLIER -124.79 49.18 1.87 Allowed 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 107.038 -1.468 . . . . 75.44 107.038 170.153 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.466 HG23 ' HB2' ' A' ' 121' ' ' ALA . 2.9 p -173.88 131.39 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-N 113.72 -1.582 . . . . 72.44 109.006 -176.12 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.454 ' HB3' ' HD3' ' A' ' 124' ' ' PRO . . . -94.09 -46.85 6.94 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 123.264 0.626 . . . . 62.25 110.072 174.441 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 2.1 p80 -163.45 151.72 13.59 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 115.653 -0.703 . . . . 75.11 111.18 -178.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 93.5 t -73.79 126.57 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.021 0.929 . . . . 71.2 109.168 175.009 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 10.1 t -128.88 83.45 2.15 Favored 'General case' 0 CA--C 1.547 0.838 0 CA-C-O 122.357 1.075 . . . . 74.31 110.127 -178.277 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.2 t -64.6 -32.95 74.82 Favored 'General case' 0 CA--C 1.547 0.828 0 CA-C-N 115.571 -0.741 . . . . 74.43 110.259 175.55 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 74.86 -82.46 0.85 Allowed Glycine 0 C--N 1.356 1.644 0 CA-C-N 115.586 -0.734 . . . . 75.32 112.181 179.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 88.5 p -165.64 164.04 19.15 Favored 'General case' 0 C--O 1.246 0.909 0 C-N-CA 124.222 1.009 . . . . 74.32 109.544 175.297 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.12 147.4 28.84 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.761 -0.654 . . . . 62.13 111.678 175.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.48 137.16 4.09 Favored Glycine 0 C--N 1.338 0.688 0 N-CA-C 111.767 -0.533 . . . . 35.34 111.767 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 25.5 t -86.57 81.4 8.28 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 123.028 0.531 . . . . 75.12 109.861 178.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -72.25 -28.49 68.01 Favored Glycine 0 C--N 1.345 1.058 0 CA-C-N 115.432 -0.804 . . . . 64.13 112.518 176.16 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -175.61 -140.95 3.58 Favored Glycine 0 C--N 1.342 0.882 0 N-CA-C 110.684 -0.966 . . . . 74.12 110.684 177.446 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 67.0 m -99.55 113.82 26.46 Favored 'General case' 0 C--O 1.241 0.65 0 N-CA-C 108.945 -0.761 . . . . 62.14 108.945 173.018 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -87.28 53.24 4.4 Favored Glycine 0 C--N 1.349 1.253 0 N-CA-C 111.751 -0.54 . . . . 72.04 111.751 179.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.67 80.38 1.19 Allowed Glycine 0 C--N 1.349 1.298 0 N-CA-C 111.799 -0.52 . . . . 45.23 111.799 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 21.2 t -158.01 -169.48 2.83 Favored 'General case' 0 C--O 1.243 0.724 0 C-N-CA 123.859 0.863 . . . . 72.02 109.024 -174.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -74.98 -165.38 14.32 Favored Glycine 0 C--N 1.344 1.027 0 N-CA-C 111.748 -0.541 . . . . 43.32 111.748 167.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 -61.59 121.9 13.92 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 122.762 0.425 . . . . 65.44 110.73 176.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -69.58 133.62 47.84 Favored 'General case' 0 N--CA 1.472 0.638 0 O-C-N 124.58 1.175 . . . . 60.53 109.299 172.125 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.482 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 33.4 tp -136.35 121.33 18.8 Favored 'General case' 0 C--O 1.215 -0.755 0 N-CA-C 106.595 -1.631 . . . . 74.43 106.595 -175.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -121.34 131.88 54.45 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.603 -0.517 . . . . 74.32 109.603 -171.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . 0.466 ' HB2' HG23 ' A' ' 99' ' ' VAL . . . -153.12 146.81 25.14 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.294 0.637 . . . . 71.15 109.701 -177.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -126.16 152.98 45.25 Favored 'General case' 0 C--O 1.244 0.768 0 CA-C-O 121.081 0.467 . . . . 72.24 110.49 177.062 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -145.5 148.58 37.6 Favored Pre-proline 0 N--CA 1.471 0.583 0 CA-C-N 114.933 -1.031 . . . . 72.33 110.362 -177.119 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.473 ' HA ' ' HB2' ' A' ' 179' ' ' ARG . 4.0 Cg_exo -73.86 115.31 4.28 Favored 'Trans proline' 0 C--N 1.37 1.695 0 C-N-CA 121.561 1.507 . . . . 73.43 110.151 167.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.406 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 23.8 tp -105.84 148.47 27.52 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 108.378 -0.971 . . . . 74.02 108.378 175.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.767 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 24.7 m -76.38 147.23 38.18 Favored 'General case' 0 CA--C 1.547 0.853 0 N-CA-C 109.963 -0.384 . . . . 62.35 109.963 173.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.505 HD21 ' HB3' ' A' ' 180' ' ' LEU . 96.6 mt -52.73 -51.42 60.57 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 121.822 0.82 . . . . 65.22 110.48 172.786 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.59 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -55.76 -28.83 58.01 Favored 'General case' 0 CA--C 1.551 1.003 0 CA-C-N 113.947 -1.479 . . . . 61.33 112.451 177.211 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.689 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 22.1 mm-40 -86.24 -21.44 27.41 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 118.18 0.446 . . . . 73.3 111.679 178.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.599 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -61.13 -34.67 75.36 Favored 'General case' 0 C--O 1.239 0.546 0 CA-C-O 121.268 0.556 . . . . 72.34 110.059 164.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.637 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 57.8 t80 -76.42 -50.84 13.1 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 114.823 -1.08 . . . . 75.21 112.887 172.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -75.27 -49.21 19.97 Favored 'General case' 0 N--CA 1.486 1.33 0 C-N-CA 122.338 0.255 . . . . 74.24 111.651 -170.364 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.15 -161.61 44.33 Favored Glycine 0 CA--C 1.535 1.331 0 CA-C-O 119.905 -0.386 . . . . 71.54 112.153 -173.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 128.63 -169.66 20.08 Favored Glycine 0 N--CA 1.476 1.305 0 CA-C-N 117.307 0.554 . . . . 52.32 114.272 171.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -94.61 121.34 36.07 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 124.156 0.982 . . . . 74.24 108.592 -178.129 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -130.66 167.32 18.96 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.759 0.823 . . . . 73.53 108.977 172.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.528 HG13 ' HB3' ' A' ' 97' ' ' ALA . 13.0 p -90.53 142.14 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 108.736 -0.839 . . . . 75.33 108.736 179.152 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.464 HG21 HG21 ' A' ' 140' ' ' VAL . 8.8 p -131.05 136.59 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 N-CA-C 108.863 -0.792 . . . . 71.53 108.863 177.522 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . 0.46 ' HA ' ' O ' ' A' ' 143' ' ' ARG . 36.6 tt0 -126.6 97.83 5.17 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.854 -0.425 . . . . 72.25 109.854 172.483 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.464 HG21 HG21 ' A' ' 138' ' ' VAL . 22.9 t -122.13 138.26 52.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 108.208 -1.034 . . . . 73.41 108.208 174.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 64.52 21.58 12.48 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 124.712 1.205 . . . . 72.13 111.341 -176.61 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.59 13.71 82.9 Favored Glycine 0 C--N 1.352 1.452 0 CA-C-N 116.056 -0.52 . . . . 64.22 113.631 -179.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.46 ' O ' ' HA ' ' A' ' 139' ' ' GLU . 72.5 mtt180 -108.71 117.67 34.79 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.29 0.636 . . . . 74.34 109.468 179.217 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 21.7 ttm180 -105.35 105.35 15.35 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 109.842 -0.429 . . . . 75.44 109.842 -176.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 61.1 t -129.92 141.98 45.01 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.53 1.132 . . . . 63.53 108.291 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 72.0 p -72.2 111.12 7.14 Favored 'General case' 0 CA--C 1.546 0.817 0 N-CA-C 109.022 -0.733 . . . . 74.44 109.022 174.212 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.2 p -96.82 147.4 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 C-N-CA 123.884 0.874 . . . . 72.24 109.327 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -109.03 127.45 54.11 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 107.888 -1.152 . . . . 73.42 107.888 171.281 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.524 HD12 HD12 ' A' ' 98' ' ' LEU . 38.1 pt -120.62 124.73 27.45 Favored Pre-proline 0 CA--C 1.547 0.858 0 N-CA-C 107.873 -1.158 . . . . 72.44 107.873 170.016 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -72.13 153.5 57.12 Favored 'Trans proline' 0 C--N 1.373 1.847 0 C-N-CA 122.346 2.031 . . . . 71.34 113.021 -173.061 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -65.59 147.68 86.63 Favored 'Trans proline' 0 C--N 1.373 1.852 0 C-N-CA 122.282 1.988 . . . . 72.11 111.428 170.041 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 101.42 53.38 1.0 Allowed Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.123 -1.191 . . . . 75.11 110.123 -171.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.599 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -128.49 161.04 38.02 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.299 0 N-CA-C 108.191 -1.041 . . . . 70.42 108.191 -179.459 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -146.16 171.39 15.0 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 124.206 1.002 . . . . 74.34 110.502 -165.562 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -56.59 125.74 23.54 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 123.416 0.686 . . . . 73.22 110.426 169.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.83 -6.0 56.21 Favored Glycine 0 C--N 1.347 1.151 0 CA-C-O 119.362 -0.688 . . . . 72.21 113.921 179.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 47.8 t -67.06 129.11 38.82 Favored 'General case' 0 C--N 1.359 0.987 0 C-N-CA 123.404 0.682 . . . . 75.41 109.548 -178.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.426 HG13 HD21 ' A' ' 175' ' ' LEU . 13.7 t -104.98 118.25 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 O-C-N 124.83 1.331 . . . . 74.11 109.102 -171.218 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.497 HD11 HG23 ' A' ' 153' ' ' VAL . 28.1 mt -104.51 111.31 33.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 123.878 0.871 . . . . 74.42 109.71 -171.311 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 54.9 ttt180 -81.35 117.89 22.2 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.573 0.749 . . . . 70.44 110.643 177.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.635 HG22 ' HB3' ' A' ' 174' ' ' LEU . 2.9 m -118.04 117.14 35.51 Favored Pre-proline 0 CA--C 1.557 1.224 0 N-CA-C 109.093 -0.706 . . . . 73.3 109.093 170.687 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -81.26 149.69 17.2 Favored 'Trans proline' 0 C--N 1.377 2.042 0 C-N-CA 122.473 2.116 . . . . 73.11 112.663 -177.538 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 82.1 24.71 54.26 Favored Glycine 0 C--N 1.349 1.286 0 CA-C-N 115.925 -0.579 . . . . 75.13 113.649 177.383 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 54.9 tpp -109.8 -57.68 2.15 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.545 0.738 . . . . 72.23 110.68 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -70.12 -82.87 0.2 Allowed Glycine 0 C--N 1.356 1.657 0 N-CA-C 111.665 -0.574 . . . . 73.22 111.665 -179.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.664 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -63.91 113.45 5.89 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 112.329 -0.308 . . . . 52.01 112.329 166.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -87.74 172.16 9.88 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 124.189 0.995 . . . . 74.24 109.899 171.26 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 92.82 -135.77 12.83 Favored Glycine 0 C--N 1.342 0.864 0 N-CA-C 112.019 -0.433 . . . . 44.34 112.019 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 62.4 m-80 -81.15 -48.86 1.05 Allowed Pre-proline 0 CA--C 1.556 1.189 0 CA-C-O 117.68 -1.152 . . . . 73.11 111.779 177.052 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -71.02 113.61 3.63 Favored 'Trans proline' 0 C--N 1.399 3.193 0 C-N-CA 121.871 1.714 . . . . 74.11 111.546 176.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -74.85 125.97 9.76 Favored 'Trans proline' 0 C--N 1.381 2.244 0 C-N-CA 121.989 1.793 . . . . 74.22 111.52 -178.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.664 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -94.67 144.89 17.43 Favored Glycine 0 C--N 1.338 0.658 0 N-CA-C 112.096 -0.402 . . . . 74.45 112.096 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . 0.412 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 63.9 m-20 -106.39 116.47 31.99 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 123.035 0.534 . . . . 74.12 110.207 -169.561 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.635 ' HB3' HG22 ' A' ' 161' ' ' VAL . 47.3 tp -89.85 109.68 20.66 Favored 'General case' 0 C--O 1.235 0.338 0 N-CA-C 107.36 -1.348 . . . . 74.11 107.36 171.428 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.426 HD21 HG13 ' A' ' 158' ' ' VAL . 70.0 mt -89.88 98.91 12.04 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.085 1.354 . . . . 72.04 109.538 -179.416 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 84.0 mt -90.22 102.86 15.58 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 124.075 0.95 . . . . 71.02 110.876 179.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 35.1 t -86.91 105.25 14.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 N-CA-C 108.161 -1.051 . . . . 72.53 108.161 175.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 7.8 m -83.48 148.99 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 CA-C-O 121.551 0.691 . . . . 72.42 111.336 -178.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . 0.473 ' HB2' ' HA ' ' A' ' 124' ' ' PRO . 35.3 mmt180 -119.04 100.15 7.17 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 107.236 -1.394 . . . . 74.13 107.236 -178.492 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.505 ' HB3' HD21 ' A' ' 127' ' ' LEU . 41.7 mt -67.47 145.86 54.56 Favored 'General case' 0 C--O 1.239 0.514 0 O-C-N 122.938 0.149 . . . . 72.45 110.771 -176.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.767 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 26.5 mt -55.98 138.92 71.76 Favored Pre-proline 0 CA--C 1.548 0.897 0 O-C-N 123.603 0.564 . . . . 72.44 111.211 -177.034 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.8 67.55 4.79 Favored 'Trans proline' 0 C--N 1.377 2.036 0 C-N-CA 123.368 2.712 . . . . 73.25 113.668 -174.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 8.8 p80 -155.47 82.3 3.84 Favored Pre-proline 0 CA--C 1.557 1.247 0 N-CA-C 108.18 -1.044 . . . . 74.32 108.18 172.055 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -62.88 126.16 17.51 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 121.726 1.617 . . . . 74.3 111.548 -175.085 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.8 p -136.75 -48.14 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 108.103 -1.073 . . . . 74.4 108.103 174.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . 0.484 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 4.2 m-85 -113.16 137.16 51.88 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.759 0.824 . . . . 73.43 110.554 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.569 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 2.7 mpt_? -125.09 154.39 41.46 Favored 'General case' 0 CA--C 1.537 0.446 0 N-CA-C 106.836 -1.542 . . . . 74.44 106.836 175.626 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 48.4 tp -134.43 137.9 44.37 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.305 -0.628 . . . . 71.02 109.305 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -142.07 115.89 9.23 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 107.592 -1.262 . . . . 71.1 107.592 169.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 66.71 -95.48 0.27 Allowed Glycine 0 C--N 1.346 1.13 0 O-C-N 123.779 0.674 . . . . 73.23 111.918 -175.282 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . 0.433 ' OE1' ' HD2' ' A' ' 243' ' ' PRO . 1.9 mp0 -120.63 -19.51 7.42 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.673 0.789 . . . . 74.4 110.267 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -83.03 144.01 30.23 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.438 0.695 . . . . 64.02 112.005 -171.421 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.504 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.6 mt -106.64 155.72 19.36 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 124.917 1.287 . . . . 74.24 108.239 177.379 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . 0.569 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 73.9 m-85 -139.9 121.84 15.59 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 107.117 -1.438 . . . . 74.34 107.117 -179.083 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -139.9 141.87 36.52 Favored 'General case' 0 CA--C 1.51 -0.58 0 N-CA-C 109.342 -0.614 . . . . 74.24 109.342 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 25.7 m -91.35 118.07 30.21 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 108.779 -0.823 . . . . 75.31 108.779 178.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.458 HD11 ' HB3' ' A' ' 212' ' ' ALA . 65.0 tp -105.94 113.3 26.76 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.714 0.805 . . . . 71.1 109.357 -178.154 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -89.54 111.55 22.49 Favored 'General case' 0 C--O 1.244 0.776 0 N-CA-C 108.879 -0.786 . . . . 61.54 108.879 172.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . 0.404 HG21 HG11 ' A' ' 210' ' ' VAL . 60.5 t -97.44 119.18 63.38 Favored Pre-proline 0 CA--C 1.536 0.414 0 N-CA-C 108.269 -1.011 . . . . 72.45 108.269 179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -56.52 135.13 68.62 Favored 'Trans proline' 0 C--N 1.371 1.731 0 C-N-CA 122.439 2.093 . . . . 74.54 110.95 176.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -50.33 -43.86 79.99 Favored Pre-proline 0 CA--C 1.564 1.482 0 C-N-CA 124.803 1.241 . . . . 53.21 113.519 -174.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . 0.405 ' O ' HG22 ' A' ' 206' ' ' VAL . 92.1 Cg_exo -49.35 -54.7 5.04 Favored 'Trans proline' 0 C--N 1.397 3.094 0 C-N-CA 122.395 2.064 . . . . 75.1 113.075 169.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 12.6 mt -66.03 -35.65 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 122.6 0.36 . . . . 74.33 110.956 -178.328 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -58.27 -44.13 88.26 Favored 'General case' 0 N--CA 1.464 0.26 0 C-N-CA 123.503 0.721 . . . . 75.21 110.885 -178.07 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 31.5 m -89.75 -57.69 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.157 0 N-CA-C 112.701 0.63 . . . . 72.41 112.701 -177.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . 0.405 HG22 ' O ' ' A' ' 202' ' ' PRO . 33.2 m -94.86 -27.01 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 118.768 0.713 . . . . 72.24 112.388 -173.299 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -86.53 -146.89 10.24 Favored Glycine 0 C--N 1.342 0.906 0 N-CA-C 112.29 -0.324 . . . . 64.4 112.29 -171.183 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 169.05 10.4 0.02 OUTLIER Glycine 0 C--N 1.339 0.732 0 CA-C-O 118.933 -0.926 . . . . 73.33 115.184 -179.222 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 53.5 mttp -138.48 119.42 14.33 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 118.255 1.027 . . . . 64.13 108.538 -179.206 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . 0.404 HG11 HG21 ' A' ' 199' ' ' VAL . 6.2 p -140.54 137.05 36.31 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 108.054 -1.091 . . . . 73.21 108.054 177.317 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 7.6 mpt_? -98.56 126.88 44.28 Favored 'General case' 0 C--O 1.24 0.555 0 N-CA-C 108.672 -0.862 . . . . 74.42 108.672 -177.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.458 ' HB3' HD11 ' A' ' 197' ' ' LEU . . . -102.2 138.42 39.16 Favored 'General case' 0 C--O 1.244 0.808 0 C-N-CA 123.537 0.735 . . . . 72.33 110.076 -176.102 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 213' ' ' MET . . . . . 0.412 ' HA ' ' HE1' ' A' ' 213' ' ' MET . 3.0 tpt -74.69 109.18 7.96 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.379 -0.828 . . . . 73.15 109.378 175.026 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 214' ' ' THR . . . . . 0.484 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 8.8 t -111.61 166.81 10.84 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 123.011 0.524 . . . . 61.54 110.162 174.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . 0.59 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 64.6 mt -72.38 -5.53 37.09 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 123.8 0.84 . . . . 74.45 111.86 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -96.16 -20.61 18.48 Favored 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.405 1.082 . . . . 73.25 111.126 177.121 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 136.41 -146.41 18.37 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 119.211 -0.772 . . . . 61.01 111.298 -171.239 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -86.06 127.78 3.07 Favored 'Trans proline' 0 CA--C 1.556 1.618 0 C-N-CA 122.541 2.16 . . . . 71.22 112.729 170.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 17.2 m -109.34 150.9 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 N-CA-C 108.974 -0.75 . . . . 71.21 108.974 164.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -111.35 108.76 18.46 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 107.874 -1.158 . . . . 72.32 107.874 178.048 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 2.8 p -104.43 133.81 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 C-N-CA 123.187 0.595 . . . . 73.51 110.31 177.225 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.19 125.57 35.12 Favored 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 115.625 -0.716 . . . . 74.54 109.779 177.457 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.41 HG11 HD13 ' A' ' 233' ' ' LEU . 28.1 m -97.4 141.12 22.54 Favored Pre-proline 0 N--CA 1.479 1.018 0 N-CA-C 108.485 -0.931 . . . . 75.01 108.485 173.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -60.62 139.89 88.24 Favored 'Trans proline' 0 C--N 1.37 1.698 0 C-N-CA 122.171 1.914 . . . . 71.1 111.971 176.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -53.31 112.39 0.92 Allowed 'Trans proline' 0 C--N 1.381 2.253 0 C-N-CA 122.629 2.219 . . . . 75.23 110.781 172.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 70.2 mtp180 66.13 72.4 0.39 Allowed 'General case' 0 CA--C 1.548 0.884 0 O-C-N 124.597 1.186 . . . . 75.02 110.428 -164.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 12.1 t -81.6 173.87 11.95 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.638 0.775 . . . . 72.4 109.299 169.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -132.24 147.38 52.41 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 123.814 0.846 . . . . 71.2 109.302 -176.437 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.08 117.6 11.86 Favored 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 123.316 0.647 . . . . 73.24 109.583 174.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.25 3.16 22.97 Favored Glycine 0 C--N 1.344 1.023 0 CA-C-N 116.133 -0.485 . . . . 71.45 113.108 -174.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 19.2 mtp-105 -83.63 160.65 21.33 Favored 'General case' 0 N--CA 1.479 1.015 0 CA-C-N 117.286 0.543 . . . . 75.42 111.223 175.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -116.05 120.83 40.36 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.549 1.139 . . . . 74.25 109.523 -176.224 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . 0.41 HD13 HG11 ' A' ' 223' ' ' VAL . 33.1 mt -110.54 100.02 8.91 Favored 'General case' 0 C--O 1.237 0.416 0 N-CA-C 107.2 -1.407 . . . . 74.23 107.2 174.548 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 44.4 ttp180 -95.65 104.13 16.04 Favored 'General case' 0 CA--C 1.542 0.636 0 CA-C-N 115.566 -0.743 . . . . 75.01 109.859 -170.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.461 HD12 HD22 ' A' ' 249' ' ' LEU . 16.5 mt -81.04 119.07 23.06 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 123.17 0.588 . . . . 74.42 110.131 -177.118 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 34.2 mtmm -66.65 120.67 13.85 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 125.085 1.354 . . . . 75.45 112.514 -168.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 65.84 33.95 87.27 Favored Glycine 0 C--N 1.351 1.405 0 O-C-N 123.983 0.802 . . . . 63.14 114.053 170.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 28.5 mmtp -116.01 2.11 13.4 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 123.474 0.71 . . . . 74.51 111.635 179.104 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -88.72 -177.58 46.66 Favored Glycine 0 C--N 1.345 1.082 0 N-CA-C 111.434 -0.666 . . . . 65.21 111.434 167.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.637 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 95.2 m-85 -74.68 151.82 87.04 Favored Pre-proline 0 N--CA 1.479 1.016 0 C-N-CA 122.545 0.338 . . . . 73.54 111.119 -177.141 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -77.58 165.68 26.77 Favored 'Trans proline' 0 C--N 1.372 1.788 0 C-N-CA 122.036 1.824 . . . . 73.32 111.631 178.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 161.07 -157.39 28.92 Favored Glycine 0 CA--C 1.528 0.876 0 CA-C-O 119.545 -0.586 . . . . 63.04 113.106 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . 0.433 ' HD2' ' OE1' ' A' ' 191' ' ' GLN . 77.1 Cg_exo -54.35 -23.24 29.83 Favored 'Trans proline' 0 C--N 1.375 1.945 0 C-N-CA 124.174 3.249 . . . . 71.31 114.315 175.582 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -90.42 19.42 5.24 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 123.362 0.665 . . . . 63.11 111.484 176.233 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 71.26 -94.18 0.54 Allowed Glycine 0 C--N 1.352 1.452 0 N-CA-C 110.893 -0.883 . . . . 74.43 110.893 -174.568 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -119.7 146.2 45.82 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 124.7 1.2 . . . . 75.35 107.847 166.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -80.44 -173.16 46.12 Favored Glycine 0 C--O 1.24 0.483 0 O-C-N 123.766 0.666 . . . . 73.1 111.751 173.021 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -137.94 163.05 32.46 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.278 0.631 . . . . 73.11 109.327 -176.37 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.504 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 18.3 tp -99.63 109.58 22.07 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 109.46 -0.57 . . . . 74.42 109.46 172.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -87.86 105.42 17.4 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 107.083 -1.451 . . . . 72.04 107.083 175.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.41 HD22 ' HB2' ' A' ' 197' ' ' LEU . 78.4 mt -87.49 145.98 26.01 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 123.02 0.528 . . . . 75.45 111.575 172.678 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -110.83 98.18 7.39 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 107.924 -1.139 . . . . 74.44 107.924 174.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 61.3 t -56.94 126.56 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 123.227 0.611 . . . . 75.05 110.737 176.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 23.2 mmt180 -132.86 97.11 3.95 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 106.968 -1.493 . . . . 75.11 106.968 178.339 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 62.4 mt -74.59 122.57 28.28 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 N-CA-C 109.274 -0.639 . . . . 71.44 109.274 -177.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.3 t . . . . . 0 CA--C 1.565 1.525 0 C-N-CA 124.719 1.207 . . . . 64.05 108.779 -177.392 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.241 0 CA-C-O 120.455 0.169 . . . . 75.33 110.976 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -79.11 -41.44 28.62 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 116.292 -0.413 . . . . 54.53 111.202 -179.012 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.44 ' HB3' HD13 ' A' ' 123' ' ' LEU . 14.8 mt -97.79 -78.77 0.48 Allowed 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 122.952 0.501 . . . . 75.41 111.082 174.178 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.759 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 24.6 m -58.62 159.16 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 N-CA-C 114.252 1.205 . . . . 71.43 114.252 -173.796 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -108.08 -43.2 4.46 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 113.428 -1.714 . . . . 74.54 109.127 178.053 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 2.9 p80 -177.9 169.74 1.97 Allowed 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 124.08 0.952 . . . . 74.35 110.445 -178.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 85.7 t -64.98 116.33 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 108.287 -1.005 . . . . 73.43 108.287 166.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.526 ' HB ' ' HB2' ' A' ' 122' ' ' GLU . 10.2 t -71.13 -46.28 61.94 Favored 'General case' 0 N--CA 1.473 0.695 0 O-C-N 123.381 0.426 . . . . 75.12 111.539 -174.109 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 32.7 t -167.89 102.27 0.47 Allowed 'General case' 0 C--O 1.238 0.452 0 N-CA-C 108.721 -0.844 . . . . 75.45 108.721 -174.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -81.54 68.33 3.48 Favored Glycine 0 C--N 1.341 0.861 0 N-CA-C 111.907 -0.477 . . . . 54.11 111.907 178.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 59.2 p -82.99 22.21 0.97 Allowed 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 124.051 0.94 . . . . 73.33 111.375 -178.253 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 78.65 -79.5 1.54 Allowed Glycine 0 C--N 1.347 1.169 0 N-CA-C 110.428 -1.069 . . . . 72.21 110.428 -170.188 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 124.77 -154.6 18.17 Favored Glycine 0 C--N 1.34 0.777 0 C-N-CA 123.299 0.476 . . . . 73.13 111.989 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 31.1 t -90.78 -57.19 2.9 Favored 'General case' 0 C--O 1.241 0.656 0 C-N-CA 123.903 0.881 . . . . 73.41 109.64 -177.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 73.7 -160.85 53.81 Favored Glycine 0 C--N 1.345 1.057 0 CA-C-N 115.779 -0.646 . . . . 63.03 112.137 -175.142 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 176.65 -158.58 24.77 Favored Glycine 0 C--N 1.341 0.809 0 C-N-CA 121.584 -0.341 . . . . 62.42 113.423 -179.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 43.9 t -122.91 -65.06 1.13 Allowed 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 124.608 1.163 . . . . 74.34 108.539 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -86.42 76.67 2.1 Favored Glycine 0 C--N 1.344 1.0 0 N-CA-C 110.779 -0.929 . . . . 63.34 110.779 175.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.18 173.27 30.04 Favored Glycine 0 C--N 1.339 0.742 0 N-CA-C 111.435 -0.666 . . . . 62.23 111.435 -170.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 49.4 m 59.29 84.0 0.12 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 124.507 1.123 . . . . 64.22 111.777 -179.59 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -73.67 -105.1 0.08 OUTLIER Glycine 0 C--N 1.342 0.897 0 CA-C-N 115.374 -0.83 . . . . 71.33 111.107 171.374 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.91 123.26 39.43 Favored 'General case' 0 CA--C 1.542 0.659 0 N-CA-C 108.953 -0.758 . . . . 74.52 108.953 172.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -70.47 130.52 42.1 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.642 -0.873 . . . . 72.24 108.642 174.37 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 50.3 tp -108.18 127.06 53.49 Favored 'General case' 0 C--O 1.217 -0.638 0 N-CA-C 106.994 -1.484 . . . . 74.33 106.994 173.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 45.3 mtp85 -120.76 108.95 14.58 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.621 -0.511 . . . . 75.54 109.621 -170.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -130.69 139.55 50.32 Favored 'General case' 0 N--CA 1.478 0.944 0 C-N-CA 123.436 0.694 . . . . 72.33 110.578 -174.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . 0.526 ' HB2' ' HB ' ' A' ' 103' ' ' THR . 34.8 tt0 -104.38 146.53 28.7 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.266 0.626 . . . . 74.34 110.294 178.436 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.759 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.8 pt? -145.7 146.32 28.79 Favored Pre-proline 0 N--CA 1.467 0.415 0 C-N-CA 124.077 0.951 . . . . 64.32 110.379 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -78.36 121.91 5.42 Favored 'Trans proline' 0 C--N 1.366 1.457 0 C-N-CA 121.977 1.785 . . . . 73.11 110.581 167.539 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.529 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 14.2 tp -111.86 162.04 15.72 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.582 0.753 . . . . 75.3 109.218 175.161 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 19.5 m -101.86 158.03 16.42 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 109.174 -0.676 . . . . 75.02 109.174 175.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.454 HD12 ' O ' ' A' ' 183' ' ' HIS . 65.1 mt -55.81 -52.19 64.87 Favored 'General case' 0 N--CA 1.486 1.352 0 CA-C-O 121.717 0.77 . . . . 73.22 111.248 179.06 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.413 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 10.9 mp0 -54.26 -33.24 58.1 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 114.495 -1.23 . . . . 65.2 111.708 175.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.4 mm-40 -85.96 -18.61 32.16 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 123.306 0.642 . . . . 75.22 111.98 -176.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.639 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -60.23 -41.34 92.9 Favored 'General case' 0 C--O 1.247 0.947 0 CA-C-O 121.805 0.812 . . . . 72.42 110.41 162.345 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.466 ' HA ' ' CE2' ' A' ' 240' ' ' PHE . 66.1 t80 -73.15 -43.2 61.91 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 114.365 -1.289 . . . . 72.4 112.812 175.003 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.8 m80 -83.94 -49.25 9.16 Favored 'General case' 0 N--CA 1.493 1.692 0 N-CA-C 112.439 0.533 . . . . 71.13 112.439 -172.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.06 -110.61 3.46 Favored Glycine 0 CA--C 1.531 1.063 0 N-CA-C 111.412 -0.675 . . . . 64.13 111.412 -173.597 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 90.0 172.99 45.13 Favored Glycine 0 C--N 1.35 1.318 0 C-N-CA 123.079 0.371 . . . . 61.14 113.923 168.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.624 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 2.1 mp0 -86.34 125.72 33.83 Favored 'General case' 0 C--N 1.351 0.671 0 N-CA-C 108.975 -0.75 . . . . 75.11 108.975 178.071 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 33.2 ttt85 -156.15 138.05 14.41 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 108.139 -1.06 . . . . 73.34 108.139 175.434 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.725 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 12.6 p -72.51 142.64 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 112.85 0.685 . . . . 73.33 112.85 -167.327 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 34.6 m -124.26 152.39 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 124.262 1.025 . . . . 75.35 109.781 174.121 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -124.5 104.31 8.66 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 107.179 -1.415 . . . . 63.13 107.179 171.14 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 7.1 p -150.9 139.12 14.43 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.965 0 C-N-CA 123.593 0.757 . . . . 72.24 109.885 -176.368 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.17 20.56 11.07 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 125.26 1.424 . . . . 74.43 112.768 -176.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.19 26.65 57.33 Favored Glycine 0 C--N 1.346 1.085 0 CA-C-N 116.538 -0.301 . . . . 63.24 112.385 -176.057 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.3 mmt180 -127.16 117.57 22.63 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.61 0.764 . . . . 74.03 110.277 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 43.1 ttp180 -98.5 104.57 16.62 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 108.321 -0.992 . . . . 72.13 108.321 173.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.2 m -146.81 137.47 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 123.672 0.789 . . . . 72.54 109.853 -177.197 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.725 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 35.7 p -73.34 118.19 15.99 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.413 0.685 . . . . 64.12 110.146 177.173 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.9 p -100.08 139.07 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 122.933 0.493 . . . . 64.02 110.129 -178.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . 0.624 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 24.8 ttp180 -106.9 106.47 17.01 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 108.344 -0.984 . . . . 75.23 108.344 173.585 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.494 ' HB ' HD12 ' A' ' 159' ' ' ILE . 34.2 pt -96.73 128.33 36.29 Favored Pre-proline 0 CA--C 1.546 0.794 0 N-CA-C 107.828 -1.175 . . . . 75.13 107.828 175.084 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -71.14 151.35 61.12 Favored 'Trans proline' 0 C--N 1.373 1.822 0 C-N-CA 122.331 2.021 . . . . 72.43 113.59 -167.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.427 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 43.4 Cg_exo -60.54 110.52 0.82 Allowed 'Trans proline' 0 C--N 1.378 2.105 0 C-N-CA 122.779 2.319 . . . . 70.41 109.939 169.755 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 131.37 59.64 0.09 OUTLIER Glycine 0 C--N 1.341 0.811 0 N-CA-C 111.01 -0.836 . . . . 73.51 111.01 -170.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.639 HG11 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -140.24 162.82 24.26 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.203 0 N-CA-C 108.453 -0.943 . . . . 72.05 108.453 177.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.537 ' HD2' ' HB3' ' A' ' 188' ' ' LEU . 38.5 mtp180 -146.67 176.52 9.79 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 124.405 1.082 . . . . 72.44 110.869 -171.006 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -56.74 117.81 4.27 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 124.537 1.135 . . . . 75.42 111.694 173.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.24 7.75 87.67 Favored Glycine 0 C--N 1.342 0.869 0 CA-C-N 115.372 -0.831 . . . . 72.52 113.645 179.128 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 33.8 t -78.76 136.32 37.35 Favored 'General case' 0 C--N 1.35 0.599 0 CA-C-O 121.145 0.498 . . . . 62.11 109.799 -178.105 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 8.2 t -103.47 119.29 51.81 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 CA-C-N 114.531 -1.213 . . . . 74.44 109.329 -172.099 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.567 HD11 HG23 ' A' ' 153' ' ' VAL . 26.4 mt -103.05 115.55 45.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.811 0.844 . . . . 75.12 110.417 -171.214 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 32.2 ttt85 -85.06 107.32 17.1 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.603 0.761 . . . . 74.41 109.813 177.098 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.433 HG22 ' O ' ' A' ' 174' ' ' LEU . 25.4 m -112.88 111.59 51.01 Favored Pre-proline 0 CA--C 1.56 1.356 0 C-N-CA 122.648 0.379 . . . . 70.42 110.404 178.119 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -65.97 148.74 86.17 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 123.286 2.657 . . . . 74.42 114.01 -173.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 70.75 23.9 77.44 Favored Glycine 0 C--N 1.352 1.433 0 CA-C-N 116.025 -0.534 . . . . 74.1 114.218 173.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 52.9 mmm -120.16 -30.64 4.6 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.876 0.87 . . . . 75.2 111.554 -172.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.87 -98.74 0.59 Allowed Glycine 0 C--N 1.346 1.104 0 O-C-N 123.146 0.279 . . . . 73.43 113.069 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.434 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -67.24 98.69 0.46 Allowed Glycine 0 C--N 1.346 1.128 0 N-CA-C 111.777 -0.529 . . . . 75.2 111.777 177.741 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.5 mm-40 -78.3 106.17 10.03 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 123.83 0.852 . . . . 75.33 110.301 -178.104 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 170.24 -158.57 30.59 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 116.096 -0.502 . . . . 72.43 112.012 178.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.479 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 25.0 t-20 -66.27 -47.54 60.16 Favored Pre-proline 0 CA--C 1.563 1.443 0 CA-C-O 118.307 -0.854 . . . . 71.03 111.65 -175.764 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.479 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 3.0 Cg_exo -77.42 112.55 3.38 Favored 'Trans proline' 0 C--N 1.387 2.588 0 C-N-CA 122.119 1.879 . . . . 74.41 110.414 165.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.32 122.55 9.82 Favored 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 121.871 1.714 . . . . 75.33 111.698 -176.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.434 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -97.65 150.12 19.4 Favored Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.788 -0.925 . . . . 75.04 110.788 175.014 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -106.88 160.05 15.79 Favored 'General case' 0 C--O 1.238 0.45 0 C-N-CA 123.622 0.769 . . . . 54.01 109.691 -178.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.433 ' O ' HG22 ' A' ' 161' ' ' VAL . 13.8 tp -115.04 114.7 25.72 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 108.204 -1.035 . . . . 73.12 108.204 -179.713 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 57.0 mt -84.72 101.69 12.4 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.673 1.189 . . . . 74.31 111.237 176.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.431 ' HB3' HD21 ' A' ' 123' ' ' LEU . 42.5 mt -90.93 105.65 17.97 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 114.95 -1.023 . . . . 74.31 111.32 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 27.3 t -85.55 99.67 7.77 Favored 'Isoleucine or valine' 0 C--O 1.242 0.685 0 N-CA-C 107.959 -1.126 . . . . 72.44 107.959 172.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.529 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 17.4 m -82.25 148.88 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 121.216 0.531 . . . . 74.3 110.235 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 39.4 mmm-85 -121.2 103.95 9.38 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.798 -1.186 . . . . 72.21 107.798 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.451 ' HB3' HD21 ' A' ' 127' ' ' LEU . 30.6 mt -67.97 149.08 50.19 Favored 'General case' 0 C--O 1.242 0.667 0 N-CA-C 109.256 -0.646 . . . . 71.41 109.256 177.339 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 40.2 mt -53.85 137.56 54.79 Favored Pre-proline 0 CA--C 1.552 1.045 0 O-C-N 123.674 0.609 . . . . 75.42 110.311 -178.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -58.78 -5.13 2.35 Favored 'Trans proline' 0 C--N 1.378 2.119 0 C-N-CA 123.141 2.56 . . . . 75.25 114.073 -177.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . 0.454 ' O ' HD12 ' A' ' 127' ' ' LEU . 6.2 t60 -83.72 107.76 11.36 Favored Pre-proline 0 CA--C 1.548 0.893 0 C-N-CA 124.654 1.182 . . . . 75.15 108.526 162.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -96.67 163.48 1.12 Allowed 'Trans proline' 0 C--N 1.369 1.631 0 C-N-CA 122.916 2.411 . . . . 74.45 111.922 168.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.66 -42.98 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 122.999 0.52 . . . . 72.2 109.769 169.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . 0.466 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 5.6 m-85 -101.92 123.97 46.74 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 115.783 -0.644 . . . . 70.45 110.795 -176.903 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -109.64 123.38 49.38 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 125.136 1.375 . . . . 73.3 108.092 179.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.537 ' HB3' ' HD2' ' A' ' 154' ' ' ARG . 22.4 tp -95.58 113.11 24.73 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-O 121.445 0.641 . . . . 65.43 111.174 -173.158 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -83.93 170.37 14.08 Favored 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 125.533 1.533 . . . . 72.04 107.826 162.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . -42.77 86.74 0.01 OUTLIER Glycine 0 C--N 1.362 2.004 0 CA-C-N 118.761 0.71 . . . . 60.42 114.357 175.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 67.18 -4.82 0.78 Allowed 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 127.658 2.383 . . . . 72.21 113.554 -175.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . 0.496 ' O ' HD13 ' A' ' 188' ' ' LEU . 27.2 t70 -105.52 156.13 18.52 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 124.899 1.28 . . . . 64.44 109.989 -174.463 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.553 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 78.4 mt -113.62 157.7 21.78 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 124.047 0.939 . . . . 72.11 112.177 -172.686 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 46.8 m-85 -139.61 122.25 16.33 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 114.419 -1.264 . . . . 74.2 108.378 174.164 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -142.61 171.1 14.51 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.144 0.978 . . . . 73.52 109.504 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 16.2 m -109.41 128.43 55.13 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 109.779 -0.452 . . . . 74.23 109.779 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.452 HD23 HD13 ' A' ' 251' ' ' LEU . 62.3 tp -114.75 115.0 26.35 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.222 1.009 . . . . 62.45 109.713 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . 0.433 ' HA ' ' HB2' ' A' ' 254' ' ' ARG . 10.3 m-20 -99.68 106.35 18.27 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.655 -0.498 . . . . 75.24 109.655 178.489 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . 0.436 HG11 HG21 ' A' ' 210' ' ' VAL . 6.4 m -107.72 147.36 35.23 Favored Pre-proline 0 N--CA 1.481 1.097 0 C-N-CA 123.232 0.613 . . . . 74.22 109.563 178.179 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.32 148.8 55.87 Favored 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 122.149 1.899 . . . . 64.2 110.565 167.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -54.14 -44.38 98.4 Favored Pre-proline 0 CA--C 1.56 1.346 0 CA-C-O 117.468 -1.253 . . . . 61.42 112.893 176.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -43.66 -52.98 4.78 Favored 'Trans proline' 0 C--N 1.403 3.396 0 C-N-CA 123.029 2.486 . . . . 75.45 113.895 171.032 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . 0.521 HG21 HG11 ' A' ' 210' ' ' VAL . 6.3 mt -71.05 -38.06 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 CA-C-N 116.62 -0.263 . . . . 73.4 110.781 -177.639 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -61.01 -38.71 87.05 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 123.321 0.648 . . . . 65.34 112.078 -178.211 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . 0.402 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 34.8 m -84.45 -38.44 13.62 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 CA-C-N 116.173 -0.467 . . . . 73.24 111.759 -176.318 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.1 m -78.2 -27.51 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 CA-C-N 118.121 0.418 . . . . 65.52 111.201 179.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . 0.464 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 79.56 53.52 4.32 Favored Glycine 0 C--N 1.339 0.72 0 CA-C-N 115.554 -0.748 . . . . 73.25 112.849 -175.773 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.8 -152.6 11.53 Favored Glycine 0 C--N 1.354 1.555 0 N-CA-C 111.762 -0.535 . . . . 75.23 111.762 178.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 57.9 mttp -125.27 139.13 53.98 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 123.371 0.668 . . . . 74.44 109.842 176.265 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . 0.521 HG11 HG21 ' A' ' 203' ' ' ILE . 13.6 m -123.71 134.63 65.9 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 CA-C-N 114.737 -1.119 . . . . 70.04 108.322 173.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 39.7 ttp-105 -81.64 113.48 19.68 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 108.835 -0.802 . . . . 72.4 108.835 175.564 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.411 ' HB2' HD12 ' A' ' 197' ' ' LEU . . . -101.19 165.6 11.21 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.374 -0.973 . . . . 72.21 108.374 175.338 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 1.9 mtp -106.4 154.14 21.23 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.593 0.711 . . . . 74.31 110.762 173.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 214' ' ' THR . . . . . 0.466 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.8 t -144.53 173.38 11.86 Favored 'General case' 0 C--O 1.242 0.705 0 CA-C-N 113.641 -1.618 . . . . 75.22 108.365 171.715 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . 0.413 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 49.9 mt -73.7 -10.53 59.78 Favored 'General case' 0 CA--C 1.553 1.069 0 CA-C-N 115.946 -0.57 . . . . 74.34 111.092 -179.723 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -86.87 -18.98 29.59 Favored 'General case' 0 CA--C 1.551 1.011 0 C-N-CA 124.58 1.152 . . . . 54.02 110.819 173.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 134.26 -157.91 23.12 Favored Glycine 0 C--N 1.353 1.48 0 CA-C-O 119.53 -0.595 . . . . 61.12 111.786 -176.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -84.4 130.96 4.7 Favored 'Trans proline' 0 C--N 1.366 1.46 0 C-N-CA 122.5 2.134 . . . . 74.31 112.227 175.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 35.1 m -113.08 161.9 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 124.22 1.008 . . . . 74.31 111.292 178.219 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -106.25 121.23 43.78 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 108.627 -0.879 . . . . 74.41 108.627 173.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 20.2 t -103.26 115.45 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 109.312 -0.625 . . . . 72.43 109.312 176.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -84.59 100.66 11.56 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 107.689 -1.226 . . . . 74.41 107.689 170.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.464 HG23 ' HA2' ' A' ' 207' ' ' GLY . 12.3 m -76.26 141.1 69.89 Favored Pre-proline 0 CA--C 1.549 0.913 0 N-CA-C 108.927 -0.768 . . . . 72.41 108.927 -178.653 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_exo -64.46 136.02 48.68 Favored 'Trans proline' 0 C--N 1.367 1.531 0 C-N-CA 122.622 2.215 . . . . 75.15 112.092 177.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -58.34 117.6 4.34 Favored 'Trans proline' 0 C--N 1.371 1.716 0 C-N-CA 122.611 2.207 . . . . 72.22 111.23 174.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . 0.402 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 93.1 mtt180 64.96 51.74 1.68 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 124.636 1.174 . . . . 73.42 110.826 -175.449 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.6 t -77.61 172.35 13.52 Favored 'General case' 0 CA--C 1.545 0.788 0 CA-C-N 115.248 -0.887 . . . . 74.52 109.555 170.556 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 28.1 mp0 -122.5 145.46 48.29 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 123.398 0.679 . . . . 74.4 110.036 -174.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.57 121.86 18.65 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.734 -0.839 . . . . 75.5 108.734 172.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.69 -7.7 19.87 Favored Glycine 0 N--CA 1.469 0.893 0 CA-C-N 116.087 -0.506 . . . . 52.54 112.324 -171.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 70.5 mtp180 -83.28 160.1 21.79 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 122.842 0.457 . . . . 73.21 110.347 173.319 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.575 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 3.4 mppt? -125.13 113.4 17.66 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.966 0.906 . . . . 73.11 109.527 177.443 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 38.3 mt -89.89 125.71 35.45 Favored 'General case' 0 C--N 1.354 0.802 0 N-CA-C 108.451 -0.944 . . . . 74.22 108.451 -177.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . 0.509 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 37.2 ttp180 -106.26 112.17 25.07 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-O 121.056 0.455 . . . . 73.44 111.22 -168.781 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.429 HD12 HD23 ' A' ' 249' ' ' LEU . 44.7 mt -86.61 127.12 34.9 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-N 115.347 -0.842 . . . . 73.3 110.11 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 35.1 mtmm -70.18 124.64 24.62 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 124.763 1.225 . . . . 73.31 111.809 -172.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 70.8 13.92 72.43 Favored Glycine 0 C--N 1.348 1.216 0 N-CA-C 114.954 0.742 . . . . 74.33 114.954 170.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -87.74 -9.96 52.5 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.226 0.61 . . . . 72.12 111.982 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -87.6 179.57 47.66 Favored Glycine 0 C--N 1.342 0.896 0 O-C-N 123.407 0.442 . . . . 70.13 112.799 177.08 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.466 ' CE2' ' HA ' ' A' ' 131' ' ' PHE . 14.4 m-85 -69.07 144.45 95.48 Favored Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 123.565 0.746 . . . . 75.44 110.99 -177.154 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 23.0 Cg_exo -66.65 130.35 23.25 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.632 2.222 . . . . 74.24 112.304 172.411 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -161.21 -151.53 6.29 Favored Glycine 0 CA--C 1.538 1.507 0 CA-C-O 119.271 -0.738 . . . . 72.12 111.99 178.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -56.18 -23.62 46.02 Favored 'Trans proline' 0 C--N 1.377 2.048 0 C-N-CA 123.996 3.131 . . . . 65.32 115.865 -174.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -101.15 22.6 12.09 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 123.298 0.639 . . . . 71.52 111.586 -179.397 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.16 -93.31 1.82 Allowed Glycine 0 C--N 1.341 0.846 0 N-CA-C 110.075 -1.21 . . . . 72.24 110.075 -172.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.467 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 46.6 mtm180 -122.14 153.68 38.41 Favored 'General case' 0 N--CA 1.478 0.935 0 N-CA-C 108.484 -0.932 . . . . 74.21 108.484 170.218 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -84.61 -162.46 34.94 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.789 -0.641 . . . . 64.13 112.186 178.365 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 42.7 m-20 -138.95 173.65 11.35 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.424 0.689 . . . . 72.22 109.853 -173.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.553 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 16.6 tp -119.82 115.85 24.68 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.397 0.679 . . . . 72.42 111.583 176.2 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . 0.412 ' CZ ' ' HD3' ' A' ' 234' ' ' ARG . 20.5 m-85 -88.95 107.44 19.02 Favored 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 123.561 0.744 . . . . 74.35 109.997 171.259 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.575 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 38.2 mt -89.93 118.72 29.7 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 125.041 1.336 . . . . 74.34 112.178 176.081 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -77.57 96.56 4.81 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 108.965 -0.754 . . . . 73.2 108.965 178.261 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 45.2 t -49.85 115.1 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 124.201 1.001 . . . . 70.03 111.354 173.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . 0.433 ' HB2' ' HA ' ' A' ' 198' ' ' ASP . 30.5 mmm180 -118.21 93.2 4.04 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 106.905 -1.517 . . . . 75.35 106.905 174.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 71.2 mt -76.48 122.94 31.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 N-CA-C 109.216 -0.661 . . . . 75.04 109.216 176.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.557 1.244 0 CA-C-O 117.446 -1.264 . . . . 73.41 107.941 -178.597 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.205 0 N-CA-C 110.071 -0.344 . . . . 63.33 110.071 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.512 ' HB1' HG11 ' A' ' 137' ' ' VAL . . . -59.39 -70.1 0.17 Allowed 'General case' 0 N--CA 1.479 0.975 0 C-N-CA 124.295 1.038 . . . . 72.03 109.663 175.43 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.457 HD13 ' HG3' ' A' ' 136' ' ' ARG . 60.7 tp -127.85 -64.3 0.97 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 105.994 -1.854 . . . . 74.4 105.994 156.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 12.4 p -107.26 154.99 8.07 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 C-N-CA 124.445 1.098 . . . . 72.1 109.306 165.636 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -141.57 1.93 1.58 Allowed 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 124.366 1.066 . . . . 75.1 110.518 173.318 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 9.2 t-80 -109.06 103.33 12.33 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.898 1.279 . . . . 72.14 109.545 -177.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 82.6 t -83.98 136.21 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 N-CA-C 108.597 -0.89 . . . . 71.33 108.597 173.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 43.1 p -83.15 134.81 34.97 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.459 0.704 . . . . 71.3 111.912 -172.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.5 m -84.3 -20.39 32.19 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 124.0 0.92 . . . . 74.14 109.991 167.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -150.55 -124.75 1.23 Allowed Glycine 0 CA--C 1.532 1.142 0 N-CA-C 109.68 -1.368 . . . . 73.11 109.68 178.431 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 60.8 p 39.5 -84.55 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 126.148 1.779 . . . . 71.23 114.367 177.009 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.455 ' O ' ' HD3' ' A' ' 120' ' ' ARG . . . -62.14 133.15 45.87 Favored Glycine 0 C--N 1.354 1.553 0 O-C-N 123.397 0.436 . . . . 71.5 112.991 -176.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 179.12 155.84 15.85 Favored Glycine 0 C--N 1.342 0.873 0 N-CA-C 112.138 -0.385 . . . . 74.31 112.138 -177.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 59.1 m -146.47 147.33 31.09 Favored 'General case' 0 C--O 1.242 0.685 0 C-N-CA 123.727 0.811 . . . . 75.54 109.919 179.243 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -120.08 -176.98 15.99 Favored Glycine 0 C--N 1.346 1.088 0 CA-C-N 116.294 -0.412 . . . . 71.24 112.429 -179.681 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 89.56 -45.95 3.14 Favored Glycine 0 C--N 1.345 1.053 0 CA-C-O 120.205 -0.22 . . . . 65.3 113.114 176.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 38.0 t -78.07 -36.42 48.28 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.1 0.56 . . . . 54.42 111.126 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 82.85 6.97 87.92 Favored Glycine 0 C--N 1.346 1.126 0 CA-C-N 115.729 -0.669 . . . . 62.23 113.022 -175.67 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.59 -59.94 4.9 Favored Glycine 0 C--N 1.354 1.573 0 C-N-CA 123.184 0.421 . . . . 65.42 113.105 -178.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.0 m 72.49 -72.46 0.11 Allowed 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 125.76 1.624 . . . . 73.33 110.704 -178.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -86.2 176.88 48.88 Favored Glycine 0 C--N 1.347 1.15 0 N-CA-C 110.125 -1.19 . . . . 74.4 110.125 165.618 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 42.1 mtm180 -64.41 117.5 7.37 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 117.689 0.744 . . . . 71.42 110.183 177.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -92.84 107.61 19.35 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 108.69 -0.856 . . . . 71.41 108.69 175.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.437 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 2.5 tt -94.36 138.61 32.12 Favored 'General case' 0 C--O 1.215 -0.722 0 N-CA-C 105.993 -1.854 . . . . 72.44 105.993 179.822 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . 0.455 ' HD3' ' O ' ' A' ' 107' ' ' GLY . 92.2 mtt180 -128.49 139.91 52.09 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 109.586 -0.524 . . . . 74.44 109.586 -169.747 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -153.83 149.77 27.73 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 123.889 0.876 . . . . 71.41 110.313 -177.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 72.6 tt0 -127.75 135.29 49.93 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.536 1.134 . . . . 74.05 109.375 -174.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -140.84 142.41 28.04 Favored Pre-proline 0 N--CA 1.478 0.973 0 C-N-CA 122.785 0.434 . . . . 72.42 110.865 -175.149 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_exo -73.6 113.34 3.76 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 121.889 1.726 . . . . 73.42 109.851 166.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.434 HD23 HG12 ' A' ' 178' ' ' VAL . 17.9 tp -109.54 165.79 11.39 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.299 1.039 . . . . 71.35 108.932 179.401 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.606 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 8.6 m -95.39 156.6 16.25 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.23 0.612 . . . . 63.14 109.903 176.266 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.633 HD21 ' HB3' ' A' ' 180' ' ' LEU . 51.9 mt -56.7 -50.35 72.43 Favored 'General case' 0 N--CA 1.487 1.405 0 CA-C-O 122.21 1.005 . . . . 71.54 109.353 174.083 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.489 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -58.51 -38.07 76.93 Favored 'General case' 0 CA--C 1.546 0.813 0 CA-C-N 113.614 -1.63 . . . . 73.45 111.802 178.823 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.428 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 12.0 mm-40 -77.94 -23.25 48.61 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 122.844 0.458 . . . . 75.35 111.831 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.606 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -66.23 -32.0 73.16 Favored 'General case' 0 C--O 1.252 1.201 0 CA-C-O 121.712 0.768 . . . . 63.43 111.156 168.505 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.458 ' HA ' ' CE2' ' A' ' 240' ' ' PHE . 36.9 t80 -75.73 -47.92 24.03 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 114.746 -1.115 . . . . 75.33 111.892 172.798 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -75.23 -48.17 24.7 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 122.59 0.356 . . . . 74.53 111.626 -170.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 63.58 -130.14 40.03 Favored Glycine 0 CA--C 1.532 1.124 0 O-C-N 123.666 0.604 . . . . 54.14 111.861 -175.204 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 94.76 -172.94 31.67 Favored Glycine 0 C--N 1.35 1.332 0 N-CA-C 114.245 0.458 . . . . 35.51 114.245 171.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 7.6 mp0 -88.93 125.96 35.18 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.152 0.981 . . . . 74.54 109.965 -176.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . 0.457 ' HG3' HD13 ' A' ' 98' ' ' LEU . 33.3 mmt180 -137.78 168.49 19.57 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 124.883 1.273 . . . . 72.24 108.325 171.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.512 HG11 ' HB1' ' A' ' 97' ' ' ALA . 6.0 p -90.23 144.79 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 108.676 -0.861 . . . . 75.21 108.676 178.092 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 7.8 p -134.23 138.2 50.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 123.249 0.62 . . . . 74.34 109.457 179.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -124.69 106.15 9.86 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 108.14 -1.059 . . . . 75.21 108.14 169.185 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.5 m -125.09 117.81 51.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 C-N-CA 124.461 1.105 . . . . 75.41 109.592 -178.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 64.43 20.47 12.17 Favored 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 124.598 1.159 . . . . 74.24 111.771 179.579 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.69 -6.9 74.23 Favored Glycine 0 C--N 1.357 1.704 0 O-C-N 123.225 0.328 . . . . 73.02 113.478 -178.302 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 6.3 tpm_? -91.6 117.41 29.71 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 108.92 -0.77 . . . . 65.35 108.92 176.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 52.5 ttp180 -99.66 122.07 42.14 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 123.583 0.753 . . . . 75.34 109.516 179.181 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 19.0 t -133.19 156.99 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 N-CA-C 108.3 -1.0 . . . . 74.54 108.3 176.148 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 24.3 p -85.35 113.71 21.87 Favored 'General case' 0 CA--C 1.547 0.838 0 N-CA-C 108.325 -0.991 . . . . 75.25 108.325 165.511 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.563 ' HB ' ' HE3' ' A' ' 164' ' ' MET . 7.2 p -98.02 123.52 50.54 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 CA-C-O 121.641 0.734 . . . . 72.42 111.402 -176.259 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -97.94 104.77 16.83 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 107.76 -1.2 . . . . 74.23 107.76 167.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 38.7 pt -97.32 103.63 16.61 Favored Pre-proline 0 CA--C 1.55 0.967 0 N-CA-C 108.154 -1.054 . . . . 75.14 108.154 167.19 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -61.09 151.21 80.16 Favored 'Trans proline' 0 C--N 1.383 2.366 0 C-N-CA 122.613 2.209 . . . . 74.32 112.788 -178.116 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -49.28 151.37 6.62 Favored 'Trans proline' 0 C--N 1.378 2.081 0 C-N-CA 123.829 3.019 . . . . 71.54 114.153 176.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 108.73 23.36 6.55 Favored Glycine 0 N--CA 1.478 1.438 0 C-N-CA 121.465 -0.398 . . . . 51.51 113.238 174.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.608 HG21 HD13 ' A' ' 159' ' ' ILE . 2.5 p -99.65 162.84 2.95 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.192 0 N-CA-C 107.831 -1.174 . . . . 73.21 107.831 179.464 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.583 ' HA ' HD13 ' A' ' 180' ' ' LEU . 0.0 OUTLIER -158.87 177.69 10.88 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.618 1.167 . . . . 74.53 111.91 -172.02 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.3 tp10 -51.58 115.5 1.65 Allowed 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 124.76 1.224 . . . . 74.11 111.722 178.09 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 80.68 10.43 85.18 Favored Glycine 0 C--N 1.356 1.64 0 CA-C-N 115.775 -0.648 . . . . 61.51 113.591 177.652 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.4 t -85.77 123.76 31.51 Favored 'General case' 0 C--O 1.245 0.822 0 C-N-CA 123.097 0.559 . . . . 74.24 109.58 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.414 HG21 ' HB ' ' A' ' 177' ' ' VAL . 3.4 t -99.6 122.4 51.38 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 124.129 0.972 . . . . 75.44 108.659 -176.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.608 HD13 HG21 ' A' ' 153' ' ' VAL . 13.5 mt -103.11 119.68 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 124.046 0.938 . . . . 74.42 109.33 -169.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 34.3 ttt180 -97.43 103.67 15.63 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 122.693 0.397 . . . . 72.44 110.361 -177.115 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 12.1 m -102.39 118.91 57.75 Favored Pre-proline 0 CA--C 1.559 1.293 0 N-CA-C 109.451 -0.574 . . . . 72.25 109.451 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.47 152.25 43.36 Favored 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.635 2.224 . . . . 71.34 113.684 -173.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 79.74 24.48 60.19 Favored Glycine 0 C--N 1.349 1.267 0 N-CA-C 115.0 0.76 . . . . 61.52 115.0 168.147 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.563 ' HE3' ' HB ' ' A' ' 147' ' ' VAL . 39.6 mtt -105.18 -62.91 1.29 Allowed 'General case' 0 N--CA 1.488 1.465 0 CA-C-N 118.285 1.042 . . . . 74.22 112.093 176.061 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -62.42 -87.01 0.04 OUTLIER Glycine 0 C--N 1.349 1.294 0 CA-C-N 115.933 -0.576 . . . . 64.22 112.937 -177.295 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.624 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -68.25 90.44 0.23 Allowed Glycine 0 C--N 1.339 0.732 0 C-N-CA 122.91 0.29 . . . . 64.25 112.949 176.71 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.597 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -83.52 104.84 13.97 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 109.245 -0.65 . . . . 73.33 109.245 175.461 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 171.03 -154.53 22.85 Favored Glycine 0 C--N 1.342 0.875 0 N-CA-C 110.984 -0.846 . . . . 42.02 110.984 -175.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . 0.459 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 6.5 t30 -69.28 -48.72 25.63 Favored Pre-proline 0 CA--C 1.562 1.427 0 CA-C-O 118.431 -0.795 . . . . 71.35 110.999 176.454 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.459 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 5.1 Cg_exo -76.89 113.31 3.61 Favored 'Trans proline' 0 C--N 1.392 2.82 0 C-N-CA 121.818 1.679 . . . . 70.33 110.276 169.16 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_exo -70.81 125.93 12.1 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.274 1.983 . . . . 74.3 110.966 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.624 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -101.78 153.3 18.74 Favored Glycine 0 CA--C 1.502 -0.773 0 N-CA-C 110.621 -0.992 . . . . 72.33 110.621 174.634 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -112.69 178.59 4.24 Favored 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 123.473 0.709 . . . . 74.41 111.511 -168.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.437 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 34.9 tp -130.16 112.92 13.86 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 114.579 -1.191 . . . . 74.1 108.615 168.419 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 72.9 mt -85.09 100.86 11.98 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.138 1.375 . . . . 72.32 111.238 177.118 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 70.7 mt -95.38 101.64 13.38 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 122.69 0.396 . . . . 70.55 110.666 174.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.414 ' HB ' HG21 ' A' ' 158' ' ' VAL . 2.5 p -87.03 108.65 18.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 N-CA-C 109.158 -0.682 . . . . 74.14 109.158 172.576 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.434 HG12 HD23 ' A' ' 125' ' ' LEU . 4.0 m -87.35 149.37 4.11 Favored 'Isoleucine or valine' 0 C--O 1.245 0.851 0 CA-C-N 115.946 -0.57 . . . . 74.3 110.665 -177.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 13.1 mmm-85 -124.97 101.31 6.99 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 107.491 -1.299 . . . . 64.32 107.491 -178.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.633 ' HB3' HD21 ' A' ' 127' ' ' LEU . 25.3 mt -69.46 148.61 49.3 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 112.082 0.401 . . . . 65.14 112.082 -172.115 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.606 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 39.8 mt -57.5 138.25 81.57 Favored Pre-proline 0 CA--C 1.559 1.295 0 C-N-CA 123.283 0.633 . . . . 73.03 110.752 179.488 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.44 83.79 1.0 Allowed 'Trans proline' 0 C--N 1.374 1.875 0 C-N-CA 123.188 2.592 . . . . 75.14 112.584 -177.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -165.19 54.03 0.34 Allowed Pre-proline 0 CA--C 1.559 1.306 0 C-N-CA 124.12 0.968 . . . . 73.43 109.314 170.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.61 124.4 15.71 Favored 'Trans proline' 0 C--N 1.389 2.668 0 C-N-CA 122.627 2.218 . . . . 75.23 112.723 -169.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.4 p -130.84 -44.42 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 124.182 0.993 . . . . 75.41 109.561 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . 0.408 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 6.4 m-85 -105.01 120.29 41.11 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.218 0.532 . . . . 73.31 111.347 -176.048 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.694 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 23.5 mtp180 -104.17 162.7 12.95 Favored 'General case' 0 N--CA 1.467 0.425 0 C-N-CA 124.18 0.992 . . . . 75.42 109.337 173.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 57.2 tp -132.42 127.53 35.56 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 123.493 0.717 . . . . 64.04 109.743 179.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -139.52 102.52 4.48 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 125.034 1.333 . . . . 73.45 108.122 176.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 56.59 58.41 14.53 Favored Glycine 0 C--N 1.353 1.479 0 O-C-N 123.951 0.782 . . . . 75.34 114.04 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . 0.56 ' NE2' ' HD2' ' A' ' 243' ' ' PRO . 52.6 mt-30 74.09 -15.81 0.57 Allowed 'General case' 0 N--CA 1.505 2.322 0 C-N-CA 125.407 1.483 . . . . 75.14 112.305 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -97.41 152.44 18.95 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.333 1.053 . . . . 65.21 108.362 -175.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.418 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 78.4 mt -110.33 168.47 9.42 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 122.024 0.916 . . . . 72.31 111.512 -173.187 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . 0.694 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 35.6 m-85 -134.14 132.29 39.68 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 114.085 -1.416 . . . . 64.15 108.062 171.182 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . 0.401 ' HB3' HD11 ' A' ' 249' ' ' LEU . . . -154.02 168.28 26.95 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.909 0.884 . . . . 73.1 109.308 174.18 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 35.5 m -105.75 128.51 53.74 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 115.702 -0.681 . . . . 71.24 109.672 178.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.484 HD11 ' HB1' ' A' ' 212' ' ' ALA . 59.9 tp -107.76 113.65 27.05 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.733 -0.84 . . . . 75.23 108.733 173.382 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -94.9 119.82 34.08 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.373 -0.973 . . . . 72.43 108.373 175.496 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . 0.462 HG12 HG22 ' A' ' 253' ' ' VAL . 7.5 p -134.52 134.77 22.68 Favored Pre-proline 0 N--CA 1.479 1.018 0 C-N-CA 124.284 1.033 . . . . 64.42 109.37 -173.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.58 149.14 91.05 Favored 'Trans proline' 0 C--N 1.372 1.782 0 C-N-CA 122.715 2.277 . . . . 72.24 113.092 175.693 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . 0.491 ' HA ' HG22 ' A' ' 255' ' ' ILE . . . -60.75 -43.19 91.16 Favored Pre-proline 0 N--CA 1.478 0.972 0 N-CA-C 113.171 0.804 . . . . 75.53 113.171 176.445 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . 0.419 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 10.6 Cg_endo -53.73 -44.36 49.84 Favored 'Trans proline' 0 C--N 1.392 2.854 0 C-N-CA 121.759 1.639 . . . . 75.52 112.294 172.025 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.7 mt -67.44 -36.22 75.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 122.821 0.449 . . . . 73.53 111.189 177.618 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -64.57 -41.42 96.3 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 123.201 0.6 . . . . 73.22 111.802 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.7 m -79.89 -42.28 22.14 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 CA-C-N 116.003 -0.544 . . . . 72.34 111.362 -177.017 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 10.1 m -80.1 -20.02 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 122.471 0.308 . . . . 73.24 111.054 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 68.92 65.92 2.45 Favored Glycine 0 C--N 1.343 0.962 0 CA-C-N 115.687 -0.688 . . . . 55.33 112.461 -176.26 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.83 -145.92 15.4 Favored Glycine 0 C--N 1.357 1.7 0 N-CA-C 111.233 -0.747 . . . . 63.2 111.233 175.316 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 24.4 pttm -133.0 149.82 52.2 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 122.853 0.461 . . . . 71.51 109.88 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 2.8 m -145.09 134.37 18.04 Favored 'Isoleucine or valine' 0 C--O 1.239 0.528 0 N-CA-C 107.539 -1.282 . . . . 73.02 107.539 176.246 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 31.7 ptt180 -79.43 137.77 37.38 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 109.472 -0.566 . . . . 75.33 109.472 176.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.484 ' HB1' HD11 ' A' ' 197' ' ' LEU . . . -108.19 134.65 50.75 Favored 'General case' 0 C--O 1.245 0.845 0 C-N-CA 123.311 0.644 . . . . 74.45 109.408 174.218 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 4.8 tpt -75.85 106.26 7.33 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 108.837 -0.801 . . . . 74.22 108.837 173.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 214' ' ' THR . . . . . 0.408 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 11.2 t -110.68 165.85 11.49 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 109.703 -0.48 . . . . 64.31 109.703 174.553 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . 0.489 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 59.7 mt -69.69 -17.7 63.5 Favored 'General case' 0 CA--C 1.551 0.99 0 CA-C-N 115.686 -0.688 . . . . 74.33 111.162 178.348 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -79.21 -19.42 50.83 Favored 'General case' 0 CA--C 1.556 1.209 0 C-N-CA 123.934 0.894 . . . . 70.21 110.948 174.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 131.77 -148.53 19.06 Favored Glycine 0 C--N 1.346 1.088 0 N-CA-C 111.378 -0.689 . . . . 75.14 111.378 -176.079 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -85.86 126.85 2.99 Favored 'Trans proline' 0 CA--C 1.557 1.64 0 C-N-CA 122.376 2.05 . . . . 74.42 112.473 172.118 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . 0.518 HG12 ' HD2' ' A' ' 238' ' ' LYS . 34.9 m -111.56 155.47 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 N-CA-C 109.132 -0.692 . . . . 71.22 109.132 169.575 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -114.36 111.8 22.04 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.944 -0.761 . . . . 72.44 108.944 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.432 HG23 HD11 ' A' ' 235' ' ' LEU . 8.5 t -96.27 115.75 36.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.381 0 C-N-CA 123.593 0.757 . . . . 71.22 109.704 -178.594 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.59 101.28 13.97 Favored 'General case' 0 C--O 1.239 0.529 0 N-CA-C 106.673 -1.603 . . . . 63.03 106.673 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 19.0 m -75.21 141.47 74.13 Favored Pre-proline 0 CA--C 1.551 1.018 0 C-N-CA 122.546 0.338 . . . . 74.04 110.546 -173.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -60.07 133.27 49.15 Favored 'Trans proline' 0 C--N 1.378 2.092 0 C-N-CA 122.679 2.253 . . . . 74.22 111.828 176.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -56.0 124.57 16.58 Favored 'Trans proline' 0 C--N 1.377 2.077 0 C-N-CA 122.692 2.261 . . . . 72.2 110.92 173.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 60.58 51.98 4.8 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 124.593 1.157 . . . . 74.33 110.77 -173.271 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.2 t -78.61 165.77 23.3 Favored 'General case' 0 CA--C 1.544 0.741 0 N-CA-C 109.229 -0.656 . . . . 73.43 109.229 170.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.7 mp0 -119.51 147.32 44.58 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 108.707 -0.849 . . . . 75.32 108.707 -174.628 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.01 143.62 52.51 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.554 0.742 . . . . 74.12 110.844 178.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 89.46 0.04 80.03 Favored Glycine 0 C--N 1.343 0.966 0 O-C-N 123.442 0.464 . . . . 62.55 113.342 -179.065 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . 0.46 ' O ' HG12 ' A' ' 253' ' ' VAL . 80.8 mtp180 -80.26 163.48 23.95 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-N 117.455 0.627 . . . . 74.43 109.855 174.426 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.8 mptp? -112.97 107.31 15.81 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 108.69 -0.856 . . . . 75.34 108.69 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 56.9 mt -85.2 116.34 23.5 Favored 'General case' 0 C--N 1.355 0.824 0 N-CA-C 107.92 -1.141 . . . . 75.2 107.92 178.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 19.6 ttm-85 -95.79 114.76 26.53 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 124.097 0.959 . . . . 74.25 109.433 -164.229 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.432 HD11 HG23 ' A' ' 221' ' ' VAL . 25.0 mt -106.77 106.07 16.41 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.081 0.552 . . . . 74.31 109.698 176.573 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . 0.539 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 44.8 mttp -62.7 148.98 44.91 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 123.651 0.781 . . . . 73.11 111.718 176.539 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.51 35.44 81.41 Favored Glycine 0 C--N 1.355 1.636 0 O-C-N 123.971 0.794 . . . . 64.22 113.228 176.009 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . 0.518 ' HD2' HG12 ' A' ' 219' ' ' VAL . 15.9 mmtm -123.82 -23.08 4.75 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 123.774 0.83 . . . . 74.32 112.116 -176.159 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -81.38 -155.66 14.05 Favored Glycine 0 C--N 1.341 0.844 0 O-C-N 123.592 0.557 . . . . 74.04 112.68 178.203 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.458 ' CE2' ' HA ' ' A' ' 131' ' ' PHE . 75.3 m-85 -96.26 143.68 26.54 Favored Pre-proline 0 N--CA 1.474 0.754 0 O-C-N 122.346 -0.502 . . . . 71.03 111.802 178.186 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . 0.566 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 27.9 Cg_exo -62.22 168.21 9.71 Favored 'Trans proline' 0 C--N 1.378 2.095 0 C-N-CA 123.245 2.63 . . . . 72.13 112.868 176.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 163.22 -159.08 31.58 Favored Glycine 0 CA--C 1.534 1.226 0 CA-C-O 119.586 -0.564 . . . . 60.35 112.959 -177.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . 0.56 ' HD2' ' NE2' ' A' ' 191' ' ' GLN . 39.8 Cg_exo -60.44 -24.04 76.73 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 123.768 2.979 . . . . 74.24 113.363 177.601 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.44 18.56 7.08 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.668 0.787 . . . . 74.34 111.507 178.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.34 -98.84 1.79 Allowed Glycine 0 C--N 1.349 1.266 0 N-CA-C 110.746 -0.942 . . . . 64.14 110.746 -174.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.566 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 51.9 ttt180 -129.32 149.69 51.0 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.362 0.665 . . . . 75.53 109.845 166.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -75.31 -171.21 28.99 Favored Glycine 0 C--N 1.348 1.234 0 O-C-N 123.592 0.558 . . . . 74.33 112.882 176.387 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . 0.539 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 1.6 p-10 -145.16 169.56 17.93 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 123.89 0.876 . . . . 72.01 110.526 -174.307 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.418 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 22.9 tp -110.61 126.39 54.41 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 124.121 0.968 . . . . 73.31 112.095 -171.075 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 15.1 m-85 -88.84 107.06 18.78 Favored 'General case' 0 C--N 1.357 0.918 0 C-N-CA 123.7 0.8 . . . . 71.24 109.308 168.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.479 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 73.5 mt -88.57 121.93 31.48 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 123.783 0.833 . . . . 73.1 111.628 171.325 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -82.35 92.83 7.05 Favored 'General case' 0 C--O 1.235 0.313 0 N-CA-C 108.032 -1.099 . . . . 71.0 108.032 174.351 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.462 HG22 HG12 ' A' ' 199' ' ' VAL . 2.4 p -58.61 114.29 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 C-N-CA 123.395 0.678 . . . . 45.14 110.484 177.586 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 21.3 mmm-85 -116.08 95.2 4.98 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 107.802 -1.184 . . . . 73.41 107.802 -177.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.491 HG22 ' HA ' ' A' ' 201' ' ' ALA . 75.2 mt -76.03 102.57 3.05 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 114.991 -1.004 . . . . 74.21 110.41 -174.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 CA--C 1.564 1.512 0 C-N-CA 124.337 1.055 . . . . 71.35 109.258 175.985 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.816 0 N-CA-C 110.171 -0.307 . . . . 53.42 110.171 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -63.87 -56.81 12.58 Favored 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 108.503 -0.925 . . . . 65.3 108.503 171.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.488 ' HA ' HD13 ' A' ' 123' ' ' LEU . 3.5 mm? -85.49 84.64 7.56 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 114.248 -1.342 . . . . 74.22 107.402 169.076 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 7.1 p -60.1 -27.94 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 C-N-CA 123.092 0.557 . . . . 74.1 111.391 -178.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . 64.86 35.85 8.21 Favored 'General case' 0 C--N 1.355 0.818 0 O-C-N 124.541 1.151 . . . . 74.23 110.905 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 66.5 t-80 -75.35 91.07 2.68 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 114.755 -1.112 . . . . 75.04 108.088 178.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 46.3 t -57.2 145.72 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 C-N-CA 124.582 1.153 . . . . 75.43 111.297 -173.391 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.5 t -134.53 153.1 52.12 Favored 'General case' 0 C--O 1.242 0.665 0 C-N-CA 123.172 0.589 . . . . 75.34 109.836 177.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 44.7 m -137.8 111.16 7.96 Favored 'General case' 0 C--O 1.24 0.576 0 C-N-CA 124.149 0.98 . . . . 72.44 108.394 177.269 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 157.67 153.01 6.54 Favored Glycine 0 C--N 1.342 0.869 0 N-CA-C 111.704 -0.558 . . . . 71.23 111.704 -178.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 20.2 m -75.42 96.67 3.48 Favored 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 123.313 0.645 . . . . 72.44 109.691 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -142.9 62.18 0.51 Allowed Glycine 0 C--N 1.343 0.969 0 N-CA-C 111.281 -0.728 . . . . 71.12 111.281 -179.048 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.05 118.72 0.53 Allowed Glycine 0 C--N 1.339 0.748 0 N-CA-C 110.818 -0.913 . . . . 74.4 110.818 -177.404 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 21.3 m -65.32 97.86 0.3 Allowed 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 123.595 0.758 . . . . 72.14 110.555 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -87.33 -90.29 1.03 Allowed Glycine 0 C--N 1.346 1.09 0 CA-C-N 116.047 -0.524 . . . . 73.33 112.492 -178.589 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 119.82 -149.47 17.84 Favored Glycine 0 C--N 1.348 1.24 0 N-CA-C 111.453 -0.659 . . . . 62.12 111.453 -176.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 35.5 p -71.41 95.99 1.42 Allowed 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 123.304 0.642 . . . . 75.05 110.045 176.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -177.63 82.1 0.07 OUTLIER Glycine 0 C--N 1.348 1.206 0 CA-C-N 116.04 -0.527 . . . . 74.1 112.072 -179.24 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -138.31 -86.76 0.16 Allowed Glycine 0 C--N 1.342 0.899 0 N-CA-C 111.345 -0.702 . . . . 74.14 111.345 176.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.1 t 66.27 -70.54 0.1 Allowed 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 125.48 1.512 . . . . 74.1 111.543 179.03 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -88.65 169.56 37.38 Favored Glycine 0 C--N 1.342 0.889 0 N-CA-C 111.104 -0.798 . . . . 73.01 111.104 167.675 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 53.2 ttp180 -57.51 125.84 24.69 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 122.912 0.485 . . . . 64.44 110.479 174.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -73.62 141.28 46.55 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.098 0.559 . . . . 72.4 110.158 177.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.532 HD11 ' HA2' ' A' ' 165' ' ' GLY . 11.6 mt -124.05 151.41 43.83 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 108.129 -1.063 . . . . 72.41 108.129 168.524 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . 0.499 ' HG2' ' HB2' ' A' ' 175' ' ' LEU . 17.3 mtp180 -142.6 151.01 41.07 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.571 0.748 . . . . 74.14 109.376 177.587 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . 0.481 ' HB2' HD21 ' A' ' 176' ' ' LEU . . . -151.63 120.11 6.44 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 123.615 0.766 . . . . 75.04 109.412 177.003 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 37.8 mm-40 -84.05 143.18 29.91 Favored 'General case' 0 C--O 1.242 0.708 0 N-CA-C 109.111 -0.699 . . . . 73.34 109.111 175.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.488 HD13 ' HA ' ' A' ' 98' ' ' LEU . 0.7 OUTLIER -145.21 145.25 26.06 Favored Pre-proline 0 N--CA 1.475 0.781 0 C-N-CA 122.38 0.272 . . . . 74.2 110.923 174.707 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -81.64 114.51 2.69 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 121.864 1.709 . . . . 74.52 110.638 165.173 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.4 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 15.1 tp -106.79 138.8 42.29 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 123.863 0.865 . . . . 73.4 109.354 -178.71 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.766 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 20.8 m -78.78 158.76 28.15 Favored 'General case' 0 CA--C 1.548 0.901 0 N-CA-C 109.605 -0.517 . . . . 75.04 109.605 172.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.417 HD12 ' O ' ' A' ' 183' ' ' HIS . 31.6 mt -61.52 -47.11 87.09 Favored 'General case' 0 N--CA 1.483 1.177 0 CA-C-O 121.909 0.861 . . . . 75.33 110.004 178.287 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -56.81 -32.76 66.03 Favored 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 114.12 -1.4 . . . . 74.41 111.172 175.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.766 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 29.6 mm-40 -76.97 -32.08 57.0 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 122.977 0.511 . . . . 73.24 111.385 178.514 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . 0.498 ' HA ' HG11 ' A' ' 153' ' ' VAL . . . -55.6 -35.1 65.46 Favored 'General case' 0 C--O 1.245 0.824 0 C-N-CA 122.999 0.519 . . . . 64.01 111.564 167.326 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.555 ' HA ' ' HE2' ' A' ' 240' ' ' PHE . 69.2 t80 -75.17 -47.62 27.55 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.447 -0.797 . . . . 72.51 112.877 171.306 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -68.95 -48.51 63.02 Favored 'General case' 0 N--CA 1.485 1.306 0 N-CA-C 112.115 0.413 . . . . 75.2 112.115 -170.092 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 57.52 -122.14 28.17 Favored Glycine 0 CA--C 1.534 1.272 0 O-C-N 123.869 0.731 . . . . 74.22 111.984 -172.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.27 -173.67 55.14 Favored Glycine 0 C--N 1.35 1.32 0 N-CA-C 114.358 0.503 . . . . 72.14 114.358 168.491 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' GLU . . . . . 0.54 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 1.3 mp0 -83.38 112.12 19.63 Favored 'General case' 0 C--N 1.356 0.856 0 N-CA-C 109.56 -0.533 . . . . 70.23 109.56 -178.552 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 10.3 mmm180 -123.07 156.47 34.84 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.291 1.036 . . . . 73.25 108.462 178.194 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.1 m -77.05 133.32 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 C-N-CA 122.46 0.304 . . . . 71.5 111.356 -176.718 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 144' ' ' ARG . 38.6 t -125.13 134.05 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.685 1.194 . . . . 73.21 108.798 172.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -125.67 97.17 5.05 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.058 0.943 . . . . 74.32 109.366 171.637 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 53.2 t -122.84 122.31 65.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 C-N-CA 123.548 0.739 . . . . 64.35 109.803 178.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.56 28.41 18.09 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 124.93 1.292 . . . . 75.43 112.381 175.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 98.37 -13.61 62.84 Favored Glycine 0 C--N 1.349 1.294 0 CA-C-N 116.107 -0.497 . . . . 63.24 113.594 178.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.98 118.0 30.35 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 117.508 0.654 . . . . 74.21 110.569 -179.716 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.401 ' HA ' ' O ' ' A' ' 138' ' ' VAL . 38.0 ttp180 -95.49 106.15 18.2 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 124.499 1.12 . . . . 63.45 108.41 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.9 t -128.33 131.21 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.19 0.996 . . . . 74.11 109.491 -179.197 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 70.0 m -72.25 115.19 11.2 Favored 'General case' 0 C--O 1.242 0.677 0 N-CA-C 108.635 -0.876 . . . . 71.34 108.635 170.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 7.1 p -96.81 143.67 11.93 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 123.044 0.538 . . . . 74.55 110.295 -178.637 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 31.2 ttm180 -107.89 100.26 9.64 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 107.585 -1.265 . . . . 72.13 107.585 171.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.426 ' HB ' HD13 ' A' ' 159' ' ' ILE . 27.7 pt -92.91 130.91 34.8 Favored Pre-proline 0 CA--C 1.548 0.881 0 N-CA-C 108.393 -0.966 . . . . 73.2 108.393 172.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -66.7 131.04 24.79 Favored 'Trans proline' 0 C--N 1.376 2.002 0 C-N-CA 122.617 2.211 . . . . 64.01 113.121 -172.164 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_exo -53.02 117.61 3.93 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.303 2.669 . . . . 75.3 111.824 167.037 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 124.46 54.26 0.18 Allowed Glycine 0 CA--C 1.506 -0.489 0 N-CA-C 110.758 -0.937 . . . . 71.42 110.758 -173.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.498 HG11 ' HA ' ' A' ' 130' ' ' ALA . 3.1 p -126.85 156.62 38.11 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.301 0 C-N-CA 123.456 0.703 . . . . 75.31 109.542 -175.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 55.4 mtp180 -138.26 176.09 9.0 Favored 'General case' 0 N--CA 1.491 1.599 0 C-N-CA 124.61 1.164 . . . . 75.12 111.284 -168.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -55.55 121.56 9.32 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 124.272 1.029 . . . . 74.33 111.04 171.367 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.14 7.86 84.8 Favored Glycine 0 C--N 1.348 1.204 0 O-C-N 123.589 0.556 . . . . 64.23 113.842 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 70.8 m -72.37 126.32 29.55 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 117.287 0.543 . . . . 75.41 109.818 176.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.444 HG12 HD21 ' A' ' 175' ' ' LEU . 32.7 t -100.47 123.03 53.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-N 114.045 -1.434 . . . . 71.24 108.265 -175.313 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.472 HD12 HG23 ' A' ' 153' ' ' VAL . 25.4 mt -110.57 118.6 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 123.414 0.686 . . . . 75.32 110.153 -172.452 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 33.2 ttm-85 -85.12 130.29 34.64 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.663 0.785 . . . . 72.12 110.619 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.616 HG22 ' HB3' ' A' ' 174' ' ' LEU . 4.2 m -124.49 125.96 25.52 Favored Pre-proline 0 CA--C 1.551 0.984 0 N-CA-C 108.691 -0.855 . . . . 64.33 108.691 166.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.34 147.17 28.81 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 122.614 2.209 . . . . 71.02 113.424 -173.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 70.62 24.89 76.52 Favored Glycine 0 C--N 1.351 1.415 0 CA-C-N 115.733 -0.667 . . . . 52.04 114.348 170.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 44.3 tpp -104.99 -37.64 6.89 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.152 0.581 . . . . 75.54 109.904 177.205 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' GLY . . . . . 0.532 ' HA2' HD11 ' A' ' 119' ' ' LEU . . . -75.71 -99.3 0.13 Allowed Glycine 0 C--N 1.347 1.167 0 CA-C-N 115.483 -0.781 . . . . 32.54 112.942 -177.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.611 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -62.1 100.99 0.33 Allowed Glycine 0 C--N 1.346 1.105 0 C-N-CA 123.596 0.617 . . . . 53.02 112.346 173.572 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' GLN . . . . . 0.504 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -84.78 105.29 15.45 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 108.597 -0.89 . . . . 74.41 108.597 178.503 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 165.52 -157.56 30.07 Favored Glycine 0 C--O 1.243 0.685 0 N-CA-C 111.065 -0.814 . . . . 73.21 111.065 -177.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -65.15 -48.87 68.8 Favored Pre-proline 0 CA--C 1.561 1.379 0 CA-C-O 118.128 -0.939 . . . . 73.04 111.28 176.795 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -80.42 106.17 1.83 Allowed 'Trans proline' 0 C--N 1.394 2.972 0 C-N-CA 122.299 1.999 . . . . 72.1 110.115 169.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.5 126.83 8.55 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.185 1.923 . . . . 63.23 110.425 -177.257 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' GLY . . . . . 0.611 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -95.5 172.66 30.4 Favored Glycine 0 C--O 1.237 0.338 0 N-CA-C 110.768 -0.933 . . . . 72.41 110.768 173.091 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -120.22 159.48 24.85 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 123.447 0.699 . . . . 71.55 110.689 -170.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' LEU . . . . . 0.616 ' HB3' HG22 ' A' ' 161' ' ' VAL . 43.1 tp -109.74 120.43 42.46 Favored 'General case' 0 C--O 1.242 0.698 0 N-CA-C 107.092 -1.447 . . . . 74.51 107.092 169.519 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' LEU . . . . . 0.499 ' HB2' ' HG2' ' A' ' 120' ' ' ARG . 52.5 mt -100.36 100.29 11.06 Favored 'General case' 0 C--O 1.241 0.616 0 O-C-N 124.495 1.122 . . . . 74.43 109.326 -178.003 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.481 HD21 ' HB2' ' A' ' 121' ' ' ALA . 26.7 mt -86.92 101.28 13.25 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 114.562 -1.199 . . . . 63.04 109.098 -179.394 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 23.1 t -93.47 105.98 17.46 Favored 'Isoleucine or valine' 0 C--O 1.244 0.812 0 N-CA-C 108.451 -0.944 . . . . 75.34 108.451 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.459 HG22 HG22 ' A' ' 153' ' ' VAL . 13.7 m -82.44 147.95 5.62 Favored 'Isoleucine or valine' 0 C--O 1.241 0.643 0 CA-C-N 115.593 -0.73 . . . . 73.15 110.271 -178.435 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 17.0 mmt180 -123.72 105.53 9.77 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 107.675 -1.231 . . . . 70.35 107.675 178.665 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.4 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 33.9 mt -67.22 148.81 51.27 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 117.725 0.239 . . . . 73.23 110.381 179.521 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.556 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 29.5 mt -57.46 157.44 13.33 Favored Pre-proline 0 CA--C 1.556 1.179 0 C-N-CA 123.78 0.832 . . . . 75.32 112.486 -171.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -57.19 -12.79 10.83 Favored 'Trans proline' 0 C--N 1.386 2.524 0 C-N-CA 123.019 2.48 . . . . 65.23 113.336 174.136 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . 0.417 ' O ' HD12 ' A' ' 127' ' ' LEU . 28.3 t60 -99.09 101.12 11.52 Favored Pre-proline 0 CA--C 1.545 0.763 0 C-N-CA 124.364 1.066 . . . . 64.4 108.528 166.235 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -102.44 128.41 0.1 Allowed 'Trans proline' 0 CA--C 1.557 1.665 0 C-N-CA 123.387 2.725 . . . . 73.04 112.396 162.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.9 p -116.93 -44.82 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 N-CA-C 109.135 -0.691 . . . . 74.25 109.135 172.138 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -100.28 123.84 45.0 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.576 -0.738 . . . . 73.31 111.438 -177.054 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 187' ' ' ARG . . . . . 0.705 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 80.2 mtt180 -109.46 160.85 15.87 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-N 114.084 -1.416 . . . . 75.43 108.118 175.42 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 188' ' ' LEU . . . . . 0.47 HD13 ' HD1' ' A' ' 240' ' ' PHE . 51.7 tp -130.78 142.64 50.41 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 108.913 -0.773 . . . . 72.2 108.913 178.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -140.85 99.95 3.72 Favored 'General case' 0 C--O 1.242 0.697 0 N-CA-C 107.411 -1.329 . . . . 74.21 107.411 175.168 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 70.18 -78.64 0.42 Allowed Glycine 0 CA--C 1.531 1.047 0 O-C-N 123.881 0.738 . . . . 73.43 112.216 -175.325 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -138.34 -14.38 1.31 Allowed 'General case' 0 CA--C 1.558 1.26 0 C-N-CA 123.866 0.867 . . . . 74.44 110.448 -176.503 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . 0.443 ' O ' HD11 ' A' ' 188' ' ' LEU . 9.2 m-20 -86.16 153.86 21.75 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 124.177 0.991 . . . . 72.52 112.103 -178.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 193' ' ' LEU . . . . . 0.516 ' HG ' ' HA2' ' A' ' 239' ' ' GLY . 85.0 mt -107.35 160.76 15.38 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 124.264 1.026 . . . . 72.32 108.519 175.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 194' ' ' TYR . . . . . 0.705 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 64.7 m-85 -136.63 121.55 18.79 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.584 -1.265 . . . . 73.42 107.584 177.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -144.14 148.29 34.86 Favored 'General case' 0 C--O 1.239 0.542 0 O-C-N 124.308 1.005 . . . . 42.32 109.197 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 49.4 m -88.37 127.18 35.49 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.258 -0.883 . . . . 74.12 109.165 173.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 197' ' ' LEU . . . . . 0.475 HD22 HD12 ' A' ' 251' ' ' LEU . 66.3 tp -105.9 110.5 22.81 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 108.215 -1.031 . . . . 73.2 108.215 178.101 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -92.35 112.02 23.81 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 108.71 -0.848 . . . . 74.23 108.71 178.061 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 2.8 p -119.51 127.22 26.56 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 124.023 0.929 . . . . 75.22 108.946 -177.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 200' ' ' PRO . . . . . 0.433 ' HD2' HD12 ' A' ' 203' ' ' ILE . 51.7 Cg_exo -56.65 142.28 91.03 Favored 'Trans proline' 0 C--N 1.376 2.02 0 C-N-CA 122.729 2.286 . . . . 73.24 111.786 174.285 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 201' ' ' ALA . . . . . 0.478 ' HA ' HG22 ' A' ' 255' ' ' ILE . . . -55.8 -42.48 96.31 Favored Pre-proline 0 CA--C 1.557 1.222 0 CA-C-O 118.252 -0.88 . . . . 74.31 112.478 176.627 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 202' ' ' PRO . . . . . 0.484 ' O ' HG21 ' A' ' 206' ' ' VAL . 63.3 Cg_exo -46.75 -55.35 3.9 Favored 'Trans proline' 0 C--N 1.394 2.967 0 C-N-CA 122.972 2.448 . . . . 75.02 114.005 167.022 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 203' ' ' ILE . . . . . 0.433 HD12 ' HD2' ' A' ' 200' ' ' PRO . 21.1 mt -61.7 -41.7 91.48 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 122.907 0.483 . . . . 75.1 111.122 -179.503 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.36 -35.39 78.98 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 115.063 -0.971 . . . . 71.52 111.832 -175.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 205' ' ' VAL . . . . . 0.514 HG21 HG13 ' A' ' 206' ' ' VAL . 25.9 m -89.35 -55.52 6.21 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 N-CA-C 112.798 0.666 . . . . 73.02 112.798 178.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . 0.514 HG13 HG21 ' A' ' 205' ' ' VAL . 18.4 m -95.13 -38.3 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 CA-C-N 118.337 0.517 . . . . 74.5 112.074 -171.504 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -91.17 -115.93 1.95 Allowed Glycine 0 C--N 1.34 0.765 0 CA-C-N 116.606 -0.27 . . . . 75.25 112.657 -164.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 142.36 14.31 0.37 Allowed Glycine 0 C--N 1.335 0.521 0 CA-C-O 119.655 -0.525 . . . . 72.52 113.732 177.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 209' ' ' LYS . . . . . 0.409 ' O ' HD11 ' A' ' 203' ' ' ILE . 15.4 tppt? -117.51 118.22 31.59 Favored 'General case' 0 C--N 1.349 0.553 0 CA-C-N 117.762 0.781 . . . . 73.14 109.453 -173.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 210' ' ' VAL . . . . . 0.421 HG23 ' HB ' ' A' ' 221' ' ' VAL . 2.9 m -145.34 146.21 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.831 0 N-CA-C 108.596 -0.89 . . . . 73.2 108.596 170.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 56.4 mtm-85 -107.16 124.31 49.52 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.648 -0.871 . . . . 70.05 108.648 174.253 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 212' ' ' ALA . . . . . 0.454 ' HB1' HD13 ' A' ' 197' ' ' LEU . . . -103.09 137.91 40.64 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.298 0.639 . . . . 54.44 109.559 178.185 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 44.1 mmm -82.98 119.91 25.04 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 122.37 0.268 . . . . 71.03 110.489 174.506 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 3.5 t -118.04 169.88 9.3 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.411 1.085 . . . . 71.2 109.816 171.026 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 83.1 mt -73.96 -10.48 59.68 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 123.735 0.814 . . . . 73.55 112.688 -172.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -93.87 -13.33 27.33 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.602 0.761 . . . . 62.33 111.366 175.041 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 140.16 -157.87 25.64 Favored Glycine 0 C--N 1.347 1.183 0 CA-C-O 119.521 -0.599 . . . . 51.23 111.611 -177.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -85.59 135.83 5.18 Favored 'Trans proline' 0 CA--C 1.551 1.343 0 C-N-CA 122.469 2.113 . . . . 62.31 112.244 172.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.9 m -113.08 159.92 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 123.38 0.672 . . . . 75.21 110.26 168.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -111.35 109.59 19.66 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 107.669 -1.234 . . . . 73.33 107.669 179.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . 0.467 HG22 HD12 ' A' ' 235' ' ' LEU . 12.7 t -96.16 125.24 49.07 Favored 'Isoleucine or valine' 0 C--O 1.243 0.754 0 C-N-CA 123.535 0.734 . . . . 74.21 109.582 177.471 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -88.67 103.59 16.07 Favored 'General case' 0 C--O 1.24 0.598 0 N-CA-C 108.767 -0.827 . . . . 72.51 108.767 170.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 17.0 m -80.04 136.01 54.43 Favored Pre-proline 0 N--CA 1.477 0.887 0 N-CA-C 107.879 -1.156 . . . . 74.41 107.879 172.068 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -61.47 129.44 28.13 Favored 'Trans proline' 0 CA--C 1.555 1.543 0 C-N-CA 122.0 1.8 . . . . 74.44 111.83 176.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -52.02 128.42 26.87 Favored 'Trans proline' 0 C--N 1.372 1.791 0 C-N-CA 122.655 2.236 . . . . 74.42 111.993 172.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 226' ' ' ARG . . . . . 0.416 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 17.5 mtp180 65.31 42.61 3.84 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 125.252 1.421 . . . . 75.42 111.949 -173.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 227' ' ' THR . . . . . 0.452 HG22 HD11 ' A' ' 255' ' ' ILE . 8.5 t -78.36 177.45 8.46 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.115 0.566 . . . . 65.52 110.462 174.584 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . 0.507 HE21 ' HD2' ' A' ' 231' ' ' ARG . 1.8 mp0 -126.85 154.08 44.83 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 123.412 0.685 . . . . 73.2 109.371 -178.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -71.61 149.43 45.61 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.236 0.614 . . . . 74.4 110.572 176.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 88.25 -4.13 85.42 Favored Glycine 0 CA--C 1.527 0.807 0 CA-C-O 119.705 -0.497 . . . . 72.54 112.853 -178.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 231' ' ' ARG . . . . . 0.507 ' HD2' HE21 ' A' ' 228' ' ' GLN . 83.3 mtp180 -77.88 162.34 26.92 Favored 'General case' 0 C--N 1.36 1.063 0 CA-C-O 121.224 0.535 . . . . 75.22 111.153 177.641 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 232' ' ' LYS . . . . . 0.475 ' HG2' ' CZ ' ' A' ' 250' ' ' TYR . 10.6 mptt -118.35 122.06 41.92 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.89 0.876 . . . . 74.55 110.311 -173.302 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 64.4 mt -110.54 117.33 33.24 Favored 'General case' 0 C--N 1.348 0.506 0 N-CA-C 107.784 -1.191 . . . . 74.31 107.784 173.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 44.1 ttp180 -112.78 111.44 22.22 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 109.29 -0.633 . . . . 74.45 109.29 -168.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.467 HD12 HG22 ' A' ' 221' ' ' VAL . 14.7 mt -96.8 120.84 37.89 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 123.581 0.752 . . . . 74.1 109.82 -174.212 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 51.1 mttp -71.14 147.04 48.78 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.256 0.622 . . . . 74.34 112.32 -177.514 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.73 15.81 69.28 Favored Glycine 0 C--N 1.352 1.453 0 O-C-N 124.054 0.846 . . . . 55.34 114.401 173.486 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 238' ' ' LYS . . . . . 0.43 ' HG3' ' HB2' ' A' ' 235' ' ' LEU . 1.3 mmpm? -101.35 -17.43 16.52 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 123.548 0.739 . . . . 74.43 111.708 -175.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 239' ' ' GLY . . . . . 0.516 ' HA2' ' HG ' ' A' ' 193' ' ' LEU . . . -74.97 -148.13 1.66 Allowed Glycine 0 C--N 1.346 1.084 0 O-C-N 123.847 0.717 . . . . 74.12 113.709 -176.679 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 240' ' ' PHE . . . . . 0.555 ' HE2' ' HA ' ' A' ' 131' ' ' PHE . 39.9 m-85 -97.32 155.53 37.26 Favored Pre-proline 0 N--CA 1.475 0.786 0 CA-C-O 119.158 -0.448 . . . . 70.21 111.576 174.557 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -55.12 146.92 56.65 Favored 'Trans proline' 0 C--N 1.385 2.466 0 C-N-CA 122.906 2.404 . . . . 72.23 112.751 179.495 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -178.98 -165.71 33.78 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.669 -0.696 . . . . 72.42 112.15 -178.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -58.05 -27.6 80.19 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.375 2.717 . . . . 74.11 114.49 -179.606 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.07 22.82 5.44 Favored 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 123.556 0.742 . . . . 64.44 111.718 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.13 -86.01 1.56 Allowed Glycine 0 C--N 1.348 1.218 0 N-CA-C 110.097 -1.201 . . . . 54.14 110.097 -174.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 246' ' ' ARG . . . . . 0.475 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 18.6 mtm180 -126.94 164.54 21.24 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 108.355 -0.98 . . . . 71.14 108.355 163.238 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -77.85 -153.87 6.5 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.541 -0.754 . . . . 71.15 113.71 -177.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -120.5 164.5 16.33 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.154 0.581 . . . . 62.51 110.262 -177.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 249' ' ' LEU . . . . . 0.495 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 15.8 tp -109.98 111.15 22.37 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.037 0.935 . . . . 73.12 108.913 168.293 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 250' ' ' TYR . . . . . 0.475 ' CZ ' ' HG2' ' A' ' 232' ' ' LYS . 17.9 t80 -90.68 104.57 17.14 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 107.914 -1.143 . . . . 75.31 107.914 178.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 251' ' ' LEU . . . . . 0.475 HD12 HD22 ' A' ' 197' ' ' LEU . 63.7 mt -89.19 148.8 23.43 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.292 1.037 . . . . 73.22 111.583 179.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -110.14 97.12 6.68 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 107.922 -1.14 . . . . 65.23 107.922 173.145 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 60.2 t -52.24 117.09 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 123.663 0.785 . . . . 73.11 110.104 174.531 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 12.8 mmm180 -124.73 93.12 3.81 Favored 'General case' 0 C--O 1.238 0.463 0 N-CA-C 107.708 -1.219 . . . . 73.22 107.708 178.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.478 HG22 ' HA ' ' A' ' 201' ' ' ALA . 60.1 mt -75.64 104.82 4.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-N 115.103 -0.953 . . . . 73.44 109.267 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.554 1.116 0 C-N-CA 124.047 0.939 . . . . 75.03 109.728 -178.001 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.438 HD21 ' HG2' ' A' ' 136' ' ' ARG . 0.2 OUTLIER . . . . . 0 N--CA 1.481 1.101 0 CA-C-O 119.818 -0.134 . . . . 73.22 111.093 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.653 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 61.5 t -60.77 125.59 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 123.037 0.535 . . . . 45.4 111.057 175.749 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -71.36 -66.97 0.55 Allowed 'General case' 0 C--N 1.346 0.45 0 CA-C-N 115.544 -0.753 . . . . 71.34 109.763 177.501 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 20.4 p-80 178.19 177.36 0.42 Allowed 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 124.634 1.174 . . . . 72.04 109.724 -176.388 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 43.9 t -71.34 136.84 24.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.078 0 C-N-CA 123.497 0.719 . . . . 60.1 110.157 177.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.8 t . . . . . 0 N--CA 1.473 0.679 0 C-N-CA 124.384 1.074 . . . . 74.22 109.448 178.17 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.464 ' HB3' ' HE ' ' A' ' 120' ' ' ARG . 5.9 m-20 . . . . . 0 N--CA 1.478 0.937 0 N-CA-C 109.545 -0.539 . . . . 71.1 109.545 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.499 HD12 ' HA2' ' A' ' 165' ' ' GLY . 12.3 mt -100.76 132.45 46.16 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 107.601 -1.259 . . . . 71.31 107.601 167.705 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' ARG . . . . . 0.464 ' HE ' ' HB3' ' A' ' 118' ' ' ASP . 21.4 mmt85 -127.84 133.49 49.38 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 107.851 -1.166 . . . . 72.44 107.851 -177.255 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -154.01 145.3 22.97 Favored 'General case' 0 N--CA 1.47 0.552 0 O-C-N 123.441 0.463 . . . . 50.25 109.756 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.672 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 41.3 mt-10 -112.09 148.36 34.1 Favored 'General case' 0 C--O 1.246 0.885 0 C-N-CA 123.59 0.756 . . . . 75.43 109.721 174.557 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.653 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.7 pt? -145.88 130.04 8.68 Favored Pre-proline 0 C--O 1.222 -0.376 0 CA-C-N 115.443 -0.799 . . . . 61.21 111.065 -176.735 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.18 117.49 4.28 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 121.819 1.679 . . . . 74.21 110.152 163.302 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.472 ' HB3' HD23 ' A' ' 180' ' ' LEU . 21.3 tp -110.59 139.8 45.5 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 123.624 0.77 . . . . 63.22 109.237 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.613 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 4.7 m -76.63 149.33 36.54 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 109.015 -0.735 . . . . 74.05 109.015 170.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.403 HD11 ' O ' ' A' ' 183' ' ' HIS . 44.4 mt -57.06 -44.58 83.18 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 122.267 1.032 . . . . 64.2 109.868 177.271 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -57.26 -37.7 72.75 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 113.383 -1.735 . . . . 63.52 111.439 176.73 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.613 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 42.1 mm-40 -77.58 -27.36 51.36 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 122.644 0.378 . . . . 74.24 111.758 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.503 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -58.75 -36.32 74.16 Favored 'General case' 0 C--O 1.243 0.741 0 C-N-CA 123.203 0.601 . . . . 64.43 111.446 167.769 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.415 ' CZ ' ' HB3' ' A' ' 216' ' ' GLU . 70.9 t80 -74.0 -51.84 14.67 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.151 -0.931 . . . . 73.44 112.427 171.15 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 34.3 m80 -63.83 -49.15 73.96 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 123.358 0.411 . . . . 73.55 112.04 -167.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 48.44 52.76 18.25 Favored Glycine 0 CA--C 1.534 1.28 0 O-C-N 124.118 0.886 . . . . 51.34 114.125 178.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -102.67 -168.61 26.45 Favored Glycine 0 C--N 1.347 1.139 0 CA-C-O 120.044 -0.309 . . . . 64.22 112.481 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.425 ' HB3' ' OG ' ' A' ' 146' ' ' SER . 2.1 mp0 -77.36 113.97 15.69 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 109.556 -0.535 . . . . 64.41 109.556 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.438 ' HG2' HD21 ' A' ' 98' ' ' LEU . 2.4 mpt_? -124.36 150.61 45.33 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 124.106 0.963 . . . . 60.12 108.681 173.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.8 p -76.35 129.74 36.89 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.093 0 CA-C-O 121.256 0.551 . . . . 72.42 111.266 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.527 HG21 HD21 ' A' ' 174' ' ' LEU . 7.9 p -111.27 141.0 27.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 C-N-CA 124.66 1.184 . . . . 71.43 108.81 170.577 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -125.72 100.68 6.53 Favored 'General case' 0 C--O 1.238 0.498 0 N-CA-C 107.819 -1.178 . . . . 74.22 107.819 178.15 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.7 m -123.84 108.03 19.97 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 C-N-CA 124.288 1.035 . . . . 41.45 110.436 -175.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 66.19 25.29 10.68 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 124.633 1.173 . . . . 55.24 111.766 179.488 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.83 4.96 78.41 Favored Glycine 0 C--N 1.353 1.482 0 CA-C-N 116.035 -0.53 . . . . 65.35 112.909 -176.366 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 30.9 tpt180 -94.02 115.41 27.74 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 108.687 -0.857 . . . . 71.4 108.687 177.158 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 75.3 ttt180 -97.74 115.58 28.28 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.729 -0.841 . . . . 71.23 108.729 177.165 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.432 HG11 ' SD ' ' A' ' 164' ' ' MET . 16.1 t -130.51 154.59 40.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 108.059 -1.089 . . . . 74.35 108.059 173.748 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.425 ' OG ' ' HB3' ' A' ' 135' ' ' GLU . 48.3 t -92.19 109.0 20.36 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.289 -1.004 . . . . 55.44 108.289 171.487 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 9.9 p -97.77 129.6 47.71 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 C-N-CA 123.702 0.801 . . . . 73.43 109.743 -178.613 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 29.1 ttt180 -107.96 97.47 7.17 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 107.719 -1.215 . . . . 72.41 107.719 173.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.555 ' HB ' HD13 ' A' ' 159' ' ' ILE . 26.1 pt -78.51 141.4 60.82 Favored Pre-proline 0 CA--C 1.552 1.053 0 N-CA-C 109.286 -0.635 . . . . 70.01 109.286 177.258 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -70.06 134.19 26.76 Favored 'Trans proline' 0 C--N 1.372 1.78 0 C-N-CA 122.299 1.999 . . . . 74.23 112.526 -173.139 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -54.31 138.85 73.38 Favored 'Trans proline' 0 C--N 1.371 1.752 0 C-N-CA 123.121 2.547 . . . . 73.13 112.02 168.725 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 105.78 36.93 2.67 Favored Glycine 0 N--CA 1.463 0.493 0 N-CA-C 111.589 -0.604 . . . . 52.35 111.589 -173.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.608 HG21 HD11 ' A' ' 159' ' ' ILE . 2.4 p -112.71 155.93 13.83 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.251 0 N-CA-C 109.099 -0.704 . . . . 62.35 109.099 -177.194 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.431 ' HD2' ' O ' ' A' ' 188' ' ' LEU . 38.7 mtp180 -142.38 173.16 11.78 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 125.177 1.391 . . . . 73.03 110.742 -168.46 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.4 tp10 -58.39 121.1 10.02 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 123.758 0.823 . . . . 74.41 110.997 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.25 7.68 88.13 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-N 116.252 -0.431 . . . . 33.31 113.48 -178.209 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.436 ' HB3' HG23 ' A' ' 153' ' ' VAL . 38.6 t -77.8 125.55 29.51 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 109.45 -0.574 . . . . 74.01 109.45 179.134 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.542 HG12 HD22 ' A' ' 175' ' ' LEU . 8.5 t -98.5 120.26 47.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-N 114.609 -1.178 . . . . 72.12 108.75 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.608 HD11 HG21 ' A' ' 153' ' ' VAL . 49.1 mt -107.21 120.43 58.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.92 0.888 . . . . 71.43 111.136 -172.508 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 25.8 ttm180 -92.58 114.13 26.6 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 123.2 0.6 . . . . 73.11 111.068 177.475 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -113.46 96.07 38.55 Favored Pre-proline 0 CA--C 1.559 1.313 0 N-CA-C 109.279 -0.637 . . . . 73.52 109.279 173.53 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -62.24 148.66 92.84 Favored 'Trans proline' 0 C--N 1.388 2.609 0 C-N-CA 123.646 2.898 . . . . 74.13 113.588 -177.59 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 85.5 -12.85 57.88 Favored Glycine 0 C--N 1.349 1.272 0 O-C-N 123.813 0.696 . . . . 75.23 113.34 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.432 ' SD ' HG11 ' A' ' 145' ' ' VAL . 36.4 mmm -92.33 -28.58 16.85 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.411 1.084 . . . . 62.34 111.912 -170.747 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 165' ' ' GLY . . . . . 0.499 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.344 1.025 0 N-CA-C 111.158 -0.777 . . . . 61.24 111.158 176.276 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo . . . . . 0 CA--C 1.537 0.667 0 N-CA-C 111.307 -0.305 . . . . 75.03 111.307 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -105.34 152.18 17.22 Favored Glycine 0 CA--C 1.504 -0.652 0 N-CA-C 109.806 -1.317 . . . . 64.33 109.806 171.516 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -112.96 168.81 9.39 Favored 'General case' 0 C--O 1.241 0.628 0 CA-C-O 121.503 0.668 . . . . 71.51 110.488 -173.233 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.527 HD21 HG21 ' A' ' 138' ' ' VAL . 12.4 tp -118.62 115.39 24.44 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 107.722 -1.214 . . . . 73.12 107.722 175.696 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.542 HD22 HG12 ' A' ' 158' ' ' VAL . 53.6 mt -88.38 100.22 12.86 Favored 'General case' 0 C--O 1.241 0.653 0 O-C-N 123.958 0.786 . . . . 74.43 110.305 177.123 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 81.5 mt -88.29 102.99 15.39 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.013 -0.994 . . . . 71.12 110.57 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.672 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 48.2 t -86.66 104.81 14.28 Favored 'Isoleucine or valine' 0 C--O 1.241 0.605 0 N-CA-C 108.307 -0.998 . . . . 52.34 108.307 173.564 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.469 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 9.6 m -82.04 150.82 4.33 Favored 'Isoleucine or valine' 0 C--O 1.245 0.821 0 CA-C-O 121.325 0.583 . . . . 64.11 110.838 -177.553 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 24.0 mmm-85 -126.99 97.11 4.83 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.242 -1.392 . . . . 72.35 107.242 -175.759 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.472 HD23 ' HB3' ' A' ' 125' ' ' LEU . 46.1 mt -66.4 147.09 53.8 Favored 'General case' 0 C--O 1.242 0.683 0 CA-C-O 120.536 0.208 . . . . 61.42 110.656 -176.449 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.411 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 37.6 mt -54.8 152.19 13.72 Favored Pre-proline 0 CA--C 1.556 1.19 0 O-C-N 124.09 0.869 . . . . 73.45 111.829 -173.878 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -58.29 -8.7 5.43 Favored 'Trans proline' 0 C--N 1.383 2.376 0 C-N-CA 123.377 2.718 . . . . 64.11 113.363 172.86 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 183' ' ' HIS . . . . . 0.403 ' O ' HD11 ' A' ' 127' ' ' LEU . 6.3 t60 -93.59 107.97 30.65 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 124.79 1.236 . . . . 72.24 108.614 168.803 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -99.52 163.69 0.55 Allowed 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 123.314 2.676 . . . . 71.44 112.427 165.022 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -156.64 -45.67 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 N-CA-C 109.02 -0.733 . . . . 61.41 109.02 168.604 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.462 ' CE2' HD13 ' A' ' 193' ' ' LEU . 5.6 m-85 -100.66 122.54 43.49 Favored 'General case' 0 C--O 1.238 0.454 0 C-N-CA 123.585 0.754 . . . . 72.42 110.699 -177.388 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 12.0 mtp180 -99.75 108.72 21.11 Favored 'General case' 0 C--O 1.237 0.441 0 C-N-CA 124.612 1.165 . . . . 72.41 108.624 170.844 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.431 ' O ' ' HD2' ' A' ' 154' ' ' ARG . 60.2 tp -84.54 110.67 18.87 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.932 -0.766 . . . . 73.35 108.932 170.725 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 24.0 mm-40 -104.11 97.05 7.07 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 107.325 -1.361 . . . . 62.22 107.325 172.334 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 67.64 -89.06 0.18 Allowed Glycine 0 CA--C 1.531 1.044 0 O-C-N 123.757 0.66 . . . . 71.5 112.807 -175.691 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 191' ' ' GLN . . . . . 0.405 HE22 ' HB3' ' A' ' 244' ' ' ALA . 50.3 tt0 -120.74 -18.12 7.78 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 125.103 1.361 . . . . 73.03 109.779 -176.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.422 ' O ' HD12 ' A' ' 188' ' ' LEU . 44.5 m-20 -96.07 160.04 14.65 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.382 1.073 . . . . 74.55 111.383 -173.529 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.585 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 96.3 mt -119.21 154.97 32.54 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.202 1.001 . . . . 63.43 112.298 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 74.0 m-85 -139.0 120.72 15.28 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 106.248 -1.76 . . . . 73.44 106.248 170.2 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 195' ' ' ALA . . . . . 0.465 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -141.7 140.06 33.07 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 108.178 -1.045 . . . . 64.43 108.178 176.667 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 19.1 m -77.15 129.98 36.71 Favored 'General case' 0 CA--C 1.539 0.548 0 O-C-N 123.347 0.405 . . . . 65.15 110.323 -175.682 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.422 HD13 ' HB2' ' A' ' 212' ' ' ALA . 51.2 tp -114.42 111.79 21.99 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 123.951 0.9 . . . . 73.12 108.785 176.694 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -101.64 107.73 19.06 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.127 -0.694 . . . . 72.12 109.127 178.258 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 199' ' ' VAL . . . . . 0.521 HG11 HG11 ' A' ' 223' ' ' VAL . 5.9 m -108.52 145.69 32.1 Favored Pre-proline 0 N--CA 1.478 0.963 0 C-N-CA 123.755 0.822 . . . . 43.12 109.472 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -70.83 149.67 60.45 Favored 'Trans proline' 0 C--N 1.366 1.481 0 C-N-CA 121.699 1.599 . . . . 73.03 110.664 173.603 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 201' ' ' ALA . . . . . 0.422 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -56.11 -43.53 99.29 Favored Pre-proline 0 CA--C 1.561 1.389 0 CA-C-O 118.374 -0.822 . . . . 71.32 113.112 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -46.21 -51.51 8.52 Favored 'Trans proline' 0 C--N 1.394 2.952 0 C-N-CA 122.921 2.414 . . . . 73.42 114.274 169.631 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 5.7 mt -69.15 -38.57 78.21 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 C-N-CA 122.335 0.254 . . . . 74.14 111.117 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.18 -41.55 88.75 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.239 0.616 . . . . 73.0 112.234 -179.193 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 205' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 33.1 m -82.84 -38.64 15.0 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 CA-C-N 115.891 -0.595 . . . . 71.12 111.53 -174.665 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.6 m -77.0 -24.79 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 CA-C-O 120.82 0.343 . . . . 73.3 110.849 177.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 76.68 52.84 5.71 Favored Glycine 0 C--N 1.346 1.112 0 CA-C-N 115.376 -0.829 . . . . 70.22 112.366 -175.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.42 -160.35 27.51 Favored Glycine 0 C--N 1.359 1.817 0 N-CA-C 112.123 -0.391 . . . . 54.31 112.123 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 21.2 ptmt -119.91 142.9 48.28 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 123.023 0.529 . . . . 72.34 109.727 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 210' ' ' VAL . . . . . 0.403 HG21 HG12 ' A' ' 199' ' ' VAL . 75.6 t -128.7 135.11 63.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 C-N-CA 124.351 1.06 . . . . 71.32 108.631 177.849 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 211' ' ' ARG . . . . . 0.607 ' HG2' ' HG2' ' A' ' 220' ' ' GLU . 99.3 mtt180 -77.95 112.56 14.97 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 109.198 -0.668 . . . . 75.55 109.198 171.904 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.422 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -99.14 129.27 45.38 Favored 'General case' 0 C--O 1.242 0.686 0 N-CA-C 108.436 -0.949 . . . . 64.4 108.436 175.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 213' ' ' MET . . . . . 0.413 ' SD ' ' N ' ' A' ' 214' ' ' THR . 1.3 tpp -69.72 130.29 41.93 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.837 -0.62 . . . . 63.03 109.79 175.054 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.497 HG21 HG13 ' A' ' 219' ' ' VAL . 7.7 t -134.07 163.67 29.06 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.507 1.123 . . . . 75.43 110.142 173.719 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 79.4 mt -71.68 -8.87 56.79 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 124.004 0.922 . . . . 72.35 113.183 -172.486 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 216' ' ' GLU . . . . . 0.415 ' HB3' ' CZ ' ' A' ' 131' ' ' PHE . 10.3 pt-20 -97.39 -18.34 19.16 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.433 0.693 . . . . 71.11 111.767 173.755 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.74 -146.36 15.74 Favored Glycine 0 C--N 1.349 1.253 0 CA-C-O 119.556 -0.58 . . . . 53.4 112.181 -176.283 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -91.17 131.15 1.42 Allowed 'Trans proline' 0 CA--C 1.559 1.736 0 C-N-CA 122.796 2.331 . . . . 72.3 112.777 170.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 219' ' ' VAL . . . . . 0.497 HG13 HG21 ' A' ' 214' ' ' THR . 20.5 m -110.13 147.25 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 108.996 -0.742 . . . . 72.44 108.996 163.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 220' ' ' GLU . . . . . 0.607 ' HG2' ' HG2' ' A' ' 211' ' ' ARG . 42.8 mt-10 -114.37 104.33 11.96 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 108.781 -0.822 . . . . 73.12 108.781 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.42 HG23 HD21 ' A' ' 235' ' ' LEU . 2.8 p -95.68 120.25 44.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 124.033 0.933 . . . . 74.44 110.373 -177.804 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.12 103.57 12.65 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 107.689 -1.226 . . . . 42.22 107.689 173.673 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.521 HG11 HG11 ' A' ' 199' ' ' VAL . 14.6 m -65.96 143.89 98.61 Favored Pre-proline 0 CA--C 1.553 1.059 0 C-N-CA 123.229 0.612 . . . . 74.13 110.168 -179.014 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -55.58 138.79 81.71 Favored 'Trans proline' 0 C--N 1.376 1.994 0 C-N-CA 122.625 2.216 . . . . 52.41 112.209 176.222 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.11 122.34 11.42 Favored 'Trans proline' 0 C--N 1.369 1.624 0 C-N-CA 122.181 1.921 . . . . 63.1 110.129 172.526 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 226' ' ' ARG . . . . . 0.479 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 96.0 mtt180 63.39 41.25 7.77 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 124.418 1.074 . . . . 71.23 110.996 -175.591 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.4 t -65.15 168.89 6.13 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 122.858 0.463 . . . . 51.23 111.009 177.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 228' ' ' GLN . . . . . 0.466 ' H ' ' HD3' ' A' ' 231' ' ' ARG . 26.2 mp0 -118.09 146.72 43.92 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 123.889 0.876 . . . . 74.41 109.165 -176.15 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -75.02 135.91 41.25 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.745 -0.835 . . . . 41.32 108.745 173.295 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 106.11 -7.91 41.36 Favored Glycine 0 C--N 1.34 0.762 0 N-CA-C 112.153 -0.379 . . . . 75.34 112.153 -175.237 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 231' ' ' ARG . . . . . 0.466 ' HD3' ' H ' ' A' ' 228' ' ' GLN . 62.0 mtp180 -79.92 160.99 25.79 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.284 0.634 . . . . 75.12 111.079 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.464 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 10.5 mptt -119.05 112.91 20.15 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 124.065 0.946 . . . . 62.44 108.503 176.824 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 233' ' ' LEU . . . . . 0.497 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 39.6 mt -89.69 110.08 21.0 Favored 'General case' 0 C--N 1.358 0.958 0 N-CA-C 108.868 -0.79 . . . . 72.35 108.868 -178.39 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 234' ' ' ARG . . . . . 0.407 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 41.4 ttp180 -83.81 102.51 12.38 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 114.923 -1.035 . . . . 64.52 111.046 -169.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.42 HD21 HG23 ' A' ' 221' ' ' VAL . 26.5 mt -95.74 98.01 10.13 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 108.513 -0.921 . . . . 74.31 108.513 174.171 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 236' ' ' LYS . . . . . 0.436 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 26.7 mtpp -80.79 143.87 32.53 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.96 0.41 . . . . 71.14 111.316 -174.403 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 75.94 24.12 70.21 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.148 -0.933 . . . . 74.24 111.809 -174.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 48.4 mmtm -128.94 10.25 5.91 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.366 1.066 . . . . 74.2 110.442 177.537 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -84.67 -158.21 28.34 Favored Glycine 0 C--N 1.359 1.838 0 O-C-N 123.13 0.269 . . . . 44.14 113.052 175.623 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.543 ' CD1' HD21 ' A' ' 193' ' ' LEU . 10.5 m-85 -98.02 166.14 14.02 Favored Pre-proline 0 N--CA 1.48 1.044 0 C-N-CA 123.131 0.573 . . . . 63.51 110.565 172.301 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -61.01 160.45 25.82 Favored 'Trans proline' 0 C--N 1.384 2.409 0 C-N-CA 122.829 2.353 . . . . 71.35 112.113 172.201 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 175.76 -171.21 44.29 Favored Glycine 0 CA--C 1.527 0.791 0 CA-C-N 116.147 -0.479 . . . . 73.32 113.515 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -57.31 -38.73 93.92 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.975 3.116 . . . . 60.05 113.29 -179.155 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 244' ' ' ALA . . . . . 0.405 ' HB3' HE22 ' A' ' 191' ' ' GLN . . . -92.33 21.84 4.94 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 123.389 0.676 . . . . 71.32 111.937 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 91.66 -102.66 2.95 Favored Glycine 0 C--N 1.347 1.194 0 N-CA-C 111.746 -0.541 . . . . 45.41 111.746 178.157 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 51.6 ttt180 -121.52 140.02 52.74 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 122.933 0.493 . . . . 73.12 109.675 174.751 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -81.06 -157.2 16.4 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 124.014 0.821 . . . . 71.33 113.076 -179.039 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 248' ' ' ASP . . . . . 0.436 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 3.5 p30 -146.62 154.25 41.27 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 123.032 0.533 . . . . 71.41 110.722 -174.604 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.585 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 26.2 tp -98.58 128.27 44.83 Favored 'General case' 0 C--O 1.22 -0.468 0 C-N-CA 124.338 1.055 . . . . 62.5 110.384 -174.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 250' ' ' TYR . . . . . 0.464 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 63.1 m-85 -102.63 107.43 18.34 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 123.57 0.748 . . . . 73.22 109.505 173.768 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.497 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 77.2 mt -87.07 111.11 20.58 Favored 'General case' 0 C--O 1.233 0.233 0 C-N-CA 123.701 0.8 . . . . 74.34 112.52 178.786 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.41 ' HG2' ' HE3' ' A' ' 232' ' ' LYS . 1.6 tm-20 -80.42 90.37 5.63 Favored 'General case' 0 CA--C 1.552 1.025 0 N-CA-C 108.457 -0.942 . . . . 73.54 108.457 -176.546 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.407 ' O ' ' HD2' ' A' ' 254' ' ' ARG . 46.0 t -53.29 128.34 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 125.991 1.716 . . . . 74.15 112.882 -177.843 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 254' ' ' ARG . . . . . 0.407 ' HD2' ' O ' ' A' ' 253' ' ' VAL . 23.5 mmm180 -126.8 98.57 5.41 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 107.255 -1.387 . . . . 74.22 107.255 173.826 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.422 HG23 ' HA ' ' A' ' 201' ' ' ALA . 63.6 mt -76.53 102.43 3.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 108.861 -0.792 . . . . 74.12 108.861 177.161 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 8.9 t . . . . . 0 C--O 1.253 1.263 0 C-N-CA 124.357 1.063 . . . . 55.31 110.173 -171.424 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.605 HD21 ' HG3' ' A' ' 136' ' ' ARG . 0.2 OUTLIER . . . . . 0 N--CA 1.482 1.164 0 CA-C-O 119.653 -0.213 . . . . 71.44 110.913 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.646 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 43.9 t -58.04 119.82 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 C-N-CA 122.988 0.515 . . . . 42.13 111.238 177.576 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -67.22 -71.4 0.2 Allowed 'General case' 0 C--O 1.238 0.485 0 O-C-N 124.275 0.984 . . . . 72.2 109.31 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.0 m80 -168.0 176.12 6.33 Favored 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 124.665 1.186 . . . . 72.33 109.757 -178.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 99.5 t -61.38 136.51 24.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.025 0 C-N-CA 124.094 0.958 . . . . 73.22 110.47 171.773 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 42.6 p . . . . . 0 CA--C 1.551 0.992 0 N-CA-C 109.122 -0.696 . . . . 75.1 109.122 170.231 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 . . . . . 0 N--CA 1.47 0.54 0 N-CA-C 108.686 -0.857 . . . . 53.43 108.686 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.491 HD21 ' HB ' ' A' ' 140' ' ' VAL . 44.5 tp -128.79 134.98 48.56 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 107.759 -1.2 . . . . 72.33 107.759 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' ARG . . . . . 0.425 ' HD3' ' HB2' ' A' ' 175' ' ' LEU . 9.8 mmt85 -115.43 134.97 54.59 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 109.438 -0.579 . . . . 73.41 109.438 -178.017 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -150.6 154.54 37.7 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 123.329 0.652 . . . . 72.31 109.38 173.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -119.78 151.35 38.94 Favored 'General case' 0 C--O 1.245 0.851 0 C-N-CA 123.134 0.574 . . . . 72.42 110.169 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.646 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.4 pt? -144.95 143.13 19.72 Favored Pre-proline 0 N--CA 1.471 0.59 0 CA-C-N 115.424 -0.807 . . . . 74.13 111.286 -178.388 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.43 113.95 3.87 Favored 'Trans proline' 0 C--N 1.37 1.68 0 C-N-CA 121.377 1.384 . . . . 55.55 109.119 160.052 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.518 HD22 HG11 ' A' ' 178' ' ' VAL . 20.0 tp -104.97 148.44 26.72 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 108.463 -0.94 . . . . 74.13 108.463 178.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.678 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 4.1 m -82.15 157.54 23.99 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 109.919 -0.401 . . . . 63.21 109.919 175.274 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.456 HD23 ' HB3' ' A' ' 180' ' ' LEU . 77.5 mt -59.16 -48.68 80.72 Favored 'General case' 0 N--CA 1.482 1.145 0 CA-C-O 122.342 1.068 . . . . 64.32 109.529 172.331 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.53 -34.46 64.7 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 113.621 -1.627 . . . . 74.41 111.963 174.693 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.459 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 17.0 mm-40 -85.63 -17.69 35.39 Favored 'General case' 0 N--CA 1.481 1.083 0 C-N-CA 123.398 0.679 . . . . 71.45 112.416 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.728 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -58.23 -43.41 87.75 Favored 'General case' 0 C--O 1.249 1.05 0 CA-C-O 121.382 0.611 . . . . 61.21 109.697 163.155 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -71.32 -60.31 2.3 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 114.842 -1.072 . . . . 74.14 111.62 174.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -69.05 -47.16 66.04 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 123.588 0.755 . . . . 71.43 112.252 -169.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 71.76 -86.25 0.45 Allowed Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.816 -0.914 . . . . 74.23 110.816 -170.75 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.0 -179.57 51.3 Favored Glycine 0 C--N 1.345 1.08 0 N-CA-C 114.528 0.571 . . . . 70.34 114.528 174.244 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 14.8 mp0 -98.61 115.27 28.27 Favored 'General case' 0 N--CA 1.471 0.584 0 N-CA-C 107.301 -1.37 . . . . 71.2 107.301 175.904 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.605 ' HG3' HD21 ' A' ' 98' ' ' LEU . 39.3 mmt-85 -132.15 138.51 48.07 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.711 1.204 . . . . 71.35 108.287 -173.278 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.409 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 27.8 m -73.61 123.01 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 121.343 0.592 . . . . 52.11 111.295 -176.8 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 13.4 p -105.43 141.36 20.94 Favored 'Isoleucine or valine' 0 C--O 1.252 1.23 0 C-N-CA 125.092 1.357 . . . . 73.34 110.195 178.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 13.2 tp10 -120.29 103.36 9.17 Favored 'General case' 0 C--O 1.243 0.75 0 C-N-CA 124.033 0.933 . . . . 74.02 109.001 174.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.51 HG21 HD22 ' A' ' 174' ' ' LEU . 2.9 m -143.87 123.56 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 123.939 0.896 . . . . 70.2 110.693 -173.189 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.03 19.9 11.95 Favored 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 124.322 1.049 . . . . 62.0 112.137 173.2 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 83.62 17.5 65.93 Favored Glycine 0 C--N 1.347 1.161 0 CA-C-N 116.366 -0.379 . . . . 73.01 112.345 -177.367 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.2 mmm180 -108.12 118.17 36.04 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 108.317 -0.994 . . . . 71.31 108.317 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 49.9 ttt180 -94.94 108.2 20.25 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 108.406 -0.961 . . . . 64.34 108.406 173.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 72.2 t -135.82 146.74 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 108.674 -0.861 . . . . 54.22 108.674 -178.548 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 67.0 p -90.17 107.63 19.25 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.563 -1.273 . . . . 73.1 107.563 167.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.9 p -97.68 140.92 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-O 121.322 0.582 . . . . 73.44 111.012 -172.513 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 14.4 ttp180 -104.13 103.39 13.17 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 107.741 -1.207 . . . . 75.11 107.741 177.241 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.44 ' HB ' HD13 ' A' ' 159' ' ' ILE . 36.5 pt -92.1 112.78 56.67 Favored Pre-proline 0 CA--C 1.555 1.137 0 N-CA-C 109.553 -0.536 . . . . 74.24 109.553 179.067 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.526 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 96.2 Cg_exo -47.82 131.01 20.1 Favored 'Trans proline' 0 C--N 1.39 2.727 0 C-N-CA 123.947 3.098 . . . . 70.14 114.676 -173.825 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.526 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 23.2 Cg_exo -67.19 135.52 37.44 Favored 'Trans proline' 0 C--N 1.379 2.162 0 C-N-CA 123.472 2.781 . . . . 71.34 112.269 -177.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.652 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 120.51 41.88 0.52 Allowed Glycine 0 C--N 1.349 1.272 0 N-CA-C 111.908 -0.477 . . . . 54.32 111.908 -175.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.728 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.6 p -115.33 162.89 13.08 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.533 0 C-N-CA 123.915 0.886 . . . . 63.11 109.76 -173.17 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 43.9 mtp180 -143.26 168.99 18.49 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 125.228 1.411 . . . . 65.41 110.09 -170.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -54.94 120.59 7.1 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.759 0.824 . . . . 75.2 111.022 170.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.87 3.65 90.39 Favored Glycine 0 C--N 1.349 1.288 0 O-C-N 123.647 0.592 . . . . 70.54 113.903 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 40.3 t -81.99 131.89 35.25 Favored 'General case' 0 C--O 1.248 0.983 0 N-CA-C 109.303 -0.628 . . . . 60.44 109.303 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 9.0 p -97.42 135.74 30.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.986 0 CA-C-N 115.103 -0.953 . . . . 71.13 109.24 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.486 HD11 HG21 ' A' ' 153' ' ' VAL . 28.1 mt -112.61 123.07 67.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 123.9 0.88 . . . . 74.02 110.707 -175.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.426 HH21 HD11 ' A' ' 175' ' ' LEU . 35.3 ttm180 -92.53 118.84 31.4 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 117.924 0.329 . . . . 72.23 110.26 174.504 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.465 HG22 ' HB3' ' A' ' 174' ' ' LEU . 4.5 m -113.0 125.65 29.47 Favored Pre-proline 0 CA--C 1.551 1.0 0 N-CA-C 108.004 -1.109 . . . . 75.23 108.004 171.789 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -79.26 148.72 21.46 Favored 'Trans proline' 0 C--N 1.367 1.532 0 C-N-CA 122.132 1.888 . . . . 63.3 113.081 -174.185 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 74.37 23.24 76.13 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 115.141 0.816 . . . . 73.25 115.141 173.057 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 50.7 tpp -102.91 -45.92 4.83 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 117.811 0.806 . . . . 70.44 110.7 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.349 1.299 0 CA-C-N 116.093 -0.503 . . . . 74.33 112.52 -177.85 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo . . . . . 0 CA--C 1.541 0.837 0 N-CA-C 111.015 -0.417 . . . . 62.41 111.015 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -108.68 168.29 13.47 Favored Glycine 0 N--CA 1.462 0.369 0 N-CA-C 111.185 -0.766 . . . . 54.44 111.185 175.662 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -118.92 169.88 9.5 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 123.61 0.764 . . . . 63.43 111.656 -165.557 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.51 HD22 HG21 ' A' ' 140' ' ' VAL . 37.0 tp -124.62 116.47 22.46 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-N 114.608 -1.178 . . . . 62.42 108.234 169.52 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.426 HD11 HH21 ' A' ' 160' ' ' ARG . 41.3 mt -92.19 100.93 13.45 Favored 'General case' 0 C--O 1.243 0.76 0 CA-C-N 114.248 -1.342 . . . . 62.41 109.868 175.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 85.2 mt -90.85 107.39 19.16 Favored 'General case' 0 CA--C 1.538 0.494 0 CA-C-N 114.462 -1.245 . . . . 74.33 111.177 178.454 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 34.9 t -86.67 106.11 15.51 Favored 'Isoleucine or valine' 0 C--O 1.249 1.05 0 N-CA-C 108.459 -0.941 . . . . 71.32 108.459 175.466 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.518 HG11 HD22 ' A' ' 125' ' ' LEU . 19.0 m -81.57 149.77 4.77 Favored 'Isoleucine or valine' 0 C--O 1.24 0.6 0 CA-C-O 121.811 0.815 . . . . 72.42 112.203 -179.268 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 25.0 mmm-85 -123.75 105.66 9.86 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 107.38 -1.341 . . . . 64.32 107.38 174.607 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.456 ' HB3' HD23 ' A' ' 127' ' ' LEU . 30.2 mt -67.73 142.66 56.21 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 118.191 0.45 . . . . 74.42 111.186 -178.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.678 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 41.3 mt -55.22 142.35 58.61 Favored Pre-proline 0 CA--C 1.555 1.153 0 O-C-N 124.029 0.831 . . . . 62.42 111.791 -175.051 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.31 63.98 7.86 Favored 'Trans proline' 0 C--N 1.378 2.105 0 C-N-CA 123.389 2.726 . . . . 64.54 113.113 -177.711 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 3.7 p80 -149.61 50.18 0.75 Allowed Pre-proline 0 CA--C 1.564 1.5 0 C-N-CA 124.043 0.937 . . . . 63.0 108.84 169.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -62.63 122.97 11.52 Favored 'Trans proline' 0 C--N 1.385 2.459 0 C-N-CA 121.814 1.676 . . . . 75.42 111.808 -166.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.3 p -122.54 -42.57 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 N-CA-C 107.894 -1.15 . . . . 71.45 107.894 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -101.1 123.45 45.27 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.765 -1.107 . . . . 71.52 109.09 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 91.5 mtm180 -119.0 119.71 35.09 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.606 1.162 . . . . 71.45 108.085 -179.367 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 66.1 tp -105.0 139.02 40.31 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.848 0.859 . . . . 72.43 110.936 -174.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 -134.53 108.03 7.86 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 124.415 1.086 . . . . 72.55 108.104 164.317 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 73.16 -82.48 0.65 Allowed Glycine 0 C--N 1.35 1.332 0 O-C-N 123.529 0.518 . . . . 64.14 112.914 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -134.84 -15.64 2.03 Favored 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 123.772 0.829 . . . . 72.21 110.748 177.183 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 52.9 m-20 -91.0 143.78 26.35 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.345 0.658 . . . . 62.35 112.396 -174.57 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.57 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 87.3 mt -112.7 161.21 17.12 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 125.112 1.365 . . . . 71.03 111.215 -174.472 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -141.0 121.83 14.41 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 107.325 -1.361 . . . . 73.53 107.325 174.6 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 195' ' ' ALA . . . . . 0.455 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -148.96 136.23 20.12 Favored 'General case' 0 N--CA 1.468 0.453 0 N-CA-C 108.891 -0.781 . . . . 65.42 108.891 -178.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 196' ' ' THR . . . . . 0.541 ' HA ' ' HB2' ' A' ' 252' ' ' GLU . 12.1 m -81.28 123.14 28.25 Favored 'General case' 0 CA--C 1.542 0.665 0 O-C-N 123.478 0.486 . . . . 70.13 110.616 -175.678 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.508 HD22 HD13 ' A' ' 251' ' ' LEU . 48.2 tp -108.71 113.28 26.11 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.825 0.85 . . . . 73.31 109.484 -179.699 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -87.23 113.11 22.68 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 108.43 -0.952 . . . . 65.25 108.43 172.097 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 4.2 p -118.37 124.9 28.22 Favored Pre-proline 0 CA--C 1.551 1.005 0 C-N-CA 124.035 0.934 . . . . 71.21 109.347 178.51 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -61.73 146.27 96.79 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 122.507 2.138 . . . . 74.33 112.287 175.558 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 201' ' ' ALA . . . . . 0.407 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -54.55 -42.98 97.49 Favored Pre-proline 0 CA--C 1.56 1.338 0 CA-C-O 117.346 -1.311 . . . . 64.34 113.965 -176.811 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 202' ' ' PRO . . . . . 0.407 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 7.1 Cg_endo -48.84 -47.6 20.68 Favored 'Trans proline' 0 C--N 1.402 3.344 0 C-N-CA 122.647 2.231 . . . . 65.3 112.821 172.189 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 15.7 mt -70.01 -38.15 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 122.725 0.41 . . . . 71.34 110.843 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.2 -41.47 98.39 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 123.307 0.643 . . . . 72.31 111.778 -177.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.7 m -80.21 -40.07 19.75 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 CA-C-N 116.108 -0.496 . . . . 65.33 111.715 -176.357 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.0 m -79.88 -24.02 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 CA-C-N 117.842 0.292 . . . . 74.42 111.194 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.504 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 73.22 61.38 3.46 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.855 -0.611 . . . . 72.33 112.317 -174.477 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.55 -142.22 9.77 Favored Glycine 0 C--N 1.356 1.672 0 N-CA-C 111.799 -0.52 . . . . 71.03 111.799 -178.862 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -131.36 144.78 51.48 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 123.812 0.845 . . . . 74.04 110.216 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 11.8 m -134.35 169.77 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.508 1.123 . . . . 75.11 109.171 175.53 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 211' ' ' ARG . . . . . 0.517 ' HD3' ' H ' ' A' ' 211' ' ' ARG . 0.0 OUTLIER -104.03 133.7 48.54 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.536 -0.756 . . . . 72.45 109.079 176.163 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -117.81 114.87 23.91 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 108.597 -0.89 . . . . 72.11 108.597 172.766 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 3.9 tpt -70.56 105.13 3.0 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.966 -0.561 . . . . 55.43 109.687 177.311 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 5.8 t -115.69 169.37 9.25 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.486 0.714 . . . . 74.3 111.255 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 46.4 mt -75.4 -3.06 31.5 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.254 1.022 . . . . 73.33 112.535 -170.399 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -106.1 -6.27 18.77 Favored 'General case' 0 N--CA 1.484 1.234 0 C-N-CA 124.029 0.931 . . . . 74.24 111.566 175.218 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 116.62 155.99 10.54 Favored Glycine 0 C--N 1.348 1.214 0 CA-C-O 118.583 -1.12 . . . . 60.22 111.634 -175.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -59.76 126.91 21.79 Favored 'Trans proline' 0 C--N 1.379 2.184 0 C-N-CA 123.096 2.531 . . . . 61.23 113.078 -168.591 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 35.1 m -108.47 166.49 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 C-N-CA 123.296 0.639 . . . . 71.23 110.184 -179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -113.22 113.26 25.08 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 108.11 -1.07 . . . . 72.13 108.11 -177.027 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.504 HG22 HD11 ' A' ' 235' ' ' LEU . 5.2 t -95.92 115.99 36.53 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-N 115.664 -0.698 . . . . 61.42 109.303 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -85.61 101.25 12.55 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.585 -1.265 . . . . 74.12 107.585 170.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.504 HG23 ' HA2' ' A' ' 207' ' ' GLY . 9.0 m -74.71 146.56 83.38 Favored Pre-proline 0 CA--C 1.559 1.323 0 N-CA-C 109.509 -0.552 . . . . 53.41 109.509 -176.131 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -60.79 136.18 64.72 Favored 'Trans proline' 0 C--N 1.376 2.021 0 C-N-CA 122.769 2.312 . . . . 71.44 112.027 177.813 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_exo -54.88 122.57 11.89 Favored 'Trans proline' 0 C--N 1.377 2.037 0 C-N-CA 122.244 1.963 . . . . 63.51 110.572 169.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 68.6 mtm180 62.57 49.99 3.74 Favored 'General case' 0 CA--C 1.551 1.002 0 O-C-N 124.333 1.021 . . . . 74.44 110.576 -177.348 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.5 t -72.87 170.21 15.19 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.007 0.523 . . . . 51.43 110.52 177.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 228' ' ' GLN . . . . . 0.633 ' H ' ' HD2' ' A' ' 231' ' ' ARG . 28.1 mp0 -121.35 147.05 46.21 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.269 0.628 . . . . 71.5 109.987 -178.424 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -76.34 123.3 25.74 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.209 1.004 . . . . 44.33 109.483 175.739 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 113.91 -10.65 22.98 Favored Glycine 0 N--CA 1.472 1.085 0 N-CA-C 111.924 -0.47 . . . . 55.01 111.924 -171.704 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 231' ' ' ARG . . . . . 0.633 ' HD2' ' H ' ' A' ' 228' ' ' GLN . 20.9 mtt180 -69.98 161.61 29.7 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.516 0.726 . . . . 64.23 111.402 173.042 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.431 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.3 mptp? -119.99 111.3 17.74 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 107.825 -1.176 . . . . 73.22 107.825 176.52 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 233' ' ' LEU . . . . . 0.554 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 60.0 mt -85.63 107.51 17.57 Favored 'General case' 0 C--N 1.356 0.868 0 N-CA-C 108.613 -0.884 . . . . 73.34 108.613 -178.349 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 38.4 ttm180 -84.4 105.92 15.6 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.248 -0.887 . . . . 70.22 109.993 -171.46 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.581 ' HB3' ' HG3' ' A' ' 238' ' ' LYS . 58.2 mt -98.07 99.13 10.37 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 108.652 -0.87 . . . . 74.14 108.652 172.586 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -75.88 144.64 41.05 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 122.489 0.316 . . . . 64.12 111.159 -177.374 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 72.92 28.13 67.43 Favored Glycine 0 C--N 1.353 1.481 0 O-C-N 123.755 0.659 . . . . 64.31 113.042 -175.67 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 238' ' ' LYS . . . . . 0.581 ' HG3' ' HB3' ' A' ' 235' ' ' LEU . 4.1 mmtm -119.8 -10.59 9.5 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 124.138 0.975 . . . . 71.52 111.512 -178.304 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 239' ' ' GLY . . . . . 0.425 ' O ' ' HD2' ' A' ' 246' ' ' ARG . . . -81.93 -154.01 12.51 Favored Glycine 0 C--N 1.339 0.719 0 O-C-N 123.414 0.446 . . . . 63.35 113.279 -179.156 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.652 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 6.1 m-85 -94.68 158.69 34.93 Favored Pre-proline 0 CA--C 1.548 0.867 0 C-N-CA 123.576 0.75 . . . . 75.5 109.811 177.033 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.66 129.32 26.64 Favored 'Trans proline' 0 C--N 1.387 2.556 0 C-N-CA 123.361 2.707 . . . . 75.55 113.482 -178.505 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -158.18 -169.09 21.34 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.626 -0.716 . . . . 44.52 112.278 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.35 -17.99 59.3 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 123.133 2.555 . . . . 65.54 113.414 -177.235 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -98.42 21.23 11.4 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 123.868 0.867 . . . . 65.4 111.233 178.441 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 88.74 -82.97 1.48 Allowed Glycine 0 C--N 1.347 1.176 0 N-CA-C 110.122 -1.191 . . . . 43.1 110.122 -174.391 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.425 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 22.5 mtm180 -127.09 158.77 36.12 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 107.324 -1.362 . . . . 71.43 107.324 165.218 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.08 -156.96 4.76 Favored Glycine 0 C--N 1.344 1.002 0 O-C-N 123.483 0.489 . . . . 64.41 114.142 -174.429 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 35.0 m-20 -117.8 151.15 37.9 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 108.871 -0.788 . . . . 72.44 108.871 -176.009 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.57 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 18.3 tp -105.19 114.57 28.83 Favored 'General case' 0 CA--C 1.531 0.233 0 N-CA-C 108.71 -0.848 . . . . 73.04 108.71 171.563 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -96.18 106.86 19.11 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 123.109 0.564 . . . . 74.41 109.984 175.819 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.554 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 73.4 mt -88.0 120.96 29.85 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 124.162 0.985 . . . . 52.51 112.789 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.541 ' HB2' ' HA ' ' A' ' 196' ' ' THR . 26.0 mt-10 -79.11 91.3 4.9 Favored 'General case' 0 C--O 1.24 0.574 0 C-N-CA 123.774 0.83 . . . . 74.25 109.279 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 48.0 t -52.37 114.81 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.655 1.182 . . . . 64.54 112.108 178.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 49.7 mmm-85 -117.09 93.68 4.28 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 106.933 -1.506 . . . . 62.35 106.933 173.391 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 72.2 mt -74.55 110.73 9.33 Favored 'Isoleucine or valine' 0 C--N 1.343 0.31 0 N-CA-C 108.274 -1.01 . . . . 60.11 108.274 177.259 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 4.5 t . . . . . 0 CA--C 1.557 1.226 0 C-N-CA 123.982 0.913 . . . . 74.31 109.539 -177.205 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.451 ' HB2' ' HB3' ' A' ' 136' ' ' ARG . 1.2 tm? . . . . . 0 C--O 1.24 0.578 0 N-CA-C 106.685 -1.598 . . . . 62.03 106.685 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.413 ' O ' ' HB3' ' A' ' 123' ' ' LEU . 86.0 t -68.3 134.82 29.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 N-CA-C 108.84 -0.8 . . . . 74.34 108.84 177.334 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -150.25 56.45 0.94 Allowed 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 107.999 -1.111 . . . . 64.21 107.999 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -65.7 109.4 2.41 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-N 113.995 -1.457 . . . . 71.33 108.659 176.623 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 39.8 t -59.55 121.77 8.05 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.765 0 O-C-N 124.287 0.992 . . . . 73.43 109.384 -178.416 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.9 t . . . . . 0 N--CA 1.471 0.579 0 C-N-CA 123.896 0.878 . . . . 74.3 109.487 -173.391 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 . . . . . 0 N--CA 1.472 0.673 0 N-CA-C 108.472 -0.936 . . . . 62.01 108.472 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.05 144.48 26.28 Favored 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 107.015 -1.476 . . . . 73.1 107.015 178.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -130.59 129.36 42.67 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 108.108 -1.071 . . . . 73.01 108.108 176.277 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -150.79 150.23 30.72 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-N 115.75 -0.659 . . . . 62.42 109.571 -179.703 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -120.24 148.0 44.24 Favored 'General case' 0 C--O 1.245 0.84 0 N-CA-C 109.11 -0.7 . . . . 74.13 109.11 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.413 ' HB3' ' O ' ' A' ' 99' ' ' VAL . 1.3 pt? -145.32 147.58 34.44 Favored Pre-proline 0 N--CA 1.467 0.404 0 C-N-CA 122.8 0.44 . . . . 52.22 111.76 179.568 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -78.04 114.21 3.55 Favored 'Trans proline' 0 C--N 1.366 1.448 0 C-N-CA 121.751 1.634 . . . . 72.12 109.935 159.096 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.475 HD22 HG11 ' A' ' 178' ' ' VAL . 34.7 tp -106.75 157.24 17.88 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 108.791 -0.818 . . . . 72.1 108.791 177.517 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.693 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 14.4 m -89.36 151.69 21.93 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 122.99 0.516 . . . . 75.04 110.344 177.519 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.583 HD23 ' HB3' ' A' ' 180' ' ' LEU . 68.9 mt -58.1 -50.57 73.01 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.725 0.81 . . . . 52.33 109.389 174.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -53.78 -39.07 65.11 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 113.95 -1.477 . . . . 72.42 111.673 178.11 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.518 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 28.4 mm-40 -86.06 -18.07 33.45 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 122.999 0.52 . . . . 73.23 111.269 -176.484 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.653 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -64.41 -36.93 85.77 Favored 'General case' 0 C--O 1.242 0.673 0 C-N-CA 123.447 0.699 . . . . 70.01 109.886 167.353 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.458 ' HA ' ' HE1' ' A' ' 240' ' ' PHE . 27.6 t80 -71.94 -55.92 6.61 Favored 'General case' 0 CA--C 1.551 0.982 0 CA-C-N 114.999 -1.001 . . . . 61.12 110.574 172.053 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -67.97 -44.89 75.65 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 112.24 0.459 . . . . 72.12 112.24 -171.164 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.81 -111.62 4.27 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 111.275 -0.73 . . . . 70.23 111.275 -173.511 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.41 -175.87 54.54 Favored Glycine 0 C--N 1.347 1.163 0 N-CA-C 114.232 0.453 . . . . 44.22 114.232 171.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.425 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 2.0 mp0 -87.4 143.96 26.98 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 109.283 -0.636 . . . . 62.33 109.283 178.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.451 ' HB3' ' HB2' ' A' ' 98' ' ' LEU . 0.6 OUTLIER -156.79 147.84 21.98 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 109.546 -0.539 . . . . 74.22 109.546 -178.268 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 32.1 m -82.14 125.38 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 CA-C-O 121.51 0.671 . . . . 73.12 111.206 -174.722 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 41.1 t -120.7 144.77 28.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 125.035 1.334 . . . . 73.3 109.442 -176.643 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -126.15 97.79 5.22 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.041 0.536 . . . . 62.12 109.584 169.283 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.0 m -107.54 132.62 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 N-CA-C 108.922 -0.77 . . . . 73.22 108.922 173.801 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.46 23.02 13.35 Favored 'General case' 0 CA--C 1.554 1.118 0 C-N-CA 123.964 0.905 . . . . 64.23 111.694 -176.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.23 0.07 88.67 Favored Glycine 0 C--N 1.357 1.703 0 CA-C-N 116.038 -0.528 . . . . 44.21 113.468 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -103.34 123.27 46.48 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.696 0.798 . . . . 61.12 110.036 -175.443 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.2 ttp-105 -88.2 105.93 17.86 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.344 0.658 . . . . 71.2 110.797 -174.394 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 38.5 t -124.42 134.41 66.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.351 1.061 . . . . 53.43 108.828 178.021 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 37.2 m -83.81 120.9 26.61 Favored 'General case' 0 CA--C 1.546 0.803 0 N-CA-C 109.682 -0.488 . . . . 73.3 109.682 176.02 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 8.1 p -99.77 148.73 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 123.317 0.647 . . . . 73.42 110.687 -178.387 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.3 ttt85 -110.02 96.39 6.2 Favored 'General case' 0 C--O 1.237 0.43 0 N-CA-C 107.324 -1.361 . . . . 72.04 107.324 160.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.476 ' HB ' HD13 ' A' ' 159' ' ' ILE . 37.9 pt -78.05 125.98 84.44 Favored Pre-proline 0 C--O 1.243 0.724 0 N-CA-C 108.617 -0.883 . . . . 62.31 108.617 173.144 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.415 ' HD2' HG23 ' A' ' 159' ' ' ILE . 97.7 Cg_exo -48.68 127.18 15.89 Favored 'Trans proline' 0 C--N 1.384 2.406 0 C-N-CA 123.04 2.494 . . . . 61.41 113.37 -178.266 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.553 ' HB2' ' HZ ' ' A' ' 240' ' ' PHE . 57.1 Cg_endo -69.36 143.85 54.16 Favored 'Trans proline' 0 C--N 1.376 2.007 0 C-N-CA 122.251 1.967 . . . . 72.35 110.355 175.02 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.44 27.37 5.56 Favored Glycine 0 C--N 1.337 0.586 0 N-CA-C 110.927 -0.869 . . . . 53.15 110.927 -171.583 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.653 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.2 p -93.67 157.32 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 N-CA-C 108.168 -1.049 . . . . 71.05 108.168 -176.603 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.4 mtp180 -147.11 169.23 19.72 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 124.141 0.976 . . . . 75.41 109.751 -166.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -51.99 123.86 11.42 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.539 0.736 . . . . 32.55 111.624 174.086 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 85.55 -7.64 75.56 Favored Glycine 0 C--N 1.349 1.302 0 CA-C-O 119.419 -0.656 . . . . 32.02 114.111 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.4 m -69.53 122.64 19.44 Favored 'General case' 0 C--N 1.351 0.633 0 CA-C-N 117.336 0.568 . . . . 54.34 110.553 -178.423 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.412 HG12 HD22 ' A' ' 175' ' ' LEU . 10.5 t -98.93 123.17 51.39 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 N-CA-C 108.486 -0.931 . . . . 72.44 108.486 179.302 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.531 HD11 HG21 ' A' ' 153' ' ' VAL . 43.5 mt -102.49 115.69 44.85 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.593 0 C-N-CA 123.926 0.89 . . . . 72.22 110.537 -169.075 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.41 ' HG3' ' HB2' ' A' ' 173' ' ' ASP . 30.3 ttm180 -89.69 115.86 27.38 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.07 0.548 . . . . 65.23 110.493 175.237 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 173' ' ' ASP . 15.0 m -119.16 116.11 34.12 Favored Pre-proline 0 CA--C 1.555 1.172 0 C-N-CA 123.363 0.665 . . . . 74.34 109.578 176.32 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 162' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 11.2 Cg_exo -72.47 148.51 48.41 Favored 'Trans proline' 0 C--N 1.368 1.594 0 C-N-CA 122.479 2.119 . . . . 64.04 111.998 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.65 18.27 28.36 Favored Glycine 0 C--N 1.341 0.825 0 N-CA-C 115.673 1.029 . . . . 73.2 115.673 172.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.413 ' HE3' HG23 ' A' ' 147' ' ' VAL . 54.2 mtt -121.6 -57.45 1.82 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 118.449 1.125 . . . . 33.5 112.128 176.902 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.35 1.329 0 O-C-N 123.372 0.42 . . . . 73.11 113.047 -174.51 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo . . . . . 0 CA--C 1.547 1.155 0 CA-C-O 119.956 -0.102 . . . . 74.21 112.167 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -95.41 159.21 22.44 Favored Glycine 0 C--N 1.348 1.212 0 O-C-N 123.385 0.428 . . . . 73.1 112.406 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.447 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 9.4 p-10 -96.46 151.54 19.47 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 123.012 0.525 . . . . 74.42 112.036 -167.475 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 11.2 tp -113.88 124.27 51.8 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 107.472 -1.307 . . . . 72.33 107.472 163.492 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.412 HD22 HG12 ' A' ' 158' ' ' VAL . 37.3 mt -99.28 100.63 11.74 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.583 1.153 . . . . 72.24 110.098 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 93.0 mt -95.8 102.74 14.57 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.93 0.892 . . . . 72.14 110.917 177.339 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 6.5 p -86.16 111.91 21.9 Favored 'Isoleucine or valine' 0 C--O 1.244 0.81 0 CA-C-O 121.635 0.731 . . . . 62.43 109.209 172.388 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.475 HG11 HD22 ' A' ' 125' ' ' LEU . 6.2 m -86.98 149.35 4.14 Favored 'Isoleucine or valine' 0 C--O 1.241 0.607 0 CA-C-N 115.638 -0.71 . . . . 65.21 111.49 -178.365 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -124.31 104.57 8.87 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 106.914 -1.513 . . . . 73.34 106.914 176.19 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.583 ' HB3' HD23 ' A' ' 127' ' ' LEU . 32.4 mt -68.09 143.36 55.5 Favored 'General case' 0 CA--C 1.54 0.59 0 O-C-N 123.098 0.249 . . . . 71.21 111.243 -175.314 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.693 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 54.8 mt -53.86 147.83 22.42 Favored Pre-proline 0 CA--C 1.553 1.063 0 C-N-CA 123.852 0.861 . . . . 72.13 111.661 -173.265 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.19 37.24 0.62 Allowed 'Trans proline' 0 C--N 1.368 1.557 0 C-N-CA 123.32 2.68 . . . . 71.24 114.394 -175.478 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -121.06 65.55 13.93 Favored Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 123.544 0.738 . . . . 65.51 109.371 170.201 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -68.28 123.7 10.87 Favored 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 121.485 1.456 . . . . 74.22 111.231 -169.534 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.7 p -134.61 -38.81 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 N-CA-C 108.499 -0.926 . . . . 74.24 108.499 178.518 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.429 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 5.5 m-85 -114.82 141.92 47.24 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 121.902 0.858 . . . . 72.35 112.259 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.536 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 43.8 mtt85 -128.54 154.0 46.62 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 113.472 -1.695 . . . . 73.2 106.838 171.466 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.467 HD13 HD23 ' A' ' 193' ' ' LEU . 42.5 tp -132.7 138.41 47.25 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 109.051 -0.722 . . . . 72.24 109.051 179.534 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -142.32 117.69 10.22 Favored 'General case' 0 C--O 1.241 0.645 0 N-CA-C 109.101 -0.703 . . . . 73.45 109.101 173.433 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 68.16 -86.82 0.18 Allowed Glycine 0 C--N 1.349 1.279 0 O-C-N 123.864 0.727 . . . . 62.23 112.986 -177.352 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 4.5 pm0 -135.41 -14.85 1.94 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.25 1.02 . . . . 74.31 111.206 -174.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -111.19 156.42 21.45 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-O 121.16 0.505 . . . . 74.12 111.36 -174.075 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.467 HD23 HD13 ' A' ' 188' ' ' LEU . 79.5 mt -109.09 170.78 7.83 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.334 1.054 . . . . 64.13 109.593 -168.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 194' ' ' TYR . . . . . 0.536 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 71.4 m-85 -142.45 122.58 13.75 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 107.51 -1.293 . . . . 74.34 107.51 177.502 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 195' ' ' ALA . . . . . 0.474 ' HB3' HD23 ' A' ' 251' ' ' LEU . . . -134.99 152.45 51.75 Favored 'General case' 0 CA--C 1.508 -0.657 0 N-CA-C 109.522 -0.547 . . . . 54.13 109.522 177.127 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 4.9 m -98.77 119.09 36.93 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 108.969 -0.752 . . . . 75.24 108.969 177.072 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.487 HD22 HD13 ' A' ' 251' ' ' LEU . 61.4 tp -105.31 111.84 24.73 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.347 1.059 . . . . 71.13 109.716 -174.491 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -94.43 104.85 16.81 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 109.333 -0.617 . . . . 74.51 109.333 176.409 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 199' ' ' VAL . . . . . 0.567 HG11 HG11 ' A' ' 223' ' ' VAL . 14.6 m -101.52 140.87 21.6 Favored Pre-proline 0 N--CA 1.476 0.825 0 N-CA-C 109.378 -0.601 . . . . 71.21 109.378 177.036 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.19 151.21 84.13 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 121.999 1.799 . . . . 73.21 110.986 171.758 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -56.69 -44.95 99.97 Favored Pre-proline 0 CA--C 1.546 0.791 0 CA-C-O 118.327 -0.844 . . . . 54.33 113.051 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 202' ' ' PRO . . . . . 0.421 ' O ' HG22 ' A' ' 206' ' ' VAL . 69.7 Cg_exo -46.69 -55.64 3.64 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 122.484 2.123 . . . . 64.42 113.495 170.738 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.2 mt -65.57 -37.25 79.56 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 122.736 0.414 . . . . 73.55 111.613 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -56.27 -58.33 8.43 Favored 'General case' 0 CA--C 1.547 0.828 0 CA-C-O 121.261 0.553 . . . . 72.53 111.087 178.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.6 m -69.79 -40.06 78.62 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.969 0 CA-C-N 115.212 -0.904 . . . . 72.15 112.461 -173.73 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 202' ' ' PRO . 18.3 m -78.17 -27.0 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 122.259 0.224 . . . . 74.12 110.977 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.548 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 77.52 63.66 2.2 Favored Glycine 0 C--N 1.341 0.835 0 CA-C-N 115.919 -0.582 . . . . 42.15 113.171 -176.4 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -91.89 -147.12 19.82 Favored Glycine 0 C--N 1.354 1.578 0 N-CA-C 111.694 -0.563 . . . . 33.35 111.694 177.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -138.18 135.5 35.7 Favored 'General case' 0 C--O 1.24 0.593 0 C-N-CA 123.154 0.582 . . . . 71.22 110.462 178.051 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 61.3 t -120.68 134.64 63.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.131 0.972 . . . . 70.23 108.964 -179.055 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.68 114.81 17.92 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.502 -0.555 . . . . 74.33 109.502 171.533 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.63 146.0 28.3 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 108.71 -0.848 . . . . 64.35 108.71 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 55.4 mmm -83.81 148.59 26.92 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 110.13 -0.322 . . . . 62.44 110.13 174.411 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.429 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 9.3 t -140.03 167.59 21.77 Favored 'General case' 0 C--O 1.242 0.691 0 C-N-CA 124.0 0.92 . . . . 72.54 109.873 173.581 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 63.7 mt -74.31 -0.56 17.46 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 123.882 0.873 . . . . 74.11 112.138 -173.697 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.65 -4.07 9.78 Favored 'General case' 0 N--CA 1.485 1.292 0 N-CA-C 112.747 0.647 . . . . 74.23 112.747 176.602 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 153.89 -160.74 29.55 Favored Glycine 0 N--CA 1.478 1.465 0 CA-C-O 119.679 -0.512 . . . . 62.41 112.859 178.583 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -94.26 132.54 0.71 Allowed 'Trans proline' 0 CA--C 1.559 1.726 0 C-N-CA 123.473 2.782 . . . . 43.15 112.596 168.853 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 34.3 m -111.38 151.97 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.64 0.776 . . . . 73.44 110.32 173.582 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -114.58 115.14 26.69 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-O 121.139 0.495 . . . . 73.44 110.099 171.806 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.528 ' HB ' HD11 ' A' ' 235' ' ' LEU . 2.6 p -104.66 121.44 56.48 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 123.359 0.664 . . . . 74.34 110.968 179.408 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.98 105.62 15.0 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 109.22 -0.659 . . . . 75.52 109.22 173.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.567 HG11 HG11 ' A' ' 199' ' ' VAL . 11.0 m -71.2 135.61 84.65 Favored Pre-proline 0 CA--C 1.556 1.189 0 N-CA-C 108.839 -0.8 . . . . 72.32 108.839 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 224' ' ' PRO . . . . . 0.427 ' HB2' HH12 ' A' ' 231' ' ' ARG . 31.5 Cg_exo -61.28 144.12 98.52 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 122.373 2.048 . . . . 64.23 112.581 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -51.24 128.35 25.04 Favored 'Trans proline' 0 C--N 1.38 2.222 0 C-N-CA 122.904 2.403 . . . . 74.43 112.046 173.008 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 42.1 mtp180 67.87 60.98 0.43 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 125.032 1.333 . . . . 75.12 110.369 -175.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -85.3 139.62 31.46 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 114.852 -1.067 . . . . 72.22 111.29 178.355 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 23.1 mp0 -112.2 158.84 19.19 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 123.768 0.827 . . . . 62.15 109.392 176.758 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -71.07 140.47 50.71 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 116.013 -0.54 . . . . 43.44 109.673 174.646 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 96.97 -3.7 62.5 Favored Glycine 0 CA--C 1.521 0.443 0 CA-C-O 119.448 -0.64 . . . . 52.12 112.996 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 231' ' ' ARG . . . . . 0.427 HH12 ' HB2' ' A' ' 224' ' ' PRO . 90.1 mtt180 -69.41 156.11 39.37 Favored 'General case' 0 N--CA 1.478 0.972 0 CA-C-N 117.649 0.724 . . . . 75.44 110.733 172.585 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 13.2 mptt -125.44 123.23 38.81 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 123.404 0.682 . . . . 74.4 109.726 177.31 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 46.6 mt -112.6 109.98 19.87 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 108.554 -0.906 . . . . 71.12 108.554 -175.618 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 234' ' ' ARG . . . . . 0.444 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 57.3 ttp85 -99.23 104.31 16.24 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 116.072 -0.513 . . . . 61.21 111.145 -168.691 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.528 HD11 ' HB ' ' A' ' 221' ' ' VAL . 37.0 mt -89.9 100.52 13.32 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 124.091 0.956 . . . . 71.31 110.145 -176.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 236' ' ' LYS . . . . . 0.424 ' HE2' ' HB3' ' A' ' 236' ' ' LYS . 42.4 mtpt -66.37 151.53 46.94 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 116.378 -0.374 . . . . 71.03 111.534 177.575 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.65 20.2 73.76 Favored Glycine 0 C--N 1.348 1.203 0 CA-C-N 115.325 -0.852 . . . . 52.11 112.845 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.0 mmtt -137.59 16.44 2.92 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.801 0.84 . . . . 73.31 111.266 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -99.11 -160.72 29.42 Favored Glycine 0 C--N 1.347 1.161 0 O-C-N 123.654 0.596 . . . . 72.15 112.038 170.829 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.553 ' HZ ' ' HB2' ' A' ' 151' ' ' PRO . 13.3 t80 -83.43 127.14 69.56 Favored Pre-proline 0 CA--C 1.552 1.043 0 CA-C-N 116.74 0.27 . . . . 55.44 110.945 -176.531 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 241' ' ' PRO . . . . . 0.567 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 13.5 Cg_exo -70.87 126.33 12.47 Favored 'Trans proline' 0 C--N 1.376 1.979 0 C-N-CA 122.269 1.979 . . . . 72.42 111.732 173.474 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -158.69 -146.13 4.45 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-O 119.149 -0.806 . . . . 50.03 112.583 -176.817 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -65.38 -24.54 57.25 Favored 'Trans proline' 0 C--N 1.376 2.01 0 C-N-CA 123.375 2.717 . . . . 62.21 112.866 -177.84 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.45 22.54 3.9 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 124.041 0.937 . . . . 70.24 111.113 178.33 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 81.18 -98.63 1.87 Allowed Glycine 0 C--N 1.345 1.042 0 N-CA-C 110.469 -1.053 . . . . 53.41 110.469 -176.067 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.567 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 23.2 ttm180 -128.62 146.53 50.83 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 109.146 -0.687 . . . . 74.25 109.146 166.148 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -85.61 -155.34 24.99 Favored Glycine 0 C--O 1.253 1.338 0 O-C-N 123.694 0.621 . . . . 41.12 112.424 175.744 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -140.27 160.52 39.78 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.835 0.854 . . . . 51.54 109.961 -174.575 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.444 ' O ' ' HA ' ' A' ' 234' ' ' ARG . 15.6 tp -99.51 122.39 42.51 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 123.919 0.887 . . . . 74.41 110.329 178.1 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -101.57 104.47 15.35 Favored 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 108.433 -0.951 . . . . 72.31 108.433 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.548 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 74.5 mt -85.72 149.93 24.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.987 0.915 . . . . 53.41 112.328 -178.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -114.47 96.01 5.55 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.539 -0.912 . . . . 70.51 108.539 176.154 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 69.1 t -52.15 125.82 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 123.582 0.753 . . . . 72.24 111.683 176.776 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 27.3 mmm-85 -136.17 101.5 4.72 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 125.257 1.423 . . . . 74.1 107.259 179.066 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 65.1 mt -80.97 125.39 39.45 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 CA-C-N 116.342 -0.39 . . . . 75.55 110.053 -175.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 10.0 t . . . . . 0 CA--C 1.55 0.966 0 C-N-CA 124.402 1.081 . . . . 72.55 109.653 -179.766 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.658 ' HB2' ' HG2' ' A' ' 136' ' ' ARG . 22.0 tp . . . . . 0 N--CA 1.471 0.623 0 N-CA-C 109.294 -0.632 . . . . 74.2 109.294 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.429 ' HA ' ' CB ' ' A' ' 123' ' ' LEU . 12.5 p -65.48 137.06 25.65 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 115.345 -0.843 . . . . 63.41 110.042 172.245 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.82 -50.14 8.96 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.215 -0.661 . . . . 62.55 109.215 174.853 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 49.0 p-80 -170.16 163.97 9.11 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 114.896 -1.047 . . . . 71.41 109.964 -175.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 1.8 p -95.38 162.09 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.086 0 N-CA-C 109.642 -0.503 . . . . 71.32 109.642 174.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 71.7 p . . . . . 0 N--CA 1.479 1.022 0 C-N-CA 124.792 1.237 . . . . 75.34 109.362 -171.972 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 120.886 0.374 . . . . 70.34 110.418 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 31.6 tp -122.64 146.2 47.67 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 107.662 -1.236 . . . . 74.35 107.662 -170.835 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 64.6 ttt-85 -141.72 143.87 33.76 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.737 -0.838 . . . . 72.44 108.737 -176.671 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.442 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -149.06 118.81 7.03 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 109.079 -0.711 . . . . 73.25 109.079 175.656 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -94.03 139.38 31.02 Favored 'General case' 0 C--O 1.247 0.959 0 N-CA-C 109.305 -0.628 . . . . 74.42 109.305 174.132 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.474 HD12 ' HG ' ' A' ' 98' ' ' LEU . 1.8 pt? -144.87 132.37 10.37 Favored Pre-proline 0 CA--C 1.541 0.622 0 C-N-CA 123.099 0.56 . . . . 73.34 111.41 -166.21 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_exo -68.82 115.08 3.77 Favored 'Trans proline' 0 C--N 1.375 1.973 0 C-N-CA 122.654 2.236 . . . . 74.25 112.194 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.443 ' HB3' HD23 ' A' ' 180' ' ' LEU . 16.9 tp -109.2 166.84 10.55 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.512 1.125 . . . . 73.35 108.202 174.481 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.561 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 25.9 m -103.32 156.64 17.59 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 109.671 -0.492 . . . . 72.02 109.671 173.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.5 HD23 ' HB3' ' A' ' 180' ' ' LEU . 87.5 mt -56.02 -50.5 70.74 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-O 121.671 0.748 . . . . 64.14 110.069 171.763 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -57.48 -34.18 68.77 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 114.517 -1.22 . . . . 71.13 111.987 176.676 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.537 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 31.3 mm-40 -74.12 -31.49 62.79 Favored 'General case' 0 N--CA 1.482 1.169 0 C-N-CA 123.171 0.588 . . . . 74.41 111.56 176.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.444 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -59.33 -37.91 79.02 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.442 0.697 . . . . 70.24 111.471 169.511 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.556 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 46.8 t80 -71.61 -47.73 52.7 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 115.79 -0.641 . . . . 75.51 112.174 173.16 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 31.8 m80 -63.09 -53.71 49.39 Favored 'General case' 0 N--CA 1.483 1.187 0 O-C-N 123.702 0.626 . . . . 64.44 111.004 -173.63 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 59.41 149.76 0.01 OUTLIER Glycine 0 CA--C 1.537 1.431 0 CA-C-N 115.772 -0.649 . . . . 74.51 113.297 -168.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 170.37 -179.06 42.74 Favored Glycine 0 CA--C 1.505 -0.551 0 C-N-CA 119.968 -1.11 . . . . 52.53 114.666 177.805 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -89.78 138.36 31.55 Favored 'General case' 0 C--O 1.24 0.596 0 CA-C-N 113.445 -1.377 . . . . 75.13 107.886 177.153 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.658 ' HG2' ' HB2' ' A' ' 98' ' ' LEU . 19.7 tpp180 -154.05 158.19 40.16 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 108.622 -0.881 . . . . 53.55 108.622 178.347 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.4 p -80.14 126.16 39.29 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.21 0 CA-C-O 121.544 0.687 . . . . 70.33 111.689 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 8.9 p -107.71 123.24 62.96 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 C-N-CA 124.732 1.213 . . . . 73.51 108.883 171.293 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -118.94 98.73 6.33 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 108.508 -0.923 . . . . 72.44 108.508 177.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.416 HG21 HD22 ' A' ' 174' ' ' LEU . 14.3 m -122.69 134.73 65.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 124.245 1.018 . . . . 73.34 109.785 -176.007 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.21 29.79 19.42 Favored 'General case' 0 CA--C 1.551 1.012 0 C-N-CA 124.18 0.992 . . . . 71.3 110.38 -173.623 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.28 6.39 79.91 Favored Glycine 0 C--N 1.358 1.797 0 CA-C-N 115.364 -0.835 . . . . 62.13 113.806 -177.734 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -99.31 115.08 28.35 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 109.103 -0.703 . . . . 73.53 109.103 -176.267 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -95.41 116.04 28.25 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 123.709 0.803 . . . . 65.43 110.144 -175.404 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.675 HG21 ' SD ' ' A' ' 164' ' ' MET . 7.5 m -142.79 156.99 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 125.368 1.467 . . . . 74.24 108.539 176.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 38.9 t -88.37 127.02 35.48 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 109.864 -0.421 . . . . 60.52 109.864 174.582 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.7 p -99.91 144.88 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 123.699 0.8 . . . . 65.0 109.567 171.797 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.6 ttt180 -109.43 116.22 31.41 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.593 -0.891 . . . . 74.03 108.593 168.294 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.435 HG22 HG21 ' A' ' 159' ' ' ILE . 35.1 pt -121.1 132.04 24.31 Favored Pre-proline 0 CA--C 1.549 0.927 0 N-CA-C 108.93 -0.767 . . . . 72.3 108.93 171.189 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -76.45 166.61 27.13 Favored 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 122.8 2.333 . . . . 73.13 113.531 -170.327 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -68.89 154.62 70.65 Favored 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.109 1.873 . . . . 65.41 110.468 165.126 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 90.41 44.35 4.66 Favored Glycine 0 C--O 1.239 0.44 0 N-CA-C 111.548 -0.621 . . . . 73.12 111.548 -173.366 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.444 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 2.7 p -116.3 156.26 17.52 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.102 0 N-CA-C 108.197 -1.038 . . . . 75.15 108.197 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.2 mtp180 -138.76 166.17 25.1 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 123.967 0.907 . . . . 72.03 110.916 -164.437 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -57.97 127.55 32.61 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 122.957 0.503 . . . . 54.51 110.823 170.333 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 77.19 6.67 86.45 Favored Glycine 0 C--N 1.349 1.261 0 O-C-N 123.717 0.636 . . . . 51.32 113.379 -178.405 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 41.2 t -69.56 122.45 19.09 Favored 'General case' 0 C--N 1.358 0.953 0 C-N-CA 122.942 0.497 . . . . 61.13 109.7 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.443 HG22 HD22 ' A' ' 175' ' ' LEU . 7.3 p -103.01 119.94 52.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 O-C-N 124.475 1.109 . . . . 65.13 109.608 -176.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.435 HG21 HG22 ' A' ' 149' ' ' ILE . 17.6 mt -115.74 116.82 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 123.864 0.865 . . . . 70.15 109.86 -173.115 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.407 ' HA ' HD23 ' A' ' 175' ' ' LEU . 44.1 ttp180 -75.8 120.3 20.97 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 118.36 0.527 . . . . 75.03 110.141 175.758 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.651 ' HB ' ' HB3' ' A' ' 174' ' ' LEU . 84.2 t -112.16 113.88 51.42 Favored Pre-proline 0 CA--C 1.552 1.027 0 C-N-CA 124.249 1.019 . . . . 72.4 109.636 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -76.95 157.4 34.61 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.664 2.242 . . . . 70.32 113.233 178.419 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 163' ' ' GLY . . . . . 0.626 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . 105.76 -25.94 22.63 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 115.365 0.906 . . . . 70.04 115.365 173.879 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.675 ' SD ' HG21 ' A' ' 145' ' ' VAL . 4.1 mpp? -111.0 -45.89 3.4 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-N 118.893 1.347 . . . . 63.01 112.431 -175.001 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.343 0.936 0 C-N-CA 121.441 -0.409 . . . . 61.42 112.624 179.313 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo . . . . . 0 CA--C 1.543 0.962 0 N-CA-C 110.241 -0.715 . . . . 65.43 110.241 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 172' ' ' GLY . . . . . 0.626 ' HA3' ' H ' ' A' ' 163' ' ' GLY . . . 103.91 119.97 4.7 Favored Glycine 0 C--N 1.34 0.778 0 N-CA-C 112.301 -0.319 . . . . 60.31 112.301 -176.329 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -134.6 107.5 7.53 Favored 'General case' 0 C--N 1.333 -0.141 0 C-N-CA 124.524 1.129 . . . . 72.31 108.153 172.429 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.651 ' HB3' ' HB ' ' A' ' 161' ' ' VAL . 27.4 tp -121.33 105.89 10.95 Favored 'General case' 0 C--O 1.226 -0.132 0 N-CA-C 107.2 -1.407 . . . . 75.22 107.2 168.003 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.443 HD22 HG22 ' A' ' 158' ' ' VAL . 59.8 mt -84.76 99.39 10.83 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.017 -0.538 . . . . 62.43 110.483 -176.015 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.442 ' HA ' ' O ' ' A' ' 121' ' ' ALA . 59.8 mt -84.35 102.81 13.0 Favored 'General case' 0 C--N 1.344 0.351 0 CA-C-N 115.569 -0.741 . . . . 74.44 109.393 176.101 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.7 t -95.98 95.05 4.54 Favored 'Isoleucine or valine' 0 C--O 1.242 0.665 0 CA-C-N 114.61 -1.177 . . . . 74.24 107.962 179.343 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.41 HG21 HG22 ' A' ' 153' ' ' VAL . 5.6 m -75.3 147.63 8.14 Favored 'Isoleucine or valine' 0 C--O 1.245 0.831 0 CA-C-O 121.521 0.676 . . . . 75.24 110.898 -171.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -121.35 94.93 4.49 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 108.119 -1.067 . . . . 71.3 108.119 -176.238 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.5 ' HB3' HD23 ' A' ' 127' ' ' LEU . 50.1 mt -67.34 147.12 53.36 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 110.269 -0.271 . . . . 73.12 110.269 -176.343 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.561 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 20.3 mt -56.59 123.41 56.95 Favored Pre-proline 0 CA--C 1.552 1.054 0 CA-C-O 119.307 -0.378 . . . . 73.13 110.362 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 17.2 Cg_exo -66.82 85.27 0.3 Allowed 'Trans proline' 0 C--N 1.379 2.143 0 C-N-CA 123.508 2.805 . . . . 75.21 113.356 -172.423 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -162.44 77.25 2.01 Favored Pre-proline 0 CA--C 1.558 1.281 0 N-CA-C 108.094 -1.076 . . . . 71.05 108.094 171.219 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -63.33 123.46 12.17 Favored 'Trans proline' 0 C--N 1.377 2.031 0 C-N-CA 122.002 1.801 . . . . 74.22 111.924 -171.219 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.8 p -134.56 -46.78 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 N-CA-C 107.517 -1.29 . . . . 62.2 107.517 174.135 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.54 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 4.3 m-85 -103.55 123.77 47.55 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.22 -0.9 . . . . 72.45 110.61 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 15.0 mtm180 -120.82 104.75 10.11 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.905 -1.517 . . . . 74.11 106.905 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.46 HD13 ' HD1' ' A' ' 240' ' ' PHE . 44.3 tp -83.6 138.55 33.31 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 108.996 -0.742 . . . . 55.34 108.996 174.657 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -141.59 104.93 4.65 Favored 'General case' 0 C--O 1.243 0.747 0 N-CA-C 107.393 -1.336 . . . . 71.34 107.393 176.273 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 74.84 -88.17 0.76 Allowed Glycine 0 C--N 1.348 1.221 0 CA-C-N 115.738 -0.665 . . . . 53.44 111.654 -174.203 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -136.59 -6.36 1.96 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 123.625 0.77 . . . . 71.1 110.854 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -98.53 149.55 22.62 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.369 0.668 . . . . 71.24 111.202 -177.162 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.601 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.7 mt -109.58 151.17 27.16 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.486 1.114 . . . . 74.54 109.207 -177.91 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -140.41 120.17 13.42 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 107.372 -1.344 . . . . 73.41 107.372 178.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 195' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -143.24 140.66 30.78 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.742 0.817 . . . . 63.42 108.939 -177.138 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 20.5 m -83.39 127.98 34.13 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-O 121.194 0.521 . . . . 60.13 110.208 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 197' ' ' LEU . . . . . . . . . . . . . 65.1 tp -112.3 120.66 42.5 Favored 'General case' 0 C--O 1.22 -0.479 0 C-N-CA 125.216 1.406 . . . . 74.21 108.941 176.696 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -99.35 123.08 43.33 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.402 -0.962 . . . . 74.32 108.402 170.363 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 4.6 m -110.2 147.78 36.99 Favored Pre-proline 0 C--O 1.245 0.849 0 C-N-CA 123.039 0.536 . . . . 74.41 109.883 -177.656 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -60.22 134.1 53.7 Favored 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 122.367 2.045 . . . . 72.14 110.877 168.134 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -53.96 -43.35 96.57 Favored Pre-proline 0 CA--C 1.564 1.493 0 C-N-CA 124.325 1.05 . . . . 71.4 113.541 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_exo -55.13 -46.48 32.71 Favored 'Trans proline' 0 C--N 1.395 3.024 0 C-N-CA 122.473 2.116 . . . . 73.34 112.97 171.303 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 7.1 mt -63.28 -38.24 81.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 123.344 0.657 . . . . 71.42 111.072 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.91 -43.62 98.29 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 123.099 0.56 . . . . 64.55 111.889 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 205' ' ' VAL . . . . . 0.515 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 35.8 m -80.81 -38.96 17.59 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 CA-C-N 116.154 -0.476 . . . . 65.3 112.178 -175.162 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.0 m -79.53 -35.78 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 CA-C-N 118.12 0.418 . . . . 53.33 110.573 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 89.81 80.02 1.34 Allowed Glycine 0 C--N 1.348 1.22 0 CA-C-N 115.613 -0.721 . . . . 75.01 112.229 -175.11 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -117.54 -160.42 11.71 Favored Glycine 0 C--N 1.357 1.732 0 N-CA-C 112.164 -0.374 . . . . 42.25 112.164 175.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 10.5 mtmp? -115.98 137.44 52.11 Favored 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 123.47 0.708 . . . . 73.45 110.373 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 28.2 t -118.82 152.06 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.745 1.218 . . . . 55.15 108.749 176.723 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -81.13 119.2 23.27 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 108.434 -0.95 . . . . 71.44 108.434 171.58 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -102.16 122.94 45.12 Favored 'General case' 0 C--O 1.239 0.511 0 N-CA-C 108.125 -1.065 . . . . 55.21 108.125 175.207 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 54.7 mmm -77.21 113.4 14.92 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.193 0.52 . . . . 64.11 110.288 178.691 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.54 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 9.1 t -109.83 167.96 9.77 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-N 114.692 -1.14 . . . . 62.04 109.766 171.227 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 215' ' ' LEU . . . . . 0.412 HD13 ' O ' ' A' ' 127' ' ' LEU . 72.1 mt -71.12 -7.5 47.0 Favored 'General case' 0 CA--C 1.546 0.821 0 CA-C-N 114.701 -1.136 . . . . 73.24 111.735 178.34 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -90.57 -19.79 23.34 Favored 'General case' 0 CA--C 1.558 1.26 0 C-N-CA 124.211 1.004 . . . . 73.33 110.951 172.754 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 137.24 -154.36 22.33 Favored Glycine 0 C--N 1.347 1.163 0 N-CA-C 110.901 -0.88 . . . . 31.11 110.901 -174.868 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -89.19 129.06 1.92 Allowed 'Trans proline' 0 CA--C 1.55 1.295 0 C-N-CA 122.649 2.232 . . . . 61.32 111.923 170.685 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.0 m -109.82 167.91 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 123.775 0.83 . . . . 74.32 111.197 174.046 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -105.69 115.79 30.85 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 123.598 0.759 . . . . 62.31 109.906 177.456 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 2.7 p -116.55 125.44 73.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 123.974 0.91 . . . . 71.31 109.566 174.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -92.31 121.83 34.18 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.124 -0.695 . . . . 34.24 109.124 175.024 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 10.0 m -81.7 145.43 54.33 Favored Pre-proline 0 CA--C 1.553 1.06 0 N-CA-C 108.989 -0.745 . . . . 43.04 108.989 177.338 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -61.99 141.92 90.94 Favored 'Trans proline' 0 C--N 1.371 1.713 0 C-N-CA 122.13 1.887 . . . . 65.33 111.914 173.372 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -60.04 122.21 11.03 Favored 'Trans proline' 0 C--N 1.368 1.592 0 C-N-CA 122.784 2.322 . . . . 75.54 112.257 174.358 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 226' ' ' ARG . . . . . 0.515 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 62.3 mtp180 65.85 39.33 4.7 Favored 'General case' 0 N--CA 1.482 1.172 0 C-N-CA 124.732 1.213 . . . . 73.3 111.427 -176.294 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 7.1 t -70.9 174.41 6.17 Favored 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 122.941 0.496 . . . . 75.13 111.272 -179.098 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.2 mp0 -123.55 143.65 50.07 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 123.859 0.863 . . . . 73.32 109.54 -176.665 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.08 123.28 21.18 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.785 0.834 . . . . 63.31 110.098 175.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 112.87 12.24 12.88 Favored Glycine 0 C--N 1.34 0.788 0 CA-C-N 116.244 -0.434 . . . . 73.41 112.605 -176.689 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 84.8 mtt180 -91.17 154.51 19.28 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 109.292 -0.633 . . . . 74.01 109.292 167.601 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.404 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.1 OUTLIER -104.27 111.45 24.08 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 123.615 0.766 . . . . 71.52 109.03 172.568 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 233' ' ' LEU . . . . . 0.475 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 67.8 mt -87.63 104.78 16.84 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 108.333 -0.988 . . . . 73.34 108.333 -177.363 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 40.5 ttm105 -76.58 110.39 11.1 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-N 115.313 -0.858 . . . . 54.21 111.755 -172.352 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.454 HD12 HD23 ' A' ' 249' ' ' LEU . 20.9 mt -91.97 106.12 18.21 Favored 'General case' 0 C--O 1.239 0.551 0 N-CA-C 107.897 -1.149 . . . . 71.22 107.897 169.338 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 93.3 mttt -66.57 132.89 49.18 Favored 'General case' 0 CA--C 1.538 0.506 0 CA-C-N 114.578 -1.192 . . . . 75.24 111.828 -167.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 79.91 -1.11 80.61 Favored Glycine 0 C--N 1.348 1.228 0 O-C-N 123.834 0.709 . . . . 54.23 114.649 173.446 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -84.57 -3.78 58.63 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.496 0.554 . . . . 71.41 112.496 -176.397 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.91 -179.31 48.92 Favored Glycine 0 C--N 1.346 1.136 0 N-CA-C 112.446 -0.262 . . . . 71.24 112.446 174.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.556 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 73.9 m-85 -86.38 155.86 56.93 Favored Pre-proline 0 N--CA 1.476 0.847 0 C-N-CA 123.197 0.599 . . . . 75.32 112.296 -173.635 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -60.97 140.5 90.5 Favored 'Trans proline' 0 C--N 1.384 2.444 0 C-N-CA 122.778 2.318 . . . . 73.25 112.772 178.314 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -150.82 -162.01 10.37 Favored Glycine 0 CA--C 1.533 1.179 0 N-CA-C 110.458 -1.057 . . . . 72.13 110.458 175.044 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -69.7 -20.68 34.81 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.803 2.335 . . . . 63.22 113.043 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.79 3.18 55.33 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.673 0.789 . . . . 73.12 112.083 -175.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.37 -105.97 1.62 Allowed Glycine 0 C--N 1.35 1.314 0 N-CA-C 110.619 -0.993 . . . . 64.31 110.619 -176.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 50.6 mtm-85 -126.58 152.28 46.82 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 108.045 -1.095 . . . . 74.3 108.045 167.395 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -78.03 -158.28 10.79 Favored Glycine 0 C--N 1.343 0.936 0 O-C-N 123.362 0.414 . . . . 72.21 112.152 174.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 38.6 m-20 -136.65 170.1 16.62 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 109.323 -0.621 . . . . 62.34 109.323 -175.437 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.601 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 23.9 tp -103.27 124.44 48.64 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.202 -0.666 . . . . 75.21 109.202 171.35 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 250' ' ' TYR . . . . . 0.404 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 48.3 m-85 -107.89 104.35 13.81 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.293 0.637 . . . . 62.11 109.405 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.475 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 85.2 mt -89.11 113.75 24.93 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.802 0.841 . . . . 71.11 112.414 -178.33 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -78.85 91.66 4.78 Favored 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 108.777 -0.823 . . . . 72.4 108.777 176.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.1 p -54.11 130.98 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.353 1.061 . . . . 74.14 111.066 176.637 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 13.2 mmt180 -131.02 99.01 4.75 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 125.12 1.368 . . . . 72.02 107.548 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 63.5 mt -76.58 124.76 35.48 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 C-N-CA 123.822 0.849 . . . . 72.35 109.269 -175.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 9.4 t . . . . . 0 C--O 1.25 1.086 0 C-N-CA 123.552 0.741 . . . . 72.5 109.781 -175.62 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.54 HD22 HD12 ' A' ' 123' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.484 1.226 0 CA-C-O 121.254 0.549 . . . . 61.11 110.108 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.558 ' HA ' ' HB2' ' A' ' 123' ' ' LEU . 11.4 p -84.08 143.46 11.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 C-N-CA 124.702 1.201 . . . . 72.42 110.624 171.715 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -77.82 -87.07 0.05 Allowed 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 108.439 -0.949 . . . . 72.22 108.439 169.518 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.4 m80 -168.78 179.54 4.16 Favored 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 125.026 1.33 . . . . 74.12 109.72 177.461 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 93.4 t -62.23 140.16 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 C-N-CA 123.654 0.782 . . . . 61.44 111.146 178.721 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 37.4 p . . . . . 0 CA--C 1.547 0.833 0 C-N-CA 123.163 0.585 . . . . 73.21 109.443 172.487 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.8 t70 . . . . . 0 CA--C 1.538 0.51 0 CA-C-O 120.638 0.256 . . . . 70.0 110.576 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.551 HD12 ' HA2' ' A' ' 165' ' ' GLY . 12.4 mt -125.59 142.46 51.5 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 107.26 -1.385 . . . . 74.04 107.26 160.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' ARG . . . . . 0.6 ' HG2' ' HB2' ' A' ' 175' ' ' LEU . 41.0 mtm180 -141.91 145.78 34.97 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 107.694 -1.224 . . . . 64.33 107.694 178.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -151.46 118.42 5.85 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 108.516 -0.92 . . . . 71.24 108.516 175.379 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -88.85 132.45 34.66 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 108.086 -1.079 . . . . 52.23 108.086 173.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.558 ' HB2' ' HA ' ' A' ' 99' ' ' VAL . 2.2 pt? -142.71 146.65 39.0 Favored Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 122.778 0.431 . . . . 72.51 111.683 -168.564 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -75.97 121.6 6.3 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.689 2.259 . . . . 62.41 111.182 173.823 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.441 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 14.2 tp -120.16 168.94 10.7 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.216 1.006 . . . . 65.44 108.793 174.69 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.628 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 11.5 m -107.06 155.98 19.25 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.136 0.574 . . . . 74.12 109.776 174.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 80.5 mt -50.49 -52.41 38.57 Favored 'General case' 0 N--CA 1.487 1.41 0 C-N-CA 124.127 0.971 . . . . 65.24 110.216 173.29 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.552 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -54.91 -39.52 68.89 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 113.506 -1.679 . . . . 71.44 112.103 177.812 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.628 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 16.0 mm-40 -76.88 -26.31 54.06 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 123.099 0.56 . . . . 72.15 112.107 -176.354 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.539 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -61.12 -44.56 97.16 Favored 'General case' 0 C--O 1.252 1.219 0 CA-C-O 121.62 0.724 . . . . 72.3 111.129 169.221 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -67.69 -46.31 72.65 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 114.029 -1.441 . . . . 72.21 112.747 176.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.2 m80 -69.2 -47.43 64.86 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 122.775 0.43 . . . . 73.5 110.759 -176.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.69 -148.24 50.99 Favored Glycine 0 C--N 1.344 1.022 0 N-CA-C 111.229 -0.749 . . . . 72.23 111.229 -169.533 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 117.26 172.72 16.21 Favored Glycine 0 N--CA 1.472 1.039 0 CA-C-N 117.224 0.512 . . . . 24.11 113.471 172.453 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 13.7 mp0 -90.11 114.42 26.34 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 107.744 -1.206 . . . . 61.13 107.744 179.427 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 4.9 mmp_? -116.75 163.19 16.51 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 123.855 0.862 . . . . 73.51 110.306 -177.146 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.6 p -88.48 124.07 41.24 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 CA-C-O 121.241 0.543 . . . . 65.04 110.241 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.408 ' HA ' HG11 ' A' ' 99' ' ' VAL . 12.0 p -114.24 145.87 19.5 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.694 0 C-N-CA 123.816 0.846 . . . . 64.44 109.962 178.463 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -125.91 109.06 12.05 Favored 'General case' 0 C--O 1.242 0.682 0 N-CA-C 108.668 -0.864 . . . . 74.45 108.668 174.254 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.9 m -130.43 117.52 39.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 123.678 0.791 . . . . 73.24 111.068 -176.198 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.05 23.39 13.79 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.835 1.254 . . . . 63.51 112.257 176.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.12 12.71 57.25 Favored Glycine 0 C--N 1.343 0.944 0 CA-C-O 120.032 -0.315 . . . . 51.11 112.995 -178.309 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.1 mpt_? -103.3 116.87 33.27 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.203 -0.665 . . . . 74.42 109.203 177.169 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 62.5 ttp85 -94.32 105.17 17.15 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 108.14 -1.059 . . . . 74.42 108.14 172.648 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 8.9 m -142.11 157.07 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 C-N-CA 124.338 1.055 . . . . 52.12 109.575 -175.15 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 54.3 p -90.94 120.08 31.66 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 122.889 0.476 . . . . 63.54 110.217 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.22 141.35 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.348 0.659 . . . . 34.44 109.425 177.412 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -107.04 103.42 12.83 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 108.298 -1.001 . . . . 63.41 108.298 174.45 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.439 ' HB ' HD13 ' A' ' 159' ' ' ILE . 37.8 pt -106.98 107.27 60.22 Favored Pre-proline 0 CA--C 1.548 0.873 0 N-CA-C 108.677 -0.861 . . . . 72.42 108.677 170.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.96 162.08 43.11 Favored 'Trans proline' 0 C--N 1.38 2.235 0 C-N-CA 122.972 2.448 . . . . 71.11 113.389 -171.035 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -59.85 114.77 2.22 Favored 'Trans proline' 0 C--N 1.376 2.017 0 C-N-CA 122.482 2.121 . . . . 73.44 110.448 169.82 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.42 ' HA2' ' CD2' ' A' ' 240' ' ' PHE . . . 140.62 61.35 0.04 OUTLIER Glycine 0 C--N 1.341 0.811 0 N-CA-C 111.811 -0.515 . . . . 71.12 111.811 -173.724 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.568 HG21 HD11 ' A' ' 159' ' ' ILE . 3.2 p -150.9 163.14 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.301 0 C-N-CA 122.505 0.322 . . . . 74.43 110.162 -178.424 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 44.8 mtp180 -146.8 177.02 9.43 Favored 'General case' 0 N--CA 1.484 1.234 0 C-N-CA 124.987 1.315 . . . . 75.42 110.113 -171.441 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.2 tp10 -51.72 118.2 3.22 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 125.053 1.341 . . . . 71.14 111.51 170.545 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 79.0 1.28 84.91 Favored Glycine 0 C--N 1.351 1.373 0 CA-C-O 119.382 -0.677 . . . . 73.51 113.866 176.045 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.4 m -73.78 136.49 43.59 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-N 117.352 0.576 . . . . 63.34 110.953 -176.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.446 HG12 HD22 ' A' ' 175' ' ' LEU . 13.2 t -101.06 122.97 53.77 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-N 114.646 -1.161 . . . . 53.42 108.894 -174.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.568 HD11 HG21 ' A' ' 153' ' ' VAL . 16.6 mt -106.4 107.35 22.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 N-CA-C 109.035 -0.728 . . . . 74.21 109.035 -175.448 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.507 ' HA ' HD23 ' A' ' 175' ' ' LEU . 58.4 ttt-85 -81.7 109.13 15.83 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 110.03 -0.359 . . . . 63.5 110.03 176.202 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.444 HG22 ' O ' ' A' ' 174' ' ' LEU . 19.5 m -101.72 97.81 8.56 Favored Pre-proline 0 CA--C 1.559 1.319 0 N-CA-C 108.647 -0.872 . . . . 72.41 108.647 172.069 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -74.55 155.98 45.07 Favored 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 123.053 2.502 . . . . 50.41 113.189 -176.49 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 73.27 24.73 74.78 Favored Glycine 0 C--N 1.345 1.076 0 CA-C-N 115.488 -0.778 . . . . 72.51 112.586 -178.092 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.405 ' HG2' HG23 ' A' ' 161' ' ' VAL . 6.7 tpt -125.68 -56.89 1.47 Allowed 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 124.01 0.924 . . . . 74.35 111.573 -166.694 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 165' ' ' GLY . . . . . 0.551 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.353 1.491 0 O-C-N 123.725 0.641 . . . . 61.45 112.14 -175.032 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo . . . . . 0 CA--C 1.54 0.818 0 CA-C-O 120.713 0.214 . . . . 50.4 112.539 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -98.87 178.69 31.05 Favored Glycine 0 C--O 1.222 -0.625 0 N-CA-C 110.565 -1.014 . . . . 52.14 110.565 166.67 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -146.56 157.14 43.68 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 118.12 0.96 . . . . 71.51 111.259 -171.653 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.444 ' O ' HG22 ' A' ' 161' ' ' VAL . 27.0 tp -114.57 115.59 27.42 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 114.655 -1.157 . . . . 72.44 108.684 176.297 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.6 ' HB2' ' HG2' ' A' ' 120' ' ' ARG . 93.8 mt -90.35 99.46 12.48 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.297 1.039 . . . . 63.11 110.254 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.422 HD12 HG21 ' A' ' 149' ' ' ILE . 45.6 mt -87.07 104.59 16.48 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 122.81 0.444 . . . . 72.15 110.51 175.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.5 t -89.39 95.78 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 107.803 -1.184 . . . . 72.42 107.803 176.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.441 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 8.1 m -82.08 144.11 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 109.769 -0.456 . . . . 74.4 109.769 -174.695 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 5.2 mmm180 -122.28 105.55 10.31 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 106.118 -1.808 . . . . 64.52 106.118 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 36.6 mt -69.61 147.88 50.11 Favored 'General case' 0 N--CA 1.473 0.706 0 O-C-N 123.373 0.421 . . . . 65.21 111.175 -172.725 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.472 HD12 HG23 ' A' ' 126' ' ' THR . 36.5 mt -55.73 121.04 36.95 Favored Pre-proline 0 C--N 1.357 0.905 0 O-C-N 123.641 0.588 . . . . 73.54 109.748 177.635 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -65.98 88.02 0.24 Allowed 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 122.969 2.446 . . . . 61.13 112.306 -178.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 13.3 p80 -156.99 62.9 2.88 Favored Pre-proline 0 CA--C 1.55 0.958 0 N-CA-C 107.794 -1.187 . . . . 74.1 107.794 169.131 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -56.14 122.06 11.1 Favored 'Trans proline' 0 C--N 1.382 2.339 0 C-N-CA 122.089 1.859 . . . . 74.24 112.639 -170.053 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.83 -45.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 N-CA-C 107.704 -1.221 . . . . 61.51 107.704 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.435 ' CE2' HD13 ' A' ' 193' ' ' LEU . 4.9 m-85 -107.41 131.98 53.68 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 123.93 0.892 . . . . 72.41 110.384 178.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 69.0 mtp180 -117.81 131.12 56.61 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.765 1.226 . . . . 74.41 108.635 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.406 HD12 ' O ' ' A' ' 192' ' ' ASP . 58.6 tp -109.9 130.84 55.48 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 121.004 0.43 . . . . 64.2 110.182 177.267 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -129.87 101.79 6.02 Favored 'General case' 0 C--O 1.24 0.572 0 N-CA-C 107.417 -1.327 . . . . 63.53 107.417 172.69 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 69.67 -82.65 0.29 Allowed Glycine 0 CA--C 1.53 1.008 0 O-C-N 123.793 0.683 . . . . 62.11 112.607 -176.371 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 191' ' ' GLN . . . . . 0.417 HE22 ' HB3' ' A' ' 244' ' ' ALA . 49.8 tt0 -134.2 -22.18 1.79 Allowed 'General case' 0 CA--C 1.552 1.053 0 C-N-CA 124.733 1.213 . . . . 73.03 109.554 -177.58 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.406 ' O ' HD12 ' A' ' 188' ' ' LEU . 41.3 m-20 -81.41 149.73 28.69 Favored 'General case' 0 C--N 1.358 0.967 0 C-N-CA 123.809 0.844 . . . . 72.43 111.385 -178.31 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.535 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.8 mt -109.58 155.04 21.92 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 124.639 1.176 . . . . 51.1 110.491 174.604 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -140.02 119.02 12.6 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 105.605 -1.998 . . . . 74.31 105.605 172.34 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 195' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -135.5 134.41 39.49 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 109.184 -0.672 . . . . 71.4 109.184 -178.235 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 196' ' ' THR . . . . . 0.437 ' HA ' ' HB3' ' A' ' 252' ' ' GLU . 24.0 m -70.91 123.64 22.49 Favored 'General case' 0 CA--C 1.541 0.612 0 O-C-N 123.654 0.596 . . . . 73.2 110.064 -179.239 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.466 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 61.3 tp -105.95 111.34 23.95 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 108.767 -0.827 . . . . 71.34 108.767 -178.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -85.04 116.74 23.6 Favored 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.492 -0.929 . . . . 55.44 108.492 176.454 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 2.2 m -122.86 141.64 35.95 Favored Pre-proline 0 N--CA 1.479 0.986 0 N-CA-C 108.996 -0.742 . . . . 50.33 108.996 177.592 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -72.7 147.1 44.44 Favored 'Trans proline' 0 C--N 1.366 1.485 0 C-N-CA 121.539 1.493 . . . . 63.42 110.521 169.618 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -58.31 -40.97 86.87 Favored Pre-proline 0 CA--C 1.558 1.26 0 C-N-CA 123.689 0.796 . . . . 62.32 112.419 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -45.68 -54.84 4.07 Favored 'Trans proline' 0 C--N 1.392 2.844 0 C-N-CA 122.524 2.15 . . . . 43.41 114.164 167.151 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 11.7 mt -65.58 -36.29 77.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 C-N-CA 122.237 0.215 . . . . 75.13 111.429 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.53 -44.27 93.23 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.16 0.584 . . . . 31.24 111.944 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.7 m -80.16 -41.15 20.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 CA-C-N 116.063 -0.517 . . . . 53.34 111.569 -176.222 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.3 m -78.88 -21.18 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 122.549 0.34 . . . . 74.04 111.148 -178.649 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.516 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 71.2 65.32 2.48 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 115.764 -0.653 . . . . 74.32 112.439 -176.484 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -93.85 -155.55 31.87 Favored Glycine 0 C--N 1.353 1.505 0 CA-C-N 116.94 0.37 . . . . 65.4 112.535 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.22 134.87 54.62 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.326 1.05 . . . . 61.01 108.438 178.332 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 46.6 t -117.97 125.77 74.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 124.078 0.951 . . . . 64.43 108.593 -178.225 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -79.6 109.14 13.71 Favored 'General case' 0 CA--C 1.542 0.659 0 N-CA-C 109.137 -0.69 . . . . 64.54 109.137 177.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.95 129.92 48.35 Favored 'General case' 0 C--O 1.238 0.483 0 C-N-CA 123.417 0.687 . . . . 70.1 109.148 179.64 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.2 116.75 18.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.004 -0.544 . . . . 70.5 109.899 174.593 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.41 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.9 t -109.67 163.56 13.36 Favored 'General case' 0 C--O 1.242 0.685 0 O-C-N 123.901 0.75 . . . . 74.43 109.402 172.09 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 215' ' ' LEU . . . . . 0.552 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 90.2 mt -71.53 -2.58 17.37 Favored 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 115.507 -0.77 . . . . 63.33 112.61 -172.74 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -112.26 -11.72 13.69 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.565 0.746 . . . . 63.11 112.111 175.41 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 153.71 -156.34 26.73 Favored Glycine 0 C--N 1.349 1.267 0 CA-C-O 119.546 -0.585 . . . . 61.32 112.799 -179.047 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -94.28 133.53 0.76 Allowed 'Trans proline' 0 CA--C 1.556 1.592 0 C-N-CA 123.001 2.467 . . . . 74.14 112.846 174.808 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 27.1 m -114.56 157.5 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 123.585 0.754 . . . . 73.34 109.639 170.351 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -114.47 113.9 25.09 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 108.999 -0.741 . . . . 72.22 108.999 177.308 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.477 HG22 HD11 ' A' ' 235' ' ' LEU . 6.3 t -95.79 117.19 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 C-N-CA 123.99 0.916 . . . . 75.04 110.026 -177.328 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.99 100.57 11.14 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 108.977 -0.749 . . . . 74.21 108.977 176.101 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.516 HG23 ' HA2' ' A' ' 207' ' ' GLY . 20.0 m -79.43 137.45 55.65 Favored Pre-proline 0 CA--C 1.551 1.019 0 N-CA-C 109.415 -0.587 . . . . 54.14 109.415 179.415 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -63.31 144.9 92.39 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.537 2.158 . . . . 61.32 112.498 176.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -55.77 120.41 8.2 Favored 'Trans proline' 0 C--N 1.381 2.258 0 C-N-CA 123.081 2.521 . . . . 43.42 112.043 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 67.3 mtt180 64.76 54.61 1.34 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.382 1.073 . . . . 64.41 110.388 -175.185 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.3 t -75.49 167.36 22.04 Favored 'General case' 0 CA--C 1.545 0.781 0 CA-C-N 115.372 -0.831 . . . . 71.31 109.159 173.298 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -128.15 146.28 50.76 Favored 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 123.217 0.607 . . . . 74.12 109.614 -177.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -68.13 127.9 34.6 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 115.318 -0.855 . . . . 74.35 109.27 175.357 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.29 0.31 23.69 Favored Glycine 0 N--CA 1.471 1.032 0 CA-C-O 119.497 -0.613 . . . . 62.42 112.841 -173.463 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 25.0 mtp180 -84.4 154.89 22.55 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 117.414 0.607 . . . . 73.15 109.865 170.025 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.658 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.0 OUTLIER -120.59 101.67 7.91 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 108.497 -0.927 . . . . 75.12 108.497 176.269 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 37.2 mt -83.37 113.98 21.11 Favored 'General case' 0 C--N 1.352 0.686 0 N-CA-C 108.964 -0.754 . . . . 73.12 108.964 -173.142 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 -87.24 106.68 18.07 Favored 'General case' 0 C--O 1.239 0.507 0 C-N-CA 123.782 0.833 . . . . 75.32 110.839 -167.506 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.477 HD11 HG22 ' A' ' 221' ' ' VAL . 15.7 mt -94.06 104.28 16.32 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 108.112 -1.07 . . . . 75.15 108.112 174.091 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -74.65 141.47 44.61 Favored 'General case' 0 C--O 1.242 0.683 0 CA-C-N 115.763 -0.653 . . . . 73.13 112.025 -170.195 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 66.59 32.99 83.16 Favored Glycine 0 C--N 1.349 1.271 0 O-C-N 124.12 0.888 . . . . 71.22 113.253 178.044 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 41.1 mmtm -116.13 -2.68 12.15 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.663 0.785 . . . . 74.21 111.166 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 239' ' ' GLY . . . . . 0.449 ' O ' ' HD2' ' A' ' 246' ' ' ARG . . . -82.03 -156.16 17.28 Favored Glycine 0 C--N 1.347 1.177 0 O-C-N 123.657 0.598 . . . . 61.33 114.181 -178.164 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.42 ' CD2' ' HA2' ' A' ' 152' ' ' GLY . 35.0 m-85 -88.34 160.29 45.64 Favored Pre-proline 0 N--CA 1.482 1.159 0 C-N-CA 123.204 0.601 . . . . 52.24 110.56 176.176 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -57.09 152.5 44.15 Favored 'Trans proline' 0 C--N 1.382 2.313 0 C-N-CA 123.031 2.487 . . . . 71.51 113.971 178.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 176.94 -167.71 39.2 Favored Glycine 0 C--N 1.341 0.853 0 CA-C-N 115.27 -0.877 . . . . 74.34 112.11 176.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.27 -15.3 35.15 Favored 'Trans proline' 0 C--N 1.382 2.291 0 C-N-CA 122.983 2.456 . . . . 71.13 112.619 -176.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 244' ' ' ALA . . . . . 0.417 ' HB3' HE22 ' A' ' 191' ' ' GLN . . . -96.77 24.12 6.39 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.175 0.99 . . . . 54.34 110.692 174.817 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 77.8 -89.62 1.06 Allowed Glycine 0 C--N 1.345 1.063 0 N-CA-C 110.943 -0.863 . . . . 70.41 110.943 -175.713 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.449 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 23.1 mtm180 -128.09 155.89 43.67 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 108.728 -0.841 . . . . 75.14 108.728 169.539 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -70.9 -160.78 3.72 Favored Glycine 0 C--N 1.348 1.231 0 O-C-N 123.727 0.642 . . . . 60.14 114.397 -176.25 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -129.21 138.33 51.64 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 122.888 0.475 . . . . 74.52 109.772 -173.319 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.535 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 30.6 tp -97.27 115.96 28.59 Favored 'General case' 0 C--O 1.214 -0.788 0 C-N-CA 123.624 0.77 . . . . 75.1 110.017 -178.308 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 250' ' ' TYR . . . . . 0.658 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 97.3 m-85 -101.65 106.95 18.06 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 123.497 0.719 . . . . 73.0 109.356 179.1 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.5 ' HA ' ' O ' ' A' ' 195' ' ' ALA . 78.3 mt -87.08 118.72 26.65 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.372 -0.831 . . . . 72.23 113.115 -175.763 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.437 ' HB3' ' HA ' ' A' ' 196' ' ' THR . 10.5 tp10 -79.76 91.71 5.34 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 108.578 -0.897 . . . . 74.21 108.578 -178.609 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 59.7 t -52.5 118.38 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 123.99 0.916 . . . . 74.03 110.875 177.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 30.7 mmm180 -123.48 94.79 4.35 Favored 'General case' 0 C--O 1.24 0.569 0 C-N-CA 124.635 1.174 . . . . 74.11 107.95 176.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 63.4 mt -76.62 114.25 16.69 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 115.716 -0.674 . . . . 55.22 109.299 177.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 6.4 t . . . . . 0 C--O 1.248 1.014 0 C-N-CA 124.619 1.168 . . . . 62.41 108.944 -179.559 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.7 tp . . . . . 0 C--O 1.236 0.358 0 N-CA-C 107.599 -1.26 . . . . 64.24 107.599 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.561 ' HB ' ' HB3' ' A' ' 123' ' ' LEU 0.269 2.4 p 36.57 -95.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 C-N-CA 126.337 1.855 . . . . 74.31 113.713 176.956 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.46 ' H ' HG13 ' A' ' 99' ' ' VAL . . . 57.31 8.32 0.57 Allowed 'General case' 0 N--CA 1.493 1.683 0 C-N-CA 124.963 1.305 . . . . 62.25 113.14 -176.725 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 35.7 t-80 -103.81 71.91 1.08 Allowed 'General case' 0 C--O 1.243 0.756 0 N-CA-C 107.374 -1.343 . . . . 74.11 107.374 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 81.0 t -72.53 137.18 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 CA-C-N 114.375 -1.284 . . . . 34.54 109.702 -179.031 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 72.2 p . . . . . 0 N--CA 1.476 0.838 0 C-N-CA 124.504 1.122 . . . . 72.42 112.724 -173.842 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.3 p30 . . . . . 0 N--CA 1.468 0.432 0 N-CA-C 106.811 -1.552 . . . . 71.14 106.811 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 1.3 tt -99.83 143.34 30.17 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 106.427 -1.694 . . . . 71.51 106.427 177.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 12.7 tpp85 -119.0 125.23 48.9 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 118.778 0.717 . . . . 72.53 110.591 -173.569 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -147.85 149.95 33.25 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.341 0.656 . . . . 71.34 109.794 178.694 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.664 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 41.8 mt-10 -127.83 149.4 50.29 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.52 0.728 . . . . 71.43 109.418 -179.074 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.561 ' HB3' ' HB ' ' A' ' 99' ' ' VAL . 1.5 pt? -143.93 147.1 36.93 Favored Pre-proline 0 N--CA 1.474 0.741 0 O-C-N 123.505 0.503 . . . . 63.51 111.323 -176.623 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -76.79 113.93 3.74 Favored 'Trans proline' 0 C--N 1.371 1.738 0 C-N-CA 121.426 1.418 . . . . 73.44 109.688 162.024 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.464 HD22 HG11 ' A' ' 178' ' ' VAL . 18.6 tp -108.28 158.8 17.15 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.758 0.823 . . . . 45.44 108.839 178.456 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.57 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 6.9 m -95.52 156.26 16.4 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 123.397 0.679 . . . . 71.33 109.191 175.824 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 82.0 mt -58.34 -49.33 77.58 Favored 'General case' 0 N--CA 1.488 1.436 0 CA-C-O 122.348 1.071 . . . . 62.14 109.455 174.302 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -57.01 -38.16 72.7 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 113.276 -1.784 . . . . 74.14 111.475 177.155 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 31.5 mm-40 -80.02 -21.16 43.86 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.231 0.612 . . . . 72.22 112.469 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.539 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -61.63 -40.33 94.47 Favored 'General case' 0 C--O 1.256 1.417 0 CA-C-O 121.665 0.745 . . . . 42.31 110.696 167.321 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.491 ' HA ' ' CE1' ' A' ' 240' ' ' PHE . 69.0 t80 -70.31 -48.35 56.98 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 113.964 -1.471 . . . . 74.44 112.774 172.611 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -71.55 -47.32 55.78 Favored 'General case' 0 N--CA 1.485 1.277 0 N-CA-C 112.067 0.395 . . . . 74.01 112.067 -172.844 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.32 -115.89 8.19 Favored Glycine 0 CA--C 1.533 1.204 0 N-CA-C 111.121 -0.791 . . . . 52.13 111.121 -175.643 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.8 174.55 39.71 Favored Glycine 0 C--N 1.346 1.124 0 N-CA-C 115.175 0.83 . . . . 54.44 115.175 167.613 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -87.61 118.26 26.98 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.346 1.059 . . . . 62.42 108.221 178.431 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -130.44 138.88 50.53 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 124.368 1.067 . . . . 74.43 108.543 -176.496 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 7.2 p -83.12 139.93 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 N-CA-C 108.697 -0.853 . . . . 74.2 108.697 174.16 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.446 HG21 HG13 ' A' ' 99' ' ' VAL . 7.1 p -143.04 153.09 16.89 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 C-N-CA 124.011 0.924 . . . . 74.53 109.324 -178.275 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -116.38 100.27 7.77 Favored 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 107.782 -1.192 . . . . 73.2 107.782 170.827 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 9.0 t -103.65 111.54 33.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 N-CA-C 108.753 -0.832 . . . . 71.34 108.753 -172.037 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.93 26.0 15.33 Favored 'General case' 0 N--CA 1.479 1.017 0 O-C-N 124.493 1.121 . . . . 72.43 111.658 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 91.75 13.63 57.77 Favored Glycine 0 C--N 1.355 1.585 0 CA-C-N 115.807 -0.633 . . . . 74.4 113.315 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 25.8 ttt180 -116.7 116.23 27.13 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 122.986 0.514 . . . . 72.23 110.134 177.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -87.5 114.09 23.8 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 122.838 0.455 . . . . 62.15 110.196 -178.175 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.6 p -148.13 152.79 12.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 C-N-CA 124.835 1.254 . . . . 72.02 109.089 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 43.7 m -82.86 122.19 27.91 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 122.835 0.454 . . . . 75.13 110.258 175.15 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.414 HG22 HG23 ' A' ' 149' ' ' ILE . 13.7 p -98.59 123.99 51.48 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 C-N-CA 123.646 0.778 . . . . 75.03 109.594 175.366 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 30.9 ttt85 -108.05 98.25 7.84 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 107.849 -1.167 . . . . 74.41 107.849 174.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.414 HG23 HG22 ' A' ' 147' ' ' VAL . 35.3 pt -96.32 131.4 28.64 Favored Pre-proline 0 N--CA 1.479 0.984 0 N-CA-C 109.673 -0.492 . . . . 75.32 109.673 178.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.404 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 58.2 Cg_endo -67.71 145.32 69.04 Favored 'Trans proline' 0 C--N 1.375 1.94 0 C-N-CA 122.852 2.368 . . . . 73.44 112.982 -174.154 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.475 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 32.1 Cg_exo -63.68 125.12 14.85 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 123.045 2.497 . . . . 74.33 110.596 171.186 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 131.44 41.25 0.21 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 111.827 -0.509 . . . . 50.31 111.827 -173.183 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.539 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -118.58 154.21 20.77 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 N-CA-C 108.775 -0.824 . . . . 74.32 108.775 -177.484 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 40.9 mtp180 -144.66 166.85 24.01 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 124.943 1.297 . . . . 72.25 109.055 -165.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -52.75 123.18 10.65 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 123.61 0.764 . . . . 60.14 111.943 176.312 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 80.62 -4.61 68.17 Favored Glycine 0 C--N 1.348 1.202 0 CA-C-N 115.896 -0.593 . . . . 64.13 113.629 179.158 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 32.4 t -68.82 127.52 33.38 Favored 'General case' 0 C--O 1.248 1.016 0 C-N-CA 123.665 0.786 . . . . 61.1 110.134 -176.257 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.515 HG12 HD22 ' A' ' 175' ' ' LEU . 8.7 t -97.89 119.46 45.94 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-N 114.303 -1.317 . . . . 63.4 108.627 -176.449 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.483 HD11 HG21 ' A' ' 153' ' ' VAL . 17.2 mt -102.94 117.07 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 123.664 0.786 . . . . 75.4 110.054 -170.68 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 22.3 ttm180 -84.02 117.39 23.37 Favored 'General case' 0 C--O 1.239 0.512 0 C-N-CA 123.53 0.732 . . . . 64.22 110.414 172.234 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.84 101.39 53.02 Favored Pre-proline 0 CA--C 1.559 1.29 0 N-CA-C 108.293 -1.003 . . . . 70.54 108.293 169.642 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -64.92 149.66 89.2 Favored 'Trans proline' 0 C--N 1.384 2.407 0 C-N-CA 123.55 2.833 . . . . 60.44 113.428 -172.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 71.3 24.2 77.22 Favored Glycine 0 C--N 1.348 1.216 0 O-C-N 123.594 0.559 . . . . 62.43 113.795 175.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 2.9 tpt -100.52 -51.86 3.5 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.149 0.98 . . . . 64.42 109.998 -177.645 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.351 1.391 0 CA-C-N 115.403 -0.817 . . . . 71.32 112.092 -179.511 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo . . . . . 0 CA--C 1.554 1.523 0 CA-C-O 121.173 0.405 . . . . 55.2 112.507 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -100.6 150.5 18.82 Favored Glycine 0 C--N 1.342 0.866 0 N-CA-C 108.988 -1.645 . . . . 61.31 108.988 174.193 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -113.09 -179.89 3.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 118.049 0.924 . . . . 74.23 111.498 -164.323 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 15.6 tp -121.98 128.63 51.69 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 107.82 -1.178 . . . . 71.53 107.82 167.3 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.515 HD22 HG12 ' A' ' 158' ' ' VAL . 76.6 mt -99.76 101.99 13.31 Favored 'General case' 0 C--O 1.243 0.746 0 C-N-CA 125.085 1.354 . . . . 75.4 110.28 178.342 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 86.4 mt -91.28 109.46 20.73 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 123.612 0.765 . . . . 74.4 111.114 175.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.664 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 21.5 t -90.2 105.22 16.0 Favored 'Isoleucine or valine' 0 C--O 1.247 0.938 0 N-CA-C 108.115 -1.068 . . . . 71.11 108.115 173.286 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.464 HG11 HD22 ' A' ' 125' ' ' LEU . 6.1 m -82.4 151.34 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 CA-C-O 121.223 0.535 . . . . 60.24 111.615 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 38.2 mmt180 -124.07 98.95 6.01 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 107.67 -1.233 . . . . 71.25 107.67 176.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 57.5 mt -67.46 144.64 55.61 Favored 'General case' 0 C--O 1.241 0.628 0 O-C-N 123.139 0.274 . . . . 72.04 110.685 -178.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.57 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 44.1 mt -59.83 147.03 80.11 Favored Pre-proline 0 CA--C 1.558 1.284 0 O-C-N 124.366 1.041 . . . . 52.15 110.967 -176.436 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -75.46 58.09 5.06 Favored 'Trans proline' 0 C--N 1.375 1.96 0 C-N-CA 123.991 3.127 . . . . 73.44 113.845 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -142.28 51.82 2.17 Favored Pre-proline 0 CA--C 1.562 1.434 0 C-N-CA 123.035 0.534 . . . . 54.04 109.831 171.791 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -64.21 123.56 12.05 Favored 'Trans proline' 0 C--N 1.388 2.632 0 C-N-CA 122.43 2.087 . . . . 61.31 111.905 -168.333 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -128.22 -37.49 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 123.81 0.844 . . . . 74.52 109.363 -177.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.435 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 6.0 m-85 -107.39 124.37 49.74 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 114.814 -1.085 . . . . 73.02 110.338 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.652 ' HB3' ' HB2' ' A' ' 194' ' ' TYR . 19.6 tpp180 -105.02 139.08 40.24 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 106.934 -1.506 . . . . 63.51 106.934 172.073 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 51.1 tp -123.41 122.62 38.74 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 122.897 0.479 . . . . 63.14 109.86 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -144.9 127.86 16.47 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 122.39 0.276 . . . . 74.13 110.322 169.16 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 63.94 33.83 88.28 Favored Glycine 0 C--N 1.356 1.648 0 O-C-N 123.91 0.756 . . . . 75.25 114.246 177.292 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 73.96 -5.24 2.08 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 125.714 1.606 . . . . 73.25 112.659 -175.567 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -93.33 149.98 20.82 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.479 0.711 . . . . 73.01 109.579 178.69 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.646 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 93.1 mt -108.92 163.57 13.17 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 124.281 1.033 . . . . 70.21 109.94 -176.409 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 194' ' ' TYR . . . . . 0.652 ' HB2' ' HB3' ' A' ' 187' ' ' ARG . 85.1 m-85 -143.38 121.52 12.18 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 106.803 -1.554 . . . . 74.51 106.803 178.01 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -147.25 164.32 33.58 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.444 0.697 . . . . 75.54 109.921 -176.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 17.5 m -106.2 125.45 51.01 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.51 -0.768 . . . . 62.0 109.17 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.56 HD22 HD13 ' A' ' 251' ' ' LEU . 65.5 tp -112.44 115.65 29.03 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.541 0.736 . . . . 73.04 109.631 177.419 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -78.7 131.03 36.46 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 108.138 -1.06 . . . . 65.44 108.138 169.249 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 199' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 255' ' ' ILE . 90.9 t -129.78 121.15 19.86 Favored Pre-proline 0 N--CA 1.474 0.728 0 N-CA-C 107.682 -1.229 . . . . 72.14 107.682 178.626 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -65.83 147.66 85.57 Favored 'Trans proline' 0 C--N 1.369 1.657 0 C-N-CA 122.143 1.895 . . . . 74.13 110.888 176.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 201' ' ' ALA . . . . . 0.445 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -53.5 -42.5 92.24 Favored Pre-proline 0 N--CA 1.48 1.065 0 C-N-CA 124.483 1.113 . . . . 65.11 113.569 -177.323 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 202' ' ' PRO . . . . . 0.445 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 10.8 Cg_endo -52.42 -51.29 11.46 Favored 'Trans proline' 0 C--N 1.397 3.107 0 C-N-CA 122.144 1.896 . . . . 74.11 112.64 172.219 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 7.0 mt -66.49 -37.11 78.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 123.211 0.604 . . . . 72.21 111.641 -179.065 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.3 -42.97 99.11 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 122.926 0.49 . . . . 52.24 111.929 -178.345 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.2 m -82.62 -35.59 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.87 0 CA-C-N 115.931 -0.577 . . . . 73.55 111.987 -175.026 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 12.4 m -87.23 -18.92 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 CA-C-N 118.043 0.383 . . . . 74.22 111.658 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.408 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 77.87 55.04 4.28 Favored Glycine 0 C--N 1.344 1.022 0 CA-C-N 115.857 -0.61 . . . . 75.24 113.218 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -84.87 -169.66 46.17 Favored Glycine 0 C--N 1.349 1.252 0 CA-C-O 121.783 0.657 . . . . 71.11 112.585 -177.754 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 209' ' ' LYS . . . . . 0.432 ' HD2' ' N ' ' A' ' 209' ' ' LYS . 0.0 OUTLIER -115.61 120.18 38.58 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 107.771 -1.196 . . . . 63.53 107.771 -173.667 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 210' ' ' VAL . . . . . 0.442 HG11 HG22 ' A' ' 199' ' ' VAL . 7.3 p -124.42 144.07 35.57 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 124.37 1.068 . . . . 44.21 109.343 -178.304 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.22 138.06 34.74 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.297 -0.631 . . . . 72.13 109.297 176.134 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -107.69 131.56 54.28 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 108.446 -0.946 . . . . 63.5 108.446 169.739 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.49 104.55 9.16 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.988 -1.116 . . . . 72.33 107.988 179.375 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.447 HG23 ' H ' ' A' ' 216' ' ' GLU . 14.8 t -112.41 168.15 9.87 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.161 0.584 . . . . 63.1 110.543 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 65.2 mt -70.03 -7.3 39.93 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 123.562 0.745 . . . . 71.23 111.788 -179.094 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 216' ' ' GLU . . . . . 0.447 ' H ' HG23 ' A' ' 214' ' ' THR . 42.6 tt0 -97.28 -18.07 19.42 Favored 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.679 1.192 . . . . 70.32 111.382 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 133.06 -147.83 19.11 Favored Glycine 0 N--CA 1.475 1.284 0 CA-C-O 119.188 -0.784 . . . . 64.15 111.82 -178.232 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -85.84 126.73 2.98 Favored 'Trans proline' 0 CA--C 1.559 1.757 0 C-N-CA 122.878 2.386 . . . . 53.42 112.021 172.239 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 26.1 m -109.68 156.1 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 122.918 0.487 . . . . 63.35 110.944 172.296 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 24.9 mm-40 -95.09 109.89 21.89 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 123.572 0.749 . . . . 72.12 109.827 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.566 HG22 HD11 ' A' ' 235' ' ' LEU . 8.7 t -104.25 117.52 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.663 0.785 . . . . 65.55 109.057 172.525 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -98.62 102.42 14.15 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 108.279 -1.008 . . . . 71.34 108.279 174.436 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.408 HG23 ' HA2' ' A' ' 207' ' ' GLY . 11.9 m -75.97 143.52 74.35 Favored Pre-proline 0 CA--C 1.551 1.011 0 N-CA-C 109.638 -0.504 . . . . 75.33 109.638 -176.827 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -64.46 140.68 70.62 Favored 'Trans proline' 0 C--N 1.368 1.587 0 C-N-CA 122.777 2.318 . . . . 63.13 112.34 174.425 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.9 129.38 34.63 Favored 'Trans proline' 0 C--N 1.376 1.992 0 C-N-CA 122.713 2.275 . . . . 53.31 111.337 171.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 64.3 mtm180 65.85 34.89 6.98 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 125.116 1.367 . . . . 73.33 110.988 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 5.7 t -66.64 164.55 16.6 Favored 'General case' 0 CA--C 1.549 0.919 0 N-CA-C 109.938 -0.393 . . . . 74.12 109.938 176.548 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -120.46 150.95 40.0 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.731 0.813 . . . . 75.52 109.697 -176.019 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -68.28 141.92 55.72 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.13 0.972 . . . . 54.21 110.727 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 91.11 -3.83 80.64 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-O 119.467 -0.629 . . . . 72.41 112.542 -176.646 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 41.1 mtp180 -72.01 161.3 31.12 Favored 'General case' 0 C--N 1.362 1.125 0 CA-C-O 122.16 0.981 . . . . 74.22 110.64 177.784 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 232' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -107.62 107.73 18.67 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 113.892 -1.503 . . . . 53.54 108.043 -173.184 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 233' ' ' LEU . . . . . 0.447 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 45.9 mt -100.38 98.31 8.96 Favored 'General case' 0 C--N 1.349 0.576 0 N-CA-C 107.328 -1.36 . . . . 63.24 107.328 175.655 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 234' ' ' ARG . . . . . 0.498 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 20.0 ttm180 -100.92 115.86 31.43 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.154 0.502 . . . . 74.12 110.698 -171.457 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.566 HD11 HG22 ' A' ' 221' ' ' VAL . 23.4 mt -96.06 117.75 31.3 Favored 'General case' 0 C--O 1.241 0.631 0 C-N-CA 124.159 0.983 . . . . 62.32 109.508 -176.02 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 49.8 mtmt -72.46 133.66 44.95 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.597 0.759 . . . . 74.21 111.151 -175.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 70.69 33.81 66.82 Favored Glycine 0 C--N 1.345 1.03 0 O-C-N 124.214 0.946 . . . . 62.02 112.954 176.107 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 72.7 mmtt -123.17 5.49 9.19 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.246 0.618 . . . . 72.13 111.958 178.507 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -85.51 -147.94 10.18 Favored Glycine 0 C--N 1.35 1.328 0 O-C-N 123.532 0.52 . . . . 71.25 112.952 177.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.491 ' CE1' ' HA ' ' A' ' 131' ' ' PHE . 16.2 m-85 -95.95 145.18 29.1 Favored Pre-proline 0 N--CA 1.478 0.931 0 C-N-CA 123.05 0.54 . . . . 71.04 111.589 173.435 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.72 156.53 39.82 Favored 'Trans proline' 0 C--N 1.375 1.968 0 C-N-CA 123.308 2.672 . . . . 72.34 112.468 173.435 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 173.92 -163.17 34.09 Favored Glycine 0 CA--C 1.535 1.335 0 CA-C-N 115.317 -0.856 . . . . 63.2 111.921 177.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.43 -16.49 43.31 Favored 'Trans proline' 0 C--N 1.379 2.179 0 C-N-CA 123.274 2.649 . . . . 41.02 112.912 -175.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -97.1 22.62 8.27 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.794 0.837 . . . . 63.05 111.222 177.692 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 79.93 -138.31 19.88 Favored Glycine 0 C--N 1.352 1.441 0 N-CA-C 110.699 -0.961 . . . . 51.31 110.699 -174.222 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 56.4 ttt180 -110.53 142.19 42.65 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 117.509 0.654 . . . . 72.03 109.648 171.207 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -77.76 -158.24 10.24 Favored Glycine 0 C--N 1.342 0.903 0 O-C-N 123.684 0.615 . . . . 43.33 112.945 177.512 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -128.52 170.58 13.02 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.803 0.841 . . . . 54.31 109.746 -172.826 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.646 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 15.7 tp -111.79 113.66 26.15 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.784 0.834 . . . . 72.42 109.806 171.424 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 250' ' ' TYR . . . . . 0.493 ' HB3' ' O ' ' A' ' 193' ' ' LEU . 2.9 t80 -88.42 108.06 19.18 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 107.567 -1.272 . . . . 74.14 107.567 174.202 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.56 HD13 HD22 ' A' ' 197' ' ' LEU . 52.3 mt -91.16 145.42 24.69 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 123.522 0.729 . . . . 73.34 110.744 170.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -107.63 101.95 11.23 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 107.161 -1.422 . . . . 75.24 107.161 167.36 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.3 p -62.38 128.25 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 CA-C-O 121.326 0.584 . . . . 72.34 110.115 177.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 9.9 mmm180 -125.72 94.33 4.09 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 107.195 -1.409 . . . . 75.14 107.195 -177.72 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 199' ' ' VAL . 67.2 mt -76.55 139.89 18.09 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 CA-C-N 115.364 -0.835 . . . . 64.34 110.379 -173.367 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.5 t . . . . . 0 CA--C 1.554 1.108 0 C-N-CA 123.781 0.832 . . . . 53.52 109.244 -175.429 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.6 tp . . . . . 0 N--CA 1.48 1.025 0 CA-C-O 121.523 0.678 . . . . 74.23 110.237 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 12.9 p 176.86 146.32 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-N 114.218 -1.356 . . . . 73.34 109.282 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -88.08 -78.53 0.32 Allowed 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 108.37 -0.974 . . . . 71.42 108.37 167.414 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 10.3 m170 -159.32 165.42 33.42 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 124.163 0.985 . . . . 64.3 109.92 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 84.2 t -64.02 136.35 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 O-C-N 124.052 0.845 . . . . 71.4 109.637 174.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 32.6 p . . . . . 0 CA--C 1.549 0.94 0 C-N-CA 123.716 0.806 . . . . 75.43 109.363 173.927 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 . . . . . 0 C--O 1.241 0.65 0 N-CA-C 108.878 -0.786 . . . . 73.23 108.878 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 30.3 mt -96.4 156.22 16.43 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 123.469 0.708 . . . . 70.22 109.19 -178.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.2 146.28 44.68 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.519 -1.289 . . . . 74.0 107.519 174.422 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -158.36 136.82 10.98 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 123.528 0.731 . . . . 71.32 109.787 -178.042 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -100.97 142.62 32.19 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.485 0.714 . . . . 54.01 109.718 -178.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -146.45 143.09 18.25 Favored Pre-proline 0 CA--C 1.552 1.049 0 C-N-CA 123.077 0.551 . . . . 71.23 110.565 174.508 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_exo -77.4 118.26 4.57 Favored 'Trans proline' 0 C--N 1.376 2.004 0 C-N-CA 122.97 2.447 . . . . 72.35 111.327 172.842 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.427 ' HG ' ' HB2' ' A' ' 129' ' ' GLU . 14.8 tp -108.62 155.59 20.51 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 123.75 0.82 . . . . 72.14 109.678 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.606 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 20.7 m -93.56 157.48 16.17 Favored 'General case' 0 CA--C 1.55 0.945 0 N-CA-C 109.363 -0.606 . . . . 55.23 109.363 174.235 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.479 HD11 ' O ' ' A' ' 183' ' ' HIS . 32.6 mt -58.22 -48.18 81.16 Favored 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 123.944 0.898 . . . . 33.44 110.382 178.786 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -54.25 -36.49 63.62 Favored 'General case' 0 C--O 1.218 -0.584 0 CA-C-N 113.796 -1.547 . . . . 61.44 110.736 176.371 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.606 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 7.5 mm-40 -79.6 -23.04 42.95 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.48 0.712 . . . . 74.14 111.411 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.792 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -63.0 -36.32 83.16 Favored 'General case' 0 C--O 1.244 0.793 0 CA-C-O 121.42 0.628 . . . . 72.2 110.304 167.334 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.415 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 26.8 t80 -81.31 -33.54 32.51 Favored 'General case' 0 CA--C 1.554 1.097 0 CA-C-N 114.709 -1.132 . . . . 75.22 111.972 176.11 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' HIS . . . . . 0.474 ' HB2' ' HA ' ' A' ' 129' ' ' GLU . 24.6 m80 -84.13 -40.96 17.58 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 112.631 0.604 . . . . 63.53 112.631 -173.243 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 72.16 -129.55 15.23 Favored Glycine 0 CA--C 1.536 1.389 0 N-CA-C 110.834 -0.907 . . . . 74.11 110.834 -166.694 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 134.97 140.2 4.19 Favored Glycine 0 N--CA 1.477 1.401 0 CA-C-N 117.805 0.802 . . . . 61.12 114.145 169.443 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -86.54 113.6 22.59 Favored 'General case' 0 C--N 1.357 0.91 0 N-CA-C 108.486 -0.931 . . . . 61.23 108.486 167.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -141.81 170.11 16.32 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.901 1.281 . . . . 71.32 108.314 175.588 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.498 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 14.7 p -95.18 143.3 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 118.639 0.654 . . . . 61.22 111.276 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 12.2 p -114.94 138.24 45.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 C-N-CA 123.833 0.853 . . . . 64.4 109.553 172.483 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -125.51 105.12 8.81 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 108.678 -0.86 . . . . 63.24 108.678 173.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.2 m -129.59 133.72 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 124.187 0.995 . . . . 63.12 110.042 -177.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.96 22.82 13.67 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 124.534 1.134 . . . . 73.44 111.313 -176.165 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.64 -6.7 79.6 Favored Glycine 0 C--N 1.354 1.538 0 CA-C-N 115.734 -0.666 . . . . 74.51 113.124 -176.078 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 53.4 ttt85 -94.81 119.67 33.77 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 123.632 0.773 . . . . 62.43 110.396 -175.687 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 20.6 ttp180 -105.07 109.63 21.69 Favored 'General case' 0 CA--C 1.552 1.024 0 C-N-CA 123.998 0.919 . . . . 62.23 110.797 -174.451 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 13.7 m -133.24 155.54 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 C-N-CA 124.708 1.203 . . . . 52.44 108.795 174.344 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.498 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 60.1 p -76.8 126.8 31.59 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 118.235 0.471 . . . . 55.41 110.684 -179.567 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.94 120.35 48.14 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.741 0 CA-C-O 121.827 0.822 . . . . 73.1 110.48 176.164 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 49.8 ttt180 -109.13 95.13 5.43 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 108.74 -0.837 . . . . 73.21 108.74 176.313 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 28.4 pt -93.66 119.78 66.8 Favored Pre-proline 0 CA--C 1.547 0.852 0 N-CA-C 107.913 -1.143 . . . . 72.13 107.913 171.423 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -76.64 163.17 32.08 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.352 2.035 . . . . 74.11 112.507 -177.403 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -54.76 142.68 73.17 Favored 'Trans proline' 0 C--N 1.375 1.963 0 C-N-CA 123.005 2.47 . . . . 72.34 112.372 171.188 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 108.66 38.31 1.92 Allowed Glycine 0 C--N 1.339 0.721 0 CA-C-N 116.773 -0.194 . . . . 72.33 113.037 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.792 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -108.66 163.07 6.23 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.359 0 N-CA-C 108.7 -0.852 . . . . 53.43 108.7 177.005 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.528 ' HB2' ' HB2' ' A' ' 157' ' ' SER . 25.1 mtp-105 -141.8 164.28 30.63 Favored 'General case' 0 N--CA 1.492 1.635 0 C-N-CA 123.963 0.905 . . . . 72.13 111.071 -165.637 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.1 tp10 -54.53 116.72 2.82 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.444 1.098 . . . . 71.1 111.226 165.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.27 4.68 90.11 Favored Glycine 0 C--N 1.357 1.706 0 CA-C-N 116.04 -0.527 . . . . 70.34 113.166 178.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.528 ' HB2' ' HB2' ' A' ' 154' ' ' ARG . 30.1 t -79.21 124.2 28.13 Favored 'General case' 0 C--O 1.25 1.11 0 N-CA-C 109.026 -0.731 . . . . 74.1 109.026 -179.686 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.44 HG12 HD22 ' A' ' 175' ' ' LEU . 20.0 t -99.05 120.68 48.71 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 CA-C-N 114.298 -1.319 . . . . 72.4 107.886 -177.728 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.434 HD11 HG21 ' A' ' 153' ' ' VAL . 13.0 mt -101.86 122.01 53.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 123.533 0.733 . . . . 54.32 110.15 -168.697 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 74.2 ttt180 -86.31 103.25 14.72 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 123.317 0.647 . . . . 74.34 109.908 177.43 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.449 HG22 ' O ' ' A' ' 174' ' ' LEU . 16.4 m -107.59 104.92 54.65 Favored Pre-proline 0 CA--C 1.564 1.5 0 C-N-CA 122.608 0.363 . . . . 74.11 110.027 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -67.41 140.69 53.47 Favored 'Trans proline' 0 C--N 1.375 1.954 0 C-N-CA 122.82 2.346 . . . . 70.33 113.332 -173.189 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 105.04 -9.97 47.32 Favored Glycine 0 C--N 1.349 1.282 0 N-CA-C 114.868 0.707 . . . . 61.44 114.868 170.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.4 mpt? -81.9 -61.35 1.94 Allowed 'General case' 0 N--CA 1.482 1.135 0 CA-C-N 117.815 0.807 . . . . 73.41 110.157 176.096 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.345 1.073 0 CA-C-N 115.345 -0.843 . . . . 74.35 111.785 176.709 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo . . . . . 0 CA--C 1.541 0.866 0 N-CA-C 111.683 -0.16 . . . . 63.22 111.683 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -80.97 -132.26 1.2 Allowed Glycine 0 C--N 1.34 0.764 0 N-CA-C 111.498 -0.641 . . . . 62.12 111.498 175.177 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -163.81 177.79 8.35 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.205 0.526 . . . . 71.42 110.885 -175.166 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.449 ' O ' HG22 ' A' ' 161' ' ' VAL . 15.0 tp -129.32 122.57 29.83 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 108.571 -0.9 . . . . 62.24 108.571 173.527 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.44 HD22 HG12 ' A' ' 158' ' ' VAL . 49.8 mt -88.11 99.41 12.17 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.139 -0.937 . . . . 64.34 110.927 179.186 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 74.9 mt -87.44 105.34 17.22 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 123.011 0.524 . . . . 64.42 110.748 175.429 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.8 t -85.49 104.45 13.37 Favored 'Isoleucine or valine' 0 C--O 1.242 0.697 0 N-CA-C 108.23 -1.026 . . . . 73.12 108.23 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.423 HG21 HG22 ' A' ' 153' ' ' VAL . 25.3 m -83.95 144.79 9.25 Favored 'Isoleucine or valine' 0 C--O 1.251 1.136 0 CA-C-O 121.481 0.657 . . . . 74.11 110.367 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 13.5 mmm180 -118.53 99.3 6.72 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 107.068 -1.456 . . . . 73.01 107.068 -178.594 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.421 HD23 ' HB3' ' A' ' 125' ' ' LEU . 29.5 mt -67.56 146.1 54.24 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 118.314 0.507 . . . . 73.41 110.303 177.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.438 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 73.1 mt -55.27 154.51 11.06 Favored Pre-proline 0 CA--C 1.553 1.063 0 O-C-N 124.489 1.118 . . . . 72.24 112.839 -170.337 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.403 ' O ' ' HD3' ' A' ' 184' ' ' PRO . 55.5 Cg_endo -66.81 0.38 3.72 Favored 'Trans proline' 0 C--N 1.381 2.287 0 C-N-CA 123.081 2.52 . . . . 62.2 112.808 171.231 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 183' ' ' HIS . . . . . 0.479 ' O ' HD11 ' A' ' 127' ' ' LEU . 14.7 t60 -95.55 99.21 4.41 Favored Pre-proline 0 CA--C 1.541 0.611 0 C-N-CA 124.974 1.31 . . . . 72.43 107.582 162.721 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 184' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 182' ' ' PRO . 44.4 Cg_endo -103.64 123.67 0.07 OUTLIER 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 123.135 2.557 . . . . 64.33 112.413 168.607 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -120.68 -43.58 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 107.74 -1.207 . . . . 63.44 107.74 171.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -113.64 126.31 55.12 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 114.674 -1.148 . . . . 62.42 110.144 176.487 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 36.5 ttp85 -119.41 127.04 52.74 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 108.51 -0.922 . . . . 71.44 108.51 172.421 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.427 HD12 ' O ' ' A' ' 192' ' ' ASP . 56.0 tp -90.18 132.53 35.42 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 108.359 -0.978 . . . . 63.15 108.359 170.461 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -144.48 130.1 19.07 Favored 'General case' 0 C--O 1.241 0.642 0 N-CA-C 109.621 -0.511 . . . . 74.12 109.621 173.179 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 70.95 -75.78 0.59 Allowed Glycine 0 C--N 1.35 1.346 0 O-C-N 124.003 0.814 . . . . 63.52 111.871 -175.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 191' ' ' GLN . . . . . 0.497 ' HB2' ' O ' ' A' ' 240' ' ' PHE . 3.7 pt20 -157.6 -10.49 0.08 Allowed 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 124.118 0.967 . . . . 60.43 110.846 174.532 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.427 ' O ' HD12 ' A' ' 188' ' ' LEU . 80.3 m-20 -96.31 162.96 13.28 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 123.014 0.526 . . . . 62.12 110.942 -175.829 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.478 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.2 mt -106.9 155.91 19.25 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 107.704 -1.221 . . . . 73.15 107.704 -178.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -137.15 121.8 18.53 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 108.642 -0.873 . . . . 70.1 108.642 -175.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 195' ' ' ALA . . . . . 0.479 ' HB3' HD23 ' A' ' 251' ' ' LEU . . . -142.63 162.12 36.29 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.697 0.799 . . . . 65.3 110.221 -178.603 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 196' ' ' THR . . . . . 0.519 ' HA ' ' HB3' ' A' ' 252' ' ' GLU . 36.0 m -109.08 119.37 39.34 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 109.018 -0.734 . . . . 71.15 109.018 174.794 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.534 HD22 HD13 ' A' ' 251' ' ' LEU . 55.1 tp -106.84 110.13 22.21 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 109.17 -0.678 . . . . 53.35 109.17 178.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -89.83 127.56 36.0 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 107.804 -1.184 . . . . 62.32 107.804 172.211 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 199' ' ' VAL . . . . . 0.507 HG12 HG11 ' A' ' 210' ' ' VAL . 15.4 m -119.99 139.83 28.87 Favored Pre-proline 0 C--O 1.244 0.78 0 N-CA-C 109.097 -0.705 . . . . 64.33 109.097 -178.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -60.05 143.99 99.51 Favored 'Trans proline' 0 C--N 1.367 1.522 0 C-N-CA 122.073 1.849 . . . . 52.21 111.085 174.039 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -53.44 -45.69 98.41 Favored Pre-proline 0 CA--C 1.555 1.165 0 CA-C-O 118.359 -0.829 . . . . 75.13 113.046 177.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -55.62 -42.33 68.8 Favored 'Trans proline' 0 C--N 1.39 2.755 0 C-N-CA 122.106 1.871 . . . . 63.15 113.261 172.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 4.0 mt -65.84 -43.6 93.12 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 C-N-CA 122.63 0.372 . . . . 72.54 111.256 176.635 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -58.56 -44.72 89.79 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 123.057 0.543 . . . . 74.11 111.451 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 205' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 33.4 m -77.39 -40.28 28.83 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 CA-C-N 115.745 -0.661 . . . . 74.33 112.081 -175.542 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.0 m -81.13 -20.72 11.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 119.1 0.863 . . . . 63.24 111.188 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.592 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 80.09 48.45 6.48 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-N 115.985 -0.552 . . . . 73.32 112.179 -175.837 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.27 -174.0 49.41 Favored Glycine 0 C--N 1.351 1.375 0 CA-C-O 121.37 0.428 . . . . 42.54 112.945 -177.104 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 209' ' ' LYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 222' ' ' ALA . 20.5 pttm -114.17 134.71 54.72 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.385 1.074 . . . . 74.31 109.797 -176.106 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 210' ' ' VAL . . . . . 0.507 HG11 HG12 ' A' ' 199' ' ' VAL . 7.6 p -133.71 157.23 42.13 Favored 'Isoleucine or valine' 0 C--O 1.241 0.608 0 C-N-CA 124.552 1.141 . . . . 75.24 108.494 -175.317 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 59.2 mmt-85 -91.55 128.93 37.57 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 109.489 -0.56 . . . . 72.44 109.489 178.033 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -102.72 122.09 43.76 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 108.643 -0.873 . . . . 71.24 108.643 171.427 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 5.6 tpt -74.04 104.66 4.95 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.732 0.813 . . . . 74.3 109.574 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 10.1 t -110.82 170.76 7.88 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 123.452 0.701 . . . . 65.31 110.623 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 62.4 mt -73.89 -2.2 22.83 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.022 0.929 . . . . 73.14 112.481 -175.233 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -114.82 -0.22 13.57 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 123.743 0.817 . . . . 70.35 112.17 174.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 133.25 -154.15 21.08 Favored Glycine 0 N--CA 1.48 1.597 0 CA-C-O 119.269 -0.74 . . . . 73.22 112.818 177.383 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -89.9 134.12 2.18 Favored 'Trans proline' 0 CA--C 1.554 1.49 0 C-N-CA 122.92 2.413 . . . . 74.11 112.259 172.083 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.1 m -113.79 158.15 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 CA-C-O 121.014 0.435 . . . . 73.11 111.74 175.368 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -96.75 104.54 16.54 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 114.966 -1.015 . . . . 63.25 108.429 -177.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.448 ' HB ' HD11 ' A' ' 235' ' ' LEU . 2.8 p -118.84 113.51 41.84 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 CA-C-O 121.437 0.637 . . . . 74.44 109.928 177.461 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 222' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 209' ' ' LYS . . . -97.28 118.69 34.3 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 108.759 -0.83 . . . . 73.01 108.759 178.061 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.592 HG23 ' HA2' ' A' ' 207' ' ' GLY . 18.2 m -72.96 148.04 88.96 Favored Pre-proline 0 CA--C 1.555 1.152 0 N-CA-C 109.523 -0.547 . . . . 75.14 109.523 176.029 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.0 151.98 73.31 Favored 'Trans proline' 0 CA--C 1.559 1.753 0 C-N-CA 122.173 1.915 . . . . 74.01 112.019 173.885 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -52.07 119.68 6.09 Favored 'Trans proline' 0 C--N 1.383 2.365 0 C-N-CA 123.646 2.898 . . . . 75.51 112.801 177.893 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 226' ' ' ARG . . . . . 0.479 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 48.6 mtm180 54.34 58.11 5.25 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 124.488 1.115 . . . . 71.5 110.668 -174.612 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 10.7 t -66.22 169.29 7.33 Favored 'General case' 0 CA--C 1.545 0.761 0 CA-C-N 115.539 -0.755 . . . . 54.15 109.506 173.079 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.8 mp0 -121.33 144.13 48.81 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 123.035 0.534 . . . . 52.4 109.83 -175.597 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -67.2 119.67 12.48 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-N 115.212 -0.904 . . . . 63.02 108.822 173.505 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.33 -12.06 19.26 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-O 119.65 -0.528 . . . . 60.23 112.315 -174.002 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 58.2 mtp180 -74.14 160.9 30.58 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 117.2 0.5 . . . . 73.41 110.604 174.475 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.403 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.3 mppt? -128.55 120.57 26.97 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.77 0.428 . . . . 74.1 110.676 -175.728 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 233' ' ' LEU . . . . . 0.493 HD11 HG12 ' A' ' 223' ' ' VAL . 59.6 mt -97.59 112.88 24.56 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 108.697 -0.853 . . . . 73.54 108.697 -178.248 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 234' ' ' ARG . . . . . 0.53 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 39.5 ttt85 -98.6 104.61 16.67 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 116.014 -0.539 . . . . 72.24 110.015 -172.211 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.516 HD12 HD23 ' A' ' 249' ' ' LEU . 27.3 mt -91.63 107.2 19.04 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.671 0.788 . . . . 62.13 109.156 -177.38 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 6.8 mtpm? -77.25 144.1 38.45 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 112.273 0.471 . . . . 71.51 112.273 -173.109 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 85.38 35.92 11.45 Favored Glycine 0 C--N 1.349 1.266 0 O-C-N 123.769 0.668 . . . . 74.22 112.323 -177.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 34.9 mmtm -125.61 -41.16 2.02 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 122.86 0.464 . . . . 72.11 112.184 -176.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -83.85 -178.04 51.69 Favored Glycine 0 C--N 1.337 0.62 0 C-N-CA 121.609 -0.329 . . . . 54.12 112.28 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.497 ' O ' ' HB2' ' A' ' 191' ' ' GLN . 72.5 m-85 -94.93 157.91 35.88 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 123.307 0.643 . . . . 74.43 111.77 -174.122 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -52.42 150.48 20.5 Favored 'Trans proline' 0 C--N 1.381 2.283 0 C-N-CA 123.254 2.636 . . . . 52.43 114.002 175.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 179.01 -159.54 24.5 Favored Glycine 0 CA--C 1.535 1.293 0 CA-C-O 119.516 -0.602 . . . . 71.5 113.099 -176.257 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -62.92 -34.34 71.85 Favored 'Trans proline' 0 C--N 1.375 1.925 0 C-N-CA 123.925 3.083 . . . . 72.52 114.217 -171.163 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.89 22.81 4.0 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.342 0.657 . . . . 73.01 111.289 178.474 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.97 -96.56 2.14 Favored Glycine 0 C--N 1.347 1.191 0 N-CA-C 111.192 -0.763 . . . . 63.43 111.192 179.113 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 42.1 ttt-85 -115.65 144.69 43.55 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 123.558 0.743 . . . . 75.43 109.09 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -80.26 168.99 52.37 Favored Glycine 0 C--O 1.253 1.297 0 O-C-N 123.604 0.565 . . . . 62.44 112.899 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 55.4 m-20 -139.57 171.97 13.48 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.342 1.057 . . . . 74.53 108.915 -173.624 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.53 ' O ' ' HA ' ' A' ' 234' ' ' ARG . 15.5 tp -98.44 128.92 45.02 Favored 'General case' 0 C--O 1.21 -0.974 0 C-N-CA 123.101 0.56 . . . . 71.43 109.761 177.129 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 53.8 t80 -111.47 102.62 10.97 Favored 'General case' 0 CA--C 1.551 1.01 0 N-CA-C 107.49 -1.3 . . . . 71.22 107.49 -178.551 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.534 HD13 HD22 ' A' ' 197' ' ' LEU . 90.3 mt -87.54 150.61 23.61 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.996 0.919 . . . . 51.31 112.688 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.519 ' HB3' ' HA ' ' A' ' 196' ' ' THR . 14.0 tp10 -105.62 98.09 7.83 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 123.494 0.717 . . . . 72.32 109.314 173.226 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 80.3 t -56.98 112.5 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 123.205 0.602 . . . . 53.12 111.019 174.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 49.3 mmm-85 -119.07 96.06 5.07 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 125.033 1.333 . . . . 75.15 108.069 177.149 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 58.8 mt -75.5 128.18 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 N-CA-C 109.561 -0.533 . . . . 41.33 109.561 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.249 1.028 0 C-N-CA 124.574 1.15 . . . . 64.4 107.911 -176.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.622 ' HB2' ' HB3' ' A' ' 136' ' ' ARG . 33.4 tp . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 109.379 -0.6 . . . . 75.43 109.379 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 24.0 t -89.6 150.93 3.57 Favored 'Isoleucine or valine' 0 C--O 1.239 0.502 0 C-N-CA 124.454 1.102 . . . . 72.02 109.14 172.67 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -77.23 -51.06 11.57 Favored 'General case' 0 CA--C 1.54 0.579 0 O-C-N 123.713 0.633 . . . . 64.21 109.484 175.307 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 46.5 p-80 -179.2 177.13 0.8 Allowed 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 124.864 1.266 . . . . 71.24 109.535 -175.126 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.524 HG11 HD12 ' A' ' 119' ' ' LEU . 29.5 m -78.51 155.12 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 C-N-CA 122.683 0.393 . . . . 72.33 111.366 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.0 t . . . . . 0 CA--C 1.546 0.799 0 CA-C-O 122.402 1.096 . . . . 71.42 109.226 179.354 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 . . . . . 0 C--O 1.241 0.655 0 N-CA-C 108.452 -0.944 . . . . 72.14 108.452 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.524 HD12 HG11 ' A' ' 102' ' ' VAL . 4.5 mm? -96.19 159.69 14.82 Favored 'General case' 0 N--CA 1.464 0.25 0 C-N-CA 124.129 0.972 . . . . 73.31 109.418 176.008 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 23.1 ptt180 -141.95 121.12 12.99 Favored 'General case' 0 C--O 1.241 0.649 0 N-CA-C 109.322 -0.622 . . . . 65.53 109.322 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -145.69 129.43 17.17 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 124.232 1.013 . . . . 65.11 109.446 -173.248 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.742 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 43.5 mt-10 -105.05 138.54 41.09 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 123.721 0.808 . . . . 62.33 109.228 178.747 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.476 HD21 HG12 ' A' ' 178' ' ' VAL . 1.8 pt? -135.64 141.52 37.47 Favored Pre-proline 0 N--CA 1.474 0.747 0 N-CA-C 110.033 -0.358 . . . . 61.34 110.033 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -73.38 113.27 3.73 Favored 'Trans proline' 0 C--N 1.368 1.586 0 C-N-CA 122.217 1.944 . . . . 64.44 109.924 171.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.547 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 11.9 tp -122.67 147.73 46.11 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 106.27 -1.752 . . . . 74.33 106.27 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 8.9 t -107.24 172.95 6.54 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 119.455 1.025 . . . . 74.1 110.491 175.067 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.5 ' O ' HD13 ' A' ' 215' ' ' LEU . 31.4 mt -55.38 -46.17 76.52 Favored 'General case' 0 N--CA 1.47 0.533 0 O-C-N 124.561 1.163 . . . . 71.12 109.949 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -51.66 -40.79 60.66 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 113.969 -1.469 . . . . 72.12 111.263 177.28 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.503 ' HB2' ' HG ' ' A' ' 125' ' ' LEU . 22.8 mm-40 -83.31 -24.02 32.33 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.195 0.598 . . . . 73.11 111.193 -178.621 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.432 ' HA ' ' CG1' ' A' ' 153' ' ' VAL . . . -59.78 -32.97 71.1 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 123.117 0.567 . . . . 72.5 111.645 167.404 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.3 t80 -77.72 -53.53 7.43 Favored 'General case' 0 C--N 1.351 0.636 0 CA-C-N 116.167 -0.47 . . . . 72.45 111.062 171.052 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -60.36 -45.85 92.04 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 123.552 0.532 . . . . 72.32 111.728 -172.137 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 59.53 -125.28 38.91 Favored Glycine 0 C--N 1.349 1.257 0 O-C-N 123.881 0.738 . . . . 65.51 111.378 -178.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.01 169.83 29.66 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 114.009 0.364 . . . . 42.4 114.009 166.412 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.417 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.6 mp0 -88.08 126.82 35.31 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 107.443 -1.318 . . . . 62.42 107.443 172.38 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.622 ' HB3' ' HB2' ' A' ' 98' ' ' LEU . 6.6 tpt180 -154.83 134.0 12.42 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 108.87 -0.789 . . . . 71.12 108.87 -177.221 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.673 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 10.9 p -74.75 143.38 13.47 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 C-N-CA 123.103 0.561 . . . . 62.25 112.477 -168.287 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.429 HG12 ' HB3' ' A' ' 98' ' ' LEU . 5.0 m -128.66 161.56 37.35 Favored 'Isoleucine or valine' 0 C--O 1.247 0.956 0 C-N-CA 124.458 1.103 . . . . 62.31 110.258 178.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 46.4 mm-40 -111.09 111.32 22.34 Favored 'General case' 0 C--O 1.238 0.499 0 C-N-CA 123.954 0.902 . . . . 71.54 109.419 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.461 HG21 HD22 ' A' ' 174' ' ' LEU . 45.2 t -138.27 119.89 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 123.503 0.721 . . . . 73.04 110.628 178.751 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 64.05 21.78 12.7 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 124.785 1.234 . . . . 63.13 112.94 171.105 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.19 14.12 77.49 Favored Glycine 0 C--N 1.349 1.251 0 CA-C-N 116.702 -0.226 . . . . 65.32 112.729 -176.159 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? -110.78 118.5 36.31 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.422 1.089 . . . . 74.02 108.152 176.019 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 54.2 ttp180 -87.1 106.33 17.79 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 107.694 -1.224 . . . . 73.32 107.694 174.843 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 8.1 m -136.01 135.78 50.13 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 123.541 0.737 . . . . 72.42 110.429 -172.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.673 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 35.9 t -83.51 128.28 34.39 Favored 'General case' 0 C--O 1.241 0.616 0 C-N-CA 123.371 0.668 . . . . 71.21 109.679 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.557 HG13 HG11 ' A' ' 161' ' ' VAL . 99.0 t -99.65 125.98 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 123.577 0.751 . . . . 65.05 110.469 177.482 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 148' ' ' ARG . . . . . 0.417 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 74.4 ttt180 -99.08 104.23 16.22 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 123.844 0.857 . . . . 74.03 109.483 172.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.574 HG22 HG21 ' A' ' 159' ' ' ILE . 28.3 pt -107.54 118.11 54.14 Favored Pre-proline 0 CA--C 1.55 0.969 0 N-CA-C 108.598 -0.89 . . . . 72.51 108.598 169.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -67.09 152.15 80.48 Favored 'Trans proline' 0 C--N 1.379 2.14 0 C-N-CA 122.668 2.245 . . . . 71.44 113.107 -175.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_exo -49.2 113.7 1.02 Allowed 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 123.609 2.873 . . . . 73.43 112.662 170.32 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 129.94 65.37 0.1 Allowed Glycine 0 C--N 1.342 0.911 0 CA-C-N 116.319 -0.401 . . . . 71.04 112.208 177.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.5 HG21 HD11 ' A' ' 159' ' ' ILE . 3.9 p -129.72 159.96 41.22 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.51 0 C-N-CA 123.15 0.58 . . . . 53.14 109.529 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 29.9 mtp-105 -136.79 168.31 19.78 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 123.8 0.84 . . . . 72.44 111.292 -164.638 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -57.1 121.64 10.52 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.403 1.081 . . . . 73.44 111.333 171.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.62 9.9 86.66 Favored Glycine 0 C--N 1.35 1.339 0 O-C-N 123.832 0.708 . . . . 71.43 113.21 178.652 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 30.3 t -73.39 122.89 22.79 Favored 'General case' 0 C--N 1.356 0.881 0 C-N-CA 123.165 0.586 . . . . 42.44 109.468 -177.705 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.556 HG12 HD22 ' A' ' 175' ' ' LEU . 11.3 t -99.46 116.25 42.19 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 O-C-N 124.399 1.062 . . . . 50.12 108.485 -178.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.574 HG21 HG22 ' A' ' 149' ' ' ILE . 18.1 mt -107.66 113.42 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 123.665 0.786 . . . . 73.54 110.247 -170.79 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 26.8 ttm180 -89.59 113.28 24.69 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 123.346 0.658 . . . . 63.12 110.878 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.557 HG11 HG13 ' A' ' 147' ' ' VAL . 22.5 m -109.48 99.48 37.34 Favored Pre-proline 0 CA--C 1.564 1.51 0 N-CA-C 109.603 -0.517 . . . . 55.35 109.603 176.333 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -69.62 150.31 68.87 Favored 'Trans proline' 0 C--N 1.377 2.058 0 C-N-CA 123.298 2.665 . . . . 74.3 113.501 -172.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.32 10.37 86.26 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-N 115.383 -0.826 . . . . 75.12 113.656 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 58.4 mtp -114.82 -20.48 10.58 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.365 0.666 . . . . 71.24 112.419 -173.473 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.342 0.867 0 CA-C-O 119.755 -0.469 . . . . 32.45 112.067 177.061 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo . . . . . 0 CA--C 1.544 0.976 0 N-CA-C 111.56 -0.208 . . . . 73.23 111.56 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -90.98 160.23 27.17 Favored Glycine 0 C--N 1.334 0.46 0 N-CA-C 110.063 -1.215 . . . . 52.41 110.063 170.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -120.03 176.95 5.18 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.012 0.525 . . . . 74.35 110.446 -174.491 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.461 HD22 HG21 ' A' ' 140' ' ' VAL . 19.5 tp -128.06 115.95 19.25 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 115.34 -0.846 . . . . 70.54 109.304 172.424 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.556 HD22 HG12 ' A' ' 158' ' ' VAL . 88.9 mt -87.87 105.69 17.6 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 125.164 1.386 . . . . 74.22 110.852 179.28 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 36.6 mt -95.91 108.06 20.39 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 123.079 0.551 . . . . 73.31 111.037 177.319 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.742 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 19.7 t -90.78 99.9 10.32 Favored 'Isoleucine or valine' 0 C--O 1.242 0.71 0 N-CA-C 107.957 -1.127 . . . . 75.13 107.957 174.054 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.476 HG12 HD21 ' A' ' 123' ' ' LEU . 4.3 m -82.21 141.48 14.97 Favored 'Isoleucine or valine' 0 C--O 1.245 0.833 0 N-CA-C 109.054 -0.721 . . . . 75.33 109.054 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 16.1 mmm-85 -119.54 104.98 10.78 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.669 -1.234 . . . . 74.24 107.669 -175.427 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.547 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 61.2 mt -68.87 147.43 51.71 Favored 'General case' 0 CA--C 1.545 0.763 0 O-C-N 123.506 0.504 . . . . 75.31 111.009 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.465 ' HB2' ' HB3' ' A' ' 183' ' ' HIS . 27.7 mt -63.64 168.78 4.96 Favored Pre-proline 0 CA--C 1.56 1.33 0 C-N-CA 124.07 0.948 . . . . 71.42 111.098 -174.361 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -75.76 43.01 1.02 Allowed 'Trans proline' 0 C--N 1.381 2.243 0 C-N-CA 122.885 2.39 . . . . 71.45 111.601 162.117 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 183' ' ' HIS . . . . . 0.465 ' HB3' ' HB2' ' A' ' 181' ' ' LEU . 8.2 t60 -125.27 95.48 41.23 Favored Pre-proline 0 CA--C 1.532 0.281 0 N-CA-C 105.88 -1.896 . . . . 73.45 105.88 -178.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -100.75 123.76 0.11 Allowed 'Trans proline' 0 CA--C 1.554 1.525 0 C-N-CA 122.636 2.224 . . . . 63.5 113.052 176.156 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.437 HG12 HD12 ' A' ' 127' ' ' LEU . 4.1 p -144.75 -42.04 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 N-CA-C 108.855 -0.794 . . . . 71.13 108.855 175.135 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.429 ' H ' HD13 ' A' ' 127' ' ' LEU . 3.8 m-85 -126.96 154.93 43.91 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.387 1.075 . . . . 73.24 110.208 174.443 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 18.6 ttp85 -156.25 142.8 18.55 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 123.221 0.608 . . . . 63.14 109.564 178.087 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.468 HD13 ' HD1' ' A' ' 240' ' ' PHE . 56.6 tp -104.63 140.61 37.78 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.762 0.825 . . . . 73.1 110.27 178.186 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -139.64 111.49 7.35 Favored 'General case' 0 C--O 1.246 0.877 0 N-CA-C 107.191 -1.411 . . . . 61.31 107.191 168.551 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 74.66 -80.93 0.88 Allowed Glycine 0 C--N 1.347 1.171 0 O-C-N 123.558 0.536 . . . . 64.2 112.611 177.662 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 191' ' ' GLN . . . . . 0.428 ' HB3' ' HA3' ' A' ' 242' ' ' GLY . 9.3 pt20 -138.39 -23.04 1.0 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 124.068 0.947 . . . . 53.23 110.168 176.302 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.439 ' O ' HD12 ' A' ' 188' ' ' LEU . 0.6 OUTLIER -89.6 157.59 17.98 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 123.832 0.853 . . . . 64.25 110.884 -173.046 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.575 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.7 mt -108.62 166.88 10.46 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 124.75 1.22 . . . . 73.33 109.508 -177.509 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -142.78 122.1 13.07 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 107.135 -1.432 . . . . 74.33 107.135 -178.841 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -148.19 152.18 36.8 Favored 'General case' 0 CA--C 1.518 -0.285 0 C-N-CA 123.823 0.849 . . . . 63.12 110.459 -174.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 7.4 m -100.94 120.87 40.8 Favored 'General case' 0 CA--C 1.541 0.604 0 O-C-N 124.025 0.828 . . . . 74.41 109.389 176.294 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.53 HD22 HD13 ' A' ' 251' ' ' LEU . 66.0 tp -107.53 111.89 24.37 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.839 0.856 . . . . 74.13 109.467 -179.346 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -95.28 119.14 33.27 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.399 0.68 . . . . 75.41 109.259 176.805 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 199' ' ' VAL . . . . . 0.527 HG11 HG11 ' A' ' 223' ' ' VAL . 6.0 m -122.99 139.97 32.53 Favored Pre-proline 0 N--CA 1.475 0.8 0 C-N-CA 123.37 0.668 . . . . 73.23 109.267 -178.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_exo -59.31 144.37 99.42 Favored 'Trans proline' 0 C--N 1.372 1.793 0 C-N-CA 122.745 2.297 . . . . 63.34 111.81 171.411 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 201' ' ' ALA . . . . . 0.401 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -55.67 -44.63 99.76 Favored Pre-proline 0 CA--C 1.554 1.12 0 CA-C-O 117.963 -1.018 . . . . 53.51 111.991 177.192 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -48.61 -51.3 10.58 Favored 'Trans proline' 0 C--N 1.399 3.232 0 C-N-CA 122.537 2.158 . . . . 61.41 112.865 169.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 4.3 mt -62.44 -38.84 82.33 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.078 0 C-N-CA 123.202 0.601 . . . . 72.24 111.03 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.45 -44.41 96.47 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.17 0.588 . . . . 61.05 112.06 -178.773 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.3 m -78.55 -39.39 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-N 116.004 -0.543 . . . . 64.15 111.426 -174.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.1 m -82.9 -20.8 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 122.434 0.294 . . . . 71.22 111.284 -179.718 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.432 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 72.6 68.16 1.66 Allowed Glycine 0 C--N 1.343 0.932 0 N-CA-C 111.324 -0.711 . . . . 60.54 111.324 -175.531 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -92.87 -164.49 37.85 Favored Glycine 0 C--N 1.352 1.472 0 N-CA-C 111.482 -0.647 . . . . 74.11 111.482 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -115.11 139.17 50.12 Favored 'General case' 0 C--O 1.241 0.647 0 C-N-CA 123.554 0.742 . . . . 73.32 109.146 -178.05 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 210' ' ' VAL . . . . . 0.544 HG23 HG13 ' A' ' 221' ' ' VAL . 6.6 m -134.39 149.22 29.77 Favored 'Isoleucine or valine' 0 C--O 1.24 0.589 0 C-N-CA 123.876 0.87 . . . . 63.13 109.073 177.794 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 211' ' ' ARG . . . . . 0.483 ' H ' ' HD2' ' A' ' 211' ' ' ARG . 0.2 OUTLIER -104.87 125.9 51.38 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 108.116 -1.068 . . . . 74.11 108.116 174.874 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.48 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -99.89 129.2 45.95 Favored 'General case' 0 C--O 1.245 0.843 0 N-CA-C 108.792 -0.818 . . . . 44.33 108.792 -175.239 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 6.1 tpt -71.47 102.6 2.71 Favored 'General case' 0 CA--C 1.537 0.452 0 O-C-N 124.198 0.936 . . . . 73.21 109.4 -178.7 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.495 HG21 HG13 ' A' ' 219' ' ' VAL . 10.0 t -110.95 166.75 10.78 Favored 'General case' 0 C--O 1.238 0.451 0 CA-C-O 121.62 0.724 . . . . 72.33 110.694 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 215' ' ' LEU . . . . . 0.5 HD13 ' O ' ' A' ' 127' ' ' LEU . 25.9 mt -66.59 -19.04 65.68 Favored 'General case' 0 CA--C 1.545 0.765 0 CA-C-N 114.634 -1.166 . . . . 73.51 110.88 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -87.48 -21.7 25.35 Favored 'General case' 0 CA--C 1.558 1.263 0 C-N-CA 125.609 1.564 . . . . 63.12 111.797 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 139.39 -146.91 18.71 Favored Glycine 0 C--N 1.352 1.431 0 CA-C-O 119.157 -0.802 . . . . 71.42 111.583 -169.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -93.51 133.79 0.94 Allowed 'Trans proline' 0 CA--C 1.557 1.666 0 C-N-CA 122.373 2.049 . . . . 61.3 112.276 165.206 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 219' ' ' VAL . . . . . 0.495 HG13 HG21 ' A' ' 214' ' ' THR . 16.5 m -108.97 143.25 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 C-N-CA 122.934 0.494 . . . . 63.31 110.453 171.818 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -91.37 108.9 20.21 Favored 'General case' 0 CA--C 1.542 0.649 0 CA-C-O 121.524 0.678 . . . . 73.55 109.598 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.544 HG13 HG23 ' A' ' 210' ' ' VAL . 2.6 p -119.19 127.15 75.85 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.761 0 C-N-CA 123.55 0.74 . . . . 72.1 110.557 173.417 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -96.88 120.21 36.79 Favored 'General case' 0 C--O 1.238 0.453 0 C-N-CA 123.982 0.913 . . . . 71.31 109.215 177.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.527 HG11 HG11 ' A' ' 199' ' ' VAL . 11.5 m -82.65 141.85 45.26 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 109.631 -0.507 . . . . 63.14 109.631 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -63.74 141.07 77.37 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 122.752 2.302 . . . . 74.12 112.202 175.504 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -62.12 125.31 16.13 Favored 'Trans proline' 0 C--N 1.37 1.693 0 C-N-CA 122.513 2.142 . . . . 73.31 111.076 173.341 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 56.6 mtm180 64.77 50.21 2.08 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 124.951 1.407 . . . . 74.01 109.993 -172.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.0 t -79.5 169.7 17.66 Favored 'General case' 0 CA--C 1.546 0.804 0 CA-C-N 115.862 -0.608 . . . . 54.31 109.619 172.761 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 228' ' ' GLN . . . . . 0.595 ' H ' ' HD3' ' A' ' 231' ' ' ARG . 26.3 mp0 -125.04 142.09 51.71 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 123.808 0.843 . . . . 73.35 109.373 -172.605 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.66 119.39 13.83 Favored 'General case' 0 C--N 1.348 0.515 0 C-N-CA 123.469 0.708 . . . . 74.43 109.221 175.327 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.75 -7.08 22.17 Favored Glycine 0 C--N 1.34 0.793 0 CA-C-N 116.156 -0.475 . . . . 73.51 111.999 -171.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 231' ' ' ARG . . . . . 0.595 ' HD3' ' H ' ' A' ' 228' ' ' GLN . 75.2 mtp180 -81.94 160.94 23.24 Favored 'General case' 0 C--N 1.354 0.761 0 C-N-CA 122.766 0.426 . . . . 73.1 110.416 173.479 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.448 ' HG2' ' CE1' ' A' ' 250' ' ' TYR . 2.7 mppt? -122.23 135.59 54.78 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.267 0.627 . . . . 74.41 110.35 -175.727 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 61.8 mt -112.19 104.74 12.95 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 107.697 -1.223 . . . . 61.11 107.697 175.568 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 234' ' ' ARG . . . . . 0.548 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 50.3 ttt180 -94.14 109.04 20.84 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 115.682 -0.69 . . . . 74.13 109.622 -173.341 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.497 HD12 HD23 ' A' ' 249' ' ' LEU . 18.5 mt -85.95 128.11 34.77 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 122.838 0.455 . . . . 73.23 110.219 -175.656 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 50.0 mtmt -71.04 122.14 19.5 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.449 1.1 . . . . 71.45 111.762 -167.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.58 16.98 70.37 Favored Glycine 0 C--N 1.351 1.385 0 O-C-N 123.793 0.683 . . . . 55.11 114.02 172.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -94.9 7.28 46.51 Favored 'General case' 0 N--CA 1.48 1.049 0 N-CA-C 112.49 0.552 . . . . 70.11 112.49 -174.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -95.62 -170.84 35.9 Favored Glycine 0 C--N 1.34 0.789 0 O-C-N 123.553 0.533 . . . . 62.2 112.347 175.812 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.468 ' HD1' HD13 ' A' ' 188' ' ' LEU . 60.3 m-85 -85.95 159.88 53.57 Favored Pre-proline 0 CA--C 1.544 0.733 0 C-N-CA 123.578 0.751 . . . . 74.13 111.107 -176.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -52.97 127.94 26.94 Favored 'Trans proline' 0 C--N 1.391 2.812 0 C-N-CA 122.713 2.276 . . . . 71.4 112.221 176.693 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 242' ' ' GLY . . . . . 0.428 ' HA3' ' HB3' ' A' ' 191' ' ' GLN . . . -157.0 -164.36 13.49 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-O 119.03 -0.872 . . . . 74.34 111.945 -177.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.39 -30.34 91.02 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 123.569 2.846 . . . . 75.31 114.153 -173.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -93.61 22.97 4.96 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 123.428 0.691 . . . . 71.11 111.329 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 87.87 -73.92 2.26 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 110.104 -1.198 . . . . 74.31 110.104 -174.237 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 50.0 mtm180 -127.02 162.52 25.82 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 124.16 0.984 . . . . 73.44 108.674 167.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -89.38 -156.86 32.34 Favored Glycine 0 C--N 1.342 0.876 0 O-C-N 123.671 0.607 . . . . 72.03 112.398 176.476 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -135.86 171.59 14.24 Favored 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 109.182 -0.673 . . . . 72.41 109.182 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.575 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 12.8 tp -106.81 117.4 33.96 Favored 'General case' 0 C--O 1.213 -0.848 0 C-N-CA 123.268 0.627 . . . . 43.33 111.171 176.11 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 250' ' ' TYR . . . . . 0.478 ' HB3' ' O ' ' A' ' 193' ' ' LEU . 1.9 t80 -89.68 103.98 16.58 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 107.979 -1.119 . . . . 73.52 107.979 173.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.53 HD13 HD22 ' A' ' 197' ' ' LEU . 76.2 mt -88.77 148.03 24.15 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 123.261 0.625 . . . . 74.15 110.921 172.515 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -109.34 97.49 7.07 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 108.768 -0.827 . . . . 74.32 108.768 175.22 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 57.3 t -53.68 113.94 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 123.28 0.632 . . . . 45.51 110.802 173.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 27.7 mmt85 -123.64 94.3 4.2 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 107.185 -1.413 . . . . 73.42 107.185 178.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.401 HG23 ' HA ' ' A' ' 201' ' ' ALA . 76.6 mt -77.82 114.76 18.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 123.718 0.807 . . . . 65.24 110.318 -176.551 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 4.2 t . . . . . 0 CA--C 1.562 1.428 0 C-N-CA 123.633 0.773 . . . . 63.54 109.527 176.051 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.463 HD21 HD13 ' A' ' 125' ' ' LEU . 30.5 tp . . . . . 0 C--O 1.241 0.658 0 CA-C-O 119.806 -0.14 . . . . 63.35 111.121 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.447 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 14.8 p -67.3 120.62 14.94 Favored 'Isoleucine or valine' 0 C--N 1.36 1.051 0 CA-C-O 121.54 0.686 . . . . 64.13 110.26 175.462 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -85.67 -60.71 1.94 Allowed 'General case' 0 C--O 1.24 0.564 0 CA-C-N 114.933 -1.031 . . . . 62.1 110.456 -175.657 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 26.6 t-80 -165.94 157.81 14.22 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 115.793 -0.64 . . . . 75.53 111.217 -171.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 25.9 t -64.42 145.14 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 125.148 1.379 . . . . 63.42 111.028 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.669 HG22 ' HG3' ' A' ' 122' ' ' GLU . 41.6 p . . . . . 0 CA--C 1.547 0.847 0 C-N-CA 123.517 0.727 . . . . 74.32 111.377 177.237 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.243 0.746 0 N-CA-C 108.061 -1.088 . . . . 41.4 108.061 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.598 HD21 HG11 ' A' ' 140' ' ' VAL . 0.5 OUTLIER -95.77 135.88 36.9 Favored 'General case' 0 C--N 1.345 0.402 0 N-CA-C 106.283 -1.747 . . . . 52.21 106.283 175.015 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 56.7 mtp180 -142.65 126.52 17.17 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 108.304 -0.998 . . . . 74.02 108.304 -175.718 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -148.78 133.27 17.65 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.335 0.654 . . . . 73.42 110.157 -178.465 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.669 ' HG3' HG22 ' A' ' 103' ' ' THR . 44.8 mt-10 -92.89 144.99 24.72 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 122.929 0.491 . . . . 62.41 109.993 173.061 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.447 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.7 pt? -146.68 132.18 9.23 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.365 -0.834 . . . . 70.41 110.533 -177.83 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -72.09 114.96 4.13 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 121.814 1.676 . . . . 75.31 111.221 175.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.463 HD13 HD21 ' A' ' 98' ' ' LEU . 22.0 tp -108.93 167.26 10.22 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.539 1.136 . . . . 65.54 108.065 176.334 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.497 HG23 HD12 ' A' ' 181' ' ' LEU . 7.8 m -103.46 159.8 15.27 Favored 'General case' 0 N--CA 1.476 0.865 0 O-C-N 121.624 -0.672 . . . . 63.33 109.513 171.442 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.555 HD23 ' HB3' ' A' ' 180' ' ' LEU . 81.2 mt -52.12 -52.77 49.5 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-O 121.311 0.577 . . . . 51.3 109.625 169.441 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.574 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.7 mp0 -55.64 -39.74 71.26 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 114.588 -1.187 . . . . 71.14 112.146 177.793 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -77.7 -21.17 52.4 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 122.765 0.426 . . . . 64.54 111.845 -178.619 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.489 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -68.55 -36.08 78.3 Favored 'General case' 0 C--O 1.248 0.99 0 C-N-CA 123.628 0.771 . . . . 71.43 110.64 168.531 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.483 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 69.2 t80 -64.44 -49.05 73.0 Favored 'General case' 0 C--N 1.346 0.448 0 CA-C-N 115.232 -0.894 . . . . 75.1 110.537 170.818 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -72.94 -28.82 62.67 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 112.855 0.687 . . . . 70.43 112.855 -173.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 67.3 -96.18 0.32 Allowed Glycine 0 C--N 1.351 1.376 0 N-CA-C 111.415 -0.674 . . . . 53.53 111.415 -174.26 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.38 150.55 25.46 Favored Glycine 0 C--N 1.349 1.29 0 N-CA-C 114.78 0.672 . . . . 71.04 114.78 167.562 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -85.59 125.57 33.22 Favored 'General case' 0 N--CA 1.473 0.684 0 N-CA-C 108.116 -1.068 . . . . 61.42 108.116 169.633 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 21.9 mmt180 -129.22 152.66 48.55 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.255 1.022 . . . . 63.42 108.742 -168.61 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 22.3 m -85.24 127.11 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.212 0 N-CA-C 110.053 -0.351 . . . . 72.21 110.053 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 85.7 t -123.73 122.78 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 123.086 0.554 . . . . 70.33 109.884 175.214 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -124.8 96.53 4.91 Favored 'General case' 0 N--CA 1.476 0.87 0 CA-C-O 121.99 0.9 . . . . 61.02 109.24 172.063 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.598 HG11 HD21 ' A' ' 119' ' ' LEU . 74.0 t -130.59 133.11 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 123.786 0.834 . . . . 71.54 109.64 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.33 28.35 17.84 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 124.621 1.168 . . . . 60.1 111.157 -178.639 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.12 -9.3 66.98 Favored Glycine 0 C--N 1.35 1.321 0 CA-C-N 115.548 -0.751 . . . . 62.03 113.447 -177.603 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.2 tpp180 -91.08 115.67 28.19 Favored 'General case' 0 C--N 1.344 0.339 0 N-CA-C 109.424 -0.584 . . . . 74.24 109.424 -176.143 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 59.0 ttp180 -103.72 111.4 23.88 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 108.636 -0.875 . . . . 74.14 108.636 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.5 p -145.89 141.86 21.74 Favored 'Isoleucine or valine' 0 C--O 1.243 0.731 0 C-N-CA 125.011 1.324 . . . . 71.43 108.325 178.794 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 32.4 p -77.69 134.14 38.19 Favored 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 116.384 -0.371 . . . . 74.24 110.016 178.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 9.0 p -98.74 136.11 31.03 Favored 'Isoleucine or valine' 0 C--N 1.341 0.2 0 N-CA-C 109.126 -0.694 . . . . 72.45 109.126 175.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.1 ttt85 -108.19 95.45 5.68 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 107.559 -1.275 . . . . 75.33 107.559 168.706 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.446 ' HB ' HD13 ' A' ' 159' ' ' ILE . 36.5 pt -87.03 113.62 54.46 Favored Pre-proline 0 CA--C 1.552 1.021 0 N-CA-C 107.777 -1.194 . . . . 52.21 107.777 171.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -61.45 137.41 69.64 Favored 'Trans proline' 0 C--N 1.381 2.251 0 C-N-CA 122.683 2.255 . . . . 70.12 112.85 -173.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.426 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 83.7 Cg_exo -50.62 120.07 5.98 Favored 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 123.281 2.654 . . . . 74.32 112.132 172.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 126.03 52.57 0.16 Allowed Glycine 0 C--N 1.341 0.826 0 N-CA-C 110.861 -0.896 . . . . 63.21 110.861 -174.158 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.574 HG21 HD11 ' A' ' 159' ' ' ILE . 1.9 p -126.05 161.87 30.71 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.197 0 C-N-CA 123.94 0.896 . . . . 71.13 109.247 -176.548 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -140.94 165.9 26.26 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 124.869 1.267 . . . . 73.23 111.576 -165.351 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -57.12 122.85 13.38 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.948 0.899 . . . . 71.11 110.008 169.118 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.86 7.88 86.44 Favored Glycine 0 C--N 1.343 0.931 0 CA-C-O 119.4 -0.667 . . . . 64.3 113.824 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.5 t -78.77 123.33 27.08 Favored 'General case' 0 C--O 1.244 0.794 0 N-CA-C 109.415 -0.587 . . . . 60.51 109.415 177.583 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.412 HG22 HD22 ' A' ' 175' ' ' LEU . 7.6 p -100.49 120.78 50.42 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.126 0 CA-C-N 115.063 -0.971 . . . . 74.35 109.569 -179.233 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.574 HD11 HG21 ' A' ' 153' ' ' VAL . 20.1 mt -106.73 116.82 51.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.963 0.905 . . . . 72.25 110.32 -167.745 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.482 ' HG3' ' HB2' ' A' ' 173' ' ' ASP . 29.6 ttm180 -89.3 113.12 24.35 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.653 0.781 . . . . 72.13 111.245 -179.305 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 18.4 m -115.41 103.27 54.3 Favored Pre-proline 0 CA--C 1.561 1.374 0 CA-C-O 121.498 0.666 . . . . 75.4 110.581 178.401 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -65.5 145.65 83.04 Favored 'Trans proline' 0 C--N 1.381 2.258 0 C-N-CA 122.716 2.278 . . . . 75.22 112.992 -177.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 94.07 -23.25 32.22 Favored Glycine 0 C--N 1.345 1.03 0 CA-C-N 115.742 -0.663 . . . . 64.31 113.962 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.481 ' HB3' ' HE2' ' A' ' 164' ' ' MET . 68.8 mtp -95.13 -23.66 17.2 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 112.927 0.714 . . . . 63.01 112.927 -169.548 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.346 1.105 0 N-CA-C 113.8 0.28 . . . . 61.11 113.8 -177.274 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo . . . . . 0 CA--C 1.537 0.649 0 N-CA-C 111.544 -0.214 . . . . 74.31 111.544 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -84.96 166.73 41.17 Favored Glycine 0 CA--C 1.509 -0.331 0 CA-C-N 116.169 -0.469 . . . . 44.41 111.946 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.482 ' HB2' ' HG3' ' A' ' 160' ' ' ARG . 8.2 p-10 -116.77 145.65 43.36 Favored 'General case' 0 C--O 1.245 0.824 0 C-N-CA 123.846 0.859 . . . . 64.21 109.28 -177.443 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.424 HD13 HD22 ' A' ' 119' ' ' LEU . 17.7 tp -106.39 122.37 46.12 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.824 -1.176 . . . . 42.42 107.824 176.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.412 HD22 HG22 ' A' ' 158' ' ' VAL . 77.1 mt -98.8 98.91 9.96 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 125.279 1.432 . . . . 74.13 110.282 -177.543 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 52.8 mt -92.57 107.39 19.18 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 123.411 0.684 . . . . 74.34 111.405 178.846 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.648 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 34.7 t -88.66 104.22 14.57 Favored 'Isoleucine or valine' 0 C--O 1.245 0.836 0 N-CA-C 108.465 -0.939 . . . . 74.42 108.465 173.551 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 9.7 m -82.0 147.59 5.99 Favored 'Isoleucine or valine' 0 C--O 1.242 0.686 0 CA-C-O 121.499 0.666 . . . . 72.05 110.318 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 24.3 mmm-85 -120.63 96.32 5.08 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 107.418 -1.327 . . . . 61.34 107.418 -179.435 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.555 ' HB3' HD23 ' A' ' 127' ' ' LEU . 31.0 mt -69.26 136.53 52.07 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 122.626 0.371 . . . . 73.13 110.368 -174.677 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.497 HD12 HG23 ' A' ' 126' ' ' THR . 53.7 mt -53.67 125.49 46.0 Favored Pre-proline 0 CA--C 1.554 1.122 0 CA-C-O 118.543 -0.742 . . . . 74.24 110.319 -177.189 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 24.0 Cg_exo -64.18 85.23 0.15 Allowed 'Trans proline' 0 C--N 1.379 2.139 0 C-N-CA 123.109 2.539 . . . . 74.13 113.471 -174.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -154.23 54.82 1.15 Allowed Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 123.758 0.823 . . . . 74.35 109.054 171.147 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -61.21 122.92 11.87 Favored 'Trans proline' 0 C--N 1.381 2.273 0 C-N-CA 122.54 2.16 . . . . 72.4 112.143 -165.055 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.29 -44.57 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 N-CA-C 107.824 -1.176 . . . . 70.11 107.824 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.456 ' HE2' HD13 ' A' ' 193' ' ' LEU . 3.6 m-85 -104.81 123.75 48.22 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.209 -0.905 . . . . 63.3 109.353 176.743 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.507 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 4.3 mmm180 -115.68 150.94 35.97 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 106.082 -1.821 . . . . 64.31 106.082 178.422 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.439 HD12 ' O ' ' A' ' 192' ' ' ASP . 63.9 tp -130.76 132.02 45.06 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 122.833 0.453 . . . . 64.52 109.832 -176.357 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -143.5 116.76 9.0 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 108.417 -0.957 . . . . 73.21 108.417 168.35 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 55.42 52.85 44.93 Favored Glycine 0 C--N 1.355 1.584 0 O-C-N 123.953 0.783 . . . . 60.22 114.04 176.009 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 191' ' ' GLN . . . . . 0.401 ' OE1' ' HD2' ' A' ' 243' ' ' PRO . 38.5 mt-30 72.5 -5.94 1.71 Allowed 'General case' 0 N--CA 1.496 1.866 0 C-N-CA 125.024 1.329 . . . . 72.13 113.168 177.8 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.439 ' O ' HD12 ' A' ' 188' ' ' LEU . 23.1 t70 -98.98 145.09 27.42 Favored 'General case' 0 C--N 1.348 0.503 0 N-CA-C 109.483 -0.562 . . . . 64.5 109.483 -176.64 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.606 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.7 mt -105.72 152.97 22.5 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.691 0.796 . . . . 71.1 109.232 -174.098 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 194' ' ' TYR . . . . . 0.507 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 98.3 m-85 -140.84 120.82 13.63 Favored 'General case' 0 C--O 1.223 -0.308 0 N-CA-C 107.649 -1.241 . . . . 75.12 107.649 -174.716 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -147.47 169.46 19.5 Favored 'General case' 0 C--O 1.24 0.595 0 C-N-CA 123.637 0.775 . . . . 74.44 110.287 -175.665 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 16.6 m -116.25 126.99 54.35 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.757 -0.656 . . . . 73.3 109.447 175.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.407 HD22 HD13 ' A' ' 251' ' ' LEU . 67.0 tp -107.39 119.46 39.46 Favored 'General case' 0 C--O 1.214 -0.804 0 C-N-CA 124.47 1.108 . . . . 71.52 108.696 176.071 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -97.31 136.79 37.29 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.257 -1.016 . . . . 62.3 108.257 167.439 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 199' ' ' VAL . . . . . 0.571 HG12 HG11 ' A' ' 210' ' ' VAL . 13.3 m -130.26 142.82 46.78 Favored Pre-proline 0 N--CA 1.476 0.833 0 N-CA-C 109.1 -0.704 . . . . 73.43 109.1 179.235 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -61.94 140.06 82.85 Favored 'Trans proline' 0 C--N 1.372 1.79 0 C-N-CA 121.942 1.761 . . . . 64.3 110.772 172.237 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 201' ' ' ALA . . . . . 0.416 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -52.78 -42.2 88.24 Favored Pre-proline 0 CA--C 1.558 1.263 0 CA-C-O 117.542 -1.218 . . . . 54.5 113.041 178.74 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 202' ' ' PRO . . . . . 0.48 ' O ' HG22 ' A' ' 206' ' ' VAL . 8.8 Cg_endo -49.78 -52.69 8.37 Favored 'Trans proline' 0 C--N 1.408 3.671 0 C-N-CA 122.851 2.367 . . . . 72.35 112.267 169.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 3.4 mt -60.98 -41.66 89.94 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 122.836 0.454 . . . . 74.51 111.271 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.49 -42.53 98.55 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.163 0.585 . . . . 51.43 112.187 -175.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 28.1 m -81.2 -35.51 14.25 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 CA-C-N 115.959 -0.564 . . . . 75.21 111.894 -173.06 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.48 HG22 ' O ' ' A' ' 202' ' ' PRO . 20.8 m -88.0 -19.21 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 O-C-N 122.118 -0.364 . . . . 74.04 111.635 178.614 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.415 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 76.37 66.67 1.81 Allowed Glycine 0 C--N 1.342 0.894 0 O-C-N 123.484 0.49 . . . . 75.33 112.181 -177.449 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.02 -168.45 42.89 Favored Glycine 0 C--N 1.348 1.203 0 N-CA-C 111.854 -0.498 . . . . 73.33 111.854 175.535 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -125.79 119.34 27.63 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 107.997 -1.112 . . . . 64.34 107.997 -179.323 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 210' ' ' VAL . . . . . 0.571 HG11 HG12 ' A' ' 199' ' ' VAL . 7.9 p -116.43 147.88 19.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.547 0 C-N-CA 124.143 0.977 . . . . 61.44 109.439 -174.1 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -76.24 123.66 26.25 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 116.026 -0.534 . . . . 73.42 109.579 172.795 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.13 130.14 47.15 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 108.052 -1.092 . . . . 72.03 108.052 173.179 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 56.3 mmm -76.55 141.01 41.32 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.131 0.491 . . . . 64.34 110.776 178.776 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.429 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 5.7 t -143.68 166.91 23.53 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-N 114.563 -1.199 . . . . 73.35 110.159 177.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 215' ' ' LEU . . . . . 0.574 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 65.1 mt -66.51 -19.84 65.88 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 124.306 1.042 . . . . 52.34 110.953 176.046 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -82.97 -18.25 40.61 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 124.859 1.263 . . . . 75.01 111.022 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 134.26 -147.49 19.11 Favored Glycine 0 C--N 1.352 1.433 0 N-CA-C 111.226 -0.75 . . . . 72.1 111.226 -174.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -93.11 129.37 0.76 Allowed 'Trans proline' 0 CA--C 1.56 1.787 0 C-N-CA 122.432 2.088 . . . . 62.43 112.775 165.42 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.7 m -109.15 166.71 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 C-N-CA 123.595 0.758 . . . . 73.12 109.56 169.539 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -113.94 116.47 29.3 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 109.867 -0.42 . . . . 74.51 109.867 178.844 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.4 p -108.78 136.82 43.38 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.681 0 C-N-CA 123.459 0.704 . . . . 71.24 110.175 173.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -95.12 115.73 27.81 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 124.025 0.93 . . . . 41.03 109.491 176.169 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.453 HG11 HG11 ' A' ' 199' ' ' VAL . 14.2 m -82.06 142.05 47.57 Favored Pre-proline 0 CA--C 1.548 0.893 0 N-CA-C 109.376 -0.601 . . . . 55.22 109.376 176.16 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_exo -61.0 141.12 93.47 Favored 'Trans proline' 0 C--N 1.368 1.558 0 C-N-CA 122.451 2.1 . . . . 75.12 112.746 172.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_exo -56.4 119.79 7.23 Favored 'Trans proline' 0 C--N 1.373 1.833 0 C-N-CA 122.588 2.192 . . . . 74.45 111.783 169.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 53.7 mtm180 60.75 51.64 4.75 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.676 1.19 . . . . 74.45 110.759 -174.082 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 227' ' ' THR . . . . . 0.473 ' OG1' ' HD2' ' A' ' 231' ' ' ARG . 12.1 t -73.17 172.68 10.64 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-N 114.955 -1.02 . . . . 73.11 110.257 174.765 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -126.49 141.81 51.75 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 123.149 0.58 . . . . 74.34 109.455 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 229' ' ' ALA . . . . . 0.466 ' HB2' ' H ' ' A' ' 255' ' ' ILE . . . -63.96 119.69 10.56 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.759 0.824 . . . . 64.31 109.836 175.112 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.98 4.78 20.75 Favored Glycine 0 C--O 1.241 0.57 0 C-N-CA 123.69 0.662 . . . . 33.41 112.314 -176.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 231' ' ' ARG . . . . . 0.473 ' HD2' ' OG1' ' A' ' 227' ' ' THR . 92.3 mtt180 -79.54 159.01 27.06 Favored 'General case' 0 C--N 1.358 0.942 0 CA-C-O 121.707 0.765 . . . . 73.0 109.551 170.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.474 ' HG3' ' HE2' ' A' ' 250' ' ' TYR . 10.1 mptt -108.34 99.13 8.57 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 114.32 -1.309 . . . . 74.11 108.452 -176.331 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 233' ' ' LEU . . . . . 0.448 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 62.6 mt -90.11 96.48 10.69 Favored 'General case' 0 C--N 1.349 0.545 0 N-CA-C 106.231 -1.766 . . . . 64.42 106.231 176.518 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 234' ' ' ARG . . . . . 0.495 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 39.1 ttp180 -96.11 101.36 13.01 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 114.915 -1.039 . . . . 71.01 110.015 -167.896 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.508 HD12 HD23 ' A' ' 249' ' ' LEU . 43.3 mt -81.08 105.92 12.67 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.934 0.894 . . . . 73.02 108.806 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt -74.61 144.18 44.02 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.171 0.588 . . . . 74.41 112.267 -171.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 71.11 19.99 77.65 Favored Glycine 0 C--N 1.349 1.275 0 O-C-N 123.764 0.665 . . . . 52.02 113.934 178.543 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 1.4 mmmp? -106.65 -12.43 15.56 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.792 0.437 . . . . 71.43 111.173 -179.356 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.17 -175.51 49.82 Favored Glycine 0 C--N 1.348 1.217 0 O-C-N 123.409 0.443 . . . . 72.31 112.138 173.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.483 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 87.5 m-85 -77.4 149.26 78.5 Favored Pre-proline 0 N--CA 1.475 0.809 0 N-CA-C 112.252 0.464 . . . . 74.04 112.252 -172.027 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 241' ' ' PRO . . . . . 0.595 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 53.3 Cg_endo -65.52 160.58 42.28 Favored 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 122.838 2.359 . . . . 55.51 113.562 -175.548 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 164.7 -151.74 20.97 Favored Glycine 0 C--N 1.346 1.097 0 CA-C-O 118.929 -0.928 . . . . 33.52 112.044 -178.539 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 243' ' ' PRO . . . . . 0.401 ' HD2' ' OE1' ' A' ' 191' ' ' GLN . 37.6 Cg_endo -61.33 -32.53 89.77 Favored 'Trans proline' 0 C--N 1.377 2.047 0 C-N-CA 123.264 2.643 . . . . 72.23 113.198 -176.513 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -84.52 18.63 2.22 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 123.485 0.714 . . . . 63.12 111.77 178.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 78.77 -78.12 1.7 Allowed Glycine 0 C--N 1.347 1.175 0 N-CA-C 110.039 -1.224 . . . . 65.34 110.039 -172.709 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.595 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 62.2 mtm180 -128.47 169.51 14.24 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 124.081 0.953 . . . . 64.03 108.579 166.245 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -82.78 -163.66 34.07 Favored Glycine 0 C--N 1.337 0.626 0 N-CA-C 111.697 -0.561 . . . . 41.11 111.697 172.59 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -130.78 170.73 13.98 Favored 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 109.238 -0.653 . . . . 72.43 109.238 -178.282 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.606 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 17.5 tp -115.87 120.65 39.9 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.868 0.867 . . . . 73.31 110.663 175.365 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 250' ' ' TYR . . . . . 0.474 ' HE2' ' HG3' ' A' ' 232' ' ' LYS . 10.7 t80 -89.31 107.93 19.34 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.613 1.165 . . . . 75.15 108.693 175.901 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.448 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 87.8 mt -94.14 117.86 30.71 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.904 -0.406 . . . . 72.04 109.904 167.123 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -88.29 93.56 9.55 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 107.327 -1.36 . . . . 74.52 107.327 171.412 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 3.3 p -60.05 133.82 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 O-C-N 123.725 0.641 . . . . 51.43 110.645 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 48.6 mmm-85 -135.26 102.01 5.03 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 125.049 1.34 . . . . 73.15 107.529 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.466 ' H ' ' HB2' ' A' ' 229' ' ' ALA . 63.0 mt -76.54 116.93 20.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.359 -0.837 . . . . 70.05 109.768 -175.089 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.0 t . . . . . 0 CA--C 1.553 1.087 0 C-N-CA 124.829 1.252 . . . . 70.32 109.214 -178.635 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.474 HD23 ' H ' ' A' ' 99' ' ' VAL . 2.0 pt? . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 119.973 -0.06 . . . . 74.31 111.084 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.711 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 13.6 p -64.45 146.7 12.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 C-N-CA 123.584 0.754 . . . . 72.12 111.894 -179.098 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.462 ' HB2' ' HD3' ' A' ' 124' ' ' PRO . . . -83.22 -58.35 2.88 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 109.479 -0.563 . . . . 62.05 109.479 173.16 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 40.0 t-80 -175.59 159.58 2.38 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 123.697 0.799 . . . . 73.43 109.857 -175.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -66.44 136.68 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.346 0.658 . . . . 71.21 110.277 171.61 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 12.6 t . . . . . 0 CA--C 1.543 0.708 0 N-CA-C 109.308 -0.627 . . . . 72.53 109.308 179.041 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 20.8 t70 . . . . . 0 N--CA 1.477 0.903 0 CA-C-O 120.879 0.371 . . . . 72.35 110.034 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.505 HD12 HD13 ' A' ' 174' ' ' LEU . 0.2 OUTLIER -138.16 137.41 37.61 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 106.392 -1.707 . . . . 73.52 106.392 177.46 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 120' ' ' ARG . . . . . 0.497 ' HD3' ' HB2' ' A' ' 175' ' ' LEU . 19.4 mmt85 -125.58 138.59 53.95 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 109.065 -0.717 . . . . 73.22 109.065 -178.57 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -159.11 126.74 4.91 Favored 'General case' 0 CA--C 1.536 0.417 0 O-C-N 123.703 0.627 . . . . 51.23 109.447 175.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -105.73 150.55 25.41 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 109.607 -0.516 . . . . 65.14 109.607 175.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.711 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.4 pt? -145.87 147.08 31.13 Favored Pre-proline 0 N--CA 1.473 0.72 0 C-N-CA 123.033 0.533 . . . . 72.41 111.925 -170.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.462 ' HD3' ' HB2' ' A' ' 100' ' ' ALA . 91.5 Cg_endo -81.76 113.41 2.51 Favored 'Trans proline' 0 C--N 1.376 1.993 0 C-N-CA 121.769 1.646 . . . . 74.22 111.082 171.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.429 ' HB3' HD23 ' A' ' 180' ' ' LEU . 19.2 tp -111.06 167.71 10.05 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.043 -1.095 . . . . 63.31 108.043 175.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.566 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 8.8 m -101.09 155.07 18.21 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 109.922 -0.399 . . . . 61.12 109.922 174.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.436 HD23 ' HB3' ' A' ' 180' ' ' LEU . 85.6 mt -51.96 -51.93 53.75 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 122.304 1.049 . . . . 72.31 109.766 171.14 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -56.83 -40.14 75.5 Favored 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 113.386 -1.734 . . . . 74.14 111.735 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.411 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 23.8 mm-40 -79.87 -18.27 51.13 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 123.358 0.663 . . . . 73.32 112.195 -179.025 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.671 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -63.25 -41.57 99.09 Favored 'General case' 0 C--O 1.249 1.036 0 C-N-CA 122.863 0.465 . . . . 74.02 110.583 165.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -67.93 -54.45 18.6 Favored 'General case' 0 C--N 1.354 0.787 0 CA-C-N 115.664 -0.698 . . . . 74.31 110.932 172.674 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.5 m80 -69.88 -30.03 67.39 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 123.941 0.776 . . . . 72.24 112.158 -170.408 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.08 -149.34 51.71 Favored Glycine 0 C--N 1.346 1.124 0 N-CA-C 111.334 -0.706 . . . . 70.21 111.334 -171.749 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 136.92 136.94 3.57 Favored Glycine 0 C--N 1.346 1.095 0 CA-C-N 116.73 0.265 . . . . 71.1 112.673 170.584 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -80.21 127.0 31.83 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.408 0.683 . . . . 75.23 109.191 174.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.2 mpt_? -136.26 168.13 19.99 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.527 0.731 . . . . 73.13 109.101 177.412 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.5 p -85.85 129.61 37.78 Favored 'Isoleucine or valine' 0 C--O 1.246 0.878 0 CA-C-O 121.311 0.577 . . . . 52.51 110.66 174.359 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.493 HG21 HD21 ' A' ' 174' ' ' LEU . 14.6 p -98.65 142.33 14.9 Favored 'Isoleucine or valine' 0 C--O 1.242 0.704 0 C-N-CA 124.215 1.006 . . . . 71.11 109.43 175.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' GLU . . . . . 0.457 ' H ' HG11 ' A' ' 99' ' ' VAL . 42.7 mm-40 -121.76 100.68 7.13 Favored 'General case' 0 C--O 1.24 0.563 0 C-N-CA 124.61 1.164 . . . . 42.2 108.142 179.042 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.2 m -124.05 107.53 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.79 0 C-N-CA 123.352 0.661 . . . . 72.43 111.063 -176.569 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.87 24.24 11.29 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 124.747 1.219 . . . . 54.21 111.909 176.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 91.12 3.49 69.9 Favored Glycine 0 C--N 1.346 1.116 0 CA-C-N 116.031 -0.531 . . . . 73.3 113.371 -177.438 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 64.0 mtp85 -95.98 119.62 34.81 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.024 -0.732 . . . . 72.22 109.024 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 33.9 ttt85 -98.82 116.63 31.49 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.483 0.713 . . . . 72.42 109.952 -178.213 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 46.3 t -136.53 145.53 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.778 0.831 . . . . 73.13 108.918 179.48 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 21.2 m -79.03 110.99 14.78 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 109.072 -0.714 . . . . 74.4 109.072 171.08 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.0 p -98.28 137.41 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 CA-C-O 121.762 0.791 . . . . 74.34 110.597 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 77.6 ttt180 -103.82 117.78 35.16 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 114.485 -1.234 . . . . 73.22 108.342 175.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 33.4 pt -122.86 127.0 25.89 Favored Pre-proline 0 N--CA 1.477 0.919 0 N-CA-C 109.01 -0.737 . . . . 74.41 109.01 169.48 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -81.86 159.97 18.63 Favored 'Trans proline' 0 C--N 1.375 1.959 0 C-N-CA 122.909 2.406 . . . . 73.24 114.523 -167.775 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -68.1 114.92 3.57 Favored 'Trans proline' 0 C--N 1.381 2.289 0 C-N-CA 123.331 2.687 . . . . 41.24 110.618 174.351 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.621 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 133.9 49.7 0.08 OUTLIER Glycine 0 N--CA 1.469 0.844 0 N-CA-C 111.299 -0.72 . . . . 45.24 111.299 -173.712 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.671 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.4 p -125.99 165.61 23.56 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.403 0 N-CA-C 108.35 -0.981 . . . . 62.45 108.35 -176.401 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 51.3 mtp180 -145.69 166.7 25.07 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 124.519 1.127 . . . . 72.43 110.375 -165.603 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -55.49 123.89 15.43 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 124.005 0.922 . . . . 75.11 111.112 169.067 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.75 5.42 74.31 Favored Glycine 0 C--N 1.35 1.337 0 O-C-N 123.752 0.657 . . . . 55.15 113.601 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 31.2 t -73.45 126.01 29.23 Favored 'General case' 0 C--O 1.243 0.715 0 N-CA-C 109.828 -0.434 . . . . 72.1 109.828 -177.648 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.442 HG22 HD22 ' A' ' 175' ' ' LEU . 7.4 p -99.43 120.05 48.26 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 CA-C-N 114.756 -1.111 . . . . 73.41 109.911 -174.871 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.448 HD11 HG21 ' A' ' 153' ' ' VAL . 24.9 mt -106.95 115.53 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 124.004 0.922 . . . . 62.42 110.081 -171.678 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.494 ' HA ' HD23 ' A' ' 175' ' ' LEU . 69.3 ttt180 -83.53 119.1 24.28 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.504 0.722 . . . . 73.23 111.024 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.655 HG23 ' HG3' ' A' ' 164' ' ' MET . 16.6 m -124.37 104.76 31.38 Favored Pre-proline 0 CA--C 1.571 1.77 0 CA-C-O 120.764 0.316 . . . . 71.33 110.209 174.745 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.17 156.59 64.42 Favored 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.865 2.376 . . . . 73.41 113.7 -178.812 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.56 23.15 65.55 Favored Glycine 0 C--N 1.348 1.247 0 CA-C-N 115.336 -0.847 . . . . 55.42 113.808 176.472 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.655 ' HG3' HG23 ' A' ' 161' ' ' VAL . 16.4 mmt -106.81 -62.08 1.45 Allowed 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.079 0.952 . . . . 72.41 111.271 178.648 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.539 0 N-CA-C 111.591 -0.603 . . . . 40.55 111.591 178.414 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo . . . . . 0 CA--C 1.538 0.701 0 N-CA-C 110.653 -0.556 . . . . 75.21 110.653 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -110.08 148.41 17.4 Favored Glycine 0 CA--C 1.503 -0.693 0 N-CA-C 111.334 -0.706 . . . . 52.12 111.334 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 -109.0 130.54 55.48 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 123.215 0.606 . . . . 75.25 109.53 -165.017 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.505 HD13 HD12 ' A' ' 119' ' ' LEU . 17.4 tp -100.6 115.12 29.42 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 107.145 -1.428 . . . . 73.22 107.145 173.732 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.497 ' HB2' ' HD3' ' A' ' 120' ' ' ARG . 65.0 mt -92.23 100.73 13.28 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-N 114.46 -1.246 . . . . 63.45 109.794 -179.162 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.414 ' HA ' ' O ' ' A' ' 121' ' ' ALA . 83.2 mt -86.63 102.49 14.23 Favored 'General case' 0 C--N 1.346 0.418 0 CA-C-N 114.773 -1.103 . . . . 73.11 110.061 176.574 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 47.2 t -90.0 99.4 9.4 Favored 'Isoleucine or valine' 0 C--O 1.243 0.714 0 N-CA-C 108.397 -0.964 . . . . 65.54 108.397 176.638 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 4.9 m -79.49 148.12 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 N-CA-C 109.493 -0.558 . . . . 75.34 109.493 -177.131 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 40.0 mmm-85 -126.63 99.2 5.69 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 105.85 -1.908 . . . . 72.3 105.85 -175.787 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.436 ' HB3' HD23 ' A' ' 127' ' ' LEU . 38.2 mt -68.65 148.34 50.58 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 122.339 0.256 . . . . 71.04 110.954 -173.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.566 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 39.1 mt -55.76 130.52 72.01 Favored Pre-proline 0 CA--C 1.552 1.04 0 CA-C-O 118.844 -0.598 . . . . 72.04 110.737 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -67.91 84.47 0.42 Allowed 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 123.279 2.653 . . . . 74.22 112.079 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 8.6 p80 -154.58 50.62 0.55 Allowed Pre-proline 0 CA--C 1.558 1.274 0 N-CA-C 107.87 -1.159 . . . . 72.12 107.87 169.347 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -62.69 126.42 18.21 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 122.713 2.275 . . . . 62.33 112.261 -163.525 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -137.74 -45.1 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 108.686 -0.857 . . . . 72.43 108.686 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.426 ' CD2' HD13 ' A' ' 193' ' ' LEU . 6.5 m-85 -103.82 123.61 47.42 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.932 0.893 . . . . 74.21 110.269 -177.749 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.601 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 92.3 mtt180 -119.15 109.18 15.58 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.623 1.169 . . . . 75.1 107.887 -176.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.503 HD22 ' CD2' ' A' ' 240' ' ' PHE . 62.0 tp -85.09 142.56 29.45 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 122.659 0.383 . . . . 73.3 110.378 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -142.45 115.61 8.88 Favored 'General case' 0 C--O 1.243 0.736 0 N-CA-C 107.782 -1.192 . . . . 71.4 107.782 164.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 67.46 -95.37 0.31 Allowed Glycine 0 C--N 1.346 1.139 0 CA-C-N 115.725 -0.67 . . . . 44.25 111.514 -173.356 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 -123.84 -23.27 4.7 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.034 0.934 . . . . 72.42 110.247 177.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -93.83 153.34 18.33 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.411 0.624 . . . . 74.11 111.038 -171.622 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.621 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 73.6 mt -113.36 167.08 10.87 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.198 -0.91 . . . . 54.12 112.581 -170.678 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 194' ' ' TYR . . . . . 0.601 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 97.4 m-85 -135.28 121.57 20.32 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 105.873 -1.899 . . . . 74.51 105.873 172.844 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 195' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -152.75 140.1 19.56 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 108.573 -0.899 . . . . 64.44 108.573 176.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.02 141.71 40.21 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 123.566 0.541 . . . . 73.4 110.128 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.548 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 57.5 tp -110.03 113.73 26.67 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.027 -0.988 . . . . 72.35 109.07 179.29 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -85.71 101.9 13.16 Favored 'General case' 0 C--O 1.24 0.566 0 N-CA-C 108.149 -1.056 . . . . 62.22 108.149 176.228 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 199' ' ' VAL . . . . . 0.435 HG11 HG13 ' A' ' 253' ' ' VAL . 4.3 p -116.82 127.44 26.72 Favored Pre-proline 0 CA--C 1.548 0.881 0 N-CA-C 109.332 -0.618 . . . . 63.11 109.332 -178.237 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -58.71 144.71 97.71 Favored 'Trans proline' 0 C--N 1.379 2.169 0 C-N-CA 122.461 2.107 . . . . 51.24 111.948 172.351 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -54.49 -42.93 97.07 Favored Pre-proline 0 CA--C 1.564 1.506 0 CA-C-O 118.106 -0.949 . . . . 42.52 112.117 175.174 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_exo -46.12 -53.24 6.07 Favored 'Trans proline' 0 C--N 1.397 3.106 0 C-N-CA 122.684 2.256 . . . . 62.31 114.126 167.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 203' ' ' ILE . . . . . 0.472 HG22 HG21 ' A' ' 223' ' ' VAL . 12.8 mt -65.96 -37.02 78.89 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 O-C-N 123.169 0.293 . . . . 43.42 110.923 -178.111 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.13 -43.86 97.23 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 123.306 0.642 . . . . 43.51 111.599 -177.419 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 32.6 m -76.79 -37.97 28.9 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 115.951 -0.568 . . . . 55.43 111.262 -176.131 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.4 m -83.44 -23.87 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 N-CA-C 111.763 0.283 . . . . 43.42 111.763 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.462 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 72.19 64.05 2.77 Favored Glycine 0 C--N 1.341 0.84 0 CA-C-N 116.227 -0.442 . . . . 71.12 112.183 -172.749 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -94.53 -154.19 30.78 Favored Glycine 0 C--N 1.355 1.625 0 CA-C-O 121.428 0.46 . . . . 52.32 112.378 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 14.7 mmmm -121.76 128.97 52.33 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 123.781 0.832 . . . . 74.32 109.104 -174.288 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 39.5 t -116.18 129.98 71.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 N-CA-C 108.91 -0.774 . . . . 75.03 108.91 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -78.24 106.09 9.91 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 107.861 -1.163 . . . . 75.41 107.861 168.064 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -98.83 133.42 43.15 Favored 'General case' 0 C--N 1.343 0.31 0 C-N-CA 123.822 0.849 . . . . 64.42 108.922 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -74.94 144.24 43.32 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 122.651 0.38 . . . . 71.23 110.402 173.88 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.41 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 7.5 t -148.27 167.43 25.16 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 124.353 1.061 . . . . 72.41 109.77 172.471 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 215' ' ' LEU . . . . . 0.407 HD13 ' O ' ' A' ' 127' ' ' LEU . 45.8 mt -71.58 -15.12 62.26 Favored 'General case' 0 CA--C 1.552 1.046 0 CA-C-N 115.178 -0.919 . . . . 74.21 110.796 176.363 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -80.73 -20.73 42.16 Favored 'General case' 0 CA--C 1.564 1.503 0 C-N-CA 124.747 1.219 . . . . 71.51 109.888 174.368 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 135.03 -151.26 20.4 Favored Glycine 0 C--N 1.361 1.932 0 CA-C-O 119.628 -0.54 . . . . 33.42 112.41 -177.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -91.84 124.54 0.78 Allowed 'Trans proline' 0 C--N 1.368 1.591 0 C-N-CA 123.33 2.687 . . . . 70.1 111.807 170.276 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 219' ' ' VAL . . . . . 0.408 HG11 ' HD3' ' A' ' 238' ' ' LYS . 22.7 m -116.98 160.71 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 C-N-CA 123.604 0.762 . . . . 51.32 110.771 179.389 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -115.28 110.39 19.35 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 109.001 -0.74 . . . . 61.44 109.001 178.283 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.553 HG23 HD21 ' A' ' 235' ' ' LEU . 5.9 p -97.09 138.29 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 123.37 0.668 . . . . 70.45 110.512 177.082 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -93.81 111.7 23.44 Favored 'General case' 0 C--O 1.239 0.533 0 C-N-CA 123.698 0.799 . . . . 73.21 109.009 173.425 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.472 HG21 HG22 ' A' ' 203' ' ' ILE . 13.8 m -86.47 140.66 34.0 Favored Pre-proline 0 CA--C 1.55 0.964 0 N-CA-C 108.91 -0.774 . . . . 43.15 108.91 177.522 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -62.12 143.38 94.62 Favored 'Trans proline' 0 CA--C 1.56 1.818 0 C-N-CA 122.501 2.134 . . . . 74.52 112.318 177.594 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.9 123.76 12.47 Favored 'Trans proline' 0 C--N 1.378 2.104 0 C-N-CA 122.408 2.072 . . . . 71.41 110.669 174.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 44.2 mtm105 64.07 48.88 2.87 Favored 'General case' 0 N--CA 1.475 0.824 0 O-C-N 124.233 0.958 . . . . 72.53 110.343 -173.537 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 227' ' ' THR . . . . . 0.454 HG23 HD11 ' A' ' 255' ' ' ILE . 11.8 t -71.16 170.63 12.55 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.319 0.58 . . . . 65.21 111.103 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.9 mp0 -121.91 139.39 53.71 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.221 1.008 . . . . 73.01 108.574 -176.835 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -76.62 127.69 33.28 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.288 0.635 . . . . 75.41 109.94 179.569 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.38 -4.71 23.36 Favored Glycine 0 C--N 1.339 0.746 0 N-CA-C 111.512 -0.635 . . . . 51.44 111.512 -173.077 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 231' ' ' ARG . . . . . 0.428 ' O ' ' HA ' ' A' ' 252' ' ' GLU . 60.6 mtt-85 -71.51 160.1 33.32 Favored 'General case' 0 C--N 1.36 1.042 0 C-N-CA 122.917 0.487 . . . . 63.25 110.762 173.669 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.445 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.1 OUTLIER -123.43 100.43 6.82 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.088 0.955 . . . . 61.44 108.774 179.69 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 233' ' ' LEU . . . . . 0.428 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 86.3 mt -84.89 104.85 15.2 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 108.92 -0.77 . . . . 55.11 108.92 -176.723 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 14.6 ttp180 -82.31 101.95 10.89 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 114.784 -1.098 . . . . 74.12 110.367 -171.626 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.553 HD21 HG23 ' A' ' 221' ' ' VAL . 48.9 mt -89.62 101.61 14.3 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 115.131 -0.94 . . . . 64.3 108.555 171.022 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 47.0 mtpt -73.06 149.15 43.41 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.354 0.662 . . . . 74.13 110.574 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 67.72 28.88 73.48 Favored Glycine 0 C--N 1.345 1.05 0 O-C-N 123.369 0.418 . . . . 74.55 113.413 -178.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 238' ' ' LYS . . . . . 0.523 ' HG3' ' HB3' ' A' ' 235' ' ' LEU . 0.0 OUTLIER -127.55 -8.38 5.69 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 124.165 0.986 . . . . 70.24 111.145 -176.973 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 239' ' ' GLY . . . . . 0.434 ' HA2' ' CD1' ' A' ' 193' ' ' LEU . . . -84.71 -163.97 37.42 Favored Glycine 0 C--N 1.344 0.977 0 CA-C-N 115.919 -0.582 . . . . 63.54 113.174 176.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.621 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 1.5 m-85 -85.99 158.88 55.39 Favored Pre-proline 0 N--CA 1.48 1.053 0 N-CA-C 109.341 -0.615 . . . . 72.24 109.341 179.014 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -47.53 129.55 16.83 Favored 'Trans proline' 0 C--N 1.382 2.32 0 C-N-CA 123.077 2.518 . . . . 70.13 113.598 174.865 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -165.34 -162.8 17.3 Favored Glycine 0 CA--C 1.535 1.282 0 CA-C-O 118.986 -0.897 . . . . 44.32 112.203 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_exo -47.05 -41.1 26.55 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 124.616 3.544 . . . . 71.41 115.378 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -87.47 21.0 2.63 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 123.965 0.906 . . . . 24.12 112.145 -177.456 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.15 -81.82 1.5 Allowed Glycine 0 C--N 1.346 1.102 0 N-CA-C 110.568 -1.013 . . . . 65.2 110.568 -173.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -113.2 135.41 53.85 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.624 -1.25 . . . . 53.43 107.624 169.78 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.48 -157.21 5.28 Favored Glycine 0 C--N 1.345 1.045 0 N-CA-C 115.152 0.821 . . . . 73.3 115.152 -169.165 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -111.27 164.58 12.74 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 123.155 0.582 . . . . 75.42 110.374 -175.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.621 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 20.0 tp -128.04 116.26 19.75 Favored 'General case' 0 C--O 1.218 -0.602 0 C-N-CA 124.644 1.178 . . . . 73.22 109.342 169.421 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 250' ' ' TYR . . . . . 0.445 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 10.6 m-85 -97.46 107.36 19.86 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 109.243 -0.651 . . . . 70.12 109.243 175.298 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.548 ' HB3' ' HB2' ' A' ' 197' ' ' LEU . 85.8 mt -86.58 115.4 24.04 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 124.004 0.922 . . . . 74.54 112.042 178.236 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.428 ' HA ' ' O ' ' A' ' 231' ' ' ARG . 36.4 tt0 -77.74 93.91 4.37 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 108.348 -0.982 . . . . 63.34 108.348 175.541 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.435 HG13 HG11 ' A' ' 199' ' ' VAL . 91.9 t -48.71 116.49 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 C-N-CA 124.705 1.202 . . . . 73.21 111.286 176.738 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 26.5 mmm180 -120.75 94.8 4.47 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 107.416 -1.328 . . . . 75.22 107.416 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.454 HD11 HG23 ' A' ' 227' ' ' THR . 60.3 mt -77.69 106.98 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-N 115.379 -0.828 . . . . 74.2 109.366 -178.02 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 CA--C 1.552 1.034 0 C-N-CA 124.034 0.934 . . . . 62.33 108.942 -179.701 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 111.289 0.107 . . . . 74.22 111.289 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 7.4 p -61.15 125.25 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 O-C-N 123.79 0.681 . . . . 64.52 110.946 -175.22 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -74.25 -75.92 0.15 Allowed 'General case' 0 C--N 1.346 0.427 0 N-CA-C 108.483 -0.932 . . . . 72.03 108.483 174.191 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -162.91 153.23 16.34 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 124.866 1.266 . . . . 72.41 108.416 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 8.4 p -67.74 121.03 16.13 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.916 0 CA-C-O 121.063 0.459 . . . . 45.02 109.798 172.162 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.574 HG21 ' HG3' ' A' ' 122' ' ' GLU . 11.4 t . . . . . 0 CA--C 1.549 0.906 0 C-N-CA 123.699 0.799 . . . . 54.01 111.86 -174.066 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 . . . . . 0 C--O 1.241 0.646 0 CA-C-O 121.973 0.892 . . . . 44.44 111.442 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.687 HD12 ' HA2' ' A' ' 165' ' ' GLY . 24.5 mt -94.36 155.26 17.07 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 106.681 -1.6 . . . . 70.24 106.681 159.284 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' ARG . . . . . 0.556 ' HE ' HD12 ' A' ' 175' ' ' LEU . 29.6 ttm180 -144.47 114.66 7.47 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 109.66 -0.496 . . . . 74.43 109.66 -174.147 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -126.8 126.46 43.42 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 123.523 0.729 . . . . 54.34 110.195 -177.805 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.574 ' HG3' HG21 ' A' ' 103' ' ' THR . 24.4 mt-10 -92.09 136.74 32.93 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 108.505 -0.924 . . . . 72.15 108.505 169.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -145.13 147.26 33.72 Favored Pre-proline 0 N--CA 1.468 0.44 0 C-N-CA 123.191 0.596 . . . . 44.03 110.578 -170.434 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.86 154.48 67.3 Favored 'Trans proline' 0 C--N 1.369 1.617 0 C-N-CA 121.877 1.718 . . . . 71.53 111.646 170.74 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 22.2 tp -149.5 150.34 32.15 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.811 0.844 . . . . 64.11 109.067 174.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.584 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 69.2 m -84.59 151.98 24.16 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 123.326 0.651 . . . . 72.42 109.487 172.916 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.52 HD11 ' O ' ' A' ' 183' ' ' HIS . 45.1 mt -58.19 -48.05 81.53 Favored 'General case' 0 N--CA 1.483 1.194 0 CA-C-O 121.881 0.848 . . . . 74.44 110.204 176.236 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.627 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.7 mp0 -57.88 -31.79 67.06 Favored 'General case' 0 N--CA 1.484 1.259 0 CA-C-N 114.328 -1.306 . . . . 63.45 111.97 178.06 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 38.0 mm-40 -88.95 -16.69 31.17 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 112.109 0.411 . . . . 63.14 112.109 178.513 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.727 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -63.26 -31.65 72.85 Favored 'General case' 0 C--O 1.25 1.12 0 CA-C-O 121.168 0.508 . . . . 55.13 110.152 162.853 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.558 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 17.1 t80 -71.87 -60.37 2.27 Favored 'General case' 0 C--N 1.351 0.642 0 CA-C-N 115.326 -0.852 . . . . 74.3 110.877 168.238 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -71.89 -28.62 63.64 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 113.605 0.965 . . . . 60.2 113.605 -168.233 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 74.09 -87.46 0.68 Allowed Glycine 0 CA--C 1.532 1.123 0 N-CA-C 110.738 -0.945 . . . . 63.51 110.738 -167.628 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 84.01 126.65 1.34 Allowed Glycine 0 C--N 1.352 1.449 0 C-N-CA 122.844 0.259 . . . . 42.32 113.129 174.008 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.43 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.7 mp0 -78.28 114.56 17.28 Favored 'General case' 0 C--N 1.345 0.392 0 N-CA-C 108.431 -0.952 . . . . 74.2 108.431 176.509 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 7.3 mpt_? -131.36 153.38 49.7 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 123.084 0.554 . . . . 73.11 109.884 176.889 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 14.7 p -72.89 140.9 17.13 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.083 0 C-N-CA 123.308 0.643 . . . . 63.32 111.779 -173.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.43 HG22 HG23 ' A' ' 140' ' ' VAL . 7.9 p -136.43 124.57 35.15 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 C-N-CA 125.239 1.416 . . . . 73.12 108.553 -179.425 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -116.57 96.44 5.51 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 107.358 -1.349 . . . . 71.15 107.358 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.558 HG12 HD13 ' A' ' 119' ' ' LEU . 90.0 t -130.73 131.49 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 122.992 0.517 . . . . 73.44 109.714 -178.531 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.02 30.08 19.6 Favored 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 124.962 1.305 . . . . 64.03 112.021 -179.278 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 92.07 -1.15 73.47 Favored Glycine 0 C--N 1.344 1.025 0 CA-C-N 115.336 -0.847 . . . . 60.13 114.137 173.741 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.84 119.15 38.64 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-N 118.284 1.042 . . . . 64.42 110.691 -179.312 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 63.2 ttp85 -92.66 106.66 18.6 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.139 0.975 . . . . 73.42 108.489 172.076 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 61.7 t -133.5 149.77 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 108.238 -1.023 . . . . 74.31 108.238 178.65 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 34.9 p -81.02 120.97 25.47 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 109.132 -0.692 . . . . 73.31 109.132 172.597 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.4 p -96.83 131.12 44.37 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 CA-C-O 121.19 0.519 . . . . 61.43 110.647 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' ARG . . . . . 0.43 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 40.6 ttp180 -104.28 102.06 11.76 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 107.746 -1.205 . . . . 74.52 107.746 175.64 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.63 ' HB ' HD13 ' A' ' 159' ' ' ILE . 30.8 pt -91.96 130.82 37.07 Favored Pre-proline 0 CA--C 1.549 0.941 0 N-CA-C 108.965 -0.754 . . . . 73.33 108.965 176.226 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -63.63 135.99 51.82 Favored 'Trans proline' 0 C--N 1.383 2.37 0 C-N-CA 122.88 2.387 . . . . 73.34 112.847 -171.581 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_exo -54.49 141.59 72.88 Favored 'Trans proline' 0 C--N 1.379 2.159 0 C-N-CA 123.427 2.751 . . . . 71.33 112.381 169.6 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 104.18 24.66 7.45 Favored Glycine 0 C--N 1.338 0.675 0 N-CA-C 111.645 -0.582 . . . . 70.41 111.645 -176.096 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.727 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.4 p -95.06 158.74 2.93 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.917 0 N-CA-C 108.504 -0.924 . . . . 54.4 108.504 -177.268 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.484 ' HA ' HD11 ' A' ' 180' ' ' LEU . 27.0 mtm180 -149.62 176.15 10.91 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 124.426 1.09 . . . . 74.52 110.135 -170.621 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -52.93 124.86 15.3 Favored 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 124.017 0.927 . . . . 62.52 111.744 173.148 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.85 10.03 83.44 Favored Glycine 0 C--N 1.347 1.182 0 O-C-N 123.534 0.521 . . . . 72.54 113.809 177.36 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.419 ' HB3' HG23 ' A' ' 153' ' ' VAL . 33.0 t -76.97 122.35 24.77 Favored 'General case' 0 C--O 1.246 0.879 0 N-CA-C 109.391 -0.596 . . . . 74.33 109.391 179.342 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.476 HG22 HD22 ' A' ' 175' ' ' LEU . 7.1 p -94.14 121.88 45.14 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.964 0 C-N-CA 123.77 0.828 . . . . 71.52 109.689 -179.335 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.63 HD13 ' HB ' ' A' ' 149' ' ' ILE . 46.3 mt -110.52 118.16 56.51 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 124.273 1.029 . . . . 72.34 109.999 -172.475 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 60.0 ttp85 -95.78 109.96 22.19 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 122.863 0.465 . . . . 74.31 110.408 -178.169 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 10.7 m -109.48 101.57 46.44 Favored Pre-proline 0 CA--C 1.569 1.7 0 C-N-CA 122.933 0.493 . . . . 62.34 110.125 -178.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' PRO . . . . . 0.45 ' HA ' ' HB3' ' A' ' 173' ' ' ASP . 33.2 Cg_exo -64.1 147.61 91.48 Favored 'Trans proline' 0 C--N 1.384 2.403 0 C-N-CA 123.554 2.836 . . . . 45.21 114.314 -172.675 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.18 5.08 89.36 Favored Glycine 0 C--N 1.348 1.249 0 CA-C-N 115.058 -0.974 . . . . 64.21 114.447 175.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 46.9 tpp -96.43 -36.14 10.92 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.092 0.557 . . . . 73.52 110.95 -177.01 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 165' ' ' GLY . . . . . 0.687 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.349 1.26 0 CA-C-N 115.635 -0.711 . . . . 53.25 114.3 -175.706 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo . . . . . 0 CA--C 1.549 1.261 0 CA-C-O 120.996 0.332 . . . . 61.01 111.77 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -101.09 160.42 18.6 Favored Glycine 0 C--N 1.34 0.763 0 N-CA-C 111.075 -0.81 . . . . 62.35 111.075 176.837 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.45 ' HB3' ' HA ' ' A' ' 162' ' ' PRO . 0.9 OUTLIER -124.94 179.59 4.96 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.696 0.798 . . . . 74.25 110.966 -167.021 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 21.2 tp -127.74 118.91 24.66 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.146 0.578 . . . . 75.24 109.686 175.697 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.556 HD12 ' HE ' ' A' ' 120' ' ' ARG . 86.0 mt -86.19 99.32 11.45 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 124.608 1.163 . . . . 63.12 110.391 177.606 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 76.5 mt -89.82 102.61 15.31 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.704 0.802 . . . . 64.2 110.576 174.603 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.453 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 29.3 t -90.9 102.79 13.79 Favored 'Isoleucine or valine' 0 C--O 1.244 0.777 0 N-CA-C 108.313 -0.995 . . . . 63.02 108.313 175.597 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 5.5 m -79.75 150.47 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 CA-C-O 121.65 0.738 . . . . 74.22 111.479 -173.569 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 19.6 mmt85 -122.26 98.47 5.95 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 114.482 -1.235 . . . . 73.24 107.811 -178.244 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.484 HD11 ' HA ' ' A' ' 154' ' ' ARG . 21.5 mt -68.34 151.49 46.81 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.207 0.603 . . . . 63.31 112.443 -177.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.584 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 60.6 mt -53.69 138.58 51.95 Favored Pre-proline 0 CA--C 1.559 1.322 0 O-C-N 124.091 0.869 . . . . 74.0 111.324 -179.304 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -57.32 -13.08 11.94 Favored 'Trans proline' 0 C--N 1.383 2.375 0 C-N-CA 124.239 3.293 . . . . 74.12 115.584 -173.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 183' ' ' HIS . . . . . 0.52 ' O ' HD11 ' A' ' 127' ' ' LEU . 1.0 OUTLIER -87.52 114.33 58.3 Favored Pre-proline 0 CA--C 1.548 0.889 0 N-CA-C 108.708 -0.849 . . . . 75.14 108.708 173.247 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -92.62 126.67 0.75 Allowed 'Trans proline' 0 C--N 1.377 2.066 0 C-N-CA 122.568 2.179 . . . . 74.01 112.287 173.144 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.9 p -127.29 -41.8 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 N-CA-C 109.565 -0.531 . . . . 53.14 109.565 174.302 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.454 ' HE2' HD13 ' A' ' 193' ' ' LEU . 6.5 m-85 -107.52 125.2 50.98 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 115.896 -0.593 . . . . 74.31 110.691 -178.074 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.578 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 6.2 mpt_? -112.38 103.97 12.11 Favored 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 107.237 -1.394 . . . . 51.53 107.237 175.13 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 42.1 tp -92.72 136.51 33.17 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.115 0.566 . . . . 71.14 109.8 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -143.68 134.05 24.64 Favored 'General case' 0 C--O 1.241 0.657 0 N-CA-C 109.225 -0.657 . . . . 75.35 109.225 165.586 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 68.28 -81.88 0.2 Allowed Glycine 0 C--N 1.352 1.426 0 O-C-N 123.913 0.758 . . . . 71.22 113.087 -178.691 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 24.1 pt20 -144.34 -17.57 0.56 Allowed 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 123.645 0.778 . . . . 50.44 110.755 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -109.86 158.27 18.35 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-O 121.269 0.557 . . . . 70.53 111.683 -170.049 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.468 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 77.4 mt -111.34 163.38 14.04 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.005 1.322 . . . . 73.31 111.779 -168.67 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 194' ' ' TYR . . . . . 0.578 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 82.5 m-85 -139.52 124.16 18.37 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 114.563 -1.199 . . . . 63.14 108.516 170.032 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 195' ' ' ALA . . . . . 0.425 ' HB3' HD11 ' A' ' 249' ' ' LEU . . . -135.84 171.43 14.47 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 122.836 0.454 . . . . 44.55 110.157 175.576 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 7.8 m -102.48 134.42 45.84 Favored 'General case' 0 CA--C 1.544 0.712 0 N-CA-C 109.389 -0.597 . . . . 71.31 109.389 178.564 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.603 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 42.7 tp -109.98 114.09 27.34 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.382 1.073 . . . . 60.52 110.133 -177.384 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -94.11 103.71 15.75 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.414 0.686 . . . . 74.01 109.746 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 199' ' ' VAL . . . . . 0.63 HG12 HG11 ' A' ' 210' ' ' VAL . 3.5 m -113.2 142.44 27.42 Favored Pre-proline 0 N--CA 1.479 1.012 0 C-N-CA 122.981 0.513 . . . . 73.12 109.668 176.666 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -68.96 155.49 68.33 Favored 'Trans proline' 0 C--N 1.365 1.439 0 C-N-CA 122.33 2.02 . . . . 74.11 111.38 167.498 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 201' ' ' ALA . . . . . 0.407 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -60.04 -45.85 98.02 Favored Pre-proline 0 N--CA 1.479 0.979 0 CA-C-O 118.737 -0.649 . . . . 73.21 112.215 177.518 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 202' ' ' PRO . . . . . 0.463 ' O ' HG22 ' A' ' 206' ' ' VAL . 9.8 Cg_endo -49.77 -45.76 30.49 Favored 'Trans proline' 0 C--N 1.391 2.781 0 C-N-CA 122.568 2.179 . . . . 12.33 113.348 171.479 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 203' ' ' ILE . . . . . 0.484 ' HA ' ' HA3' ' A' ' 207' ' ' GLY . 3.5 mt -67.64 -43.94 86.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 O-C-N 121.967 -0.458 . . . . 72.51 111.569 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -52.51 -43.96 65.42 Favored 'General case' 0 CA--C 1.538 0.489 0 O-C-N 124.446 1.091 . . . . 51.21 111.177 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 205' ' ' VAL . . . . . 0.621 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 28.8 m -88.91 -58.46 3.46 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.262 0 N-CA-C 113.015 0.746 . . . . 64.34 113.015 -176.555 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.533 HG13 HG23 ' A' ' 205' ' ' VAL . 18.6 m -104.43 -25.28 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 113.328 0.862 . . . . 70.55 113.328 -172.124 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.484 ' HA3' ' HA ' ' A' ' 203' ' ' ILE . . . -74.96 -70.82 1.21 Allowed Glycine 0 C--N 1.346 1.123 0 C-N-CA 121.565 -0.35 . . . . 62.21 112.289 -168.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 92.15 -2.06 74.6 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-O 119.2 -0.778 . . . . 74.34 114.131 170.341 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 40.8 mtmt -139.33 138.93 37.09 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 108.352 -0.981 . . . . 73.1 108.352 178.641 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 210' ' ' VAL . . . . . 0.63 HG11 HG12 ' A' ' 199' ' ' VAL . 7.3 p -160.58 145.98 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 C-N-CA 123.897 0.879 . . . . 72.43 108.71 -178.771 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 211' ' ' ARG . . . . . 0.456 ' HA ' ' HA ' ' A' ' 220' ' ' GLU . 69.0 mtt180 -93.56 123.88 37.17 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 122.759 0.424 . . . . 74.24 109.951 177.52 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.477 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -101.18 165.02 11.51 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 124.237 1.015 . . . . 50.51 109.146 173.557 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 66.2 mmm -103.34 146.75 28.0 Favored 'General case' 0 C--O 1.239 0.551 0 CA-C-O 121.162 0.506 . . . . 73.2 110.419 175.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.433 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.3 t -138.6 169.08 18.43 Favored 'General case' 0 C--O 1.238 0.467 0 CA-C-N 114.726 -1.125 . . . . 64.23 109.709 173.721 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 215' ' ' LEU . . . . . 0.627 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 81.9 mt -70.92 -3.3 18.53 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 114.844 -1.071 . . . . 54.41 113.223 -174.111 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 1.8 pp20? -121.0 -1.45 9.85 Favored 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.274 0.629 . . . . 73.1 112.52 178.453 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.16 -158.51 27.71 Favored Glycine 0 N--CA 1.475 1.278 0 CA-C-O 119.719 -0.489 . . . . 44.25 113.443 176.043 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -90.76 129.47 1.43 Allowed 'Trans proline' 0 C--N 1.367 1.52 0 C-N-CA 123.223 2.616 . . . . 62.22 112.412 174.026 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 31.5 m -109.66 151.43 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 123.819 0.848 . . . . 71.31 109.434 171.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 220' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 211' ' ' ARG . 32.9 tt0 -114.58 114.62 25.97 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.647 -0.501 . . . . 64.32 109.647 173.055 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.466 HG23 HD21 ' A' ' 235' ' ' LEU . 4.5 p -100.56 144.32 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 C-N-CA 124.703 1.201 . . . . 61.21 110.744 178.706 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -95.96 113.02 24.6 Favored 'General case' 0 C--O 1.24 0.561 0 N-CA-C 109.159 -0.682 . . . . 73.34 109.159 173.0 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.53 HG11 HG11 ' A' ' 199' ' ' VAL . 14.1 m -84.53 138.6 38.4 Favored Pre-proline 0 N--CA 1.481 1.097 0 N-CA-C 108.86 -0.792 . . . . 74.33 108.86 176.36 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -54.3 140.68 72.51 Favored 'Trans proline' 0 C--N 1.379 2.136 0 C-N-CA 122.625 2.217 . . . . 72.53 112.622 177.283 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -54.17 112.74 1.07 Allowed 'Trans proline' 0 C--N 1.379 2.181 0 C-N-CA 122.881 2.388 . . . . 75.13 111.282 174.55 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 226' ' ' ARG . . . . . 0.621 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 60.6 mtp180 63.27 58.43 1.4 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.531 1.133 . . . . 74.52 110.634 -171.164 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.8 t -71.15 171.82 10.31 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.334 -0.848 . . . . 65.44 110.431 175.22 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.5 mp0 -121.18 146.35 46.87 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.711 0.804 . . . . 73.34 109.225 -175.669 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -72.52 113.73 9.87 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 123.218 0.607 . . . . 65.22 110.292 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.6 4.88 19.23 Favored Glycine 0 C--N 1.339 0.712 0 CA-C-N 115.73 -0.668 . . . . 72.21 112.399 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 61.3 mtp180 -76.17 153.25 36.32 Favored 'General case' 0 N--CA 1.477 0.918 0 CA-C-N 117.345 0.573 . . . . 73.44 109.962 172.092 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 0.2 OUTLIER -111.71 119.27 38.08 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 123.727 0.811 . . . . 60.34 108.934 -179.746 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 70.2 mt -106.02 114.49 28.66 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 122.85 0.46 . . . . 74.03 109.827 -178.022 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 234' ' ' ARG . . . . . 0.589 ' HG3' ' HB3' ' A' ' 248' ' ' ASP . 39.7 ttp180 -82.48 104.22 12.61 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 124.863 1.265 . . . . 74.41 111.354 -171.23 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.498 ' HB2' ' HB3' ' A' ' 249' ' ' LEU . 38.2 mt -89.48 97.63 11.3 Favored 'General case' 0 C--O 1.239 0.531 0 C-N-CA 123.231 0.612 . . . . 71.04 109.594 172.618 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -72.81 134.95 45.12 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 114.766 -1.106 . . . . 63.53 110.119 -178.323 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 85.26 24.65 43.02 Favored Glycine 0 C--N 1.34 0.77 0 O-C-N 123.493 0.496 . . . . 73.15 113.247 178.542 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -124.52 -6.88 7.5 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 123.223 0.609 . . . . 75.43 112.353 176.627 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -85.32 -161.67 34.74 Favored Glycine 0 C--N 1.345 1.082 0 O-C-N 123.53 0.518 . . . . 34.53 112.506 175.423 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.558 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 92.2 m-85 -97.24 147.0 32.32 Favored Pre-proline 0 N--CA 1.481 1.082 0 C-N-CA 123.524 0.729 . . . . 75.25 111.282 175.434 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.43 132.52 33.75 Favored 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 122.257 1.971 . . . . 64.42 111.315 171.452 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -156.83 -148.64 5.15 Favored Glycine 0 CA--C 1.532 1.152 0 CA-C-O 119.01 -0.883 . . . . 71.32 111.595 -176.044 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -51.63 -53.96 6.15 Favored 'Trans proline' 0 C--N 1.377 2.055 0 C-N-CA 123.953 3.102 . . . . 63.44 114.999 -177.11 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -83.67 -24.46 31.32 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 122.608 0.363 . . . . 72.2 111.778 -177.737 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 141.86 -155.4 25.4 Favored Glycine 0 N--CA 1.47 0.92 0 N-CA-C 110.091 -1.204 . . . . 32.25 110.091 -177.088 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 22.1 ttm180 -65.13 134.73 54.39 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 118.511 1.155 . . . . 73.13 109.351 171.857 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -75.05 -170.85 27.49 Favored Glycine 0 C--O 1.249 1.052 0 CA-C-O 121.974 0.763 . . . . 60.43 114.686 -170.555 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 248' ' ' ASP . . . . . 0.589 ' HB3' ' HG3' ' A' ' 234' ' ' ARG . 12.1 m-20 -129.33 136.9 50.61 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 114.268 -0.966 . . . . 74.42 109.565 -169.555 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.498 ' HB3' ' HB2' ' A' ' 235' ' ' LEU . 20.7 tp -97.01 111.74 23.82 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.889 -0.411 . . . . 74.13 109.889 179.559 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -91.85 106.63 18.61 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.222 0.534 . . . . 74.12 109.813 177.489 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.603 ' HB3' ' HB2' ' A' ' 197' ' ' LEU . 85.9 mt -87.53 120.01 28.41 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 124.245 1.018 . . . . 62.4 112.379 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -80.61 93.86 6.2 Favored 'General case' 0 CA--C 1.539 0.535 0 N-CA-C 108.093 -1.077 . . . . 65.41 108.093 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.402 HG22 HD23 ' A' ' 197' ' ' LEU . 60.3 t -48.96 123.68 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.561 1.144 . . . . 65.03 111.184 175.706 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 38.5 mmm-85 -128.69 100.94 5.92 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 107.219 -1.4 . . . . 70.12 107.219 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 56.5 mt -83.34 117.84 29.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 115.149 -0.932 . . . . 63.5 110.05 -177.162 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.8 t . . . . . 0 CA--C 1.556 1.187 0 C-N-CA 124.23 1.012 . . . . 65.23 108.603 174.53 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.667 HD22 ' HG3' ' A' ' 136' ' ' ARG . 20.4 tp . . . . . 0 N--CA 1.474 0.737 0 N-CA-C 110.236 -0.283 . . . . 53.02 110.236 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.583 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 10.0 p -60.76 126.79 19.26 Favored 'Isoleucine or valine' 0 C--N 1.36 1.063 0 O-C-N 123.465 0.478 . . . . 72.3 111.025 175.579 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -83.31 -65.9 0.95 Allowed 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.493 -0.776 . . . . 62.42 109.699 -179.104 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -150.13 147.45 27.77 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 114.987 -1.006 . . . . 74.1 110.258 -169.421 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 92.9 t -78.81 124.59 37.4 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 N-CA-C 109.259 -0.645 . . . . 74.31 109.259 169.776 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 70.1 p . . . . . 0 CA--C 1.55 0.956 0 C-N-CA 123.359 0.664 . . . . 64.31 109.471 176.042 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 16.2 t70 . . . . . 0 N--CA 1.475 0.818 0 N-CA-C 108.591 -0.892 . . . . 74.5 108.591 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 28.6 tp -101.61 142.07 33.53 Favored 'General case' 0 C--O 1.22 -0.453 0 N-CA-C 107.356 -1.35 . . . . 72.33 107.356 -178.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 37.3 ttp-105 -143.28 132.93 23.73 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 108.513 -0.921 . . . . 71.54 108.513 -178.091 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -144.75 138.41 27.16 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 123.953 0.901 . . . . 73.22 109.052 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -103.26 148.98 25.15 Favored 'General case' 0 C--O 1.252 1.191 0 CA-C-O 120.935 0.398 . . . . 72.15 110.101 176.344 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.583 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.6 pt? -146.95 130.93 8.44 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.674 -0.694 . . . . 73.24 111.967 -170.675 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.97 120.64 7.63 Favored 'Trans proline' 0 C--N 1.378 2.084 0 C-N-CA 122.49 2.127 . . . . 72.25 111.477 174.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 18.0 tp -120.42 152.79 37.45 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.542 1.137 . . . . 64.45 109.165 179.675 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.474 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 22.4 m -86.25 155.41 20.7 Favored 'General case' 0 CA--C 1.551 0.993 0 N-CA-C 109.365 -0.606 . . . . 54.21 109.365 172.009 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.433 HD11 ' O ' ' A' ' 183' ' ' HIS . 28.6 mt -55.34 -49.23 72.76 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-O 121.923 0.868 . . . . 70.24 109.934 175.113 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.607 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.3 mp0 -55.96 -35.44 66.69 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 113.943 -1.48 . . . . 64.35 111.544 177.665 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.474 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 35.7 mm-40 -83.11 -19.57 36.5 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 122.993 0.517 . . . . 73.33 112.077 -179.474 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.59 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -65.27 -31.66 72.92 Favored 'General case' 0 C--O 1.246 0.919 0 CA-C-O 121.169 0.509 . . . . 72.44 110.162 165.502 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.443 ' HA ' ' CE1' ' A' ' 240' ' ' PHE . 6.6 t80 -77.28 -47.36 20.29 Favored 'General case' 0 CA--C 1.546 0.789 0 CA-C-N 115.366 -0.834 . . . . 71.51 112.279 170.823 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -76.75 -30.19 56.46 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 112.54 0.57 . . . . 75.43 112.54 -171.224 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 67.92 -107.08 1.91 Allowed Glycine 0 CA--C 1.533 1.218 0 N-CA-C 111.564 -0.614 . . . . 4.34 111.564 -173.31 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.33 162.43 36.39 Favored Glycine 0 C--N 1.353 1.496 0 N-CA-C 114.904 0.722 . . . . 63.14 114.904 168.621 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.457 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 1.6 mp0 -96.03 114.17 25.86 Favored 'General case' 0 C--N 1.357 0.917 0 N-CA-C 108.856 -0.794 . . . . 75.21 108.856 179.185 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.667 ' HG3' HD22 ' A' ' 98' ' ' LEU . 4.6 mmp_? -130.37 139.25 50.66 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.836 0.854 . . . . 51.34 109.372 -174.78 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 17.9 m -74.55 128.23 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 CA-C-O 121.638 0.732 . . . . 75.4 111.614 -172.561 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.439 HG13 HG11 ' A' ' 99' ' ' VAL . 21.7 t -119.87 129.65 75.16 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 C-N-CA 125.292 1.437 . . . . 75.22 109.168 -177.531 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -121.8 97.74 5.63 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 108.746 -0.835 . . . . 73.32 108.746 177.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.461 HG21 HD22 ' A' ' 174' ' ' LEU . 27.9 m -137.82 142.87 35.02 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.885 0 C-N-CA 125.09 1.356 . . . . 72.04 108.336 -177.304 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.55 19.2 11.47 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 124.081 0.953 . . . . 72.01 112.665 176.48 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.08 22.87 75.82 Favored Glycine 0 C--N 1.352 1.463 0 CA-C-N 116.393 -0.367 . . . . 64.3 112.359 -174.89 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -120.79 135.65 55.1 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.366 1.067 . . . . 75.31 108.861 -178.458 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 41.1 ttt180 -111.41 106.24 15.09 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.005 -0.739 . . . . 74.22 109.005 175.135 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 29.2 t -132.59 126.89 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 N-CA-C 108.461 -0.94 . . . . 64.14 108.461 -178.33 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 72.6 p -71.53 122.87 21.24 Favored 'General case' 0 CA--C 1.54 0.592 0 N-CA-C 109.084 -0.71 . . . . 55.21 109.084 171.651 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 7.3 p -96.79 140.72 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 109.769 -0.456 . . . . 73.33 109.769 -177.742 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.9 ttp180 -109.35 99.96 9.13 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 107.395 -1.335 . . . . 70.13 107.395 171.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.522 ' HB ' HD13 ' A' ' 159' ' ' ILE . 35.8 pt -89.27 127.53 54.8 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 108.467 -0.938 . . . . 72.23 108.467 175.128 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.09 135.86 33.2 Favored 'Trans proline' 0 C--N 1.376 2.008 0 C-N-CA 122.477 2.118 . . . . 42.25 113.061 -173.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_exo -46.25 119.92 3.37 Favored 'Trans proline' 0 C--N 1.376 2.012 0 C-N-CA 123.937 3.091 . . . . 73.45 112.75 167.098 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 123.48 58.17 0.19 Allowed Glycine 0 N--CA 1.465 0.625 0 N-CA-C 110.635 -0.986 . . . . 74.5 110.635 -175.892 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.59 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.0 p -134.17 161.48 40.7 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.319 0 C-N-CA 123.698 0.799 . . . . 73.11 109.397 -178.162 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 14.5 mtp180 -141.35 170.94 14.78 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 126.05 1.74 . . . . 71.02 109.747 -169.624 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -55.24 126.54 25.33 Favored 'General case' 0 CA--C 1.551 1.015 0 CA-C-N 116.027 -0.533 . . . . 71.35 110.695 164.719 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.38 2.7 74.97 Favored Glycine 0 C--N 1.346 1.126 0 CA-C-O 119.781 -0.455 . . . . 60.13 113.891 179.532 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 42.1 t -77.76 130.96 37.39 Favored 'General case' 0 C--O 1.247 0.932 0 N-CA-C 109.677 -0.49 . . . . 61.25 109.677 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.488 HG12 HD22 ' A' ' 175' ' ' LEU . 15.3 t -106.78 121.52 59.62 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-N 114.743 -1.117 . . . . 75.02 109.275 -168.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.528 HD11 HG21 ' A' ' 153' ' ' VAL . 23.6 mt -109.73 113.93 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 123.65 0.78 . . . . 74.55 110.686 -171.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 48.6 ttm-85 -83.19 119.42 24.52 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.22 0.608 . . . . 71.01 110.119 177.036 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 173' ' ' ASP . 5.1 m -123.94 132.14 24.28 Favored Pre-proline 0 N--CA 1.481 1.106 0 C-N-CA 123.138 0.575 . . . . 65.34 109.822 -178.362 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.92 157.26 43.22 Favored 'Trans proline' 0 C--N 1.374 1.899 0 C-N-CA 122.54 2.16 . . . . 73.34 113.889 -175.733 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.52 24.14 63.56 Favored Glycine 0 C--N 1.35 1.31 0 CA-C-N 115.128 -0.942 . . . . 45.21 115.389 171.564 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.4 ' SD ' HD23 ' A' ' 174' ' ' LEU . 62.3 mtt -124.66 -61.09 1.34 Allowed 'General case' 0 N--CA 1.493 1.708 0 CA-C-N 119.075 1.437 . . . . 53.31 112.919 -179.137 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.693 0 C-N-CA 121.699 -0.286 . . . . 75.12 113.605 -176.223 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo . . . . . 0 CA--C 1.547 1.16 0 N-CA-C 111.031 -0.411 . . . . 70.11 111.031 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . 85.11 109.28 0.67 Allowed Glycine 0 C--O 1.22 -0.757 0 CA-C-O 119.22 -0.767 . . . . 72.21 112.762 178.756 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.509 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 47.3 m-20 -144.98 134.52 23.24 Favored 'General case' 0 N--CA 1.481 1.119 0 CA-C-N 117.899 0.849 . . . . 72.52 111.489 172.398 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.461 HD22 HG21 ' A' ' 140' ' ' VAL . 28.1 tp -112.16 126.6 55.38 Favored 'General case' 0 C--N 1.347 0.477 0 N-CA-C 108.459 -0.941 . . . . 70.51 108.459 171.082 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.488 HD22 HG12 ' A' ' 158' ' ' VAL . 29.9 mt -93.99 100.73 12.82 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.539 1.135 . . . . 73.52 110.163 176.661 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 62.9 mt -87.11 104.45 16.36 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.532 0.733 . . . . 74.13 111.272 176.826 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 23.4 t -90.08 100.3 10.77 Favored 'Isoleucine or valine' 0 C--O 1.243 0.748 0 N-CA-C 108.101 -1.074 . . . . 65.21 108.101 175.863 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 3.2 m -78.25 149.88 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-O 121.624 0.726 . . . . 74.11 111.32 -174.176 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 33.0 mmt180 -119.22 95.29 4.74 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.497 -1.229 . . . . 73.54 107.963 -177.321 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 39.6 mt -67.99 147.91 51.77 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 110.192 -0.299 . . . . 55.33 110.192 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.402 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 47.5 mt -54.2 146.83 29.15 Favored Pre-proline 0 CA--C 1.562 1.415 0 C-N-CA 124.111 0.964 . . . . 73.33 111.417 -174.33 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -61.51 77.11 0.09 OUTLIER 'Trans proline' 0 C--N 1.379 2.173 0 C-N-CA 123.176 2.584 . . . . 73.03 111.447 171.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 183' ' ' HIS . . . . . 0.433 ' O ' HD11 ' A' ' 127' ' ' LEU . 8.2 t60 170.78 87.69 0.04 OUTLIER Pre-proline 0 CA--C 1.547 0.859 0 C-N-CA 126.242 1.817 . . . . 70.13 107.287 -166.671 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -98.76 125.27 0.17 Allowed 'Trans proline' 0 CA--C 1.564 1.994 0 C-N-CA 123.316 2.678 . . . . 74.43 113.188 172.805 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -122.64 -42.0 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.632 -0.668 . . . . 71.43 109.413 174.146 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 4.7 m-85 -98.08 128.36 44.56 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.19 -0.914 . . . . 71.45 110.304 -178.616 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 10.4 mtt180 -112.63 103.98 12.04 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 106.218 -1.771 . . . . 72.41 106.218 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.428 HD12 ' O ' ' A' ' 192' ' ' ASP . 42.7 tp -81.44 110.84 17.24 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-O 121.259 0.552 . . . . 74.22 109.576 176.585 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.11 99.49 10.5 Favored 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 106.393 -1.706 . . . . 61.24 106.393 171.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 62.7 -94.9 0.11 Allowed Glycine 0 C--N 1.349 1.294 0 O-C-N 124.018 0.823 . . . . 65.4 113.352 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 191' ' ' GLN . . . . . 0.542 HE22 ' HB3' ' A' ' 244' ' ' ALA . 8.7 pt20 -108.46 -19.2 13.53 Favored 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 123.742 0.817 . . . . 51.23 110.849 178.042 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.428 ' O ' HD12 ' A' ' 188' ' ' LEU . 29.0 m-20 -97.0 155.03 16.95 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 123.876 0.87 . . . . 72.1 111.63 -172.541 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.455 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 82.6 mt -109.53 154.33 22.86 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 124.206 1.003 . . . . 74.45 109.484 -177.55 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -137.17 121.83 18.55 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 107.502 -1.296 . . . . 74.25 107.502 171.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -134.03 141.51 47.24 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 108.632 -0.877 . . . . 53.11 108.632 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 3.5 m -82.3 122.46 27.98 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 109.747 -0.464 . . . . 65.12 109.747 -178.706 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.446 HD13 ' HB2' ' A' ' 212' ' ' ALA . 57.2 tp -107.75 112.2 24.76 Favored 'General case' 0 C--O 1.216 -0.69 0 C-N-CA 124.335 1.054 . . . . 64.52 109.116 -178.706 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -93.52 108.23 19.96 Favored 'General case' 0 N--CA 1.474 0.755 0 CA-C-O 121.338 0.59 . . . . 72.22 109.617 177.384 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 199' ' ' VAL . . . . . 0.48 HG22 HG21 ' A' ' 210' ' ' VAL . 65.2 t -101.37 126.0 35.93 Favored Pre-proline 0 N--CA 1.474 0.74 0 C-N-CA 124.148 0.979 . . . . 61.43 109.344 -176.659 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_exo -57.18 139.29 89.59 Favored 'Trans proline' 0 C--N 1.369 1.622 0 C-N-CA 122.624 2.216 . . . . 62.21 111.503 171.87 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -55.31 -41.83 92.79 Favored Pre-proline 0 N--CA 1.482 1.136 0 N-CA-C 113.673 0.99 . . . . 74.32 113.673 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo -47.58 -52.91 7.25 Favored 'Trans proline' 0 C--N 1.386 2.519 0 C-N-CA 122.166 1.911 . . . . 73.15 113.621 168.013 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 203' ' ' ILE . . . . . 0.53 HG21 HG13 ' A' ' 210' ' ' VAL . 9.3 mt -67.73 -33.33 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 123.035 0.534 . . . . 64.34 111.689 -179.502 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -68.39 -42.24 79.34 Favored 'General case' 0 C--O 1.245 0.861 0 C-N-CA 123.122 0.569 . . . . 52.12 111.855 -177.015 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.2 m -77.44 -40.78 29.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 CA-C-N 115.729 -0.669 . . . . 65.44 110.968 -177.434 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.1 m -79.16 -30.38 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 CA-C-O 120.841 0.353 . . . . 75.22 111.437 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.512 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 79.87 67.37 1.58 Allowed Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.683 -0.689 . . . . 74.14 112.513 -175.323 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -97.92 -148.99 24.56 Favored Glycine 0 C--N 1.35 1.347 0 CA-C-N 116.688 0.244 . . . . 43.0 112.546 176.796 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 209' ' ' LYS . . . . . 0.676 ' HD3' ' HB2' ' A' ' 220' ' ' GLU . 4.7 ttmp? -125.54 131.44 52.77 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.517 0.727 . . . . 74.21 109.081 -178.427 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 210' ' ' VAL . . . . . 0.53 HG13 HG21 ' A' ' 203' ' ' ILE . 5.7 m -120.87 135.76 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.357 -0.979 . . . . 74.52 108.357 172.897 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 211' ' ' ARG . . . . . 0.533 ' HD3' ' HB2' ' A' ' 218' ' ' PRO . 35.0 ttm105 -96.26 117.15 30.2 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 121.279 0.561 . . . . 74.33 109.699 178.766 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.446 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -99.78 155.4 17.66 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.027 0.931 . . . . 75.24 109.681 178.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 58.1 mmm -92.4 128.21 38.17 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 109.82 -0.437 . . . . 54.23 109.82 172.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.0 t -114.42 173.01 6.67 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-N 115.277 -0.874 . . . . 65.24 109.172 167.357 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 215' ' ' LEU . . . . . 0.607 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 73.1 mt -75.28 -2.99 30.72 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-N 115.449 -0.796 . . . . 75.52 112.614 -172.794 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.65 7.76 11.12 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 123.541 0.736 . . . . 72.22 112.122 179.219 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 137.01 -161.16 25.11 Favored Glycine 0 N--CA 1.476 1.362 0 CA-C-O 119.817 -0.435 . . . . 44.1 112.91 178.143 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 218' ' ' PRO . . . . . 0.533 ' HB2' ' HD3' ' A' ' 211' ' ' ARG . 98.5 Cg_endo -94.35 125.17 0.45 Allowed 'Trans proline' 0 C--N 1.37 1.681 0 C-N-CA 123.499 2.799 . . . . 60.23 112.763 176.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.7 m -108.85 146.28 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 123.322 0.649 . . . . 71.53 110.52 175.822 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 220' ' ' GLU . . . . . 0.676 ' HB2' ' HD3' ' A' ' 209' ' ' LYS . 9.9 pt-20 -113.73 104.66 12.43 Favored 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 108.996 -0.742 . . . . 75.11 108.996 -177.251 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.5 p -97.61 135.54 31.65 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 CA-C-N 115.656 -0.702 . . . . 70.52 110.832 -179.084 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -93.93 117.63 30.37 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-N 115.269 -0.878 . . . . 63.54 109.418 176.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.512 HG23 ' HA2' ' A' ' 207' ' ' GLY . 21.4 m -84.22 140.06 39.34 Favored Pre-proline 0 CA--C 1.553 1.096 0 N-CA-C 109.615 -0.513 . . . . 72.54 109.615 176.915 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -64.37 144.23 85.13 Favored 'Trans proline' 0 C--N 1.378 2.081 0 C-N-CA 122.583 2.189 . . . . 42.24 112.065 173.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -56.52 126.89 23.77 Favored 'Trans proline' 0 C--N 1.371 1.73 0 C-N-CA 122.746 2.297 . . . . 74.13 111.76 171.573 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 50.9 mtt180 65.64 44.28 3.02 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 124.445 1.098 . . . . 74.42 110.592 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 5.5 t -77.43 168.84 19.35 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 122.874 0.469 . . . . 45.44 110.046 177.765 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -130.72 152.06 50.48 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 122.893 0.477 . . . . 71.22 109.782 -178.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.61 134.06 48.32 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.752 0.821 . . . . 74.14 111.166 178.454 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.2 -8.11 20.91 Favored Glycine 0 C--N 1.341 0.854 0 CA-C-O 119.562 -0.576 . . . . 73.44 112.755 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -78.84 159.31 27.88 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-N 117.45 0.625 . . . . 73.45 109.483 175.01 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.561 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 12.9 mptt -118.57 102.6 9.01 Favored 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 123.748 0.819 . . . . 74.04 109.37 177.41 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 233' ' ' LEU . . . . . 0.433 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 83.3 mt -78.92 104.61 9.67 Favored 'General case' 0 C--N 1.355 0.805 0 N-CA-C 108.463 -0.94 . . . . 74.35 108.463 -176.116 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 22.3 ttp85 -79.65 121.49 25.36 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 115.261 -0.881 . . . . 71.43 110.446 -169.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 34.4 mt -105.94 120.09 40.87 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.733 0.813 . . . . 64.2 109.93 175.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -70.55 128.32 35.74 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 124.327 1.051 . . . . 63.12 112.237 -169.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 81.56 7.48 88.13 Favored Glycine 0 C--N 1.349 1.267 0 O-C-N 123.718 0.636 . . . . 74.52 114.453 171.579 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 38.2 mmtm -85.16 -23.33 28.42 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 117.192 0.496 . . . . 63.22 112.237 -178.141 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -81.62 173.74 53.97 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 111.861 -0.495 . . . . 75.34 111.861 176.229 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.443 ' CE1' ' HA ' ' A' ' 131' ' ' PHE . 88.2 m-85 -81.15 150.82 68.96 Favored Pre-proline 0 N--CA 1.477 0.894 0 N-CA-C 112.739 0.644 . . . . 73.21 112.739 -172.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -55.61 132.15 50.37 Favored 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.066 2.511 . . . . 75.54 111.226 170.151 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -160.81 -150.8 6.0 Favored Glycine 0 CA--C 1.532 1.154 0 CA-C-O 119.595 -0.558 . . . . 62.0 112.05 -174.572 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -65.77 -27.56 52.02 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 123.168 2.579 . . . . 72.34 113.287 -174.812 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 244' ' ' ALA . . . . . 0.542 ' HB3' HE22 ' A' ' 191' ' ' GLN . . . -109.51 21.79 16.57 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 123.667 0.787 . . . . 64.14 111.052 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.08 -151.6 33.61 Favored Glycine 0 C--N 1.347 1.171 0 N-CA-C 110.489 -1.045 . . . . 72.52 110.489 -170.47 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -61.83 138.9 58.39 Favored 'General case' 0 N--CA 1.477 0.924 0 CA-C-N 117.979 0.889 . . . . 73.45 110.162 174.124 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -78.54 -158.87 12.57 Favored Glycine 0 C--O 1.247 0.94 0 CA-C-N 115.969 -0.56 . . . . 33.13 112.146 172.667 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 -144.35 156.02 44.05 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.011 0.524 . . . . 75.52 109.938 -173.167 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.455 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 20.6 tp -97.67 109.84 22.52 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.462 0.649 . . . . 72.01 110.039 179.037 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 250' ' ' TYR . . . . . 0.561 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 97.5 m-85 -91.33 106.96 18.87 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-N 115.108 -0.951 . . . . 72.4 109.942 176.824 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.442 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 72.5 mt -89.25 112.76 23.89 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 123.939 0.895 . . . . 74.43 112.486 -179.289 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -78.62 91.37 4.61 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.945 -0.761 . . . . 74.42 108.945 178.259 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.1 p -55.54 125.9 11.64 Favored 'Isoleucine or valine' 0 C--N 1.353 0.732 0 CA-C-N 115.043 -0.98 . . . . 74.15 110.324 175.271 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 44.8 mmm-85 -131.15 109.83 10.73 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 106.536 -1.653 . . . . 74.31 106.536 175.587 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 66.3 mt -83.67 121.21 36.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.454 0 CA-C-N 115.966 -0.561 . . . . 62.35 111.799 -171.212 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 21.5 m . . . . . 0 CA--C 1.558 1.284 0 C-N-CA 124.586 1.154 . . . . 51.13 108.992 175.158 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.514 ' HB3' HD12 ' A' ' 123' ' ' LEU . 86.5 mt . . . . . 0 N--CA 1.472 0.644 0 N-CA-C 109.543 -0.54 . . . . 73.42 109.543 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.495 ' HB ' HG23 ' A' ' 138' ' ' VAL . 6.4 t -82.9 119.64 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 115.092 -0.958 . . . . 55.44 109.468 178.641 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -75.35 -51.43 13.19 Favored 'General case' 0 N--CA 1.478 0.936 0 O-C-N 124.352 1.032 . . . . 71.51 110.579 177.839 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -165.79 178.15 6.75 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 125.094 1.358 . . . . 74.42 109.338 -172.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.497 HG12 ' HB2' ' A' ' 121' ' ' ALA . 19.0 m -92.04 156.39 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 112.151 0.426 . . . . 51.45 112.151 179.43 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 60.9 p . . . . . 0 C--O 1.238 0.473 0 CA-C-N 115.11 -0.95 . . . . 71.42 109.268 172.775 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.468 ' HB3' ' CZ ' ' A' ' 120' ' ' ARG . 5.9 m-20 . . . . . 0 C--O 1.24 0.595 0 N-CA-C 108.667 -0.864 . . . . 63.24 108.667 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.502 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 14.1 tp -131.63 131.48 43.24 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 107.42 -1.326 . . . . 74.13 107.42 179.364 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' ARG . . . . . 0.711 ' HG3' ' HB2' ' A' ' 175' ' ' LEU . 0.0 OUTLIER -134.41 133.93 41.09 Favored 'General case' 0 N--CA 1.482 1.135 0 N-CA-C 109.173 -0.677 . . . . 73.43 109.173 -177.172 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.497 ' HB2' HG12 ' A' ' 102' ' ' VAL . . . -146.46 164.17 33.33 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 124.079 0.952 . . . . 53.23 110.479 -176.919 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.644 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 46.3 mt-10 -126.42 151.01 48.29 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.079 0.951 . . . . 75.5 108.685 173.728 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.514 HD12 ' HB3' ' A' ' 98' ' ' LEU . 1.4 pt? -145.88 135.3 11.44 Favored Pre-proline 0 N--CA 1.477 0.897 0 C-N-CA 122.967 0.507 . . . . 55.35 110.171 -178.187 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -71.21 113.08 3.48 Favored 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 121.648 1.566 . . . . 64.32 109.583 167.675 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.459 HD22 HG11 ' A' ' 178' ' ' VAL . 17.2 tp -108.29 157.81 18.03 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 108.264 -1.013 . . . . 74.01 108.264 178.385 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.521 HG23 HD12 ' A' ' 181' ' ' LEU . 3.4 m -95.41 161.0 14.26 Favored 'General case' 0 CA--C 1.544 0.736 0 N-CA-C 109.4 -0.593 . . . . 72.44 109.4 173.629 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.47 HD23 ' HB3' ' A' ' 180' ' ' LEU . 67.7 mt -61.33 -46.17 91.36 Favored 'General case' 0 N--CA 1.476 0.836 0 CA-C-O 121.42 0.629 . . . . 72.32 110.104 175.674 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -60.15 -34.83 74.11 Favored 'General case' 0 N--CA 1.484 1.252 0 CA-C-N 114.636 -1.165 . . . . 73.11 111.871 176.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -72.94 -33.57 66.01 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 123.308 0.643 . . . . 72.13 110.472 177.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.491 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -62.68 -36.68 83.68 Favored 'General case' 0 C--O 1.246 0.891 0 C-N-CA 123.955 0.902 . . . . 72.01 111.883 171.347 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.5 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 31.7 t80 -66.87 -61.28 2.03 Favored 'General case' 0 N--CA 1.472 0.671 0 O-C-N 123.961 0.788 . . . . 72.11 111.72 175.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 40.7 m80 -77.68 -26.32 50.16 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 115.54 -0.754 . . . . 74.5 112.645 -170.088 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 62.68 -121.72 25.87 Favored Glycine 0 C--N 1.349 1.295 0 O-C-N 123.374 0.421 . . . . 53.43 112.281 -175.657 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 89.59 172.63 45.52 Favored Glycine 0 C--N 1.345 1.059 0 N-CA-C 114.288 0.475 . . . . 75.43 114.288 173.53 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 23.4 mp0 -84.17 136.66 33.88 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 123.512 0.725 . . . . 62.42 109.392 176.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.32 148.12 30.05 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 106.947 -1.501 . . . . 74.53 106.947 170.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 34.7 m -77.41 127.68 38.19 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-O 121.786 0.803 . . . . 70.0 111.643 -173.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.495 HG23 ' HB ' ' A' ' 99' ' ' VAL . 6.7 p -97.54 128.36 48.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.905 -1.146 . . . . 51.44 107.905 170.524 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 139' ' ' GLU . . . . . 0.445 ' HA ' ' O ' ' A' ' 143' ' ' ARG . 42.4 tt0 -123.27 95.06 4.45 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 107.908 -1.145 . . . . 75.25 107.908 -179.6 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.479 ' O ' ' HG2' ' A' ' 143' ' ' ARG . 15.3 m -136.92 138.16 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 124.714 1.206 . . . . 72.4 108.653 -173.418 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.86 20.41 10.63 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 123.741 0.816 . . . . 64.23 111.864 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.55 1.73 87.52 Favored Glycine 0 C--N 1.349 1.274 0 CA-C-O 119.549 -0.584 . . . . 45.44 113.754 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.479 ' HG2' ' O ' ' A' ' 140' ' ' VAL . 8.5 ptm180 -99.98 127.21 46.22 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 118.066 0.933 . . . . 72.34 109.253 176.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -114.16 113.77 25.14 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 124.073 0.949 . . . . 74.11 108.645 178.032 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 4.1 p -148.71 146.39 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 123.456 0.702 . . . . 75.33 109.912 -178.635 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 19.7 m -70.03 112.95 6.78 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.025 0.53 . . . . 75.25 110.931 178.775 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 14.2 p -98.99 137.31 26.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.042 0.537 . . . . 54.33 110.021 175.193 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 59.1 ttp180 -104.75 122.76 46.38 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 107.455 -1.313 . . . . 75.4 107.455 171.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.621 ' HB ' HD13 ' A' ' 159' ' ' ILE . 28.0 pt -107.46 127.47 27.78 Favored Pre-proline 0 CA--C 1.552 1.024 0 N-CA-C 108.172 -1.047 . . . . 72.43 108.172 172.393 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -53.61 130.85 40.84 Favored 'Trans proline' 0 C--N 1.387 2.594 0 C-N-CA 123.29 2.66 . . . . 64.02 113.914 -171.875 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -59.81 109.96 0.67 Allowed 'Trans proline' 0 C--N 1.378 2.085 0 C-N-CA 122.486 2.124 . . . . 62.51 109.952 170.569 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.423 ' HA2' ' CD2' ' A' ' 240' ' ' PHE . . . 139.19 28.48 0.23 Allowed Glycine 0 N--CA 1.468 0.776 0 CA-C-N 116.291 -0.413 . . . . 43.0 112.306 -169.811 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.556 HG21 HD11 ' A' ' 159' ' ' ILE . 2.1 p -104.94 157.36 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.269 0 N-CA-C 109.815 -0.439 . . . . 74.23 109.815 -173.607 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -139.64 163.95 31.2 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 124.951 1.301 . . . . 74.13 110.635 -165.735 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 20.3 tp10 -47.32 117.9 1.95 Allowed 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 124.479 1.112 . . . . 64.23 112.779 169.506 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.83 7.58 86.25 Favored Glycine 0 C--N 1.353 1.514 0 CA-C-N 115.573 -0.74 . . . . 62.32 113.978 178.259 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 33.6 t -76.55 129.51 36.57 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 117.311 0.556 . . . . 74.1 109.861 -178.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.431 HG22 HD22 ' A' ' 175' ' ' LEU . 7.1 p -96.56 131.43 43.35 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.093 0 CA-C-N 115.363 -0.835 . . . . 70.34 109.758 -177.391 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.621 HD13 ' HB ' ' A' ' 149' ' ' ILE . 23.1 mt -116.98 115.8 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 123.675 0.79 . . . . 74.13 110.693 -173.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 18.1 ttm180 -86.78 117.76 25.74 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.059 0.544 . . . . 72.53 110.369 -179.184 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.431 ' HA ' ' HD3' ' A' ' 162' ' ' PRO . 9.0 m -120.29 107.19 39.57 Favored Pre-proline 0 CA--C 1.563 1.446 0 N-CA-C 109.621 -0.511 . . . . 74.45 109.621 178.054 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 162' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 7.9 Cg_exo -72.41 152.87 55.38 Favored 'Trans proline' 0 C--N 1.376 2.014 0 C-N-CA 123.105 2.537 . . . . 71.51 112.834 -174.282 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 72.36 24.7 75.9 Favored Glycine 0 C--N 1.35 1.339 0 O-C-N 123.61 0.569 . . . . 52.32 113.126 179.019 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 48.7 tpp -111.08 -37.53 5.32 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.101 0.56 . . . . 55.53 110.6 -178.396 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.151 0 CA-C-N 116.106 -0.497 . . . . 63.3 113.467 174.926 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo . . . . . 0 CA--C 1.539 0.756 0 N-CA-C 110.995 -0.425 . . . . 64.23 110.995 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -76.12 151.6 40.7 Favored Glycine 0 C--N 1.336 0.579 0 N-CA-C 111.796 -0.522 . . . . 54.32 111.796 174.203 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -103.72 172.74 6.64 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.761 0.825 . . . . 74.21 109.154 178.723 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.502 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 37.5 tp -129.85 114.37 15.82 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 109.336 -0.616 . . . . 75.3 109.336 170.464 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.711 ' HB2' ' HG3' ' A' ' 120' ' ' ARG . 32.4 mt -85.56 102.39 13.49 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 114.903 -1.044 . . . . 75.2 110.837 176.811 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.44 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 79.0 mt -91.59 102.55 15.2 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.087 0.955 . . . . 60.01 111.71 179.137 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.644 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 43.3 t -86.48 103.83 13.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 N-CA-C 108.678 -0.86 . . . . 75.24 108.678 174.115 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.459 HG11 HD22 ' A' ' 125' ' ' LEU . 9.4 m -80.01 151.97 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-O 121.683 0.754 . . . . 71.31 112.124 -177.755 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 7.0 mmm180 -124.69 97.44 5.29 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 125.404 1.482 . . . . 73.31 107.598 178.901 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.47 ' HB3' HD23 ' A' ' 127' ' ' LEU . 54.9 mt -67.15 134.18 51.27 Favored 'General case' 0 CA--C 1.546 0.793 0 O-C-N 123.156 0.285 . . . . 65.2 110.902 -178.47 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.521 HD12 HG23 ' A' ' 126' ' ' THR . 37.1 mt -55.1 146.49 39.44 Favored Pre-proline 0 C--N 1.364 1.222 0 C-N-CA 124.197 0.999 . . . . 74.15 111.379 -174.505 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_exo -70.13 79.07 1.08 Allowed 'Trans proline' 0 C--N 1.376 2.0 0 C-N-CA 123.196 2.597 . . . . 74.24 113.043 -176.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 42.7 p-80 -161.31 57.71 0.86 Allowed Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 124.152 0.981 . . . . 74.01 109.457 173.322 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -66.5 122.52 9.97 Favored 'Trans proline' 0 C--N 1.376 2.009 0 C-N-CA 121.976 1.784 . . . . 54.3 112.019 -168.485 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.459 ' O ' ' HA ' ' A' ' 195' ' ' ALA . 2.9 p -134.92 -41.07 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 C-N-CA 123.364 0.666 . . . . 74.42 109.322 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.451 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 8.8 m-85 -109.89 124.36 51.23 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 122.917 0.487 . . . . 74.02 110.925 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.45 114.79 25.51 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.069 1.348 . . . . 71.42 107.824 175.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 54.9 tp -86.43 144.78 27.13 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 122.897 0.479 . . . . 74.53 110.441 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -142.98 99.87 3.54 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 106.073 -1.825 . . . . 51.1 106.073 177.311 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 65.26 -88.6 0.1 OUTLIER Glycine 0 C--N 1.344 1.003 0 N-CA-C 112.088 -0.405 . . . . 41.2 112.088 -172.567 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -130.66 -10.69 3.97 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 123.92 0.888 . . . . 72.1 110.58 175.784 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -85.87 150.41 24.55 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.71 0.804 . . . . 72.01 111.489 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.653 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 95.9 mt -114.91 161.12 18.7 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 124.25 1.02 . . . . 75.02 111.588 -177.856 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 194' ' ' TYR . . . . . 0.467 ' HA ' ' O ' ' A' ' 250' ' ' TYR . 89.1 m-85 -140.89 118.41 11.54 Favored 'General case' 0 C--O 1.233 0.227 0 N-CA-C 107.091 -1.448 . . . . 75.01 107.091 173.922 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 195' ' ' ALA . . . . . 0.472 ' HB3' HD11 ' A' ' 249' ' ' LEU . . . -141.23 128.7 21.27 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.82 -0.437 . . . . 71.45 109.82 -176.328 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 14.2 m -76.8 114.92 16.1 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-O 121.163 0.506 . . . . 72.45 110.915 -173.269 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.526 HD22 HD13 ' A' ' 251' ' ' LEU . 69.3 tp -106.58 113.06 26.34 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.329 1.052 . . . . 73.22 109.689 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -84.51 129.49 34.85 Favored 'General case' 0 C--O 1.242 0.701 0 N-CA-C 109.061 -0.718 . . . . 73.12 109.061 169.206 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 12.1 m -125.84 141.78 40.33 Favored Pre-proline 0 N--CA 1.48 1.042 0 N-CA-C 108.25 -1.019 . . . . 75.12 108.25 176.238 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -64.67 141.17 71.45 Favored 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 121.693 1.595 . . . . 74.5 110.698 170.44 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 201' ' ' ALA . . . . . 0.412 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -55.83 -41.86 93.1 Favored Pre-proline 0 CA--C 1.558 1.288 0 C-N-CA 123.878 0.871 . . . . 72.55 113.308 -178.312 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 202' ' ' PRO . . . . . 0.425 ' O ' HG22 ' A' ' 206' ' ' VAL . 83.1 Cg_exo -49.04 -47.77 20.56 Favored 'Trans proline' 0 C--N 1.39 2.744 0 C-N-CA 122.434 2.09 . . . . 61.24 114.081 169.101 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 203' ' ' ILE . . . . . 0.482 ' HA ' ' HA3' ' A' ' 207' ' ' GLY . 5.6 mt -66.46 -44.37 90.51 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 CA-C-N 117.822 0.283 . . . . 73.31 111.252 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -50.69 -43.85 57.78 Favored 'General case' 0 CA--C 1.538 0.514 0 O-C-N 124.546 1.154 . . . . 60.42 111.51 -178.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 205' ' ' VAL . . . . . 0.644 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 29.6 m -89.34 -59.61 2.74 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.404 0 N-CA-C 113.226 0.824 . . . . 63.43 113.226 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.425 HG22 ' O ' ' A' ' 202' ' ' PRO . 27.3 m -102.39 -24.61 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 N-CA-C 113.537 0.94 . . . . 71.43 113.537 -171.797 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.482 ' HA3' ' HA ' ' A' ' 203' ' ' ILE . . . -75.0 -76.01 0.78 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 121.181 -0.533 . . . . 61.0 111.993 -173.411 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 94.69 -0.36 65.05 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-O 119.155 -0.803 . . . . 75.42 114.02 172.57 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 209' ' ' LYS . . . . . 0.462 ' O ' HD13 ' A' ' 203' ' ' ILE . 48.6 mtmt -138.11 132.89 32.71 Favored 'General case' 0 N--CA 1.481 1.082 0 CA-C-N 118.165 0.982 . . . . 62.45 108.838 178.553 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 7.7 p -153.65 141.64 13.44 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 C-N-CA 124.124 0.97 . . . . 63.35 108.758 -174.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 16.6 ptp180 -77.5 148.92 35.06 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 110.172 -0.307 . . . . 74.51 110.172 175.516 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.454 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -140.1 159.86 41.24 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.33 0.652 . . . . 63.33 109.82 174.342 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -106.28 143.7 34.03 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-N 115.599 -0.728 . . . . 65.42 110.702 179.259 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.451 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 8.9 t -133.4 165.43 24.86 Favored 'General case' 0 C--O 1.24 0.566 0 C-N-CA 124.102 0.961 . . . . 64.41 109.489 171.292 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 81.4 mt -64.44 -14.82 58.89 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.268 1.027 . . . . 72.51 111.789 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -95.86 -21.39 18.11 Favored 'General case' 0 CA--C 1.558 1.281 0 C-N-CA 123.443 0.697 . . . . 53.4 111.787 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.13 -151.66 23.84 Favored Glycine 0 N--CA 1.478 1.438 0 CA-C-O 119.26 -0.744 . . . . 54.12 112.67 -176.405 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -91.76 133.26 1.37 Allowed 'Trans proline' 0 CA--C 1.559 1.752 0 C-N-CA 123.115 2.543 . . . . 35.35 113.695 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 36.0 m -114.89 159.36 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 123.939 0.896 . . . . 61.44 110.495 171.565 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -114.08 113.43 24.72 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 123.859 0.863 . . . . 71.54 109.069 175.913 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.462 HG22 HD11 ' A' ' 235' ' ' LEU . 20.5 t -95.14 126.24 47.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 123.661 0.785 . . . . 75.42 109.548 -178.615 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -106.5 99.44 9.02 Favored 'General case' 0 C--O 1.24 0.582 0 N-CA-C 107.003 -1.481 . . . . 64.42 107.003 173.311 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.516 HG12 HD13 ' A' ' 233' ' ' LEU . 3.3 m -79.09 132.23 64.06 Favored Pre-proline 0 CA--C 1.553 1.065 0 N-CA-C 108.031 -1.1 . . . . 55.24 108.031 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -56.37 129.61 35.69 Favored 'Trans proline' 0 C--N 1.375 1.956 0 C-N-CA 122.133 1.889 . . . . 74.11 111.665 176.467 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -42.35 124.27 3.05 Favored 'Trans proline' 0 C--N 1.385 2.462 0 C-N-CA 124.69 3.593 . . . . 62.15 114.361 -173.903 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 226' ' ' ARG . . . . . 0.644 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 52.8 mtm180 64.09 73.44 0.43 Allowed 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 124.333 1.053 . . . . 75.3 111.046 -173.766 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 227' ' ' THR . . . . . 0.465 HG23 HD11 ' A' ' 255' ' ' ILE . 8.2 t -88.59 171.99 9.63 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 123.647 0.779 . . . . 73.23 110.457 175.446 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -127.9 140.2 52.15 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 123.741 0.816 . . . . 62.11 109.249 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.53 128.8 37.78 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.228 0.611 . . . . 43.44 109.863 177.594 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.24 -4.07 22.05 Favored Glycine 0 C--N 1.339 0.729 0 O-C-N 123.342 0.401 . . . . 50.01 113.276 -170.692 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 231' ' ' ARG . . . . . 0.425 ' O ' HG12 ' A' ' 253' ' ' VAL . 69.5 mtp180 -93.59 162.48 13.94 Favored 'General case' 0 N--CA 1.477 0.902 0 CA-C-N 117.39 0.595 . . . . 71.42 111.553 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.798 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 3.2 mptp? -118.35 104.6 10.89 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 108.946 -0.761 . . . . 72.24 108.946 -176.679 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 233' ' ' LEU . . . . . 0.548 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 23.4 mt -84.42 115.33 22.48 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.52 0.728 . . . . 62.2 109.898 -172.227 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 234' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 58.5 ttt180 -86.67 110.21 19.71 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 123.497 0.719 . . . . 71.22 111.631 -170.476 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.543 HD12 HD23 ' A' ' 249' ' ' LEU . 15.5 mt -99.95 104.0 15.59 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.024 -1.102 . . . . 73.34 108.024 170.474 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 56.0 mttp -74.66 138.86 43.15 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.942 0.497 . . . . 52.32 111.712 -171.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 237' ' ' GLY . . . . . 0.441 ' O ' ' HD3' ' A' ' 246' ' ' ARG . . . 80.05 6.84 88.98 Favored Glycine 0 C--N 1.348 1.243 0 O-C-N 123.903 0.752 . . . . 63.42 113.486 178.207 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 33.5 mmtp -106.96 8.59 30.58 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-N 117.263 0.532 . . . . 72.4 111.831 179.092 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -97.35 -178.5 34.2 Favored Glycine 0 C--N 1.344 1.023 0 O-C-N 123.481 0.488 . . . . 60.44 112.03 170.58 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.562 ' CE1' HD21 ' A' ' 193' ' ' LEU . 25.7 m-85 -76.28 163.1 68.51 Favored Pre-proline 0 CA--C 1.549 0.93 0 C-N-CA 124.257 1.023 . . . . 74.13 112.588 -174.854 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -52.47 129.05 30.21 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 123.248 2.632 . . . . 75.11 112.804 173.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -156.33 -162.26 11.31 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.091 -0.838 . . . . 75.34 112.043 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -61.39 -30.98 88.14 Favored 'Trans proline' 0 C--N 1.377 2.047 0 C-N-CA 123.465 2.777 . . . . 73.51 112.916 -175.87 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -90.95 22.13 3.82 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.961 0.905 . . . . 74.23 111.438 179.473 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 82.27 -70.82 3.08 Favored Glycine 0 C--N 1.35 1.307 0 N-CA-C 111.104 -0.798 . . . . 73.11 111.104 -175.222 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.441 ' HD3' ' O ' ' A' ' 237' ' ' GLY . 78.2 mtt180 -116.32 161.47 18.97 Favored 'General case' 0 C--O 1.243 0.749 0 C-N-CA 124.459 1.103 . . . . 75.31 108.578 172.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -96.13 -158.3 31.93 Favored Glycine 0 C--O 1.243 0.704 0 CA-C-N 115.699 -0.682 . . . . 54.03 112.308 177.38 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -132.35 155.63 48.07 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 109.641 -0.504 . . . . 65.41 109.641 -175.671 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.653 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 14.3 tp -103.25 129.02 50.1 Favored 'General case' 0 C--O 1.214 -0.812 0 C-N-CA 123.648 0.779 . . . . 71.12 109.12 171.811 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 250' ' ' TYR . . . . . 0.798 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 92.7 m-85 -115.36 107.64 15.48 Favored 'General case' 0 N--CA 1.477 0.906 0 N-CA-C 108.907 -0.775 . . . . 74.21 108.907 176.693 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.548 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 42.1 mt -87.5 126.15 34.74 Favored 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 123.568 0.747 . . . . 72.42 111.876 -173.891 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -78.91 90.84 4.74 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 107.366 -1.346 . . . . 75.12 107.366 176.03 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.425 HG12 ' O ' ' A' ' 231' ' ' ARG . 2.8 p -63.29 124.12 17.35 Favored 'Isoleucine or valine' 0 C--O 1.239 0.55 0 CA-C-O 121.802 0.81 . . . . 73.22 110.472 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 29.7 mmm180 -124.25 95.34 4.51 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 107.574 -1.269 . . . . 72.55 107.574 -178.527 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.465 HD11 HG23 ' A' ' 227' ' ' THR . 69.1 mt -75.83 107.14 6.34 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 115.204 -0.907 . . . . 50.03 109.394 -177.725 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.2 t . . . . . 0 CA--C 1.549 0.928 0 C-N-CA 124.539 1.136 . . . . 72.5 109.139 -179.317 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.643 ' HG ' ' HG2' ' A' ' 136' ' ' ARG . 68.2 mt . . . . . 0 N--CA 1.481 1.097 0 N-CA-C 110.449 -0.204 . . . . 75.51 110.449 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.451 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 11.8 p -56.28 134.62 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 O-C-N 123.858 0.724 . . . . 61.31 111.531 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.96 -60.73 2.19 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 108.746 -0.835 . . . . 53.13 108.746 174.661 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 31.2 m80 -162.94 159.48 23.66 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 124.98 1.312 . . . . 64.13 108.82 -177.635 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.477 ' HA ' ' HB2' ' A' ' 121' ' ' ALA . 13.0 p -78.0 127.7 38.44 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.007 0 CA-C-O 121.025 0.44 . . . . 62.55 110.451 178.934 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.471 HG23 ' HA ' ' A' ' 121' ' ' ALA . 43.8 p . . . . . 0 N--CA 1.475 0.799 0 C-N-CA 123.537 0.735 . . . . 62.44 110.474 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.0 p30 . . . . . 0 C--O 1.243 0.741 0 N-CA-C 107.734 -1.21 . . . . 64.35 107.734 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.517 HD13 HG23 ' A' ' 140' ' ' VAL . 39.7 mt -95.04 139.02 31.98 Favored 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 107.402 -1.332 . . . . 74.24 107.402 -176.936 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -146.3 135.8 23.03 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.379 -0.971 . . . . 61.5 108.379 178.403 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.477 ' HB2' ' HA ' ' A' ' 102' ' ' VAL . . . -156.95 139.2 14.67 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.189 -0.671 . . . . 75.53 109.189 -171.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -96.7 148.02 23.31 Favored 'General case' 0 C--O 1.244 0.764 0 N-CA-C 109.38 -0.6 . . . . 62.34 109.38 173.422 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.627 HD12 ' HB3' ' A' ' 98' ' ' LEU . 1.6 pt? -144.12 132.18 10.84 Favored Pre-proline 0 N--CA 1.473 0.71 0 CA-C-N 115.991 -0.55 . . . . 61.42 110.83 -171.203 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -68.5 117.2 4.82 Favored 'Trans proline' 0 C--N 1.374 1.895 0 C-N-CA 121.963 1.775 . . . . 75.52 110.932 174.975 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.473 HD22 HG11 ' A' ' 178' ' ' VAL . 16.0 tp -119.8 150.56 40.22 Favored 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 108.828 -0.804 . . . . 62.31 108.828 178.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.498 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 10.5 m -89.16 158.28 17.97 Favored 'General case' 0 CA--C 1.547 0.854 0 N-CA-C 109.31 -0.626 . . . . 65.34 109.31 175.345 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.474 HD11 ' O ' ' A' ' 183' ' ' HIS . 55.9 mt -54.56 -51.32 65.6 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 123.886 0.875 . . . . 74.21 111.062 177.317 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.436 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 2.1 mp0 -55.67 -37.59 68.5 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 114.325 -1.307 . . . . 74.34 111.024 176.834 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.498 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 10.3 mm-40 -79.18 -18.12 53.64 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.557 0.743 . . . . 64.31 111.313 -177.698 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.678 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -66.12 -42.37 89.27 Favored 'General case' 0 C--O 1.252 1.221 0 CA-C-O 121.004 0.43 . . . . 72.03 110.951 165.785 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -65.02 -48.88 72.32 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 115.824 -0.626 . . . . 73.31 111.318 172.507 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.6 m80 -73.82 -48.07 34.02 Favored 'General case' 0 N--CA 1.481 1.116 0 O-C-N 123.773 0.671 . . . . 70.03 111.839 -171.444 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 58.51 -109.54 2.03 Favored Glycine 0 CA--C 1.533 1.176 0 N-CA-C 111.351 -0.7 . . . . 72.51 111.351 -172.199 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.21 -162.89 50.13 Favored Glycine 0 C--N 1.346 1.106 0 N-CA-C 114.983 0.753 . . . . 73.33 114.983 166.606 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -79.06 135.97 37.03 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 124.424 1.09 . . . . 73.42 110.989 -174.737 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.643 ' HG2' ' HG ' ' A' ' 98' ' ' LEU . 13.8 tpt180 -156.86 167.97 28.87 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.137 0.975 . . . . 72.12 109.215 175.877 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.0 p -110.25 136.72 45.36 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 CA-C-O 121.148 0.499 . . . . 72.34 110.613 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 15.5 m -121.23 137.81 53.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 C-N-CA 124.011 0.925 . . . . 71.44 108.864 172.64 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -126.47 98.44 5.42 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-O 121.894 0.854 . . . . 63.51 109.228 171.368 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.517 HG23 HD13 ' A' ' 119' ' ' LEU . 10.6 m -130.24 139.41 51.47 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 124.517 1.127 . . . . 63.2 108.63 -179.161 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.54 24.77 14.17 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 124.256 1.023 . . . . 74.42 111.465 -176.234 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.11 -3.9 74.18 Favored Glycine 0 C--N 1.351 1.406 0 CA-C-N 115.809 -0.632 . . . . 71.03 113.038 -177.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -97.17 116.37 29.26 Favored 'General case' 0 C--N 1.346 0.456 0 C-N-CA 123.409 0.684 . . . . 75.11 109.425 -176.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 44.1 ttm180 -101.45 106.12 17.21 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 108.598 -0.89 . . . . 73.55 108.598 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 38.5 t -127.74 142.85 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 124.025 0.93 . . . . 43.42 109.223 -177.311 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 9.6 p -77.28 114.5 16.17 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 123.28 0.632 . . . . 62.51 110.041 175.21 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.8 p -98.88 136.43 29.93 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 C-N-CA 123.808 0.843 . . . . 72.15 110.345 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 59.6 ttp180 -111.2 95.44 5.53 Favored 'General case' 0 C--O 1.242 0.705 0 N-CA-C 108.227 -1.027 . . . . 72.34 108.227 168.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.413 ' HB ' HD13 ' A' ' 159' ' ' ILE . 34.9 pt -82.48 128.5 66.62 Favored Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 108.492 -0.929 . . . . 71.33 108.492 175.067 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -68.98 147.19 67.35 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.41 2.073 . . . . 74.31 113.059 -168.461 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -64.32 111.91 1.76 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 122.362 2.041 . . . . 72.01 110.636 172.837 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.771 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 142.23 30.45 0.13 Allowed Glycine 0 C--N 1.354 1.578 0 C-N-CA 121.435 -0.412 . . . . 74.32 114.051 -174.632 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.678 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.0 p -106.26 164.57 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.683 0 C-N-CA 123.506 0.722 . . . . 73.22 109.891 -176.166 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 52.9 mtm-85 -144.56 167.19 23.1 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 125.106 1.363 . . . . 71.43 108.979 -172.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 155' ' ' GLU . . . . . 0.453 ' HB2' ' HB2' ' A' ' 180' ' ' LEU . 13.3 tp10 -54.82 122.48 10.86 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 123.329 0.651 . . . . 75.42 110.14 168.218 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 89.12 -11.6 68.94 Favored Glycine 0 C--N 1.344 0.983 0 CA-C-O 119.632 -0.538 . . . . 75.22 113.395 179.797 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 35.0 t -70.86 129.53 39.31 Favored 'General case' 0 C--O 1.245 0.863 0 CA-C-N 117.206 0.503 . . . . 71.2 109.756 -178.015 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.546 HG12 HD22 ' A' ' 175' ' ' LEU . 18.6 t -104.01 119.37 52.64 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 CA-C-N 114.386 -1.279 . . . . 53.22 109.073 -173.068 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.516 HD11 HG21 ' A' ' 153' ' ' VAL . 23.4 mt -103.13 117.45 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 C-N-CA 123.803 0.841 . . . . 71.42 110.023 -171.095 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 55.9 ttt85 -90.52 111.64 23.01 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 123.686 0.794 . . . . 63.32 110.226 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.3 m -120.31 102.37 45.79 Favored Pre-proline 0 CA--C 1.568 1.665 0 C-N-CA 122.618 0.367 . . . . 60.23 110.611 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -63.56 150.99 87.11 Favored 'Trans proline' 0 C--N 1.375 1.93 0 C-N-CA 122.938 2.425 . . . . 62.22 113.175 -177.059 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 106.11 -26.11 21.57 Favored Glycine 0 CA--C 1.535 1.329 0 CA-C-O 119.038 -0.868 . . . . 72.44 114.777 177.024 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -81.24 -55.15 4.92 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-N 118.674 1.237 . . . . 65.05 111.23 -178.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.348 1.219 0 CA-C-N 115.993 -0.549 . . . . 74.01 113.755 -177.792 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo . . . . . 0 CA--C 1.55 1.288 0 N-CA-C 111.489 -0.235 . . . . 74.52 111.489 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -65.49 -171.54 3.38 Favored Glycine 0 C--N 1.346 1.106 0 CA-C-N 115.866 -0.606 . . . . 63.01 113.943 -177.492 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 10.5 p-10 -108.58 172.9 6.57 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 123.828 0.851 . . . . 54.14 112.129 -168.177 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 19.2 tp -120.41 116.76 26.11 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 114.44 -1.255 . . . . 70.25 107.867 172.205 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.546 HD22 HG12 ' A' ' 158' ' ' VAL . 65.3 mt -88.11 100.03 12.64 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.982 0.913 . . . . 74.13 110.901 177.467 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 70.8 mt -91.46 104.9 17.36 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 123.222 0.609 . . . . 72.41 111.044 176.664 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.407 HG22 HG13 ' A' ' 158' ' ' VAL . 12.4 t -91.58 101.11 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 108.399 -0.963 . . . . 70.23 108.399 177.848 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.473 HG11 HD22 ' A' ' 125' ' ' LEU . 3.7 m -76.84 150.12 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 CA-C-O 121.612 0.72 . . . . 64.01 112.16 -172.814 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 42.8 mmt180 -116.18 91.55 3.63 Favored 'General case' 0 C--O 1.238 0.448 0 C-N-CA 125.352 1.461 . . . . 75.45 107.686 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.453 ' HB2' ' HB2' ' A' ' 155' ' ' GLU . 21.3 mt -69.9 148.77 48.58 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 120.716 0.293 . . . . 72.45 110.28 175.431 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.1 mt -54.74 144.41 45.8 Favored Pre-proline 0 CA--C 1.556 1.195 0 C-N-CA 123.927 0.891 . . . . 65.45 112.131 -175.319 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.462 ' O ' ' HD3' ' A' ' 184' ' ' PRO . 23.9 Cg_exo -65.62 1.4 2.21 Favored 'Trans proline' 0 C--N 1.385 2.474 0 C-N-CA 123.529 2.819 . . . . 61.34 113.347 175.52 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 183' ' ' HIS . . . . . 0.474 ' O ' HD11 ' A' ' 127' ' ' LEU . 8.4 t60 -91.36 98.31 1.7 Allowed Pre-proline 0 CA--C 1.549 0.93 0 N-CA-C 107.546 -1.279 . . . . 71.1 107.546 159.34 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 184' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 182' ' ' PRO . 60.6 Cg_endo -102.16 124.7 0.09 OUTLIER 'Trans proline' 0 C--N 1.37 1.665 0 C-N-CA 122.913 2.408 . . . . 72.44 111.729 168.22 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -114.28 -42.2 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 CA-C-O 121.348 0.594 . . . . 73.15 109.728 177.801 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.482 ' HD2' HD22 ' A' ' 193' ' ' LEU . 5.5 m-85 -101.54 125.44 48.19 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 115.562 -0.745 . . . . 74.4 109.96 -177.384 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 37.2 ttp-105 -98.74 111.98 24.19 Favored 'General case' 0 C--O 1.243 0.758 0 N-CA-C 107.167 -1.419 . . . . 63.42 107.167 169.597 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 54.2 tp -83.45 116.99 22.77 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 108.443 -0.947 . . . . 62.25 108.443 172.482 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -126.76 99.21 5.67 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 124.488 1.115 . . . . 63.5 108.253 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 55.87 56.49 23.65 Favored Glycine 0 C--N 1.353 1.475 0 CA-C-O 119.504 -0.609 . . . . 62.22 113.76 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 69.13 -6.16 0.96 Allowed 'General case' 0 N--CA 1.504 2.25 0 C-N-CA 125.281 1.432 . . . . 63.32 113.15 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -97.82 150.12 21.61 Favored 'General case' 0 C--N 1.35 0.616 0 C-N-CA 124.864 1.266 . . . . 74.02 108.756 -178.254 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.595 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 94.9 mt -111.43 148.98 31.92 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 121.616 0.722 . . . . 64.0 112.418 -176.246 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -132.96 121.33 22.64 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 114.062 -1.427 . . . . 75.44 107.728 171.182 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -132.9 170.51 15.22 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 124.294 1.038 . . . . 55.52 109.071 177.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 54.9 m -109.96 133.38 53.24 Favored 'General case' 0 CA--C 1.537 0.449 0 N-CA-C 109.034 -0.728 . . . . 73.15 109.034 172.664 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 197' ' ' LEU . . . . . . . . . . . . . 52.5 tp -112.51 112.11 23.42 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 108.466 -0.938 . . . . 71.23 108.466 175.846 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -90.77 102.46 15.22 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 108.824 -0.806 . . . . 64.44 108.824 175.71 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 199' ' ' VAL . . . . . 0.402 HG21 HG11 ' A' ' 223' ' ' VAL . 7.7 p -109.3 131.88 21.59 Favored Pre-proline 0 CA--C 1.548 0.882 0 CA-C-N 114.98 -1.009 . . . . 72.21 109.291 -176.508 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -56.32 145.34 78.57 Favored 'Trans proline' 0 C--N 1.373 1.847 0 C-N-CA 122.785 2.323 . . . . 74.01 113.181 174.051 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 201' ' ' ALA . . . . . 0.463 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -54.73 -45.86 99.52 Favored Pre-proline 0 CA--C 1.563 1.465 0 C-N-CA 124.112 0.965 . . . . 74.54 113.4 176.67 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 202' ' ' PRO . . . . . 0.42 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 26.0 Cg_endo -58.76 -44.18 38.25 Favored 'Trans proline' 0 C--N 1.392 2.826 0 C-N-CA 122.014 1.809 . . . . 72.55 111.941 175.692 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.5 mt -63.68 -37.62 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 C-N-CA 123.105 0.562 . . . . 61.24 110.931 178.788 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -61.89 -46.76 87.97 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.436 0.695 . . . . 75.24 112.011 -177.604 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.3 m -77.08 -36.91 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 N-CA-C 112.235 0.457 . . . . 71.11 112.235 -177.329 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m -80.57 -25.24 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 CA-C-O 120.838 0.351 . . . . 74.01 110.978 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.498 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 72.93 69.4 1.4 Allowed Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.421 -0.809 . . . . 62.32 112.244 -173.939 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -96.08 -149.17 25.28 Favored Glycine 0 C--N 1.352 1.452 0 CA-C-O 121.312 0.395 . . . . 55.22 113.117 -178.488 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 53.1 tttp -125.82 125.93 43.69 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 124.845 1.258 . . . . 73.03 108.792 -172.506 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 210' ' ' VAL . . . . . 0.506 HG23 HG13 ' A' ' 221' ' ' VAL . 11.4 m -130.5 163.2 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.203 1.001 . . . . 64.02 108.598 173.474 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 39.0 ptt85 -104.57 148.16 26.82 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 109.665 -0.495 . . . . 74.34 109.665 176.08 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -120.45 135.23 55.12 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 108.852 -0.795 . . . . 62.1 108.852 174.741 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 5.0 tpt -87.02 107.57 18.48 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 108.906 -0.776 . . . . 74.3 108.906 178.368 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.44 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 14.6 t -110.33 168.62 9.31 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 121.075 0.464 . . . . 71.51 109.78 174.287 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 215' ' ' LEU . . . . . 0.436 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 61.9 mt -74.55 -9.91 59.03 Favored 'General case' 0 CA--C 1.542 0.653 0 CA-C-N 115.667 -0.697 . . . . 64.32 112.519 -173.79 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -86.36 -21.75 27.03 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.598 0.759 . . . . 73.05 110.625 173.429 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 139.96 -169.73 24.57 Favored Glycine 0 C--N 1.345 1.032 0 N-CA-C 111.281 -0.728 . . . . 74.31 111.281 -173.645 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -76.01 126.85 9.6 Favored 'Trans proline' 0 C--N 1.363 1.336 0 C-N-CA 122.42 2.08 . . . . 65.13 112.015 176.049 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 33.4 m -110.25 163.53 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 123.549 0.74 . . . . 74.34 109.268 171.592 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -114.04 127.24 55.85 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.41 -0.589 . . . . 74.23 109.41 174.48 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.541 ' HB ' HD11 ' A' ' 235' ' ' LEU . 3.2 p -120.76 118.44 56.44 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 C-N-CA 123.818 0.847 . . . . 64.25 110.007 175.194 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.37 113.5 24.81 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 108.24 -1.022 . . . . 70.41 108.24 174.338 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.498 HG23 ' HA2' ' A' ' 207' ' ' GLY . 10.4 m -73.31 139.71 78.96 Favored Pre-proline 0 CA--C 1.553 1.096 0 N-CA-C 108.751 -0.833 . . . . 71.15 108.751 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -74.52 145.39 33.37 Favored 'Trans proline' 0 CA--C 1.557 1.674 0 C-N-CA 122.143 1.895 . . . . 53.42 111.309 178.884 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_exo -54.32 130.36 39.43 Favored 'Trans proline' 0 C--N 1.38 2.235 0 C-N-CA 123.325 2.683 . . . . 73.22 113.247 -179.008 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 61.69 61.28 1.47 Allowed 'General case' 0 N--CA 1.477 0.892 0 O-C-N 124.639 1.212 . . . . 73.33 111.201 -176.212 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.9 t -87.81 172.04 9.94 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 109.56 -0.533 . . . . 72.22 109.56 172.37 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.2 mp0 -130.66 153.25 49.15 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 108.72 -0.845 . . . . 65.22 108.72 -178.858 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -72.36 139.69 48.02 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 122.779 0.432 . . . . 74.32 110.028 176.756 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 101.75 -6.84 55.01 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 116.052 -0.522 . . . . 70.11 112.395 -178.379 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 58.6 mtp180 -82.48 160.72 22.6 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.006 0.522 . . . . 71.02 110.251 179.081 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.481 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 11.9 mptt -118.3 116.97 27.85 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.828 0.851 . . . . 60.35 109.73 -178.293 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 73.6 mt -92.0 107.42 19.2 Favored 'General case' 0 C--O 1.24 0.603 0 N-CA-C 107.265 -1.383 . . . . 72.43 107.265 175.505 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 234' ' ' ARG . . . . . 0.446 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 66.5 ttt180 -88.56 103.14 15.62 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.362 -0.835 . . . . 75.11 110.313 -166.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.541 HD11 ' HB ' ' A' ' 221' ' ' VAL . 33.3 mt -93.28 97.58 10.71 Favored 'General case' 0 C--N 1.348 0.508 0 N-CA-C 108.706 -0.85 . . . . 62.4 108.706 178.076 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 236' ' ' LYS . . . . . 0.57 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 10.3 mtmp? -81.38 144.38 31.48 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.332 -0.849 . . . . 44.51 111.525 -172.524 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 76.46 18.39 79.16 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.499 -0.773 . . . . 75.41 112.817 -172.261 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 73.1 mmtt -121.05 7.11 10.3 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.278 0.631 . . . . 71.33 111.934 -178.821 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 239' ' ' GLY . . . . . 0.411 ' HA2' ' CD1' ' A' ' 193' ' ' LEU . . . -92.22 -169.44 40.73 Favored Glycine 0 C--N 1.338 0.681 0 O-C-N 123.578 0.549 . . . . 53.22 112.131 174.679 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.771 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 3.9 m-85 -76.77 144.23 72.64 Favored Pre-proline 0 CA--C 1.547 0.849 0 C-N-CA 122.302 0.241 . . . . 71.2 110.614 -175.634 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.89 127.73 21.22 Favored 'Trans proline' 0 C--N 1.377 2.055 0 C-N-CA 122.885 2.39 . . . . 62.1 111.646 176.826 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -164.36 -154.09 7.71 Favored Glycine 0 CA--C 1.537 1.458 0 CA-C-O 119.448 -0.64 . . . . 71.3 113.298 -174.618 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -60.67 -24.28 78.17 Favored 'Trans proline' 0 C--N 1.379 2.166 0 C-N-CA 124.263 3.309 . . . . 72.44 114.164 -178.111 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.0 23.01 5.21 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 123.453 0.701 . . . . 74.32 111.461 176.402 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 74.33 -78.54 0.97 Allowed Glycine 0 C--N 1.348 1.206 0 N-CA-C 110.938 -0.865 . . . . 73.02 110.938 -173.797 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 12.8 ttt85 -129.65 141.74 50.86 Favored 'General case' 0 CA--C 1.546 0.8 0 N-CA-C 108.348 -0.982 . . . . 72.24 108.348 172.563 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.74 -156.78 5.28 Favored Glycine 0 N--CA 1.475 1.252 0 N-CA-C 113.805 0.282 . . . . 74.22 113.805 -178.032 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 248' ' ' ASP . . . . . 0.57 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 0.7 OUTLIER -148.44 156.46 42.51 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 123.125 0.57 . . . . 65.22 111.281 179.39 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.595 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 28.5 tp -110.42 133.63 53.09 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.73 1.212 . . . . 74.02 111.196 -172.137 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -106.21 107.2 18.09 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.147 0.979 . . . . 72.32 109.402 174.704 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.481 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 84.8 mt -87.56 115.57 25.08 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.1 0.56 . . . . 73.11 111.839 176.546 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -79.89 93.74 5.72 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 108.472 -0.936 . . . . 74.32 108.472 179.056 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 59.6 t -48.18 121.0 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.553 1.141 . . . . 40.05 110.659 174.851 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 25.6 mmm180 -128.9 95.45 4.09 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.194 -1.41 . . . . 74.14 107.194 177.364 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.463 HG23 ' HA ' ' A' ' 201' ' ' ALA . 66.5 mt -75.32 120.38 24.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-N 114.898 -1.046 . . . . 73.22 109.407 -176.873 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.556 1.189 0 C-N-CA 123.637 0.775 . . . . 74.14 109.315 -173.697 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.53 HD23 HH11 ' A' ' 136' ' ' ARG . 55.1 tp . . . . . 0 N--CA 1.478 0.961 0 N-CA-C 109.928 -0.397 . . . . 61.25 109.928 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.568 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 8.1 p -87.54 158.81 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 C-N-CA 123.216 0.606 . . . . 64.53 110.093 168.598 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -88.82 -89.62 0.14 Allowed 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 123.278 0.631 . . . . 62.32 109.896 170.241 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -160.74 176.52 11.41 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 125.106 1.363 . . . . 72.21 108.915 -174.443 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 9.1 p -68.68 125.62 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 CA-C-O 121.224 0.535 . . . . 74.31 110.557 178.186 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 81.9 p . . . . . 0 CA--C 1.547 0.833 0 C-N-CA 124.122 0.969 . . . . 65.35 109.826 175.45 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 . . . . . 0 C--O 1.241 0.649 0 CA-C-O 121.518 0.675 . . . . 62.41 110.603 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.532 HD12 ' HA2' ' A' ' 165' ' ' GLY . 14.5 mt -104.53 155.11 19.1 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.179 -1.415 . . . . 72.43 107.179 162.788 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 10.8 ttm180 -145.11 118.26 8.89 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 108.87 -0.789 . . . . 73.35 108.87 -175.137 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.412 ' HB3' HD23 ' A' ' 176' ' ' LEU . . . -141.37 141.61 33.8 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 123.702 0.801 . . . . 61.32 109.724 -176.577 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.709 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 39.4 mt-10 -116.95 149.82 39.55 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.066 0.546 . . . . 73.04 110.811 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.568 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.6 pt? -145.85 144.89 23.29 Favored Pre-proline 0 N--CA 1.471 0.599 0 CA-C-N 115.392 -0.822 . . . . 72.23 110.873 -179.44 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -77.55 115.3 3.86 Favored 'Trans proline' 0 C--N 1.371 1.739 0 C-N-CA 121.825 1.683 . . . . 63.14 110.711 168.676 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.554 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 15.7 tp -107.37 154.1 21.8 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.532 0.733 . . . . 65.55 109.407 179.36 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.573 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 11.5 m -87.74 160.97 17.86 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.137 0.575 . . . . 65.52 109.527 175.455 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.504 HD13 HG12 ' A' ' 185' ' ' VAL . 30.2 mt -63.07 -48.96 76.42 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 123.884 0.874 . . . . 65.51 110.562 178.58 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -57.28 -31.59 65.76 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 114.777 -1.101 . . . . 72.5 110.937 176.621 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.573 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 8.8 mm-40 -83.82 -23.99 31.17 Favored 'General case' 0 C--O 1.212 -0.869 0 C-N-CA 122.996 0.519 . . . . 73.45 111.054 -179.091 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.7 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -60.62 -35.21 75.6 Favored 'General case' 0 C--O 1.248 1.015 0 CA-C-O 121.804 0.811 . . . . 70.51 110.3 165.536 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.526 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 55.3 t80 -72.03 -47.42 51.9 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.419 -1.264 . . . . 71.21 111.82 172.213 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.3 m80 -83.96 -16.82 42.71 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 113.283 0.846 . . . . 70.1 113.283 -171.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 89.75 -117.72 5.06 Favored Glycine 0 CA--C 1.535 1.326 0 N-CA-C 111.987 -0.445 . . . . 43.54 111.987 -170.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 148.91 94.01 0.12 Allowed Glycine 0 C--N 1.353 1.488 0 CA-C-N 117.828 0.814 . . . . 73.44 113.571 175.12 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -85.21 123.06 30.28 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 123.273 0.629 . . . . 63.35 109.397 175.882 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.577 ' NH2' HD13 ' A' ' 176' ' ' LEU . 16.9 ptt-85 -148.65 168.45 22.81 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.204 0.602 . . . . 53.35 111.526 -170.157 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 23.1 m -89.84 106.23 16.93 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 CA-C-N 115.022 -0.99 . . . . 75.43 108.624 169.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.552 HG21 HD21 ' A' ' 174' ' ' LEU . 7.4 p -98.89 123.1 51.3 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 123.153 0.581 . . . . 61.14 109.789 -179.38 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -119.03 98.73 6.32 Favored 'General case' 0 C--O 1.241 0.614 0 C-N-CA 124.256 1.023 . . . . 73.41 109.186 -178.718 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.433 HG21 HD22 ' A' ' 174' ' ' LEU . 8.6 m -131.8 121.45 47.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 124.457 1.103 . . . . 70.53 109.919 -173.605 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.25 22.84 13.55 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 124.533 1.133 . . . . 73.12 111.954 -178.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 88.8 2.39 78.64 Favored Glycine 0 C--N 1.345 1.067 0 CA-C-O 119.815 -0.436 . . . . 72.13 113.388 -177.17 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -92.8 113.92 26.33 Favored 'General case' 0 C--N 1.348 0.515 0 N-CA-C 108.625 -0.88 . . . . 74.41 108.625 175.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 59.9 ttp180 -106.22 110.85 23.22 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 108.116 -1.068 . . . . 62.22 108.116 176.1 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 5.7 m -141.38 155.72 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 124.52 1.128 . . . . 74.14 109.078 -177.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 47.4 t -87.21 115.5 24.65 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.128 -0.693 . . . . 65.22 109.128 177.312 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.2 p -99.33 136.66 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-O 121.095 0.474 . . . . 52.22 110.718 179.167 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.5 ttp180 -110.29 98.76 7.92 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 107.743 -1.206 . . . . 74.22 107.743 172.799 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.473 HD13 HH12 ' A' ' 136' ' ' ARG . 28.9 pt -89.88 131.24 39.99 Favored Pre-proline 0 N--CA 1.475 0.809 0 N-CA-C 108.684 -0.858 . . . . 73.33 108.684 177.27 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -72.01 157.7 53.98 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.45 2.1 . . . . 72.33 112.828 -172.1 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -68.5 148.17 72.39 Favored 'Trans proline' 0 C--N 1.375 1.959 0 C-N-CA 122.283 1.988 . . . . 74.12 111.356 172.204 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 100.04 41.49 2.83 Favored Glycine 0 C--N 1.34 0.786 0 N-CA-C 110.988 -0.845 . . . . 65.13 110.988 -176.504 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.7 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -111.37 160.74 10.47 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.267 0 N-CA-C 108.265 -1.013 . . . . 72.43 108.265 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.401 ' HD3' ' HB3' ' A' ' 188' ' ' LEU . 74.8 mtm180 -148.47 176.74 10.05 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 123.909 0.884 . . . . 72.01 111.735 -166.118 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -55.61 115.74 2.51 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 114.214 -1.357 . . . . 50.22 111.072 170.546 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 75.89 10.22 85.06 Favored Glycine 0 C--N 1.345 1.053 0 O-C-N 123.601 0.563 . . . . 34.52 113.683 178.689 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 37.5 t -75.13 125.97 30.05 Favored 'General case' 0 C--O 1.245 0.819 0 C-N-CA 122.97 0.508 . . . . 71.05 109.906 -178.797 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.446 HG12 HD22 ' A' ' 175' ' ' LEU . 21.2 t -95.83 121.57 46.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 C-N-CA 124.719 1.208 . . . . 74.45 109.457 -175.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.538 HD11 HG21 ' A' ' 153' ' ' VAL . 27.3 mt -107.28 111.21 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 123.46 0.704 . . . . 51.42 109.634 -174.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 25.1 ttp180 -84.83 117.76 24.07 Favored 'General case' 0 CA--C 1.538 0.493 0 O-C-N 123.655 0.597 . . . . 63.32 109.989 179.192 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.5 m -114.86 96.47 44.67 Favored Pre-proline 0 CA--C 1.561 1.394 0 CA-C-O 121.431 0.634 . . . . 71.24 109.419 175.505 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -63.22 136.61 56.68 Favored 'Trans proline' 0 C--N 1.379 2.153 0 C-N-CA 123.391 2.727 . . . . 72.54 113.224 -175.616 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.59 -17.14 59.43 Favored Glycine 0 C--N 1.345 1.064 0 N-CA-C 114.39 0.516 . . . . 43.33 114.39 174.51 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 10.4 mtm -100.69 -6.29 25.31 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 117.718 0.759 . . . . 65.1 112.187 -174.268 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 165' ' ' GLY . . . . . 0.532 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.351 1.391 0 N-CA-C 111.813 -0.515 . . . . 75.52 111.813 175.285 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo . . . . . 0 CA--C 1.541 0.852 0 CA-C-O 121.047 0.353 . . . . 74.43 111.688 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -98.63 151.93 19.64 Favored Glycine 0 N--CA 1.452 -0.294 0 N-CA-C 110.123 -1.191 . . . . 74.12 110.123 171.039 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -116.49 167.83 10.71 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 124.422 1.089 . . . . 74.44 109.751 -173.598 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.552 HD21 HG21 ' A' ' 138' ' ' VAL . 11.8 tp -120.22 129.64 54.17 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.167 -1.049 . . . . 62.1 108.167 176.479 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.446 HD22 HG12 ' A' ' 158' ' ' VAL . 83.1 mt -103.79 98.6 8.43 Favored 'General case' 0 C--O 1.233 0.212 0 C-N-CA 124.345 1.058 . . . . 54.05 109.636 -175.39 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.577 HD13 ' NH2' ' A' ' 136' ' ' ARG . 45.4 mt -92.88 101.23 13.59 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.357 -0.838 . . . . 70.11 109.649 178.827 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.709 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 25.5 t -90.71 107.65 18.78 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 N-CA-C 108.422 -0.955 . . . . 71.12 108.422 179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.554 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 3.2 m -87.43 148.93 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 109.463 -0.569 . . . . 61.34 109.463 -177.733 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 10.0 mmm-85 -123.51 104.17 8.9 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 107.466 -1.309 . . . . 74.22 107.466 -174.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 27.4 mt -69.15 151.55 46.22 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-O 121.213 0.53 . . . . 64.21 111.3 -178.694 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 52.9 mt -54.56 150.7 16.59 Favored Pre-proline 0 CA--C 1.561 1.397 0 CA-C-N 114.608 -1.178 . . . . 72.11 112.383 -177.172 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -61.1 -8.05 9.26 Favored 'Trans proline' 0 C--N 1.385 2.489 0 C-N-CA 123.144 2.562 . . . . 74.02 113.459 177.39 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 183' ' ' HIS . . . . . 0.472 ' O ' HD11 ' A' ' 127' ' ' LEU . 5.2 t60 -93.44 104.83 13.53 Favored Pre-proline 0 CA--C 1.544 0.743 0 C-N-CA 124.436 1.094 . . . . 72.32 108.726 164.011 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -101.16 128.82 0.13 Allowed 'Trans proline' 0 CA--C 1.559 1.746 0 C-N-CA 123.379 2.72 . . . . 61.32 112.486 165.69 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.504 HG12 HD13 ' A' ' 127' ' ' LEU . 2.6 p -113.85 -46.21 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 122.899 0.48 . . . . 74.04 109.998 172.802 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -98.98 122.68 42.55 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.031 0.443 . . . . 74.31 110.774 -174.195 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.63 ' HB3' ' HB2' ' A' ' 194' ' ' TYR . 28.7 ttm180 -97.88 109.13 21.94 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 107.6 -1.259 . . . . 75.21 107.6 170.536 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.401 ' HB3' ' HD3' ' A' ' 154' ' ' ARG . 50.1 tp -89.56 112.62 23.87 Favored 'General case' 0 CA--C 1.543 0.702 0 N-CA-C 108.597 -0.89 . . . . 61.13 108.597 173.515 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -108.97 102.13 11.16 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 108.291 -1.003 . . . . 74.4 108.291 176.162 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 72.16 -87.41 0.49 Allowed Glycine 0 C--N 1.347 1.166 0 O-C-N 123.704 0.627 . . . . 71.4 111.765 -174.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 5.0 pm0 -134.01 -4.94 2.75 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 124.17 0.988 . . . . 73.33 110.574 178.639 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 56.5 m-20 -93.66 151.4 19.68 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.598 0.759 . . . . 71.45 111.198 -177.257 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.425 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 88.8 mt -107.44 147.07 30.9 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 124.372 1.069 . . . . 72.3 109.429 -178.493 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 194' ' ' TYR . . . . . 0.63 ' HB2' ' HB3' ' A' ' 187' ' ' ARG . 89.4 m-85 -133.46 121.07 21.69 Favored 'General case' 0 C--O 1.232 0.182 0 N-CA-C 107.389 -1.337 . . . . 75.31 107.389 175.233 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -134.76 170.88 15.16 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 123.916 0.886 . . . . 73.43 108.892 178.126 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 87.1 m -109.55 124.2 50.71 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.64 -0.709 . . . . 52.04 109.288 175.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.417 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 57.6 tp -107.06 111.75 24.36 Favored 'General case' 0 C--O 1.225 -0.201 0 C-N-CA 124.154 0.982 . . . . 74.52 109.106 177.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -87.45 125.53 34.34 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 107.758 -1.201 . . . . 75.13 107.758 172.203 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 199' ' ' VAL . . . . . 0.495 HG12 HG21 ' A' ' 210' ' ' VAL . 15.4 m -120.15 135.19 24.23 Favored Pre-proline 0 N--CA 1.475 0.82 0 N-CA-C 108.901 -0.777 . . . . 75.23 108.901 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -57.69 140.21 92.79 Favored 'Trans proline' 0 C--N 1.367 1.549 0 C-N-CA 122.314 2.01 . . . . 65.25 111.624 169.069 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -50.24 -44.21 80.33 Favored Pre-proline 0 CA--C 1.567 1.621 0 CA-C-O 118.057 -0.973 . . . . 63.33 113.069 179.384 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo -47.59 -52.61 7.75 Favored 'Trans proline' 0 C--N 1.404 3.485 0 C-N-CA 122.816 2.344 . . . . 74.31 112.754 168.687 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 11.8 mt -68.34 -33.4 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 C-N-CA 123.079 0.552 . . . . 70.41 111.7 -176.316 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.61 -47.97 83.51 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.329 0.651 . . . . 74.04 110.863 178.227 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 205' ' ' VAL . . . . . 0.457 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 32.8 m -81.78 -35.57 13.66 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.898 0 CA-C-N 115.695 -0.684 . . . . 51.43 112.362 -174.587 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.2 m -84.61 -22.97 7.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 CA-C-N 118.24 0.473 . . . . 64.25 111.245 -179.039 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 71.7 56.7 6.42 Favored Glycine 0 C--N 1.343 0.939 0 CA-C-N 115.823 -0.626 . . . . 72.02 112.31 -174.735 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -84.75 -152.96 17.98 Favored Glycine 0 C--N 1.355 1.624 0 N-CA-C 111.979 -0.449 . . . . 72.12 111.979 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -111.79 140.54 46.34 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.106 -0.702 . . . . 71.22 109.106 177.29 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 210' ' ' VAL . . . . . 0.495 HG21 HG12 ' A' ' 199' ' ' VAL . 41.1 t -125.66 149.47 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 108.066 -1.087 . . . . 63.2 108.066 168.635 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 211' ' ' ARG . . . . . 0.435 ' HD2' ' HG2' ' A' ' 220' ' ' GLU . 0.2 OUTLIER -90.06 125.27 35.35 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 108.268 -1.012 . . . . 74.41 108.268 166.946 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -100.43 129.11 46.35 Favored 'General case' 0 C--O 1.248 0.999 0 N-CA-C 108.59 -0.893 . . . . 64.35 108.59 178.537 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 4.2 tpt -76.25 105.16 7.14 Favored 'General case' 0 CA--C 1.537 0.471 0 O-C-N 123.697 0.623 . . . . 62.32 109.435 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 9.2 t -117.26 169.68 9.28 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 123.418 0.687 . . . . 71.01 110.524 177.378 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 63.3 mt -76.1 -5.6 47.31 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 123.957 0.903 . . . . 55.35 111.423 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -88.12 -20.38 25.73 Favored 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 124.077 0.951 . . . . 73.34 110.348 172.346 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 130.64 -149.87 19.15 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-O 119.073 -0.848 . . . . 65.02 111.108 -174.26 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -86.83 120.38 1.67 Allowed 'Trans proline' 0 CA--C 1.553 1.428 0 C-N-CA 122.211 1.941 . . . . 73.41 111.604 169.781 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 20.0 m -108.24 155.39 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 108.968 -0.753 . . . . 63.21 108.968 173.59 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 220' ' ' GLU . . . . . 0.435 ' HG2' ' HD2' ' A' ' 211' ' ' ARG . 33.4 mt-10 -109.46 107.36 17.47 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 108.788 -0.819 . . . . 72.14 108.788 -175.305 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.2 p -96.38 132.54 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 123.739 0.816 . . . . 63.42 110.342 177.542 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -90.69 105.41 17.8 Favored 'General case' 0 C--O 1.24 0.588 0 C-N-CA 123.648 0.779 . . . . 42.3 108.961 173.733 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.11 133.51 93.63 Favored Pre-proline 0 CA--C 1.557 1.24 0 C-N-CA 124.038 0.935 . . . . 62.2 110.063 177.578 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_exo -65.04 140.69 66.88 Favored 'Trans proline' 0 C--N 1.379 2.144 0 C-N-CA 122.89 2.393 . . . . 75.42 111.539 172.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -58.98 124.41 15.63 Favored 'Trans proline' 0 C--N 1.376 2.008 0 C-N-CA 122.724 2.283 . . . . 75.24 111.418 178.147 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 226' ' ' ARG . . . . . 0.457 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 85.3 mtm180 60.41 76.74 0.35 Allowed 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 124.423 1.089 . . . . 74.03 110.865 -177.533 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 7.5 t -103.71 173.81 6.14 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 123.365 0.666 . . . . 71.31 109.594 174.899 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.3 mp0 -131.44 155.53 47.18 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 123.655 0.782 . . . . 65.42 109.019 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.11 130.23 42.12 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.297 0.639 . . . . 74.12 110.279 177.191 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.03 -11.5 22.48 Favored Glycine 0 C--N 1.337 0.588 0 C-N-CA 123.505 0.574 . . . . 64.33 112.129 -176.087 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 73.3 mtp180 -81.7 155.58 25.48 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 122.818 0.447 . . . . 74.11 110.481 178.419 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.505 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 0.5 OUTLIER -118.53 125.29 49.55 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.776 0.83 . . . . 74.44 109.762 -179.115 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 28.1 mt -100.79 111.55 23.79 Favored 'General case' 0 C--N 1.353 0.759 0 N-CA-C 108.127 -1.064 . . . . 73.02 108.127 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 234' ' ' ARG . . . . . 0.428 ' HG3' ' HB3' ' A' ' 248' ' ' ASP . 57.4 ttm-85 -82.91 105.4 13.88 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.9 0.88 . . . . 70.11 110.894 -170.268 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.534 HD12 HD23 ' A' ' 249' ' ' LEU . 30.0 mt -87.03 97.46 10.73 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 107.782 -1.192 . . . . 62.13 107.782 171.103 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -71.76 138.2 48.25 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 114.831 -1.077 . . . . 71.03 111.634 -169.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 75.89 4.08 76.05 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 123.801 0.688 . . . . 63.4 113.991 177.219 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 238' ' ' LYS . . . . . 0.604 ' HE2' ' HA ' ' A' ' 238' ' ' LYS . 9.6 mmpt? -94.17 -3.13 51.47 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.253 0.621 . . . . 73.13 111.955 -177.484 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.27 -170.68 47.2 Favored Glycine 0 C--N 1.343 0.967 0 N-CA-C 111.941 -0.463 . . . . 53.51 111.941 171.236 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.526 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 97.3 m-85 -83.6 154.9 65.68 Favored Pre-proline 0 N--CA 1.477 0.917 0 C-N-CA 122.822 0.449 . . . . 61.04 111.687 -177.148 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 241' ' ' PRO . . . . . 0.474 ' HA ' ' O ' ' A' ' 245' ' ' GLY . 26.3 Cg_exo -64.5 127.05 18.06 Favored 'Trans proline' 0 C--N 1.375 1.962 0 C-N-CA 122.144 1.896 . . . . 54.43 110.468 166.829 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -165.22 -156.9 9.4 Favored Glycine 0 C--N 1.342 0.916 0 CA-C-O 119.219 -0.767 . . . . 75.24 112.329 -177.063 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -59.43 -10.78 11.83 Favored 'Trans proline' 0 N--CA 1.504 2.14 0 C-N-CA 124.017 3.145 . . . . 73.52 115.257 -178.086 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -109.49 19.14 19.62 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.287 0.635 . . . . 43.22 111.06 176.704 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 245' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 241' ' ' PRO . . . 77.45 -76.49 1.68 Allowed Glycine 0 C--N 1.345 1.067 0 N-CA-C 110.993 -0.843 . . . . 63.34 110.993 -173.34 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 55.5 mtm180 -123.77 155.88 37.1 Favored 'General case' 0 N--CA 1.476 0.875 0 N-CA-C 107.801 -1.185 . . . . 75.12 107.801 170.548 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -90.74 -177.89 43.85 Favored Glycine 0 C--N 1.338 0.682 0 O-C-N 123.34 0.4 . . . . 50.12 113.245 176.249 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 248' ' ' ASP . . . . . 0.428 ' HB3' ' HG3' ' A' ' 234' ' ' ARG . 60.9 m-20 -136.01 142.5 44.48 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.82 0.848 . . . . 70.34 109.189 -175.949 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.534 HD23 HD12 ' A' ' 235' ' ' LEU . 19.3 tp -97.53 112.97 24.6 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 109.346 -0.613 . . . . 62.24 109.346 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -90.29 105.86 18.1 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 108.754 -0.832 . . . . 75.02 108.754 176.509 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.505 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 93.6 mt -87.92 110.77 20.8 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.376 0.67 . . . . 52.23 112.01 176.746 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -79.06 92.98 5.06 Favored 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 109.117 -0.697 . . . . 75.25 109.117 -178.662 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 70.6 t -48.04 117.66 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 C-N-CA 124.911 1.284 . . . . 75.15 110.997 173.874 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 26.3 mmm180 -128.98 101.24 5.97 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 106.435 -1.691 . . . . 72.44 106.435 174.856 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 60.4 mt -77.17 117.51 22.24 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 CA-C-N 115.582 -0.735 . . . . 75.44 110.94 -172.001 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 3.3 t . . . . . 0 CA--C 1.559 1.326 0 C-N-CA 124.092 0.957 . . . . 72.21 109.211 177.725 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.625 ' HG ' ' HG2' ' A' ' 136' ' ' ARG . 89.0 mt . . . . . 0 N--CA 1.478 0.926 0 N-CA-C 109.844 -0.428 . . . . 61.12 109.844 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.472 ' HB ' HG23 ' A' ' 138' ' ' VAL . 30.0 t -58.89 131.13 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 C-N-CA 123.574 0.749 . . . . 50.55 111.798 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -70.67 -52.52 20.6 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.322 -0.853 . . . . 73.45 109.732 176.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -179.96 174.99 0.85 Allowed 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.556 1.142 . . . . 75.35 109.266 -178.124 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 88.7 t -65.19 132.16 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 N-CA-C 108.762 -0.829 . . . . 72.21 108.762 171.677 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.431 HG23 ' HA ' ' A' ' 121' ' ' ALA . 24.5 p . . . . . 0 CA--C 1.547 0.842 0 CA-C-O 121.557 0.694 . . . . 71.11 110.962 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 . . . . . 0 CA--C 1.54 0.574 0 CA-C-O 120.974 0.416 . . . . 73.31 110.816 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.49 HD22 HD13 ' A' ' 174' ' ' LEU . 4.9 tt -136.89 149.07 47.43 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 106.611 -1.626 . . . . 53.41 106.611 -179.312 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' ARG . . . . . 0.435 ' N ' HD23 ' A' ' 119' ' ' LEU . 0.1 OUTLIER -138.11 148.69 45.23 Favored 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 119.335 0.97 . . . . 71.24 110.351 179.533 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.431 ' HA ' HG23 ' A' ' 103' ' ' THR . . . -156.89 163.26 39.37 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.525 1.13 . . . . 71.23 108.709 -177.798 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -126.45 151.56 47.59 Favored 'General case' 0 C--O 1.248 0.99 0 CA-C-O 121.063 0.459 . . . . 73.02 110.224 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.473 HD12 ' HB3' ' A' ' 98' ' ' LEU . 1.6 pt? -140.41 135.02 15.65 Favored Pre-proline 0 N--CA 1.468 0.451 0 CA-C-N 115.681 -0.691 . . . . 73.34 111.593 -174.6 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -66.09 114.55 3.05 Favored 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 121.781 1.654 . . . . 72.25 110.351 161.152 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.461 HD22 HG11 ' A' ' 178' ' ' VAL . 16.1 tp -115.48 166.29 12.05 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.313 1.045 . . . . 71.55 108.222 175.443 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 17.6 m -108.74 161.53 15.02 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.208 0.603 . . . . 70.12 109.46 174.469 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.491 HD11 ' O ' ' A' ' 183' ' ' HIS . 30.8 mt -55.97 -51.94 65.94 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.808 0.843 . . . . 61.13 109.7 173.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.574 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.9 mp0 -57.36 -38.38 74.07 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 114.408 -1.269 . . . . 72.4 111.667 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -76.83 -21.86 54.42 Favored 'General case' 0 N--CA 1.479 1.025 0 C-N-CA 123.362 0.665 . . . . 70.21 111.672 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.624 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -71.85 -25.82 62.12 Favored 'General case' 0 C--O 1.249 1.073 0 C-N-CA 123.704 0.802 . . . . 51.44 110.94 170.882 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.521 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 36.9 t80 -82.39 -47.39 12.36 Favored 'General case' 0 C--N 1.35 0.602 0 CA-C-N 115.477 -0.783 . . . . 75.25 111.736 171.601 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -74.32 -47.46 34.43 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 123.237 0.335 . . . . 74.43 111.338 -172.093 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.16 -153.09 52.63 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 111.183 -0.767 . . . . 74.24 111.183 -168.441 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 119.46 -175.96 15.96 Favored Glycine 0 C--N 1.343 0.953 0 N-CA-C 114.379 0.511 . . . . 51.14 114.379 171.149 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.619 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.7 mp0 -90.74 136.28 33.17 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.993 0.917 . . . . 65.34 109.372 -177.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.625 ' HG2' ' HG ' ' A' ' 98' ' ' LEU . 0.2 OUTLIER -153.11 150.89 29.57 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 110.375 -0.231 . . . . 75.2 110.375 176.059 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 25.3 m -75.87 136.82 24.03 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 123.251 0.62 . . . . 70.13 111.836 -173.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.472 HG23 ' HB ' ' A' ' 99' ' ' VAL . 5.8 p -142.86 135.9 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 C-N-CA 124.212 1.005 . . . . 72.25 111.297 178.158 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -100.37 98.39 9.04 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 109.483 -0.562 . . . . 75.42 109.483 169.597 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.0 m -108.36 124.87 65.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 N-CA-C 108.895 -0.78 . . . . 72.33 108.895 171.61 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.09 21.83 13.09 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 124.324 1.05 . . . . 61.51 111.436 -174.086 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.28 -1.78 86.38 Favored Glycine 0 C--N 1.356 1.656 0 CA-C-N 115.835 -0.62 . . . . 61.42 113.238 -178.663 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.3 mmt85 -94.3 117.11 29.62 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 123.207 0.603 . . . . 72.02 109.905 -178.295 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 43.1 ttm180 -84.9 115.94 23.05 Favored 'General case' 0 C--N 1.352 0.705 0 N-CA-C 109.756 -0.461 . . . . 73.42 109.756 175.702 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 12.2 m -136.68 155.27 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 C-N-CA 125.136 1.375 . . . . 74.33 108.708 177.698 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 60.8 p -86.81 114.98 23.93 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 109.139 -0.689 . . . . 73.52 109.139 174.134 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.0 p -96.15 124.67 48.96 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 CA-C-O 121.172 0.51 . . . . 71.1 109.924 176.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' ARG . . . . . 0.619 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 13.7 ttp180 -99.03 104.94 17.01 Favored 'General case' 0 C--O 1.244 0.799 0 N-CA-C 108.841 -0.8 . . . . 71.03 108.841 175.511 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 32.7 pt -95.63 131.3 29.71 Favored Pre-proline 0 CA--C 1.548 0.878 0 N-CA-C 108.737 -0.838 . . . . 72.21 108.737 174.673 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -71.39 146.1 49.57 Favored 'Trans proline' 0 C--N 1.371 1.728 0 C-N-CA 122.554 2.169 . . . . 63.21 112.923 -174.697 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.64 142.5 89.84 Favored 'Trans proline' 0 C--N 1.378 2.108 0 C-N-CA 122.881 2.387 . . . . 75.13 111.425 172.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.71 52.39 0.75 Allowed Glycine 0 C--N 1.339 0.709 0 N-CA-C 110.7 -0.96 . . . . 53.55 110.7 -173.246 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.624 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.3 p -130.65 162.12 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 108.165 -1.05 . . . . 72.01 108.165 179.581 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.6 ' HA ' HD11 ' A' ' 180' ' ' LEU . 0.0 OUTLIER -162.37 173.67 13.81 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 124.925 1.29 . . . . 73.35 110.379 -179.352 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.4 tp10 -47.3 118.38 2.15 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 124.601 1.16 . . . . 70.24 112.711 -176.607 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 100.5 -24.86 30.47 Favored Glycine 0 C--N 1.349 1.296 0 CA-C-O 119.153 -0.804 . . . . 53.2 113.562 178.797 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.56 ' HB2' HG23 ' A' ' 153' ' ' VAL . 43.6 m -60.09 125.7 24.68 Favored 'General case' 0 C--O 1.248 0.998 0 C-N-CA 123.34 0.656 . . . . 63.21 111.127 -174.493 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.532 HG22 HD22 ' A' ' 175' ' ' LEU . 14.8 p -100.57 123.21 53.37 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.095 0 CA-C-N 114.801 -1.091 . . . . 64.1 109.071 -179.027 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.424 HD11 HG21 ' A' ' 153' ' ' VAL . 25.9 mt -105.38 112.97 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.329 1.052 . . . . 64.41 109.545 -170.166 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 34.6 ttt-85 -92.75 105.32 17.48 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 122.822 0.449 . . . . 74.23 110.256 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.426 HG22 ' HB3' ' A' ' 174' ' ' LEU . 10.5 m -97.79 112.38 61.41 Favored Pre-proline 0 CA--C 1.561 1.396 0 N-CA-C 108.072 -1.084 . . . . 72.35 108.072 176.209 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 162' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 7.6 Cg_exo -73.65 156.22 49.26 Favored 'Trans proline' 0 C--N 1.374 1.875 0 C-N-CA 123.132 2.555 . . . . 75.21 113.213 -171.598 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 66.09 24.44 71.79 Favored Glycine 0 C--N 1.347 1.188 0 O-C-N 123.715 0.635 . . . . 52.54 114.14 177.367 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.6 tpt -101.8 -63.21 1.17 Allowed 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.293 0.637 . . . . 74.41 111.288 -170.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.514 0 N-CA-C 111.412 -0.675 . . . . 51.14 111.412 178.863 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo . . . . . 0 CA--C 1.544 0.992 0 CA-C-O 120.859 0.275 . . . . 72.05 112.108 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -99.89 -137.09 9.64 Favored Glycine 0 C--N 1.342 0.916 0 N-CA-C 111.156 -0.778 . . . . 71.33 111.156 176.761 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -167.38 165.55 14.92 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 117.377 0.588 . . . . 75.14 111.245 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.49 HD13 HD22 ' A' ' 119' ' ' LEU . 35.5 tp -124.98 122.63 37.86 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 114.822 -1.081 . . . . 70.33 108.191 166.844 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.532 HD22 HG22 ' A' ' 158' ' ' VAL . 30.2 mt -95.17 101.42 13.16 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.542 1.137 . . . . 52.42 110.188 178.535 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 56.5 mt -93.5 105.42 17.47 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.56 0.744 . . . . 72.04 111.653 178.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 15.4 t -88.66 108.36 18.77 Favored 'Isoleucine or valine' 0 C--O 1.246 0.876 0 N-CA-C 108.977 -0.749 . . . . 60.04 108.977 176.286 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.461 HG11 HD22 ' A' ' 125' ' ' LEU . 25.5 m -77.69 148.3 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 N-CA-C 112.991 0.738 . . . . 62.42 112.991 -176.779 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -124.08 96.89 5.11 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 113.91 -1.495 . . . . 71.04 107.613 175.321 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.6 HD11 ' HA ' ' A' ' 154' ' ' ARG . 35.1 mt -69.09 147.74 51.02 Favored 'General case' 0 C--O 1.241 0.624 0 O-C-N 123.132 0.27 . . . . 63.34 110.725 -179.246 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.413 ' HA ' ' HD3' ' A' ' 182' ' ' PRO . 40.8 mt -54.13 128.55 57.51 Favored Pre-proline 0 CA--C 1.551 0.988 0 O-C-N 124.354 1.034 . . . . 54.11 110.055 177.745 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 182' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 31.7 Cg_exo -60.27 82.04 0.07 OUTLIER 'Trans proline' 0 C--N 1.377 2.034 0 C-N-CA 123.792 2.994 . . . . 65.32 113.563 -176.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 183' ' ' HIS . . . . . 0.491 ' O ' HD11 ' A' ' 127' ' ' LEU . 2.3 p80 -170.05 109.08 0.45 Allowed Pre-proline 0 CA--C 1.551 0.986 0 N-CA-C 106.652 -1.61 . . . . 71.22 106.652 171.521 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -89.52 127.31 1.63 Allowed 'Trans proline' 0 C--N 1.36 1.159 0 C-N-CA 122.096 1.864 . . . . 64.11 112.622 178.783 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 5.2 p -137.21 -47.78 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 109.515 -0.55 . . . . 64.12 109.515 168.586 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -109.84 123.55 49.76 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 121.436 0.636 . . . . 72.1 111.731 -176.765 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.478 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 0.1 OUTLIER -113.47 162.5 16.06 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.672 1.589 . . . . 71.4 109.351 -179.461 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.437 HD12 ' O ' ' A' ' 192' ' ' ASP . 43.2 tp -130.49 136.71 49.25 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 123.665 0.786 . . . . 64.31 109.958 179.832 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 189' ' ' GLU . . . . . 0.476 ' HB3' ' CE1' ' A' ' 194' ' ' TYR . 10.0 tp10 -142.07 109.94 5.82 Favored 'General case' 0 C--O 1.242 0.683 0 C-N-CA 124.184 0.994 . . . . 73.32 108.345 176.147 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 72.22 -83.33 0.53 Allowed Glycine 0 C--N 1.347 1.153 0 N-CA-C 111.447 -0.661 . . . . 64.4 111.447 -174.468 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 191' ' ' GLN . . . . . 0.539 ' NE2' ' HB3' ' A' ' 244' ' ' ALA . 29.7 pt20 -141.74 -8.26 0.95 Allowed 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.85 0.86 . . . . 72.23 110.017 178.206 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.437 ' O ' HD12 ' A' ' 188' ' ' LEU . 17.1 m-20 -93.88 156.35 16.69 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.447 0.699 . . . . 75.21 111.169 -171.406 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.469 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 90.4 mt -104.59 150.89 24.26 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 124.816 1.246 . . . . 53.41 108.913 -177.856 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 194' ' ' TYR . . . . . 0.478 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 77.4 m-85 -138.26 128.39 25.75 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 107.167 -1.42 . . . . 72.4 107.167 -177.687 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -154.18 171.27 19.44 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 123.842 0.857 . . . . 62.34 109.197 -176.719 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 14.6 m -120.41 135.28 55.09 Favored 'General case' 0 C--O 1.238 0.5 0 N-CA-C 108.867 -0.79 . . . . 74.11 108.867 176.663 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.558 HD23 HD12 ' A' ' 233' ' ' LEU . 70.1 tp -123.63 114.18 19.66 Favored 'General case' 0 C--O 1.217 -0.62 0 C-N-CA 124.112 0.965 . . . . 63.31 109.542 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -84.78 119.78 25.69 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 108.266 -1.012 . . . . 75.52 108.266 171.032 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 84.2 t -110.22 126.4 29.02 Favored Pre-proline 0 N--CA 1.469 0.486 0 N-CA-C 108.632 -0.877 . . . . 72.01 108.632 -178.543 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -54.56 133.33 56.2 Favored 'Trans proline' 0 C--N 1.375 1.958 0 C-N-CA 122.767 2.311 . . . . 64.51 110.903 172.4 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -51.68 -45.37 91.52 Favored Pre-proline 0 CA--C 1.556 1.191 0 C-N-CA 124.568 1.147 . . . . 71.21 113.685 -175.89 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -53.41 -45.53 40.35 Favored 'Trans proline' 0 C--N 1.39 2.751 0 C-N-CA 121.841 1.694 . . . . 74.23 113.666 173.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 203' ' ' ILE . . . . . 0.437 HG21 HG13 ' A' ' 210' ' ' VAL . 8.7 mt -67.62 -37.71 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 C-N-CA 122.386 0.274 . . . . 75.15 111.276 178.437 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -67.19 -34.53 77.7 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 122.977 0.511 . . . . 42.32 112.319 -176.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.3 m -83.77 -39.17 14.74 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 CA-C-N 116.159 -0.473 . . . . 54.22 111.052 -177.593 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m -82.68 -24.81 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-N 118.12 0.418 . . . . 72.03 110.939 179.676 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 79.02 67.54 1.58 Allowed Glycine 0 C--N 1.341 0.813 0 CA-C-N 116.084 -0.507 . . . . 72.51 112.493 -177.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -101.46 -147.23 19.95 Favored Glycine 0 C--N 1.35 1.31 0 CA-C-N 116.854 0.327 . . . . 64.24 112.337 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 59.1 pttt -127.64 138.19 52.76 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 124.319 1.048 . . . . 64.51 109.43 -177.528 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 210' ' ' VAL . . . . . 0.437 HG13 HG21 ' A' ' 203' ' ' ILE . 17.9 m -126.28 143.74 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.117 0.967 . . . . 73.34 109.179 175.31 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 10.0 mpt_? -85.36 107.16 17.23 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 108.958 -0.756 . . . . 63.04 108.958 174.253 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.6 117.59 35.22 Favored 'General case' 0 CA--C 1.517 -0.31 0 N-CA-C 107.62 -1.252 . . . . 64.24 107.62 174.39 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 213' ' ' MET . . . . . 0.504 ' HA ' ' HA ' ' A' ' 218' ' ' PRO . 1.2 ppp? -79.38 138.23 37.59 Favored 'General case' 0 C--O 1.243 0.754 0 N-CA-C 109.29 -0.633 . . . . 74.22 109.29 179.003 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.527 HG23 ' HG2' ' A' ' 216' ' ' GLU . 4.5 t -128.9 174.95 9.04 Favored 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 124.155 0.982 . . . . 73.24 108.805 177.344 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 215' ' ' LEU . . . . . 0.574 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 73.9 mt -72.99 -3.34 25.46 Favored 'General case' 0 CA--C 1.549 0.929 0 N-CA-C 113.613 0.968 . . . . 70.32 113.613 -169.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 216' ' ' GLU . . . . . 0.527 ' HG2' HG23 ' A' ' 214' ' ' THR . 14.3 pt-20 -104.8 -4.62 22.07 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 123.806 0.842 . . . . 53.12 111.183 175.487 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 129.28 -174.09 19.35 Favored Glycine 0 C--N 1.344 0.982 0 N-CA-C 110.686 -0.966 . . . . 63.23 110.686 -172.073 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 218' ' ' PRO . . . . . 0.504 ' HA ' ' HA ' ' A' ' 213' ' ' MET . 2.2 Cg_endo -81.84 133.38 7.96 Favored 'Trans proline' 0 CA--C 1.55 1.283 0 C-N-CA 122.52 2.147 . . . . 65.22 112.13 179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 34.5 m -110.27 165.15 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.076 0 C-N-CA 123.077 0.551 . . . . 74.11 111.915 171.371 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -111.41 113.03 25.19 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 124.058 0.943 . . . . 74.23 109.011 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.567 HG22 HD11 ' A' ' 235' ' ' LEU . 21.8 t -97.19 117.65 42.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 123.439 0.696 . . . . 72.2 110.36 178.731 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -87.57 105.53 17.39 Favored 'General case' 0 C--O 1.239 0.519 0 N-CA-C 107.442 -1.318 . . . . 64.04 107.442 171.869 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 6.2 m -80.95 142.38 51.96 Favored Pre-proline 0 CA--C 1.553 1.085 0 N-CA-C 109.383 -0.599 . . . . 54.1 109.383 -177.578 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -62.62 144.28 93.98 Favored 'Trans proline' 0 C--N 1.371 1.725 0 C-N-CA 123.003 2.469 . . . . 54.15 112.977 177.022 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.04 122.99 10.94 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.411 2.074 . . . . 73.3 111.306 174.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 73.5 mtt180 67.99 36.38 3.39 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.693 1.197 . . . . 65.45 110.822 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 227' ' ' THR . . . . . 0.509 HG23 HD11 ' A' ' 255' ' ' ILE . 9.3 t -67.53 172.06 5.49 Favored 'General case' 0 CA--C 1.551 1.017 0 CA-C-N 115.865 -0.607 . . . . 64.41 110.86 -178.585 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.2 mp0 -117.51 138.03 52.16 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.645 0.778 . . . . 60.44 109.623 -174.314 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -66.66 114.64 5.73 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.365 0.666 . . . . 54.13 110.046 176.317 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.79 3.71 19.86 Favored Glycine 0 C--N 1.336 0.549 0 CA-C-N 115.897 -0.592 . . . . 70.11 112.251 -176.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 231' ' ' ARG . . . . . 0.414 ' O ' HG12 ' A' ' 253' ' ' VAL . 57.3 mtp180 -78.39 161.83 26.87 Favored 'General case' 0 C--O 1.243 0.725 0 CA-C-O 121.684 0.754 . . . . 64.23 110.838 173.129 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.429 ' HD2' ' N ' ' A' ' 232' ' ' LYS . 0.1 OUTLIER -99.96 100.7 11.64 Favored 'General case' 0 C--O 1.24 0.565 0 CA-C-N 114.235 -1.348 . . . . 74.01 108.367 -178.447 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 233' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 33.3 mt -84.53 97.71 9.72 Favored 'General case' 0 C--N 1.351 0.646 0 N-CA-C 105.217 -2.142 . . . . 74.43 105.217 173.826 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 234' ' ' ARG . . . . . 0.469 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 51.6 ttp85 -96.13 103.64 15.54 Favored 'General case' 0 C--O 1.24 0.593 0 CA-C-N 114.781 -1.099 . . . . 72.5 109.437 -165.854 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.585 HD12 HD23 ' A' ' 249' ' ' LEU . 20.2 mt -85.02 97.83 10.06 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.589 -1.263 . . . . 75.21 107.589 177.664 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 10.4 mtmp? -69.43 135.97 50.96 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 114.639 -1.164 . . . . 71.11 111.479 -169.67 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 80.17 13.82 81.39 Favored Glycine 0 C--N 1.347 1.194 0 O-C-N 123.577 0.548 . . . . 32.31 113.354 177.395 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 238' ' ' LYS . . . . . 0.676 ' HE2' ' HA ' ' A' ' 238' ' ' LYS . 9.3 mmpt? -96.98 -18.79 19.21 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 122.877 0.471 . . . . 71.45 112.222 -178.318 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 239' ' ' GLY . . . . . 0.466 ' HA2' ' HG ' ' A' ' 193' ' ' LEU . . . -82.75 169.64 49.02 Favored Glycine 0 C--N 1.338 0.689 0 N-CA-C 112.028 -0.429 . . . . 63.04 112.028 176.688 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.521 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 98.0 m-85 -66.06 154.91 88.69 Favored Pre-proline 0 N--CA 1.479 0.994 0 C-N-CA 123.45 0.7 . . . . 74.22 111.933 -172.849 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -66.55 128.13 18.55 Favored 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 121.948 1.765 . . . . 64.35 110.289 165.163 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -151.5 -159.02 8.65 Favored Glycine 0 N--CA 1.465 0.632 0 CA-C-O 119.714 -0.492 . . . . 65.3 112.732 -178.591 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -65.95 -13.02 37.92 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.375 2.716 . . . . 65.41 114.324 -170.358 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 244' ' ' ALA . . . . . 0.539 ' HB3' ' NE2' ' A' ' 191' ' ' GLN . . . -116.9 25.03 10.81 Favored 'General case' 0 N--CA 1.482 1.126 0 C-N-CA 122.86 0.464 . . . . 62.43 110.684 178.767 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 102.87 -101.92 2.17 Favored Glycine 0 C--N 1.348 1.206 0 CA-C-O 119.764 -0.465 . . . . 62.1 112.149 174.44 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 9.5 ttm180 -124.43 155.31 39.09 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 108.573 -0.899 . . . . 74.33 108.573 173.092 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -94.74 -173.48 38.01 Favored Glycine 0 C--N 1.335 0.511 0 CA-C-O 121.271 0.373 . . . . 54.13 113.114 -177.754 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -135.95 168.06 20.04 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 108.062 -1.088 . . . . 70.22 108.062 -177.342 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.585 HD23 HD12 ' A' ' 235' ' ' LEU . 16.7 tp -104.96 124.16 49.03 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 122.786 0.434 . . . . 71.12 110.366 173.037 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 250' ' ' TYR . . . . . 0.433 ' HB3' ' HA ' ' A' ' 194' ' ' TYR . 11.6 t80 -89.3 108.53 19.68 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 124.62 1.168 . . . . 74.32 108.077 171.232 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 65.7 mt -96.89 120.83 37.97 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.793 -0.447 . . . . 70.11 109.793 164.938 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -83.55 94.41 8.05 Favored 'General case' 0 C--O 1.237 0.41 0 N-CA-C 108.012 -1.107 . . . . 72.32 108.012 168.853 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 231' ' ' ARG . 2.3 p -59.48 126.9 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 CA-C-O 121.291 0.567 . . . . 71.21 110.203 177.513 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 10.2 mmm180 -127.19 94.74 4.09 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 107.299 -1.371 . . . . 75.12 107.299 -177.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.509 HD11 HG23 ' A' ' 227' ' ' THR . 64.6 mt -74.77 120.04 23.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 115.193 -0.912 . . . . 73.1 109.74 -172.54 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.4 t . . . . . 0 CA--C 1.557 1.214 0 C-N-CA 125.161 1.384 . . . . 73.4 108.506 -174.129 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.531 HD11 HD13 ' A' ' 149' ' ' ILE . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.476 0 N-CA-C 107.038 -1.468 . . . . 72.11 107.038 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.507 HG23 ' HB1' ' A' ' 121' ' ' ALA . 2.9 p -173.88 131.39 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-N 113.72 -1.582 . . . . 61.53 109.006 -176.12 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.482 ' HB2' ' HD3' ' A' ' 124' ' ' PRO . . . -94.09 -46.85 6.94 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 123.264 0.626 . . . . 62.25 110.072 174.441 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 2.1 p80 -163.45 151.72 13.59 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 115.653 -0.703 . . . . 62.22 111.18 -178.343 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 93.5 t -73.79 126.57 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.021 0.929 . . . . 64.0 109.168 175.009 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 10.1 t . . . . . 0 CA--C 1.547 0.838 0 CA-C-O 122.357 1.075 . . . . 62.21 110.127 -178.277 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.0 t70 . . . . . 0 N--CA 1.472 0.638 0 N-CA-C 109.299 -0.63 . . . . 54.04 109.299 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.461 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 33.4 tp -136.35 121.33 18.8 Favored 'General case' 0 C--O 1.215 -0.755 0 N-CA-C 106.595 -1.631 . . . . 72.2 106.595 -175.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -121.34 131.88 54.45 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.603 -0.517 . . . . 73.33 109.603 -171.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.507 ' HB1' HG23 ' A' ' 99' ' ' VAL . . . -153.12 146.81 25.14 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.294 0.637 . . . . 65.11 109.701 -177.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -126.16 152.98 45.25 Favored 'General case' 0 C--O 1.244 0.768 0 CA-C-O 121.081 0.467 . . . . 54.21 110.49 177.062 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -145.5 148.58 37.6 Favored Pre-proline 0 N--CA 1.471 0.583 0 CA-C-N 114.933 -1.031 . . . . 71.13 110.362 -177.119 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.482 ' HD3' ' HB2' ' A' ' 100' ' ' ALA . 4.0 Cg_exo -73.86 115.31 4.28 Favored 'Trans proline' 0 C--N 1.37 1.695 0 C-N-CA 121.561 1.507 . . . . 73.23 110.151 167.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 23.8 tp -105.84 148.47 27.52 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 108.378 -0.971 . . . . 74.02 108.378 175.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.765 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 24.7 m -76.38 147.23 38.18 Favored 'General case' 0 CA--C 1.547 0.853 0 N-CA-C 109.963 -0.384 . . . . 51.53 109.963 173.915 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.532 HD23 ' HB3' ' A' ' 180' ' ' LEU . 96.6 mt -52.73 -51.42 60.57 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 121.822 0.82 . . . . 65.22 110.48 172.786 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.594 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -55.76 -28.83 58.01 Favored 'General case' 0 CA--C 1.551 1.003 0 CA-C-N 113.947 -1.479 . . . . 61.33 112.451 177.211 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.68 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 22.1 mm-40 -86.24 -21.44 27.41 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 118.18 0.446 . . . . 73.3 111.679 178.14 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.655 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -61.13 -34.67 75.36 Favored 'General case' 0 C--O 1.239 0.546 0 CA-C-O 121.268 0.556 . . . . 72.34 110.059 164.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.639 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 57.8 t80 -76.42 -50.84 13.1 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 114.823 -1.08 . . . . 71.41 112.887 172.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -75.27 -49.21 19.97 Favored 'General case' 0 N--CA 1.486 1.33 0 C-N-CA 122.338 0.255 . . . . 63.25 111.651 -170.364 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.15 -161.61 44.33 Favored Glycine 0 CA--C 1.535 1.331 0 CA-C-O 119.905 -0.386 . . . . 71.54 112.153 -173.518 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 128.63 -169.66 20.08 Favored Glycine 0 N--CA 1.476 1.305 0 CA-C-N 117.307 0.554 . . . . 52.32 114.272 171.03 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -94.61 121.34 36.07 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 124.156 0.982 . . . . 72.3 108.592 -178.129 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -130.66 167.32 18.96 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.759 0.823 . . . . 53.41 108.977 172.743 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.427 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 13.0 p -90.53 142.14 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 108.736 -0.839 . . . . 70.31 108.736 179.152 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.479 HG22 HG23 ' A' ' 140' ' ' VAL . 8.8 p -131.05 136.59 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 N-CA-C 108.863 -0.792 . . . . 71.53 108.863 177.522 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' GLU . . . . . 0.459 ' HA ' ' O ' ' A' ' 143' ' ' ARG . 36.6 tt0 -126.6 97.83 5.17 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.854 -0.425 . . . . 63.21 109.854 172.483 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.479 HG23 HG22 ' A' ' 138' ' ' VAL . 22.9 t -122.13 138.26 52.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 108.208 -1.034 . . . . 65.24 108.208 174.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 64.52 21.58 12.48 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 124.712 1.205 . . . . 70.13 111.341 -176.61 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.59 13.71 82.9 Favored Glycine 0 C--N 1.352 1.452 0 CA-C-N 116.056 -0.52 . . . . 64.22 113.631 -179.198 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.459 ' O ' ' HA ' ' A' ' 139' ' ' GLU . 72.5 mtt180 -108.71 117.67 34.79 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.29 0.636 . . . . 74.34 109.468 179.217 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 21.7 ttm180 -105.35 105.35 15.35 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 109.842 -0.429 . . . . 72.53 109.842 -176.648 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 61.1 t -129.92 141.98 45.01 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.53 1.132 . . . . 63.53 108.291 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.427 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 72.0 p -72.2 111.12 7.14 Favored 'General case' 0 CA--C 1.546 0.817 0 N-CA-C 109.022 -0.733 . . . . 74.44 109.022 174.212 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.2 p -96.82 147.4 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 C-N-CA 123.884 0.874 . . . . 72.24 109.327 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -109.03 127.45 54.11 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 107.888 -1.152 . . . . 71.32 107.888 171.281 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.531 HD13 HD11 ' A' ' 98' ' ' LEU . 38.1 pt -120.62 124.73 27.45 Favored Pre-proline 0 CA--C 1.547 0.858 0 N-CA-C 107.873 -1.158 . . . . 71.42 107.873 170.016 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -72.13 153.5 57.12 Favored 'Trans proline' 0 C--N 1.373 1.847 0 C-N-CA 122.346 2.031 . . . . 71.12 113.021 -173.061 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -65.59 147.68 86.63 Favored 'Trans proline' 0 C--N 1.373 1.852 0 C-N-CA 122.282 1.988 . . . . 62.43 111.428 170.041 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 101.42 53.38 1.0 Allowed Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.123 -1.191 . . . . 75.11 110.123 -171.502 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.655 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -128.49 161.04 38.02 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.299 0 N-CA-C 108.191 -1.041 . . . . 51.32 108.191 -179.459 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -146.16 171.39 15.0 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 124.206 1.002 . . . . 43.02 110.502 -165.562 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -56.59 125.74 23.54 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 123.416 0.686 . . . . 73.22 110.426 169.517 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.83 -6.0 56.21 Favored Glycine 0 C--N 1.347 1.151 0 CA-C-O 119.362 -0.688 . . . . 63.1 113.921 179.73 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 47.8 t -67.06 129.11 38.82 Favored 'General case' 0 C--N 1.359 0.987 0 C-N-CA 123.404 0.682 . . . . 75.41 109.548 -178.06 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.469 HG12 HD22 ' A' ' 175' ' ' LEU . 13.7 t -104.98 118.25 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 O-C-N 124.83 1.331 . . . . 74.11 109.102 -171.218 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.457 HD11 HG21 ' A' ' 153' ' ' VAL . 28.1 mt -104.51 111.31 33.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 123.878 0.871 . . . . 74.42 109.71 -171.311 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 54.9 ttt180 -81.35 117.89 22.2 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.573 0.749 . . . . 70.44 110.643 177.817 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.641 HG22 ' HB3' ' A' ' 174' ' ' LEU . 2.9 m -118.04 117.14 35.51 Favored Pre-proline 0 CA--C 1.557 1.224 0 N-CA-C 109.093 -0.706 . . . . 73.3 109.093 170.687 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -81.26 149.69 17.2 Favored 'Trans proline' 0 C--N 1.377 2.042 0 C-N-CA 122.473 2.116 . . . . 73.04 112.663 -177.538 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 82.1 24.71 54.26 Favored Glycine 0 C--N 1.349 1.286 0 CA-C-N 115.925 -0.579 . . . . 75.13 113.649 177.383 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 54.9 tpp -109.8 -57.68 2.15 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.545 0.738 . . . . 71.32 110.68 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 1.657 0 N-CA-C 111.665 -0.574 . . . . 60.3 111.665 -179.755 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo . . . . . 0 CA--C 1.543 0.935 0 N-CA-C 111.52 -0.223 . . . . 54.22 111.52 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -94.67 144.89 17.43 Favored Glycine 0 C--N 1.338 0.658 0 N-CA-C 112.096 -0.402 . . . . 74.03 112.096 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 173' ' ' ASP . . . . . 0.412 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 63.9 m-20 -106.39 116.47 31.99 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 123.035 0.534 . . . . 74.12 110.207 -169.561 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.641 ' HB3' HG22 ' A' ' 161' ' ' VAL . 47.3 tp -89.85 109.68 20.66 Favored 'General case' 0 C--O 1.235 0.338 0 N-CA-C 107.36 -1.348 . . . . 44.23 107.36 171.428 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.469 HD22 HG12 ' A' ' 158' ' ' VAL . 70.0 mt -89.88 98.91 12.04 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.085 1.354 . . . . 62.33 109.538 -179.416 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 84.0 mt -90.22 102.86 15.58 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 124.075 0.95 . . . . 71.02 110.876 179.694 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 35.1 t -86.91 105.25 14.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 N-CA-C 108.161 -1.051 . . . . 62.54 108.161 175.39 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 7.8 m -83.48 148.99 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 CA-C-O 121.551 0.691 . . . . 51.51 111.336 -178.388 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 179' ' ' ARG . . . . . 0.445 ' HB2' ' HA ' ' A' ' 124' ' ' PRO . 35.3 mmt180 -119.04 100.15 7.17 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 107.236 -1.394 . . . . 74.13 107.236 -178.492 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.532 ' HB3' HD23 ' A' ' 127' ' ' LEU . 41.7 mt -67.47 145.86 54.56 Favored 'General case' 0 C--O 1.239 0.514 0 O-C-N 122.938 0.149 . . . . 72.45 110.771 -176.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.765 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 26.5 mt -55.98 138.92 71.76 Favored Pre-proline 0 CA--C 1.548 0.897 0 O-C-N 123.603 0.564 . . . . 71.3 111.211 -177.034 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.8 67.55 4.79 Favored 'Trans proline' 0 C--N 1.377 2.036 0 C-N-CA 123.368 2.712 . . . . 73.25 113.668 -174.594 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 8.8 p80 -155.47 82.3 3.84 Favored Pre-proline 0 CA--C 1.557 1.247 0 N-CA-C 108.18 -1.044 . . . . 52.01 108.18 172.055 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -62.88 126.16 17.51 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 121.726 1.617 . . . . 72.33 111.548 -175.085 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.8 p -136.75 -48.14 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 108.103 -1.073 . . . . 74.4 108.103 174.384 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.494 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 4.2 m-85 -113.16 137.16 51.88 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.759 0.824 . . . . 64.43 110.554 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.572 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 2.7 mpt_? -125.09 154.39 41.46 Favored 'General case' 0 CA--C 1.537 0.446 0 N-CA-C 106.836 -1.542 . . . . 74.02 106.836 175.626 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 48.4 tp -134.43 137.9 44.37 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.305 -0.628 . . . . 71.02 109.305 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -142.07 115.89 9.23 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 107.592 -1.262 . . . . 71.1 107.592 169.311 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 66.71 -95.48 0.27 Allowed Glycine 0 C--N 1.346 1.13 0 O-C-N 123.779 0.674 . . . . 61.33 111.918 -175.282 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 191' ' ' GLN . . . . . 0.434 ' OE1' ' HD2' ' A' ' 243' ' ' PRO . 1.9 mp0 -120.63 -19.51 7.42 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.673 0.789 . . . . 71.41 110.267 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -83.03 144.01 30.23 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.438 0.695 . . . . 64.02 112.005 -171.421 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.512 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.6 mt -106.64 155.72 19.36 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 124.917 1.287 . . . . 74.24 108.239 177.379 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 194' ' ' TYR . . . . . 0.572 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 73.9 m-85 -139.9 121.84 15.59 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 107.117 -1.438 . . . . 74.34 107.117 -179.083 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -139.9 141.87 36.52 Favored 'General case' 0 CA--C 1.51 -0.58 0 N-CA-C 109.342 -0.614 . . . . 74.24 109.342 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 25.7 m -91.35 118.07 30.21 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 108.779 -0.823 . . . . 70.12 108.779 178.512 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.478 HD13 ' HB2' ' A' ' 212' ' ' ALA . 65.0 tp -105.94 113.3 26.76 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.714 0.805 . . . . 71.1 109.357 -178.154 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 198' ' ' ASP . . . . . 0.402 ' HA ' ' O ' ' A' ' 254' ' ' ARG . 14.5 p-10 -89.54 111.55 22.49 Favored 'General case' 0 C--O 1.244 0.776 0 N-CA-C 108.879 -0.786 . . . . 61.54 108.879 172.877 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 60.5 t -97.44 119.18 63.38 Favored Pre-proline 0 CA--C 1.536 0.414 0 N-CA-C 108.269 -1.011 . . . . 62.52 108.269 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -56.52 135.13 68.62 Favored 'Trans proline' 0 C--N 1.371 1.731 0 C-N-CA 122.439 2.093 . . . . 70.33 110.95 176.39 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -50.33 -43.86 79.99 Favored Pre-proline 0 CA--C 1.564 1.482 0 C-N-CA 124.803 1.241 . . . . 53.21 113.519 -174.537 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 202' ' ' PRO . . . . . 0.447 ' O ' HG22 ' A' ' 206' ' ' VAL . 92.1 Cg_exo -49.35 -54.7 5.04 Favored 'Trans proline' 0 C--N 1.397 3.094 0 C-N-CA 122.395 2.064 . . . . 73.03 113.075 169.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 12.6 mt -66.03 -35.65 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 122.6 0.36 . . . . 74.33 110.956 -178.328 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -58.27 -44.13 88.26 Favored 'General case' 0 N--CA 1.464 0.26 0 C-N-CA 123.503 0.721 . . . . 72.12 110.885 -178.07 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 31.5 m -89.75 -57.69 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.157 0 N-CA-C 112.701 0.63 . . . . 63.43 112.701 -177.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.447 HG22 ' O ' ' A' ' 202' ' ' PRO . 33.2 m -94.86 -27.01 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 118.768 0.713 . . . . 51.44 112.388 -173.299 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -86.53 -146.89 10.24 Favored Glycine 0 C--N 1.342 0.906 0 N-CA-C 112.29 -0.324 . . . . 64.4 112.29 -171.183 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 169.05 10.4 0.02 OUTLIER Glycine 0 C--N 1.339 0.732 0 CA-C-O 118.933 -0.926 . . . . 73.21 115.184 -179.222 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 53.5 mttp -138.48 119.42 14.33 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 118.255 1.027 . . . . 64.13 108.538 -179.206 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 6.2 p -140.54 137.05 36.31 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 108.054 -1.091 . . . . 73.21 108.054 177.317 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 211' ' ' ARG . . . . . 0.406 ' N ' ' HD2' ' A' ' 211' ' ' ARG . 7.6 mpt_? -98.56 126.88 44.28 Favored 'General case' 0 C--O 1.24 0.555 0 N-CA-C 108.672 -0.862 . . . . 70.54 108.672 -177.187 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.478 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -102.2 138.42 39.16 Favored 'General case' 0 C--O 1.244 0.808 0 C-N-CA 123.537 0.735 . . . . 70.53 110.076 -176.102 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 3.0 tpt -74.69 109.18 7.96 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.379 -0.828 . . . . 70.24 109.378 175.026 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.494 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 8.8 t -111.61 166.81 10.84 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 123.011 0.524 . . . . 61.54 110.162 174.888 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 215' ' ' LEU . . . . . 0.594 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 64.6 mt -72.38 -5.53 37.09 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 123.8 0.84 . . . . 74.45 111.86 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -96.16 -20.61 18.48 Favored 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.405 1.082 . . . . 73.25 111.126 177.121 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 136.41 -146.41 18.37 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 119.211 -0.772 . . . . 43.25 111.298 -171.239 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -86.06 127.78 3.07 Favored 'Trans proline' 0 CA--C 1.556 1.618 0 C-N-CA 122.541 2.16 . . . . 71.22 112.729 170.777 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 219' ' ' VAL . . . . . 0.452 HG13 HG21 ' A' ' 214' ' ' THR . 17.2 m -109.34 150.9 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 N-CA-C 108.974 -0.75 . . . . 61.34 108.974 164.801 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -111.35 108.76 18.46 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 107.874 -1.158 . . . . 72.24 107.874 178.048 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 2.8 p -104.43 133.81 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 C-N-CA 123.187 0.595 . . . . 73.51 110.31 177.225 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.19 125.57 35.12 Favored 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 115.625 -0.716 . . . . 74.54 109.779 177.457 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.458 HG12 HD11 ' A' ' 233' ' ' LEU . 28.1 m -97.4 141.12 22.54 Favored Pre-proline 0 N--CA 1.479 1.018 0 N-CA-C 108.485 -0.931 . . . . 73.44 108.485 173.967 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -60.62 139.89 88.24 Favored 'Trans proline' 0 C--N 1.37 1.698 0 C-N-CA 122.171 1.914 . . . . 71.1 111.971 176.736 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -53.31 112.39 0.92 Allowed 'Trans proline' 0 C--N 1.381 2.253 0 C-N-CA 122.629 2.219 . . . . 75.23 110.781 172.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 70.2 mtp180 66.13 72.4 0.39 Allowed 'General case' 0 CA--C 1.548 0.884 0 O-C-N 124.597 1.186 . . . . 74.41 110.428 -164.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 12.1 t -81.6 173.87 11.95 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.638 0.775 . . . . 72.4 109.299 169.903 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.0 mp0 -132.24 147.38 52.41 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 123.814 0.846 . . . . 64.25 109.302 -176.437 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.08 117.6 11.86 Favored 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 123.316 0.647 . . . . 72.24 109.583 174.496 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.25 3.16 22.97 Favored Glycine 0 C--N 1.344 1.023 0 CA-C-N 116.133 -0.485 . . . . 40.34 113.108 -174.676 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 19.2 mtp-105 -83.63 160.65 21.33 Favored 'General case' 0 N--CA 1.479 1.015 0 CA-C-N 117.286 0.543 . . . . 75.12 111.223 175.767 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 232' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -116.05 120.83 40.36 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.549 1.139 . . . . 74.25 109.523 -176.224 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 233' ' ' LEU . . . . . 0.458 HD11 HG12 ' A' ' 223' ' ' VAL . 33.1 mt -110.54 100.02 8.91 Favored 'General case' 0 C--O 1.237 0.416 0 N-CA-C 107.2 -1.407 . . . . 70.12 107.2 174.548 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 234' ' ' ARG . . . . . 0.444 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 44.4 ttp180 -95.65 104.13 16.04 Favored 'General case' 0 CA--C 1.542 0.636 0 CA-C-N 115.566 -0.743 . . . . 62.13 109.859 -170.914 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.492 HD12 HD23 ' A' ' 249' ' ' LEU . 16.5 mt -81.04 119.07 23.06 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 123.17 0.588 . . . . 72.13 110.131 -177.118 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 34.2 mtmm -66.65 120.67 13.85 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 125.085 1.354 . . . . 72.12 112.514 -168.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 65.84 33.95 87.27 Favored Glycine 0 C--N 1.351 1.405 0 O-C-N 123.983 0.802 . . . . 63.14 114.053 170.169 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 28.5 mmtp -116.01 2.11 13.4 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 123.474 0.71 . . . . 73.51 111.635 179.104 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -88.72 -177.58 46.66 Favored Glycine 0 C--N 1.345 1.082 0 N-CA-C 111.434 -0.666 . . . . 65.21 111.434 167.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.639 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 95.2 m-85 -74.68 151.82 87.04 Favored Pre-proline 0 N--CA 1.479 1.016 0 C-N-CA 122.545 0.338 . . . . 73.54 111.119 -177.141 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -77.58 165.68 26.77 Favored 'Trans proline' 0 C--N 1.372 1.788 0 C-N-CA 122.036 1.824 . . . . 73.32 111.631 178.817 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 161.07 -157.39 28.92 Favored Glycine 0 CA--C 1.528 0.876 0 CA-C-O 119.545 -0.586 . . . . 63.04 113.106 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 243' ' ' PRO . . . . . 0.434 ' HD2' ' OE1' ' A' ' 191' ' ' GLN . 77.1 Cg_exo -54.35 -23.24 29.83 Favored 'Trans proline' 0 C--N 1.375 1.945 0 C-N-CA 124.174 3.249 . . . . 60.44 114.315 175.582 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -90.42 19.42 5.24 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 123.362 0.665 . . . . 63.11 111.484 176.233 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 71.26 -94.18 0.54 Allowed Glycine 0 C--N 1.352 1.452 0 N-CA-C 110.893 -0.883 . . . . 74.43 110.893 -174.568 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -119.7 146.2 45.82 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 124.7 1.2 . . . . 72.53 107.847 166.581 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -80.44 -173.16 46.12 Favored Glycine 0 C--O 1.24 0.483 0 O-C-N 123.766 0.666 . . . . 73.1 111.751 173.021 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -137.94 163.05 32.46 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.278 0.631 . . . . 70.04 109.327 -176.37 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.512 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 18.3 tp -99.63 109.58 22.07 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 109.46 -0.57 . . . . 71.05 109.46 172.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -87.86 105.42 17.4 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 107.083 -1.451 . . . . 71.1 107.083 175.888 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.422 HD22 ' HB2' ' A' ' 197' ' ' LEU . 78.4 mt -87.49 145.98 26.01 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 123.02 0.528 . . . . 75.45 111.575 172.678 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -110.83 98.18 7.39 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 107.924 -1.139 . . . . 71.31 107.924 174.423 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 61.3 t -56.94 126.56 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 123.227 0.611 . . . . 73.42 110.737 176.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 254' ' ' ARG . . . . . 0.402 ' O ' ' HA ' ' A' ' 198' ' ' ASP . 23.2 mmt180 -132.86 97.11 3.95 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 106.968 -1.493 . . . . 53.11 106.968 178.339 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 62.4 mt -74.59 122.57 28.28 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 N-CA-C 109.274 -0.639 . . . . 61.05 109.274 -177.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.3 t . . . . . 0 CA--C 1.565 1.525 0 C-N-CA 124.719 1.207 . . . . 63.5 108.779 -177.392 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 14.8 mt . . . . . 0 N--CA 1.482 1.148 0 CA-C-O 119.612 -0.232 . . . . 73.41 111.082 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.784 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 24.6 m -58.62 159.16 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 N-CA-C 114.252 1.205 . . . . 71.43 114.252 -173.796 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -108.08 -43.2 4.46 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 113.428 -1.714 . . . . 74.54 109.127 178.053 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 2.9 p80 -177.9 169.74 1.97 Allowed 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 124.08 0.952 . . . . 73.23 110.445 -178.758 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 85.7 t -64.98 116.33 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 108.287 -1.005 . . . . 73.43 108.287 166.312 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.52 ' HB ' ' HB2' ' A' ' 122' ' ' GLU . 10.2 t . . . . . 0 N--CA 1.473 0.695 0 O-C-N 123.381 0.426 . . . . 75.12 111.539 -174.109 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.472 0.653 0 N-CA-C 108.642 -0.873 . . . . 64.32 108.642 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 50.3 tp -108.18 127.06 53.49 Favored 'General case' 0 C--O 1.217 -0.638 0 N-CA-C 106.994 -1.484 . . . . 74.33 106.994 173.644 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 45.3 mtp85 -120.76 108.95 14.58 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.621 -0.511 . . . . 75.54 109.621 -170.079 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -130.69 139.55 50.32 Favored 'General case' 0 N--CA 1.478 0.944 0 C-N-CA 123.436 0.694 . . . . 33.24 110.578 -174.543 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' GLU . . . . . 0.52 ' HB2' ' HB ' ' A' ' 103' ' ' THR . 34.8 tt0 -104.38 146.53 28.7 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.266 0.626 . . . . 74.34 110.294 178.436 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.784 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.8 pt? -145.7 146.32 28.79 Favored Pre-proline 0 N--CA 1.467 0.415 0 C-N-CA 124.077 0.951 . . . . 64.32 110.379 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -78.36 121.91 5.42 Favored 'Trans proline' 0 C--N 1.366 1.457 0 C-N-CA 121.977 1.785 . . . . 73.11 110.581 167.539 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.529 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 14.2 tp -111.86 162.04 15.72 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.582 0.753 . . . . 71.13 109.218 175.161 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 19.5 m -101.86 158.03 16.42 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 109.174 -0.676 . . . . 75.02 109.174 175.631 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.477 HD23 ' HB3' ' A' ' 180' ' ' LEU . 65.1 mt -55.81 -52.19 64.87 Favored 'General case' 0 N--CA 1.486 1.352 0 CA-C-O 121.717 0.77 . . . . 63.43 111.248 179.06 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.414 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 10.9 mp0 -54.26 -33.24 58.1 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 114.495 -1.23 . . . . 65.2 111.708 175.871 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.4 mm-40 -85.96 -18.61 32.16 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 123.306 0.642 . . . . 73.25 111.98 -176.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.681 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -60.23 -41.34 92.9 Favored 'General case' 0 C--O 1.247 0.947 0 CA-C-O 121.805 0.812 . . . . 72.42 110.41 162.345 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.465 ' HA ' ' CE2' ' A' ' 240' ' ' PHE . 66.1 t80 -73.15 -43.2 61.91 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 114.365 -1.289 . . . . 72.4 112.812 175.003 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.8 m80 -83.94 -49.25 9.16 Favored 'General case' 0 N--CA 1.493 1.692 0 N-CA-C 112.439 0.533 . . . . 71.13 112.439 -172.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.06 -110.61 3.46 Favored Glycine 0 CA--C 1.531 1.063 0 N-CA-C 111.412 -0.675 . . . . 52.33 111.412 -173.597 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 90.0 172.99 45.13 Favored Glycine 0 C--N 1.35 1.318 0 C-N-CA 123.079 0.371 . . . . 61.14 113.923 168.878 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.63 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 2.1 mp0 -86.34 125.72 33.83 Favored 'General case' 0 C--N 1.351 0.671 0 N-CA-C 108.975 -0.75 . . . . 71.54 108.975 178.071 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 33.2 ttt85 -156.15 138.05 14.41 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 108.139 -1.06 . . . . 73.34 108.139 175.434 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.705 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 12.6 p -72.51 142.64 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 112.85 0.685 . . . . 73.03 112.85 -167.327 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 34.6 m -124.26 152.39 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 124.262 1.025 . . . . 75.35 109.781 174.121 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -124.5 104.31 8.66 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 107.179 -1.415 . . . . 63.13 107.179 171.14 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 7.1 p -150.9 139.12 14.43 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.965 0 C-N-CA 123.593 0.757 . . . . 54.54 109.885 -176.368 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.17 20.56 11.07 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 125.26 1.424 . . . . 74.43 112.768 -176.504 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.19 26.65 57.33 Favored Glycine 0 C--N 1.346 1.085 0 CA-C-N 116.538 -0.301 . . . . 54.41 112.385 -176.057 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.3 mmt180 -127.16 117.57 22.63 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.61 0.764 . . . . 64.21 110.277 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 43.1 ttp180 -98.5 104.57 16.62 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 108.321 -0.992 . . . . 72.13 108.321 173.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.2 m -146.81 137.47 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 123.672 0.789 . . . . 53.43 109.853 -177.197 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.705 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 35.7 p -73.34 118.19 15.99 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.413 0.685 . . . . 64.12 110.146 177.173 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.9 p -100.08 139.07 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 122.933 0.493 . . . . 64.02 110.129 -178.453 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' ARG . . . . . 0.63 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 24.8 ttp180 -106.9 106.47 17.01 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 108.344 -0.984 . . . . 75.23 108.344 173.585 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.465 ' HB ' HD13 ' A' ' 159' ' ' ILE . 34.2 pt -96.73 128.33 36.29 Favored Pre-proline 0 CA--C 1.546 0.794 0 N-CA-C 107.828 -1.175 . . . . 73.42 107.828 175.084 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -71.14 151.35 61.12 Favored 'Trans proline' 0 C--N 1.373 1.822 0 C-N-CA 122.331 2.021 . . . . 71.43 113.59 -167.743 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.422 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 43.4 Cg_exo -60.54 110.52 0.82 Allowed 'Trans proline' 0 C--N 1.378 2.105 0 C-N-CA 122.779 2.319 . . . . 70.41 109.939 169.755 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 131.37 59.64 0.09 OUTLIER Glycine 0 C--N 1.341 0.811 0 N-CA-C 111.01 -0.836 . . . . 73.45 111.01 -170.863 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.681 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -140.24 162.82 24.26 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.203 0 N-CA-C 108.453 -0.943 . . . . 60.31 108.453 177.395 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.545 ' HD2' ' HB3' ' A' ' 188' ' ' LEU . 38.5 mtp180 -146.67 176.52 9.79 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 124.405 1.082 . . . . 72.44 110.869 -171.006 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -56.74 117.81 4.27 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 124.537 1.135 . . . . 75.42 111.694 173.363 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.24 7.75 87.67 Favored Glycine 0 C--N 1.342 0.869 0 CA-C-N 115.372 -0.831 . . . . 72.52 113.645 179.128 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 33.8 t -78.76 136.32 37.35 Favored 'General case' 0 C--N 1.35 0.599 0 CA-C-O 121.145 0.498 . . . . 53.15 109.799 -178.105 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.435 HG12 HD22 ' A' ' 175' ' ' LEU . 8.2 t -103.47 119.29 51.81 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 CA-C-N 114.531 -1.213 . . . . 74.44 109.329 -172.099 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.578 HD11 HG21 ' A' ' 153' ' ' VAL . 26.4 mt -103.05 115.55 45.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.811 0.844 . . . . 75.12 110.417 -171.214 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 32.2 ttt85 -85.06 107.32 17.1 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.603 0.761 . . . . 62.05 109.813 177.098 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.452 HG22 ' O ' ' A' ' 174' ' ' LEU . 25.4 m -112.88 111.59 51.01 Favored Pre-proline 0 CA--C 1.56 1.356 0 C-N-CA 122.648 0.379 . . . . 64.3 110.404 178.119 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -65.97 148.74 86.17 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 123.286 2.657 . . . . 71.14 114.01 -173.465 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 70.75 23.9 77.44 Favored Glycine 0 C--N 1.352 1.433 0 CA-C-N 116.025 -0.534 . . . . 42.52 114.218 173.684 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 52.9 mmm -120.16 -30.64 4.6 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.876 0.87 . . . . 75.2 111.554 -172.882 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.346 1.104 0 O-C-N 123.146 0.279 . . . . 73.43 113.069 -179.462 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo . . . . . 0 CA--C 1.535 0.561 0 CA-C-O 119.686 -0.214 . . . . 75.33 111.698 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -97.65 150.12 19.4 Favored Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.788 -0.925 . . . . 75.04 110.788 175.014 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -106.88 160.05 15.79 Favored 'General case' 0 C--O 1.238 0.45 0 C-N-CA 123.622 0.769 . . . . 51.32 109.691 -178.546 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.452 ' O ' HG22 ' A' ' 161' ' ' VAL . 13.8 tp -115.04 114.7 25.72 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 108.204 -1.035 . . . . 64.43 108.204 -179.713 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.435 HD22 HG12 ' A' ' 158' ' ' VAL . 57.0 mt -84.72 101.69 12.4 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.673 1.189 . . . . 74.31 111.237 176.381 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.422 ' HB3' HD21 ' A' ' 123' ' ' LEU . 42.5 mt -90.93 105.65 17.97 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 114.95 -1.023 . . . . 74.31 111.32 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 27.3 t -85.55 99.67 7.77 Favored 'Isoleucine or valine' 0 C--O 1.242 0.685 0 N-CA-C 107.959 -1.126 . . . . 44.41 107.959 172.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.529 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 17.4 m -82.25 148.88 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 121.216 0.531 . . . . 71.15 110.235 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 39.4 mmm-85 -121.2 103.95 9.38 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.798 -1.186 . . . . 65.41 107.798 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.477 ' HB3' HD23 ' A' ' 127' ' ' LEU . 30.6 mt -67.97 149.08 50.19 Favored 'General case' 0 C--O 1.242 0.667 0 N-CA-C 109.256 -0.646 . . . . 45.12 109.256 177.339 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 40.2 mt -53.85 137.56 54.79 Favored Pre-proline 0 CA--C 1.552 1.045 0 O-C-N 123.674 0.609 . . . . 74.14 110.311 -178.218 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -58.78 -5.13 2.35 Favored 'Trans proline' 0 C--N 1.378 2.119 0 C-N-CA 123.141 2.56 . . . . 61.13 114.073 -177.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 183' ' ' HIS . . . . . 0.456 ' O ' HD11 ' A' ' 127' ' ' LEU . 6.2 t60 -83.72 107.76 11.36 Favored Pre-proline 0 CA--C 1.548 0.893 0 C-N-CA 124.654 1.182 . . . . 72.42 108.526 162.83 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -96.67 163.48 1.12 Allowed 'Trans proline' 0 C--N 1.369 1.631 0 C-N-CA 122.916 2.411 . . . . 74.45 111.922 168.864 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.66 -42.98 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 122.999 0.52 . . . . 72.2 109.769 169.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.503 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 5.6 m-85 -101.92 123.97 46.74 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 115.783 -0.644 . . . . 70.45 110.795 -176.903 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -109.64 123.38 49.38 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 125.136 1.375 . . . . 73.3 108.092 179.311 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.545 ' HB3' ' HD2' ' A' ' 154' ' ' ARG . 22.4 tp -95.58 113.11 24.73 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-O 121.445 0.641 . . . . 60.24 111.174 -173.158 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -83.93 170.37 14.08 Favored 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 125.533 1.533 . . . . 72.04 107.826 162.234 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . -42.77 86.74 0.01 OUTLIER Glycine 0 C--N 1.362 2.004 0 CA-C-N 118.761 0.71 . . . . 53.53 114.357 175.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 67.18 -4.82 0.78 Allowed 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 127.658 2.383 . . . . 64.23 113.554 -175.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.503 ' O ' HD12 ' A' ' 188' ' ' LEU . 27.2 t70 -105.52 156.13 18.52 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 124.899 1.28 . . . . 64.44 109.989 -174.463 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.536 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 78.4 mt -113.62 157.7 21.78 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 124.047 0.939 . . . . 72.11 112.177 -172.686 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 46.8 m-85 -139.61 122.25 16.33 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 114.419 -1.264 . . . . 74.03 108.378 174.164 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -142.61 171.1 14.51 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.144 0.978 . . . . 62.5 109.504 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 16.2 m -109.41 128.43 55.13 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 109.779 -0.452 . . . . 74.23 109.779 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.476 HD22 HD13 ' A' ' 251' ' ' LEU . 62.3 tp -114.75 115.0 26.35 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.222 1.009 . . . . 61.25 109.713 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 198' ' ' ASP . . . . . 0.436 ' HA ' ' HB2' ' A' ' 254' ' ' ARG . 10.3 m-20 -99.68 106.35 18.27 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.655 -0.498 . . . . 72.05 109.655 178.489 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 199' ' ' VAL . . . . . 0.496 HG12 HG21 ' A' ' 210' ' ' VAL . 6.4 m -107.72 147.36 35.23 Favored Pre-proline 0 N--CA 1.481 1.097 0 C-N-CA 123.232 0.613 . . . . 74.22 109.563 178.179 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.32 148.8 55.87 Favored 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 122.149 1.899 . . . . 64.2 110.565 167.714 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -54.14 -44.38 98.4 Favored Pre-proline 0 CA--C 1.56 1.346 0 CA-C-O 117.468 -1.253 . . . . 61.42 112.893 176.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -43.66 -52.98 4.78 Favored 'Trans proline' 0 C--N 1.403 3.396 0 C-N-CA 123.029 2.486 . . . . 75.45 113.895 171.032 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 203' ' ' ILE . . . . . 0.522 HG21 HG13 ' A' ' 210' ' ' VAL . 6.3 mt -71.05 -38.06 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 CA-C-N 116.62 -0.263 . . . . 63.22 110.781 -177.639 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -61.01 -38.71 87.05 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 123.321 0.648 . . . . 65.34 112.078 -178.211 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.8 m -84.45 -38.44 13.62 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 CA-C-N 116.173 -0.467 . . . . 65.03 111.759 -176.318 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.1 m -78.2 -27.51 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 CA-C-N 118.121 0.418 . . . . 60.12 111.201 179.408 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 207' ' ' GLY . . . . . 0.456 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 79.56 53.52 4.32 Favored Glycine 0 C--N 1.339 0.72 0 CA-C-N 115.554 -0.748 . . . . 73.25 112.849 -175.773 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.8 -152.6 11.53 Favored Glycine 0 C--N 1.354 1.555 0 N-CA-C 111.762 -0.535 . . . . 75.23 111.762 178.257 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 57.9 mttp -125.27 139.13 53.98 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 123.371 0.668 . . . . 74.44 109.842 176.265 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 210' ' ' VAL . . . . . 0.522 HG13 HG21 ' A' ' 203' ' ' ILE . 13.6 m -123.71 134.63 65.9 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 CA-C-N 114.737 -1.119 . . . . 70.04 108.322 173.913 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 39.7 ttp-105 -81.64 113.48 19.68 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 108.835 -0.802 . . . . 72.2 108.835 175.564 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.42 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -101.19 165.6 11.21 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.374 -0.973 . . . . 65.21 108.374 175.338 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 1.9 mtp -106.4 154.14 21.23 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.593 0.711 . . . . 74.31 110.762 173.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.503 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.8 t -144.53 173.38 11.86 Favored 'General case' 0 C--O 1.242 0.705 0 CA-C-N 113.641 -1.618 . . . . 61.14 108.365 171.715 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 215' ' ' LEU . . . . . 0.414 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 49.9 mt -73.7 -10.53 59.78 Favored 'General case' 0 CA--C 1.553 1.069 0 CA-C-N 115.946 -0.57 . . . . 74.01 111.092 -179.723 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 216' ' ' GLU . . . . . 0.407 ' H ' HG23 ' A' ' 214' ' ' THR . 35.1 tt0 -86.87 -18.98 29.59 Favored 'General case' 0 CA--C 1.551 1.011 0 C-N-CA 124.58 1.152 . . . . 54.02 110.819 173.697 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 134.26 -157.91 23.12 Favored Glycine 0 C--N 1.353 1.48 0 CA-C-O 119.53 -0.595 . . . . 61.12 111.786 -176.765 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -84.4 130.96 4.7 Favored 'Trans proline' 0 C--N 1.366 1.46 0 C-N-CA 122.5 2.134 . . . . 74.31 112.227 175.481 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 35.1 m -113.08 161.9 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 124.22 1.008 . . . . 74.31 111.292 178.219 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -106.25 121.23 43.78 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 108.627 -0.879 . . . . 70.25 108.627 173.832 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 20.2 t -103.26 115.45 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 109.312 -0.625 . . . . 72.43 109.312 176.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -84.59 100.66 11.56 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 107.689 -1.226 . . . . 74.11 107.689 170.436 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.456 HG23 ' HA2' ' A' ' 207' ' ' GLY . 12.3 m -76.26 141.1 69.89 Favored Pre-proline 0 CA--C 1.549 0.913 0 N-CA-C 108.927 -0.768 . . . . 71.34 108.927 -178.653 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_exo -64.46 136.02 48.68 Favored 'Trans proline' 0 C--N 1.367 1.531 0 C-N-CA 122.622 2.215 . . . . 62.32 112.092 177.617 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -58.34 117.6 4.34 Favored 'Trans proline' 0 C--N 1.371 1.716 0 C-N-CA 122.611 2.207 . . . . 61.1 111.23 174.079 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 64.96 51.74 1.68 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 124.636 1.174 . . . . 73.42 110.826 -175.449 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.6 t -77.61 172.35 13.52 Favored 'General case' 0 CA--C 1.545 0.788 0 CA-C-N 115.248 -0.887 . . . . 74.52 109.555 170.556 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 28.1 mp0 -122.5 145.46 48.29 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 123.398 0.679 . . . . 74.4 110.036 -174.831 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.57 121.86 18.65 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.734 -0.839 . . . . 75.5 108.734 172.48 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.69 -7.7 19.87 Favored Glycine 0 N--CA 1.469 0.893 0 CA-C-N 116.087 -0.506 . . . . 52.54 112.324 -171.279 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 70.5 mtp180 -83.28 160.1 21.79 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 122.842 0.457 . . . . 62.42 110.347 173.319 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 3.4 mppt? -125.13 113.4 17.66 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.966 0.906 . . . . 73.11 109.527 177.443 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 38.3 mt -89.89 125.71 35.45 Favored 'General case' 0 C--N 1.354 0.802 0 N-CA-C 108.451 -0.944 . . . . 53.43 108.451 -177.811 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 234' ' ' ARG . . . . . 0.51 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 37.2 ttp180 -106.26 112.17 25.07 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-O 121.056 0.455 . . . . 63.44 111.22 -168.781 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.472 HD12 HD23 ' A' ' 249' ' ' LEU . 44.7 mt -86.61 127.12 34.9 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-N 115.347 -0.842 . . . . 73.3 110.11 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 35.1 mtmm -70.18 124.64 24.62 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 124.763 1.225 . . . . 73.31 111.809 -172.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 70.8 13.92 72.43 Favored Glycine 0 C--N 1.348 1.216 0 N-CA-C 114.954 0.742 . . . . 74.33 114.954 170.522 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -87.74 -9.96 52.5 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.226 0.61 . . . . 70.03 111.982 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -87.6 179.57 47.66 Favored Glycine 0 C--N 1.342 0.896 0 O-C-N 123.407 0.442 . . . . 70.13 112.799 177.08 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.465 ' CE2' ' HA ' ' A' ' 131' ' ' PHE . 14.4 m-85 -69.07 144.45 95.48 Favored Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 123.565 0.746 . . . . 75.44 110.99 -177.154 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 241' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 23.0 Cg_exo -66.65 130.35 23.25 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.632 2.222 . . . . 70.24 112.304 172.411 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -161.21 -151.53 6.29 Favored Glycine 0 CA--C 1.538 1.507 0 CA-C-O 119.271 -0.738 . . . . 72.12 111.99 178.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -56.18 -23.62 46.02 Favored 'Trans proline' 0 C--N 1.377 2.048 0 C-N-CA 123.996 3.131 . . . . 65.32 115.865 -174.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -101.15 22.6 12.09 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 123.298 0.639 . . . . 71.52 111.586 -179.397 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.16 -93.31 1.82 Allowed Glycine 0 C--N 1.341 0.846 0 N-CA-C 110.075 -1.21 . . . . 72.24 110.075 -172.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.468 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 46.6 mtm180 -122.14 153.68 38.41 Favored 'General case' 0 N--CA 1.478 0.935 0 N-CA-C 108.484 -0.932 . . . . 74.21 108.484 170.218 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -84.61 -162.46 34.94 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.789 -0.641 . . . . 41.11 112.186 178.365 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 42.7 m-20 -138.95 173.65 11.35 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.424 0.689 . . . . 71.13 109.853 -173.857 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.536 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 16.6 tp -119.82 115.85 24.68 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.397 0.679 . . . . 72.42 111.583 176.2 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 250' ' ' TYR . . . . . 0.425 ' CZ ' ' HD3' ' A' ' 234' ' ' ARG . 20.5 m-85 -88.95 107.44 19.02 Favored 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 123.561 0.744 . . . . 72.51 109.997 171.259 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.573 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 38.2 mt -89.93 118.72 29.7 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 125.041 1.336 . . . . 74.34 112.178 176.081 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -77.57 96.56 4.81 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 108.965 -0.754 . . . . 73.2 108.965 178.261 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 45.2 t -49.85 115.1 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 124.201 1.001 . . . . 52.14 111.354 173.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 254' ' ' ARG . . . . . 0.436 ' HB2' ' HA ' ' A' ' 198' ' ' ASP . 30.5 mmm180 -118.21 93.2 4.04 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 106.905 -1.517 . . . . 75.35 106.905 174.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 71.2 mt -76.48 122.94 31.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 N-CA-C 109.216 -0.661 . . . . 75.04 109.216 176.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.557 1.244 0 CA-C-O 117.446 -1.264 . . . . 64.21 107.941 -178.597 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.459 HD13 ' HG3' ' A' ' 136' ' ' ARG . 60.7 tp . . . . . 0 CA--C 1.535 0.384 0 N-CA-C 105.994 -1.854 . . . . 74.4 105.994 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.406 HG22 ' H ' ' A' ' 101' ' ' HIS . 12.4 p -107.26 154.99 8.07 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 C-N-CA 124.445 1.098 . . . . 71.43 109.306 165.636 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -141.57 1.93 1.58 Allowed 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 124.366 1.066 . . . . 75.1 110.518 173.318 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' HIS . . . . . 0.406 ' H ' HG22 ' A' ' 99' ' ' VAL . 9.2 t-80 -109.06 103.33 12.33 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.898 1.279 . . . . 72.14 109.545 -177.772 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 82.6 t -83.98 136.21 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 N-CA-C 108.597 -0.89 . . . . 61.52 108.597 173.846 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 43.1 p . . . . . 0 N--CA 1.472 0.671 0 C-N-CA 123.459 0.704 . . . . 71.3 111.912 -172.092 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 . . . . . 0 N--CA 1.47 0.558 0 N-CA-C 108.69 -0.856 . . . . 71.41 108.69 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.437 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 2.5 tt -94.36 138.61 32.12 Favored 'General case' 0 C--O 1.215 -0.722 0 N-CA-C 105.993 -1.854 . . . . 64.04 105.993 179.822 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -128.49 139.91 52.09 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 109.586 -0.524 . . . . 72.23 109.586 -169.747 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.402 ' HB1' HG21 ' A' ' 99' ' ' VAL . . . -153.83 149.77 27.73 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 123.889 0.876 . . . . 70.41 110.313 -177.041 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 72.6 tt0 -127.75 135.29 49.93 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.536 1.134 . . . . 74.05 109.375 -174.829 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -140.84 142.41 28.04 Favored Pre-proline 0 N--CA 1.478 0.973 0 C-N-CA 122.785 0.434 . . . . 72.35 110.865 -175.149 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_exo -73.6 113.34 3.76 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 121.889 1.726 . . . . 73.42 109.851 166.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.451 HD22 HG11 ' A' ' 178' ' ' VAL . 17.9 tp -109.54 165.79 11.39 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.299 1.039 . . . . 70.25 108.932 179.401 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.592 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 8.6 m -95.39 156.6 16.25 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.23 0.612 . . . . 44.0 109.903 176.266 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.669 HD23 ' HB3' ' A' ' 180' ' ' LEU . 51.9 mt -56.7 -50.35 72.43 Favored 'General case' 0 N--CA 1.487 1.405 0 CA-C-O 122.21 1.005 . . . . 71.54 109.353 174.083 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.483 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -58.51 -38.07 76.93 Favored 'General case' 0 CA--C 1.546 0.813 0 CA-C-N 113.614 -1.63 . . . . 61.14 111.802 178.823 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.404 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 12.0 mm-40 -77.94 -23.25 48.61 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 122.844 0.458 . . . . 73.22 111.831 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.642 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -66.23 -32.0 73.16 Favored 'General case' 0 C--O 1.252 1.201 0 CA-C-O 121.712 0.768 . . . . 63.43 111.156 168.505 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.468 ' HA ' ' CE2' ' A' ' 240' ' ' PHE . 36.9 t80 -75.73 -47.92 24.03 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 114.746 -1.115 . . . . 73.31 111.892 172.798 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -75.23 -48.17 24.7 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 122.59 0.356 . . . . 71.34 111.626 -170.771 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 63.58 -130.14 40.03 Favored Glycine 0 CA--C 1.532 1.124 0 O-C-N 123.666 0.604 . . . . 42.23 111.861 -175.204 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 94.76 -172.94 31.67 Favored Glycine 0 C--N 1.35 1.332 0 N-CA-C 114.245 0.458 . . . . 35.51 114.245 171.712 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 7.6 mp0 -88.93 125.96 35.18 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.152 0.981 . . . . 53.12 109.965 -176.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' ARG . . . . . 0.459 ' HG3' HD13 ' A' ' 98' ' ' LEU . 33.3 mmt180 -137.78 168.49 19.57 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 124.883 1.273 . . . . 72.24 108.325 171.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.0 p -90.23 144.79 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 108.676 -0.861 . . . . 71.12 108.676 178.092 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 144' ' ' ARG . 7.8 p -134.23 138.2 50.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 123.249 0.62 . . . . 74.34 109.457 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -124.69 106.15 9.86 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 108.14 -1.059 . . . . 75.21 108.14 169.185 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.5 m -125.09 117.81 51.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 C-N-CA 124.461 1.105 . . . . 72.05 109.592 -178.692 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' ALA . . . . . 0.416 ' HB3' HD11 ' A' ' 119' ' ' LEU . . . 64.43 20.47 12.17 Favored 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 124.598 1.159 . . . . 73.23 111.771 179.579 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.69 -6.9 74.23 Favored Glycine 0 C--N 1.357 1.704 0 O-C-N 123.225 0.328 . . . . 73.02 113.478 -178.302 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 6.3 tpm_? -91.6 117.41 29.71 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 108.92 -0.77 . . . . 65.35 108.92 176.691 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.401 ' HA ' ' O ' ' A' ' 138' ' ' VAL . 52.5 ttp180 -99.66 122.07 42.14 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 123.583 0.753 . . . . 75.34 109.516 179.181 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 19.0 t -133.19 156.99 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 N-CA-C 108.3 -1.0 . . . . 74.54 108.3 176.148 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 24.3 p -85.35 113.71 21.87 Favored 'General case' 0 CA--C 1.547 0.838 0 N-CA-C 108.325 -0.991 . . . . 75.25 108.325 165.511 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.2 p -98.02 123.52 50.54 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 CA-C-O 121.641 0.734 . . . . 72.42 111.402 -176.259 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -97.94 104.77 16.83 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 107.76 -1.2 . . . . 74.23 107.76 167.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 38.7 pt -97.32 103.63 16.61 Favored Pre-proline 0 CA--C 1.55 0.967 0 N-CA-C 108.154 -1.054 . . . . 51.41 108.154 167.19 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -61.09 151.21 80.16 Favored 'Trans proline' 0 C--N 1.383 2.366 0 C-N-CA 122.613 2.209 . . . . 74.32 112.788 -178.116 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -49.28 151.37 6.62 Favored 'Trans proline' 0 C--N 1.378 2.081 0 C-N-CA 123.829 3.019 . . . . 71.54 114.153 176.499 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 108.73 23.36 6.55 Favored Glycine 0 N--CA 1.478 1.438 0 C-N-CA 121.465 -0.398 . . . . 51.51 113.238 174.409 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.642 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -99.65 162.84 2.95 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.192 0 N-CA-C 107.831 -1.174 . . . . 71.41 107.831 179.464 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.601 ' HA ' HD11 ' A' ' 180' ' ' LEU . 0.0 OUTLIER -158.87 177.69 10.88 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.618 1.167 . . . . 74.11 111.91 -172.02 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.3 tp10 -51.58 115.5 1.65 Allowed 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 124.76 1.224 . . . . 72.32 111.722 178.09 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 80.68 10.43 85.18 Favored Glycine 0 C--N 1.356 1.64 0 CA-C-N 115.775 -0.648 . . . . 54.34 113.591 177.652 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.4 t -85.77 123.76 31.51 Favored 'General case' 0 C--O 1.245 0.822 0 C-N-CA 123.097 0.559 . . . . 73.41 109.58 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 3.4 t -99.6 122.4 51.38 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 124.129 0.972 . . . . 72.21 108.659 -176.896 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.627 HD11 HG21 ' A' ' 153' ' ' VAL . 13.5 mt -103.11 119.68 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 124.046 0.938 . . . . 74.42 109.33 -169.883 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 34.3 ttt180 -97.43 103.67 15.63 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 122.693 0.397 . . . . 65.54 110.361 -177.115 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 12.1 m -102.39 118.91 57.75 Favored Pre-proline 0 CA--C 1.559 1.293 0 N-CA-C 109.451 -0.574 . . . . 53.13 109.451 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.47 152.25 43.36 Favored 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.635 2.224 . . . . 64.34 113.684 -173.32 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 79.74 24.48 60.19 Favored Glycine 0 C--N 1.349 1.267 0 N-CA-C 115.0 0.76 . . . . 61.52 115.0 168.147 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 39.6 mtt -105.18 -62.91 1.29 Allowed 'General case' 0 N--CA 1.488 1.465 0 CA-C-N 118.285 1.042 . . . . 74.22 112.093 176.061 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.349 1.294 0 CA-C-N 115.933 -0.576 . . . . 41.14 112.937 -177.295 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_exo . . . . . 0 CA--C 1.541 0.857 0 N-CA-C 110.966 -0.436 . . . . 74.3 110.966 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -101.78 153.3 18.74 Favored Glycine 0 CA--C 1.502 -0.773 0 N-CA-C 110.621 -0.992 . . . . 71.22 110.621 174.634 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -112.69 178.59 4.24 Favored 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 123.473 0.709 . . . . 74.41 111.511 -168.155 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.437 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 34.9 tp -130.16 112.92 13.86 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 114.579 -1.191 . . . . 74.1 108.615 168.419 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 72.9 mt -85.09 100.86 11.98 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.138 1.375 . . . . 44.25 111.238 177.118 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 70.7 mt -95.38 101.64 13.38 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 122.69 0.396 . . . . 55.04 110.666 174.41 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 2.5 p -87.03 108.65 18.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 N-CA-C 109.158 -0.682 . . . . 62.25 109.158 172.576 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.451 HG11 HD22 ' A' ' 125' ' ' LEU . 4.0 m -87.35 149.37 4.11 Favored 'Isoleucine or valine' 0 C--O 1.245 0.851 0 CA-C-N 115.946 -0.57 . . . . 74.12 110.665 -177.777 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 13.1 mmm-85 -124.97 101.31 6.99 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 107.491 -1.299 . . . . 64.13 107.491 -178.521 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 180' ' ' LEU . . . . . 0.669 ' HB3' HD23 ' A' ' 127' ' ' LEU . 25.3 mt -69.46 148.61 49.3 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 112.082 0.401 . . . . 61.31 112.082 -172.115 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.592 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 39.8 mt -57.5 138.25 81.57 Favored Pre-proline 0 CA--C 1.559 1.295 0 C-N-CA 123.283 0.633 . . . . 73.03 110.752 179.488 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.44 83.79 1.0 Allowed 'Trans proline' 0 C--N 1.374 1.875 0 C-N-CA 123.188 2.592 . . . . 63.11 112.584 -177.908 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -165.19 54.03 0.34 Allowed Pre-proline 0 CA--C 1.559 1.306 0 C-N-CA 124.12 0.968 . . . . 73.43 109.314 170.779 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.61 124.4 15.71 Favored 'Trans proline' 0 C--N 1.389 2.668 0 C-N-CA 122.627 2.218 . . . . 63.32 112.723 -169.358 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.4 p -130.84 -44.42 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 124.182 0.993 . . . . 75.41 109.561 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 186' ' ' PHE . . . . . 0.41 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 6.4 m-85 -105.01 120.29 41.11 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.218 0.532 . . . . 73.31 111.347 -176.048 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.705 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 23.5 mtp180 -104.17 162.7 12.95 Favored 'General case' 0 N--CA 1.467 0.425 0 C-N-CA 124.18 0.992 . . . . 75.42 109.337 173.833 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.418 HD12 ' O ' ' A' ' 192' ' ' ASP . 57.2 tp -132.42 127.53 35.56 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 123.493 0.717 . . . . 64.04 109.743 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -139.52 102.52 4.48 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 125.034 1.333 . . . . 73.2 108.122 176.637 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 56.59 58.41 14.53 Favored Glycine 0 C--N 1.353 1.479 0 O-C-N 123.951 0.782 . . . . 75.34 114.04 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 191' ' ' GLN . . . . . 0.568 ' NE2' ' HD2' ' A' ' 243' ' ' PRO . 52.6 mt-30 74.09 -15.81 0.57 Allowed 'General case' 0 N--CA 1.505 2.322 0 C-N-CA 125.407 1.483 . . . . 70.12 112.305 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.418 ' O ' HD12 ' A' ' 188' ' ' LEU . 9.7 t0 -97.41 152.44 18.95 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.333 1.053 . . . . 65.21 108.362 -175.358 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.4 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 78.4 mt -110.33 168.47 9.42 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 122.024 0.916 . . . . 61.54 111.512 -173.187 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 194' ' ' TYR . . . . . 0.705 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 35.6 m-85 -134.14 132.29 39.68 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 114.085 -1.416 . . . . 55.43 108.062 171.182 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 195' ' ' ALA . . . . . 0.436 ' HB3' HD11 ' A' ' 249' ' ' LEU . . . -154.02 168.28 26.95 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.909 0.884 . . . . 43.11 109.308 174.18 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 35.5 m -105.75 128.51 53.74 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 115.702 -0.681 . . . . 71.24 109.672 178.428 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.512 HD13 ' HB2' ' A' ' 212' ' ' ALA . 59.9 tp -107.76 113.65 27.05 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.733 -0.84 . . . . 75.23 108.733 173.382 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -94.9 119.82 34.08 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.373 -0.973 . . . . 72.43 108.373 175.496 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 199' ' ' VAL . . . . . 0.461 HG11 HG23 ' A' ' 253' ' ' VAL . 7.5 p -134.52 134.77 22.68 Favored Pre-proline 0 N--CA 1.479 1.018 0 C-N-CA 124.284 1.033 . . . . 64.42 109.37 -173.963 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.58 149.14 91.05 Favored 'Trans proline' 0 C--N 1.372 1.782 0 C-N-CA 122.715 2.277 . . . . 63.3 113.092 175.693 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 201' ' ' ALA . . . . . 0.492 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -60.75 -43.19 91.16 Favored Pre-proline 0 N--CA 1.478 0.972 0 N-CA-C 113.171 0.804 . . . . 75.53 113.171 176.445 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 202' ' ' PRO . . . . . 0.422 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 10.6 Cg_endo -53.73 -44.36 49.84 Favored 'Trans proline' 0 C--N 1.392 2.854 0 C-N-CA 121.759 1.639 . . . . 74.32 112.294 172.025 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.7 mt -67.44 -36.22 75.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 122.821 0.449 . . . . 73.53 111.189 177.618 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -64.57 -41.42 96.3 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 123.201 0.6 . . . . 73.22 111.802 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.7 m -79.89 -42.28 22.14 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 CA-C-N 116.003 -0.544 . . . . 72.34 111.362 -177.017 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 10.1 m -80.1 -20.02 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 122.471 0.308 . . . . 71.21 111.054 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 68.92 65.92 2.45 Favored Glycine 0 C--N 1.343 0.962 0 CA-C-N 115.687 -0.688 . . . . 51.43 112.461 -176.26 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.83 -145.92 15.4 Favored Glycine 0 C--N 1.357 1.7 0 N-CA-C 111.233 -0.747 . . . . 63.1 111.233 175.316 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 24.4 pttm -133.0 149.82 52.2 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 122.853 0.461 . . . . 71.51 109.88 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 2.8 m -145.09 134.37 18.04 Favored 'Isoleucine or valine' 0 C--O 1.239 0.528 0 N-CA-C 107.539 -1.282 . . . . 73.02 107.539 176.246 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 31.7 ptt180 -79.43 137.77 37.38 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 109.472 -0.566 . . . . 62.12 109.472 176.038 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.512 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -108.19 134.65 50.75 Favored 'General case' 0 C--O 1.245 0.845 0 C-N-CA 123.311 0.644 . . . . 74.45 109.408 174.218 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 4.8 tpt -75.85 106.26 7.33 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 108.837 -0.801 . . . . 74.22 108.837 173.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 214' ' ' THR . . . . . 0.41 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 11.2 t -110.68 165.85 11.49 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 109.703 -0.48 . . . . 64.31 109.703 174.553 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 215' ' ' LEU . . . . . 0.483 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 59.7 mt -69.69 -17.7 63.5 Favored 'General case' 0 CA--C 1.551 0.99 0 CA-C-N 115.686 -0.688 . . . . 61.02 111.162 178.348 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -79.21 -19.42 50.83 Favored 'General case' 0 CA--C 1.556 1.209 0 C-N-CA 123.934 0.894 . . . . 50.41 110.948 174.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 131.77 -148.53 19.06 Favored Glycine 0 C--N 1.346 1.088 0 N-CA-C 111.378 -0.689 . . . . 70.33 111.378 -176.079 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -85.86 126.85 2.99 Favored 'Trans proline' 0 CA--C 1.557 1.64 0 C-N-CA 122.376 2.05 . . . . 74.42 112.473 172.118 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 219' ' ' VAL . . . . . 0.525 HG11 ' HD2' ' A' ' 238' ' ' LYS . 34.9 m -111.56 155.47 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 N-CA-C 109.132 -0.692 . . . . 71.22 109.132 169.575 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -114.36 111.8 22.04 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.944 -0.761 . . . . 72.44 108.944 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.458 HG22 HD11 ' A' ' 235' ' ' LEU . 8.5 t -96.27 115.75 36.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.381 0 C-N-CA 123.593 0.757 . . . . 71.22 109.704 -178.594 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.59 101.28 13.97 Favored 'General case' 0 C--O 1.239 0.529 0 N-CA-C 106.673 -1.603 . . . . 54.23 106.673 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 19.0 m -75.21 141.47 74.13 Favored Pre-proline 0 CA--C 1.551 1.018 0 C-N-CA 122.546 0.338 . . . . 74.04 110.546 -173.319 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -60.07 133.27 49.15 Favored 'Trans proline' 0 C--N 1.378 2.092 0 C-N-CA 122.679 2.253 . . . . 42.24 111.828 176.776 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -56.0 124.57 16.58 Favored 'Trans proline' 0 C--N 1.377 2.077 0 C-N-CA 122.692 2.261 . . . . 71.41 110.92 173.31 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 60.58 51.98 4.8 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 124.593 1.157 . . . . 72.34 110.77 -173.271 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.2 t -78.61 165.77 23.3 Favored 'General case' 0 CA--C 1.544 0.741 0 N-CA-C 109.229 -0.656 . . . . 73.43 109.229 170.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 228' ' ' GLN . . . . . 0.43 ' H ' ' HD3' ' A' ' 231' ' ' ARG . 25.7 mp0 -119.51 147.32 44.58 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 108.707 -0.849 . . . . 72.15 108.707 -174.628 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.01 143.62 52.51 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.554 0.742 . . . . 74.12 110.844 178.778 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 89.46 0.04 80.03 Favored Glycine 0 C--N 1.343 0.966 0 O-C-N 123.442 0.464 . . . . 34.0 113.342 -179.065 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 231' ' ' ARG . . . . . 0.462 ' O ' HG12 ' A' ' 253' ' ' VAL . 80.8 mtp180 -80.26 163.48 23.95 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-N 117.455 0.627 . . . . 74.43 109.855 174.426 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.465 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.8 mptp? -112.97 107.31 15.81 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 108.69 -0.856 . . . . 75.34 108.69 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 56.9 mt -85.2 116.34 23.5 Favored 'General case' 0 C--N 1.355 0.824 0 N-CA-C 107.92 -1.141 . . . . 75.2 107.92 178.407 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 19.6 ttm-85 -95.79 114.76 26.53 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 124.097 0.959 . . . . 74.25 109.433 -164.229 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.458 HD11 HG22 ' A' ' 221' ' ' VAL . 25.0 mt -106.77 106.07 16.41 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.081 0.552 . . . . 73.3 109.698 176.573 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 236' ' ' LYS . . . . . 0.56 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 44.8 mttp -62.7 148.98 44.91 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 123.651 0.781 . . . . 55.24 111.718 176.539 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.51 35.44 81.41 Favored Glycine 0 C--N 1.355 1.636 0 O-C-N 123.971 0.794 . . . . 64.22 113.228 176.009 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 238' ' ' LYS . . . . . 0.525 ' HD2' HG11 ' A' ' 219' ' ' VAL . 15.9 mmtm -123.82 -23.08 4.75 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 123.774 0.83 . . . . 62.02 112.116 -176.159 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -81.38 -155.66 14.05 Favored Glycine 0 C--N 1.341 0.844 0 O-C-N 123.592 0.557 . . . . 74.04 112.68 178.203 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.468 ' CE2' ' HA ' ' A' ' 131' ' ' PHE . 75.3 m-85 -96.26 143.68 26.54 Favored Pre-proline 0 N--CA 1.474 0.754 0 O-C-N 122.346 -0.502 . . . . 71.03 111.802 178.186 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 241' ' ' PRO . . . . . 0.581 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 27.9 Cg_exo -62.22 168.21 9.71 Favored 'Trans proline' 0 C--N 1.378 2.095 0 C-N-CA 123.245 2.63 . . . . 72.13 112.868 176.684 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 163.22 -159.08 31.58 Favored Glycine 0 CA--C 1.534 1.226 0 CA-C-O 119.586 -0.564 . . . . 60.35 112.959 -177.791 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 243' ' ' PRO . . . . . 0.568 ' HD2' ' NE2' ' A' ' 191' ' ' GLN . 39.8 Cg_exo -60.44 -24.04 76.73 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 123.768 2.979 . . . . 74.24 113.363 177.601 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.44 18.56 7.08 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.668 0.787 . . . . 74.32 111.507 178.722 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.34 -98.84 1.79 Allowed Glycine 0 C--N 1.349 1.266 0 N-CA-C 110.746 -0.942 . . . . 64.14 110.746 -174.486 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.581 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 51.9 ttt180 -129.32 149.69 51.0 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.362 0.665 . . . . 75.53 109.845 166.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -75.31 -171.21 28.99 Favored Glycine 0 C--N 1.348 1.234 0 O-C-N 123.592 0.558 . . . . 50.23 112.882 176.387 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 248' ' ' ASP . . . . . 0.56 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 1.6 p-10 -145.16 169.56 17.93 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 123.89 0.876 . . . . 72.01 110.526 -174.307 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.436 HD11 ' HB3' ' A' ' 195' ' ' ALA . 22.9 tp -110.61 126.39 54.41 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 124.121 0.968 . . . . 72.24 112.095 -171.075 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 15.1 m-85 -88.84 107.06 18.78 Favored 'General case' 0 C--N 1.357 0.918 0 C-N-CA 123.7 0.8 . . . . 71.24 109.308 168.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.465 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 73.5 mt -88.57 121.93 31.48 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 123.783 0.833 . . . . 73.1 111.628 171.325 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -82.35 92.83 7.05 Favored 'General case' 0 C--O 1.235 0.313 0 N-CA-C 108.032 -1.099 . . . . 64.12 108.032 174.351 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.462 HG12 ' O ' ' A' ' 231' ' ' ARG . 2.4 p -58.61 114.29 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 C-N-CA 123.395 0.678 . . . . 45.14 110.484 177.586 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 21.3 mmm-85 -116.08 95.2 4.98 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 107.802 -1.184 . . . . 61.33 107.802 -177.759 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.492 HG23 ' HA ' ' A' ' 201' ' ' ALA . 75.2 mt -76.03 102.57 3.05 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 114.991 -1.004 . . . . 72.44 110.41 -174.839 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 CA--C 1.564 1.512 0 C-N-CA 124.337 1.055 . . . . 71.35 109.258 175.985 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.46 ' HA ' HD13 ' A' ' 123' ' ' LEU . 3.5 mm? . . . . . 0 CA--C 1.537 0.453 0 N-CA-C 107.402 -1.333 . . . . 74.22 107.402 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.446 HG13 ' H ' ' A' ' 101' ' ' HIS . 7.1 p -60.1 -27.94 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 C-N-CA 123.092 0.557 . . . . 74.1 111.391 -178.485 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . 64.86 35.85 8.21 Favored 'General case' 0 C--N 1.355 0.818 0 O-C-N 124.541 1.151 . . . . 74.23 110.905 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' HIS . . . . . 0.446 ' H ' HG13 ' A' ' 99' ' ' VAL . 66.5 t-80 -75.35 91.07 2.68 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 114.755 -1.112 . . . . 75.04 108.088 178.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 46.3 t -57.2 145.72 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 C-N-CA 124.582 1.153 . . . . 75.43 111.297 -173.391 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.5 t . . . . . 0 C--O 1.242 0.665 0 C-N-CA 123.172 0.589 . . . . 63.43 109.836 177.885 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 . . . . . 0 N--CA 1.474 0.751 0 CA-C-O 120.919 0.39 . . . . 64.0 110.158 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.542 HD12 ' HA2' ' A' ' 165' ' ' GLY . 11.6 mt -124.05 151.41 43.83 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 108.129 -1.063 . . . . 45.31 108.129 168.524 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' ARG . . . . . 0.515 ' HG2' ' HB2' ' A' ' 175' ' ' LEU . 17.3 mtp180 -142.6 151.01 41.07 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.571 0.748 . . . . 73.35 109.376 177.587 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.497 ' HB3' HD23 ' A' ' 176' ' ' LEU . . . -151.63 120.11 6.44 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 123.615 0.766 . . . . 54.31 109.412 177.003 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 37.8 mm-40 -84.05 143.18 29.91 Favored 'General case' 0 C--O 1.242 0.708 0 N-CA-C 109.111 -0.699 . . . . 73.34 109.111 175.58 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.46 HD13 ' HA ' ' A' ' 98' ' ' LEU . 0.7 OUTLIER -145.21 145.25 26.06 Favored Pre-proline 0 N--CA 1.475 0.781 0 C-N-CA 122.38 0.272 . . . . 74.2 110.923 174.707 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -81.64 114.51 2.69 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 121.864 1.709 . . . . 63.5 110.638 165.173 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 15.1 tp -106.79 138.8 42.29 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 123.863 0.865 . . . . 73.4 109.354 -178.71 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' THR . . . . . 0.751 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 20.8 m -78.78 158.76 28.15 Favored 'General case' 0 CA--C 1.548 0.901 0 N-CA-C 109.605 -0.517 . . . . 55.23 109.605 172.667 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.418 HD11 ' O ' ' A' ' 183' ' ' HIS . 31.6 mt -61.52 -47.11 87.09 Favored 'General case' 0 N--CA 1.483 1.177 0 CA-C-O 121.909 0.861 . . . . 61.34 110.004 178.287 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -56.81 -32.76 66.03 Favored 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 114.12 -1.4 . . . . 65.32 111.172 175.652 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.751 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 29.6 mm-40 -76.97 -32.08 57.0 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 122.977 0.511 . . . . 73.24 111.385 178.514 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' ALA . . . . . 0.533 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -55.6 -35.1 65.46 Favored 'General case' 0 C--O 1.245 0.824 0 C-N-CA 122.999 0.519 . . . . 63.0 111.564 167.326 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' PHE . . . . . 0.561 ' HA ' ' HE2' ' A' ' 240' ' ' PHE . 69.2 t80 -75.17 -47.62 27.55 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.447 -0.797 . . . . 72.51 112.877 171.306 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -68.95 -48.51 63.02 Favored 'General case' 0 N--CA 1.485 1.306 0 N-CA-C 112.115 0.413 . . . . 53.04 112.115 -170.092 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 57.52 -122.14 28.17 Favored Glycine 0 CA--C 1.534 1.272 0 O-C-N 123.869 0.731 . . . . 74.22 111.984 -172.874 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.27 -173.67 55.14 Favored Glycine 0 C--N 1.35 1.32 0 N-CA-C 114.358 0.503 . . . . 53.3 114.358 168.491 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' GLU . . . . . 0.532 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 1.3 mp0 -83.38 112.12 19.63 Favored 'General case' 0 C--N 1.356 0.856 0 N-CA-C 109.56 -0.533 . . . . 53.2 109.56 -178.552 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 10.3 mmm180 -123.07 156.47 34.84 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.291 1.036 . . . . 71.22 108.462 178.194 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.1 m -77.05 133.32 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 C-N-CA 122.46 0.304 . . . . 71.5 111.356 -176.718 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 144' ' ' ARG . 38.6 t -125.13 134.05 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.685 1.194 . . . . 73.21 108.798 172.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -125.67 97.17 5.05 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.058 0.943 . . . . 74.32 109.366 171.637 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 53.2 t -122.84 122.31 65.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 C-N-CA 123.548 0.739 . . . . 50.14 109.803 178.881 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.56 28.41 18.09 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 124.93 1.292 . . . . 60.21 112.381 175.558 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 98.37 -13.61 62.84 Favored Glycine 0 C--N 1.349 1.294 0 CA-C-N 116.107 -0.497 . . . . 53.2 113.594 178.086 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.98 118.0 30.35 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 117.508 0.654 . . . . 73.24 110.569 -179.716 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 138' ' ' VAL . 38.0 ttp180 -95.49 106.15 18.2 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 124.499 1.12 . . . . 61.33 108.41 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.9 t -128.33 131.21 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.19 0.996 . . . . 73.11 109.491 -179.197 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 70.0 m -72.25 115.19 11.2 Favored 'General case' 0 C--O 1.242 0.677 0 N-CA-C 108.635 -0.876 . . . . 34.02 108.635 170.699 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 7.1 p -96.81 143.67 11.93 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 123.044 0.538 . . . . 65.42 110.295 -178.637 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 31.2 ttm180 -107.89 100.26 9.64 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 107.585 -1.265 . . . . 72.13 107.585 171.762 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.409 ' HB ' HD13 ' A' ' 159' ' ' ILE . 27.7 pt -92.91 130.91 34.8 Favored Pre-proline 0 CA--C 1.548 0.881 0 N-CA-C 108.393 -0.966 . . . . 51.23 108.393 172.807 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -66.7 131.04 24.79 Favored 'Trans proline' 0 C--N 1.376 2.002 0 C-N-CA 122.617 2.211 . . . . 54.14 113.121 -172.164 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_exo -53.02 117.61 3.93 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.303 2.669 . . . . 75.3 111.824 167.037 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 124.46 54.26 0.18 Allowed Glycine 0 CA--C 1.506 -0.489 0 N-CA-C 110.758 -0.937 . . . . 71.42 110.758 -173.683 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.533 HG13 ' HA ' ' A' ' 130' ' ' ALA . 3.1 p -126.85 156.62 38.11 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.301 0 C-N-CA 123.456 0.703 . . . . 64.44 109.542 -175.483 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 55.4 mtp180 -138.26 176.09 9.0 Favored 'General case' 0 N--CA 1.491 1.599 0 C-N-CA 124.61 1.164 . . . . 74.53 111.284 -168.539 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -55.55 121.56 9.32 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 124.272 1.029 . . . . 74.33 111.04 171.367 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.14 7.86 84.8 Favored Glycine 0 C--N 1.348 1.204 0 O-C-N 123.589 0.556 . . . . 64.23 113.842 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 70.8 m -72.37 126.32 29.55 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 117.287 0.543 . . . . 61.25 109.818 176.684 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.461 HG12 HD22 ' A' ' 175' ' ' LEU . 32.7 t -100.47 123.03 53.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-N 114.045 -1.434 . . . . 64.31 108.265 -175.313 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.453 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 25.4 mt -110.57 118.6 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 123.414 0.686 . . . . 72.33 110.153 -172.452 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 33.2 ttm-85 -85.12 130.29 34.64 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.663 0.785 . . . . 72.12 110.619 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.621 HG22 ' HB3' ' A' ' 174' ' ' LEU . 4.2 m -124.49 125.96 25.52 Favored Pre-proline 0 CA--C 1.551 0.984 0 N-CA-C 108.691 -0.855 . . . . 64.33 108.691 166.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.34 147.17 28.81 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 122.614 2.209 . . . . 71.02 113.424 -173.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 70.62 24.89 76.52 Favored Glycine 0 C--N 1.351 1.415 0 CA-C-N 115.733 -0.667 . . . . 52.04 114.348 170.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 44.3 tpp -104.99 -37.64 6.89 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.152 0.581 . . . . 74.33 109.904 177.205 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 165' ' ' GLY . . . . . 0.542 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.347 1.167 0 CA-C-N 115.483 -0.781 . . . . 32.54 112.942 -177.801 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo . . . . . 0 CA--C 1.537 0.67 0 N-CA-C 110.425 -0.644 . . . . 63.23 110.425 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -95.5 172.66 30.4 Favored Glycine 0 C--O 1.237 0.338 0 N-CA-C 110.768 -0.933 . . . . 65.13 110.768 173.091 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -120.22 159.48 24.85 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 123.447 0.699 . . . . 71.55 110.689 -170.224 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 174' ' ' LEU . . . . . 0.621 ' HB3' HG22 ' A' ' 161' ' ' VAL . 43.1 tp -109.74 120.43 42.46 Favored 'General case' 0 C--O 1.242 0.698 0 N-CA-C 107.092 -1.447 . . . . 74.32 107.092 169.519 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 175' ' ' LEU . . . . . 0.515 ' HB2' ' HG2' ' A' ' 120' ' ' ARG . 52.5 mt -100.36 100.29 11.06 Favored 'General case' 0 C--O 1.241 0.616 0 O-C-N 124.495 1.122 . . . . 51.41 109.326 -178.003 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.497 HD23 ' HB3' ' A' ' 121' ' ' ALA . 26.7 mt -86.92 101.28 13.25 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 114.562 -1.199 . . . . 63.04 109.098 -179.394 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 23.1 t -93.47 105.98 17.46 Favored 'Isoleucine or valine' 0 C--O 1.244 0.812 0 N-CA-C 108.451 -0.944 . . . . 70.13 108.451 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.448 HG21 HG22 ' A' ' 153' ' ' VAL . 13.7 m -82.44 147.95 5.62 Favored 'Isoleucine or valine' 0 C--O 1.241 0.643 0 CA-C-N 115.593 -0.73 . . . . 73.15 110.271 -178.435 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 17.0 mmt180 -123.72 105.53 9.77 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 107.675 -1.231 . . . . 64.35 107.675 178.665 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 33.9 mt -67.22 148.81 51.27 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 117.725 0.239 . . . . 73.23 110.381 179.521 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 181' ' ' LEU . . . . . 0.544 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 29.5 mt -57.46 157.44 13.33 Favored Pre-proline 0 CA--C 1.556 1.179 0 C-N-CA 123.78 0.832 . . . . 74.2 112.486 -171.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -57.19 -12.79 10.83 Favored 'Trans proline' 0 C--N 1.386 2.524 0 C-N-CA 123.019 2.48 . . . . 43.42 113.336 174.136 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 183' ' ' HIS . . . . . 0.418 ' O ' HD11 ' A' ' 127' ' ' LEU . 28.3 t60 -99.09 101.12 11.52 Favored Pre-proline 0 CA--C 1.545 0.763 0 C-N-CA 124.364 1.066 . . . . 63.24 108.528 166.235 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -102.44 128.41 0.1 Allowed 'Trans proline' 0 CA--C 1.557 1.665 0 C-N-CA 123.387 2.725 . . . . 51.54 112.396 162.819 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.9 p -116.93 -44.82 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 N-CA-C 109.135 -0.691 . . . . 63.4 109.135 172.138 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -100.28 123.84 45.0 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.576 -0.738 . . . . 70.35 111.438 -177.054 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 187' ' ' ARG . . . . . 0.706 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 80.2 mtt180 -109.46 160.85 15.87 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-N 114.084 -1.416 . . . . 72.04 108.118 175.42 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 188' ' ' LEU . . . . . 0.559 HD13 ' HD1' ' A' ' 240' ' ' PHE . 51.7 tp -130.78 142.64 50.41 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 108.913 -0.773 . . . . 61.03 108.913 178.651 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -140.85 99.95 3.72 Favored 'General case' 0 C--O 1.242 0.697 0 N-CA-C 107.411 -1.329 . . . . 74.21 107.411 175.168 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 70.18 -78.64 0.42 Allowed Glycine 0 CA--C 1.531 1.047 0 O-C-N 123.881 0.738 . . . . 73.43 112.216 -175.325 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 38.8 tt0 -138.34 -14.38 1.31 Allowed 'General case' 0 CA--C 1.558 1.26 0 C-N-CA 123.866 0.867 . . . . 74.23 110.448 -176.503 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.503 ' O ' HD12 ' A' ' 188' ' ' LEU . 9.2 m-20 -86.16 153.86 21.75 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 124.177 0.991 . . . . 72.52 112.103 -178.771 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 193' ' ' LEU . . . . . 0.514 ' HG ' ' HA2' ' A' ' 239' ' ' GLY . 85.0 mt -107.35 160.76 15.38 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 124.264 1.026 . . . . 72.25 108.519 175.834 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 194' ' ' TYR . . . . . 0.706 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 64.7 m-85 -136.63 121.55 18.79 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.584 -1.265 . . . . 54.33 107.584 177.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -144.14 148.29 34.86 Favored 'General case' 0 C--O 1.239 0.542 0 O-C-N 124.308 1.005 . . . . 42.32 109.197 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 49.4 m -88.37 127.18 35.49 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.258 -0.883 . . . . 70.32 109.165 173.15 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 197' ' ' LEU . . . . . 0.497 HD22 HD13 ' A' ' 251' ' ' LEU . 66.3 tp -105.9 110.5 22.81 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 108.215 -1.031 . . . . 73.2 108.215 178.101 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -92.35 112.02 23.81 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 108.71 -0.848 . . . . 74.23 108.71 178.061 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 199' ' ' VAL . . . . . 0.428 HG21 HG21 ' A' ' 223' ' ' VAL . 2.8 p -119.51 127.22 26.56 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 124.023 0.929 . . . . 75.22 108.946 -177.424 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 200' ' ' PRO . . . . . 0.448 ' HD2' HD12 ' A' ' 203' ' ' ILE . 51.7 Cg_exo -56.65 142.28 91.03 Favored 'Trans proline' 0 C--N 1.376 2.02 0 C-N-CA 122.729 2.286 . . . . 73.24 111.786 174.285 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 201' ' ' ALA . . . . . 0.468 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -55.8 -42.48 96.31 Favored Pre-proline 0 CA--C 1.557 1.222 0 CA-C-O 118.252 -0.88 . . . . 74.31 112.478 176.627 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 202' ' ' PRO . . . . . 0.51 ' O ' HG22 ' A' ' 206' ' ' VAL . 63.3 Cg_exo -46.75 -55.35 3.9 Favored 'Trans proline' 0 C--N 1.394 2.967 0 C-N-CA 122.972 2.448 . . . . 75.02 114.005 167.022 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 203' ' ' ILE . . . . . 0.454 HG23 ' H ' ' A' ' 208' ' ' GLY . 21.1 mt -61.7 -41.7 91.48 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 122.907 0.483 . . . . 75.1 111.122 -179.503 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.36 -35.39 78.98 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 115.063 -0.971 . . . . 71.52 111.832 -175.564 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 205' ' ' VAL . . . . . 0.589 HG23 HG13 ' A' ' 206' ' ' VAL . 25.9 m -89.35 -55.52 6.21 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 N-CA-C 112.798 0.666 . . . . 71.42 112.798 178.909 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.589 HG13 HG23 ' A' ' 205' ' ' VAL . 18.4 m -95.13 -38.3 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 CA-C-N 118.337 0.517 . . . . 74.5 112.074 -171.504 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -91.17 -115.93 1.95 Allowed Glycine 0 C--N 1.34 0.765 0 CA-C-N 116.606 -0.27 . . . . 74.44 112.657 -164.499 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 208' ' ' GLY . . . . . 0.454 ' H ' HG23 ' A' ' 203' ' ' ILE . . . 142.36 14.31 0.37 Allowed Glycine 0 C--N 1.335 0.521 0 CA-C-O 119.655 -0.525 . . . . 72.52 113.732 177.841 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 209' ' ' LYS . . . . . 0.444 ' O ' HD13 ' A' ' 203' ' ' ILE . 15.4 tppt? -117.51 118.22 31.59 Favored 'General case' 0 C--N 1.349 0.553 0 CA-C-N 117.762 0.781 . . . . 70.44 109.453 -173.889 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 210' ' ' VAL . . . . . 0.426 HG23 ' HB ' ' A' ' 221' ' ' VAL . 2.9 m -145.34 146.21 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.831 0 N-CA-C 108.596 -0.89 . . . . 72.23 108.596 170.438 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 56.4 mtm-85 -107.16 124.31 49.52 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.648 -0.871 . . . . 70.05 108.648 174.253 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 212' ' ' ALA . . . . . 0.471 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -103.09 137.91 40.64 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.298 0.639 . . . . 33.1 109.559 178.185 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 44.1 mmm -82.98 119.91 25.04 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 122.37 0.268 . . . . 70.43 110.489 174.506 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 3.5 t -118.04 169.88 9.3 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.411 1.085 . . . . 71.2 109.816 171.026 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 83.1 mt -73.96 -10.48 59.68 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 123.735 0.814 . . . . 73.55 112.688 -172.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -93.87 -13.33 27.33 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.602 0.761 . . . . 62.33 111.366 175.041 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 140.16 -157.87 25.64 Favored Glycine 0 C--N 1.347 1.183 0 CA-C-O 119.521 -0.599 . . . . 35.34 111.611 -177.883 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -85.59 135.83 5.18 Favored 'Trans proline' 0 CA--C 1.551 1.343 0 C-N-CA 122.469 2.113 . . . . 62.31 112.244 172.673 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.9 m -113.08 159.92 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 123.38 0.672 . . . . 64.13 110.26 168.6 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -111.35 109.59 19.66 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 107.669 -1.234 . . . . 73.33 107.669 179.501 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.517 HG22 HD11 ' A' ' 235' ' ' LEU . 12.7 t -96.16 125.24 49.07 Favored 'Isoleucine or valine' 0 C--O 1.243 0.754 0 C-N-CA 123.535 0.734 . . . . 70.23 109.582 177.471 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -88.67 103.59 16.07 Favored 'General case' 0 C--O 1.24 0.598 0 N-CA-C 108.767 -0.827 . . . . 63.44 108.767 170.421 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.428 HG21 HG21 ' A' ' 199' ' ' VAL . 17.0 m -80.04 136.01 54.43 Favored Pre-proline 0 N--CA 1.477 0.887 0 N-CA-C 107.879 -1.156 . . . . 74.41 107.879 172.068 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -61.47 129.44 28.13 Favored 'Trans proline' 0 CA--C 1.555 1.543 0 C-N-CA 122.0 1.8 . . . . 74.44 111.83 176.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -52.02 128.42 26.87 Favored 'Trans proline' 0 C--N 1.372 1.791 0 C-N-CA 122.655 2.236 . . . . 74.42 111.993 172.051 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 17.5 mtp180 65.31 42.61 3.84 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 125.252 1.421 . . . . 73.31 111.949 -173.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 227' ' ' THR . . . . . 0.507 HG23 HD11 ' A' ' 255' ' ' ILE . 8.5 t -78.36 177.45 8.46 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.115 0.566 . . . . 62.23 110.462 174.584 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 24.5 mp0 -126.85 154.08 44.83 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 123.412 0.685 . . . . 64.32 109.371 -178.577 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -71.61 149.43 45.61 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.236 0.614 . . . . 72.45 110.572 176.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 88.25 -4.13 85.42 Favored Glycine 0 CA--C 1.527 0.807 0 CA-C-O 119.705 -0.497 . . . . 52.51 112.853 -178.672 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 83.3 mtp180 -77.88 162.34 26.92 Favored 'General case' 0 C--N 1.36 1.063 0 CA-C-O 121.224 0.535 . . . . 75.22 111.153 177.641 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 232' ' ' LYS . . . . . 0.497 ' HG2' ' CZ ' ' A' ' 250' ' ' TYR . 10.6 mptt -118.35 122.06 41.92 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.89 0.876 . . . . 73.5 110.311 -173.302 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 64.4 mt -110.54 117.33 33.24 Favored 'General case' 0 C--N 1.348 0.506 0 N-CA-C 107.784 -1.191 . . . . 74.31 107.784 173.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 44.1 ttp180 -112.78 111.44 22.22 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 109.29 -0.633 . . . . 63.5 109.29 -168.629 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.517 HD11 HG22 ' A' ' 221' ' ' VAL . 14.7 mt -96.8 120.84 37.89 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 123.581 0.752 . . . . 74.04 109.82 -174.212 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 51.1 mttp -71.14 147.04 48.78 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.256 0.622 . . . . 72.04 112.32 -177.514 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.73 15.81 69.28 Favored Glycine 0 C--N 1.352 1.453 0 O-C-N 124.054 0.846 . . . . 55.34 114.401 173.486 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 238' ' ' LYS . . . . . 0.442 ' HG3' ' HB2' ' A' ' 235' ' ' LEU . 1.3 mmpm? -101.35 -17.43 16.52 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 123.548 0.739 . . . . 74.35 111.708 -175.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 239' ' ' GLY . . . . . 0.514 ' HA2' ' HG ' ' A' ' 193' ' ' LEU . . . -74.97 -148.13 1.66 Allowed Glycine 0 C--N 1.346 1.084 0 O-C-N 123.847 0.717 . . . . 63.44 113.709 -176.679 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 240' ' ' PHE . . . . . 0.561 ' HE2' ' HA ' ' A' ' 131' ' ' PHE . 39.9 m-85 -97.32 155.53 37.26 Favored Pre-proline 0 N--CA 1.475 0.786 0 CA-C-O 119.158 -0.448 . . . . 70.21 111.576 174.557 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -55.12 146.92 56.65 Favored 'Trans proline' 0 C--N 1.385 2.466 0 C-N-CA 122.906 2.404 . . . . 64.4 112.751 179.495 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -178.98 -165.71 33.78 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.669 -0.696 . . . . 72.42 112.15 -178.88 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -58.05 -27.6 80.19 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.375 2.717 . . . . 65.22 114.49 -179.606 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.07 22.82 5.44 Favored 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 123.556 0.742 . . . . 44.22 111.718 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.13 -86.01 1.56 Allowed Glycine 0 C--N 1.348 1.218 0 N-CA-C 110.097 -1.201 . . . . 54.14 110.097 -174.865 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 246' ' ' ARG . . . . . 0.484 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 18.6 mtm180 -126.94 164.54 21.24 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 108.355 -0.98 . . . . 55.32 108.355 163.238 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -77.85 -153.87 6.5 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.541 -0.754 . . . . 55.51 113.71 -177.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -120.5 164.5 16.33 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.154 0.581 . . . . 62.51 110.262 -177.535 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 249' ' ' LEU . . . . . 0.5 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 15.8 tp -109.98 111.15 22.37 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.037 0.935 . . . . 61.24 108.913 168.293 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 250' ' ' TYR . . . . . 0.497 ' CZ ' ' HG2' ' A' ' 232' ' ' LYS . 17.9 t80 -90.68 104.57 17.14 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 107.914 -1.143 . . . . 75.31 107.914 178.528 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 251' ' ' LEU . . . . . 0.497 HD13 HD22 ' A' ' 197' ' ' LEU . 63.7 mt -89.19 148.8 23.43 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.292 1.037 . . . . 63.03 111.583 179.0 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -110.14 97.12 6.68 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 107.922 -1.14 . . . . 65.23 107.922 173.145 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 60.2 t -52.24 117.09 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 123.663 0.785 . . . . 62.22 110.104 174.531 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 12.8 mmm180 -124.73 93.12 3.81 Favored 'General case' 0 C--O 1.238 0.463 0 N-CA-C 107.708 -1.219 . . . . 73.22 107.708 178.6 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.507 HD11 HG23 ' A' ' 227' ' ' THR . 60.1 mt -75.64 104.82 4.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-N 115.103 -0.953 . . . . 73.44 109.267 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.554 1.116 0 C-N-CA 124.047 0.939 . . . . 75.03 109.728 -178.001 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.14 0 CA-C-O 120.452 0.167 . . . . 71.14 110.662 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.34 -63.97 1.29 Allowed 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.487 0.715 . . . . 30.52 110.639 -178.315 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.438 HD21 ' HG2' ' A' ' 136' ' ' ARG . 0.2 OUTLIER -103.84 -38.35 7.07 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.856 0.863 . . . . 73.22 111.093 -178.529 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.653 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 61.5 t -60.77 125.59 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 123.037 0.535 . . . . 45.4 111.057 175.749 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -71.36 -66.97 0.55 Allowed 'General case' 0 C--N 1.346 0.45 0 CA-C-N 115.544 -0.753 . . . . 71.34 109.763 177.501 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 20.4 p-80 178.19 177.36 0.42 Allowed 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 124.634 1.174 . . . . 72.04 109.724 -176.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 43.9 t -71.34 136.84 24.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.078 0 C-N-CA 123.497 0.719 . . . . 60.1 110.157 177.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.8 t -135.73 165.65 25.09 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.384 1.074 . . . . 74.22 109.448 178.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.2 t -115.55 138.34 51.15 Favored 'General case' 0 C--O 1.239 0.517 0 N-CA-C 108.417 -0.957 . . . . 73.41 108.417 175.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 63.61 48.37 78.24 Favored Glycine 0 C--N 1.35 1.359 0 N-CA-C 111.75 -0.54 . . . . 74.03 111.75 -174.088 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 32.0 p -60.28 -56.09 25.75 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.276 1.03 . . . . 61.4 111.913 -173.145 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 165.79 154.61 8.25 Favored Glycine 0 C--O 1.244 0.744 0 N-CA-C 111.088 -0.805 . . . . 51.31 111.088 179.087 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLY . . . . . 0.492 ' HA3' HG21 ' A' ' 158' ' ' VAL . . . 61.9 47.64 88.81 Favored Glycine 0 C--N 1.348 1.203 0 O-C-N 124.065 0.509 . . . . 43.45 112.989 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 69.5 m -71.99 87.44 1.04 Allowed 'General case' 0 CA--C 1.546 0.826 0 CA-C-O 121.502 0.667 . . . . 74.32 109.857 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 171.5 27.72 0.02 OUTLIER Glycine 0 C--N 1.336 0.561 0 CA-C-N 114.612 -1.176 . . . . 62.31 110.632 -178.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -105.47 107.13 2.76 Favored Glycine 0 C--N 1.354 1.557 0 N-CA-C 111.361 -0.696 . . . . 74.32 111.361 178.497 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 29.1 m -65.92 106.08 1.48 Allowed 'General case' 0 C--N 1.35 0.61 0 C-N-CA 123.562 0.745 . . . . 72.43 110.483 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -160.74 -135.19 1.78 Allowed Glycine 0 C--N 1.339 0.71 0 CA-C-N 116.081 -0.509 . . . . 73.31 111.845 -178.276 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.444 ' O ' ' HA2' ' A' ' 172' ' ' GLY . . . 71.22 -85.33 0.41 Allowed Glycine 0 C--N 1.336 0.557 0 CA-C-O 119.612 -0.549 . . . . 71.33 112.153 -177.806 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 79.0 p 47.6 40.39 11.57 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 125.129 1.372 . . . . 71.22 110.933 -174.174 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 158.53 -133.66 3.53 Favored Glycine 0 C--N 1.336 0.563 0 N-CA-C 109.333 -1.507 . . . . 52.42 109.333 -171.613 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -96.35 120.35 36.49 Favored 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 108.566 -0.901 . . . . 73.0 108.566 178.467 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.464 ' HB3' ' HE ' ' A' ' 120' ' ' ARG . 5.9 m-20 -79.39 121.19 24.84 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.545 -0.539 . . . . 71.1 109.545 174.21 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.499 HD12 ' HA2' ' A' ' 165' ' ' GLY . 12.3 mt -100.76 132.45 46.16 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 107.601 -1.259 . . . . 71.31 107.601 167.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.464 ' HE ' ' HB3' ' A' ' 118' ' ' ASP . 21.4 mmt85 -127.84 133.49 49.38 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 107.851 -1.166 . . . . 72.44 107.851 -177.255 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -154.01 145.3 22.97 Favored 'General case' 0 N--CA 1.47 0.552 0 O-C-N 123.441 0.463 . . . . 50.25 109.756 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.672 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 41.3 mt-10 -112.09 148.36 34.1 Favored 'General case' 0 C--O 1.246 0.885 0 C-N-CA 123.59 0.756 . . . . 75.43 109.721 174.557 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.653 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.7 pt? -145.88 130.04 8.68 Favored Pre-proline 0 C--O 1.222 -0.376 0 CA-C-N 115.443 -0.799 . . . . 61.21 111.065 -176.735 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.18 117.49 4.28 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 121.819 1.679 . . . . 74.21 110.152 163.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.472 ' HB3' HD23 ' A' ' 180' ' ' LEU . 21.3 tp -110.59 139.8 45.5 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 123.624 0.77 . . . . 63.22 109.237 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.613 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 4.7 m -76.63 149.33 36.54 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 109.015 -0.735 . . . . 74.05 109.015 170.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.403 HD11 ' O ' ' A' ' 183' ' ' HIS . 44.4 mt -57.06 -44.58 83.18 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 122.267 1.032 . . . . 64.2 109.868 177.271 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -57.26 -37.7 72.75 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 113.383 -1.735 . . . . 63.52 111.439 176.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.613 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 42.1 mm-40 -77.58 -27.36 51.36 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 122.644 0.378 . . . . 74.24 111.758 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.503 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -58.75 -36.32 74.16 Favored 'General case' 0 C--O 1.243 0.741 0 C-N-CA 123.203 0.601 . . . . 64.43 111.446 167.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.415 ' CZ ' ' HB3' ' A' ' 216' ' ' GLU . 70.9 t80 -74.0 -51.84 14.67 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.151 -0.931 . . . . 73.44 112.427 171.15 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 34.3 m80 -63.83 -49.15 73.96 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 123.358 0.411 . . . . 73.55 112.04 -167.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 48.44 52.76 18.25 Favored Glycine 0 CA--C 1.534 1.28 0 O-C-N 124.118 0.886 . . . . 51.34 114.125 178.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -102.67 -168.61 26.45 Favored Glycine 0 C--N 1.347 1.139 0 CA-C-O 120.044 -0.309 . . . . 64.22 112.481 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.425 ' HB3' ' OG ' ' A' ' 146' ' ' SER . 2.1 mp0 -77.36 113.97 15.69 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 109.556 -0.535 . . . . 64.41 109.556 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.438 ' HG2' HD21 ' A' ' 98' ' ' LEU . 2.4 mpt_? -124.36 150.61 45.33 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 124.106 0.963 . . . . 60.12 108.681 173.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.8 p -76.35 129.74 36.89 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.093 0 CA-C-O 121.256 0.551 . . . . 72.42 111.266 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.527 HG21 HD21 ' A' ' 174' ' ' LEU . 7.9 p -111.27 141.0 27.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 C-N-CA 124.66 1.184 . . . . 71.43 108.81 170.577 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -125.72 100.68 6.53 Favored 'General case' 0 C--O 1.238 0.498 0 N-CA-C 107.819 -1.178 . . . . 74.22 107.819 178.15 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.7 m -123.84 108.03 19.97 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 C-N-CA 124.288 1.035 . . . . 41.45 110.436 -175.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 66.19 25.29 10.68 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 124.633 1.173 . . . . 55.24 111.766 179.488 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.83 4.96 78.41 Favored Glycine 0 C--N 1.353 1.482 0 CA-C-N 116.035 -0.53 . . . . 65.35 112.909 -176.366 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 30.9 tpt180 -94.02 115.41 27.74 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 108.687 -0.857 . . . . 71.4 108.687 177.158 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 75.3 ttt180 -97.74 115.58 28.28 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.729 -0.841 . . . . 71.23 108.729 177.165 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.432 HG11 ' SD ' ' A' ' 164' ' ' MET . 16.1 t -130.51 154.59 40.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 108.059 -1.089 . . . . 74.35 108.059 173.748 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.425 ' OG ' ' HB3' ' A' ' 135' ' ' GLU . 48.3 t -92.19 109.0 20.36 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.289 -1.004 . . . . 55.44 108.289 171.487 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 9.9 p -97.77 129.6 47.71 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 C-N-CA 123.702 0.801 . . . . 73.43 109.743 -178.613 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 29.1 ttt180 -107.96 97.47 7.17 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 107.719 -1.215 . . . . 72.41 107.719 173.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.555 ' HB ' HD13 ' A' ' 159' ' ' ILE . 26.1 pt -78.51 141.4 60.82 Favored Pre-proline 0 CA--C 1.552 1.053 0 N-CA-C 109.286 -0.635 . . . . 70.01 109.286 177.258 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -70.06 134.19 26.76 Favored 'Trans proline' 0 C--N 1.372 1.78 0 C-N-CA 122.299 1.999 . . . . 74.23 112.526 -173.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -54.31 138.85 73.38 Favored 'Trans proline' 0 C--N 1.371 1.752 0 C-N-CA 123.121 2.547 . . . . 73.13 112.02 168.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 105.78 36.93 2.67 Favored Glycine 0 N--CA 1.463 0.493 0 N-CA-C 111.589 -0.604 . . . . 52.35 111.589 -173.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.608 HG21 HD11 ' A' ' 159' ' ' ILE . 2.4 p -112.71 155.93 13.83 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.251 0 N-CA-C 109.099 -0.704 . . . . 62.35 109.099 -177.194 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.431 ' HD2' ' O ' ' A' ' 188' ' ' LEU . 38.7 mtp180 -142.38 173.16 11.78 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 125.177 1.391 . . . . 73.03 110.742 -168.46 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.4 tp10 -58.39 121.1 10.02 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 123.758 0.823 . . . . 74.41 110.997 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.25 7.68 88.13 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-N 116.252 -0.431 . . . . 33.31 113.48 -178.209 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.436 ' HB3' HG23 ' A' ' 153' ' ' VAL . 38.6 t -77.8 125.55 29.51 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 109.45 -0.574 . . . . 74.01 109.45 179.134 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.542 HG12 HD22 ' A' ' 175' ' ' LEU . 8.5 t -98.5 120.26 47.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-N 114.609 -1.178 . . . . 72.12 108.75 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.608 HD11 HG21 ' A' ' 153' ' ' VAL . 49.1 mt -107.21 120.43 58.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.92 0.888 . . . . 71.43 111.136 -172.508 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 25.8 ttm180 -92.58 114.13 26.6 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 123.2 0.6 . . . . 73.11 111.068 177.475 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -113.46 96.07 38.55 Favored Pre-proline 0 CA--C 1.559 1.313 0 N-CA-C 109.279 -0.637 . . . . 73.52 109.279 173.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -62.24 148.66 92.84 Favored 'Trans proline' 0 C--N 1.388 2.609 0 C-N-CA 123.646 2.898 . . . . 74.13 113.588 -177.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 85.5 -12.85 57.88 Favored Glycine 0 C--N 1.349 1.272 0 O-C-N 123.813 0.696 . . . . 75.23 113.34 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.432 ' SD ' HG11 ' A' ' 145' ' ' VAL . 36.4 mmm -92.33 -28.58 16.85 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.411 1.084 . . . . 62.34 111.912 -170.747 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' GLY . . . . . 0.499 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . -82.64 -94.76 0.55 Allowed Glycine 0 C--N 1.344 1.025 0 N-CA-C 111.158 -0.777 . . . . 61.24 111.158 176.276 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.529 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -59.12 98.63 0.11 Allowed Glycine 0 C--N 1.345 1.042 0 C-N-CA 123.625 0.631 . . . . 45.22 112.894 172.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.7 mm-40 -75.97 104.93 6.74 Favored 'General case' 0 C--O 1.241 0.649 0 C-N-CA 124.296 1.038 . . . . 62.32 108.645 177.087 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 164.57 -163.18 36.05 Favored Glycine 0 C--N 1.338 0.65 0 O-C-N 123.314 0.384 . . . . 64.1 112.335 -179.263 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.446 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 60.8 t30 -74.76 -46.27 5.24 Favored Pre-proline 0 CA--C 1.558 1.274 0 CA-C-O 118.2 -0.905 . . . . 74.44 111.261 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.446 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 16.4 Cg_exo -70.39 106.23 1.74 Allowed 'Trans proline' 0 C--N 1.39 2.742 0 C-N-CA 121.527 1.485 . . . . 74.2 109.849 167.438 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.28 123.02 9.54 Favored 'Trans proline' 0 C--N 1.375 1.927 0 C-N-CA 121.985 1.79 . . . . 75.03 111.307 -171.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.529 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -105.34 152.18 17.22 Favored Glycine 0 CA--C 1.504 -0.652 0 N-CA-C 109.806 -1.317 . . . . 64.33 109.806 171.516 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -112.96 168.81 9.39 Favored 'General case' 0 C--O 1.241 0.628 0 CA-C-O 121.503 0.668 . . . . 71.51 110.488 -173.233 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.527 HD21 HG21 ' A' ' 138' ' ' VAL . 12.4 tp -118.62 115.39 24.44 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 107.722 -1.214 . . . . 73.12 107.722 175.696 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.542 HD22 HG12 ' A' ' 158' ' ' VAL . 53.6 mt -88.38 100.22 12.86 Favored 'General case' 0 C--O 1.241 0.653 0 O-C-N 123.958 0.786 . . . . 74.43 110.305 177.123 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 81.5 mt -88.29 102.99 15.39 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.013 -0.994 . . . . 71.12 110.57 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.672 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 48.2 t -86.66 104.81 14.28 Favored 'Isoleucine or valine' 0 C--O 1.241 0.605 0 N-CA-C 108.307 -0.998 . . . . 52.34 108.307 173.564 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.469 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 9.6 m -82.04 150.82 4.33 Favored 'Isoleucine or valine' 0 C--O 1.245 0.821 0 CA-C-O 121.325 0.583 . . . . 64.11 110.838 -177.553 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 24.0 mmm-85 -126.99 97.11 4.83 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.242 -1.392 . . . . 72.35 107.242 -175.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.472 HD23 ' HB3' ' A' ' 125' ' ' LEU . 46.1 mt -66.4 147.09 53.8 Favored 'General case' 0 C--O 1.242 0.683 0 CA-C-O 120.536 0.208 . . . . 61.42 110.656 -176.449 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.411 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 37.6 mt -54.8 152.19 13.72 Favored Pre-proline 0 CA--C 1.556 1.19 0 O-C-N 124.09 0.869 . . . . 73.45 111.829 -173.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -58.29 -8.7 5.43 Favored 'Trans proline' 0 C--N 1.383 2.376 0 C-N-CA 123.377 2.718 . . . . 64.11 113.363 172.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' HIS . . . . . 0.403 ' O ' HD11 ' A' ' 127' ' ' LEU . 6.3 t60 -93.59 107.97 30.65 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 124.79 1.236 . . . . 72.24 108.614 168.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -99.52 163.69 0.55 Allowed 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 123.314 2.676 . . . . 71.44 112.427 165.022 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -156.64 -45.67 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 N-CA-C 109.02 -0.733 . . . . 61.41 109.02 168.604 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.462 ' CE2' HD13 ' A' ' 193' ' ' LEU . 5.6 m-85 -100.66 122.54 43.49 Favored 'General case' 0 C--O 1.238 0.454 0 C-N-CA 123.585 0.754 . . . . 72.42 110.699 -177.388 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 12.0 mtp180 -99.75 108.72 21.11 Favored 'General case' 0 C--O 1.237 0.441 0 C-N-CA 124.612 1.165 . . . . 72.41 108.624 170.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.431 ' O ' ' HD2' ' A' ' 154' ' ' ARG . 60.2 tp -84.54 110.67 18.87 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.932 -0.766 . . . . 73.35 108.932 170.725 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 24.0 mm-40 -104.11 97.05 7.07 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 107.325 -1.361 . . . . 62.22 107.325 172.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 67.64 -89.06 0.18 Allowed Glycine 0 CA--C 1.531 1.044 0 O-C-N 123.757 0.66 . . . . 71.5 112.807 -175.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 191' ' ' GLN . . . . . 0.405 HE22 ' HB3' ' A' ' 244' ' ' ALA . 50.3 tt0 -120.74 -18.12 7.78 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 125.103 1.361 . . . . 73.03 109.779 -176.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.422 ' O ' HD12 ' A' ' 188' ' ' LEU . 44.5 m-20 -96.07 160.04 14.65 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.382 1.073 . . . . 74.55 111.383 -173.529 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.585 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 96.3 mt -119.21 154.97 32.54 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.202 1.001 . . . . 63.43 112.298 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 74.0 m-85 -139.0 120.72 15.28 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 106.248 -1.76 . . . . 73.44 106.248 170.2 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 195' ' ' ALA . . . . . 0.465 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -141.7 140.06 33.07 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 108.178 -1.045 . . . . 64.43 108.178 176.667 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 19.1 m -77.15 129.98 36.71 Favored 'General case' 0 CA--C 1.539 0.548 0 O-C-N 123.347 0.405 . . . . 65.15 110.323 -175.682 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.422 HD13 ' HB2' ' A' ' 212' ' ' ALA . 51.2 tp -114.42 111.79 21.99 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 123.951 0.9 . . . . 73.12 108.785 176.694 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -101.64 107.73 19.06 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.127 -0.694 . . . . 72.12 109.127 178.258 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 199' ' ' VAL . . . . . 0.521 HG11 HG11 ' A' ' 223' ' ' VAL . 5.9 m -108.52 145.69 32.1 Favored Pre-proline 0 N--CA 1.478 0.963 0 C-N-CA 123.755 0.822 . . . . 43.12 109.472 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -70.83 149.67 60.45 Favored 'Trans proline' 0 C--N 1.366 1.481 0 C-N-CA 121.699 1.599 . . . . 73.03 110.664 173.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 201' ' ' ALA . . . . . 0.422 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -56.11 -43.53 99.29 Favored Pre-proline 0 CA--C 1.561 1.389 0 CA-C-O 118.374 -0.822 . . . . 71.32 113.112 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -46.21 -51.51 8.52 Favored 'Trans proline' 0 C--N 1.394 2.952 0 C-N-CA 122.921 2.414 . . . . 73.42 114.274 169.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 5.7 mt -69.15 -38.57 78.21 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 C-N-CA 122.335 0.254 . . . . 74.14 111.117 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.18 -41.55 88.75 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.239 0.616 . . . . 73.0 112.234 -179.193 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 205' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 33.1 m -82.84 -38.64 15.0 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 CA-C-N 115.891 -0.595 . . . . 71.12 111.53 -174.665 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.6 m -77.0 -24.79 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 CA-C-O 120.82 0.343 . . . . 73.3 110.849 177.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 76.68 52.84 5.71 Favored Glycine 0 C--N 1.346 1.112 0 CA-C-N 115.376 -0.829 . . . . 70.22 112.366 -175.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.42 -160.35 27.51 Favored Glycine 0 C--N 1.359 1.817 0 N-CA-C 112.123 -0.391 . . . . 54.31 112.123 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 21.2 ptmt -119.91 142.9 48.28 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 123.023 0.529 . . . . 72.34 109.727 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 210' ' ' VAL . . . . . 0.403 HG21 HG12 ' A' ' 199' ' ' VAL . 75.6 t -128.7 135.11 63.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 C-N-CA 124.351 1.06 . . . . 71.32 108.631 177.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 211' ' ' ARG . . . . . 0.607 ' HG2' ' HG2' ' A' ' 220' ' ' GLU . 99.3 mtt180 -77.95 112.56 14.97 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 109.198 -0.668 . . . . 75.55 109.198 171.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.422 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -99.14 129.27 45.38 Favored 'General case' 0 C--O 1.242 0.686 0 N-CA-C 108.436 -0.949 . . . . 64.4 108.436 175.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 213' ' ' MET . . . . . 0.413 ' SD ' ' N ' ' A' ' 214' ' ' THR . 1.3 tpp -69.72 130.29 41.93 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.837 -0.62 . . . . 63.03 109.79 175.054 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.497 HG21 HG13 ' A' ' 219' ' ' VAL . 7.7 t -134.07 163.67 29.06 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.507 1.123 . . . . 75.43 110.142 173.719 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 79.4 mt -71.68 -8.87 56.79 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 124.004 0.922 . . . . 72.35 113.183 -172.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 216' ' ' GLU . . . . . 0.415 ' HB3' ' CZ ' ' A' ' 131' ' ' PHE . 10.3 pt-20 -97.39 -18.34 19.16 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.433 0.693 . . . . 71.11 111.767 173.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.74 -146.36 15.74 Favored Glycine 0 C--N 1.349 1.253 0 CA-C-O 119.556 -0.58 . . . . 53.4 112.181 -176.283 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -91.17 131.15 1.42 Allowed 'Trans proline' 0 CA--C 1.559 1.736 0 C-N-CA 122.796 2.331 . . . . 72.3 112.777 170.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 219' ' ' VAL . . . . . 0.497 HG13 HG21 ' A' ' 214' ' ' THR . 20.5 m -110.13 147.25 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 108.996 -0.742 . . . . 72.44 108.996 163.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 220' ' ' GLU . . . . . 0.607 ' HG2' ' HG2' ' A' ' 211' ' ' ARG . 42.8 mt-10 -114.37 104.33 11.96 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 108.781 -0.822 . . . . 73.12 108.781 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.42 HG23 HD21 ' A' ' 235' ' ' LEU . 2.8 p -95.68 120.25 44.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 124.033 0.933 . . . . 74.44 110.373 -177.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.12 103.57 12.65 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 107.689 -1.226 . . . . 42.22 107.689 173.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.521 HG11 HG11 ' A' ' 199' ' ' VAL . 14.6 m -65.96 143.89 98.61 Favored Pre-proline 0 CA--C 1.553 1.059 0 C-N-CA 123.229 0.612 . . . . 74.13 110.168 -179.014 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -55.58 138.79 81.71 Favored 'Trans proline' 0 C--N 1.376 1.994 0 C-N-CA 122.625 2.216 . . . . 52.41 112.209 176.222 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.11 122.34 11.42 Favored 'Trans proline' 0 C--N 1.369 1.624 0 C-N-CA 122.181 1.921 . . . . 63.1 110.129 172.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 226' ' ' ARG . . . . . 0.479 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 96.0 mtt180 63.39 41.25 7.77 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 124.418 1.074 . . . . 71.23 110.996 -175.591 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.4 t -65.15 168.89 6.13 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 122.858 0.463 . . . . 51.23 111.009 177.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 228' ' ' GLN . . . . . 0.466 ' H ' ' HD3' ' A' ' 231' ' ' ARG . 26.2 mp0 -118.09 146.72 43.92 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 123.889 0.876 . . . . 74.41 109.165 -176.15 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -75.02 135.91 41.25 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.745 -0.835 . . . . 41.32 108.745 173.295 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 106.11 -7.91 41.36 Favored Glycine 0 C--N 1.34 0.762 0 N-CA-C 112.153 -0.379 . . . . 75.34 112.153 -175.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 231' ' ' ARG . . . . . 0.466 ' HD3' ' H ' ' A' ' 228' ' ' GLN . 62.0 mtp180 -79.92 160.99 25.79 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.284 0.634 . . . . 75.12 111.079 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.464 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 10.5 mptt -119.05 112.91 20.15 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 124.065 0.946 . . . . 62.44 108.503 176.824 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 233' ' ' LEU . . . . . 0.497 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 39.6 mt -89.69 110.08 21.0 Favored 'General case' 0 C--N 1.358 0.958 0 N-CA-C 108.868 -0.79 . . . . 72.35 108.868 -178.39 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 234' ' ' ARG . . . . . 0.407 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 41.4 ttp180 -83.81 102.51 12.38 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 114.923 -1.035 . . . . 64.52 111.046 -169.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.42 HD21 HG23 ' A' ' 221' ' ' VAL . 26.5 mt -95.74 98.01 10.13 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 108.513 -0.921 . . . . 74.31 108.513 174.171 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 236' ' ' LYS . . . . . 0.436 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 26.7 mtpp -80.79 143.87 32.53 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.96 0.41 . . . . 71.14 111.316 -174.403 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 75.94 24.12 70.21 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.148 -0.933 . . . . 74.24 111.809 -174.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 48.4 mmtm -128.94 10.25 5.91 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.366 1.066 . . . . 74.2 110.442 177.537 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -84.67 -158.21 28.34 Favored Glycine 0 C--N 1.359 1.838 0 O-C-N 123.13 0.269 . . . . 44.14 113.052 175.623 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.543 ' CD1' HD21 ' A' ' 193' ' ' LEU . 10.5 m-85 -98.02 166.14 14.02 Favored Pre-proline 0 N--CA 1.48 1.044 0 C-N-CA 123.131 0.573 . . . . 63.51 110.565 172.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -61.01 160.45 25.82 Favored 'Trans proline' 0 C--N 1.384 2.409 0 C-N-CA 122.829 2.353 . . . . 71.35 112.113 172.201 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 175.76 -171.21 44.29 Favored Glycine 0 CA--C 1.527 0.791 0 CA-C-N 116.147 -0.479 . . . . 73.32 113.515 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -57.31 -38.73 93.92 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.975 3.116 . . . . 60.05 113.29 -179.155 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 244' ' ' ALA . . . . . 0.405 ' HB3' HE22 ' A' ' 191' ' ' GLN . . . -92.33 21.84 4.94 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 123.389 0.676 . . . . 71.32 111.937 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 91.66 -102.66 2.95 Favored Glycine 0 C--N 1.347 1.194 0 N-CA-C 111.746 -0.541 . . . . 45.41 111.746 178.157 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 51.6 ttt180 -121.52 140.02 52.74 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 122.933 0.493 . . . . 73.12 109.675 174.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -81.06 -157.2 16.4 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 124.014 0.821 . . . . 71.33 113.076 -179.039 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 248' ' ' ASP . . . . . 0.436 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 3.5 p30 -146.62 154.25 41.27 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 123.032 0.533 . . . . 71.41 110.722 -174.604 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.585 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 26.2 tp -98.58 128.27 44.83 Favored 'General case' 0 C--O 1.22 -0.468 0 C-N-CA 124.338 1.055 . . . . 62.5 110.384 -174.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 250' ' ' TYR . . . . . 0.464 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 63.1 m-85 -102.63 107.43 18.34 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 123.57 0.748 . . . . 73.22 109.505 173.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.497 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 77.2 mt -87.07 111.11 20.58 Favored 'General case' 0 C--O 1.233 0.233 0 C-N-CA 123.701 0.8 . . . . 74.34 112.52 178.786 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.41 ' HG2' ' HE3' ' A' ' 232' ' ' LYS . 1.6 tm-20 -80.42 90.37 5.63 Favored 'General case' 0 CA--C 1.552 1.025 0 N-CA-C 108.457 -0.942 . . . . 73.54 108.457 -176.546 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.407 ' O ' ' HD2' ' A' ' 254' ' ' ARG . 46.0 t -53.29 128.34 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 125.991 1.716 . . . . 74.15 112.882 -177.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 254' ' ' ARG . . . . . 0.407 ' HD2' ' O ' ' A' ' 253' ' ' VAL . 23.5 mmm180 -126.8 98.57 5.41 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 107.255 -1.387 . . . . 74.22 107.255 173.826 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.422 HG23 ' HA ' ' A' ' 201' ' ' ALA . 63.6 mt -76.53 102.43 3.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 108.861 -0.792 . . . . 74.12 108.861 177.161 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 8.9 t . . . . . 0 C--O 1.253 1.263 0 C-N-CA 124.357 1.063 . . . . 55.31 110.173 -171.424 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.822 0 N-CA-C 109.421 -0.585 . . . . 41.23 109.421 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.74 -54.38 11.98 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 123.537 0.735 . . . . 62.31 111.175 -175.587 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.605 HD21 ' HG3' ' A' ' 136' ' ' ARG . 0.2 OUTLIER -139.79 -49.91 0.48 Allowed 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 115.782 -0.645 . . . . 71.44 110.913 -177.991 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.646 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 43.9 t -58.04 119.82 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 C-N-CA 122.988 0.515 . . . . 42.13 111.238 177.576 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -67.22 -71.4 0.2 Allowed 'General case' 0 C--O 1.238 0.485 0 O-C-N 124.275 0.984 . . . . 72.2 109.31 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.0 m80 -168.0 176.12 6.33 Favored 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 124.665 1.186 . . . . 72.33 109.757 -178.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 99.5 t -61.38 136.51 24.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.025 0 C-N-CA 124.094 0.958 . . . . 73.22 110.47 171.773 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 42.6 p -68.11 110.79 4.13 Favored 'General case' 0 CA--C 1.551 0.992 0 N-CA-C 109.122 -0.696 . . . . 75.1 109.122 170.231 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 13.7 p -65.55 116.6 6.97 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.83 0.852 . . . . 75.1 110.046 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 87.76 40.48 6.71 Favored Glycine 0 C--N 1.345 1.043 0 N-CA-C 110.955 -0.858 . . . . 70.3 110.955 -169.424 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 25.9 p -62.35 111.57 2.06 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 124.063 0.945 . . . . 74.02 111.321 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -146.94 -170.3 15.19 Favored Glycine 0 C--N 1.345 1.061 0 CA-C-N 116.338 -0.392 . . . . 70.05 112.855 -176.073 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 131.61 -61.4 0.66 Allowed Glycine 0 C--N 1.346 1.113 0 N-CA-C 111.591 -0.604 . . . . 33.03 111.591 178.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 25.8 t -168.88 -175.21 2.3 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 124.187 0.995 . . . . 70.31 109.196 -175.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -77.77 161.94 50.04 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.833 -0.507 . . . . 61.53 111.833 172.473 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -115.97 -63.6 0.36 Allowed Glycine 0 N--CA 1.473 1.159 0 N-CA-C 111.745 -0.542 . . . . 73.12 111.745 178.509 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 23.7 t -70.79 -175.46 1.1 Allowed 'General case' 0 CA--C 1.558 1.269 0 C-N-CA 123.726 0.811 . . . . 75.23 110.866 178.383 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -57.84 -38.68 89.54 Favored Glycine 0 C--N 1.355 1.621 0 N-CA-C 113.853 0.301 . . . . 75.31 113.853 -177.424 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 174.25 -57.49 0.13 Allowed Glycine 0 C--N 1.34 0.798 0 N-CA-C 110.457 -1.057 . . . . 72.24 110.457 178.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 16.6 p -83.14 137.35 34.11 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 123.911 0.884 . . . . 71.1 110.152 174.571 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 96.07 129.64 6.07 Favored Glycine 0 C--N 1.345 1.073 0 N-CA-C 110.559 -1.017 . . . . 63.11 110.559 -174.101 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.3 ptp180 -72.72 145.31 47.23 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 117.161 0.481 . . . . 74.31 111.057 -173.464 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -87.51 149.96 24.05 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 108.686 -0.857 . . . . 53.43 108.686 165.462 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.491 HD21 ' HB ' ' A' ' 140' ' ' VAL . 44.5 tp -128.79 134.98 48.56 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 107.759 -1.2 . . . . 72.33 107.759 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.425 ' HD3' ' HB2' ' A' ' 175' ' ' LEU . 9.8 mmt85 -115.43 134.97 54.59 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 109.438 -0.579 . . . . 73.41 109.438 -178.017 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -150.6 154.54 37.7 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 123.329 0.652 . . . . 72.31 109.38 173.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -119.78 151.35 38.94 Favored 'General case' 0 C--O 1.245 0.851 0 C-N-CA 123.134 0.574 . . . . 72.42 110.169 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.646 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.4 pt? -144.95 143.13 19.72 Favored Pre-proline 0 N--CA 1.471 0.59 0 CA-C-N 115.424 -0.807 . . . . 74.13 111.286 -178.388 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.43 113.95 3.87 Favored 'Trans proline' 0 C--N 1.37 1.68 0 C-N-CA 121.377 1.384 . . . . 55.55 109.119 160.052 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.518 HD22 HG11 ' A' ' 178' ' ' VAL . 20.0 tp -104.97 148.44 26.72 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 108.463 -0.94 . . . . 74.13 108.463 178.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.678 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 4.1 m -82.15 157.54 23.99 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 109.919 -0.401 . . . . 63.21 109.919 175.274 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.456 HD23 ' HB3' ' A' ' 180' ' ' LEU . 77.5 mt -59.16 -48.68 80.72 Favored 'General case' 0 N--CA 1.482 1.145 0 CA-C-O 122.342 1.068 . . . . 64.32 109.529 172.331 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.53 -34.46 64.7 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 113.621 -1.627 . . . . 74.41 111.963 174.693 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.459 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 17.0 mm-40 -85.63 -17.69 35.39 Favored 'General case' 0 N--CA 1.481 1.083 0 C-N-CA 123.398 0.679 . . . . 71.45 112.416 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.728 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -58.23 -43.41 87.75 Favored 'General case' 0 C--O 1.249 1.05 0 CA-C-O 121.382 0.611 . . . . 61.21 109.697 163.155 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -71.32 -60.31 2.3 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 114.842 -1.072 . . . . 74.14 111.62 174.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -69.05 -47.16 66.04 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 123.588 0.755 . . . . 71.43 112.252 -169.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 71.76 -86.25 0.45 Allowed Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.816 -0.914 . . . . 74.23 110.816 -170.75 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.0 -179.57 51.3 Favored Glycine 0 C--N 1.345 1.08 0 N-CA-C 114.528 0.571 . . . . 70.34 114.528 174.244 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 14.8 mp0 -98.61 115.27 28.27 Favored 'General case' 0 N--CA 1.471 0.584 0 N-CA-C 107.301 -1.37 . . . . 71.2 107.301 175.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.605 ' HG3' HD21 ' A' ' 98' ' ' LEU . 39.3 mmt-85 -132.15 138.51 48.07 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.711 1.204 . . . . 71.35 108.287 -173.278 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.409 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 27.8 m -73.61 123.01 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 121.343 0.592 . . . . 52.11 111.295 -176.8 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 13.4 p -105.43 141.36 20.94 Favored 'Isoleucine or valine' 0 C--O 1.252 1.23 0 C-N-CA 125.092 1.357 . . . . 73.34 110.195 178.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 13.2 tp10 -120.29 103.36 9.17 Favored 'General case' 0 C--O 1.243 0.75 0 C-N-CA 124.033 0.933 . . . . 74.02 109.001 174.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.51 HG21 HD22 ' A' ' 174' ' ' LEU . 2.9 m -143.87 123.56 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 123.939 0.896 . . . . 70.2 110.693 -173.189 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.03 19.9 11.95 Favored 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 124.322 1.049 . . . . 62.0 112.137 173.2 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 83.62 17.5 65.93 Favored Glycine 0 C--N 1.347 1.161 0 CA-C-N 116.366 -0.379 . . . . 73.01 112.345 -177.367 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.2 mmm180 -108.12 118.17 36.04 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 108.317 -0.994 . . . . 71.31 108.317 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 49.9 ttt180 -94.94 108.2 20.25 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 108.406 -0.961 . . . . 64.34 108.406 173.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 72.2 t -135.82 146.74 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 108.674 -0.861 . . . . 54.22 108.674 -178.548 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 67.0 p -90.17 107.63 19.25 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.563 -1.273 . . . . 73.1 107.563 167.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.9 p -97.68 140.92 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-O 121.322 0.582 . . . . 73.44 111.012 -172.513 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 14.4 ttp180 -104.13 103.39 13.17 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 107.741 -1.207 . . . . 75.11 107.741 177.241 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.44 ' HB ' HD13 ' A' ' 159' ' ' ILE . 36.5 pt -92.1 112.78 56.67 Favored Pre-proline 0 CA--C 1.555 1.137 0 N-CA-C 109.553 -0.536 . . . . 74.24 109.553 179.067 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.526 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 96.2 Cg_exo -47.82 131.01 20.1 Favored 'Trans proline' 0 C--N 1.39 2.727 0 C-N-CA 123.947 3.098 . . . . 70.14 114.676 -173.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.526 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 23.2 Cg_exo -67.19 135.52 37.44 Favored 'Trans proline' 0 C--N 1.379 2.162 0 C-N-CA 123.472 2.781 . . . . 71.34 112.269 -177.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.652 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 120.51 41.88 0.52 Allowed Glycine 0 C--N 1.349 1.272 0 N-CA-C 111.908 -0.477 . . . . 54.32 111.908 -175.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.728 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.6 p -115.33 162.89 13.08 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.533 0 C-N-CA 123.915 0.886 . . . . 63.11 109.76 -173.17 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 43.9 mtp180 -143.26 168.99 18.49 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 125.228 1.411 . . . . 65.41 110.09 -170.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -54.94 120.59 7.1 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.759 0.824 . . . . 75.2 111.022 170.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.87 3.65 90.39 Favored Glycine 0 C--N 1.349 1.288 0 O-C-N 123.647 0.592 . . . . 70.54 113.903 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 40.3 t -81.99 131.89 35.25 Favored 'General case' 0 C--O 1.248 0.983 0 N-CA-C 109.303 -0.628 . . . . 60.44 109.303 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 9.0 p -97.42 135.74 30.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.986 0 CA-C-N 115.103 -0.953 . . . . 71.13 109.24 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.486 HD11 HG21 ' A' ' 153' ' ' VAL . 28.1 mt -112.61 123.07 67.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 123.9 0.88 . . . . 74.02 110.707 -175.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.426 HH21 HD11 ' A' ' 175' ' ' LEU . 35.3 ttm180 -92.53 118.84 31.4 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 117.924 0.329 . . . . 72.23 110.26 174.504 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.465 HG22 ' HB3' ' A' ' 174' ' ' LEU . 4.5 m -113.0 125.65 29.47 Favored Pre-proline 0 CA--C 1.551 1.0 0 N-CA-C 108.004 -1.109 . . . . 75.23 108.004 171.789 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -79.26 148.72 21.46 Favored 'Trans proline' 0 C--N 1.367 1.532 0 C-N-CA 122.132 1.888 . . . . 63.3 113.081 -174.185 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 74.37 23.24 76.13 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 115.141 0.816 . . . . 73.25 115.141 173.057 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 50.7 tpp -102.91 -45.92 4.83 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 117.811 0.806 . . . . 70.44 110.7 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -74.57 -88.21 0.22 Allowed Glycine 0 C--N 1.349 1.299 0 CA-C-N 116.093 -0.503 . . . . 74.33 112.52 -177.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.655 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -58.71 99.36 0.12 Allowed Glycine 0 C--N 1.347 1.165 0 C-N-CA 123.567 0.603 . . . . 25.11 112.536 173.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.4 mm-40 -87.31 104.31 16.29 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 123.785 0.834 . . . . 63.41 109.105 178.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 156.38 -164.44 32.48 Favored Glycine 0 C--N 1.339 0.723 0 N-CA-C 111.472 -0.651 . . . . 73.15 111.472 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -60.38 -45.25 97.46 Favored Pre-proline 0 CA--C 1.561 1.368 0 CA-C-O 118.178 -0.915 . . . . 74.45 112.014 177.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -74.81 106.71 2.32 Favored 'Trans proline' 0 C--N 1.39 2.728 0 C-N-CA 121.885 1.724 . . . . 75.14 110.341 168.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -77.56 126.07 8.0 Favored 'Trans proline' 0 C--N 1.375 1.954 0 C-N-CA 121.494 1.463 . . . . 62.41 111.015 -175.042 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.655 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -108.68 168.29 13.47 Favored Glycine 0 N--CA 1.462 0.369 0 N-CA-C 111.185 -0.766 . . . . 54.44 111.185 175.662 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -118.92 169.88 9.5 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 123.61 0.764 . . . . 63.43 111.656 -165.557 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.51 HD22 HG21 ' A' ' 140' ' ' VAL . 37.0 tp -124.62 116.47 22.46 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-N 114.608 -1.178 . . . . 62.42 108.234 169.52 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.426 HD11 HH21 ' A' ' 160' ' ' ARG . 41.3 mt -92.19 100.93 13.45 Favored 'General case' 0 C--O 1.243 0.76 0 CA-C-N 114.248 -1.342 . . . . 62.41 109.868 175.89 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 85.2 mt -90.85 107.39 19.16 Favored 'General case' 0 CA--C 1.538 0.494 0 CA-C-N 114.462 -1.245 . . . . 74.33 111.177 178.454 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 34.9 t -86.67 106.11 15.51 Favored 'Isoleucine or valine' 0 C--O 1.249 1.05 0 N-CA-C 108.459 -0.941 . . . . 71.32 108.459 175.466 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.518 HG11 HD22 ' A' ' 125' ' ' LEU . 19.0 m -81.57 149.77 4.77 Favored 'Isoleucine or valine' 0 C--O 1.24 0.6 0 CA-C-O 121.811 0.815 . . . . 72.42 112.203 -179.268 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 25.0 mmm-85 -123.75 105.66 9.86 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 107.38 -1.341 . . . . 64.32 107.38 174.607 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.456 ' HB3' HD23 ' A' ' 127' ' ' LEU . 30.2 mt -67.73 142.66 56.21 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 118.191 0.45 . . . . 74.42 111.186 -178.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.678 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 41.3 mt -55.22 142.35 58.61 Favored Pre-proline 0 CA--C 1.555 1.153 0 O-C-N 124.029 0.831 . . . . 62.42 111.791 -175.051 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.31 63.98 7.86 Favored 'Trans proline' 0 C--N 1.378 2.105 0 C-N-CA 123.389 2.726 . . . . 64.54 113.113 -177.711 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 3.7 p80 -149.61 50.18 0.75 Allowed Pre-proline 0 CA--C 1.564 1.5 0 C-N-CA 124.043 0.937 . . . . 63.0 108.84 169.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -62.63 122.97 11.52 Favored 'Trans proline' 0 C--N 1.385 2.459 0 C-N-CA 121.814 1.676 . . . . 75.42 111.808 -166.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.3 p -122.54 -42.57 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 N-CA-C 107.894 -1.15 . . . . 71.45 107.894 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -101.1 123.45 45.27 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.765 -1.107 . . . . 71.52 109.09 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 91.5 mtm180 -119.0 119.71 35.09 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.606 1.162 . . . . 71.45 108.085 -179.367 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 66.1 tp -105.0 139.02 40.31 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.848 0.859 . . . . 72.43 110.936 -174.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 -134.53 108.03 7.86 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 124.415 1.086 . . . . 72.55 108.104 164.317 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 73.16 -82.48 0.65 Allowed Glycine 0 C--N 1.35 1.332 0 O-C-N 123.529 0.518 . . . . 64.14 112.914 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -134.84 -15.64 2.03 Favored 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 123.772 0.829 . . . . 72.21 110.748 177.183 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 52.9 m-20 -91.0 143.78 26.35 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.345 0.658 . . . . 62.35 112.396 -174.57 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.57 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 87.3 mt -112.7 161.21 17.12 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 125.112 1.365 . . . . 71.03 111.215 -174.472 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -141.0 121.83 14.41 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 107.325 -1.361 . . . . 73.53 107.325 174.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 195' ' ' ALA . . . . . 0.455 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -148.96 136.23 20.12 Favored 'General case' 0 N--CA 1.468 0.453 0 N-CA-C 108.891 -0.781 . . . . 65.42 108.891 -178.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 196' ' ' THR . . . . . 0.541 ' HA ' ' HB2' ' A' ' 252' ' ' GLU . 12.1 m -81.28 123.14 28.25 Favored 'General case' 0 CA--C 1.542 0.665 0 O-C-N 123.478 0.486 . . . . 70.13 110.616 -175.678 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.508 HD22 HD13 ' A' ' 251' ' ' LEU . 48.2 tp -108.71 113.28 26.11 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.825 0.85 . . . . 73.31 109.484 -179.699 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -87.23 113.11 22.68 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 108.43 -0.952 . . . . 65.25 108.43 172.097 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 4.2 p -118.37 124.9 28.22 Favored Pre-proline 0 CA--C 1.551 1.005 0 C-N-CA 124.035 0.934 . . . . 71.21 109.347 178.51 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -61.73 146.27 96.79 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 122.507 2.138 . . . . 74.33 112.287 175.558 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 201' ' ' ALA . . . . . 0.407 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -54.55 -42.98 97.49 Favored Pre-proline 0 CA--C 1.56 1.338 0 CA-C-O 117.346 -1.311 . . . . 64.34 113.965 -176.811 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 202' ' ' PRO . . . . . 0.407 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 7.1 Cg_endo -48.84 -47.6 20.68 Favored 'Trans proline' 0 C--N 1.402 3.344 0 C-N-CA 122.647 2.231 . . . . 65.3 112.821 172.189 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 15.7 mt -70.01 -38.15 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 122.725 0.41 . . . . 71.34 110.843 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.2 -41.47 98.39 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 123.307 0.643 . . . . 72.31 111.778 -177.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.7 m -80.21 -40.07 19.75 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 CA-C-N 116.108 -0.496 . . . . 65.33 111.715 -176.357 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.0 m -79.88 -24.02 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 CA-C-N 117.842 0.292 . . . . 74.42 111.194 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.504 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 73.22 61.38 3.46 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.855 -0.611 . . . . 72.33 112.317 -174.477 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.55 -142.22 9.77 Favored Glycine 0 C--N 1.356 1.672 0 N-CA-C 111.799 -0.52 . . . . 71.03 111.799 -178.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -131.36 144.78 51.48 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 123.812 0.845 . . . . 74.04 110.216 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 11.8 m -134.35 169.77 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.508 1.123 . . . . 75.11 109.171 175.53 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 211' ' ' ARG . . . . . 0.517 ' HD3' ' H ' ' A' ' 211' ' ' ARG . 0.0 OUTLIER -104.03 133.7 48.54 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.536 -0.756 . . . . 72.45 109.079 176.163 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -117.81 114.87 23.91 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 108.597 -0.89 . . . . 72.11 108.597 172.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 3.9 tpt -70.56 105.13 3.0 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.966 -0.561 . . . . 55.43 109.687 177.311 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 5.8 t -115.69 169.37 9.25 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.486 0.714 . . . . 74.3 111.255 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 46.4 mt -75.4 -3.06 31.5 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.254 1.022 . . . . 73.33 112.535 -170.399 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -106.1 -6.27 18.77 Favored 'General case' 0 N--CA 1.484 1.234 0 C-N-CA 124.029 0.931 . . . . 74.24 111.566 175.218 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 116.62 155.99 10.54 Favored Glycine 0 C--N 1.348 1.214 0 CA-C-O 118.583 -1.12 . . . . 60.22 111.634 -175.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -59.76 126.91 21.79 Favored 'Trans proline' 0 C--N 1.379 2.184 0 C-N-CA 123.096 2.531 . . . . 61.23 113.078 -168.591 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 35.1 m -108.47 166.49 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 C-N-CA 123.296 0.639 . . . . 71.23 110.184 -179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -113.22 113.26 25.08 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 108.11 -1.07 . . . . 72.13 108.11 -177.027 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.504 HG22 HD11 ' A' ' 235' ' ' LEU . 5.2 t -95.92 115.99 36.53 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-N 115.664 -0.698 . . . . 61.42 109.303 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -85.61 101.25 12.55 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.585 -1.265 . . . . 74.12 107.585 170.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.504 HG23 ' HA2' ' A' ' 207' ' ' GLY . 9.0 m -74.71 146.56 83.38 Favored Pre-proline 0 CA--C 1.559 1.323 0 N-CA-C 109.509 -0.552 . . . . 53.41 109.509 -176.131 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -60.79 136.18 64.72 Favored 'Trans proline' 0 C--N 1.376 2.021 0 C-N-CA 122.769 2.312 . . . . 71.44 112.027 177.813 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_exo -54.88 122.57 11.89 Favored 'Trans proline' 0 C--N 1.377 2.037 0 C-N-CA 122.244 1.963 . . . . 63.51 110.572 169.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 68.6 mtm180 62.57 49.99 3.74 Favored 'General case' 0 CA--C 1.551 1.002 0 O-C-N 124.333 1.021 . . . . 74.44 110.576 -177.348 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.5 t -72.87 170.21 15.19 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.007 0.523 . . . . 51.43 110.52 177.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 228' ' ' GLN . . . . . 0.633 ' H ' ' HD2' ' A' ' 231' ' ' ARG . 28.1 mp0 -121.35 147.05 46.21 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.269 0.628 . . . . 71.5 109.987 -178.424 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -76.34 123.3 25.74 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.209 1.004 . . . . 44.33 109.483 175.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 113.91 -10.65 22.98 Favored Glycine 0 N--CA 1.472 1.085 0 N-CA-C 111.924 -0.47 . . . . 55.01 111.924 -171.704 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 231' ' ' ARG . . . . . 0.633 ' HD2' ' H ' ' A' ' 228' ' ' GLN . 20.9 mtt180 -69.98 161.61 29.7 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.516 0.726 . . . . 64.23 111.402 173.042 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.431 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.3 mptp? -119.99 111.3 17.74 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 107.825 -1.176 . . . . 73.22 107.825 176.52 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 233' ' ' LEU . . . . . 0.554 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 60.0 mt -85.63 107.51 17.57 Favored 'General case' 0 C--N 1.356 0.868 0 N-CA-C 108.613 -0.884 . . . . 73.34 108.613 -178.349 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 38.4 ttm180 -84.4 105.92 15.6 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.248 -0.887 . . . . 70.22 109.993 -171.46 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.581 ' HB3' ' HG3' ' A' ' 238' ' ' LYS . 58.2 mt -98.07 99.13 10.37 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 108.652 -0.87 . . . . 74.14 108.652 172.586 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -75.88 144.64 41.05 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 122.489 0.316 . . . . 64.12 111.159 -177.374 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 72.92 28.13 67.43 Favored Glycine 0 C--N 1.353 1.481 0 O-C-N 123.755 0.659 . . . . 64.31 113.042 -175.67 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 238' ' ' LYS . . . . . 0.581 ' HG3' ' HB3' ' A' ' 235' ' ' LEU . 4.1 mmtm -119.8 -10.59 9.5 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 124.138 0.975 . . . . 71.52 111.512 -178.304 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 239' ' ' GLY . . . . . 0.425 ' O ' ' HD2' ' A' ' 246' ' ' ARG . . . -81.93 -154.01 12.51 Favored Glycine 0 C--N 1.339 0.719 0 O-C-N 123.414 0.446 . . . . 63.35 113.279 -179.156 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.652 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 6.1 m-85 -94.68 158.69 34.93 Favored Pre-proline 0 CA--C 1.548 0.867 0 C-N-CA 123.576 0.75 . . . . 75.5 109.811 177.033 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.66 129.32 26.64 Favored 'Trans proline' 0 C--N 1.387 2.556 0 C-N-CA 123.361 2.707 . . . . 75.55 113.482 -178.505 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -158.18 -169.09 21.34 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.626 -0.716 . . . . 44.52 112.278 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.35 -17.99 59.3 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 123.133 2.555 . . . . 65.54 113.414 -177.235 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -98.42 21.23 11.4 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 123.868 0.867 . . . . 65.4 111.233 178.441 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 88.74 -82.97 1.48 Allowed Glycine 0 C--N 1.347 1.176 0 N-CA-C 110.122 -1.191 . . . . 43.1 110.122 -174.391 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.425 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 22.5 mtm180 -127.09 158.77 36.12 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 107.324 -1.362 . . . . 71.43 107.324 165.218 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.08 -156.96 4.76 Favored Glycine 0 C--N 1.344 1.002 0 O-C-N 123.483 0.489 . . . . 64.41 114.142 -174.429 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 35.0 m-20 -117.8 151.15 37.9 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 108.871 -0.788 . . . . 72.44 108.871 -176.009 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.57 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 18.3 tp -105.19 114.57 28.83 Favored 'General case' 0 CA--C 1.531 0.233 0 N-CA-C 108.71 -0.848 . . . . 73.04 108.71 171.563 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -96.18 106.86 19.11 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 123.109 0.564 . . . . 74.41 109.984 175.819 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.554 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 73.4 mt -88.0 120.96 29.85 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 124.162 0.985 . . . . 52.51 112.789 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.541 ' HB2' ' HA ' ' A' ' 196' ' ' THR . 26.0 mt-10 -79.11 91.3 4.9 Favored 'General case' 0 C--O 1.24 0.574 0 C-N-CA 123.774 0.83 . . . . 74.25 109.279 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 48.0 t -52.37 114.81 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.655 1.182 . . . . 64.54 112.108 178.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 49.7 mmm-85 -117.09 93.68 4.28 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 106.933 -1.506 . . . . 62.35 106.933 173.391 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 72.2 mt -74.55 110.73 9.33 Favored 'Isoleucine or valine' 0 C--N 1.343 0.31 0 N-CA-C 108.274 -1.01 . . . . 60.11 108.274 177.259 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 4.5 t . . . . . 0 CA--C 1.557 1.226 0 C-N-CA 123.982 0.913 . . . . 74.31 109.539 -177.205 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.229 0 N-CA-C 110.361 -0.237 . . . . 74.12 110.361 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -62.42 -32.33 73.16 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.49 0.716 . . . . 75.42 111.36 178.401 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.451 ' HB2' ' HB3' ' A' ' 136' ' ' ARG . 1.2 tm? -112.43 111.02 21.57 Favored 'General case' 0 C--O 1.24 0.578 0 N-CA-C 106.685 -1.598 . . . . 62.03 106.685 169.345 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.413 ' O ' ' HB3' ' A' ' 123' ' ' LEU . 86.0 t -68.3 134.82 29.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 N-CA-C 108.84 -0.8 . . . . 74.34 108.84 177.334 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -150.25 56.45 0.94 Allowed 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 107.999 -1.111 . . . . 64.21 107.999 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -65.7 109.4 2.41 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-N 113.995 -1.457 . . . . 71.33 108.659 176.623 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 39.8 t -59.55 121.77 8.05 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.765 0 O-C-N 124.287 0.992 . . . . 73.43 109.384 -178.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.9 t -151.21 149.73 29.76 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.896 0.878 . . . . 74.3 109.487 -173.391 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.5 m -95.81 67.5 2.75 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.019 -0.734 . . . . 72.21 109.019 177.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -92.66 160.22 25.29 Favored Glycine 0 C--N 1.347 1.178 0 CA-C-N 115.052 -0.977 . . . . 73.41 113.954 -172.453 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 17.4 m -94.0 162.45 13.88 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 124.053 0.941 . . . . 65.53 111.608 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 99.13 116.8 3.82 Favored Glycine 0 C--N 1.349 1.277 0 N-CA-C 111.551 -0.62 . . . . 12.35 111.551 177.186 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -115.65 164.1 12.23 Favored Glycine 0 C--N 1.346 1.089 0 CA-C-N 116.952 0.376 . . . . 73.31 112.694 -176.141 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 34.9 t -91.36 -43.27 9.86 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.821 0.848 . . . . 72.22 109.543 175.047 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 141.8 -91.77 0.18 Allowed Glycine 0 C--O 1.239 0.434 0 CA-C-N 115.105 -0.952 . . . . 51.04 110.876 -177.002 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 60.11 -150.18 40.64 Favored Glycine 0 C--N 1.35 1.342 0 O-C-N 124.158 0.564 . . . . 72.04 112.846 179.264 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 24.5 p -175.96 135.87 0.29 Allowed 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.295 1.038 . . . . 74.53 109.237 172.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 70.17 -152.12 50.72 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 123.659 0.599 . . . . 75.41 113.106 177.394 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 168.85 177.43 39.7 Favored Glycine 0 C--O 1.24 0.506 0 N-CA-C 110.502 -1.039 . . . . 74.35 110.502 -177.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' SER . . . . . 0.419 ' HB3' ' HA2' ' A' ' 172' ' ' GLY . 34.6 t -137.31 98.44 3.72 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 117.5 0.65 . . . . 43.21 110.335 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 63.5 -124.19 30.88 Favored Glycine 0 C--N 1.346 1.094 0 CA-C-N 115.295 -0.866 . . . . 53.2 112.848 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -79.22 119.41 22.26 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 122.718 0.407 . . . . 73.55 109.963 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -92.72 133.72 35.74 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 108.472 -0.936 . . . . 62.01 108.472 172.52 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.05 144.48 26.28 Favored 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 107.015 -1.476 . . . . 73.1 107.015 178.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -130.59 129.36 42.67 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 108.108 -1.071 . . . . 73.01 108.108 176.277 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -150.79 150.23 30.72 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-N 115.75 -0.659 . . . . 62.42 109.571 -179.703 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -120.24 148.0 44.24 Favored 'General case' 0 C--O 1.245 0.84 0 N-CA-C 109.11 -0.7 . . . . 74.13 109.11 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.413 ' HB3' ' O ' ' A' ' 99' ' ' VAL . 1.3 pt? -145.32 147.58 34.44 Favored Pre-proline 0 N--CA 1.467 0.404 0 C-N-CA 122.8 0.44 . . . . 52.22 111.76 179.568 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -78.04 114.21 3.55 Favored 'Trans proline' 0 C--N 1.366 1.448 0 C-N-CA 121.751 1.634 . . . . 72.12 109.935 159.096 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.475 HD22 HG11 ' A' ' 178' ' ' VAL . 34.7 tp -106.75 157.24 17.88 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 108.791 -0.818 . . . . 72.1 108.791 177.517 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.693 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 14.4 m -89.36 151.69 21.93 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 122.99 0.516 . . . . 75.04 110.344 177.519 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.583 HD23 ' HB3' ' A' ' 180' ' ' LEU . 68.9 mt -58.1 -50.57 73.01 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.725 0.81 . . . . 52.33 109.389 174.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -53.78 -39.07 65.11 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 113.95 -1.477 . . . . 72.42 111.673 178.11 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.518 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 28.4 mm-40 -86.06 -18.07 33.45 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 122.999 0.52 . . . . 73.23 111.269 -176.484 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.653 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -64.41 -36.93 85.77 Favored 'General case' 0 C--O 1.242 0.673 0 C-N-CA 123.447 0.699 . . . . 70.01 109.886 167.353 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.458 ' HA ' ' HE1' ' A' ' 240' ' ' PHE . 27.6 t80 -71.94 -55.92 6.61 Favored 'General case' 0 CA--C 1.551 0.982 0 CA-C-N 114.999 -1.001 . . . . 61.12 110.574 172.053 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -67.97 -44.89 75.65 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 112.24 0.459 . . . . 72.12 112.24 -171.164 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.81 -111.62 4.27 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 111.275 -0.73 . . . . 70.23 111.275 -173.511 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.41 -175.87 54.54 Favored Glycine 0 C--N 1.347 1.163 0 N-CA-C 114.232 0.453 . . . . 44.22 114.232 171.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.425 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 2.0 mp0 -87.4 143.96 26.98 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 109.283 -0.636 . . . . 62.33 109.283 178.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.451 ' HB3' ' HB2' ' A' ' 98' ' ' LEU . 0.6 OUTLIER -156.79 147.84 21.98 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 109.546 -0.539 . . . . 74.22 109.546 -178.268 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 32.1 m -82.14 125.38 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 CA-C-O 121.51 0.671 . . . . 73.12 111.206 -174.722 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 41.1 t -120.7 144.77 28.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 125.035 1.334 . . . . 73.3 109.442 -176.643 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -126.15 97.79 5.22 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.041 0.536 . . . . 62.12 109.584 169.283 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.0 m -107.54 132.62 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 N-CA-C 108.922 -0.77 . . . . 73.22 108.922 173.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.46 23.02 13.35 Favored 'General case' 0 CA--C 1.554 1.118 0 C-N-CA 123.964 0.905 . . . . 64.23 111.694 -176.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.23 0.07 88.67 Favored Glycine 0 C--N 1.357 1.703 0 CA-C-N 116.038 -0.528 . . . . 44.21 113.468 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -103.34 123.27 46.48 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.696 0.798 . . . . 61.12 110.036 -175.443 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.2 ttp-105 -88.2 105.93 17.86 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.344 0.658 . . . . 71.2 110.797 -174.394 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 38.5 t -124.42 134.41 66.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.351 1.061 . . . . 53.43 108.828 178.021 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 37.2 m -83.81 120.9 26.61 Favored 'General case' 0 CA--C 1.546 0.803 0 N-CA-C 109.682 -0.488 . . . . 73.3 109.682 176.02 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 8.1 p -99.77 148.73 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 123.317 0.647 . . . . 73.42 110.687 -178.387 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.3 ttt85 -110.02 96.39 6.2 Favored 'General case' 0 C--O 1.237 0.43 0 N-CA-C 107.324 -1.361 . . . . 72.04 107.324 160.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.476 ' HB ' HD13 ' A' ' 159' ' ' ILE . 37.9 pt -78.05 125.98 84.44 Favored Pre-proline 0 C--O 1.243 0.724 0 N-CA-C 108.617 -0.883 . . . . 62.31 108.617 173.144 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.415 ' HD2' HG23 ' A' ' 159' ' ' ILE . 97.7 Cg_exo -48.68 127.18 15.89 Favored 'Trans proline' 0 C--N 1.384 2.406 0 C-N-CA 123.04 2.494 . . . . 61.41 113.37 -178.266 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.553 ' HB2' ' HZ ' ' A' ' 240' ' ' PHE . 57.1 Cg_endo -69.36 143.85 54.16 Favored 'Trans proline' 0 C--N 1.376 2.007 0 C-N-CA 122.251 1.967 . . . . 72.35 110.355 175.02 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.44 27.37 5.56 Favored Glycine 0 C--N 1.337 0.586 0 N-CA-C 110.927 -0.869 . . . . 53.15 110.927 -171.583 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.653 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.2 p -93.67 157.32 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 N-CA-C 108.168 -1.049 . . . . 71.05 108.168 -176.603 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.4 mtp180 -147.11 169.23 19.72 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 124.141 0.976 . . . . 75.41 109.751 -166.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -51.99 123.86 11.42 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.539 0.736 . . . . 32.55 111.624 174.086 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 85.55 -7.64 75.56 Favored Glycine 0 C--N 1.349 1.302 0 CA-C-O 119.419 -0.656 . . . . 32.02 114.111 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.4 m -69.53 122.64 19.44 Favored 'General case' 0 C--N 1.351 0.633 0 CA-C-N 117.336 0.568 . . . . 54.34 110.553 -178.423 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.412 HG12 HD22 ' A' ' 175' ' ' LEU . 10.5 t -98.93 123.17 51.39 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 N-CA-C 108.486 -0.931 . . . . 72.44 108.486 179.302 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.531 HD11 HG21 ' A' ' 153' ' ' VAL . 43.5 mt -102.49 115.69 44.85 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.593 0 C-N-CA 123.926 0.89 . . . . 72.22 110.537 -169.075 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.41 ' HG3' ' HB2' ' A' ' 173' ' ' ASP . 30.3 ttm180 -89.69 115.86 27.38 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.07 0.548 . . . . 65.23 110.493 175.237 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 173' ' ' ASP . 15.0 m -119.16 116.11 34.12 Favored Pre-proline 0 CA--C 1.555 1.172 0 C-N-CA 123.363 0.665 . . . . 74.34 109.578 176.32 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 162' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 11.2 Cg_exo -72.47 148.51 48.41 Favored 'Trans proline' 0 C--N 1.368 1.594 0 C-N-CA 122.479 2.119 . . . . 64.04 111.998 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.65 18.27 28.36 Favored Glycine 0 C--N 1.341 0.825 0 N-CA-C 115.673 1.029 . . . . 73.2 115.673 172.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.413 ' HE3' HG23 ' A' ' 147' ' ' VAL . 54.2 mtt -121.6 -57.45 1.82 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 118.449 1.125 . . . . 33.5 112.128 176.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -61.36 -88.79 0.03 OUTLIER Glycine 0 C--N 1.35 1.329 0 O-C-N 123.372 0.42 . . . . 73.11 113.047 -174.51 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.622 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -68.99 92.93 0.31 Allowed Glycine 0 C--N 1.338 0.648 0 O-C-N 123.648 0.264 . . . . 33.24 112.631 176.047 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.6 mm100 -92.2 128.97 38.25 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 123.182 0.593 . . . . 75.14 109.733 171.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 174.82 -59.65 0.12 Allowed Glycine 0 C--N 1.337 0.626 0 N-CA-C 110.945 -0.862 . . . . 61.32 110.945 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.403 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 3.2 t30 -162.62 -51.63 0.01 OUTLIER Pre-proline 0 CA--C 1.561 1.401 0 C-N-CA 124.402 1.081 . . . . 54.51 109.498 176.516 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.428 ' HA ' ' HD3' ' A' ' 171' ' ' PRO . 94.8 Cg_endo -81.44 122.76 4.15 Favored 'Trans proline' 0 C--N 1.395 2.997 0 C-N-CA 121.775 1.65 . . . . 34.42 111.089 171.103 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 170' ' ' PRO . 34.2 Cg_exo -61.81 121.91 10.21 Favored 'Trans proline' 0 C--N 1.378 2.116 0 C-N-CA 122.627 2.218 . . . . 74.21 112.167 -176.87 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.622 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -95.41 159.21 22.44 Favored Glycine 0 C--N 1.348 1.212 0 O-C-N 123.385 0.428 . . . . 73.1 112.406 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.447 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 9.4 p-10 -96.46 151.54 19.47 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 123.012 0.525 . . . . 74.42 112.036 -167.475 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 11.2 tp -113.88 124.27 51.8 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 107.472 -1.307 . . . . 72.33 107.472 163.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.412 HD22 HG12 ' A' ' 158' ' ' VAL . 37.3 mt -99.28 100.63 11.74 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.583 1.153 . . . . 72.24 110.098 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 93.0 mt -95.8 102.74 14.57 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.93 0.892 . . . . 72.14 110.917 177.339 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 6.5 p -86.16 111.91 21.9 Favored 'Isoleucine or valine' 0 C--O 1.244 0.81 0 CA-C-O 121.635 0.731 . . . . 62.43 109.209 172.388 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.475 HG11 HD22 ' A' ' 125' ' ' LEU . 6.2 m -86.98 149.35 4.14 Favored 'Isoleucine or valine' 0 C--O 1.241 0.607 0 CA-C-N 115.638 -0.71 . . . . 65.21 111.49 -178.365 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -124.31 104.57 8.87 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 106.914 -1.513 . . . . 73.34 106.914 176.19 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.583 ' HB3' HD23 ' A' ' 127' ' ' LEU . 32.4 mt -68.09 143.36 55.5 Favored 'General case' 0 CA--C 1.54 0.59 0 O-C-N 123.098 0.249 . . . . 71.21 111.243 -175.314 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.693 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 54.8 mt -53.86 147.83 22.42 Favored Pre-proline 0 CA--C 1.553 1.063 0 C-N-CA 123.852 0.861 . . . . 72.13 111.661 -173.265 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.19 37.24 0.62 Allowed 'Trans proline' 0 C--N 1.368 1.557 0 C-N-CA 123.32 2.68 . . . . 71.24 114.394 -175.478 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -121.06 65.55 13.93 Favored Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 123.544 0.738 . . . . 65.51 109.371 170.201 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -68.28 123.7 10.87 Favored 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 121.485 1.456 . . . . 74.22 111.231 -169.534 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.7 p -134.61 -38.81 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 N-CA-C 108.499 -0.926 . . . . 74.24 108.499 178.518 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.429 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 5.5 m-85 -114.82 141.92 47.24 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 121.902 0.858 . . . . 72.35 112.259 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.536 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 43.8 mtt85 -128.54 154.0 46.62 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 113.472 -1.695 . . . . 73.2 106.838 171.466 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.467 HD13 HD23 ' A' ' 193' ' ' LEU . 42.5 tp -132.7 138.41 47.25 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 109.051 -0.722 . . . . 72.24 109.051 179.534 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -142.32 117.69 10.22 Favored 'General case' 0 C--O 1.241 0.645 0 N-CA-C 109.101 -0.703 . . . . 73.45 109.101 173.433 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 68.16 -86.82 0.18 Allowed Glycine 0 C--N 1.349 1.279 0 O-C-N 123.864 0.727 . . . . 62.23 112.986 -177.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 4.5 pm0 -135.41 -14.85 1.94 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.25 1.02 . . . . 74.31 111.206 -174.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -111.19 156.42 21.45 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-O 121.16 0.505 . . . . 74.12 111.36 -174.075 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.467 HD23 HD13 ' A' ' 188' ' ' LEU . 79.5 mt -109.09 170.78 7.83 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.334 1.054 . . . . 64.13 109.593 -168.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 194' ' ' TYR . . . . . 0.536 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 71.4 m-85 -142.45 122.58 13.75 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 107.51 -1.293 . . . . 74.34 107.51 177.502 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 195' ' ' ALA . . . . . 0.474 ' HB3' HD23 ' A' ' 251' ' ' LEU . . . -134.99 152.45 51.75 Favored 'General case' 0 CA--C 1.508 -0.657 0 N-CA-C 109.522 -0.547 . . . . 54.13 109.522 177.127 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 4.9 m -98.77 119.09 36.93 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 108.969 -0.752 . . . . 75.24 108.969 177.072 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.487 HD22 HD13 ' A' ' 251' ' ' LEU . 61.4 tp -105.31 111.84 24.73 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.347 1.059 . . . . 71.13 109.716 -174.491 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -94.43 104.85 16.81 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 109.333 -0.617 . . . . 74.51 109.333 176.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 199' ' ' VAL . . . . . 0.567 HG11 HG11 ' A' ' 223' ' ' VAL . 14.6 m -101.52 140.87 21.6 Favored Pre-proline 0 N--CA 1.476 0.825 0 N-CA-C 109.378 -0.601 . . . . 71.21 109.378 177.036 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.19 151.21 84.13 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 121.999 1.799 . . . . 73.21 110.986 171.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -56.69 -44.95 99.97 Favored Pre-proline 0 CA--C 1.546 0.791 0 CA-C-O 118.327 -0.844 . . . . 54.33 113.051 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 202' ' ' PRO . . . . . 0.421 ' O ' HG22 ' A' ' 206' ' ' VAL . 69.7 Cg_exo -46.69 -55.64 3.64 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 122.484 2.123 . . . . 64.42 113.495 170.738 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.2 mt -65.57 -37.25 79.56 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 122.736 0.414 . . . . 73.55 111.613 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -56.27 -58.33 8.43 Favored 'General case' 0 CA--C 1.547 0.828 0 CA-C-O 121.261 0.553 . . . . 72.53 111.087 178.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.6 m -69.79 -40.06 78.62 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.969 0 CA-C-N 115.212 -0.904 . . . . 72.15 112.461 -173.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 202' ' ' PRO . 18.3 m -78.17 -27.0 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 122.259 0.224 . . . . 74.12 110.977 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.548 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 77.52 63.66 2.2 Favored Glycine 0 C--N 1.341 0.835 0 CA-C-N 115.919 -0.582 . . . . 42.15 113.171 -176.4 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -91.89 -147.12 19.82 Favored Glycine 0 C--N 1.354 1.578 0 N-CA-C 111.694 -0.563 . . . . 33.35 111.694 177.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -138.18 135.5 35.7 Favored 'General case' 0 C--O 1.24 0.593 0 C-N-CA 123.154 0.582 . . . . 71.22 110.462 178.051 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 61.3 t -120.68 134.64 63.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.131 0.972 . . . . 70.23 108.964 -179.055 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.68 114.81 17.92 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.502 -0.555 . . . . 74.33 109.502 171.533 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.63 146.0 28.3 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 108.71 -0.848 . . . . 64.35 108.71 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 55.4 mmm -83.81 148.59 26.92 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 110.13 -0.322 . . . . 62.44 110.13 174.411 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.429 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 9.3 t -140.03 167.59 21.77 Favored 'General case' 0 C--O 1.242 0.691 0 C-N-CA 124.0 0.92 . . . . 72.54 109.873 173.581 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 63.7 mt -74.31 -0.56 17.46 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 123.882 0.873 . . . . 74.11 112.138 -173.697 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.65 -4.07 9.78 Favored 'General case' 0 N--CA 1.485 1.292 0 N-CA-C 112.747 0.647 . . . . 74.23 112.747 176.602 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 153.89 -160.74 29.55 Favored Glycine 0 N--CA 1.478 1.465 0 CA-C-O 119.679 -0.512 . . . . 62.41 112.859 178.583 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -94.26 132.54 0.71 Allowed 'Trans proline' 0 CA--C 1.559 1.726 0 C-N-CA 123.473 2.782 . . . . 43.15 112.596 168.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 34.3 m -111.38 151.97 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.64 0.776 . . . . 73.44 110.32 173.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -114.58 115.14 26.69 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-O 121.139 0.495 . . . . 73.44 110.099 171.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.528 ' HB ' HD11 ' A' ' 235' ' ' LEU . 2.6 p -104.66 121.44 56.48 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 123.359 0.664 . . . . 74.34 110.968 179.408 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.98 105.62 15.0 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 109.22 -0.659 . . . . 75.52 109.22 173.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.567 HG11 HG11 ' A' ' 199' ' ' VAL . 11.0 m -71.2 135.61 84.65 Favored Pre-proline 0 CA--C 1.556 1.189 0 N-CA-C 108.839 -0.8 . . . . 72.32 108.839 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 224' ' ' PRO . . . . . 0.427 ' HB2' HH12 ' A' ' 231' ' ' ARG . 31.5 Cg_exo -61.28 144.12 98.52 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 122.373 2.048 . . . . 64.23 112.581 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -51.24 128.35 25.04 Favored 'Trans proline' 0 C--N 1.38 2.222 0 C-N-CA 122.904 2.403 . . . . 74.43 112.046 173.008 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 42.1 mtp180 67.87 60.98 0.43 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 125.032 1.333 . . . . 75.12 110.369 -175.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -85.3 139.62 31.46 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 114.852 -1.067 . . . . 72.22 111.29 178.355 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 23.1 mp0 -112.2 158.84 19.19 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 123.768 0.827 . . . . 62.15 109.392 176.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -71.07 140.47 50.71 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 116.013 -0.54 . . . . 43.44 109.673 174.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 96.97 -3.7 62.5 Favored Glycine 0 CA--C 1.521 0.443 0 CA-C-O 119.448 -0.64 . . . . 52.12 112.996 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 231' ' ' ARG . . . . . 0.427 HH12 ' HB2' ' A' ' 224' ' ' PRO . 90.1 mtt180 -69.41 156.11 39.37 Favored 'General case' 0 N--CA 1.478 0.972 0 CA-C-N 117.649 0.724 . . . . 75.44 110.733 172.585 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 13.2 mptt -125.44 123.23 38.81 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 123.404 0.682 . . . . 74.4 109.726 177.31 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 46.6 mt -112.6 109.98 19.87 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 108.554 -0.906 . . . . 71.12 108.554 -175.618 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 234' ' ' ARG . . . . . 0.444 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 57.3 ttp85 -99.23 104.31 16.24 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 116.072 -0.513 . . . . 61.21 111.145 -168.691 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.528 HD11 ' HB ' ' A' ' 221' ' ' VAL . 37.0 mt -89.9 100.52 13.32 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 124.091 0.956 . . . . 71.31 110.145 -176.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 236' ' ' LYS . . . . . 0.424 ' HE2' ' HB3' ' A' ' 236' ' ' LYS . 42.4 mtpt -66.37 151.53 46.94 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 116.378 -0.374 . . . . 71.03 111.534 177.575 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.65 20.2 73.76 Favored Glycine 0 C--N 1.348 1.203 0 CA-C-N 115.325 -0.852 . . . . 52.11 112.845 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.0 mmtt -137.59 16.44 2.92 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.801 0.84 . . . . 73.31 111.266 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -99.11 -160.72 29.42 Favored Glycine 0 C--N 1.347 1.161 0 O-C-N 123.654 0.596 . . . . 72.15 112.038 170.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.553 ' HZ ' ' HB2' ' A' ' 151' ' ' PRO . 13.3 t80 -83.43 127.14 69.56 Favored Pre-proline 0 CA--C 1.552 1.043 0 CA-C-N 116.74 0.27 . . . . 55.44 110.945 -176.531 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 241' ' ' PRO . . . . . 0.567 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 13.5 Cg_exo -70.87 126.33 12.47 Favored 'Trans proline' 0 C--N 1.376 1.979 0 C-N-CA 122.269 1.979 . . . . 72.42 111.732 173.474 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -158.69 -146.13 4.45 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-O 119.149 -0.806 . . . . 50.03 112.583 -176.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -65.38 -24.54 57.25 Favored 'Trans proline' 0 C--N 1.376 2.01 0 C-N-CA 123.375 2.717 . . . . 62.21 112.866 -177.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.45 22.54 3.9 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 124.041 0.937 . . . . 70.24 111.113 178.33 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 81.18 -98.63 1.87 Allowed Glycine 0 C--N 1.345 1.042 0 N-CA-C 110.469 -1.053 . . . . 53.41 110.469 -176.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.567 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 23.2 ttm180 -128.62 146.53 50.83 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 109.146 -0.687 . . . . 74.25 109.146 166.148 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -85.61 -155.34 24.99 Favored Glycine 0 C--O 1.253 1.338 0 O-C-N 123.694 0.621 . . . . 41.12 112.424 175.744 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -140.27 160.52 39.78 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.835 0.854 . . . . 51.54 109.961 -174.575 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.444 ' O ' ' HA ' ' A' ' 234' ' ' ARG . 15.6 tp -99.51 122.39 42.51 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 123.919 0.887 . . . . 74.41 110.329 178.1 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -101.57 104.47 15.35 Favored 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 108.433 -0.951 . . . . 72.31 108.433 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.548 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 74.5 mt -85.72 149.93 24.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.987 0.915 . . . . 53.41 112.328 -178.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -114.47 96.01 5.55 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.539 -0.912 . . . . 70.51 108.539 176.154 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 69.1 t -52.15 125.82 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 123.582 0.753 . . . . 72.24 111.683 176.776 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 27.3 mmm-85 -136.17 101.5 4.72 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 125.257 1.423 . . . . 74.1 107.259 179.066 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 65.1 mt -80.97 125.39 39.45 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 CA-C-N 116.342 -0.39 . . . . 75.55 110.053 -175.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 10.0 t . . . . . 0 CA--C 1.55 0.966 0 C-N-CA 124.402 1.081 . . . . 72.55 109.653 -179.766 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.192 0 N-CA-C 110.22 -0.289 . . . . 74.43 110.22 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -157.35 -71.91 0.1 Allowed 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 123.033 0.533 . . . . 73.11 110.09 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.658 ' HB2' ' HG2' ' A' ' 136' ' ' ARG . 22.0 tp -80.58 -50.45 9.97 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.294 -0.632 . . . . 74.2 109.294 177.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.429 ' HA ' ' CB ' ' A' ' 123' ' ' LEU . 12.5 p -65.48 137.06 25.65 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 115.345 -0.843 . . . . 63.41 110.042 172.245 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.82 -50.14 8.96 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.215 -0.661 . . . . 62.55 109.215 174.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 49.0 p-80 -170.16 163.97 9.11 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 114.896 -1.047 . . . . 71.41 109.964 -175.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 1.8 p -95.38 162.09 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.086 0 N-CA-C 109.642 -0.503 . . . . 71.32 109.642 174.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 71.7 p -140.16 -176.66 4.68 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 124.792 1.237 . . . . 75.34 109.362 -171.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 44.7 t -75.75 166.41 23.58 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 124.05 0.94 . . . . 42.14 112.251 -175.369 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -94.4 174.64 33.83 Favored Glycine 0 C--N 1.353 1.481 0 CA-C-N 115.513 -0.767 . . . . 64.43 112.103 176.175 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 34.9 t -75.64 167.62 21.55 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 124.139 0.976 . . . . 54.22 111.839 -174.322 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -109.38 132.67 11.19 Favored Glycine 0 C--N 1.344 1.003 0 CA-C-N 115.721 -0.672 . . . . 71.53 111.748 -179.329 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.79 47.99 23.63 Favored Glycine 0 C--N 1.348 1.233 0 O-C-N 123.964 0.449 . . . . 53.34 112.582 179.466 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 21.1 m -76.17 76.89 2.99 Favored 'General case' 0 CA--C 1.554 1.098 0 C-N-CA 123.608 0.763 . . . . 75.05 110.367 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -87.29 -60.67 1.63 Allowed Glycine 0 C--N 1.348 1.243 0 CA-C-N 115.628 -0.715 . . . . 71.15 113.016 -176.54 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -85.63 56.78 4.9 Favored Glycine 0 C--N 1.344 1.022 0 N-CA-C 112.039 -0.424 . . . . 70.21 112.039 -179.52 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 35.3 p -160.86 138.38 9.29 Favored 'General case' 0 C--O 1.239 0.55 0 C-N-CA 124.425 1.09 . . . . 71.33 108.612 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -134.91 172.09 22.14 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 111.266 -0.734 . . . . 63.2 111.266 178.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 162.64 -159.1 31.39 Favored Glycine 0 C--N 1.336 0.58 0 N-CA-C 111.967 -0.453 . . . . 62.35 111.967 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 17.3 m -89.33 14.34 11.37 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 123.973 0.909 . . . . 75.11 112.443 -175.748 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 146.33 -142.46 10.51 Favored Glycine 0 C--N 1.35 1.36 0 N-CA-C 112.328 -0.309 . . . . 74.43 112.328 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.33 138.63 41.91 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 124.479 1.112 . . . . 64.23 110.487 -174.44 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.627 ' HB3' ' HB2' ' A' ' 167' ' ' GLN . 6.7 p-10 -70.36 146.56 50.38 Favored 'General case' 0 N--CA 1.486 1.361 0 CA-C-O 120.886 0.374 . . . . 70.34 110.418 170.694 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 31.6 tp -122.64 146.2 47.67 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 107.662 -1.236 . . . . 74.35 107.662 -170.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 64.6 ttt-85 -141.72 143.87 33.76 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.737 -0.838 . . . . 72.44 108.737 -176.671 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.442 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -149.06 118.81 7.03 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 109.079 -0.711 . . . . 73.25 109.079 175.656 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -94.03 139.38 31.02 Favored 'General case' 0 C--O 1.247 0.959 0 N-CA-C 109.305 -0.628 . . . . 74.42 109.305 174.132 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.474 HD12 ' HG ' ' A' ' 98' ' ' LEU . 1.8 pt? -144.87 132.37 10.37 Favored Pre-proline 0 CA--C 1.541 0.622 0 C-N-CA 123.099 0.56 . . . . 73.34 111.41 -166.21 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_exo -68.82 115.08 3.77 Favored 'Trans proline' 0 C--N 1.375 1.973 0 C-N-CA 122.654 2.236 . . . . 74.25 112.194 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.443 ' HB3' HD23 ' A' ' 180' ' ' LEU . 16.9 tp -109.2 166.84 10.55 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.512 1.125 . . . . 73.35 108.202 174.481 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.561 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 25.9 m -103.32 156.64 17.59 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 109.671 -0.492 . . . . 72.02 109.671 173.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.5 HD23 ' HB3' ' A' ' 180' ' ' LEU . 87.5 mt -56.02 -50.5 70.74 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-O 121.671 0.748 . . . . 64.14 110.069 171.763 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -57.48 -34.18 68.77 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 114.517 -1.22 . . . . 71.13 111.987 176.676 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.537 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 31.3 mm-40 -74.12 -31.49 62.79 Favored 'General case' 0 N--CA 1.482 1.169 0 C-N-CA 123.171 0.588 . . . . 74.41 111.56 176.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.444 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -59.33 -37.91 79.02 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.442 0.697 . . . . 70.24 111.471 169.511 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.556 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 46.8 t80 -71.61 -47.73 52.7 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 115.79 -0.641 . . . . 75.51 112.174 173.16 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 31.8 m80 -63.09 -53.71 49.39 Favored 'General case' 0 N--CA 1.483 1.187 0 O-C-N 123.702 0.626 . . . . 64.44 111.004 -173.63 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 59.41 149.76 0.01 OUTLIER Glycine 0 CA--C 1.537 1.431 0 CA-C-N 115.772 -0.649 . . . . 74.51 113.297 -168.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 170.37 -179.06 42.74 Favored Glycine 0 CA--C 1.505 -0.551 0 C-N-CA 119.968 -1.11 . . . . 52.53 114.666 177.805 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -89.78 138.36 31.55 Favored 'General case' 0 C--O 1.24 0.596 0 CA-C-N 113.445 -1.377 . . . . 75.13 107.886 177.153 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.658 ' HG2' ' HB2' ' A' ' 98' ' ' LEU . 19.7 tpp180 -154.05 158.19 40.16 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 108.622 -0.881 . . . . 53.55 108.622 178.347 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.4 p -80.14 126.16 39.29 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.21 0 CA-C-O 121.544 0.687 . . . . 70.33 111.689 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 8.9 p -107.71 123.24 62.96 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 C-N-CA 124.732 1.213 . . . . 73.51 108.883 171.293 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -118.94 98.73 6.33 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 108.508 -0.923 . . . . 72.44 108.508 177.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.416 HG21 HD22 ' A' ' 174' ' ' LEU . 14.3 m -122.69 134.73 65.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 124.245 1.018 . . . . 73.34 109.785 -176.007 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.21 29.79 19.42 Favored 'General case' 0 CA--C 1.551 1.012 0 C-N-CA 124.18 0.992 . . . . 71.3 110.38 -173.623 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.28 6.39 79.91 Favored Glycine 0 C--N 1.358 1.797 0 CA-C-N 115.364 -0.835 . . . . 62.13 113.806 -177.734 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -99.31 115.08 28.35 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 109.103 -0.703 . . . . 73.53 109.103 -176.267 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -95.41 116.04 28.25 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 123.709 0.803 . . . . 65.43 110.144 -175.404 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.675 HG21 ' SD ' ' A' ' 164' ' ' MET . 7.5 m -142.79 156.99 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 125.368 1.467 . . . . 74.24 108.539 176.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 38.9 t -88.37 127.02 35.48 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 109.864 -0.421 . . . . 60.52 109.864 174.582 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.7 p -99.91 144.88 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 123.699 0.8 . . . . 65.0 109.567 171.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.6 ttt180 -109.43 116.22 31.41 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.593 -0.891 . . . . 74.03 108.593 168.294 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.435 HG22 HG21 ' A' ' 159' ' ' ILE . 35.1 pt -121.1 132.04 24.31 Favored Pre-proline 0 CA--C 1.549 0.927 0 N-CA-C 108.93 -0.767 . . . . 72.3 108.93 171.189 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -76.45 166.61 27.13 Favored 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 122.8 2.333 . . . . 73.13 113.531 -170.327 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -68.89 154.62 70.65 Favored 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.109 1.873 . . . . 65.41 110.468 165.126 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 90.41 44.35 4.66 Favored Glycine 0 C--O 1.239 0.44 0 N-CA-C 111.548 -0.621 . . . . 73.12 111.548 -173.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.444 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 2.7 p -116.3 156.26 17.52 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.102 0 N-CA-C 108.197 -1.038 . . . . 75.15 108.197 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.2 mtp180 -138.76 166.17 25.1 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 123.967 0.907 . . . . 72.03 110.916 -164.437 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -57.97 127.55 32.61 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 122.957 0.503 . . . . 54.51 110.823 170.333 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 77.19 6.67 86.45 Favored Glycine 0 C--N 1.349 1.261 0 O-C-N 123.717 0.636 . . . . 51.32 113.379 -178.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 41.2 t -69.56 122.45 19.09 Favored 'General case' 0 C--N 1.358 0.953 0 C-N-CA 122.942 0.497 . . . . 61.13 109.7 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.443 HG22 HD22 ' A' ' 175' ' ' LEU . 7.3 p -103.01 119.94 52.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 O-C-N 124.475 1.109 . . . . 65.13 109.608 -176.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.435 HG21 HG22 ' A' ' 149' ' ' ILE . 17.6 mt -115.74 116.82 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 123.864 0.865 . . . . 70.15 109.86 -173.115 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.407 ' HA ' HD23 ' A' ' 175' ' ' LEU . 44.1 ttp180 -75.8 120.3 20.97 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 118.36 0.527 . . . . 75.03 110.141 175.758 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.651 ' HB ' ' HB3' ' A' ' 174' ' ' LEU . 84.2 t -112.16 113.88 51.42 Favored Pre-proline 0 CA--C 1.552 1.027 0 C-N-CA 124.249 1.019 . . . . 72.4 109.636 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -76.95 157.4 34.61 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.664 2.242 . . . . 70.32 113.233 178.419 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' GLY . . . . . 0.626 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . 105.76 -25.94 22.63 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 115.365 0.906 . . . . 70.04 115.365 173.879 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.675 ' SD ' HG21 ' A' ' 145' ' ' VAL . 4.1 mpp? -111.0 -45.89 3.4 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-N 118.893 1.347 . . . . 63.01 112.431 -175.001 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -76.47 -165.88 21.99 Favored Glycine 0 C--N 1.343 0.936 0 C-N-CA 121.441 -0.409 . . . . 61.42 112.624 179.313 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -111.85 -66.45 0.51 Allowed Glycine 0 C--N 1.339 0.727 0 N-CA-C 112.14 -0.384 . . . . 63.31 112.14 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.627 ' HB2' ' HB3' ' A' ' 118' ' ' ASP . 11.8 mm-40 -58.7 175.38 0.26 Allowed 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 124.917 1.287 . . . . 64.01 113.1 -177.558 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 129.11 -174.68 19.12 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 115.341 -0.845 . . . . 74.22 112.013 171.327 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -80.79 -46.11 1.24 Allowed Pre-proline 0 CA--C 1.56 1.346 0 N-CA-C 109.496 -0.557 . . . . 75.11 109.496 169.271 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -89.2 163.87 5.67 Favored 'Trans proline' 0 C--N 1.388 2.623 0 C-N-CA 121.561 1.508 . . . . 62.42 110.263 162.354 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -63.22 124.94 14.74 Favored 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 121.481 1.454 . . . . 65.43 110.241 169.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.626 ' HA3' ' H ' ' A' ' 163' ' ' GLY . . . 103.91 119.97 4.7 Favored Glycine 0 C--N 1.34 0.778 0 N-CA-C 112.301 -0.319 . . . . 60.31 112.301 -176.329 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -134.6 107.5 7.53 Favored 'General case' 0 C--N 1.333 -0.141 0 C-N-CA 124.524 1.129 . . . . 72.31 108.153 172.429 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.651 ' HB3' ' HB ' ' A' ' 161' ' ' VAL . 27.4 tp -121.33 105.89 10.95 Favored 'General case' 0 C--O 1.226 -0.132 0 N-CA-C 107.2 -1.407 . . . . 75.22 107.2 168.003 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.443 HD22 HG22 ' A' ' 158' ' ' VAL . 59.8 mt -84.76 99.39 10.83 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.017 -0.538 . . . . 62.43 110.483 -176.015 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.442 ' HA ' ' O ' ' A' ' 121' ' ' ALA . 59.8 mt -84.35 102.81 13.0 Favored 'General case' 0 C--N 1.344 0.351 0 CA-C-N 115.569 -0.741 . . . . 74.44 109.393 176.101 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.7 t -95.98 95.05 4.54 Favored 'Isoleucine or valine' 0 C--O 1.242 0.665 0 CA-C-N 114.61 -1.177 . . . . 74.24 107.962 179.343 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.41 HG21 HG22 ' A' ' 153' ' ' VAL . 5.6 m -75.3 147.63 8.14 Favored 'Isoleucine or valine' 0 C--O 1.245 0.831 0 CA-C-O 121.521 0.676 . . . . 75.24 110.898 -171.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -121.35 94.93 4.49 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 108.119 -1.067 . . . . 71.3 108.119 -176.238 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.5 ' HB3' HD23 ' A' ' 127' ' ' LEU . 50.1 mt -67.34 147.12 53.36 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 110.269 -0.271 . . . . 73.12 110.269 -176.343 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.561 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 20.3 mt -56.59 123.41 56.95 Favored Pre-proline 0 CA--C 1.552 1.054 0 CA-C-O 119.307 -0.378 . . . . 73.13 110.362 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 17.2 Cg_exo -66.82 85.27 0.3 Allowed 'Trans proline' 0 C--N 1.379 2.143 0 C-N-CA 123.508 2.805 . . . . 75.21 113.356 -172.423 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -162.44 77.25 2.01 Favored Pre-proline 0 CA--C 1.558 1.281 0 N-CA-C 108.094 -1.076 . . . . 71.05 108.094 171.219 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -63.33 123.46 12.17 Favored 'Trans proline' 0 C--N 1.377 2.031 0 C-N-CA 122.002 1.801 . . . . 74.22 111.924 -171.219 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.8 p -134.56 -46.78 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 N-CA-C 107.517 -1.29 . . . . 62.2 107.517 174.135 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.54 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 4.3 m-85 -103.55 123.77 47.55 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.22 -0.9 . . . . 72.45 110.61 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 15.0 mtm180 -120.82 104.75 10.11 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.905 -1.517 . . . . 74.11 106.905 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.46 HD13 ' HD1' ' A' ' 240' ' ' PHE . 44.3 tp -83.6 138.55 33.31 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 108.996 -0.742 . . . . 55.34 108.996 174.657 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -141.59 104.93 4.65 Favored 'General case' 0 C--O 1.243 0.747 0 N-CA-C 107.393 -1.336 . . . . 71.34 107.393 176.273 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 74.84 -88.17 0.76 Allowed Glycine 0 C--N 1.348 1.221 0 CA-C-N 115.738 -0.665 . . . . 53.44 111.654 -174.203 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -136.59 -6.36 1.96 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 123.625 0.77 . . . . 71.1 110.854 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -98.53 149.55 22.62 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.369 0.668 . . . . 71.24 111.202 -177.162 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.601 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.7 mt -109.58 151.17 27.16 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.486 1.114 . . . . 74.54 109.207 -177.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -140.41 120.17 13.42 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 107.372 -1.344 . . . . 73.41 107.372 178.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 195' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -143.24 140.66 30.78 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.742 0.817 . . . . 63.42 108.939 -177.138 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 20.5 m -83.39 127.98 34.13 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-O 121.194 0.521 . . . . 60.13 110.208 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 197' ' ' LEU . . . . . . . . . . . . . 65.1 tp -112.3 120.66 42.5 Favored 'General case' 0 C--O 1.22 -0.479 0 C-N-CA 125.216 1.406 . . . . 74.21 108.941 176.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -99.35 123.08 43.33 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.402 -0.962 . . . . 74.32 108.402 170.363 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 4.6 m -110.2 147.78 36.99 Favored Pre-proline 0 C--O 1.245 0.849 0 C-N-CA 123.039 0.536 . . . . 74.41 109.883 -177.656 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -60.22 134.1 53.7 Favored 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 122.367 2.045 . . . . 72.14 110.877 168.134 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -53.96 -43.35 96.57 Favored Pre-proline 0 CA--C 1.564 1.493 0 C-N-CA 124.325 1.05 . . . . 71.4 113.541 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_exo -55.13 -46.48 32.71 Favored 'Trans proline' 0 C--N 1.395 3.024 0 C-N-CA 122.473 2.116 . . . . 73.34 112.97 171.303 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 7.1 mt -63.28 -38.24 81.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 123.344 0.657 . . . . 71.42 111.072 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.91 -43.62 98.29 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 123.099 0.56 . . . . 64.55 111.889 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 205' ' ' VAL . . . . . 0.515 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 35.8 m -80.81 -38.96 17.59 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 CA-C-N 116.154 -0.476 . . . . 65.3 112.178 -175.162 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.0 m -79.53 -35.78 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 CA-C-N 118.12 0.418 . . . . 53.33 110.573 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 89.81 80.02 1.34 Allowed Glycine 0 C--N 1.348 1.22 0 CA-C-N 115.613 -0.721 . . . . 75.01 112.229 -175.11 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -117.54 -160.42 11.71 Favored Glycine 0 C--N 1.357 1.732 0 N-CA-C 112.164 -0.374 . . . . 42.25 112.164 175.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 10.5 mtmp? -115.98 137.44 52.11 Favored 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 123.47 0.708 . . . . 73.45 110.373 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 28.2 t -118.82 152.06 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.745 1.218 . . . . 55.15 108.749 176.723 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -81.13 119.2 23.27 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 108.434 -0.95 . . . . 71.44 108.434 171.58 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -102.16 122.94 45.12 Favored 'General case' 0 C--O 1.239 0.511 0 N-CA-C 108.125 -1.065 . . . . 55.21 108.125 175.207 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 54.7 mmm -77.21 113.4 14.92 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.193 0.52 . . . . 64.11 110.288 178.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.54 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 9.1 t -109.83 167.96 9.77 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-N 114.692 -1.14 . . . . 62.04 109.766 171.227 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 215' ' ' LEU . . . . . 0.412 HD13 ' O ' ' A' ' 127' ' ' LEU . 72.1 mt -71.12 -7.5 47.0 Favored 'General case' 0 CA--C 1.546 0.821 0 CA-C-N 114.701 -1.136 . . . . 73.24 111.735 178.34 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -90.57 -19.79 23.34 Favored 'General case' 0 CA--C 1.558 1.26 0 C-N-CA 124.211 1.004 . . . . 73.33 110.951 172.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 137.24 -154.36 22.33 Favored Glycine 0 C--N 1.347 1.163 0 N-CA-C 110.901 -0.88 . . . . 31.11 110.901 -174.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -89.19 129.06 1.92 Allowed 'Trans proline' 0 CA--C 1.55 1.295 0 C-N-CA 122.649 2.232 . . . . 61.32 111.923 170.685 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.0 m -109.82 167.91 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 123.775 0.83 . . . . 74.32 111.197 174.046 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -105.69 115.79 30.85 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 123.598 0.759 . . . . 62.31 109.906 177.456 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 2.7 p -116.55 125.44 73.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 123.974 0.91 . . . . 71.31 109.566 174.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -92.31 121.83 34.18 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.124 -0.695 . . . . 34.24 109.124 175.024 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 10.0 m -81.7 145.43 54.33 Favored Pre-proline 0 CA--C 1.553 1.06 0 N-CA-C 108.989 -0.745 . . . . 43.04 108.989 177.338 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -61.99 141.92 90.94 Favored 'Trans proline' 0 C--N 1.371 1.713 0 C-N-CA 122.13 1.887 . . . . 65.33 111.914 173.372 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -60.04 122.21 11.03 Favored 'Trans proline' 0 C--N 1.368 1.592 0 C-N-CA 122.784 2.322 . . . . 75.54 112.257 174.358 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 226' ' ' ARG . . . . . 0.515 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 62.3 mtp180 65.85 39.33 4.7 Favored 'General case' 0 N--CA 1.482 1.172 0 C-N-CA 124.732 1.213 . . . . 73.3 111.427 -176.294 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 7.1 t -70.9 174.41 6.17 Favored 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 122.941 0.496 . . . . 75.13 111.272 -179.098 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.2 mp0 -123.55 143.65 50.07 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 123.859 0.863 . . . . 73.32 109.54 -176.665 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.08 123.28 21.18 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.785 0.834 . . . . 63.31 110.098 175.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 112.87 12.24 12.88 Favored Glycine 0 C--N 1.34 0.788 0 CA-C-N 116.244 -0.434 . . . . 73.41 112.605 -176.689 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 84.8 mtt180 -91.17 154.51 19.28 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 109.292 -0.633 . . . . 74.01 109.292 167.601 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.404 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.1 OUTLIER -104.27 111.45 24.08 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 123.615 0.766 . . . . 71.52 109.03 172.568 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 233' ' ' LEU . . . . . 0.475 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 67.8 mt -87.63 104.78 16.84 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 108.333 -0.988 . . . . 73.34 108.333 -177.363 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 40.5 ttm105 -76.58 110.39 11.1 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-N 115.313 -0.858 . . . . 54.21 111.755 -172.352 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.454 HD12 HD23 ' A' ' 249' ' ' LEU . 20.9 mt -91.97 106.12 18.21 Favored 'General case' 0 C--O 1.239 0.551 0 N-CA-C 107.897 -1.149 . . . . 71.22 107.897 169.338 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 93.3 mttt -66.57 132.89 49.18 Favored 'General case' 0 CA--C 1.538 0.506 0 CA-C-N 114.578 -1.192 . . . . 75.24 111.828 -167.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 79.91 -1.11 80.61 Favored Glycine 0 C--N 1.348 1.228 0 O-C-N 123.834 0.709 . . . . 54.23 114.649 173.446 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -84.57 -3.78 58.63 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.496 0.554 . . . . 71.41 112.496 -176.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.91 -179.31 48.92 Favored Glycine 0 C--N 1.346 1.136 0 N-CA-C 112.446 -0.262 . . . . 71.24 112.446 174.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.556 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 73.9 m-85 -86.38 155.86 56.93 Favored Pre-proline 0 N--CA 1.476 0.847 0 C-N-CA 123.197 0.599 . . . . 75.32 112.296 -173.635 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -60.97 140.5 90.5 Favored 'Trans proline' 0 C--N 1.384 2.444 0 C-N-CA 122.778 2.318 . . . . 73.25 112.772 178.314 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -150.82 -162.01 10.37 Favored Glycine 0 CA--C 1.533 1.179 0 N-CA-C 110.458 -1.057 . . . . 72.13 110.458 175.044 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -69.7 -20.68 34.81 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.803 2.335 . . . . 63.22 113.043 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.79 3.18 55.33 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.673 0.789 . . . . 73.12 112.083 -175.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.37 -105.97 1.62 Allowed Glycine 0 C--N 1.35 1.314 0 N-CA-C 110.619 -0.993 . . . . 64.31 110.619 -176.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 50.6 mtm-85 -126.58 152.28 46.82 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 108.045 -1.095 . . . . 74.3 108.045 167.395 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -78.03 -158.28 10.79 Favored Glycine 0 C--N 1.343 0.936 0 O-C-N 123.362 0.414 . . . . 72.21 112.152 174.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 38.6 m-20 -136.65 170.1 16.62 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 109.323 -0.621 . . . . 62.34 109.323 -175.437 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.601 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 23.9 tp -103.27 124.44 48.64 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.202 -0.666 . . . . 75.21 109.202 171.35 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 250' ' ' TYR . . . . . 0.404 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 48.3 m-85 -107.89 104.35 13.81 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.293 0.637 . . . . 62.11 109.405 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.475 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 85.2 mt -89.11 113.75 24.93 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.802 0.841 . . . . 71.11 112.414 -178.33 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -78.85 91.66 4.78 Favored 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 108.777 -0.823 . . . . 72.4 108.777 176.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.1 p -54.11 130.98 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.353 1.061 . . . . 74.14 111.066 176.637 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 13.2 mmt180 -131.02 99.01 4.75 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 125.12 1.368 . . . . 72.02 107.548 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 63.5 mt -76.58 124.76 35.48 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 C-N-CA 123.822 0.849 . . . . 72.35 109.269 -175.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 9.4 t . . . . . 0 C--O 1.25 1.086 0 C-N-CA 123.552 0.741 . . . . 72.5 109.781 -175.62 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.454 ' HB1' HG13 ' A' ' 99' ' ' VAL . . . . . . . . 0 N--CA 1.484 1.238 0 N-CA-C 109.959 -0.385 . . . . 50.55 109.959 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -149.25 -84.77 0.09 Allowed 'General case' 0 N--CA 1.48 1.06 0 C-N-CA 122.508 0.323 . . . . 73.43 110.71 -179.563 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.54 HD22 HD12 ' A' ' 123' ' ' LEU . 0.0 OUTLIER -82.9 -24.21 33.23 Favored 'General case' 0 N--CA 1.484 1.226 0 CA-C-O 121.254 0.549 . . . . 61.11 110.108 178.237 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.558 ' HA ' ' HB2' ' A' ' 123' ' ' LEU . 11.4 p -84.08 143.46 11.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 C-N-CA 124.702 1.201 . . . . 72.42 110.624 171.715 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -77.82 -87.07 0.05 Allowed 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 108.439 -0.949 . . . . 72.22 108.439 169.518 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.4 m80 -168.78 179.54 4.16 Favored 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 125.026 1.33 . . . . 74.12 109.72 177.461 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 93.4 t -62.23 140.16 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 C-N-CA 123.654 0.782 . . . . 61.44 111.146 178.721 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 37.4 p -66.57 110.21 3.09 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 123.163 0.585 . . . . 73.21 109.443 172.487 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 48.0 t -58.2 98.55 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 124.745 1.218 . . . . 50.4 112.109 -175.161 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -173.35 -175.19 40.93 Favored Glycine 0 C--N 1.342 0.867 0 CA-C-N 115.764 -0.653 . . . . 51.43 111.592 178.415 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 32.2 p -77.65 -66.13 0.88 Allowed 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.335 0.654 . . . . 72.25 109.793 177.283 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -161.5 154.16 25.08 Favored Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.665 -0.574 . . . . 72.44 111.665 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -109.76 -89.48 1.99 Allowed Glycine 0 C--N 1.345 1.035 0 C-N-CA 123.335 0.493 . . . . 75.11 112.478 -177.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 13.0 t -154.1 34.76 0.43 Allowed 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 121.403 0.62 . . . . 73.02 110.105 -174.096 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -79.95 156.12 39.66 Favored Glycine 0 C--N 1.342 0.912 0 CA-C-N 115.62 -0.718 . . . . 74.52 112.656 176.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 101.74 43.36 2.13 Favored Glycine 0 C--N 1.338 0.675 0 C-N-CA 123.642 0.639 . . . . 74.51 113.15 176.759 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 39.6 m -76.01 110.34 10.4 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 122.721 0.408 . . . . 53.52 110.386 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 77.75 -73.28 2.11 Favored Glycine 0 C--N 1.344 1.021 0 N-CA-C 110.676 -0.97 . . . . 61.03 110.676 -174.414 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.554 ' HA3' ' HG2' ' A' ' 171' ' ' PRO . . . -76.97 98.45 1.32 Allowed Glycine 0 C--N 1.344 0.994 0 N-CA-C 110.645 -0.982 . . . . 75.3 110.645 170.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 14.3 p -76.13 92.8 3.26 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 123.4 0.68 . . . . 65.32 110.87 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -127.24 -177.08 14.71 Favored Glycine 0 C--N 1.342 0.878 0 CA-C-N 115.268 -0.878 . . . . 71.01 111.071 172.211 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.577 ' HB3' ' HA2' ' A' ' 166' ' ' GLY . 20.0 tpp180 -63.1 124.64 21.65 Favored 'General case' 0 C--O 1.248 1.006 0 C-N-CA 122.9 0.48 . . . . 73.52 110.921 -176.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -61.24 125.33 23.35 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 114.361 -1.29 . . . . 70.0 110.576 171.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.551 HD12 ' HA2' ' A' ' 165' ' ' GLY . 12.4 mt -125.59 142.46 51.5 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 107.26 -1.385 . . . . 74.04 107.26 160.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.6 ' HG2' ' HB2' ' A' ' 175' ' ' LEU . 41.0 mtm180 -141.91 145.78 34.97 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 107.694 -1.224 . . . . 64.33 107.694 178.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -151.46 118.42 5.85 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 108.516 -0.92 . . . . 71.24 108.516 175.379 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -88.85 132.45 34.66 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 108.086 -1.079 . . . . 52.23 108.086 173.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.558 ' HB2' ' HA ' ' A' ' 99' ' ' VAL . 2.2 pt? -142.71 146.65 39.0 Favored Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 122.778 0.431 . . . . 72.51 111.683 -168.564 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -75.97 121.6 6.3 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.689 2.259 . . . . 62.41 111.182 173.823 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.441 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 14.2 tp -120.16 168.94 10.7 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.216 1.006 . . . . 65.44 108.793 174.69 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.628 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 11.5 m -107.06 155.98 19.25 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.136 0.574 . . . . 74.12 109.776 174.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 80.5 mt -50.49 -52.41 38.57 Favored 'General case' 0 N--CA 1.487 1.41 0 C-N-CA 124.127 0.971 . . . . 65.24 110.216 173.29 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.552 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -54.91 -39.52 68.89 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 113.506 -1.679 . . . . 71.44 112.103 177.812 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.628 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 16.0 mm-40 -76.88 -26.31 54.06 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 123.099 0.56 . . . . 72.15 112.107 -176.354 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.539 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -61.12 -44.56 97.16 Favored 'General case' 0 C--O 1.252 1.219 0 CA-C-O 121.62 0.724 . . . . 72.3 111.129 169.221 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -67.69 -46.31 72.65 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 114.029 -1.441 . . . . 72.21 112.747 176.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.2 m80 -69.2 -47.43 64.86 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 122.775 0.43 . . . . 73.5 110.759 -176.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.69 -148.24 50.99 Favored Glycine 0 C--N 1.344 1.022 0 N-CA-C 111.229 -0.749 . . . . 72.23 111.229 -169.533 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 117.26 172.72 16.21 Favored Glycine 0 N--CA 1.472 1.039 0 CA-C-N 117.224 0.512 . . . . 24.11 113.471 172.453 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 13.7 mp0 -90.11 114.42 26.34 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 107.744 -1.206 . . . . 61.13 107.744 179.427 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 4.9 mmp_? -116.75 163.19 16.51 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 123.855 0.862 . . . . 73.51 110.306 -177.146 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.6 p -88.48 124.07 41.24 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 CA-C-O 121.241 0.543 . . . . 65.04 110.241 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.408 ' HA ' HG11 ' A' ' 99' ' ' VAL . 12.0 p -114.24 145.87 19.5 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.694 0 C-N-CA 123.816 0.846 . . . . 64.44 109.962 178.463 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -125.91 109.06 12.05 Favored 'General case' 0 C--O 1.242 0.682 0 N-CA-C 108.668 -0.864 . . . . 74.45 108.668 174.254 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.9 m -130.43 117.52 39.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 123.678 0.791 . . . . 73.24 111.068 -176.198 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.05 23.39 13.79 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.835 1.254 . . . . 63.51 112.257 176.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.12 12.71 57.25 Favored Glycine 0 C--N 1.343 0.944 0 CA-C-O 120.032 -0.315 . . . . 51.11 112.995 -178.309 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.1 mpt_? -103.3 116.87 33.27 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.203 -0.665 . . . . 74.42 109.203 177.169 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 62.5 ttp85 -94.32 105.17 17.15 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 108.14 -1.059 . . . . 74.42 108.14 172.648 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 8.9 m -142.11 157.07 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 C-N-CA 124.338 1.055 . . . . 52.12 109.575 -175.15 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 54.3 p -90.94 120.08 31.66 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 122.889 0.476 . . . . 63.54 110.217 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.22 141.35 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.348 0.659 . . . . 34.44 109.425 177.412 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -107.04 103.42 12.83 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 108.298 -1.001 . . . . 63.41 108.298 174.45 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.439 ' HB ' HD13 ' A' ' 159' ' ' ILE . 37.8 pt -106.98 107.27 60.22 Favored Pre-proline 0 CA--C 1.548 0.873 0 N-CA-C 108.677 -0.861 . . . . 72.42 108.677 170.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.96 162.08 43.11 Favored 'Trans proline' 0 C--N 1.38 2.235 0 C-N-CA 122.972 2.448 . . . . 71.11 113.389 -171.035 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -59.85 114.77 2.22 Favored 'Trans proline' 0 C--N 1.376 2.017 0 C-N-CA 122.482 2.121 . . . . 73.44 110.448 169.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.42 ' HA2' ' CD2' ' A' ' 240' ' ' PHE . . . 140.62 61.35 0.04 OUTLIER Glycine 0 C--N 1.341 0.811 0 N-CA-C 111.811 -0.515 . . . . 71.12 111.811 -173.724 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.568 HG21 HD11 ' A' ' 159' ' ' ILE . 3.2 p -150.9 163.14 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.301 0 C-N-CA 122.505 0.322 . . . . 74.43 110.162 -178.424 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 44.8 mtp180 -146.8 177.02 9.43 Favored 'General case' 0 N--CA 1.484 1.234 0 C-N-CA 124.987 1.315 . . . . 75.42 110.113 -171.441 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.2 tp10 -51.72 118.2 3.22 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 125.053 1.341 . . . . 71.14 111.51 170.545 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 79.0 1.28 84.91 Favored Glycine 0 C--N 1.351 1.373 0 CA-C-O 119.382 -0.677 . . . . 73.51 113.866 176.045 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.4 m -73.78 136.49 43.59 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-N 117.352 0.576 . . . . 63.34 110.953 -176.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.446 HG12 HD22 ' A' ' 175' ' ' LEU . 13.2 t -101.06 122.97 53.77 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-N 114.646 -1.161 . . . . 53.42 108.894 -174.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.568 HD11 HG21 ' A' ' 153' ' ' VAL . 16.6 mt -106.4 107.35 22.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 N-CA-C 109.035 -0.728 . . . . 74.21 109.035 -175.448 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.507 ' HA ' HD23 ' A' ' 175' ' ' LEU . 58.4 ttt-85 -81.7 109.13 15.83 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 110.03 -0.359 . . . . 63.5 110.03 176.202 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.444 HG22 ' O ' ' A' ' 174' ' ' LEU . 19.5 m -101.72 97.81 8.56 Favored Pre-proline 0 CA--C 1.559 1.319 0 N-CA-C 108.647 -0.872 . . . . 72.41 108.647 172.069 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -74.55 155.98 45.07 Favored 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 123.053 2.502 . . . . 50.41 113.189 -176.49 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 73.27 24.73 74.78 Favored Glycine 0 C--N 1.345 1.076 0 CA-C-N 115.488 -0.778 . . . . 72.51 112.586 -178.092 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.405 ' HG2' HG23 ' A' ' 161' ' ' VAL . 6.7 tpt -125.68 -56.89 1.47 Allowed 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 124.01 0.924 . . . . 74.35 111.573 -166.694 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 165' ' ' GLY . . . . . 0.551 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . -70.43 -79.96 0.32 Allowed Glycine 0 C--N 1.353 1.491 0 O-C-N 123.725 0.641 . . . . 61.45 112.14 -175.032 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.577 ' HA2' ' HB3' ' A' ' 117' ' ' ARG . . . -60.5 116.96 9.96 Favored Glycine 0 C--N 1.338 0.69 0 O-C-N 123.98 0.459 . . . . 50.42 113.688 169.493 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.6 mm-40 -81.51 146.57 30.12 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 124.049 0.94 . . . . 73.14 109.846 177.344 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 118.3 -177.63 16.55 Favored Glycine 0 N--CA 1.465 0.577 0 CA-C-N 116.536 -0.302 . . . . 44.51 112.478 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -65.16 -43.51 66.29 Favored Pre-proline 0 CA--C 1.554 1.114 0 CA-C-O 118.367 -0.825 . . . . 75.25 112.183 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.43 118.69 5.77 Favored 'Trans proline' 0 C--N 1.393 2.891 0 C-N-CA 121.424 1.416 . . . . 55.41 110.157 167.365 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.554 ' HG2' ' HA3' ' A' ' 114' ' ' GLY . 62.6 Cg_endo -73.8 125.2 9.78 Favored 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 121.731 1.621 . . . . 50.4 112.539 -175.087 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.521 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -98.87 178.69 31.05 Favored Glycine 0 C--O 1.222 -0.625 0 N-CA-C 110.565 -1.014 . . . . 52.14 110.565 166.67 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -146.56 157.14 43.68 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 118.12 0.96 . . . . 71.51 111.259 -171.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.444 ' O ' HG22 ' A' ' 161' ' ' VAL . 27.0 tp -114.57 115.59 27.42 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 114.655 -1.157 . . . . 72.44 108.684 176.297 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.6 ' HB2' ' HG2' ' A' ' 120' ' ' ARG . 93.8 mt -90.35 99.46 12.48 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.297 1.039 . . . . 63.11 110.254 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.422 HD12 HG21 ' A' ' 149' ' ' ILE . 45.6 mt -87.07 104.59 16.48 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 122.81 0.444 . . . . 72.15 110.51 175.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.5 t -89.39 95.78 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 107.803 -1.184 . . . . 72.42 107.803 176.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.441 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 8.1 m -82.08 144.11 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 109.769 -0.456 . . . . 74.4 109.769 -174.695 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 5.2 mmm180 -122.28 105.55 10.31 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 106.118 -1.808 . . . . 64.52 106.118 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 36.6 mt -69.61 147.88 50.11 Favored 'General case' 0 N--CA 1.473 0.706 0 O-C-N 123.373 0.421 . . . . 65.21 111.175 -172.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.472 HD12 HG23 ' A' ' 126' ' ' THR . 36.5 mt -55.73 121.04 36.95 Favored Pre-proline 0 C--N 1.357 0.905 0 O-C-N 123.641 0.588 . . . . 73.54 109.748 177.635 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -65.98 88.02 0.24 Allowed 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 122.969 2.446 . . . . 61.13 112.306 -178.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 13.3 p80 -156.99 62.9 2.88 Favored Pre-proline 0 CA--C 1.55 0.958 0 N-CA-C 107.794 -1.187 . . . . 74.1 107.794 169.131 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -56.14 122.06 11.1 Favored 'Trans proline' 0 C--N 1.382 2.339 0 C-N-CA 122.089 1.859 . . . . 74.24 112.639 -170.053 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.83 -45.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 N-CA-C 107.704 -1.221 . . . . 61.51 107.704 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.435 ' CE2' HD13 ' A' ' 193' ' ' LEU . 4.9 m-85 -107.41 131.98 53.68 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 123.93 0.892 . . . . 72.41 110.384 178.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 69.0 mtp180 -117.81 131.12 56.61 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.765 1.226 . . . . 74.41 108.635 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.406 HD12 ' O ' ' A' ' 192' ' ' ASP . 58.6 tp -109.9 130.84 55.48 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 121.004 0.43 . . . . 64.2 110.182 177.267 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -129.87 101.79 6.02 Favored 'General case' 0 C--O 1.24 0.572 0 N-CA-C 107.417 -1.327 . . . . 63.53 107.417 172.69 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 69.67 -82.65 0.29 Allowed Glycine 0 CA--C 1.53 1.008 0 O-C-N 123.793 0.683 . . . . 62.11 112.607 -176.371 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 191' ' ' GLN . . . . . 0.417 HE22 ' HB3' ' A' ' 244' ' ' ALA . 49.8 tt0 -134.2 -22.18 1.79 Allowed 'General case' 0 CA--C 1.552 1.053 0 C-N-CA 124.733 1.213 . . . . 73.03 109.554 -177.58 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.406 ' O ' HD12 ' A' ' 188' ' ' LEU . 41.3 m-20 -81.41 149.73 28.69 Favored 'General case' 0 C--N 1.358 0.967 0 C-N-CA 123.809 0.844 . . . . 72.43 111.385 -178.31 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.535 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.8 mt -109.58 155.04 21.92 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 124.639 1.176 . . . . 51.1 110.491 174.604 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -140.02 119.02 12.6 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 105.605 -1.998 . . . . 74.31 105.605 172.34 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 195' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -135.5 134.41 39.49 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 109.184 -0.672 . . . . 71.4 109.184 -178.235 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 196' ' ' THR . . . . . 0.437 ' HA ' ' HB3' ' A' ' 252' ' ' GLU . 24.0 m -70.91 123.64 22.49 Favored 'General case' 0 CA--C 1.541 0.612 0 O-C-N 123.654 0.596 . . . . 73.2 110.064 -179.239 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.466 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 61.3 tp -105.95 111.34 23.95 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 108.767 -0.827 . . . . 71.34 108.767 -178.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -85.04 116.74 23.6 Favored 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.492 -0.929 . . . . 55.44 108.492 176.454 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 2.2 m -122.86 141.64 35.95 Favored Pre-proline 0 N--CA 1.479 0.986 0 N-CA-C 108.996 -0.742 . . . . 50.33 108.996 177.592 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -72.7 147.1 44.44 Favored 'Trans proline' 0 C--N 1.366 1.485 0 C-N-CA 121.539 1.493 . . . . 63.42 110.521 169.618 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -58.31 -40.97 86.87 Favored Pre-proline 0 CA--C 1.558 1.26 0 C-N-CA 123.689 0.796 . . . . 62.32 112.419 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -45.68 -54.84 4.07 Favored 'Trans proline' 0 C--N 1.392 2.844 0 C-N-CA 122.524 2.15 . . . . 43.41 114.164 167.151 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 11.7 mt -65.58 -36.29 77.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 C-N-CA 122.237 0.215 . . . . 75.13 111.429 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.53 -44.27 93.23 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.16 0.584 . . . . 31.24 111.944 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.7 m -80.16 -41.15 20.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 CA-C-N 116.063 -0.517 . . . . 53.34 111.569 -176.222 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.3 m -78.88 -21.18 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 122.549 0.34 . . . . 74.04 111.148 -178.649 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.516 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 71.2 65.32 2.48 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 115.764 -0.653 . . . . 74.32 112.439 -176.484 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -93.85 -155.55 31.87 Favored Glycine 0 C--N 1.353 1.505 0 CA-C-N 116.94 0.37 . . . . 65.4 112.535 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.22 134.87 54.62 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.326 1.05 . . . . 61.01 108.438 178.332 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 46.6 t -117.97 125.77 74.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 124.078 0.951 . . . . 64.43 108.593 -178.225 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -79.6 109.14 13.71 Favored 'General case' 0 CA--C 1.542 0.659 0 N-CA-C 109.137 -0.69 . . . . 64.54 109.137 177.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.95 129.92 48.35 Favored 'General case' 0 C--O 1.238 0.483 0 C-N-CA 123.417 0.687 . . . . 70.1 109.148 179.64 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.2 116.75 18.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.004 -0.544 . . . . 70.5 109.899 174.593 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.41 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.9 t -109.67 163.56 13.36 Favored 'General case' 0 C--O 1.242 0.685 0 O-C-N 123.901 0.75 . . . . 74.43 109.402 172.09 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 215' ' ' LEU . . . . . 0.552 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 90.2 mt -71.53 -2.58 17.37 Favored 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 115.507 -0.77 . . . . 63.33 112.61 -172.74 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -112.26 -11.72 13.69 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.565 0.746 . . . . 63.11 112.111 175.41 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 153.71 -156.34 26.73 Favored Glycine 0 C--N 1.349 1.267 0 CA-C-O 119.546 -0.585 . . . . 61.32 112.799 -179.047 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -94.28 133.53 0.76 Allowed 'Trans proline' 0 CA--C 1.556 1.592 0 C-N-CA 123.001 2.467 . . . . 74.14 112.846 174.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 27.1 m -114.56 157.5 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 123.585 0.754 . . . . 73.34 109.639 170.351 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -114.47 113.9 25.09 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 108.999 -0.741 . . . . 72.22 108.999 177.308 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.477 HG22 HD11 ' A' ' 235' ' ' LEU . 6.3 t -95.79 117.19 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 C-N-CA 123.99 0.916 . . . . 75.04 110.026 -177.328 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.99 100.57 11.14 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 108.977 -0.749 . . . . 74.21 108.977 176.101 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.516 HG23 ' HA2' ' A' ' 207' ' ' GLY . 20.0 m -79.43 137.45 55.65 Favored Pre-proline 0 CA--C 1.551 1.019 0 N-CA-C 109.415 -0.587 . . . . 54.14 109.415 179.415 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -63.31 144.9 92.39 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.537 2.158 . . . . 61.32 112.498 176.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -55.77 120.41 8.2 Favored 'Trans proline' 0 C--N 1.381 2.258 0 C-N-CA 123.081 2.521 . . . . 43.42 112.043 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 67.3 mtt180 64.76 54.61 1.34 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.382 1.073 . . . . 64.41 110.388 -175.185 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.3 t -75.49 167.36 22.04 Favored 'General case' 0 CA--C 1.545 0.781 0 CA-C-N 115.372 -0.831 . . . . 71.31 109.159 173.298 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -128.15 146.28 50.76 Favored 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 123.217 0.607 . . . . 74.12 109.614 -177.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -68.13 127.9 34.6 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 115.318 -0.855 . . . . 74.35 109.27 175.357 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.29 0.31 23.69 Favored Glycine 0 N--CA 1.471 1.032 0 CA-C-O 119.497 -0.613 . . . . 62.42 112.841 -173.463 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 25.0 mtp180 -84.4 154.89 22.55 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 117.414 0.607 . . . . 73.15 109.865 170.025 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.658 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.0 OUTLIER -120.59 101.67 7.91 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 108.497 -0.927 . . . . 75.12 108.497 176.269 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 37.2 mt -83.37 113.98 21.11 Favored 'General case' 0 C--N 1.352 0.686 0 N-CA-C 108.964 -0.754 . . . . 73.12 108.964 -173.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 -87.24 106.68 18.07 Favored 'General case' 0 C--O 1.239 0.507 0 C-N-CA 123.782 0.833 . . . . 75.32 110.839 -167.506 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.477 HD11 HG22 ' A' ' 221' ' ' VAL . 15.7 mt -94.06 104.28 16.32 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 108.112 -1.07 . . . . 75.15 108.112 174.091 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -74.65 141.47 44.61 Favored 'General case' 0 C--O 1.242 0.683 0 CA-C-N 115.763 -0.653 . . . . 73.13 112.025 -170.195 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 66.59 32.99 83.16 Favored Glycine 0 C--N 1.349 1.271 0 O-C-N 124.12 0.888 . . . . 71.22 113.253 178.044 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 41.1 mmtm -116.13 -2.68 12.15 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.663 0.785 . . . . 74.21 111.166 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 239' ' ' GLY . . . . . 0.449 ' O ' ' HD2' ' A' ' 246' ' ' ARG . . . -82.03 -156.16 17.28 Favored Glycine 0 C--N 1.347 1.177 0 O-C-N 123.657 0.598 . . . . 61.33 114.181 -178.164 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.42 ' CD2' ' HA2' ' A' ' 152' ' ' GLY . 35.0 m-85 -88.34 160.29 45.64 Favored Pre-proline 0 N--CA 1.482 1.159 0 C-N-CA 123.204 0.601 . . . . 52.24 110.56 176.176 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -57.09 152.5 44.15 Favored 'Trans proline' 0 C--N 1.382 2.313 0 C-N-CA 123.031 2.487 . . . . 71.51 113.971 178.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 176.94 -167.71 39.2 Favored Glycine 0 C--N 1.341 0.853 0 CA-C-N 115.27 -0.877 . . . . 74.34 112.11 176.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.27 -15.3 35.15 Favored 'Trans proline' 0 C--N 1.382 2.291 0 C-N-CA 122.983 2.456 . . . . 71.13 112.619 -176.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 244' ' ' ALA . . . . . 0.417 ' HB3' HE22 ' A' ' 191' ' ' GLN . . . -96.77 24.12 6.39 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.175 0.99 . . . . 54.34 110.692 174.817 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 77.8 -89.62 1.06 Allowed Glycine 0 C--N 1.345 1.063 0 N-CA-C 110.943 -0.863 . . . . 70.41 110.943 -175.713 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.449 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 23.1 mtm180 -128.09 155.89 43.67 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 108.728 -0.841 . . . . 75.14 108.728 169.539 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -70.9 -160.78 3.72 Favored Glycine 0 C--N 1.348 1.231 0 O-C-N 123.727 0.642 . . . . 60.14 114.397 -176.25 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -129.21 138.33 51.64 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 122.888 0.475 . . . . 74.52 109.772 -173.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.535 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 30.6 tp -97.27 115.96 28.59 Favored 'General case' 0 C--O 1.214 -0.788 0 C-N-CA 123.624 0.77 . . . . 75.1 110.017 -178.308 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 250' ' ' TYR . . . . . 0.658 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 97.3 m-85 -101.65 106.95 18.06 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 123.497 0.719 . . . . 73.0 109.356 179.1 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.5 ' HA ' ' O ' ' A' ' 195' ' ' ALA . 78.3 mt -87.08 118.72 26.65 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.372 -0.831 . . . . 72.23 113.115 -175.763 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.437 ' HB3' ' HA ' ' A' ' 196' ' ' THR . 10.5 tp10 -79.76 91.71 5.34 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 108.578 -0.897 . . . . 74.21 108.578 -178.609 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 59.7 t -52.5 118.38 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 123.99 0.916 . . . . 74.03 110.875 177.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 30.7 mmm180 -123.48 94.79 4.35 Favored 'General case' 0 C--O 1.24 0.569 0 C-N-CA 124.635 1.174 . . . . 74.11 107.95 176.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 63.4 mt -76.62 114.25 16.69 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 115.716 -0.674 . . . . 55.22 109.299 177.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 6.4 t . . . . . 0 C--O 1.248 1.014 0 C-N-CA 124.619 1.168 . . . . 62.41 108.944 -179.559 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.072 0 N-CA-C 109.406 -0.59 . . . . 43.14 109.406 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -63.1 -63.77 1.1 Allowed 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 123.622 0.769 . . . . 72.52 110.467 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.7 tp -128.46 149.03 50.75 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.599 -1.26 . . . . 64.24 107.599 160.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.561 ' HB ' ' HB3' ' A' ' 123' ' ' LEU 0.269 2.4 p 36.57 -95.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 C-N-CA 126.337 1.855 . . . . 74.31 113.713 176.956 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.46 ' H ' HG13 ' A' ' 99' ' ' VAL . . . 57.31 8.32 0.57 Allowed 'General case' 0 N--CA 1.493 1.683 0 C-N-CA 124.963 1.305 . . . . 62.25 113.14 -176.725 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 35.7 t-80 -103.81 71.91 1.08 Allowed 'General case' 0 C--O 1.243 0.756 0 N-CA-C 107.374 -1.343 . . . . 74.11 107.374 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 104' ' ' SER . 81.0 t -72.53 137.18 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 CA-C-N 114.375 -1.284 . . . . 34.54 109.702 -179.031 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 72.2 p -79.97 14.49 1.79 Allowed 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 124.504 1.122 . . . . 72.42 112.724 -173.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.426 ' H ' HG12 ' A' ' 102' ' ' VAL . 28.6 m 65.2 12.61 8.15 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 124.879 1.272 . . . . 71.53 111.877 -174.739 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -113.74 150.63 18.53 Favored Glycine 0 C--N 1.349 1.294 0 CA-C-N 115.953 -0.567 . . . . 75.02 112.499 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 34.8 t -163.97 97.86 0.84 Allowed 'General case' 0 C--O 1.247 0.925 0 C-N-CA 124.286 1.034 . . . . 64.4 108.971 178.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -86.32 -162.85 37.45 Favored Glycine 0 C--N 1.344 0.995 0 CA-C-N 116.675 -0.238 . . . . 75.23 113.07 -175.341 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -113.61 93.58 0.67 Allowed Glycine 0 C--N 1.34 0.795 0 N-CA-C 110.983 -0.847 . . . . 62.22 110.983 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.635 ' HB2' ' HB3' ' A' ' 118' ' ' ASP . 38.2 t -57.53 112.7 1.51 Allowed 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.705 1.202 . . . . 71.34 111.419 177.472 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -136.48 -128.62 2.73 Favored Glycine 0 C--N 1.338 0.657 0 N-CA-C 110.695 -0.962 . . . . 72.25 110.695 178.573 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 68.08 -83.82 0.17 Allowed Glycine 0 C--N 1.354 1.54 0 C-N-CA 123.107 0.384 . . . . 73.22 112.491 175.095 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.5 t -144.02 99.33 3.37 Favored 'General case' 0 C--O 1.242 0.671 0 N-CA-C 108.525 -0.917 . . . . 74.42 108.525 172.493 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 88.93 141.53 8.14 Favored Glycine 0 CA--C 1.527 0.806 0 CA-C-N 115.744 -0.662 . . . . 73.51 112.234 178.081 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 121.64 -84.5 0.37 Allowed Glycine 0 C--O 1.238 0.378 0 N-CA-C 110.339 -1.105 . . . . 70.04 110.339 -176.817 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 76.0 p 44.74 61.98 2.25 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 125.296 1.438 . . . . 64.04 110.998 -173.172 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.99 -176.24 45.81 Favored Glycine 0 N--CA 1.461 0.3 0 CA-C-N 114.076 -1.42 . . . . 75.02 110.168 -178.523 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 5.4 ptm180 -75.46 120.39 20.83 Favored 'General case' 0 C--O 1.247 0.937 0 CA-C-N 117.851 0.826 . . . . 75.05 109.957 179.374 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.635 ' HB3' ' HB2' ' A' ' 109' ' ' SER . 4.3 p30 -81.26 135.35 35.72 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 106.811 -1.552 . . . . 71.14 106.811 162.296 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 1.3 tt -99.83 143.34 30.17 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 106.427 -1.694 . . . . 71.51 106.427 177.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 12.7 tpp85 -119.0 125.23 48.9 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 118.778 0.717 . . . . 72.53 110.591 -173.569 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -147.85 149.95 33.25 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.341 0.656 . . . . 71.34 109.794 178.694 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.664 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 41.8 mt-10 -127.83 149.4 50.29 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.52 0.728 . . . . 71.43 109.418 -179.074 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.561 ' HB3' ' HB ' ' A' ' 99' ' ' VAL . 1.5 pt? -143.93 147.1 36.93 Favored Pre-proline 0 N--CA 1.474 0.741 0 O-C-N 123.505 0.503 . . . . 63.51 111.323 -176.623 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -76.79 113.93 3.74 Favored 'Trans proline' 0 C--N 1.371 1.738 0 C-N-CA 121.426 1.418 . . . . 73.44 109.688 162.024 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.464 HD22 HG11 ' A' ' 178' ' ' VAL . 18.6 tp -108.28 158.8 17.15 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.758 0.823 . . . . 45.44 108.839 178.456 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.57 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 6.9 m -95.52 156.26 16.4 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 123.397 0.679 . . . . 71.33 109.191 175.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 82.0 mt -58.34 -49.33 77.58 Favored 'General case' 0 N--CA 1.488 1.436 0 CA-C-O 122.348 1.071 . . . . 62.14 109.455 174.302 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -57.01 -38.16 72.7 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 113.276 -1.784 . . . . 74.14 111.475 177.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 31.5 mm-40 -80.02 -21.16 43.86 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.231 0.612 . . . . 72.22 112.469 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.539 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -61.63 -40.33 94.47 Favored 'General case' 0 C--O 1.256 1.417 0 CA-C-O 121.665 0.745 . . . . 42.31 110.696 167.321 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.491 ' HA ' ' CE1' ' A' ' 240' ' ' PHE . 69.0 t80 -70.31 -48.35 56.98 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 113.964 -1.471 . . . . 74.44 112.774 172.611 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -71.55 -47.32 55.78 Favored 'General case' 0 N--CA 1.485 1.277 0 N-CA-C 112.067 0.395 . . . . 74.01 112.067 -172.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.32 -115.89 8.19 Favored Glycine 0 CA--C 1.533 1.204 0 N-CA-C 111.121 -0.791 . . . . 52.13 111.121 -175.643 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.8 174.55 39.71 Favored Glycine 0 C--N 1.346 1.124 0 N-CA-C 115.175 0.83 . . . . 54.44 115.175 167.613 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -87.61 118.26 26.98 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.346 1.059 . . . . 62.42 108.221 178.431 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -130.44 138.88 50.53 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 124.368 1.067 . . . . 74.43 108.543 -176.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 7.2 p -83.12 139.93 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 N-CA-C 108.697 -0.853 . . . . 74.2 108.697 174.16 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.446 HG21 HG13 ' A' ' 99' ' ' VAL . 7.1 p -143.04 153.09 16.89 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 C-N-CA 124.011 0.924 . . . . 74.53 109.324 -178.275 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -116.38 100.27 7.77 Favored 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 107.782 -1.192 . . . . 73.2 107.782 170.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 9.0 t -103.65 111.54 33.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 N-CA-C 108.753 -0.832 . . . . 71.34 108.753 -172.037 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.93 26.0 15.33 Favored 'General case' 0 N--CA 1.479 1.017 0 O-C-N 124.493 1.121 . . . . 72.43 111.658 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 91.75 13.63 57.77 Favored Glycine 0 C--N 1.355 1.585 0 CA-C-N 115.807 -0.633 . . . . 74.4 113.315 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 25.8 ttt180 -116.7 116.23 27.13 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 122.986 0.514 . . . . 72.23 110.134 177.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -87.5 114.09 23.8 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 122.838 0.455 . . . . 62.15 110.196 -178.175 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.6 p -148.13 152.79 12.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 C-N-CA 124.835 1.254 . . . . 72.02 109.089 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 43.7 m -82.86 122.19 27.91 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 122.835 0.454 . . . . 75.13 110.258 175.15 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.414 HG22 HG23 ' A' ' 149' ' ' ILE . 13.7 p -98.59 123.99 51.48 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 C-N-CA 123.646 0.778 . . . . 75.03 109.594 175.366 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 30.9 ttt85 -108.05 98.25 7.84 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 107.849 -1.167 . . . . 74.41 107.849 174.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.414 HG23 HG22 ' A' ' 147' ' ' VAL . 35.3 pt -96.32 131.4 28.64 Favored Pre-proline 0 N--CA 1.479 0.984 0 N-CA-C 109.673 -0.492 . . . . 75.32 109.673 178.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.404 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 58.2 Cg_endo -67.71 145.32 69.04 Favored 'Trans proline' 0 C--N 1.375 1.94 0 C-N-CA 122.852 2.368 . . . . 73.44 112.982 -174.154 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.475 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 32.1 Cg_exo -63.68 125.12 14.85 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 123.045 2.497 . . . . 74.33 110.596 171.186 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 131.44 41.25 0.21 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 111.827 -0.509 . . . . 50.31 111.827 -173.183 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.539 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -118.58 154.21 20.77 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 N-CA-C 108.775 -0.824 . . . . 74.32 108.775 -177.484 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 40.9 mtp180 -144.66 166.85 24.01 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 124.943 1.297 . . . . 72.25 109.055 -165.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -52.75 123.18 10.65 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 123.61 0.764 . . . . 60.14 111.943 176.312 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 80.62 -4.61 68.17 Favored Glycine 0 C--N 1.348 1.202 0 CA-C-N 115.896 -0.593 . . . . 64.13 113.629 179.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 32.4 t -68.82 127.52 33.38 Favored 'General case' 0 C--O 1.248 1.016 0 C-N-CA 123.665 0.786 . . . . 61.1 110.134 -176.257 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.515 HG12 HD22 ' A' ' 175' ' ' LEU . 8.7 t -97.89 119.46 45.94 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-N 114.303 -1.317 . . . . 63.4 108.627 -176.449 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.483 HD11 HG21 ' A' ' 153' ' ' VAL . 17.2 mt -102.94 117.07 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 123.664 0.786 . . . . 75.4 110.054 -170.68 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 22.3 ttm180 -84.02 117.39 23.37 Favored 'General case' 0 C--O 1.239 0.512 0 C-N-CA 123.53 0.732 . . . . 64.22 110.414 172.234 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.84 101.39 53.02 Favored Pre-proline 0 CA--C 1.559 1.29 0 N-CA-C 108.293 -1.003 . . . . 70.54 108.293 169.642 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -64.92 149.66 89.2 Favored 'Trans proline' 0 C--N 1.384 2.407 0 C-N-CA 123.55 2.833 . . . . 60.44 113.428 -172.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 71.3 24.2 77.22 Favored Glycine 0 C--N 1.348 1.216 0 O-C-N 123.594 0.559 . . . . 62.43 113.795 175.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 2.9 tpt -100.52 -51.86 3.5 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.149 0.98 . . . . 64.42 109.998 -177.645 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -82.84 -89.16 0.7 Allowed Glycine 0 C--N 1.351 1.391 0 CA-C-N 115.403 -0.817 . . . . 71.32 112.092 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -65.36 91.76 0.13 Allowed Glycine 0 C--N 1.354 1.538 0 C-N-CA 123.04 0.352 . . . . 41.12 113.15 179.472 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.1 mm-40 -70.26 146.1 50.87 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 123.289 0.636 . . . . 64.24 111.145 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 123.25 -168.07 15.47 Favored Glycine 0 N--CA 1.476 1.361 0 CA-C-O 119.733 -0.482 . . . . 74.13 112.874 176.554 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.411 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 93.0 m-20 -53.25 -47.62 95.36 Favored Pre-proline 0 CA--C 1.567 1.624 0 C-N-CA 124.062 0.945 . . . . 73.45 112.69 -178.3 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.411 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 2.0 Cg_endo -85.08 113.44 1.51 Allowed 'Trans proline' 0 C--N 1.388 2.614 0 C-N-CA 122.572 2.181 . . . . 72.42 110.355 168.409 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -80.35 123.7 5.05 Favored 'Trans proline' 0 C--N 1.371 1.725 0 C-N-CA 121.745 1.63 . . . . 55.2 112.507 -175.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -100.6 150.5 18.82 Favored Glycine 0 C--N 1.342 0.866 0 N-CA-C 108.988 -1.645 . . . . 61.31 108.988 174.193 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -113.09 -179.89 3.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 118.049 0.924 . . . . 74.23 111.498 -164.323 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 15.6 tp -121.98 128.63 51.69 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 107.82 -1.178 . . . . 71.53 107.82 167.3 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.515 HD22 HG12 ' A' ' 158' ' ' VAL . 76.6 mt -99.76 101.99 13.31 Favored 'General case' 0 C--O 1.243 0.746 0 C-N-CA 125.085 1.354 . . . . 75.4 110.28 178.342 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 86.4 mt -91.28 109.46 20.73 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 123.612 0.765 . . . . 74.4 111.114 175.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.664 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 21.5 t -90.2 105.22 16.0 Favored 'Isoleucine or valine' 0 C--O 1.247 0.938 0 N-CA-C 108.115 -1.068 . . . . 71.11 108.115 173.286 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.464 HG11 HD22 ' A' ' 125' ' ' LEU . 6.1 m -82.4 151.34 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 CA-C-O 121.223 0.535 . . . . 60.24 111.615 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 38.2 mmt180 -124.07 98.95 6.01 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 107.67 -1.233 . . . . 71.25 107.67 176.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 57.5 mt -67.46 144.64 55.61 Favored 'General case' 0 C--O 1.241 0.628 0 O-C-N 123.139 0.274 . . . . 72.04 110.685 -178.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.57 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 44.1 mt -59.83 147.03 80.11 Favored Pre-proline 0 CA--C 1.558 1.284 0 O-C-N 124.366 1.041 . . . . 52.15 110.967 -176.436 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -75.46 58.09 5.06 Favored 'Trans proline' 0 C--N 1.375 1.96 0 C-N-CA 123.991 3.127 . . . . 73.44 113.845 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -142.28 51.82 2.17 Favored Pre-proline 0 CA--C 1.562 1.434 0 C-N-CA 123.035 0.534 . . . . 54.04 109.831 171.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -64.21 123.56 12.05 Favored 'Trans proline' 0 C--N 1.388 2.632 0 C-N-CA 122.43 2.087 . . . . 61.31 111.905 -168.333 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -128.22 -37.49 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 123.81 0.844 . . . . 74.52 109.363 -177.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.435 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 6.0 m-85 -107.39 124.37 49.74 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 114.814 -1.085 . . . . 73.02 110.338 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.652 ' HB3' ' HB2' ' A' ' 194' ' ' TYR . 19.6 tpp180 -105.02 139.08 40.24 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 106.934 -1.506 . . . . 63.51 106.934 172.073 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 51.1 tp -123.41 122.62 38.74 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 122.897 0.479 . . . . 63.14 109.86 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -144.9 127.86 16.47 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 122.39 0.276 . . . . 74.13 110.322 169.16 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 63.94 33.83 88.28 Favored Glycine 0 C--N 1.356 1.648 0 O-C-N 123.91 0.756 . . . . 75.25 114.246 177.292 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 73.96 -5.24 2.08 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 125.714 1.606 . . . . 73.25 112.659 -175.567 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -93.33 149.98 20.82 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.479 0.711 . . . . 73.01 109.579 178.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.646 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 93.1 mt -108.92 163.57 13.17 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 124.281 1.033 . . . . 70.21 109.94 -176.409 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 194' ' ' TYR . . . . . 0.652 ' HB2' ' HB3' ' A' ' 187' ' ' ARG . 85.1 m-85 -143.38 121.52 12.18 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 106.803 -1.554 . . . . 74.51 106.803 178.01 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -147.25 164.32 33.58 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.444 0.697 . . . . 75.54 109.921 -176.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 17.5 m -106.2 125.45 51.01 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.51 -0.768 . . . . 62.0 109.17 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.56 HD22 HD13 ' A' ' 251' ' ' LEU . 65.5 tp -112.44 115.65 29.03 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.541 0.736 . . . . 73.04 109.631 177.419 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -78.7 131.03 36.46 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 108.138 -1.06 . . . . 65.44 108.138 169.249 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 199' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 255' ' ' ILE . 90.9 t -129.78 121.15 19.86 Favored Pre-proline 0 N--CA 1.474 0.728 0 N-CA-C 107.682 -1.229 . . . . 72.14 107.682 178.626 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -65.83 147.66 85.57 Favored 'Trans proline' 0 C--N 1.369 1.657 0 C-N-CA 122.143 1.895 . . . . 74.13 110.888 176.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 201' ' ' ALA . . . . . 0.445 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -53.5 -42.5 92.24 Favored Pre-proline 0 N--CA 1.48 1.065 0 C-N-CA 124.483 1.113 . . . . 65.11 113.569 -177.323 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 202' ' ' PRO . . . . . 0.445 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 10.8 Cg_endo -52.42 -51.29 11.46 Favored 'Trans proline' 0 C--N 1.397 3.107 0 C-N-CA 122.144 1.896 . . . . 74.11 112.64 172.219 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 7.0 mt -66.49 -37.11 78.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 123.211 0.604 . . . . 72.21 111.641 -179.065 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.3 -42.97 99.11 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 122.926 0.49 . . . . 52.24 111.929 -178.345 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.2 m -82.62 -35.59 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.87 0 CA-C-N 115.931 -0.577 . . . . 73.55 111.987 -175.026 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 12.4 m -87.23 -18.92 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 CA-C-N 118.043 0.383 . . . . 74.22 111.658 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.408 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 77.87 55.04 4.28 Favored Glycine 0 C--N 1.344 1.022 0 CA-C-N 115.857 -0.61 . . . . 75.24 113.218 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -84.87 -169.66 46.17 Favored Glycine 0 C--N 1.349 1.252 0 CA-C-O 121.783 0.657 . . . . 71.11 112.585 -177.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 209' ' ' LYS . . . . . 0.432 ' HD2' ' N ' ' A' ' 209' ' ' LYS . 0.0 OUTLIER -115.61 120.18 38.58 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 107.771 -1.196 . . . . 63.53 107.771 -173.667 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 210' ' ' VAL . . . . . 0.442 HG11 HG22 ' A' ' 199' ' ' VAL . 7.3 p -124.42 144.07 35.57 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 124.37 1.068 . . . . 44.21 109.343 -178.304 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.22 138.06 34.74 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.297 -0.631 . . . . 72.13 109.297 176.134 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -107.69 131.56 54.28 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 108.446 -0.946 . . . . 63.5 108.446 169.739 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.49 104.55 9.16 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.988 -1.116 . . . . 72.33 107.988 179.375 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.447 HG23 ' H ' ' A' ' 216' ' ' GLU . 14.8 t -112.41 168.15 9.87 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.161 0.584 . . . . 63.1 110.543 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 65.2 mt -70.03 -7.3 39.93 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 123.562 0.745 . . . . 71.23 111.788 -179.094 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 216' ' ' GLU . . . . . 0.447 ' H ' HG23 ' A' ' 214' ' ' THR . 42.6 tt0 -97.28 -18.07 19.42 Favored 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.679 1.192 . . . . 70.32 111.382 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 133.06 -147.83 19.11 Favored Glycine 0 N--CA 1.475 1.284 0 CA-C-O 119.188 -0.784 . . . . 64.15 111.82 -178.232 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -85.84 126.73 2.98 Favored 'Trans proline' 0 CA--C 1.559 1.757 0 C-N-CA 122.878 2.386 . . . . 53.42 112.021 172.239 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 26.1 m -109.68 156.1 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 122.918 0.487 . . . . 63.35 110.944 172.296 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 24.9 mm-40 -95.09 109.89 21.89 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 123.572 0.749 . . . . 72.12 109.827 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.566 HG22 HD11 ' A' ' 235' ' ' LEU . 8.7 t -104.25 117.52 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.663 0.785 . . . . 65.55 109.057 172.525 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -98.62 102.42 14.15 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 108.279 -1.008 . . . . 71.34 108.279 174.436 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.408 HG23 ' HA2' ' A' ' 207' ' ' GLY . 11.9 m -75.97 143.52 74.35 Favored Pre-proline 0 CA--C 1.551 1.011 0 N-CA-C 109.638 -0.504 . . . . 75.33 109.638 -176.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -64.46 140.68 70.62 Favored 'Trans proline' 0 C--N 1.368 1.587 0 C-N-CA 122.777 2.318 . . . . 63.13 112.34 174.425 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.9 129.38 34.63 Favored 'Trans proline' 0 C--N 1.376 1.992 0 C-N-CA 122.713 2.275 . . . . 53.31 111.337 171.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 64.3 mtm180 65.85 34.89 6.98 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 125.116 1.367 . . . . 73.33 110.988 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 5.7 t -66.64 164.55 16.6 Favored 'General case' 0 CA--C 1.549 0.919 0 N-CA-C 109.938 -0.393 . . . . 74.12 109.938 176.548 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -120.46 150.95 40.0 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.731 0.813 . . . . 75.52 109.697 -176.019 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -68.28 141.92 55.72 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.13 0.972 . . . . 54.21 110.727 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 91.11 -3.83 80.64 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-O 119.467 -0.629 . . . . 72.41 112.542 -176.646 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 41.1 mtp180 -72.01 161.3 31.12 Favored 'General case' 0 C--N 1.362 1.125 0 CA-C-O 122.16 0.981 . . . . 74.22 110.64 177.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 232' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -107.62 107.73 18.67 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 113.892 -1.503 . . . . 53.54 108.043 -173.184 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 233' ' ' LEU . . . . . 0.447 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 45.9 mt -100.38 98.31 8.96 Favored 'General case' 0 C--N 1.349 0.576 0 N-CA-C 107.328 -1.36 . . . . 63.24 107.328 175.655 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 234' ' ' ARG . . . . . 0.498 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 20.0 ttm180 -100.92 115.86 31.43 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.154 0.502 . . . . 74.12 110.698 -171.457 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.566 HD11 HG22 ' A' ' 221' ' ' VAL . 23.4 mt -96.06 117.75 31.3 Favored 'General case' 0 C--O 1.241 0.631 0 C-N-CA 124.159 0.983 . . . . 62.32 109.508 -176.02 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 49.8 mtmt -72.46 133.66 44.95 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.597 0.759 . . . . 74.21 111.151 -175.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 70.69 33.81 66.82 Favored Glycine 0 C--N 1.345 1.03 0 O-C-N 124.214 0.946 . . . . 62.02 112.954 176.107 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 72.7 mmtt -123.17 5.49 9.19 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.246 0.618 . . . . 72.13 111.958 178.507 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -85.51 -147.94 10.18 Favored Glycine 0 C--N 1.35 1.328 0 O-C-N 123.532 0.52 . . . . 71.25 112.952 177.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.491 ' CE1' ' HA ' ' A' ' 131' ' ' PHE . 16.2 m-85 -95.95 145.18 29.1 Favored Pre-proline 0 N--CA 1.478 0.931 0 C-N-CA 123.05 0.54 . . . . 71.04 111.589 173.435 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.72 156.53 39.82 Favored 'Trans proline' 0 C--N 1.375 1.968 0 C-N-CA 123.308 2.672 . . . . 72.34 112.468 173.435 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 173.92 -163.17 34.09 Favored Glycine 0 CA--C 1.535 1.335 0 CA-C-N 115.317 -0.856 . . . . 63.2 111.921 177.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.43 -16.49 43.31 Favored 'Trans proline' 0 C--N 1.379 2.179 0 C-N-CA 123.274 2.649 . . . . 41.02 112.912 -175.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -97.1 22.62 8.27 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.794 0.837 . . . . 63.05 111.222 177.692 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 79.93 -138.31 19.88 Favored Glycine 0 C--N 1.352 1.441 0 N-CA-C 110.699 -0.961 . . . . 51.31 110.699 -174.222 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 56.4 ttt180 -110.53 142.19 42.65 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 117.509 0.654 . . . . 72.03 109.648 171.207 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -77.76 -158.24 10.24 Favored Glycine 0 C--N 1.342 0.903 0 O-C-N 123.684 0.615 . . . . 43.33 112.945 177.512 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -128.52 170.58 13.02 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.803 0.841 . . . . 54.31 109.746 -172.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.646 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 15.7 tp -111.79 113.66 26.15 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.784 0.834 . . . . 72.42 109.806 171.424 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 250' ' ' TYR . . . . . 0.493 ' HB3' ' O ' ' A' ' 193' ' ' LEU . 2.9 t80 -88.42 108.06 19.18 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 107.567 -1.272 . . . . 74.14 107.567 174.202 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.56 HD13 HD22 ' A' ' 197' ' ' LEU . 52.3 mt -91.16 145.42 24.69 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 123.522 0.729 . . . . 73.34 110.744 170.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -107.63 101.95 11.23 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 107.161 -1.422 . . . . 75.24 107.161 167.36 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.3 p -62.38 128.25 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 CA-C-O 121.326 0.584 . . . . 72.34 110.115 177.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 9.9 mmm180 -125.72 94.33 4.09 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 107.195 -1.409 . . . . 75.14 107.195 -177.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 199' ' ' VAL . 67.2 mt -76.55 139.89 18.09 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 CA-C-N 115.364 -0.835 . . . . 64.34 110.379 -173.367 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.5 t . . . . . 0 CA--C 1.554 1.108 0 C-N-CA 123.781 0.832 . . . . 53.52 109.244 -175.429 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.173 0 N-CA-C 110.349 -0.241 . . . . 72.23 110.349 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -99.81 -68.19 0.82 Allowed 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 122.736 0.415 . . . . 73.22 110.809 179.376 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.6 tp -120.52 62.78 0.85 Allowed 'General case' 0 N--CA 1.48 1.025 0 CA-C-O 121.523 0.678 . . . . 74.23 110.237 -173.181 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 12.9 p 176.86 146.32 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-N 114.218 -1.356 . . . . 73.34 109.282 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -88.08 -78.53 0.32 Allowed 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 108.37 -0.974 . . . . 71.42 108.37 167.414 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 10.3 m170 -159.32 165.42 33.42 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 124.163 0.985 . . . . 64.3 109.92 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 84.2 t -64.02 136.35 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 O-C-N 124.052 0.845 . . . . 71.4 109.637 174.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 32.6 p -67.69 86.84 0.21 Allowed 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 123.716 0.806 . . . . 75.43 109.363 173.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.1 m -68.25 140.02 56.01 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.879 -1.055 . . . . 74.41 111.733 -171.62 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 134.07 155.81 7.7 Favored Glycine 0 C--N 1.345 1.061 0 O-C-N 123.736 0.647 . . . . 63.31 111.809 176.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 19.0 t -74.35 97.28 3.0 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.171 -0.677 . . . . 74.42 109.171 176.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 157.26 -172.15 34.68 Favored Glycine 0 C--N 1.342 0.884 0 CA-C-N 115.417 -0.811 . . . . 61.41 111.476 -176.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.14 143.3 5.9 Favored Glycine 0 C--N 1.342 0.898 0 CA-C-O 120.125 -0.264 . . . . 74.21 112.543 179.084 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 41.5 m -78.55 80.51 4.93 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 123.428 0.691 . . . . 41.43 109.842 177.021 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -177.88 150.59 10.03 Favored Glycine 0 C--N 1.343 0.946 0 CA-C-N 115.558 -0.746 . . . . 61.42 111.497 178.028 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 88.47 122.57 1.94 Allowed Glycine 0 C--N 1.343 0.949 0 O-C-N 123.64 0.259 . . . . 60.01 113.303 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 62.4 m -149.97 115.51 5.52 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 123.323 0.649 . . . . 74.43 109.944 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 63.88 -124.9 31.64 Favored Glycine 0 C--N 1.353 1.486 0 O-C-N 123.913 0.758 . . . . 70.34 113.327 175.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -75.95 75.5 1.5 Allowed Glycine 0 C--N 1.346 1.122 0 N-CA-C 111.939 -0.465 . . . . 72.4 111.939 177.394 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 56.3 m -146.44 138.05 24.64 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.19 0.996 . . . . 62.24 109.261 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -75.75 157.72 49.29 Favored Glycine 0 C--N 1.351 1.361 0 CA-C-O 119.436 -0.647 . . . . 70.43 111.727 175.272 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 72.8 mtp180 -61.95 114.51 3.42 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 122.694 0.398 . . . . 71.44 111.118 -177.066 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -91.14 150.3 21.44 Favored 'General case' 0 C--O 1.241 0.65 0 N-CA-C 108.878 -0.786 . . . . 73.23 108.878 175.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 30.3 mt -96.4 156.22 16.43 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 123.469 0.708 . . . . 70.22 109.19 -178.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.2 146.28 44.68 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.519 -1.289 . . . . 74.0 107.519 174.422 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -158.36 136.82 10.98 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 123.528 0.731 . . . . 71.32 109.787 -178.042 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -100.97 142.62 32.19 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.485 0.714 . . . . 54.01 109.718 -178.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -146.45 143.09 18.25 Favored Pre-proline 0 CA--C 1.552 1.049 0 C-N-CA 123.077 0.551 . . . . 71.23 110.565 174.508 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_exo -77.4 118.26 4.57 Favored 'Trans proline' 0 C--N 1.376 2.004 0 C-N-CA 122.97 2.447 . . . . 72.35 111.327 172.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.427 ' HG ' ' HB2' ' A' ' 129' ' ' GLU . 14.8 tp -108.62 155.59 20.51 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 123.75 0.82 . . . . 72.14 109.678 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.606 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 20.7 m -93.56 157.48 16.17 Favored 'General case' 0 CA--C 1.55 0.945 0 N-CA-C 109.363 -0.606 . . . . 55.23 109.363 174.235 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.479 HD11 ' O ' ' A' ' 183' ' ' HIS . 32.6 mt -58.22 -48.18 81.16 Favored 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 123.944 0.898 . . . . 33.44 110.382 178.786 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -54.25 -36.49 63.62 Favored 'General case' 0 C--O 1.218 -0.584 0 CA-C-N 113.796 -1.547 . . . . 61.44 110.736 176.371 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.606 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 7.5 mm-40 -79.6 -23.04 42.95 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.48 0.712 . . . . 74.14 111.411 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.792 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -63.0 -36.32 83.16 Favored 'General case' 0 C--O 1.244 0.793 0 CA-C-O 121.42 0.628 . . . . 72.2 110.304 167.334 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.415 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 26.8 t80 -81.31 -33.54 32.51 Favored 'General case' 0 CA--C 1.554 1.097 0 CA-C-N 114.709 -1.132 . . . . 75.22 111.972 176.11 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' HIS . . . . . 0.474 ' HB2' ' HA ' ' A' ' 129' ' ' GLU . 24.6 m80 -84.13 -40.96 17.58 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 112.631 0.604 . . . . 63.53 112.631 -173.243 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 72.16 -129.55 15.23 Favored Glycine 0 CA--C 1.536 1.389 0 N-CA-C 110.834 -0.907 . . . . 74.11 110.834 -166.694 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 134.97 140.2 4.19 Favored Glycine 0 N--CA 1.477 1.401 0 CA-C-N 117.805 0.802 . . . . 61.12 114.145 169.443 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -86.54 113.6 22.59 Favored 'General case' 0 C--N 1.357 0.91 0 N-CA-C 108.486 -0.931 . . . . 61.23 108.486 167.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -141.81 170.11 16.32 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.901 1.281 . . . . 71.32 108.314 175.588 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.498 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 14.7 p -95.18 143.3 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 118.639 0.654 . . . . 61.22 111.276 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 12.2 p -114.94 138.24 45.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 C-N-CA 123.833 0.853 . . . . 64.4 109.553 172.483 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -125.51 105.12 8.81 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 108.678 -0.86 . . . . 63.24 108.678 173.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.2 m -129.59 133.72 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 124.187 0.995 . . . . 63.12 110.042 -177.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.96 22.82 13.67 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 124.534 1.134 . . . . 73.44 111.313 -176.165 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.64 -6.7 79.6 Favored Glycine 0 C--N 1.354 1.538 0 CA-C-N 115.734 -0.666 . . . . 74.51 113.124 -176.078 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 53.4 ttt85 -94.81 119.67 33.77 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 123.632 0.773 . . . . 62.43 110.396 -175.687 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 20.6 ttp180 -105.07 109.63 21.69 Favored 'General case' 0 CA--C 1.552 1.024 0 C-N-CA 123.998 0.919 . . . . 62.23 110.797 -174.451 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 13.7 m -133.24 155.54 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 C-N-CA 124.708 1.203 . . . . 52.44 108.795 174.344 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.498 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 60.1 p -76.8 126.8 31.59 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 118.235 0.471 . . . . 55.41 110.684 -179.567 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.94 120.35 48.14 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.741 0 CA-C-O 121.827 0.822 . . . . 73.1 110.48 176.164 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 49.8 ttt180 -109.13 95.13 5.43 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 108.74 -0.837 . . . . 73.21 108.74 176.313 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 28.4 pt -93.66 119.78 66.8 Favored Pre-proline 0 CA--C 1.547 0.852 0 N-CA-C 107.913 -1.143 . . . . 72.13 107.913 171.423 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -76.64 163.17 32.08 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.352 2.035 . . . . 74.11 112.507 -177.403 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -54.76 142.68 73.17 Favored 'Trans proline' 0 C--N 1.375 1.963 0 C-N-CA 123.005 2.47 . . . . 72.34 112.372 171.188 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 108.66 38.31 1.92 Allowed Glycine 0 C--N 1.339 0.721 0 CA-C-N 116.773 -0.194 . . . . 72.33 113.037 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.792 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -108.66 163.07 6.23 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.359 0 N-CA-C 108.7 -0.852 . . . . 53.43 108.7 177.005 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.528 ' HB2' ' HB2' ' A' ' 157' ' ' SER . 25.1 mtp-105 -141.8 164.28 30.63 Favored 'General case' 0 N--CA 1.492 1.635 0 C-N-CA 123.963 0.905 . . . . 72.13 111.071 -165.637 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.1 tp10 -54.53 116.72 2.82 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.444 1.098 . . . . 71.1 111.226 165.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.27 4.68 90.11 Favored Glycine 0 C--N 1.357 1.706 0 CA-C-N 116.04 -0.527 . . . . 70.34 113.166 178.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.528 ' HB2' ' HB2' ' A' ' 154' ' ' ARG . 30.1 t -79.21 124.2 28.13 Favored 'General case' 0 C--O 1.25 1.11 0 N-CA-C 109.026 -0.731 . . . . 74.1 109.026 -179.686 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.44 HG12 HD22 ' A' ' 175' ' ' LEU . 20.0 t -99.05 120.68 48.71 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 CA-C-N 114.298 -1.319 . . . . 72.4 107.886 -177.728 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.434 HD11 HG21 ' A' ' 153' ' ' VAL . 13.0 mt -101.86 122.01 53.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 123.533 0.733 . . . . 54.32 110.15 -168.697 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 74.2 ttt180 -86.31 103.25 14.72 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 123.317 0.647 . . . . 74.34 109.908 177.43 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.449 HG22 ' O ' ' A' ' 174' ' ' LEU . 16.4 m -107.59 104.92 54.65 Favored Pre-proline 0 CA--C 1.564 1.5 0 C-N-CA 122.608 0.363 . . . . 74.11 110.027 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -67.41 140.69 53.47 Favored 'Trans proline' 0 C--N 1.375 1.954 0 C-N-CA 122.82 2.346 . . . . 70.33 113.332 -173.189 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 105.04 -9.97 47.32 Favored Glycine 0 C--N 1.349 1.282 0 N-CA-C 114.868 0.707 . . . . 61.44 114.868 170.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.4 mpt? -81.9 -61.35 1.94 Allowed 'General case' 0 N--CA 1.482 1.135 0 CA-C-N 117.815 0.807 . . . . 73.41 110.157 176.096 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -87.8 171.41 41.16 Favored Glycine 0 C--N 1.345 1.073 0 CA-C-N 115.345 -0.843 . . . . 74.35 111.785 176.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 60.72 51.52 58.14 Favored Glycine 0 C--N 1.343 0.965 0 O-C-N 124.238 0.611 . . . . 52.12 112.611 176.274 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.6 mm-40 -76.56 104.88 7.3 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 120.982 0.42 . . . . 62.33 110.434 -176.505 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -176.93 -146.2 6.02 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.572 -1.011 . . . . 51.31 110.572 -178.434 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.411 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 17.7 m120 -73.06 -46.28 8.25 Favored Pre-proline 0 CA--C 1.56 1.35 0 CA-C-O 118.7 -0.667 . . . . 63.02 111.033 176.188 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.411 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 95.1 Cg_endo -94.58 107.42 0.14 Allowed 'Trans proline' 0 C--N 1.393 2.871 0 C-N-CA 122.284 1.989 . . . . 61.14 111.573 167.594 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -65.34 127.84 19.07 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 122.585 2.19 . . . . 63.22 111.683 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -80.97 -132.26 1.2 Allowed Glycine 0 C--N 1.34 0.764 0 N-CA-C 111.498 -0.641 . . . . 62.12 111.498 175.177 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -163.81 177.79 8.35 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.205 0.526 . . . . 71.42 110.885 -175.166 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.449 ' O ' HG22 ' A' ' 161' ' ' VAL . 15.0 tp -129.32 122.57 29.83 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 108.571 -0.9 . . . . 62.24 108.571 173.527 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.44 HD22 HG12 ' A' ' 158' ' ' VAL . 49.8 mt -88.11 99.41 12.17 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.139 -0.937 . . . . 64.34 110.927 179.186 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 74.9 mt -87.44 105.34 17.22 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 123.011 0.524 . . . . 64.42 110.748 175.429 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.8 t -85.49 104.45 13.37 Favored 'Isoleucine or valine' 0 C--O 1.242 0.697 0 N-CA-C 108.23 -1.026 . . . . 73.12 108.23 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.423 HG21 HG22 ' A' ' 153' ' ' VAL . 25.3 m -83.95 144.79 9.25 Favored 'Isoleucine or valine' 0 C--O 1.251 1.136 0 CA-C-O 121.481 0.657 . . . . 74.11 110.367 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 13.5 mmm180 -118.53 99.3 6.72 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 107.068 -1.456 . . . . 73.01 107.068 -178.594 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.421 HD23 ' HB3' ' A' ' 125' ' ' LEU . 29.5 mt -67.56 146.1 54.24 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 118.314 0.507 . . . . 73.41 110.303 177.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.438 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 73.1 mt -55.27 154.51 11.06 Favored Pre-proline 0 CA--C 1.553 1.063 0 O-C-N 124.489 1.118 . . . . 72.24 112.839 -170.337 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.403 ' O ' ' HD3' ' A' ' 184' ' ' PRO . 55.5 Cg_endo -66.81 0.38 3.72 Favored 'Trans proline' 0 C--N 1.381 2.287 0 C-N-CA 123.081 2.52 . . . . 62.2 112.808 171.231 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 183' ' ' HIS . . . . . 0.479 ' O ' HD11 ' A' ' 127' ' ' LEU . 14.7 t60 -95.55 99.21 4.41 Favored Pre-proline 0 CA--C 1.541 0.611 0 C-N-CA 124.974 1.31 . . . . 72.43 107.582 162.721 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 184' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 182' ' ' PRO . 44.4 Cg_endo -103.64 123.67 0.07 OUTLIER 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 123.135 2.557 . . . . 64.33 112.413 168.607 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -120.68 -43.58 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 107.74 -1.207 . . . . 63.44 107.74 171.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -113.64 126.31 55.12 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 114.674 -1.148 . . . . 62.42 110.144 176.487 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 36.5 ttp85 -119.41 127.04 52.74 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 108.51 -0.922 . . . . 71.44 108.51 172.421 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.427 HD12 ' O ' ' A' ' 192' ' ' ASP . 56.0 tp -90.18 132.53 35.42 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 108.359 -0.978 . . . . 63.15 108.359 170.461 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -144.48 130.1 19.07 Favored 'General case' 0 C--O 1.241 0.642 0 N-CA-C 109.621 -0.511 . . . . 74.12 109.621 173.179 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 70.95 -75.78 0.59 Allowed Glycine 0 C--N 1.35 1.346 0 O-C-N 124.003 0.814 . . . . 63.52 111.871 -175.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 191' ' ' GLN . . . . . 0.497 ' HB2' ' O ' ' A' ' 240' ' ' PHE . 3.7 pt20 -157.6 -10.49 0.08 Allowed 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 124.118 0.967 . . . . 60.43 110.846 174.532 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.427 ' O ' HD12 ' A' ' 188' ' ' LEU . 80.3 m-20 -96.31 162.96 13.28 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 123.014 0.526 . . . . 62.12 110.942 -175.829 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.478 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.2 mt -106.9 155.91 19.25 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 107.704 -1.221 . . . . 73.15 107.704 -178.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -137.15 121.8 18.53 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 108.642 -0.873 . . . . 70.1 108.642 -175.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 195' ' ' ALA . . . . . 0.479 ' HB3' HD23 ' A' ' 251' ' ' LEU . . . -142.63 162.12 36.29 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.697 0.799 . . . . 65.3 110.221 -178.603 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 196' ' ' THR . . . . . 0.519 ' HA ' ' HB3' ' A' ' 252' ' ' GLU . 36.0 m -109.08 119.37 39.34 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 109.018 -0.734 . . . . 71.15 109.018 174.794 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.534 HD22 HD13 ' A' ' 251' ' ' LEU . 55.1 tp -106.84 110.13 22.21 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 109.17 -0.678 . . . . 53.35 109.17 178.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -89.83 127.56 36.0 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 107.804 -1.184 . . . . 62.32 107.804 172.211 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 199' ' ' VAL . . . . . 0.507 HG12 HG11 ' A' ' 210' ' ' VAL . 15.4 m -119.99 139.83 28.87 Favored Pre-proline 0 C--O 1.244 0.78 0 N-CA-C 109.097 -0.705 . . . . 64.33 109.097 -178.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -60.05 143.99 99.51 Favored 'Trans proline' 0 C--N 1.367 1.522 0 C-N-CA 122.073 1.849 . . . . 52.21 111.085 174.039 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -53.44 -45.69 98.41 Favored Pre-proline 0 CA--C 1.555 1.165 0 CA-C-O 118.359 -0.829 . . . . 75.13 113.046 177.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -55.62 -42.33 68.8 Favored 'Trans proline' 0 C--N 1.39 2.755 0 C-N-CA 122.106 1.871 . . . . 63.15 113.261 172.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 4.0 mt -65.84 -43.6 93.12 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 C-N-CA 122.63 0.372 . . . . 72.54 111.256 176.635 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -58.56 -44.72 89.79 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 123.057 0.543 . . . . 74.11 111.451 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 205' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 33.4 m -77.39 -40.28 28.83 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 CA-C-N 115.745 -0.661 . . . . 74.33 112.081 -175.542 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.0 m -81.13 -20.72 11.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 119.1 0.863 . . . . 63.24 111.188 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.592 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 80.09 48.45 6.48 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-N 115.985 -0.552 . . . . 73.32 112.179 -175.837 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.27 -174.0 49.41 Favored Glycine 0 C--N 1.351 1.375 0 CA-C-O 121.37 0.428 . . . . 42.54 112.945 -177.104 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 209' ' ' LYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 222' ' ' ALA . 20.5 pttm -114.17 134.71 54.72 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.385 1.074 . . . . 74.31 109.797 -176.106 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 210' ' ' VAL . . . . . 0.507 HG11 HG12 ' A' ' 199' ' ' VAL . 7.6 p -133.71 157.23 42.13 Favored 'Isoleucine or valine' 0 C--O 1.241 0.608 0 C-N-CA 124.552 1.141 . . . . 75.24 108.494 -175.317 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 59.2 mmt-85 -91.55 128.93 37.57 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 109.489 -0.56 . . . . 72.44 109.489 178.033 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -102.72 122.09 43.76 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 108.643 -0.873 . . . . 71.24 108.643 171.427 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 5.6 tpt -74.04 104.66 4.95 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.732 0.813 . . . . 74.3 109.574 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 10.1 t -110.82 170.76 7.88 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 123.452 0.701 . . . . 65.31 110.623 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 62.4 mt -73.89 -2.2 22.83 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.022 0.929 . . . . 73.14 112.481 -175.233 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -114.82 -0.22 13.57 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 123.743 0.817 . . . . 70.35 112.17 174.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 133.25 -154.15 21.08 Favored Glycine 0 N--CA 1.48 1.597 0 CA-C-O 119.269 -0.74 . . . . 73.22 112.818 177.383 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -89.9 134.12 2.18 Favored 'Trans proline' 0 CA--C 1.554 1.49 0 C-N-CA 122.92 2.413 . . . . 74.11 112.259 172.083 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.1 m -113.79 158.15 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 CA-C-O 121.014 0.435 . . . . 73.11 111.74 175.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -96.75 104.54 16.54 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 114.966 -1.015 . . . . 63.25 108.429 -177.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.448 ' HB ' HD11 ' A' ' 235' ' ' LEU . 2.8 p -118.84 113.51 41.84 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 CA-C-O 121.437 0.637 . . . . 74.44 109.928 177.461 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 222' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 209' ' ' LYS . . . -97.28 118.69 34.3 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 108.759 -0.83 . . . . 73.01 108.759 178.061 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.592 HG23 ' HA2' ' A' ' 207' ' ' GLY . 18.2 m -72.96 148.04 88.96 Favored Pre-proline 0 CA--C 1.555 1.152 0 N-CA-C 109.523 -0.547 . . . . 75.14 109.523 176.029 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.0 151.98 73.31 Favored 'Trans proline' 0 CA--C 1.559 1.753 0 C-N-CA 122.173 1.915 . . . . 74.01 112.019 173.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -52.07 119.68 6.09 Favored 'Trans proline' 0 C--N 1.383 2.365 0 C-N-CA 123.646 2.898 . . . . 75.51 112.801 177.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 226' ' ' ARG . . . . . 0.479 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 48.6 mtm180 54.34 58.11 5.25 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 124.488 1.115 . . . . 71.5 110.668 -174.612 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 10.7 t -66.22 169.29 7.33 Favored 'General case' 0 CA--C 1.545 0.761 0 CA-C-N 115.539 -0.755 . . . . 54.15 109.506 173.079 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.8 mp0 -121.33 144.13 48.81 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 123.035 0.534 . . . . 52.4 109.83 -175.597 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -67.2 119.67 12.48 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-N 115.212 -0.904 . . . . 63.02 108.822 173.505 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.33 -12.06 19.26 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-O 119.65 -0.528 . . . . 60.23 112.315 -174.002 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 58.2 mtp180 -74.14 160.9 30.58 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 117.2 0.5 . . . . 73.41 110.604 174.475 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.403 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.3 mppt? -128.55 120.57 26.97 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.77 0.428 . . . . 74.1 110.676 -175.728 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 233' ' ' LEU . . . . . 0.493 HD11 HG12 ' A' ' 223' ' ' VAL . 59.6 mt -97.59 112.88 24.56 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 108.697 -0.853 . . . . 73.54 108.697 -178.248 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 234' ' ' ARG . . . . . 0.53 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 39.5 ttt85 -98.6 104.61 16.67 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 116.014 -0.539 . . . . 72.24 110.015 -172.211 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.516 HD12 HD23 ' A' ' 249' ' ' LEU . 27.3 mt -91.63 107.2 19.04 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.671 0.788 . . . . 62.13 109.156 -177.38 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 6.8 mtpm? -77.25 144.1 38.45 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 112.273 0.471 . . . . 71.51 112.273 -173.109 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 85.38 35.92 11.45 Favored Glycine 0 C--N 1.349 1.266 0 O-C-N 123.769 0.668 . . . . 74.22 112.323 -177.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 34.9 mmtm -125.61 -41.16 2.02 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 122.86 0.464 . . . . 72.11 112.184 -176.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -83.85 -178.04 51.69 Favored Glycine 0 C--N 1.337 0.62 0 C-N-CA 121.609 -0.329 . . . . 54.12 112.28 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.497 ' O ' ' HB2' ' A' ' 191' ' ' GLN . 72.5 m-85 -94.93 157.91 35.88 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 123.307 0.643 . . . . 74.43 111.77 -174.122 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -52.42 150.48 20.5 Favored 'Trans proline' 0 C--N 1.381 2.283 0 C-N-CA 123.254 2.636 . . . . 52.43 114.002 175.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 179.01 -159.54 24.5 Favored Glycine 0 CA--C 1.535 1.293 0 CA-C-O 119.516 -0.602 . . . . 71.5 113.099 -176.257 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -62.92 -34.34 71.85 Favored 'Trans proline' 0 C--N 1.375 1.925 0 C-N-CA 123.925 3.083 . . . . 72.52 114.217 -171.163 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.89 22.81 4.0 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.342 0.657 . . . . 73.01 111.289 178.474 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.97 -96.56 2.14 Favored Glycine 0 C--N 1.347 1.191 0 N-CA-C 111.192 -0.763 . . . . 63.43 111.192 179.113 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 42.1 ttt-85 -115.65 144.69 43.55 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 123.558 0.743 . . . . 75.43 109.09 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -80.26 168.99 52.37 Favored Glycine 0 C--O 1.253 1.297 0 O-C-N 123.604 0.565 . . . . 62.44 112.899 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 55.4 m-20 -139.57 171.97 13.48 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.342 1.057 . . . . 74.53 108.915 -173.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.53 ' O ' ' HA ' ' A' ' 234' ' ' ARG . 15.5 tp -98.44 128.92 45.02 Favored 'General case' 0 C--O 1.21 -0.974 0 C-N-CA 123.101 0.56 . . . . 71.43 109.761 177.129 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 53.8 t80 -111.47 102.62 10.97 Favored 'General case' 0 CA--C 1.551 1.01 0 N-CA-C 107.49 -1.3 . . . . 71.22 107.49 -178.551 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.534 HD13 HD22 ' A' ' 197' ' ' LEU . 90.3 mt -87.54 150.61 23.61 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.996 0.919 . . . . 51.31 112.688 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.519 ' HB3' ' HA ' ' A' ' 196' ' ' THR . 14.0 tp10 -105.62 98.09 7.83 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 123.494 0.717 . . . . 72.32 109.314 173.226 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 80.3 t -56.98 112.5 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 123.205 0.602 . . . . 53.12 111.019 174.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 49.3 mmm-85 -119.07 96.06 5.07 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 125.033 1.333 . . . . 75.15 108.069 177.149 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 58.8 mt -75.5 128.18 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 N-CA-C 109.561 -0.533 . . . . 41.33 109.561 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.249 1.028 0 C-N-CA 124.574 1.15 . . . . 64.4 107.911 -176.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 110.653 -0.128 . . . . 73.41 110.653 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -156.19 -53.53 0.08 Allowed 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 122.936 0.495 . . . . 64.1 110.67 179.463 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.622 ' HB2' ' HB3' ' A' ' 136' ' ' ARG . 33.4 tp -83.31 -74.89 0.34 Allowed 'General case' 0 N--CA 1.476 0.868 0 N-CA-C 109.379 -0.6 . . . . 75.43 109.379 -179.521 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 24.0 t -89.6 150.93 3.57 Favored 'Isoleucine or valine' 0 C--O 1.239 0.502 0 C-N-CA 124.454 1.102 . . . . 72.02 109.14 172.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -77.23 -51.06 11.57 Favored 'General case' 0 CA--C 1.54 0.579 0 O-C-N 123.713 0.633 . . . . 64.21 109.484 175.307 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 46.5 p-80 -179.2 177.13 0.8 Allowed 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 124.864 1.266 . . . . 71.24 109.535 -175.126 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.524 HG11 HD12 ' A' ' 119' ' ' LEU . 29.5 m -78.51 155.12 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 C-N-CA 122.683 0.393 . . . . 72.33 111.366 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.0 t -131.96 51.25 2.16 Favored 'General case' 0 CA--C 1.546 0.799 0 CA-C-O 122.402 1.096 . . . . 71.42 109.226 179.354 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 30.2 t -73.74 97.3 2.68 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 114.806 -1.088 . . . . 60.41 109.785 178.565 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -139.67 -115.3 1.25 Allowed Glycine 0 C--N 1.343 0.931 0 N-CA-C 110.545 -1.022 . . . . 33.15 110.545 178.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 61.4 m -79.27 177.74 8.6 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 117.331 0.566 . . . . 55.34 110.3 172.352 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 78.13 54.07 4.58 Favored Glycine 0 C--N 1.346 1.096 0 N-CA-C 110.849 -0.9 . . . . 62.13 110.849 -171.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.65 167.95 31.05 Favored Glycine 0 C--N 1.346 1.108 0 CA-C-N 115.19 -0.505 . . . . 55.23 112.206 -176.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 52.3 p -86.53 -22.32 26.41 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 123.579 0.751 . . . . 71.32 111.173 177.287 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 86.57 66.72 1.37 Allowed Glycine 0 C--N 1.352 1.441 0 N-CA-C 110.154 -1.178 . . . . 34.23 110.154 -172.473 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -162.01 64.32 0.26 Allowed Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.934 -0.867 . . . . 65.44 110.934 -176.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 31.0 t -55.35 -30.72 60.82 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.565 1.146 . . . . 64.44 111.966 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 81.3 -13.31 34.11 Favored Glycine 0 C--N 1.35 1.319 0 N-CA-C 114.678 0.631 . . . . 34.14 114.678 171.438 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -94.1 0.75 66.87 Favored Glycine 0 C--N 1.352 1.438 0 CA-C-N 117.438 0.619 . . . . 54.43 113.092 -176.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 70.5 p -141.51 -165.23 1.94 Allowed 'General case' 0 C--O 1.243 0.746 0 C-N-CA 124.04 0.936 . . . . 72.44 109.158 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -72.78 -115.89 0.06 OUTLIER Glycine 0 C--N 1.349 1.255 0 N-CA-C 110.537 -1.025 . . . . 44.15 110.537 169.498 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 65.4 mtt85 -91.57 118.12 30.33 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 117.892 0.846 . . . . 62.35 109.102 168.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -87.6 128.34 35.27 Favored 'General case' 0 C--O 1.241 0.655 0 N-CA-C 108.452 -0.944 . . . . 72.14 108.452 171.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.524 HD12 HG11 ' A' ' 102' ' ' VAL . 4.5 mm? -96.19 159.69 14.82 Favored 'General case' 0 N--CA 1.464 0.25 0 C-N-CA 124.129 0.972 . . . . 73.31 109.418 176.008 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 23.1 ptt180 -141.95 121.12 12.99 Favored 'General case' 0 C--O 1.241 0.649 0 N-CA-C 109.322 -0.622 . . . . 65.53 109.322 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -145.69 129.43 17.17 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 124.232 1.013 . . . . 65.11 109.446 -173.248 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.742 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 43.5 mt-10 -105.05 138.54 41.09 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 123.721 0.808 . . . . 62.33 109.228 178.747 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.476 HD21 HG12 ' A' ' 178' ' ' VAL . 1.8 pt? -135.64 141.52 37.47 Favored Pre-proline 0 N--CA 1.474 0.747 0 N-CA-C 110.033 -0.358 . . . . 61.34 110.033 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -73.38 113.27 3.73 Favored 'Trans proline' 0 C--N 1.368 1.586 0 C-N-CA 122.217 1.944 . . . . 64.44 109.924 171.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.547 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 11.9 tp -122.67 147.73 46.11 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 106.27 -1.752 . . . . 74.33 106.27 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 8.9 t -107.24 172.95 6.54 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 119.455 1.025 . . . . 74.1 110.491 175.067 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.5 ' O ' HD13 ' A' ' 215' ' ' LEU . 31.4 mt -55.38 -46.17 76.52 Favored 'General case' 0 N--CA 1.47 0.533 0 O-C-N 124.561 1.163 . . . . 71.12 109.949 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -51.66 -40.79 60.66 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 113.969 -1.469 . . . . 72.12 111.263 177.28 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.503 ' HB2' ' HG ' ' A' ' 125' ' ' LEU . 22.8 mm-40 -83.31 -24.02 32.33 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.195 0.598 . . . . 73.11 111.193 -178.621 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.432 ' HA ' ' CG1' ' A' ' 153' ' ' VAL . . . -59.78 -32.97 71.1 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 123.117 0.567 . . . . 72.5 111.645 167.404 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.3 t80 -77.72 -53.53 7.43 Favored 'General case' 0 C--N 1.351 0.636 0 CA-C-N 116.167 -0.47 . . . . 72.45 111.062 171.052 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -60.36 -45.85 92.04 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 123.552 0.532 . . . . 72.32 111.728 -172.137 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 59.53 -125.28 38.91 Favored Glycine 0 C--N 1.349 1.257 0 O-C-N 123.881 0.738 . . . . 65.51 111.378 -178.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.01 169.83 29.66 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 114.009 0.364 . . . . 42.4 114.009 166.412 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.417 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.6 mp0 -88.08 126.82 35.31 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 107.443 -1.318 . . . . 62.42 107.443 172.38 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.622 ' HB3' ' HB2' ' A' ' 98' ' ' LEU . 6.6 tpt180 -154.83 134.0 12.42 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 108.87 -0.789 . . . . 71.12 108.87 -177.221 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.673 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 10.9 p -74.75 143.38 13.47 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 C-N-CA 123.103 0.561 . . . . 62.25 112.477 -168.287 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.429 HG12 ' HB3' ' A' ' 98' ' ' LEU . 5.0 m -128.66 161.56 37.35 Favored 'Isoleucine or valine' 0 C--O 1.247 0.956 0 C-N-CA 124.458 1.103 . . . . 62.31 110.258 178.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 46.4 mm-40 -111.09 111.32 22.34 Favored 'General case' 0 C--O 1.238 0.499 0 C-N-CA 123.954 0.902 . . . . 71.54 109.419 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.461 HG21 HD22 ' A' ' 174' ' ' LEU . 45.2 t -138.27 119.89 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 123.503 0.721 . . . . 73.04 110.628 178.751 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 64.05 21.78 12.7 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 124.785 1.234 . . . . 63.13 112.94 171.105 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.19 14.12 77.49 Favored Glycine 0 C--N 1.349 1.251 0 CA-C-N 116.702 -0.226 . . . . 65.32 112.729 -176.159 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? -110.78 118.5 36.31 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.422 1.089 . . . . 74.02 108.152 176.019 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 54.2 ttp180 -87.1 106.33 17.79 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 107.694 -1.224 . . . . 73.32 107.694 174.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 8.1 m -136.01 135.78 50.13 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 123.541 0.737 . . . . 72.42 110.429 -172.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.673 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 35.9 t -83.51 128.28 34.39 Favored 'General case' 0 C--O 1.241 0.616 0 C-N-CA 123.371 0.668 . . . . 71.21 109.679 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.557 HG13 HG11 ' A' ' 161' ' ' VAL . 99.0 t -99.65 125.98 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 123.577 0.751 . . . . 65.05 110.469 177.482 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' ARG . . . . . 0.417 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 74.4 ttt180 -99.08 104.23 16.22 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 123.844 0.857 . . . . 74.03 109.483 172.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.574 HG22 HG21 ' A' ' 159' ' ' ILE . 28.3 pt -107.54 118.11 54.14 Favored Pre-proline 0 CA--C 1.55 0.969 0 N-CA-C 108.598 -0.89 . . . . 72.51 108.598 169.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -67.09 152.15 80.48 Favored 'Trans proline' 0 C--N 1.379 2.14 0 C-N-CA 122.668 2.245 . . . . 71.44 113.107 -175.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_exo -49.2 113.7 1.02 Allowed 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 123.609 2.873 . . . . 73.43 112.662 170.32 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 129.94 65.37 0.1 Allowed Glycine 0 C--N 1.342 0.911 0 CA-C-N 116.319 -0.401 . . . . 71.04 112.208 177.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.5 HG21 HD11 ' A' ' 159' ' ' ILE . 3.9 p -129.72 159.96 41.22 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.51 0 C-N-CA 123.15 0.58 . . . . 53.14 109.529 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 29.9 mtp-105 -136.79 168.31 19.78 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 123.8 0.84 . . . . 72.44 111.292 -164.638 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -57.1 121.64 10.52 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.403 1.081 . . . . 73.44 111.333 171.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.62 9.9 86.66 Favored Glycine 0 C--N 1.35 1.339 0 O-C-N 123.832 0.708 . . . . 71.43 113.21 178.652 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 30.3 t -73.39 122.89 22.79 Favored 'General case' 0 C--N 1.356 0.881 0 C-N-CA 123.165 0.586 . . . . 42.44 109.468 -177.705 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.556 HG12 HD22 ' A' ' 175' ' ' LEU . 11.3 t -99.46 116.25 42.19 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 O-C-N 124.399 1.062 . . . . 50.12 108.485 -178.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.574 HG21 HG22 ' A' ' 149' ' ' ILE . 18.1 mt -107.66 113.42 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 123.665 0.786 . . . . 73.54 110.247 -170.79 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 26.8 ttm180 -89.59 113.28 24.69 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 123.346 0.658 . . . . 63.12 110.878 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.557 HG11 HG13 ' A' ' 147' ' ' VAL . 22.5 m -109.48 99.48 37.34 Favored Pre-proline 0 CA--C 1.564 1.51 0 N-CA-C 109.603 -0.517 . . . . 55.35 109.603 176.333 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -69.62 150.31 68.87 Favored 'Trans proline' 0 C--N 1.377 2.058 0 C-N-CA 123.298 2.665 . . . . 74.3 113.501 -172.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.32 10.37 86.26 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-N 115.383 -0.826 . . . . 75.12 113.656 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 58.4 mtp -114.82 -20.48 10.58 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.365 0.666 . . . . 71.24 112.419 -173.473 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -86.81 -104.38 0.81 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.755 -0.469 . . . . 32.45 112.067 177.061 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.43 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -65.92 105.56 1.3 Allowed Glycine 0 C--N 1.349 1.281 0 N-CA-C 111.46 -0.656 . . . . 75.31 111.46 176.231 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.6 mm-40 -79.0 134.39 36.79 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.512 0.725 . . . . 72.05 110.332 -176.358 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 145.25 -164.13 28.02 Favored Glycine 0 C--N 1.341 0.809 0 CA-C-N 115.967 -0.56 . . . . 72.12 111.854 -176.806 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 34.7 t-20 -67.08 -52.46 30.63 Favored Pre-proline 0 CA--C 1.565 1.546 0 CA-C-O 118.015 -0.993 . . . . 42.34 110.316 -178.724 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -75.33 106.27 2.24 Favored 'Trans proline' 0 C--N 1.396 3.041 0 CA-C-N 121.375 1.527 . . . . 62.52 110.229 170.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.45 124.81 9.66 Favored 'Trans proline' 0 C--N 1.372 1.799 0 C-N-CA 121.343 1.362 . . . . 73.23 111.56 -171.361 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.43 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -90.98 160.23 27.17 Favored Glycine 0 C--N 1.334 0.46 0 N-CA-C 110.063 -1.215 . . . . 52.41 110.063 170.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -120.03 176.95 5.18 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.012 0.525 . . . . 74.35 110.446 -174.491 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.461 HD22 HG21 ' A' ' 140' ' ' VAL . 19.5 tp -128.06 115.95 19.25 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 115.34 -0.846 . . . . 70.54 109.304 172.424 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.556 HD22 HG12 ' A' ' 158' ' ' VAL . 88.9 mt -87.87 105.69 17.6 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 125.164 1.386 . . . . 74.22 110.852 179.28 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 36.6 mt -95.91 108.06 20.39 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 123.079 0.551 . . . . 73.31 111.037 177.319 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.742 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 19.7 t -90.78 99.9 10.32 Favored 'Isoleucine or valine' 0 C--O 1.242 0.71 0 N-CA-C 107.957 -1.127 . . . . 75.13 107.957 174.054 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.476 HG12 HD21 ' A' ' 123' ' ' LEU . 4.3 m -82.21 141.48 14.97 Favored 'Isoleucine or valine' 0 C--O 1.245 0.833 0 N-CA-C 109.054 -0.721 . . . . 75.33 109.054 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 16.1 mmm-85 -119.54 104.98 10.78 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.669 -1.234 . . . . 74.24 107.669 -175.427 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.547 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 61.2 mt -68.87 147.43 51.71 Favored 'General case' 0 CA--C 1.545 0.763 0 O-C-N 123.506 0.504 . . . . 75.31 111.009 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.465 ' HB2' ' HB3' ' A' ' 183' ' ' HIS . 27.7 mt -63.64 168.78 4.96 Favored Pre-proline 0 CA--C 1.56 1.33 0 C-N-CA 124.07 0.948 . . . . 71.42 111.098 -174.361 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -75.76 43.01 1.02 Allowed 'Trans proline' 0 C--N 1.381 2.243 0 C-N-CA 122.885 2.39 . . . . 71.45 111.601 162.117 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' HIS . . . . . 0.465 ' HB3' ' HB2' ' A' ' 181' ' ' LEU . 8.2 t60 -125.27 95.48 41.23 Favored Pre-proline 0 CA--C 1.532 0.281 0 N-CA-C 105.88 -1.896 . . . . 73.45 105.88 -178.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -100.75 123.76 0.11 Allowed 'Trans proline' 0 CA--C 1.554 1.525 0 C-N-CA 122.636 2.224 . . . . 63.5 113.052 176.156 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.437 HG12 HD12 ' A' ' 127' ' ' LEU . 4.1 p -144.75 -42.04 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 N-CA-C 108.855 -0.794 . . . . 71.13 108.855 175.135 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.429 ' H ' HD13 ' A' ' 127' ' ' LEU . 3.8 m-85 -126.96 154.93 43.91 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.387 1.075 . . . . 73.24 110.208 174.443 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 18.6 ttp85 -156.25 142.8 18.55 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 123.221 0.608 . . . . 63.14 109.564 178.087 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.468 HD13 ' HD1' ' A' ' 240' ' ' PHE . 56.6 tp -104.63 140.61 37.78 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.762 0.825 . . . . 73.1 110.27 178.186 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -139.64 111.49 7.35 Favored 'General case' 0 C--O 1.246 0.877 0 N-CA-C 107.191 -1.411 . . . . 61.31 107.191 168.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 74.66 -80.93 0.88 Allowed Glycine 0 C--N 1.347 1.171 0 O-C-N 123.558 0.536 . . . . 64.2 112.611 177.662 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 191' ' ' GLN . . . . . 0.428 ' HB3' ' HA3' ' A' ' 242' ' ' GLY . 9.3 pt20 -138.39 -23.04 1.0 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 124.068 0.947 . . . . 53.23 110.168 176.302 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.439 ' O ' HD12 ' A' ' 188' ' ' LEU . 0.6 OUTLIER -89.6 157.59 17.98 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 123.832 0.853 . . . . 64.25 110.884 -173.046 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.575 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.7 mt -108.62 166.88 10.46 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 124.75 1.22 . . . . 73.33 109.508 -177.509 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -142.78 122.1 13.07 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 107.135 -1.432 . . . . 74.33 107.135 -178.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -148.19 152.18 36.8 Favored 'General case' 0 CA--C 1.518 -0.285 0 C-N-CA 123.823 0.849 . . . . 63.12 110.459 -174.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 7.4 m -100.94 120.87 40.8 Favored 'General case' 0 CA--C 1.541 0.604 0 O-C-N 124.025 0.828 . . . . 74.41 109.389 176.294 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.53 HD22 HD13 ' A' ' 251' ' ' LEU . 66.0 tp -107.53 111.89 24.37 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.839 0.856 . . . . 74.13 109.467 -179.346 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -95.28 119.14 33.27 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.399 0.68 . . . . 75.41 109.259 176.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 199' ' ' VAL . . . . . 0.527 HG11 HG11 ' A' ' 223' ' ' VAL . 6.0 m -122.99 139.97 32.53 Favored Pre-proline 0 N--CA 1.475 0.8 0 C-N-CA 123.37 0.668 . . . . 73.23 109.267 -178.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_exo -59.31 144.37 99.42 Favored 'Trans proline' 0 C--N 1.372 1.793 0 C-N-CA 122.745 2.297 . . . . 63.34 111.81 171.411 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 201' ' ' ALA . . . . . 0.401 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -55.67 -44.63 99.76 Favored Pre-proline 0 CA--C 1.554 1.12 0 CA-C-O 117.963 -1.018 . . . . 53.51 111.991 177.192 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -48.61 -51.3 10.58 Favored 'Trans proline' 0 C--N 1.399 3.232 0 C-N-CA 122.537 2.158 . . . . 61.41 112.865 169.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 4.3 mt -62.44 -38.84 82.33 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.078 0 C-N-CA 123.202 0.601 . . . . 72.24 111.03 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.45 -44.41 96.47 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.17 0.588 . . . . 61.05 112.06 -178.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.3 m -78.55 -39.39 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-N 116.004 -0.543 . . . . 64.15 111.426 -174.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.1 m -82.9 -20.8 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 122.434 0.294 . . . . 71.22 111.284 -179.718 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.432 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 72.6 68.16 1.66 Allowed Glycine 0 C--N 1.343 0.932 0 N-CA-C 111.324 -0.711 . . . . 60.54 111.324 -175.531 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -92.87 -164.49 37.85 Favored Glycine 0 C--N 1.352 1.472 0 N-CA-C 111.482 -0.647 . . . . 74.11 111.482 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -115.11 139.17 50.12 Favored 'General case' 0 C--O 1.241 0.647 0 C-N-CA 123.554 0.742 . . . . 73.32 109.146 -178.05 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 210' ' ' VAL . . . . . 0.544 HG23 HG13 ' A' ' 221' ' ' VAL . 6.6 m -134.39 149.22 29.77 Favored 'Isoleucine or valine' 0 C--O 1.24 0.589 0 C-N-CA 123.876 0.87 . . . . 63.13 109.073 177.794 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 211' ' ' ARG . . . . . 0.483 ' H ' ' HD2' ' A' ' 211' ' ' ARG . 0.2 OUTLIER -104.87 125.9 51.38 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 108.116 -1.068 . . . . 74.11 108.116 174.874 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.48 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -99.89 129.2 45.95 Favored 'General case' 0 C--O 1.245 0.843 0 N-CA-C 108.792 -0.818 . . . . 44.33 108.792 -175.239 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 6.1 tpt -71.47 102.6 2.71 Favored 'General case' 0 CA--C 1.537 0.452 0 O-C-N 124.198 0.936 . . . . 73.21 109.4 -178.7 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.495 HG21 HG13 ' A' ' 219' ' ' VAL . 10.0 t -110.95 166.75 10.78 Favored 'General case' 0 C--O 1.238 0.451 0 CA-C-O 121.62 0.724 . . . . 72.33 110.694 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 215' ' ' LEU . . . . . 0.5 HD13 ' O ' ' A' ' 127' ' ' LEU . 25.9 mt -66.59 -19.04 65.68 Favored 'General case' 0 CA--C 1.545 0.765 0 CA-C-N 114.634 -1.166 . . . . 73.51 110.88 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -87.48 -21.7 25.35 Favored 'General case' 0 CA--C 1.558 1.263 0 C-N-CA 125.609 1.564 . . . . 63.12 111.797 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 139.39 -146.91 18.71 Favored Glycine 0 C--N 1.352 1.431 0 CA-C-O 119.157 -0.802 . . . . 71.42 111.583 -169.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -93.51 133.79 0.94 Allowed 'Trans proline' 0 CA--C 1.557 1.666 0 C-N-CA 122.373 2.049 . . . . 61.3 112.276 165.206 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 219' ' ' VAL . . . . . 0.495 HG13 HG21 ' A' ' 214' ' ' THR . 16.5 m -108.97 143.25 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 C-N-CA 122.934 0.494 . . . . 63.31 110.453 171.818 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -91.37 108.9 20.21 Favored 'General case' 0 CA--C 1.542 0.649 0 CA-C-O 121.524 0.678 . . . . 73.55 109.598 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.544 HG13 HG23 ' A' ' 210' ' ' VAL . 2.6 p -119.19 127.15 75.85 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.761 0 C-N-CA 123.55 0.74 . . . . 72.1 110.557 173.417 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -96.88 120.21 36.79 Favored 'General case' 0 C--O 1.238 0.453 0 C-N-CA 123.982 0.913 . . . . 71.31 109.215 177.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.527 HG11 HG11 ' A' ' 199' ' ' VAL . 11.5 m -82.65 141.85 45.26 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 109.631 -0.507 . . . . 63.14 109.631 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -63.74 141.07 77.37 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 122.752 2.302 . . . . 74.12 112.202 175.504 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -62.12 125.31 16.13 Favored 'Trans proline' 0 C--N 1.37 1.693 0 C-N-CA 122.513 2.142 . . . . 73.31 111.076 173.341 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 56.6 mtm180 64.77 50.21 2.08 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 124.951 1.407 . . . . 74.01 109.993 -172.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.0 t -79.5 169.7 17.66 Favored 'General case' 0 CA--C 1.546 0.804 0 CA-C-N 115.862 -0.608 . . . . 54.31 109.619 172.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 228' ' ' GLN . . . . . 0.595 ' H ' ' HD3' ' A' ' 231' ' ' ARG . 26.3 mp0 -125.04 142.09 51.71 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 123.808 0.843 . . . . 73.35 109.373 -172.605 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.66 119.39 13.83 Favored 'General case' 0 C--N 1.348 0.515 0 C-N-CA 123.469 0.708 . . . . 74.43 109.221 175.327 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.75 -7.08 22.17 Favored Glycine 0 C--N 1.34 0.793 0 CA-C-N 116.156 -0.475 . . . . 73.51 111.999 -171.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 231' ' ' ARG . . . . . 0.595 ' HD3' ' H ' ' A' ' 228' ' ' GLN . 75.2 mtp180 -81.94 160.94 23.24 Favored 'General case' 0 C--N 1.354 0.761 0 C-N-CA 122.766 0.426 . . . . 73.1 110.416 173.479 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.448 ' HG2' ' CE1' ' A' ' 250' ' ' TYR . 2.7 mppt? -122.23 135.59 54.78 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.267 0.627 . . . . 74.41 110.35 -175.727 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 61.8 mt -112.19 104.74 12.95 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 107.697 -1.223 . . . . 61.11 107.697 175.568 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 234' ' ' ARG . . . . . 0.548 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 50.3 ttt180 -94.14 109.04 20.84 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 115.682 -0.69 . . . . 74.13 109.622 -173.341 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.497 HD12 HD23 ' A' ' 249' ' ' LEU . 18.5 mt -85.95 128.11 34.77 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 122.838 0.455 . . . . 73.23 110.219 -175.656 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 50.0 mtmt -71.04 122.14 19.5 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.449 1.1 . . . . 71.45 111.762 -167.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.58 16.98 70.37 Favored Glycine 0 C--N 1.351 1.385 0 O-C-N 123.793 0.683 . . . . 55.11 114.02 172.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -94.9 7.28 46.51 Favored 'General case' 0 N--CA 1.48 1.049 0 N-CA-C 112.49 0.552 . . . . 70.11 112.49 -174.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -95.62 -170.84 35.9 Favored Glycine 0 C--N 1.34 0.789 0 O-C-N 123.553 0.533 . . . . 62.2 112.347 175.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.468 ' HD1' HD13 ' A' ' 188' ' ' LEU . 60.3 m-85 -85.95 159.88 53.57 Favored Pre-proline 0 CA--C 1.544 0.733 0 C-N-CA 123.578 0.751 . . . . 74.13 111.107 -176.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -52.97 127.94 26.94 Favored 'Trans proline' 0 C--N 1.391 2.812 0 C-N-CA 122.713 2.276 . . . . 71.4 112.221 176.693 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 242' ' ' GLY . . . . . 0.428 ' HA3' ' HB3' ' A' ' 191' ' ' GLN . . . -157.0 -164.36 13.49 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-O 119.03 -0.872 . . . . 74.34 111.945 -177.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.39 -30.34 91.02 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 123.569 2.846 . . . . 75.31 114.153 -173.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -93.61 22.97 4.96 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 123.428 0.691 . . . . 71.11 111.329 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 87.87 -73.92 2.26 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 110.104 -1.198 . . . . 74.31 110.104 -174.237 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 50.0 mtm180 -127.02 162.52 25.82 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 124.16 0.984 . . . . 73.44 108.674 167.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -89.38 -156.86 32.34 Favored Glycine 0 C--N 1.342 0.876 0 O-C-N 123.671 0.607 . . . . 72.03 112.398 176.476 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -135.86 171.59 14.24 Favored 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 109.182 -0.673 . . . . 72.41 109.182 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.575 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 12.8 tp -106.81 117.4 33.96 Favored 'General case' 0 C--O 1.213 -0.848 0 C-N-CA 123.268 0.627 . . . . 43.33 111.171 176.11 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 250' ' ' TYR . . . . . 0.478 ' HB3' ' O ' ' A' ' 193' ' ' LEU . 1.9 t80 -89.68 103.98 16.58 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 107.979 -1.119 . . . . 73.52 107.979 173.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.53 HD13 HD22 ' A' ' 197' ' ' LEU . 76.2 mt -88.77 148.03 24.15 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 123.261 0.625 . . . . 74.15 110.921 172.515 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -109.34 97.49 7.07 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 108.768 -0.827 . . . . 74.32 108.768 175.22 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 57.3 t -53.68 113.94 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 123.28 0.632 . . . . 45.51 110.802 173.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 27.7 mmt85 -123.64 94.3 4.2 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 107.185 -1.413 . . . . 73.42 107.185 178.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.401 HG23 ' HA ' ' A' ' 201' ' ' ALA . 76.6 mt -77.82 114.76 18.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 123.718 0.807 . . . . 65.24 110.318 -176.551 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 4.2 t . . . . . 0 CA--C 1.562 1.428 0 C-N-CA 123.633 0.773 . . . . 63.54 109.527 176.051 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.53 ' HB2' ' HG2' ' A' ' 139' ' ' GLU . . . . . . . . 0 N--CA 1.481 1.121 0 N-CA-C 110.343 -0.243 . . . . 73.24 110.343 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -82.14 -61.54 1.88 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 123.42 0.688 . . . . 73.21 111.348 -174.092 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.463 HD21 HD13 ' A' ' 125' ' ' LEU . 30.5 tp -83.82 -55.43 4.26 Favored 'General case' 0 C--O 1.241 0.658 0 C-N-CA 122.882 0.473 . . . . 63.35 111.121 -170.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.447 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 14.8 p -67.3 120.62 14.94 Favored 'Isoleucine or valine' 0 C--N 1.36 1.051 0 CA-C-O 121.54 0.686 . . . . 64.13 110.26 175.462 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -85.67 -60.71 1.94 Allowed 'General case' 0 C--O 1.24 0.564 0 CA-C-N 114.933 -1.031 . . . . 62.1 110.456 -175.657 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 26.6 t-80 -165.94 157.81 14.22 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 115.793 -0.64 . . . . 75.53 111.217 -171.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 25.9 t -64.42 145.14 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 125.148 1.379 . . . . 63.42 111.028 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.669 HG22 ' HG3' ' A' ' 122' ' ' GLU . 41.6 p -63.66 -45.99 87.65 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 123.517 0.727 . . . . 74.32 111.377 177.237 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 46.0 t -99.74 -75.71 0.56 Allowed 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 123.95 0.9 . . . . 40.53 109.887 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 160.4 -60.59 0.3 Allowed Glycine 0 C--N 1.345 1.047 0 N-CA-C 110.385 -1.086 . . . . 60.33 110.385 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 57.6 p -89.27 70.27 8.21 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 123.687 0.795 . . . . 71.52 110.21 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.444 ' O ' HD23 ' A' ' 119' ' ' LEU . . . 85.63 -81.97 1.7 Allowed Glycine 0 C--N 1.347 1.17 0 CA-C-N 115.696 -0.683 . . . . 52.14 111.443 -176.242 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 162.39 156.71 8.59 Favored Glycine 0 C--O 1.243 0.659 0 CA-C-O 119.589 -0.561 . . . . 74.12 111.834 179.729 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 40.9 m -57.09 109.75 0.71 Allowed 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 123.499 0.72 . . . . 74.2 111.582 -176.068 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -67.69 135.58 30.89 Favored Glycine 0 C--N 1.343 0.955 0 CA-C-N 115.386 -0.825 . . . . 45.45 112.709 -177.443 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 140.24 38.76 0.09 OUTLIER Glycine 0 C--N 1.335 0.519 0 N-CA-C 111.842 -0.503 . . . . 73.14 111.842 -179.04 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 35.3 t -158.08 -61.69 0.08 Allowed 'General case' 0 CA--C 1.541 0.631 0 N-CA-C 109.519 -0.548 . . . . 64.24 109.519 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -70.63 -54.28 10.52 Favored Glycine 0 C--N 1.344 1.024 0 CA-C-N 115.708 -0.678 . . . . 73.33 112.809 -178.502 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.71 -49.78 3.9 Favored Glycine 0 C--N 1.343 0.947 0 N-CA-C 114.183 0.433 . . . . 61.14 114.183 172.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.2 t -74.94 119.92 19.78 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 122.86 0.464 . . . . 51.15 110.312 -176.326 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 62.54 -132.68 44.54 Favored Glycine 0 C--N 1.352 1.468 0 O-C-N 123.846 0.716 . . . . 74.11 111.849 -177.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.634 ' H ' ' HA3' ' A' ' 166' ' ' GLY . 4.4 tpm_? -90.53 122.53 33.44 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 123.165 0.586 . . . . 70.21 109.558 168.562 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -60.58 109.26 0.98 Allowed 'General case' 0 C--O 1.243 0.746 0 N-CA-C 108.061 -1.088 . . . . 41.4 108.061 165.373 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.598 HD21 HG11 ' A' ' 140' ' ' VAL . 0.5 OUTLIER -95.77 135.88 36.9 Favored 'General case' 0 C--N 1.345 0.402 0 N-CA-C 106.283 -1.747 . . . . 52.21 106.283 175.015 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 56.7 mtp180 -142.65 126.52 17.17 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 108.304 -0.998 . . . . 74.02 108.304 -175.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -148.78 133.27 17.65 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.335 0.654 . . . . 73.42 110.157 -178.465 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.669 ' HG3' HG22 ' A' ' 103' ' ' THR . 44.8 mt-10 -92.89 144.99 24.72 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 122.929 0.491 . . . . 62.41 109.993 173.061 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.447 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.7 pt? -146.68 132.18 9.23 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.365 -0.834 . . . . 70.41 110.533 -177.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -72.09 114.96 4.13 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 121.814 1.676 . . . . 75.31 111.221 175.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.463 HD13 HD21 ' A' ' 98' ' ' LEU . 22.0 tp -108.93 167.26 10.22 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.539 1.136 . . . . 65.54 108.065 176.334 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.497 HG23 HD12 ' A' ' 181' ' ' LEU . 7.8 m -103.46 159.8 15.27 Favored 'General case' 0 N--CA 1.476 0.865 0 O-C-N 121.624 -0.672 . . . . 63.33 109.513 171.442 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.555 HD23 ' HB3' ' A' ' 180' ' ' LEU . 81.2 mt -52.12 -52.77 49.5 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-O 121.311 0.577 . . . . 51.3 109.625 169.441 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.574 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.7 mp0 -55.64 -39.74 71.26 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 114.588 -1.187 . . . . 71.14 112.146 177.793 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -77.7 -21.17 52.4 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 122.765 0.426 . . . . 64.54 111.845 -178.619 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.489 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -68.55 -36.08 78.3 Favored 'General case' 0 C--O 1.248 0.99 0 C-N-CA 123.628 0.771 . . . . 71.43 110.64 168.531 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.483 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 69.2 t80 -64.44 -49.05 73.0 Favored 'General case' 0 C--N 1.346 0.448 0 CA-C-N 115.232 -0.894 . . . . 75.1 110.537 170.818 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -72.94 -28.82 62.67 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 112.855 0.687 . . . . 70.43 112.855 -173.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 67.3 -96.18 0.32 Allowed Glycine 0 C--N 1.351 1.376 0 N-CA-C 111.415 -0.674 . . . . 53.53 111.415 -174.26 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.38 150.55 25.46 Favored Glycine 0 C--N 1.349 1.29 0 N-CA-C 114.78 0.672 . . . . 71.04 114.78 167.562 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -85.59 125.57 33.22 Favored 'General case' 0 N--CA 1.473 0.684 0 N-CA-C 108.116 -1.068 . . . . 61.42 108.116 169.633 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 21.9 mmt180 -129.22 152.66 48.55 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.255 1.022 . . . . 63.42 108.742 -168.61 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 22.3 m -85.24 127.11 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.212 0 N-CA-C 110.053 -0.351 . . . . 72.21 110.053 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 85.7 t -123.73 122.78 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 123.086 0.554 . . . . 70.33 109.884 175.214 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' GLU . . . . . 0.53 ' HG2' ' HB2' ' A' ' 96' ' ' ALA . 11.7 pt-20 -124.8 96.53 4.91 Favored 'General case' 0 N--CA 1.476 0.87 0 CA-C-O 121.99 0.9 . . . . 61.02 109.24 172.063 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.598 HG11 HD21 ' A' ' 119' ' ' LEU . 74.0 t -130.59 133.11 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 123.786 0.834 . . . . 71.54 109.64 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.33 28.35 17.84 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 124.621 1.168 . . . . 60.1 111.157 -178.639 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.12 -9.3 66.98 Favored Glycine 0 C--N 1.35 1.321 0 CA-C-N 115.548 -0.751 . . . . 62.03 113.447 -177.603 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.2 tpp180 -91.08 115.67 28.19 Favored 'General case' 0 C--N 1.344 0.339 0 N-CA-C 109.424 -0.584 . . . . 74.24 109.424 -176.143 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 59.0 ttp180 -103.72 111.4 23.88 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 108.636 -0.875 . . . . 74.14 108.636 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.5 p -145.89 141.86 21.74 Favored 'Isoleucine or valine' 0 C--O 1.243 0.731 0 C-N-CA 125.011 1.324 . . . . 71.43 108.325 178.794 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 32.4 p -77.69 134.14 38.19 Favored 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 116.384 -0.371 . . . . 74.24 110.016 178.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 9.0 p -98.74 136.11 31.03 Favored 'Isoleucine or valine' 0 C--N 1.341 0.2 0 N-CA-C 109.126 -0.694 . . . . 72.45 109.126 175.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.1 ttt85 -108.19 95.45 5.68 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 107.559 -1.275 . . . . 75.33 107.559 168.706 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.446 ' HB ' HD13 ' A' ' 159' ' ' ILE . 36.5 pt -87.03 113.62 54.46 Favored Pre-proline 0 CA--C 1.552 1.021 0 N-CA-C 107.777 -1.194 . . . . 52.21 107.777 171.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -61.45 137.41 69.64 Favored 'Trans proline' 0 C--N 1.381 2.251 0 C-N-CA 122.683 2.255 . . . . 70.12 112.85 -173.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.426 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 83.7 Cg_exo -50.62 120.07 5.98 Favored 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 123.281 2.654 . . . . 74.32 112.132 172.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 126.03 52.57 0.16 Allowed Glycine 0 C--N 1.341 0.826 0 N-CA-C 110.861 -0.896 . . . . 63.21 110.861 -174.158 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.574 HG21 HD11 ' A' ' 159' ' ' ILE . 1.9 p -126.05 161.87 30.71 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.197 0 C-N-CA 123.94 0.896 . . . . 71.13 109.247 -176.548 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -140.94 165.9 26.26 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 124.869 1.267 . . . . 73.23 111.576 -165.351 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -57.12 122.85 13.38 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.948 0.899 . . . . 71.11 110.008 169.118 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.86 7.88 86.44 Favored Glycine 0 C--N 1.343 0.931 0 CA-C-O 119.4 -0.667 . . . . 64.3 113.824 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.5 t -78.77 123.33 27.08 Favored 'General case' 0 C--O 1.244 0.794 0 N-CA-C 109.415 -0.587 . . . . 60.51 109.415 177.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.412 HG22 HD22 ' A' ' 175' ' ' LEU . 7.6 p -100.49 120.78 50.42 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.126 0 CA-C-N 115.063 -0.971 . . . . 74.35 109.569 -179.233 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.574 HD11 HG21 ' A' ' 153' ' ' VAL . 20.1 mt -106.73 116.82 51.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.963 0.905 . . . . 72.25 110.32 -167.745 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.482 ' HG3' ' HB2' ' A' ' 173' ' ' ASP . 29.6 ttm180 -89.3 113.12 24.35 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.653 0.781 . . . . 72.13 111.245 -179.305 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 18.4 m -115.41 103.27 54.3 Favored Pre-proline 0 CA--C 1.561 1.374 0 CA-C-O 121.498 0.666 . . . . 75.4 110.581 178.401 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -65.5 145.65 83.04 Favored 'Trans proline' 0 C--N 1.381 2.258 0 C-N-CA 122.716 2.278 . . . . 75.22 112.992 -177.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 94.07 -23.25 32.22 Favored Glycine 0 C--N 1.345 1.03 0 CA-C-N 115.742 -0.663 . . . . 64.31 113.962 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.481 ' HB3' ' HE2' ' A' ' 164' ' ' MET . 68.8 mtp -95.13 -23.66 17.2 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 112.927 0.714 . . . . 63.01 112.927 -169.548 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -78.18 -112.82 0.19 Allowed Glycine 0 C--N 1.346 1.105 0 N-CA-C 113.8 0.28 . . . . 61.11 113.8 -177.274 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.634 ' HA3' ' H ' ' A' ' 117' ' ' ARG . . . -68.97 105.66 1.55 Allowed Glycine 0 C--N 1.341 0.853 0 C-N-CA 122.836 0.255 . . . . 73.23 112.828 178.087 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -68.2 151.44 46.96 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.354 0.662 . . . . 62.31 110.578 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 138.32 -169.61 24.2 Favored Glycine 0 N--CA 1.466 0.688 0 CA-C-N 115.798 -0.637 . . . . 43.34 111.772 -176.839 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 41.1 t30 -64.58 -49.21 71.79 Favored Pre-proline 0 CA--C 1.553 1.07 0 CA-C-O 117.696 -1.145 . . . . 72.31 111.239 177.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -78.72 104.46 1.81 Allowed 'Trans proline' 0 C--N 1.396 3.047 0 C-N-CA 121.596 1.531 . . . . 71.44 110.525 168.139 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -65.9 125.24 13.87 Favored 'Trans proline' 0 C--N 1.381 2.28 0 C-N-CA 122.285 1.99 . . . . 74.31 111.544 -174.588 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.442 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -84.96 166.73 41.17 Favored Glycine 0 CA--C 1.509 -0.331 0 CA-C-N 116.169 -0.469 . . . . 44.41 111.946 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.482 ' HB2' ' HG3' ' A' ' 160' ' ' ARG . 8.2 p-10 -116.77 145.65 43.36 Favored 'General case' 0 C--O 1.245 0.824 0 C-N-CA 123.846 0.859 . . . . 64.21 109.28 -177.443 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.424 HD13 HD22 ' A' ' 119' ' ' LEU . 17.7 tp -106.39 122.37 46.12 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.824 -1.176 . . . . 42.42 107.824 176.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.412 HD22 HG22 ' A' ' 158' ' ' VAL . 77.1 mt -98.8 98.91 9.96 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 125.279 1.432 . . . . 74.13 110.282 -177.543 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 52.8 mt -92.57 107.39 19.18 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 123.411 0.684 . . . . 74.34 111.405 178.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.648 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 34.7 t -88.66 104.22 14.57 Favored 'Isoleucine or valine' 0 C--O 1.245 0.836 0 N-CA-C 108.465 -0.939 . . . . 74.42 108.465 173.551 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 9.7 m -82.0 147.59 5.99 Favored 'Isoleucine or valine' 0 C--O 1.242 0.686 0 CA-C-O 121.499 0.666 . . . . 72.05 110.318 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 24.3 mmm-85 -120.63 96.32 5.08 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 107.418 -1.327 . . . . 61.34 107.418 -179.435 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.555 ' HB3' HD23 ' A' ' 127' ' ' LEU . 31.0 mt -69.26 136.53 52.07 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 122.626 0.371 . . . . 73.13 110.368 -174.677 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.497 HD12 HG23 ' A' ' 126' ' ' THR . 53.7 mt -53.67 125.49 46.0 Favored Pre-proline 0 CA--C 1.554 1.122 0 CA-C-O 118.543 -0.742 . . . . 74.24 110.319 -177.189 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 24.0 Cg_exo -64.18 85.23 0.15 Allowed 'Trans proline' 0 C--N 1.379 2.139 0 C-N-CA 123.109 2.539 . . . . 74.13 113.471 -174.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -154.23 54.82 1.15 Allowed Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 123.758 0.823 . . . . 74.35 109.054 171.147 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -61.21 122.92 11.87 Favored 'Trans proline' 0 C--N 1.381 2.273 0 C-N-CA 122.54 2.16 . . . . 72.4 112.143 -165.055 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.29 -44.57 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 N-CA-C 107.824 -1.176 . . . . 70.11 107.824 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.456 ' HE2' HD13 ' A' ' 193' ' ' LEU . 3.6 m-85 -104.81 123.75 48.22 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.209 -0.905 . . . . 63.3 109.353 176.743 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.507 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 4.3 mmm180 -115.68 150.94 35.97 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 106.082 -1.821 . . . . 64.31 106.082 178.422 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.439 HD12 ' O ' ' A' ' 192' ' ' ASP . 63.9 tp -130.76 132.02 45.06 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 122.833 0.453 . . . . 64.52 109.832 -176.357 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -143.5 116.76 9.0 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 108.417 -0.957 . . . . 73.21 108.417 168.35 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 55.42 52.85 44.93 Favored Glycine 0 C--N 1.355 1.584 0 O-C-N 123.953 0.783 . . . . 60.22 114.04 176.009 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 191' ' ' GLN . . . . . 0.401 ' OE1' ' HD2' ' A' ' 243' ' ' PRO . 38.5 mt-30 72.5 -5.94 1.71 Allowed 'General case' 0 N--CA 1.496 1.866 0 C-N-CA 125.024 1.329 . . . . 72.13 113.168 177.8 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.439 ' O ' HD12 ' A' ' 188' ' ' LEU . 23.1 t70 -98.98 145.09 27.42 Favored 'General case' 0 C--N 1.348 0.503 0 N-CA-C 109.483 -0.562 . . . . 64.5 109.483 -176.64 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.606 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.7 mt -105.72 152.97 22.5 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.691 0.796 . . . . 71.1 109.232 -174.098 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 194' ' ' TYR . . . . . 0.507 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 98.3 m-85 -140.84 120.82 13.63 Favored 'General case' 0 C--O 1.223 -0.308 0 N-CA-C 107.649 -1.241 . . . . 75.12 107.649 -174.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -147.47 169.46 19.5 Favored 'General case' 0 C--O 1.24 0.595 0 C-N-CA 123.637 0.775 . . . . 74.44 110.287 -175.665 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 16.6 m -116.25 126.99 54.35 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.757 -0.656 . . . . 73.3 109.447 175.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.407 HD22 HD13 ' A' ' 251' ' ' LEU . 67.0 tp -107.39 119.46 39.46 Favored 'General case' 0 C--O 1.214 -0.804 0 C-N-CA 124.47 1.108 . . . . 71.52 108.696 176.071 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -97.31 136.79 37.29 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.257 -1.016 . . . . 62.3 108.257 167.439 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 199' ' ' VAL . . . . . 0.571 HG12 HG11 ' A' ' 210' ' ' VAL . 13.3 m -130.26 142.82 46.78 Favored Pre-proline 0 N--CA 1.476 0.833 0 N-CA-C 109.1 -0.704 . . . . 73.43 109.1 179.235 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -61.94 140.06 82.85 Favored 'Trans proline' 0 C--N 1.372 1.79 0 C-N-CA 121.942 1.761 . . . . 64.3 110.772 172.237 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 201' ' ' ALA . . . . . 0.416 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -52.78 -42.2 88.24 Favored Pre-proline 0 CA--C 1.558 1.263 0 CA-C-O 117.542 -1.218 . . . . 54.5 113.041 178.74 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 202' ' ' PRO . . . . . 0.48 ' O ' HG22 ' A' ' 206' ' ' VAL . 8.8 Cg_endo -49.78 -52.69 8.37 Favored 'Trans proline' 0 C--N 1.408 3.671 0 C-N-CA 122.851 2.367 . . . . 72.35 112.267 169.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 3.4 mt -60.98 -41.66 89.94 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 122.836 0.454 . . . . 74.51 111.271 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.49 -42.53 98.55 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.163 0.585 . . . . 51.43 112.187 -175.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 28.1 m -81.2 -35.51 14.25 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 CA-C-N 115.959 -0.564 . . . . 75.21 111.894 -173.06 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.48 HG22 ' O ' ' A' ' 202' ' ' PRO . 20.8 m -88.0 -19.21 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 O-C-N 122.118 -0.364 . . . . 74.04 111.635 178.614 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.415 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 76.37 66.67 1.81 Allowed Glycine 0 C--N 1.342 0.894 0 O-C-N 123.484 0.49 . . . . 75.33 112.181 -177.449 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.02 -168.45 42.89 Favored Glycine 0 C--N 1.348 1.203 0 N-CA-C 111.854 -0.498 . . . . 73.33 111.854 175.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -125.79 119.34 27.63 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 107.997 -1.112 . . . . 64.34 107.997 -179.323 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 210' ' ' VAL . . . . . 0.571 HG11 HG12 ' A' ' 199' ' ' VAL . 7.9 p -116.43 147.88 19.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.547 0 C-N-CA 124.143 0.977 . . . . 61.44 109.439 -174.1 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -76.24 123.66 26.25 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 116.026 -0.534 . . . . 73.42 109.579 172.795 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.13 130.14 47.15 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 108.052 -1.092 . . . . 72.03 108.052 173.179 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 56.3 mmm -76.55 141.01 41.32 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.131 0.491 . . . . 64.34 110.776 178.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.429 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 5.7 t -143.68 166.91 23.53 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-N 114.563 -1.199 . . . . 73.35 110.159 177.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 215' ' ' LEU . . . . . 0.574 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 65.1 mt -66.51 -19.84 65.88 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 124.306 1.042 . . . . 52.34 110.953 176.046 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -82.97 -18.25 40.61 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 124.859 1.263 . . . . 75.01 111.022 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 134.26 -147.49 19.11 Favored Glycine 0 C--N 1.352 1.433 0 N-CA-C 111.226 -0.75 . . . . 72.1 111.226 -174.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -93.11 129.37 0.76 Allowed 'Trans proline' 0 CA--C 1.56 1.787 0 C-N-CA 122.432 2.088 . . . . 62.43 112.775 165.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.7 m -109.15 166.71 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 C-N-CA 123.595 0.758 . . . . 73.12 109.56 169.539 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -113.94 116.47 29.3 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 109.867 -0.42 . . . . 74.51 109.867 178.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.4 p -108.78 136.82 43.38 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.681 0 C-N-CA 123.459 0.704 . . . . 71.24 110.175 173.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -95.12 115.73 27.81 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 124.025 0.93 . . . . 41.03 109.491 176.169 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.453 HG11 HG11 ' A' ' 199' ' ' VAL . 14.2 m -82.06 142.05 47.57 Favored Pre-proline 0 CA--C 1.548 0.893 0 N-CA-C 109.376 -0.601 . . . . 55.22 109.376 176.16 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_exo -61.0 141.12 93.47 Favored 'Trans proline' 0 C--N 1.368 1.558 0 C-N-CA 122.451 2.1 . . . . 75.12 112.746 172.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_exo -56.4 119.79 7.23 Favored 'Trans proline' 0 C--N 1.373 1.833 0 C-N-CA 122.588 2.192 . . . . 74.45 111.783 169.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 53.7 mtm180 60.75 51.64 4.75 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.676 1.19 . . . . 74.45 110.759 -174.082 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 227' ' ' THR . . . . . 0.473 ' OG1' ' HD2' ' A' ' 231' ' ' ARG . 12.1 t -73.17 172.68 10.64 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-N 114.955 -1.02 . . . . 73.11 110.257 174.765 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -126.49 141.81 51.75 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 123.149 0.58 . . . . 74.34 109.455 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 229' ' ' ALA . . . . . 0.466 ' HB2' ' H ' ' A' ' 255' ' ' ILE . . . -63.96 119.69 10.56 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.759 0.824 . . . . 64.31 109.836 175.112 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.98 4.78 20.75 Favored Glycine 0 C--O 1.241 0.57 0 C-N-CA 123.69 0.662 . . . . 33.41 112.314 -176.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 231' ' ' ARG . . . . . 0.473 ' HD2' ' OG1' ' A' ' 227' ' ' THR . 92.3 mtt180 -79.54 159.01 27.06 Favored 'General case' 0 C--N 1.358 0.942 0 CA-C-O 121.707 0.765 . . . . 73.0 109.551 170.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.474 ' HG3' ' HE2' ' A' ' 250' ' ' TYR . 10.1 mptt -108.34 99.13 8.57 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 114.32 -1.309 . . . . 74.11 108.452 -176.331 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 233' ' ' LEU . . . . . 0.448 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 62.6 mt -90.11 96.48 10.69 Favored 'General case' 0 C--N 1.349 0.545 0 N-CA-C 106.231 -1.766 . . . . 64.42 106.231 176.518 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 234' ' ' ARG . . . . . 0.495 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 39.1 ttp180 -96.11 101.36 13.01 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 114.915 -1.039 . . . . 71.01 110.015 -167.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.508 HD12 HD23 ' A' ' 249' ' ' LEU . 43.3 mt -81.08 105.92 12.67 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.934 0.894 . . . . 73.02 108.806 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt -74.61 144.18 44.02 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.171 0.588 . . . . 74.41 112.267 -171.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 71.11 19.99 77.65 Favored Glycine 0 C--N 1.349 1.275 0 O-C-N 123.764 0.665 . . . . 52.02 113.934 178.543 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 1.4 mmmp? -106.65 -12.43 15.56 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.792 0.437 . . . . 71.43 111.173 -179.356 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.17 -175.51 49.82 Favored Glycine 0 C--N 1.348 1.217 0 O-C-N 123.409 0.443 . . . . 72.31 112.138 173.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.483 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 87.5 m-85 -77.4 149.26 78.5 Favored Pre-proline 0 N--CA 1.475 0.809 0 N-CA-C 112.252 0.464 . . . . 74.04 112.252 -172.027 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 241' ' ' PRO . . . . . 0.595 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 53.3 Cg_endo -65.52 160.58 42.28 Favored 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 122.838 2.359 . . . . 55.51 113.562 -175.548 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 164.7 -151.74 20.97 Favored Glycine 0 C--N 1.346 1.097 0 CA-C-O 118.929 -0.928 . . . . 33.52 112.044 -178.539 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 243' ' ' PRO . . . . . 0.401 ' HD2' ' OE1' ' A' ' 191' ' ' GLN . 37.6 Cg_endo -61.33 -32.53 89.77 Favored 'Trans proline' 0 C--N 1.377 2.047 0 C-N-CA 123.264 2.643 . . . . 72.23 113.198 -176.513 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -84.52 18.63 2.22 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 123.485 0.714 . . . . 63.12 111.77 178.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 78.77 -78.12 1.7 Allowed Glycine 0 C--N 1.347 1.175 0 N-CA-C 110.039 -1.224 . . . . 65.34 110.039 -172.709 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.595 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 62.2 mtm180 -128.47 169.51 14.24 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 124.081 0.953 . . . . 64.03 108.579 166.245 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -82.78 -163.66 34.07 Favored Glycine 0 C--N 1.337 0.626 0 N-CA-C 111.697 -0.561 . . . . 41.11 111.697 172.59 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -130.78 170.73 13.98 Favored 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 109.238 -0.653 . . . . 72.43 109.238 -178.282 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.606 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 17.5 tp -115.87 120.65 39.9 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.868 0.867 . . . . 73.31 110.663 175.365 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 250' ' ' TYR . . . . . 0.474 ' HE2' ' HG3' ' A' ' 232' ' ' LYS . 10.7 t80 -89.31 107.93 19.34 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.613 1.165 . . . . 75.15 108.693 175.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.448 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 87.8 mt -94.14 117.86 30.71 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.904 -0.406 . . . . 72.04 109.904 167.123 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -88.29 93.56 9.55 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 107.327 -1.36 . . . . 74.52 107.327 171.412 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 3.3 p -60.05 133.82 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 O-C-N 123.725 0.641 . . . . 51.43 110.645 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 48.6 mmm-85 -135.26 102.01 5.03 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 125.049 1.34 . . . . 73.15 107.529 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.466 ' H ' ' HB2' ' A' ' 229' ' ' ALA . 63.0 mt -76.54 116.93 20.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.359 -0.837 . . . . 70.05 109.768 -175.089 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.0 t . . . . . 0 CA--C 1.553 1.087 0 C-N-CA 124.829 1.252 . . . . 70.32 109.214 -178.635 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.155 0 N-CA-C 110.121 -0.325 . . . . 64.21 110.121 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.416 ' HB3' ' HB3' ' A' ' 136' ' ' ARG . . . -106.47 -18.86 13.85 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 123.006 0.523 . . . . 74.33 112.277 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.474 HD23 ' H ' ' A' ' 99' ' ' VAL . 2.0 pt? -140.27 -50.2 0.47 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 117.529 0.15 . . . . 74.31 111.084 178.078 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.711 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 13.6 p -64.45 146.7 12.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 C-N-CA 123.584 0.754 . . . . 72.12 111.894 -179.098 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.462 ' HB2' ' HD3' ' A' ' 124' ' ' PRO . . . -83.22 -58.35 2.88 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 109.479 -0.563 . . . . 62.05 109.479 173.16 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 40.0 t-80 -175.59 159.58 2.38 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 123.697 0.799 . . . . 73.43 109.857 -175.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -66.44 136.68 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.346 0.658 . . . . 71.21 110.277 171.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 12.6 t -127.95 154.73 45.25 Favored 'General case' 0 CA--C 1.543 0.708 0 N-CA-C 109.308 -0.627 . . . . 72.53 109.308 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 28.6 m -89.55 95.07 10.11 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 123.186 0.594 . . . . 75.13 109.789 -175.358 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' GLY . . . . . 0.563 ' HA3' ' HG3' ' A' ' 120' ' ' ARG . . . -92.77 -176.22 41.26 Favored Glycine 0 C--N 1.348 1.244 0 CA-C-N 116.483 -0.326 . . . . 61.32 113.172 -177.426 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 23.3 m -72.6 113.27 9.45 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 123.064 0.546 . . . . 73.05 110.693 -179.399 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.59 129.0 36.09 Favored Glycine 0 C--N 1.346 1.095 0 N-CA-C 110.821 -0.912 . . . . 74.22 110.821 170.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -73.37 75.39 1.0 Allowed Glycine 0 C--N 1.349 1.305 0 CA-C-N 117.011 0.406 . . . . 51.12 113.363 -177.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 37.2 t -77.43 -54.37 6.52 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 123.768 0.827 . . . . 73.42 109.402 -179.254 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -92.77 4.64 75.85 Favored Glycine 0 C--N 1.346 1.129 0 CA-C-N 115.585 -0.734 . . . . 35.35 111.929 171.568 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -80.82 154.4 35.71 Favored Glycine 0 C--N 1.351 1.388 0 C-N-CA 123.286 0.47 . . . . 52.52 112.035 177.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 15.5 m -75.83 103.43 5.91 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 123.264 0.625 . . . . 71.22 109.511 177.206 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 127.63 165.24 11.83 Favored Glycine 0 C--N 1.344 1.012 0 N-CA-C 112.182 -0.367 . . . . 74.32 112.182 -177.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 154.09 7.34 0.09 OUTLIER Glycine 0 N--CA 1.473 1.137 0 CA-C-O 120.058 -0.301 . . . . 54.51 113.08 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 47.2 t -71.59 -50.41 31.17 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.712 0.805 . . . . 74.12 109.958 177.012 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -96.61 148.27 18.94 Favored Glycine 0 C--N 1.34 0.795 0 N-CA-C 110.968 -0.853 . . . . 74.02 110.968 173.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 43.3 ttm105 -65.77 127.9 33.83 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.514 0.726 . . . . 74.14 111.428 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -72.47 147.34 46.17 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.535 0.734 . . . . 72.35 110.034 172.783 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.505 HD12 HD13 ' A' ' 174' ' ' LEU . 0.2 OUTLIER -138.16 137.41 37.61 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 106.392 -1.707 . . . . 73.52 106.392 177.46 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.563 ' HG3' ' HA3' ' A' ' 105' ' ' GLY . 19.4 mmt85 -125.58 138.59 53.95 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 109.065 -0.717 . . . . 73.22 109.065 -178.57 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -159.11 126.74 4.91 Favored 'General case' 0 CA--C 1.536 0.417 0 O-C-N 123.703 0.627 . . . . 51.23 109.447 175.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -105.73 150.55 25.41 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 109.607 -0.516 . . . . 65.14 109.607 175.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.711 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.4 pt? -145.87 147.08 31.13 Favored Pre-proline 0 N--CA 1.473 0.72 0 C-N-CA 123.033 0.533 . . . . 72.41 111.925 -170.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.462 ' HD3' ' HB2' ' A' ' 100' ' ' ALA . 91.5 Cg_endo -81.76 113.41 2.51 Favored 'Trans proline' 0 C--N 1.376 1.993 0 C-N-CA 121.769 1.646 . . . . 74.22 111.082 171.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.429 ' HB3' HD23 ' A' ' 180' ' ' LEU . 19.2 tp -111.06 167.71 10.05 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.043 -1.095 . . . . 63.31 108.043 175.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.566 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 8.8 m -101.09 155.07 18.21 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 109.922 -0.399 . . . . 61.12 109.922 174.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.436 HD23 ' HB3' ' A' ' 180' ' ' LEU . 85.6 mt -51.96 -51.93 53.75 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 122.304 1.049 . . . . 72.31 109.766 171.14 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -56.83 -40.14 75.5 Favored 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 113.386 -1.734 . . . . 74.14 111.735 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.411 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 23.8 mm-40 -79.87 -18.27 51.13 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 123.358 0.663 . . . . 73.32 112.195 -179.025 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.671 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -63.25 -41.57 99.09 Favored 'General case' 0 C--O 1.249 1.036 0 C-N-CA 122.863 0.465 . . . . 74.02 110.583 165.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -67.93 -54.45 18.6 Favored 'General case' 0 C--N 1.354 0.787 0 CA-C-N 115.664 -0.698 . . . . 74.31 110.932 172.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.5 m80 -69.88 -30.03 67.39 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 123.941 0.776 . . . . 72.24 112.158 -170.408 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.08 -149.34 51.71 Favored Glycine 0 C--N 1.346 1.124 0 N-CA-C 111.334 -0.706 . . . . 70.21 111.334 -171.749 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 136.92 136.94 3.57 Favored Glycine 0 C--N 1.346 1.095 0 CA-C-N 116.73 0.265 . . . . 71.1 112.673 170.584 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -80.21 127.0 31.83 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.408 0.683 . . . . 75.23 109.191 174.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.416 ' HB3' ' HB3' ' A' ' 97' ' ' ALA . 8.2 mpt_? -136.26 168.13 19.99 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.527 0.731 . . . . 73.13 109.101 177.412 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.5 p -85.85 129.61 37.78 Favored 'Isoleucine or valine' 0 C--O 1.246 0.878 0 CA-C-O 121.311 0.577 . . . . 52.51 110.66 174.359 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.493 HG21 HD21 ' A' ' 174' ' ' LEU . 14.6 p -98.65 142.33 14.9 Favored 'Isoleucine or valine' 0 C--O 1.242 0.704 0 C-N-CA 124.215 1.006 . . . . 71.11 109.43 175.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' GLU . . . . . 0.457 ' H ' HG11 ' A' ' 99' ' ' VAL . 42.7 mm-40 -121.76 100.68 7.13 Favored 'General case' 0 C--O 1.24 0.563 0 C-N-CA 124.61 1.164 . . . . 42.2 108.142 179.042 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.2 m -124.05 107.53 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.79 0 C-N-CA 123.352 0.661 . . . . 72.43 111.063 -176.569 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.87 24.24 11.29 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 124.747 1.219 . . . . 54.21 111.909 176.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 91.12 3.49 69.9 Favored Glycine 0 C--N 1.346 1.116 0 CA-C-N 116.031 -0.531 . . . . 73.3 113.371 -177.438 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 64.0 mtp85 -95.98 119.62 34.81 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.024 -0.732 . . . . 72.22 109.024 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 33.9 ttt85 -98.82 116.63 31.49 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.483 0.713 . . . . 72.42 109.952 -178.213 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 46.3 t -136.53 145.53 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.778 0.831 . . . . 73.13 108.918 179.48 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 21.2 m -79.03 110.99 14.78 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 109.072 -0.714 . . . . 74.4 109.072 171.08 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.0 p -98.28 137.41 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 CA-C-O 121.762 0.791 . . . . 74.34 110.597 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 77.6 ttt180 -103.82 117.78 35.16 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 114.485 -1.234 . . . . 73.22 108.342 175.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 33.4 pt -122.86 127.0 25.89 Favored Pre-proline 0 N--CA 1.477 0.919 0 N-CA-C 109.01 -0.737 . . . . 74.41 109.01 169.48 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -81.86 159.97 18.63 Favored 'Trans proline' 0 C--N 1.375 1.959 0 C-N-CA 122.909 2.406 . . . . 73.24 114.523 -167.775 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -68.1 114.92 3.57 Favored 'Trans proline' 0 C--N 1.381 2.289 0 C-N-CA 123.331 2.687 . . . . 41.24 110.618 174.351 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.621 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 133.9 49.7 0.08 OUTLIER Glycine 0 N--CA 1.469 0.844 0 N-CA-C 111.299 -0.72 . . . . 45.24 111.299 -173.712 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.671 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.4 p -125.99 165.61 23.56 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.403 0 N-CA-C 108.35 -0.981 . . . . 62.45 108.35 -176.401 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 51.3 mtp180 -145.69 166.7 25.07 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 124.519 1.127 . . . . 72.43 110.375 -165.603 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -55.49 123.89 15.43 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 124.005 0.922 . . . . 75.11 111.112 169.067 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.75 5.42 74.31 Favored Glycine 0 C--N 1.35 1.337 0 O-C-N 123.752 0.657 . . . . 55.15 113.601 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 31.2 t -73.45 126.01 29.23 Favored 'General case' 0 C--O 1.243 0.715 0 N-CA-C 109.828 -0.434 . . . . 72.1 109.828 -177.648 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.442 HG22 HD22 ' A' ' 175' ' ' LEU . 7.4 p -99.43 120.05 48.26 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 CA-C-N 114.756 -1.111 . . . . 73.41 109.911 -174.871 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.448 HD11 HG21 ' A' ' 153' ' ' VAL . 24.9 mt -106.95 115.53 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 124.004 0.922 . . . . 62.42 110.081 -171.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.494 ' HA ' HD23 ' A' ' 175' ' ' LEU . 69.3 ttt180 -83.53 119.1 24.28 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.504 0.722 . . . . 73.23 111.024 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.655 HG23 ' HG3' ' A' ' 164' ' ' MET . 16.6 m -124.37 104.76 31.38 Favored Pre-proline 0 CA--C 1.571 1.77 0 CA-C-O 120.764 0.316 . . . . 71.33 110.209 174.745 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.17 156.59 64.42 Favored 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.865 2.376 . . . . 73.41 113.7 -178.812 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.56 23.15 65.55 Favored Glycine 0 C--N 1.348 1.247 0 CA-C-N 115.336 -0.847 . . . . 55.42 113.808 176.472 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.655 ' HG3' HG23 ' A' ' 161' ' ' VAL . 16.4 mmt -106.81 -62.08 1.45 Allowed 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.079 0.952 . . . . 72.41 111.271 178.648 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -65.56 -74.48 0.5 Allowed Glycine 0 C--N 1.354 1.539 0 N-CA-C 111.591 -0.603 . . . . 40.55 111.591 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.779 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -72.67 116.41 5.69 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 111.803 -0.519 . . . . 72.32 111.803 166.635 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.3 mm-40 -88.94 158.7 17.96 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 124.258 1.023 . . . . 54.15 110.916 177.636 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 76.8 -123.9 6.83 Favored Glycine 0 C--N 1.342 0.907 0 CA-C-N 115.502 -0.772 . . . . 75.11 113.378 172.448 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -76.22 -48.9 3.25 Favored Pre-proline 0 CA--C 1.551 0.99 0 CA-C-O 117.76 -1.114 . . . . 75.41 112.006 -173.391 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -79.3 105.2 1.86 Allowed 'Trans proline' 0 C--N 1.393 2.881 0 C-N-CA 121.683 1.589 . . . . 74.14 110.809 172.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -77.57 125.09 7.36 Favored 'Trans proline' 0 C--N 1.379 2.159 0 C-N-CA 122.104 1.869 . . . . 75.21 110.653 -175.528 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.779 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -110.08 148.41 17.4 Favored Glycine 0 CA--C 1.503 -0.693 0 N-CA-C 111.334 -0.706 . . . . 52.12 111.334 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 -109.0 130.54 55.48 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 123.215 0.606 . . . . 75.25 109.53 -165.017 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.505 HD13 HD12 ' A' ' 119' ' ' LEU . 17.4 tp -100.6 115.12 29.42 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 107.145 -1.428 . . . . 73.22 107.145 173.732 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.497 ' HB2' ' HD3' ' A' ' 120' ' ' ARG . 65.0 mt -92.23 100.73 13.28 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-N 114.46 -1.246 . . . . 63.45 109.794 -179.162 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.414 ' HA ' ' O ' ' A' ' 121' ' ' ALA . 83.2 mt -86.63 102.49 14.23 Favored 'General case' 0 C--N 1.346 0.418 0 CA-C-N 114.773 -1.103 . . . . 73.11 110.061 176.574 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 47.2 t -90.0 99.4 9.4 Favored 'Isoleucine or valine' 0 C--O 1.243 0.714 0 N-CA-C 108.397 -0.964 . . . . 65.54 108.397 176.638 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 4.9 m -79.49 148.12 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 N-CA-C 109.493 -0.558 . . . . 75.34 109.493 -177.131 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 40.0 mmm-85 -126.63 99.2 5.69 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 105.85 -1.908 . . . . 72.3 105.85 -175.787 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.436 ' HB3' HD23 ' A' ' 127' ' ' LEU . 38.2 mt -68.65 148.34 50.58 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 122.339 0.256 . . . . 71.04 110.954 -173.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.566 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 39.1 mt -55.76 130.52 72.01 Favored Pre-proline 0 CA--C 1.552 1.04 0 CA-C-O 118.844 -0.598 . . . . 72.04 110.737 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -67.91 84.47 0.42 Allowed 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 123.279 2.653 . . . . 74.22 112.079 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 8.6 p80 -154.58 50.62 0.55 Allowed Pre-proline 0 CA--C 1.558 1.274 0 N-CA-C 107.87 -1.159 . . . . 72.12 107.87 169.347 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -62.69 126.42 18.21 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 122.713 2.275 . . . . 62.33 112.261 -163.525 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -137.74 -45.1 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 108.686 -0.857 . . . . 72.43 108.686 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.426 ' CD2' HD13 ' A' ' 193' ' ' LEU . 6.5 m-85 -103.82 123.61 47.42 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.932 0.893 . . . . 74.21 110.269 -177.749 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.601 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 92.3 mtt180 -119.15 109.18 15.58 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.623 1.169 . . . . 75.1 107.887 -176.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.503 HD22 ' CD2' ' A' ' 240' ' ' PHE . 62.0 tp -85.09 142.56 29.45 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 122.659 0.383 . . . . 73.3 110.378 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -142.45 115.61 8.88 Favored 'General case' 0 C--O 1.243 0.736 0 N-CA-C 107.782 -1.192 . . . . 71.4 107.782 164.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 67.46 -95.37 0.31 Allowed Glycine 0 C--N 1.346 1.139 0 CA-C-N 115.725 -0.67 . . . . 44.25 111.514 -173.356 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 -123.84 -23.27 4.7 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.034 0.934 . . . . 72.42 110.247 177.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -93.83 153.34 18.33 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.411 0.624 . . . . 74.11 111.038 -171.622 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.621 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 73.6 mt -113.36 167.08 10.87 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.198 -0.91 . . . . 54.12 112.581 -170.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 194' ' ' TYR . . . . . 0.601 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 97.4 m-85 -135.28 121.57 20.32 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 105.873 -1.899 . . . . 74.51 105.873 172.844 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 195' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -152.75 140.1 19.56 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 108.573 -0.899 . . . . 64.44 108.573 176.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.02 141.71 40.21 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 123.566 0.541 . . . . 73.4 110.128 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.548 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 57.5 tp -110.03 113.73 26.67 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.027 -0.988 . . . . 72.35 109.07 179.29 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -85.71 101.9 13.16 Favored 'General case' 0 C--O 1.24 0.566 0 N-CA-C 108.149 -1.056 . . . . 62.22 108.149 176.228 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 199' ' ' VAL . . . . . 0.435 HG11 HG13 ' A' ' 253' ' ' VAL . 4.3 p -116.82 127.44 26.72 Favored Pre-proline 0 CA--C 1.548 0.881 0 N-CA-C 109.332 -0.618 . . . . 63.11 109.332 -178.237 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -58.71 144.71 97.71 Favored 'Trans proline' 0 C--N 1.379 2.169 0 C-N-CA 122.461 2.107 . . . . 51.24 111.948 172.351 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -54.49 -42.93 97.07 Favored Pre-proline 0 CA--C 1.564 1.506 0 CA-C-O 118.106 -0.949 . . . . 42.52 112.117 175.174 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_exo -46.12 -53.24 6.07 Favored 'Trans proline' 0 C--N 1.397 3.106 0 C-N-CA 122.684 2.256 . . . . 62.31 114.126 167.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 203' ' ' ILE . . . . . 0.472 HG22 HG21 ' A' ' 223' ' ' VAL . 12.8 mt -65.96 -37.02 78.89 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 O-C-N 123.169 0.293 . . . . 43.42 110.923 -178.111 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.13 -43.86 97.23 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 123.306 0.642 . . . . 43.51 111.599 -177.419 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 32.6 m -76.79 -37.97 28.9 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 115.951 -0.568 . . . . 55.43 111.262 -176.131 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.4 m -83.44 -23.87 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 N-CA-C 111.763 0.283 . . . . 43.42 111.763 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.462 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 72.19 64.05 2.77 Favored Glycine 0 C--N 1.341 0.84 0 CA-C-N 116.227 -0.442 . . . . 71.12 112.183 -172.749 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -94.53 -154.19 30.78 Favored Glycine 0 C--N 1.355 1.625 0 CA-C-O 121.428 0.46 . . . . 52.32 112.378 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 14.7 mmmm -121.76 128.97 52.33 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 123.781 0.832 . . . . 74.32 109.104 -174.288 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 39.5 t -116.18 129.98 71.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 N-CA-C 108.91 -0.774 . . . . 75.03 108.91 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -78.24 106.09 9.91 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 107.861 -1.163 . . . . 75.41 107.861 168.064 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -98.83 133.42 43.15 Favored 'General case' 0 C--N 1.343 0.31 0 C-N-CA 123.822 0.849 . . . . 64.42 108.922 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -74.94 144.24 43.32 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 122.651 0.38 . . . . 71.23 110.402 173.88 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.41 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 7.5 t -148.27 167.43 25.16 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 124.353 1.061 . . . . 72.41 109.77 172.471 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 215' ' ' LEU . . . . . 0.407 HD13 ' O ' ' A' ' 127' ' ' LEU . 45.8 mt -71.58 -15.12 62.26 Favored 'General case' 0 CA--C 1.552 1.046 0 CA-C-N 115.178 -0.919 . . . . 74.21 110.796 176.363 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -80.73 -20.73 42.16 Favored 'General case' 0 CA--C 1.564 1.503 0 C-N-CA 124.747 1.219 . . . . 71.51 109.888 174.368 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 135.03 -151.26 20.4 Favored Glycine 0 C--N 1.361 1.932 0 CA-C-O 119.628 -0.54 . . . . 33.42 112.41 -177.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -91.84 124.54 0.78 Allowed 'Trans proline' 0 C--N 1.368 1.591 0 C-N-CA 123.33 2.687 . . . . 70.1 111.807 170.276 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 219' ' ' VAL . . . . . 0.408 HG11 ' HD3' ' A' ' 238' ' ' LYS . 22.7 m -116.98 160.71 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 C-N-CA 123.604 0.762 . . . . 51.32 110.771 179.389 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -115.28 110.39 19.35 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 109.001 -0.74 . . . . 61.44 109.001 178.283 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.553 HG23 HD21 ' A' ' 235' ' ' LEU . 5.9 p -97.09 138.29 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 123.37 0.668 . . . . 70.45 110.512 177.082 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -93.81 111.7 23.44 Favored 'General case' 0 C--O 1.239 0.533 0 C-N-CA 123.698 0.799 . . . . 73.21 109.009 173.425 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.472 HG21 HG22 ' A' ' 203' ' ' ILE . 13.8 m -86.47 140.66 34.0 Favored Pre-proline 0 CA--C 1.55 0.964 0 N-CA-C 108.91 -0.774 . . . . 43.15 108.91 177.522 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -62.12 143.38 94.62 Favored 'Trans proline' 0 CA--C 1.56 1.818 0 C-N-CA 122.501 2.134 . . . . 74.52 112.318 177.594 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.9 123.76 12.47 Favored 'Trans proline' 0 C--N 1.378 2.104 0 C-N-CA 122.408 2.072 . . . . 71.41 110.669 174.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 44.2 mtm105 64.07 48.88 2.87 Favored 'General case' 0 N--CA 1.475 0.824 0 O-C-N 124.233 0.958 . . . . 72.53 110.343 -173.537 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 227' ' ' THR . . . . . 0.454 HG23 HD11 ' A' ' 255' ' ' ILE . 11.8 t -71.16 170.63 12.55 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.319 0.58 . . . . 65.21 111.103 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.9 mp0 -121.91 139.39 53.71 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.221 1.008 . . . . 73.01 108.574 -176.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -76.62 127.69 33.28 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.288 0.635 . . . . 75.41 109.94 179.569 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.38 -4.71 23.36 Favored Glycine 0 C--N 1.339 0.746 0 N-CA-C 111.512 -0.635 . . . . 51.44 111.512 -173.077 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 231' ' ' ARG . . . . . 0.428 ' O ' ' HA ' ' A' ' 252' ' ' GLU . 60.6 mtt-85 -71.51 160.1 33.32 Favored 'General case' 0 C--N 1.36 1.042 0 C-N-CA 122.917 0.487 . . . . 63.25 110.762 173.669 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.445 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.1 OUTLIER -123.43 100.43 6.82 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.088 0.955 . . . . 61.44 108.774 179.69 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 233' ' ' LEU . . . . . 0.428 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 86.3 mt -84.89 104.85 15.2 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 108.92 -0.77 . . . . 55.11 108.92 -176.723 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 14.6 ttp180 -82.31 101.95 10.89 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 114.784 -1.098 . . . . 74.12 110.367 -171.626 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.553 HD21 HG23 ' A' ' 221' ' ' VAL . 48.9 mt -89.62 101.61 14.3 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 115.131 -0.94 . . . . 64.3 108.555 171.022 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 47.0 mtpt -73.06 149.15 43.41 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.354 0.662 . . . . 74.13 110.574 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 67.72 28.88 73.48 Favored Glycine 0 C--N 1.345 1.05 0 O-C-N 123.369 0.418 . . . . 74.55 113.413 -178.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 238' ' ' LYS . . . . . 0.523 ' HG3' ' HB3' ' A' ' 235' ' ' LEU . 0.0 OUTLIER -127.55 -8.38 5.69 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 124.165 0.986 . . . . 70.24 111.145 -176.973 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 239' ' ' GLY . . . . . 0.434 ' HA2' ' CD1' ' A' ' 193' ' ' LEU . . . -84.71 -163.97 37.42 Favored Glycine 0 C--N 1.344 0.977 0 CA-C-N 115.919 -0.582 . . . . 63.54 113.174 176.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.621 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 1.5 m-85 -85.99 158.88 55.39 Favored Pre-proline 0 N--CA 1.48 1.053 0 N-CA-C 109.341 -0.615 . . . . 72.24 109.341 179.014 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -47.53 129.55 16.83 Favored 'Trans proline' 0 C--N 1.382 2.32 0 C-N-CA 123.077 2.518 . . . . 70.13 113.598 174.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -165.34 -162.8 17.3 Favored Glycine 0 CA--C 1.535 1.282 0 CA-C-O 118.986 -0.897 . . . . 44.32 112.203 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_exo -47.05 -41.1 26.55 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 124.616 3.544 . . . . 71.41 115.378 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -87.47 21.0 2.63 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 123.965 0.906 . . . . 24.12 112.145 -177.456 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.15 -81.82 1.5 Allowed Glycine 0 C--N 1.346 1.102 0 N-CA-C 110.568 -1.013 . . . . 65.2 110.568 -173.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -113.2 135.41 53.85 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.624 -1.25 . . . . 53.43 107.624 169.78 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.48 -157.21 5.28 Favored Glycine 0 C--N 1.345 1.045 0 N-CA-C 115.152 0.821 . . . . 73.3 115.152 -169.165 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -111.27 164.58 12.74 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 123.155 0.582 . . . . 75.42 110.374 -175.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.621 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 20.0 tp -128.04 116.26 19.75 Favored 'General case' 0 C--O 1.218 -0.602 0 C-N-CA 124.644 1.178 . . . . 73.22 109.342 169.421 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 250' ' ' TYR . . . . . 0.445 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 10.6 m-85 -97.46 107.36 19.86 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 109.243 -0.651 . . . . 70.12 109.243 175.298 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.548 ' HB3' ' HB2' ' A' ' 197' ' ' LEU . 85.8 mt -86.58 115.4 24.04 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 124.004 0.922 . . . . 74.54 112.042 178.236 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.428 ' HA ' ' O ' ' A' ' 231' ' ' ARG . 36.4 tt0 -77.74 93.91 4.37 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 108.348 -0.982 . . . . 63.34 108.348 175.541 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.435 HG13 HG11 ' A' ' 199' ' ' VAL . 91.9 t -48.71 116.49 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 C-N-CA 124.705 1.202 . . . . 73.21 111.286 176.738 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 26.5 mmm180 -120.75 94.8 4.47 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 107.416 -1.328 . . . . 75.22 107.416 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.454 HD11 HG23 ' A' ' 227' ' ' THR . 60.3 mt -77.69 106.98 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-N 115.379 -0.828 . . . . 74.2 109.366 -178.02 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 CA--C 1.552 1.034 0 C-N-CA 124.034 0.934 . . . . 62.33 108.942 -179.701 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.417 ' HB1' ' O ' ' A' ' 99' ' ' VAL . . . . . . . . 0 N--CA 1.477 0.878 0 N-CA-C 109.671 -0.492 . . . . 71.32 109.671 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.539 ' HB3' ' HB3' ' A' ' 136' ' ' ARG . . . -84.66 -67.08 0.82 Allowed 'General case' 0 CA--C 1.546 0.79 0 O-C-N 123.384 0.427 . . . . 71.04 110.497 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -100.69 -37.63 8.66 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 122.776 0.43 . . . . 74.22 111.289 174.673 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.417 ' O ' ' HB1' ' A' ' 96' ' ' ALA . 7.4 p -61.15 125.25 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 O-C-N 123.79 0.681 . . . . 64.52 110.946 -175.22 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -74.25 -75.92 0.15 Allowed 'General case' 0 C--N 1.346 0.427 0 N-CA-C 108.483 -0.932 . . . . 72.03 108.483 174.191 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -162.91 153.23 16.34 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 124.866 1.266 . . . . 72.41 108.416 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 8.4 p -67.74 121.03 16.13 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.916 0 CA-C-O 121.063 0.459 . . . . 45.02 109.798 172.162 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.574 HG21 ' HG3' ' A' ' 122' ' ' GLU . 11.4 t -96.46 -27.88 14.68 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 123.699 0.799 . . . . 54.01 111.86 -174.066 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.403 ' HB2' ' HB3' ' A' ' 120' ' ' ARG . 42.3 m -149.9 173.14 14.12 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 123.935 0.894 . . . . 72.55 109.821 -177.061 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -169.96 62.48 0.18 Allowed Glycine 0 C--N 1.338 0.67 0 N-CA-C 111.057 -0.817 . . . . 74.31 111.057 177.52 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 32.7 t -148.72 119.52 7.57 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.272 0.629 . . . . 74.43 109.606 -174.32 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.76 75.13 2.29 Favored Glycine 0 C--N 1.348 1.239 0 O-C-N 123.439 0.462 . . . . 44.04 112.868 -177.461 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -83.81 167.64 44.44 Favored Glycine 0 C--N 1.342 0.894 0 N-CA-C 112.167 -0.373 . . . . 61.03 112.167 175.214 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 28.4 m 61.74 35.41 16.86 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 123.581 0.752 . . . . 73.43 110.683 -173.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -70.38 -33.0 68.14 Favored Glycine 0 C--N 1.351 1.379 0 CA-C-N 114.921 -1.036 . . . . 75.13 112.03 175.515 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 66.68 -96.71 0.31 Allowed Glycine 0 C--N 1.349 1.25 0 O-C-N 123.621 0.248 . . . . 74.32 113.653 173.096 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 39.3 p -70.37 -30.05 66.87 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 124.011 0.924 . . . . 43.51 111.397 -177.499 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -164.27 -126.02 0.8 Allowed Glycine 0 C--N 1.338 0.651 0 N-CA-C 111.015 -0.834 . . . . 54.51 111.015 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 171.96 146.64 5.4 Favored Glycine 0 C--N 1.339 0.748 0 N-CA-C 111.29 -0.724 . . . . 55.31 111.29 177.922 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 62.6 p -100.19 -170.28 1.85 Allowed 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 123.766 0.826 . . . . 73.45 110.817 -176.726 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -55.34 122.68 27.28 Favored Glycine 0 C--N 1.361 1.952 0 N-CA-C 110.568 -1.013 . . . . 72.21 110.568 170.257 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 40.4 ttm180 -61.72 131.22 49.21 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.011 0.524 . . . . 75.44 111.875 -167.457 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -77.1 152.33 35.03 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 115.228 -0.896 . . . . 44.44 111.442 -178.132 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.687 HD12 ' HA2' ' A' ' 165' ' ' GLY . 24.5 mt -94.36 155.26 17.07 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 106.681 -1.6 . . . . 70.24 106.681 159.284 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.556 ' HE ' HD12 ' A' ' 175' ' ' LEU . 29.6 ttm180 -144.47 114.66 7.47 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 109.66 -0.496 . . . . 74.43 109.66 -174.147 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -126.8 126.46 43.42 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 123.523 0.729 . . . . 54.34 110.195 -177.805 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.574 ' HG3' HG21 ' A' ' 103' ' ' THR . 24.4 mt-10 -92.09 136.74 32.93 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 108.505 -0.924 . . . . 72.15 108.505 169.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -145.13 147.26 33.72 Favored Pre-proline 0 N--CA 1.468 0.44 0 C-N-CA 123.191 0.596 . . . . 44.03 110.578 -170.434 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.86 154.48 67.3 Favored 'Trans proline' 0 C--N 1.369 1.617 0 C-N-CA 121.877 1.718 . . . . 71.53 111.646 170.74 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 22.2 tp -149.5 150.34 32.15 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.811 0.844 . . . . 64.11 109.067 174.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.584 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 69.2 m -84.59 151.98 24.16 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 123.326 0.651 . . . . 72.42 109.487 172.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.52 HD11 ' O ' ' A' ' 183' ' ' HIS . 45.1 mt -58.19 -48.05 81.53 Favored 'General case' 0 N--CA 1.483 1.194 0 CA-C-O 121.881 0.848 . . . . 74.44 110.204 176.236 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.627 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.7 mp0 -57.88 -31.79 67.06 Favored 'General case' 0 N--CA 1.484 1.259 0 CA-C-N 114.328 -1.306 . . . . 63.45 111.97 178.06 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 38.0 mm-40 -88.95 -16.69 31.17 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 112.109 0.411 . . . . 63.14 112.109 178.513 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.727 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -63.26 -31.65 72.85 Favored 'General case' 0 C--O 1.25 1.12 0 CA-C-O 121.168 0.508 . . . . 55.13 110.152 162.853 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.558 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 17.1 t80 -71.87 -60.37 2.27 Favored 'General case' 0 C--N 1.351 0.642 0 CA-C-N 115.326 -0.852 . . . . 74.3 110.877 168.238 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -71.89 -28.62 63.64 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 113.605 0.965 . . . . 60.2 113.605 -168.233 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 74.09 -87.46 0.68 Allowed Glycine 0 CA--C 1.532 1.123 0 N-CA-C 110.738 -0.945 . . . . 63.51 110.738 -167.628 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 84.01 126.65 1.34 Allowed Glycine 0 C--N 1.352 1.449 0 C-N-CA 122.844 0.259 . . . . 42.32 113.129 174.008 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.43 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.7 mp0 -78.28 114.56 17.28 Favored 'General case' 0 C--N 1.345 0.392 0 N-CA-C 108.431 -0.952 . . . . 74.2 108.431 176.509 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.539 ' HB3' ' HB3' ' A' ' 97' ' ' ALA . 7.3 mpt_? -131.36 153.38 49.7 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 123.084 0.554 . . . . 73.11 109.884 176.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 14.7 p -72.89 140.9 17.13 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.083 0 C-N-CA 123.308 0.643 . . . . 63.32 111.779 -173.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.43 HG22 HG23 ' A' ' 140' ' ' VAL . 7.9 p -136.43 124.57 35.15 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 C-N-CA 125.239 1.416 . . . . 73.12 108.553 -179.425 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -116.57 96.44 5.51 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 107.358 -1.349 . . . . 71.15 107.358 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.558 HG12 HD13 ' A' ' 119' ' ' LEU . 90.0 t -130.73 131.49 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 122.992 0.517 . . . . 73.44 109.714 -178.531 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.02 30.08 19.6 Favored 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 124.962 1.305 . . . . 64.03 112.021 -179.278 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 92.07 -1.15 73.47 Favored Glycine 0 C--N 1.344 1.025 0 CA-C-N 115.336 -0.847 . . . . 60.13 114.137 173.741 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.84 119.15 38.64 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-N 118.284 1.042 . . . . 64.42 110.691 -179.312 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 63.2 ttp85 -92.66 106.66 18.6 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.139 0.975 . . . . 73.42 108.489 172.076 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 61.7 t -133.5 149.77 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 108.238 -1.023 . . . . 74.31 108.238 178.65 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 34.9 p -81.02 120.97 25.47 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 109.132 -0.692 . . . . 73.31 109.132 172.597 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.4 p -96.83 131.12 44.37 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 CA-C-O 121.19 0.519 . . . . 61.43 110.647 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' ARG . . . . . 0.43 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 40.6 ttp180 -104.28 102.06 11.76 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 107.746 -1.205 . . . . 74.52 107.746 175.64 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.63 ' HB ' HD13 ' A' ' 159' ' ' ILE . 30.8 pt -91.96 130.82 37.07 Favored Pre-proline 0 CA--C 1.549 0.941 0 N-CA-C 108.965 -0.754 . . . . 73.33 108.965 176.226 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -63.63 135.99 51.82 Favored 'Trans proline' 0 C--N 1.383 2.37 0 C-N-CA 122.88 2.387 . . . . 73.34 112.847 -171.581 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_exo -54.49 141.59 72.88 Favored 'Trans proline' 0 C--N 1.379 2.159 0 C-N-CA 123.427 2.751 . . . . 71.33 112.381 169.6 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 104.18 24.66 7.45 Favored Glycine 0 C--N 1.338 0.675 0 N-CA-C 111.645 -0.582 . . . . 70.41 111.645 -176.096 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.727 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.4 p -95.06 158.74 2.93 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.917 0 N-CA-C 108.504 -0.924 . . . . 54.4 108.504 -177.268 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.484 ' HA ' HD11 ' A' ' 180' ' ' LEU . 27.0 mtm180 -149.62 176.15 10.91 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 124.426 1.09 . . . . 74.52 110.135 -170.621 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -52.93 124.86 15.3 Favored 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 124.017 0.927 . . . . 62.52 111.744 173.148 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.85 10.03 83.44 Favored Glycine 0 C--N 1.347 1.182 0 O-C-N 123.534 0.521 . . . . 72.54 113.809 177.36 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.419 ' HB3' HG23 ' A' ' 153' ' ' VAL . 33.0 t -76.97 122.35 24.77 Favored 'General case' 0 C--O 1.246 0.879 0 N-CA-C 109.391 -0.596 . . . . 74.33 109.391 179.342 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.476 HG22 HD22 ' A' ' 175' ' ' LEU . 7.1 p -94.14 121.88 45.14 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.964 0 C-N-CA 123.77 0.828 . . . . 71.52 109.689 -179.335 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.63 HD13 ' HB ' ' A' ' 149' ' ' ILE . 46.3 mt -110.52 118.16 56.51 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 124.273 1.029 . . . . 72.34 109.999 -172.475 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 60.0 ttp85 -95.78 109.96 22.19 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 122.863 0.465 . . . . 74.31 110.408 -178.169 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 10.7 m -109.48 101.57 46.44 Favored Pre-proline 0 CA--C 1.569 1.7 0 C-N-CA 122.933 0.493 . . . . 62.34 110.125 -178.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' PRO . . . . . 0.45 ' HA ' ' HB3' ' A' ' 173' ' ' ASP . 33.2 Cg_exo -64.1 147.61 91.48 Favored 'Trans proline' 0 C--N 1.384 2.403 0 C-N-CA 123.554 2.836 . . . . 45.21 114.314 -172.675 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.18 5.08 89.36 Favored Glycine 0 C--N 1.348 1.249 0 CA-C-N 115.058 -0.974 . . . . 64.21 114.447 175.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 46.9 tpp -96.43 -36.14 10.92 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.092 0.557 . . . . 73.52 110.95 -177.01 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' GLY . . . . . 0.687 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . -83.45 -105.96 0.52 Allowed Glycine 0 C--N 1.349 1.26 0 CA-C-N 115.635 -0.711 . . . . 53.25 114.3 -175.706 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.483 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -64.67 93.99 0.16 Allowed Glycine 0 C--N 1.348 1.247 0 C-N-CA 123.351 0.501 . . . . 40.51 113.125 179.24 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -67.79 117.28 9.47 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 123.662 0.785 . . . . 72.34 110.173 178.014 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 165.11 -172.06 40.64 Favored Glycine 0 C--N 1.34 0.773 0 O-C-N 123.601 0.563 . . . . 72.24 112.983 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -61.5 -40.4 70.84 Favored Pre-proline 0 CA--C 1.56 1.343 0 C-N-CA 123.739 0.816 . . . . 75.13 111.867 174.358 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -82.01 104.52 1.41 Allowed 'Trans proline' 0 C--N 1.393 2.918 0 C-N-CA 122.064 1.843 . . . . 73.03 109.73 162.564 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -71.74 125.29 10.95 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 121.937 1.758 . . . . 61.01 111.77 -174.448 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.483 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -101.09 160.42 18.6 Favored Glycine 0 C--N 1.34 0.763 0 N-CA-C 111.075 -0.81 . . . . 62.35 111.075 176.837 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.45 ' HB3' ' HA ' ' A' ' 162' ' ' PRO . 0.9 OUTLIER -124.94 179.59 4.96 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.696 0.798 . . . . 74.25 110.966 -167.021 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 21.2 tp -127.74 118.91 24.66 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.146 0.578 . . . . 75.24 109.686 175.697 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.556 HD12 ' HE ' ' A' ' 120' ' ' ARG . 86.0 mt -86.19 99.32 11.45 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 124.608 1.163 . . . . 63.12 110.391 177.606 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 76.5 mt -89.82 102.61 15.31 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.704 0.802 . . . . 64.2 110.576 174.603 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.453 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 29.3 t -90.9 102.79 13.79 Favored 'Isoleucine or valine' 0 C--O 1.244 0.777 0 N-CA-C 108.313 -0.995 . . . . 63.02 108.313 175.597 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 5.5 m -79.75 150.47 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 CA-C-O 121.65 0.738 . . . . 74.22 111.479 -173.569 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 19.6 mmt85 -122.26 98.47 5.95 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 114.482 -1.235 . . . . 73.24 107.811 -178.244 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.484 HD11 ' HA ' ' A' ' 154' ' ' ARG . 21.5 mt -68.34 151.49 46.81 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.207 0.603 . . . . 63.31 112.443 -177.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.584 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 60.6 mt -53.69 138.58 51.95 Favored Pre-proline 0 CA--C 1.559 1.322 0 O-C-N 124.091 0.869 . . . . 74.0 111.324 -179.304 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -57.32 -13.08 11.94 Favored 'Trans proline' 0 C--N 1.383 2.375 0 C-N-CA 124.239 3.293 . . . . 74.12 115.584 -173.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 183' ' ' HIS . . . . . 0.52 ' O ' HD11 ' A' ' 127' ' ' LEU . 1.0 OUTLIER -87.52 114.33 58.3 Favored Pre-proline 0 CA--C 1.548 0.889 0 N-CA-C 108.708 -0.849 . . . . 75.14 108.708 173.247 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -92.62 126.67 0.75 Allowed 'Trans proline' 0 C--N 1.377 2.066 0 C-N-CA 122.568 2.179 . . . . 74.01 112.287 173.144 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.9 p -127.29 -41.8 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 N-CA-C 109.565 -0.531 . . . . 53.14 109.565 174.302 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.454 ' HE2' HD13 ' A' ' 193' ' ' LEU . 6.5 m-85 -107.52 125.2 50.98 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 115.896 -0.593 . . . . 74.31 110.691 -178.074 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.578 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 6.2 mpt_? -112.38 103.97 12.11 Favored 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 107.237 -1.394 . . . . 51.53 107.237 175.13 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 42.1 tp -92.72 136.51 33.17 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.115 0.566 . . . . 71.14 109.8 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -143.68 134.05 24.64 Favored 'General case' 0 C--O 1.241 0.657 0 N-CA-C 109.225 -0.657 . . . . 75.35 109.225 165.586 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 68.28 -81.88 0.2 Allowed Glycine 0 C--N 1.352 1.426 0 O-C-N 123.913 0.758 . . . . 71.22 113.087 -178.691 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 24.1 pt20 -144.34 -17.57 0.56 Allowed 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 123.645 0.778 . . . . 50.44 110.755 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -109.86 158.27 18.35 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-O 121.269 0.557 . . . . 70.53 111.683 -170.049 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.468 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 77.4 mt -111.34 163.38 14.04 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.005 1.322 . . . . 73.31 111.779 -168.67 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 194' ' ' TYR . . . . . 0.578 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 82.5 m-85 -139.52 124.16 18.37 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 114.563 -1.199 . . . . 63.14 108.516 170.032 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 195' ' ' ALA . . . . . 0.425 ' HB3' HD11 ' A' ' 249' ' ' LEU . . . -135.84 171.43 14.47 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 122.836 0.454 . . . . 44.55 110.157 175.576 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 7.8 m -102.48 134.42 45.84 Favored 'General case' 0 CA--C 1.544 0.712 0 N-CA-C 109.389 -0.597 . . . . 71.31 109.389 178.564 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.603 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 42.7 tp -109.98 114.09 27.34 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.382 1.073 . . . . 60.52 110.133 -177.384 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -94.11 103.71 15.75 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.414 0.686 . . . . 74.01 109.746 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 199' ' ' VAL . . . . . 0.63 HG12 HG11 ' A' ' 210' ' ' VAL . 3.5 m -113.2 142.44 27.42 Favored Pre-proline 0 N--CA 1.479 1.012 0 C-N-CA 122.981 0.513 . . . . 73.12 109.668 176.666 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -68.96 155.49 68.33 Favored 'Trans proline' 0 C--N 1.365 1.439 0 C-N-CA 122.33 2.02 . . . . 74.11 111.38 167.498 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 201' ' ' ALA . . . . . 0.407 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -60.04 -45.85 98.02 Favored Pre-proline 0 N--CA 1.479 0.979 0 CA-C-O 118.737 -0.649 . . . . 73.21 112.215 177.518 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 202' ' ' PRO . . . . . 0.463 ' O ' HG22 ' A' ' 206' ' ' VAL . 9.8 Cg_endo -49.77 -45.76 30.49 Favored 'Trans proline' 0 C--N 1.391 2.781 0 C-N-CA 122.568 2.179 . . . . 12.33 113.348 171.479 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 203' ' ' ILE . . . . . 0.484 ' HA ' ' HA3' ' A' ' 207' ' ' GLY . 3.5 mt -67.64 -43.94 86.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 O-C-N 121.967 -0.458 . . . . 72.51 111.569 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -52.51 -43.96 65.42 Favored 'General case' 0 CA--C 1.538 0.489 0 O-C-N 124.446 1.091 . . . . 51.21 111.177 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 205' ' ' VAL . . . . . 0.621 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 28.8 m -88.91 -58.46 3.46 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.262 0 N-CA-C 113.015 0.746 . . . . 64.34 113.015 -176.555 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.533 HG13 HG23 ' A' ' 205' ' ' VAL . 18.6 m -104.43 -25.28 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 113.328 0.862 . . . . 70.55 113.328 -172.124 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.484 ' HA3' ' HA ' ' A' ' 203' ' ' ILE . . . -74.96 -70.82 1.21 Allowed Glycine 0 C--N 1.346 1.123 0 C-N-CA 121.565 -0.35 . . . . 62.21 112.289 -168.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 92.15 -2.06 74.6 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-O 119.2 -0.778 . . . . 74.34 114.131 170.341 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 40.8 mtmt -139.33 138.93 37.09 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 108.352 -0.981 . . . . 73.1 108.352 178.641 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 210' ' ' VAL . . . . . 0.63 HG11 HG12 ' A' ' 199' ' ' VAL . 7.3 p -160.58 145.98 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 C-N-CA 123.897 0.879 . . . . 72.43 108.71 -178.771 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 211' ' ' ARG . . . . . 0.456 ' HA ' ' HA ' ' A' ' 220' ' ' GLU . 69.0 mtt180 -93.56 123.88 37.17 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 122.759 0.424 . . . . 74.24 109.951 177.52 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.477 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -101.18 165.02 11.51 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 124.237 1.015 . . . . 50.51 109.146 173.557 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 66.2 mmm -103.34 146.75 28.0 Favored 'General case' 0 C--O 1.239 0.551 0 CA-C-O 121.162 0.506 . . . . 73.2 110.419 175.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.433 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.3 t -138.6 169.08 18.43 Favored 'General case' 0 C--O 1.238 0.467 0 CA-C-N 114.726 -1.125 . . . . 64.23 109.709 173.721 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 215' ' ' LEU . . . . . 0.627 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 81.9 mt -70.92 -3.3 18.53 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 114.844 -1.071 . . . . 54.41 113.223 -174.111 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 1.8 pp20? -121.0 -1.45 9.85 Favored 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.274 0.629 . . . . 73.1 112.52 178.453 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.16 -158.51 27.71 Favored Glycine 0 N--CA 1.475 1.278 0 CA-C-O 119.719 -0.489 . . . . 44.25 113.443 176.043 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -90.76 129.47 1.43 Allowed 'Trans proline' 0 C--N 1.367 1.52 0 C-N-CA 123.223 2.616 . . . . 62.22 112.412 174.026 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 31.5 m -109.66 151.43 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 123.819 0.848 . . . . 71.31 109.434 171.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 220' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 211' ' ' ARG . 32.9 tt0 -114.58 114.62 25.97 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.647 -0.501 . . . . 64.32 109.647 173.055 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.466 HG23 HD21 ' A' ' 235' ' ' LEU . 4.5 p -100.56 144.32 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 C-N-CA 124.703 1.201 . . . . 61.21 110.744 178.706 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -95.96 113.02 24.6 Favored 'General case' 0 C--O 1.24 0.561 0 N-CA-C 109.159 -0.682 . . . . 73.34 109.159 173.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.53 HG11 HG11 ' A' ' 199' ' ' VAL . 14.1 m -84.53 138.6 38.4 Favored Pre-proline 0 N--CA 1.481 1.097 0 N-CA-C 108.86 -0.792 . . . . 74.33 108.86 176.36 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -54.3 140.68 72.51 Favored 'Trans proline' 0 C--N 1.379 2.136 0 C-N-CA 122.625 2.217 . . . . 72.53 112.622 177.283 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -54.17 112.74 1.07 Allowed 'Trans proline' 0 C--N 1.379 2.181 0 C-N-CA 122.881 2.388 . . . . 75.13 111.282 174.55 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 226' ' ' ARG . . . . . 0.621 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 60.6 mtp180 63.27 58.43 1.4 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.531 1.133 . . . . 74.52 110.634 -171.164 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.8 t -71.15 171.82 10.31 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.334 -0.848 . . . . 65.44 110.431 175.22 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.5 mp0 -121.18 146.35 46.87 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.711 0.804 . . . . 73.34 109.225 -175.669 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -72.52 113.73 9.87 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 123.218 0.607 . . . . 65.22 110.292 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.6 4.88 19.23 Favored Glycine 0 C--N 1.339 0.712 0 CA-C-N 115.73 -0.668 . . . . 72.21 112.399 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 61.3 mtp180 -76.17 153.25 36.32 Favored 'General case' 0 N--CA 1.477 0.918 0 CA-C-N 117.345 0.573 . . . . 73.44 109.962 172.092 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 0.2 OUTLIER -111.71 119.27 38.08 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 123.727 0.811 . . . . 60.34 108.934 -179.746 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 70.2 mt -106.02 114.49 28.66 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 122.85 0.46 . . . . 74.03 109.827 -178.022 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 234' ' ' ARG . . . . . 0.589 ' HG3' ' HB3' ' A' ' 248' ' ' ASP . 39.7 ttp180 -82.48 104.22 12.61 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 124.863 1.265 . . . . 74.41 111.354 -171.23 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.498 ' HB2' ' HB3' ' A' ' 249' ' ' LEU . 38.2 mt -89.48 97.63 11.3 Favored 'General case' 0 C--O 1.239 0.531 0 C-N-CA 123.231 0.612 . . . . 71.04 109.594 172.618 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -72.81 134.95 45.12 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 114.766 -1.106 . . . . 63.53 110.119 -178.323 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 85.26 24.65 43.02 Favored Glycine 0 C--N 1.34 0.77 0 O-C-N 123.493 0.496 . . . . 73.15 113.247 178.542 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -124.52 -6.88 7.5 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 123.223 0.609 . . . . 75.43 112.353 176.627 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -85.32 -161.67 34.74 Favored Glycine 0 C--N 1.345 1.082 0 O-C-N 123.53 0.518 . . . . 34.53 112.506 175.423 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.558 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 92.2 m-85 -97.24 147.0 32.32 Favored Pre-proline 0 N--CA 1.481 1.082 0 C-N-CA 123.524 0.729 . . . . 75.25 111.282 175.434 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.43 132.52 33.75 Favored 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 122.257 1.971 . . . . 64.42 111.315 171.452 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -156.83 -148.64 5.15 Favored Glycine 0 CA--C 1.532 1.152 0 CA-C-O 119.01 -0.883 . . . . 71.32 111.595 -176.044 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -51.63 -53.96 6.15 Favored 'Trans proline' 0 C--N 1.377 2.055 0 C-N-CA 123.953 3.102 . . . . 63.44 114.999 -177.11 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -83.67 -24.46 31.32 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 122.608 0.363 . . . . 72.2 111.778 -177.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 141.86 -155.4 25.4 Favored Glycine 0 N--CA 1.47 0.92 0 N-CA-C 110.091 -1.204 . . . . 32.25 110.091 -177.088 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 22.1 ttm180 -65.13 134.73 54.39 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 118.511 1.155 . . . . 73.13 109.351 171.857 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -75.05 -170.85 27.49 Favored Glycine 0 C--O 1.249 1.052 0 CA-C-O 121.974 0.763 . . . . 60.43 114.686 -170.555 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 248' ' ' ASP . . . . . 0.589 ' HB3' ' HG3' ' A' ' 234' ' ' ARG . 12.1 m-20 -129.33 136.9 50.61 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 114.268 -0.966 . . . . 74.42 109.565 -169.555 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.498 ' HB3' ' HB2' ' A' ' 235' ' ' LEU . 20.7 tp -97.01 111.74 23.82 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.889 -0.411 . . . . 74.13 109.889 179.559 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -91.85 106.63 18.61 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.222 0.534 . . . . 74.12 109.813 177.489 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.603 ' HB3' ' HB2' ' A' ' 197' ' ' LEU . 85.9 mt -87.53 120.01 28.41 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 124.245 1.018 . . . . 62.4 112.379 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -80.61 93.86 6.2 Favored 'General case' 0 CA--C 1.539 0.535 0 N-CA-C 108.093 -1.077 . . . . 65.41 108.093 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.402 HG22 HD23 ' A' ' 197' ' ' LEU . 60.3 t -48.96 123.68 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.561 1.144 . . . . 65.03 111.184 175.706 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 38.5 mmm-85 -128.69 100.94 5.92 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 107.219 -1.4 . . . . 70.12 107.219 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 56.5 mt -83.34 117.84 29.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 115.149 -0.932 . . . . 63.5 110.05 -177.162 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.8 t . . . . . 0 CA--C 1.556 1.187 0 C-N-CA 124.23 1.012 . . . . 65.23 108.603 174.53 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 109.968 -0.382 . . . . 64.54 109.968 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -177.48 -68.85 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.944 0 C-N-CA 124.839 1.255 . . . . 71.33 107.971 176.574 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.667 HD22 ' HG3' ' A' ' 136' ' ' ARG . 20.4 tp -92.46 -55.14 3.51 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 115.488 -0.778 . . . . 53.02 110.236 -176.797 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.583 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 10.0 p -60.76 126.79 19.26 Favored 'Isoleucine or valine' 0 C--N 1.36 1.063 0 O-C-N 123.465 0.478 . . . . 72.3 111.025 175.579 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -83.31 -65.9 0.95 Allowed 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.493 -0.776 . . . . 62.42 109.699 -179.104 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -150.13 147.45 27.77 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 114.987 -1.006 . . . . 74.1 110.258 -169.421 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 92.9 t -78.81 124.59 37.4 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 N-CA-C 109.259 -0.645 . . . . 74.31 109.259 169.776 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 70.1 p -76.53 93.4 3.55 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 123.359 0.664 . . . . 64.31 109.471 176.042 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.7 m -72.72 86.15 1.22 Allowed 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 123.52 0.728 . . . . 63.02 109.226 178.572 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -154.56 120.3 1.01 Allowed Glycine 0 C--N 1.34 0.788 0 CA-C-N 115.027 -0.988 . . . . 62.34 110.779 -177.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 39.8 t -73.04 161.69 30.36 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 123.609 0.763 . . . . 74.43 111.994 -174.173 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -122.23 57.14 0.63 Allowed Glycine 0 C--N 1.338 0.691 0 CA-C-N 114.888 -1.051 . . . . 72.52 110.647 175.337 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -68.39 -21.86 74.47 Favored Glycine 0 C--N 1.354 1.578 0 O-C-N 124.02 0.482 . . . . 74.44 113.791 -179.076 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 19.4 m -63.09 90.79 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.024 0 C-N-CA 123.796 0.839 . . . . 65.2 110.551 177.326 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 158.04 -42.33 0.51 Allowed Glycine 0 C--N 1.338 0.659 0 CA-C-N 115.483 -0.78 . . . . 45.33 111.23 -175.384 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 85.47 -48.92 4.1 Favored Glycine 0 C--N 1.354 1.571 0 C-N-CA 122.78 0.229 . . . . 72.11 112.543 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 36.7 m -71.19 108.2 4.58 Favored 'General case' 0 CA--C 1.553 1.089 0 C-N-CA 124.006 0.923 . . . . 75.2 110.407 177.209 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -140.65 178.78 19.77 Favored Glycine 0 C--N 1.343 0.925 0 N-CA-C 111.417 -0.673 . . . . 52.41 111.417 176.777 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -133.39 -173.02 13.12 Favored Glycine 0 C--N 1.346 1.109 0 CA-C-N 117.235 0.518 . . . . 43.21 113.432 -178.332 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 15.9 m -65.1 -56.18 14.48 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 124.22 1.008 . . . . 72.11 111.162 -178.683 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -83.14 117.59 4.45 Favored Glycine 0 C--N 1.344 1.01 0 N-CA-C 111.588 -0.605 . . . . 73.11 111.588 176.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 27.7 ptt180 -73.29 154.39 40.17 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 123.452 0.701 . . . . 73.21 112.337 -177.065 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.682 ' HB2' ' HB2' ' A' ' 167' ' ' GLN . 16.2 t70 -72.27 133.61 45.14 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 108.591 -0.892 . . . . 74.5 108.591 170.119 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 28.6 tp -101.61 142.07 33.53 Favored 'General case' 0 C--O 1.22 -0.453 0 N-CA-C 107.356 -1.35 . . . . 72.33 107.356 -178.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 37.3 ttp-105 -143.28 132.93 23.73 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 108.513 -0.921 . . . . 71.54 108.513 -178.091 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -144.75 138.41 27.16 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 123.953 0.901 . . . . 73.22 109.052 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -103.26 148.98 25.15 Favored 'General case' 0 C--O 1.252 1.191 0 CA-C-O 120.935 0.398 . . . . 72.15 110.101 176.344 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.583 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.6 pt? -146.95 130.93 8.44 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.674 -0.694 . . . . 73.24 111.967 -170.675 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.97 120.64 7.63 Favored 'Trans proline' 0 C--N 1.378 2.084 0 C-N-CA 122.49 2.127 . . . . 72.25 111.477 174.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 18.0 tp -120.42 152.79 37.45 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.542 1.137 . . . . 64.45 109.165 179.675 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.474 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 22.4 m -86.25 155.41 20.7 Favored 'General case' 0 CA--C 1.551 0.993 0 N-CA-C 109.365 -0.606 . . . . 54.21 109.365 172.009 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.433 HD11 ' O ' ' A' ' 183' ' ' HIS . 28.6 mt -55.34 -49.23 72.76 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-O 121.923 0.868 . . . . 70.24 109.934 175.113 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.607 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.3 mp0 -55.96 -35.44 66.69 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 113.943 -1.48 . . . . 64.35 111.544 177.665 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.474 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 35.7 mm-40 -83.11 -19.57 36.5 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 122.993 0.517 . . . . 73.33 112.077 -179.474 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.59 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -65.27 -31.66 72.92 Favored 'General case' 0 C--O 1.246 0.919 0 CA-C-O 121.169 0.509 . . . . 72.44 110.162 165.502 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.443 ' HA ' ' CE1' ' A' ' 240' ' ' PHE . 6.6 t80 -77.28 -47.36 20.29 Favored 'General case' 0 CA--C 1.546 0.789 0 CA-C-N 115.366 -0.834 . . . . 71.51 112.279 170.823 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -76.75 -30.19 56.46 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 112.54 0.57 . . . . 75.43 112.54 -171.224 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 67.92 -107.08 1.91 Allowed Glycine 0 CA--C 1.533 1.218 0 N-CA-C 111.564 -0.614 . . . . 4.34 111.564 -173.31 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.33 162.43 36.39 Favored Glycine 0 C--N 1.353 1.496 0 N-CA-C 114.904 0.722 . . . . 63.14 114.904 168.621 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.457 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 1.6 mp0 -96.03 114.17 25.86 Favored 'General case' 0 C--N 1.357 0.917 0 N-CA-C 108.856 -0.794 . . . . 75.21 108.856 179.185 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.667 ' HG3' HD22 ' A' ' 98' ' ' LEU . 4.6 mmp_? -130.37 139.25 50.66 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.836 0.854 . . . . 51.34 109.372 -174.78 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 17.9 m -74.55 128.23 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 CA-C-O 121.638 0.732 . . . . 75.4 111.614 -172.561 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.439 HG13 HG11 ' A' ' 99' ' ' VAL . 21.7 t -119.87 129.65 75.16 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 C-N-CA 125.292 1.437 . . . . 75.22 109.168 -177.531 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -121.8 97.74 5.63 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 108.746 -0.835 . . . . 73.32 108.746 177.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.461 HG21 HD22 ' A' ' 174' ' ' LEU . 27.9 m -137.82 142.87 35.02 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.885 0 C-N-CA 125.09 1.356 . . . . 72.04 108.336 -177.304 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.55 19.2 11.47 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 124.081 0.953 . . . . 72.01 112.665 176.48 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.08 22.87 75.82 Favored Glycine 0 C--N 1.352 1.463 0 CA-C-N 116.393 -0.367 . . . . 64.3 112.359 -174.89 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -120.79 135.65 55.1 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.366 1.067 . . . . 75.31 108.861 -178.458 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 41.1 ttt180 -111.41 106.24 15.09 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.005 -0.739 . . . . 74.22 109.005 175.135 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 29.2 t -132.59 126.89 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 N-CA-C 108.461 -0.94 . . . . 64.14 108.461 -178.33 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 72.6 p -71.53 122.87 21.24 Favored 'General case' 0 CA--C 1.54 0.592 0 N-CA-C 109.084 -0.71 . . . . 55.21 109.084 171.651 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 7.3 p -96.79 140.72 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 109.769 -0.456 . . . . 73.33 109.769 -177.742 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.9 ttp180 -109.35 99.96 9.13 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 107.395 -1.335 . . . . 70.13 107.395 171.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.522 ' HB ' HD13 ' A' ' 159' ' ' ILE . 35.8 pt -89.27 127.53 54.8 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 108.467 -0.938 . . . . 72.23 108.467 175.128 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.09 135.86 33.2 Favored 'Trans proline' 0 C--N 1.376 2.008 0 C-N-CA 122.477 2.118 . . . . 42.25 113.061 -173.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_exo -46.25 119.92 3.37 Favored 'Trans proline' 0 C--N 1.376 2.012 0 C-N-CA 123.937 3.091 . . . . 73.45 112.75 167.098 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 123.48 58.17 0.19 Allowed Glycine 0 N--CA 1.465 0.625 0 N-CA-C 110.635 -0.986 . . . . 74.5 110.635 -175.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.59 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.0 p -134.17 161.48 40.7 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.319 0 C-N-CA 123.698 0.799 . . . . 73.11 109.397 -178.162 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 14.5 mtp180 -141.35 170.94 14.78 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 126.05 1.74 . . . . 71.02 109.747 -169.624 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -55.24 126.54 25.33 Favored 'General case' 0 CA--C 1.551 1.015 0 CA-C-N 116.027 -0.533 . . . . 71.35 110.695 164.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.38 2.7 74.97 Favored Glycine 0 C--N 1.346 1.126 0 CA-C-O 119.781 -0.455 . . . . 60.13 113.891 179.532 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 42.1 t -77.76 130.96 37.39 Favored 'General case' 0 C--O 1.247 0.932 0 N-CA-C 109.677 -0.49 . . . . 61.25 109.677 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.488 HG12 HD22 ' A' ' 175' ' ' LEU . 15.3 t -106.78 121.52 59.62 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-N 114.743 -1.117 . . . . 75.02 109.275 -168.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.528 HD11 HG21 ' A' ' 153' ' ' VAL . 23.6 mt -109.73 113.93 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 123.65 0.78 . . . . 74.55 110.686 -171.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 48.6 ttm-85 -83.19 119.42 24.52 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.22 0.608 . . . . 71.01 110.119 177.036 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 173' ' ' ASP . 5.1 m -123.94 132.14 24.28 Favored Pre-proline 0 N--CA 1.481 1.106 0 C-N-CA 123.138 0.575 . . . . 65.34 109.822 -178.362 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.92 157.26 43.22 Favored 'Trans proline' 0 C--N 1.374 1.899 0 C-N-CA 122.54 2.16 . . . . 73.34 113.889 -175.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.52 24.14 63.56 Favored Glycine 0 C--N 1.35 1.31 0 CA-C-N 115.128 -0.942 . . . . 45.21 115.389 171.564 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.4 ' SD ' HD23 ' A' ' 174' ' ' LEU . 62.3 mtt -124.66 -61.09 1.34 Allowed 'General case' 0 N--CA 1.493 1.708 0 CA-C-N 119.075 1.437 . . . . 53.31 112.919 -179.137 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -86.43 -115.88 0.95 Allowed Glycine 0 N--CA 1.481 1.693 0 C-N-CA 121.699 -0.286 . . . . 75.12 113.605 -176.223 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -154.08 -58.73 0.01 OUTLIER Glycine 0 C--N 1.35 1.306 0 CA-C-O 119.749 -0.473 . . . . 72.33 112.412 174.51 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.682 ' HB2' ' HB2' ' A' ' 118' ' ' ASP . 13.1 mm-40 -72.42 150.68 43.14 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 112.047 0.388 . . . . 72.15 112.047 -177.043 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 148.2 -153.33 25.2 Favored Glycine 0 C--N 1.348 1.214 0 CA-C-N 114.854 -1.066 . . . . 73.31 111.461 177.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -88.15 -45.82 0.47 Allowed Pre-proline 0 CA--C 1.562 1.44 0 CA-C-O 118.858 -0.591 . . . . 74.22 110.098 172.465 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -90.54 165.87 4.24 Favored 'Trans proline' 0 C--N 1.386 2.51 0 C-N-CA 122.155 1.903 . . . . 70.33 112.014 165.627 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -68.28 126.33 14.16 Favored 'Trans proline' 0 C--N 1.373 1.858 0 C-N-CA 122.067 1.845 . . . . 70.11 111.031 170.048 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . 85.11 109.28 0.67 Allowed Glycine 0 C--O 1.22 -0.757 0 CA-C-O 119.22 -0.767 . . . . 72.21 112.762 178.756 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.509 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 47.3 m-20 -144.98 134.52 23.24 Favored 'General case' 0 N--CA 1.481 1.119 0 CA-C-N 117.899 0.849 . . . . 72.52 111.489 172.398 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.461 HD22 HG21 ' A' ' 140' ' ' VAL . 28.1 tp -112.16 126.6 55.38 Favored 'General case' 0 C--N 1.347 0.477 0 N-CA-C 108.459 -0.941 . . . . 70.51 108.459 171.082 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.488 HD22 HG12 ' A' ' 158' ' ' VAL . 29.9 mt -93.99 100.73 12.82 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.539 1.135 . . . . 73.52 110.163 176.661 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 62.9 mt -87.11 104.45 16.36 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.532 0.733 . . . . 74.13 111.272 176.826 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 23.4 t -90.08 100.3 10.77 Favored 'Isoleucine or valine' 0 C--O 1.243 0.748 0 N-CA-C 108.101 -1.074 . . . . 65.21 108.101 175.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 3.2 m -78.25 149.88 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-O 121.624 0.726 . . . . 74.11 111.32 -174.176 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 33.0 mmt180 -119.22 95.29 4.74 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.497 -1.229 . . . . 73.54 107.963 -177.321 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 39.6 mt -67.99 147.91 51.77 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 110.192 -0.299 . . . . 55.33 110.192 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.402 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 47.5 mt -54.2 146.83 29.15 Favored Pre-proline 0 CA--C 1.562 1.415 0 C-N-CA 124.111 0.964 . . . . 73.33 111.417 -174.33 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -61.51 77.11 0.09 OUTLIER 'Trans proline' 0 C--N 1.379 2.173 0 C-N-CA 123.176 2.584 . . . . 73.03 111.447 171.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 183' ' ' HIS . . . . . 0.433 ' O ' HD11 ' A' ' 127' ' ' LEU . 8.2 t60 170.78 87.69 0.04 OUTLIER Pre-proline 0 CA--C 1.547 0.859 0 C-N-CA 126.242 1.817 . . . . 70.13 107.287 -166.671 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -98.76 125.27 0.17 Allowed 'Trans proline' 0 CA--C 1.564 1.994 0 C-N-CA 123.316 2.678 . . . . 74.43 113.188 172.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -122.64 -42.0 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.632 -0.668 . . . . 71.43 109.413 174.146 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 4.7 m-85 -98.08 128.36 44.56 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.19 -0.914 . . . . 71.45 110.304 -178.616 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 10.4 mtt180 -112.63 103.98 12.04 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 106.218 -1.771 . . . . 72.41 106.218 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.428 HD12 ' O ' ' A' ' 192' ' ' ASP . 42.7 tp -81.44 110.84 17.24 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-O 121.259 0.552 . . . . 74.22 109.576 176.585 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.11 99.49 10.5 Favored 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 106.393 -1.706 . . . . 61.24 106.393 171.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 62.7 -94.9 0.11 Allowed Glycine 0 C--N 1.349 1.294 0 O-C-N 124.018 0.823 . . . . 65.4 113.352 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 191' ' ' GLN . . . . . 0.542 HE22 ' HB3' ' A' ' 244' ' ' ALA . 8.7 pt20 -108.46 -19.2 13.53 Favored 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 123.742 0.817 . . . . 51.23 110.849 178.042 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.428 ' O ' HD12 ' A' ' 188' ' ' LEU . 29.0 m-20 -97.0 155.03 16.95 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 123.876 0.87 . . . . 72.1 111.63 -172.541 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.455 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 82.6 mt -109.53 154.33 22.86 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 124.206 1.003 . . . . 74.45 109.484 -177.55 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -137.17 121.83 18.55 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 107.502 -1.296 . . . . 74.25 107.502 171.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -134.03 141.51 47.24 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 108.632 -0.877 . . . . 53.11 108.632 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 3.5 m -82.3 122.46 27.98 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 109.747 -0.464 . . . . 65.12 109.747 -178.706 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.446 HD13 ' HB2' ' A' ' 212' ' ' ALA . 57.2 tp -107.75 112.2 24.76 Favored 'General case' 0 C--O 1.216 -0.69 0 C-N-CA 124.335 1.054 . . . . 64.52 109.116 -178.706 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -93.52 108.23 19.96 Favored 'General case' 0 N--CA 1.474 0.755 0 CA-C-O 121.338 0.59 . . . . 72.22 109.617 177.384 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 199' ' ' VAL . . . . . 0.48 HG22 HG21 ' A' ' 210' ' ' VAL . 65.2 t -101.37 126.0 35.93 Favored Pre-proline 0 N--CA 1.474 0.74 0 C-N-CA 124.148 0.979 . . . . 61.43 109.344 -176.659 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_exo -57.18 139.29 89.59 Favored 'Trans proline' 0 C--N 1.369 1.622 0 C-N-CA 122.624 2.216 . . . . 62.21 111.503 171.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -55.31 -41.83 92.79 Favored Pre-proline 0 N--CA 1.482 1.136 0 N-CA-C 113.673 0.99 . . . . 74.32 113.673 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo -47.58 -52.91 7.25 Favored 'Trans proline' 0 C--N 1.386 2.519 0 C-N-CA 122.166 1.911 . . . . 73.15 113.621 168.013 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 203' ' ' ILE . . . . . 0.53 HG21 HG13 ' A' ' 210' ' ' VAL . 9.3 mt -67.73 -33.33 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 123.035 0.534 . . . . 64.34 111.689 -179.502 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -68.39 -42.24 79.34 Favored 'General case' 0 C--O 1.245 0.861 0 C-N-CA 123.122 0.569 . . . . 52.12 111.855 -177.015 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.2 m -77.44 -40.78 29.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 CA-C-N 115.729 -0.669 . . . . 65.44 110.968 -177.434 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.1 m -79.16 -30.38 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 CA-C-O 120.841 0.353 . . . . 75.22 111.437 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.512 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 79.87 67.37 1.58 Allowed Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.683 -0.689 . . . . 74.14 112.513 -175.323 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -97.92 -148.99 24.56 Favored Glycine 0 C--N 1.35 1.347 0 CA-C-N 116.688 0.244 . . . . 43.0 112.546 176.796 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 209' ' ' LYS . . . . . 0.676 ' HD3' ' HB2' ' A' ' 220' ' ' GLU . 4.7 ttmp? -125.54 131.44 52.77 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.517 0.727 . . . . 74.21 109.081 -178.427 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 210' ' ' VAL . . . . . 0.53 HG13 HG21 ' A' ' 203' ' ' ILE . 5.7 m -120.87 135.76 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.357 -0.979 . . . . 74.52 108.357 172.897 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 211' ' ' ARG . . . . . 0.533 ' HD3' ' HB2' ' A' ' 218' ' ' PRO . 35.0 ttm105 -96.26 117.15 30.2 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 121.279 0.561 . . . . 74.33 109.699 178.766 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.446 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -99.78 155.4 17.66 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.027 0.931 . . . . 75.24 109.681 178.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 58.1 mmm -92.4 128.21 38.17 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 109.82 -0.437 . . . . 54.23 109.82 172.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.0 t -114.42 173.01 6.67 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-N 115.277 -0.874 . . . . 65.24 109.172 167.357 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 215' ' ' LEU . . . . . 0.607 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 73.1 mt -75.28 -2.99 30.72 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-N 115.449 -0.796 . . . . 75.52 112.614 -172.794 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.65 7.76 11.12 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 123.541 0.736 . . . . 72.22 112.122 179.219 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 137.01 -161.16 25.11 Favored Glycine 0 N--CA 1.476 1.362 0 CA-C-O 119.817 -0.435 . . . . 44.1 112.91 178.143 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 218' ' ' PRO . . . . . 0.533 ' HB2' ' HD3' ' A' ' 211' ' ' ARG . 98.5 Cg_endo -94.35 125.17 0.45 Allowed 'Trans proline' 0 C--N 1.37 1.681 0 C-N-CA 123.499 2.799 . . . . 60.23 112.763 176.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.7 m -108.85 146.28 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 123.322 0.649 . . . . 71.53 110.52 175.822 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 220' ' ' GLU . . . . . 0.676 ' HB2' ' HD3' ' A' ' 209' ' ' LYS . 9.9 pt-20 -113.73 104.66 12.43 Favored 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 108.996 -0.742 . . . . 75.11 108.996 -177.251 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.5 p -97.61 135.54 31.65 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 CA-C-N 115.656 -0.702 . . . . 70.52 110.832 -179.084 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -93.93 117.63 30.37 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-N 115.269 -0.878 . . . . 63.54 109.418 176.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.512 HG23 ' HA2' ' A' ' 207' ' ' GLY . 21.4 m -84.22 140.06 39.34 Favored Pre-proline 0 CA--C 1.553 1.096 0 N-CA-C 109.615 -0.513 . . . . 72.54 109.615 176.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -64.37 144.23 85.13 Favored 'Trans proline' 0 C--N 1.378 2.081 0 C-N-CA 122.583 2.189 . . . . 42.24 112.065 173.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -56.52 126.89 23.77 Favored 'Trans proline' 0 C--N 1.371 1.73 0 C-N-CA 122.746 2.297 . . . . 74.13 111.76 171.573 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 50.9 mtt180 65.64 44.28 3.02 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 124.445 1.098 . . . . 74.42 110.592 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 5.5 t -77.43 168.84 19.35 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 122.874 0.469 . . . . 45.44 110.046 177.765 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -130.72 152.06 50.48 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 122.893 0.477 . . . . 71.22 109.782 -178.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.61 134.06 48.32 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.752 0.821 . . . . 74.14 111.166 178.454 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.2 -8.11 20.91 Favored Glycine 0 C--N 1.341 0.854 0 CA-C-O 119.562 -0.576 . . . . 73.44 112.755 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -78.84 159.31 27.88 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-N 117.45 0.625 . . . . 73.45 109.483 175.01 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.561 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 12.9 mptt -118.57 102.6 9.01 Favored 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 123.748 0.819 . . . . 74.04 109.37 177.41 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 233' ' ' LEU . . . . . 0.433 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 83.3 mt -78.92 104.61 9.67 Favored 'General case' 0 C--N 1.355 0.805 0 N-CA-C 108.463 -0.94 . . . . 74.35 108.463 -176.116 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 22.3 ttp85 -79.65 121.49 25.36 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 115.261 -0.881 . . . . 71.43 110.446 -169.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 34.4 mt -105.94 120.09 40.87 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.733 0.813 . . . . 64.2 109.93 175.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -70.55 128.32 35.74 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 124.327 1.051 . . . . 63.12 112.237 -169.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 81.56 7.48 88.13 Favored Glycine 0 C--N 1.349 1.267 0 O-C-N 123.718 0.636 . . . . 74.52 114.453 171.579 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 38.2 mmtm -85.16 -23.33 28.42 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 117.192 0.496 . . . . 63.22 112.237 -178.141 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -81.62 173.74 53.97 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 111.861 -0.495 . . . . 75.34 111.861 176.229 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.443 ' CE1' ' HA ' ' A' ' 131' ' ' PHE . 88.2 m-85 -81.15 150.82 68.96 Favored Pre-proline 0 N--CA 1.477 0.894 0 N-CA-C 112.739 0.644 . . . . 73.21 112.739 -172.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -55.61 132.15 50.37 Favored 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.066 2.511 . . . . 75.54 111.226 170.151 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -160.81 -150.8 6.0 Favored Glycine 0 CA--C 1.532 1.154 0 CA-C-O 119.595 -0.558 . . . . 62.0 112.05 -174.572 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -65.77 -27.56 52.02 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 123.168 2.579 . . . . 72.34 113.287 -174.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 244' ' ' ALA . . . . . 0.542 ' HB3' HE22 ' A' ' 191' ' ' GLN . . . -109.51 21.79 16.57 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 123.667 0.787 . . . . 64.14 111.052 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.08 -151.6 33.61 Favored Glycine 0 C--N 1.347 1.171 0 N-CA-C 110.489 -1.045 . . . . 72.52 110.489 -170.47 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -61.83 138.9 58.39 Favored 'General case' 0 N--CA 1.477 0.924 0 CA-C-N 117.979 0.889 . . . . 73.45 110.162 174.124 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -78.54 -158.87 12.57 Favored Glycine 0 C--O 1.247 0.94 0 CA-C-N 115.969 -0.56 . . . . 33.13 112.146 172.667 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 -144.35 156.02 44.05 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.011 0.524 . . . . 75.52 109.938 -173.167 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.455 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 20.6 tp -97.67 109.84 22.52 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.462 0.649 . . . . 72.01 110.039 179.037 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 250' ' ' TYR . . . . . 0.561 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 97.5 m-85 -91.33 106.96 18.87 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-N 115.108 -0.951 . . . . 72.4 109.942 176.824 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.442 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 72.5 mt -89.25 112.76 23.89 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 123.939 0.895 . . . . 74.43 112.486 -179.289 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -78.62 91.37 4.61 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.945 -0.761 . . . . 74.42 108.945 178.259 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.1 p -55.54 125.9 11.64 Favored 'Isoleucine or valine' 0 C--N 1.353 0.732 0 CA-C-N 115.043 -0.98 . . . . 74.15 110.324 175.271 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 44.8 mmm-85 -131.15 109.83 10.73 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 106.536 -1.653 . . . . 74.31 106.536 175.587 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 66.3 mt -83.67 121.21 36.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.454 0 CA-C-N 115.966 -0.561 . . . . 62.35 111.799 -171.212 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 21.5 m . . . . . 0 CA--C 1.558 1.284 0 C-N-CA 124.586 1.154 . . . . 51.13 108.992 175.158 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.533 ' HB1' ' O ' ' A' ' 99' ' ' VAL . . . . . . . . 0 N--CA 1.477 0.909 0 N-CA-C 109.788 -0.449 . . . . 64.45 109.788 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.16 -79.08 0.13 Allowed 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 122.693 0.397 . . . . 55.24 110.836 -176.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.514 ' HB3' HD12 ' A' ' 123' ' ' LEU . 86.5 mt -91.17 -56.4 3.17 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.437 0.695 . . . . 73.42 109.543 -178.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.533 ' O ' ' HB1' ' A' ' 96' ' ' ALA . 6.4 t -82.9 119.64 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 115.092 -0.958 . . . . 55.44 109.468 178.641 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -75.35 -51.43 13.19 Favored 'General case' 0 N--CA 1.478 0.936 0 O-C-N 124.352 1.032 . . . . 71.51 110.579 177.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -165.79 178.15 6.75 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 125.094 1.358 . . . . 74.42 109.338 -172.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.497 HG12 ' HB2' ' A' ' 121' ' ' ALA . 19.0 m -92.04 156.39 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 112.151 0.426 . . . . 51.45 112.151 179.43 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 60.9 p -72.89 -53.59 10.95 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-N 115.11 -0.95 . . . . 71.42 109.268 172.775 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.5 t -171.33 151.7 3.16 Favored 'General case' 0 C--O 1.245 0.864 0 CA-C-N 114.572 -1.195 . . . . 74.2 109.364 177.754 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -93.89 161.2 24.54 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-N 116.003 -0.544 . . . . 33.14 112.039 173.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' SER . . . . . 0.688 ' HB2' ' HB2' ' A' ' 118' ' ' ASP . 41.0 m -131.14 169.64 15.62 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 124.015 0.926 . . . . 72.31 108.654 173.152 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -171.39 111.49 0.4 Allowed Glycine 0 C--N 1.34 0.782 0 N-CA-C 112.11 -0.396 . . . . 63.3 112.11 -175.497 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -85.32 98.63 2.27 Favored Glycine 0 C--N 1.34 0.78 0 N-CA-C 111.869 -0.492 . . . . 30.3 111.869 -178.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.0 m -57.56 -34.08 68.81 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 123.694 0.797 . . . . 72.21 111.441 176.511 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -148.19 168.24 28.95 Favored Glycine 0 C--N 1.338 0.644 0 CA-C-N 114.75 -1.114 . . . . 72.22 110.724 172.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 83.72 -59.46 4.96 Favored Glycine 0 C--N 1.344 1.001 0 N-CA-C 111.375 -0.69 . . . . 62.21 111.375 -174.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 33.2 t -72.83 113.86 10.33 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 123.138 0.575 . . . . 64.11 110.683 178.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -115.5 -14.28 8.28 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-N 116.194 -0.457 . . . . 74.11 112.896 178.341 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -83.96 -52.39 3.67 Favored Glycine 0 C--N 1.351 1.39 0 CA-C-N 116.695 0.248 . . . . 62.34 112.767 -177.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 44.9 m -107.85 141.6 39.19 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 123.673 0.789 . . . . 65.42 109.746 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -78.02 -93.43 0.27 Allowed Glycine 0 C--N 1.347 1.173 0 N-CA-C 111.644 -0.582 . . . . 74.12 111.644 177.719 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.574 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 9.9 mpt_? -96.33 122.37 39.14 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 108.39 -0.967 . . . . 62.25 108.39 168.436 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.688 ' HB2' ' HB2' ' A' ' 106' ' ' SER . 5.9 m-20 -73.36 147.92 43.91 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 108.667 -0.864 . . . . 63.24 108.667 173.759 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.502 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 14.1 tp -131.63 131.48 43.24 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 107.42 -1.326 . . . . 74.13 107.42 179.364 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.711 ' HG3' ' HB2' ' A' ' 175' ' ' LEU . 0.0 OUTLIER -134.41 133.93 41.09 Favored 'General case' 0 N--CA 1.482 1.135 0 N-CA-C 109.173 -0.677 . . . . 73.43 109.173 -177.172 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.497 ' HB2' HG12 ' A' ' 102' ' ' VAL . . . -146.46 164.17 33.33 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 124.079 0.952 . . . . 53.23 110.479 -176.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.644 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 46.3 mt-10 -126.42 151.01 48.29 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.079 0.951 . . . . 75.5 108.685 173.728 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.514 HD12 ' HB3' ' A' ' 98' ' ' LEU . 1.4 pt? -145.88 135.3 11.44 Favored Pre-proline 0 N--CA 1.477 0.897 0 C-N-CA 122.967 0.507 . . . . 55.35 110.171 -178.187 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -71.21 113.08 3.48 Favored 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 121.648 1.566 . . . . 64.32 109.583 167.675 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.459 HD22 HG11 ' A' ' 178' ' ' VAL . 17.2 tp -108.29 157.81 18.03 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 108.264 -1.013 . . . . 74.01 108.264 178.385 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.521 HG23 HD12 ' A' ' 181' ' ' LEU . 3.4 m -95.41 161.0 14.26 Favored 'General case' 0 CA--C 1.544 0.736 0 N-CA-C 109.4 -0.593 . . . . 72.44 109.4 173.629 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.47 HD23 ' HB3' ' A' ' 180' ' ' LEU . 67.7 mt -61.33 -46.17 91.36 Favored 'General case' 0 N--CA 1.476 0.836 0 CA-C-O 121.42 0.629 . . . . 72.32 110.104 175.674 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -60.15 -34.83 74.11 Favored 'General case' 0 N--CA 1.484 1.252 0 CA-C-N 114.636 -1.165 . . . . 73.11 111.871 176.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -72.94 -33.57 66.01 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 123.308 0.643 . . . . 72.13 110.472 177.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.491 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -62.68 -36.68 83.68 Favored 'General case' 0 C--O 1.246 0.891 0 C-N-CA 123.955 0.902 . . . . 72.01 111.883 171.347 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.5 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 31.7 t80 -66.87 -61.28 2.03 Favored 'General case' 0 N--CA 1.472 0.671 0 O-C-N 123.961 0.788 . . . . 72.11 111.72 175.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 40.7 m80 -77.68 -26.32 50.16 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 115.54 -0.754 . . . . 74.5 112.645 -170.088 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 62.68 -121.72 25.87 Favored Glycine 0 C--N 1.349 1.295 0 O-C-N 123.374 0.421 . . . . 53.43 112.281 -175.657 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 89.59 172.63 45.52 Favored Glycine 0 C--N 1.345 1.059 0 N-CA-C 114.288 0.475 . . . . 75.43 114.288 173.53 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 23.4 mp0 -84.17 136.66 33.88 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 123.512 0.725 . . . . 62.42 109.392 176.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.32 148.12 30.05 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 106.947 -1.501 . . . . 74.53 106.947 170.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 34.7 m -77.41 127.68 38.19 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-O 121.786 0.803 . . . . 70.0 111.643 -173.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.495 HG23 ' HB ' ' A' ' 99' ' ' VAL . 6.7 p -97.54 128.36 48.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.905 -1.146 . . . . 51.44 107.905 170.524 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' GLU . . . . . 0.445 ' HA ' ' O ' ' A' ' 143' ' ' ARG . 42.4 tt0 -123.27 95.06 4.45 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 107.908 -1.145 . . . . 75.25 107.908 -179.6 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.479 ' O ' ' HG2' ' A' ' 143' ' ' ARG . 15.3 m -136.92 138.16 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 124.714 1.206 . . . . 72.4 108.653 -173.418 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.86 20.41 10.63 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 123.741 0.816 . . . . 64.23 111.864 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.55 1.73 87.52 Favored Glycine 0 C--N 1.349 1.274 0 CA-C-O 119.549 -0.584 . . . . 45.44 113.754 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.479 ' HG2' ' O ' ' A' ' 140' ' ' VAL . 8.5 ptm180 -99.98 127.21 46.22 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 118.066 0.933 . . . . 72.34 109.253 176.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -114.16 113.77 25.14 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 124.073 0.949 . . . . 74.11 108.645 178.032 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 4.1 p -148.71 146.39 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 123.456 0.702 . . . . 75.33 109.912 -178.635 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 19.7 m -70.03 112.95 6.78 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.025 0.53 . . . . 75.25 110.931 178.775 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 14.2 p -98.99 137.31 26.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.042 0.537 . . . . 54.33 110.021 175.193 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 59.1 ttp180 -104.75 122.76 46.38 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 107.455 -1.313 . . . . 75.4 107.455 171.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.621 ' HB ' HD13 ' A' ' 159' ' ' ILE . 28.0 pt -107.46 127.47 27.78 Favored Pre-proline 0 CA--C 1.552 1.024 0 N-CA-C 108.172 -1.047 . . . . 72.43 108.172 172.393 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -53.61 130.85 40.84 Favored 'Trans proline' 0 C--N 1.387 2.594 0 C-N-CA 123.29 2.66 . . . . 64.02 113.914 -171.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -59.81 109.96 0.67 Allowed 'Trans proline' 0 C--N 1.378 2.085 0 C-N-CA 122.486 2.124 . . . . 62.51 109.952 170.569 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.423 ' HA2' ' CD2' ' A' ' 240' ' ' PHE . . . 139.19 28.48 0.23 Allowed Glycine 0 N--CA 1.468 0.776 0 CA-C-N 116.291 -0.413 . . . . 43.0 112.306 -169.811 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.556 HG21 HD11 ' A' ' 159' ' ' ILE . 2.1 p -104.94 157.36 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.269 0 N-CA-C 109.815 -0.439 . . . . 74.23 109.815 -173.607 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -139.64 163.95 31.2 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 124.951 1.301 . . . . 74.13 110.635 -165.735 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 20.3 tp10 -47.32 117.9 1.95 Allowed 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 124.479 1.112 . . . . 64.23 112.779 169.506 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.83 7.58 86.25 Favored Glycine 0 C--N 1.353 1.514 0 CA-C-N 115.573 -0.74 . . . . 62.32 113.978 178.259 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 33.6 t -76.55 129.51 36.57 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 117.311 0.556 . . . . 74.1 109.861 -178.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.431 HG22 HD22 ' A' ' 175' ' ' LEU . 7.1 p -96.56 131.43 43.35 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.093 0 CA-C-N 115.363 -0.835 . . . . 70.34 109.758 -177.391 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.621 HD13 ' HB ' ' A' ' 149' ' ' ILE . 23.1 mt -116.98 115.8 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 123.675 0.79 . . . . 74.13 110.693 -173.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 18.1 ttm180 -86.78 117.76 25.74 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.059 0.544 . . . . 72.53 110.369 -179.184 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.431 ' HA ' ' HD3' ' A' ' 162' ' ' PRO . 9.0 m -120.29 107.19 39.57 Favored Pre-proline 0 CA--C 1.563 1.446 0 N-CA-C 109.621 -0.511 . . . . 74.45 109.621 178.054 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 162' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 7.9 Cg_exo -72.41 152.87 55.38 Favored 'Trans proline' 0 C--N 1.376 2.014 0 C-N-CA 123.105 2.537 . . . . 71.51 112.834 -174.282 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 72.36 24.7 75.9 Favored Glycine 0 C--N 1.35 1.339 0 O-C-N 123.61 0.569 . . . . 52.32 113.126 179.019 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 48.7 tpp -111.08 -37.53 5.32 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.101 0.56 . . . . 55.53 110.6 -178.396 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -76.72 -140.0 1.05 Allowed Glycine 0 CA--C 1.532 1.151 0 CA-C-N 116.106 -0.497 . . . . 63.3 113.467 174.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.574 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -68.07 111.53 4.09 Favored Glycine 0 C--N 1.344 0.977 0 C-N-CA 122.945 0.307 . . . . 63.23 113.453 -176.026 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 17.2 mm-40 -88.09 163.1 16.4 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 123.761 0.825 . . . . 70.13 110.767 176.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 156.79 -78.25 0.19 Allowed Glycine 0 C--N 1.338 0.678 0 N-CA-C 109.587 -1.405 . . . . 54.24 109.587 179.354 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -135.89 -57.1 0.02 OUTLIER Pre-proline 0 CA--C 1.562 1.431 0 CA-C-O 118.427 -0.797 . . . . 72.35 109.713 170.265 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.44 ' HA ' ' HD3' ' A' ' 171' ' ' PRO . 69.2 Cg_endo -76.48 111.75 3.32 Favored 'Trans proline' 0 C--N 1.39 2.752 0 CA-C-N 121.327 1.51 . . . . 74.43 110.302 167.02 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 170' ' ' PRO . 4.6 Cg_exo -74.7 126.39 10.13 Favored 'Trans proline' 0 C--N 1.372 1.785 0 C-N-CA 122.228 1.952 . . . . 64.23 110.995 -176.846 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -76.12 151.6 40.7 Favored Glycine 0 C--N 1.336 0.579 0 N-CA-C 111.796 -0.522 . . . . 54.32 111.796 174.203 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -103.72 172.74 6.64 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.761 0.825 . . . . 74.21 109.154 178.723 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.502 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 37.5 tp -129.85 114.37 15.82 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 109.336 -0.616 . . . . 75.3 109.336 170.464 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.711 ' HB2' ' HG3' ' A' ' 120' ' ' ARG . 32.4 mt -85.56 102.39 13.49 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 114.903 -1.044 . . . . 75.2 110.837 176.811 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.44 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 79.0 mt -91.59 102.55 15.2 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.087 0.955 . . . . 60.01 111.71 179.137 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.644 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 43.3 t -86.48 103.83 13.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 N-CA-C 108.678 -0.86 . . . . 75.24 108.678 174.115 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.459 HG11 HD22 ' A' ' 125' ' ' LEU . 9.4 m -80.01 151.97 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-O 121.683 0.754 . . . . 71.31 112.124 -177.755 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 7.0 mmm180 -124.69 97.44 5.29 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 125.404 1.482 . . . . 73.31 107.598 178.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.47 ' HB3' HD23 ' A' ' 127' ' ' LEU . 54.9 mt -67.15 134.18 51.27 Favored 'General case' 0 CA--C 1.546 0.793 0 O-C-N 123.156 0.285 . . . . 65.2 110.902 -178.47 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.521 HD12 HG23 ' A' ' 126' ' ' THR . 37.1 mt -55.1 146.49 39.44 Favored Pre-proline 0 C--N 1.364 1.222 0 C-N-CA 124.197 0.999 . . . . 74.15 111.379 -174.505 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_exo -70.13 79.07 1.08 Allowed 'Trans proline' 0 C--N 1.376 2.0 0 C-N-CA 123.196 2.597 . . . . 74.24 113.043 -176.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 42.7 p-80 -161.31 57.71 0.86 Allowed Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 124.152 0.981 . . . . 74.01 109.457 173.322 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -66.5 122.52 9.97 Favored 'Trans proline' 0 C--N 1.376 2.009 0 C-N-CA 121.976 1.784 . . . . 54.3 112.019 -168.485 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.459 ' O ' ' HA ' ' A' ' 195' ' ' ALA . 2.9 p -134.92 -41.07 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 C-N-CA 123.364 0.666 . . . . 74.42 109.322 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.451 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 8.8 m-85 -109.89 124.36 51.23 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 122.917 0.487 . . . . 74.02 110.925 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.45 114.79 25.51 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.069 1.348 . . . . 71.42 107.824 175.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 54.9 tp -86.43 144.78 27.13 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 122.897 0.479 . . . . 74.53 110.441 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -142.98 99.87 3.54 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 106.073 -1.825 . . . . 51.1 106.073 177.311 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 65.26 -88.6 0.1 OUTLIER Glycine 0 C--N 1.344 1.003 0 N-CA-C 112.088 -0.405 . . . . 41.2 112.088 -172.567 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -130.66 -10.69 3.97 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 123.92 0.888 . . . . 72.1 110.58 175.784 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -85.87 150.41 24.55 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.71 0.804 . . . . 72.01 111.489 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.653 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 95.9 mt -114.91 161.12 18.7 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 124.25 1.02 . . . . 75.02 111.588 -177.856 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 194' ' ' TYR . . . . . 0.467 ' HA ' ' O ' ' A' ' 250' ' ' TYR . 89.1 m-85 -140.89 118.41 11.54 Favored 'General case' 0 C--O 1.233 0.227 0 N-CA-C 107.091 -1.448 . . . . 75.01 107.091 173.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 195' ' ' ALA . . . . . 0.472 ' HB3' HD11 ' A' ' 249' ' ' LEU . . . -141.23 128.7 21.27 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.82 -0.437 . . . . 71.45 109.82 -176.328 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 14.2 m -76.8 114.92 16.1 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-O 121.163 0.506 . . . . 72.45 110.915 -173.269 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.526 HD22 HD13 ' A' ' 251' ' ' LEU . 69.3 tp -106.58 113.06 26.34 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.329 1.052 . . . . 73.22 109.689 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -84.51 129.49 34.85 Favored 'General case' 0 C--O 1.242 0.701 0 N-CA-C 109.061 -0.718 . . . . 73.12 109.061 169.206 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 12.1 m -125.84 141.78 40.33 Favored Pre-proline 0 N--CA 1.48 1.042 0 N-CA-C 108.25 -1.019 . . . . 75.12 108.25 176.238 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -64.67 141.17 71.45 Favored 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 121.693 1.595 . . . . 74.5 110.698 170.44 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 201' ' ' ALA . . . . . 0.412 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -55.83 -41.86 93.1 Favored Pre-proline 0 CA--C 1.558 1.288 0 C-N-CA 123.878 0.871 . . . . 72.55 113.308 -178.312 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 202' ' ' PRO . . . . . 0.425 ' O ' HG22 ' A' ' 206' ' ' VAL . 83.1 Cg_exo -49.04 -47.77 20.56 Favored 'Trans proline' 0 C--N 1.39 2.744 0 C-N-CA 122.434 2.09 . . . . 61.24 114.081 169.101 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 203' ' ' ILE . . . . . 0.482 ' HA ' ' HA3' ' A' ' 207' ' ' GLY . 5.6 mt -66.46 -44.37 90.51 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 CA-C-N 117.822 0.283 . . . . 73.31 111.252 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -50.69 -43.85 57.78 Favored 'General case' 0 CA--C 1.538 0.514 0 O-C-N 124.546 1.154 . . . . 60.42 111.51 -178.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 205' ' ' VAL . . . . . 0.644 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 29.6 m -89.34 -59.61 2.74 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.404 0 N-CA-C 113.226 0.824 . . . . 63.43 113.226 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.425 HG22 ' O ' ' A' ' 202' ' ' PRO . 27.3 m -102.39 -24.61 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 N-CA-C 113.537 0.94 . . . . 71.43 113.537 -171.797 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.482 ' HA3' ' HA ' ' A' ' 203' ' ' ILE . . . -75.0 -76.01 0.78 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 121.181 -0.533 . . . . 61.0 111.993 -173.411 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 94.69 -0.36 65.05 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-O 119.155 -0.803 . . . . 75.42 114.02 172.57 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 209' ' ' LYS . . . . . 0.462 ' O ' HD13 ' A' ' 203' ' ' ILE . 48.6 mtmt -138.11 132.89 32.71 Favored 'General case' 0 N--CA 1.481 1.082 0 CA-C-N 118.165 0.982 . . . . 62.45 108.838 178.553 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 7.7 p -153.65 141.64 13.44 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 C-N-CA 124.124 0.97 . . . . 63.35 108.758 -174.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 16.6 ptp180 -77.5 148.92 35.06 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 110.172 -0.307 . . . . 74.51 110.172 175.516 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.454 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -140.1 159.86 41.24 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.33 0.652 . . . . 63.33 109.82 174.342 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -106.28 143.7 34.03 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-N 115.599 -0.728 . . . . 65.42 110.702 179.259 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.451 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 8.9 t -133.4 165.43 24.86 Favored 'General case' 0 C--O 1.24 0.566 0 C-N-CA 124.102 0.961 . . . . 64.41 109.489 171.292 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 81.4 mt -64.44 -14.82 58.89 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.268 1.027 . . . . 72.51 111.789 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -95.86 -21.39 18.11 Favored 'General case' 0 CA--C 1.558 1.281 0 C-N-CA 123.443 0.697 . . . . 53.4 111.787 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.13 -151.66 23.84 Favored Glycine 0 N--CA 1.478 1.438 0 CA-C-O 119.26 -0.744 . . . . 54.12 112.67 -176.405 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -91.76 133.26 1.37 Allowed 'Trans proline' 0 CA--C 1.559 1.752 0 C-N-CA 123.115 2.543 . . . . 35.35 113.695 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 36.0 m -114.89 159.36 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 123.939 0.896 . . . . 61.44 110.495 171.565 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -114.08 113.43 24.72 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 123.859 0.863 . . . . 71.54 109.069 175.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.462 HG22 HD11 ' A' ' 235' ' ' LEU . 20.5 t -95.14 126.24 47.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 123.661 0.785 . . . . 75.42 109.548 -178.615 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -106.5 99.44 9.02 Favored 'General case' 0 C--O 1.24 0.582 0 N-CA-C 107.003 -1.481 . . . . 64.42 107.003 173.311 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.516 HG12 HD13 ' A' ' 233' ' ' LEU . 3.3 m -79.09 132.23 64.06 Favored Pre-proline 0 CA--C 1.553 1.065 0 N-CA-C 108.031 -1.1 . . . . 55.24 108.031 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -56.37 129.61 35.69 Favored 'Trans proline' 0 C--N 1.375 1.956 0 C-N-CA 122.133 1.889 . . . . 74.11 111.665 176.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -42.35 124.27 3.05 Favored 'Trans proline' 0 C--N 1.385 2.462 0 C-N-CA 124.69 3.593 . . . . 62.15 114.361 -173.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 226' ' ' ARG . . . . . 0.644 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 52.8 mtm180 64.09 73.44 0.43 Allowed 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 124.333 1.053 . . . . 75.3 111.046 -173.766 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 227' ' ' THR . . . . . 0.465 HG23 HD11 ' A' ' 255' ' ' ILE . 8.2 t -88.59 171.99 9.63 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 123.647 0.779 . . . . 73.23 110.457 175.446 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -127.9 140.2 52.15 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 123.741 0.816 . . . . 62.11 109.249 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.53 128.8 37.78 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.228 0.611 . . . . 43.44 109.863 177.594 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.24 -4.07 22.05 Favored Glycine 0 C--N 1.339 0.729 0 O-C-N 123.342 0.401 . . . . 50.01 113.276 -170.692 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 231' ' ' ARG . . . . . 0.425 ' O ' HG12 ' A' ' 253' ' ' VAL . 69.5 mtp180 -93.59 162.48 13.94 Favored 'General case' 0 N--CA 1.477 0.902 0 CA-C-N 117.39 0.595 . . . . 71.42 111.553 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.798 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 3.2 mptp? -118.35 104.6 10.89 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 108.946 -0.761 . . . . 72.24 108.946 -176.679 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 233' ' ' LEU . . . . . 0.548 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 23.4 mt -84.42 115.33 22.48 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.52 0.728 . . . . 62.2 109.898 -172.227 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 234' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 58.5 ttt180 -86.67 110.21 19.71 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 123.497 0.719 . . . . 71.22 111.631 -170.476 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.543 HD12 HD23 ' A' ' 249' ' ' LEU . 15.5 mt -99.95 104.0 15.59 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.024 -1.102 . . . . 73.34 108.024 170.474 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 56.0 mttp -74.66 138.86 43.15 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.942 0.497 . . . . 52.32 111.712 -171.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 237' ' ' GLY . . . . . 0.441 ' O ' ' HD3' ' A' ' 246' ' ' ARG . . . 80.05 6.84 88.98 Favored Glycine 0 C--N 1.348 1.243 0 O-C-N 123.903 0.752 . . . . 63.42 113.486 178.207 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 33.5 mmtp -106.96 8.59 30.58 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-N 117.263 0.532 . . . . 72.4 111.831 179.092 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -97.35 -178.5 34.2 Favored Glycine 0 C--N 1.344 1.023 0 O-C-N 123.481 0.488 . . . . 60.44 112.03 170.58 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.562 ' CE1' HD21 ' A' ' 193' ' ' LEU . 25.7 m-85 -76.28 163.1 68.51 Favored Pre-proline 0 CA--C 1.549 0.93 0 C-N-CA 124.257 1.023 . . . . 74.13 112.588 -174.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -52.47 129.05 30.21 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 123.248 2.632 . . . . 75.11 112.804 173.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -156.33 -162.26 11.31 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.091 -0.838 . . . . 75.34 112.043 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -61.39 -30.98 88.14 Favored 'Trans proline' 0 C--N 1.377 2.047 0 C-N-CA 123.465 2.777 . . . . 73.51 112.916 -175.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -90.95 22.13 3.82 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.961 0.905 . . . . 74.23 111.438 179.473 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 82.27 -70.82 3.08 Favored Glycine 0 C--N 1.35 1.307 0 N-CA-C 111.104 -0.798 . . . . 73.11 111.104 -175.222 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.441 ' HD3' ' O ' ' A' ' 237' ' ' GLY . 78.2 mtt180 -116.32 161.47 18.97 Favored 'General case' 0 C--O 1.243 0.749 0 C-N-CA 124.459 1.103 . . . . 75.31 108.578 172.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -96.13 -158.3 31.93 Favored Glycine 0 C--O 1.243 0.704 0 CA-C-N 115.699 -0.682 . . . . 54.03 112.308 177.38 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -132.35 155.63 48.07 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 109.641 -0.504 . . . . 65.41 109.641 -175.671 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.653 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 14.3 tp -103.25 129.02 50.1 Favored 'General case' 0 C--O 1.214 -0.812 0 C-N-CA 123.648 0.779 . . . . 71.12 109.12 171.811 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 250' ' ' TYR . . . . . 0.798 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 92.7 m-85 -115.36 107.64 15.48 Favored 'General case' 0 N--CA 1.477 0.906 0 N-CA-C 108.907 -0.775 . . . . 74.21 108.907 176.693 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.548 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 42.1 mt -87.5 126.15 34.74 Favored 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 123.568 0.747 . . . . 72.42 111.876 -173.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -78.91 90.84 4.74 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 107.366 -1.346 . . . . 75.12 107.366 176.03 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.425 HG12 ' O ' ' A' ' 231' ' ' ARG . 2.8 p -63.29 124.12 17.35 Favored 'Isoleucine or valine' 0 C--O 1.239 0.55 0 CA-C-O 121.802 0.81 . . . . 73.22 110.472 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 29.7 mmm180 -124.25 95.34 4.51 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 107.574 -1.269 . . . . 72.55 107.574 -178.527 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.465 HD11 HG23 ' A' ' 227' ' ' THR . 69.1 mt -75.83 107.14 6.34 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 115.204 -0.907 . . . . 50.03 109.394 -177.725 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.2 t . . . . . 0 CA--C 1.549 0.928 0 C-N-CA 124.539 1.136 . . . . 72.5 109.139 -179.317 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.378 0 N-CA-C 110.403 -0.221 . . . . 63.2 110.403 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -117.15 -77.89 0.57 Allowed 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 122.998 0.519 . . . . 74.11 109.917 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.643 ' HG ' ' HG2' ' A' ' 136' ' ' ARG . 68.2 mt -85.38 -57.08 3.21 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 122.694 0.398 . . . . 75.51 110.449 177.778 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.451 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 11.8 p -56.28 134.62 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 O-C-N 123.858 0.724 . . . . 61.31 111.531 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.96 -60.73 2.19 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 108.746 -0.835 . . . . 53.13 108.746 174.661 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 31.2 m80 -162.94 159.48 23.66 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 124.98 1.312 . . . . 64.13 108.82 -177.635 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.477 ' HA ' ' HB2' ' A' ' 121' ' ' ALA . 13.0 p -78.0 127.7 38.44 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.007 0 CA-C-O 121.025 0.44 . . . . 62.55 110.451 178.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.471 HG23 ' HA ' ' A' ' 121' ' ' ALA . 43.8 p -82.57 150.4 26.92 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.537 0.735 . . . . 62.44 110.474 -179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 29.1 t -68.02 145.69 54.25 Favored 'General case' 0 CA--C 1.551 0.99 0 C-N-CA 123.402 0.681 . . . . 52.0 109.51 175.588 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' GLY . . . . . 0.505 ' HA3' ' HD2' ' A' ' 120' ' ' ARG . . . -151.85 131.73 3.54 Favored Glycine 0 C--N 1.344 1.019 0 C-N-CA 121.457 -0.401 . . . . 65.12 113.038 -174.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 35.1 p -63.58 147.86 50.36 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.867 0.867 . . . . 75.45 111.144 178.319 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 171.38 -30.45 0.12 Allowed Glycine 0 C--N 1.342 0.881 0 CA-C-N 115.974 -0.557 . . . . 71.4 112.258 -177.381 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.56 -165.63 26.14 Favored Glycine 0 C--N 1.346 1.09 0 C-N-CA 123.19 0.424 . . . . 34.53 112.738 177.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.501 ' HA ' ' HB3' ' A' ' 115' ' ' SER . 69.8 p -132.62 121.65 23.51 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 123.509 0.724 . . . . 70.13 110.109 178.398 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -65.6 -38.83 95.05 Favored Glycine 0 C--N 1.355 1.591 0 O-C-N 123.661 0.601 . . . . 75.21 111.683 174.346 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -97.43 -158.74 30.85 Favored Glycine 0 C--N 1.352 1.44 0 N-CA-C 111.425 -0.67 . . . . 75.1 111.425 169.324 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 25.7 m -75.97 -33.74 59.78 Favored 'General case' 0 N--CA 1.479 0.986 0 C-N-CA 123.713 0.805 . . . . 72.14 110.869 174.71 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -149.25 -32.39 0.05 OUTLIER Glycine 0 C--N 1.343 0.938 0 N-CA-C 111.144 -0.782 . . . . 60.51 111.144 179.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -66.92 88.4 0.14 Allowed Glycine 0 C--N 1.353 1.508 0 N-CA-C 111.424 -0.67 . . . . 54.14 111.424 172.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' SER . . . . . 0.501 ' HB3' ' HA ' ' A' ' 109' ' ' SER . 19.5 p -112.79 124.92 53.67 Favored 'General case' 0 C--O 1.238 0.487 0 C-N-CA 123.907 0.883 . . . . 62.44 109.22 179.316 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -81.88 66.17 3.9 Favored Glycine 0 C--N 1.344 1.019 0 N-CA-C 110.72 -0.952 . . . . 64.43 110.72 172.456 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 11.7 mmm180 -71.65 147.72 47.22 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 124.107 0.963 . . . . 72.41 110.746 -177.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -72.97 150.47 42.46 Favored 'General case' 0 C--O 1.243 0.741 0 N-CA-C 107.734 -1.21 . . . . 64.35 107.734 170.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.517 HD13 HG23 ' A' ' 140' ' ' VAL . 39.7 mt -95.04 139.02 31.98 Favored 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 107.402 -1.332 . . . . 74.24 107.402 -176.936 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.505 ' HD2' ' HA3' ' A' ' 105' ' ' GLY . 17.8 ptp180 -146.3 135.8 23.03 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.379 -0.971 . . . . 61.5 108.379 178.403 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.477 ' HB2' ' HA ' ' A' ' 102' ' ' VAL . . . -156.95 139.2 14.67 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.189 -0.671 . . . . 75.53 109.189 -171.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -96.7 148.02 23.31 Favored 'General case' 0 C--O 1.244 0.764 0 N-CA-C 109.38 -0.6 . . . . 62.34 109.38 173.422 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.627 HD12 ' HB3' ' A' ' 98' ' ' LEU . 1.6 pt? -144.12 132.18 10.84 Favored Pre-proline 0 N--CA 1.473 0.71 0 CA-C-N 115.991 -0.55 . . . . 61.42 110.83 -171.203 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -68.5 117.2 4.82 Favored 'Trans proline' 0 C--N 1.374 1.895 0 C-N-CA 121.963 1.775 . . . . 75.52 110.932 174.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.473 HD22 HG11 ' A' ' 178' ' ' VAL . 16.0 tp -119.8 150.56 40.22 Favored 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 108.828 -0.804 . . . . 62.31 108.828 178.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.498 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 10.5 m -89.16 158.28 17.97 Favored 'General case' 0 CA--C 1.547 0.854 0 N-CA-C 109.31 -0.626 . . . . 65.34 109.31 175.345 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.474 HD11 ' O ' ' A' ' 183' ' ' HIS . 55.9 mt -54.56 -51.32 65.6 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 123.886 0.875 . . . . 74.21 111.062 177.317 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.436 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 2.1 mp0 -55.67 -37.59 68.5 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 114.325 -1.307 . . . . 74.34 111.024 176.834 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.498 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 10.3 mm-40 -79.18 -18.12 53.64 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.557 0.743 . . . . 64.31 111.313 -177.698 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.678 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -66.12 -42.37 89.27 Favored 'General case' 0 C--O 1.252 1.221 0 CA-C-O 121.004 0.43 . . . . 72.03 110.951 165.785 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -65.02 -48.88 72.32 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 115.824 -0.626 . . . . 73.31 111.318 172.507 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.6 m80 -73.82 -48.07 34.02 Favored 'General case' 0 N--CA 1.481 1.116 0 O-C-N 123.773 0.671 . . . . 70.03 111.839 -171.444 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 58.51 -109.54 2.03 Favored Glycine 0 CA--C 1.533 1.176 0 N-CA-C 111.351 -0.7 . . . . 72.51 111.351 -172.199 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.21 -162.89 50.13 Favored Glycine 0 C--N 1.346 1.106 0 N-CA-C 114.983 0.753 . . . . 73.33 114.983 166.606 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -79.06 135.97 37.03 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 124.424 1.09 . . . . 73.42 110.989 -174.737 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.643 ' HG2' ' HG ' ' A' ' 98' ' ' LEU . 13.8 tpt180 -156.86 167.97 28.87 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.137 0.975 . . . . 72.12 109.215 175.877 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.0 p -110.25 136.72 45.36 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 CA-C-O 121.148 0.499 . . . . 72.34 110.613 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 15.5 m -121.23 137.81 53.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 C-N-CA 124.011 0.925 . . . . 71.44 108.864 172.64 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -126.47 98.44 5.42 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-O 121.894 0.854 . . . . 63.51 109.228 171.368 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.517 HG23 HD13 ' A' ' 119' ' ' LEU . 10.6 m -130.24 139.41 51.47 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 124.517 1.127 . . . . 63.2 108.63 -179.161 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.54 24.77 14.17 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 124.256 1.023 . . . . 74.42 111.465 -176.234 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.11 -3.9 74.18 Favored Glycine 0 C--N 1.351 1.406 0 CA-C-N 115.809 -0.632 . . . . 71.03 113.038 -177.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -97.17 116.37 29.26 Favored 'General case' 0 C--N 1.346 0.456 0 C-N-CA 123.409 0.684 . . . . 75.11 109.425 -176.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 44.1 ttm180 -101.45 106.12 17.21 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 108.598 -0.89 . . . . 73.55 108.598 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 38.5 t -127.74 142.85 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 124.025 0.93 . . . . 43.42 109.223 -177.311 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 9.6 p -77.28 114.5 16.17 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 123.28 0.632 . . . . 62.51 110.041 175.21 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.8 p -98.88 136.43 29.93 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 C-N-CA 123.808 0.843 . . . . 72.15 110.345 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 59.6 ttp180 -111.2 95.44 5.53 Favored 'General case' 0 C--O 1.242 0.705 0 N-CA-C 108.227 -1.027 . . . . 72.34 108.227 168.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.413 ' HB ' HD13 ' A' ' 159' ' ' ILE . 34.9 pt -82.48 128.5 66.62 Favored Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 108.492 -0.929 . . . . 71.33 108.492 175.067 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -68.98 147.19 67.35 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.41 2.073 . . . . 74.31 113.059 -168.461 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -64.32 111.91 1.76 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 122.362 2.041 . . . . 72.01 110.636 172.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.771 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 142.23 30.45 0.13 Allowed Glycine 0 C--N 1.354 1.578 0 C-N-CA 121.435 -0.412 . . . . 74.32 114.051 -174.632 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.678 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.0 p -106.26 164.57 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.683 0 C-N-CA 123.506 0.722 . . . . 73.22 109.891 -176.166 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 52.9 mtm-85 -144.56 167.19 23.1 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 125.106 1.363 . . . . 71.43 108.979 -172.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' GLU . . . . . 0.453 ' HB2' ' HB2' ' A' ' 180' ' ' LEU . 13.3 tp10 -54.82 122.48 10.86 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 123.329 0.651 . . . . 75.42 110.14 168.218 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 89.12 -11.6 68.94 Favored Glycine 0 C--N 1.344 0.983 0 CA-C-O 119.632 -0.538 . . . . 75.22 113.395 179.797 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 35.0 t -70.86 129.53 39.31 Favored 'General case' 0 C--O 1.245 0.863 0 CA-C-N 117.206 0.503 . . . . 71.2 109.756 -178.015 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.546 HG12 HD22 ' A' ' 175' ' ' LEU . 18.6 t -104.01 119.37 52.64 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 CA-C-N 114.386 -1.279 . . . . 53.22 109.073 -173.068 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.516 HD11 HG21 ' A' ' 153' ' ' VAL . 23.4 mt -103.13 117.45 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 C-N-CA 123.803 0.841 . . . . 71.42 110.023 -171.095 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 55.9 ttt85 -90.52 111.64 23.01 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 123.686 0.794 . . . . 63.32 110.226 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.3 m -120.31 102.37 45.79 Favored Pre-proline 0 CA--C 1.568 1.665 0 C-N-CA 122.618 0.367 . . . . 60.23 110.611 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -63.56 150.99 87.11 Favored 'Trans proline' 0 C--N 1.375 1.93 0 C-N-CA 122.938 2.425 . . . . 62.22 113.175 -177.059 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 106.11 -26.11 21.57 Favored Glycine 0 CA--C 1.535 1.329 0 CA-C-O 119.038 -0.868 . . . . 72.44 114.777 177.024 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -81.24 -55.15 4.92 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-N 118.674 1.237 . . . . 65.05 111.23 -178.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -70.61 -179.51 27.98 Favored Glycine 0 C--N 1.348 1.219 0 CA-C-N 115.993 -0.549 . . . . 74.01 113.755 -177.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -95.59 -50.46 1.99 Allowed Glycine 0 C--N 1.343 0.96 0 CA-C-O 119.487 -0.618 . . . . 41.42 113.578 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' GLN . . . . . 0.559 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -38.4 127.44 1.41 Allowed 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 115.66 1.726 . . . . 70.22 115.66 -161.981 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 91.35 165.88 40.04 Favored Glycine 0 C--N 1.353 1.513 0 O-C-N 124.42 1.075 . . . . 61.13 111.944 -178.101 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -65.8 -43.38 59.24 Favored Pre-proline 0 CA--C 1.559 1.324 0 CA-C-O 118.682 -0.675 . . . . 75.42 110.326 173.644 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -67.46 143.5 63.49 Favored 'Trans proline' 0 C--N 1.388 2.648 0 C-N-CA 121.25 1.3 . . . . 73.34 110.248 161.356 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -64.34 126.81 17.72 Favored 'Trans proline' 0 C--N 1.371 1.741 0 C-N-CA 122.007 1.805 . . . . 74.52 111.489 -176.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -65.49 -171.54 3.38 Favored Glycine 0 C--N 1.346 1.106 0 CA-C-N 115.866 -0.606 . . . . 63.01 113.943 -177.492 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 10.5 p-10 -108.58 172.9 6.57 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 123.828 0.851 . . . . 54.14 112.129 -168.177 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 19.2 tp -120.41 116.76 26.11 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 114.44 -1.255 . . . . 70.25 107.867 172.205 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.546 HD22 HG12 ' A' ' 158' ' ' VAL . 65.3 mt -88.11 100.03 12.64 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.982 0.913 . . . . 74.13 110.901 177.467 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 70.8 mt -91.46 104.9 17.36 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 123.222 0.609 . . . . 72.41 111.044 176.664 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.407 HG22 HG13 ' A' ' 158' ' ' VAL . 12.4 t -91.58 101.11 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 108.399 -0.963 . . . . 70.23 108.399 177.848 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.473 HG11 HD22 ' A' ' 125' ' ' LEU . 3.7 m -76.84 150.12 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 CA-C-O 121.612 0.72 . . . . 64.01 112.16 -172.814 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 42.8 mmt180 -116.18 91.55 3.63 Favored 'General case' 0 C--O 1.238 0.448 0 C-N-CA 125.352 1.461 . . . . 75.45 107.686 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.453 ' HB2' ' HB2' ' A' ' 155' ' ' GLU . 21.3 mt -69.9 148.77 48.58 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 120.716 0.293 . . . . 72.45 110.28 175.431 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.1 mt -54.74 144.41 45.8 Favored Pre-proline 0 CA--C 1.556 1.195 0 C-N-CA 123.927 0.891 . . . . 65.45 112.131 -175.319 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.462 ' O ' ' HD3' ' A' ' 184' ' ' PRO . 23.9 Cg_exo -65.62 1.4 2.21 Favored 'Trans proline' 0 C--N 1.385 2.474 0 C-N-CA 123.529 2.819 . . . . 61.34 113.347 175.52 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 183' ' ' HIS . . . . . 0.474 ' O ' HD11 ' A' ' 127' ' ' LEU . 8.4 t60 -91.36 98.31 1.7 Allowed Pre-proline 0 CA--C 1.549 0.93 0 N-CA-C 107.546 -1.279 . . . . 71.1 107.546 159.34 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 184' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 182' ' ' PRO . 60.6 Cg_endo -102.16 124.7 0.09 OUTLIER 'Trans proline' 0 C--N 1.37 1.665 0 C-N-CA 122.913 2.408 . . . . 72.44 111.729 168.22 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -114.28 -42.2 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 CA-C-O 121.348 0.594 . . . . 73.15 109.728 177.801 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.482 ' HD2' HD22 ' A' ' 193' ' ' LEU . 5.5 m-85 -101.54 125.44 48.19 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 115.562 -0.745 . . . . 74.4 109.96 -177.384 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 37.2 ttp-105 -98.74 111.98 24.19 Favored 'General case' 0 C--O 1.243 0.758 0 N-CA-C 107.167 -1.419 . . . . 63.42 107.167 169.597 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 54.2 tp -83.45 116.99 22.77 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 108.443 -0.947 . . . . 62.25 108.443 172.482 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -126.76 99.21 5.67 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 124.488 1.115 . . . . 63.5 108.253 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 55.87 56.49 23.65 Favored Glycine 0 C--N 1.353 1.475 0 CA-C-O 119.504 -0.609 . . . . 62.22 113.76 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 69.13 -6.16 0.96 Allowed 'General case' 0 N--CA 1.504 2.25 0 C-N-CA 125.281 1.432 . . . . 63.32 113.15 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -97.82 150.12 21.61 Favored 'General case' 0 C--N 1.35 0.616 0 C-N-CA 124.864 1.266 . . . . 74.02 108.756 -178.254 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.595 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 94.9 mt -111.43 148.98 31.92 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 121.616 0.722 . . . . 64.0 112.418 -176.246 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -132.96 121.33 22.64 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 114.062 -1.427 . . . . 75.44 107.728 171.182 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -132.9 170.51 15.22 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 124.294 1.038 . . . . 55.52 109.071 177.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 54.9 m -109.96 133.38 53.24 Favored 'General case' 0 CA--C 1.537 0.449 0 N-CA-C 109.034 -0.728 . . . . 73.15 109.034 172.664 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 197' ' ' LEU . . . . . . . . . . . . . 52.5 tp -112.51 112.11 23.42 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 108.466 -0.938 . . . . 71.23 108.466 175.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -90.77 102.46 15.22 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 108.824 -0.806 . . . . 64.44 108.824 175.71 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 199' ' ' VAL . . . . . 0.402 HG21 HG11 ' A' ' 223' ' ' VAL . 7.7 p -109.3 131.88 21.59 Favored Pre-proline 0 CA--C 1.548 0.882 0 CA-C-N 114.98 -1.009 . . . . 72.21 109.291 -176.508 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -56.32 145.34 78.57 Favored 'Trans proline' 0 C--N 1.373 1.847 0 C-N-CA 122.785 2.323 . . . . 74.01 113.181 174.051 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 201' ' ' ALA . . . . . 0.463 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -54.73 -45.86 99.52 Favored Pre-proline 0 CA--C 1.563 1.465 0 C-N-CA 124.112 0.965 . . . . 74.54 113.4 176.67 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 202' ' ' PRO . . . . . 0.42 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 26.0 Cg_endo -58.76 -44.18 38.25 Favored 'Trans proline' 0 C--N 1.392 2.826 0 C-N-CA 122.014 1.809 . . . . 72.55 111.941 175.692 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.5 mt -63.68 -37.62 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 C-N-CA 123.105 0.562 . . . . 61.24 110.931 178.788 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -61.89 -46.76 87.97 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.436 0.695 . . . . 75.24 112.011 -177.604 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.3 m -77.08 -36.91 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 N-CA-C 112.235 0.457 . . . . 71.11 112.235 -177.329 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m -80.57 -25.24 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 CA-C-O 120.838 0.351 . . . . 74.01 110.978 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.498 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 72.93 69.4 1.4 Allowed Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.421 -0.809 . . . . 62.32 112.244 -173.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -96.08 -149.17 25.28 Favored Glycine 0 C--N 1.352 1.452 0 CA-C-O 121.312 0.395 . . . . 55.22 113.117 -178.488 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 53.1 tttp -125.82 125.93 43.69 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 124.845 1.258 . . . . 73.03 108.792 -172.506 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 210' ' ' VAL . . . . . 0.506 HG23 HG13 ' A' ' 221' ' ' VAL . 11.4 m -130.5 163.2 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.203 1.001 . . . . 64.02 108.598 173.474 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 39.0 ptt85 -104.57 148.16 26.82 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 109.665 -0.495 . . . . 74.34 109.665 176.08 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -120.45 135.23 55.12 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 108.852 -0.795 . . . . 62.1 108.852 174.741 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 5.0 tpt -87.02 107.57 18.48 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 108.906 -0.776 . . . . 74.3 108.906 178.368 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.44 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 14.6 t -110.33 168.62 9.31 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 121.075 0.464 . . . . 71.51 109.78 174.287 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 215' ' ' LEU . . . . . 0.436 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 61.9 mt -74.55 -9.91 59.03 Favored 'General case' 0 CA--C 1.542 0.653 0 CA-C-N 115.667 -0.697 . . . . 64.32 112.519 -173.79 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -86.36 -21.75 27.03 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.598 0.759 . . . . 73.05 110.625 173.429 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 139.96 -169.73 24.57 Favored Glycine 0 C--N 1.345 1.032 0 N-CA-C 111.281 -0.728 . . . . 74.31 111.281 -173.645 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -76.01 126.85 9.6 Favored 'Trans proline' 0 C--N 1.363 1.336 0 C-N-CA 122.42 2.08 . . . . 65.13 112.015 176.049 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 33.4 m -110.25 163.53 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 123.549 0.74 . . . . 74.34 109.268 171.592 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -114.04 127.24 55.85 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.41 -0.589 . . . . 74.23 109.41 174.48 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.541 ' HB ' HD11 ' A' ' 235' ' ' LEU . 3.2 p -120.76 118.44 56.44 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 C-N-CA 123.818 0.847 . . . . 64.25 110.007 175.194 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.37 113.5 24.81 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 108.24 -1.022 . . . . 70.41 108.24 174.338 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.498 HG23 ' HA2' ' A' ' 207' ' ' GLY . 10.4 m -73.31 139.71 78.96 Favored Pre-proline 0 CA--C 1.553 1.096 0 N-CA-C 108.751 -0.833 . . . . 71.15 108.751 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -74.52 145.39 33.37 Favored 'Trans proline' 0 CA--C 1.557 1.674 0 C-N-CA 122.143 1.895 . . . . 53.42 111.309 178.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_exo -54.32 130.36 39.43 Favored 'Trans proline' 0 C--N 1.38 2.235 0 C-N-CA 123.325 2.683 . . . . 73.22 113.247 -179.008 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 61.69 61.28 1.47 Allowed 'General case' 0 N--CA 1.477 0.892 0 O-C-N 124.639 1.212 . . . . 73.33 111.201 -176.212 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.9 t -87.81 172.04 9.94 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 109.56 -0.533 . . . . 72.22 109.56 172.37 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.2 mp0 -130.66 153.25 49.15 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 108.72 -0.845 . . . . 65.22 108.72 -178.858 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -72.36 139.69 48.02 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 122.779 0.432 . . . . 74.32 110.028 176.756 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 101.75 -6.84 55.01 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 116.052 -0.522 . . . . 70.11 112.395 -178.379 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 58.6 mtp180 -82.48 160.72 22.6 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.006 0.522 . . . . 71.02 110.251 179.081 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.481 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 11.9 mptt -118.3 116.97 27.85 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.828 0.851 . . . . 60.35 109.73 -178.293 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 73.6 mt -92.0 107.42 19.2 Favored 'General case' 0 C--O 1.24 0.603 0 N-CA-C 107.265 -1.383 . . . . 72.43 107.265 175.505 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 234' ' ' ARG . . . . . 0.446 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 66.5 ttt180 -88.56 103.14 15.62 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.362 -0.835 . . . . 75.11 110.313 -166.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.541 HD11 ' HB ' ' A' ' 221' ' ' VAL . 33.3 mt -93.28 97.58 10.71 Favored 'General case' 0 C--N 1.348 0.508 0 N-CA-C 108.706 -0.85 . . . . 62.4 108.706 178.076 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 236' ' ' LYS . . . . . 0.57 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 10.3 mtmp? -81.38 144.38 31.48 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.332 -0.849 . . . . 44.51 111.525 -172.524 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 76.46 18.39 79.16 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.499 -0.773 . . . . 75.41 112.817 -172.261 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 73.1 mmtt -121.05 7.11 10.3 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.278 0.631 . . . . 71.33 111.934 -178.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 239' ' ' GLY . . . . . 0.411 ' HA2' ' CD1' ' A' ' 193' ' ' LEU . . . -92.22 -169.44 40.73 Favored Glycine 0 C--N 1.338 0.681 0 O-C-N 123.578 0.549 . . . . 53.22 112.131 174.679 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.771 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 3.9 m-85 -76.77 144.23 72.64 Favored Pre-proline 0 CA--C 1.547 0.849 0 C-N-CA 122.302 0.241 . . . . 71.2 110.614 -175.634 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.89 127.73 21.22 Favored 'Trans proline' 0 C--N 1.377 2.055 0 C-N-CA 122.885 2.39 . . . . 62.1 111.646 176.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -164.36 -154.09 7.71 Favored Glycine 0 CA--C 1.537 1.458 0 CA-C-O 119.448 -0.64 . . . . 71.3 113.298 -174.618 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -60.67 -24.28 78.17 Favored 'Trans proline' 0 C--N 1.379 2.166 0 C-N-CA 124.263 3.309 . . . . 72.44 114.164 -178.111 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.0 23.01 5.21 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 123.453 0.701 . . . . 74.32 111.461 176.402 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 74.33 -78.54 0.97 Allowed Glycine 0 C--N 1.348 1.206 0 N-CA-C 110.938 -0.865 . . . . 73.02 110.938 -173.797 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 12.8 ttt85 -129.65 141.74 50.86 Favored 'General case' 0 CA--C 1.546 0.8 0 N-CA-C 108.348 -0.982 . . . . 72.24 108.348 172.563 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.74 -156.78 5.28 Favored Glycine 0 N--CA 1.475 1.252 0 N-CA-C 113.805 0.282 . . . . 74.22 113.805 -178.032 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 248' ' ' ASP . . . . . 0.57 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 0.7 OUTLIER -148.44 156.46 42.51 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 123.125 0.57 . . . . 65.22 111.281 179.39 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.595 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 28.5 tp -110.42 133.63 53.09 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.73 1.212 . . . . 74.02 111.196 -172.137 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -106.21 107.2 18.09 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.147 0.979 . . . . 72.32 109.402 174.704 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.481 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 84.8 mt -87.56 115.57 25.08 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.1 0.56 . . . . 73.11 111.839 176.546 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -79.89 93.74 5.72 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 108.472 -0.936 . . . . 74.32 108.472 179.056 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 59.6 t -48.18 121.0 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.553 1.141 . . . . 40.05 110.659 174.851 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 25.6 mmm180 -128.9 95.45 4.09 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.194 -1.41 . . . . 74.14 107.194 177.364 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.463 HG23 ' HA ' ' A' ' 201' ' ' ALA . 66.5 mt -75.32 120.38 24.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-N 114.898 -1.046 . . . . 73.22 109.407 -176.873 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.556 1.189 0 C-N-CA 123.637 0.775 . . . . 74.14 109.315 -173.697 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.076 0 N-CA-C 109.827 -0.435 . . . . 74.22 109.827 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -160.78 -64.44 0.06 Allowed 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 122.808 0.443 . . . . 63.45 110.409 -177.459 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.53 HD23 HH11 ' A' ' 136' ' ' ARG . 55.1 tp -81.47 -52.15 7.55 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 123.236 0.614 . . . . 61.25 109.928 -178.281 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.568 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 8.1 p -87.54 158.81 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 C-N-CA 123.216 0.606 . . . . 64.53 110.093 168.598 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -88.82 -89.62 0.14 Allowed 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 123.278 0.631 . . . . 62.32 109.896 170.241 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -160.74 176.52 11.41 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 125.106 1.363 . . . . 72.21 108.915 -174.443 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 9.1 p -68.68 125.62 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 CA-C-O 121.224 0.535 . . . . 74.31 110.557 178.186 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 81.9 p -71.23 107.35 4.19 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 124.122 0.969 . . . . 65.35 109.826 175.45 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 43.0 t -73.56 82.73 1.51 Allowed 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.404 0.681 . . . . 72.13 110.216 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -165.33 136.81 4.37 Favored Glycine 0 C--N 1.342 0.907 0 N-CA-C 111.407 -0.677 . . . . 75.13 111.407 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 50.6 m -70.56 141.58 51.84 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 123.839 0.856 . . . . 72.41 111.305 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -137.31 111.47 0.84 Allowed Glycine 0 C--N 1.346 1.117 0 N-CA-C 111.897 -0.481 . . . . 74.5 111.897 -175.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.89 58.2 3.66 Favored Glycine 0 C--N 1.346 1.12 0 C-N-CA 123.134 0.397 . . . . 43.41 112.596 -178.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 25.8 m -79.65 90.1 5.16 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 123.528 0.731 . . . . 43.11 109.858 179.018 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 80.0 -73.95 2.37 Favored Glycine 0 C--N 1.346 1.134 0 CA-C-N 115.46 -0.791 . . . . 45.2 111.709 -177.237 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 64.31 19.07 63.81 Favored Glycine 0 C--N 1.351 1.402 0 O-C-N 123.861 0.389 . . . . 51.24 113.892 179.229 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 18.0 p -69.8 109.03 4.2 Favored 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 123.61 0.764 . . . . 74.42 110.904 -177.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.84 -115.18 4.44 Favored Glycine 0 C--N 1.348 1.245 0 CA-C-N 115.932 -0.576 . . . . 73.5 112.233 -177.222 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -161.68 153.84 24.67 Favored Glycine 0 C--N 1.342 0.89 0 N-CA-C 112.343 -0.303 . . . . 72.2 112.343 -179.369 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 60.4 m -149.29 178.74 8.5 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 124.699 1.2 . . . . 73.34 109.627 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -63.46 149.93 49.82 Favored Glycine 0 C--N 1.353 1.474 0 N-CA-C 111.729 -0.549 . . . . 43.22 111.729 173.384 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.501 ' HB3' ' HA3' ' A' ' 166' ' ' GLY . 59.6 ttt180 -59.85 120.58 9.85 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.881 0.872 . . . . 72.34 111.176 -174.802 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -88.12 147.73 24.78 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-O 121.518 0.675 . . . . 62.41 110.603 -179.459 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.532 HD12 ' HA2' ' A' ' 165' ' ' GLY . 14.5 mt -104.53 155.11 19.1 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.179 -1.415 . . . . 72.43 107.179 162.788 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 10.8 ttm180 -145.11 118.26 8.89 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 108.87 -0.789 . . . . 73.35 108.87 -175.137 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.412 ' HB3' HD23 ' A' ' 176' ' ' LEU . . . -141.37 141.61 33.8 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 123.702 0.801 . . . . 61.32 109.724 -176.577 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.709 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 39.4 mt-10 -116.95 149.82 39.55 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.066 0.546 . . . . 73.04 110.811 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.568 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.6 pt? -145.85 144.89 23.29 Favored Pre-proline 0 N--CA 1.471 0.599 0 CA-C-N 115.392 -0.822 . . . . 72.23 110.873 -179.44 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -77.55 115.3 3.86 Favored 'Trans proline' 0 C--N 1.371 1.739 0 C-N-CA 121.825 1.683 . . . . 63.14 110.711 168.676 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.554 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 15.7 tp -107.37 154.1 21.8 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.532 0.733 . . . . 65.55 109.407 179.36 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.573 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 11.5 m -87.74 160.97 17.86 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.137 0.575 . . . . 65.52 109.527 175.455 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.504 HD13 HG12 ' A' ' 185' ' ' VAL . 30.2 mt -63.07 -48.96 76.42 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 123.884 0.874 . . . . 65.51 110.562 178.58 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -57.28 -31.59 65.76 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 114.777 -1.101 . . . . 72.5 110.937 176.621 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.573 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 8.8 mm-40 -83.82 -23.99 31.17 Favored 'General case' 0 C--O 1.212 -0.869 0 C-N-CA 122.996 0.519 . . . . 73.45 111.054 -179.091 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.7 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -60.62 -35.21 75.6 Favored 'General case' 0 C--O 1.248 1.015 0 CA-C-O 121.804 0.811 . . . . 70.51 110.3 165.536 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.526 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 55.3 t80 -72.03 -47.42 51.9 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.419 -1.264 . . . . 71.21 111.82 172.213 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.3 m80 -83.96 -16.82 42.71 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 113.283 0.846 . . . . 70.1 113.283 -171.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 89.75 -117.72 5.06 Favored Glycine 0 CA--C 1.535 1.326 0 N-CA-C 111.987 -0.445 . . . . 43.54 111.987 -170.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 148.91 94.01 0.12 Allowed Glycine 0 C--N 1.353 1.488 0 CA-C-N 117.828 0.814 . . . . 73.44 113.571 175.12 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -85.21 123.06 30.28 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 123.273 0.629 . . . . 63.35 109.397 175.882 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.577 ' NH2' HD13 ' A' ' 176' ' ' LEU . 16.9 ptt-85 -148.65 168.45 22.81 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.204 0.602 . . . . 53.35 111.526 -170.157 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 23.1 m -89.84 106.23 16.93 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 CA-C-N 115.022 -0.99 . . . . 75.43 108.624 169.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.552 HG21 HD21 ' A' ' 174' ' ' LEU . 7.4 p -98.89 123.1 51.3 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 123.153 0.581 . . . . 61.14 109.789 -179.38 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -119.03 98.73 6.32 Favored 'General case' 0 C--O 1.241 0.614 0 C-N-CA 124.256 1.023 . . . . 73.41 109.186 -178.718 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.433 HG21 HD22 ' A' ' 174' ' ' LEU . 8.6 m -131.8 121.45 47.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 124.457 1.103 . . . . 70.53 109.919 -173.605 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.25 22.84 13.55 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 124.533 1.133 . . . . 73.12 111.954 -178.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 88.8 2.39 78.64 Favored Glycine 0 C--N 1.345 1.067 0 CA-C-O 119.815 -0.436 . . . . 72.13 113.388 -177.17 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -92.8 113.92 26.33 Favored 'General case' 0 C--N 1.348 0.515 0 N-CA-C 108.625 -0.88 . . . . 74.41 108.625 175.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 59.9 ttp180 -106.22 110.85 23.22 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 108.116 -1.068 . . . . 62.22 108.116 176.1 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 5.7 m -141.38 155.72 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 124.52 1.128 . . . . 74.14 109.078 -177.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 47.4 t -87.21 115.5 24.65 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.128 -0.693 . . . . 65.22 109.128 177.312 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.2 p -99.33 136.66 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-O 121.095 0.474 . . . . 52.22 110.718 179.167 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.5 ttp180 -110.29 98.76 7.92 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 107.743 -1.206 . . . . 74.22 107.743 172.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.473 HD13 HH12 ' A' ' 136' ' ' ARG . 28.9 pt -89.88 131.24 39.99 Favored Pre-proline 0 N--CA 1.475 0.809 0 N-CA-C 108.684 -0.858 . . . . 73.33 108.684 177.27 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -72.01 157.7 53.98 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.45 2.1 . . . . 72.33 112.828 -172.1 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -68.5 148.17 72.39 Favored 'Trans proline' 0 C--N 1.375 1.959 0 C-N-CA 122.283 1.988 . . . . 74.12 111.356 172.204 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 100.04 41.49 2.83 Favored Glycine 0 C--N 1.34 0.786 0 N-CA-C 110.988 -0.845 . . . . 65.13 110.988 -176.504 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.7 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -111.37 160.74 10.47 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.267 0 N-CA-C 108.265 -1.013 . . . . 72.43 108.265 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.401 ' HD3' ' HB3' ' A' ' 188' ' ' LEU . 74.8 mtm180 -148.47 176.74 10.05 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 123.909 0.884 . . . . 72.01 111.735 -166.118 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -55.61 115.74 2.51 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 114.214 -1.357 . . . . 50.22 111.072 170.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 75.89 10.22 85.06 Favored Glycine 0 C--N 1.345 1.053 0 O-C-N 123.601 0.563 . . . . 34.52 113.683 178.689 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 37.5 t -75.13 125.97 30.05 Favored 'General case' 0 C--O 1.245 0.819 0 C-N-CA 122.97 0.508 . . . . 71.05 109.906 -178.797 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.446 HG12 HD22 ' A' ' 175' ' ' LEU . 21.2 t -95.83 121.57 46.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 C-N-CA 124.719 1.208 . . . . 74.45 109.457 -175.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.538 HD11 HG21 ' A' ' 153' ' ' VAL . 27.3 mt -107.28 111.21 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 123.46 0.704 . . . . 51.42 109.634 -174.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 25.1 ttp180 -84.83 117.76 24.07 Favored 'General case' 0 CA--C 1.538 0.493 0 O-C-N 123.655 0.597 . . . . 63.32 109.989 179.192 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.5 m -114.86 96.47 44.67 Favored Pre-proline 0 CA--C 1.561 1.394 0 CA-C-O 121.431 0.634 . . . . 71.24 109.419 175.505 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -63.22 136.61 56.68 Favored 'Trans proline' 0 C--N 1.379 2.153 0 C-N-CA 123.391 2.727 . . . . 72.54 113.224 -175.616 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.59 -17.14 59.43 Favored Glycine 0 C--N 1.345 1.064 0 N-CA-C 114.39 0.516 . . . . 43.33 114.39 174.51 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 10.4 mtm -100.69 -6.29 25.31 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 117.718 0.759 . . . . 65.1 112.187 -174.268 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' GLY . . . . . 0.532 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . -88.33 -115.19 1.25 Allowed Glycine 0 C--N 1.351 1.391 0 N-CA-C 111.813 -0.515 . . . . 75.52 111.813 175.285 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.501 ' HA3' ' HB3' ' A' ' 117' ' ' ARG . . . -67.71 129.91 27.85 Favored Glycine 0 C--N 1.347 1.169 0 N-CA-C 112.012 -0.435 . . . . 73.22 112.012 178.373 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.0 mm-40 -89.65 154.18 20.16 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.477 0.711 . . . . 61.23 110.986 -177.745 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 137.68 -166.89 24.98 Favored Glycine 0 N--CA 1.472 1.041 0 N-CA-C 111.788 -0.525 . . . . 72.23 111.788 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -71.51 -42.18 10.73 Favored Pre-proline 0 CA--C 1.56 1.361 0 CA-C-O 118.331 -0.843 . . . . 65.15 110.805 174.085 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -69.57 116.26 4.46 Favored 'Trans proline' 0 C--N 1.394 2.953 0 C-N-CA 122.015 1.81 . . . . 61.13 110.401 164.32 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -71.08 125.08 11.11 Favored 'Trans proline' 0 C--N 1.375 1.957 0 C-N-CA 121.546 1.497 . . . . 74.43 111.688 177.257 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -98.63 151.93 19.64 Favored Glycine 0 N--CA 1.452 -0.294 0 N-CA-C 110.123 -1.191 . . . . 74.12 110.123 171.039 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -116.49 167.83 10.71 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 124.422 1.089 . . . . 74.44 109.751 -173.598 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.552 HD21 HG21 ' A' ' 138' ' ' VAL . 11.8 tp -120.22 129.64 54.17 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.167 -1.049 . . . . 62.1 108.167 176.479 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.446 HD22 HG12 ' A' ' 158' ' ' VAL . 83.1 mt -103.79 98.6 8.43 Favored 'General case' 0 C--O 1.233 0.212 0 C-N-CA 124.345 1.058 . . . . 54.05 109.636 -175.39 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.577 HD13 ' NH2' ' A' ' 136' ' ' ARG . 45.4 mt -92.88 101.23 13.59 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.357 -0.838 . . . . 70.11 109.649 178.827 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.709 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 25.5 t -90.71 107.65 18.78 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 N-CA-C 108.422 -0.955 . . . . 71.12 108.422 179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.554 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 3.2 m -87.43 148.93 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 109.463 -0.569 . . . . 61.34 109.463 -177.733 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 10.0 mmm-85 -123.51 104.17 8.9 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 107.466 -1.309 . . . . 74.22 107.466 -174.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 27.4 mt -69.15 151.55 46.22 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-O 121.213 0.53 . . . . 64.21 111.3 -178.694 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 52.9 mt -54.56 150.7 16.59 Favored Pre-proline 0 CA--C 1.561 1.397 0 CA-C-N 114.608 -1.178 . . . . 72.11 112.383 -177.172 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -61.1 -8.05 9.26 Favored 'Trans proline' 0 C--N 1.385 2.489 0 C-N-CA 123.144 2.562 . . . . 74.02 113.459 177.39 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 183' ' ' HIS . . . . . 0.472 ' O ' HD11 ' A' ' 127' ' ' LEU . 5.2 t60 -93.44 104.83 13.53 Favored Pre-proline 0 CA--C 1.544 0.743 0 C-N-CA 124.436 1.094 . . . . 72.32 108.726 164.011 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -101.16 128.82 0.13 Allowed 'Trans proline' 0 CA--C 1.559 1.746 0 C-N-CA 123.379 2.72 . . . . 61.32 112.486 165.69 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.504 HG12 HD13 ' A' ' 127' ' ' LEU . 2.6 p -113.85 -46.21 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 122.899 0.48 . . . . 74.04 109.998 172.802 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -98.98 122.68 42.55 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.031 0.443 . . . . 74.31 110.774 -174.195 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.63 ' HB3' ' HB2' ' A' ' 194' ' ' TYR . 28.7 ttm180 -97.88 109.13 21.94 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 107.6 -1.259 . . . . 75.21 107.6 170.536 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.401 ' HB3' ' HD3' ' A' ' 154' ' ' ARG . 50.1 tp -89.56 112.62 23.87 Favored 'General case' 0 CA--C 1.543 0.702 0 N-CA-C 108.597 -0.89 . . . . 61.13 108.597 173.515 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -108.97 102.13 11.16 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 108.291 -1.003 . . . . 74.4 108.291 176.162 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 72.16 -87.41 0.49 Allowed Glycine 0 C--N 1.347 1.166 0 O-C-N 123.704 0.627 . . . . 71.4 111.765 -174.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 5.0 pm0 -134.01 -4.94 2.75 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 124.17 0.988 . . . . 73.33 110.574 178.639 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 56.5 m-20 -93.66 151.4 19.68 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.598 0.759 . . . . 71.45 111.198 -177.257 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.425 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 88.8 mt -107.44 147.07 30.9 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 124.372 1.069 . . . . 72.3 109.429 -178.493 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 194' ' ' TYR . . . . . 0.63 ' HB2' ' HB3' ' A' ' 187' ' ' ARG . 89.4 m-85 -133.46 121.07 21.69 Favored 'General case' 0 C--O 1.232 0.182 0 N-CA-C 107.389 -1.337 . . . . 75.31 107.389 175.233 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -134.76 170.88 15.16 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 123.916 0.886 . . . . 73.43 108.892 178.126 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 87.1 m -109.55 124.2 50.71 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.64 -0.709 . . . . 52.04 109.288 175.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.417 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 57.6 tp -107.06 111.75 24.36 Favored 'General case' 0 C--O 1.225 -0.201 0 C-N-CA 124.154 0.982 . . . . 74.52 109.106 177.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -87.45 125.53 34.34 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 107.758 -1.201 . . . . 75.13 107.758 172.203 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 199' ' ' VAL . . . . . 0.495 HG12 HG21 ' A' ' 210' ' ' VAL . 15.4 m -120.15 135.19 24.23 Favored Pre-proline 0 N--CA 1.475 0.82 0 N-CA-C 108.901 -0.777 . . . . 75.23 108.901 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -57.69 140.21 92.79 Favored 'Trans proline' 0 C--N 1.367 1.549 0 C-N-CA 122.314 2.01 . . . . 65.25 111.624 169.069 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -50.24 -44.21 80.33 Favored Pre-proline 0 CA--C 1.567 1.621 0 CA-C-O 118.057 -0.973 . . . . 63.33 113.069 179.384 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo -47.59 -52.61 7.75 Favored 'Trans proline' 0 C--N 1.404 3.485 0 C-N-CA 122.816 2.344 . . . . 74.31 112.754 168.687 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 11.8 mt -68.34 -33.4 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 C-N-CA 123.079 0.552 . . . . 70.41 111.7 -176.316 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.61 -47.97 83.51 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.329 0.651 . . . . 74.04 110.863 178.227 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 205' ' ' VAL . . . . . 0.457 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 32.8 m -81.78 -35.57 13.66 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.898 0 CA-C-N 115.695 -0.684 . . . . 51.43 112.362 -174.587 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.2 m -84.61 -22.97 7.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 CA-C-N 118.24 0.473 . . . . 64.25 111.245 -179.039 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 71.7 56.7 6.42 Favored Glycine 0 C--N 1.343 0.939 0 CA-C-N 115.823 -0.626 . . . . 72.02 112.31 -174.735 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -84.75 -152.96 17.98 Favored Glycine 0 C--N 1.355 1.624 0 N-CA-C 111.979 -0.449 . . . . 72.12 111.979 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -111.79 140.54 46.34 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.106 -0.702 . . . . 71.22 109.106 177.29 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 210' ' ' VAL . . . . . 0.495 HG21 HG12 ' A' ' 199' ' ' VAL . 41.1 t -125.66 149.47 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 108.066 -1.087 . . . . 63.2 108.066 168.635 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 211' ' ' ARG . . . . . 0.435 ' HD2' ' HG2' ' A' ' 220' ' ' GLU . 0.2 OUTLIER -90.06 125.27 35.35 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 108.268 -1.012 . . . . 74.41 108.268 166.946 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -100.43 129.11 46.35 Favored 'General case' 0 C--O 1.248 0.999 0 N-CA-C 108.59 -0.893 . . . . 64.35 108.59 178.537 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 4.2 tpt -76.25 105.16 7.14 Favored 'General case' 0 CA--C 1.537 0.471 0 O-C-N 123.697 0.623 . . . . 62.32 109.435 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 9.2 t -117.26 169.68 9.28 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 123.418 0.687 . . . . 71.01 110.524 177.378 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 63.3 mt -76.1 -5.6 47.31 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 123.957 0.903 . . . . 55.35 111.423 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -88.12 -20.38 25.73 Favored 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 124.077 0.951 . . . . 73.34 110.348 172.346 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 130.64 -149.87 19.15 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-O 119.073 -0.848 . . . . 65.02 111.108 -174.26 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -86.83 120.38 1.67 Allowed 'Trans proline' 0 CA--C 1.553 1.428 0 C-N-CA 122.211 1.941 . . . . 73.41 111.604 169.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 20.0 m -108.24 155.39 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 108.968 -0.753 . . . . 63.21 108.968 173.59 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 220' ' ' GLU . . . . . 0.435 ' HG2' ' HD2' ' A' ' 211' ' ' ARG . 33.4 mt-10 -109.46 107.36 17.47 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 108.788 -0.819 . . . . 72.14 108.788 -175.305 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.2 p -96.38 132.54 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 123.739 0.816 . . . . 63.42 110.342 177.542 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -90.69 105.41 17.8 Favored 'General case' 0 C--O 1.24 0.588 0 C-N-CA 123.648 0.779 . . . . 42.3 108.961 173.733 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.11 133.51 93.63 Favored Pre-proline 0 CA--C 1.557 1.24 0 C-N-CA 124.038 0.935 . . . . 62.2 110.063 177.578 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_exo -65.04 140.69 66.88 Favored 'Trans proline' 0 C--N 1.379 2.144 0 C-N-CA 122.89 2.393 . . . . 75.42 111.539 172.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -58.98 124.41 15.63 Favored 'Trans proline' 0 C--N 1.376 2.008 0 C-N-CA 122.724 2.283 . . . . 75.24 111.418 178.147 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 226' ' ' ARG . . . . . 0.457 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 85.3 mtm180 60.41 76.74 0.35 Allowed 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 124.423 1.089 . . . . 74.03 110.865 -177.533 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 7.5 t -103.71 173.81 6.14 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 123.365 0.666 . . . . 71.31 109.594 174.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.3 mp0 -131.44 155.53 47.18 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 123.655 0.782 . . . . 65.42 109.019 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.11 130.23 42.12 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.297 0.639 . . . . 74.12 110.279 177.191 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.03 -11.5 22.48 Favored Glycine 0 C--N 1.337 0.588 0 C-N-CA 123.505 0.574 . . . . 64.33 112.129 -176.087 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 73.3 mtp180 -81.7 155.58 25.48 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 122.818 0.447 . . . . 74.11 110.481 178.419 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.505 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 0.5 OUTLIER -118.53 125.29 49.55 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.776 0.83 . . . . 74.44 109.762 -179.115 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 28.1 mt -100.79 111.55 23.79 Favored 'General case' 0 C--N 1.353 0.759 0 N-CA-C 108.127 -1.064 . . . . 73.02 108.127 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 234' ' ' ARG . . . . . 0.428 ' HG3' ' HB3' ' A' ' 248' ' ' ASP . 57.4 ttm-85 -82.91 105.4 13.88 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.9 0.88 . . . . 70.11 110.894 -170.268 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.534 HD12 HD23 ' A' ' 249' ' ' LEU . 30.0 mt -87.03 97.46 10.73 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 107.782 -1.192 . . . . 62.13 107.782 171.103 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -71.76 138.2 48.25 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 114.831 -1.077 . . . . 71.03 111.634 -169.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 75.89 4.08 76.05 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 123.801 0.688 . . . . 63.4 113.991 177.219 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 238' ' ' LYS . . . . . 0.604 ' HE2' ' HA ' ' A' ' 238' ' ' LYS . 9.6 mmpt? -94.17 -3.13 51.47 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.253 0.621 . . . . 73.13 111.955 -177.484 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.27 -170.68 47.2 Favored Glycine 0 C--N 1.343 0.967 0 N-CA-C 111.941 -0.463 . . . . 53.51 111.941 171.236 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.526 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 97.3 m-85 -83.6 154.9 65.68 Favored Pre-proline 0 N--CA 1.477 0.917 0 C-N-CA 122.822 0.449 . . . . 61.04 111.687 -177.148 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 241' ' ' PRO . . . . . 0.474 ' HA ' ' O ' ' A' ' 245' ' ' GLY . 26.3 Cg_exo -64.5 127.05 18.06 Favored 'Trans proline' 0 C--N 1.375 1.962 0 C-N-CA 122.144 1.896 . . . . 54.43 110.468 166.829 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -165.22 -156.9 9.4 Favored Glycine 0 C--N 1.342 0.916 0 CA-C-O 119.219 -0.767 . . . . 75.24 112.329 -177.063 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -59.43 -10.78 11.83 Favored 'Trans proline' 0 N--CA 1.504 2.14 0 C-N-CA 124.017 3.145 . . . . 73.52 115.257 -178.086 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -109.49 19.14 19.62 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.287 0.635 . . . . 43.22 111.06 176.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 241' ' ' PRO . . . 77.45 -76.49 1.68 Allowed Glycine 0 C--N 1.345 1.067 0 N-CA-C 110.993 -0.843 . . . . 63.34 110.993 -173.34 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 55.5 mtm180 -123.77 155.88 37.1 Favored 'General case' 0 N--CA 1.476 0.875 0 N-CA-C 107.801 -1.185 . . . . 75.12 107.801 170.548 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -90.74 -177.89 43.85 Favored Glycine 0 C--N 1.338 0.682 0 O-C-N 123.34 0.4 . . . . 50.12 113.245 176.249 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 248' ' ' ASP . . . . . 0.428 ' HB3' ' HG3' ' A' ' 234' ' ' ARG . 60.9 m-20 -136.01 142.5 44.48 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.82 0.848 . . . . 70.34 109.189 -175.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.534 HD23 HD12 ' A' ' 235' ' ' LEU . 19.3 tp -97.53 112.97 24.6 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 109.346 -0.613 . . . . 62.24 109.346 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -90.29 105.86 18.1 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 108.754 -0.832 . . . . 75.02 108.754 176.509 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.505 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 93.6 mt -87.92 110.77 20.8 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.376 0.67 . . . . 52.23 112.01 176.746 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -79.06 92.98 5.06 Favored 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 109.117 -0.697 . . . . 75.25 109.117 -178.662 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 70.6 t -48.04 117.66 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 C-N-CA 124.911 1.284 . . . . 75.15 110.997 173.874 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 26.3 mmm180 -128.98 101.24 5.97 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 106.435 -1.691 . . . . 72.44 106.435 174.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 60.4 mt -77.17 117.51 22.24 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 CA-C-N 115.582 -0.735 . . . . 75.44 110.94 -172.001 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 3.3 t . . . . . 0 CA--C 1.559 1.326 0 C-N-CA 124.092 0.957 . . . . 72.21 109.211 177.725 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.403 ' HB2' ' H ' ' A' ' 139' ' ' GLU . . . . . . . . 0 N--CA 1.471 0.578 0 N-CA-C 108.742 -0.836 . . . . 74.32 108.742 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.74 -54.34 6.2 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.213 0.605 . . . . 61.51 111.531 -171.468 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.625 ' HG ' ' HG2' ' A' ' 136' ' ' ARG . 89.0 mt -82.86 -71.93 0.47 Allowed 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 109.844 -0.428 . . . . 61.12 109.844 177.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.472 ' HB ' HG23 ' A' ' 138' ' ' VAL . 30.0 t -58.89 131.13 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 C-N-CA 123.574 0.749 . . . . 50.55 111.798 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -70.67 -52.52 20.6 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.322 -0.853 . . . . 73.45 109.732 176.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -179.96 174.99 0.85 Allowed 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.556 1.142 . . . . 75.35 109.266 -178.124 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 88.7 t -65.19 132.16 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 N-CA-C 108.762 -0.829 . . . . 72.21 108.762 171.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.431 HG23 ' HA ' ' A' ' 121' ' ' ALA . 24.5 p -63.48 90.61 0.05 OUTLIER 'General case' 0 CA--C 1.547 0.842 0 CA-C-O 121.557 0.694 . . . . 71.11 110.962 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.0 p -76.57 91.67 3.41 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 114.741 -1.118 . . . . 43.3 109.154 176.621 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -172.37 159.7 30.73 Favored Glycine 0 C--N 1.339 0.696 0 CA-C-N 115.265 -0.88 . . . . 44.45 112.132 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 49.8 m -121.93 142.75 49.96 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.045 0.938 . . . . 60.32 109.285 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 178.39 -114.3 0.45 Allowed Glycine 0 C--N 1.339 0.716 0 N-CA-C 111.584 -0.606 . . . . 30.11 111.584 -179.309 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -107.73 107.94 2.67 Favored Glycine 0 C--N 1.341 0.814 0 N-CA-C 112.12 -0.392 . . . . 73.21 112.12 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 42.6 p -75.25 158.78 32.39 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 123.269 0.627 . . . . 64.55 110.135 175.157 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -68.41 149.82 50.22 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 123.196 0.31 . . . . 72.44 112.441 176.736 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -88.01 17.34 47.07 Favored Glycine 0 C--N 1.344 0.982 0 CA-C-O 119.975 -0.347 . . . . 50.24 113.076 178.329 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 41.3 t -84.0 -71.13 0.52 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.816 0.846 . . . . 75.53 109.599 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 65.68 -97.89 0.31 Allowed Glycine 0 C--N 1.351 1.393 0 O-C-N 123.475 0.485 . . . . 62.53 112.317 -178.324 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.74 -169.59 50.16 Favored Glycine 0 C--N 1.35 1.31 0 O-C-N 123.72 0.306 . . . . 62.21 112.782 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 25.2 m -77.59 147.27 35.75 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 123.223 0.609 . . . . 54.11 109.463 173.671 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 91.87 139.23 8.56 Favored Glycine 0 C--N 1.347 1.174 0 N-CA-C 112.032 -0.427 . . . . 50.41 112.032 -178.684 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 2.2 tmm_? -76.59 118.85 19.66 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.379 -0.6 . . . . 75.42 109.379 -176.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -89.1 146.23 24.95 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 123.717 0.807 . . . . 73.31 110.816 -179.062 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.49 HD22 HD13 ' A' ' 174' ' ' LEU . 4.9 tt -136.89 149.07 47.43 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 106.611 -1.626 . . . . 53.41 106.611 -179.312 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.435 ' N ' HD23 ' A' ' 119' ' ' LEU . 0.1 OUTLIER -138.11 148.69 45.23 Favored 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 119.335 0.97 . . . . 71.24 110.351 179.533 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.431 ' HA ' HG23 ' A' ' 103' ' ' THR . . . -156.89 163.26 39.37 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.525 1.13 . . . . 71.23 108.709 -177.798 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -126.45 151.56 47.59 Favored 'General case' 0 C--O 1.248 0.99 0 CA-C-O 121.063 0.459 . . . . 73.02 110.224 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.473 HD12 ' HB3' ' A' ' 98' ' ' LEU . 1.6 pt? -140.41 135.02 15.65 Favored Pre-proline 0 N--CA 1.468 0.451 0 CA-C-N 115.681 -0.691 . . . . 73.34 111.593 -174.6 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -66.09 114.55 3.05 Favored 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 121.781 1.654 . . . . 72.25 110.351 161.152 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.461 HD22 HG11 ' A' ' 178' ' ' VAL . 16.1 tp -115.48 166.29 12.05 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.313 1.045 . . . . 71.55 108.222 175.443 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 17.6 m -108.74 161.53 15.02 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.208 0.603 . . . . 70.12 109.46 174.469 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.491 HD11 ' O ' ' A' ' 183' ' ' HIS . 30.8 mt -55.97 -51.94 65.94 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.808 0.843 . . . . 61.13 109.7 173.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.574 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.9 mp0 -57.36 -38.38 74.07 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 114.408 -1.269 . . . . 72.4 111.667 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -76.83 -21.86 54.42 Favored 'General case' 0 N--CA 1.479 1.025 0 C-N-CA 123.362 0.665 . . . . 70.21 111.672 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.624 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -71.85 -25.82 62.12 Favored 'General case' 0 C--O 1.249 1.073 0 C-N-CA 123.704 0.802 . . . . 51.44 110.94 170.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.521 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 36.9 t80 -82.39 -47.39 12.36 Favored 'General case' 0 C--N 1.35 0.602 0 CA-C-N 115.477 -0.783 . . . . 75.25 111.736 171.601 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -74.32 -47.46 34.43 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 123.237 0.335 . . . . 74.43 111.338 -172.093 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.16 -153.09 52.63 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 111.183 -0.767 . . . . 74.24 111.183 -168.441 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 119.46 -175.96 15.96 Favored Glycine 0 C--N 1.343 0.953 0 N-CA-C 114.379 0.511 . . . . 51.14 114.379 171.149 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.619 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.7 mp0 -90.74 136.28 33.17 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.993 0.917 . . . . 65.34 109.372 -177.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.625 ' HG2' ' HG ' ' A' ' 98' ' ' LEU . 0.2 OUTLIER -153.11 150.89 29.57 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 110.375 -0.231 . . . . 75.2 110.375 176.059 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 25.3 m -75.87 136.82 24.03 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 123.251 0.62 . . . . 70.13 111.836 -173.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.472 HG23 ' HB ' ' A' ' 99' ' ' VAL . 5.8 p -142.86 135.9 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 C-N-CA 124.212 1.005 . . . . 72.25 111.297 178.158 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' GLU . . . . . 0.403 ' H ' ' HB2' ' A' ' 96' ' ' ALA . 1.4 mp0 -100.37 98.39 9.04 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 109.483 -0.562 . . . . 75.42 109.483 169.597 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.0 m -108.36 124.87 65.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 N-CA-C 108.895 -0.78 . . . . 72.33 108.895 171.61 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.09 21.83 13.09 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 124.324 1.05 . . . . 61.51 111.436 -174.086 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.28 -1.78 86.38 Favored Glycine 0 C--N 1.356 1.656 0 CA-C-N 115.835 -0.62 . . . . 61.42 113.238 -178.663 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.3 mmt85 -94.3 117.11 29.62 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 123.207 0.603 . . . . 72.02 109.905 -178.295 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 43.1 ttm180 -84.9 115.94 23.05 Favored 'General case' 0 C--N 1.352 0.705 0 N-CA-C 109.756 -0.461 . . . . 73.42 109.756 175.702 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 12.2 m -136.68 155.27 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 C-N-CA 125.136 1.375 . . . . 74.33 108.708 177.698 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 60.8 p -86.81 114.98 23.93 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 109.139 -0.689 . . . . 73.52 109.139 174.134 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.0 p -96.15 124.67 48.96 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 CA-C-O 121.172 0.51 . . . . 71.1 109.924 176.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' ARG . . . . . 0.619 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 13.7 ttp180 -99.03 104.94 17.01 Favored 'General case' 0 C--O 1.244 0.799 0 N-CA-C 108.841 -0.8 . . . . 71.03 108.841 175.511 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 32.7 pt -95.63 131.3 29.71 Favored Pre-proline 0 CA--C 1.548 0.878 0 N-CA-C 108.737 -0.838 . . . . 72.21 108.737 174.673 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -71.39 146.1 49.57 Favored 'Trans proline' 0 C--N 1.371 1.728 0 C-N-CA 122.554 2.169 . . . . 63.21 112.923 -174.697 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.64 142.5 89.84 Favored 'Trans proline' 0 C--N 1.378 2.108 0 C-N-CA 122.881 2.387 . . . . 75.13 111.425 172.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.71 52.39 0.75 Allowed Glycine 0 C--N 1.339 0.709 0 N-CA-C 110.7 -0.96 . . . . 53.55 110.7 -173.246 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.624 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.3 p -130.65 162.12 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 108.165 -1.05 . . . . 72.01 108.165 179.581 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.6 ' HA ' HD11 ' A' ' 180' ' ' LEU . 0.0 OUTLIER -162.37 173.67 13.81 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 124.925 1.29 . . . . 73.35 110.379 -179.352 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.4 tp10 -47.3 118.38 2.15 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 124.601 1.16 . . . . 70.24 112.711 -176.607 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 100.5 -24.86 30.47 Favored Glycine 0 C--N 1.349 1.296 0 CA-C-O 119.153 -0.804 . . . . 53.2 113.562 178.797 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.56 ' HB2' HG23 ' A' ' 153' ' ' VAL . 43.6 m -60.09 125.7 24.68 Favored 'General case' 0 C--O 1.248 0.998 0 C-N-CA 123.34 0.656 . . . . 63.21 111.127 -174.493 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.532 HG22 HD22 ' A' ' 175' ' ' LEU . 14.8 p -100.57 123.21 53.37 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.095 0 CA-C-N 114.801 -1.091 . . . . 64.1 109.071 -179.027 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.424 HD11 HG21 ' A' ' 153' ' ' VAL . 25.9 mt -105.38 112.97 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.329 1.052 . . . . 64.41 109.545 -170.166 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 34.6 ttt-85 -92.75 105.32 17.48 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 122.822 0.449 . . . . 74.23 110.256 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.426 HG22 ' HB3' ' A' ' 174' ' ' LEU . 10.5 m -97.79 112.38 61.41 Favored Pre-proline 0 CA--C 1.561 1.396 0 N-CA-C 108.072 -1.084 . . . . 72.35 108.072 176.209 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 162' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 7.6 Cg_exo -73.65 156.22 49.26 Favored 'Trans proline' 0 C--N 1.374 1.875 0 C-N-CA 123.132 2.555 . . . . 75.21 113.213 -171.598 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 66.09 24.44 71.79 Favored Glycine 0 C--N 1.347 1.188 0 O-C-N 123.715 0.635 . . . . 52.54 114.14 177.367 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.6 tpt -101.8 -63.21 1.17 Allowed 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.293 0.637 . . . . 74.41 111.288 -170.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -68.48 -62.8 3.89 Favored Glycine 0 C--N 1.353 1.514 0 N-CA-C 111.412 -0.675 . . . . 51.14 111.412 178.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.602 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -69.72 99.77 0.7 Allowed Glycine 0 C--N 1.341 0.822 0 CA-C-N 115.121 -0.54 . . . . 62.3 111.87 173.048 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -89.25 169.51 11.38 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.579 0.752 . . . . 75.5 110.56 176.632 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 89.57 -143.28 17.13 Favored Glycine 0 C--O 1.242 0.622 0 N-CA-C 111.344 -0.703 . . . . 44.45 111.344 -174.111 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 29.5 p-10 -92.23 -13.56 0.19 Allowed Pre-proline 0 CA--C 1.563 1.453 0 N-CA-C 114.8 1.407 . . . . 54.03 114.8 175.447 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -91.53 101.75 0.23 Allowed 'Trans proline' 0 C--N 1.398 3.145 0 CA-C-N 123.099 2.142 . . . . 71.33 110.997 165.714 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -73.22 126.72 11.33 Favored 'Trans proline' 0 C--N 1.371 1.749 0 C-N-CA 122.421 2.081 . . . . 72.05 112.108 -176.595 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.602 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -99.89 -137.09 9.64 Favored Glycine 0 C--N 1.342 0.916 0 N-CA-C 111.156 -0.778 . . . . 71.33 111.156 176.761 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -167.38 165.55 14.92 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 117.377 0.588 . . . . 75.14 111.245 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.49 HD13 HD22 ' A' ' 119' ' ' LEU . 35.5 tp -124.98 122.63 37.86 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 114.822 -1.081 . . . . 70.33 108.191 166.844 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.532 HD22 HG22 ' A' ' 158' ' ' VAL . 30.2 mt -95.17 101.42 13.16 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.542 1.137 . . . . 52.42 110.188 178.535 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 56.5 mt -93.5 105.42 17.47 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.56 0.744 . . . . 72.04 111.653 178.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 15.4 t -88.66 108.36 18.77 Favored 'Isoleucine or valine' 0 C--O 1.246 0.876 0 N-CA-C 108.977 -0.749 . . . . 60.04 108.977 176.286 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.461 HG11 HD22 ' A' ' 125' ' ' LEU . 25.5 m -77.69 148.3 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 N-CA-C 112.991 0.738 . . . . 62.42 112.991 -176.779 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -124.08 96.89 5.11 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 113.91 -1.495 . . . . 71.04 107.613 175.321 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.6 HD11 ' HA ' ' A' ' 154' ' ' ARG . 35.1 mt -69.09 147.74 51.02 Favored 'General case' 0 C--O 1.241 0.624 0 O-C-N 123.132 0.27 . . . . 63.34 110.725 -179.246 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.413 ' HA ' ' HD3' ' A' ' 182' ' ' PRO . 40.8 mt -54.13 128.55 57.51 Favored Pre-proline 0 CA--C 1.551 0.988 0 O-C-N 124.354 1.034 . . . . 54.11 110.055 177.745 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 31.7 Cg_exo -60.27 82.04 0.07 OUTLIER 'Trans proline' 0 C--N 1.377 2.034 0 C-N-CA 123.792 2.994 . . . . 65.32 113.563 -176.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 183' ' ' HIS . . . . . 0.491 ' O ' HD11 ' A' ' 127' ' ' LEU . 2.3 p80 -170.05 109.08 0.45 Allowed Pre-proline 0 CA--C 1.551 0.986 0 N-CA-C 106.652 -1.61 . . . . 71.22 106.652 171.521 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -89.52 127.31 1.63 Allowed 'Trans proline' 0 C--N 1.36 1.159 0 C-N-CA 122.096 1.864 . . . . 64.11 112.622 178.783 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 5.2 p -137.21 -47.78 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 109.515 -0.55 . . . . 64.12 109.515 168.586 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -109.84 123.55 49.76 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 121.436 0.636 . . . . 72.1 111.731 -176.765 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.478 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 0.1 OUTLIER -113.47 162.5 16.06 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.672 1.589 . . . . 71.4 109.351 -179.461 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.437 HD12 ' O ' ' A' ' 192' ' ' ASP . 43.2 tp -130.49 136.71 49.25 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 123.665 0.786 . . . . 64.31 109.958 179.832 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.476 ' HB3' ' CE1' ' A' ' 194' ' ' TYR . 10.0 tp10 -142.07 109.94 5.82 Favored 'General case' 0 C--O 1.242 0.683 0 C-N-CA 124.184 0.994 . . . . 73.32 108.345 176.147 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 72.22 -83.33 0.53 Allowed Glycine 0 C--N 1.347 1.153 0 N-CA-C 111.447 -0.661 . . . . 64.4 111.447 -174.468 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 191' ' ' GLN . . . . . 0.539 ' NE2' ' HB3' ' A' ' 244' ' ' ALA . 29.7 pt20 -141.74 -8.26 0.95 Allowed 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.85 0.86 . . . . 72.23 110.017 178.206 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.437 ' O ' HD12 ' A' ' 188' ' ' LEU . 17.1 m-20 -93.88 156.35 16.69 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.447 0.699 . . . . 75.21 111.169 -171.406 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.469 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 90.4 mt -104.59 150.89 24.26 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 124.816 1.246 . . . . 53.41 108.913 -177.856 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 194' ' ' TYR . . . . . 0.478 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 77.4 m-85 -138.26 128.39 25.75 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 107.167 -1.42 . . . . 72.4 107.167 -177.687 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -154.18 171.27 19.44 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 123.842 0.857 . . . . 62.34 109.197 -176.719 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 14.6 m -120.41 135.28 55.09 Favored 'General case' 0 C--O 1.238 0.5 0 N-CA-C 108.867 -0.79 . . . . 74.11 108.867 176.663 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.558 HD23 HD12 ' A' ' 233' ' ' LEU . 70.1 tp -123.63 114.18 19.66 Favored 'General case' 0 C--O 1.217 -0.62 0 C-N-CA 124.112 0.965 . . . . 63.31 109.542 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -84.78 119.78 25.69 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 108.266 -1.012 . . . . 75.52 108.266 171.032 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 84.2 t -110.22 126.4 29.02 Favored Pre-proline 0 N--CA 1.469 0.486 0 N-CA-C 108.632 -0.877 . . . . 72.01 108.632 -178.543 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -54.56 133.33 56.2 Favored 'Trans proline' 0 C--N 1.375 1.958 0 C-N-CA 122.767 2.311 . . . . 64.51 110.903 172.4 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -51.68 -45.37 91.52 Favored Pre-proline 0 CA--C 1.556 1.191 0 C-N-CA 124.568 1.147 . . . . 71.21 113.685 -175.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -53.41 -45.53 40.35 Favored 'Trans proline' 0 C--N 1.39 2.751 0 C-N-CA 121.841 1.694 . . . . 74.23 113.666 173.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 203' ' ' ILE . . . . . 0.437 HG21 HG13 ' A' ' 210' ' ' VAL . 8.7 mt -67.62 -37.71 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 C-N-CA 122.386 0.274 . . . . 75.15 111.276 178.437 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -67.19 -34.53 77.7 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 122.977 0.511 . . . . 42.32 112.319 -176.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.3 m -83.77 -39.17 14.74 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 CA-C-N 116.159 -0.473 . . . . 54.22 111.052 -177.593 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m -82.68 -24.81 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-N 118.12 0.418 . . . . 72.03 110.939 179.676 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 79.02 67.54 1.58 Allowed Glycine 0 C--N 1.341 0.813 0 CA-C-N 116.084 -0.507 . . . . 72.51 112.493 -177.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -101.46 -147.23 19.95 Favored Glycine 0 C--N 1.35 1.31 0 CA-C-N 116.854 0.327 . . . . 64.24 112.337 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 59.1 pttt -127.64 138.19 52.76 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 124.319 1.048 . . . . 64.51 109.43 -177.528 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 210' ' ' VAL . . . . . 0.437 HG13 HG21 ' A' ' 203' ' ' ILE . 17.9 m -126.28 143.74 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.117 0.967 . . . . 73.34 109.179 175.31 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 10.0 mpt_? -85.36 107.16 17.23 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 108.958 -0.756 . . . . 63.04 108.958 174.253 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.6 117.59 35.22 Favored 'General case' 0 CA--C 1.517 -0.31 0 N-CA-C 107.62 -1.252 . . . . 64.24 107.62 174.39 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 213' ' ' MET . . . . . 0.504 ' HA ' ' HA ' ' A' ' 218' ' ' PRO . 1.2 ppp? -79.38 138.23 37.59 Favored 'General case' 0 C--O 1.243 0.754 0 N-CA-C 109.29 -0.633 . . . . 74.22 109.29 179.003 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.527 HG23 ' HG2' ' A' ' 216' ' ' GLU . 4.5 t -128.9 174.95 9.04 Favored 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 124.155 0.982 . . . . 73.24 108.805 177.344 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 215' ' ' LEU . . . . . 0.574 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 73.9 mt -72.99 -3.34 25.46 Favored 'General case' 0 CA--C 1.549 0.929 0 N-CA-C 113.613 0.968 . . . . 70.32 113.613 -169.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 216' ' ' GLU . . . . . 0.527 ' HG2' HG23 ' A' ' 214' ' ' THR . 14.3 pt-20 -104.8 -4.62 22.07 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 123.806 0.842 . . . . 53.12 111.183 175.487 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 129.28 -174.09 19.35 Favored Glycine 0 C--N 1.344 0.982 0 N-CA-C 110.686 -0.966 . . . . 63.23 110.686 -172.073 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 218' ' ' PRO . . . . . 0.504 ' HA ' ' HA ' ' A' ' 213' ' ' MET . 2.2 Cg_endo -81.84 133.38 7.96 Favored 'Trans proline' 0 CA--C 1.55 1.283 0 C-N-CA 122.52 2.147 . . . . 65.22 112.13 179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 34.5 m -110.27 165.15 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.076 0 C-N-CA 123.077 0.551 . . . . 74.11 111.915 171.371 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -111.41 113.03 25.19 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 124.058 0.943 . . . . 74.23 109.011 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.567 HG22 HD11 ' A' ' 235' ' ' LEU . 21.8 t -97.19 117.65 42.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 123.439 0.696 . . . . 72.2 110.36 178.731 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -87.57 105.53 17.39 Favored 'General case' 0 C--O 1.239 0.519 0 N-CA-C 107.442 -1.318 . . . . 64.04 107.442 171.869 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 6.2 m -80.95 142.38 51.96 Favored Pre-proline 0 CA--C 1.553 1.085 0 N-CA-C 109.383 -0.599 . . . . 54.1 109.383 -177.578 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -62.62 144.28 93.98 Favored 'Trans proline' 0 C--N 1.371 1.725 0 C-N-CA 123.003 2.469 . . . . 54.15 112.977 177.022 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.04 122.99 10.94 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.411 2.074 . . . . 73.3 111.306 174.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 73.5 mtt180 67.99 36.38 3.39 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.693 1.197 . . . . 65.45 110.822 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 227' ' ' THR . . . . . 0.509 HG23 HD11 ' A' ' 255' ' ' ILE . 9.3 t -67.53 172.06 5.49 Favored 'General case' 0 CA--C 1.551 1.017 0 CA-C-N 115.865 -0.607 . . . . 64.41 110.86 -178.585 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.2 mp0 -117.51 138.03 52.16 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.645 0.778 . . . . 60.44 109.623 -174.314 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -66.66 114.64 5.73 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.365 0.666 . . . . 54.13 110.046 176.317 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.79 3.71 19.86 Favored Glycine 0 C--N 1.336 0.549 0 CA-C-N 115.897 -0.592 . . . . 70.11 112.251 -176.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 231' ' ' ARG . . . . . 0.414 ' O ' HG12 ' A' ' 253' ' ' VAL . 57.3 mtp180 -78.39 161.83 26.87 Favored 'General case' 0 C--O 1.243 0.725 0 CA-C-O 121.684 0.754 . . . . 64.23 110.838 173.129 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.429 ' HD2' ' N ' ' A' ' 232' ' ' LYS . 0.1 OUTLIER -99.96 100.7 11.64 Favored 'General case' 0 C--O 1.24 0.565 0 CA-C-N 114.235 -1.348 . . . . 74.01 108.367 -178.447 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 233' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 33.3 mt -84.53 97.71 9.72 Favored 'General case' 0 C--N 1.351 0.646 0 N-CA-C 105.217 -2.142 . . . . 74.43 105.217 173.826 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 234' ' ' ARG . . . . . 0.469 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 51.6 ttp85 -96.13 103.64 15.54 Favored 'General case' 0 C--O 1.24 0.593 0 CA-C-N 114.781 -1.099 . . . . 72.5 109.437 -165.854 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.585 HD12 HD23 ' A' ' 249' ' ' LEU . 20.2 mt -85.02 97.83 10.06 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.589 -1.263 . . . . 75.21 107.589 177.664 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 10.4 mtmp? -69.43 135.97 50.96 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 114.639 -1.164 . . . . 71.11 111.479 -169.67 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 80.17 13.82 81.39 Favored Glycine 0 C--N 1.347 1.194 0 O-C-N 123.577 0.548 . . . . 32.31 113.354 177.395 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 238' ' ' LYS . . . . . 0.676 ' HE2' ' HA ' ' A' ' 238' ' ' LYS . 9.3 mmpt? -96.98 -18.79 19.21 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 122.877 0.471 . . . . 71.45 112.222 -178.318 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 239' ' ' GLY . . . . . 0.466 ' HA2' ' HG ' ' A' ' 193' ' ' LEU . . . -82.75 169.64 49.02 Favored Glycine 0 C--N 1.338 0.689 0 N-CA-C 112.028 -0.429 . . . . 63.04 112.028 176.688 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.521 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 98.0 m-85 -66.06 154.91 88.69 Favored Pre-proline 0 N--CA 1.479 0.994 0 C-N-CA 123.45 0.7 . . . . 74.22 111.933 -172.849 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -66.55 128.13 18.55 Favored 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 121.948 1.765 . . . . 64.35 110.289 165.163 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -151.5 -159.02 8.65 Favored Glycine 0 N--CA 1.465 0.632 0 CA-C-O 119.714 -0.492 . . . . 65.3 112.732 -178.591 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -65.95 -13.02 37.92 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.375 2.716 . . . . 65.41 114.324 -170.358 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 244' ' ' ALA . . . . . 0.539 ' HB3' ' NE2' ' A' ' 191' ' ' GLN . . . -116.9 25.03 10.81 Favored 'General case' 0 N--CA 1.482 1.126 0 C-N-CA 122.86 0.464 . . . . 62.43 110.684 178.767 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 102.87 -101.92 2.17 Favored Glycine 0 C--N 1.348 1.206 0 CA-C-O 119.764 -0.465 . . . . 62.1 112.149 174.44 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 9.5 ttm180 -124.43 155.31 39.09 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 108.573 -0.899 . . . . 74.33 108.573 173.092 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -94.74 -173.48 38.01 Favored Glycine 0 C--N 1.335 0.511 0 CA-C-O 121.271 0.373 . . . . 54.13 113.114 -177.754 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -135.95 168.06 20.04 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 108.062 -1.088 . . . . 70.22 108.062 -177.342 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.585 HD23 HD12 ' A' ' 235' ' ' LEU . 16.7 tp -104.96 124.16 49.03 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 122.786 0.434 . . . . 71.12 110.366 173.037 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 250' ' ' TYR . . . . . 0.433 ' HB3' ' HA ' ' A' ' 194' ' ' TYR . 11.6 t80 -89.3 108.53 19.68 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 124.62 1.168 . . . . 74.32 108.077 171.232 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 65.7 mt -96.89 120.83 37.97 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.793 -0.447 . . . . 70.11 109.793 164.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -83.55 94.41 8.05 Favored 'General case' 0 C--O 1.237 0.41 0 N-CA-C 108.012 -1.107 . . . . 72.32 108.012 168.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 231' ' ' ARG . 2.3 p -59.48 126.9 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 CA-C-O 121.291 0.567 . . . . 71.21 110.203 177.513 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 10.2 mmm180 -127.19 94.74 4.09 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 107.299 -1.371 . . . . 75.12 107.299 -177.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.509 HD11 HG23 ' A' ' 227' ' ' THR . 64.6 mt -74.77 120.04 23.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 115.193 -0.912 . . . . 73.1 109.74 -172.54 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.4 t . . . . . 0 CA--C 1.557 1.214 0 C-N-CA 125.161 1.384 . . . . 73.4 108.506 -174.129 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.955 0 N-CA-C 110.17 -0.307 . . . . 52.3 110.17 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.513 ' HB1' HG13 ' A' ' 137' ' ' VAL . . . -73.41 -98.25 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.078 0 C-N-CA 124.049 0.94 . . . . 74.15 109.867 174.032 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.531 HD11 HD13 ' A' ' 149' ' ' ILE . 0.9 OUTLIER -124.79 49.18 1.87 Allowed 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 107.038 -1.468 . . . . 72.11 107.038 170.153 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.507 HG23 ' HB1' ' A' ' 121' ' ' ALA . 2.9 p -173.88 131.39 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-N 113.72 -1.582 . . . . 61.53 109.006 -176.12 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.482 ' HB2' ' HD3' ' A' ' 124' ' ' PRO . . . -94.09 -46.85 6.94 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 123.264 0.626 . . . . 62.25 110.072 174.441 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 2.1 p80 -163.45 151.72 13.59 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 115.653 -0.703 . . . . 62.22 111.18 -178.343 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 93.5 t -73.79 126.57 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.021 0.929 . . . . 64.0 109.168 175.009 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 10.1 t -128.88 83.45 2.15 Favored 'General case' 0 CA--C 1.547 0.838 0 CA-C-O 122.357 1.075 . . . . 62.21 110.127 -178.277 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.2 t -64.6 -32.95 74.82 Favored 'General case' 0 CA--C 1.547 0.828 0 CA-C-N 115.571 -0.741 . . . . 72.2 110.259 175.55 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 74.86 -82.46 0.85 Allowed Glycine 0 C--N 1.356 1.644 0 CA-C-N 115.586 -0.734 . . . . 50.3 112.181 179.413 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 88.5 p -165.64 164.04 19.15 Favored 'General case' 0 C--O 1.246 0.909 0 C-N-CA 124.222 1.009 . . . . 74.32 109.544 175.297 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.12 147.4 28.84 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.761 -0.654 . . . . 62.13 111.678 175.264 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.48 137.16 4.09 Favored Glycine 0 C--N 1.338 0.688 0 N-CA-C 111.767 -0.533 . . . . 33.43 111.767 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 25.5 t -86.57 81.4 8.28 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 123.028 0.531 . . . . 53.52 109.861 178.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -72.25 -28.49 68.01 Favored Glycine 0 C--N 1.345 1.058 0 CA-C-N 115.432 -0.804 . . . . 61.41 112.518 176.16 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -175.61 -140.95 3.58 Favored Glycine 0 C--N 1.342 0.882 0 N-CA-C 110.684 -0.966 . . . . 74.12 110.684 177.446 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 67.0 m -99.55 113.82 26.46 Favored 'General case' 0 C--O 1.241 0.65 0 N-CA-C 108.945 -0.761 . . . . 62.14 108.945 173.018 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -87.28 53.24 4.4 Favored Glycine 0 C--N 1.349 1.253 0 N-CA-C 111.751 -0.54 . . . . 72.04 111.751 179.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.67 80.38 1.19 Allowed Glycine 0 C--N 1.349 1.298 0 N-CA-C 111.799 -0.52 . . . . 31.3 111.799 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 21.2 t -158.01 -169.48 2.83 Favored 'General case' 0 C--O 1.243 0.724 0 C-N-CA 123.859 0.863 . . . . 72.02 109.024 -174.506 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -74.98 -165.38 14.32 Favored Glycine 0 C--N 1.344 1.027 0 N-CA-C 111.748 -0.541 . . . . 43.31 111.748 167.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 -61.59 121.9 13.92 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 122.762 0.425 . . . . 65.44 110.73 176.757 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -69.58 133.62 47.84 Favored 'General case' 0 N--CA 1.472 0.638 0 O-C-N 124.58 1.175 . . . . 54.04 109.299 172.125 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.461 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 33.4 tp -136.35 121.33 18.8 Favored 'General case' 0 C--O 1.215 -0.755 0 N-CA-C 106.595 -1.631 . . . . 72.2 106.595 -175.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -121.34 131.88 54.45 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.603 -0.517 . . . . 73.33 109.603 -171.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.507 ' HB1' HG23 ' A' ' 99' ' ' VAL . . . -153.12 146.81 25.14 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.294 0.637 . . . . 65.11 109.701 -177.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -126.16 152.98 45.25 Favored 'General case' 0 C--O 1.244 0.768 0 CA-C-O 121.081 0.467 . . . . 54.21 110.49 177.062 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -145.5 148.58 37.6 Favored Pre-proline 0 N--CA 1.471 0.583 0 CA-C-N 114.933 -1.031 . . . . 71.13 110.362 -177.119 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.482 ' HD3' ' HB2' ' A' ' 100' ' ' ALA . 4.0 Cg_exo -73.86 115.31 4.28 Favored 'Trans proline' 0 C--N 1.37 1.695 0 C-N-CA 121.561 1.507 . . . . 73.23 110.151 167.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 23.8 tp -105.84 148.47 27.52 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 108.378 -0.971 . . . . 74.02 108.378 175.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.765 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 24.7 m -76.38 147.23 38.18 Favored 'General case' 0 CA--C 1.547 0.853 0 N-CA-C 109.963 -0.384 . . . . 51.53 109.963 173.915 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.532 HD23 ' HB3' ' A' ' 180' ' ' LEU . 96.6 mt -52.73 -51.42 60.57 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 121.822 0.82 . . . . 65.22 110.48 172.786 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.594 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -55.76 -28.83 58.01 Favored 'General case' 0 CA--C 1.551 1.003 0 CA-C-N 113.947 -1.479 . . . . 61.33 112.451 177.211 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.68 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 22.1 mm-40 -86.24 -21.44 27.41 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 118.18 0.446 . . . . 73.3 111.679 178.14 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.655 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -61.13 -34.67 75.36 Favored 'General case' 0 C--O 1.239 0.546 0 CA-C-O 121.268 0.556 . . . . 72.34 110.059 164.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.639 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 57.8 t80 -76.42 -50.84 13.1 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 114.823 -1.08 . . . . 71.41 112.887 172.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -75.27 -49.21 19.97 Favored 'General case' 0 N--CA 1.486 1.33 0 C-N-CA 122.338 0.255 . . . . 63.25 111.651 -170.364 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.15 -161.61 44.33 Favored Glycine 0 CA--C 1.535 1.331 0 CA-C-O 119.905 -0.386 . . . . 71.54 112.153 -173.518 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 128.63 -169.66 20.08 Favored Glycine 0 N--CA 1.476 1.305 0 CA-C-N 117.307 0.554 . . . . 52.32 114.272 171.03 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -94.61 121.34 36.07 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 124.156 0.982 . . . . 72.3 108.592 -178.129 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -130.66 167.32 18.96 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.759 0.823 . . . . 53.41 108.977 172.743 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.513 HG13 ' HB1' ' A' ' 97' ' ' ALA . 13.0 p -90.53 142.14 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 108.736 -0.839 . . . . 70.31 108.736 179.152 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.479 HG22 HG23 ' A' ' 140' ' ' VAL . 8.8 p -131.05 136.59 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 N-CA-C 108.863 -0.792 . . . . 71.53 108.863 177.522 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' GLU . . . . . 0.459 ' HA ' ' O ' ' A' ' 143' ' ' ARG . 36.6 tt0 -126.6 97.83 5.17 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.854 -0.425 . . . . 63.21 109.854 172.483 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.479 HG23 HG22 ' A' ' 138' ' ' VAL . 22.9 t -122.13 138.26 52.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 108.208 -1.034 . . . . 65.24 108.208 174.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 64.52 21.58 12.48 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 124.712 1.205 . . . . 70.13 111.341 -176.61 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.59 13.71 82.9 Favored Glycine 0 C--N 1.352 1.452 0 CA-C-N 116.056 -0.52 . . . . 64.22 113.631 -179.198 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.459 ' O ' ' HA ' ' A' ' 139' ' ' GLU . 72.5 mtt180 -108.71 117.67 34.79 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.29 0.636 . . . . 74.34 109.468 179.217 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 21.7 ttm180 -105.35 105.35 15.35 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 109.842 -0.429 . . . . 72.53 109.842 -176.648 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 61.1 t -129.92 141.98 45.01 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.53 1.132 . . . . 63.53 108.291 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.427 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 72.0 p -72.2 111.12 7.14 Favored 'General case' 0 CA--C 1.546 0.817 0 N-CA-C 109.022 -0.733 . . . . 74.44 109.022 174.212 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.2 p -96.82 147.4 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 C-N-CA 123.884 0.874 . . . . 72.24 109.327 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -109.03 127.45 54.11 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 107.888 -1.152 . . . . 71.32 107.888 171.281 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.531 HD13 HD11 ' A' ' 98' ' ' LEU . 38.1 pt -120.62 124.73 27.45 Favored Pre-proline 0 CA--C 1.547 0.858 0 N-CA-C 107.873 -1.158 . . . . 71.42 107.873 170.016 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -72.13 153.5 57.12 Favored 'Trans proline' 0 C--N 1.373 1.847 0 C-N-CA 122.346 2.031 . . . . 71.12 113.021 -173.061 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -65.59 147.68 86.63 Favored 'Trans proline' 0 C--N 1.373 1.852 0 C-N-CA 122.282 1.988 . . . . 62.43 111.428 170.041 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 101.42 53.38 1.0 Allowed Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.123 -1.191 . . . . 75.11 110.123 -171.502 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.655 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -128.49 161.04 38.02 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.299 0 N-CA-C 108.191 -1.041 . . . . 51.32 108.191 -179.459 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -146.16 171.39 15.0 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 124.206 1.002 . . . . 43.02 110.502 -165.562 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -56.59 125.74 23.54 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 123.416 0.686 . . . . 73.22 110.426 169.517 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.83 -6.0 56.21 Favored Glycine 0 C--N 1.347 1.151 0 CA-C-O 119.362 -0.688 . . . . 63.1 113.921 179.73 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 47.8 t -67.06 129.11 38.82 Favored 'General case' 0 C--N 1.359 0.987 0 C-N-CA 123.404 0.682 . . . . 75.41 109.548 -178.06 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.469 HG12 HD22 ' A' ' 175' ' ' LEU . 13.7 t -104.98 118.25 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 O-C-N 124.83 1.331 . . . . 74.11 109.102 -171.218 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.457 HD11 HG21 ' A' ' 153' ' ' VAL . 28.1 mt -104.51 111.31 33.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 123.878 0.871 . . . . 74.42 109.71 -171.311 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 54.9 ttt180 -81.35 117.89 22.2 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.573 0.749 . . . . 70.44 110.643 177.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.641 HG22 ' HB3' ' A' ' 174' ' ' LEU . 2.9 m -118.04 117.14 35.51 Favored Pre-proline 0 CA--C 1.557 1.224 0 N-CA-C 109.093 -0.706 . . . . 73.3 109.093 170.687 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -81.26 149.69 17.2 Favored 'Trans proline' 0 C--N 1.377 2.042 0 C-N-CA 122.473 2.116 . . . . 73.04 112.663 -177.538 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 82.1 24.71 54.26 Favored Glycine 0 C--N 1.349 1.286 0 CA-C-N 115.925 -0.579 . . . . 75.13 113.649 177.383 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 54.9 tpp -109.8 -57.68 2.15 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.545 0.738 . . . . 71.32 110.68 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -70.12 -82.87 0.2 Allowed Glycine 0 C--N 1.356 1.657 0 N-CA-C 111.665 -0.574 . . . . 60.3 111.665 -179.755 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.742 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -63.91 113.45 5.89 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 112.329 -0.308 . . . . 52.01 112.329 166.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -87.74 172.16 9.88 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 124.189 0.995 . . . . 73.12 109.899 171.26 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 92.82 -135.77 12.83 Favored Glycine 0 C--N 1.342 0.864 0 N-CA-C 112.019 -0.433 . . . . 41.13 112.019 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 62.4 m-80 -81.15 -48.86 1.05 Allowed Pre-proline 0 CA--C 1.556 1.189 0 CA-C-O 117.68 -1.152 . . . . 71.13 111.779 177.052 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -71.02 113.61 3.63 Favored 'Trans proline' 0 C--N 1.399 3.193 0 C-N-CA 121.871 1.714 . . . . 60.43 111.546 176.363 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -74.85 125.97 9.76 Favored 'Trans proline' 0 C--N 1.381 2.244 0 C-N-CA 121.989 1.793 . . . . 54.22 111.52 -178.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.742 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -94.67 144.89 17.43 Favored Glycine 0 C--N 1.338 0.658 0 N-CA-C 112.096 -0.402 . . . . 74.03 112.096 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 173' ' ' ASP . . . . . 0.412 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 63.9 m-20 -106.39 116.47 31.99 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 123.035 0.534 . . . . 74.12 110.207 -169.561 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.641 ' HB3' HG22 ' A' ' 161' ' ' VAL . 47.3 tp -89.85 109.68 20.66 Favored 'General case' 0 C--O 1.235 0.338 0 N-CA-C 107.36 -1.348 . . . . 44.23 107.36 171.428 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.469 HD22 HG12 ' A' ' 158' ' ' VAL . 70.0 mt -89.88 98.91 12.04 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.085 1.354 . . . . 62.33 109.538 -179.416 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 84.0 mt -90.22 102.86 15.58 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 124.075 0.95 . . . . 71.02 110.876 179.694 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 35.1 t -86.91 105.25 14.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 N-CA-C 108.161 -1.051 . . . . 62.54 108.161 175.39 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 7.8 m -83.48 148.99 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 CA-C-O 121.551 0.691 . . . . 51.51 111.336 -178.388 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 179' ' ' ARG . . . . . 0.445 ' HB2' ' HA ' ' A' ' 124' ' ' PRO . 35.3 mmt180 -119.04 100.15 7.17 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 107.236 -1.394 . . . . 74.13 107.236 -178.492 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.532 ' HB3' HD23 ' A' ' 127' ' ' LEU . 41.7 mt -67.47 145.86 54.56 Favored 'General case' 0 C--O 1.239 0.514 0 O-C-N 122.938 0.149 . . . . 72.45 110.771 -176.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.765 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 26.5 mt -55.98 138.92 71.76 Favored Pre-proline 0 CA--C 1.548 0.897 0 O-C-N 123.603 0.564 . . . . 71.3 111.211 -177.034 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.8 67.55 4.79 Favored 'Trans proline' 0 C--N 1.377 2.036 0 C-N-CA 123.368 2.712 . . . . 73.25 113.668 -174.594 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 8.8 p80 -155.47 82.3 3.84 Favored Pre-proline 0 CA--C 1.557 1.247 0 N-CA-C 108.18 -1.044 . . . . 52.01 108.18 172.055 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -62.88 126.16 17.51 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 121.726 1.617 . . . . 72.33 111.548 -175.085 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.8 p -136.75 -48.14 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 108.103 -1.073 . . . . 74.4 108.103 174.384 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.494 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 4.2 m-85 -113.16 137.16 51.88 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.759 0.824 . . . . 64.43 110.554 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.572 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 2.7 mpt_? -125.09 154.39 41.46 Favored 'General case' 0 CA--C 1.537 0.446 0 N-CA-C 106.836 -1.542 . . . . 74.02 106.836 175.626 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 48.4 tp -134.43 137.9 44.37 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.305 -0.628 . . . . 71.02 109.305 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -142.07 115.89 9.23 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 107.592 -1.262 . . . . 71.1 107.592 169.311 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 66.71 -95.48 0.27 Allowed Glycine 0 C--N 1.346 1.13 0 O-C-N 123.779 0.674 . . . . 61.33 111.918 -175.282 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 191' ' ' GLN . . . . . 0.434 ' OE1' ' HD2' ' A' ' 243' ' ' PRO . 1.9 mp0 -120.63 -19.51 7.42 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.673 0.789 . . . . 71.41 110.267 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -83.03 144.01 30.23 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.438 0.695 . . . . 64.02 112.005 -171.421 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.512 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.6 mt -106.64 155.72 19.36 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 124.917 1.287 . . . . 74.24 108.239 177.379 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 194' ' ' TYR . . . . . 0.572 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 73.9 m-85 -139.9 121.84 15.59 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 107.117 -1.438 . . . . 74.34 107.117 -179.083 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -139.9 141.87 36.52 Favored 'General case' 0 CA--C 1.51 -0.58 0 N-CA-C 109.342 -0.614 . . . . 74.24 109.342 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 25.7 m -91.35 118.07 30.21 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 108.779 -0.823 . . . . 70.12 108.779 178.512 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.478 HD13 ' HB2' ' A' ' 212' ' ' ALA . 65.0 tp -105.94 113.3 26.76 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.714 0.805 . . . . 71.1 109.357 -178.154 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 198' ' ' ASP . . . . . 0.402 ' HA ' ' O ' ' A' ' 254' ' ' ARG . 14.5 p-10 -89.54 111.55 22.49 Favored 'General case' 0 C--O 1.244 0.776 0 N-CA-C 108.879 -0.786 . . . . 61.54 108.879 172.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 60.5 t -97.44 119.18 63.38 Favored Pre-proline 0 CA--C 1.536 0.414 0 N-CA-C 108.269 -1.011 . . . . 62.52 108.269 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -56.52 135.13 68.62 Favored 'Trans proline' 0 C--N 1.371 1.731 0 C-N-CA 122.439 2.093 . . . . 70.33 110.95 176.39 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -50.33 -43.86 79.99 Favored Pre-proline 0 CA--C 1.564 1.482 0 C-N-CA 124.803 1.241 . . . . 53.21 113.519 -174.537 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 202' ' ' PRO . . . . . 0.447 ' O ' HG22 ' A' ' 206' ' ' VAL . 92.1 Cg_exo -49.35 -54.7 5.04 Favored 'Trans proline' 0 C--N 1.397 3.094 0 C-N-CA 122.395 2.064 . . . . 73.03 113.075 169.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 12.6 mt -66.03 -35.65 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 122.6 0.36 . . . . 74.33 110.956 -178.328 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -58.27 -44.13 88.26 Favored 'General case' 0 N--CA 1.464 0.26 0 C-N-CA 123.503 0.721 . . . . 72.12 110.885 -178.07 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 31.5 m -89.75 -57.69 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.157 0 N-CA-C 112.701 0.63 . . . . 63.43 112.701 -177.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.447 HG22 ' O ' ' A' ' 202' ' ' PRO . 33.2 m -94.86 -27.01 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 118.768 0.713 . . . . 51.44 112.388 -173.299 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -86.53 -146.89 10.24 Favored Glycine 0 C--N 1.342 0.906 0 N-CA-C 112.29 -0.324 . . . . 64.4 112.29 -171.183 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 169.05 10.4 0.02 OUTLIER Glycine 0 C--N 1.339 0.732 0 CA-C-O 118.933 -0.926 . . . . 73.21 115.184 -179.222 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 53.5 mttp -138.48 119.42 14.33 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 118.255 1.027 . . . . 64.13 108.538 -179.206 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 6.2 p -140.54 137.05 36.31 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 108.054 -1.091 . . . . 73.21 108.054 177.317 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 211' ' ' ARG . . . . . 0.406 ' N ' ' HD2' ' A' ' 211' ' ' ARG . 7.6 mpt_? -98.56 126.88 44.28 Favored 'General case' 0 C--O 1.24 0.555 0 N-CA-C 108.672 -0.862 . . . . 70.54 108.672 -177.187 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.478 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -102.2 138.42 39.16 Favored 'General case' 0 C--O 1.244 0.808 0 C-N-CA 123.537 0.735 . . . . 70.53 110.076 -176.102 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 3.0 tpt -74.69 109.18 7.96 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.379 -0.828 . . . . 70.24 109.378 175.026 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.494 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 8.8 t -111.61 166.81 10.84 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 123.011 0.524 . . . . 61.54 110.162 174.888 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 215' ' ' LEU . . . . . 0.594 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 64.6 mt -72.38 -5.53 37.09 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 123.8 0.84 . . . . 74.45 111.86 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -96.16 -20.61 18.48 Favored 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.405 1.082 . . . . 73.25 111.126 177.121 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 136.41 -146.41 18.37 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 119.211 -0.772 . . . . 43.25 111.298 -171.239 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -86.06 127.78 3.07 Favored 'Trans proline' 0 CA--C 1.556 1.618 0 C-N-CA 122.541 2.16 . . . . 71.22 112.729 170.777 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 219' ' ' VAL . . . . . 0.452 HG13 HG21 ' A' ' 214' ' ' THR . 17.2 m -109.34 150.9 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 N-CA-C 108.974 -0.75 . . . . 61.34 108.974 164.801 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -111.35 108.76 18.46 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 107.874 -1.158 . . . . 72.24 107.874 178.048 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 2.8 p -104.43 133.81 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 C-N-CA 123.187 0.595 . . . . 73.51 110.31 177.225 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.19 125.57 35.12 Favored 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 115.625 -0.716 . . . . 74.54 109.779 177.457 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.458 HG12 HD11 ' A' ' 233' ' ' LEU . 28.1 m -97.4 141.12 22.54 Favored Pre-proline 0 N--CA 1.479 1.018 0 N-CA-C 108.485 -0.931 . . . . 73.44 108.485 173.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -60.62 139.89 88.24 Favored 'Trans proline' 0 C--N 1.37 1.698 0 C-N-CA 122.171 1.914 . . . . 71.1 111.971 176.736 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -53.31 112.39 0.92 Allowed 'Trans proline' 0 C--N 1.381 2.253 0 C-N-CA 122.629 2.219 . . . . 75.23 110.781 172.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 70.2 mtp180 66.13 72.4 0.39 Allowed 'General case' 0 CA--C 1.548 0.884 0 O-C-N 124.597 1.186 . . . . 74.41 110.428 -164.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 12.1 t -81.6 173.87 11.95 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.638 0.775 . . . . 72.4 109.299 169.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.0 mp0 -132.24 147.38 52.41 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 123.814 0.846 . . . . 64.25 109.302 -176.437 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.08 117.6 11.86 Favored 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 123.316 0.647 . . . . 72.24 109.583 174.496 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.25 3.16 22.97 Favored Glycine 0 C--N 1.344 1.023 0 CA-C-N 116.133 -0.485 . . . . 40.34 113.108 -174.676 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 19.2 mtp-105 -83.63 160.65 21.33 Favored 'General case' 0 N--CA 1.479 1.015 0 CA-C-N 117.286 0.543 . . . . 75.12 111.223 175.767 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 232' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -116.05 120.83 40.36 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.549 1.139 . . . . 74.25 109.523 -176.224 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 233' ' ' LEU . . . . . 0.458 HD11 HG12 ' A' ' 223' ' ' VAL . 33.1 mt -110.54 100.02 8.91 Favored 'General case' 0 C--O 1.237 0.416 0 N-CA-C 107.2 -1.407 . . . . 70.12 107.2 174.548 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 234' ' ' ARG . . . . . 0.444 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 44.4 ttp180 -95.65 104.13 16.04 Favored 'General case' 0 CA--C 1.542 0.636 0 CA-C-N 115.566 -0.743 . . . . 62.13 109.859 -170.914 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.492 HD12 HD23 ' A' ' 249' ' ' LEU . 16.5 mt -81.04 119.07 23.06 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 123.17 0.588 . . . . 72.13 110.131 -177.118 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 34.2 mtmm -66.65 120.67 13.85 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 125.085 1.354 . . . . 72.12 112.514 -168.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 65.84 33.95 87.27 Favored Glycine 0 C--N 1.351 1.405 0 O-C-N 123.983 0.802 . . . . 63.14 114.053 170.169 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 28.5 mmtp -116.01 2.11 13.4 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 123.474 0.71 . . . . 73.51 111.635 179.104 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -88.72 -177.58 46.66 Favored Glycine 0 C--N 1.345 1.082 0 N-CA-C 111.434 -0.666 . . . . 65.21 111.434 167.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.639 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 95.2 m-85 -74.68 151.82 87.04 Favored Pre-proline 0 N--CA 1.479 1.016 0 C-N-CA 122.545 0.338 . . . . 73.54 111.119 -177.141 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -77.58 165.68 26.77 Favored 'Trans proline' 0 C--N 1.372 1.788 0 C-N-CA 122.036 1.824 . . . . 73.32 111.631 178.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 161.07 -157.39 28.92 Favored Glycine 0 CA--C 1.528 0.876 0 CA-C-O 119.545 -0.586 . . . . 63.04 113.106 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 243' ' ' PRO . . . . . 0.434 ' HD2' ' OE1' ' A' ' 191' ' ' GLN . 77.1 Cg_exo -54.35 -23.24 29.83 Favored 'Trans proline' 0 C--N 1.375 1.945 0 C-N-CA 124.174 3.249 . . . . 60.44 114.315 175.582 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -90.42 19.42 5.24 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 123.362 0.665 . . . . 63.11 111.484 176.233 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 71.26 -94.18 0.54 Allowed Glycine 0 C--N 1.352 1.452 0 N-CA-C 110.893 -0.883 . . . . 74.43 110.893 -174.568 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -119.7 146.2 45.82 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 124.7 1.2 . . . . 72.53 107.847 166.581 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -80.44 -173.16 46.12 Favored Glycine 0 C--O 1.24 0.483 0 O-C-N 123.766 0.666 . . . . 73.1 111.751 173.021 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -137.94 163.05 32.46 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.278 0.631 . . . . 70.04 109.327 -176.37 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.512 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 18.3 tp -99.63 109.58 22.07 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 109.46 -0.57 . . . . 71.05 109.46 172.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -87.86 105.42 17.4 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 107.083 -1.451 . . . . 71.1 107.083 175.888 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.422 HD22 ' HB2' ' A' ' 197' ' ' LEU . 78.4 mt -87.49 145.98 26.01 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 123.02 0.528 . . . . 75.45 111.575 172.678 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -110.83 98.18 7.39 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 107.924 -1.139 . . . . 71.31 107.924 174.423 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 61.3 t -56.94 126.56 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 123.227 0.611 . . . . 73.42 110.737 176.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 254' ' ' ARG . . . . . 0.402 ' O ' ' HA ' ' A' ' 198' ' ' ASP . 23.2 mmt180 -132.86 97.11 3.95 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 106.968 -1.493 . . . . 53.11 106.968 178.339 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 62.4 mt -74.59 122.57 28.28 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 N-CA-C 109.274 -0.639 . . . . 61.05 109.274 -177.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.3 t . . . . . 0 CA--C 1.565 1.525 0 C-N-CA 124.719 1.207 . . . . 63.5 108.779 -177.392 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.241 0 CA-C-O 120.455 0.169 . . . . 75.33 110.976 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -79.11 -41.44 28.62 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 116.292 -0.413 . . . . 54.53 111.202 -179.012 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 14.8 mt -97.79 -78.77 0.48 Allowed 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 122.952 0.501 . . . . 73.41 111.082 174.178 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.784 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 24.6 m -58.62 159.16 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 N-CA-C 114.252 1.205 . . . . 71.43 114.252 -173.796 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -108.08 -43.2 4.46 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 113.428 -1.714 . . . . 74.54 109.127 178.053 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 2.9 p80 -177.9 169.74 1.97 Allowed 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 124.08 0.952 . . . . 73.23 110.445 -178.758 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 85.7 t -64.98 116.33 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 108.287 -1.005 . . . . 73.43 108.287 166.312 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.52 ' HB ' ' HB2' ' A' ' 122' ' ' GLU . 10.2 t -71.13 -46.28 61.94 Favored 'General case' 0 N--CA 1.473 0.695 0 O-C-N 123.381 0.426 . . . . 75.12 111.539 -174.109 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 32.7 t -167.89 102.27 0.47 Allowed 'General case' 0 C--O 1.238 0.452 0 N-CA-C 108.721 -0.844 . . . . 72.11 108.721 -174.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -81.54 68.33 3.48 Favored Glycine 0 C--N 1.341 0.861 0 N-CA-C 111.907 -0.477 . . . . 50.11 111.907 178.048 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 59.2 p -82.99 22.21 0.97 Allowed 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 124.051 0.94 . . . . 64.45 111.375 -178.253 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 78.65 -79.5 1.54 Allowed Glycine 0 C--N 1.347 1.169 0 N-CA-C 110.428 -1.069 . . . . 65.11 110.428 -170.188 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 124.77 -154.6 18.17 Favored Glycine 0 C--N 1.34 0.777 0 C-N-CA 123.299 0.476 . . . . 22.23 111.989 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 31.1 t -90.78 -57.19 2.9 Favored 'General case' 0 C--O 1.241 0.656 0 C-N-CA 123.903 0.881 . . . . 43.2 109.64 -177.493 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 73.7 -160.85 53.81 Favored Glycine 0 C--N 1.345 1.057 0 CA-C-N 115.779 -0.646 . . . . 63.03 112.137 -175.142 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 176.65 -158.58 24.77 Favored Glycine 0 C--N 1.341 0.809 0 C-N-CA 121.584 -0.341 . . . . 62.42 113.423 -179.699 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 43.9 t -122.91 -65.06 1.13 Allowed 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 124.608 1.163 . . . . 74.34 108.539 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -86.42 76.67 2.1 Favored Glycine 0 C--N 1.344 1.0 0 N-CA-C 110.779 -0.929 . . . . 63.34 110.779 175.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.18 173.27 30.04 Favored Glycine 0 C--N 1.339 0.742 0 N-CA-C 111.435 -0.666 . . . . 62.23 111.435 -170.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 49.4 m 59.29 84.0 0.12 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 124.507 1.123 . . . . 64.22 111.777 -179.59 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -73.67 -105.1 0.08 OUTLIER Glycine 0 C--N 1.342 0.897 0 CA-C-N 115.374 -0.83 . . . . 71.33 111.107 171.374 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.91 123.26 39.43 Favored 'General case' 0 CA--C 1.542 0.659 0 N-CA-C 108.953 -0.758 . . . . 74.33 108.953 172.81 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -70.47 130.52 42.1 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.642 -0.873 . . . . 64.32 108.642 174.37 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 50.3 tp -108.18 127.06 53.49 Favored 'General case' 0 C--O 1.217 -0.638 0 N-CA-C 106.994 -1.484 . . . . 74.33 106.994 173.644 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 45.3 mtp85 -120.76 108.95 14.58 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.621 -0.511 . . . . 75.54 109.621 -170.079 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -130.69 139.55 50.32 Favored 'General case' 0 N--CA 1.478 0.944 0 C-N-CA 123.436 0.694 . . . . 33.24 110.578 -174.543 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' GLU . . . . . 0.52 ' HB2' ' HB ' ' A' ' 103' ' ' THR . 34.8 tt0 -104.38 146.53 28.7 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.266 0.626 . . . . 74.34 110.294 178.436 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.784 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.8 pt? -145.7 146.32 28.79 Favored Pre-proline 0 N--CA 1.467 0.415 0 C-N-CA 124.077 0.951 . . . . 64.32 110.379 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -78.36 121.91 5.42 Favored 'Trans proline' 0 C--N 1.366 1.457 0 C-N-CA 121.977 1.785 . . . . 73.11 110.581 167.539 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.529 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 14.2 tp -111.86 162.04 15.72 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.582 0.753 . . . . 71.13 109.218 175.161 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 19.5 m -101.86 158.03 16.42 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 109.174 -0.676 . . . . 75.02 109.174 175.631 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.477 HD23 ' HB3' ' A' ' 180' ' ' LEU . 65.1 mt -55.81 -52.19 64.87 Favored 'General case' 0 N--CA 1.486 1.352 0 CA-C-O 121.717 0.77 . . . . 63.43 111.248 179.06 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.414 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 10.9 mp0 -54.26 -33.24 58.1 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 114.495 -1.23 . . . . 65.2 111.708 175.871 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.4 mm-40 -85.96 -18.61 32.16 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 123.306 0.642 . . . . 73.25 111.98 -176.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.681 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -60.23 -41.34 92.9 Favored 'General case' 0 C--O 1.247 0.947 0 CA-C-O 121.805 0.812 . . . . 72.42 110.41 162.345 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.465 ' HA ' ' CE2' ' A' ' 240' ' ' PHE . 66.1 t80 -73.15 -43.2 61.91 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 114.365 -1.289 . . . . 72.4 112.812 175.003 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.8 m80 -83.94 -49.25 9.16 Favored 'General case' 0 N--CA 1.493 1.692 0 N-CA-C 112.439 0.533 . . . . 71.13 112.439 -172.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.06 -110.61 3.46 Favored Glycine 0 CA--C 1.531 1.063 0 N-CA-C 111.412 -0.675 . . . . 52.33 111.412 -173.597 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 90.0 172.99 45.13 Favored Glycine 0 C--N 1.35 1.318 0 C-N-CA 123.079 0.371 . . . . 61.14 113.923 168.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.63 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 2.1 mp0 -86.34 125.72 33.83 Favored 'General case' 0 C--N 1.351 0.671 0 N-CA-C 108.975 -0.75 . . . . 71.54 108.975 178.071 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 33.2 ttt85 -156.15 138.05 14.41 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 108.139 -1.06 . . . . 73.34 108.139 175.434 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.705 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 12.6 p -72.51 142.64 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 112.85 0.685 . . . . 73.03 112.85 -167.327 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 34.6 m -124.26 152.39 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 124.262 1.025 . . . . 75.35 109.781 174.121 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -124.5 104.31 8.66 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 107.179 -1.415 . . . . 63.13 107.179 171.14 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 7.1 p -150.9 139.12 14.43 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.965 0 C-N-CA 123.593 0.757 . . . . 54.54 109.885 -176.368 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.17 20.56 11.07 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 125.26 1.424 . . . . 74.43 112.768 -176.504 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.19 26.65 57.33 Favored Glycine 0 C--N 1.346 1.085 0 CA-C-N 116.538 -0.301 . . . . 54.41 112.385 -176.057 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.3 mmt180 -127.16 117.57 22.63 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.61 0.764 . . . . 64.21 110.277 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 43.1 ttp180 -98.5 104.57 16.62 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 108.321 -0.992 . . . . 72.13 108.321 173.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.2 m -146.81 137.47 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 123.672 0.789 . . . . 53.43 109.853 -177.197 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.705 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 35.7 p -73.34 118.19 15.99 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.413 0.685 . . . . 64.12 110.146 177.173 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.9 p -100.08 139.07 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 122.933 0.493 . . . . 64.02 110.129 -178.453 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' ARG . . . . . 0.63 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 24.8 ttp180 -106.9 106.47 17.01 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 108.344 -0.984 . . . . 75.23 108.344 173.585 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.465 ' HB ' HD13 ' A' ' 159' ' ' ILE . 34.2 pt -96.73 128.33 36.29 Favored Pre-proline 0 CA--C 1.546 0.794 0 N-CA-C 107.828 -1.175 . . . . 73.42 107.828 175.084 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -71.14 151.35 61.12 Favored 'Trans proline' 0 C--N 1.373 1.822 0 C-N-CA 122.331 2.021 . . . . 71.43 113.59 -167.743 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.422 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 43.4 Cg_exo -60.54 110.52 0.82 Allowed 'Trans proline' 0 C--N 1.378 2.105 0 C-N-CA 122.779 2.319 . . . . 70.41 109.939 169.755 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 131.37 59.64 0.09 OUTLIER Glycine 0 C--N 1.341 0.811 0 N-CA-C 111.01 -0.836 . . . . 73.45 111.01 -170.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.681 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -140.24 162.82 24.26 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.203 0 N-CA-C 108.453 -0.943 . . . . 60.31 108.453 177.395 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.545 ' HD2' ' HB3' ' A' ' 188' ' ' LEU . 38.5 mtp180 -146.67 176.52 9.79 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 124.405 1.082 . . . . 72.44 110.869 -171.006 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -56.74 117.81 4.27 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 124.537 1.135 . . . . 75.42 111.694 173.363 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.24 7.75 87.67 Favored Glycine 0 C--N 1.342 0.869 0 CA-C-N 115.372 -0.831 . . . . 72.52 113.645 179.128 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 33.8 t -78.76 136.32 37.35 Favored 'General case' 0 C--N 1.35 0.599 0 CA-C-O 121.145 0.498 . . . . 53.15 109.799 -178.105 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.435 HG12 HD22 ' A' ' 175' ' ' LEU . 8.2 t -103.47 119.29 51.81 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 CA-C-N 114.531 -1.213 . . . . 74.44 109.329 -172.099 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.578 HD11 HG21 ' A' ' 153' ' ' VAL . 26.4 mt -103.05 115.55 45.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.811 0.844 . . . . 75.12 110.417 -171.214 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 32.2 ttt85 -85.06 107.32 17.1 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.603 0.761 . . . . 62.05 109.813 177.098 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.452 HG22 ' O ' ' A' ' 174' ' ' LEU . 25.4 m -112.88 111.59 51.01 Favored Pre-proline 0 CA--C 1.56 1.356 0 C-N-CA 122.648 0.379 . . . . 64.3 110.404 178.119 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -65.97 148.74 86.17 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 123.286 2.657 . . . . 71.14 114.01 -173.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 70.75 23.9 77.44 Favored Glycine 0 C--N 1.352 1.433 0 CA-C-N 116.025 -0.534 . . . . 42.52 114.218 173.684 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 52.9 mmm -120.16 -30.64 4.6 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.876 0.87 . . . . 75.2 111.554 -172.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.87 -98.74 0.59 Allowed Glycine 0 C--N 1.346 1.104 0 O-C-N 123.146 0.279 . . . . 73.43 113.069 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.504 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -67.24 98.69 0.46 Allowed Glycine 0 C--N 1.346 1.128 0 N-CA-C 111.777 -0.529 . . . . 52.14 111.777 177.741 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.5 mm-40 -78.3 106.17 10.03 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 123.83 0.852 . . . . 75.33 110.301 -178.104 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 170.24 -158.57 30.59 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 116.096 -0.502 . . . . 72.43 112.012 178.747 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.485 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 25.0 t-20 -66.27 -47.54 60.16 Favored Pre-proline 0 CA--C 1.563 1.443 0 CA-C-O 118.307 -0.854 . . . . 70.44 111.65 -175.764 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.485 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 3.0 Cg_exo -77.42 112.55 3.38 Favored 'Trans proline' 0 C--N 1.387 2.588 0 C-N-CA 122.119 1.879 . . . . 74.41 110.414 165.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.32 122.55 9.82 Favored 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 121.871 1.714 . . . . 75.33 111.698 -176.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.504 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -97.65 150.12 19.4 Favored Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.788 -0.925 . . . . 75.04 110.788 175.014 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -106.88 160.05 15.79 Favored 'General case' 0 C--O 1.238 0.45 0 C-N-CA 123.622 0.769 . . . . 51.32 109.691 -178.546 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.452 ' O ' HG22 ' A' ' 161' ' ' VAL . 13.8 tp -115.04 114.7 25.72 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 108.204 -1.035 . . . . 64.43 108.204 -179.713 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.435 HD22 HG12 ' A' ' 158' ' ' VAL . 57.0 mt -84.72 101.69 12.4 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.673 1.189 . . . . 74.31 111.237 176.381 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.422 ' HB3' HD21 ' A' ' 123' ' ' LEU . 42.5 mt -90.93 105.65 17.97 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 114.95 -1.023 . . . . 74.31 111.32 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 27.3 t -85.55 99.67 7.77 Favored 'Isoleucine or valine' 0 C--O 1.242 0.685 0 N-CA-C 107.959 -1.126 . . . . 44.41 107.959 172.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.529 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 17.4 m -82.25 148.88 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 121.216 0.531 . . . . 71.15 110.235 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 39.4 mmm-85 -121.2 103.95 9.38 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.798 -1.186 . . . . 65.41 107.798 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.477 ' HB3' HD23 ' A' ' 127' ' ' LEU . 30.6 mt -67.97 149.08 50.19 Favored 'General case' 0 C--O 1.242 0.667 0 N-CA-C 109.256 -0.646 . . . . 45.12 109.256 177.339 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 40.2 mt -53.85 137.56 54.79 Favored Pre-proline 0 CA--C 1.552 1.045 0 O-C-N 123.674 0.609 . . . . 74.14 110.311 -178.218 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -58.78 -5.13 2.35 Favored 'Trans proline' 0 C--N 1.378 2.119 0 C-N-CA 123.141 2.56 . . . . 61.13 114.073 -177.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 183' ' ' HIS . . . . . 0.456 ' O ' HD11 ' A' ' 127' ' ' LEU . 6.2 t60 -83.72 107.76 11.36 Favored Pre-proline 0 CA--C 1.548 0.893 0 C-N-CA 124.654 1.182 . . . . 72.42 108.526 162.83 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -96.67 163.48 1.12 Allowed 'Trans proline' 0 C--N 1.369 1.631 0 C-N-CA 122.916 2.411 . . . . 74.45 111.922 168.864 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.66 -42.98 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 122.999 0.52 . . . . 72.2 109.769 169.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.503 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 5.6 m-85 -101.92 123.97 46.74 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 115.783 -0.644 . . . . 70.45 110.795 -176.903 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -109.64 123.38 49.38 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 125.136 1.375 . . . . 73.3 108.092 179.311 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.545 ' HB3' ' HD2' ' A' ' 154' ' ' ARG . 22.4 tp -95.58 113.11 24.73 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-O 121.445 0.641 . . . . 60.24 111.174 -173.158 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -83.93 170.37 14.08 Favored 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 125.533 1.533 . . . . 72.04 107.826 162.234 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . -42.77 86.74 0.01 OUTLIER Glycine 0 C--N 1.362 2.004 0 CA-C-N 118.761 0.71 . . . . 53.53 114.357 175.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 67.18 -4.82 0.78 Allowed 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 127.658 2.383 . . . . 64.23 113.554 -175.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.503 ' O ' HD12 ' A' ' 188' ' ' LEU . 27.2 t70 -105.52 156.13 18.52 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 124.899 1.28 . . . . 64.44 109.989 -174.463 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.536 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 78.4 mt -113.62 157.7 21.78 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 124.047 0.939 . . . . 72.11 112.177 -172.686 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 46.8 m-85 -139.61 122.25 16.33 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 114.419 -1.264 . . . . 74.03 108.378 174.164 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -142.61 171.1 14.51 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.144 0.978 . . . . 62.5 109.504 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 16.2 m -109.41 128.43 55.13 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 109.779 -0.452 . . . . 74.23 109.779 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.476 HD22 HD13 ' A' ' 251' ' ' LEU . 62.3 tp -114.75 115.0 26.35 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.222 1.009 . . . . 61.25 109.713 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 198' ' ' ASP . . . . . 0.436 ' HA ' ' HB2' ' A' ' 254' ' ' ARG . 10.3 m-20 -99.68 106.35 18.27 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.655 -0.498 . . . . 72.05 109.655 178.489 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 199' ' ' VAL . . . . . 0.496 HG12 HG21 ' A' ' 210' ' ' VAL . 6.4 m -107.72 147.36 35.23 Favored Pre-proline 0 N--CA 1.481 1.097 0 C-N-CA 123.232 0.613 . . . . 74.22 109.563 178.179 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.32 148.8 55.87 Favored 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 122.149 1.899 . . . . 64.2 110.565 167.714 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -54.14 -44.38 98.4 Favored Pre-proline 0 CA--C 1.56 1.346 0 CA-C-O 117.468 -1.253 . . . . 61.42 112.893 176.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -43.66 -52.98 4.78 Favored 'Trans proline' 0 C--N 1.403 3.396 0 C-N-CA 123.029 2.486 . . . . 75.45 113.895 171.032 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 203' ' ' ILE . . . . . 0.522 HG21 HG13 ' A' ' 210' ' ' VAL . 6.3 mt -71.05 -38.06 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 CA-C-N 116.62 -0.263 . . . . 63.22 110.781 -177.639 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -61.01 -38.71 87.05 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 123.321 0.648 . . . . 65.34 112.078 -178.211 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.8 m -84.45 -38.44 13.62 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 CA-C-N 116.173 -0.467 . . . . 65.03 111.759 -176.318 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.1 m -78.2 -27.51 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 CA-C-N 118.121 0.418 . . . . 60.12 111.201 179.408 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 207' ' ' GLY . . . . . 0.456 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 79.56 53.52 4.32 Favored Glycine 0 C--N 1.339 0.72 0 CA-C-N 115.554 -0.748 . . . . 73.25 112.849 -175.773 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.8 -152.6 11.53 Favored Glycine 0 C--N 1.354 1.555 0 N-CA-C 111.762 -0.535 . . . . 75.23 111.762 178.257 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 57.9 mttp -125.27 139.13 53.98 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 123.371 0.668 . . . . 74.44 109.842 176.265 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 210' ' ' VAL . . . . . 0.522 HG13 HG21 ' A' ' 203' ' ' ILE . 13.6 m -123.71 134.63 65.9 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 CA-C-N 114.737 -1.119 . . . . 70.04 108.322 173.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 39.7 ttp-105 -81.64 113.48 19.68 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 108.835 -0.802 . . . . 72.2 108.835 175.564 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.42 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -101.19 165.6 11.21 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.374 -0.973 . . . . 65.21 108.374 175.338 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 1.9 mtp -106.4 154.14 21.23 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.593 0.711 . . . . 74.31 110.762 173.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.503 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.8 t -144.53 173.38 11.86 Favored 'General case' 0 C--O 1.242 0.705 0 CA-C-N 113.641 -1.618 . . . . 61.14 108.365 171.715 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 215' ' ' LEU . . . . . 0.414 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 49.9 mt -73.7 -10.53 59.78 Favored 'General case' 0 CA--C 1.553 1.069 0 CA-C-N 115.946 -0.57 . . . . 74.01 111.092 -179.723 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 216' ' ' GLU . . . . . 0.407 ' H ' HG23 ' A' ' 214' ' ' THR . 35.1 tt0 -86.87 -18.98 29.59 Favored 'General case' 0 CA--C 1.551 1.011 0 C-N-CA 124.58 1.152 . . . . 54.02 110.819 173.697 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 134.26 -157.91 23.12 Favored Glycine 0 C--N 1.353 1.48 0 CA-C-O 119.53 -0.595 . . . . 61.12 111.786 -176.765 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -84.4 130.96 4.7 Favored 'Trans proline' 0 C--N 1.366 1.46 0 C-N-CA 122.5 2.134 . . . . 74.31 112.227 175.481 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 35.1 m -113.08 161.9 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 124.22 1.008 . . . . 74.31 111.292 178.219 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -106.25 121.23 43.78 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 108.627 -0.879 . . . . 70.25 108.627 173.832 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 20.2 t -103.26 115.45 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 109.312 -0.625 . . . . 72.43 109.312 176.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -84.59 100.66 11.56 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 107.689 -1.226 . . . . 74.11 107.689 170.436 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.456 HG23 ' HA2' ' A' ' 207' ' ' GLY . 12.3 m -76.26 141.1 69.89 Favored Pre-proline 0 CA--C 1.549 0.913 0 N-CA-C 108.927 -0.768 . . . . 71.34 108.927 -178.653 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_exo -64.46 136.02 48.68 Favored 'Trans proline' 0 C--N 1.367 1.531 0 C-N-CA 122.622 2.215 . . . . 62.32 112.092 177.617 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -58.34 117.6 4.34 Favored 'Trans proline' 0 C--N 1.371 1.716 0 C-N-CA 122.611 2.207 . . . . 61.1 111.23 174.079 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 64.96 51.74 1.68 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 124.636 1.174 . . . . 73.42 110.826 -175.449 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.6 t -77.61 172.35 13.52 Favored 'General case' 0 CA--C 1.545 0.788 0 CA-C-N 115.248 -0.887 . . . . 74.52 109.555 170.556 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 28.1 mp0 -122.5 145.46 48.29 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 123.398 0.679 . . . . 74.4 110.036 -174.831 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.57 121.86 18.65 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.734 -0.839 . . . . 75.5 108.734 172.48 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.69 -7.7 19.87 Favored Glycine 0 N--CA 1.469 0.893 0 CA-C-N 116.087 -0.506 . . . . 52.54 112.324 -171.279 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 70.5 mtp180 -83.28 160.1 21.79 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 122.842 0.457 . . . . 62.42 110.347 173.319 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 3.4 mppt? -125.13 113.4 17.66 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.966 0.906 . . . . 73.11 109.527 177.443 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 38.3 mt -89.89 125.71 35.45 Favored 'General case' 0 C--N 1.354 0.802 0 N-CA-C 108.451 -0.944 . . . . 53.43 108.451 -177.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 234' ' ' ARG . . . . . 0.51 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 37.2 ttp180 -106.26 112.17 25.07 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-O 121.056 0.455 . . . . 63.44 111.22 -168.781 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.472 HD12 HD23 ' A' ' 249' ' ' LEU . 44.7 mt -86.61 127.12 34.9 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-N 115.347 -0.842 . . . . 73.3 110.11 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 35.1 mtmm -70.18 124.64 24.62 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 124.763 1.225 . . . . 73.31 111.809 -172.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 70.8 13.92 72.43 Favored Glycine 0 C--N 1.348 1.216 0 N-CA-C 114.954 0.742 . . . . 74.33 114.954 170.522 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -87.74 -9.96 52.5 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.226 0.61 . . . . 70.03 111.982 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -87.6 179.57 47.66 Favored Glycine 0 C--N 1.342 0.896 0 O-C-N 123.407 0.442 . . . . 70.13 112.799 177.08 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.465 ' CE2' ' HA ' ' A' ' 131' ' ' PHE . 14.4 m-85 -69.07 144.45 95.48 Favored Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 123.565 0.746 . . . . 75.44 110.99 -177.154 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 241' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 23.0 Cg_exo -66.65 130.35 23.25 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.632 2.222 . . . . 70.24 112.304 172.411 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -161.21 -151.53 6.29 Favored Glycine 0 CA--C 1.538 1.507 0 CA-C-O 119.271 -0.738 . . . . 72.12 111.99 178.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -56.18 -23.62 46.02 Favored 'Trans proline' 0 C--N 1.377 2.048 0 C-N-CA 123.996 3.131 . . . . 65.32 115.865 -174.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -101.15 22.6 12.09 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 123.298 0.639 . . . . 71.52 111.586 -179.397 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.16 -93.31 1.82 Allowed Glycine 0 C--N 1.341 0.846 0 N-CA-C 110.075 -1.21 . . . . 72.24 110.075 -172.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.468 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 46.6 mtm180 -122.14 153.68 38.41 Favored 'General case' 0 N--CA 1.478 0.935 0 N-CA-C 108.484 -0.932 . . . . 74.21 108.484 170.218 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -84.61 -162.46 34.94 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.789 -0.641 . . . . 41.11 112.186 178.365 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 42.7 m-20 -138.95 173.65 11.35 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.424 0.689 . . . . 71.13 109.853 -173.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.536 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 16.6 tp -119.82 115.85 24.68 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.397 0.679 . . . . 72.42 111.583 176.2 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 250' ' ' TYR . . . . . 0.425 ' CZ ' ' HD3' ' A' ' 234' ' ' ARG . 20.5 m-85 -88.95 107.44 19.02 Favored 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 123.561 0.744 . . . . 72.51 109.997 171.259 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.573 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 38.2 mt -89.93 118.72 29.7 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 125.041 1.336 . . . . 74.34 112.178 176.081 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -77.57 96.56 4.81 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 108.965 -0.754 . . . . 73.2 108.965 178.261 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 45.2 t -49.85 115.1 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 124.201 1.001 . . . . 52.14 111.354 173.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 254' ' ' ARG . . . . . 0.436 ' HB2' ' HA ' ' A' ' 198' ' ' ASP . 30.5 mmm180 -118.21 93.2 4.04 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 106.905 -1.517 . . . . 75.35 106.905 174.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 71.2 mt -76.48 122.94 31.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 N-CA-C 109.216 -0.661 . . . . 75.04 109.216 176.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.557 1.244 0 CA-C-O 117.446 -1.264 . . . . 64.21 107.941 -178.597 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.205 0 N-CA-C 110.071 -0.344 . . . . 63.33 110.071 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.521 ' HB1' HG13 ' A' ' 137' ' ' VAL . . . -59.39 -70.1 0.17 Allowed 'General case' 0 N--CA 1.479 0.975 0 C-N-CA 124.295 1.038 . . . . 54.34 109.663 175.43 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.459 HD13 ' HG3' ' A' ' 136' ' ' ARG . 60.7 tp -127.85 -64.3 0.97 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 105.994 -1.854 . . . . 74.4 105.994 156.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.406 HG22 ' H ' ' A' ' 101' ' ' HIS . 12.4 p -107.26 154.99 8.07 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 C-N-CA 124.445 1.098 . . . . 71.43 109.306 165.636 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -141.57 1.93 1.58 Allowed 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 124.366 1.066 . . . . 75.1 110.518 173.318 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' HIS . . . . . 0.406 ' H ' HG22 ' A' ' 99' ' ' VAL . 9.2 t-80 -109.06 103.33 12.33 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.898 1.279 . . . . 72.14 109.545 -177.772 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 82.6 t -83.98 136.21 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 N-CA-C 108.597 -0.89 . . . . 61.52 108.597 173.846 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 43.1 p -83.15 134.81 34.97 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.459 0.704 . . . . 71.3 111.912 -172.092 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.5 m -84.3 -20.39 32.19 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 124.0 0.92 . . . . 54.44 109.991 167.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -150.55 -124.75 1.23 Allowed Glycine 0 CA--C 1.532 1.142 0 N-CA-C 109.68 -1.368 . . . . 55.04 109.68 178.431 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 60.8 p 39.5 -84.55 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 126.148 1.779 . . . . 71.23 114.367 177.009 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.466 ' O ' ' HD3' ' A' ' 120' ' ' ARG . . . -62.14 133.15 45.87 Favored Glycine 0 C--N 1.354 1.553 0 O-C-N 123.397 0.436 . . . . 71.5 112.991 -176.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 179.12 155.84 15.85 Favored Glycine 0 C--N 1.342 0.873 0 N-CA-C 112.138 -0.385 . . . . 74.31 112.138 -177.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 59.1 m -146.47 147.33 31.09 Favored 'General case' 0 C--O 1.242 0.685 0 C-N-CA 123.727 0.811 . . . . 75.54 109.919 179.243 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -120.08 -176.98 15.99 Favored Glycine 0 C--N 1.346 1.088 0 CA-C-N 116.294 -0.412 . . . . 71.24 112.429 -179.681 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 89.56 -45.95 3.14 Favored Glycine 0 C--N 1.345 1.053 0 CA-C-O 120.205 -0.22 . . . . 55.31 113.114 176.679 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 38.0 t -78.07 -36.42 48.28 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.1 0.56 . . . . 53.51 111.126 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 82.85 6.97 87.92 Favored Glycine 0 C--N 1.346 1.126 0 CA-C-N 115.729 -0.669 . . . . 62.23 113.022 -175.67 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.59 -59.94 4.9 Favored Glycine 0 C--N 1.354 1.573 0 C-N-CA 123.184 0.421 . . . . 65.42 113.105 -178.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.0 m 72.49 -72.46 0.11 Allowed 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 125.76 1.624 . . . . 73.33 110.704 -178.292 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -86.2 176.88 48.88 Favored Glycine 0 C--N 1.347 1.15 0 N-CA-C 110.125 -1.19 . . . . 74.4 110.125 165.618 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 42.1 mtm180 -64.41 117.5 7.37 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 117.689 0.744 . . . . 54.45 110.183 177.813 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -92.84 107.61 19.35 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 108.69 -0.856 . . . . 71.41 108.69 175.702 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.437 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 2.5 tt -94.36 138.61 32.12 Favored 'General case' 0 C--O 1.215 -0.722 0 N-CA-C 105.993 -1.854 . . . . 64.04 105.993 179.822 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.466 ' HD3' ' O ' ' A' ' 107' ' ' GLY . 92.2 mtt180 -128.49 139.91 52.09 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 109.586 -0.524 . . . . 72.23 109.586 -169.747 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.402 ' HB1' HG21 ' A' ' 99' ' ' VAL . . . -153.83 149.77 27.73 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 123.889 0.876 . . . . 70.41 110.313 -177.041 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 72.6 tt0 -127.75 135.29 49.93 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.536 1.134 . . . . 74.05 109.375 -174.829 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -140.84 142.41 28.04 Favored Pre-proline 0 N--CA 1.478 0.973 0 C-N-CA 122.785 0.434 . . . . 72.35 110.865 -175.149 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_exo -73.6 113.34 3.76 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 121.889 1.726 . . . . 73.42 109.851 166.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.451 HD22 HG11 ' A' ' 178' ' ' VAL . 17.9 tp -109.54 165.79 11.39 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.299 1.039 . . . . 70.25 108.932 179.401 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.592 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 8.6 m -95.39 156.6 16.25 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.23 0.612 . . . . 44.0 109.903 176.266 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.669 HD23 ' HB3' ' A' ' 180' ' ' LEU . 51.9 mt -56.7 -50.35 72.43 Favored 'General case' 0 N--CA 1.487 1.405 0 CA-C-O 122.21 1.005 . . . . 71.54 109.353 174.083 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.483 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -58.51 -38.07 76.93 Favored 'General case' 0 CA--C 1.546 0.813 0 CA-C-N 113.614 -1.63 . . . . 61.14 111.802 178.823 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.404 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 12.0 mm-40 -77.94 -23.25 48.61 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 122.844 0.458 . . . . 73.22 111.831 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.642 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -66.23 -32.0 73.16 Favored 'General case' 0 C--O 1.252 1.201 0 CA-C-O 121.712 0.768 . . . . 63.43 111.156 168.505 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.468 ' HA ' ' CE2' ' A' ' 240' ' ' PHE . 36.9 t80 -75.73 -47.92 24.03 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 114.746 -1.115 . . . . 73.31 111.892 172.798 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -75.23 -48.17 24.7 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 122.59 0.356 . . . . 71.34 111.626 -170.771 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 63.58 -130.14 40.03 Favored Glycine 0 CA--C 1.532 1.124 0 O-C-N 123.666 0.604 . . . . 42.23 111.861 -175.204 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 94.76 -172.94 31.67 Favored Glycine 0 C--N 1.35 1.332 0 N-CA-C 114.245 0.458 . . . . 35.51 114.245 171.712 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 7.6 mp0 -88.93 125.96 35.18 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.152 0.981 . . . . 53.12 109.965 -176.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' ARG . . . . . 0.459 ' HG3' HD13 ' A' ' 98' ' ' LEU . 33.3 mmt180 -137.78 168.49 19.57 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 124.883 1.273 . . . . 72.24 108.325 171.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.521 HG13 ' HB1' ' A' ' 97' ' ' ALA . 6.0 p -90.23 144.79 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 108.676 -0.861 . . . . 71.12 108.676 178.092 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 144' ' ' ARG . 7.8 p -134.23 138.2 50.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 123.249 0.62 . . . . 74.34 109.457 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -124.69 106.15 9.86 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 108.14 -1.059 . . . . 75.21 108.14 169.185 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.5 m -125.09 117.81 51.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 C-N-CA 124.461 1.105 . . . . 72.05 109.592 -178.692 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' ALA . . . . . 0.416 ' HB3' HD11 ' A' ' 119' ' ' LEU . . . 64.43 20.47 12.17 Favored 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 124.598 1.159 . . . . 73.23 111.771 179.579 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.69 -6.9 74.23 Favored Glycine 0 C--N 1.357 1.704 0 O-C-N 123.225 0.328 . . . . 73.02 113.478 -178.302 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 6.3 tpm_? -91.6 117.41 29.71 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 108.92 -0.77 . . . . 65.35 108.92 176.691 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.401 ' HA ' ' O ' ' A' ' 138' ' ' VAL . 52.5 ttp180 -99.66 122.07 42.14 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 123.583 0.753 . . . . 75.34 109.516 179.181 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 19.0 t -133.19 156.99 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 N-CA-C 108.3 -1.0 . . . . 74.54 108.3 176.148 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 24.3 p -85.35 113.71 21.87 Favored 'General case' 0 CA--C 1.547 0.838 0 N-CA-C 108.325 -0.991 . . . . 75.25 108.325 165.511 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.2 p -98.02 123.52 50.54 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 CA-C-O 121.641 0.734 . . . . 72.42 111.402 -176.259 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -97.94 104.77 16.83 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 107.76 -1.2 . . . . 74.23 107.76 167.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 38.7 pt -97.32 103.63 16.61 Favored Pre-proline 0 CA--C 1.55 0.967 0 N-CA-C 108.154 -1.054 . . . . 51.41 108.154 167.19 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -61.09 151.21 80.16 Favored 'Trans proline' 0 C--N 1.383 2.366 0 C-N-CA 122.613 2.209 . . . . 74.32 112.788 -178.116 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -49.28 151.37 6.62 Favored 'Trans proline' 0 C--N 1.378 2.081 0 C-N-CA 123.829 3.019 . . . . 71.54 114.153 176.499 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 108.73 23.36 6.55 Favored Glycine 0 N--CA 1.478 1.438 0 C-N-CA 121.465 -0.398 . . . . 51.51 113.238 174.409 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.642 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -99.65 162.84 2.95 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.192 0 N-CA-C 107.831 -1.174 . . . . 71.41 107.831 179.464 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.601 ' HA ' HD11 ' A' ' 180' ' ' LEU . 0.0 OUTLIER -158.87 177.69 10.88 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.618 1.167 . . . . 74.11 111.91 -172.02 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.3 tp10 -51.58 115.5 1.65 Allowed 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 124.76 1.224 . . . . 72.32 111.722 178.09 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 80.68 10.43 85.18 Favored Glycine 0 C--N 1.356 1.64 0 CA-C-N 115.775 -0.648 . . . . 54.34 113.591 177.652 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.4 t -85.77 123.76 31.51 Favored 'General case' 0 C--O 1.245 0.822 0 C-N-CA 123.097 0.559 . . . . 73.41 109.58 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 3.4 t -99.6 122.4 51.38 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 124.129 0.972 . . . . 72.21 108.659 -176.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.627 HD11 HG21 ' A' ' 153' ' ' VAL . 13.5 mt -103.11 119.68 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 124.046 0.938 . . . . 74.42 109.33 -169.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 34.3 ttt180 -97.43 103.67 15.63 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 122.693 0.397 . . . . 65.54 110.361 -177.115 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 12.1 m -102.39 118.91 57.75 Favored Pre-proline 0 CA--C 1.559 1.293 0 N-CA-C 109.451 -0.574 . . . . 53.13 109.451 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.47 152.25 43.36 Favored 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.635 2.224 . . . . 64.34 113.684 -173.32 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 79.74 24.48 60.19 Favored Glycine 0 C--N 1.349 1.267 0 N-CA-C 115.0 0.76 . . . . 61.52 115.0 168.147 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 39.6 mtt -105.18 -62.91 1.29 Allowed 'General case' 0 N--CA 1.488 1.465 0 CA-C-N 118.285 1.042 . . . . 74.22 112.093 176.061 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -62.42 -87.01 0.04 OUTLIER Glycine 0 C--N 1.349 1.294 0 CA-C-N 115.933 -0.576 . . . . 41.14 112.937 -177.295 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.705 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -68.25 90.44 0.23 Allowed Glycine 0 C--N 1.339 0.732 0 C-N-CA 122.91 0.29 . . . . 53.41 112.949 176.71 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 17.2 mm-40 -83.52 104.84 13.97 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 109.245 -0.65 . . . . 71.31 109.245 175.461 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 171.03 -154.53 22.85 Favored Glycine 0 C--N 1.342 0.875 0 N-CA-C 110.984 -0.846 . . . . 15.22 110.984 -175.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 169' ' ' ASN . . . . . 0.456 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 6.5 t30 -69.28 -48.72 25.63 Favored Pre-proline 0 CA--C 1.562 1.427 0 CA-C-O 118.431 -0.795 . . . . 62.43 110.999 176.454 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.456 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 5.1 Cg_exo -76.89 113.31 3.61 Favored 'Trans proline' 0 C--N 1.392 2.82 0 C-N-CA 121.818 1.679 . . . . 70.33 110.276 169.16 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_exo -70.81 125.93 12.1 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.274 1.983 . . . . 74.3 110.966 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.705 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -101.78 153.3 18.74 Favored Glycine 0 CA--C 1.502 -0.773 0 N-CA-C 110.621 -0.992 . . . . 71.22 110.621 174.634 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -112.69 178.59 4.24 Favored 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 123.473 0.709 . . . . 74.41 111.511 -168.155 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.437 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 34.9 tp -130.16 112.92 13.86 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 114.579 -1.191 . . . . 74.1 108.615 168.419 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 72.9 mt -85.09 100.86 11.98 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.138 1.375 . . . . 44.25 111.238 177.118 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 70.7 mt -95.38 101.64 13.38 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 122.69 0.396 . . . . 55.04 110.666 174.41 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 2.5 p -87.03 108.65 18.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 N-CA-C 109.158 -0.682 . . . . 62.25 109.158 172.576 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.451 HG11 HD22 ' A' ' 125' ' ' LEU . 4.0 m -87.35 149.37 4.11 Favored 'Isoleucine or valine' 0 C--O 1.245 0.851 0 CA-C-N 115.946 -0.57 . . . . 74.12 110.665 -177.777 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 13.1 mmm-85 -124.97 101.31 6.99 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 107.491 -1.299 . . . . 64.13 107.491 -178.521 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.669 ' HB3' HD23 ' A' ' 127' ' ' LEU . 25.3 mt -69.46 148.61 49.3 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 112.082 0.401 . . . . 61.31 112.082 -172.115 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.592 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 39.8 mt -57.5 138.25 81.57 Favored Pre-proline 0 CA--C 1.559 1.295 0 C-N-CA 123.283 0.633 . . . . 73.03 110.752 179.488 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.44 83.79 1.0 Allowed 'Trans proline' 0 C--N 1.374 1.875 0 C-N-CA 123.188 2.592 . . . . 63.11 112.584 -177.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -165.19 54.03 0.34 Allowed Pre-proline 0 CA--C 1.559 1.306 0 C-N-CA 124.12 0.968 . . . . 73.43 109.314 170.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.61 124.4 15.71 Favored 'Trans proline' 0 C--N 1.389 2.668 0 C-N-CA 122.627 2.218 . . . . 63.32 112.723 -169.358 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.4 p -130.84 -44.42 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 124.182 0.993 . . . . 75.41 109.561 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 186' ' ' PHE . . . . . 0.41 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 6.4 m-85 -105.01 120.29 41.11 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.218 0.532 . . . . 73.31 111.347 -176.048 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.705 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 23.5 mtp180 -104.17 162.7 12.95 Favored 'General case' 0 N--CA 1.467 0.425 0 C-N-CA 124.18 0.992 . . . . 75.42 109.337 173.833 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.418 HD12 ' O ' ' A' ' 192' ' ' ASP . 57.2 tp -132.42 127.53 35.56 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 123.493 0.717 . . . . 64.04 109.743 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -139.52 102.52 4.48 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 125.034 1.333 . . . . 73.2 108.122 176.637 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 56.59 58.41 14.53 Favored Glycine 0 C--N 1.353 1.479 0 O-C-N 123.951 0.782 . . . . 75.34 114.04 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 191' ' ' GLN . . . . . 0.568 ' NE2' ' HD2' ' A' ' 243' ' ' PRO . 52.6 mt-30 74.09 -15.81 0.57 Allowed 'General case' 0 N--CA 1.505 2.322 0 C-N-CA 125.407 1.483 . . . . 70.12 112.305 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.418 ' O ' HD12 ' A' ' 188' ' ' LEU . 9.7 t0 -97.41 152.44 18.95 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.333 1.053 . . . . 65.21 108.362 -175.358 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.4 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 78.4 mt -110.33 168.47 9.42 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 122.024 0.916 . . . . 61.54 111.512 -173.187 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 194' ' ' TYR . . . . . 0.705 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 35.6 m-85 -134.14 132.29 39.68 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 114.085 -1.416 . . . . 55.43 108.062 171.182 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 195' ' ' ALA . . . . . 0.436 ' HB3' HD11 ' A' ' 249' ' ' LEU . . . -154.02 168.28 26.95 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.909 0.884 . . . . 43.11 109.308 174.18 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 35.5 m -105.75 128.51 53.74 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 115.702 -0.681 . . . . 71.24 109.672 178.428 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.512 HD13 ' HB2' ' A' ' 212' ' ' ALA . 59.9 tp -107.76 113.65 27.05 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.733 -0.84 . . . . 75.23 108.733 173.382 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -94.9 119.82 34.08 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.373 -0.973 . . . . 72.43 108.373 175.496 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 199' ' ' VAL . . . . . 0.461 HG11 HG23 ' A' ' 253' ' ' VAL . 7.5 p -134.52 134.77 22.68 Favored Pre-proline 0 N--CA 1.479 1.018 0 C-N-CA 124.284 1.033 . . . . 64.42 109.37 -173.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.58 149.14 91.05 Favored 'Trans proline' 0 C--N 1.372 1.782 0 C-N-CA 122.715 2.277 . . . . 63.3 113.092 175.693 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 201' ' ' ALA . . . . . 0.492 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -60.75 -43.19 91.16 Favored Pre-proline 0 N--CA 1.478 0.972 0 N-CA-C 113.171 0.804 . . . . 75.53 113.171 176.445 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 202' ' ' PRO . . . . . 0.422 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 10.6 Cg_endo -53.73 -44.36 49.84 Favored 'Trans proline' 0 C--N 1.392 2.854 0 C-N-CA 121.759 1.639 . . . . 74.32 112.294 172.025 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.7 mt -67.44 -36.22 75.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 122.821 0.449 . . . . 73.53 111.189 177.618 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -64.57 -41.42 96.3 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 123.201 0.6 . . . . 73.22 111.802 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.7 m -79.89 -42.28 22.14 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 CA-C-N 116.003 -0.544 . . . . 72.34 111.362 -177.017 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 10.1 m -80.1 -20.02 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 122.471 0.308 . . . . 71.21 111.054 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 68.92 65.92 2.45 Favored Glycine 0 C--N 1.343 0.962 0 CA-C-N 115.687 -0.688 . . . . 51.43 112.461 -176.26 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.83 -145.92 15.4 Favored Glycine 0 C--N 1.357 1.7 0 N-CA-C 111.233 -0.747 . . . . 63.1 111.233 175.316 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 24.4 pttm -133.0 149.82 52.2 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 122.853 0.461 . . . . 71.51 109.88 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 2.8 m -145.09 134.37 18.04 Favored 'Isoleucine or valine' 0 C--O 1.239 0.528 0 N-CA-C 107.539 -1.282 . . . . 73.02 107.539 176.246 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 31.7 ptt180 -79.43 137.77 37.38 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 109.472 -0.566 . . . . 62.12 109.472 176.038 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.512 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -108.19 134.65 50.75 Favored 'General case' 0 C--O 1.245 0.845 0 C-N-CA 123.311 0.644 . . . . 74.45 109.408 174.218 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 4.8 tpt -75.85 106.26 7.33 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 108.837 -0.801 . . . . 74.22 108.837 173.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 214' ' ' THR . . . . . 0.41 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 11.2 t -110.68 165.85 11.49 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 109.703 -0.48 . . . . 64.31 109.703 174.553 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 215' ' ' LEU . . . . . 0.483 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 59.7 mt -69.69 -17.7 63.5 Favored 'General case' 0 CA--C 1.551 0.99 0 CA-C-N 115.686 -0.688 . . . . 61.02 111.162 178.348 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -79.21 -19.42 50.83 Favored 'General case' 0 CA--C 1.556 1.209 0 C-N-CA 123.934 0.894 . . . . 50.41 110.948 174.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 131.77 -148.53 19.06 Favored Glycine 0 C--N 1.346 1.088 0 N-CA-C 111.378 -0.689 . . . . 70.33 111.378 -176.079 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -85.86 126.85 2.99 Favored 'Trans proline' 0 CA--C 1.557 1.64 0 C-N-CA 122.376 2.05 . . . . 74.42 112.473 172.118 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 219' ' ' VAL . . . . . 0.525 HG11 ' HD2' ' A' ' 238' ' ' LYS . 34.9 m -111.56 155.47 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 N-CA-C 109.132 -0.692 . . . . 71.22 109.132 169.575 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -114.36 111.8 22.04 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.944 -0.761 . . . . 72.44 108.944 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.458 HG22 HD11 ' A' ' 235' ' ' LEU . 8.5 t -96.27 115.75 36.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.381 0 C-N-CA 123.593 0.757 . . . . 71.22 109.704 -178.594 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.59 101.28 13.97 Favored 'General case' 0 C--O 1.239 0.529 0 N-CA-C 106.673 -1.603 . . . . 54.23 106.673 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 19.0 m -75.21 141.47 74.13 Favored Pre-proline 0 CA--C 1.551 1.018 0 C-N-CA 122.546 0.338 . . . . 74.04 110.546 -173.319 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -60.07 133.27 49.15 Favored 'Trans proline' 0 C--N 1.378 2.092 0 C-N-CA 122.679 2.253 . . . . 42.24 111.828 176.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -56.0 124.57 16.58 Favored 'Trans proline' 0 C--N 1.377 2.077 0 C-N-CA 122.692 2.261 . . . . 71.41 110.92 173.31 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 60.58 51.98 4.8 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 124.593 1.157 . . . . 72.34 110.77 -173.271 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.2 t -78.61 165.77 23.3 Favored 'General case' 0 CA--C 1.544 0.741 0 N-CA-C 109.229 -0.656 . . . . 73.43 109.229 170.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 228' ' ' GLN . . . . . 0.43 ' H ' ' HD3' ' A' ' 231' ' ' ARG . 25.7 mp0 -119.51 147.32 44.58 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 108.707 -0.849 . . . . 72.15 108.707 -174.628 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.01 143.62 52.51 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.554 0.742 . . . . 74.12 110.844 178.778 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 89.46 0.04 80.03 Favored Glycine 0 C--N 1.343 0.966 0 O-C-N 123.442 0.464 . . . . 34.0 113.342 -179.065 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 231' ' ' ARG . . . . . 0.462 ' O ' HG12 ' A' ' 253' ' ' VAL . 80.8 mtp180 -80.26 163.48 23.95 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-N 117.455 0.627 . . . . 74.43 109.855 174.426 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.465 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.8 mptp? -112.97 107.31 15.81 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 108.69 -0.856 . . . . 75.34 108.69 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 56.9 mt -85.2 116.34 23.5 Favored 'General case' 0 C--N 1.355 0.824 0 N-CA-C 107.92 -1.141 . . . . 75.2 107.92 178.407 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 19.6 ttm-85 -95.79 114.76 26.53 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 124.097 0.959 . . . . 74.25 109.433 -164.229 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.458 HD11 HG22 ' A' ' 221' ' ' VAL . 25.0 mt -106.77 106.07 16.41 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.081 0.552 . . . . 73.3 109.698 176.573 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 236' ' ' LYS . . . . . 0.56 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 44.8 mttp -62.7 148.98 44.91 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 123.651 0.781 . . . . 55.24 111.718 176.539 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.51 35.44 81.41 Favored Glycine 0 C--N 1.355 1.636 0 O-C-N 123.971 0.794 . . . . 64.22 113.228 176.009 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 238' ' ' LYS . . . . . 0.525 ' HD2' HG11 ' A' ' 219' ' ' VAL . 15.9 mmtm -123.82 -23.08 4.75 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 123.774 0.83 . . . . 62.02 112.116 -176.159 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -81.38 -155.66 14.05 Favored Glycine 0 C--N 1.341 0.844 0 O-C-N 123.592 0.557 . . . . 74.04 112.68 178.203 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.468 ' CE2' ' HA ' ' A' ' 131' ' ' PHE . 75.3 m-85 -96.26 143.68 26.54 Favored Pre-proline 0 N--CA 1.474 0.754 0 O-C-N 122.346 -0.502 . . . . 71.03 111.802 178.186 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 241' ' ' PRO . . . . . 0.581 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 27.9 Cg_exo -62.22 168.21 9.71 Favored 'Trans proline' 0 C--N 1.378 2.095 0 C-N-CA 123.245 2.63 . . . . 72.13 112.868 176.684 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 163.22 -159.08 31.58 Favored Glycine 0 CA--C 1.534 1.226 0 CA-C-O 119.586 -0.564 . . . . 60.35 112.959 -177.791 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 243' ' ' PRO . . . . . 0.568 ' HD2' ' NE2' ' A' ' 191' ' ' GLN . 39.8 Cg_exo -60.44 -24.04 76.73 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 123.768 2.979 . . . . 74.24 113.363 177.601 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.44 18.56 7.08 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.668 0.787 . . . . 74.32 111.507 178.722 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.34 -98.84 1.79 Allowed Glycine 0 C--N 1.349 1.266 0 N-CA-C 110.746 -0.942 . . . . 64.14 110.746 -174.486 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.581 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 51.9 ttt180 -129.32 149.69 51.0 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.362 0.665 . . . . 75.53 109.845 166.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -75.31 -171.21 28.99 Favored Glycine 0 C--N 1.348 1.234 0 O-C-N 123.592 0.558 . . . . 50.23 112.882 176.387 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 248' ' ' ASP . . . . . 0.56 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 1.6 p-10 -145.16 169.56 17.93 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 123.89 0.876 . . . . 72.01 110.526 -174.307 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.436 HD11 ' HB3' ' A' ' 195' ' ' ALA . 22.9 tp -110.61 126.39 54.41 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 124.121 0.968 . . . . 72.24 112.095 -171.075 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 15.1 m-85 -88.84 107.06 18.78 Favored 'General case' 0 C--N 1.357 0.918 0 C-N-CA 123.7 0.8 . . . . 71.24 109.308 168.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.465 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 73.5 mt -88.57 121.93 31.48 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 123.783 0.833 . . . . 73.1 111.628 171.325 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -82.35 92.83 7.05 Favored 'General case' 0 C--O 1.235 0.313 0 N-CA-C 108.032 -1.099 . . . . 64.12 108.032 174.351 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.462 HG12 ' O ' ' A' ' 231' ' ' ARG . 2.4 p -58.61 114.29 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 C-N-CA 123.395 0.678 . . . . 45.14 110.484 177.586 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 21.3 mmm-85 -116.08 95.2 4.98 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 107.802 -1.184 . . . . 61.33 107.802 -177.759 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.492 HG23 ' HA ' ' A' ' 201' ' ' ALA . 75.2 mt -76.03 102.57 3.05 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 114.991 -1.004 . . . . 72.44 110.41 -174.839 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 CA--C 1.564 1.512 0 C-N-CA 124.337 1.055 . . . . 71.35 109.258 175.985 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.816 0 N-CA-C 110.171 -0.307 . . . . 52.41 110.171 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -63.87 -56.81 12.58 Favored 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 108.503 -0.925 . . . . 65.3 108.503 171.214 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.46 ' HA ' HD13 ' A' ' 123' ' ' LEU . 3.5 mm? -85.49 84.64 7.56 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 114.248 -1.342 . . . . 74.22 107.402 169.076 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.446 HG13 ' H ' ' A' ' 101' ' ' HIS . 7.1 p -60.1 -27.94 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 C-N-CA 123.092 0.557 . . . . 74.1 111.391 -178.485 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . 64.86 35.85 8.21 Favored 'General case' 0 C--N 1.355 0.818 0 O-C-N 124.541 1.151 . . . . 74.23 110.905 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' HIS . . . . . 0.446 ' H ' HG13 ' A' ' 99' ' ' VAL . 66.5 t-80 -75.35 91.07 2.68 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 114.755 -1.112 . . . . 75.04 108.088 178.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 46.3 t -57.2 145.72 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 C-N-CA 124.582 1.153 . . . . 75.43 111.297 -173.391 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.5 t -134.53 153.1 52.12 Favored 'General case' 0 C--O 1.242 0.665 0 C-N-CA 123.172 0.589 . . . . 63.43 109.836 177.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 44.7 m -137.8 111.16 7.96 Favored 'General case' 0 C--O 1.24 0.576 0 C-N-CA 124.149 0.98 . . . . 63.23 108.394 177.269 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 157.67 153.01 6.54 Favored Glycine 0 C--N 1.342 0.869 0 N-CA-C 111.704 -0.558 . . . . 70.32 111.704 -178.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 20.2 m -75.42 96.67 3.48 Favored 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 123.313 0.645 . . . . 72.44 109.691 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -142.9 62.18 0.51 Allowed Glycine 0 C--N 1.343 0.969 0 N-CA-C 111.281 -0.728 . . . . 33.4 111.281 -179.048 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.05 118.72 0.53 Allowed Glycine 0 C--N 1.339 0.748 0 N-CA-C 110.818 -0.913 . . . . 74.4 110.818 -177.404 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 21.3 m -65.32 97.86 0.3 Allowed 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 123.595 0.758 . . . . 72.14 110.555 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -87.33 -90.29 1.03 Allowed Glycine 0 C--N 1.346 1.09 0 CA-C-N 116.047 -0.524 . . . . 73.33 112.492 -178.589 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 119.82 -149.47 17.84 Favored Glycine 0 C--N 1.348 1.24 0 N-CA-C 111.453 -0.659 . . . . 51.45 111.453 -176.877 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 35.5 p -71.41 95.99 1.42 Allowed 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 123.304 0.642 . . . . 73.52 110.045 176.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -177.63 82.1 0.07 OUTLIER Glycine 0 C--N 1.348 1.206 0 CA-C-N 116.04 -0.527 . . . . 70.54 112.072 -179.24 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -138.31 -86.76 0.16 Allowed Glycine 0 C--N 1.342 0.899 0 N-CA-C 111.345 -0.702 . . . . 73.1 111.345 176.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.1 t 66.27 -70.54 0.1 Allowed 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 125.48 1.512 . . . . 74.1 111.543 179.03 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -88.65 169.56 37.38 Favored Glycine 0 C--N 1.342 0.889 0 N-CA-C 111.104 -0.798 . . . . 73.01 111.104 167.675 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 53.2 ttp180 -57.51 125.84 24.69 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 122.912 0.485 . . . . 63.32 110.479 174.753 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -73.62 141.28 46.55 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.098 0.559 . . . . 64.0 110.158 177.214 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.542 HD12 ' HA2' ' A' ' 165' ' ' GLY . 11.6 mt -124.05 151.41 43.83 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 108.129 -1.063 . . . . 45.31 108.129 168.524 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ARG . . . . . 0.515 ' HG2' ' HB2' ' A' ' 175' ' ' LEU . 17.3 mtp180 -142.6 151.01 41.07 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.571 0.748 . . . . 73.35 109.376 177.587 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.497 ' HB3' HD23 ' A' ' 176' ' ' LEU . . . -151.63 120.11 6.44 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 123.615 0.766 . . . . 54.31 109.412 177.003 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 37.8 mm-40 -84.05 143.18 29.91 Favored 'General case' 0 C--O 1.242 0.708 0 N-CA-C 109.111 -0.699 . . . . 73.34 109.111 175.58 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.46 HD13 ' HA ' ' A' ' 98' ' ' LEU . 0.7 OUTLIER -145.21 145.25 26.06 Favored Pre-proline 0 N--CA 1.475 0.781 0 C-N-CA 122.38 0.272 . . . . 74.2 110.923 174.707 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -81.64 114.51 2.69 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 121.864 1.709 . . . . 63.5 110.638 165.173 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 15.1 tp -106.79 138.8 42.29 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 123.863 0.865 . . . . 73.4 109.354 -178.71 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.751 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 20.8 m -78.78 158.76 28.15 Favored 'General case' 0 CA--C 1.548 0.901 0 N-CA-C 109.605 -0.517 . . . . 55.23 109.605 172.667 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.418 HD11 ' O ' ' A' ' 183' ' ' HIS . 31.6 mt -61.52 -47.11 87.09 Favored 'General case' 0 N--CA 1.483 1.177 0 CA-C-O 121.909 0.861 . . . . 61.34 110.004 178.287 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -56.81 -32.76 66.03 Favored 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 114.12 -1.4 . . . . 65.32 111.172 175.652 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.751 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 29.6 mm-40 -76.97 -32.08 57.0 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 122.977 0.511 . . . . 73.24 111.385 178.514 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.533 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -55.6 -35.1 65.46 Favored 'General case' 0 C--O 1.245 0.824 0 C-N-CA 122.999 0.519 . . . . 63.0 111.564 167.326 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.561 ' HA ' ' HE2' ' A' ' 240' ' ' PHE . 69.2 t80 -75.17 -47.62 27.55 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.447 -0.797 . . . . 72.51 112.877 171.306 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -68.95 -48.51 63.02 Favored 'General case' 0 N--CA 1.485 1.306 0 N-CA-C 112.115 0.413 . . . . 53.04 112.115 -170.092 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 57.52 -122.14 28.17 Favored Glycine 0 CA--C 1.534 1.272 0 O-C-N 123.869 0.731 . . . . 74.22 111.984 -172.874 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.27 -173.67 55.14 Favored Glycine 0 C--N 1.35 1.32 0 N-CA-C 114.358 0.503 . . . . 53.3 114.358 168.491 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' GLU . . . . . 0.532 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 1.3 mp0 -83.38 112.12 19.63 Favored 'General case' 0 C--N 1.356 0.856 0 N-CA-C 109.56 -0.533 . . . . 53.2 109.56 -178.552 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 10.3 mmm180 -123.07 156.47 34.84 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.291 1.036 . . . . 71.22 108.462 178.194 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.1 m -77.05 133.32 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 C-N-CA 122.46 0.304 . . . . 71.5 111.356 -176.718 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 144' ' ' ARG . 38.6 t -125.13 134.05 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.685 1.194 . . . . 73.21 108.798 172.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -125.67 97.17 5.05 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.058 0.943 . . . . 74.32 109.366 171.637 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 53.2 t -122.84 122.31 65.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 C-N-CA 123.548 0.739 . . . . 50.14 109.803 178.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.56 28.41 18.09 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 124.93 1.292 . . . . 60.21 112.381 175.558 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 98.37 -13.61 62.84 Favored Glycine 0 C--N 1.349 1.294 0 CA-C-N 116.107 -0.497 . . . . 53.2 113.594 178.086 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.98 118.0 30.35 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 117.508 0.654 . . . . 73.24 110.569 -179.716 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 138' ' ' VAL . 38.0 ttp180 -95.49 106.15 18.2 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 124.499 1.12 . . . . 61.33 108.41 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.9 t -128.33 131.21 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.19 0.996 . . . . 73.11 109.491 -179.197 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 70.0 m -72.25 115.19 11.2 Favored 'General case' 0 C--O 1.242 0.677 0 N-CA-C 108.635 -0.876 . . . . 34.02 108.635 170.699 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 7.1 p -96.81 143.67 11.93 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 123.044 0.538 . . . . 65.42 110.295 -178.637 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 31.2 ttm180 -107.89 100.26 9.64 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 107.585 -1.265 . . . . 72.13 107.585 171.762 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.409 ' HB ' HD13 ' A' ' 159' ' ' ILE . 27.7 pt -92.91 130.91 34.8 Favored Pre-proline 0 CA--C 1.548 0.881 0 N-CA-C 108.393 -0.966 . . . . 51.23 108.393 172.807 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -66.7 131.04 24.79 Favored 'Trans proline' 0 C--N 1.376 2.002 0 C-N-CA 122.617 2.211 . . . . 54.14 113.121 -172.164 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_exo -53.02 117.61 3.93 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.303 2.669 . . . . 75.3 111.824 167.037 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 124.46 54.26 0.18 Allowed Glycine 0 CA--C 1.506 -0.489 0 N-CA-C 110.758 -0.937 . . . . 71.42 110.758 -173.683 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.533 HG13 ' HA ' ' A' ' 130' ' ' ALA . 3.1 p -126.85 156.62 38.11 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.301 0 C-N-CA 123.456 0.703 . . . . 64.44 109.542 -175.483 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 55.4 mtp180 -138.26 176.09 9.0 Favored 'General case' 0 N--CA 1.491 1.599 0 C-N-CA 124.61 1.164 . . . . 74.53 111.284 -168.539 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -55.55 121.56 9.32 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 124.272 1.029 . . . . 74.33 111.04 171.367 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.14 7.86 84.8 Favored Glycine 0 C--N 1.348 1.204 0 O-C-N 123.589 0.556 . . . . 64.23 113.842 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 70.8 m -72.37 126.32 29.55 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 117.287 0.543 . . . . 61.25 109.818 176.684 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.461 HG12 HD22 ' A' ' 175' ' ' LEU . 32.7 t -100.47 123.03 53.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-N 114.045 -1.434 . . . . 64.31 108.265 -175.313 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.453 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 25.4 mt -110.57 118.6 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 123.414 0.686 . . . . 72.33 110.153 -172.452 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 33.2 ttm-85 -85.12 130.29 34.64 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.663 0.785 . . . . 72.12 110.619 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.621 HG22 ' HB3' ' A' ' 174' ' ' LEU . 4.2 m -124.49 125.96 25.52 Favored Pre-proline 0 CA--C 1.551 0.984 0 N-CA-C 108.691 -0.855 . . . . 64.33 108.691 166.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.34 147.17 28.81 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 122.614 2.209 . . . . 71.02 113.424 -173.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 70.62 24.89 76.52 Favored Glycine 0 C--N 1.351 1.415 0 CA-C-N 115.733 -0.667 . . . . 52.04 114.348 170.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 44.3 tpp -104.99 -37.64 6.89 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.152 0.581 . . . . 74.33 109.904 177.205 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' GLY . . . . . 0.542 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . -75.71 -99.3 0.13 Allowed Glycine 0 C--N 1.347 1.167 0 CA-C-N 115.483 -0.781 . . . . 32.54 112.942 -177.801 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.67 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -62.1 100.99 0.33 Allowed Glycine 0 C--N 1.346 1.105 0 C-N-CA 123.596 0.617 . . . . 53.02 112.346 173.572 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.7 mm-40 -84.78 105.29 15.45 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 108.597 -0.89 . . . . 74.41 108.597 178.503 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 165.52 -157.56 30.07 Favored Glycine 0 C--O 1.243 0.685 0 N-CA-C 111.065 -0.814 . . . . 73.21 111.065 -177.557 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -65.15 -48.87 68.8 Favored Pre-proline 0 CA--C 1.561 1.379 0 CA-C-O 118.128 -0.939 . . . . 73.04 111.28 176.795 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -80.42 106.17 1.83 Allowed 'Trans proline' 0 C--N 1.394 2.972 0 C-N-CA 122.299 1.999 . . . . 65.41 110.115 169.796 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.5 126.83 8.55 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.185 1.923 . . . . 63.23 110.425 -177.257 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 172' ' ' GLY . . . . . 0.67 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -95.5 172.66 30.4 Favored Glycine 0 C--O 1.237 0.338 0 N-CA-C 110.768 -0.933 . . . . 65.13 110.768 173.091 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -120.22 159.48 24.85 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 123.447 0.699 . . . . 71.55 110.689 -170.224 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' LEU . . . . . 0.621 ' HB3' HG22 ' A' ' 161' ' ' VAL . 43.1 tp -109.74 120.43 42.46 Favored 'General case' 0 C--O 1.242 0.698 0 N-CA-C 107.092 -1.447 . . . . 74.32 107.092 169.519 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 175' ' ' LEU . . . . . 0.515 ' HB2' ' HG2' ' A' ' 120' ' ' ARG . 52.5 mt -100.36 100.29 11.06 Favored 'General case' 0 C--O 1.241 0.616 0 O-C-N 124.495 1.122 . . . . 51.41 109.326 -178.003 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.497 HD23 ' HB3' ' A' ' 121' ' ' ALA . 26.7 mt -86.92 101.28 13.25 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 114.562 -1.199 . . . . 63.04 109.098 -179.394 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 23.1 t -93.47 105.98 17.46 Favored 'Isoleucine or valine' 0 C--O 1.244 0.812 0 N-CA-C 108.451 -0.944 . . . . 70.13 108.451 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.448 HG21 HG22 ' A' ' 153' ' ' VAL . 13.7 m -82.44 147.95 5.62 Favored 'Isoleucine or valine' 0 C--O 1.241 0.643 0 CA-C-N 115.593 -0.73 . . . . 73.15 110.271 -178.435 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 17.0 mmt180 -123.72 105.53 9.77 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 107.675 -1.231 . . . . 64.35 107.675 178.665 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 33.9 mt -67.22 148.81 51.27 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 117.725 0.239 . . . . 73.23 110.381 179.521 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.544 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 29.5 mt -57.46 157.44 13.33 Favored Pre-proline 0 CA--C 1.556 1.179 0 C-N-CA 123.78 0.832 . . . . 74.2 112.486 -171.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -57.19 -12.79 10.83 Favored 'Trans proline' 0 C--N 1.386 2.524 0 C-N-CA 123.019 2.48 . . . . 43.42 113.336 174.136 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 183' ' ' HIS . . . . . 0.418 ' O ' HD11 ' A' ' 127' ' ' LEU . 28.3 t60 -99.09 101.12 11.52 Favored Pre-proline 0 CA--C 1.545 0.763 0 C-N-CA 124.364 1.066 . . . . 63.24 108.528 166.235 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -102.44 128.41 0.1 Allowed 'Trans proline' 0 CA--C 1.557 1.665 0 C-N-CA 123.387 2.725 . . . . 51.54 112.396 162.819 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.9 p -116.93 -44.82 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 N-CA-C 109.135 -0.691 . . . . 63.4 109.135 172.138 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -100.28 123.84 45.0 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.576 -0.738 . . . . 70.35 111.438 -177.054 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 187' ' ' ARG . . . . . 0.706 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 80.2 mtt180 -109.46 160.85 15.87 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-N 114.084 -1.416 . . . . 72.04 108.118 175.42 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 188' ' ' LEU . . . . . 0.559 HD13 ' HD1' ' A' ' 240' ' ' PHE . 51.7 tp -130.78 142.64 50.41 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 108.913 -0.773 . . . . 61.03 108.913 178.651 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -140.85 99.95 3.72 Favored 'General case' 0 C--O 1.242 0.697 0 N-CA-C 107.411 -1.329 . . . . 74.21 107.411 175.168 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 70.18 -78.64 0.42 Allowed Glycine 0 CA--C 1.531 1.047 0 O-C-N 123.881 0.738 . . . . 73.43 112.216 -175.325 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 38.8 tt0 -138.34 -14.38 1.31 Allowed 'General case' 0 CA--C 1.558 1.26 0 C-N-CA 123.866 0.867 . . . . 74.23 110.448 -176.503 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.503 ' O ' HD12 ' A' ' 188' ' ' LEU . 9.2 m-20 -86.16 153.86 21.75 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 124.177 0.991 . . . . 72.52 112.103 -178.771 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 193' ' ' LEU . . . . . 0.514 ' HG ' ' HA2' ' A' ' 239' ' ' GLY . 85.0 mt -107.35 160.76 15.38 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 124.264 1.026 . . . . 72.25 108.519 175.834 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 194' ' ' TYR . . . . . 0.706 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 64.7 m-85 -136.63 121.55 18.79 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.584 -1.265 . . . . 54.33 107.584 177.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -144.14 148.29 34.86 Favored 'General case' 0 C--O 1.239 0.542 0 O-C-N 124.308 1.005 . . . . 42.32 109.197 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 49.4 m -88.37 127.18 35.49 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.258 -0.883 . . . . 70.32 109.165 173.15 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 197' ' ' LEU . . . . . 0.497 HD22 HD13 ' A' ' 251' ' ' LEU . 66.3 tp -105.9 110.5 22.81 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 108.215 -1.031 . . . . 73.2 108.215 178.101 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -92.35 112.02 23.81 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 108.71 -0.848 . . . . 74.23 108.71 178.061 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 199' ' ' VAL . . . . . 0.428 HG21 HG21 ' A' ' 223' ' ' VAL . 2.8 p -119.51 127.22 26.56 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 124.023 0.929 . . . . 75.22 108.946 -177.424 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 200' ' ' PRO . . . . . 0.448 ' HD2' HD12 ' A' ' 203' ' ' ILE . 51.7 Cg_exo -56.65 142.28 91.03 Favored 'Trans proline' 0 C--N 1.376 2.02 0 C-N-CA 122.729 2.286 . . . . 73.24 111.786 174.285 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 201' ' ' ALA . . . . . 0.468 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -55.8 -42.48 96.31 Favored Pre-proline 0 CA--C 1.557 1.222 0 CA-C-O 118.252 -0.88 . . . . 74.31 112.478 176.627 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 202' ' ' PRO . . . . . 0.51 ' O ' HG22 ' A' ' 206' ' ' VAL . 63.3 Cg_exo -46.75 -55.35 3.9 Favored 'Trans proline' 0 C--N 1.394 2.967 0 C-N-CA 122.972 2.448 . . . . 75.02 114.005 167.022 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 203' ' ' ILE . . . . . 0.454 HG23 ' H ' ' A' ' 208' ' ' GLY . 21.1 mt -61.7 -41.7 91.48 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 122.907 0.483 . . . . 75.1 111.122 -179.503 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.36 -35.39 78.98 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 115.063 -0.971 . . . . 71.52 111.832 -175.564 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 205' ' ' VAL . . . . . 0.589 HG23 HG13 ' A' ' 206' ' ' VAL . 25.9 m -89.35 -55.52 6.21 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 N-CA-C 112.798 0.666 . . . . 71.42 112.798 178.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.589 HG13 HG23 ' A' ' 205' ' ' VAL . 18.4 m -95.13 -38.3 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 CA-C-N 118.337 0.517 . . . . 74.5 112.074 -171.504 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -91.17 -115.93 1.95 Allowed Glycine 0 C--N 1.34 0.765 0 CA-C-N 116.606 -0.27 . . . . 74.44 112.657 -164.499 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 208' ' ' GLY . . . . . 0.454 ' H ' HG23 ' A' ' 203' ' ' ILE . . . 142.36 14.31 0.37 Allowed Glycine 0 C--N 1.335 0.521 0 CA-C-O 119.655 -0.525 . . . . 72.52 113.732 177.841 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 209' ' ' LYS . . . . . 0.444 ' O ' HD13 ' A' ' 203' ' ' ILE . 15.4 tppt? -117.51 118.22 31.59 Favored 'General case' 0 C--N 1.349 0.553 0 CA-C-N 117.762 0.781 . . . . 70.44 109.453 -173.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 210' ' ' VAL . . . . . 0.426 HG23 ' HB ' ' A' ' 221' ' ' VAL . 2.9 m -145.34 146.21 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.831 0 N-CA-C 108.596 -0.89 . . . . 72.23 108.596 170.438 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 56.4 mtm-85 -107.16 124.31 49.52 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.648 -0.871 . . . . 70.05 108.648 174.253 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 212' ' ' ALA . . . . . 0.471 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -103.09 137.91 40.64 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.298 0.639 . . . . 33.1 109.559 178.185 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 44.1 mmm -82.98 119.91 25.04 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 122.37 0.268 . . . . 70.43 110.489 174.506 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 3.5 t -118.04 169.88 9.3 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.411 1.085 . . . . 71.2 109.816 171.026 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 83.1 mt -73.96 -10.48 59.68 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 123.735 0.814 . . . . 73.55 112.688 -172.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -93.87 -13.33 27.33 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.602 0.761 . . . . 62.33 111.366 175.041 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 140.16 -157.87 25.64 Favored Glycine 0 C--N 1.347 1.183 0 CA-C-O 119.521 -0.599 . . . . 35.34 111.611 -177.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -85.59 135.83 5.18 Favored 'Trans proline' 0 CA--C 1.551 1.343 0 C-N-CA 122.469 2.113 . . . . 62.31 112.244 172.673 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.9 m -113.08 159.92 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 123.38 0.672 . . . . 64.13 110.26 168.6 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -111.35 109.59 19.66 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 107.669 -1.234 . . . . 73.33 107.669 179.501 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.517 HG22 HD11 ' A' ' 235' ' ' LEU . 12.7 t -96.16 125.24 49.07 Favored 'Isoleucine or valine' 0 C--O 1.243 0.754 0 C-N-CA 123.535 0.734 . . . . 70.23 109.582 177.471 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -88.67 103.59 16.07 Favored 'General case' 0 C--O 1.24 0.598 0 N-CA-C 108.767 -0.827 . . . . 63.44 108.767 170.421 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.428 HG21 HG21 ' A' ' 199' ' ' VAL . 17.0 m -80.04 136.01 54.43 Favored Pre-proline 0 N--CA 1.477 0.887 0 N-CA-C 107.879 -1.156 . . . . 74.41 107.879 172.068 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -61.47 129.44 28.13 Favored 'Trans proline' 0 CA--C 1.555 1.543 0 C-N-CA 122.0 1.8 . . . . 74.44 111.83 176.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -52.02 128.42 26.87 Favored 'Trans proline' 0 C--N 1.372 1.791 0 C-N-CA 122.655 2.236 . . . . 74.42 111.993 172.051 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 17.5 mtp180 65.31 42.61 3.84 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 125.252 1.421 . . . . 73.31 111.949 -173.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 227' ' ' THR . . . . . 0.507 HG23 HD11 ' A' ' 255' ' ' ILE . 8.5 t -78.36 177.45 8.46 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.115 0.566 . . . . 62.23 110.462 174.584 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 24.5 mp0 -126.85 154.08 44.83 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 123.412 0.685 . . . . 64.32 109.371 -178.577 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -71.61 149.43 45.61 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.236 0.614 . . . . 72.45 110.572 176.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 88.25 -4.13 85.42 Favored Glycine 0 CA--C 1.527 0.807 0 CA-C-O 119.705 -0.497 . . . . 52.51 112.853 -178.672 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 83.3 mtp180 -77.88 162.34 26.92 Favored 'General case' 0 C--N 1.36 1.063 0 CA-C-O 121.224 0.535 . . . . 75.22 111.153 177.641 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 232' ' ' LYS . . . . . 0.497 ' HG2' ' CZ ' ' A' ' 250' ' ' TYR . 10.6 mptt -118.35 122.06 41.92 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.89 0.876 . . . . 73.5 110.311 -173.302 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 64.4 mt -110.54 117.33 33.24 Favored 'General case' 0 C--N 1.348 0.506 0 N-CA-C 107.784 -1.191 . . . . 74.31 107.784 173.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 44.1 ttp180 -112.78 111.44 22.22 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 109.29 -0.633 . . . . 63.5 109.29 -168.629 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.517 HD11 HG22 ' A' ' 221' ' ' VAL . 14.7 mt -96.8 120.84 37.89 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 123.581 0.752 . . . . 74.04 109.82 -174.212 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 51.1 mttp -71.14 147.04 48.78 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.256 0.622 . . . . 72.04 112.32 -177.514 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.73 15.81 69.28 Favored Glycine 0 C--N 1.352 1.453 0 O-C-N 124.054 0.846 . . . . 55.34 114.401 173.486 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 238' ' ' LYS . . . . . 0.442 ' HG3' ' HB2' ' A' ' 235' ' ' LEU . 1.3 mmpm? -101.35 -17.43 16.52 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 123.548 0.739 . . . . 74.35 111.708 -175.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 239' ' ' GLY . . . . . 0.514 ' HA2' ' HG ' ' A' ' 193' ' ' LEU . . . -74.97 -148.13 1.66 Allowed Glycine 0 C--N 1.346 1.084 0 O-C-N 123.847 0.717 . . . . 63.44 113.709 -176.679 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 240' ' ' PHE . . . . . 0.561 ' HE2' ' HA ' ' A' ' 131' ' ' PHE . 39.9 m-85 -97.32 155.53 37.26 Favored Pre-proline 0 N--CA 1.475 0.786 0 CA-C-O 119.158 -0.448 . . . . 70.21 111.576 174.557 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -55.12 146.92 56.65 Favored 'Trans proline' 0 C--N 1.385 2.466 0 C-N-CA 122.906 2.404 . . . . 64.4 112.751 179.495 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -178.98 -165.71 33.78 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.669 -0.696 . . . . 72.42 112.15 -178.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -58.05 -27.6 80.19 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.375 2.717 . . . . 65.22 114.49 -179.606 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.07 22.82 5.44 Favored 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 123.556 0.742 . . . . 44.22 111.718 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.13 -86.01 1.56 Allowed Glycine 0 C--N 1.348 1.218 0 N-CA-C 110.097 -1.201 . . . . 54.14 110.097 -174.865 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 246' ' ' ARG . . . . . 0.484 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 18.6 mtm180 -126.94 164.54 21.24 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 108.355 -0.98 . . . . 55.32 108.355 163.238 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -77.85 -153.87 6.5 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.541 -0.754 . . . . 55.51 113.71 -177.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -120.5 164.5 16.33 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.154 0.581 . . . . 62.51 110.262 -177.535 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 249' ' ' LEU . . . . . 0.5 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 15.8 tp -109.98 111.15 22.37 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.037 0.935 . . . . 61.24 108.913 168.293 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 250' ' ' TYR . . . . . 0.497 ' CZ ' ' HG2' ' A' ' 232' ' ' LYS . 17.9 t80 -90.68 104.57 17.14 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 107.914 -1.143 . . . . 75.31 107.914 178.528 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 251' ' ' LEU . . . . . 0.497 HD13 HD22 ' A' ' 197' ' ' LEU . 63.7 mt -89.19 148.8 23.43 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.292 1.037 . . . . 63.03 111.583 179.0 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -110.14 97.12 6.68 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 107.922 -1.14 . . . . 65.23 107.922 173.145 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 60.2 t -52.24 117.09 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 123.663 0.785 . . . . 62.22 110.104 174.531 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 12.8 mmm180 -124.73 93.12 3.81 Favored 'General case' 0 C--O 1.238 0.463 0 N-CA-C 107.708 -1.219 . . . . 73.22 107.708 178.6 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.507 HD11 HG23 ' A' ' 227' ' ' THR . 60.1 mt -75.64 104.82 4.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-N 115.103 -0.953 . . . . 73.44 109.267 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.554 1.116 0 C-N-CA 124.047 0.939 . . . . 75.03 109.728 -178.001 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.438 HD21 ' HG2' ' A' ' 136' ' ' ARG . 0.2 OUTLIER . . . . . 0 N--CA 1.481 1.101 0 CA-C-O 119.818 -0.134 . . . . 73.22 111.093 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.653 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 61.5 t -60.77 125.59 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 123.037 0.535 . . . . 45.4 111.057 175.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -71.36 -66.97 0.55 Allowed 'General case' 0 C--N 1.346 0.45 0 CA-C-N 115.544 -0.753 . . . . 71.34 109.763 177.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 20.4 p-80 178.19 177.36 0.42 Allowed 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 124.634 1.174 . . . . 72.04 109.724 -176.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 43.9 t -71.34 136.84 24.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.078 0 C-N-CA 123.497 0.719 . . . . 60.1 110.157 177.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.8 t . . . . . 0 N--CA 1.473 0.679 0 C-N-CA 124.384 1.074 . . . . 74.22 109.448 178.17 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.464 ' HB3' ' HE ' ' A' ' 120' ' ' ARG . 5.9 m-20 . . . . . 0 N--CA 1.478 0.937 0 N-CA-C 109.545 -0.539 . . . . 71.1 109.545 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.499 HD12 ' HA2' ' A' ' 165' ' ' GLY . 12.3 mt -100.76 132.45 46.16 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 107.601 -1.259 . . . . 71.31 107.601 167.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . 0.464 ' HE ' ' HB3' ' A' ' 118' ' ' ASP . 21.4 mmt85 -127.84 133.49 49.38 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 107.851 -1.166 . . . . 72.44 107.851 -177.255 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -154.01 145.3 22.97 Favored 'General case' 0 N--CA 1.47 0.552 0 O-C-N 123.441 0.463 . . . . 50.25 109.756 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.672 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 41.3 mt-10 -112.09 148.36 34.1 Favored 'General case' 0 C--O 1.246 0.885 0 C-N-CA 123.59 0.756 . . . . 75.43 109.721 174.557 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.653 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.7 pt? -145.88 130.04 8.68 Favored Pre-proline 0 C--O 1.222 -0.376 0 CA-C-N 115.443 -0.799 . . . . 61.21 111.065 -176.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.18 117.49 4.28 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 121.819 1.679 . . . . 74.21 110.152 163.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.472 ' HB3' HD23 ' A' ' 180' ' ' LEU . 21.3 tp -110.59 139.8 45.5 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 123.624 0.77 . . . . 63.22 109.237 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.613 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 4.7 m -76.63 149.33 36.54 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 109.015 -0.735 . . . . 74.05 109.015 170.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.403 HD11 ' O ' ' A' ' 183' ' ' HIS . 44.4 mt -57.06 -44.58 83.18 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 122.267 1.032 . . . . 64.2 109.868 177.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -57.26 -37.7 72.75 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 113.383 -1.735 . . . . 63.52 111.439 176.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.613 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 42.1 mm-40 -77.58 -27.36 51.36 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 122.644 0.378 . . . . 74.24 111.758 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.503 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -58.75 -36.32 74.16 Favored 'General case' 0 C--O 1.243 0.741 0 C-N-CA 123.203 0.601 . . . . 64.43 111.446 167.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.415 ' CZ ' ' HB3' ' A' ' 216' ' ' GLU . 70.9 t80 -74.0 -51.84 14.67 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.151 -0.931 . . . . 73.44 112.427 171.15 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 34.3 m80 -63.83 -49.15 73.96 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 123.358 0.411 . . . . 73.55 112.04 -167.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 48.44 52.76 18.25 Favored Glycine 0 CA--C 1.534 1.28 0 O-C-N 124.118 0.886 . . . . 51.34 114.125 178.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -102.67 -168.61 26.45 Favored Glycine 0 C--N 1.347 1.139 0 CA-C-O 120.044 -0.309 . . . . 64.22 112.481 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.425 ' HB3' ' OG ' ' A' ' 146' ' ' SER . 2.1 mp0 -77.36 113.97 15.69 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 109.556 -0.535 . . . . 64.41 109.556 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.438 ' HG2' HD21 ' A' ' 98' ' ' LEU . 2.4 mpt_? -124.36 150.61 45.33 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 124.106 0.963 . . . . 60.12 108.681 173.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.8 p -76.35 129.74 36.89 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.093 0 CA-C-O 121.256 0.551 . . . . 72.42 111.266 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.527 HG21 HD21 ' A' ' 174' ' ' LEU . 7.9 p -111.27 141.0 27.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 C-N-CA 124.66 1.184 . . . . 71.43 108.81 170.577 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -125.72 100.68 6.53 Favored 'General case' 0 C--O 1.238 0.498 0 N-CA-C 107.819 -1.178 . . . . 74.22 107.819 178.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.7 m -123.84 108.03 19.97 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 C-N-CA 124.288 1.035 . . . . 41.45 110.436 -175.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 66.19 25.29 10.68 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 124.633 1.173 . . . . 55.24 111.766 179.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.83 4.96 78.41 Favored Glycine 0 C--N 1.353 1.482 0 CA-C-N 116.035 -0.53 . . . . 65.35 112.909 -176.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 30.9 tpt180 -94.02 115.41 27.74 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 108.687 -0.857 . . . . 71.4 108.687 177.158 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 75.3 ttt180 -97.74 115.58 28.28 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.729 -0.841 . . . . 71.23 108.729 177.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.432 HG11 ' SD ' ' A' ' 164' ' ' MET . 16.1 t -130.51 154.59 40.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 108.059 -1.089 . . . . 74.35 108.059 173.748 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.425 ' OG ' ' HB3' ' A' ' 135' ' ' GLU . 48.3 t -92.19 109.0 20.36 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.289 -1.004 . . . . 55.44 108.289 171.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 9.9 p -97.77 129.6 47.71 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 C-N-CA 123.702 0.801 . . . . 73.43 109.743 -178.613 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 29.1 ttt180 -107.96 97.47 7.17 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 107.719 -1.215 . . . . 72.41 107.719 173.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.555 ' HB ' HD13 ' A' ' 159' ' ' ILE . 26.1 pt -78.51 141.4 60.82 Favored Pre-proline 0 CA--C 1.552 1.053 0 N-CA-C 109.286 -0.635 . . . . 70.01 109.286 177.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -70.06 134.19 26.76 Favored 'Trans proline' 0 C--N 1.372 1.78 0 C-N-CA 122.299 1.999 . . . . 74.23 112.526 -173.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -54.31 138.85 73.38 Favored 'Trans proline' 0 C--N 1.371 1.752 0 C-N-CA 123.121 2.547 . . . . 73.13 112.02 168.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 105.78 36.93 2.67 Favored Glycine 0 N--CA 1.463 0.493 0 N-CA-C 111.589 -0.604 . . . . 52.35 111.589 -173.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.608 HG21 HD11 ' A' ' 159' ' ' ILE . 2.4 p -112.71 155.93 13.83 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.251 0 N-CA-C 109.099 -0.704 . . . . 62.35 109.099 -177.194 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.431 ' HD2' ' O ' ' A' ' 188' ' ' LEU . 38.7 mtp180 -142.38 173.16 11.78 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 125.177 1.391 . . . . 73.03 110.742 -168.46 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.4 tp10 -58.39 121.1 10.02 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 123.758 0.823 . . . . 74.41 110.997 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.25 7.68 88.13 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-N 116.252 -0.431 . . . . 33.31 113.48 -178.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.436 ' HB3' HG23 ' A' ' 153' ' ' VAL . 38.6 t -77.8 125.55 29.51 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 109.45 -0.574 . . . . 74.01 109.45 179.134 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.542 HG12 HD22 ' A' ' 175' ' ' LEU . 8.5 t -98.5 120.26 47.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-N 114.609 -1.178 . . . . 72.12 108.75 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.608 HD11 HG21 ' A' ' 153' ' ' VAL . 49.1 mt -107.21 120.43 58.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.92 0.888 . . . . 71.43 111.136 -172.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 25.8 ttm180 -92.58 114.13 26.6 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 123.2 0.6 . . . . 73.11 111.068 177.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -113.46 96.07 38.55 Favored Pre-proline 0 CA--C 1.559 1.313 0 N-CA-C 109.279 -0.637 . . . . 73.52 109.279 173.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -62.24 148.66 92.84 Favored 'Trans proline' 0 C--N 1.388 2.609 0 C-N-CA 123.646 2.898 . . . . 74.13 113.588 -177.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 85.5 -12.85 57.88 Favored Glycine 0 C--N 1.349 1.272 0 O-C-N 123.813 0.696 . . . . 75.23 113.34 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.432 ' SD ' HG11 ' A' ' 145' ' ' VAL . 36.4 mmm -92.33 -28.58 16.85 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.411 1.084 . . . . 62.34 111.912 -170.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . 0.499 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.344 1.025 0 N-CA-C 111.158 -0.777 . . . . 61.24 111.158 176.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo . . . . . 0 CA--C 1.537 0.667 0 N-CA-C 111.307 -0.305 . . . . 75.03 111.307 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -105.34 152.18 17.22 Favored Glycine 0 CA--C 1.504 -0.652 0 N-CA-C 109.806 -1.317 . . . . 64.33 109.806 171.516 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -112.96 168.81 9.39 Favored 'General case' 0 C--O 1.241 0.628 0 CA-C-O 121.503 0.668 . . . . 71.51 110.488 -173.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.527 HD21 HG21 ' A' ' 138' ' ' VAL . 12.4 tp -118.62 115.39 24.44 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 107.722 -1.214 . . . . 73.12 107.722 175.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.542 HD22 HG12 ' A' ' 158' ' ' VAL . 53.6 mt -88.38 100.22 12.86 Favored 'General case' 0 C--O 1.241 0.653 0 O-C-N 123.958 0.786 . . . . 74.43 110.305 177.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 81.5 mt -88.29 102.99 15.39 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.013 -0.994 . . . . 71.12 110.57 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.672 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 48.2 t -86.66 104.81 14.28 Favored 'Isoleucine or valine' 0 C--O 1.241 0.605 0 N-CA-C 108.307 -0.998 . . . . 52.34 108.307 173.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.469 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 9.6 m -82.04 150.82 4.33 Favored 'Isoleucine or valine' 0 C--O 1.245 0.821 0 CA-C-O 121.325 0.583 . . . . 64.11 110.838 -177.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 24.0 mmm-85 -126.99 97.11 4.83 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.242 -1.392 . . . . 72.35 107.242 -175.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.472 HD23 ' HB3' ' A' ' 125' ' ' LEU . 46.1 mt -66.4 147.09 53.8 Favored 'General case' 0 C--O 1.242 0.683 0 CA-C-O 120.536 0.208 . . . . 61.42 110.656 -176.449 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.411 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 37.6 mt -54.8 152.19 13.72 Favored Pre-proline 0 CA--C 1.556 1.19 0 O-C-N 124.09 0.869 . . . . 73.45 111.829 -173.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -58.29 -8.7 5.43 Favored 'Trans proline' 0 C--N 1.383 2.376 0 C-N-CA 123.377 2.718 . . . . 64.11 113.363 172.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . 0.403 ' O ' HD11 ' A' ' 127' ' ' LEU . 6.3 t60 -93.59 107.97 30.65 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 124.79 1.236 . . . . 72.24 108.614 168.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -99.52 163.69 0.55 Allowed 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 123.314 2.676 . . . . 71.44 112.427 165.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -156.64 -45.67 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 N-CA-C 109.02 -0.733 . . . . 61.41 109.02 168.604 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.462 ' CE2' HD13 ' A' ' 193' ' ' LEU . 5.6 m-85 -100.66 122.54 43.49 Favored 'General case' 0 C--O 1.238 0.454 0 C-N-CA 123.585 0.754 . . . . 72.42 110.699 -177.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 12.0 mtp180 -99.75 108.72 21.11 Favored 'General case' 0 C--O 1.237 0.441 0 C-N-CA 124.612 1.165 . . . . 72.41 108.624 170.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.431 ' O ' ' HD2' ' A' ' 154' ' ' ARG . 60.2 tp -84.54 110.67 18.87 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.932 -0.766 . . . . 73.35 108.932 170.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 24.0 mm-40 -104.11 97.05 7.07 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 107.325 -1.361 . . . . 62.22 107.325 172.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 67.64 -89.06 0.18 Allowed Glycine 0 CA--C 1.531 1.044 0 O-C-N 123.757 0.66 . . . . 71.5 112.807 -175.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . 0.405 HE22 ' HB3' ' A' ' 244' ' ' ALA . 50.3 tt0 -120.74 -18.12 7.78 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 125.103 1.361 . . . . 73.03 109.779 -176.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.422 ' O ' HD12 ' A' ' 188' ' ' LEU . 44.5 m-20 -96.07 160.04 14.65 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.382 1.073 . . . . 74.55 111.383 -173.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.585 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 96.3 mt -119.21 154.97 32.54 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.202 1.001 . . . . 63.43 112.298 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 74.0 m-85 -139.0 120.72 15.28 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 106.248 -1.76 . . . . 73.44 106.248 170.2 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . 0.465 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -141.7 140.06 33.07 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 108.178 -1.045 . . . . 64.43 108.178 176.667 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 19.1 m -77.15 129.98 36.71 Favored 'General case' 0 CA--C 1.539 0.548 0 O-C-N 123.347 0.405 . . . . 65.15 110.323 -175.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.422 HD13 ' HB2' ' A' ' 212' ' ' ALA . 51.2 tp -114.42 111.79 21.99 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 123.951 0.9 . . . . 73.12 108.785 176.694 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -101.64 107.73 19.06 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.127 -0.694 . . . . 72.12 109.127 178.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . 0.521 HG11 HG11 ' A' ' 223' ' ' VAL . 5.9 m -108.52 145.69 32.1 Favored Pre-proline 0 N--CA 1.478 0.963 0 C-N-CA 123.755 0.822 . . . . 43.12 109.472 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -70.83 149.67 60.45 Favored 'Trans proline' 0 C--N 1.366 1.481 0 C-N-CA 121.699 1.599 . . . . 73.03 110.664 173.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . 0.422 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -56.11 -43.53 99.29 Favored Pre-proline 0 CA--C 1.561 1.389 0 CA-C-O 118.374 -0.822 . . . . 71.32 113.112 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -46.21 -51.51 8.52 Favored 'Trans proline' 0 C--N 1.394 2.952 0 C-N-CA 122.921 2.414 . . . . 73.42 114.274 169.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 5.7 mt -69.15 -38.57 78.21 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 C-N-CA 122.335 0.254 . . . . 74.14 111.117 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.18 -41.55 88.75 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.239 0.616 . . . . 73.0 112.234 -179.193 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 33.1 m -82.84 -38.64 15.0 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 CA-C-N 115.891 -0.595 . . . . 71.12 111.53 -174.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.6 m -77.0 -24.79 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 CA-C-O 120.82 0.343 . . . . 73.3 110.849 177.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 76.68 52.84 5.71 Favored Glycine 0 C--N 1.346 1.112 0 CA-C-N 115.376 -0.829 . . . . 70.22 112.366 -175.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.42 -160.35 27.51 Favored Glycine 0 C--N 1.359 1.817 0 N-CA-C 112.123 -0.391 . . . . 54.31 112.123 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 21.2 ptmt -119.91 142.9 48.28 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 123.023 0.529 . . . . 72.34 109.727 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . 0.403 HG21 HG12 ' A' ' 199' ' ' VAL . 75.6 t -128.7 135.11 63.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 C-N-CA 124.351 1.06 . . . . 71.32 108.631 177.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . 0.607 ' HG2' ' HG2' ' A' ' 220' ' ' GLU . 99.3 mtt180 -77.95 112.56 14.97 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 109.198 -0.668 . . . . 75.55 109.198 171.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.422 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -99.14 129.27 45.38 Favored 'General case' 0 C--O 1.242 0.686 0 N-CA-C 108.436 -0.949 . . . . 64.4 108.436 175.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . 0.413 ' SD ' ' N ' ' A' ' 214' ' ' THR . 1.3 tpp -69.72 130.29 41.93 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.837 -0.62 . . . . 63.03 109.79 175.054 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.497 HG21 HG13 ' A' ' 219' ' ' VAL . 7.7 t -134.07 163.67 29.06 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.507 1.123 . . . . 75.43 110.142 173.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 79.4 mt -71.68 -8.87 56.79 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 124.004 0.922 . . . . 72.35 113.183 -172.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . 0.415 ' HB3' ' CZ ' ' A' ' 131' ' ' PHE . 10.3 pt-20 -97.39 -18.34 19.16 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.433 0.693 . . . . 71.11 111.767 173.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.74 -146.36 15.74 Favored Glycine 0 C--N 1.349 1.253 0 CA-C-O 119.556 -0.58 . . . . 53.4 112.181 -176.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -91.17 131.15 1.42 Allowed 'Trans proline' 0 CA--C 1.559 1.736 0 C-N-CA 122.796 2.331 . . . . 72.3 112.777 170.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . 0.497 HG13 HG21 ' A' ' 214' ' ' THR . 20.5 m -110.13 147.25 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 108.996 -0.742 . . . . 72.44 108.996 163.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . 0.607 ' HG2' ' HG2' ' A' ' 211' ' ' ARG . 42.8 mt-10 -114.37 104.33 11.96 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 108.781 -0.822 . . . . 73.12 108.781 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.42 HG23 HD21 ' A' ' 235' ' ' LEU . 2.8 p -95.68 120.25 44.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 124.033 0.933 . . . . 74.44 110.373 -177.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.12 103.57 12.65 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 107.689 -1.226 . . . . 42.22 107.689 173.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.521 HG11 HG11 ' A' ' 199' ' ' VAL . 14.6 m -65.96 143.89 98.61 Favored Pre-proline 0 CA--C 1.553 1.059 0 C-N-CA 123.229 0.612 . . . . 74.13 110.168 -179.014 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -55.58 138.79 81.71 Favored 'Trans proline' 0 C--N 1.376 1.994 0 C-N-CA 122.625 2.216 . . . . 52.41 112.209 176.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.11 122.34 11.42 Favored 'Trans proline' 0 C--N 1.369 1.624 0 C-N-CA 122.181 1.921 . . . . 63.1 110.129 172.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . 0.479 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 96.0 mtt180 63.39 41.25 7.77 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 124.418 1.074 . . . . 71.23 110.996 -175.591 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.4 t -65.15 168.89 6.13 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 122.858 0.463 . . . . 51.23 111.009 177.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . 0.466 ' H ' ' HD3' ' A' ' 231' ' ' ARG . 26.2 mp0 -118.09 146.72 43.92 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 123.889 0.876 . . . . 74.41 109.165 -176.15 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -75.02 135.91 41.25 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.745 -0.835 . . . . 41.32 108.745 173.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 106.11 -7.91 41.36 Favored Glycine 0 C--N 1.34 0.762 0 N-CA-C 112.153 -0.379 . . . . 75.34 112.153 -175.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . 0.466 ' HD3' ' H ' ' A' ' 228' ' ' GLN . 62.0 mtp180 -79.92 160.99 25.79 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.284 0.634 . . . . 75.12 111.079 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.464 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 10.5 mptt -119.05 112.91 20.15 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 124.065 0.946 . . . . 62.44 108.503 176.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . 0.497 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 39.6 mt -89.69 110.08 21.0 Favored 'General case' 0 C--N 1.358 0.958 0 N-CA-C 108.868 -0.79 . . . . 72.35 108.868 -178.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . 0.407 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 41.4 ttp180 -83.81 102.51 12.38 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 114.923 -1.035 . . . . 64.52 111.046 -169.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.42 HD21 HG23 ' A' ' 221' ' ' VAL . 26.5 mt -95.74 98.01 10.13 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 108.513 -0.921 . . . . 74.31 108.513 174.171 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . 0.436 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 26.7 mtpp -80.79 143.87 32.53 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.96 0.41 . . . . 71.14 111.316 -174.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 75.94 24.12 70.21 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.148 -0.933 . . . . 74.24 111.809 -174.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 48.4 mmtm -128.94 10.25 5.91 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.366 1.066 . . . . 74.2 110.442 177.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -84.67 -158.21 28.34 Favored Glycine 0 C--N 1.359 1.838 0 O-C-N 123.13 0.269 . . . . 44.14 113.052 175.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.543 ' CD1' HD21 ' A' ' 193' ' ' LEU . 10.5 m-85 -98.02 166.14 14.02 Favored Pre-proline 0 N--CA 1.48 1.044 0 C-N-CA 123.131 0.573 . . . . 63.51 110.565 172.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -61.01 160.45 25.82 Favored 'Trans proline' 0 C--N 1.384 2.409 0 C-N-CA 122.829 2.353 . . . . 71.35 112.113 172.201 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 175.76 -171.21 44.29 Favored Glycine 0 CA--C 1.527 0.791 0 CA-C-N 116.147 -0.479 . . . . 73.32 113.515 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -57.31 -38.73 93.92 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.975 3.116 . . . . 60.05 113.29 -179.155 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . 0.405 ' HB3' HE22 ' A' ' 191' ' ' GLN . . . -92.33 21.84 4.94 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 123.389 0.676 . . . . 71.32 111.937 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 91.66 -102.66 2.95 Favored Glycine 0 C--N 1.347 1.194 0 N-CA-C 111.746 -0.541 . . . . 45.41 111.746 178.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 51.6 ttt180 -121.52 140.02 52.74 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 122.933 0.493 . . . . 73.12 109.675 174.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -81.06 -157.2 16.4 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 124.014 0.821 . . . . 71.33 113.076 -179.039 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . 0.436 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 3.5 p30 -146.62 154.25 41.27 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 123.032 0.533 . . . . 71.41 110.722 -174.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.585 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 26.2 tp -98.58 128.27 44.83 Favored 'General case' 0 C--O 1.22 -0.468 0 C-N-CA 124.338 1.055 . . . . 62.5 110.384 -174.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . 0.464 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 63.1 m-85 -102.63 107.43 18.34 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 123.57 0.748 . . . . 73.22 109.505 173.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.497 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 77.2 mt -87.07 111.11 20.58 Favored 'General case' 0 C--O 1.233 0.233 0 C-N-CA 123.701 0.8 . . . . 74.34 112.52 178.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.41 ' HG2' ' HE3' ' A' ' 232' ' ' LYS . 1.6 tm-20 -80.42 90.37 5.63 Favored 'General case' 0 CA--C 1.552 1.025 0 N-CA-C 108.457 -0.942 . . . . 73.54 108.457 -176.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.407 ' O ' ' HD2' ' A' ' 254' ' ' ARG . 46.0 t -53.29 128.34 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 125.991 1.716 . . . . 74.15 112.882 -177.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . 0.407 ' HD2' ' O ' ' A' ' 253' ' ' VAL . 23.5 mmm180 -126.8 98.57 5.41 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 107.255 -1.387 . . . . 74.22 107.255 173.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.422 HG23 ' HA ' ' A' ' 201' ' ' ALA . 63.6 mt -76.53 102.43 3.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 108.861 -0.792 . . . . 74.12 108.861 177.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 8.9 t . . . . . 0 C--O 1.253 1.263 0 C-N-CA 124.357 1.063 . . . . 55.31 110.173 -171.424 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.605 HD21 ' HG3' ' A' ' 136' ' ' ARG . 0.2 OUTLIER . . . . . 0 N--CA 1.482 1.164 0 CA-C-O 119.653 -0.213 . . . . 71.44 110.913 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.646 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 43.9 t -58.04 119.82 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 C-N-CA 122.988 0.515 . . . . 42.13 111.238 177.576 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -67.22 -71.4 0.2 Allowed 'General case' 0 C--O 1.238 0.485 0 O-C-N 124.275 0.984 . . . . 72.2 109.31 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.0 m80 -168.0 176.12 6.33 Favored 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 124.665 1.186 . . . . 72.33 109.757 -178.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 99.5 t -61.38 136.51 24.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.025 0 C-N-CA 124.094 0.958 . . . . 73.22 110.47 171.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 42.6 p . . . . . 0 CA--C 1.551 0.992 0 N-CA-C 109.122 -0.696 . . . . 75.1 109.122 170.231 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 . . . . . 0 N--CA 1.47 0.54 0 N-CA-C 108.686 -0.857 . . . . 53.43 108.686 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.491 HD21 ' HB ' ' A' ' 140' ' ' VAL . 44.5 tp -128.79 134.98 48.56 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 107.759 -1.2 . . . . 72.33 107.759 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . 0.425 ' HD3' ' HB2' ' A' ' 175' ' ' LEU . 9.8 mmt85 -115.43 134.97 54.59 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 109.438 -0.579 . . . . 73.41 109.438 -178.017 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -150.6 154.54 37.7 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 123.329 0.652 . . . . 72.31 109.38 173.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -119.78 151.35 38.94 Favored 'General case' 0 C--O 1.245 0.851 0 C-N-CA 123.134 0.574 . . . . 72.42 110.169 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.646 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.4 pt? -144.95 143.13 19.72 Favored Pre-proline 0 N--CA 1.471 0.59 0 CA-C-N 115.424 -0.807 . . . . 74.13 111.286 -178.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.43 113.95 3.87 Favored 'Trans proline' 0 C--N 1.37 1.68 0 C-N-CA 121.377 1.384 . . . . 55.55 109.119 160.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.518 HD22 HG11 ' A' ' 178' ' ' VAL . 20.0 tp -104.97 148.44 26.72 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 108.463 -0.94 . . . . 74.13 108.463 178.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.678 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 4.1 m -82.15 157.54 23.99 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 109.919 -0.401 . . . . 63.21 109.919 175.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.456 HD23 ' HB3' ' A' ' 180' ' ' LEU . 77.5 mt -59.16 -48.68 80.72 Favored 'General case' 0 N--CA 1.482 1.145 0 CA-C-O 122.342 1.068 . . . . 64.32 109.529 172.331 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.53 -34.46 64.7 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 113.621 -1.627 . . . . 74.41 111.963 174.693 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.459 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 17.0 mm-40 -85.63 -17.69 35.39 Favored 'General case' 0 N--CA 1.481 1.083 0 C-N-CA 123.398 0.679 . . . . 71.45 112.416 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.728 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -58.23 -43.41 87.75 Favored 'General case' 0 C--O 1.249 1.05 0 CA-C-O 121.382 0.611 . . . . 61.21 109.697 163.155 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -71.32 -60.31 2.3 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 114.842 -1.072 . . . . 74.14 111.62 174.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -69.05 -47.16 66.04 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 123.588 0.755 . . . . 71.43 112.252 -169.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 71.76 -86.25 0.45 Allowed Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.816 -0.914 . . . . 74.23 110.816 -170.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.0 -179.57 51.3 Favored Glycine 0 C--N 1.345 1.08 0 N-CA-C 114.528 0.571 . . . . 70.34 114.528 174.244 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 14.8 mp0 -98.61 115.27 28.27 Favored 'General case' 0 N--CA 1.471 0.584 0 N-CA-C 107.301 -1.37 . . . . 71.2 107.301 175.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.605 ' HG3' HD21 ' A' ' 98' ' ' LEU . 39.3 mmt-85 -132.15 138.51 48.07 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.711 1.204 . . . . 71.35 108.287 -173.278 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.409 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 27.8 m -73.61 123.01 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 121.343 0.592 . . . . 52.11 111.295 -176.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 13.4 p -105.43 141.36 20.94 Favored 'Isoleucine or valine' 0 C--O 1.252 1.23 0 C-N-CA 125.092 1.357 . . . . 73.34 110.195 178.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 13.2 tp10 -120.29 103.36 9.17 Favored 'General case' 0 C--O 1.243 0.75 0 C-N-CA 124.033 0.933 . . . . 74.02 109.001 174.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.51 HG21 HD22 ' A' ' 174' ' ' LEU . 2.9 m -143.87 123.56 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 123.939 0.896 . . . . 70.2 110.693 -173.189 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.03 19.9 11.95 Favored 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 124.322 1.049 . . . . 62.0 112.137 173.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 83.62 17.5 65.93 Favored Glycine 0 C--N 1.347 1.161 0 CA-C-N 116.366 -0.379 . . . . 73.01 112.345 -177.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.2 mmm180 -108.12 118.17 36.04 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 108.317 -0.994 . . . . 71.31 108.317 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 49.9 ttt180 -94.94 108.2 20.25 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 108.406 -0.961 . . . . 64.34 108.406 173.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 72.2 t -135.82 146.74 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 108.674 -0.861 . . . . 54.22 108.674 -178.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 67.0 p -90.17 107.63 19.25 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.563 -1.273 . . . . 73.1 107.563 167.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.9 p -97.68 140.92 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-O 121.322 0.582 . . . . 73.44 111.012 -172.513 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 14.4 ttp180 -104.13 103.39 13.17 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 107.741 -1.207 . . . . 75.11 107.741 177.241 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.44 ' HB ' HD13 ' A' ' 159' ' ' ILE . 36.5 pt -92.1 112.78 56.67 Favored Pre-proline 0 CA--C 1.555 1.137 0 N-CA-C 109.553 -0.536 . . . . 74.24 109.553 179.067 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.526 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 96.2 Cg_exo -47.82 131.01 20.1 Favored 'Trans proline' 0 C--N 1.39 2.727 0 C-N-CA 123.947 3.098 . . . . 70.14 114.676 -173.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.526 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 23.2 Cg_exo -67.19 135.52 37.44 Favored 'Trans proline' 0 C--N 1.379 2.162 0 C-N-CA 123.472 2.781 . . . . 71.34 112.269 -177.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.652 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 120.51 41.88 0.52 Allowed Glycine 0 C--N 1.349 1.272 0 N-CA-C 111.908 -0.477 . . . . 54.32 111.908 -175.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.728 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.6 p -115.33 162.89 13.08 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.533 0 C-N-CA 123.915 0.886 . . . . 63.11 109.76 -173.17 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 43.9 mtp180 -143.26 168.99 18.49 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 125.228 1.411 . . . . 65.41 110.09 -170.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -54.94 120.59 7.1 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.759 0.824 . . . . 75.2 111.022 170.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.87 3.65 90.39 Favored Glycine 0 C--N 1.349 1.288 0 O-C-N 123.647 0.592 . . . . 70.54 113.903 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 40.3 t -81.99 131.89 35.25 Favored 'General case' 0 C--O 1.248 0.983 0 N-CA-C 109.303 -0.628 . . . . 60.44 109.303 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 9.0 p -97.42 135.74 30.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.986 0 CA-C-N 115.103 -0.953 . . . . 71.13 109.24 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.486 HD11 HG21 ' A' ' 153' ' ' VAL . 28.1 mt -112.61 123.07 67.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 123.9 0.88 . . . . 74.02 110.707 -175.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.426 HH21 HD11 ' A' ' 175' ' ' LEU . 35.3 ttm180 -92.53 118.84 31.4 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 117.924 0.329 . . . . 72.23 110.26 174.504 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.465 HG22 ' HB3' ' A' ' 174' ' ' LEU . 4.5 m -113.0 125.65 29.47 Favored Pre-proline 0 CA--C 1.551 1.0 0 N-CA-C 108.004 -1.109 . . . . 75.23 108.004 171.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -79.26 148.72 21.46 Favored 'Trans proline' 0 C--N 1.367 1.532 0 C-N-CA 122.132 1.888 . . . . 63.3 113.081 -174.185 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 74.37 23.24 76.13 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 115.141 0.816 . . . . 73.25 115.141 173.057 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 50.7 tpp -102.91 -45.92 4.83 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 117.811 0.806 . . . . 70.44 110.7 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.349 1.299 0 CA-C-N 116.093 -0.503 . . . . 74.33 112.52 -177.85 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo . . . . . 0 CA--C 1.541 0.837 0 N-CA-C 111.015 -0.417 . . . . 62.41 111.015 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -108.68 168.29 13.47 Favored Glycine 0 N--CA 1.462 0.369 0 N-CA-C 111.185 -0.766 . . . . 54.44 111.185 175.662 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -118.92 169.88 9.5 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 123.61 0.764 . . . . 63.43 111.656 -165.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.51 HD22 HG21 ' A' ' 140' ' ' VAL . 37.0 tp -124.62 116.47 22.46 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-N 114.608 -1.178 . . . . 62.42 108.234 169.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.426 HD11 HH21 ' A' ' 160' ' ' ARG . 41.3 mt -92.19 100.93 13.45 Favored 'General case' 0 C--O 1.243 0.76 0 CA-C-N 114.248 -1.342 . . . . 62.41 109.868 175.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 85.2 mt -90.85 107.39 19.16 Favored 'General case' 0 CA--C 1.538 0.494 0 CA-C-N 114.462 -1.245 . . . . 74.33 111.177 178.454 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 34.9 t -86.67 106.11 15.51 Favored 'Isoleucine or valine' 0 C--O 1.249 1.05 0 N-CA-C 108.459 -0.941 . . . . 71.32 108.459 175.466 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.518 HG11 HD22 ' A' ' 125' ' ' LEU . 19.0 m -81.57 149.77 4.77 Favored 'Isoleucine or valine' 0 C--O 1.24 0.6 0 CA-C-O 121.811 0.815 . . . . 72.42 112.203 -179.268 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 25.0 mmm-85 -123.75 105.66 9.86 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 107.38 -1.341 . . . . 64.32 107.38 174.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.456 ' HB3' HD23 ' A' ' 127' ' ' LEU . 30.2 mt -67.73 142.66 56.21 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 118.191 0.45 . . . . 74.42 111.186 -178.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.678 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 41.3 mt -55.22 142.35 58.61 Favored Pre-proline 0 CA--C 1.555 1.153 0 O-C-N 124.029 0.831 . . . . 62.42 111.791 -175.051 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.31 63.98 7.86 Favored 'Trans proline' 0 C--N 1.378 2.105 0 C-N-CA 123.389 2.726 . . . . 64.54 113.113 -177.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 3.7 p80 -149.61 50.18 0.75 Allowed Pre-proline 0 CA--C 1.564 1.5 0 C-N-CA 124.043 0.937 . . . . 63.0 108.84 169.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -62.63 122.97 11.52 Favored 'Trans proline' 0 C--N 1.385 2.459 0 C-N-CA 121.814 1.676 . . . . 75.42 111.808 -166.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.3 p -122.54 -42.57 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 N-CA-C 107.894 -1.15 . . . . 71.45 107.894 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -101.1 123.45 45.27 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.765 -1.107 . . . . 71.52 109.09 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 91.5 mtm180 -119.0 119.71 35.09 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.606 1.162 . . . . 71.45 108.085 -179.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 66.1 tp -105.0 139.02 40.31 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.848 0.859 . . . . 72.43 110.936 -174.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 -134.53 108.03 7.86 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 124.415 1.086 . . . . 72.55 108.104 164.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 73.16 -82.48 0.65 Allowed Glycine 0 C--N 1.35 1.332 0 O-C-N 123.529 0.518 . . . . 64.14 112.914 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -134.84 -15.64 2.03 Favored 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 123.772 0.829 . . . . 72.21 110.748 177.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 52.9 m-20 -91.0 143.78 26.35 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.345 0.658 . . . . 62.35 112.396 -174.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.57 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 87.3 mt -112.7 161.21 17.12 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 125.112 1.365 . . . . 71.03 111.215 -174.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -141.0 121.83 14.41 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 107.325 -1.361 . . . . 73.53 107.325 174.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . 0.455 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -148.96 136.23 20.12 Favored 'General case' 0 N--CA 1.468 0.453 0 N-CA-C 108.891 -0.781 . . . . 65.42 108.891 -178.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . 0.541 ' HA ' ' HB2' ' A' ' 252' ' ' GLU . 12.1 m -81.28 123.14 28.25 Favored 'General case' 0 CA--C 1.542 0.665 0 O-C-N 123.478 0.486 . . . . 70.13 110.616 -175.678 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.508 HD22 HD13 ' A' ' 251' ' ' LEU . 48.2 tp -108.71 113.28 26.11 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.825 0.85 . . . . 73.31 109.484 -179.699 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -87.23 113.11 22.68 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 108.43 -0.952 . . . . 65.25 108.43 172.097 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 4.2 p -118.37 124.9 28.22 Favored Pre-proline 0 CA--C 1.551 1.005 0 C-N-CA 124.035 0.934 . . . . 71.21 109.347 178.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -61.73 146.27 96.79 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 122.507 2.138 . . . . 74.33 112.287 175.558 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . 0.407 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -54.55 -42.98 97.49 Favored Pre-proline 0 CA--C 1.56 1.338 0 CA-C-O 117.346 -1.311 . . . . 64.34 113.965 -176.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . 0.407 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 7.1 Cg_endo -48.84 -47.6 20.68 Favored 'Trans proline' 0 C--N 1.402 3.344 0 C-N-CA 122.647 2.231 . . . . 65.3 112.821 172.189 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 15.7 mt -70.01 -38.15 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 122.725 0.41 . . . . 71.34 110.843 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.2 -41.47 98.39 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 123.307 0.643 . . . . 72.31 111.778 -177.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.7 m -80.21 -40.07 19.75 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 CA-C-N 116.108 -0.496 . . . . 65.33 111.715 -176.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.0 m -79.88 -24.02 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 CA-C-N 117.842 0.292 . . . . 74.42 111.194 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.504 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 73.22 61.38 3.46 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.855 -0.611 . . . . 72.33 112.317 -174.477 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.55 -142.22 9.77 Favored Glycine 0 C--N 1.356 1.672 0 N-CA-C 111.799 -0.52 . . . . 71.03 111.799 -178.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -131.36 144.78 51.48 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 123.812 0.845 . . . . 74.04 110.216 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 11.8 m -134.35 169.77 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.508 1.123 . . . . 75.11 109.171 175.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . 0.517 ' HD3' ' H ' ' A' ' 211' ' ' ARG . 0.0 OUTLIER -104.03 133.7 48.54 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.536 -0.756 . . . . 72.45 109.079 176.163 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -117.81 114.87 23.91 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 108.597 -0.89 . . . . 72.11 108.597 172.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 3.9 tpt -70.56 105.13 3.0 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.966 -0.561 . . . . 55.43 109.687 177.311 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 5.8 t -115.69 169.37 9.25 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.486 0.714 . . . . 74.3 111.255 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 46.4 mt -75.4 -3.06 31.5 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.254 1.022 . . . . 73.33 112.535 -170.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -106.1 -6.27 18.77 Favored 'General case' 0 N--CA 1.484 1.234 0 C-N-CA 124.029 0.931 . . . . 74.24 111.566 175.218 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 116.62 155.99 10.54 Favored Glycine 0 C--N 1.348 1.214 0 CA-C-O 118.583 -1.12 . . . . 60.22 111.634 -175.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -59.76 126.91 21.79 Favored 'Trans proline' 0 C--N 1.379 2.184 0 C-N-CA 123.096 2.531 . . . . 61.23 113.078 -168.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 35.1 m -108.47 166.49 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 C-N-CA 123.296 0.639 . . . . 71.23 110.184 -179.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -113.22 113.26 25.08 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 108.11 -1.07 . . . . 72.13 108.11 -177.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.504 HG22 HD11 ' A' ' 235' ' ' LEU . 5.2 t -95.92 115.99 36.53 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-N 115.664 -0.698 . . . . 61.42 109.303 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -85.61 101.25 12.55 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.585 -1.265 . . . . 74.12 107.585 170.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.504 HG23 ' HA2' ' A' ' 207' ' ' GLY . 9.0 m -74.71 146.56 83.38 Favored Pre-proline 0 CA--C 1.559 1.323 0 N-CA-C 109.509 -0.552 . . . . 53.41 109.509 -176.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -60.79 136.18 64.72 Favored 'Trans proline' 0 C--N 1.376 2.021 0 C-N-CA 122.769 2.312 . . . . 71.44 112.027 177.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_exo -54.88 122.57 11.89 Favored 'Trans proline' 0 C--N 1.377 2.037 0 C-N-CA 122.244 1.963 . . . . 63.51 110.572 169.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 68.6 mtm180 62.57 49.99 3.74 Favored 'General case' 0 CA--C 1.551 1.002 0 O-C-N 124.333 1.021 . . . . 74.44 110.576 -177.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.5 t -72.87 170.21 15.19 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.007 0.523 . . . . 51.43 110.52 177.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . 0.633 ' H ' ' HD2' ' A' ' 231' ' ' ARG . 2.0 mp0 -121.35 147.05 46.21 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.269 0.628 . . . . 71.5 109.987 -178.424 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -76.34 123.3 25.74 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.209 1.004 . . . . 44.33 109.483 175.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 113.91 -10.65 22.98 Favored Glycine 0 N--CA 1.472 1.085 0 N-CA-C 111.924 -0.47 . . . . 55.01 111.924 -171.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . 0.633 ' HD2' ' H ' ' A' ' 228' ' ' GLN . 20.9 mtt180 -69.98 161.61 29.7 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.516 0.726 . . . . 64.23 111.402 173.042 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.431 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.3 mptp? -119.99 111.3 17.74 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 107.825 -1.176 . . . . 73.22 107.825 176.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . 0.554 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 60.0 mt -85.63 107.51 17.57 Favored 'General case' 0 C--N 1.356 0.868 0 N-CA-C 108.613 -0.884 . . . . 73.34 108.613 -178.349 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 38.4 ttm180 -84.4 105.92 15.6 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.248 -0.887 . . . . 70.22 109.993 -171.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.581 ' HB3' ' HG3' ' A' ' 238' ' ' LYS . 58.2 mt -98.07 99.13 10.37 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 108.652 -0.87 . . . . 74.14 108.652 172.586 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -75.88 144.64 41.05 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 122.489 0.316 . . . . 64.12 111.159 -177.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 72.92 28.13 67.43 Favored Glycine 0 C--N 1.353 1.481 0 O-C-N 123.755 0.659 . . . . 64.31 113.042 -175.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . 0.581 ' HG3' ' HB3' ' A' ' 235' ' ' LEU . 4.1 mmtm -119.8 -10.59 9.5 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 124.138 0.975 . . . . 71.52 111.512 -178.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . 0.425 ' O ' ' HD2' ' A' ' 246' ' ' ARG . . . -81.93 -154.01 12.51 Favored Glycine 0 C--N 1.339 0.719 0 O-C-N 123.414 0.446 . . . . 63.35 113.279 -179.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.652 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 6.1 m-85 -94.68 158.69 34.93 Favored Pre-proline 0 CA--C 1.548 0.867 0 C-N-CA 123.576 0.75 . . . . 75.5 109.811 177.033 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.66 129.32 26.64 Favored 'Trans proline' 0 C--N 1.387 2.556 0 C-N-CA 123.361 2.707 . . . . 75.55 113.482 -178.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -158.18 -169.09 21.34 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.626 -0.716 . . . . 44.52 112.278 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.35 -17.99 59.3 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 123.133 2.555 . . . . 65.54 113.414 -177.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -98.42 21.23 11.4 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 123.868 0.867 . . . . 65.4 111.233 178.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 88.74 -82.97 1.48 Allowed Glycine 0 C--N 1.347 1.176 0 N-CA-C 110.122 -1.191 . . . . 43.1 110.122 -174.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.425 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 22.5 mtm180 -127.09 158.77 36.12 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 107.324 -1.362 . . . . 71.43 107.324 165.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.08 -156.96 4.76 Favored Glycine 0 C--N 1.344 1.002 0 O-C-N 123.483 0.489 . . . . 64.41 114.142 -174.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 35.0 m-20 -117.8 151.15 37.9 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 108.871 -0.788 . . . . 72.44 108.871 -176.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.57 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 18.3 tp -105.19 114.57 28.83 Favored 'General case' 0 CA--C 1.531 0.233 0 N-CA-C 108.71 -0.848 . . . . 73.04 108.71 171.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -96.18 106.86 19.11 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 123.109 0.564 . . . . 74.41 109.984 175.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.554 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 73.4 mt -88.0 120.96 29.85 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 124.162 0.985 . . . . 52.51 112.789 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.541 ' HB2' ' HA ' ' A' ' 196' ' ' THR . 26.0 mt-10 -79.11 91.3 4.9 Favored 'General case' 0 C--O 1.24 0.574 0 C-N-CA 123.774 0.83 . . . . 74.25 109.279 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 48.0 t -52.37 114.81 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.655 1.182 . . . . 64.54 112.108 178.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 49.7 mmm-85 -117.09 93.68 4.28 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 106.933 -1.506 . . . . 62.35 106.933 173.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 72.2 mt -74.55 110.73 9.33 Favored 'Isoleucine or valine' 0 C--N 1.343 0.31 0 N-CA-C 108.274 -1.01 . . . . 60.11 108.274 177.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 4.5 t . . . . . 0 CA--C 1.557 1.226 0 C-N-CA 123.982 0.913 . . . . 74.31 109.539 -177.205 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.451 ' HB2' ' HB3' ' A' ' 136' ' ' ARG . 1.2 tm? . . . . . 0 C--O 1.24 0.578 0 N-CA-C 106.685 -1.598 . . . . 62.03 106.685 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.413 ' O ' ' HB3' ' A' ' 123' ' ' LEU . 86.0 t -68.3 134.82 29.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 N-CA-C 108.84 -0.8 . . . . 74.34 108.84 177.334 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -150.25 56.45 0.94 Allowed 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 107.999 -1.111 . . . . 64.21 107.999 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -65.7 109.4 2.41 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-N 113.995 -1.457 . . . . 71.33 108.659 176.623 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 39.8 t -59.55 121.77 8.05 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.765 0 O-C-N 124.287 0.992 . . . . 73.43 109.384 -178.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.9 t . . . . . 0 N--CA 1.471 0.579 0 C-N-CA 123.896 0.878 . . . . 74.3 109.487 -173.391 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 . . . . . 0 N--CA 1.472 0.673 0 N-CA-C 108.472 -0.936 . . . . 62.01 108.472 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.05 144.48 26.28 Favored 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 107.015 -1.476 . . . . 73.1 107.015 178.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -130.59 129.36 42.67 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 108.108 -1.071 . . . . 73.01 108.108 176.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -150.79 150.23 30.72 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-N 115.75 -0.659 . . . . 62.42 109.571 -179.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -120.24 148.0 44.24 Favored 'General case' 0 C--O 1.245 0.84 0 N-CA-C 109.11 -0.7 . . . . 74.13 109.11 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.413 ' HB3' ' O ' ' A' ' 99' ' ' VAL . 1.3 pt? -145.32 147.58 34.44 Favored Pre-proline 0 N--CA 1.467 0.404 0 C-N-CA 122.8 0.44 . . . . 52.22 111.76 179.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -78.04 114.21 3.55 Favored 'Trans proline' 0 C--N 1.366 1.448 0 C-N-CA 121.751 1.634 . . . . 72.12 109.935 159.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.475 HD22 HG11 ' A' ' 178' ' ' VAL . 34.7 tp -106.75 157.24 17.88 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 108.791 -0.818 . . . . 72.1 108.791 177.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.693 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 14.4 m -89.36 151.69 21.93 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 122.99 0.516 . . . . 75.04 110.344 177.519 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.583 HD23 ' HB3' ' A' ' 180' ' ' LEU . 68.9 mt -58.1 -50.57 73.01 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.725 0.81 . . . . 52.33 109.389 174.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -53.78 -39.07 65.11 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 113.95 -1.477 . . . . 72.42 111.673 178.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.518 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 28.4 mm-40 -86.06 -18.07 33.45 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 122.999 0.52 . . . . 73.23 111.269 -176.484 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.653 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -64.41 -36.93 85.77 Favored 'General case' 0 C--O 1.242 0.673 0 C-N-CA 123.447 0.699 . . . . 70.01 109.886 167.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.458 ' HA ' ' HE1' ' A' ' 240' ' ' PHE . 27.6 t80 -71.94 -55.92 6.61 Favored 'General case' 0 CA--C 1.551 0.982 0 CA-C-N 114.999 -1.001 . . . . 61.12 110.574 172.053 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -67.97 -44.89 75.65 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 112.24 0.459 . . . . 72.12 112.24 -171.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.81 -111.62 4.27 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 111.275 -0.73 . . . . 70.23 111.275 -173.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.41 -175.87 54.54 Favored Glycine 0 C--N 1.347 1.163 0 N-CA-C 114.232 0.453 . . . . 44.22 114.232 171.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.425 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 2.0 mp0 -87.4 143.96 26.98 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 109.283 -0.636 . . . . 62.33 109.283 178.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.451 ' HB3' ' HB2' ' A' ' 98' ' ' LEU . 0.6 OUTLIER -156.79 147.84 21.98 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 109.546 -0.539 . . . . 74.22 109.546 -178.268 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 32.1 m -82.14 125.38 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 CA-C-O 121.51 0.671 . . . . 73.12 111.206 -174.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 41.1 t -120.7 144.77 28.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 125.035 1.334 . . . . 73.3 109.442 -176.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -126.15 97.79 5.22 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.041 0.536 . . . . 62.12 109.584 169.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.0 m -107.54 132.62 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 N-CA-C 108.922 -0.77 . . . . 73.22 108.922 173.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.46 23.02 13.35 Favored 'General case' 0 CA--C 1.554 1.118 0 C-N-CA 123.964 0.905 . . . . 64.23 111.694 -176.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.23 0.07 88.67 Favored Glycine 0 C--N 1.357 1.703 0 CA-C-N 116.038 -0.528 . . . . 44.21 113.468 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -103.34 123.27 46.48 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.696 0.798 . . . . 61.12 110.036 -175.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.2 ttp-105 -88.2 105.93 17.86 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.344 0.658 . . . . 71.2 110.797 -174.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 38.5 t -124.42 134.41 66.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.351 1.061 . . . . 53.43 108.828 178.021 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 37.2 m -83.81 120.9 26.61 Favored 'General case' 0 CA--C 1.546 0.803 0 N-CA-C 109.682 -0.488 . . . . 73.3 109.682 176.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 8.1 p -99.77 148.73 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 123.317 0.647 . . . . 73.42 110.687 -178.387 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.3 ttt85 -110.02 96.39 6.2 Favored 'General case' 0 C--O 1.237 0.43 0 N-CA-C 107.324 -1.361 . . . . 72.04 107.324 160.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.476 ' HB ' HD13 ' A' ' 159' ' ' ILE . 37.9 pt -78.05 125.98 84.44 Favored Pre-proline 0 C--O 1.243 0.724 0 N-CA-C 108.617 -0.883 . . . . 62.31 108.617 173.144 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.415 ' HD2' HG23 ' A' ' 159' ' ' ILE . 97.7 Cg_exo -48.68 127.18 15.89 Favored 'Trans proline' 0 C--N 1.384 2.406 0 C-N-CA 123.04 2.494 . . . . 61.41 113.37 -178.266 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.553 ' HB2' ' HZ ' ' A' ' 240' ' ' PHE . 57.1 Cg_endo -69.36 143.85 54.16 Favored 'Trans proline' 0 C--N 1.376 2.007 0 C-N-CA 122.251 1.967 . . . . 72.35 110.355 175.02 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.44 27.37 5.56 Favored Glycine 0 C--N 1.337 0.586 0 N-CA-C 110.927 -0.869 . . . . 53.15 110.927 -171.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.653 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.2 p -93.67 157.32 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 N-CA-C 108.168 -1.049 . . . . 71.05 108.168 -176.603 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.4 mtp180 -147.11 169.23 19.72 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 124.141 0.976 . . . . 75.41 109.751 -166.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -51.99 123.86 11.42 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.539 0.736 . . . . 32.55 111.624 174.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 85.55 -7.64 75.56 Favored Glycine 0 C--N 1.349 1.302 0 CA-C-O 119.419 -0.656 . . . . 32.02 114.111 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.4 m -69.53 122.64 19.44 Favored 'General case' 0 C--N 1.351 0.633 0 CA-C-N 117.336 0.568 . . . . 54.34 110.553 -178.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.412 HG12 HD22 ' A' ' 175' ' ' LEU . 10.5 t -98.93 123.17 51.39 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 N-CA-C 108.486 -0.931 . . . . 72.44 108.486 179.302 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.531 HD11 HG21 ' A' ' 153' ' ' VAL . 43.5 mt -102.49 115.69 44.85 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.593 0 C-N-CA 123.926 0.89 . . . . 72.22 110.537 -169.075 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.41 ' HG3' ' HB2' ' A' ' 173' ' ' ASP . 30.3 ttm180 -89.69 115.86 27.38 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.07 0.548 . . . . 65.23 110.493 175.237 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 173' ' ' ASP . 15.0 m -119.16 116.11 34.12 Favored Pre-proline 0 CA--C 1.555 1.172 0 C-N-CA 123.363 0.665 . . . . 74.34 109.578 176.32 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 11.2 Cg_exo -72.47 148.51 48.41 Favored 'Trans proline' 0 C--N 1.368 1.594 0 C-N-CA 122.479 2.119 . . . . 64.04 111.998 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.65 18.27 28.36 Favored Glycine 0 C--N 1.341 0.825 0 N-CA-C 115.673 1.029 . . . . 73.2 115.673 172.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.413 ' HE3' HG23 ' A' ' 147' ' ' VAL . 54.2 mtt -121.6 -57.45 1.82 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 118.449 1.125 . . . . 33.5 112.128 176.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.35 1.329 0 O-C-N 123.372 0.42 . . . . 73.11 113.047 -174.51 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo . . . . . 0 CA--C 1.547 1.155 0 CA-C-O 119.956 -0.102 . . . . 74.21 112.167 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -95.41 159.21 22.44 Favored Glycine 0 C--N 1.348 1.212 0 O-C-N 123.385 0.428 . . . . 73.1 112.406 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.447 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 9.4 p-10 -96.46 151.54 19.47 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 123.012 0.525 . . . . 74.42 112.036 -167.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 11.2 tp -113.88 124.27 51.8 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 107.472 -1.307 . . . . 72.33 107.472 163.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.412 HD22 HG12 ' A' ' 158' ' ' VAL . 37.3 mt -99.28 100.63 11.74 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.583 1.153 . . . . 72.24 110.098 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 93.0 mt -95.8 102.74 14.57 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.93 0.892 . . . . 72.14 110.917 177.339 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 6.5 p -86.16 111.91 21.9 Favored 'Isoleucine or valine' 0 C--O 1.244 0.81 0 CA-C-O 121.635 0.731 . . . . 62.43 109.209 172.388 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.475 HG11 HD22 ' A' ' 125' ' ' LEU . 6.2 m -86.98 149.35 4.14 Favored 'Isoleucine or valine' 0 C--O 1.241 0.607 0 CA-C-N 115.638 -0.71 . . . . 65.21 111.49 -178.365 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -124.31 104.57 8.87 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 106.914 -1.513 . . . . 73.34 106.914 176.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.583 ' HB3' HD23 ' A' ' 127' ' ' LEU . 32.4 mt -68.09 143.36 55.5 Favored 'General case' 0 CA--C 1.54 0.59 0 O-C-N 123.098 0.249 . . . . 71.21 111.243 -175.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.693 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 54.8 mt -53.86 147.83 22.42 Favored Pre-proline 0 CA--C 1.553 1.063 0 C-N-CA 123.852 0.861 . . . . 72.13 111.661 -173.265 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.19 37.24 0.62 Allowed 'Trans proline' 0 C--N 1.368 1.557 0 C-N-CA 123.32 2.68 . . . . 71.24 114.394 -175.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -121.06 65.55 13.93 Favored Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 123.544 0.738 . . . . 65.51 109.371 170.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -68.28 123.7 10.87 Favored 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 121.485 1.456 . . . . 74.22 111.231 -169.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.7 p -134.61 -38.81 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 N-CA-C 108.499 -0.926 . . . . 74.24 108.499 178.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.429 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 5.5 m-85 -114.82 141.92 47.24 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 121.902 0.858 . . . . 72.35 112.259 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.536 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 43.8 mtt85 -128.54 154.0 46.62 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 113.472 -1.695 . . . . 73.2 106.838 171.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.467 HD13 HD23 ' A' ' 193' ' ' LEU . 42.5 tp -132.7 138.41 47.25 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 109.051 -0.722 . . . . 72.24 109.051 179.534 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -142.32 117.69 10.22 Favored 'General case' 0 C--O 1.241 0.645 0 N-CA-C 109.101 -0.703 . . . . 73.45 109.101 173.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 68.16 -86.82 0.18 Allowed Glycine 0 C--N 1.349 1.279 0 O-C-N 123.864 0.727 . . . . 62.23 112.986 -177.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 4.5 pm0 -135.41 -14.85 1.94 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.25 1.02 . . . . 74.31 111.206 -174.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -111.19 156.42 21.45 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-O 121.16 0.505 . . . . 74.12 111.36 -174.075 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.467 HD23 HD13 ' A' ' 188' ' ' LEU . 79.5 mt -109.09 170.78 7.83 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.334 1.054 . . . . 64.13 109.593 -168.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . 0.536 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 71.4 m-85 -142.45 122.58 13.75 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 107.51 -1.293 . . . . 74.34 107.51 177.502 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . 0.474 ' HB3' HD23 ' A' ' 251' ' ' LEU . . . -134.99 152.45 51.75 Favored 'General case' 0 CA--C 1.508 -0.657 0 N-CA-C 109.522 -0.547 . . . . 54.13 109.522 177.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 4.9 m -98.77 119.09 36.93 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 108.969 -0.752 . . . . 75.24 108.969 177.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.487 HD22 HD13 ' A' ' 251' ' ' LEU . 61.4 tp -105.31 111.84 24.73 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.347 1.059 . . . . 71.13 109.716 -174.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -94.43 104.85 16.81 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 109.333 -0.617 . . . . 74.51 109.333 176.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . 0.567 HG11 HG11 ' A' ' 223' ' ' VAL . 14.6 m -101.52 140.87 21.6 Favored Pre-proline 0 N--CA 1.476 0.825 0 N-CA-C 109.378 -0.601 . . . . 71.21 109.378 177.036 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.19 151.21 84.13 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 121.999 1.799 . . . . 73.21 110.986 171.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -56.69 -44.95 99.97 Favored Pre-proline 0 CA--C 1.546 0.791 0 CA-C-O 118.327 -0.844 . . . . 54.33 113.051 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . 0.421 ' O ' HG22 ' A' ' 206' ' ' VAL . 69.7 Cg_exo -46.69 -55.64 3.64 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 122.484 2.123 . . . . 64.42 113.495 170.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.2 mt -65.57 -37.25 79.56 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 122.736 0.414 . . . . 73.55 111.613 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -56.27 -58.33 8.43 Favored 'General case' 0 CA--C 1.547 0.828 0 CA-C-O 121.261 0.553 . . . . 72.53 111.087 178.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.6 m -69.79 -40.06 78.62 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.969 0 CA-C-N 115.212 -0.904 . . . . 72.15 112.461 -173.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 202' ' ' PRO . 18.3 m -78.17 -27.0 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 122.259 0.224 . . . . 74.12 110.977 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.548 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 77.52 63.66 2.2 Favored Glycine 0 C--N 1.341 0.835 0 CA-C-N 115.919 -0.582 . . . . 42.15 113.171 -176.4 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -91.89 -147.12 19.82 Favored Glycine 0 C--N 1.354 1.578 0 N-CA-C 111.694 -0.563 . . . . 33.35 111.694 177.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -138.18 135.5 35.7 Favored 'General case' 0 C--O 1.24 0.593 0 C-N-CA 123.154 0.582 . . . . 71.22 110.462 178.051 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 61.3 t -120.68 134.64 63.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.131 0.972 . . . . 70.23 108.964 -179.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.68 114.81 17.92 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.502 -0.555 . . . . 74.33 109.502 171.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.63 146.0 28.3 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 108.71 -0.848 . . . . 64.35 108.71 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 55.4 mmm -83.81 148.59 26.92 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 110.13 -0.322 . . . . 62.44 110.13 174.411 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.429 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 9.3 t -140.03 167.59 21.77 Favored 'General case' 0 C--O 1.242 0.691 0 C-N-CA 124.0 0.92 . . . . 72.54 109.873 173.581 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 63.7 mt -74.31 -0.56 17.46 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 123.882 0.873 . . . . 74.11 112.138 -173.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.65 -4.07 9.78 Favored 'General case' 0 N--CA 1.485 1.292 0 N-CA-C 112.747 0.647 . . . . 74.23 112.747 176.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 153.89 -160.74 29.55 Favored Glycine 0 N--CA 1.478 1.465 0 CA-C-O 119.679 -0.512 . . . . 62.41 112.859 178.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -94.26 132.54 0.71 Allowed 'Trans proline' 0 CA--C 1.559 1.726 0 C-N-CA 123.473 2.782 . . . . 43.15 112.596 168.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 34.3 m -111.38 151.97 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.64 0.776 . . . . 73.44 110.32 173.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -114.58 115.14 26.69 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-O 121.139 0.495 . . . . 73.44 110.099 171.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.528 ' HB ' HD11 ' A' ' 235' ' ' LEU . 2.6 p -104.66 121.44 56.48 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 123.359 0.664 . . . . 74.34 110.968 179.408 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.98 105.62 15.0 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 109.22 -0.659 . . . . 75.52 109.22 173.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.567 HG11 HG11 ' A' ' 199' ' ' VAL . 11.0 m -71.2 135.61 84.65 Favored Pre-proline 0 CA--C 1.556 1.189 0 N-CA-C 108.839 -0.8 . . . . 72.32 108.839 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . 0.427 ' HB2' HH12 ' A' ' 231' ' ' ARG . 31.5 Cg_exo -61.28 144.12 98.52 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 122.373 2.048 . . . . 64.23 112.581 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -51.24 128.35 25.04 Favored 'Trans proline' 0 C--N 1.38 2.222 0 C-N-CA 122.904 2.403 . . . . 74.43 112.046 173.008 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 42.1 mtp180 67.87 60.98 0.43 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 125.032 1.333 . . . . 75.12 110.369 -175.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -85.3 139.62 31.46 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 114.852 -1.067 . . . . 72.22 111.29 178.355 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 23.1 mp0 -112.2 158.84 19.19 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 123.768 0.827 . . . . 62.15 109.392 176.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -71.07 140.47 50.71 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 116.013 -0.54 . . . . 43.44 109.673 174.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 96.97 -3.7 62.5 Favored Glycine 0 CA--C 1.521 0.443 0 CA-C-O 119.448 -0.64 . . . . 52.12 112.996 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . 0.427 HH12 ' HB2' ' A' ' 224' ' ' PRO . 90.1 mtt180 -69.41 156.11 39.37 Favored 'General case' 0 N--CA 1.478 0.972 0 CA-C-N 117.649 0.724 . . . . 75.44 110.733 172.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 13.2 mptt -125.44 123.23 38.81 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 123.404 0.682 . . . . 74.4 109.726 177.31 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 46.6 mt -112.6 109.98 19.87 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 108.554 -0.906 . . . . 71.12 108.554 -175.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . 0.444 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 57.3 ttp85 -99.23 104.31 16.24 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 116.072 -0.513 . . . . 61.21 111.145 -168.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.528 HD11 ' HB ' ' A' ' 221' ' ' VAL . 37.0 mt -89.9 100.52 13.32 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 124.091 0.956 . . . . 71.31 110.145 -176.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . 0.424 ' HE2' ' HB3' ' A' ' 236' ' ' LYS . 42.4 mtpt -66.37 151.53 46.94 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 116.378 -0.374 . . . . 71.03 111.534 177.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.65 20.2 73.76 Favored Glycine 0 C--N 1.348 1.203 0 CA-C-N 115.325 -0.852 . . . . 52.11 112.845 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.0 mmtt -137.59 16.44 2.92 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.801 0.84 . . . . 73.31 111.266 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -99.11 -160.72 29.42 Favored Glycine 0 C--N 1.347 1.161 0 O-C-N 123.654 0.596 . . . . 72.15 112.038 170.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.553 ' HZ ' ' HB2' ' A' ' 151' ' ' PRO . 13.3 t80 -83.43 127.14 69.56 Favored Pre-proline 0 CA--C 1.552 1.043 0 CA-C-N 116.74 0.27 . . . . 55.44 110.945 -176.531 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . 0.567 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 13.5 Cg_exo -70.87 126.33 12.47 Favored 'Trans proline' 0 C--N 1.376 1.979 0 C-N-CA 122.269 1.979 . . . . 72.42 111.732 173.474 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -158.69 -146.13 4.45 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-O 119.149 -0.806 . . . . 50.03 112.583 -176.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -65.38 -24.54 57.25 Favored 'Trans proline' 0 C--N 1.376 2.01 0 C-N-CA 123.375 2.717 . . . . 62.21 112.866 -177.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.45 22.54 3.9 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 124.041 0.937 . . . . 70.24 111.113 178.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 81.18 -98.63 1.87 Allowed Glycine 0 C--N 1.345 1.042 0 N-CA-C 110.469 -1.053 . . . . 53.41 110.469 -176.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.567 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 23.2 ttm180 -128.62 146.53 50.83 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 109.146 -0.687 . . . . 74.25 109.146 166.148 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -85.61 -155.34 24.99 Favored Glycine 0 C--O 1.253 1.338 0 O-C-N 123.694 0.621 . . . . 41.12 112.424 175.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -140.27 160.52 39.78 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.835 0.854 . . . . 51.54 109.961 -174.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.444 ' O ' ' HA ' ' A' ' 234' ' ' ARG . 15.6 tp -99.51 122.39 42.51 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 123.919 0.887 . . . . 74.41 110.329 178.1 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -101.57 104.47 15.35 Favored 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 108.433 -0.951 . . . . 72.31 108.433 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.548 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 74.5 mt -85.72 149.93 24.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.987 0.915 . . . . 53.41 112.328 -178.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -114.47 96.01 5.55 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.539 -0.912 . . . . 70.51 108.539 176.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 69.1 t -52.15 125.82 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 123.582 0.753 . . . . 72.24 111.683 176.776 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 27.3 mmm-85 -136.17 101.5 4.72 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 125.257 1.423 . . . . 74.1 107.259 179.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 65.1 mt -80.97 125.39 39.45 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 CA-C-N 116.342 -0.39 . . . . 75.55 110.053 -175.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 10.0 t . . . . . 0 CA--C 1.55 0.966 0 C-N-CA 124.402 1.081 . . . . 72.55 109.653 -179.766 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.658 ' HB2' ' HG2' ' A' ' 136' ' ' ARG . 22.0 tp . . . . . 0 N--CA 1.471 0.623 0 N-CA-C 109.294 -0.632 . . . . 74.2 109.294 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.429 ' HA ' ' CB ' ' A' ' 123' ' ' LEU . 12.5 p -65.48 137.06 25.65 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 115.345 -0.843 . . . . 63.41 110.042 172.245 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.82 -50.14 8.96 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.215 -0.661 . . . . 62.55 109.215 174.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 49.0 p-80 -170.16 163.97 9.11 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 114.896 -1.047 . . . . 71.41 109.964 -175.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 1.8 p -95.38 162.09 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.086 0 N-CA-C 109.642 -0.503 . . . . 71.32 109.642 174.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 71.7 p . . . . . 0 N--CA 1.479 1.022 0 C-N-CA 124.792 1.237 . . . . 75.34 109.362 -171.972 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 120.886 0.374 . . . . 70.34 110.418 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 31.6 tp -122.64 146.2 47.67 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 107.662 -1.236 . . . . 74.35 107.662 -170.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 64.6 ttt-85 -141.72 143.87 33.76 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.737 -0.838 . . . . 72.44 108.737 -176.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.442 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -149.06 118.81 7.03 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 109.079 -0.711 . . . . 73.25 109.079 175.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -94.03 139.38 31.02 Favored 'General case' 0 C--O 1.247 0.959 0 N-CA-C 109.305 -0.628 . . . . 74.42 109.305 174.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.474 HD12 ' HG ' ' A' ' 98' ' ' LEU . 1.8 pt? -144.87 132.37 10.37 Favored Pre-proline 0 CA--C 1.541 0.622 0 C-N-CA 123.099 0.56 . . . . 73.34 111.41 -166.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_exo -68.82 115.08 3.77 Favored 'Trans proline' 0 C--N 1.375 1.973 0 C-N-CA 122.654 2.236 . . . . 74.25 112.194 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.443 ' HB3' HD23 ' A' ' 180' ' ' LEU . 16.9 tp -109.2 166.84 10.55 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.512 1.125 . . . . 73.35 108.202 174.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.561 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 25.9 m -103.32 156.64 17.59 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 109.671 -0.492 . . . . 72.02 109.671 173.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.5 HD23 ' HB3' ' A' ' 180' ' ' LEU . 87.5 mt -56.02 -50.5 70.74 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-O 121.671 0.748 . . . . 64.14 110.069 171.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -57.48 -34.18 68.77 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 114.517 -1.22 . . . . 71.13 111.987 176.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.537 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 31.3 mm-40 -74.12 -31.49 62.79 Favored 'General case' 0 N--CA 1.482 1.169 0 C-N-CA 123.171 0.588 . . . . 74.41 111.56 176.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.444 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -59.33 -37.91 79.02 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.442 0.697 . . . . 70.24 111.471 169.511 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.556 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 46.8 t80 -71.61 -47.73 52.7 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 115.79 -0.641 . . . . 75.51 112.174 173.16 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 31.8 m80 -63.09 -53.71 49.39 Favored 'General case' 0 N--CA 1.483 1.187 0 O-C-N 123.702 0.626 . . . . 64.44 111.004 -173.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 59.41 149.76 0.01 OUTLIER Glycine 0 CA--C 1.537 1.431 0 CA-C-N 115.772 -0.649 . . . . 74.51 113.297 -168.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 170.37 -179.06 42.74 Favored Glycine 0 CA--C 1.505 -0.551 0 C-N-CA 119.968 -1.11 . . . . 52.53 114.666 177.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -89.78 138.36 31.55 Favored 'General case' 0 C--O 1.24 0.596 0 CA-C-N 113.445 -1.377 . . . . 75.13 107.886 177.153 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.658 ' HG2' ' HB2' ' A' ' 98' ' ' LEU . 19.7 tpp180 -154.05 158.19 40.16 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 108.622 -0.881 . . . . 53.55 108.622 178.347 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.4 p -80.14 126.16 39.29 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.21 0 CA-C-O 121.544 0.687 . . . . 70.33 111.689 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 8.9 p -107.71 123.24 62.96 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 C-N-CA 124.732 1.213 . . . . 73.51 108.883 171.293 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -118.94 98.73 6.33 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 108.508 -0.923 . . . . 72.44 108.508 177.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.416 HG21 HD22 ' A' ' 174' ' ' LEU . 14.3 m -122.69 134.73 65.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 124.245 1.018 . . . . 73.34 109.785 -176.007 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.21 29.79 19.42 Favored 'General case' 0 CA--C 1.551 1.012 0 C-N-CA 124.18 0.992 . . . . 71.3 110.38 -173.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.28 6.39 79.91 Favored Glycine 0 C--N 1.358 1.797 0 CA-C-N 115.364 -0.835 . . . . 62.13 113.806 -177.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -99.31 115.08 28.35 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 109.103 -0.703 . . . . 73.53 109.103 -176.267 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -95.41 116.04 28.25 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 123.709 0.803 . . . . 65.43 110.144 -175.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.675 HG21 ' SD ' ' A' ' 164' ' ' MET . 7.5 m -142.79 156.99 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 125.368 1.467 . . . . 74.24 108.539 176.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 38.9 t -88.37 127.02 35.48 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 109.864 -0.421 . . . . 60.52 109.864 174.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.7 p -99.91 144.88 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 123.699 0.8 . . . . 65.0 109.567 171.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.6 ttt180 -109.43 116.22 31.41 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.593 -0.891 . . . . 74.03 108.593 168.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.435 HG22 HG21 ' A' ' 159' ' ' ILE . 35.1 pt -121.1 132.04 24.31 Favored Pre-proline 0 CA--C 1.549 0.927 0 N-CA-C 108.93 -0.767 . . . . 72.3 108.93 171.189 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -76.45 166.61 27.13 Favored 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 122.8 2.333 . . . . 73.13 113.531 -170.327 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -68.89 154.62 70.65 Favored 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.109 1.873 . . . . 65.41 110.468 165.126 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 90.41 44.35 4.66 Favored Glycine 0 C--O 1.239 0.44 0 N-CA-C 111.548 -0.621 . . . . 73.12 111.548 -173.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.444 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 2.7 p -116.3 156.26 17.52 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.102 0 N-CA-C 108.197 -1.038 . . . . 75.15 108.197 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.2 mtp180 -138.76 166.17 25.1 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 123.967 0.907 . . . . 72.03 110.916 -164.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -57.97 127.55 32.61 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 122.957 0.503 . . . . 54.51 110.823 170.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 77.19 6.67 86.45 Favored Glycine 0 C--N 1.349 1.261 0 O-C-N 123.717 0.636 . . . . 51.32 113.379 -178.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 41.2 t -69.56 122.45 19.09 Favored 'General case' 0 C--N 1.358 0.953 0 C-N-CA 122.942 0.497 . . . . 61.13 109.7 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.443 HG22 HD22 ' A' ' 175' ' ' LEU . 7.3 p -103.01 119.94 52.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 O-C-N 124.475 1.109 . . . . 65.13 109.608 -176.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.435 HG21 HG22 ' A' ' 149' ' ' ILE . 17.6 mt -115.74 116.82 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 123.864 0.865 . . . . 70.15 109.86 -173.115 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.407 ' HA ' HD23 ' A' ' 175' ' ' LEU . 44.1 ttp180 -75.8 120.3 20.97 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 118.36 0.527 . . . . 75.03 110.141 175.758 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.651 ' HB ' ' HB3' ' A' ' 174' ' ' LEU . 84.2 t -112.16 113.88 51.42 Favored Pre-proline 0 CA--C 1.552 1.027 0 C-N-CA 124.249 1.019 . . . . 72.4 109.636 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -76.95 157.4 34.61 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.664 2.242 . . . . 70.32 113.233 178.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . 0.626 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . 105.76 -25.94 22.63 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 115.365 0.906 . . . . 70.04 115.365 173.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.675 ' SD ' HG21 ' A' ' 145' ' ' VAL . 4.1 mpp? -111.0 -45.89 3.4 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-N 118.893 1.347 . . . . 63.01 112.431 -175.001 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.343 0.936 0 C-N-CA 121.441 -0.409 . . . . 61.42 112.624 179.313 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo . . . . . 0 CA--C 1.543 0.962 0 N-CA-C 110.241 -0.715 . . . . 65.43 110.241 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . 0.626 ' HA3' ' H ' ' A' ' 163' ' ' GLY . . . 103.91 119.97 4.7 Favored Glycine 0 C--N 1.34 0.778 0 N-CA-C 112.301 -0.319 . . . . 60.31 112.301 -176.329 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -134.6 107.5 7.53 Favored 'General case' 0 C--N 1.333 -0.141 0 C-N-CA 124.524 1.129 . . . . 72.31 108.153 172.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.651 ' HB3' ' HB ' ' A' ' 161' ' ' VAL . 27.4 tp -121.33 105.89 10.95 Favored 'General case' 0 C--O 1.226 -0.132 0 N-CA-C 107.2 -1.407 . . . . 75.22 107.2 168.003 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.443 HD22 HG22 ' A' ' 158' ' ' VAL . 59.8 mt -84.76 99.39 10.83 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.017 -0.538 . . . . 62.43 110.483 -176.015 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.442 ' HA ' ' O ' ' A' ' 121' ' ' ALA . 59.8 mt -84.35 102.81 13.0 Favored 'General case' 0 C--N 1.344 0.351 0 CA-C-N 115.569 -0.741 . . . . 74.44 109.393 176.101 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.7 t -95.98 95.05 4.54 Favored 'Isoleucine or valine' 0 C--O 1.242 0.665 0 CA-C-N 114.61 -1.177 . . . . 74.24 107.962 179.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.41 HG21 HG22 ' A' ' 153' ' ' VAL . 5.6 m -75.3 147.63 8.14 Favored 'Isoleucine or valine' 0 C--O 1.245 0.831 0 CA-C-O 121.521 0.676 . . . . 75.24 110.898 -171.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -121.35 94.93 4.49 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 108.119 -1.067 . . . . 71.3 108.119 -176.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.5 ' HB3' HD23 ' A' ' 127' ' ' LEU . 50.1 mt -67.34 147.12 53.36 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 110.269 -0.271 . . . . 73.12 110.269 -176.343 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.561 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 20.3 mt -56.59 123.41 56.95 Favored Pre-proline 0 CA--C 1.552 1.054 0 CA-C-O 119.307 -0.378 . . . . 73.13 110.362 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 17.2 Cg_exo -66.82 85.27 0.3 Allowed 'Trans proline' 0 C--N 1.379 2.143 0 C-N-CA 123.508 2.805 . . . . 75.21 113.356 -172.423 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -162.44 77.25 2.01 Favored Pre-proline 0 CA--C 1.558 1.281 0 N-CA-C 108.094 -1.076 . . . . 71.05 108.094 171.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -63.33 123.46 12.17 Favored 'Trans proline' 0 C--N 1.377 2.031 0 C-N-CA 122.002 1.801 . . . . 74.22 111.924 -171.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.8 p -134.56 -46.78 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 N-CA-C 107.517 -1.29 . . . . 62.2 107.517 174.135 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.54 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 4.3 m-85 -103.55 123.77 47.55 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.22 -0.9 . . . . 72.45 110.61 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 15.0 mtm180 -120.82 104.75 10.11 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.905 -1.517 . . . . 74.11 106.905 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.46 HD13 ' HD1' ' A' ' 240' ' ' PHE . 44.3 tp -83.6 138.55 33.31 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 108.996 -0.742 . . . . 55.34 108.996 174.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -141.59 104.93 4.65 Favored 'General case' 0 C--O 1.243 0.747 0 N-CA-C 107.393 -1.336 . . . . 71.34 107.393 176.273 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 74.84 -88.17 0.76 Allowed Glycine 0 C--N 1.348 1.221 0 CA-C-N 115.738 -0.665 . . . . 53.44 111.654 -174.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -136.59 -6.36 1.96 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 123.625 0.77 . . . . 71.1 110.854 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -98.53 149.55 22.62 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.369 0.668 . . . . 71.24 111.202 -177.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.601 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.7 mt -109.58 151.17 27.16 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.486 1.114 . . . . 74.54 109.207 -177.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -140.41 120.17 13.42 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 107.372 -1.344 . . . . 73.41 107.372 178.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -143.24 140.66 30.78 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.742 0.817 . . . . 63.42 108.939 -177.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 20.5 m -83.39 127.98 34.13 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-O 121.194 0.521 . . . . 60.13 110.208 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . . . . . . . . . 65.1 tp -112.3 120.66 42.5 Favored 'General case' 0 C--O 1.22 -0.479 0 C-N-CA 125.216 1.406 . . . . 74.21 108.941 176.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -99.35 123.08 43.33 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.402 -0.962 . . . . 74.32 108.402 170.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 4.6 m -110.2 147.78 36.99 Favored Pre-proline 0 C--O 1.245 0.849 0 C-N-CA 123.039 0.536 . . . . 74.41 109.883 -177.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -60.22 134.1 53.7 Favored 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 122.367 2.045 . . . . 72.14 110.877 168.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -53.96 -43.35 96.57 Favored Pre-proline 0 CA--C 1.564 1.493 0 C-N-CA 124.325 1.05 . . . . 71.4 113.541 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_exo -55.13 -46.48 32.71 Favored 'Trans proline' 0 C--N 1.395 3.024 0 C-N-CA 122.473 2.116 . . . . 73.34 112.97 171.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 7.1 mt -63.28 -38.24 81.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 123.344 0.657 . . . . 71.42 111.072 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.91 -43.62 98.29 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 123.099 0.56 . . . . 64.55 111.889 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . 0.515 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 35.8 m -80.81 -38.96 17.59 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 CA-C-N 116.154 -0.476 . . . . 65.3 112.178 -175.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.0 m -79.53 -35.78 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 CA-C-N 118.12 0.418 . . . . 53.33 110.573 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 89.81 80.02 1.34 Allowed Glycine 0 C--N 1.348 1.22 0 CA-C-N 115.613 -0.721 . . . . 75.01 112.229 -175.11 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -117.54 -160.42 11.71 Favored Glycine 0 C--N 1.357 1.732 0 N-CA-C 112.164 -0.374 . . . . 42.25 112.164 175.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 10.5 mtmp? -115.98 137.44 52.11 Favored 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 123.47 0.708 . . . . 73.45 110.373 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 28.2 t -118.82 152.06 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.745 1.218 . . . . 55.15 108.749 176.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -81.13 119.2 23.27 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 108.434 -0.95 . . . . 71.44 108.434 171.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -102.16 122.94 45.12 Favored 'General case' 0 C--O 1.239 0.511 0 N-CA-C 108.125 -1.065 . . . . 55.21 108.125 175.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 54.7 mmm -77.21 113.4 14.92 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.193 0.52 . . . . 64.11 110.288 178.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.54 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 9.1 t -109.83 167.96 9.77 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-N 114.692 -1.14 . . . . 62.04 109.766 171.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . 0.412 HD13 ' O ' ' A' ' 127' ' ' LEU . 72.1 mt -71.12 -7.5 47.0 Favored 'General case' 0 CA--C 1.546 0.821 0 CA-C-N 114.701 -1.136 . . . . 73.24 111.735 178.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -90.57 -19.79 23.34 Favored 'General case' 0 CA--C 1.558 1.26 0 C-N-CA 124.211 1.004 . . . . 73.33 110.951 172.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 137.24 -154.36 22.33 Favored Glycine 0 C--N 1.347 1.163 0 N-CA-C 110.901 -0.88 . . . . 31.11 110.901 -174.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -89.19 129.06 1.92 Allowed 'Trans proline' 0 CA--C 1.55 1.295 0 C-N-CA 122.649 2.232 . . . . 61.32 111.923 170.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.0 m -109.82 167.91 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 123.775 0.83 . . . . 74.32 111.197 174.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -105.69 115.79 30.85 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 123.598 0.759 . . . . 62.31 109.906 177.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 2.7 p -116.55 125.44 73.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 123.974 0.91 . . . . 71.31 109.566 174.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -92.31 121.83 34.18 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.124 -0.695 . . . . 34.24 109.124 175.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 10.0 m -81.7 145.43 54.33 Favored Pre-proline 0 CA--C 1.553 1.06 0 N-CA-C 108.989 -0.745 . . . . 43.04 108.989 177.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -61.99 141.92 90.94 Favored 'Trans proline' 0 C--N 1.371 1.713 0 C-N-CA 122.13 1.887 . . . . 65.33 111.914 173.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -60.04 122.21 11.03 Favored 'Trans proline' 0 C--N 1.368 1.592 0 C-N-CA 122.784 2.322 . . . . 75.54 112.257 174.358 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . 0.515 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 62.3 mtp180 65.85 39.33 4.7 Favored 'General case' 0 N--CA 1.482 1.172 0 C-N-CA 124.732 1.213 . . . . 73.3 111.427 -176.294 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 7.1 t -70.9 174.41 6.17 Favored 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 122.941 0.496 . . . . 75.13 111.272 -179.098 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.2 mp0 -123.55 143.65 50.07 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 123.859 0.863 . . . . 73.32 109.54 -176.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.08 123.28 21.18 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.785 0.834 . . . . 63.31 110.098 175.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 112.87 12.24 12.88 Favored Glycine 0 C--N 1.34 0.788 0 CA-C-N 116.244 -0.434 . . . . 73.41 112.605 -176.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 84.8 mtt180 -91.17 154.51 19.28 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 109.292 -0.633 . . . . 74.01 109.292 167.601 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.404 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.1 OUTLIER -104.27 111.45 24.08 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 123.615 0.766 . . . . 71.52 109.03 172.568 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . 0.475 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 67.8 mt -87.63 104.78 16.84 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 108.333 -0.988 . . . . 73.34 108.333 -177.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 40.5 ttm105 -76.58 110.39 11.1 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-N 115.313 -0.858 . . . . 54.21 111.755 -172.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.454 HD12 HD23 ' A' ' 249' ' ' LEU . 20.9 mt -91.97 106.12 18.21 Favored 'General case' 0 C--O 1.239 0.551 0 N-CA-C 107.897 -1.149 . . . . 71.22 107.897 169.338 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 93.3 mttt -66.57 132.89 49.18 Favored 'General case' 0 CA--C 1.538 0.506 0 CA-C-N 114.578 -1.192 . . . . 75.24 111.828 -167.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 79.91 -1.11 80.61 Favored Glycine 0 C--N 1.348 1.228 0 O-C-N 123.834 0.709 . . . . 54.23 114.649 173.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -84.57 -3.78 58.63 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.496 0.554 . . . . 71.41 112.496 -176.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.91 -179.31 48.92 Favored Glycine 0 C--N 1.346 1.136 0 N-CA-C 112.446 -0.262 . . . . 71.24 112.446 174.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.556 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 73.9 m-85 -86.38 155.86 56.93 Favored Pre-proline 0 N--CA 1.476 0.847 0 C-N-CA 123.197 0.599 . . . . 75.32 112.296 -173.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -60.97 140.5 90.5 Favored 'Trans proline' 0 C--N 1.384 2.444 0 C-N-CA 122.778 2.318 . . . . 73.25 112.772 178.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -150.82 -162.01 10.37 Favored Glycine 0 CA--C 1.533 1.179 0 N-CA-C 110.458 -1.057 . . . . 72.13 110.458 175.044 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -69.7 -20.68 34.81 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.803 2.335 . . . . 63.22 113.043 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.79 3.18 55.33 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.673 0.789 . . . . 73.12 112.083 -175.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.37 -105.97 1.62 Allowed Glycine 0 C--N 1.35 1.314 0 N-CA-C 110.619 -0.993 . . . . 64.31 110.619 -176.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 50.6 mtm-85 -126.58 152.28 46.82 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 108.045 -1.095 . . . . 74.3 108.045 167.395 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -78.03 -158.28 10.79 Favored Glycine 0 C--N 1.343 0.936 0 O-C-N 123.362 0.414 . . . . 72.21 112.152 174.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 38.6 m-20 -136.65 170.1 16.62 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 109.323 -0.621 . . . . 62.34 109.323 -175.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.601 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 23.9 tp -103.27 124.44 48.64 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.202 -0.666 . . . . 75.21 109.202 171.35 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . 0.404 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 48.3 m-85 -107.89 104.35 13.81 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.293 0.637 . . . . 62.11 109.405 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.475 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 85.2 mt -89.11 113.75 24.93 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.802 0.841 . . . . 71.11 112.414 -178.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -78.85 91.66 4.78 Favored 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 108.777 -0.823 . . . . 72.4 108.777 176.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.1 p -54.11 130.98 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.353 1.061 . . . . 74.14 111.066 176.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 13.2 mmt180 -131.02 99.01 4.75 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 125.12 1.368 . . . . 72.02 107.548 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 63.5 mt -76.58 124.76 35.48 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 C-N-CA 123.822 0.849 . . . . 72.35 109.269 -175.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 9.4 t . . . . . 0 C--O 1.25 1.086 0 C-N-CA 123.552 0.741 . . . . 72.5 109.781 -175.62 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.54 HD22 HD12 ' A' ' 123' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.484 1.226 0 CA-C-O 121.254 0.549 . . . . 61.11 110.108 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.558 ' HA ' ' HB2' ' A' ' 123' ' ' LEU . 11.4 p -84.08 143.46 11.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 C-N-CA 124.702 1.201 . . . . 72.42 110.624 171.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -77.82 -87.07 0.05 Allowed 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 108.439 -0.949 . . . . 72.22 108.439 169.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.4 m80 -168.78 179.54 4.16 Favored 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 125.026 1.33 . . . . 74.12 109.72 177.461 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 93.4 t -62.23 140.16 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 C-N-CA 123.654 0.782 . . . . 61.44 111.146 178.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 37.4 p . . . . . 0 CA--C 1.547 0.833 0 C-N-CA 123.163 0.585 . . . . 73.21 109.443 172.487 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.8 t70 . . . . . 0 CA--C 1.538 0.51 0 CA-C-O 120.638 0.256 . . . . 70.0 110.576 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.551 HD12 ' HA2' ' A' ' 165' ' ' GLY . 12.4 mt -125.59 142.46 51.5 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 107.26 -1.385 . . . . 74.04 107.26 160.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . 0.6 ' HG2' ' HB2' ' A' ' 175' ' ' LEU . 41.0 mtm180 -141.91 145.78 34.97 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 107.694 -1.224 . . . . 64.33 107.694 178.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -151.46 118.42 5.85 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 108.516 -0.92 . . . . 71.24 108.516 175.379 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -88.85 132.45 34.66 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 108.086 -1.079 . . . . 52.23 108.086 173.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.558 ' HB2' ' HA ' ' A' ' 99' ' ' VAL . 2.2 pt? -142.71 146.65 39.0 Favored Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 122.778 0.431 . . . . 72.51 111.683 -168.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -75.97 121.6 6.3 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.689 2.259 . . . . 62.41 111.182 173.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.441 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 14.2 tp -120.16 168.94 10.7 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.216 1.006 . . . . 65.44 108.793 174.69 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.628 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 11.5 m -107.06 155.98 19.25 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.136 0.574 . . . . 74.12 109.776 174.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 80.5 mt -50.49 -52.41 38.57 Favored 'General case' 0 N--CA 1.487 1.41 0 C-N-CA 124.127 0.971 . . . . 65.24 110.216 173.29 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.552 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -54.91 -39.52 68.89 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 113.506 -1.679 . . . . 71.44 112.103 177.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.628 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 16.0 mm-40 -76.88 -26.31 54.06 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 123.099 0.56 . . . . 72.15 112.107 -176.354 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.539 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -61.12 -44.56 97.16 Favored 'General case' 0 C--O 1.252 1.219 0 CA-C-O 121.62 0.724 . . . . 72.3 111.129 169.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -67.69 -46.31 72.65 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 114.029 -1.441 . . . . 72.21 112.747 176.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.2 m80 -69.2 -47.43 64.86 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 122.775 0.43 . . . . 73.5 110.759 -176.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.69 -148.24 50.99 Favored Glycine 0 C--N 1.344 1.022 0 N-CA-C 111.229 -0.749 . . . . 72.23 111.229 -169.533 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 117.26 172.72 16.21 Favored Glycine 0 N--CA 1.472 1.039 0 CA-C-N 117.224 0.512 . . . . 24.11 113.471 172.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 13.7 mp0 -90.11 114.42 26.34 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 107.744 -1.206 . . . . 61.13 107.744 179.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 4.9 mmp_? -116.75 163.19 16.51 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 123.855 0.862 . . . . 73.51 110.306 -177.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.6 p -88.48 124.07 41.24 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 CA-C-O 121.241 0.543 . . . . 65.04 110.241 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.408 ' HA ' HG11 ' A' ' 99' ' ' VAL . 12.0 p -114.24 145.87 19.5 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.694 0 C-N-CA 123.816 0.846 . . . . 64.44 109.962 178.463 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -125.91 109.06 12.05 Favored 'General case' 0 C--O 1.242 0.682 0 N-CA-C 108.668 -0.864 . . . . 74.45 108.668 174.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.9 m -130.43 117.52 39.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 123.678 0.791 . . . . 73.24 111.068 -176.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.05 23.39 13.79 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.835 1.254 . . . . 63.51 112.257 176.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.12 12.71 57.25 Favored Glycine 0 C--N 1.343 0.944 0 CA-C-O 120.032 -0.315 . . . . 51.11 112.995 -178.309 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.1 mpt_? -103.3 116.87 33.27 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.203 -0.665 . . . . 74.42 109.203 177.169 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 62.5 ttp85 -94.32 105.17 17.15 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 108.14 -1.059 . . . . 74.42 108.14 172.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 8.9 m -142.11 157.07 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 C-N-CA 124.338 1.055 . . . . 52.12 109.575 -175.15 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 54.3 p -90.94 120.08 31.66 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 122.889 0.476 . . . . 63.54 110.217 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.22 141.35 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.348 0.659 . . . . 34.44 109.425 177.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -107.04 103.42 12.83 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 108.298 -1.001 . . . . 63.41 108.298 174.45 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.439 ' HB ' HD13 ' A' ' 159' ' ' ILE . 37.8 pt -106.98 107.27 60.22 Favored Pre-proline 0 CA--C 1.548 0.873 0 N-CA-C 108.677 -0.861 . . . . 72.42 108.677 170.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.96 162.08 43.11 Favored 'Trans proline' 0 C--N 1.38 2.235 0 C-N-CA 122.972 2.448 . . . . 71.11 113.389 -171.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -59.85 114.77 2.22 Favored 'Trans proline' 0 C--N 1.376 2.017 0 C-N-CA 122.482 2.121 . . . . 73.44 110.448 169.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.42 ' HA2' ' CD2' ' A' ' 240' ' ' PHE . . . 140.62 61.35 0.04 OUTLIER Glycine 0 C--N 1.341 0.811 0 N-CA-C 111.811 -0.515 . . . . 71.12 111.811 -173.724 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.568 HG21 HD11 ' A' ' 159' ' ' ILE . 3.2 p -150.9 163.14 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.301 0 C-N-CA 122.505 0.322 . . . . 74.43 110.162 -178.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 44.8 mtp180 -146.8 177.02 9.43 Favored 'General case' 0 N--CA 1.484 1.234 0 C-N-CA 124.987 1.315 . . . . 75.42 110.113 -171.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.2 tp10 -51.72 118.2 3.22 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 125.053 1.341 . . . . 71.14 111.51 170.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 79.0 1.28 84.91 Favored Glycine 0 C--N 1.351 1.373 0 CA-C-O 119.382 -0.677 . . . . 73.51 113.866 176.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.4 m -73.78 136.49 43.59 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-N 117.352 0.576 . . . . 63.34 110.953 -176.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.446 HG12 HD22 ' A' ' 175' ' ' LEU . 13.2 t -101.06 122.97 53.77 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-N 114.646 -1.161 . . . . 53.42 108.894 -174.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.568 HD11 HG21 ' A' ' 153' ' ' VAL . 16.6 mt -106.4 107.35 22.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 N-CA-C 109.035 -0.728 . . . . 74.21 109.035 -175.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.507 ' HA ' HD23 ' A' ' 175' ' ' LEU . 58.4 ttt-85 -81.7 109.13 15.83 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 110.03 -0.359 . . . . 63.5 110.03 176.202 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.444 HG22 ' O ' ' A' ' 174' ' ' LEU . 19.5 m -101.72 97.81 8.56 Favored Pre-proline 0 CA--C 1.559 1.319 0 N-CA-C 108.647 -0.872 . . . . 72.41 108.647 172.069 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -74.55 155.98 45.07 Favored 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 123.053 2.502 . . . . 50.41 113.189 -176.49 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 73.27 24.73 74.78 Favored Glycine 0 C--N 1.345 1.076 0 CA-C-N 115.488 -0.778 . . . . 72.51 112.586 -178.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.405 ' HG2' HG23 ' A' ' 161' ' ' VAL . 6.7 tpt -125.68 -56.89 1.47 Allowed 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 124.01 0.924 . . . . 74.35 111.573 -166.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . 0.551 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.353 1.491 0 O-C-N 123.725 0.641 . . . . 61.45 112.14 -175.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo . . . . . 0 CA--C 1.54 0.818 0 CA-C-O 120.713 0.214 . . . . 50.4 112.539 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -98.87 178.69 31.05 Favored Glycine 0 C--O 1.222 -0.625 0 N-CA-C 110.565 -1.014 . . . . 52.14 110.565 166.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -146.56 157.14 43.68 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 118.12 0.96 . . . . 71.51 111.259 -171.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.444 ' O ' HG22 ' A' ' 161' ' ' VAL . 27.0 tp -114.57 115.59 27.42 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 114.655 -1.157 . . . . 72.44 108.684 176.297 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.6 ' HB2' ' HG2' ' A' ' 120' ' ' ARG . 93.8 mt -90.35 99.46 12.48 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.297 1.039 . . . . 63.11 110.254 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.422 HD12 HG21 ' A' ' 149' ' ' ILE . 45.6 mt -87.07 104.59 16.48 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 122.81 0.444 . . . . 72.15 110.51 175.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.5 t -89.39 95.78 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 107.803 -1.184 . . . . 72.42 107.803 176.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.441 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 8.1 m -82.08 144.11 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 109.769 -0.456 . . . . 74.4 109.769 -174.695 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 5.2 mmm180 -122.28 105.55 10.31 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 106.118 -1.808 . . . . 64.52 106.118 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 36.6 mt -69.61 147.88 50.11 Favored 'General case' 0 N--CA 1.473 0.706 0 O-C-N 123.373 0.421 . . . . 65.21 111.175 -172.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.472 HD12 HG23 ' A' ' 126' ' ' THR . 36.5 mt -55.73 121.04 36.95 Favored Pre-proline 0 C--N 1.357 0.905 0 O-C-N 123.641 0.588 . . . . 73.54 109.748 177.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -65.98 88.02 0.24 Allowed 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 122.969 2.446 . . . . 61.13 112.306 -178.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 13.3 p80 -156.99 62.9 2.88 Favored Pre-proline 0 CA--C 1.55 0.958 0 N-CA-C 107.794 -1.187 . . . . 74.1 107.794 169.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -56.14 122.06 11.1 Favored 'Trans proline' 0 C--N 1.382 2.339 0 C-N-CA 122.089 1.859 . . . . 74.24 112.639 -170.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.83 -45.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 N-CA-C 107.704 -1.221 . . . . 61.51 107.704 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.435 ' CE2' HD13 ' A' ' 193' ' ' LEU . 4.9 m-85 -107.41 131.98 53.68 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 123.93 0.892 . . . . 72.41 110.384 178.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 69.0 mtp180 -117.81 131.12 56.61 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.765 1.226 . . . . 74.41 108.635 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.406 HD12 ' O ' ' A' ' 192' ' ' ASP . 58.6 tp -109.9 130.84 55.48 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 121.004 0.43 . . . . 64.2 110.182 177.267 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -129.87 101.79 6.02 Favored 'General case' 0 C--O 1.24 0.572 0 N-CA-C 107.417 -1.327 . . . . 63.53 107.417 172.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 69.67 -82.65 0.29 Allowed Glycine 0 CA--C 1.53 1.008 0 O-C-N 123.793 0.683 . . . . 62.11 112.607 -176.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . 0.417 HE22 ' HB3' ' A' ' 244' ' ' ALA . 49.8 tt0 -134.2 -22.18 1.79 Allowed 'General case' 0 CA--C 1.552 1.053 0 C-N-CA 124.733 1.213 . . . . 73.03 109.554 -177.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.406 ' O ' HD12 ' A' ' 188' ' ' LEU . 41.3 m-20 -81.41 149.73 28.69 Favored 'General case' 0 C--N 1.358 0.967 0 C-N-CA 123.809 0.844 . . . . 72.43 111.385 -178.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.535 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.8 mt -109.58 155.04 21.92 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 124.639 1.176 . . . . 51.1 110.491 174.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -140.02 119.02 12.6 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 105.605 -1.998 . . . . 74.31 105.605 172.34 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -135.5 134.41 39.49 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 109.184 -0.672 . . . . 71.4 109.184 -178.235 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . 0.437 ' HA ' ' HB3' ' A' ' 252' ' ' GLU . 24.0 m -70.91 123.64 22.49 Favored 'General case' 0 CA--C 1.541 0.612 0 O-C-N 123.654 0.596 . . . . 73.2 110.064 -179.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.466 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 61.3 tp -105.95 111.34 23.95 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 108.767 -0.827 . . . . 71.34 108.767 -178.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -85.04 116.74 23.6 Favored 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.492 -0.929 . . . . 55.44 108.492 176.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 2.2 m -122.86 141.64 35.95 Favored Pre-proline 0 N--CA 1.479 0.986 0 N-CA-C 108.996 -0.742 . . . . 50.33 108.996 177.592 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -72.7 147.1 44.44 Favored 'Trans proline' 0 C--N 1.366 1.485 0 C-N-CA 121.539 1.493 . . . . 63.42 110.521 169.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -58.31 -40.97 86.87 Favored Pre-proline 0 CA--C 1.558 1.26 0 C-N-CA 123.689 0.796 . . . . 62.32 112.419 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -45.68 -54.84 4.07 Favored 'Trans proline' 0 C--N 1.392 2.844 0 C-N-CA 122.524 2.15 . . . . 43.41 114.164 167.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 11.7 mt -65.58 -36.29 77.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 C-N-CA 122.237 0.215 . . . . 75.13 111.429 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.53 -44.27 93.23 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.16 0.584 . . . . 31.24 111.944 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.7 m -80.16 -41.15 20.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 CA-C-N 116.063 -0.517 . . . . 53.34 111.569 -176.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.3 m -78.88 -21.18 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 122.549 0.34 . . . . 74.04 111.148 -178.649 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.516 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 71.2 65.32 2.48 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 115.764 -0.653 . . . . 74.32 112.439 -176.484 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -93.85 -155.55 31.87 Favored Glycine 0 C--N 1.353 1.505 0 CA-C-N 116.94 0.37 . . . . 65.4 112.535 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.22 134.87 54.62 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.326 1.05 . . . . 61.01 108.438 178.332 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 46.6 t -117.97 125.77 74.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 124.078 0.951 . . . . 64.43 108.593 -178.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -79.6 109.14 13.71 Favored 'General case' 0 CA--C 1.542 0.659 0 N-CA-C 109.137 -0.69 . . . . 64.54 109.137 177.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.95 129.92 48.35 Favored 'General case' 0 C--O 1.238 0.483 0 C-N-CA 123.417 0.687 . . . . 70.1 109.148 179.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.2 116.75 18.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.004 -0.544 . . . . 70.5 109.899 174.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.41 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.9 t -109.67 163.56 13.36 Favored 'General case' 0 C--O 1.242 0.685 0 O-C-N 123.901 0.75 . . . . 74.43 109.402 172.09 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . 0.552 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 90.2 mt -71.53 -2.58 17.37 Favored 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 115.507 -0.77 . . . . 63.33 112.61 -172.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -112.26 -11.72 13.69 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.565 0.746 . . . . 63.11 112.111 175.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 153.71 -156.34 26.73 Favored Glycine 0 C--N 1.349 1.267 0 CA-C-O 119.546 -0.585 . . . . 61.32 112.799 -179.047 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -94.28 133.53 0.76 Allowed 'Trans proline' 0 CA--C 1.556 1.592 0 C-N-CA 123.001 2.467 . . . . 74.14 112.846 174.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 27.1 m -114.56 157.5 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 123.585 0.754 . . . . 73.34 109.639 170.351 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -114.47 113.9 25.09 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 108.999 -0.741 . . . . 72.22 108.999 177.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.477 HG22 HD11 ' A' ' 235' ' ' LEU . 6.3 t -95.79 117.19 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 C-N-CA 123.99 0.916 . . . . 75.04 110.026 -177.328 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.99 100.57 11.14 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 108.977 -0.749 . . . . 74.21 108.977 176.101 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.516 HG23 ' HA2' ' A' ' 207' ' ' GLY . 20.0 m -79.43 137.45 55.65 Favored Pre-proline 0 CA--C 1.551 1.019 0 N-CA-C 109.415 -0.587 . . . . 54.14 109.415 179.415 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -63.31 144.9 92.39 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.537 2.158 . . . . 61.32 112.498 176.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -55.77 120.41 8.2 Favored 'Trans proline' 0 C--N 1.381 2.258 0 C-N-CA 123.081 2.521 . . . . 43.42 112.043 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 67.3 mtt180 64.76 54.61 1.34 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.382 1.073 . . . . 64.41 110.388 -175.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.3 t -75.49 167.36 22.04 Favored 'General case' 0 CA--C 1.545 0.781 0 CA-C-N 115.372 -0.831 . . . . 71.31 109.159 173.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -128.15 146.28 50.76 Favored 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 123.217 0.607 . . . . 74.12 109.614 -177.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -68.13 127.9 34.6 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 115.318 -0.855 . . . . 74.35 109.27 175.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.29 0.31 23.69 Favored Glycine 0 N--CA 1.471 1.032 0 CA-C-O 119.497 -0.613 . . . . 62.42 112.841 -173.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 25.0 mtp180 -84.4 154.89 22.55 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 117.414 0.607 . . . . 73.15 109.865 170.025 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.658 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.0 OUTLIER -120.59 101.67 7.91 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 108.497 -0.927 . . . . 75.12 108.497 176.269 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 37.2 mt -83.37 113.98 21.11 Favored 'General case' 0 C--N 1.352 0.686 0 N-CA-C 108.964 -0.754 . . . . 73.12 108.964 -173.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 -87.24 106.68 18.07 Favored 'General case' 0 C--O 1.239 0.507 0 C-N-CA 123.782 0.833 . . . . 75.32 110.839 -167.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.477 HD11 HG22 ' A' ' 221' ' ' VAL . 15.7 mt -94.06 104.28 16.32 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 108.112 -1.07 . . . . 75.15 108.112 174.091 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -74.65 141.47 44.61 Favored 'General case' 0 C--O 1.242 0.683 0 CA-C-N 115.763 -0.653 . . . . 73.13 112.025 -170.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 66.59 32.99 83.16 Favored Glycine 0 C--N 1.349 1.271 0 O-C-N 124.12 0.888 . . . . 71.22 113.253 178.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 41.1 mmtm -116.13 -2.68 12.15 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.663 0.785 . . . . 74.21 111.166 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . 0.449 ' O ' ' HD2' ' A' ' 246' ' ' ARG . . . -82.03 -156.16 17.28 Favored Glycine 0 C--N 1.347 1.177 0 O-C-N 123.657 0.598 . . . . 61.33 114.181 -178.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.42 ' CD2' ' HA2' ' A' ' 152' ' ' GLY . 35.0 m-85 -88.34 160.29 45.64 Favored Pre-proline 0 N--CA 1.482 1.159 0 C-N-CA 123.204 0.601 . . . . 52.24 110.56 176.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -57.09 152.5 44.15 Favored 'Trans proline' 0 C--N 1.382 2.313 0 C-N-CA 123.031 2.487 . . . . 71.51 113.971 178.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 176.94 -167.71 39.2 Favored Glycine 0 C--N 1.341 0.853 0 CA-C-N 115.27 -0.877 . . . . 74.34 112.11 176.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.27 -15.3 35.15 Favored 'Trans proline' 0 C--N 1.382 2.291 0 C-N-CA 122.983 2.456 . . . . 71.13 112.619 -176.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . 0.417 ' HB3' HE22 ' A' ' 191' ' ' GLN . . . -96.77 24.12 6.39 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.175 0.99 . . . . 54.34 110.692 174.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 77.8 -89.62 1.06 Allowed Glycine 0 C--N 1.345 1.063 0 N-CA-C 110.943 -0.863 . . . . 70.41 110.943 -175.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.449 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 23.1 mtm180 -128.09 155.89 43.67 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 108.728 -0.841 . . . . 75.14 108.728 169.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -70.9 -160.78 3.72 Favored Glycine 0 C--N 1.348 1.231 0 O-C-N 123.727 0.642 . . . . 60.14 114.397 -176.25 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -129.21 138.33 51.64 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 122.888 0.475 . . . . 74.52 109.772 -173.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.535 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 30.6 tp -97.27 115.96 28.59 Favored 'General case' 0 C--O 1.214 -0.788 0 C-N-CA 123.624 0.77 . . . . 75.1 110.017 -178.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . 0.658 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 97.3 m-85 -101.65 106.95 18.06 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 123.497 0.719 . . . . 73.0 109.356 179.1 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.5 ' HA ' ' O ' ' A' ' 195' ' ' ALA . 78.3 mt -87.08 118.72 26.65 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.372 -0.831 . . . . 72.23 113.115 -175.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.437 ' HB3' ' HA ' ' A' ' 196' ' ' THR . 10.5 tp10 -79.76 91.71 5.34 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 108.578 -0.897 . . . . 74.21 108.578 -178.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 59.7 t -52.5 118.38 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 123.99 0.916 . . . . 74.03 110.875 177.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 30.7 mmm180 -123.48 94.79 4.35 Favored 'General case' 0 C--O 1.24 0.569 0 C-N-CA 124.635 1.174 . . . . 74.11 107.95 176.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 63.4 mt -76.62 114.25 16.69 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 115.716 -0.674 . . . . 55.22 109.299 177.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 6.4 t . . . . . 0 C--O 1.248 1.014 0 C-N-CA 124.619 1.168 . . . . 62.41 108.944 -179.559 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.7 tp . . . . . 0 C--O 1.236 0.358 0 N-CA-C 107.599 -1.26 . . . . 64.24 107.599 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.561 ' HB ' ' HB3' ' A' ' 123' ' ' LEU 0.269 2.4 p 36.57 -95.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 C-N-CA 126.337 1.855 . . . . 74.31 113.713 176.956 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.46 ' H ' HG13 ' A' ' 99' ' ' VAL . . . 57.31 8.32 0.57 Allowed 'General case' 0 N--CA 1.493 1.683 0 C-N-CA 124.963 1.305 . . . . 62.25 113.14 -176.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 35.7 t-80 -103.81 71.91 1.08 Allowed 'General case' 0 C--O 1.243 0.756 0 N-CA-C 107.374 -1.343 . . . . 74.11 107.374 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 81.0 t -72.53 137.18 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 CA-C-N 114.375 -1.284 . . . . 34.54 109.702 -179.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 72.2 p . . . . . 0 N--CA 1.476 0.838 0 C-N-CA 124.504 1.122 . . . . 72.42 112.724 -173.842 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.3 p30 . . . . . 0 N--CA 1.468 0.432 0 N-CA-C 106.811 -1.552 . . . . 71.14 106.811 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 1.3 tt -99.83 143.34 30.17 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 106.427 -1.694 . . . . 71.51 106.427 177.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 12.7 tpp85 -119.0 125.23 48.9 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 118.778 0.717 . . . . 72.53 110.591 -173.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -147.85 149.95 33.25 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.341 0.656 . . . . 71.34 109.794 178.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.664 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 41.8 mt-10 -127.83 149.4 50.29 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.52 0.728 . . . . 71.43 109.418 -179.074 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.561 ' HB3' ' HB ' ' A' ' 99' ' ' VAL . 1.5 pt? -143.93 147.1 36.93 Favored Pre-proline 0 N--CA 1.474 0.741 0 O-C-N 123.505 0.503 . . . . 63.51 111.323 -176.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -76.79 113.93 3.74 Favored 'Trans proline' 0 C--N 1.371 1.738 0 C-N-CA 121.426 1.418 . . . . 73.44 109.688 162.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.464 HD22 HG11 ' A' ' 178' ' ' VAL . 18.6 tp -108.28 158.8 17.15 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.758 0.823 . . . . 45.44 108.839 178.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.57 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 6.9 m -95.52 156.26 16.4 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 123.397 0.679 . . . . 71.33 109.191 175.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 82.0 mt -58.34 -49.33 77.58 Favored 'General case' 0 N--CA 1.488 1.436 0 CA-C-O 122.348 1.071 . . . . 62.14 109.455 174.302 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -57.01 -38.16 72.7 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 113.276 -1.784 . . . . 74.14 111.475 177.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 31.5 mm-40 -80.02 -21.16 43.86 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.231 0.612 . . . . 72.22 112.469 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.539 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -61.63 -40.33 94.47 Favored 'General case' 0 C--O 1.256 1.417 0 CA-C-O 121.665 0.745 . . . . 42.31 110.696 167.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.491 ' HA ' ' CE1' ' A' ' 240' ' ' PHE . 69.0 t80 -70.31 -48.35 56.98 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 113.964 -1.471 . . . . 74.44 112.774 172.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -71.55 -47.32 55.78 Favored 'General case' 0 N--CA 1.485 1.277 0 N-CA-C 112.067 0.395 . . . . 74.01 112.067 -172.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.32 -115.89 8.19 Favored Glycine 0 CA--C 1.533 1.204 0 N-CA-C 111.121 -0.791 . . . . 52.13 111.121 -175.643 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.8 174.55 39.71 Favored Glycine 0 C--N 1.346 1.124 0 N-CA-C 115.175 0.83 . . . . 54.44 115.175 167.613 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -87.61 118.26 26.98 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.346 1.059 . . . . 62.42 108.221 178.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -130.44 138.88 50.53 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 124.368 1.067 . . . . 74.43 108.543 -176.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 7.2 p -83.12 139.93 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 N-CA-C 108.697 -0.853 . . . . 74.2 108.697 174.16 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.446 HG21 HG13 ' A' ' 99' ' ' VAL . 7.1 p -143.04 153.09 16.89 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 C-N-CA 124.011 0.924 . . . . 74.53 109.324 -178.275 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -116.38 100.27 7.77 Favored 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 107.782 -1.192 . . . . 73.2 107.782 170.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 9.0 t -103.65 111.54 33.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 N-CA-C 108.753 -0.832 . . . . 71.34 108.753 -172.037 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.93 26.0 15.33 Favored 'General case' 0 N--CA 1.479 1.017 0 O-C-N 124.493 1.121 . . . . 72.43 111.658 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 91.75 13.63 57.77 Favored Glycine 0 C--N 1.355 1.585 0 CA-C-N 115.807 -0.633 . . . . 74.4 113.315 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 25.8 ttt180 -116.7 116.23 27.13 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 122.986 0.514 . . . . 72.23 110.134 177.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -87.5 114.09 23.8 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 122.838 0.455 . . . . 62.15 110.196 -178.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.6 p -148.13 152.79 12.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 C-N-CA 124.835 1.254 . . . . 72.02 109.089 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 43.7 m -82.86 122.19 27.91 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 122.835 0.454 . . . . 75.13 110.258 175.15 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.414 HG22 HG23 ' A' ' 149' ' ' ILE . 13.7 p -98.59 123.99 51.48 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 C-N-CA 123.646 0.778 . . . . 75.03 109.594 175.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 30.9 ttt85 -108.05 98.25 7.84 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 107.849 -1.167 . . . . 74.41 107.849 174.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.414 HG23 HG22 ' A' ' 147' ' ' VAL . 35.3 pt -96.32 131.4 28.64 Favored Pre-proline 0 N--CA 1.479 0.984 0 N-CA-C 109.673 -0.492 . . . . 75.32 109.673 178.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.404 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 58.2 Cg_endo -67.71 145.32 69.04 Favored 'Trans proline' 0 C--N 1.375 1.94 0 C-N-CA 122.852 2.368 . . . . 73.44 112.982 -174.154 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.475 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 32.1 Cg_exo -63.68 125.12 14.85 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 123.045 2.497 . . . . 74.33 110.596 171.186 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 131.44 41.25 0.21 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 111.827 -0.509 . . . . 50.31 111.827 -173.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.539 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -118.58 154.21 20.77 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 N-CA-C 108.775 -0.824 . . . . 74.32 108.775 -177.484 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 40.9 mtp180 -144.66 166.85 24.01 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 124.943 1.297 . . . . 72.25 109.055 -165.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -52.75 123.18 10.65 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 123.61 0.764 . . . . 60.14 111.943 176.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 80.62 -4.61 68.17 Favored Glycine 0 C--N 1.348 1.202 0 CA-C-N 115.896 -0.593 . . . . 64.13 113.629 179.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 32.4 t -68.82 127.52 33.38 Favored 'General case' 0 C--O 1.248 1.016 0 C-N-CA 123.665 0.786 . . . . 61.1 110.134 -176.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.515 HG12 HD22 ' A' ' 175' ' ' LEU . 8.7 t -97.89 119.46 45.94 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-N 114.303 -1.317 . . . . 63.4 108.627 -176.449 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.483 HD11 HG21 ' A' ' 153' ' ' VAL . 17.2 mt -102.94 117.07 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 123.664 0.786 . . . . 75.4 110.054 -170.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 22.3 ttm180 -84.02 117.39 23.37 Favored 'General case' 0 C--O 1.239 0.512 0 C-N-CA 123.53 0.732 . . . . 64.22 110.414 172.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.84 101.39 53.02 Favored Pre-proline 0 CA--C 1.559 1.29 0 N-CA-C 108.293 -1.003 . . . . 70.54 108.293 169.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -64.92 149.66 89.2 Favored 'Trans proline' 0 C--N 1.384 2.407 0 C-N-CA 123.55 2.833 . . . . 60.44 113.428 -172.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 71.3 24.2 77.22 Favored Glycine 0 C--N 1.348 1.216 0 O-C-N 123.594 0.559 . . . . 62.43 113.795 175.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 2.9 tpt -100.52 -51.86 3.5 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.149 0.98 . . . . 64.42 109.998 -177.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.351 1.391 0 CA-C-N 115.403 -0.817 . . . . 71.32 112.092 -179.511 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo . . . . . 0 CA--C 1.554 1.523 0 CA-C-O 121.173 0.405 . . . . 55.2 112.507 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -100.6 150.5 18.82 Favored Glycine 0 C--N 1.342 0.866 0 N-CA-C 108.988 -1.645 . . . . 61.31 108.988 174.193 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -113.09 -179.89 3.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 118.049 0.924 . . . . 74.23 111.498 -164.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 15.6 tp -121.98 128.63 51.69 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 107.82 -1.178 . . . . 71.53 107.82 167.3 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.515 HD22 HG12 ' A' ' 158' ' ' VAL . 76.6 mt -99.76 101.99 13.31 Favored 'General case' 0 C--O 1.243 0.746 0 C-N-CA 125.085 1.354 . . . . 75.4 110.28 178.342 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 86.4 mt -91.28 109.46 20.73 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 123.612 0.765 . . . . 74.4 111.114 175.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.664 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 21.5 t -90.2 105.22 16.0 Favored 'Isoleucine or valine' 0 C--O 1.247 0.938 0 N-CA-C 108.115 -1.068 . . . . 71.11 108.115 173.286 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.464 HG11 HD22 ' A' ' 125' ' ' LEU . 6.1 m -82.4 151.34 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 CA-C-O 121.223 0.535 . . . . 60.24 111.615 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 38.2 mmt180 -124.07 98.95 6.01 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 107.67 -1.233 . . . . 71.25 107.67 176.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 57.5 mt -67.46 144.64 55.61 Favored 'General case' 0 C--O 1.241 0.628 0 O-C-N 123.139 0.274 . . . . 72.04 110.685 -178.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.57 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 44.1 mt -59.83 147.03 80.11 Favored Pre-proline 0 CA--C 1.558 1.284 0 O-C-N 124.366 1.041 . . . . 52.15 110.967 -176.436 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -75.46 58.09 5.06 Favored 'Trans proline' 0 C--N 1.375 1.96 0 C-N-CA 123.991 3.127 . . . . 73.44 113.845 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -142.28 51.82 2.17 Favored Pre-proline 0 CA--C 1.562 1.434 0 C-N-CA 123.035 0.534 . . . . 54.04 109.831 171.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -64.21 123.56 12.05 Favored 'Trans proline' 0 C--N 1.388 2.632 0 C-N-CA 122.43 2.087 . . . . 61.31 111.905 -168.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -128.22 -37.49 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 123.81 0.844 . . . . 74.52 109.363 -177.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.435 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 6.0 m-85 -107.39 124.37 49.74 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 114.814 -1.085 . . . . 73.02 110.338 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.652 ' HB3' ' HB2' ' A' ' 194' ' ' TYR . 19.6 tpp180 -105.02 139.08 40.24 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 106.934 -1.506 . . . . 63.51 106.934 172.073 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 51.1 tp -123.41 122.62 38.74 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 122.897 0.479 . . . . 63.14 109.86 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -144.9 127.86 16.47 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 122.39 0.276 . . . . 74.13 110.322 169.16 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 63.94 33.83 88.28 Favored Glycine 0 C--N 1.356 1.648 0 O-C-N 123.91 0.756 . . . . 75.25 114.246 177.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 73.96 -5.24 2.08 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 125.714 1.606 . . . . 73.25 112.659 -175.567 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -93.33 149.98 20.82 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.479 0.711 . . . . 73.01 109.579 178.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.646 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 93.1 mt -108.92 163.57 13.17 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 124.281 1.033 . . . . 70.21 109.94 -176.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . 0.652 ' HB2' ' HB3' ' A' ' 187' ' ' ARG . 85.1 m-85 -143.38 121.52 12.18 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 106.803 -1.554 . . . . 74.51 106.803 178.01 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -147.25 164.32 33.58 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.444 0.697 . . . . 75.54 109.921 -176.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 17.5 m -106.2 125.45 51.01 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.51 -0.768 . . . . 62.0 109.17 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.56 HD22 HD13 ' A' ' 251' ' ' LEU . 65.5 tp -112.44 115.65 29.03 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.541 0.736 . . . . 73.04 109.631 177.419 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -78.7 131.03 36.46 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 108.138 -1.06 . . . . 65.44 108.138 169.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 255' ' ' ILE . 90.9 t -129.78 121.15 19.86 Favored Pre-proline 0 N--CA 1.474 0.728 0 N-CA-C 107.682 -1.229 . . . . 72.14 107.682 178.626 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -65.83 147.66 85.57 Favored 'Trans proline' 0 C--N 1.369 1.657 0 C-N-CA 122.143 1.895 . . . . 74.13 110.888 176.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . 0.445 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -53.5 -42.5 92.24 Favored Pre-proline 0 N--CA 1.48 1.065 0 C-N-CA 124.483 1.113 . . . . 65.11 113.569 -177.323 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . 0.445 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 10.8 Cg_endo -52.42 -51.29 11.46 Favored 'Trans proline' 0 C--N 1.397 3.107 0 C-N-CA 122.144 1.896 . . . . 74.11 112.64 172.219 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 7.0 mt -66.49 -37.11 78.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 123.211 0.604 . . . . 72.21 111.641 -179.065 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.3 -42.97 99.11 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 122.926 0.49 . . . . 52.24 111.929 -178.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.2 m -82.62 -35.59 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.87 0 CA-C-N 115.931 -0.577 . . . . 73.55 111.987 -175.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 12.4 m -87.23 -18.92 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 CA-C-N 118.043 0.383 . . . . 74.22 111.658 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.408 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 77.87 55.04 4.28 Favored Glycine 0 C--N 1.344 1.022 0 CA-C-N 115.857 -0.61 . . . . 75.24 113.218 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -84.87 -169.66 46.17 Favored Glycine 0 C--N 1.349 1.252 0 CA-C-O 121.783 0.657 . . . . 71.11 112.585 -177.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . 0.432 ' HD2' ' N ' ' A' ' 209' ' ' LYS . 0.0 OUTLIER -115.61 120.18 38.58 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 107.771 -1.196 . . . . 63.53 107.771 -173.667 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . 0.442 HG11 HG22 ' A' ' 199' ' ' VAL . 7.3 p -124.42 144.07 35.57 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 124.37 1.068 . . . . 44.21 109.343 -178.304 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.22 138.06 34.74 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.297 -0.631 . . . . 72.13 109.297 176.134 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -107.69 131.56 54.28 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 108.446 -0.946 . . . . 63.5 108.446 169.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.49 104.55 9.16 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.988 -1.116 . . . . 72.33 107.988 179.375 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.447 HG23 ' H ' ' A' ' 216' ' ' GLU . 14.8 t -112.41 168.15 9.87 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.161 0.584 . . . . 63.1 110.543 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 65.2 mt -70.03 -7.3 39.93 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 123.562 0.745 . . . . 71.23 111.788 -179.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . 0.447 ' H ' HG23 ' A' ' 214' ' ' THR . 42.6 tt0 -97.28 -18.07 19.42 Favored 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.679 1.192 . . . . 70.32 111.382 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 133.06 -147.83 19.11 Favored Glycine 0 N--CA 1.475 1.284 0 CA-C-O 119.188 -0.784 . . . . 64.15 111.82 -178.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -85.84 126.73 2.98 Favored 'Trans proline' 0 CA--C 1.559 1.757 0 C-N-CA 122.878 2.386 . . . . 53.42 112.021 172.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 26.1 m -109.68 156.1 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 122.918 0.487 . . . . 63.35 110.944 172.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 24.9 mm-40 -95.09 109.89 21.89 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 123.572 0.749 . . . . 72.12 109.827 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.566 HG22 HD11 ' A' ' 235' ' ' LEU . 8.7 t -104.25 117.52 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.663 0.785 . . . . 65.55 109.057 172.525 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -98.62 102.42 14.15 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 108.279 -1.008 . . . . 71.34 108.279 174.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.408 HG23 ' HA2' ' A' ' 207' ' ' GLY . 11.9 m -75.97 143.52 74.35 Favored Pre-proline 0 CA--C 1.551 1.011 0 N-CA-C 109.638 -0.504 . . . . 75.33 109.638 -176.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -64.46 140.68 70.62 Favored 'Trans proline' 0 C--N 1.368 1.587 0 C-N-CA 122.777 2.318 . . . . 63.13 112.34 174.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.9 129.38 34.63 Favored 'Trans proline' 0 C--N 1.376 1.992 0 C-N-CA 122.713 2.275 . . . . 53.31 111.337 171.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 64.3 mtm180 65.85 34.89 6.98 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 125.116 1.367 . . . . 73.33 110.988 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 5.7 t -66.64 164.55 16.6 Favored 'General case' 0 CA--C 1.549 0.919 0 N-CA-C 109.938 -0.393 . . . . 74.12 109.938 176.548 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -120.46 150.95 40.0 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.731 0.813 . . . . 75.52 109.697 -176.019 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -68.28 141.92 55.72 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.13 0.972 . . . . 54.21 110.727 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 91.11 -3.83 80.64 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-O 119.467 -0.629 . . . . 72.41 112.542 -176.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 41.1 mtp180 -72.01 161.3 31.12 Favored 'General case' 0 C--N 1.362 1.125 0 CA-C-O 122.16 0.981 . . . . 74.22 110.64 177.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -107.62 107.73 18.67 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 113.892 -1.503 . . . . 53.54 108.043 -173.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . 0.447 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 45.9 mt -100.38 98.31 8.96 Favored 'General case' 0 C--N 1.349 0.576 0 N-CA-C 107.328 -1.36 . . . . 63.24 107.328 175.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . 0.498 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 20.0 ttm180 -100.92 115.86 31.43 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.154 0.502 . . . . 74.12 110.698 -171.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.566 HD11 HG22 ' A' ' 221' ' ' VAL . 23.4 mt -96.06 117.75 31.3 Favored 'General case' 0 C--O 1.241 0.631 0 C-N-CA 124.159 0.983 . . . . 62.32 109.508 -176.02 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 49.8 mtmt -72.46 133.66 44.95 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.597 0.759 . . . . 74.21 111.151 -175.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 70.69 33.81 66.82 Favored Glycine 0 C--N 1.345 1.03 0 O-C-N 124.214 0.946 . . . . 62.02 112.954 176.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 72.7 mmtt -123.17 5.49 9.19 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.246 0.618 . . . . 72.13 111.958 178.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -85.51 -147.94 10.18 Favored Glycine 0 C--N 1.35 1.328 0 O-C-N 123.532 0.52 . . . . 71.25 112.952 177.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.491 ' CE1' ' HA ' ' A' ' 131' ' ' PHE . 16.2 m-85 -95.95 145.18 29.1 Favored Pre-proline 0 N--CA 1.478 0.931 0 C-N-CA 123.05 0.54 . . . . 71.04 111.589 173.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.72 156.53 39.82 Favored 'Trans proline' 0 C--N 1.375 1.968 0 C-N-CA 123.308 2.672 . . . . 72.34 112.468 173.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 173.92 -163.17 34.09 Favored Glycine 0 CA--C 1.535 1.335 0 CA-C-N 115.317 -0.856 . . . . 63.2 111.921 177.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.43 -16.49 43.31 Favored 'Trans proline' 0 C--N 1.379 2.179 0 C-N-CA 123.274 2.649 . . . . 41.02 112.912 -175.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -97.1 22.62 8.27 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.794 0.837 . . . . 63.05 111.222 177.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 79.93 -138.31 19.88 Favored Glycine 0 C--N 1.352 1.441 0 N-CA-C 110.699 -0.961 . . . . 51.31 110.699 -174.222 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 56.4 ttt180 -110.53 142.19 42.65 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 117.509 0.654 . . . . 72.03 109.648 171.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -77.76 -158.24 10.24 Favored Glycine 0 C--N 1.342 0.903 0 O-C-N 123.684 0.615 . . . . 43.33 112.945 177.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -128.52 170.58 13.02 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.803 0.841 . . . . 54.31 109.746 -172.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.646 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 15.7 tp -111.79 113.66 26.15 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.784 0.834 . . . . 72.42 109.806 171.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . 0.493 ' HB3' ' O ' ' A' ' 193' ' ' LEU . 2.9 t80 -88.42 108.06 19.18 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 107.567 -1.272 . . . . 74.14 107.567 174.202 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.56 HD13 HD22 ' A' ' 197' ' ' LEU . 52.3 mt -91.16 145.42 24.69 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 123.522 0.729 . . . . 73.34 110.744 170.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -107.63 101.95 11.23 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 107.161 -1.422 . . . . 75.24 107.161 167.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.3 p -62.38 128.25 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 CA-C-O 121.326 0.584 . . . . 72.34 110.115 177.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 9.9 mmm180 -125.72 94.33 4.09 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 107.195 -1.409 . . . . 75.14 107.195 -177.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 199' ' ' VAL . 67.2 mt -76.55 139.89 18.09 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 CA-C-N 115.364 -0.835 . . . . 64.34 110.379 -173.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.5 t . . . . . 0 CA--C 1.554 1.108 0 C-N-CA 123.781 0.832 . . . . 53.52 109.244 -175.429 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.6 tp . . . . . 0 N--CA 1.48 1.025 0 CA-C-O 121.523 0.678 . . . . 74.23 110.237 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 12.9 p 176.86 146.32 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-N 114.218 -1.356 . . . . 73.34 109.282 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -88.08 -78.53 0.32 Allowed 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 108.37 -0.974 . . . . 71.42 108.37 167.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 10.3 m170 -159.32 165.42 33.42 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 124.163 0.985 . . . . 64.3 109.92 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 84.2 t -64.02 136.35 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 O-C-N 124.052 0.845 . . . . 71.4 109.637 174.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 32.6 p . . . . . 0 CA--C 1.549 0.94 0 C-N-CA 123.716 0.806 . . . . 75.43 109.363 173.927 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 . . . . . 0 C--O 1.241 0.65 0 N-CA-C 108.878 -0.786 . . . . 73.23 108.878 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 30.3 mt -96.4 156.22 16.43 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 123.469 0.708 . . . . 70.22 109.19 -178.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.2 146.28 44.68 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.519 -1.289 . . . . 74.0 107.519 174.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -158.36 136.82 10.98 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 123.528 0.731 . . . . 71.32 109.787 -178.042 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -100.97 142.62 32.19 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.485 0.714 . . . . 54.01 109.718 -178.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -146.45 143.09 18.25 Favored Pre-proline 0 CA--C 1.552 1.049 0 C-N-CA 123.077 0.551 . . . . 71.23 110.565 174.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_exo -77.4 118.26 4.57 Favored 'Trans proline' 0 C--N 1.376 2.004 0 C-N-CA 122.97 2.447 . . . . 72.35 111.327 172.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.427 ' HG ' ' HB2' ' A' ' 129' ' ' GLU . 14.8 tp -108.62 155.59 20.51 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 123.75 0.82 . . . . 72.14 109.678 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.606 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 20.7 m -93.56 157.48 16.17 Favored 'General case' 0 CA--C 1.55 0.945 0 N-CA-C 109.363 -0.606 . . . . 55.23 109.363 174.235 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.479 HD11 ' O ' ' A' ' 183' ' ' HIS . 32.6 mt -58.22 -48.18 81.16 Favored 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 123.944 0.898 . . . . 33.44 110.382 178.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -54.25 -36.49 63.62 Favored 'General case' 0 C--O 1.218 -0.584 0 CA-C-N 113.796 -1.547 . . . . 61.44 110.736 176.371 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.606 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 7.5 mm-40 -79.6 -23.04 42.95 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.48 0.712 . . . . 74.14 111.411 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.792 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -63.0 -36.32 83.16 Favored 'General case' 0 C--O 1.244 0.793 0 CA-C-O 121.42 0.628 . . . . 72.2 110.304 167.334 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.415 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 26.8 t80 -81.31 -33.54 32.51 Favored 'General case' 0 CA--C 1.554 1.097 0 CA-C-N 114.709 -1.132 . . . . 75.22 111.972 176.11 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . 0.474 ' HB2' ' HA ' ' A' ' 129' ' ' GLU . 24.6 m80 -84.13 -40.96 17.58 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 112.631 0.604 . . . . 63.53 112.631 -173.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 72.16 -129.55 15.23 Favored Glycine 0 CA--C 1.536 1.389 0 N-CA-C 110.834 -0.907 . . . . 74.11 110.834 -166.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 134.97 140.2 4.19 Favored Glycine 0 N--CA 1.477 1.401 0 CA-C-N 117.805 0.802 . . . . 61.12 114.145 169.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -86.54 113.6 22.59 Favored 'General case' 0 C--N 1.357 0.91 0 N-CA-C 108.486 -0.931 . . . . 61.23 108.486 167.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -141.81 170.11 16.32 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.901 1.281 . . . . 71.32 108.314 175.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.498 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 14.7 p -95.18 143.3 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 118.639 0.654 . . . . 61.22 111.276 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 12.2 p -114.94 138.24 45.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 C-N-CA 123.833 0.853 . . . . 64.4 109.553 172.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -125.51 105.12 8.81 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 108.678 -0.86 . . . . 63.24 108.678 173.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.2 m -129.59 133.72 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 124.187 0.995 . . . . 63.12 110.042 -177.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.96 22.82 13.67 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 124.534 1.134 . . . . 73.44 111.313 -176.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.64 -6.7 79.6 Favored Glycine 0 C--N 1.354 1.538 0 CA-C-N 115.734 -0.666 . . . . 74.51 113.124 -176.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 53.4 ttt85 -94.81 119.67 33.77 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 123.632 0.773 . . . . 62.43 110.396 -175.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 20.6 ttp180 -105.07 109.63 21.69 Favored 'General case' 0 CA--C 1.552 1.024 0 C-N-CA 123.998 0.919 . . . . 62.23 110.797 -174.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 13.7 m -133.24 155.54 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 C-N-CA 124.708 1.203 . . . . 52.44 108.795 174.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.498 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 60.1 p -76.8 126.8 31.59 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 118.235 0.471 . . . . 55.41 110.684 -179.567 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.94 120.35 48.14 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.741 0 CA-C-O 121.827 0.822 . . . . 73.1 110.48 176.164 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 49.8 ttt180 -109.13 95.13 5.43 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 108.74 -0.837 . . . . 73.21 108.74 176.313 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 28.4 pt -93.66 119.78 66.8 Favored Pre-proline 0 CA--C 1.547 0.852 0 N-CA-C 107.913 -1.143 . . . . 72.13 107.913 171.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -76.64 163.17 32.08 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.352 2.035 . . . . 74.11 112.507 -177.403 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -54.76 142.68 73.17 Favored 'Trans proline' 0 C--N 1.375 1.963 0 C-N-CA 123.005 2.47 . . . . 72.34 112.372 171.188 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 108.66 38.31 1.92 Allowed Glycine 0 C--N 1.339 0.721 0 CA-C-N 116.773 -0.194 . . . . 72.33 113.037 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.792 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -108.66 163.07 6.23 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.359 0 N-CA-C 108.7 -0.852 . . . . 53.43 108.7 177.005 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.528 ' HB2' ' HB2' ' A' ' 157' ' ' SER . 25.1 mtp-105 -141.8 164.28 30.63 Favored 'General case' 0 N--CA 1.492 1.635 0 C-N-CA 123.963 0.905 . . . . 72.13 111.071 -165.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.1 tp10 -54.53 116.72 2.82 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.444 1.098 . . . . 71.1 111.226 165.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.27 4.68 90.11 Favored Glycine 0 C--N 1.357 1.706 0 CA-C-N 116.04 -0.527 . . . . 70.34 113.166 178.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.528 ' HB2' ' HB2' ' A' ' 154' ' ' ARG . 30.1 t -79.21 124.2 28.13 Favored 'General case' 0 C--O 1.25 1.11 0 N-CA-C 109.026 -0.731 . . . . 74.1 109.026 -179.686 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.44 HG12 HD22 ' A' ' 175' ' ' LEU . 20.0 t -99.05 120.68 48.71 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 CA-C-N 114.298 -1.319 . . . . 72.4 107.886 -177.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.434 HD11 HG21 ' A' ' 153' ' ' VAL . 13.0 mt -101.86 122.01 53.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 123.533 0.733 . . . . 54.32 110.15 -168.697 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 74.2 ttt180 -86.31 103.25 14.72 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 123.317 0.647 . . . . 74.34 109.908 177.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.449 HG22 ' O ' ' A' ' 174' ' ' LEU . 16.4 m -107.59 104.92 54.65 Favored Pre-proline 0 CA--C 1.564 1.5 0 C-N-CA 122.608 0.363 . . . . 74.11 110.027 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -67.41 140.69 53.47 Favored 'Trans proline' 0 C--N 1.375 1.954 0 C-N-CA 122.82 2.346 . . . . 70.33 113.332 -173.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 105.04 -9.97 47.32 Favored Glycine 0 C--N 1.349 1.282 0 N-CA-C 114.868 0.707 . . . . 61.44 114.868 170.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.4 mpt? -81.9 -61.35 1.94 Allowed 'General case' 0 N--CA 1.482 1.135 0 CA-C-N 117.815 0.807 . . . . 73.41 110.157 176.096 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.345 1.073 0 CA-C-N 115.345 -0.843 . . . . 74.35 111.785 176.709 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo . . . . . 0 CA--C 1.541 0.866 0 N-CA-C 111.683 -0.16 . . . . 63.22 111.683 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -80.97 -132.26 1.2 Allowed Glycine 0 C--N 1.34 0.764 0 N-CA-C 111.498 -0.641 . . . . 62.12 111.498 175.177 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -163.81 177.79 8.35 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.205 0.526 . . . . 71.42 110.885 -175.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.449 ' O ' HG22 ' A' ' 161' ' ' VAL . 15.0 tp -129.32 122.57 29.83 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 108.571 -0.9 . . . . 62.24 108.571 173.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.44 HD22 HG12 ' A' ' 158' ' ' VAL . 49.8 mt -88.11 99.41 12.17 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.139 -0.937 . . . . 64.34 110.927 179.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 74.9 mt -87.44 105.34 17.22 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 123.011 0.524 . . . . 64.42 110.748 175.429 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.8 t -85.49 104.45 13.37 Favored 'Isoleucine or valine' 0 C--O 1.242 0.697 0 N-CA-C 108.23 -1.026 . . . . 73.12 108.23 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.423 HG21 HG22 ' A' ' 153' ' ' VAL . 25.3 m -83.95 144.79 9.25 Favored 'Isoleucine or valine' 0 C--O 1.251 1.136 0 CA-C-O 121.481 0.657 . . . . 74.11 110.367 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 13.5 mmm180 -118.53 99.3 6.72 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 107.068 -1.456 . . . . 73.01 107.068 -178.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.421 HD23 ' HB3' ' A' ' 125' ' ' LEU . 29.5 mt -67.56 146.1 54.24 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 118.314 0.507 . . . . 73.41 110.303 177.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.438 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 73.1 mt -55.27 154.51 11.06 Favored Pre-proline 0 CA--C 1.553 1.063 0 O-C-N 124.489 1.118 . . . . 72.24 112.839 -170.337 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.403 ' O ' ' HD3' ' A' ' 184' ' ' PRO . 55.5 Cg_endo -66.81 0.38 3.72 Favored 'Trans proline' 0 C--N 1.381 2.287 0 C-N-CA 123.081 2.52 . . . . 62.2 112.808 171.231 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . 0.479 ' O ' HD11 ' A' ' 127' ' ' LEU . 14.7 t60 -95.55 99.21 4.41 Favored Pre-proline 0 CA--C 1.541 0.611 0 C-N-CA 124.974 1.31 . . . . 72.43 107.582 162.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 182' ' ' PRO . 44.4 Cg_endo -103.64 123.67 0.07 OUTLIER 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 123.135 2.557 . . . . 64.33 112.413 168.607 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -120.68 -43.58 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 107.74 -1.207 . . . . 63.44 107.74 171.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -113.64 126.31 55.12 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 114.674 -1.148 . . . . 62.42 110.144 176.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 36.5 ttp85 -119.41 127.04 52.74 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 108.51 -0.922 . . . . 71.44 108.51 172.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.427 HD12 ' O ' ' A' ' 192' ' ' ASP . 56.0 tp -90.18 132.53 35.42 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 108.359 -0.978 . . . . 63.15 108.359 170.461 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -144.48 130.1 19.07 Favored 'General case' 0 C--O 1.241 0.642 0 N-CA-C 109.621 -0.511 . . . . 74.12 109.621 173.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 70.95 -75.78 0.59 Allowed Glycine 0 C--N 1.35 1.346 0 O-C-N 124.003 0.814 . . . . 63.52 111.871 -175.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . 0.497 ' HB2' ' O ' ' A' ' 240' ' ' PHE . 3.7 pt20 -157.6 -10.49 0.08 Allowed 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 124.118 0.967 . . . . 60.43 110.846 174.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.427 ' O ' HD12 ' A' ' 188' ' ' LEU . 80.3 m-20 -96.31 162.96 13.28 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 123.014 0.526 . . . . 62.12 110.942 -175.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.478 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.2 mt -106.9 155.91 19.25 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 107.704 -1.221 . . . . 73.15 107.704 -178.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -137.15 121.8 18.53 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 108.642 -0.873 . . . . 70.1 108.642 -175.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . 0.479 ' HB3' HD23 ' A' ' 251' ' ' LEU . . . -142.63 162.12 36.29 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.697 0.799 . . . . 65.3 110.221 -178.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . 0.519 ' HA ' ' HB3' ' A' ' 252' ' ' GLU . 36.0 m -109.08 119.37 39.34 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 109.018 -0.734 . . . . 71.15 109.018 174.794 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.534 HD22 HD13 ' A' ' 251' ' ' LEU . 55.1 tp -106.84 110.13 22.21 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 109.17 -0.678 . . . . 53.35 109.17 178.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -89.83 127.56 36.0 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 107.804 -1.184 . . . . 62.32 107.804 172.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . 0.507 HG12 HG11 ' A' ' 210' ' ' VAL . 15.4 m -119.99 139.83 28.87 Favored Pre-proline 0 C--O 1.244 0.78 0 N-CA-C 109.097 -0.705 . . . . 64.33 109.097 -178.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -60.05 143.99 99.51 Favored 'Trans proline' 0 C--N 1.367 1.522 0 C-N-CA 122.073 1.849 . . . . 52.21 111.085 174.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -53.44 -45.69 98.41 Favored Pre-proline 0 CA--C 1.555 1.165 0 CA-C-O 118.359 -0.829 . . . . 75.13 113.046 177.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -55.62 -42.33 68.8 Favored 'Trans proline' 0 C--N 1.39 2.755 0 C-N-CA 122.106 1.871 . . . . 63.15 113.261 172.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 4.0 mt -65.84 -43.6 93.12 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 C-N-CA 122.63 0.372 . . . . 72.54 111.256 176.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -58.56 -44.72 89.79 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 123.057 0.543 . . . . 74.11 111.451 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 33.4 m -77.39 -40.28 28.83 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 CA-C-N 115.745 -0.661 . . . . 74.33 112.081 -175.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.0 m -81.13 -20.72 11.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 119.1 0.863 . . . . 63.24 111.188 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.592 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 80.09 48.45 6.48 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-N 115.985 -0.552 . . . . 73.32 112.179 -175.837 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.27 -174.0 49.41 Favored Glycine 0 C--N 1.351 1.375 0 CA-C-O 121.37 0.428 . . . . 42.54 112.945 -177.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 222' ' ' ALA . 20.5 pttm -114.17 134.71 54.72 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.385 1.074 . . . . 74.31 109.797 -176.106 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . 0.507 HG11 HG12 ' A' ' 199' ' ' VAL . 7.6 p -133.71 157.23 42.13 Favored 'Isoleucine or valine' 0 C--O 1.241 0.608 0 C-N-CA 124.552 1.141 . . . . 75.24 108.494 -175.317 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 59.2 mmt-85 -91.55 128.93 37.57 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 109.489 -0.56 . . . . 72.44 109.489 178.033 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -102.72 122.09 43.76 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 108.643 -0.873 . . . . 71.24 108.643 171.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 5.6 tpt -74.04 104.66 4.95 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.732 0.813 . . . . 74.3 109.574 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 10.1 t -110.82 170.76 7.88 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 123.452 0.701 . . . . 65.31 110.623 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 62.4 mt -73.89 -2.2 22.83 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.022 0.929 . . . . 73.14 112.481 -175.233 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -114.82 -0.22 13.57 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 123.743 0.817 . . . . 70.35 112.17 174.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 133.25 -154.15 21.08 Favored Glycine 0 N--CA 1.48 1.597 0 CA-C-O 119.269 -0.74 . . . . 73.22 112.818 177.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -89.9 134.12 2.18 Favored 'Trans proline' 0 CA--C 1.554 1.49 0 C-N-CA 122.92 2.413 . . . . 74.11 112.259 172.083 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.1 m -113.79 158.15 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 CA-C-O 121.014 0.435 . . . . 73.11 111.74 175.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -96.75 104.54 16.54 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 114.966 -1.015 . . . . 63.25 108.429 -177.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.448 ' HB ' HD11 ' A' ' 235' ' ' LEU . 2.8 p -118.84 113.51 41.84 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 CA-C-O 121.437 0.637 . . . . 74.44 109.928 177.461 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 209' ' ' LYS . . . -97.28 118.69 34.3 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 108.759 -0.83 . . . . 73.01 108.759 178.061 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.592 HG23 ' HA2' ' A' ' 207' ' ' GLY . 18.2 m -72.96 148.04 88.96 Favored Pre-proline 0 CA--C 1.555 1.152 0 N-CA-C 109.523 -0.547 . . . . 75.14 109.523 176.029 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.0 151.98 73.31 Favored 'Trans proline' 0 CA--C 1.559 1.753 0 C-N-CA 122.173 1.915 . . . . 74.01 112.019 173.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -52.07 119.68 6.09 Favored 'Trans proline' 0 C--N 1.383 2.365 0 C-N-CA 123.646 2.898 . . . . 75.51 112.801 177.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . 0.479 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 48.6 mtm180 54.34 58.11 5.25 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 124.488 1.115 . . . . 71.5 110.668 -174.612 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 10.7 t -66.22 169.29 7.33 Favored 'General case' 0 CA--C 1.545 0.761 0 CA-C-N 115.539 -0.755 . . . . 54.15 109.506 173.079 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.8 mp0 -121.33 144.13 48.81 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 123.035 0.534 . . . . 52.4 109.83 -175.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -67.2 119.67 12.48 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-N 115.212 -0.904 . . . . 63.02 108.822 173.505 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.33 -12.06 19.26 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-O 119.65 -0.528 . . . . 60.23 112.315 -174.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 58.2 mtp180 -74.14 160.9 30.58 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 117.2 0.5 . . . . 73.41 110.604 174.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.403 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.3 mppt? -128.55 120.57 26.97 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.77 0.428 . . . . 74.1 110.676 -175.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . 0.493 HD11 HG12 ' A' ' 223' ' ' VAL . 59.6 mt -97.59 112.88 24.56 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 108.697 -0.853 . . . . 73.54 108.697 -178.248 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . 0.53 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 39.5 ttt85 -98.6 104.61 16.67 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 116.014 -0.539 . . . . 72.24 110.015 -172.211 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.516 HD12 HD23 ' A' ' 249' ' ' LEU . 27.3 mt -91.63 107.2 19.04 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.671 0.788 . . . . 62.13 109.156 -177.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 6.8 mtpm? -77.25 144.1 38.45 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 112.273 0.471 . . . . 71.51 112.273 -173.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 85.38 35.92 11.45 Favored Glycine 0 C--N 1.349 1.266 0 O-C-N 123.769 0.668 . . . . 74.22 112.323 -177.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 34.9 mmtm -125.61 -41.16 2.02 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 122.86 0.464 . . . . 72.11 112.184 -176.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -83.85 -178.04 51.69 Favored Glycine 0 C--N 1.337 0.62 0 C-N-CA 121.609 -0.329 . . . . 54.12 112.28 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.497 ' O ' ' HB2' ' A' ' 191' ' ' GLN . 72.5 m-85 -94.93 157.91 35.88 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 123.307 0.643 . . . . 74.43 111.77 -174.122 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -52.42 150.48 20.5 Favored 'Trans proline' 0 C--N 1.381 2.283 0 C-N-CA 123.254 2.636 . . . . 52.43 114.002 175.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 179.01 -159.54 24.5 Favored Glycine 0 CA--C 1.535 1.293 0 CA-C-O 119.516 -0.602 . . . . 71.5 113.099 -176.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -62.92 -34.34 71.85 Favored 'Trans proline' 0 C--N 1.375 1.925 0 C-N-CA 123.925 3.083 . . . . 72.52 114.217 -171.163 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.89 22.81 4.0 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.342 0.657 . . . . 73.01 111.289 178.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.97 -96.56 2.14 Favored Glycine 0 C--N 1.347 1.191 0 N-CA-C 111.192 -0.763 . . . . 63.43 111.192 179.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 42.1 ttt-85 -115.65 144.69 43.55 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 123.558 0.743 . . . . 75.43 109.09 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -80.26 168.99 52.37 Favored Glycine 0 C--O 1.253 1.297 0 O-C-N 123.604 0.565 . . . . 62.44 112.899 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 55.4 m-20 -139.57 171.97 13.48 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.342 1.057 . . . . 74.53 108.915 -173.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.53 ' O ' ' HA ' ' A' ' 234' ' ' ARG . 15.5 tp -98.44 128.92 45.02 Favored 'General case' 0 C--O 1.21 -0.974 0 C-N-CA 123.101 0.56 . . . . 71.43 109.761 177.129 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 53.8 t80 -111.47 102.62 10.97 Favored 'General case' 0 CA--C 1.551 1.01 0 N-CA-C 107.49 -1.3 . . . . 71.22 107.49 -178.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.534 HD13 HD22 ' A' ' 197' ' ' LEU . 90.3 mt -87.54 150.61 23.61 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.996 0.919 . . . . 51.31 112.688 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.519 ' HB3' ' HA ' ' A' ' 196' ' ' THR . 14.0 tp10 -105.62 98.09 7.83 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 123.494 0.717 . . . . 72.32 109.314 173.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 80.3 t -56.98 112.5 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 123.205 0.602 . . . . 53.12 111.019 174.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 49.3 mmm-85 -119.07 96.06 5.07 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 125.033 1.333 . . . . 75.15 108.069 177.149 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 58.8 mt -75.5 128.18 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 N-CA-C 109.561 -0.533 . . . . 41.33 109.561 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.249 1.028 0 C-N-CA 124.574 1.15 . . . . 64.4 107.911 -176.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.622 ' HB2' ' HB3' ' A' ' 136' ' ' ARG . 33.4 tp . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 109.379 -0.6 . . . . 75.43 109.379 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 24.0 t -89.6 150.93 3.57 Favored 'Isoleucine or valine' 0 C--O 1.239 0.502 0 C-N-CA 124.454 1.102 . . . . 72.02 109.14 172.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -77.23 -51.06 11.57 Favored 'General case' 0 CA--C 1.54 0.579 0 O-C-N 123.713 0.633 . . . . 64.21 109.484 175.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 46.5 p-80 -179.2 177.13 0.8 Allowed 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 124.864 1.266 . . . . 71.24 109.535 -175.126 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.524 HG11 HD12 ' A' ' 119' ' ' LEU . 29.5 m -78.51 155.12 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 C-N-CA 122.683 0.393 . . . . 72.33 111.366 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.0 t . . . . . 0 CA--C 1.546 0.799 0 CA-C-O 122.402 1.096 . . . . 71.42 109.226 179.354 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 . . . . . 0 C--O 1.241 0.655 0 N-CA-C 108.452 -0.944 . . . . 72.14 108.452 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.524 HD12 HG11 ' A' ' 102' ' ' VAL . 4.5 mm? -96.19 159.69 14.82 Favored 'General case' 0 N--CA 1.464 0.25 0 C-N-CA 124.129 0.972 . . . . 73.31 109.418 176.008 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 23.1 ptt180 -141.95 121.12 12.99 Favored 'General case' 0 C--O 1.241 0.649 0 N-CA-C 109.322 -0.622 . . . . 65.53 109.322 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -145.69 129.43 17.17 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 124.232 1.013 . . . . 65.11 109.446 -173.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.742 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 43.5 mt-10 -105.05 138.54 41.09 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 123.721 0.808 . . . . 62.33 109.228 178.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.476 HD21 HG12 ' A' ' 178' ' ' VAL . 1.8 pt? -135.64 141.52 37.47 Favored Pre-proline 0 N--CA 1.474 0.747 0 N-CA-C 110.033 -0.358 . . . . 61.34 110.033 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -73.38 113.27 3.73 Favored 'Trans proline' 0 C--N 1.368 1.586 0 C-N-CA 122.217 1.944 . . . . 64.44 109.924 171.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.547 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 11.9 tp -122.67 147.73 46.11 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 106.27 -1.752 . . . . 74.33 106.27 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 8.9 t -107.24 172.95 6.54 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 119.455 1.025 . . . . 74.1 110.491 175.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.5 ' O ' HD13 ' A' ' 215' ' ' LEU . 31.4 mt -55.38 -46.17 76.52 Favored 'General case' 0 N--CA 1.47 0.533 0 O-C-N 124.561 1.163 . . . . 71.12 109.949 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -51.66 -40.79 60.66 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 113.969 -1.469 . . . . 72.12 111.263 177.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.503 ' HB2' ' HG ' ' A' ' 125' ' ' LEU . 22.8 mm-40 -83.31 -24.02 32.33 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.195 0.598 . . . . 73.11 111.193 -178.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.432 ' HA ' ' CG1' ' A' ' 153' ' ' VAL . . . -59.78 -32.97 71.1 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 123.117 0.567 . . . . 72.5 111.645 167.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.3 t80 -77.72 -53.53 7.43 Favored 'General case' 0 C--N 1.351 0.636 0 CA-C-N 116.167 -0.47 . . . . 72.45 111.062 171.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -60.36 -45.85 92.04 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 123.552 0.532 . . . . 72.32 111.728 -172.137 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 59.53 -125.28 38.91 Favored Glycine 0 C--N 1.349 1.257 0 O-C-N 123.881 0.738 . . . . 65.51 111.378 -178.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.01 169.83 29.66 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 114.009 0.364 . . . . 42.4 114.009 166.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.417 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.6 mp0 -88.08 126.82 35.31 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 107.443 -1.318 . . . . 62.42 107.443 172.38 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.622 ' HB3' ' HB2' ' A' ' 98' ' ' LEU . 6.6 tpt180 -154.83 134.0 12.42 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 108.87 -0.789 . . . . 71.12 108.87 -177.221 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.673 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 10.9 p -74.75 143.38 13.47 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 C-N-CA 123.103 0.561 . . . . 62.25 112.477 -168.287 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.429 HG12 ' HB3' ' A' ' 98' ' ' LEU . 5.0 m -128.66 161.56 37.35 Favored 'Isoleucine or valine' 0 C--O 1.247 0.956 0 C-N-CA 124.458 1.103 . . . . 62.31 110.258 178.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 46.4 mm-40 -111.09 111.32 22.34 Favored 'General case' 0 C--O 1.238 0.499 0 C-N-CA 123.954 0.902 . . . . 71.54 109.419 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.461 HG21 HD22 ' A' ' 174' ' ' LEU . 45.2 t -138.27 119.89 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 123.503 0.721 . . . . 73.04 110.628 178.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 64.05 21.78 12.7 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 124.785 1.234 . . . . 63.13 112.94 171.105 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.19 14.12 77.49 Favored Glycine 0 C--N 1.349 1.251 0 CA-C-N 116.702 -0.226 . . . . 65.32 112.729 -176.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? -110.78 118.5 36.31 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.422 1.089 . . . . 74.02 108.152 176.019 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 54.2 ttp180 -87.1 106.33 17.79 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 107.694 -1.224 . . . . 73.32 107.694 174.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 8.1 m -136.01 135.78 50.13 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 123.541 0.737 . . . . 72.42 110.429 -172.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.673 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 35.9 t -83.51 128.28 34.39 Favored 'General case' 0 C--O 1.241 0.616 0 C-N-CA 123.371 0.668 . . . . 71.21 109.679 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.557 HG13 HG11 ' A' ' 161' ' ' VAL . 99.0 t -99.65 125.98 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 123.577 0.751 . . . . 65.05 110.469 177.482 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . 0.417 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 74.4 ttt180 -99.08 104.23 16.22 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 123.844 0.857 . . . . 74.03 109.483 172.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.574 HG22 HG21 ' A' ' 159' ' ' ILE . 28.3 pt -107.54 118.11 54.14 Favored Pre-proline 0 CA--C 1.55 0.969 0 N-CA-C 108.598 -0.89 . . . . 72.51 108.598 169.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -67.09 152.15 80.48 Favored 'Trans proline' 0 C--N 1.379 2.14 0 C-N-CA 122.668 2.245 . . . . 71.44 113.107 -175.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_exo -49.2 113.7 1.02 Allowed 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 123.609 2.873 . . . . 73.43 112.662 170.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 129.94 65.37 0.1 Allowed Glycine 0 C--N 1.342 0.911 0 CA-C-N 116.319 -0.401 . . . . 71.04 112.208 177.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.5 HG21 HD11 ' A' ' 159' ' ' ILE . 3.9 p -129.72 159.96 41.22 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.51 0 C-N-CA 123.15 0.58 . . . . 53.14 109.529 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 29.9 mtp-105 -136.79 168.31 19.78 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 123.8 0.84 . . . . 72.44 111.292 -164.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -57.1 121.64 10.52 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.403 1.081 . . . . 73.44 111.333 171.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.62 9.9 86.66 Favored Glycine 0 C--N 1.35 1.339 0 O-C-N 123.832 0.708 . . . . 71.43 113.21 178.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 30.3 t -73.39 122.89 22.79 Favored 'General case' 0 C--N 1.356 0.881 0 C-N-CA 123.165 0.586 . . . . 42.44 109.468 -177.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.556 HG12 HD22 ' A' ' 175' ' ' LEU . 11.3 t -99.46 116.25 42.19 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 O-C-N 124.399 1.062 . . . . 50.12 108.485 -178.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.574 HG21 HG22 ' A' ' 149' ' ' ILE . 18.1 mt -107.66 113.42 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 123.665 0.786 . . . . 73.54 110.247 -170.79 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 26.8 ttm180 -89.59 113.28 24.69 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 123.346 0.658 . . . . 63.12 110.878 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.557 HG11 HG13 ' A' ' 147' ' ' VAL . 22.5 m -109.48 99.48 37.34 Favored Pre-proline 0 CA--C 1.564 1.51 0 N-CA-C 109.603 -0.517 . . . . 55.35 109.603 176.333 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -69.62 150.31 68.87 Favored 'Trans proline' 0 C--N 1.377 2.058 0 C-N-CA 123.298 2.665 . . . . 74.3 113.501 -172.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.32 10.37 86.26 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-N 115.383 -0.826 . . . . 75.12 113.656 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 58.4 mtp -114.82 -20.48 10.58 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.365 0.666 . . . . 71.24 112.419 -173.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.342 0.867 0 CA-C-O 119.755 -0.469 . . . . 32.45 112.067 177.061 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo . . . . . 0 CA--C 1.544 0.976 0 N-CA-C 111.56 -0.208 . . . . 73.23 111.56 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -90.98 160.23 27.17 Favored Glycine 0 C--N 1.334 0.46 0 N-CA-C 110.063 -1.215 . . . . 52.41 110.063 170.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -120.03 176.95 5.18 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.012 0.525 . . . . 74.35 110.446 -174.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.461 HD22 HG21 ' A' ' 140' ' ' VAL . 19.5 tp -128.06 115.95 19.25 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 115.34 -0.846 . . . . 70.54 109.304 172.424 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.556 HD22 HG12 ' A' ' 158' ' ' VAL . 88.9 mt -87.87 105.69 17.6 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 125.164 1.386 . . . . 74.22 110.852 179.28 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 36.6 mt -95.91 108.06 20.39 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 123.079 0.551 . . . . 73.31 111.037 177.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.742 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 19.7 t -90.78 99.9 10.32 Favored 'Isoleucine or valine' 0 C--O 1.242 0.71 0 N-CA-C 107.957 -1.127 . . . . 75.13 107.957 174.054 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.476 HG12 HD21 ' A' ' 123' ' ' LEU . 4.3 m -82.21 141.48 14.97 Favored 'Isoleucine or valine' 0 C--O 1.245 0.833 0 N-CA-C 109.054 -0.721 . . . . 75.33 109.054 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 16.1 mmm-85 -119.54 104.98 10.78 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.669 -1.234 . . . . 74.24 107.669 -175.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.547 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 61.2 mt -68.87 147.43 51.71 Favored 'General case' 0 CA--C 1.545 0.763 0 O-C-N 123.506 0.504 . . . . 75.31 111.009 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.465 ' HB2' ' HB3' ' A' ' 183' ' ' HIS . 27.7 mt -63.64 168.78 4.96 Favored Pre-proline 0 CA--C 1.56 1.33 0 C-N-CA 124.07 0.948 . . . . 71.42 111.098 -174.361 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -75.76 43.01 1.02 Allowed 'Trans proline' 0 C--N 1.381 2.243 0 C-N-CA 122.885 2.39 . . . . 71.45 111.601 162.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . 0.465 ' HB3' ' HB2' ' A' ' 181' ' ' LEU . 8.2 t60 -125.27 95.48 41.23 Favored Pre-proline 0 CA--C 1.532 0.281 0 N-CA-C 105.88 -1.896 . . . . 73.45 105.88 -178.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -100.75 123.76 0.11 Allowed 'Trans proline' 0 CA--C 1.554 1.525 0 C-N-CA 122.636 2.224 . . . . 63.5 113.052 176.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.437 HG12 HD12 ' A' ' 127' ' ' LEU . 4.1 p -144.75 -42.04 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 N-CA-C 108.855 -0.794 . . . . 71.13 108.855 175.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.429 ' H ' HD13 ' A' ' 127' ' ' LEU . 3.8 m-85 -126.96 154.93 43.91 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.387 1.075 . . . . 73.24 110.208 174.443 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 18.6 ttp85 -156.25 142.8 18.55 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 123.221 0.608 . . . . 63.14 109.564 178.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.468 HD13 ' HD1' ' A' ' 240' ' ' PHE . 56.6 tp -104.63 140.61 37.78 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.762 0.825 . . . . 73.1 110.27 178.186 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -139.64 111.49 7.35 Favored 'General case' 0 C--O 1.246 0.877 0 N-CA-C 107.191 -1.411 . . . . 61.31 107.191 168.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 74.66 -80.93 0.88 Allowed Glycine 0 C--N 1.347 1.171 0 O-C-N 123.558 0.536 . . . . 64.2 112.611 177.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . 0.428 ' HB3' ' HA3' ' A' ' 242' ' ' GLY . 9.3 pt20 -138.39 -23.04 1.0 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 124.068 0.947 . . . . 53.23 110.168 176.302 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.439 ' O ' HD12 ' A' ' 188' ' ' LEU . 0.6 OUTLIER -89.6 157.59 17.98 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 123.832 0.853 . . . . 64.25 110.884 -173.046 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.575 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.7 mt -108.62 166.88 10.46 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 124.75 1.22 . . . . 73.33 109.508 -177.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -142.78 122.1 13.07 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 107.135 -1.432 . . . . 74.33 107.135 -178.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -148.19 152.18 36.8 Favored 'General case' 0 CA--C 1.518 -0.285 0 C-N-CA 123.823 0.849 . . . . 63.12 110.459 -174.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 7.4 m -100.94 120.87 40.8 Favored 'General case' 0 CA--C 1.541 0.604 0 O-C-N 124.025 0.828 . . . . 74.41 109.389 176.294 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.53 HD22 HD13 ' A' ' 251' ' ' LEU . 66.0 tp -107.53 111.89 24.37 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.839 0.856 . . . . 74.13 109.467 -179.346 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -95.28 119.14 33.27 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.399 0.68 . . . . 75.41 109.259 176.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . 0.527 HG11 HG11 ' A' ' 223' ' ' VAL . 6.0 m -122.99 139.97 32.53 Favored Pre-proline 0 N--CA 1.475 0.8 0 C-N-CA 123.37 0.668 . . . . 73.23 109.267 -178.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_exo -59.31 144.37 99.42 Favored 'Trans proline' 0 C--N 1.372 1.793 0 C-N-CA 122.745 2.297 . . . . 63.34 111.81 171.411 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . 0.401 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -55.67 -44.63 99.76 Favored Pre-proline 0 CA--C 1.554 1.12 0 CA-C-O 117.963 -1.018 . . . . 53.51 111.991 177.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -48.61 -51.3 10.58 Favored 'Trans proline' 0 C--N 1.399 3.232 0 C-N-CA 122.537 2.158 . . . . 61.41 112.865 169.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 4.3 mt -62.44 -38.84 82.33 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.078 0 C-N-CA 123.202 0.601 . . . . 72.24 111.03 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.45 -44.41 96.47 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.17 0.588 . . . . 61.05 112.06 -178.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.3 m -78.55 -39.39 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-N 116.004 -0.543 . . . . 64.15 111.426 -174.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.1 m -82.9 -20.8 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 122.434 0.294 . . . . 71.22 111.284 -179.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.432 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 72.6 68.16 1.66 Allowed Glycine 0 C--N 1.343 0.932 0 N-CA-C 111.324 -0.711 . . . . 60.54 111.324 -175.531 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -92.87 -164.49 37.85 Favored Glycine 0 C--N 1.352 1.472 0 N-CA-C 111.482 -0.647 . . . . 74.11 111.482 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -115.11 139.17 50.12 Favored 'General case' 0 C--O 1.241 0.647 0 C-N-CA 123.554 0.742 . . . . 73.32 109.146 -178.05 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . 0.544 HG23 HG13 ' A' ' 221' ' ' VAL . 6.6 m -134.39 149.22 29.77 Favored 'Isoleucine or valine' 0 C--O 1.24 0.589 0 C-N-CA 123.876 0.87 . . . . 63.13 109.073 177.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . 0.483 ' H ' ' HD2' ' A' ' 211' ' ' ARG . 0.2 OUTLIER -104.87 125.9 51.38 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 108.116 -1.068 . . . . 74.11 108.116 174.874 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.48 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -99.89 129.2 45.95 Favored 'General case' 0 C--O 1.245 0.843 0 N-CA-C 108.792 -0.818 . . . . 44.33 108.792 -175.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 6.1 tpt -71.47 102.6 2.71 Favored 'General case' 0 CA--C 1.537 0.452 0 O-C-N 124.198 0.936 . . . . 73.21 109.4 -178.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.495 HG21 HG13 ' A' ' 219' ' ' VAL . 10.0 t -110.95 166.75 10.78 Favored 'General case' 0 C--O 1.238 0.451 0 CA-C-O 121.62 0.724 . . . . 72.33 110.694 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . 0.5 HD13 ' O ' ' A' ' 127' ' ' LEU . 25.9 mt -66.59 -19.04 65.68 Favored 'General case' 0 CA--C 1.545 0.765 0 CA-C-N 114.634 -1.166 . . . . 73.51 110.88 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -87.48 -21.7 25.35 Favored 'General case' 0 CA--C 1.558 1.263 0 C-N-CA 125.609 1.564 . . . . 63.12 111.797 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 139.39 -146.91 18.71 Favored Glycine 0 C--N 1.352 1.431 0 CA-C-O 119.157 -0.802 . . . . 71.42 111.583 -169.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -93.51 133.79 0.94 Allowed 'Trans proline' 0 CA--C 1.557 1.666 0 C-N-CA 122.373 2.049 . . . . 61.3 112.276 165.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . 0.495 HG13 HG21 ' A' ' 214' ' ' THR . 16.5 m -108.97 143.25 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 C-N-CA 122.934 0.494 . . . . 63.31 110.453 171.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -91.37 108.9 20.21 Favored 'General case' 0 CA--C 1.542 0.649 0 CA-C-O 121.524 0.678 . . . . 73.55 109.598 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.544 HG13 HG23 ' A' ' 210' ' ' VAL . 2.6 p -119.19 127.15 75.85 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.761 0 C-N-CA 123.55 0.74 . . . . 72.1 110.557 173.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -96.88 120.21 36.79 Favored 'General case' 0 C--O 1.238 0.453 0 C-N-CA 123.982 0.913 . . . . 71.31 109.215 177.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.527 HG11 HG11 ' A' ' 199' ' ' VAL . 11.5 m -82.65 141.85 45.26 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 109.631 -0.507 . . . . 63.14 109.631 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -63.74 141.07 77.37 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 122.752 2.302 . . . . 74.12 112.202 175.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -62.12 125.31 16.13 Favored 'Trans proline' 0 C--N 1.37 1.693 0 C-N-CA 122.513 2.142 . . . . 73.31 111.076 173.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 56.6 mtm180 64.77 50.21 2.08 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 124.951 1.407 . . . . 74.01 109.993 -172.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.0 t -79.5 169.7 17.66 Favored 'General case' 0 CA--C 1.546 0.804 0 CA-C-N 115.862 -0.608 . . . . 54.31 109.619 172.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . 0.595 ' H ' ' HD3' ' A' ' 231' ' ' ARG . 26.3 mp0 -125.04 142.09 51.71 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 123.808 0.843 . . . . 73.35 109.373 -172.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.66 119.39 13.83 Favored 'General case' 0 C--N 1.348 0.515 0 C-N-CA 123.469 0.708 . . . . 74.43 109.221 175.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.75 -7.08 22.17 Favored Glycine 0 C--N 1.34 0.793 0 CA-C-N 116.156 -0.475 . . . . 73.51 111.999 -171.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . 0.595 ' HD3' ' H ' ' A' ' 228' ' ' GLN . 75.2 mtp180 -81.94 160.94 23.24 Favored 'General case' 0 C--N 1.354 0.761 0 C-N-CA 122.766 0.426 . . . . 73.1 110.416 173.479 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.448 ' HG2' ' CE1' ' A' ' 250' ' ' TYR . 2.7 mppt? -122.23 135.59 54.78 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.267 0.627 . . . . 74.41 110.35 -175.727 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 61.8 mt -112.19 104.74 12.95 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 107.697 -1.223 . . . . 61.11 107.697 175.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . 0.548 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 50.3 ttt180 -94.14 109.04 20.84 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 115.682 -0.69 . . . . 74.13 109.622 -173.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.497 HD12 HD23 ' A' ' 249' ' ' LEU . 18.5 mt -85.95 128.11 34.77 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 122.838 0.455 . . . . 73.23 110.219 -175.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 50.0 mtmt -71.04 122.14 19.5 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.449 1.1 . . . . 71.45 111.762 -167.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.58 16.98 70.37 Favored Glycine 0 C--N 1.351 1.385 0 O-C-N 123.793 0.683 . . . . 55.11 114.02 172.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -94.9 7.28 46.51 Favored 'General case' 0 N--CA 1.48 1.049 0 N-CA-C 112.49 0.552 . . . . 70.11 112.49 -174.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -95.62 -170.84 35.9 Favored Glycine 0 C--N 1.34 0.789 0 O-C-N 123.553 0.533 . . . . 62.2 112.347 175.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.468 ' HD1' HD13 ' A' ' 188' ' ' LEU . 60.3 m-85 -85.95 159.88 53.57 Favored Pre-proline 0 CA--C 1.544 0.733 0 C-N-CA 123.578 0.751 . . . . 74.13 111.107 -176.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -52.97 127.94 26.94 Favored 'Trans proline' 0 C--N 1.391 2.812 0 C-N-CA 122.713 2.276 . . . . 71.4 112.221 176.693 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . 0.428 ' HA3' ' HB3' ' A' ' 191' ' ' GLN . . . -157.0 -164.36 13.49 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-O 119.03 -0.872 . . . . 74.34 111.945 -177.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.39 -30.34 91.02 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 123.569 2.846 . . . . 75.31 114.153 -173.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -93.61 22.97 4.96 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 123.428 0.691 . . . . 71.11 111.329 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 87.87 -73.92 2.26 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 110.104 -1.198 . . . . 74.31 110.104 -174.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 50.0 mtm180 -127.02 162.52 25.82 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 124.16 0.984 . . . . 73.44 108.674 167.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -89.38 -156.86 32.34 Favored Glycine 0 C--N 1.342 0.876 0 O-C-N 123.671 0.607 . . . . 72.03 112.398 176.476 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -135.86 171.59 14.24 Favored 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 109.182 -0.673 . . . . 72.41 109.182 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.575 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 12.8 tp -106.81 117.4 33.96 Favored 'General case' 0 C--O 1.213 -0.848 0 C-N-CA 123.268 0.627 . . . . 43.33 111.171 176.11 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . 0.478 ' HB3' ' O ' ' A' ' 193' ' ' LEU . 1.9 t80 -89.68 103.98 16.58 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 107.979 -1.119 . . . . 73.52 107.979 173.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.53 HD13 HD22 ' A' ' 197' ' ' LEU . 76.2 mt -88.77 148.03 24.15 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 123.261 0.625 . . . . 74.15 110.921 172.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -109.34 97.49 7.07 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 108.768 -0.827 . . . . 74.32 108.768 175.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 57.3 t -53.68 113.94 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 123.28 0.632 . . . . 45.51 110.802 173.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 27.7 mmt85 -123.64 94.3 4.2 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 107.185 -1.413 . . . . 73.42 107.185 178.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.401 HG23 ' HA ' ' A' ' 201' ' ' ALA . 76.6 mt -77.82 114.76 18.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 123.718 0.807 . . . . 65.24 110.318 -176.551 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 4.2 t . . . . . 0 CA--C 1.562 1.428 0 C-N-CA 123.633 0.773 . . . . 63.54 109.527 176.051 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.463 HD21 HD13 ' A' ' 125' ' ' LEU . 30.5 tp . . . . . 0 C--O 1.241 0.658 0 CA-C-O 119.806 -0.14 . . . . 63.35 111.121 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.447 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 14.8 p -67.3 120.62 14.94 Favored 'Isoleucine or valine' 0 C--N 1.36 1.051 0 CA-C-O 121.54 0.686 . . . . 64.13 110.26 175.462 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -85.67 -60.71 1.94 Allowed 'General case' 0 C--O 1.24 0.564 0 CA-C-N 114.933 -1.031 . . . . 62.1 110.456 -175.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 26.6 t-80 -165.94 157.81 14.22 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 115.793 -0.64 . . . . 75.53 111.217 -171.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 25.9 t -64.42 145.14 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 125.148 1.379 . . . . 63.42 111.028 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.669 HG22 ' HG3' ' A' ' 122' ' ' GLU . 41.6 p . . . . . 0 CA--C 1.547 0.847 0 C-N-CA 123.517 0.727 . . . . 74.32 111.377 177.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.243 0.746 0 N-CA-C 108.061 -1.088 . . . . 41.4 108.061 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.598 HD21 HG11 ' A' ' 140' ' ' VAL . 0.5 OUTLIER -95.77 135.88 36.9 Favored 'General case' 0 C--N 1.345 0.402 0 N-CA-C 106.283 -1.747 . . . . 52.21 106.283 175.015 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 56.7 mtp180 -142.65 126.52 17.17 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 108.304 -0.998 . . . . 74.02 108.304 -175.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -148.78 133.27 17.65 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.335 0.654 . . . . 73.42 110.157 -178.465 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.669 ' HG3' HG22 ' A' ' 103' ' ' THR . 44.8 mt-10 -92.89 144.99 24.72 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 122.929 0.491 . . . . 62.41 109.993 173.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.447 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.7 pt? -146.68 132.18 9.23 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.365 -0.834 . . . . 70.41 110.533 -177.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -72.09 114.96 4.13 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 121.814 1.676 . . . . 75.31 111.221 175.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.463 HD13 HD21 ' A' ' 98' ' ' LEU . 22.0 tp -108.93 167.26 10.22 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.539 1.136 . . . . 65.54 108.065 176.334 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.497 HG23 HD12 ' A' ' 181' ' ' LEU . 7.8 m -103.46 159.8 15.27 Favored 'General case' 0 N--CA 1.476 0.865 0 O-C-N 121.624 -0.672 . . . . 63.33 109.513 171.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.555 HD23 ' HB3' ' A' ' 180' ' ' LEU . 81.2 mt -52.12 -52.77 49.5 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-O 121.311 0.577 . . . . 51.3 109.625 169.441 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.574 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.7 mp0 -55.64 -39.74 71.26 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 114.588 -1.187 . . . . 71.14 112.146 177.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -77.7 -21.17 52.4 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 122.765 0.426 . . . . 64.54 111.845 -178.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.489 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -68.55 -36.08 78.3 Favored 'General case' 0 C--O 1.248 0.99 0 C-N-CA 123.628 0.771 . . . . 71.43 110.64 168.531 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.483 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 69.2 t80 -64.44 -49.05 73.0 Favored 'General case' 0 C--N 1.346 0.448 0 CA-C-N 115.232 -0.894 . . . . 75.1 110.537 170.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -72.94 -28.82 62.67 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 112.855 0.687 . . . . 70.43 112.855 -173.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 67.3 -96.18 0.32 Allowed Glycine 0 C--N 1.351 1.376 0 N-CA-C 111.415 -0.674 . . . . 53.53 111.415 -174.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.38 150.55 25.46 Favored Glycine 0 C--N 1.349 1.29 0 N-CA-C 114.78 0.672 . . . . 71.04 114.78 167.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -85.59 125.57 33.22 Favored 'General case' 0 N--CA 1.473 0.684 0 N-CA-C 108.116 -1.068 . . . . 61.42 108.116 169.633 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 21.9 mmt180 -129.22 152.66 48.55 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.255 1.022 . . . . 63.42 108.742 -168.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 22.3 m -85.24 127.11 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.212 0 N-CA-C 110.053 -0.351 . . . . 72.21 110.053 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 85.7 t -123.73 122.78 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 123.086 0.554 . . . . 70.33 109.884 175.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -124.8 96.53 4.91 Favored 'General case' 0 N--CA 1.476 0.87 0 CA-C-O 121.99 0.9 . . . . 61.02 109.24 172.063 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.598 HG11 HD21 ' A' ' 119' ' ' LEU . 74.0 t -130.59 133.11 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 123.786 0.834 . . . . 71.54 109.64 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.33 28.35 17.84 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 124.621 1.168 . . . . 60.1 111.157 -178.639 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.12 -9.3 66.98 Favored Glycine 0 C--N 1.35 1.321 0 CA-C-N 115.548 -0.751 . . . . 62.03 113.447 -177.603 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.2 tpp180 -91.08 115.67 28.19 Favored 'General case' 0 C--N 1.344 0.339 0 N-CA-C 109.424 -0.584 . . . . 74.24 109.424 -176.143 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 59.0 ttp180 -103.72 111.4 23.88 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 108.636 -0.875 . . . . 74.14 108.636 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.5 p -145.89 141.86 21.74 Favored 'Isoleucine or valine' 0 C--O 1.243 0.731 0 C-N-CA 125.011 1.324 . . . . 71.43 108.325 178.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 32.4 p -77.69 134.14 38.19 Favored 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 116.384 -0.371 . . . . 74.24 110.016 178.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 9.0 p -98.74 136.11 31.03 Favored 'Isoleucine or valine' 0 C--N 1.341 0.2 0 N-CA-C 109.126 -0.694 . . . . 72.45 109.126 175.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.1 ttt85 -108.19 95.45 5.68 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 107.559 -1.275 . . . . 75.33 107.559 168.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.446 ' HB ' HD13 ' A' ' 159' ' ' ILE . 36.5 pt -87.03 113.62 54.46 Favored Pre-proline 0 CA--C 1.552 1.021 0 N-CA-C 107.777 -1.194 . . . . 52.21 107.777 171.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -61.45 137.41 69.64 Favored 'Trans proline' 0 C--N 1.381 2.251 0 C-N-CA 122.683 2.255 . . . . 70.12 112.85 -173.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.426 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 83.7 Cg_exo -50.62 120.07 5.98 Favored 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 123.281 2.654 . . . . 74.32 112.132 172.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 126.03 52.57 0.16 Allowed Glycine 0 C--N 1.341 0.826 0 N-CA-C 110.861 -0.896 . . . . 63.21 110.861 -174.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.574 HG21 HD11 ' A' ' 159' ' ' ILE . 1.9 p -126.05 161.87 30.71 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.197 0 C-N-CA 123.94 0.896 . . . . 71.13 109.247 -176.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -140.94 165.9 26.26 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 124.869 1.267 . . . . 73.23 111.576 -165.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -57.12 122.85 13.38 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.948 0.899 . . . . 71.11 110.008 169.118 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.86 7.88 86.44 Favored Glycine 0 C--N 1.343 0.931 0 CA-C-O 119.4 -0.667 . . . . 64.3 113.824 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.5 t -78.77 123.33 27.08 Favored 'General case' 0 C--O 1.244 0.794 0 N-CA-C 109.415 -0.587 . . . . 60.51 109.415 177.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.412 HG22 HD22 ' A' ' 175' ' ' LEU . 7.6 p -100.49 120.78 50.42 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.126 0 CA-C-N 115.063 -0.971 . . . . 74.35 109.569 -179.233 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.574 HD11 HG21 ' A' ' 153' ' ' VAL . 20.1 mt -106.73 116.82 51.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.963 0.905 . . . . 72.25 110.32 -167.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.482 ' HG3' ' HB2' ' A' ' 173' ' ' ASP . 29.6 ttm180 -89.3 113.12 24.35 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.653 0.781 . . . . 72.13 111.245 -179.305 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 18.4 m -115.41 103.27 54.3 Favored Pre-proline 0 CA--C 1.561 1.374 0 CA-C-O 121.498 0.666 . . . . 75.4 110.581 178.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -65.5 145.65 83.04 Favored 'Trans proline' 0 C--N 1.381 2.258 0 C-N-CA 122.716 2.278 . . . . 75.22 112.992 -177.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 94.07 -23.25 32.22 Favored Glycine 0 C--N 1.345 1.03 0 CA-C-N 115.742 -0.663 . . . . 64.31 113.962 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.481 ' HB3' ' HE2' ' A' ' 164' ' ' MET . 68.8 mtp -95.13 -23.66 17.2 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 112.927 0.714 . . . . 63.01 112.927 -169.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.346 1.105 0 N-CA-C 113.8 0.28 . . . . 61.11 113.8 -177.274 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo . . . . . 0 CA--C 1.537 0.649 0 N-CA-C 111.544 -0.214 . . . . 74.31 111.544 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -84.96 166.73 41.17 Favored Glycine 0 CA--C 1.509 -0.331 0 CA-C-N 116.169 -0.469 . . . . 44.41 111.946 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.482 ' HB2' ' HG3' ' A' ' 160' ' ' ARG . 8.2 p-10 -116.77 145.65 43.36 Favored 'General case' 0 C--O 1.245 0.824 0 C-N-CA 123.846 0.859 . . . . 64.21 109.28 -177.443 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.424 HD13 HD22 ' A' ' 119' ' ' LEU . 17.7 tp -106.39 122.37 46.12 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.824 -1.176 . . . . 42.42 107.824 176.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.412 HD22 HG22 ' A' ' 158' ' ' VAL . 77.1 mt -98.8 98.91 9.96 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 125.279 1.432 . . . . 74.13 110.282 -177.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 52.8 mt -92.57 107.39 19.18 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 123.411 0.684 . . . . 74.34 111.405 178.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.648 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 34.7 t -88.66 104.22 14.57 Favored 'Isoleucine or valine' 0 C--O 1.245 0.836 0 N-CA-C 108.465 -0.939 . . . . 74.42 108.465 173.551 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 9.7 m -82.0 147.59 5.99 Favored 'Isoleucine or valine' 0 C--O 1.242 0.686 0 CA-C-O 121.499 0.666 . . . . 72.05 110.318 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 24.3 mmm-85 -120.63 96.32 5.08 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 107.418 -1.327 . . . . 61.34 107.418 -179.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.555 ' HB3' HD23 ' A' ' 127' ' ' LEU . 31.0 mt -69.26 136.53 52.07 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 122.626 0.371 . . . . 73.13 110.368 -174.677 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.497 HD12 HG23 ' A' ' 126' ' ' THR . 53.7 mt -53.67 125.49 46.0 Favored Pre-proline 0 CA--C 1.554 1.122 0 CA-C-O 118.543 -0.742 . . . . 74.24 110.319 -177.189 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 24.0 Cg_exo -64.18 85.23 0.15 Allowed 'Trans proline' 0 C--N 1.379 2.139 0 C-N-CA 123.109 2.539 . . . . 74.13 113.471 -174.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -154.23 54.82 1.15 Allowed Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 123.758 0.823 . . . . 74.35 109.054 171.147 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -61.21 122.92 11.87 Favored 'Trans proline' 0 C--N 1.381 2.273 0 C-N-CA 122.54 2.16 . . . . 72.4 112.143 -165.055 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.29 -44.57 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 N-CA-C 107.824 -1.176 . . . . 70.11 107.824 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.456 ' HE2' HD13 ' A' ' 193' ' ' LEU . 3.6 m-85 -104.81 123.75 48.22 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.209 -0.905 . . . . 63.3 109.353 176.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.507 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 4.3 mmm180 -115.68 150.94 35.97 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 106.082 -1.821 . . . . 64.31 106.082 178.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.439 HD12 ' O ' ' A' ' 192' ' ' ASP . 63.9 tp -130.76 132.02 45.06 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 122.833 0.453 . . . . 64.52 109.832 -176.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -143.5 116.76 9.0 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 108.417 -0.957 . . . . 73.21 108.417 168.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 55.42 52.85 44.93 Favored Glycine 0 C--N 1.355 1.584 0 O-C-N 123.953 0.783 . . . . 60.22 114.04 176.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . 0.401 ' OE1' ' HD2' ' A' ' 243' ' ' PRO . 38.5 mt-30 72.5 -5.94 1.71 Allowed 'General case' 0 N--CA 1.496 1.866 0 C-N-CA 125.024 1.329 . . . . 72.13 113.168 177.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.439 ' O ' HD12 ' A' ' 188' ' ' LEU . 23.1 t70 -98.98 145.09 27.42 Favored 'General case' 0 C--N 1.348 0.503 0 N-CA-C 109.483 -0.562 . . . . 64.5 109.483 -176.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.606 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.7 mt -105.72 152.97 22.5 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.691 0.796 . . . . 71.1 109.232 -174.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . 0.507 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 98.3 m-85 -140.84 120.82 13.63 Favored 'General case' 0 C--O 1.223 -0.308 0 N-CA-C 107.649 -1.241 . . . . 75.12 107.649 -174.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -147.47 169.46 19.5 Favored 'General case' 0 C--O 1.24 0.595 0 C-N-CA 123.637 0.775 . . . . 74.44 110.287 -175.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 16.6 m -116.25 126.99 54.35 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.757 -0.656 . . . . 73.3 109.447 175.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.407 HD22 HD13 ' A' ' 251' ' ' LEU . 67.0 tp -107.39 119.46 39.46 Favored 'General case' 0 C--O 1.214 -0.804 0 C-N-CA 124.47 1.108 . . . . 71.52 108.696 176.071 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -97.31 136.79 37.29 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.257 -1.016 . . . . 62.3 108.257 167.439 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . 0.571 HG12 HG11 ' A' ' 210' ' ' VAL . 13.3 m -130.26 142.82 46.78 Favored Pre-proline 0 N--CA 1.476 0.833 0 N-CA-C 109.1 -0.704 . . . . 73.43 109.1 179.235 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -61.94 140.06 82.85 Favored 'Trans proline' 0 C--N 1.372 1.79 0 C-N-CA 121.942 1.761 . . . . 64.3 110.772 172.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . 0.416 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -52.78 -42.2 88.24 Favored Pre-proline 0 CA--C 1.558 1.263 0 CA-C-O 117.542 -1.218 . . . . 54.5 113.041 178.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . 0.48 ' O ' HG22 ' A' ' 206' ' ' VAL . 8.8 Cg_endo -49.78 -52.69 8.37 Favored 'Trans proline' 0 C--N 1.408 3.671 0 C-N-CA 122.851 2.367 . . . . 72.35 112.267 169.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 3.4 mt -60.98 -41.66 89.94 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 122.836 0.454 . . . . 74.51 111.271 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.49 -42.53 98.55 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.163 0.585 . . . . 51.43 112.187 -175.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 28.1 m -81.2 -35.51 14.25 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 CA-C-N 115.959 -0.564 . . . . 75.21 111.894 -173.06 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.48 HG22 ' O ' ' A' ' 202' ' ' PRO . 20.8 m -88.0 -19.21 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 O-C-N 122.118 -0.364 . . . . 74.04 111.635 178.614 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.415 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 76.37 66.67 1.81 Allowed Glycine 0 C--N 1.342 0.894 0 O-C-N 123.484 0.49 . . . . 75.33 112.181 -177.449 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.02 -168.45 42.89 Favored Glycine 0 C--N 1.348 1.203 0 N-CA-C 111.854 -0.498 . . . . 73.33 111.854 175.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -125.79 119.34 27.63 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 107.997 -1.112 . . . . 64.34 107.997 -179.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . 0.571 HG11 HG12 ' A' ' 199' ' ' VAL . 7.9 p -116.43 147.88 19.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.547 0 C-N-CA 124.143 0.977 . . . . 61.44 109.439 -174.1 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -76.24 123.66 26.25 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 116.026 -0.534 . . . . 73.42 109.579 172.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.13 130.14 47.15 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 108.052 -1.092 . . . . 72.03 108.052 173.179 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 56.3 mmm -76.55 141.01 41.32 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.131 0.491 . . . . 64.34 110.776 178.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.429 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 5.7 t -143.68 166.91 23.53 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-N 114.563 -1.199 . . . . 73.35 110.159 177.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . 0.574 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 65.1 mt -66.51 -19.84 65.88 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 124.306 1.042 . . . . 52.34 110.953 176.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -82.97 -18.25 40.61 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 124.859 1.263 . . . . 75.01 111.022 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 134.26 -147.49 19.11 Favored Glycine 0 C--N 1.352 1.433 0 N-CA-C 111.226 -0.75 . . . . 72.1 111.226 -174.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -93.11 129.37 0.76 Allowed 'Trans proline' 0 CA--C 1.56 1.787 0 C-N-CA 122.432 2.088 . . . . 62.43 112.775 165.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.7 m -109.15 166.71 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 C-N-CA 123.595 0.758 . . . . 73.12 109.56 169.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -113.94 116.47 29.3 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 109.867 -0.42 . . . . 74.51 109.867 178.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.4 p -108.78 136.82 43.38 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.681 0 C-N-CA 123.459 0.704 . . . . 71.24 110.175 173.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -95.12 115.73 27.81 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 124.025 0.93 . . . . 41.03 109.491 176.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.453 HG11 HG11 ' A' ' 199' ' ' VAL . 14.2 m -82.06 142.05 47.57 Favored Pre-proline 0 CA--C 1.548 0.893 0 N-CA-C 109.376 -0.601 . . . . 55.22 109.376 176.16 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_exo -61.0 141.12 93.47 Favored 'Trans proline' 0 C--N 1.368 1.558 0 C-N-CA 122.451 2.1 . . . . 75.12 112.746 172.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_exo -56.4 119.79 7.23 Favored 'Trans proline' 0 C--N 1.373 1.833 0 C-N-CA 122.588 2.192 . . . . 74.45 111.783 169.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 53.7 mtm180 60.75 51.64 4.75 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.676 1.19 . . . . 74.45 110.759 -174.082 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . 0.473 ' OG1' ' HD2' ' A' ' 231' ' ' ARG . 12.1 t -73.17 172.68 10.64 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-N 114.955 -1.02 . . . . 73.11 110.257 174.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -126.49 141.81 51.75 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 123.149 0.58 . . . . 74.34 109.455 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . 0.466 ' HB2' ' H ' ' A' ' 255' ' ' ILE . . . -63.96 119.69 10.56 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.759 0.824 . . . . 64.31 109.836 175.112 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.98 4.78 20.75 Favored Glycine 0 C--O 1.241 0.57 0 C-N-CA 123.69 0.662 . . . . 33.41 112.314 -176.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . 0.473 ' HD2' ' OG1' ' A' ' 227' ' ' THR . 92.3 mtt180 -79.54 159.01 27.06 Favored 'General case' 0 C--N 1.358 0.942 0 CA-C-O 121.707 0.765 . . . . 73.0 109.551 170.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.474 ' HG3' ' HE2' ' A' ' 250' ' ' TYR . 10.1 mptt -108.34 99.13 8.57 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 114.32 -1.309 . . . . 74.11 108.452 -176.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . 0.448 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 62.6 mt -90.11 96.48 10.69 Favored 'General case' 0 C--N 1.349 0.545 0 N-CA-C 106.231 -1.766 . . . . 64.42 106.231 176.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . 0.495 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 39.1 ttp180 -96.11 101.36 13.01 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 114.915 -1.039 . . . . 71.01 110.015 -167.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.508 HD12 HD23 ' A' ' 249' ' ' LEU . 43.3 mt -81.08 105.92 12.67 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.934 0.894 . . . . 73.02 108.806 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt -74.61 144.18 44.02 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.171 0.588 . . . . 74.41 112.267 -171.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 71.11 19.99 77.65 Favored Glycine 0 C--N 1.349 1.275 0 O-C-N 123.764 0.665 . . . . 52.02 113.934 178.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 1.4 mmmp? -106.65 -12.43 15.56 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.792 0.437 . . . . 71.43 111.173 -179.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.17 -175.51 49.82 Favored Glycine 0 C--N 1.348 1.217 0 O-C-N 123.409 0.443 . . . . 72.31 112.138 173.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.483 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 87.5 m-85 -77.4 149.26 78.5 Favored Pre-proline 0 N--CA 1.475 0.809 0 N-CA-C 112.252 0.464 . . . . 74.04 112.252 -172.027 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . 0.595 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 53.3 Cg_endo -65.52 160.58 42.28 Favored 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 122.838 2.359 . . . . 55.51 113.562 -175.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 164.7 -151.74 20.97 Favored Glycine 0 C--N 1.346 1.097 0 CA-C-O 118.929 -0.928 . . . . 33.52 112.044 -178.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . 0.401 ' HD2' ' OE1' ' A' ' 191' ' ' GLN . 37.6 Cg_endo -61.33 -32.53 89.77 Favored 'Trans proline' 0 C--N 1.377 2.047 0 C-N-CA 123.264 2.643 . . . . 72.23 113.198 -176.513 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -84.52 18.63 2.22 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 123.485 0.714 . . . . 63.12 111.77 178.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 78.77 -78.12 1.7 Allowed Glycine 0 C--N 1.347 1.175 0 N-CA-C 110.039 -1.224 . . . . 65.34 110.039 -172.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.595 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 62.2 mtm180 -128.47 169.51 14.24 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 124.081 0.953 . . . . 64.03 108.579 166.245 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -82.78 -163.66 34.07 Favored Glycine 0 C--N 1.337 0.626 0 N-CA-C 111.697 -0.561 . . . . 41.11 111.697 172.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -130.78 170.73 13.98 Favored 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 109.238 -0.653 . . . . 72.43 109.238 -178.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.606 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 17.5 tp -115.87 120.65 39.9 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.868 0.867 . . . . 73.31 110.663 175.365 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . 0.474 ' HE2' ' HG3' ' A' ' 232' ' ' LYS . 10.7 t80 -89.31 107.93 19.34 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.613 1.165 . . . . 75.15 108.693 175.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.448 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 87.8 mt -94.14 117.86 30.71 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.904 -0.406 . . . . 72.04 109.904 167.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -88.29 93.56 9.55 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 107.327 -1.36 . . . . 74.52 107.327 171.412 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 3.3 p -60.05 133.82 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 O-C-N 123.725 0.641 . . . . 51.43 110.645 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 48.6 mmm-85 -135.26 102.01 5.03 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 125.049 1.34 . . . . 73.15 107.529 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.466 ' H ' ' HB2' ' A' ' 229' ' ' ALA . 63.0 mt -76.54 116.93 20.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.359 -0.837 . . . . 70.05 109.768 -175.089 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.0 t . . . . . 0 CA--C 1.553 1.087 0 C-N-CA 124.829 1.252 . . . . 70.32 109.214 -178.635 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.474 HD23 ' H ' ' A' ' 99' ' ' VAL . 2.0 pt? . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 119.973 -0.06 . . . . 74.31 111.084 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.711 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 13.6 p -64.45 146.7 12.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 C-N-CA 123.584 0.754 . . . . 72.12 111.894 -179.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.462 ' HB2' ' HD3' ' A' ' 124' ' ' PRO . . . -83.22 -58.35 2.88 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 109.479 -0.563 . . . . 62.05 109.479 173.16 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 40.0 t-80 -175.59 159.58 2.38 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 123.697 0.799 . . . . 73.43 109.857 -175.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -66.44 136.68 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.346 0.658 . . . . 71.21 110.277 171.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 12.6 t . . . . . 0 CA--C 1.543 0.708 0 N-CA-C 109.308 -0.627 . . . . 72.53 109.308 179.041 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 20.8 t70 . . . . . 0 N--CA 1.477 0.903 0 CA-C-O 120.879 0.371 . . . . 72.35 110.034 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.505 HD12 HD13 ' A' ' 174' ' ' LEU . 0.2 OUTLIER -138.16 137.41 37.61 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 106.392 -1.707 . . . . 73.52 106.392 177.46 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . 0.497 ' HD3' ' HB2' ' A' ' 175' ' ' LEU . 19.4 mmt85 -125.58 138.59 53.95 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 109.065 -0.717 . . . . 73.22 109.065 -178.57 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -159.11 126.74 4.91 Favored 'General case' 0 CA--C 1.536 0.417 0 O-C-N 123.703 0.627 . . . . 51.23 109.447 175.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -105.73 150.55 25.41 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 109.607 -0.516 . . . . 65.14 109.607 175.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.711 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.4 pt? -145.87 147.08 31.13 Favored Pre-proline 0 N--CA 1.473 0.72 0 C-N-CA 123.033 0.533 . . . . 72.41 111.925 -170.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.462 ' HD3' ' HB2' ' A' ' 100' ' ' ALA . 91.5 Cg_endo -81.76 113.41 2.51 Favored 'Trans proline' 0 C--N 1.376 1.993 0 C-N-CA 121.769 1.646 . . . . 74.22 111.082 171.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.429 ' HB3' HD23 ' A' ' 180' ' ' LEU . 19.2 tp -111.06 167.71 10.05 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.043 -1.095 . . . . 63.31 108.043 175.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.566 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 8.8 m -101.09 155.07 18.21 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 109.922 -0.399 . . . . 61.12 109.922 174.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.436 HD23 ' HB3' ' A' ' 180' ' ' LEU . 85.6 mt -51.96 -51.93 53.75 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 122.304 1.049 . . . . 72.31 109.766 171.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -56.83 -40.14 75.5 Favored 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 113.386 -1.734 . . . . 74.14 111.735 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.411 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 23.8 mm-40 -79.87 -18.27 51.13 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 123.358 0.663 . . . . 73.32 112.195 -179.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.671 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -63.25 -41.57 99.09 Favored 'General case' 0 C--O 1.249 1.036 0 C-N-CA 122.863 0.465 . . . . 74.02 110.583 165.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -67.93 -54.45 18.6 Favored 'General case' 0 C--N 1.354 0.787 0 CA-C-N 115.664 -0.698 . . . . 74.31 110.932 172.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.5 m80 -69.88 -30.03 67.39 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 123.941 0.776 . . . . 72.24 112.158 -170.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.08 -149.34 51.71 Favored Glycine 0 C--N 1.346 1.124 0 N-CA-C 111.334 -0.706 . . . . 70.21 111.334 -171.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 136.92 136.94 3.57 Favored Glycine 0 C--N 1.346 1.095 0 CA-C-N 116.73 0.265 . . . . 71.1 112.673 170.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -80.21 127.0 31.83 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.408 0.683 . . . . 75.23 109.191 174.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 8.2 mpt_? -136.26 168.13 19.99 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.527 0.731 . . . . 73.13 109.101 177.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.5 p -85.85 129.61 37.78 Favored 'Isoleucine or valine' 0 C--O 1.246 0.878 0 CA-C-O 121.311 0.577 . . . . 52.51 110.66 174.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.493 HG21 HD21 ' A' ' 174' ' ' LEU . 14.6 p -98.65 142.33 14.9 Favored 'Isoleucine or valine' 0 C--O 1.242 0.704 0 C-N-CA 124.215 1.006 . . . . 71.11 109.43 175.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . 0.457 ' H ' HG11 ' A' ' 99' ' ' VAL . 42.7 mm-40 -121.76 100.68 7.13 Favored 'General case' 0 C--O 1.24 0.563 0 C-N-CA 124.61 1.164 . . . . 42.2 108.142 179.042 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.2 m -124.05 107.53 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.79 0 C-N-CA 123.352 0.661 . . . . 72.43 111.063 -176.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.87 24.24 11.29 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 124.747 1.219 . . . . 54.21 111.909 176.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 91.12 3.49 69.9 Favored Glycine 0 C--N 1.346 1.116 0 CA-C-N 116.031 -0.531 . . . . 73.3 113.371 -177.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 64.0 mtp85 -95.98 119.62 34.81 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.024 -0.732 . . . . 72.22 109.024 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 33.9 ttt85 -98.82 116.63 31.49 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.483 0.713 . . . . 72.42 109.952 -178.213 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 46.3 t -136.53 145.53 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.778 0.831 . . . . 73.13 108.918 179.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 21.2 m -79.03 110.99 14.78 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 109.072 -0.714 . . . . 74.4 109.072 171.08 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.0 p -98.28 137.41 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 CA-C-O 121.762 0.791 . . . . 74.34 110.597 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 77.6 ttt180 -103.82 117.78 35.16 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 114.485 -1.234 . . . . 73.22 108.342 175.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 33.4 pt -122.86 127.0 25.89 Favored Pre-proline 0 N--CA 1.477 0.919 0 N-CA-C 109.01 -0.737 . . . . 74.41 109.01 169.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -81.86 159.97 18.63 Favored 'Trans proline' 0 C--N 1.375 1.959 0 C-N-CA 122.909 2.406 . . . . 73.24 114.523 -167.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -68.1 114.92 3.57 Favored 'Trans proline' 0 C--N 1.381 2.289 0 C-N-CA 123.331 2.687 . . . . 41.24 110.618 174.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.621 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 133.9 49.7 0.08 OUTLIER Glycine 0 N--CA 1.469 0.844 0 N-CA-C 111.299 -0.72 . . . . 45.24 111.299 -173.712 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.671 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.4 p -125.99 165.61 23.56 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.403 0 N-CA-C 108.35 -0.981 . . . . 62.45 108.35 -176.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 51.3 mtp180 -145.69 166.7 25.07 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 124.519 1.127 . . . . 72.43 110.375 -165.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -55.49 123.89 15.43 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 124.005 0.922 . . . . 75.11 111.112 169.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.75 5.42 74.31 Favored Glycine 0 C--N 1.35 1.337 0 O-C-N 123.752 0.657 . . . . 55.15 113.601 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 31.2 t -73.45 126.01 29.23 Favored 'General case' 0 C--O 1.243 0.715 0 N-CA-C 109.828 -0.434 . . . . 72.1 109.828 -177.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.442 HG22 HD22 ' A' ' 175' ' ' LEU . 7.4 p -99.43 120.05 48.26 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 CA-C-N 114.756 -1.111 . . . . 73.41 109.911 -174.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.448 HD11 HG21 ' A' ' 153' ' ' VAL . 24.9 mt -106.95 115.53 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 124.004 0.922 . . . . 62.42 110.081 -171.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.494 ' HA ' HD23 ' A' ' 175' ' ' LEU . 69.3 ttt180 -83.53 119.1 24.28 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.504 0.722 . . . . 73.23 111.024 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.655 HG23 ' HG3' ' A' ' 164' ' ' MET . 16.6 m -124.37 104.76 31.38 Favored Pre-proline 0 CA--C 1.571 1.77 0 CA-C-O 120.764 0.316 . . . . 71.33 110.209 174.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.17 156.59 64.42 Favored 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.865 2.376 . . . . 73.41 113.7 -178.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.56 23.15 65.55 Favored Glycine 0 C--N 1.348 1.247 0 CA-C-N 115.336 -0.847 . . . . 55.42 113.808 176.472 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.655 ' HG3' HG23 ' A' ' 161' ' ' VAL . 16.4 mmt -106.81 -62.08 1.45 Allowed 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.079 0.952 . . . . 72.41 111.271 178.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.539 0 N-CA-C 111.591 -0.603 . . . . 40.55 111.591 178.414 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo . . . . . 0 CA--C 1.538 0.701 0 N-CA-C 110.653 -0.556 . . . . 75.21 110.653 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -110.08 148.41 17.4 Favored Glycine 0 CA--C 1.503 -0.693 0 N-CA-C 111.334 -0.706 . . . . 52.12 111.334 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 -109.0 130.54 55.48 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 123.215 0.606 . . . . 75.25 109.53 -165.017 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.505 HD13 HD12 ' A' ' 119' ' ' LEU . 17.4 tp -100.6 115.12 29.42 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 107.145 -1.428 . . . . 73.22 107.145 173.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.497 ' HB2' ' HD3' ' A' ' 120' ' ' ARG . 65.0 mt -92.23 100.73 13.28 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-N 114.46 -1.246 . . . . 63.45 109.794 -179.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.414 ' HA ' ' O ' ' A' ' 121' ' ' ALA . 83.2 mt -86.63 102.49 14.23 Favored 'General case' 0 C--N 1.346 0.418 0 CA-C-N 114.773 -1.103 . . . . 73.11 110.061 176.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 47.2 t -90.0 99.4 9.4 Favored 'Isoleucine or valine' 0 C--O 1.243 0.714 0 N-CA-C 108.397 -0.964 . . . . 65.54 108.397 176.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 4.9 m -79.49 148.12 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 N-CA-C 109.493 -0.558 . . . . 75.34 109.493 -177.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 40.0 mmm-85 -126.63 99.2 5.69 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 105.85 -1.908 . . . . 72.3 105.85 -175.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.436 ' HB3' HD23 ' A' ' 127' ' ' LEU . 38.2 mt -68.65 148.34 50.58 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 122.339 0.256 . . . . 71.04 110.954 -173.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.566 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 39.1 mt -55.76 130.52 72.01 Favored Pre-proline 0 CA--C 1.552 1.04 0 CA-C-O 118.844 -0.598 . . . . 72.04 110.737 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -67.91 84.47 0.42 Allowed 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 123.279 2.653 . . . . 74.22 112.079 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 8.6 p80 -154.58 50.62 0.55 Allowed Pre-proline 0 CA--C 1.558 1.274 0 N-CA-C 107.87 -1.159 . . . . 72.12 107.87 169.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -62.69 126.42 18.21 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 122.713 2.275 . . . . 62.33 112.261 -163.525 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -137.74 -45.1 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 108.686 -0.857 . . . . 72.43 108.686 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.426 ' CD2' HD13 ' A' ' 193' ' ' LEU . 6.5 m-85 -103.82 123.61 47.42 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.932 0.893 . . . . 74.21 110.269 -177.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.601 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 92.3 mtt180 -119.15 109.18 15.58 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.623 1.169 . . . . 75.1 107.887 -176.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.503 HD22 ' CD2' ' A' ' 240' ' ' PHE . 62.0 tp -85.09 142.56 29.45 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 122.659 0.383 . . . . 73.3 110.378 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -142.45 115.61 8.88 Favored 'General case' 0 C--O 1.243 0.736 0 N-CA-C 107.782 -1.192 . . . . 71.4 107.782 164.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 67.46 -95.37 0.31 Allowed Glycine 0 C--N 1.346 1.139 0 CA-C-N 115.725 -0.67 . . . . 44.25 111.514 -173.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 -123.84 -23.27 4.7 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.034 0.934 . . . . 72.42 110.247 177.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -93.83 153.34 18.33 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.411 0.624 . . . . 74.11 111.038 -171.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.621 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 73.6 mt -113.36 167.08 10.87 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.198 -0.91 . . . . 54.12 112.581 -170.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . 0.601 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 97.4 m-85 -135.28 121.57 20.32 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 105.873 -1.899 . . . . 74.51 105.873 172.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -152.75 140.1 19.56 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 108.573 -0.899 . . . . 64.44 108.573 176.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.02 141.71 40.21 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 123.566 0.541 . . . . 73.4 110.128 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.548 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 57.5 tp -110.03 113.73 26.67 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.027 -0.988 . . . . 72.35 109.07 179.29 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -85.71 101.9 13.16 Favored 'General case' 0 C--O 1.24 0.566 0 N-CA-C 108.149 -1.056 . . . . 62.22 108.149 176.228 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . 0.435 HG11 HG13 ' A' ' 253' ' ' VAL . 4.3 p -116.82 127.44 26.72 Favored Pre-proline 0 CA--C 1.548 0.881 0 N-CA-C 109.332 -0.618 . . . . 63.11 109.332 -178.237 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -58.71 144.71 97.71 Favored 'Trans proline' 0 C--N 1.379 2.169 0 C-N-CA 122.461 2.107 . . . . 51.24 111.948 172.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -54.49 -42.93 97.07 Favored Pre-proline 0 CA--C 1.564 1.506 0 CA-C-O 118.106 -0.949 . . . . 42.52 112.117 175.174 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_exo -46.12 -53.24 6.07 Favored 'Trans proline' 0 C--N 1.397 3.106 0 C-N-CA 122.684 2.256 . . . . 62.31 114.126 167.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . 0.472 HG22 HG21 ' A' ' 223' ' ' VAL . 12.8 mt -65.96 -37.02 78.89 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 O-C-N 123.169 0.293 . . . . 43.42 110.923 -178.111 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.13 -43.86 97.23 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 123.306 0.642 . . . . 43.51 111.599 -177.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 32.6 m -76.79 -37.97 28.9 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 115.951 -0.568 . . . . 55.43 111.262 -176.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.4 m -83.44 -23.87 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 N-CA-C 111.763 0.283 . . . . 43.42 111.763 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.462 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 72.19 64.05 2.77 Favored Glycine 0 C--N 1.341 0.84 0 CA-C-N 116.227 -0.442 . . . . 71.12 112.183 -172.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -94.53 -154.19 30.78 Favored Glycine 0 C--N 1.355 1.625 0 CA-C-O 121.428 0.46 . . . . 52.32 112.378 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 14.7 mmmm -121.76 128.97 52.33 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 123.781 0.832 . . . . 74.32 109.104 -174.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 39.5 t -116.18 129.98 71.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 N-CA-C 108.91 -0.774 . . . . 75.03 108.91 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -78.24 106.09 9.91 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 107.861 -1.163 . . . . 75.41 107.861 168.064 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -98.83 133.42 43.15 Favored 'General case' 0 C--N 1.343 0.31 0 C-N-CA 123.822 0.849 . . . . 64.42 108.922 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -74.94 144.24 43.32 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 122.651 0.38 . . . . 71.23 110.402 173.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.41 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 7.5 t -148.27 167.43 25.16 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 124.353 1.061 . . . . 72.41 109.77 172.471 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . 0.407 HD13 ' O ' ' A' ' 127' ' ' LEU . 45.8 mt -71.58 -15.12 62.26 Favored 'General case' 0 CA--C 1.552 1.046 0 CA-C-N 115.178 -0.919 . . . . 74.21 110.796 176.363 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -80.73 -20.73 42.16 Favored 'General case' 0 CA--C 1.564 1.503 0 C-N-CA 124.747 1.219 . . . . 71.51 109.888 174.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 135.03 -151.26 20.4 Favored Glycine 0 C--N 1.361 1.932 0 CA-C-O 119.628 -0.54 . . . . 33.42 112.41 -177.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -91.84 124.54 0.78 Allowed 'Trans proline' 0 C--N 1.368 1.591 0 C-N-CA 123.33 2.687 . . . . 70.1 111.807 170.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . 0.408 HG11 ' HD3' ' A' ' 238' ' ' LYS . 22.7 m -116.98 160.71 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 C-N-CA 123.604 0.762 . . . . 51.32 110.771 179.389 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -115.28 110.39 19.35 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 109.001 -0.74 . . . . 61.44 109.001 178.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.553 HG23 HD21 ' A' ' 235' ' ' LEU . 5.9 p -97.09 138.29 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 123.37 0.668 . . . . 70.45 110.512 177.082 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -93.81 111.7 23.44 Favored 'General case' 0 C--O 1.239 0.533 0 C-N-CA 123.698 0.799 . . . . 73.21 109.009 173.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.472 HG21 HG22 ' A' ' 203' ' ' ILE . 13.8 m -86.47 140.66 34.0 Favored Pre-proline 0 CA--C 1.55 0.964 0 N-CA-C 108.91 -0.774 . . . . 43.15 108.91 177.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -62.12 143.38 94.62 Favored 'Trans proline' 0 CA--C 1.56 1.818 0 C-N-CA 122.501 2.134 . . . . 74.52 112.318 177.594 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.9 123.76 12.47 Favored 'Trans proline' 0 C--N 1.378 2.104 0 C-N-CA 122.408 2.072 . . . . 71.41 110.669 174.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 44.2 mtm105 64.07 48.88 2.87 Favored 'General case' 0 N--CA 1.475 0.824 0 O-C-N 124.233 0.958 . . . . 72.53 110.343 -173.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . 0.454 HG23 HD11 ' A' ' 255' ' ' ILE . 11.8 t -71.16 170.63 12.55 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.319 0.58 . . . . 65.21 111.103 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.9 mp0 -121.91 139.39 53.71 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.221 1.008 . . . . 73.01 108.574 -176.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -76.62 127.69 33.28 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.288 0.635 . . . . 75.41 109.94 179.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.38 -4.71 23.36 Favored Glycine 0 C--N 1.339 0.746 0 N-CA-C 111.512 -0.635 . . . . 51.44 111.512 -173.077 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . 0.428 ' O ' ' HA ' ' A' ' 252' ' ' GLU . 60.6 mtt-85 -71.51 160.1 33.32 Favored 'General case' 0 C--N 1.36 1.042 0 C-N-CA 122.917 0.487 . . . . 63.25 110.762 173.669 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.445 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.1 OUTLIER -123.43 100.43 6.82 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.088 0.955 . . . . 61.44 108.774 179.69 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . 0.428 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 86.3 mt -84.89 104.85 15.2 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 108.92 -0.77 . . . . 55.11 108.92 -176.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 14.6 ttp180 -82.31 101.95 10.89 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 114.784 -1.098 . . . . 74.12 110.367 -171.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.553 HD21 HG23 ' A' ' 221' ' ' VAL . 48.9 mt -89.62 101.61 14.3 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 115.131 -0.94 . . . . 64.3 108.555 171.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 47.0 mtpt -73.06 149.15 43.41 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.354 0.662 . . . . 74.13 110.574 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 67.72 28.88 73.48 Favored Glycine 0 C--N 1.345 1.05 0 O-C-N 123.369 0.418 . . . . 74.55 113.413 -178.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . 0.523 ' HG3' ' HB3' ' A' ' 235' ' ' LEU . 0.0 OUTLIER -127.55 -8.38 5.69 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 124.165 0.986 . . . . 70.24 111.145 -176.973 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . 0.434 ' HA2' ' CD1' ' A' ' 193' ' ' LEU . . . -84.71 -163.97 37.42 Favored Glycine 0 C--N 1.344 0.977 0 CA-C-N 115.919 -0.582 . . . . 63.54 113.174 176.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.621 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 1.5 m-85 -85.99 158.88 55.39 Favored Pre-proline 0 N--CA 1.48 1.053 0 N-CA-C 109.341 -0.615 . . . . 72.24 109.341 179.014 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -47.53 129.55 16.83 Favored 'Trans proline' 0 C--N 1.382 2.32 0 C-N-CA 123.077 2.518 . . . . 70.13 113.598 174.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -165.34 -162.8 17.3 Favored Glycine 0 CA--C 1.535 1.282 0 CA-C-O 118.986 -0.897 . . . . 44.32 112.203 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_exo -47.05 -41.1 26.55 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 124.616 3.544 . . . . 71.41 115.378 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -87.47 21.0 2.63 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 123.965 0.906 . . . . 24.12 112.145 -177.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.15 -81.82 1.5 Allowed Glycine 0 C--N 1.346 1.102 0 N-CA-C 110.568 -1.013 . . . . 65.2 110.568 -173.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -113.2 135.41 53.85 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.624 -1.25 . . . . 53.43 107.624 169.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.48 -157.21 5.28 Favored Glycine 0 C--N 1.345 1.045 0 N-CA-C 115.152 0.821 . . . . 73.3 115.152 -169.165 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -111.27 164.58 12.74 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 123.155 0.582 . . . . 75.42 110.374 -175.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.621 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 20.0 tp -128.04 116.26 19.75 Favored 'General case' 0 C--O 1.218 -0.602 0 C-N-CA 124.644 1.178 . . . . 73.22 109.342 169.421 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . 0.445 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 10.6 m-85 -97.46 107.36 19.86 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 109.243 -0.651 . . . . 70.12 109.243 175.298 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.548 ' HB3' ' HB2' ' A' ' 197' ' ' LEU . 85.8 mt -86.58 115.4 24.04 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 124.004 0.922 . . . . 74.54 112.042 178.236 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.428 ' HA ' ' O ' ' A' ' 231' ' ' ARG . 36.4 tt0 -77.74 93.91 4.37 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 108.348 -0.982 . . . . 63.34 108.348 175.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.435 HG13 HG11 ' A' ' 199' ' ' VAL . 91.9 t -48.71 116.49 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 C-N-CA 124.705 1.202 . . . . 73.21 111.286 176.738 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 26.5 mmm180 -120.75 94.8 4.47 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 107.416 -1.328 . . . . 75.22 107.416 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.454 HD11 HG23 ' A' ' 227' ' ' THR . 60.3 mt -77.69 106.98 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-N 115.379 -0.828 . . . . 74.2 109.366 -178.02 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 CA--C 1.552 1.034 0 C-N-CA 124.034 0.934 . . . . 62.33 108.942 -179.701 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 111.289 0.107 . . . . 74.22 111.289 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 7.4 p -61.15 125.25 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 O-C-N 123.79 0.681 . . . . 64.52 110.946 -175.22 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -74.25 -75.92 0.15 Allowed 'General case' 0 C--N 1.346 0.427 0 N-CA-C 108.483 -0.932 . . . . 72.03 108.483 174.191 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -162.91 153.23 16.34 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 124.866 1.266 . . . . 72.41 108.416 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 8.4 p -67.74 121.03 16.13 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.916 0 CA-C-O 121.063 0.459 . . . . 45.02 109.798 172.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.574 HG21 ' HG3' ' A' ' 122' ' ' GLU . 11.4 t . . . . . 0 CA--C 1.549 0.906 0 C-N-CA 123.699 0.799 . . . . 54.01 111.86 -174.066 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 . . . . . 0 C--O 1.241 0.646 0 CA-C-O 121.973 0.892 . . . . 44.44 111.442 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.687 HD12 ' HA2' ' A' ' 165' ' ' GLY . 24.5 mt -94.36 155.26 17.07 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 106.681 -1.6 . . . . 70.24 106.681 159.284 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . 0.556 ' HE ' HD12 ' A' ' 175' ' ' LEU . 29.6 ttm180 -144.47 114.66 7.47 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 109.66 -0.496 . . . . 74.43 109.66 -174.147 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -126.8 126.46 43.42 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 123.523 0.729 . . . . 54.34 110.195 -177.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.574 ' HG3' HG21 ' A' ' 103' ' ' THR . 24.4 mt-10 -92.09 136.74 32.93 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 108.505 -0.924 . . . . 72.15 108.505 169.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -145.13 147.26 33.72 Favored Pre-proline 0 N--CA 1.468 0.44 0 C-N-CA 123.191 0.596 . . . . 44.03 110.578 -170.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.86 154.48 67.3 Favored 'Trans proline' 0 C--N 1.369 1.617 0 C-N-CA 121.877 1.718 . . . . 71.53 111.646 170.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 22.2 tp -149.5 150.34 32.15 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.811 0.844 . . . . 64.11 109.067 174.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.584 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 69.2 m -84.59 151.98 24.16 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 123.326 0.651 . . . . 72.42 109.487 172.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.52 HD11 ' O ' ' A' ' 183' ' ' HIS . 45.1 mt -58.19 -48.05 81.53 Favored 'General case' 0 N--CA 1.483 1.194 0 CA-C-O 121.881 0.848 . . . . 74.44 110.204 176.236 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.627 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.7 mp0 -57.88 -31.79 67.06 Favored 'General case' 0 N--CA 1.484 1.259 0 CA-C-N 114.328 -1.306 . . . . 63.45 111.97 178.06 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 38.0 mm-40 -88.95 -16.69 31.17 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 112.109 0.411 . . . . 63.14 112.109 178.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.727 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -63.26 -31.65 72.85 Favored 'General case' 0 C--O 1.25 1.12 0 CA-C-O 121.168 0.508 . . . . 55.13 110.152 162.853 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.558 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 17.1 t80 -71.87 -60.37 2.27 Favored 'General case' 0 C--N 1.351 0.642 0 CA-C-N 115.326 -0.852 . . . . 74.3 110.877 168.238 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -71.89 -28.62 63.64 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 113.605 0.965 . . . . 60.2 113.605 -168.233 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 74.09 -87.46 0.68 Allowed Glycine 0 CA--C 1.532 1.123 0 N-CA-C 110.738 -0.945 . . . . 63.51 110.738 -167.628 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 84.01 126.65 1.34 Allowed Glycine 0 C--N 1.352 1.449 0 C-N-CA 122.844 0.259 . . . . 42.32 113.129 174.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.43 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.7 mp0 -78.28 114.56 17.28 Favored 'General case' 0 C--N 1.345 0.392 0 N-CA-C 108.431 -0.952 . . . . 74.2 108.431 176.509 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 7.3 mpt_? -131.36 153.38 49.7 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 123.084 0.554 . . . . 73.11 109.884 176.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 14.7 p -72.89 140.9 17.13 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.083 0 C-N-CA 123.308 0.643 . . . . 63.32 111.779 -173.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.43 HG22 HG23 ' A' ' 140' ' ' VAL . 7.9 p -136.43 124.57 35.15 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 C-N-CA 125.239 1.416 . . . . 73.12 108.553 -179.425 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -116.57 96.44 5.51 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 107.358 -1.349 . . . . 71.15 107.358 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.558 HG12 HD13 ' A' ' 119' ' ' LEU . 90.0 t -130.73 131.49 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 122.992 0.517 . . . . 73.44 109.714 -178.531 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.02 30.08 19.6 Favored 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 124.962 1.305 . . . . 64.03 112.021 -179.278 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 92.07 -1.15 73.47 Favored Glycine 0 C--N 1.344 1.025 0 CA-C-N 115.336 -0.847 . . . . 60.13 114.137 173.741 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.84 119.15 38.64 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-N 118.284 1.042 . . . . 64.42 110.691 -179.312 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 63.2 ttp85 -92.66 106.66 18.6 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.139 0.975 . . . . 73.42 108.489 172.076 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 61.7 t -133.5 149.77 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 108.238 -1.023 . . . . 74.31 108.238 178.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 34.9 p -81.02 120.97 25.47 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 109.132 -0.692 . . . . 73.31 109.132 172.597 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.4 p -96.83 131.12 44.37 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 CA-C-O 121.19 0.519 . . . . 61.43 110.647 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . 0.43 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 40.6 ttp180 -104.28 102.06 11.76 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 107.746 -1.205 . . . . 74.52 107.746 175.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.63 ' HB ' HD13 ' A' ' 159' ' ' ILE . 30.8 pt -91.96 130.82 37.07 Favored Pre-proline 0 CA--C 1.549 0.941 0 N-CA-C 108.965 -0.754 . . . . 73.33 108.965 176.226 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -63.63 135.99 51.82 Favored 'Trans proline' 0 C--N 1.383 2.37 0 C-N-CA 122.88 2.387 . . . . 73.34 112.847 -171.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_exo -54.49 141.59 72.88 Favored 'Trans proline' 0 C--N 1.379 2.159 0 C-N-CA 123.427 2.751 . . . . 71.33 112.381 169.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 104.18 24.66 7.45 Favored Glycine 0 C--N 1.338 0.675 0 N-CA-C 111.645 -0.582 . . . . 70.41 111.645 -176.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.727 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.4 p -95.06 158.74 2.93 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.917 0 N-CA-C 108.504 -0.924 . . . . 54.4 108.504 -177.268 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.484 ' HA ' HD11 ' A' ' 180' ' ' LEU . 27.0 mtm180 -149.62 176.15 10.91 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 124.426 1.09 . . . . 74.52 110.135 -170.621 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -52.93 124.86 15.3 Favored 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 124.017 0.927 . . . . 62.52 111.744 173.148 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.85 10.03 83.44 Favored Glycine 0 C--N 1.347 1.182 0 O-C-N 123.534 0.521 . . . . 72.54 113.809 177.36 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.419 ' HB3' HG23 ' A' ' 153' ' ' VAL . 33.0 t -76.97 122.35 24.77 Favored 'General case' 0 C--O 1.246 0.879 0 N-CA-C 109.391 -0.596 . . . . 74.33 109.391 179.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.476 HG22 HD22 ' A' ' 175' ' ' LEU . 7.1 p -94.14 121.88 45.14 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.964 0 C-N-CA 123.77 0.828 . . . . 71.52 109.689 -179.335 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.63 HD13 ' HB ' ' A' ' 149' ' ' ILE . 46.3 mt -110.52 118.16 56.51 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 124.273 1.029 . . . . 72.34 109.999 -172.475 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 60.0 ttp85 -95.78 109.96 22.19 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 122.863 0.465 . . . . 74.31 110.408 -178.169 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 10.7 m -109.48 101.57 46.44 Favored Pre-proline 0 CA--C 1.569 1.7 0 C-N-CA 122.933 0.493 . . . . 62.34 110.125 -178.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . 0.45 ' HA ' ' HB3' ' A' ' 173' ' ' ASP . 33.2 Cg_exo -64.1 147.61 91.48 Favored 'Trans proline' 0 C--N 1.384 2.403 0 C-N-CA 123.554 2.836 . . . . 45.21 114.314 -172.675 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.18 5.08 89.36 Favored Glycine 0 C--N 1.348 1.249 0 CA-C-N 115.058 -0.974 . . . . 64.21 114.447 175.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 46.9 tpp -96.43 -36.14 10.92 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.092 0.557 . . . . 73.52 110.95 -177.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . 0.687 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.349 1.26 0 CA-C-N 115.635 -0.711 . . . . 53.25 114.3 -175.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo . . . . . 0 CA--C 1.549 1.261 0 CA-C-O 120.996 0.332 . . . . 61.01 111.77 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -101.09 160.42 18.6 Favored Glycine 0 C--N 1.34 0.763 0 N-CA-C 111.075 -0.81 . . . . 62.35 111.075 176.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.45 ' HB3' ' HA ' ' A' ' 162' ' ' PRO . 0.9 OUTLIER -124.94 179.59 4.96 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.696 0.798 . . . . 74.25 110.966 -167.021 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 21.2 tp -127.74 118.91 24.66 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.146 0.578 . . . . 75.24 109.686 175.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.556 HD12 ' HE ' ' A' ' 120' ' ' ARG . 86.0 mt -86.19 99.32 11.45 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 124.608 1.163 . . . . 63.12 110.391 177.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 76.5 mt -89.82 102.61 15.31 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.704 0.802 . . . . 64.2 110.576 174.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.453 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 29.3 t -90.9 102.79 13.79 Favored 'Isoleucine or valine' 0 C--O 1.244 0.777 0 N-CA-C 108.313 -0.995 . . . . 63.02 108.313 175.597 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 5.5 m -79.75 150.47 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 CA-C-O 121.65 0.738 . . . . 74.22 111.479 -173.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 19.6 mmt85 -122.26 98.47 5.95 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 114.482 -1.235 . . . . 73.24 107.811 -178.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.484 HD11 ' HA ' ' A' ' 154' ' ' ARG . 21.5 mt -68.34 151.49 46.81 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.207 0.603 . . . . 63.31 112.443 -177.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.584 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 60.6 mt -53.69 138.58 51.95 Favored Pre-proline 0 CA--C 1.559 1.322 0 O-C-N 124.091 0.869 . . . . 74.0 111.324 -179.304 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -57.32 -13.08 11.94 Favored 'Trans proline' 0 C--N 1.383 2.375 0 C-N-CA 124.239 3.293 . . . . 74.12 115.584 -173.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . 0.52 ' O ' HD11 ' A' ' 127' ' ' LEU . 1.0 OUTLIER -87.52 114.33 58.3 Favored Pre-proline 0 CA--C 1.548 0.889 0 N-CA-C 108.708 -0.849 . . . . 75.14 108.708 173.247 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -92.62 126.67 0.75 Allowed 'Trans proline' 0 C--N 1.377 2.066 0 C-N-CA 122.568 2.179 . . . . 74.01 112.287 173.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.9 p -127.29 -41.8 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 N-CA-C 109.565 -0.531 . . . . 53.14 109.565 174.302 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.454 ' HE2' HD13 ' A' ' 193' ' ' LEU . 6.5 m-85 -107.52 125.2 50.98 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 115.896 -0.593 . . . . 74.31 110.691 -178.074 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.578 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 6.2 mpt_? -112.38 103.97 12.11 Favored 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 107.237 -1.394 . . . . 51.53 107.237 175.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 42.1 tp -92.72 136.51 33.17 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.115 0.566 . . . . 71.14 109.8 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -143.68 134.05 24.64 Favored 'General case' 0 C--O 1.241 0.657 0 N-CA-C 109.225 -0.657 . . . . 75.35 109.225 165.586 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 68.28 -81.88 0.2 Allowed Glycine 0 C--N 1.352 1.426 0 O-C-N 123.913 0.758 . . . . 71.22 113.087 -178.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 24.1 pt20 -144.34 -17.57 0.56 Allowed 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 123.645 0.778 . . . . 50.44 110.755 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -109.86 158.27 18.35 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-O 121.269 0.557 . . . . 70.53 111.683 -170.049 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.468 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 77.4 mt -111.34 163.38 14.04 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.005 1.322 . . . . 73.31 111.779 -168.67 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . 0.578 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 82.5 m-85 -139.52 124.16 18.37 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 114.563 -1.199 . . . . 63.14 108.516 170.032 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . 0.425 ' HB3' HD11 ' A' ' 249' ' ' LEU . . . -135.84 171.43 14.47 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 122.836 0.454 . . . . 44.55 110.157 175.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 7.8 m -102.48 134.42 45.84 Favored 'General case' 0 CA--C 1.544 0.712 0 N-CA-C 109.389 -0.597 . . . . 71.31 109.389 178.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.603 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 42.7 tp -109.98 114.09 27.34 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.382 1.073 . . . . 60.52 110.133 -177.384 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -94.11 103.71 15.75 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.414 0.686 . . . . 74.01 109.746 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . 0.63 HG12 HG11 ' A' ' 210' ' ' VAL . 3.5 m -113.2 142.44 27.42 Favored Pre-proline 0 N--CA 1.479 1.012 0 C-N-CA 122.981 0.513 . . . . 73.12 109.668 176.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -68.96 155.49 68.33 Favored 'Trans proline' 0 C--N 1.365 1.439 0 C-N-CA 122.33 2.02 . . . . 74.11 111.38 167.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . 0.407 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -60.04 -45.85 98.02 Favored Pre-proline 0 N--CA 1.479 0.979 0 CA-C-O 118.737 -0.649 . . . . 73.21 112.215 177.518 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . 0.463 ' O ' HG22 ' A' ' 206' ' ' VAL . 9.8 Cg_endo -49.77 -45.76 30.49 Favored 'Trans proline' 0 C--N 1.391 2.781 0 C-N-CA 122.568 2.179 . . . . 12.33 113.348 171.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . 0.484 ' HA ' ' HA3' ' A' ' 207' ' ' GLY . 3.5 mt -67.64 -43.94 86.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 O-C-N 121.967 -0.458 . . . . 72.51 111.569 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -52.51 -43.96 65.42 Favored 'General case' 0 CA--C 1.538 0.489 0 O-C-N 124.446 1.091 . . . . 51.21 111.177 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . 0.621 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 28.8 m -88.91 -58.46 3.46 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.262 0 N-CA-C 113.015 0.746 . . . . 64.34 113.015 -176.555 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.533 HG13 HG23 ' A' ' 205' ' ' VAL . 18.6 m -104.43 -25.28 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 113.328 0.862 . . . . 70.55 113.328 -172.124 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.484 ' HA3' ' HA ' ' A' ' 203' ' ' ILE . . . -74.96 -70.82 1.21 Allowed Glycine 0 C--N 1.346 1.123 0 C-N-CA 121.565 -0.35 . . . . 62.21 112.289 -168.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 92.15 -2.06 74.6 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-O 119.2 -0.778 . . . . 74.34 114.131 170.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 40.8 mtmt -139.33 138.93 37.09 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 108.352 -0.981 . . . . 73.1 108.352 178.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . 0.63 HG11 HG12 ' A' ' 199' ' ' VAL . 7.3 p -160.58 145.98 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 C-N-CA 123.897 0.879 . . . . 72.43 108.71 -178.771 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . 0.456 ' HA ' ' HA ' ' A' ' 220' ' ' GLU . 69.0 mtt180 -93.56 123.88 37.17 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 122.759 0.424 . . . . 74.24 109.951 177.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.477 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -101.18 165.02 11.51 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 124.237 1.015 . . . . 50.51 109.146 173.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 66.2 mmm -103.34 146.75 28.0 Favored 'General case' 0 C--O 1.239 0.551 0 CA-C-O 121.162 0.506 . . . . 73.2 110.419 175.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.433 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.3 t -138.6 169.08 18.43 Favored 'General case' 0 C--O 1.238 0.467 0 CA-C-N 114.726 -1.125 . . . . 64.23 109.709 173.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . 0.627 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 81.9 mt -70.92 -3.3 18.53 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 114.844 -1.071 . . . . 54.41 113.223 -174.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 1.8 pp20? -121.0 -1.45 9.85 Favored 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.274 0.629 . . . . 73.1 112.52 178.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.16 -158.51 27.71 Favored Glycine 0 N--CA 1.475 1.278 0 CA-C-O 119.719 -0.489 . . . . 44.25 113.443 176.043 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -90.76 129.47 1.43 Allowed 'Trans proline' 0 C--N 1.367 1.52 0 C-N-CA 123.223 2.616 . . . . 62.22 112.412 174.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 31.5 m -109.66 151.43 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 123.819 0.848 . . . . 71.31 109.434 171.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 211' ' ' ARG . 32.9 tt0 -114.58 114.62 25.97 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.647 -0.501 . . . . 64.32 109.647 173.055 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.466 HG23 HD21 ' A' ' 235' ' ' LEU . 4.5 p -100.56 144.32 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 C-N-CA 124.703 1.201 . . . . 61.21 110.744 178.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -95.96 113.02 24.6 Favored 'General case' 0 C--O 1.24 0.561 0 N-CA-C 109.159 -0.682 . . . . 73.34 109.159 173.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.53 HG11 HG11 ' A' ' 199' ' ' VAL . 14.1 m -84.53 138.6 38.4 Favored Pre-proline 0 N--CA 1.481 1.097 0 N-CA-C 108.86 -0.792 . . . . 74.33 108.86 176.36 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -54.3 140.68 72.51 Favored 'Trans proline' 0 C--N 1.379 2.136 0 C-N-CA 122.625 2.217 . . . . 72.53 112.622 177.283 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -54.17 112.74 1.07 Allowed 'Trans proline' 0 C--N 1.379 2.181 0 C-N-CA 122.881 2.388 . . . . 75.13 111.282 174.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . 0.621 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 60.6 mtp180 63.27 58.43 1.4 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.531 1.133 . . . . 74.52 110.634 -171.164 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.8 t -71.15 171.82 10.31 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.334 -0.848 . . . . 65.44 110.431 175.22 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.5 mp0 -121.18 146.35 46.87 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.711 0.804 . . . . 73.34 109.225 -175.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -72.52 113.73 9.87 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 123.218 0.607 . . . . 65.22 110.292 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.6 4.88 19.23 Favored Glycine 0 C--N 1.339 0.712 0 CA-C-N 115.73 -0.668 . . . . 72.21 112.399 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 61.3 mtp180 -76.17 153.25 36.32 Favored 'General case' 0 N--CA 1.477 0.918 0 CA-C-N 117.345 0.573 . . . . 73.44 109.962 172.092 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 0.2 OUTLIER -111.71 119.27 38.08 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 123.727 0.811 . . . . 60.34 108.934 -179.746 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 70.2 mt -106.02 114.49 28.66 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 122.85 0.46 . . . . 74.03 109.827 -178.022 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . 0.589 ' HG3' ' HB3' ' A' ' 248' ' ' ASP . 39.7 ttp180 -82.48 104.22 12.61 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 124.863 1.265 . . . . 74.41 111.354 -171.23 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.498 ' HB2' ' HB3' ' A' ' 249' ' ' LEU . 38.2 mt -89.48 97.63 11.3 Favored 'General case' 0 C--O 1.239 0.531 0 C-N-CA 123.231 0.612 . . . . 71.04 109.594 172.618 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -72.81 134.95 45.12 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 114.766 -1.106 . . . . 63.53 110.119 -178.323 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 85.26 24.65 43.02 Favored Glycine 0 C--N 1.34 0.77 0 O-C-N 123.493 0.496 . . . . 73.15 113.247 178.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -124.52 -6.88 7.5 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 123.223 0.609 . . . . 75.43 112.353 176.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -85.32 -161.67 34.74 Favored Glycine 0 C--N 1.345 1.082 0 O-C-N 123.53 0.518 . . . . 34.53 112.506 175.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.558 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 92.2 m-85 -97.24 147.0 32.32 Favored Pre-proline 0 N--CA 1.481 1.082 0 C-N-CA 123.524 0.729 . . . . 75.25 111.282 175.434 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.43 132.52 33.75 Favored 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 122.257 1.971 . . . . 64.42 111.315 171.452 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -156.83 -148.64 5.15 Favored Glycine 0 CA--C 1.532 1.152 0 CA-C-O 119.01 -0.883 . . . . 71.32 111.595 -176.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -51.63 -53.96 6.15 Favored 'Trans proline' 0 C--N 1.377 2.055 0 C-N-CA 123.953 3.102 . . . . 63.44 114.999 -177.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -83.67 -24.46 31.32 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 122.608 0.363 . . . . 72.2 111.778 -177.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 141.86 -155.4 25.4 Favored Glycine 0 N--CA 1.47 0.92 0 N-CA-C 110.091 -1.204 . . . . 32.25 110.091 -177.088 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 22.1 ttm180 -65.13 134.73 54.39 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 118.511 1.155 . . . . 73.13 109.351 171.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -75.05 -170.85 27.49 Favored Glycine 0 C--O 1.249 1.052 0 CA-C-O 121.974 0.763 . . . . 60.43 114.686 -170.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . 0.589 ' HB3' ' HG3' ' A' ' 234' ' ' ARG . 12.1 m-20 -129.33 136.9 50.61 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 114.268 -0.966 . . . . 74.42 109.565 -169.555 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.498 ' HB3' ' HB2' ' A' ' 235' ' ' LEU . 20.7 tp -97.01 111.74 23.82 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.889 -0.411 . . . . 74.13 109.889 179.559 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -91.85 106.63 18.61 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.222 0.534 . . . . 74.12 109.813 177.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.603 ' HB3' ' HB2' ' A' ' 197' ' ' LEU . 85.9 mt -87.53 120.01 28.41 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 124.245 1.018 . . . . 62.4 112.379 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -80.61 93.86 6.2 Favored 'General case' 0 CA--C 1.539 0.535 0 N-CA-C 108.093 -1.077 . . . . 65.41 108.093 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.402 HG22 HD23 ' A' ' 197' ' ' LEU . 60.3 t -48.96 123.68 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.561 1.144 . . . . 65.03 111.184 175.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 38.5 mmm-85 -128.69 100.94 5.92 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 107.219 -1.4 . . . . 70.12 107.219 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 56.5 mt -83.34 117.84 29.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 115.149 -0.932 . . . . 63.5 110.05 -177.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.8 t . . . . . 0 CA--C 1.556 1.187 0 C-N-CA 124.23 1.012 . . . . 65.23 108.603 174.53 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.667 HD22 ' HG3' ' A' ' 136' ' ' ARG . 20.4 tp . . . . . 0 N--CA 1.474 0.737 0 N-CA-C 110.236 -0.283 . . . . 53.02 110.236 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.583 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 10.0 p -60.76 126.79 19.26 Favored 'Isoleucine or valine' 0 C--N 1.36 1.063 0 O-C-N 123.465 0.478 . . . . 72.3 111.025 175.579 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -83.31 -65.9 0.95 Allowed 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.493 -0.776 . . . . 62.42 109.699 -179.104 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -150.13 147.45 27.77 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 114.987 -1.006 . . . . 74.1 110.258 -169.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 92.9 t -78.81 124.59 37.4 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 N-CA-C 109.259 -0.645 . . . . 74.31 109.259 169.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 70.1 p . . . . . 0 CA--C 1.55 0.956 0 C-N-CA 123.359 0.664 . . . . 64.31 109.471 176.042 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 16.2 t70 . . . . . 0 N--CA 1.475 0.818 0 N-CA-C 108.591 -0.892 . . . . 74.5 108.591 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 28.6 tp -101.61 142.07 33.53 Favored 'General case' 0 C--O 1.22 -0.453 0 N-CA-C 107.356 -1.35 . . . . 72.33 107.356 -178.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 37.3 ttp-105 -143.28 132.93 23.73 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 108.513 -0.921 . . . . 71.54 108.513 -178.091 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -144.75 138.41 27.16 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 123.953 0.901 . . . . 73.22 109.052 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -103.26 148.98 25.15 Favored 'General case' 0 C--O 1.252 1.191 0 CA-C-O 120.935 0.398 . . . . 72.15 110.101 176.344 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.583 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.6 pt? -146.95 130.93 8.44 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.674 -0.694 . . . . 73.24 111.967 -170.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.97 120.64 7.63 Favored 'Trans proline' 0 C--N 1.378 2.084 0 C-N-CA 122.49 2.127 . . . . 72.25 111.477 174.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 18.0 tp -120.42 152.79 37.45 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.542 1.137 . . . . 64.45 109.165 179.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.474 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 22.4 m -86.25 155.41 20.7 Favored 'General case' 0 CA--C 1.551 0.993 0 N-CA-C 109.365 -0.606 . . . . 54.21 109.365 172.009 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.433 HD11 ' O ' ' A' ' 183' ' ' HIS . 28.6 mt -55.34 -49.23 72.76 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-O 121.923 0.868 . . . . 70.24 109.934 175.113 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.607 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.3 mp0 -55.96 -35.44 66.69 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 113.943 -1.48 . . . . 64.35 111.544 177.665 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.474 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 35.7 mm-40 -83.11 -19.57 36.5 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 122.993 0.517 . . . . 73.33 112.077 -179.474 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.59 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -65.27 -31.66 72.92 Favored 'General case' 0 C--O 1.246 0.919 0 CA-C-O 121.169 0.509 . . . . 72.44 110.162 165.502 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.443 ' HA ' ' CE1' ' A' ' 240' ' ' PHE . 6.6 t80 -77.28 -47.36 20.29 Favored 'General case' 0 CA--C 1.546 0.789 0 CA-C-N 115.366 -0.834 . . . . 71.51 112.279 170.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -76.75 -30.19 56.46 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 112.54 0.57 . . . . 75.43 112.54 -171.224 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 67.92 -107.08 1.91 Allowed Glycine 0 CA--C 1.533 1.218 0 N-CA-C 111.564 -0.614 . . . . 4.34 111.564 -173.31 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.33 162.43 36.39 Favored Glycine 0 C--N 1.353 1.496 0 N-CA-C 114.904 0.722 . . . . 63.14 114.904 168.621 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.457 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 1.6 mp0 -96.03 114.17 25.86 Favored 'General case' 0 C--N 1.357 0.917 0 N-CA-C 108.856 -0.794 . . . . 75.21 108.856 179.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.667 ' HG3' HD22 ' A' ' 98' ' ' LEU . 4.6 mmp_? -130.37 139.25 50.66 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.836 0.854 . . . . 51.34 109.372 -174.78 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 17.9 m -74.55 128.23 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 CA-C-O 121.638 0.732 . . . . 75.4 111.614 -172.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.439 HG13 HG11 ' A' ' 99' ' ' VAL . 21.7 t -119.87 129.65 75.16 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 C-N-CA 125.292 1.437 . . . . 75.22 109.168 -177.531 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -121.8 97.74 5.63 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 108.746 -0.835 . . . . 73.32 108.746 177.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.461 HG21 HD22 ' A' ' 174' ' ' LEU . 27.9 m -137.82 142.87 35.02 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.885 0 C-N-CA 125.09 1.356 . . . . 72.04 108.336 -177.304 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.55 19.2 11.47 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 124.081 0.953 . . . . 72.01 112.665 176.48 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.08 22.87 75.82 Favored Glycine 0 C--N 1.352 1.463 0 CA-C-N 116.393 -0.367 . . . . 64.3 112.359 -174.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -120.79 135.65 55.1 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.366 1.067 . . . . 75.31 108.861 -178.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 41.1 ttt180 -111.41 106.24 15.09 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.005 -0.739 . . . . 74.22 109.005 175.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 29.2 t -132.59 126.89 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 N-CA-C 108.461 -0.94 . . . . 64.14 108.461 -178.33 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 72.6 p -71.53 122.87 21.24 Favored 'General case' 0 CA--C 1.54 0.592 0 N-CA-C 109.084 -0.71 . . . . 55.21 109.084 171.651 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 7.3 p -96.79 140.72 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 109.769 -0.456 . . . . 73.33 109.769 -177.742 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.9 ttp180 -109.35 99.96 9.13 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 107.395 -1.335 . . . . 70.13 107.395 171.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.522 ' HB ' HD13 ' A' ' 159' ' ' ILE . 35.8 pt -89.27 127.53 54.8 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 108.467 -0.938 . . . . 72.23 108.467 175.128 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.09 135.86 33.2 Favored 'Trans proline' 0 C--N 1.376 2.008 0 C-N-CA 122.477 2.118 . . . . 42.25 113.061 -173.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_exo -46.25 119.92 3.37 Favored 'Trans proline' 0 C--N 1.376 2.012 0 C-N-CA 123.937 3.091 . . . . 73.45 112.75 167.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 123.48 58.17 0.19 Allowed Glycine 0 N--CA 1.465 0.625 0 N-CA-C 110.635 -0.986 . . . . 74.5 110.635 -175.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.59 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.0 p -134.17 161.48 40.7 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.319 0 C-N-CA 123.698 0.799 . . . . 73.11 109.397 -178.162 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 14.5 mtp180 -141.35 170.94 14.78 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 126.05 1.74 . . . . 71.02 109.747 -169.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -55.24 126.54 25.33 Favored 'General case' 0 CA--C 1.551 1.015 0 CA-C-N 116.027 -0.533 . . . . 71.35 110.695 164.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.38 2.7 74.97 Favored Glycine 0 C--N 1.346 1.126 0 CA-C-O 119.781 -0.455 . . . . 60.13 113.891 179.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 42.1 t -77.76 130.96 37.39 Favored 'General case' 0 C--O 1.247 0.932 0 N-CA-C 109.677 -0.49 . . . . 61.25 109.677 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.488 HG12 HD22 ' A' ' 175' ' ' LEU . 15.3 t -106.78 121.52 59.62 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-N 114.743 -1.117 . . . . 75.02 109.275 -168.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.528 HD11 HG21 ' A' ' 153' ' ' VAL . 23.6 mt -109.73 113.93 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 123.65 0.78 . . . . 74.55 110.686 -171.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 48.6 ttm-85 -83.19 119.42 24.52 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.22 0.608 . . . . 71.01 110.119 177.036 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 173' ' ' ASP . 5.1 m -123.94 132.14 24.28 Favored Pre-proline 0 N--CA 1.481 1.106 0 C-N-CA 123.138 0.575 . . . . 65.34 109.822 -178.362 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.92 157.26 43.22 Favored 'Trans proline' 0 C--N 1.374 1.899 0 C-N-CA 122.54 2.16 . . . . 73.34 113.889 -175.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.52 24.14 63.56 Favored Glycine 0 C--N 1.35 1.31 0 CA-C-N 115.128 -0.942 . . . . 45.21 115.389 171.564 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.4 ' SD ' HD23 ' A' ' 174' ' ' LEU . 62.3 mtt -124.66 -61.09 1.34 Allowed 'General case' 0 N--CA 1.493 1.708 0 CA-C-N 119.075 1.437 . . . . 53.31 112.919 -179.137 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.693 0 C-N-CA 121.699 -0.286 . . . . 75.12 113.605 -176.223 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo . . . . . 0 CA--C 1.547 1.16 0 N-CA-C 111.031 -0.411 . . . . 70.11 111.031 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . 85.11 109.28 0.67 Allowed Glycine 0 C--O 1.22 -0.757 0 CA-C-O 119.22 -0.767 . . . . 72.21 112.762 178.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.509 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 47.3 m-20 -144.98 134.52 23.24 Favored 'General case' 0 N--CA 1.481 1.119 0 CA-C-N 117.899 0.849 . . . . 72.52 111.489 172.398 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.461 HD22 HG21 ' A' ' 140' ' ' VAL . 28.1 tp -112.16 126.6 55.38 Favored 'General case' 0 C--N 1.347 0.477 0 N-CA-C 108.459 -0.941 . . . . 70.51 108.459 171.082 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.488 HD22 HG12 ' A' ' 158' ' ' VAL . 29.9 mt -93.99 100.73 12.82 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.539 1.135 . . . . 73.52 110.163 176.661 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 62.9 mt -87.11 104.45 16.36 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.532 0.733 . . . . 74.13 111.272 176.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 23.4 t -90.08 100.3 10.77 Favored 'Isoleucine or valine' 0 C--O 1.243 0.748 0 N-CA-C 108.101 -1.074 . . . . 65.21 108.101 175.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 3.2 m -78.25 149.88 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-O 121.624 0.726 . . . . 74.11 111.32 -174.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 33.0 mmt180 -119.22 95.29 4.74 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.497 -1.229 . . . . 73.54 107.963 -177.321 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 39.6 mt -67.99 147.91 51.77 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 110.192 -0.299 . . . . 55.33 110.192 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.402 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 47.5 mt -54.2 146.83 29.15 Favored Pre-proline 0 CA--C 1.562 1.415 0 C-N-CA 124.111 0.964 . . . . 73.33 111.417 -174.33 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -61.51 77.11 0.09 OUTLIER 'Trans proline' 0 C--N 1.379 2.173 0 C-N-CA 123.176 2.584 . . . . 73.03 111.447 171.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . 0.433 ' O ' HD11 ' A' ' 127' ' ' LEU . 8.2 t60 170.78 87.69 0.04 OUTLIER Pre-proline 0 CA--C 1.547 0.859 0 C-N-CA 126.242 1.817 . . . . 70.13 107.287 -166.671 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -98.76 125.27 0.17 Allowed 'Trans proline' 0 CA--C 1.564 1.994 0 C-N-CA 123.316 2.678 . . . . 74.43 113.188 172.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -122.64 -42.0 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.632 -0.668 . . . . 71.43 109.413 174.146 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 4.7 m-85 -98.08 128.36 44.56 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.19 -0.914 . . . . 71.45 110.304 -178.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 10.4 mtt180 -112.63 103.98 12.04 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 106.218 -1.771 . . . . 72.41 106.218 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.428 HD12 ' O ' ' A' ' 192' ' ' ASP . 42.7 tp -81.44 110.84 17.24 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-O 121.259 0.552 . . . . 74.22 109.576 176.585 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.11 99.49 10.5 Favored 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 106.393 -1.706 . . . . 61.24 106.393 171.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 62.7 -94.9 0.11 Allowed Glycine 0 C--N 1.349 1.294 0 O-C-N 124.018 0.823 . . . . 65.4 113.352 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . 0.542 HE22 ' HB3' ' A' ' 244' ' ' ALA . 8.7 pt20 -108.46 -19.2 13.53 Favored 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 123.742 0.817 . . . . 51.23 110.849 178.042 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.428 ' O ' HD12 ' A' ' 188' ' ' LEU . 29.0 m-20 -97.0 155.03 16.95 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 123.876 0.87 . . . . 72.1 111.63 -172.541 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.455 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 82.6 mt -109.53 154.33 22.86 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 124.206 1.003 . . . . 74.45 109.484 -177.55 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -137.17 121.83 18.55 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 107.502 -1.296 . . . . 74.25 107.502 171.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -134.03 141.51 47.24 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 108.632 -0.877 . . . . 53.11 108.632 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 3.5 m -82.3 122.46 27.98 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 109.747 -0.464 . . . . 65.12 109.747 -178.706 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.446 HD13 ' HB2' ' A' ' 212' ' ' ALA . 57.2 tp -107.75 112.2 24.76 Favored 'General case' 0 C--O 1.216 -0.69 0 C-N-CA 124.335 1.054 . . . . 64.52 109.116 -178.706 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -93.52 108.23 19.96 Favored 'General case' 0 N--CA 1.474 0.755 0 CA-C-O 121.338 0.59 . . . . 72.22 109.617 177.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . 0.48 HG22 HG21 ' A' ' 210' ' ' VAL . 65.2 t -101.37 126.0 35.93 Favored Pre-proline 0 N--CA 1.474 0.74 0 C-N-CA 124.148 0.979 . . . . 61.43 109.344 -176.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_exo -57.18 139.29 89.59 Favored 'Trans proline' 0 C--N 1.369 1.622 0 C-N-CA 122.624 2.216 . . . . 62.21 111.503 171.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -55.31 -41.83 92.79 Favored Pre-proline 0 N--CA 1.482 1.136 0 N-CA-C 113.673 0.99 . . . . 74.32 113.673 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo -47.58 -52.91 7.25 Favored 'Trans proline' 0 C--N 1.386 2.519 0 C-N-CA 122.166 1.911 . . . . 73.15 113.621 168.013 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . 0.53 HG21 HG13 ' A' ' 210' ' ' VAL . 9.3 mt -67.73 -33.33 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 123.035 0.534 . . . . 64.34 111.689 -179.502 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -68.39 -42.24 79.34 Favored 'General case' 0 C--O 1.245 0.861 0 C-N-CA 123.122 0.569 . . . . 52.12 111.855 -177.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.2 m -77.44 -40.78 29.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 CA-C-N 115.729 -0.669 . . . . 65.44 110.968 -177.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.1 m -79.16 -30.38 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 CA-C-O 120.841 0.353 . . . . 75.22 111.437 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.512 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 79.87 67.37 1.58 Allowed Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.683 -0.689 . . . . 74.14 112.513 -175.323 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -97.92 -148.99 24.56 Favored Glycine 0 C--N 1.35 1.347 0 CA-C-N 116.688 0.244 . . . . 43.0 112.546 176.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . 0.676 ' HD3' ' HB2' ' A' ' 220' ' ' GLU . 4.7 ttmp? -125.54 131.44 52.77 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.517 0.727 . . . . 74.21 109.081 -178.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . 0.53 HG13 HG21 ' A' ' 203' ' ' ILE . 5.7 m -120.87 135.76 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.357 -0.979 . . . . 74.52 108.357 172.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . 0.533 ' HD3' ' HB2' ' A' ' 218' ' ' PRO . 35.0 ttm105 -96.26 117.15 30.2 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 121.279 0.561 . . . . 74.33 109.699 178.766 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.446 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -99.78 155.4 17.66 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.027 0.931 . . . . 75.24 109.681 178.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 58.1 mmm -92.4 128.21 38.17 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 109.82 -0.437 . . . . 54.23 109.82 172.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.0 t -114.42 173.01 6.67 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-N 115.277 -0.874 . . . . 65.24 109.172 167.357 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . 0.607 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 73.1 mt -75.28 -2.99 30.72 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-N 115.449 -0.796 . . . . 75.52 112.614 -172.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.65 7.76 11.12 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 123.541 0.736 . . . . 72.22 112.122 179.219 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 137.01 -161.16 25.11 Favored Glycine 0 N--CA 1.476 1.362 0 CA-C-O 119.817 -0.435 . . . . 44.1 112.91 178.143 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . 0.533 ' HB2' ' HD3' ' A' ' 211' ' ' ARG . 98.5 Cg_endo -94.35 125.17 0.45 Allowed 'Trans proline' 0 C--N 1.37 1.681 0 C-N-CA 123.499 2.799 . . . . 60.23 112.763 176.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.7 m -108.85 146.28 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 123.322 0.649 . . . . 71.53 110.52 175.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . 0.676 ' HB2' ' HD3' ' A' ' 209' ' ' LYS . 9.9 pt-20 -113.73 104.66 12.43 Favored 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 108.996 -0.742 . . . . 75.11 108.996 -177.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.5 p -97.61 135.54 31.65 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 CA-C-N 115.656 -0.702 . . . . 70.52 110.832 -179.084 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -93.93 117.63 30.37 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-N 115.269 -0.878 . . . . 63.54 109.418 176.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.512 HG23 ' HA2' ' A' ' 207' ' ' GLY . 21.4 m -84.22 140.06 39.34 Favored Pre-proline 0 CA--C 1.553 1.096 0 N-CA-C 109.615 -0.513 . . . . 72.54 109.615 176.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -64.37 144.23 85.13 Favored 'Trans proline' 0 C--N 1.378 2.081 0 C-N-CA 122.583 2.189 . . . . 42.24 112.065 173.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -56.52 126.89 23.77 Favored 'Trans proline' 0 C--N 1.371 1.73 0 C-N-CA 122.746 2.297 . . . . 74.13 111.76 171.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 50.9 mtt180 65.64 44.28 3.02 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 124.445 1.098 . . . . 74.42 110.592 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 5.5 t -77.43 168.84 19.35 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 122.874 0.469 . . . . 45.44 110.046 177.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -130.72 152.06 50.48 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 122.893 0.477 . . . . 71.22 109.782 -178.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.61 134.06 48.32 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.752 0.821 . . . . 74.14 111.166 178.454 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.2 -8.11 20.91 Favored Glycine 0 C--N 1.341 0.854 0 CA-C-O 119.562 -0.576 . . . . 73.44 112.755 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -78.84 159.31 27.88 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-N 117.45 0.625 . . . . 73.45 109.483 175.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.561 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 12.9 mptt -118.57 102.6 9.01 Favored 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 123.748 0.819 . . . . 74.04 109.37 177.41 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . 0.433 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 83.3 mt -78.92 104.61 9.67 Favored 'General case' 0 C--N 1.355 0.805 0 N-CA-C 108.463 -0.94 . . . . 74.35 108.463 -176.116 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 22.3 ttp85 -79.65 121.49 25.36 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 115.261 -0.881 . . . . 71.43 110.446 -169.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 34.4 mt -105.94 120.09 40.87 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.733 0.813 . . . . 64.2 109.93 175.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -70.55 128.32 35.74 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 124.327 1.051 . . . . 63.12 112.237 -169.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 81.56 7.48 88.13 Favored Glycine 0 C--N 1.349 1.267 0 O-C-N 123.718 0.636 . . . . 74.52 114.453 171.579 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 38.2 mmtm -85.16 -23.33 28.42 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 117.192 0.496 . . . . 63.22 112.237 -178.141 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -81.62 173.74 53.97 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 111.861 -0.495 . . . . 75.34 111.861 176.229 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.443 ' CE1' ' HA ' ' A' ' 131' ' ' PHE . 88.2 m-85 -81.15 150.82 68.96 Favored Pre-proline 0 N--CA 1.477 0.894 0 N-CA-C 112.739 0.644 . . . . 73.21 112.739 -172.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -55.61 132.15 50.37 Favored 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.066 2.511 . . . . 75.54 111.226 170.151 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -160.81 -150.8 6.0 Favored Glycine 0 CA--C 1.532 1.154 0 CA-C-O 119.595 -0.558 . . . . 62.0 112.05 -174.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -65.77 -27.56 52.02 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 123.168 2.579 . . . . 72.34 113.287 -174.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . 0.542 ' HB3' HE22 ' A' ' 191' ' ' GLN . . . -109.51 21.79 16.57 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 123.667 0.787 . . . . 64.14 111.052 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.08 -151.6 33.61 Favored Glycine 0 C--N 1.347 1.171 0 N-CA-C 110.489 -1.045 . . . . 72.52 110.489 -170.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -61.83 138.9 58.39 Favored 'General case' 0 N--CA 1.477 0.924 0 CA-C-N 117.979 0.889 . . . . 73.45 110.162 174.124 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -78.54 -158.87 12.57 Favored Glycine 0 C--O 1.247 0.94 0 CA-C-N 115.969 -0.56 . . . . 33.13 112.146 172.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 -144.35 156.02 44.05 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.011 0.524 . . . . 75.52 109.938 -173.167 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.455 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 20.6 tp -97.67 109.84 22.52 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.462 0.649 . . . . 72.01 110.039 179.037 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . 0.561 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 97.5 m-85 -91.33 106.96 18.87 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-N 115.108 -0.951 . . . . 72.4 109.942 176.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.442 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 72.5 mt -89.25 112.76 23.89 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 123.939 0.895 . . . . 74.43 112.486 -179.289 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -78.62 91.37 4.61 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.945 -0.761 . . . . 74.42 108.945 178.259 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.1 p -55.54 125.9 11.64 Favored 'Isoleucine or valine' 0 C--N 1.353 0.732 0 CA-C-N 115.043 -0.98 . . . . 74.15 110.324 175.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 44.8 mmm-85 -131.15 109.83 10.73 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 106.536 -1.653 . . . . 74.31 106.536 175.587 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 66.3 mt -83.67 121.21 36.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.454 0 CA-C-N 115.966 -0.561 . . . . 62.35 111.799 -171.212 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 21.5 m . . . . . 0 CA--C 1.558 1.284 0 C-N-CA 124.586 1.154 . . . . 51.13 108.992 175.158 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.514 ' HB3' HD12 ' A' ' 123' ' ' LEU . 86.5 mt . . . . . 0 N--CA 1.472 0.644 0 N-CA-C 109.543 -0.54 . . . . 73.42 109.543 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.495 ' HB ' HG23 ' A' ' 138' ' ' VAL . 6.4 t -82.9 119.64 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 115.092 -0.958 . . . . 55.44 109.468 178.641 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -75.35 -51.43 13.19 Favored 'General case' 0 N--CA 1.478 0.936 0 O-C-N 124.352 1.032 . . . . 71.51 110.579 177.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -165.79 178.15 6.75 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 125.094 1.358 . . . . 74.42 109.338 -172.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.497 HG12 ' HB2' ' A' ' 121' ' ' ALA . 19.0 m -92.04 156.39 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 112.151 0.426 . . . . 51.45 112.151 179.43 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 60.9 p . . . . . 0 C--O 1.238 0.473 0 CA-C-N 115.11 -0.95 . . . . 71.42 109.268 172.775 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.468 ' HB3' ' CZ ' ' A' ' 120' ' ' ARG . 5.9 m-20 . . . . . 0 C--O 1.24 0.595 0 N-CA-C 108.667 -0.864 . . . . 63.24 108.667 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.502 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 14.1 tp -131.63 131.48 43.24 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 107.42 -1.326 . . . . 74.13 107.42 179.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . 0.711 ' HG3' ' HB2' ' A' ' 175' ' ' LEU . 0.0 OUTLIER -134.41 133.93 41.09 Favored 'General case' 0 N--CA 1.482 1.135 0 N-CA-C 109.173 -0.677 . . . . 73.43 109.173 -177.172 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.497 ' HB2' HG12 ' A' ' 102' ' ' VAL . . . -146.46 164.17 33.33 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 124.079 0.952 . . . . 53.23 110.479 -176.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.644 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 46.3 mt-10 -126.42 151.01 48.29 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.079 0.951 . . . . 75.5 108.685 173.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.514 HD12 ' HB3' ' A' ' 98' ' ' LEU . 1.4 pt? -145.88 135.3 11.44 Favored Pre-proline 0 N--CA 1.477 0.897 0 C-N-CA 122.967 0.507 . . . . 55.35 110.171 -178.187 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -71.21 113.08 3.48 Favored 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 121.648 1.566 . . . . 64.32 109.583 167.675 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.459 HD22 HG11 ' A' ' 178' ' ' VAL . 17.2 tp -108.29 157.81 18.03 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 108.264 -1.013 . . . . 74.01 108.264 178.385 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.521 HG23 HD12 ' A' ' 181' ' ' LEU . 3.4 m -95.41 161.0 14.26 Favored 'General case' 0 CA--C 1.544 0.736 0 N-CA-C 109.4 -0.593 . . . . 72.44 109.4 173.629 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.47 HD23 ' HB3' ' A' ' 180' ' ' LEU . 67.7 mt -61.33 -46.17 91.36 Favored 'General case' 0 N--CA 1.476 0.836 0 CA-C-O 121.42 0.629 . . . . 72.32 110.104 175.674 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -60.15 -34.83 74.11 Favored 'General case' 0 N--CA 1.484 1.252 0 CA-C-N 114.636 -1.165 . . . . 73.11 111.871 176.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -72.94 -33.57 66.01 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 123.308 0.643 . . . . 72.13 110.472 177.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.491 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -62.68 -36.68 83.68 Favored 'General case' 0 C--O 1.246 0.891 0 C-N-CA 123.955 0.902 . . . . 72.01 111.883 171.347 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.5 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 31.7 t80 -66.87 -61.28 2.03 Favored 'General case' 0 N--CA 1.472 0.671 0 O-C-N 123.961 0.788 . . . . 72.11 111.72 175.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 40.7 m80 -77.68 -26.32 50.16 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 115.54 -0.754 . . . . 74.5 112.645 -170.088 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 62.68 -121.72 25.87 Favored Glycine 0 C--N 1.349 1.295 0 O-C-N 123.374 0.421 . . . . 53.43 112.281 -175.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 89.59 172.63 45.52 Favored Glycine 0 C--N 1.345 1.059 0 N-CA-C 114.288 0.475 . . . . 75.43 114.288 173.53 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 23.4 mp0 -84.17 136.66 33.88 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 123.512 0.725 . . . . 62.42 109.392 176.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.32 148.12 30.05 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 106.947 -1.501 . . . . 74.53 106.947 170.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 34.7 m -77.41 127.68 38.19 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-O 121.786 0.803 . . . . 70.0 111.643 -173.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.495 HG23 ' HB ' ' A' ' 99' ' ' VAL . 6.7 p -97.54 128.36 48.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.905 -1.146 . . . . 51.44 107.905 170.524 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . 0.445 ' HA ' ' O ' ' A' ' 143' ' ' ARG . 42.4 tt0 -123.27 95.06 4.45 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 107.908 -1.145 . . . . 75.25 107.908 -179.6 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.479 ' O ' ' HG2' ' A' ' 143' ' ' ARG . 15.3 m -136.92 138.16 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 124.714 1.206 . . . . 72.4 108.653 -173.418 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.86 20.41 10.63 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 123.741 0.816 . . . . 64.23 111.864 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.55 1.73 87.52 Favored Glycine 0 C--N 1.349 1.274 0 CA-C-O 119.549 -0.584 . . . . 45.44 113.754 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.479 ' HG2' ' O ' ' A' ' 140' ' ' VAL . 8.5 ptm180 -99.98 127.21 46.22 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 118.066 0.933 . . . . 72.34 109.253 176.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -114.16 113.77 25.14 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 124.073 0.949 . . . . 74.11 108.645 178.032 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 4.1 p -148.71 146.39 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 123.456 0.702 . . . . 75.33 109.912 -178.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 19.7 m -70.03 112.95 6.78 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.025 0.53 . . . . 75.25 110.931 178.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 14.2 p -98.99 137.31 26.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.042 0.537 . . . . 54.33 110.021 175.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 59.1 ttp180 -104.75 122.76 46.38 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 107.455 -1.313 . . . . 75.4 107.455 171.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.621 ' HB ' HD13 ' A' ' 159' ' ' ILE . 28.0 pt -107.46 127.47 27.78 Favored Pre-proline 0 CA--C 1.552 1.024 0 N-CA-C 108.172 -1.047 . . . . 72.43 108.172 172.393 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -53.61 130.85 40.84 Favored 'Trans proline' 0 C--N 1.387 2.594 0 C-N-CA 123.29 2.66 . . . . 64.02 113.914 -171.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -59.81 109.96 0.67 Allowed 'Trans proline' 0 C--N 1.378 2.085 0 C-N-CA 122.486 2.124 . . . . 62.51 109.952 170.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.423 ' HA2' ' CD2' ' A' ' 240' ' ' PHE . . . 139.19 28.48 0.23 Allowed Glycine 0 N--CA 1.468 0.776 0 CA-C-N 116.291 -0.413 . . . . 43.0 112.306 -169.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.556 HG21 HD11 ' A' ' 159' ' ' ILE . 2.1 p -104.94 157.36 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.269 0 N-CA-C 109.815 -0.439 . . . . 74.23 109.815 -173.607 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -139.64 163.95 31.2 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 124.951 1.301 . . . . 74.13 110.635 -165.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 20.3 tp10 -47.32 117.9 1.95 Allowed 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 124.479 1.112 . . . . 64.23 112.779 169.506 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.83 7.58 86.25 Favored Glycine 0 C--N 1.353 1.514 0 CA-C-N 115.573 -0.74 . . . . 62.32 113.978 178.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 33.6 t -76.55 129.51 36.57 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 117.311 0.556 . . . . 74.1 109.861 -178.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.431 HG22 HD22 ' A' ' 175' ' ' LEU . 7.1 p -96.56 131.43 43.35 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.093 0 CA-C-N 115.363 -0.835 . . . . 70.34 109.758 -177.391 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.621 HD13 ' HB ' ' A' ' 149' ' ' ILE . 23.1 mt -116.98 115.8 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 123.675 0.79 . . . . 74.13 110.693 -173.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 18.1 ttm180 -86.78 117.76 25.74 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.059 0.544 . . . . 72.53 110.369 -179.184 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.431 ' HA ' ' HD3' ' A' ' 162' ' ' PRO . 9.0 m -120.29 107.19 39.57 Favored Pre-proline 0 CA--C 1.563 1.446 0 N-CA-C 109.621 -0.511 . . . . 74.45 109.621 178.054 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 7.9 Cg_exo -72.41 152.87 55.38 Favored 'Trans proline' 0 C--N 1.376 2.014 0 C-N-CA 123.105 2.537 . . . . 71.51 112.834 -174.282 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 72.36 24.7 75.9 Favored Glycine 0 C--N 1.35 1.339 0 O-C-N 123.61 0.569 . . . . 52.32 113.126 179.019 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 48.7 tpp -111.08 -37.53 5.32 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.101 0.56 . . . . 55.53 110.6 -178.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.151 0 CA-C-N 116.106 -0.497 . . . . 63.3 113.467 174.926 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo . . . . . 0 CA--C 1.539 0.756 0 N-CA-C 110.995 -0.425 . . . . 64.23 110.995 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -76.12 151.6 40.7 Favored Glycine 0 C--N 1.336 0.579 0 N-CA-C 111.796 -0.522 . . . . 54.32 111.796 174.203 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -103.72 172.74 6.64 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.761 0.825 . . . . 74.21 109.154 178.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.502 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 37.5 tp -129.85 114.37 15.82 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 109.336 -0.616 . . . . 75.3 109.336 170.464 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.711 ' HB2' ' HG3' ' A' ' 120' ' ' ARG . 32.4 mt -85.56 102.39 13.49 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 114.903 -1.044 . . . . 75.2 110.837 176.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.44 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 79.0 mt -91.59 102.55 15.2 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.087 0.955 . . . . 60.01 111.71 179.137 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.644 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 43.3 t -86.48 103.83 13.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 N-CA-C 108.678 -0.86 . . . . 75.24 108.678 174.115 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.459 HG11 HD22 ' A' ' 125' ' ' LEU . 9.4 m -80.01 151.97 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-O 121.683 0.754 . . . . 71.31 112.124 -177.755 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 7.0 mmm180 -124.69 97.44 5.29 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 125.404 1.482 . . . . 73.31 107.598 178.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.47 ' HB3' HD23 ' A' ' 127' ' ' LEU . 54.9 mt -67.15 134.18 51.27 Favored 'General case' 0 CA--C 1.546 0.793 0 O-C-N 123.156 0.285 . . . . 65.2 110.902 -178.47 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.521 HD12 HG23 ' A' ' 126' ' ' THR . 37.1 mt -55.1 146.49 39.44 Favored Pre-proline 0 C--N 1.364 1.222 0 C-N-CA 124.197 0.999 . . . . 74.15 111.379 -174.505 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_exo -70.13 79.07 1.08 Allowed 'Trans proline' 0 C--N 1.376 2.0 0 C-N-CA 123.196 2.597 . . . . 74.24 113.043 -176.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 7.9 p80 -161.31 57.71 0.86 Allowed Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 124.152 0.981 . . . . 74.01 109.457 173.322 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -66.5 122.52 9.97 Favored 'Trans proline' 0 C--N 1.376 2.009 0 C-N-CA 121.976 1.784 . . . . 54.3 112.019 -168.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.459 ' O ' ' HA ' ' A' ' 195' ' ' ALA . 2.9 p -134.92 -41.07 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 C-N-CA 123.364 0.666 . . . . 74.42 109.322 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.451 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 8.8 m-85 -109.89 124.36 51.23 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 122.917 0.487 . . . . 74.02 110.925 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.45 114.79 25.51 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.069 1.348 . . . . 71.42 107.824 175.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 54.9 tp -86.43 144.78 27.13 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 122.897 0.479 . . . . 74.53 110.441 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -142.98 99.87 3.54 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 106.073 -1.825 . . . . 51.1 106.073 177.311 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 65.26 -88.6 0.1 OUTLIER Glycine 0 C--N 1.344 1.003 0 N-CA-C 112.088 -0.405 . . . . 41.2 112.088 -172.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -130.66 -10.69 3.97 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 123.92 0.888 . . . . 72.1 110.58 175.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -85.87 150.41 24.55 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.71 0.804 . . . . 72.01 111.489 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.653 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 95.9 mt -114.91 161.12 18.7 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 124.25 1.02 . . . . 75.02 111.588 -177.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . 0.467 ' HA ' ' O ' ' A' ' 250' ' ' TYR . 89.1 m-85 -140.89 118.41 11.54 Favored 'General case' 0 C--O 1.233 0.227 0 N-CA-C 107.091 -1.448 . . . . 75.01 107.091 173.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . 0.472 ' HB3' HD11 ' A' ' 249' ' ' LEU . . . -141.23 128.7 21.27 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.82 -0.437 . . . . 71.45 109.82 -176.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 14.2 m -76.8 114.92 16.1 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-O 121.163 0.506 . . . . 72.45 110.915 -173.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.526 HD22 HD13 ' A' ' 251' ' ' LEU . 69.3 tp -106.58 113.06 26.34 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.329 1.052 . . . . 73.22 109.689 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -84.51 129.49 34.85 Favored 'General case' 0 C--O 1.242 0.701 0 N-CA-C 109.061 -0.718 . . . . 73.12 109.061 169.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 12.1 m -125.84 141.78 40.33 Favored Pre-proline 0 N--CA 1.48 1.042 0 N-CA-C 108.25 -1.019 . . . . 75.12 108.25 176.238 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -64.67 141.17 71.45 Favored 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 121.693 1.595 . . . . 74.5 110.698 170.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . 0.412 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -55.83 -41.86 93.1 Favored Pre-proline 0 CA--C 1.558 1.288 0 C-N-CA 123.878 0.871 . . . . 72.55 113.308 -178.312 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . 0.425 ' O ' HG22 ' A' ' 206' ' ' VAL . 83.1 Cg_exo -49.04 -47.77 20.56 Favored 'Trans proline' 0 C--N 1.39 2.744 0 C-N-CA 122.434 2.09 . . . . 61.24 114.081 169.101 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . 0.482 ' HA ' ' HA3' ' A' ' 207' ' ' GLY . 5.6 mt -66.46 -44.37 90.51 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 CA-C-N 117.822 0.283 . . . . 73.31 111.252 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -50.69 -43.85 57.78 Favored 'General case' 0 CA--C 1.538 0.514 0 O-C-N 124.546 1.154 . . . . 60.42 111.51 -178.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . 0.644 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 29.6 m -89.34 -59.61 2.74 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.404 0 N-CA-C 113.226 0.824 . . . . 63.43 113.226 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.425 HG22 ' O ' ' A' ' 202' ' ' PRO . 27.3 m -102.39 -24.61 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 N-CA-C 113.537 0.94 . . . . 71.43 113.537 -171.797 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.482 ' HA3' ' HA ' ' A' ' 203' ' ' ILE . . . -75.0 -76.01 0.78 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 121.181 -0.533 . . . . 61.0 111.993 -173.411 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 94.69 -0.36 65.05 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-O 119.155 -0.803 . . . . 75.42 114.02 172.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . 0.462 ' O ' HD13 ' A' ' 203' ' ' ILE . 48.6 mtmt -138.11 132.89 32.71 Favored 'General case' 0 N--CA 1.481 1.082 0 CA-C-N 118.165 0.982 . . . . 62.45 108.838 178.553 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 7.7 p -153.65 141.64 13.44 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 C-N-CA 124.124 0.97 . . . . 63.35 108.758 -174.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 16.6 ptp180 -77.5 148.92 35.06 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 110.172 -0.307 . . . . 74.51 110.172 175.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.454 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -140.1 159.86 41.24 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.33 0.652 . . . . 63.33 109.82 174.342 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -106.28 143.7 34.03 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-N 115.599 -0.728 . . . . 65.42 110.702 179.259 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.451 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 8.9 t -133.4 165.43 24.86 Favored 'General case' 0 C--O 1.24 0.566 0 C-N-CA 124.102 0.961 . . . . 64.41 109.489 171.292 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 81.4 mt -64.44 -14.82 58.89 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.268 1.027 . . . . 72.51 111.789 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -95.86 -21.39 18.11 Favored 'General case' 0 CA--C 1.558 1.281 0 C-N-CA 123.443 0.697 . . . . 53.4 111.787 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.13 -151.66 23.84 Favored Glycine 0 N--CA 1.478 1.438 0 CA-C-O 119.26 -0.744 . . . . 54.12 112.67 -176.405 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -91.76 133.26 1.37 Allowed 'Trans proline' 0 CA--C 1.559 1.752 0 C-N-CA 123.115 2.543 . . . . 35.35 113.695 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 36.0 m -114.89 159.36 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 123.939 0.896 . . . . 61.44 110.495 171.565 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -114.08 113.43 24.72 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 123.859 0.863 . . . . 71.54 109.069 175.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.462 HG22 HD11 ' A' ' 235' ' ' LEU . 20.5 t -95.14 126.24 47.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 123.661 0.785 . . . . 75.42 109.548 -178.615 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -106.5 99.44 9.02 Favored 'General case' 0 C--O 1.24 0.582 0 N-CA-C 107.003 -1.481 . . . . 64.42 107.003 173.311 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.516 HG12 HD13 ' A' ' 233' ' ' LEU . 3.3 m -79.09 132.23 64.06 Favored Pre-proline 0 CA--C 1.553 1.065 0 N-CA-C 108.031 -1.1 . . . . 55.24 108.031 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -56.37 129.61 35.69 Favored 'Trans proline' 0 C--N 1.375 1.956 0 C-N-CA 122.133 1.889 . . . . 74.11 111.665 176.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -42.35 124.27 3.05 Favored 'Trans proline' 0 C--N 1.385 2.462 0 C-N-CA 124.69 3.593 . . . . 62.15 114.361 -173.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . 0.644 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 52.8 mtm180 64.09 73.44 0.43 Allowed 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 124.333 1.053 . . . . 75.3 111.046 -173.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . 0.465 HG23 HD11 ' A' ' 255' ' ' ILE . 8.2 t -88.59 171.99 9.63 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 123.647 0.779 . . . . 73.23 110.457 175.446 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -127.9 140.2 52.15 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 123.741 0.816 . . . . 62.11 109.249 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.53 128.8 37.78 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.228 0.611 . . . . 43.44 109.863 177.594 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.24 -4.07 22.05 Favored Glycine 0 C--N 1.339 0.729 0 O-C-N 123.342 0.401 . . . . 50.01 113.276 -170.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . 0.425 ' O ' HG12 ' A' ' 253' ' ' VAL . 69.5 mtp180 -93.59 162.48 13.94 Favored 'General case' 0 N--CA 1.477 0.902 0 CA-C-N 117.39 0.595 . . . . 71.42 111.553 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.798 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 3.2 mptp? -118.35 104.6 10.89 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 108.946 -0.761 . . . . 72.24 108.946 -176.679 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . 0.548 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 23.4 mt -84.42 115.33 22.48 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.52 0.728 . . . . 62.2 109.898 -172.227 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 58.5 ttt180 -86.67 110.21 19.71 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 123.497 0.719 . . . . 71.22 111.631 -170.476 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.543 HD12 HD23 ' A' ' 249' ' ' LEU . 15.5 mt -99.95 104.0 15.59 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.024 -1.102 . . . . 73.34 108.024 170.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 56.0 mttp -74.66 138.86 43.15 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.942 0.497 . . . . 52.32 111.712 -171.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . 0.441 ' O ' ' HD3' ' A' ' 246' ' ' ARG . . . 80.05 6.84 88.98 Favored Glycine 0 C--N 1.348 1.243 0 O-C-N 123.903 0.752 . . . . 63.42 113.486 178.207 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 33.5 mmtp -106.96 8.59 30.58 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-N 117.263 0.532 . . . . 72.4 111.831 179.092 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -97.35 -178.5 34.2 Favored Glycine 0 C--N 1.344 1.023 0 O-C-N 123.481 0.488 . . . . 60.44 112.03 170.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.562 ' CE1' HD21 ' A' ' 193' ' ' LEU . 25.7 m-85 -76.28 163.1 68.51 Favored Pre-proline 0 CA--C 1.549 0.93 0 C-N-CA 124.257 1.023 . . . . 74.13 112.588 -174.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -52.47 129.05 30.21 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 123.248 2.632 . . . . 75.11 112.804 173.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -156.33 -162.26 11.31 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.091 -0.838 . . . . 75.34 112.043 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -61.39 -30.98 88.14 Favored 'Trans proline' 0 C--N 1.377 2.047 0 C-N-CA 123.465 2.777 . . . . 73.51 112.916 -175.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -90.95 22.13 3.82 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.961 0.905 . . . . 74.23 111.438 179.473 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 82.27 -70.82 3.08 Favored Glycine 0 C--N 1.35 1.307 0 N-CA-C 111.104 -0.798 . . . . 73.11 111.104 -175.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.441 ' HD3' ' O ' ' A' ' 237' ' ' GLY . 78.2 mtt180 -116.32 161.47 18.97 Favored 'General case' 0 C--O 1.243 0.749 0 C-N-CA 124.459 1.103 . . . . 75.31 108.578 172.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -96.13 -158.3 31.93 Favored Glycine 0 C--O 1.243 0.704 0 CA-C-N 115.699 -0.682 . . . . 54.03 112.308 177.38 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -132.35 155.63 48.07 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 109.641 -0.504 . . . . 65.41 109.641 -175.671 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.653 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 14.3 tp -103.25 129.02 50.1 Favored 'General case' 0 C--O 1.214 -0.812 0 C-N-CA 123.648 0.779 . . . . 71.12 109.12 171.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . 0.798 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 92.7 m-85 -115.36 107.64 15.48 Favored 'General case' 0 N--CA 1.477 0.906 0 N-CA-C 108.907 -0.775 . . . . 74.21 108.907 176.693 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.548 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 42.1 mt -87.5 126.15 34.74 Favored 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 123.568 0.747 . . . . 72.42 111.876 -173.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -78.91 90.84 4.74 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 107.366 -1.346 . . . . 75.12 107.366 176.03 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.425 HG12 ' O ' ' A' ' 231' ' ' ARG . 2.8 p -63.29 124.12 17.35 Favored 'Isoleucine or valine' 0 C--O 1.239 0.55 0 CA-C-O 121.802 0.81 . . . . 73.22 110.472 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 29.7 mmm180 -124.25 95.34 4.51 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 107.574 -1.269 . . . . 72.55 107.574 -178.527 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.465 HD11 HG23 ' A' ' 227' ' ' THR . 69.1 mt -75.83 107.14 6.34 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 115.204 -0.907 . . . . 50.03 109.394 -177.725 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.2 t . . . . . 0 CA--C 1.549 0.928 0 C-N-CA 124.539 1.136 . . . . 72.5 109.139 -179.317 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.643 ' HG ' ' HG2' ' A' ' 136' ' ' ARG . 68.2 mt . . . . . 0 N--CA 1.481 1.097 0 N-CA-C 110.449 -0.204 . . . . 75.51 110.449 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.451 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 11.8 p -56.28 134.62 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 O-C-N 123.858 0.724 . . . . 61.31 111.531 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.96 -60.73 2.19 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 108.746 -0.835 . . . . 53.13 108.746 174.661 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 31.2 m80 -162.94 159.48 23.66 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 124.98 1.312 . . . . 64.13 108.82 -177.635 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.477 ' HA ' ' HB2' ' A' ' 121' ' ' ALA . 13.0 p -78.0 127.7 38.44 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.007 0 CA-C-O 121.025 0.44 . . . . 62.55 110.451 178.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.471 HG23 ' HA ' ' A' ' 121' ' ' ALA . 43.8 p . . . . . 0 N--CA 1.475 0.799 0 C-N-CA 123.537 0.735 . . . . 62.44 110.474 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.0 p30 . . . . . 0 C--O 1.243 0.741 0 N-CA-C 107.734 -1.21 . . . . 64.35 107.734 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.517 HD13 HG23 ' A' ' 140' ' ' VAL . 39.7 mt -95.04 139.02 31.98 Favored 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 107.402 -1.332 . . . . 74.24 107.402 -176.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -146.3 135.8 23.03 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.379 -0.971 . . . . 61.5 108.379 178.403 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.477 ' HB2' ' HA ' ' A' ' 102' ' ' VAL . . . -156.95 139.2 14.67 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.189 -0.671 . . . . 75.53 109.189 -171.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -96.7 148.02 23.31 Favored 'General case' 0 C--O 1.244 0.764 0 N-CA-C 109.38 -0.6 . . . . 62.34 109.38 173.422 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.627 HD12 ' HB3' ' A' ' 98' ' ' LEU . 1.6 pt? -144.12 132.18 10.84 Favored Pre-proline 0 N--CA 1.473 0.71 0 CA-C-N 115.991 -0.55 . . . . 61.42 110.83 -171.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -68.5 117.2 4.82 Favored 'Trans proline' 0 C--N 1.374 1.895 0 C-N-CA 121.963 1.775 . . . . 75.52 110.932 174.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.473 HD22 HG11 ' A' ' 178' ' ' VAL . 16.0 tp -119.8 150.56 40.22 Favored 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 108.828 -0.804 . . . . 62.31 108.828 178.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.498 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 10.5 m -89.16 158.28 17.97 Favored 'General case' 0 CA--C 1.547 0.854 0 N-CA-C 109.31 -0.626 . . . . 65.34 109.31 175.345 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.474 HD11 ' O ' ' A' ' 183' ' ' HIS . 55.9 mt -54.56 -51.32 65.6 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 123.886 0.875 . . . . 74.21 111.062 177.317 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.436 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 2.1 mp0 -55.67 -37.59 68.5 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 114.325 -1.307 . . . . 74.34 111.024 176.834 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.498 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 10.3 mm-40 -79.18 -18.12 53.64 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.557 0.743 . . . . 64.31 111.313 -177.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.678 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -66.12 -42.37 89.27 Favored 'General case' 0 C--O 1.252 1.221 0 CA-C-O 121.004 0.43 . . . . 72.03 110.951 165.785 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -65.02 -48.88 72.32 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 115.824 -0.626 . . . . 73.31 111.318 172.507 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.6 m80 -73.82 -48.07 34.02 Favored 'General case' 0 N--CA 1.481 1.116 0 O-C-N 123.773 0.671 . . . . 70.03 111.839 -171.444 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 58.51 -109.54 2.03 Favored Glycine 0 CA--C 1.533 1.176 0 N-CA-C 111.351 -0.7 . . . . 72.51 111.351 -172.199 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.21 -162.89 50.13 Favored Glycine 0 C--N 1.346 1.106 0 N-CA-C 114.983 0.753 . . . . 73.33 114.983 166.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -79.06 135.97 37.03 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 124.424 1.09 . . . . 73.42 110.989 -174.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.643 ' HG2' ' HG ' ' A' ' 98' ' ' LEU . 13.8 tpt180 -156.86 167.97 28.87 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.137 0.975 . . . . 72.12 109.215 175.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.0 p -110.25 136.72 45.36 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 CA-C-O 121.148 0.499 . . . . 72.34 110.613 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 15.5 m -121.23 137.81 53.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 C-N-CA 124.011 0.925 . . . . 71.44 108.864 172.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -126.47 98.44 5.42 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-O 121.894 0.854 . . . . 63.51 109.228 171.368 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.517 HG23 HD13 ' A' ' 119' ' ' LEU . 10.6 m -130.24 139.41 51.47 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 124.517 1.127 . . . . 63.2 108.63 -179.161 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.54 24.77 14.17 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 124.256 1.023 . . . . 74.42 111.465 -176.234 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.11 -3.9 74.18 Favored Glycine 0 C--N 1.351 1.406 0 CA-C-N 115.809 -0.632 . . . . 71.03 113.038 -177.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -97.17 116.37 29.26 Favored 'General case' 0 C--N 1.346 0.456 0 C-N-CA 123.409 0.684 . . . . 75.11 109.425 -176.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 44.1 ttm180 -101.45 106.12 17.21 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 108.598 -0.89 . . . . 73.55 108.598 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 38.5 t -127.74 142.85 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 124.025 0.93 . . . . 43.42 109.223 -177.311 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 9.6 p -77.28 114.5 16.17 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 123.28 0.632 . . . . 62.51 110.041 175.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.8 p -98.88 136.43 29.93 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 C-N-CA 123.808 0.843 . . . . 72.15 110.345 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 59.6 ttp180 -111.2 95.44 5.53 Favored 'General case' 0 C--O 1.242 0.705 0 N-CA-C 108.227 -1.027 . . . . 72.34 108.227 168.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.413 ' HB ' HD13 ' A' ' 159' ' ' ILE . 34.9 pt -82.48 128.5 66.62 Favored Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 108.492 -0.929 . . . . 71.33 108.492 175.067 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -68.98 147.19 67.35 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.41 2.073 . . . . 74.31 113.059 -168.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -64.32 111.91 1.76 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 122.362 2.041 . . . . 72.01 110.636 172.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.771 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 142.23 30.45 0.13 Allowed Glycine 0 C--N 1.354 1.578 0 C-N-CA 121.435 -0.412 . . . . 74.32 114.051 -174.632 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.678 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.0 p -106.26 164.57 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.683 0 C-N-CA 123.506 0.722 . . . . 73.22 109.891 -176.166 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 52.9 mtm-85 -144.56 167.19 23.1 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 125.106 1.363 . . . . 71.43 108.979 -172.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . 0.453 ' HB2' ' HB2' ' A' ' 180' ' ' LEU . 13.3 tp10 -54.82 122.48 10.86 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 123.329 0.651 . . . . 75.42 110.14 168.218 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 89.12 -11.6 68.94 Favored Glycine 0 C--N 1.344 0.983 0 CA-C-O 119.632 -0.538 . . . . 75.22 113.395 179.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 35.0 t -70.86 129.53 39.31 Favored 'General case' 0 C--O 1.245 0.863 0 CA-C-N 117.206 0.503 . . . . 71.2 109.756 -178.015 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.546 HG12 HD22 ' A' ' 175' ' ' LEU . 18.6 t -104.01 119.37 52.64 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 CA-C-N 114.386 -1.279 . . . . 53.22 109.073 -173.068 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.516 HD11 HG21 ' A' ' 153' ' ' VAL . 23.4 mt -103.13 117.45 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 C-N-CA 123.803 0.841 . . . . 71.42 110.023 -171.095 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 55.9 ttt85 -90.52 111.64 23.01 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 123.686 0.794 . . . . 63.32 110.226 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.3 m -120.31 102.37 45.79 Favored Pre-proline 0 CA--C 1.568 1.665 0 C-N-CA 122.618 0.367 . . . . 60.23 110.611 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -63.56 150.99 87.11 Favored 'Trans proline' 0 C--N 1.375 1.93 0 C-N-CA 122.938 2.425 . . . . 62.22 113.175 -177.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 106.11 -26.11 21.57 Favored Glycine 0 CA--C 1.535 1.329 0 CA-C-O 119.038 -0.868 . . . . 72.44 114.777 177.024 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -81.24 -55.15 4.92 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-N 118.674 1.237 . . . . 65.05 111.23 -178.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.348 1.219 0 CA-C-N 115.993 -0.549 . . . . 74.01 113.755 -177.792 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo . . . . . 0 CA--C 1.55 1.288 0 N-CA-C 111.489 -0.235 . . . . 74.52 111.489 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -65.49 -171.54 3.38 Favored Glycine 0 C--N 1.346 1.106 0 CA-C-N 115.866 -0.606 . . . . 63.01 113.943 -177.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 10.5 p-10 -108.58 172.9 6.57 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 123.828 0.851 . . . . 54.14 112.129 -168.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 19.2 tp -120.41 116.76 26.11 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 114.44 -1.255 . . . . 70.25 107.867 172.205 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.546 HD22 HG12 ' A' ' 158' ' ' VAL . 65.3 mt -88.11 100.03 12.64 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.982 0.913 . . . . 74.13 110.901 177.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 70.8 mt -91.46 104.9 17.36 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 123.222 0.609 . . . . 72.41 111.044 176.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.407 HG22 HG13 ' A' ' 158' ' ' VAL . 12.4 t -91.58 101.11 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 108.399 -0.963 . . . . 70.23 108.399 177.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.473 HG11 HD22 ' A' ' 125' ' ' LEU . 3.7 m -76.84 150.12 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 CA-C-O 121.612 0.72 . . . . 64.01 112.16 -172.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 42.8 mmt180 -116.18 91.55 3.63 Favored 'General case' 0 C--O 1.238 0.448 0 C-N-CA 125.352 1.461 . . . . 75.45 107.686 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.453 ' HB2' ' HB2' ' A' ' 155' ' ' GLU . 21.3 mt -69.9 148.77 48.58 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 120.716 0.293 . . . . 72.45 110.28 175.431 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.1 mt -54.74 144.41 45.8 Favored Pre-proline 0 CA--C 1.556 1.195 0 C-N-CA 123.927 0.891 . . . . 65.45 112.131 -175.319 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.462 ' O ' ' HD3' ' A' ' 184' ' ' PRO . 23.9 Cg_exo -65.62 1.4 2.21 Favored 'Trans proline' 0 C--N 1.385 2.474 0 C-N-CA 123.529 2.819 . . . . 61.34 113.347 175.52 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . 0.474 ' O ' HD11 ' A' ' 127' ' ' LEU . 8.4 t60 -91.36 98.31 1.7 Allowed Pre-proline 0 CA--C 1.549 0.93 0 N-CA-C 107.546 -1.279 . . . . 71.1 107.546 159.34 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 182' ' ' PRO . 60.6 Cg_endo -102.16 124.7 0.09 OUTLIER 'Trans proline' 0 C--N 1.37 1.665 0 C-N-CA 122.913 2.408 . . . . 72.44 111.729 168.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -114.28 -42.2 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 CA-C-O 121.348 0.594 . . . . 73.15 109.728 177.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.482 ' HD2' HD22 ' A' ' 193' ' ' LEU . 5.5 m-85 -101.54 125.44 48.19 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 115.562 -0.745 . . . . 74.4 109.96 -177.384 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 37.2 ttp-105 -98.74 111.98 24.19 Favored 'General case' 0 C--O 1.243 0.758 0 N-CA-C 107.167 -1.419 . . . . 63.42 107.167 169.597 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 54.2 tp -83.45 116.99 22.77 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 108.443 -0.947 . . . . 62.25 108.443 172.482 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -126.76 99.21 5.67 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 124.488 1.115 . . . . 63.5 108.253 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 55.87 56.49 23.65 Favored Glycine 0 C--N 1.353 1.475 0 CA-C-O 119.504 -0.609 . . . . 62.22 113.76 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 69.13 -6.16 0.96 Allowed 'General case' 0 N--CA 1.504 2.25 0 C-N-CA 125.281 1.432 . . . . 63.32 113.15 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -97.82 150.12 21.61 Favored 'General case' 0 C--N 1.35 0.616 0 C-N-CA 124.864 1.266 . . . . 74.02 108.756 -178.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.595 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 94.9 mt -111.43 148.98 31.92 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 121.616 0.722 . . . . 64.0 112.418 -176.246 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -132.96 121.33 22.64 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 114.062 -1.427 . . . . 75.44 107.728 171.182 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -132.9 170.51 15.22 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 124.294 1.038 . . . . 55.52 109.071 177.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 54.9 m -109.96 133.38 53.24 Favored 'General case' 0 CA--C 1.537 0.449 0 N-CA-C 109.034 -0.728 . . . . 73.15 109.034 172.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . . . . . . . . . 52.5 tp -112.51 112.11 23.42 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 108.466 -0.938 . . . . 71.23 108.466 175.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -90.77 102.46 15.22 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 108.824 -0.806 . . . . 64.44 108.824 175.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . 0.402 HG21 HG11 ' A' ' 223' ' ' VAL . 7.7 p -109.3 131.88 21.59 Favored Pre-proline 0 CA--C 1.548 0.882 0 CA-C-N 114.98 -1.009 . . . . 72.21 109.291 -176.508 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -56.32 145.34 78.57 Favored 'Trans proline' 0 C--N 1.373 1.847 0 C-N-CA 122.785 2.323 . . . . 74.01 113.181 174.051 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . 0.463 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -54.73 -45.86 99.52 Favored Pre-proline 0 CA--C 1.563 1.465 0 C-N-CA 124.112 0.965 . . . . 74.54 113.4 176.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . 0.42 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 26.0 Cg_endo -58.76 -44.18 38.25 Favored 'Trans proline' 0 C--N 1.392 2.826 0 C-N-CA 122.014 1.809 . . . . 72.55 111.941 175.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.5 mt -63.68 -37.62 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 C-N-CA 123.105 0.562 . . . . 61.24 110.931 178.788 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -61.89 -46.76 87.97 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.436 0.695 . . . . 75.24 112.011 -177.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.3 m -77.08 -36.91 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 N-CA-C 112.235 0.457 . . . . 71.11 112.235 -177.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m -80.57 -25.24 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 CA-C-O 120.838 0.351 . . . . 74.01 110.978 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.498 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 72.93 69.4 1.4 Allowed Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.421 -0.809 . . . . 62.32 112.244 -173.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -96.08 -149.17 25.28 Favored Glycine 0 C--N 1.352 1.452 0 CA-C-O 121.312 0.395 . . . . 55.22 113.117 -178.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 53.1 tttp -125.82 125.93 43.69 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 124.845 1.258 . . . . 73.03 108.792 -172.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . 0.506 HG23 HG13 ' A' ' 221' ' ' VAL . 11.4 m -130.5 163.2 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.203 1.001 . . . . 64.02 108.598 173.474 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 39.0 ptt85 -104.57 148.16 26.82 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 109.665 -0.495 . . . . 74.34 109.665 176.08 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -120.45 135.23 55.12 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 108.852 -0.795 . . . . 62.1 108.852 174.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 5.0 tpt -87.02 107.57 18.48 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 108.906 -0.776 . . . . 74.3 108.906 178.368 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.44 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 14.6 t -110.33 168.62 9.31 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 121.075 0.464 . . . . 71.51 109.78 174.287 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . 0.436 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 61.9 mt -74.55 -9.91 59.03 Favored 'General case' 0 CA--C 1.542 0.653 0 CA-C-N 115.667 -0.697 . . . . 64.32 112.519 -173.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -86.36 -21.75 27.03 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.598 0.759 . . . . 73.05 110.625 173.429 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 139.96 -169.73 24.57 Favored Glycine 0 C--N 1.345 1.032 0 N-CA-C 111.281 -0.728 . . . . 74.31 111.281 -173.645 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -76.01 126.85 9.6 Favored 'Trans proline' 0 C--N 1.363 1.336 0 C-N-CA 122.42 2.08 . . . . 65.13 112.015 176.049 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 33.4 m -110.25 163.53 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 123.549 0.74 . . . . 74.34 109.268 171.592 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -114.04 127.24 55.85 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.41 -0.589 . . . . 74.23 109.41 174.48 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.541 ' HB ' HD11 ' A' ' 235' ' ' LEU . 3.2 p -120.76 118.44 56.44 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 C-N-CA 123.818 0.847 . . . . 64.25 110.007 175.194 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.37 113.5 24.81 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 108.24 -1.022 . . . . 70.41 108.24 174.338 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.498 HG23 ' HA2' ' A' ' 207' ' ' GLY . 10.4 m -73.31 139.71 78.96 Favored Pre-proline 0 CA--C 1.553 1.096 0 N-CA-C 108.751 -0.833 . . . . 71.15 108.751 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -74.52 145.39 33.37 Favored 'Trans proline' 0 CA--C 1.557 1.674 0 C-N-CA 122.143 1.895 . . . . 53.42 111.309 178.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_exo -54.32 130.36 39.43 Favored 'Trans proline' 0 C--N 1.38 2.235 0 C-N-CA 123.325 2.683 . . . . 73.22 113.247 -179.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 61.69 61.28 1.47 Allowed 'General case' 0 N--CA 1.477 0.892 0 O-C-N 124.639 1.212 . . . . 73.33 111.201 -176.212 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.9 t -87.81 172.04 9.94 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 109.56 -0.533 . . . . 72.22 109.56 172.37 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . 0.547 HE21 ' HD2' ' A' ' 231' ' ' ARG . 1.9 mp0 -130.66 153.25 49.15 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 108.72 -0.845 . . . . 65.22 108.72 -178.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -72.36 139.69 48.02 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 122.779 0.432 . . . . 74.32 110.028 176.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 101.75 -6.84 55.01 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 116.052 -0.522 . . . . 70.11 112.395 -178.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . 0.547 ' HD2' HE21 ' A' ' 228' ' ' GLN . 58.6 mtp180 -82.48 160.72 22.6 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.006 0.522 . . . . 71.02 110.251 179.081 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.481 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 11.9 mptt -118.3 116.97 27.85 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.828 0.851 . . . . 60.35 109.73 -178.293 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 73.6 mt -92.0 107.42 19.2 Favored 'General case' 0 C--O 1.24 0.603 0 N-CA-C 107.265 -1.383 . . . . 72.43 107.265 175.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . 0.446 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 66.5 ttt180 -88.56 103.14 15.62 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.362 -0.835 . . . . 75.11 110.313 -166.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.541 HD11 ' HB ' ' A' ' 221' ' ' VAL . 33.3 mt -93.28 97.58 10.71 Favored 'General case' 0 C--N 1.348 0.508 0 N-CA-C 108.706 -0.85 . . . . 62.4 108.706 178.076 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . 0.57 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 10.3 mtmp? -81.38 144.38 31.48 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.332 -0.849 . . . . 44.51 111.525 -172.524 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 76.46 18.39 79.16 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.499 -0.773 . . . . 75.41 112.817 -172.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 73.1 mmtt -121.05 7.11 10.3 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.278 0.631 . . . . 71.33 111.934 -178.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . 0.411 ' HA2' ' CD1' ' A' ' 193' ' ' LEU . . . -92.22 -169.44 40.73 Favored Glycine 0 C--N 1.338 0.681 0 O-C-N 123.578 0.549 . . . . 53.22 112.131 174.679 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.771 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 3.9 m-85 -76.77 144.23 72.64 Favored Pre-proline 0 CA--C 1.547 0.849 0 C-N-CA 122.302 0.241 . . . . 71.2 110.614 -175.634 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.89 127.73 21.22 Favored 'Trans proline' 0 C--N 1.377 2.055 0 C-N-CA 122.885 2.39 . . . . 62.1 111.646 176.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -164.36 -154.09 7.71 Favored Glycine 0 CA--C 1.537 1.458 0 CA-C-O 119.448 -0.64 . . . . 71.3 113.298 -174.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -60.67 -24.28 78.17 Favored 'Trans proline' 0 C--N 1.379 2.166 0 C-N-CA 124.263 3.309 . . . . 72.44 114.164 -178.111 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.0 23.01 5.21 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 123.453 0.701 . . . . 74.32 111.461 176.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 74.33 -78.54 0.97 Allowed Glycine 0 C--N 1.348 1.206 0 N-CA-C 110.938 -0.865 . . . . 73.02 110.938 -173.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 12.8 ttt85 -129.65 141.74 50.86 Favored 'General case' 0 CA--C 1.546 0.8 0 N-CA-C 108.348 -0.982 . . . . 72.24 108.348 172.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.74 -156.78 5.28 Favored Glycine 0 N--CA 1.475 1.252 0 N-CA-C 113.805 0.282 . . . . 74.22 113.805 -178.032 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . 0.57 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 0.7 OUTLIER -148.44 156.46 42.51 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 123.125 0.57 . . . . 65.22 111.281 179.39 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.595 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 28.5 tp -110.42 133.63 53.09 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.73 1.212 . . . . 74.02 111.196 -172.137 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -106.21 107.2 18.09 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.147 0.979 . . . . 72.32 109.402 174.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.481 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 84.8 mt -87.56 115.57 25.08 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.1 0.56 . . . . 73.11 111.839 176.546 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -79.89 93.74 5.72 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 108.472 -0.936 . . . . 74.32 108.472 179.056 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 59.6 t -48.18 121.0 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.553 1.141 . . . . 40.05 110.659 174.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 25.6 mmm180 -128.9 95.45 4.09 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.194 -1.41 . . . . 74.14 107.194 177.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.463 HG23 ' HA ' ' A' ' 201' ' ' ALA . 66.5 mt -75.32 120.38 24.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-N 114.898 -1.046 . . . . 73.22 109.407 -176.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.556 1.189 0 C-N-CA 123.637 0.775 . . . . 74.14 109.315 -173.697 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.53 HD23 HH11 ' A' ' 136' ' ' ARG . 55.1 tp . . . . . 0 N--CA 1.478 0.961 0 N-CA-C 109.928 -0.397 . . . . 61.25 109.928 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.568 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 8.1 p -87.54 158.81 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 C-N-CA 123.216 0.606 . . . . 64.53 110.093 168.598 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -88.82 -89.62 0.14 Allowed 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 123.278 0.631 . . . . 62.32 109.896 170.241 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -160.74 176.52 11.41 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 125.106 1.363 . . . . 72.21 108.915 -174.443 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 9.1 p -68.68 125.62 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 CA-C-O 121.224 0.535 . . . . 74.31 110.557 178.186 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 81.9 p . . . . . 0 CA--C 1.547 0.833 0 C-N-CA 124.122 0.969 . . . . 65.35 109.826 175.45 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 . . . . . 0 C--O 1.241 0.649 0 CA-C-O 121.518 0.675 . . . . 62.41 110.603 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.532 HD12 ' HA2' ' A' ' 165' ' ' GLY . 14.5 mt -104.53 155.11 19.1 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.179 -1.415 . . . . 72.43 107.179 162.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 10.8 ttm180 -145.11 118.26 8.89 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 108.87 -0.789 . . . . 73.35 108.87 -175.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.412 ' HB3' HD23 ' A' ' 176' ' ' LEU . . . -141.37 141.61 33.8 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 123.702 0.801 . . . . 61.32 109.724 -176.577 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.709 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 39.4 mt-10 -116.95 149.82 39.55 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.066 0.546 . . . . 73.04 110.811 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.568 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.6 pt? -145.85 144.89 23.29 Favored Pre-proline 0 N--CA 1.471 0.599 0 CA-C-N 115.392 -0.822 . . . . 72.23 110.873 -179.44 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -77.55 115.3 3.86 Favored 'Trans proline' 0 C--N 1.371 1.739 0 C-N-CA 121.825 1.683 . . . . 63.14 110.711 168.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.554 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 15.7 tp -107.37 154.1 21.8 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.532 0.733 . . . . 65.55 109.407 179.36 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.573 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 11.5 m -87.74 160.97 17.86 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.137 0.575 . . . . 65.52 109.527 175.455 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.504 HD13 HG12 ' A' ' 185' ' ' VAL . 30.2 mt -63.07 -48.96 76.42 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 123.884 0.874 . . . . 65.51 110.562 178.58 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -57.28 -31.59 65.76 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 114.777 -1.101 . . . . 72.5 110.937 176.621 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.573 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 8.8 mm-40 -83.82 -23.99 31.17 Favored 'General case' 0 C--O 1.212 -0.869 0 C-N-CA 122.996 0.519 . . . . 73.45 111.054 -179.091 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.7 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -60.62 -35.21 75.6 Favored 'General case' 0 C--O 1.248 1.015 0 CA-C-O 121.804 0.811 . . . . 70.51 110.3 165.536 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.526 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 55.3 t80 -72.03 -47.42 51.9 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.419 -1.264 . . . . 71.21 111.82 172.213 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.3 m80 -83.96 -16.82 42.71 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 113.283 0.846 . . . . 70.1 113.283 -171.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 89.75 -117.72 5.06 Favored Glycine 0 CA--C 1.535 1.326 0 N-CA-C 111.987 -0.445 . . . . 43.54 111.987 -170.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 148.91 94.01 0.12 Allowed Glycine 0 C--N 1.353 1.488 0 CA-C-N 117.828 0.814 . . . . 73.44 113.571 175.12 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -85.21 123.06 30.28 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 123.273 0.629 . . . . 63.35 109.397 175.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.577 ' NH2' HD13 ' A' ' 176' ' ' LEU . 16.9 ptt-85 -148.65 168.45 22.81 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.204 0.602 . . . . 53.35 111.526 -170.157 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 23.1 m -89.84 106.23 16.93 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 CA-C-N 115.022 -0.99 . . . . 75.43 108.624 169.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.552 HG21 HD21 ' A' ' 174' ' ' LEU . 7.4 p -98.89 123.1 51.3 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 123.153 0.581 . . . . 61.14 109.789 -179.38 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -119.03 98.73 6.32 Favored 'General case' 0 C--O 1.241 0.614 0 C-N-CA 124.256 1.023 . . . . 73.41 109.186 -178.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.433 HG21 HD22 ' A' ' 174' ' ' LEU . 8.6 m -131.8 121.45 47.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 124.457 1.103 . . . . 70.53 109.919 -173.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.25 22.84 13.55 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 124.533 1.133 . . . . 73.12 111.954 -178.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 88.8 2.39 78.64 Favored Glycine 0 C--N 1.345 1.067 0 CA-C-O 119.815 -0.436 . . . . 72.13 113.388 -177.17 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -92.8 113.92 26.33 Favored 'General case' 0 C--N 1.348 0.515 0 N-CA-C 108.625 -0.88 . . . . 74.41 108.625 175.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 59.9 ttp180 -106.22 110.85 23.22 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 108.116 -1.068 . . . . 62.22 108.116 176.1 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 5.7 m -141.38 155.72 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 124.52 1.128 . . . . 74.14 109.078 -177.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 47.4 t -87.21 115.5 24.65 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.128 -0.693 . . . . 65.22 109.128 177.312 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.2 p -99.33 136.66 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-O 121.095 0.474 . . . . 52.22 110.718 179.167 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.5 ttp180 -110.29 98.76 7.92 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 107.743 -1.206 . . . . 74.22 107.743 172.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.473 HD13 HH12 ' A' ' 136' ' ' ARG . 28.9 pt -89.88 131.24 39.99 Favored Pre-proline 0 N--CA 1.475 0.809 0 N-CA-C 108.684 -0.858 . . . . 73.33 108.684 177.27 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -72.01 157.7 53.98 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.45 2.1 . . . . 72.33 112.828 -172.1 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -68.5 148.17 72.39 Favored 'Trans proline' 0 C--N 1.375 1.959 0 C-N-CA 122.283 1.988 . . . . 74.12 111.356 172.204 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 100.04 41.49 2.83 Favored Glycine 0 C--N 1.34 0.786 0 N-CA-C 110.988 -0.845 . . . . 65.13 110.988 -176.504 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.7 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -111.37 160.74 10.47 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.267 0 N-CA-C 108.265 -1.013 . . . . 72.43 108.265 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.401 ' HD3' ' HB3' ' A' ' 188' ' ' LEU . 74.8 mtm180 -148.47 176.74 10.05 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 123.909 0.884 . . . . 72.01 111.735 -166.118 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -55.61 115.74 2.51 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 114.214 -1.357 . . . . 50.22 111.072 170.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 75.89 10.22 85.06 Favored Glycine 0 C--N 1.345 1.053 0 O-C-N 123.601 0.563 . . . . 34.52 113.683 178.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 37.5 t -75.13 125.97 30.05 Favored 'General case' 0 C--O 1.245 0.819 0 C-N-CA 122.97 0.508 . . . . 71.05 109.906 -178.797 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.446 HG12 HD22 ' A' ' 175' ' ' LEU . 21.2 t -95.83 121.57 46.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 C-N-CA 124.719 1.208 . . . . 74.45 109.457 -175.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.538 HD11 HG21 ' A' ' 153' ' ' VAL . 27.3 mt -107.28 111.21 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 123.46 0.704 . . . . 51.42 109.634 -174.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 25.1 ttp180 -84.83 117.76 24.07 Favored 'General case' 0 CA--C 1.538 0.493 0 O-C-N 123.655 0.597 . . . . 63.32 109.989 179.192 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.5 m -114.86 96.47 44.67 Favored Pre-proline 0 CA--C 1.561 1.394 0 CA-C-O 121.431 0.634 . . . . 71.24 109.419 175.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -63.22 136.61 56.68 Favored 'Trans proline' 0 C--N 1.379 2.153 0 C-N-CA 123.391 2.727 . . . . 72.54 113.224 -175.616 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.59 -17.14 59.43 Favored Glycine 0 C--N 1.345 1.064 0 N-CA-C 114.39 0.516 . . . . 43.33 114.39 174.51 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 10.4 mtm -100.69 -6.29 25.31 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 117.718 0.759 . . . . 65.1 112.187 -174.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . 0.532 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.351 1.391 0 N-CA-C 111.813 -0.515 . . . . 75.52 111.813 175.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo . . . . . 0 CA--C 1.541 0.852 0 CA-C-O 121.047 0.353 . . . . 74.43 111.688 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -98.63 151.93 19.64 Favored Glycine 0 N--CA 1.452 -0.294 0 N-CA-C 110.123 -1.191 . . . . 74.12 110.123 171.039 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -116.49 167.83 10.71 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 124.422 1.089 . . . . 74.44 109.751 -173.598 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.552 HD21 HG21 ' A' ' 138' ' ' VAL . 11.8 tp -120.22 129.64 54.17 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.167 -1.049 . . . . 62.1 108.167 176.479 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.446 HD22 HG12 ' A' ' 158' ' ' VAL . 83.1 mt -103.79 98.6 8.43 Favored 'General case' 0 C--O 1.233 0.212 0 C-N-CA 124.345 1.058 . . . . 54.05 109.636 -175.39 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.577 HD13 ' NH2' ' A' ' 136' ' ' ARG . 45.4 mt -92.88 101.23 13.59 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.357 -0.838 . . . . 70.11 109.649 178.827 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.709 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 25.5 t -90.71 107.65 18.78 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 N-CA-C 108.422 -0.955 . . . . 71.12 108.422 179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.554 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 3.2 m -87.43 148.93 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 109.463 -0.569 . . . . 61.34 109.463 -177.733 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 10.0 mmm-85 -123.51 104.17 8.9 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 107.466 -1.309 . . . . 74.22 107.466 -174.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 27.4 mt -69.15 151.55 46.22 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-O 121.213 0.53 . . . . 64.21 111.3 -178.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 52.9 mt -54.56 150.7 16.59 Favored Pre-proline 0 CA--C 1.561 1.397 0 CA-C-N 114.608 -1.178 . . . . 72.11 112.383 -177.172 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -61.1 -8.05 9.26 Favored 'Trans proline' 0 C--N 1.385 2.489 0 C-N-CA 123.144 2.562 . . . . 74.02 113.459 177.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . 0.472 ' O ' HD11 ' A' ' 127' ' ' LEU . 5.2 t60 -93.44 104.83 13.53 Favored Pre-proline 0 CA--C 1.544 0.743 0 C-N-CA 124.436 1.094 . . . . 72.32 108.726 164.011 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -101.16 128.82 0.13 Allowed 'Trans proline' 0 CA--C 1.559 1.746 0 C-N-CA 123.379 2.72 . . . . 61.32 112.486 165.69 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.504 HG12 HD13 ' A' ' 127' ' ' LEU . 2.6 p -113.85 -46.21 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 122.899 0.48 . . . . 74.04 109.998 172.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -98.98 122.68 42.55 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.031 0.443 . . . . 74.31 110.774 -174.195 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.63 ' HB3' ' HB2' ' A' ' 194' ' ' TYR . 28.7 ttm180 -97.88 109.13 21.94 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 107.6 -1.259 . . . . 75.21 107.6 170.536 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.401 ' HB3' ' HD3' ' A' ' 154' ' ' ARG . 50.1 tp -89.56 112.62 23.87 Favored 'General case' 0 CA--C 1.543 0.702 0 N-CA-C 108.597 -0.89 . . . . 61.13 108.597 173.515 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -108.97 102.13 11.16 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 108.291 -1.003 . . . . 74.4 108.291 176.162 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 72.16 -87.41 0.49 Allowed Glycine 0 C--N 1.347 1.166 0 O-C-N 123.704 0.627 . . . . 71.4 111.765 -174.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 5.0 pm0 -134.01 -4.94 2.75 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 124.17 0.988 . . . . 73.33 110.574 178.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 56.5 m-20 -93.66 151.4 19.68 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.598 0.759 . . . . 71.45 111.198 -177.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.425 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 88.8 mt -107.44 147.07 30.9 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 124.372 1.069 . . . . 72.3 109.429 -178.493 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . 0.63 ' HB2' ' HB3' ' A' ' 187' ' ' ARG . 89.4 m-85 -133.46 121.07 21.69 Favored 'General case' 0 C--O 1.232 0.182 0 N-CA-C 107.389 -1.337 . . . . 75.31 107.389 175.233 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -134.76 170.88 15.16 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 123.916 0.886 . . . . 73.43 108.892 178.126 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 87.1 m -109.55 124.2 50.71 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.64 -0.709 . . . . 52.04 109.288 175.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.417 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 57.6 tp -107.06 111.75 24.36 Favored 'General case' 0 C--O 1.225 -0.201 0 C-N-CA 124.154 0.982 . . . . 74.52 109.106 177.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -87.45 125.53 34.34 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 107.758 -1.201 . . . . 75.13 107.758 172.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . 0.495 HG12 HG21 ' A' ' 210' ' ' VAL . 15.4 m -120.15 135.19 24.23 Favored Pre-proline 0 N--CA 1.475 0.82 0 N-CA-C 108.901 -0.777 . . . . 75.23 108.901 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -57.69 140.21 92.79 Favored 'Trans proline' 0 C--N 1.367 1.549 0 C-N-CA 122.314 2.01 . . . . 65.25 111.624 169.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -50.24 -44.21 80.33 Favored Pre-proline 0 CA--C 1.567 1.621 0 CA-C-O 118.057 -0.973 . . . . 63.33 113.069 179.384 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo -47.59 -52.61 7.75 Favored 'Trans proline' 0 C--N 1.404 3.485 0 C-N-CA 122.816 2.344 . . . . 74.31 112.754 168.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 11.8 mt -68.34 -33.4 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 C-N-CA 123.079 0.552 . . . . 70.41 111.7 -176.316 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.61 -47.97 83.51 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.329 0.651 . . . . 74.04 110.863 178.227 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . 0.457 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 32.8 m -81.78 -35.57 13.66 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.898 0 CA-C-N 115.695 -0.684 . . . . 51.43 112.362 -174.587 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.2 m -84.61 -22.97 7.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 CA-C-N 118.24 0.473 . . . . 64.25 111.245 -179.039 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 71.7 56.7 6.42 Favored Glycine 0 C--N 1.343 0.939 0 CA-C-N 115.823 -0.626 . . . . 72.02 112.31 -174.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -84.75 -152.96 17.98 Favored Glycine 0 C--N 1.355 1.624 0 N-CA-C 111.979 -0.449 . . . . 72.12 111.979 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -111.79 140.54 46.34 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.106 -0.702 . . . . 71.22 109.106 177.29 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . 0.495 HG21 HG12 ' A' ' 199' ' ' VAL . 41.1 t -125.66 149.47 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 108.066 -1.087 . . . . 63.2 108.066 168.635 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . 0.435 ' HD2' ' HG2' ' A' ' 220' ' ' GLU . 0.2 OUTLIER -90.06 125.27 35.35 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 108.268 -1.012 . . . . 74.41 108.268 166.946 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -100.43 129.11 46.35 Favored 'General case' 0 C--O 1.248 0.999 0 N-CA-C 108.59 -0.893 . . . . 64.35 108.59 178.537 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 4.2 tpt -76.25 105.16 7.14 Favored 'General case' 0 CA--C 1.537 0.471 0 O-C-N 123.697 0.623 . . . . 62.32 109.435 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 9.2 t -117.26 169.68 9.28 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 123.418 0.687 . . . . 71.01 110.524 177.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 63.3 mt -76.1 -5.6 47.31 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 123.957 0.903 . . . . 55.35 111.423 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -88.12 -20.38 25.73 Favored 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 124.077 0.951 . . . . 73.34 110.348 172.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 130.64 -149.87 19.15 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-O 119.073 -0.848 . . . . 65.02 111.108 -174.26 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -86.83 120.38 1.67 Allowed 'Trans proline' 0 CA--C 1.553 1.428 0 C-N-CA 122.211 1.941 . . . . 73.41 111.604 169.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 20.0 m -108.24 155.39 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 108.968 -0.753 . . . . 63.21 108.968 173.59 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . 0.435 ' HG2' ' HD2' ' A' ' 211' ' ' ARG . 33.4 mt-10 -109.46 107.36 17.47 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 108.788 -0.819 . . . . 72.14 108.788 -175.305 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.2 p -96.38 132.54 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 123.739 0.816 . . . . 63.42 110.342 177.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -90.69 105.41 17.8 Favored 'General case' 0 C--O 1.24 0.588 0 C-N-CA 123.648 0.779 . . . . 42.3 108.961 173.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.11 133.51 93.63 Favored Pre-proline 0 CA--C 1.557 1.24 0 C-N-CA 124.038 0.935 . . . . 62.2 110.063 177.578 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_exo -65.04 140.69 66.88 Favored 'Trans proline' 0 C--N 1.379 2.144 0 C-N-CA 122.89 2.393 . . . . 75.42 111.539 172.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -58.98 124.41 15.63 Favored 'Trans proline' 0 C--N 1.376 2.008 0 C-N-CA 122.724 2.283 . . . . 75.24 111.418 178.147 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . 0.457 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 85.3 mtm180 60.41 76.74 0.35 Allowed 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 124.423 1.089 . . . . 74.03 110.865 -177.533 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 7.5 t -103.71 173.81 6.14 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 123.365 0.666 . . . . 71.31 109.594 174.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -131.44 155.53 47.18 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 123.655 0.782 . . . . 65.42 109.019 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.11 130.23 42.12 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.297 0.639 . . . . 74.12 110.279 177.191 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.03 -11.5 22.48 Favored Glycine 0 C--N 1.337 0.588 0 C-N-CA 123.505 0.574 . . . . 64.33 112.129 -176.087 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 73.3 mtp180 -81.7 155.58 25.48 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 122.818 0.447 . . . . 74.11 110.481 178.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.505 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 0.5 OUTLIER -118.53 125.29 49.55 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.776 0.83 . . . . 74.44 109.762 -179.115 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 28.1 mt -100.79 111.55 23.79 Favored 'General case' 0 C--N 1.353 0.759 0 N-CA-C 108.127 -1.064 . . . . 73.02 108.127 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . 0.428 ' HG3' ' HB3' ' A' ' 248' ' ' ASP . 57.4 ttm-85 -82.91 105.4 13.88 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.9 0.88 . . . . 70.11 110.894 -170.268 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.534 HD12 HD23 ' A' ' 249' ' ' LEU . 30.0 mt -87.03 97.46 10.73 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 107.782 -1.192 . . . . 62.13 107.782 171.103 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -71.76 138.2 48.25 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 114.831 -1.077 . . . . 71.03 111.634 -169.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 75.89 4.08 76.05 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 123.801 0.688 . . . . 63.4 113.991 177.219 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . 0.604 ' HE2' ' HA ' ' A' ' 238' ' ' LYS . 9.6 mmpt? -94.17 -3.13 51.47 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.253 0.621 . . . . 73.13 111.955 -177.484 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.27 -170.68 47.2 Favored Glycine 0 C--N 1.343 0.967 0 N-CA-C 111.941 -0.463 . . . . 53.51 111.941 171.236 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.526 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 97.3 m-85 -83.6 154.9 65.68 Favored Pre-proline 0 N--CA 1.477 0.917 0 C-N-CA 122.822 0.449 . . . . 61.04 111.687 -177.148 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . 0.474 ' HA ' ' O ' ' A' ' 245' ' ' GLY . 26.3 Cg_exo -64.5 127.05 18.06 Favored 'Trans proline' 0 C--N 1.375 1.962 0 C-N-CA 122.144 1.896 . . . . 54.43 110.468 166.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -165.22 -156.9 9.4 Favored Glycine 0 C--N 1.342 0.916 0 CA-C-O 119.219 -0.767 . . . . 75.24 112.329 -177.063 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -59.43 -10.78 11.83 Favored 'Trans proline' 0 N--CA 1.504 2.14 0 C-N-CA 124.017 3.145 . . . . 73.52 115.257 -178.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -109.49 19.14 19.62 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.287 0.635 . . . . 43.22 111.06 176.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 241' ' ' PRO . . . 77.45 -76.49 1.68 Allowed Glycine 0 C--N 1.345 1.067 0 N-CA-C 110.993 -0.843 . . . . 63.34 110.993 -173.34 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 55.5 mtm180 -123.77 155.88 37.1 Favored 'General case' 0 N--CA 1.476 0.875 0 N-CA-C 107.801 -1.185 . . . . 75.12 107.801 170.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -90.74 -177.89 43.85 Favored Glycine 0 C--N 1.338 0.682 0 O-C-N 123.34 0.4 . . . . 50.12 113.245 176.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . 0.428 ' HB3' ' HG3' ' A' ' 234' ' ' ARG . 60.9 m-20 -136.01 142.5 44.48 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.82 0.848 . . . . 70.34 109.189 -175.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.534 HD23 HD12 ' A' ' 235' ' ' LEU . 19.3 tp -97.53 112.97 24.6 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 109.346 -0.613 . . . . 62.24 109.346 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -90.29 105.86 18.1 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 108.754 -0.832 . . . . 75.02 108.754 176.509 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.505 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 93.6 mt -87.92 110.77 20.8 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.376 0.67 . . . . 52.23 112.01 176.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -79.06 92.98 5.06 Favored 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 109.117 -0.697 . . . . 75.25 109.117 -178.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 70.6 t -48.04 117.66 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 C-N-CA 124.911 1.284 . . . . 75.15 110.997 173.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 26.3 mmm180 -128.98 101.24 5.97 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 106.435 -1.691 . . . . 72.44 106.435 174.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 60.4 mt -77.17 117.51 22.24 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 CA-C-N 115.582 -0.735 . . . . 75.44 110.94 -172.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 3.3 t . . . . . 0 CA--C 1.559 1.326 0 C-N-CA 124.092 0.957 . . . . 72.21 109.211 177.725 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.625 ' HG ' ' HG2' ' A' ' 136' ' ' ARG . 89.0 mt . . . . . 0 N--CA 1.478 0.926 0 N-CA-C 109.844 -0.428 . . . . 61.12 109.844 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.472 ' HB ' HG23 ' A' ' 138' ' ' VAL . 30.0 t -58.89 131.13 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 C-N-CA 123.574 0.749 . . . . 50.55 111.798 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -70.67 -52.52 20.6 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.322 -0.853 . . . . 73.45 109.732 176.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -179.96 174.99 0.85 Allowed 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.556 1.142 . . . . 75.35 109.266 -178.124 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 88.7 t -65.19 132.16 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 N-CA-C 108.762 -0.829 . . . . 72.21 108.762 171.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.431 HG23 ' HA ' ' A' ' 121' ' ' ALA . 24.5 p . . . . . 0 CA--C 1.547 0.842 0 CA-C-O 121.557 0.694 . . . . 71.11 110.962 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 . . . . . 0 CA--C 1.54 0.574 0 CA-C-O 120.974 0.416 . . . . 73.31 110.816 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.49 HD22 HD13 ' A' ' 174' ' ' LEU . 4.9 tt -136.89 149.07 47.43 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 106.611 -1.626 . . . . 53.41 106.611 -179.312 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . 0.435 ' N ' HD23 ' A' ' 119' ' ' LEU . 0.1 OUTLIER -138.11 148.69 45.23 Favored 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 119.335 0.97 . . . . 71.24 110.351 179.533 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.431 ' HA ' HG23 ' A' ' 103' ' ' THR . . . -156.89 163.26 39.37 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.525 1.13 . . . . 71.23 108.709 -177.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -126.45 151.56 47.59 Favored 'General case' 0 C--O 1.248 0.99 0 CA-C-O 121.063 0.459 . . . . 73.02 110.224 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.473 HD12 ' HB3' ' A' ' 98' ' ' LEU . 1.6 pt? -140.41 135.02 15.65 Favored Pre-proline 0 N--CA 1.468 0.451 0 CA-C-N 115.681 -0.691 . . . . 73.34 111.593 -174.6 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -66.09 114.55 3.05 Favored 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 121.781 1.654 . . . . 72.25 110.351 161.152 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.461 HD22 HG11 ' A' ' 178' ' ' VAL . 16.1 tp -115.48 166.29 12.05 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.313 1.045 . . . . 71.55 108.222 175.443 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 17.6 m -108.74 161.53 15.02 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.208 0.603 . . . . 70.12 109.46 174.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.491 HD11 ' O ' ' A' ' 183' ' ' HIS . 30.8 mt -55.97 -51.94 65.94 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.808 0.843 . . . . 61.13 109.7 173.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.574 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.9 mp0 -57.36 -38.38 74.07 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 114.408 -1.269 . . . . 72.4 111.667 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -76.83 -21.86 54.42 Favored 'General case' 0 N--CA 1.479 1.025 0 C-N-CA 123.362 0.665 . . . . 70.21 111.672 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.624 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -71.85 -25.82 62.12 Favored 'General case' 0 C--O 1.249 1.073 0 C-N-CA 123.704 0.802 . . . . 51.44 110.94 170.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.521 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 36.9 t80 -82.39 -47.39 12.36 Favored 'General case' 0 C--N 1.35 0.602 0 CA-C-N 115.477 -0.783 . . . . 75.25 111.736 171.601 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -74.32 -47.46 34.43 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 123.237 0.335 . . . . 74.43 111.338 -172.093 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.16 -153.09 52.63 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 111.183 -0.767 . . . . 74.24 111.183 -168.441 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 119.46 -175.96 15.96 Favored Glycine 0 C--N 1.343 0.953 0 N-CA-C 114.379 0.511 . . . . 51.14 114.379 171.149 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.619 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.7 mp0 -90.74 136.28 33.17 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.993 0.917 . . . . 65.34 109.372 -177.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.625 ' HG2' ' HG ' ' A' ' 98' ' ' LEU . 0.2 OUTLIER -153.11 150.89 29.57 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 110.375 -0.231 . . . . 75.2 110.375 176.059 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 25.3 m -75.87 136.82 24.03 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 123.251 0.62 . . . . 70.13 111.836 -173.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.472 HG23 ' HB ' ' A' ' 99' ' ' VAL . 5.8 p -142.86 135.9 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 C-N-CA 124.212 1.005 . . . . 72.25 111.297 178.158 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -100.37 98.39 9.04 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 109.483 -0.562 . . . . 75.42 109.483 169.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.0 m -108.36 124.87 65.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 N-CA-C 108.895 -0.78 . . . . 72.33 108.895 171.61 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.09 21.83 13.09 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 124.324 1.05 . . . . 61.51 111.436 -174.086 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.28 -1.78 86.38 Favored Glycine 0 C--N 1.356 1.656 0 CA-C-N 115.835 -0.62 . . . . 61.42 113.238 -178.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.3 mmt85 -94.3 117.11 29.62 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 123.207 0.603 . . . . 72.02 109.905 -178.295 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 43.1 ttm180 -84.9 115.94 23.05 Favored 'General case' 0 C--N 1.352 0.705 0 N-CA-C 109.756 -0.461 . . . . 73.42 109.756 175.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 12.2 m -136.68 155.27 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 C-N-CA 125.136 1.375 . . . . 74.33 108.708 177.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 60.8 p -86.81 114.98 23.93 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 109.139 -0.689 . . . . 73.52 109.139 174.134 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.0 p -96.15 124.67 48.96 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 CA-C-O 121.172 0.51 . . . . 71.1 109.924 176.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . 0.619 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 13.7 ttp180 -99.03 104.94 17.01 Favored 'General case' 0 C--O 1.244 0.799 0 N-CA-C 108.841 -0.8 . . . . 71.03 108.841 175.511 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 32.7 pt -95.63 131.3 29.71 Favored Pre-proline 0 CA--C 1.548 0.878 0 N-CA-C 108.737 -0.838 . . . . 72.21 108.737 174.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -71.39 146.1 49.57 Favored 'Trans proline' 0 C--N 1.371 1.728 0 C-N-CA 122.554 2.169 . . . . 63.21 112.923 -174.697 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.64 142.5 89.84 Favored 'Trans proline' 0 C--N 1.378 2.108 0 C-N-CA 122.881 2.387 . . . . 75.13 111.425 172.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.71 52.39 0.75 Allowed Glycine 0 C--N 1.339 0.709 0 N-CA-C 110.7 -0.96 . . . . 53.55 110.7 -173.246 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.624 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.3 p -130.65 162.12 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 108.165 -1.05 . . . . 72.01 108.165 179.581 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.6 ' HA ' HD11 ' A' ' 180' ' ' LEU . 0.0 OUTLIER -162.37 173.67 13.81 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 124.925 1.29 . . . . 73.35 110.379 -179.352 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.4 tp10 -47.3 118.38 2.15 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 124.601 1.16 . . . . 70.24 112.711 -176.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 100.5 -24.86 30.47 Favored Glycine 0 C--N 1.349 1.296 0 CA-C-O 119.153 -0.804 . . . . 53.2 113.562 178.797 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.56 ' HB2' HG23 ' A' ' 153' ' ' VAL . 43.6 m -60.09 125.7 24.68 Favored 'General case' 0 C--O 1.248 0.998 0 C-N-CA 123.34 0.656 . . . . 63.21 111.127 -174.493 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.532 HG22 HD22 ' A' ' 175' ' ' LEU . 14.8 p -100.57 123.21 53.37 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.095 0 CA-C-N 114.801 -1.091 . . . . 64.1 109.071 -179.027 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.424 HD11 HG21 ' A' ' 153' ' ' VAL . 25.9 mt -105.38 112.97 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.329 1.052 . . . . 64.41 109.545 -170.166 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 34.6 ttt-85 -92.75 105.32 17.48 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 122.822 0.449 . . . . 74.23 110.256 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.426 HG22 ' HB3' ' A' ' 174' ' ' LEU . 10.5 m -97.79 112.38 61.41 Favored Pre-proline 0 CA--C 1.561 1.396 0 N-CA-C 108.072 -1.084 . . . . 72.35 108.072 176.209 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 7.6 Cg_exo -73.65 156.22 49.26 Favored 'Trans proline' 0 C--N 1.374 1.875 0 C-N-CA 123.132 2.555 . . . . 75.21 113.213 -171.598 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 66.09 24.44 71.79 Favored Glycine 0 C--N 1.347 1.188 0 O-C-N 123.715 0.635 . . . . 52.54 114.14 177.367 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.6 tpt -101.8 -63.21 1.17 Allowed 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.293 0.637 . . . . 74.41 111.288 -170.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.514 0 N-CA-C 111.412 -0.675 . . . . 51.14 111.412 178.863 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo . . . . . 0 CA--C 1.544 0.992 0 CA-C-O 120.859 0.275 . . . . 72.05 112.108 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -99.89 -137.09 9.64 Favored Glycine 0 C--N 1.342 0.916 0 N-CA-C 111.156 -0.778 . . . . 71.33 111.156 176.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -167.38 165.55 14.92 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 117.377 0.588 . . . . 75.14 111.245 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.49 HD13 HD22 ' A' ' 119' ' ' LEU . 35.5 tp -124.98 122.63 37.86 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 114.822 -1.081 . . . . 70.33 108.191 166.844 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.532 HD22 HG22 ' A' ' 158' ' ' VAL . 30.2 mt -95.17 101.42 13.16 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.542 1.137 . . . . 52.42 110.188 178.535 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 56.5 mt -93.5 105.42 17.47 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.56 0.744 . . . . 72.04 111.653 178.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 15.4 t -88.66 108.36 18.77 Favored 'Isoleucine or valine' 0 C--O 1.246 0.876 0 N-CA-C 108.977 -0.749 . . . . 60.04 108.977 176.286 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.461 HG11 HD22 ' A' ' 125' ' ' LEU . 25.5 m -77.69 148.3 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 N-CA-C 112.991 0.738 . . . . 62.42 112.991 -176.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -124.08 96.89 5.11 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 113.91 -1.495 . . . . 71.04 107.613 175.321 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.6 HD11 ' HA ' ' A' ' 154' ' ' ARG . 35.1 mt -69.09 147.74 51.02 Favored 'General case' 0 C--O 1.241 0.624 0 O-C-N 123.132 0.27 . . . . 63.34 110.725 -179.246 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.413 ' HA ' ' HD3' ' A' ' 182' ' ' PRO . 40.8 mt -54.13 128.55 57.51 Favored Pre-proline 0 CA--C 1.551 0.988 0 O-C-N 124.354 1.034 . . . . 54.11 110.055 177.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 31.7 Cg_exo -60.27 82.04 0.07 OUTLIER 'Trans proline' 0 C--N 1.377 2.034 0 C-N-CA 123.792 2.994 . . . . 65.32 113.563 -176.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . 0.491 ' O ' HD11 ' A' ' 127' ' ' LEU . 2.3 p80 -170.05 109.08 0.45 Allowed Pre-proline 0 CA--C 1.551 0.986 0 N-CA-C 106.652 -1.61 . . . . 71.22 106.652 171.521 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -89.52 127.31 1.63 Allowed 'Trans proline' 0 C--N 1.36 1.159 0 C-N-CA 122.096 1.864 . . . . 64.11 112.622 178.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 5.2 p -137.21 -47.78 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 109.515 -0.55 . . . . 64.12 109.515 168.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -109.84 123.55 49.76 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 121.436 0.636 . . . . 72.1 111.731 -176.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.478 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 0.1 OUTLIER -113.47 162.5 16.06 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.672 1.589 . . . . 71.4 109.351 -179.461 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.437 HD12 ' O ' ' A' ' 192' ' ' ASP . 43.2 tp -130.49 136.71 49.25 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 123.665 0.786 . . . . 64.31 109.958 179.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . 0.476 ' HB3' ' CE1' ' A' ' 194' ' ' TYR . 10.0 tp10 -142.07 109.94 5.82 Favored 'General case' 0 C--O 1.242 0.683 0 C-N-CA 124.184 0.994 . . . . 73.32 108.345 176.147 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 72.22 -83.33 0.53 Allowed Glycine 0 C--N 1.347 1.153 0 N-CA-C 111.447 -0.661 . . . . 64.4 111.447 -174.468 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . 0.539 ' NE2' ' HB3' ' A' ' 244' ' ' ALA . 29.7 pt20 -141.74 -8.26 0.95 Allowed 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.85 0.86 . . . . 72.23 110.017 178.206 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.437 ' O ' HD12 ' A' ' 188' ' ' LEU . 17.1 m-20 -93.88 156.35 16.69 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.447 0.699 . . . . 75.21 111.169 -171.406 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.469 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 90.4 mt -104.59 150.89 24.26 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 124.816 1.246 . . . . 53.41 108.913 -177.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . 0.478 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 77.4 m-85 -138.26 128.39 25.75 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 107.167 -1.42 . . . . 72.4 107.167 -177.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -154.18 171.27 19.44 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 123.842 0.857 . . . . 62.34 109.197 -176.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 14.6 m -120.41 135.28 55.09 Favored 'General case' 0 C--O 1.238 0.5 0 N-CA-C 108.867 -0.79 . . . . 74.11 108.867 176.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.558 HD23 HD12 ' A' ' 233' ' ' LEU . 70.1 tp -123.63 114.18 19.66 Favored 'General case' 0 C--O 1.217 -0.62 0 C-N-CA 124.112 0.965 . . . . 63.31 109.542 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -84.78 119.78 25.69 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 108.266 -1.012 . . . . 75.52 108.266 171.032 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 84.2 t -110.22 126.4 29.02 Favored Pre-proline 0 N--CA 1.469 0.486 0 N-CA-C 108.632 -0.877 . . . . 72.01 108.632 -178.543 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -54.56 133.33 56.2 Favored 'Trans proline' 0 C--N 1.375 1.958 0 C-N-CA 122.767 2.311 . . . . 64.51 110.903 172.4 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -51.68 -45.37 91.52 Favored Pre-proline 0 CA--C 1.556 1.191 0 C-N-CA 124.568 1.147 . . . . 71.21 113.685 -175.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -53.41 -45.53 40.35 Favored 'Trans proline' 0 C--N 1.39 2.751 0 C-N-CA 121.841 1.694 . . . . 74.23 113.666 173.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . 0.437 HG21 HG13 ' A' ' 210' ' ' VAL . 8.7 mt -67.62 -37.71 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 C-N-CA 122.386 0.274 . . . . 75.15 111.276 178.437 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -67.19 -34.53 77.7 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 122.977 0.511 . . . . 42.32 112.319 -176.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.3 m -83.77 -39.17 14.74 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 CA-C-N 116.159 -0.473 . . . . 54.22 111.052 -177.593 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m -82.68 -24.81 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-N 118.12 0.418 . . . . 72.03 110.939 179.676 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 79.02 67.54 1.58 Allowed Glycine 0 C--N 1.341 0.813 0 CA-C-N 116.084 -0.507 . . . . 72.51 112.493 -177.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -101.46 -147.23 19.95 Favored Glycine 0 C--N 1.35 1.31 0 CA-C-N 116.854 0.327 . . . . 64.24 112.337 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 59.1 pttt -127.64 138.19 52.76 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 124.319 1.048 . . . . 64.51 109.43 -177.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . 0.437 HG13 HG21 ' A' ' 203' ' ' ILE . 17.9 m -126.28 143.74 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.117 0.967 . . . . 73.34 109.179 175.31 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 10.0 mpt_? -85.36 107.16 17.23 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 108.958 -0.756 . . . . 63.04 108.958 174.253 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.6 117.59 35.22 Favored 'General case' 0 CA--C 1.517 -0.31 0 N-CA-C 107.62 -1.252 . . . . 64.24 107.62 174.39 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . 0.504 ' HA ' ' HA ' ' A' ' 218' ' ' PRO . 1.2 ppp? -79.38 138.23 37.59 Favored 'General case' 0 C--O 1.243 0.754 0 N-CA-C 109.29 -0.633 . . . . 74.22 109.29 179.003 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.527 HG23 ' HG2' ' A' ' 216' ' ' GLU . 4.5 t -128.9 174.95 9.04 Favored 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 124.155 0.982 . . . . 73.24 108.805 177.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . 0.574 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 73.9 mt -72.99 -3.34 25.46 Favored 'General case' 0 CA--C 1.549 0.929 0 N-CA-C 113.613 0.968 . . . . 70.32 113.613 -169.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . 0.527 ' HG2' HG23 ' A' ' 214' ' ' THR . 14.3 pt-20 -104.8 -4.62 22.07 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 123.806 0.842 . . . . 53.12 111.183 175.487 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 129.28 -174.09 19.35 Favored Glycine 0 C--N 1.344 0.982 0 N-CA-C 110.686 -0.966 . . . . 63.23 110.686 -172.073 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . 0.504 ' HA ' ' HA ' ' A' ' 213' ' ' MET . 2.2 Cg_endo -81.84 133.38 7.96 Favored 'Trans proline' 0 CA--C 1.55 1.283 0 C-N-CA 122.52 2.147 . . . . 65.22 112.13 179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 34.5 m -110.27 165.15 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.076 0 C-N-CA 123.077 0.551 . . . . 74.11 111.915 171.371 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -111.41 113.03 25.19 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 124.058 0.943 . . . . 74.23 109.011 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.567 HG22 HD11 ' A' ' 235' ' ' LEU . 21.8 t -97.19 117.65 42.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 123.439 0.696 . . . . 72.2 110.36 178.731 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -87.57 105.53 17.39 Favored 'General case' 0 C--O 1.239 0.519 0 N-CA-C 107.442 -1.318 . . . . 64.04 107.442 171.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 6.2 m -80.95 142.38 51.96 Favored Pre-proline 0 CA--C 1.553 1.085 0 N-CA-C 109.383 -0.599 . . . . 54.1 109.383 -177.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -62.62 144.28 93.98 Favored 'Trans proline' 0 C--N 1.371 1.725 0 C-N-CA 123.003 2.469 . . . . 54.15 112.977 177.022 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.04 122.99 10.94 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.411 2.074 . . . . 73.3 111.306 174.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 73.5 mtt180 67.99 36.38 3.39 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.693 1.197 . . . . 65.45 110.822 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . 0.509 HG23 HD11 ' A' ' 255' ' ' ILE . 9.3 t -67.53 172.06 5.49 Favored 'General case' 0 CA--C 1.551 1.017 0 CA-C-N 115.865 -0.607 . . . . 64.41 110.86 -178.585 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.2 mp0 -117.51 138.03 52.16 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.645 0.778 . . . . 60.44 109.623 -174.314 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -66.66 114.64 5.73 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.365 0.666 . . . . 54.13 110.046 176.317 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.79 3.71 19.86 Favored Glycine 0 C--N 1.336 0.549 0 CA-C-N 115.897 -0.592 . . . . 70.11 112.251 -176.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . 0.414 ' O ' HG12 ' A' ' 253' ' ' VAL . 57.3 mtp180 -78.39 161.83 26.87 Favored 'General case' 0 C--O 1.243 0.725 0 CA-C-O 121.684 0.754 . . . . 64.23 110.838 173.129 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.429 ' HD2' ' N ' ' A' ' 232' ' ' LYS . 0.1 OUTLIER -99.96 100.7 11.64 Favored 'General case' 0 C--O 1.24 0.565 0 CA-C-N 114.235 -1.348 . . . . 74.01 108.367 -178.447 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 33.3 mt -84.53 97.71 9.72 Favored 'General case' 0 C--N 1.351 0.646 0 N-CA-C 105.217 -2.142 . . . . 74.43 105.217 173.826 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . 0.469 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 51.6 ttp85 -96.13 103.64 15.54 Favored 'General case' 0 C--O 1.24 0.593 0 CA-C-N 114.781 -1.099 . . . . 72.5 109.437 -165.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.585 HD12 HD23 ' A' ' 249' ' ' LEU . 20.2 mt -85.02 97.83 10.06 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.589 -1.263 . . . . 75.21 107.589 177.664 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 10.4 mtmp? -69.43 135.97 50.96 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 114.639 -1.164 . . . . 71.11 111.479 -169.67 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 80.17 13.82 81.39 Favored Glycine 0 C--N 1.347 1.194 0 O-C-N 123.577 0.548 . . . . 32.31 113.354 177.395 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . 0.676 ' HE2' ' HA ' ' A' ' 238' ' ' LYS . 9.3 mmpt? -96.98 -18.79 19.21 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 122.877 0.471 . . . . 71.45 112.222 -178.318 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . 0.466 ' HA2' ' HG ' ' A' ' 193' ' ' LEU . . . -82.75 169.64 49.02 Favored Glycine 0 C--N 1.338 0.689 0 N-CA-C 112.028 -0.429 . . . . 63.04 112.028 176.688 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.521 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 98.0 m-85 -66.06 154.91 88.69 Favored Pre-proline 0 N--CA 1.479 0.994 0 C-N-CA 123.45 0.7 . . . . 74.22 111.933 -172.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -66.55 128.13 18.55 Favored 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 121.948 1.765 . . . . 64.35 110.289 165.163 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -151.5 -159.02 8.65 Favored Glycine 0 N--CA 1.465 0.632 0 CA-C-O 119.714 -0.492 . . . . 65.3 112.732 -178.591 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -65.95 -13.02 37.92 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.375 2.716 . . . . 65.41 114.324 -170.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . 0.539 ' HB3' ' NE2' ' A' ' 191' ' ' GLN . . . -116.9 25.03 10.81 Favored 'General case' 0 N--CA 1.482 1.126 0 C-N-CA 122.86 0.464 . . . . 62.43 110.684 178.767 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 102.87 -101.92 2.17 Favored Glycine 0 C--N 1.348 1.206 0 CA-C-O 119.764 -0.465 . . . . 62.1 112.149 174.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 9.5 ttm180 -124.43 155.31 39.09 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 108.573 -0.899 . . . . 74.33 108.573 173.092 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -94.74 -173.48 38.01 Favored Glycine 0 C--N 1.335 0.511 0 CA-C-O 121.271 0.373 . . . . 54.13 113.114 -177.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -135.95 168.06 20.04 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 108.062 -1.088 . . . . 70.22 108.062 -177.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.585 HD23 HD12 ' A' ' 235' ' ' LEU . 16.7 tp -104.96 124.16 49.03 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 122.786 0.434 . . . . 71.12 110.366 173.037 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . 0.433 ' HB3' ' HA ' ' A' ' 194' ' ' TYR . 11.6 t80 -89.3 108.53 19.68 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 124.62 1.168 . . . . 74.32 108.077 171.232 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 65.7 mt -96.89 120.83 37.97 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.793 -0.447 . . . . 70.11 109.793 164.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -83.55 94.41 8.05 Favored 'General case' 0 C--O 1.237 0.41 0 N-CA-C 108.012 -1.107 . . . . 72.32 108.012 168.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 231' ' ' ARG . 2.3 p -59.48 126.9 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 CA-C-O 121.291 0.567 . . . . 71.21 110.203 177.513 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 10.2 mmm180 -127.19 94.74 4.09 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 107.299 -1.371 . . . . 75.12 107.299 -177.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.509 HD11 HG23 ' A' ' 227' ' ' THR . 64.6 mt -74.77 120.04 23.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 115.193 -0.912 . . . . 73.1 109.74 -172.54 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.4 t . . . . . 0 CA--C 1.557 1.214 0 C-N-CA 125.161 1.384 . . . . 73.4 108.506 -174.129 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.531 HD11 HD13 ' A' ' 149' ' ' ILE . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.476 0 N-CA-C 107.038 -1.468 . . . . 72.11 107.038 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.507 HG23 ' HB1' ' A' ' 121' ' ' ALA . 2.9 p -173.88 131.39 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-N 113.72 -1.582 . . . . 61.53 109.006 -176.12 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.482 ' HB2' ' HD3' ' A' ' 124' ' ' PRO . . . -94.09 -46.85 6.94 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 123.264 0.626 . . . . 62.25 110.072 174.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 2.1 p80 -163.45 151.72 13.59 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 115.653 -0.703 . . . . 62.22 111.18 -178.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 93.5 t -73.79 126.57 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.021 0.929 . . . . 64.0 109.168 175.009 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 10.1 t . . . . . 0 CA--C 1.547 0.838 0 CA-C-O 122.357 1.075 . . . . 62.21 110.127 -178.277 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.0 t70 . . . . . 0 N--CA 1.472 0.638 0 N-CA-C 109.299 -0.63 . . . . 54.04 109.299 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.461 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 33.4 tp -136.35 121.33 18.8 Favored 'General case' 0 C--O 1.215 -0.755 0 N-CA-C 106.595 -1.631 . . . . 72.2 106.595 -175.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -121.34 131.88 54.45 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.603 -0.517 . . . . 73.33 109.603 -171.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.507 ' HB1' HG23 ' A' ' 99' ' ' VAL . . . -153.12 146.81 25.14 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.294 0.637 . . . . 65.11 109.701 -177.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -126.16 152.98 45.25 Favored 'General case' 0 C--O 1.244 0.768 0 CA-C-O 121.081 0.467 . . . . 54.21 110.49 177.062 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -145.5 148.58 37.6 Favored Pre-proline 0 N--CA 1.471 0.583 0 CA-C-N 114.933 -1.031 . . . . 71.13 110.362 -177.119 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.482 ' HD3' ' HB2' ' A' ' 100' ' ' ALA . 4.0 Cg_exo -73.86 115.31 4.28 Favored 'Trans proline' 0 C--N 1.37 1.695 0 C-N-CA 121.561 1.507 . . . . 73.23 110.151 167.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 23.8 tp -105.84 148.47 27.52 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 108.378 -0.971 . . . . 74.02 108.378 175.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.765 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 24.7 m -76.38 147.23 38.18 Favored 'General case' 0 CA--C 1.547 0.853 0 N-CA-C 109.963 -0.384 . . . . 51.53 109.963 173.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.532 HD23 ' HB3' ' A' ' 180' ' ' LEU . 96.6 mt -52.73 -51.42 60.57 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 121.822 0.82 . . . . 65.22 110.48 172.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.594 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -55.76 -28.83 58.01 Favored 'General case' 0 CA--C 1.551 1.003 0 CA-C-N 113.947 -1.479 . . . . 61.33 112.451 177.211 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.68 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 22.1 mm-40 -86.24 -21.44 27.41 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 118.18 0.446 . . . . 73.3 111.679 178.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.655 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -61.13 -34.67 75.36 Favored 'General case' 0 C--O 1.239 0.546 0 CA-C-O 121.268 0.556 . . . . 72.34 110.059 164.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.639 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 57.8 t80 -76.42 -50.84 13.1 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 114.823 -1.08 . . . . 71.41 112.887 172.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -75.27 -49.21 19.97 Favored 'General case' 0 N--CA 1.486 1.33 0 C-N-CA 122.338 0.255 . . . . 63.25 111.651 -170.364 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.15 -161.61 44.33 Favored Glycine 0 CA--C 1.535 1.331 0 CA-C-O 119.905 -0.386 . . . . 71.54 112.153 -173.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 128.63 -169.66 20.08 Favored Glycine 0 N--CA 1.476 1.305 0 CA-C-N 117.307 0.554 . . . . 52.32 114.272 171.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -94.61 121.34 36.07 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 124.156 0.982 . . . . 72.3 108.592 -178.129 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -130.66 167.32 18.96 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.759 0.823 . . . . 53.41 108.977 172.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.427 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 13.0 p -90.53 142.14 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 108.736 -0.839 . . . . 70.31 108.736 179.152 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.479 HG22 HG23 ' A' ' 140' ' ' VAL . 8.8 p -131.05 136.59 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 N-CA-C 108.863 -0.792 . . . . 71.53 108.863 177.522 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . 0.459 ' HA ' ' O ' ' A' ' 143' ' ' ARG . 36.6 tt0 -126.6 97.83 5.17 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.854 -0.425 . . . . 63.21 109.854 172.483 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.479 HG23 HG22 ' A' ' 138' ' ' VAL . 22.9 t -122.13 138.26 52.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 108.208 -1.034 . . . . 65.24 108.208 174.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 64.52 21.58 12.48 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 124.712 1.205 . . . . 70.13 111.341 -176.61 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.59 13.71 82.9 Favored Glycine 0 C--N 1.352 1.452 0 CA-C-N 116.056 -0.52 . . . . 64.22 113.631 -179.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.459 ' O ' ' HA ' ' A' ' 139' ' ' GLU . 72.5 mtt180 -108.71 117.67 34.79 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.29 0.636 . . . . 74.34 109.468 179.217 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 21.7 ttm180 -105.35 105.35 15.35 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 109.842 -0.429 . . . . 72.53 109.842 -176.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 61.1 t -129.92 141.98 45.01 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.53 1.132 . . . . 63.53 108.291 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.427 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 72.0 p -72.2 111.12 7.14 Favored 'General case' 0 CA--C 1.546 0.817 0 N-CA-C 109.022 -0.733 . . . . 74.44 109.022 174.212 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.2 p -96.82 147.4 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 C-N-CA 123.884 0.874 . . . . 72.24 109.327 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -109.03 127.45 54.11 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 107.888 -1.152 . . . . 71.32 107.888 171.281 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.531 HD13 HD11 ' A' ' 98' ' ' LEU . 38.1 pt -120.62 124.73 27.45 Favored Pre-proline 0 CA--C 1.547 0.858 0 N-CA-C 107.873 -1.158 . . . . 71.42 107.873 170.016 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -72.13 153.5 57.12 Favored 'Trans proline' 0 C--N 1.373 1.847 0 C-N-CA 122.346 2.031 . . . . 71.12 113.021 -173.061 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -65.59 147.68 86.63 Favored 'Trans proline' 0 C--N 1.373 1.852 0 C-N-CA 122.282 1.988 . . . . 62.43 111.428 170.041 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 101.42 53.38 1.0 Allowed Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.123 -1.191 . . . . 75.11 110.123 -171.502 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.655 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -128.49 161.04 38.02 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.299 0 N-CA-C 108.191 -1.041 . . . . 51.32 108.191 -179.459 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -146.16 171.39 15.0 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 124.206 1.002 . . . . 43.02 110.502 -165.562 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -56.59 125.74 23.54 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 123.416 0.686 . . . . 73.22 110.426 169.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.83 -6.0 56.21 Favored Glycine 0 C--N 1.347 1.151 0 CA-C-O 119.362 -0.688 . . . . 63.1 113.921 179.73 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 47.8 t -67.06 129.11 38.82 Favored 'General case' 0 C--N 1.359 0.987 0 C-N-CA 123.404 0.682 . . . . 75.41 109.548 -178.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.469 HG12 HD22 ' A' ' 175' ' ' LEU . 13.7 t -104.98 118.25 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 O-C-N 124.83 1.331 . . . . 74.11 109.102 -171.218 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.457 HD11 HG21 ' A' ' 153' ' ' VAL . 28.1 mt -104.51 111.31 33.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 123.878 0.871 . . . . 74.42 109.71 -171.311 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 54.9 ttt180 -81.35 117.89 22.2 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.573 0.749 . . . . 70.44 110.643 177.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.641 HG22 ' HB3' ' A' ' 174' ' ' LEU . 2.9 m -118.04 117.14 35.51 Favored Pre-proline 0 CA--C 1.557 1.224 0 N-CA-C 109.093 -0.706 . . . . 73.3 109.093 170.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -81.26 149.69 17.2 Favored 'Trans proline' 0 C--N 1.377 2.042 0 C-N-CA 122.473 2.116 . . . . 73.04 112.663 -177.538 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 82.1 24.71 54.26 Favored Glycine 0 C--N 1.349 1.286 0 CA-C-N 115.925 -0.579 . . . . 75.13 113.649 177.383 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 54.9 tpp -109.8 -57.68 2.15 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.545 0.738 . . . . 71.32 110.68 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 1.657 0 N-CA-C 111.665 -0.574 . . . . 60.3 111.665 -179.755 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo . . . . . 0 CA--C 1.543 0.935 0 N-CA-C 111.52 -0.223 . . . . 54.22 111.52 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -94.67 144.89 17.43 Favored Glycine 0 C--N 1.338 0.658 0 N-CA-C 112.096 -0.402 . . . . 74.03 112.096 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . 0.412 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 63.9 m-20 -106.39 116.47 31.99 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 123.035 0.534 . . . . 74.12 110.207 -169.561 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.641 ' HB3' HG22 ' A' ' 161' ' ' VAL . 47.3 tp -89.85 109.68 20.66 Favored 'General case' 0 C--O 1.235 0.338 0 N-CA-C 107.36 -1.348 . . . . 44.23 107.36 171.428 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.469 HD22 HG12 ' A' ' 158' ' ' VAL . 70.0 mt -89.88 98.91 12.04 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.085 1.354 . . . . 62.33 109.538 -179.416 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 84.0 mt -90.22 102.86 15.58 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 124.075 0.95 . . . . 71.02 110.876 179.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 35.1 t -86.91 105.25 14.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 N-CA-C 108.161 -1.051 . . . . 62.54 108.161 175.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 7.8 m -83.48 148.99 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 CA-C-O 121.551 0.691 . . . . 51.51 111.336 -178.388 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . 0.445 ' HB2' ' HA ' ' A' ' 124' ' ' PRO . 35.3 mmt180 -119.04 100.15 7.17 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 107.236 -1.394 . . . . 74.13 107.236 -178.492 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.532 ' HB3' HD23 ' A' ' 127' ' ' LEU . 41.7 mt -67.47 145.86 54.56 Favored 'General case' 0 C--O 1.239 0.514 0 O-C-N 122.938 0.149 . . . . 72.45 110.771 -176.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.765 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 26.5 mt -55.98 138.92 71.76 Favored Pre-proline 0 CA--C 1.548 0.897 0 O-C-N 123.603 0.564 . . . . 71.3 111.211 -177.034 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.8 67.55 4.79 Favored 'Trans proline' 0 C--N 1.377 2.036 0 C-N-CA 123.368 2.712 . . . . 73.25 113.668 -174.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 8.8 p80 -155.47 82.3 3.84 Favored Pre-proline 0 CA--C 1.557 1.247 0 N-CA-C 108.18 -1.044 . . . . 52.01 108.18 172.055 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -62.88 126.16 17.51 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 121.726 1.617 . . . . 72.33 111.548 -175.085 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.8 p -136.75 -48.14 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 108.103 -1.073 . . . . 74.4 108.103 174.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.494 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 4.2 m-85 -113.16 137.16 51.88 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.759 0.824 . . . . 64.43 110.554 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.572 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 2.7 mpt_? -125.09 154.39 41.46 Favored 'General case' 0 CA--C 1.537 0.446 0 N-CA-C 106.836 -1.542 . . . . 74.02 106.836 175.626 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 48.4 tp -134.43 137.9 44.37 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.305 -0.628 . . . . 71.02 109.305 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -142.07 115.89 9.23 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 107.592 -1.262 . . . . 71.1 107.592 169.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 66.71 -95.48 0.27 Allowed Glycine 0 C--N 1.346 1.13 0 O-C-N 123.779 0.674 . . . . 61.33 111.918 -175.282 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . 0.434 ' OE1' ' HD2' ' A' ' 243' ' ' PRO . 1.9 mp0 -120.63 -19.51 7.42 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.673 0.789 . . . . 71.41 110.267 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -83.03 144.01 30.23 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.438 0.695 . . . . 64.02 112.005 -171.421 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.512 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.6 mt -106.64 155.72 19.36 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 124.917 1.287 . . . . 74.24 108.239 177.379 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . 0.572 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 73.9 m-85 -139.9 121.84 15.59 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 107.117 -1.438 . . . . 74.34 107.117 -179.083 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -139.9 141.87 36.52 Favored 'General case' 0 CA--C 1.51 -0.58 0 N-CA-C 109.342 -0.614 . . . . 74.24 109.342 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 25.7 m -91.35 118.07 30.21 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 108.779 -0.823 . . . . 70.12 108.779 178.512 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.478 HD13 ' HB2' ' A' ' 212' ' ' ALA . 65.0 tp -105.94 113.3 26.76 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.714 0.805 . . . . 71.1 109.357 -178.154 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . 0.402 ' HA ' ' O ' ' A' ' 254' ' ' ARG . 14.5 p-10 -89.54 111.55 22.49 Favored 'General case' 0 C--O 1.244 0.776 0 N-CA-C 108.879 -0.786 . . . . 61.54 108.879 172.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 60.5 t -97.44 119.18 63.38 Favored Pre-proline 0 CA--C 1.536 0.414 0 N-CA-C 108.269 -1.011 . . . . 62.52 108.269 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -56.52 135.13 68.62 Favored 'Trans proline' 0 C--N 1.371 1.731 0 C-N-CA 122.439 2.093 . . . . 70.33 110.95 176.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -50.33 -43.86 79.99 Favored Pre-proline 0 CA--C 1.564 1.482 0 C-N-CA 124.803 1.241 . . . . 53.21 113.519 -174.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . 0.447 ' O ' HG22 ' A' ' 206' ' ' VAL . 92.1 Cg_exo -49.35 -54.7 5.04 Favored 'Trans proline' 0 C--N 1.397 3.094 0 C-N-CA 122.395 2.064 . . . . 73.03 113.075 169.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 12.6 mt -66.03 -35.65 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 122.6 0.36 . . . . 74.33 110.956 -178.328 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -58.27 -44.13 88.26 Favored 'General case' 0 N--CA 1.464 0.26 0 C-N-CA 123.503 0.721 . . . . 72.12 110.885 -178.07 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 31.5 m -89.75 -57.69 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.157 0 N-CA-C 112.701 0.63 . . . . 63.43 112.701 -177.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.447 HG22 ' O ' ' A' ' 202' ' ' PRO . 33.2 m -94.86 -27.01 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 118.768 0.713 . . . . 51.44 112.388 -173.299 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -86.53 -146.89 10.24 Favored Glycine 0 C--N 1.342 0.906 0 N-CA-C 112.29 -0.324 . . . . 64.4 112.29 -171.183 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 169.05 10.4 0.02 OUTLIER Glycine 0 C--N 1.339 0.732 0 CA-C-O 118.933 -0.926 . . . . 73.21 115.184 -179.222 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 53.5 mttp -138.48 119.42 14.33 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 118.255 1.027 . . . . 64.13 108.538 -179.206 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 6.2 p -140.54 137.05 36.31 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 108.054 -1.091 . . . . 73.21 108.054 177.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . 0.406 ' N ' ' HD2' ' A' ' 211' ' ' ARG . 7.6 mpt_? -98.56 126.88 44.28 Favored 'General case' 0 C--O 1.24 0.555 0 N-CA-C 108.672 -0.862 . . . . 70.54 108.672 -177.187 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.478 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -102.2 138.42 39.16 Favored 'General case' 0 C--O 1.244 0.808 0 C-N-CA 123.537 0.735 . . . . 70.53 110.076 -176.102 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 3.0 tpt -74.69 109.18 7.96 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.379 -0.828 . . . . 70.24 109.378 175.026 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.494 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 8.8 t -111.61 166.81 10.84 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 123.011 0.524 . . . . 61.54 110.162 174.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . 0.594 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 64.6 mt -72.38 -5.53 37.09 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 123.8 0.84 . . . . 74.45 111.86 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -96.16 -20.61 18.48 Favored 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.405 1.082 . . . . 73.25 111.126 177.121 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 136.41 -146.41 18.37 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 119.211 -0.772 . . . . 43.25 111.298 -171.239 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -86.06 127.78 3.07 Favored 'Trans proline' 0 CA--C 1.556 1.618 0 C-N-CA 122.541 2.16 . . . . 71.22 112.729 170.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . 0.452 HG13 HG21 ' A' ' 214' ' ' THR . 17.2 m -109.34 150.9 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 N-CA-C 108.974 -0.75 . . . . 61.34 108.974 164.801 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -111.35 108.76 18.46 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 107.874 -1.158 . . . . 72.24 107.874 178.048 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 2.8 p -104.43 133.81 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 C-N-CA 123.187 0.595 . . . . 73.51 110.31 177.225 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.19 125.57 35.12 Favored 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 115.625 -0.716 . . . . 74.54 109.779 177.457 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.458 HG12 HD11 ' A' ' 233' ' ' LEU . 28.1 m -97.4 141.12 22.54 Favored Pre-proline 0 N--CA 1.479 1.018 0 N-CA-C 108.485 -0.931 . . . . 73.44 108.485 173.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -60.62 139.89 88.24 Favored 'Trans proline' 0 C--N 1.37 1.698 0 C-N-CA 122.171 1.914 . . . . 71.1 111.971 176.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -53.31 112.39 0.92 Allowed 'Trans proline' 0 C--N 1.381 2.253 0 C-N-CA 122.629 2.219 . . . . 75.23 110.781 172.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 70.2 mtp180 66.13 72.4 0.39 Allowed 'General case' 0 CA--C 1.548 0.884 0 O-C-N 124.597 1.186 . . . . 74.41 110.428 -164.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 12.1 t -81.6 173.87 11.95 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.638 0.775 . . . . 72.4 109.299 169.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . 0.464 HE21 ' HD2' ' A' ' 231' ' ' ARG . 2.2 mp0 -132.24 147.38 52.41 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 123.814 0.846 . . . . 64.25 109.302 -176.437 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.08 117.6 11.86 Favored 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 123.316 0.647 . . . . 72.24 109.583 174.496 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.25 3.16 22.97 Favored Glycine 0 C--N 1.344 1.023 0 CA-C-N 116.133 -0.485 . . . . 40.34 113.108 -174.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . 0.464 ' HD2' HE21 ' A' ' 228' ' ' GLN . 19.2 mtp-105 -83.63 160.65 21.33 Favored 'General case' 0 N--CA 1.479 1.015 0 CA-C-N 117.286 0.543 . . . . 75.12 111.223 175.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -116.05 120.83 40.36 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.549 1.139 . . . . 74.25 109.523 -176.224 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . 0.458 HD11 HG12 ' A' ' 223' ' ' VAL . 33.1 mt -110.54 100.02 8.91 Favored 'General case' 0 C--O 1.237 0.416 0 N-CA-C 107.2 -1.407 . . . . 70.12 107.2 174.548 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . 0.444 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 44.4 ttp180 -95.65 104.13 16.04 Favored 'General case' 0 CA--C 1.542 0.636 0 CA-C-N 115.566 -0.743 . . . . 62.13 109.859 -170.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.492 HD12 HD23 ' A' ' 249' ' ' LEU . 16.5 mt -81.04 119.07 23.06 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 123.17 0.588 . . . . 72.13 110.131 -177.118 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 34.2 mtmm -66.65 120.67 13.85 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 125.085 1.354 . . . . 72.12 112.514 -168.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 65.84 33.95 87.27 Favored Glycine 0 C--N 1.351 1.405 0 O-C-N 123.983 0.802 . . . . 63.14 114.053 170.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 28.5 mmtp -116.01 2.11 13.4 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 123.474 0.71 . . . . 73.51 111.635 179.104 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -88.72 -177.58 46.66 Favored Glycine 0 C--N 1.345 1.082 0 N-CA-C 111.434 -0.666 . . . . 65.21 111.434 167.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.639 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 95.2 m-85 -74.68 151.82 87.04 Favored Pre-proline 0 N--CA 1.479 1.016 0 C-N-CA 122.545 0.338 . . . . 73.54 111.119 -177.141 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -77.58 165.68 26.77 Favored 'Trans proline' 0 C--N 1.372 1.788 0 C-N-CA 122.036 1.824 . . . . 73.32 111.631 178.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 161.07 -157.39 28.92 Favored Glycine 0 CA--C 1.528 0.876 0 CA-C-O 119.545 -0.586 . . . . 63.04 113.106 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . 0.434 ' HD2' ' OE1' ' A' ' 191' ' ' GLN . 77.1 Cg_exo -54.35 -23.24 29.83 Favored 'Trans proline' 0 C--N 1.375 1.945 0 C-N-CA 124.174 3.249 . . . . 60.44 114.315 175.582 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -90.42 19.42 5.24 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 123.362 0.665 . . . . 63.11 111.484 176.233 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 71.26 -94.18 0.54 Allowed Glycine 0 C--N 1.352 1.452 0 N-CA-C 110.893 -0.883 . . . . 74.43 110.893 -174.568 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -119.7 146.2 45.82 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 124.7 1.2 . . . . 72.53 107.847 166.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -80.44 -173.16 46.12 Favored Glycine 0 C--O 1.24 0.483 0 O-C-N 123.766 0.666 . . . . 73.1 111.751 173.021 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -137.94 163.05 32.46 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.278 0.631 . . . . 70.04 109.327 -176.37 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.512 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 18.3 tp -99.63 109.58 22.07 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 109.46 -0.57 . . . . 71.05 109.46 172.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -87.86 105.42 17.4 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 107.083 -1.451 . . . . 71.1 107.083 175.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.422 HD22 ' HB2' ' A' ' 197' ' ' LEU . 78.4 mt -87.49 145.98 26.01 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 123.02 0.528 . . . . 75.45 111.575 172.678 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -110.83 98.18 7.39 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 107.924 -1.139 . . . . 71.31 107.924 174.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 61.3 t -56.94 126.56 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 123.227 0.611 . . . . 73.42 110.737 176.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . 0.402 ' O ' ' HA ' ' A' ' 198' ' ' ASP . 23.2 mmt180 -132.86 97.11 3.95 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 106.968 -1.493 . . . . 53.11 106.968 178.339 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 62.4 mt -74.59 122.57 28.28 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 N-CA-C 109.274 -0.639 . . . . 61.05 109.274 -177.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.3 t . . . . . 0 CA--C 1.565 1.525 0 C-N-CA 124.719 1.207 . . . . 63.5 108.779 -177.392 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 14.8 mt . . . . . 0 N--CA 1.482 1.148 0 CA-C-O 119.612 -0.232 . . . . 73.41 111.082 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.784 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 24.6 m -58.62 159.16 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 N-CA-C 114.252 1.205 . . . . 71.43 114.252 -173.796 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -108.08 -43.2 4.46 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 113.428 -1.714 . . . . 74.54 109.127 178.053 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 2.9 p80 -177.9 169.74 1.97 Allowed 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 124.08 0.952 . . . . 73.23 110.445 -178.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 85.7 t -64.98 116.33 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 108.287 -1.005 . . . . 73.43 108.287 166.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.52 ' HB ' ' HB2' ' A' ' 122' ' ' GLU . 10.2 t . . . . . 0 N--CA 1.473 0.695 0 O-C-N 123.381 0.426 . . . . 75.12 111.539 -174.109 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.472 0.653 0 N-CA-C 108.642 -0.873 . . . . 64.32 108.642 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 50.3 tp -108.18 127.06 53.49 Favored 'General case' 0 C--O 1.217 -0.638 0 N-CA-C 106.994 -1.484 . . . . 74.33 106.994 173.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 45.3 mtp85 -120.76 108.95 14.58 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.621 -0.511 . . . . 75.54 109.621 -170.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -130.69 139.55 50.32 Favored 'General case' 0 N--CA 1.478 0.944 0 C-N-CA 123.436 0.694 . . . . 33.24 110.578 -174.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . 0.52 ' HB2' ' HB ' ' A' ' 103' ' ' THR . 34.8 tt0 -104.38 146.53 28.7 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.266 0.626 . . . . 74.34 110.294 178.436 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.784 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.8 pt? -145.7 146.32 28.79 Favored Pre-proline 0 N--CA 1.467 0.415 0 C-N-CA 124.077 0.951 . . . . 64.32 110.379 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -78.36 121.91 5.42 Favored 'Trans proline' 0 C--N 1.366 1.457 0 C-N-CA 121.977 1.785 . . . . 73.11 110.581 167.539 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.529 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 14.2 tp -111.86 162.04 15.72 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.582 0.753 . . . . 71.13 109.218 175.161 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 19.5 m -101.86 158.03 16.42 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 109.174 -0.676 . . . . 75.02 109.174 175.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.477 HD23 ' HB3' ' A' ' 180' ' ' LEU . 65.1 mt -55.81 -52.19 64.87 Favored 'General case' 0 N--CA 1.486 1.352 0 CA-C-O 121.717 0.77 . . . . 63.43 111.248 179.06 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.414 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 10.9 mp0 -54.26 -33.24 58.1 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 114.495 -1.23 . . . . 65.2 111.708 175.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.4 mm-40 -85.96 -18.61 32.16 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 123.306 0.642 . . . . 73.25 111.98 -176.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.681 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -60.23 -41.34 92.9 Favored 'General case' 0 C--O 1.247 0.947 0 CA-C-O 121.805 0.812 . . . . 72.42 110.41 162.345 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.465 ' HA ' ' CE2' ' A' ' 240' ' ' PHE . 66.1 t80 -73.15 -43.2 61.91 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 114.365 -1.289 . . . . 72.4 112.812 175.003 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.8 m80 -83.94 -49.25 9.16 Favored 'General case' 0 N--CA 1.493 1.692 0 N-CA-C 112.439 0.533 . . . . 71.13 112.439 -172.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.06 -110.61 3.46 Favored Glycine 0 CA--C 1.531 1.063 0 N-CA-C 111.412 -0.675 . . . . 52.33 111.412 -173.597 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 90.0 172.99 45.13 Favored Glycine 0 C--N 1.35 1.318 0 C-N-CA 123.079 0.371 . . . . 61.14 113.923 168.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.63 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 2.1 mp0 -86.34 125.72 33.83 Favored 'General case' 0 C--N 1.351 0.671 0 N-CA-C 108.975 -0.75 . . . . 71.54 108.975 178.071 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 33.2 ttt85 -156.15 138.05 14.41 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 108.139 -1.06 . . . . 73.34 108.139 175.434 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.705 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 12.6 p -72.51 142.64 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 112.85 0.685 . . . . 73.03 112.85 -167.327 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 34.6 m -124.26 152.39 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 124.262 1.025 . . . . 75.35 109.781 174.121 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -124.5 104.31 8.66 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 107.179 -1.415 . . . . 63.13 107.179 171.14 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 7.1 p -150.9 139.12 14.43 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.965 0 C-N-CA 123.593 0.757 . . . . 54.54 109.885 -176.368 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.17 20.56 11.07 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 125.26 1.424 . . . . 74.43 112.768 -176.504 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.19 26.65 57.33 Favored Glycine 0 C--N 1.346 1.085 0 CA-C-N 116.538 -0.301 . . . . 54.41 112.385 -176.057 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.3 mmt180 -127.16 117.57 22.63 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.61 0.764 . . . . 64.21 110.277 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 43.1 ttp180 -98.5 104.57 16.62 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 108.321 -0.992 . . . . 72.13 108.321 173.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.2 m -146.81 137.47 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 123.672 0.789 . . . . 53.43 109.853 -177.197 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.705 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 35.7 p -73.34 118.19 15.99 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.413 0.685 . . . . 64.12 110.146 177.173 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.9 p -100.08 139.07 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 122.933 0.493 . . . . 64.02 110.129 -178.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . 0.63 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 24.8 ttp180 -106.9 106.47 17.01 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 108.344 -0.984 . . . . 75.23 108.344 173.585 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.465 ' HB ' HD13 ' A' ' 159' ' ' ILE . 34.2 pt -96.73 128.33 36.29 Favored Pre-proline 0 CA--C 1.546 0.794 0 N-CA-C 107.828 -1.175 . . . . 73.42 107.828 175.084 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -71.14 151.35 61.12 Favored 'Trans proline' 0 C--N 1.373 1.822 0 C-N-CA 122.331 2.021 . . . . 71.43 113.59 -167.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.422 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 43.4 Cg_exo -60.54 110.52 0.82 Allowed 'Trans proline' 0 C--N 1.378 2.105 0 C-N-CA 122.779 2.319 . . . . 70.41 109.939 169.755 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 131.37 59.64 0.09 OUTLIER Glycine 0 C--N 1.341 0.811 0 N-CA-C 111.01 -0.836 . . . . 73.45 111.01 -170.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.681 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -140.24 162.82 24.26 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.203 0 N-CA-C 108.453 -0.943 . . . . 60.31 108.453 177.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.545 ' HD2' ' HB3' ' A' ' 188' ' ' LEU . 38.5 mtp180 -146.67 176.52 9.79 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 124.405 1.082 . . . . 72.44 110.869 -171.006 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -56.74 117.81 4.27 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 124.537 1.135 . . . . 75.42 111.694 173.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.24 7.75 87.67 Favored Glycine 0 C--N 1.342 0.869 0 CA-C-N 115.372 -0.831 . . . . 72.52 113.645 179.128 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 33.8 t -78.76 136.32 37.35 Favored 'General case' 0 C--N 1.35 0.599 0 CA-C-O 121.145 0.498 . . . . 53.15 109.799 -178.105 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.435 HG12 HD22 ' A' ' 175' ' ' LEU . 8.2 t -103.47 119.29 51.81 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 CA-C-N 114.531 -1.213 . . . . 74.44 109.329 -172.099 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.578 HD11 HG21 ' A' ' 153' ' ' VAL . 26.4 mt -103.05 115.55 45.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.811 0.844 . . . . 75.12 110.417 -171.214 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 32.2 ttt85 -85.06 107.32 17.1 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.603 0.761 . . . . 62.05 109.813 177.098 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.452 HG22 ' O ' ' A' ' 174' ' ' LEU . 25.4 m -112.88 111.59 51.01 Favored Pre-proline 0 CA--C 1.56 1.356 0 C-N-CA 122.648 0.379 . . . . 64.3 110.404 178.119 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -65.97 148.74 86.17 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 123.286 2.657 . . . . 71.14 114.01 -173.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 70.75 23.9 77.44 Favored Glycine 0 C--N 1.352 1.433 0 CA-C-N 116.025 -0.534 . . . . 42.52 114.218 173.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 52.9 mmm -120.16 -30.64 4.6 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.876 0.87 . . . . 75.2 111.554 -172.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.346 1.104 0 O-C-N 123.146 0.279 . . . . 73.43 113.069 -179.462 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo . . . . . 0 CA--C 1.535 0.561 0 CA-C-O 119.686 -0.214 . . . . 75.33 111.698 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -97.65 150.12 19.4 Favored Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.788 -0.925 . . . . 75.04 110.788 175.014 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -106.88 160.05 15.79 Favored 'General case' 0 C--O 1.238 0.45 0 C-N-CA 123.622 0.769 . . . . 51.32 109.691 -178.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.452 ' O ' HG22 ' A' ' 161' ' ' VAL . 13.8 tp -115.04 114.7 25.72 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 108.204 -1.035 . . . . 64.43 108.204 -179.713 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.435 HD22 HG12 ' A' ' 158' ' ' VAL . 57.0 mt -84.72 101.69 12.4 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.673 1.189 . . . . 74.31 111.237 176.381 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.422 ' HB3' HD21 ' A' ' 123' ' ' LEU . 42.5 mt -90.93 105.65 17.97 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 114.95 -1.023 . . . . 74.31 111.32 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 27.3 t -85.55 99.67 7.77 Favored 'Isoleucine or valine' 0 C--O 1.242 0.685 0 N-CA-C 107.959 -1.126 . . . . 44.41 107.959 172.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.529 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 17.4 m -82.25 148.88 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 121.216 0.531 . . . . 71.15 110.235 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 39.4 mmm-85 -121.2 103.95 9.38 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.798 -1.186 . . . . 65.41 107.798 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.477 ' HB3' HD23 ' A' ' 127' ' ' LEU . 30.6 mt -67.97 149.08 50.19 Favored 'General case' 0 C--O 1.242 0.667 0 N-CA-C 109.256 -0.646 . . . . 45.12 109.256 177.339 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 40.2 mt -53.85 137.56 54.79 Favored Pre-proline 0 CA--C 1.552 1.045 0 O-C-N 123.674 0.609 . . . . 74.14 110.311 -178.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -58.78 -5.13 2.35 Favored 'Trans proline' 0 C--N 1.378 2.119 0 C-N-CA 123.141 2.56 . . . . 61.13 114.073 -177.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . 0.456 ' O ' HD11 ' A' ' 127' ' ' LEU . 6.2 t60 -83.72 107.76 11.36 Favored Pre-proline 0 CA--C 1.548 0.893 0 C-N-CA 124.654 1.182 . . . . 72.42 108.526 162.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -96.67 163.48 1.12 Allowed 'Trans proline' 0 C--N 1.369 1.631 0 C-N-CA 122.916 2.411 . . . . 74.45 111.922 168.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.66 -42.98 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 122.999 0.52 . . . . 72.2 109.769 169.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.503 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 5.6 m-85 -101.92 123.97 46.74 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 115.783 -0.644 . . . . 70.45 110.795 -176.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -109.64 123.38 49.38 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 125.136 1.375 . . . . 73.3 108.092 179.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.545 ' HB3' ' HD2' ' A' ' 154' ' ' ARG . 22.4 tp -95.58 113.11 24.73 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-O 121.445 0.641 . . . . 60.24 111.174 -173.158 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -83.93 170.37 14.08 Favored 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 125.533 1.533 . . . . 72.04 107.826 162.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . -42.77 86.74 0.01 OUTLIER Glycine 0 C--N 1.362 2.004 0 CA-C-N 118.761 0.71 . . . . 53.53 114.357 175.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 67.18 -4.82 0.78 Allowed 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 127.658 2.383 . . . . 64.23 113.554 -175.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.503 ' O ' HD12 ' A' ' 188' ' ' LEU . 27.2 t70 -105.52 156.13 18.52 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 124.899 1.28 . . . . 64.44 109.989 -174.463 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.536 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 78.4 mt -113.62 157.7 21.78 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 124.047 0.939 . . . . 72.11 112.177 -172.686 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 46.8 m-85 -139.61 122.25 16.33 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 114.419 -1.264 . . . . 74.03 108.378 174.164 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -142.61 171.1 14.51 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.144 0.978 . . . . 62.5 109.504 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 16.2 m -109.41 128.43 55.13 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 109.779 -0.452 . . . . 74.23 109.779 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.476 HD22 HD13 ' A' ' 251' ' ' LEU . 62.3 tp -114.75 115.0 26.35 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.222 1.009 . . . . 61.25 109.713 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . 0.436 ' HA ' ' HB2' ' A' ' 254' ' ' ARG . 10.3 m-20 -99.68 106.35 18.27 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.655 -0.498 . . . . 72.05 109.655 178.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . 0.496 HG12 HG21 ' A' ' 210' ' ' VAL . 6.4 m -107.72 147.36 35.23 Favored Pre-proline 0 N--CA 1.481 1.097 0 C-N-CA 123.232 0.613 . . . . 74.22 109.563 178.179 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.32 148.8 55.87 Favored 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 122.149 1.899 . . . . 64.2 110.565 167.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -54.14 -44.38 98.4 Favored Pre-proline 0 CA--C 1.56 1.346 0 CA-C-O 117.468 -1.253 . . . . 61.42 112.893 176.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -43.66 -52.98 4.78 Favored 'Trans proline' 0 C--N 1.403 3.396 0 C-N-CA 123.029 2.486 . . . . 75.45 113.895 171.032 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . 0.522 HG21 HG13 ' A' ' 210' ' ' VAL . 6.3 mt -71.05 -38.06 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 CA-C-N 116.62 -0.263 . . . . 63.22 110.781 -177.639 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -61.01 -38.71 87.05 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 123.321 0.648 . . . . 65.34 112.078 -178.211 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.8 m -84.45 -38.44 13.62 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 CA-C-N 116.173 -0.467 . . . . 65.03 111.759 -176.318 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.1 m -78.2 -27.51 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 CA-C-N 118.121 0.418 . . . . 60.12 111.201 179.408 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . 0.456 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 79.56 53.52 4.32 Favored Glycine 0 C--N 1.339 0.72 0 CA-C-N 115.554 -0.748 . . . . 73.25 112.849 -175.773 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.8 -152.6 11.53 Favored Glycine 0 C--N 1.354 1.555 0 N-CA-C 111.762 -0.535 . . . . 75.23 111.762 178.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 57.9 mttp -125.27 139.13 53.98 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 123.371 0.668 . . . . 74.44 109.842 176.265 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . 0.522 HG13 HG21 ' A' ' 203' ' ' ILE . 13.6 m -123.71 134.63 65.9 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 CA-C-N 114.737 -1.119 . . . . 70.04 108.322 173.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 39.7 ttp-105 -81.64 113.48 19.68 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 108.835 -0.802 . . . . 72.2 108.835 175.564 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.42 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -101.19 165.6 11.21 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.374 -0.973 . . . . 65.21 108.374 175.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 1.9 mtp -106.4 154.14 21.23 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.593 0.711 . . . . 74.31 110.762 173.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.503 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.8 t -144.53 173.38 11.86 Favored 'General case' 0 C--O 1.242 0.705 0 CA-C-N 113.641 -1.618 . . . . 61.14 108.365 171.715 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . 0.414 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 49.9 mt -73.7 -10.53 59.78 Favored 'General case' 0 CA--C 1.553 1.069 0 CA-C-N 115.946 -0.57 . . . . 74.01 111.092 -179.723 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . 0.407 ' H ' HG23 ' A' ' 214' ' ' THR . 35.1 tt0 -86.87 -18.98 29.59 Favored 'General case' 0 CA--C 1.551 1.011 0 C-N-CA 124.58 1.152 . . . . 54.02 110.819 173.697 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 134.26 -157.91 23.12 Favored Glycine 0 C--N 1.353 1.48 0 CA-C-O 119.53 -0.595 . . . . 61.12 111.786 -176.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -84.4 130.96 4.7 Favored 'Trans proline' 0 C--N 1.366 1.46 0 C-N-CA 122.5 2.134 . . . . 74.31 112.227 175.481 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 35.1 m -113.08 161.9 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 124.22 1.008 . . . . 74.31 111.292 178.219 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -106.25 121.23 43.78 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 108.627 -0.879 . . . . 70.25 108.627 173.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 20.2 t -103.26 115.45 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 109.312 -0.625 . . . . 72.43 109.312 176.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -84.59 100.66 11.56 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 107.689 -1.226 . . . . 74.11 107.689 170.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.456 HG23 ' HA2' ' A' ' 207' ' ' GLY . 12.3 m -76.26 141.1 69.89 Favored Pre-proline 0 CA--C 1.549 0.913 0 N-CA-C 108.927 -0.768 . . . . 71.34 108.927 -178.653 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_exo -64.46 136.02 48.68 Favored 'Trans proline' 0 C--N 1.367 1.531 0 C-N-CA 122.622 2.215 . . . . 62.32 112.092 177.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -58.34 117.6 4.34 Favored 'Trans proline' 0 C--N 1.371 1.716 0 C-N-CA 122.611 2.207 . . . . 61.1 111.23 174.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 64.96 51.74 1.68 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 124.636 1.174 . . . . 73.42 110.826 -175.449 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.6 t -77.61 172.35 13.52 Favored 'General case' 0 CA--C 1.545 0.788 0 CA-C-N 115.248 -0.887 . . . . 74.52 109.555 170.556 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 28.1 mp0 -122.5 145.46 48.29 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 123.398 0.679 . . . . 74.4 110.036 -174.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.57 121.86 18.65 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.734 -0.839 . . . . 75.5 108.734 172.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.69 -7.7 19.87 Favored Glycine 0 N--CA 1.469 0.893 0 CA-C-N 116.087 -0.506 . . . . 52.54 112.324 -171.279 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 70.5 mtp180 -83.28 160.1 21.79 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 122.842 0.457 . . . . 62.42 110.347 173.319 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 3.4 mppt? -125.13 113.4 17.66 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.966 0.906 . . . . 73.11 109.527 177.443 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 38.3 mt -89.89 125.71 35.45 Favored 'General case' 0 C--N 1.354 0.802 0 N-CA-C 108.451 -0.944 . . . . 53.43 108.451 -177.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . 0.51 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 37.2 ttp180 -106.26 112.17 25.07 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-O 121.056 0.455 . . . . 63.44 111.22 -168.781 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.472 HD12 HD23 ' A' ' 249' ' ' LEU . 44.7 mt -86.61 127.12 34.9 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-N 115.347 -0.842 . . . . 73.3 110.11 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 35.1 mtmm -70.18 124.64 24.62 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 124.763 1.225 . . . . 73.31 111.809 -172.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 70.8 13.92 72.43 Favored Glycine 0 C--N 1.348 1.216 0 N-CA-C 114.954 0.742 . . . . 74.33 114.954 170.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -87.74 -9.96 52.5 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.226 0.61 . . . . 70.03 111.982 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -87.6 179.57 47.66 Favored Glycine 0 C--N 1.342 0.896 0 O-C-N 123.407 0.442 . . . . 70.13 112.799 177.08 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.465 ' CE2' ' HA ' ' A' ' 131' ' ' PHE . 14.4 m-85 -69.07 144.45 95.48 Favored Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 123.565 0.746 . . . . 75.44 110.99 -177.154 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 23.0 Cg_exo -66.65 130.35 23.25 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.632 2.222 . . . . 70.24 112.304 172.411 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -161.21 -151.53 6.29 Favored Glycine 0 CA--C 1.538 1.507 0 CA-C-O 119.271 -0.738 . . . . 72.12 111.99 178.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -56.18 -23.62 46.02 Favored 'Trans proline' 0 C--N 1.377 2.048 0 C-N-CA 123.996 3.131 . . . . 65.32 115.865 -174.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -101.15 22.6 12.09 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 123.298 0.639 . . . . 71.52 111.586 -179.397 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.16 -93.31 1.82 Allowed Glycine 0 C--N 1.341 0.846 0 N-CA-C 110.075 -1.21 . . . . 72.24 110.075 -172.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.468 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 46.6 mtm180 -122.14 153.68 38.41 Favored 'General case' 0 N--CA 1.478 0.935 0 N-CA-C 108.484 -0.932 . . . . 74.21 108.484 170.218 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -84.61 -162.46 34.94 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.789 -0.641 . . . . 41.11 112.186 178.365 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 42.7 m-20 -138.95 173.65 11.35 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.424 0.689 . . . . 71.13 109.853 -173.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.536 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 16.6 tp -119.82 115.85 24.68 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.397 0.679 . . . . 72.42 111.583 176.2 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . 0.425 ' CZ ' ' HD3' ' A' ' 234' ' ' ARG . 20.5 m-85 -88.95 107.44 19.02 Favored 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 123.561 0.744 . . . . 72.51 109.997 171.259 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.573 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 38.2 mt -89.93 118.72 29.7 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 125.041 1.336 . . . . 74.34 112.178 176.081 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -77.57 96.56 4.81 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 108.965 -0.754 . . . . 73.2 108.965 178.261 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 45.2 t -49.85 115.1 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 124.201 1.001 . . . . 52.14 111.354 173.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . 0.436 ' HB2' ' HA ' ' A' ' 198' ' ' ASP . 30.5 mmm180 -118.21 93.2 4.04 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 106.905 -1.517 . . . . 75.35 106.905 174.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 71.2 mt -76.48 122.94 31.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 N-CA-C 109.216 -0.661 . . . . 75.04 109.216 176.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.557 1.244 0 CA-C-O 117.446 -1.264 . . . . 64.21 107.941 -178.597 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.459 HD13 ' HG3' ' A' ' 136' ' ' ARG . 60.7 tp . . . . . 0 CA--C 1.535 0.384 0 N-CA-C 105.994 -1.854 . . . . 74.4 105.994 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.406 HG22 ' H ' ' A' ' 101' ' ' HIS . 12.4 p -107.26 154.99 8.07 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 C-N-CA 124.445 1.098 . . . . 71.43 109.306 165.636 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -141.57 1.93 1.58 Allowed 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 124.366 1.066 . . . . 75.1 110.518 173.318 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . 0.406 ' H ' HG22 ' A' ' 99' ' ' VAL . 9.2 t-80 -109.06 103.33 12.33 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.898 1.279 . . . . 72.14 109.545 -177.772 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 82.6 t -83.98 136.21 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 N-CA-C 108.597 -0.89 . . . . 61.52 108.597 173.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 43.1 p . . . . . 0 N--CA 1.472 0.671 0 C-N-CA 123.459 0.704 . . . . 71.3 111.912 -172.092 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 . . . . . 0 N--CA 1.47 0.558 0 N-CA-C 108.69 -0.856 . . . . 71.41 108.69 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.437 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 2.5 tt -94.36 138.61 32.12 Favored 'General case' 0 C--O 1.215 -0.722 0 N-CA-C 105.993 -1.854 . . . . 64.04 105.993 179.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -128.49 139.91 52.09 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 109.586 -0.524 . . . . 72.23 109.586 -169.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.402 ' HB1' HG21 ' A' ' 99' ' ' VAL . . . -153.83 149.77 27.73 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 123.889 0.876 . . . . 70.41 110.313 -177.041 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 72.6 tt0 -127.75 135.29 49.93 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.536 1.134 . . . . 74.05 109.375 -174.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -140.84 142.41 28.04 Favored Pre-proline 0 N--CA 1.478 0.973 0 C-N-CA 122.785 0.434 . . . . 72.35 110.865 -175.149 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_exo -73.6 113.34 3.76 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 121.889 1.726 . . . . 73.42 109.851 166.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.451 HD22 HG11 ' A' ' 178' ' ' VAL . 17.9 tp -109.54 165.79 11.39 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.299 1.039 . . . . 70.25 108.932 179.401 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.592 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 8.6 m -95.39 156.6 16.25 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.23 0.612 . . . . 44.0 109.903 176.266 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.669 HD23 ' HB3' ' A' ' 180' ' ' LEU . 51.9 mt -56.7 -50.35 72.43 Favored 'General case' 0 N--CA 1.487 1.405 0 CA-C-O 122.21 1.005 . . . . 71.54 109.353 174.083 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.483 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -58.51 -38.07 76.93 Favored 'General case' 0 CA--C 1.546 0.813 0 CA-C-N 113.614 -1.63 . . . . 61.14 111.802 178.823 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.404 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 12.0 mm-40 -77.94 -23.25 48.61 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 122.844 0.458 . . . . 73.22 111.831 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.642 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -66.23 -32.0 73.16 Favored 'General case' 0 C--O 1.252 1.201 0 CA-C-O 121.712 0.768 . . . . 63.43 111.156 168.505 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.468 ' HA ' ' CE2' ' A' ' 240' ' ' PHE . 36.9 t80 -75.73 -47.92 24.03 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 114.746 -1.115 . . . . 73.31 111.892 172.798 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -75.23 -48.17 24.7 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 122.59 0.356 . . . . 71.34 111.626 -170.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 63.58 -130.14 40.03 Favored Glycine 0 CA--C 1.532 1.124 0 O-C-N 123.666 0.604 . . . . 42.23 111.861 -175.204 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 94.76 -172.94 31.67 Favored Glycine 0 C--N 1.35 1.332 0 N-CA-C 114.245 0.458 . . . . 35.51 114.245 171.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 7.6 mp0 -88.93 125.96 35.18 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.152 0.981 . . . . 53.12 109.965 -176.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . 0.459 ' HG3' HD13 ' A' ' 98' ' ' LEU . 33.3 mmt180 -137.78 168.49 19.57 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 124.883 1.273 . . . . 72.24 108.325 171.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.0 p -90.23 144.79 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 108.676 -0.861 . . . . 71.12 108.676 178.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 144' ' ' ARG . 7.8 p -134.23 138.2 50.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 123.249 0.62 . . . . 74.34 109.457 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -124.69 106.15 9.86 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 108.14 -1.059 . . . . 75.21 108.14 169.185 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.5 m -125.09 117.81 51.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 C-N-CA 124.461 1.105 . . . . 72.05 109.592 -178.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . 0.416 ' HB3' HD11 ' A' ' 119' ' ' LEU . . . 64.43 20.47 12.17 Favored 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 124.598 1.159 . . . . 73.23 111.771 179.579 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.69 -6.9 74.23 Favored Glycine 0 C--N 1.357 1.704 0 O-C-N 123.225 0.328 . . . . 73.02 113.478 -178.302 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 6.3 tpm_? -91.6 117.41 29.71 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 108.92 -0.77 . . . . 65.35 108.92 176.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.401 ' HA ' ' O ' ' A' ' 138' ' ' VAL . 52.5 ttp180 -99.66 122.07 42.14 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 123.583 0.753 . . . . 75.34 109.516 179.181 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 19.0 t -133.19 156.99 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 N-CA-C 108.3 -1.0 . . . . 74.54 108.3 176.148 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 24.3 p -85.35 113.71 21.87 Favored 'General case' 0 CA--C 1.547 0.838 0 N-CA-C 108.325 -0.991 . . . . 75.25 108.325 165.511 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.2 p -98.02 123.52 50.54 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 CA-C-O 121.641 0.734 . . . . 72.42 111.402 -176.259 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -97.94 104.77 16.83 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 107.76 -1.2 . . . . 74.23 107.76 167.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 38.7 pt -97.32 103.63 16.61 Favored Pre-proline 0 CA--C 1.55 0.967 0 N-CA-C 108.154 -1.054 . . . . 51.41 108.154 167.19 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -61.09 151.21 80.16 Favored 'Trans proline' 0 C--N 1.383 2.366 0 C-N-CA 122.613 2.209 . . . . 74.32 112.788 -178.116 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -49.28 151.37 6.62 Favored 'Trans proline' 0 C--N 1.378 2.081 0 C-N-CA 123.829 3.019 . . . . 71.54 114.153 176.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 108.73 23.36 6.55 Favored Glycine 0 N--CA 1.478 1.438 0 C-N-CA 121.465 -0.398 . . . . 51.51 113.238 174.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.642 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -99.65 162.84 2.95 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.192 0 N-CA-C 107.831 -1.174 . . . . 71.41 107.831 179.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.601 ' HA ' HD11 ' A' ' 180' ' ' LEU . 0.0 OUTLIER -158.87 177.69 10.88 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.618 1.167 . . . . 74.11 111.91 -172.02 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.3 tp10 -51.58 115.5 1.65 Allowed 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 124.76 1.224 . . . . 72.32 111.722 178.09 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 80.68 10.43 85.18 Favored Glycine 0 C--N 1.356 1.64 0 CA-C-N 115.775 -0.648 . . . . 54.34 113.591 177.652 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.4 t -85.77 123.76 31.51 Favored 'General case' 0 C--O 1.245 0.822 0 C-N-CA 123.097 0.559 . . . . 73.41 109.58 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 3.4 t -99.6 122.4 51.38 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 124.129 0.972 . . . . 72.21 108.659 -176.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.627 HD11 HG21 ' A' ' 153' ' ' VAL . 13.5 mt -103.11 119.68 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 124.046 0.938 . . . . 74.42 109.33 -169.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 34.3 ttt180 -97.43 103.67 15.63 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 122.693 0.397 . . . . 65.54 110.361 -177.115 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 12.1 m -102.39 118.91 57.75 Favored Pre-proline 0 CA--C 1.559 1.293 0 N-CA-C 109.451 -0.574 . . . . 53.13 109.451 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.47 152.25 43.36 Favored 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.635 2.224 . . . . 64.34 113.684 -173.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 79.74 24.48 60.19 Favored Glycine 0 C--N 1.349 1.267 0 N-CA-C 115.0 0.76 . . . . 61.52 115.0 168.147 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 39.6 mtt -105.18 -62.91 1.29 Allowed 'General case' 0 N--CA 1.488 1.465 0 CA-C-N 118.285 1.042 . . . . 74.22 112.093 176.061 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.349 1.294 0 CA-C-N 115.933 -0.576 . . . . 41.14 112.937 -177.295 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_exo . . . . . 0 CA--C 1.541 0.857 0 N-CA-C 110.966 -0.436 . . . . 74.3 110.966 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -101.78 153.3 18.74 Favored Glycine 0 CA--C 1.502 -0.773 0 N-CA-C 110.621 -0.992 . . . . 71.22 110.621 174.634 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -112.69 178.59 4.24 Favored 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 123.473 0.709 . . . . 74.41 111.511 -168.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.437 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 34.9 tp -130.16 112.92 13.86 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 114.579 -1.191 . . . . 74.1 108.615 168.419 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 72.9 mt -85.09 100.86 11.98 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.138 1.375 . . . . 44.25 111.238 177.118 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 70.7 mt -95.38 101.64 13.38 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 122.69 0.396 . . . . 55.04 110.666 174.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 2.5 p -87.03 108.65 18.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 N-CA-C 109.158 -0.682 . . . . 62.25 109.158 172.576 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.451 HG11 HD22 ' A' ' 125' ' ' LEU . 4.0 m -87.35 149.37 4.11 Favored 'Isoleucine or valine' 0 C--O 1.245 0.851 0 CA-C-N 115.946 -0.57 . . . . 74.12 110.665 -177.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 13.1 mmm-85 -124.97 101.31 6.99 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 107.491 -1.299 . . . . 64.13 107.491 -178.521 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . 0.669 ' HB3' HD23 ' A' ' 127' ' ' LEU . 25.3 mt -69.46 148.61 49.3 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 112.082 0.401 . . . . 61.31 112.082 -172.115 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.592 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 39.8 mt -57.5 138.25 81.57 Favored Pre-proline 0 CA--C 1.559 1.295 0 C-N-CA 123.283 0.633 . . . . 73.03 110.752 179.488 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.44 83.79 1.0 Allowed 'Trans proline' 0 C--N 1.374 1.875 0 C-N-CA 123.188 2.592 . . . . 63.11 112.584 -177.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -165.19 54.03 0.34 Allowed Pre-proline 0 CA--C 1.559 1.306 0 C-N-CA 124.12 0.968 . . . . 73.43 109.314 170.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.61 124.4 15.71 Favored 'Trans proline' 0 C--N 1.389 2.668 0 C-N-CA 122.627 2.218 . . . . 63.32 112.723 -169.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.4 p -130.84 -44.42 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 124.182 0.993 . . . . 75.41 109.561 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . 0.41 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 6.4 m-85 -105.01 120.29 41.11 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.218 0.532 . . . . 73.31 111.347 -176.048 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.705 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 23.5 mtp180 -104.17 162.7 12.95 Favored 'General case' 0 N--CA 1.467 0.425 0 C-N-CA 124.18 0.992 . . . . 75.42 109.337 173.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.418 HD12 ' O ' ' A' ' 192' ' ' ASP . 57.2 tp -132.42 127.53 35.56 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 123.493 0.717 . . . . 64.04 109.743 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -139.52 102.52 4.48 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 125.034 1.333 . . . . 73.2 108.122 176.637 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 56.59 58.41 14.53 Favored Glycine 0 C--N 1.353 1.479 0 O-C-N 123.951 0.782 . . . . 75.34 114.04 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . 0.568 ' NE2' ' HD2' ' A' ' 243' ' ' PRO . 52.6 mt-30 74.09 -15.81 0.57 Allowed 'General case' 0 N--CA 1.505 2.322 0 C-N-CA 125.407 1.483 . . . . 70.12 112.305 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.418 ' O ' HD12 ' A' ' 188' ' ' LEU . 9.7 t0 -97.41 152.44 18.95 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.333 1.053 . . . . 65.21 108.362 -175.358 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.4 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 78.4 mt -110.33 168.47 9.42 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 122.024 0.916 . . . . 61.54 111.512 -173.187 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . 0.705 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 35.6 m-85 -134.14 132.29 39.68 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 114.085 -1.416 . . . . 55.43 108.062 171.182 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . 0.436 ' HB3' HD11 ' A' ' 249' ' ' LEU . . . -154.02 168.28 26.95 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.909 0.884 . . . . 43.11 109.308 174.18 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 35.5 m -105.75 128.51 53.74 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 115.702 -0.681 . . . . 71.24 109.672 178.428 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.512 HD13 ' HB2' ' A' ' 212' ' ' ALA . 59.9 tp -107.76 113.65 27.05 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.733 -0.84 . . . . 75.23 108.733 173.382 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -94.9 119.82 34.08 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.373 -0.973 . . . . 72.43 108.373 175.496 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . 0.461 HG11 HG23 ' A' ' 253' ' ' VAL . 7.5 p -134.52 134.77 22.68 Favored Pre-proline 0 N--CA 1.479 1.018 0 C-N-CA 124.284 1.033 . . . . 64.42 109.37 -173.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.58 149.14 91.05 Favored 'Trans proline' 0 C--N 1.372 1.782 0 C-N-CA 122.715 2.277 . . . . 63.3 113.092 175.693 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . 0.492 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -60.75 -43.19 91.16 Favored Pre-proline 0 N--CA 1.478 0.972 0 N-CA-C 113.171 0.804 . . . . 75.53 113.171 176.445 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . 0.422 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 10.6 Cg_endo -53.73 -44.36 49.84 Favored 'Trans proline' 0 C--N 1.392 2.854 0 C-N-CA 121.759 1.639 . . . . 74.32 112.294 172.025 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.7 mt -67.44 -36.22 75.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 122.821 0.449 . . . . 73.53 111.189 177.618 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -64.57 -41.42 96.3 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 123.201 0.6 . . . . 73.22 111.802 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.7 m -79.89 -42.28 22.14 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 CA-C-N 116.003 -0.544 . . . . 72.34 111.362 -177.017 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 10.1 m -80.1 -20.02 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 122.471 0.308 . . . . 71.21 111.054 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 68.92 65.92 2.45 Favored Glycine 0 C--N 1.343 0.962 0 CA-C-N 115.687 -0.688 . . . . 51.43 112.461 -176.26 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.83 -145.92 15.4 Favored Glycine 0 C--N 1.357 1.7 0 N-CA-C 111.233 -0.747 . . . . 63.1 111.233 175.316 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 24.4 pttm -133.0 149.82 52.2 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 122.853 0.461 . . . . 71.51 109.88 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 2.8 m -145.09 134.37 18.04 Favored 'Isoleucine or valine' 0 C--O 1.239 0.528 0 N-CA-C 107.539 -1.282 . . . . 73.02 107.539 176.246 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 31.7 ptt180 -79.43 137.77 37.38 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 109.472 -0.566 . . . . 62.12 109.472 176.038 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.512 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -108.19 134.65 50.75 Favored 'General case' 0 C--O 1.245 0.845 0 C-N-CA 123.311 0.644 . . . . 74.45 109.408 174.218 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 4.8 tpt -75.85 106.26 7.33 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 108.837 -0.801 . . . . 74.22 108.837 173.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . 0.41 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 11.2 t -110.68 165.85 11.49 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 109.703 -0.48 . . . . 64.31 109.703 174.553 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . 0.483 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 59.7 mt -69.69 -17.7 63.5 Favored 'General case' 0 CA--C 1.551 0.99 0 CA-C-N 115.686 -0.688 . . . . 61.02 111.162 178.348 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -79.21 -19.42 50.83 Favored 'General case' 0 CA--C 1.556 1.209 0 C-N-CA 123.934 0.894 . . . . 50.41 110.948 174.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 131.77 -148.53 19.06 Favored Glycine 0 C--N 1.346 1.088 0 N-CA-C 111.378 -0.689 . . . . 70.33 111.378 -176.079 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -85.86 126.85 2.99 Favored 'Trans proline' 0 CA--C 1.557 1.64 0 C-N-CA 122.376 2.05 . . . . 74.42 112.473 172.118 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . 0.525 HG11 ' HD2' ' A' ' 238' ' ' LYS . 34.9 m -111.56 155.47 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 N-CA-C 109.132 -0.692 . . . . 71.22 109.132 169.575 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -114.36 111.8 22.04 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.944 -0.761 . . . . 72.44 108.944 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.458 HG22 HD11 ' A' ' 235' ' ' LEU . 8.5 t -96.27 115.75 36.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.381 0 C-N-CA 123.593 0.757 . . . . 71.22 109.704 -178.594 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.59 101.28 13.97 Favored 'General case' 0 C--O 1.239 0.529 0 N-CA-C 106.673 -1.603 . . . . 54.23 106.673 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 19.0 m -75.21 141.47 74.13 Favored Pre-proline 0 CA--C 1.551 1.018 0 C-N-CA 122.546 0.338 . . . . 74.04 110.546 -173.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -60.07 133.27 49.15 Favored 'Trans proline' 0 C--N 1.378 2.092 0 C-N-CA 122.679 2.253 . . . . 42.24 111.828 176.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -56.0 124.57 16.58 Favored 'Trans proline' 0 C--N 1.377 2.077 0 C-N-CA 122.692 2.261 . . . . 71.41 110.92 173.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 60.58 51.98 4.8 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 124.593 1.157 . . . . 72.34 110.77 -173.271 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.2 t -78.61 165.77 23.3 Favored 'General case' 0 CA--C 1.544 0.741 0 N-CA-C 109.229 -0.656 . . . . 73.43 109.229 170.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . 0.43 ' H ' ' HD3' ' A' ' 231' ' ' ARG . 25.7 mp0 -119.51 147.32 44.58 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 108.707 -0.849 . . . . 72.15 108.707 -174.628 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.01 143.62 52.51 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.554 0.742 . . . . 74.12 110.844 178.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 89.46 0.04 80.03 Favored Glycine 0 C--N 1.343 0.966 0 O-C-N 123.442 0.464 . . . . 34.0 113.342 -179.065 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . 0.462 ' O ' HG12 ' A' ' 253' ' ' VAL . 80.8 mtp180 -80.26 163.48 23.95 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-N 117.455 0.627 . . . . 74.43 109.855 174.426 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.465 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.8 mptp? -112.97 107.31 15.81 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 108.69 -0.856 . . . . 75.34 108.69 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 56.9 mt -85.2 116.34 23.5 Favored 'General case' 0 C--N 1.355 0.824 0 N-CA-C 107.92 -1.141 . . . . 75.2 107.92 178.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 19.6 ttm-85 -95.79 114.76 26.53 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 124.097 0.959 . . . . 74.25 109.433 -164.229 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.458 HD11 HG22 ' A' ' 221' ' ' VAL . 25.0 mt -106.77 106.07 16.41 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.081 0.552 . . . . 73.3 109.698 176.573 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . 0.56 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 44.8 mttp -62.7 148.98 44.91 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 123.651 0.781 . . . . 55.24 111.718 176.539 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.51 35.44 81.41 Favored Glycine 0 C--N 1.355 1.636 0 O-C-N 123.971 0.794 . . . . 64.22 113.228 176.009 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . 0.525 ' HD2' HG11 ' A' ' 219' ' ' VAL . 15.9 mmtm -123.82 -23.08 4.75 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 123.774 0.83 . . . . 62.02 112.116 -176.159 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -81.38 -155.66 14.05 Favored Glycine 0 C--N 1.341 0.844 0 O-C-N 123.592 0.557 . . . . 74.04 112.68 178.203 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.468 ' CE2' ' HA ' ' A' ' 131' ' ' PHE . 75.3 m-85 -96.26 143.68 26.54 Favored Pre-proline 0 N--CA 1.474 0.754 0 O-C-N 122.346 -0.502 . . . . 71.03 111.802 178.186 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . 0.581 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 27.9 Cg_exo -62.22 168.21 9.71 Favored 'Trans proline' 0 C--N 1.378 2.095 0 C-N-CA 123.245 2.63 . . . . 72.13 112.868 176.684 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 163.22 -159.08 31.58 Favored Glycine 0 CA--C 1.534 1.226 0 CA-C-O 119.586 -0.564 . . . . 60.35 112.959 -177.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . 0.568 ' HD2' ' NE2' ' A' ' 191' ' ' GLN . 39.8 Cg_exo -60.44 -24.04 76.73 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 123.768 2.979 . . . . 74.24 113.363 177.601 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.44 18.56 7.08 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.668 0.787 . . . . 74.32 111.507 178.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.34 -98.84 1.79 Allowed Glycine 0 C--N 1.349 1.266 0 N-CA-C 110.746 -0.942 . . . . 64.14 110.746 -174.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.581 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 51.9 ttt180 -129.32 149.69 51.0 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.362 0.665 . . . . 75.53 109.845 166.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -75.31 -171.21 28.99 Favored Glycine 0 C--N 1.348 1.234 0 O-C-N 123.592 0.558 . . . . 50.23 112.882 176.387 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . 0.56 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 1.6 p-10 -145.16 169.56 17.93 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 123.89 0.876 . . . . 72.01 110.526 -174.307 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.436 HD11 ' HB3' ' A' ' 195' ' ' ALA . 22.9 tp -110.61 126.39 54.41 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 124.121 0.968 . . . . 72.24 112.095 -171.075 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 15.1 m-85 -88.84 107.06 18.78 Favored 'General case' 0 C--N 1.357 0.918 0 C-N-CA 123.7 0.8 . . . . 71.24 109.308 168.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.465 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 73.5 mt -88.57 121.93 31.48 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 123.783 0.833 . . . . 73.1 111.628 171.325 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -82.35 92.83 7.05 Favored 'General case' 0 C--O 1.235 0.313 0 N-CA-C 108.032 -1.099 . . . . 64.12 108.032 174.351 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.462 HG12 ' O ' ' A' ' 231' ' ' ARG . 2.4 p -58.61 114.29 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 C-N-CA 123.395 0.678 . . . . 45.14 110.484 177.586 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 21.3 mmm-85 -116.08 95.2 4.98 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 107.802 -1.184 . . . . 61.33 107.802 -177.759 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.492 HG23 ' HA ' ' A' ' 201' ' ' ALA . 75.2 mt -76.03 102.57 3.05 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 114.991 -1.004 . . . . 72.44 110.41 -174.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 CA--C 1.564 1.512 0 C-N-CA 124.337 1.055 . . . . 71.35 109.258 175.985 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.46 ' HA ' HD13 ' A' ' 123' ' ' LEU . 3.5 mm? . . . . . 0 CA--C 1.537 0.453 0 N-CA-C 107.402 -1.333 . . . . 74.22 107.402 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.446 HG13 ' H ' ' A' ' 101' ' ' HIS . 7.1 p -60.1 -27.94 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 C-N-CA 123.092 0.557 . . . . 74.1 111.391 -178.485 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . 64.86 35.85 8.21 Favored 'General case' 0 C--N 1.355 0.818 0 O-C-N 124.541 1.151 . . . . 74.23 110.905 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . 0.446 ' H ' HG13 ' A' ' 99' ' ' VAL . 66.5 t-80 -75.35 91.07 2.68 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 114.755 -1.112 . . . . 75.04 108.088 178.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 46.3 t -57.2 145.72 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 C-N-CA 124.582 1.153 . . . . 75.43 111.297 -173.391 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.5 t . . . . . 0 C--O 1.242 0.665 0 C-N-CA 123.172 0.589 . . . . 63.43 109.836 177.885 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 . . . . . 0 N--CA 1.474 0.751 0 CA-C-O 120.919 0.39 . . . . 64.0 110.158 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.542 HD12 ' HA2' ' A' ' 165' ' ' GLY . 11.6 mt -124.05 151.41 43.83 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 108.129 -1.063 . . . . 45.31 108.129 168.524 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . 0.515 ' HG2' ' HB2' ' A' ' 175' ' ' LEU . 17.3 mtp180 -142.6 151.01 41.07 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.571 0.748 . . . . 73.35 109.376 177.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.497 ' HB3' HD23 ' A' ' 176' ' ' LEU . . . -151.63 120.11 6.44 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 123.615 0.766 . . . . 54.31 109.412 177.003 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 37.8 mm-40 -84.05 143.18 29.91 Favored 'General case' 0 C--O 1.242 0.708 0 N-CA-C 109.111 -0.699 . . . . 73.34 109.111 175.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.46 HD13 ' HA ' ' A' ' 98' ' ' LEU . 0.7 OUTLIER -145.21 145.25 26.06 Favored Pre-proline 0 N--CA 1.475 0.781 0 C-N-CA 122.38 0.272 . . . . 74.2 110.923 174.707 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -81.64 114.51 2.69 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 121.864 1.709 . . . . 63.5 110.638 165.173 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 15.1 tp -106.79 138.8 42.29 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 123.863 0.865 . . . . 73.4 109.354 -178.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . 0.751 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 20.8 m -78.78 158.76 28.15 Favored 'General case' 0 CA--C 1.548 0.901 0 N-CA-C 109.605 -0.517 . . . . 55.23 109.605 172.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.418 HD11 ' O ' ' A' ' 183' ' ' HIS . 31.6 mt -61.52 -47.11 87.09 Favored 'General case' 0 N--CA 1.483 1.177 0 CA-C-O 121.909 0.861 . . . . 61.34 110.004 178.287 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -56.81 -32.76 66.03 Favored 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 114.12 -1.4 . . . . 65.32 111.172 175.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.751 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 29.6 mm-40 -76.97 -32.08 57.0 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 122.977 0.511 . . . . 73.24 111.385 178.514 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' ALA . . . . . 0.533 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -55.6 -35.1 65.46 Favored 'General case' 0 C--O 1.245 0.824 0 C-N-CA 122.999 0.519 . . . . 63.0 111.564 167.326 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' PHE . . . . . 0.561 ' HA ' ' HE2' ' A' ' 240' ' ' PHE . 69.2 t80 -75.17 -47.62 27.55 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.447 -0.797 . . . . 72.51 112.877 171.306 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -68.95 -48.51 63.02 Favored 'General case' 0 N--CA 1.485 1.306 0 N-CA-C 112.115 0.413 . . . . 53.04 112.115 -170.092 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 57.52 -122.14 28.17 Favored Glycine 0 CA--C 1.534 1.272 0 O-C-N 123.869 0.731 . . . . 74.22 111.984 -172.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.27 -173.67 55.14 Favored Glycine 0 C--N 1.35 1.32 0 N-CA-C 114.358 0.503 . . . . 53.3 114.358 168.491 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' GLU . . . . . 0.532 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 1.3 mp0 -83.38 112.12 19.63 Favored 'General case' 0 C--N 1.356 0.856 0 N-CA-C 109.56 -0.533 . . . . 53.2 109.56 -178.552 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 10.3 mmm180 -123.07 156.47 34.84 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.291 1.036 . . . . 71.22 108.462 178.194 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.1 m -77.05 133.32 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 C-N-CA 122.46 0.304 . . . . 71.5 111.356 -176.718 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 144' ' ' ARG . 38.6 t -125.13 134.05 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.685 1.194 . . . . 73.21 108.798 172.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -125.67 97.17 5.05 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.058 0.943 . . . . 74.32 109.366 171.637 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 53.2 t -122.84 122.31 65.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 C-N-CA 123.548 0.739 . . . . 50.14 109.803 178.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.56 28.41 18.09 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 124.93 1.292 . . . . 60.21 112.381 175.558 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 98.37 -13.61 62.84 Favored Glycine 0 C--N 1.349 1.294 0 CA-C-N 116.107 -0.497 . . . . 53.2 113.594 178.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.98 118.0 30.35 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 117.508 0.654 . . . . 73.24 110.569 -179.716 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 138' ' ' VAL . 38.0 ttp180 -95.49 106.15 18.2 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 124.499 1.12 . . . . 61.33 108.41 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.9 t -128.33 131.21 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.19 0.996 . . . . 73.11 109.491 -179.197 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 70.0 m -72.25 115.19 11.2 Favored 'General case' 0 C--O 1.242 0.677 0 N-CA-C 108.635 -0.876 . . . . 34.02 108.635 170.699 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 7.1 p -96.81 143.67 11.93 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 123.044 0.538 . . . . 65.42 110.295 -178.637 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 31.2 ttm180 -107.89 100.26 9.64 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 107.585 -1.265 . . . . 72.13 107.585 171.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.409 ' HB ' HD13 ' A' ' 159' ' ' ILE . 27.7 pt -92.91 130.91 34.8 Favored Pre-proline 0 CA--C 1.548 0.881 0 N-CA-C 108.393 -0.966 . . . . 51.23 108.393 172.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -66.7 131.04 24.79 Favored 'Trans proline' 0 C--N 1.376 2.002 0 C-N-CA 122.617 2.211 . . . . 54.14 113.121 -172.164 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_exo -53.02 117.61 3.93 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.303 2.669 . . . . 75.3 111.824 167.037 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 124.46 54.26 0.18 Allowed Glycine 0 CA--C 1.506 -0.489 0 N-CA-C 110.758 -0.937 . . . . 71.42 110.758 -173.683 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.533 HG13 ' HA ' ' A' ' 130' ' ' ALA . 3.1 p -126.85 156.62 38.11 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.301 0 C-N-CA 123.456 0.703 . . . . 64.44 109.542 -175.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 55.4 mtp180 -138.26 176.09 9.0 Favored 'General case' 0 N--CA 1.491 1.599 0 C-N-CA 124.61 1.164 . . . . 74.53 111.284 -168.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -55.55 121.56 9.32 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 124.272 1.029 . . . . 74.33 111.04 171.367 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.14 7.86 84.8 Favored Glycine 0 C--N 1.348 1.204 0 O-C-N 123.589 0.556 . . . . 64.23 113.842 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 70.8 m -72.37 126.32 29.55 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 117.287 0.543 . . . . 61.25 109.818 176.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.461 HG12 HD22 ' A' ' 175' ' ' LEU . 32.7 t -100.47 123.03 53.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-N 114.045 -1.434 . . . . 64.31 108.265 -175.313 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.453 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 25.4 mt -110.57 118.6 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 123.414 0.686 . . . . 72.33 110.153 -172.452 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 33.2 ttm-85 -85.12 130.29 34.64 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.663 0.785 . . . . 72.12 110.619 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.621 HG22 ' HB3' ' A' ' 174' ' ' LEU . 4.2 m -124.49 125.96 25.52 Favored Pre-proline 0 CA--C 1.551 0.984 0 N-CA-C 108.691 -0.855 . . . . 64.33 108.691 166.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.34 147.17 28.81 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 122.614 2.209 . . . . 71.02 113.424 -173.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 70.62 24.89 76.52 Favored Glycine 0 C--N 1.351 1.415 0 CA-C-N 115.733 -0.667 . . . . 52.04 114.348 170.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 44.3 tpp -104.99 -37.64 6.89 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.152 0.581 . . . . 74.33 109.904 177.205 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' GLY . . . . . 0.542 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . . . . . . 0 C--N 1.347 1.167 0 CA-C-N 115.483 -0.781 . . . . 32.54 112.942 -177.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo . . . . . 0 CA--C 1.537 0.67 0 N-CA-C 110.425 -0.644 . . . . 63.23 110.425 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -95.5 172.66 30.4 Favored Glycine 0 C--O 1.237 0.338 0 N-CA-C 110.768 -0.933 . . . . 65.13 110.768 173.091 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -120.22 159.48 24.85 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 123.447 0.699 . . . . 71.55 110.689 -170.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' LEU . . . . . 0.621 ' HB3' HG22 ' A' ' 161' ' ' VAL . 43.1 tp -109.74 120.43 42.46 Favored 'General case' 0 C--O 1.242 0.698 0 N-CA-C 107.092 -1.447 . . . . 74.32 107.092 169.519 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' LEU . . . . . 0.515 ' HB2' ' HG2' ' A' ' 120' ' ' ARG . 52.5 mt -100.36 100.29 11.06 Favored 'General case' 0 C--O 1.241 0.616 0 O-C-N 124.495 1.122 . . . . 51.41 109.326 -178.003 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.497 HD23 ' HB3' ' A' ' 121' ' ' ALA . 26.7 mt -86.92 101.28 13.25 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 114.562 -1.199 . . . . 63.04 109.098 -179.394 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 23.1 t -93.47 105.98 17.46 Favored 'Isoleucine or valine' 0 C--O 1.244 0.812 0 N-CA-C 108.451 -0.944 . . . . 70.13 108.451 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.448 HG21 HG22 ' A' ' 153' ' ' VAL . 13.7 m -82.44 147.95 5.62 Favored 'Isoleucine or valine' 0 C--O 1.241 0.643 0 CA-C-N 115.593 -0.73 . . . . 73.15 110.271 -178.435 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 17.0 mmt180 -123.72 105.53 9.77 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 107.675 -1.231 . . . . 64.35 107.675 178.665 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 33.9 mt -67.22 148.81 51.27 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 117.725 0.239 . . . . 73.23 110.381 179.521 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 181' ' ' LEU . . . . . 0.544 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 29.5 mt -57.46 157.44 13.33 Favored Pre-proline 0 CA--C 1.556 1.179 0 C-N-CA 123.78 0.832 . . . . 74.2 112.486 -171.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -57.19 -12.79 10.83 Favored 'Trans proline' 0 C--N 1.386 2.524 0 C-N-CA 123.019 2.48 . . . . 43.42 113.336 174.136 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 183' ' ' HIS . . . . . 0.418 ' O ' HD11 ' A' ' 127' ' ' LEU . 28.3 t60 -99.09 101.12 11.52 Favored Pre-proline 0 CA--C 1.545 0.763 0 C-N-CA 124.364 1.066 . . . . 63.24 108.528 166.235 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -102.44 128.41 0.1 Allowed 'Trans proline' 0 CA--C 1.557 1.665 0 C-N-CA 123.387 2.725 . . . . 51.54 112.396 162.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.9 p -116.93 -44.82 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 N-CA-C 109.135 -0.691 . . . . 63.4 109.135 172.138 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -100.28 123.84 45.0 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.576 -0.738 . . . . 70.35 111.438 -177.054 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 187' ' ' ARG . . . . . 0.706 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 80.2 mtt180 -109.46 160.85 15.87 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-N 114.084 -1.416 . . . . 72.04 108.118 175.42 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 188' ' ' LEU . . . . . 0.559 HD13 ' HD1' ' A' ' 240' ' ' PHE . 51.7 tp -130.78 142.64 50.41 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 108.913 -0.773 . . . . 61.03 108.913 178.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -140.85 99.95 3.72 Favored 'General case' 0 C--O 1.242 0.697 0 N-CA-C 107.411 -1.329 . . . . 74.21 107.411 175.168 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 70.18 -78.64 0.42 Allowed Glycine 0 CA--C 1.531 1.047 0 O-C-N 123.881 0.738 . . . . 73.43 112.216 -175.325 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 191' ' ' GLN . . . . . 0.441 HE22 ' HD2' ' A' ' 243' ' ' PRO . 7.6 tt0 -138.34 -14.38 1.31 Allowed 'General case' 0 CA--C 1.558 1.26 0 C-N-CA 123.866 0.867 . . . . 74.23 110.448 -176.503 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.503 ' O ' HD12 ' A' ' 188' ' ' LEU . 9.2 m-20 -86.16 153.86 21.75 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 124.177 0.991 . . . . 72.52 112.103 -178.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 193' ' ' LEU . . . . . 0.514 ' HG ' ' HA2' ' A' ' 239' ' ' GLY . 85.0 mt -107.35 160.76 15.38 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 124.264 1.026 . . . . 72.25 108.519 175.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 194' ' ' TYR . . . . . 0.706 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 64.7 m-85 -136.63 121.55 18.79 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.584 -1.265 . . . . 54.33 107.584 177.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -144.14 148.29 34.86 Favored 'General case' 0 C--O 1.239 0.542 0 O-C-N 124.308 1.005 . . . . 42.32 109.197 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 49.4 m -88.37 127.18 35.49 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.258 -0.883 . . . . 70.32 109.165 173.15 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 197' ' ' LEU . . . . . 0.497 HD22 HD13 ' A' ' 251' ' ' LEU . 66.3 tp -105.9 110.5 22.81 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 108.215 -1.031 . . . . 73.2 108.215 178.101 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -92.35 112.02 23.81 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 108.71 -0.848 . . . . 74.23 108.71 178.061 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 199' ' ' VAL . . . . . 0.428 HG21 HG21 ' A' ' 223' ' ' VAL . 2.8 p -119.51 127.22 26.56 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 124.023 0.929 . . . . 75.22 108.946 -177.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 200' ' ' PRO . . . . . 0.448 ' HD2' HD12 ' A' ' 203' ' ' ILE . 51.7 Cg_exo -56.65 142.28 91.03 Favored 'Trans proline' 0 C--N 1.376 2.02 0 C-N-CA 122.729 2.286 . . . . 73.24 111.786 174.285 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 201' ' ' ALA . . . . . 0.468 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -55.8 -42.48 96.31 Favored Pre-proline 0 CA--C 1.557 1.222 0 CA-C-O 118.252 -0.88 . . . . 74.31 112.478 176.627 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 202' ' ' PRO . . . . . 0.51 ' O ' HG22 ' A' ' 206' ' ' VAL . 63.3 Cg_exo -46.75 -55.35 3.9 Favored 'Trans proline' 0 C--N 1.394 2.967 0 C-N-CA 122.972 2.448 . . . . 75.02 114.005 167.022 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 203' ' ' ILE . . . . . 0.454 HG23 ' H ' ' A' ' 208' ' ' GLY . 21.1 mt -61.7 -41.7 91.48 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 122.907 0.483 . . . . 75.1 111.122 -179.503 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.36 -35.39 78.98 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 115.063 -0.971 . . . . 71.52 111.832 -175.564 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 205' ' ' VAL . . . . . 0.589 HG23 HG13 ' A' ' 206' ' ' VAL . 25.9 m -89.35 -55.52 6.21 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 N-CA-C 112.798 0.666 . . . . 71.42 112.798 178.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.589 HG13 HG23 ' A' ' 205' ' ' VAL . 18.4 m -95.13 -38.3 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 CA-C-N 118.337 0.517 . . . . 74.5 112.074 -171.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -91.17 -115.93 1.95 Allowed Glycine 0 C--N 1.34 0.765 0 CA-C-N 116.606 -0.27 . . . . 74.44 112.657 -164.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 208' ' ' GLY . . . . . 0.454 ' H ' HG23 ' A' ' 203' ' ' ILE . . . 142.36 14.31 0.37 Allowed Glycine 0 C--N 1.335 0.521 0 CA-C-O 119.655 -0.525 . . . . 72.52 113.732 177.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 209' ' ' LYS . . . . . 0.444 ' O ' HD13 ' A' ' 203' ' ' ILE . 15.4 tppt? -117.51 118.22 31.59 Favored 'General case' 0 C--N 1.349 0.553 0 CA-C-N 117.762 0.781 . . . . 70.44 109.453 -173.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 210' ' ' VAL . . . . . 0.426 HG23 ' HB ' ' A' ' 221' ' ' VAL . 2.9 m -145.34 146.21 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.831 0 N-CA-C 108.596 -0.89 . . . . 72.23 108.596 170.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 56.4 mtm-85 -107.16 124.31 49.52 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.648 -0.871 . . . . 70.05 108.648 174.253 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 212' ' ' ALA . . . . . 0.471 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -103.09 137.91 40.64 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.298 0.639 . . . . 33.1 109.559 178.185 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 44.1 mmm -82.98 119.91 25.04 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 122.37 0.268 . . . . 70.43 110.489 174.506 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 3.5 t -118.04 169.88 9.3 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.411 1.085 . . . . 71.2 109.816 171.026 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 83.1 mt -73.96 -10.48 59.68 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 123.735 0.814 . . . . 73.55 112.688 -172.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -93.87 -13.33 27.33 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.602 0.761 . . . . 62.33 111.366 175.041 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 140.16 -157.87 25.64 Favored Glycine 0 C--N 1.347 1.183 0 CA-C-O 119.521 -0.599 . . . . 35.34 111.611 -177.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -85.59 135.83 5.18 Favored 'Trans proline' 0 CA--C 1.551 1.343 0 C-N-CA 122.469 2.113 . . . . 62.31 112.244 172.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.9 m -113.08 159.92 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 123.38 0.672 . . . . 64.13 110.26 168.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -111.35 109.59 19.66 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 107.669 -1.234 . . . . 73.33 107.669 179.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.517 HG22 HD11 ' A' ' 235' ' ' LEU . 12.7 t -96.16 125.24 49.07 Favored 'Isoleucine or valine' 0 C--O 1.243 0.754 0 C-N-CA 123.535 0.734 . . . . 70.23 109.582 177.471 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -88.67 103.59 16.07 Favored 'General case' 0 C--O 1.24 0.598 0 N-CA-C 108.767 -0.827 . . . . 63.44 108.767 170.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.428 HG21 HG21 ' A' ' 199' ' ' VAL . 17.0 m -80.04 136.01 54.43 Favored Pre-proline 0 N--CA 1.477 0.887 0 N-CA-C 107.879 -1.156 . . . . 74.41 107.879 172.068 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -61.47 129.44 28.13 Favored 'Trans proline' 0 CA--C 1.555 1.543 0 C-N-CA 122.0 1.8 . . . . 74.44 111.83 176.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -52.02 128.42 26.87 Favored 'Trans proline' 0 C--N 1.372 1.791 0 C-N-CA 122.655 2.236 . . . . 74.42 111.993 172.051 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 17.5 mtp180 65.31 42.61 3.84 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 125.252 1.421 . . . . 73.31 111.949 -173.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 227' ' ' THR . . . . . 0.507 HG23 HD11 ' A' ' 255' ' ' ILE . 8.5 t -78.36 177.45 8.46 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.115 0.566 . . . . 62.23 110.462 174.584 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . 0.583 HE21 ' HD2' ' A' ' 231' ' ' ARG . 1.8 mp0 -126.85 154.08 44.83 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 123.412 0.685 . . . . 64.32 109.371 -178.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -71.61 149.43 45.61 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.236 0.614 . . . . 72.45 110.572 176.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 88.25 -4.13 85.42 Favored Glycine 0 CA--C 1.527 0.807 0 CA-C-O 119.705 -0.497 . . . . 52.51 112.853 -178.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 231' ' ' ARG . . . . . 0.583 ' HD2' HE21 ' A' ' 228' ' ' GLN . 83.3 mtp180 -77.88 162.34 26.92 Favored 'General case' 0 C--N 1.36 1.063 0 CA-C-O 121.224 0.535 . . . . 75.22 111.153 177.641 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 232' ' ' LYS . . . . . 0.497 ' HG2' ' CZ ' ' A' ' 250' ' ' TYR . 10.6 mptt -118.35 122.06 41.92 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.89 0.876 . . . . 73.5 110.311 -173.302 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 64.4 mt -110.54 117.33 33.24 Favored 'General case' 0 C--N 1.348 0.506 0 N-CA-C 107.784 -1.191 . . . . 74.31 107.784 173.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 44.1 ttp180 -112.78 111.44 22.22 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 109.29 -0.633 . . . . 63.5 109.29 -168.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.517 HD11 HG22 ' A' ' 221' ' ' VAL . 14.7 mt -96.8 120.84 37.89 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 123.581 0.752 . . . . 74.04 109.82 -174.212 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 51.1 mttp -71.14 147.04 48.78 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.256 0.622 . . . . 72.04 112.32 -177.514 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.73 15.81 69.28 Favored Glycine 0 C--N 1.352 1.453 0 O-C-N 124.054 0.846 . . . . 55.34 114.401 173.486 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 238' ' ' LYS . . . . . 0.442 ' HG3' ' HB2' ' A' ' 235' ' ' LEU . 1.3 mmpm? -101.35 -17.43 16.52 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 123.548 0.739 . . . . 74.35 111.708 -175.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 239' ' ' GLY . . . . . 0.514 ' HA2' ' HG ' ' A' ' 193' ' ' LEU . . . -74.97 -148.13 1.66 Allowed Glycine 0 C--N 1.346 1.084 0 O-C-N 123.847 0.717 . . . . 63.44 113.709 -176.679 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 240' ' ' PHE . . . . . 0.561 ' HE2' ' HA ' ' A' ' 131' ' ' PHE . 39.9 m-85 -97.32 155.53 37.26 Favored Pre-proline 0 N--CA 1.475 0.786 0 CA-C-O 119.158 -0.448 . . . . 70.21 111.576 174.557 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -55.12 146.92 56.65 Favored 'Trans proline' 0 C--N 1.385 2.466 0 C-N-CA 122.906 2.404 . . . . 64.4 112.751 179.495 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -178.98 -165.71 33.78 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.669 -0.696 . . . . 72.42 112.15 -178.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 243' ' ' PRO . . . . . 0.441 ' HD2' HE22 ' A' ' 191' ' ' GLN . 46.1 Cg_exo -58.05 -27.6 80.19 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.375 2.717 . . . . 65.22 114.49 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.07 22.82 5.44 Favored 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 123.556 0.742 . . . . 44.22 111.718 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.13 -86.01 1.56 Allowed Glycine 0 C--N 1.348 1.218 0 N-CA-C 110.097 -1.201 . . . . 54.14 110.097 -174.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 246' ' ' ARG . . . . . 0.484 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 18.6 mtm180 -126.94 164.54 21.24 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 108.355 -0.98 . . . . 55.32 108.355 163.238 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -77.85 -153.87 6.5 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.541 -0.754 . . . . 55.51 113.71 -177.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -120.5 164.5 16.33 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.154 0.581 . . . . 62.51 110.262 -177.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 249' ' ' LEU . . . . . 0.5 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 15.8 tp -109.98 111.15 22.37 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.037 0.935 . . . . 61.24 108.913 168.293 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 250' ' ' TYR . . . . . 0.497 ' CZ ' ' HG2' ' A' ' 232' ' ' LYS . 17.9 t80 -90.68 104.57 17.14 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 107.914 -1.143 . . . . 75.31 107.914 178.528 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 251' ' ' LEU . . . . . 0.497 HD13 HD22 ' A' ' 197' ' ' LEU . 63.7 mt -89.19 148.8 23.43 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.292 1.037 . . . . 63.03 111.583 179.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -110.14 97.12 6.68 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 107.922 -1.14 . . . . 65.23 107.922 173.145 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 60.2 t -52.24 117.09 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 123.663 0.785 . . . . 62.22 110.104 174.531 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 12.8 mmm180 -124.73 93.12 3.81 Favored 'General case' 0 C--O 1.238 0.463 0 N-CA-C 107.708 -1.219 . . . . 73.22 107.708 178.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.507 HD11 HG23 ' A' ' 227' ' ' THR . 60.1 mt -75.64 104.82 4.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-N 115.103 -0.953 . . . . 73.44 109.267 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.554 1.116 0 C-N-CA 124.047 0.939 . . . . 75.03 109.728 -178.001 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.14 0 CA-C-O 120.452 0.167 . . . . 71.14 110.662 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.34 -63.97 1.29 Allowed 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.487 0.715 . . . . 30.52 110.639 -178.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.438 HD21 ' HG2' ' A' ' 136' ' ' ARG . 0.2 OUTLIER -103.84 -38.35 7.07 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.856 0.863 . . . . 73.22 111.093 -178.529 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.653 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 61.5 t -60.77 125.59 17.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 123.037 0.535 . . . . 45.4 111.057 175.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -71.36 -66.97 0.55 Allowed 'General case' 0 C--N 1.346 0.45 0 CA-C-N 115.544 -0.753 . . . . 71.34 109.763 177.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 20.4 p-80 178.19 177.36 0.42 Allowed 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 124.634 1.174 . . . . 72.04 109.724 -176.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 43.9 t -71.34 136.84 24.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.078 0 C-N-CA 123.497 0.719 . . . . 60.1 110.157 177.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.8 t -135.73 165.65 25.09 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.384 1.074 . . . . 74.22 109.448 178.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.2 t -115.55 138.34 51.15 Favored 'General case' 0 C--O 1.239 0.517 0 N-CA-C 108.417 -0.957 . . . . 73.41 108.417 175.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 63.61 48.37 78.24 Favored Glycine 0 C--N 1.35 1.359 0 N-CA-C 111.75 -0.54 . . . . 74.03 111.75 -174.088 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 32.0 p -60.28 -56.09 25.75 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.276 1.03 . . . . 61.4 111.913 -173.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 165.79 154.61 8.25 Favored Glycine 0 C--O 1.244 0.744 0 N-CA-C 111.088 -0.805 . . . . 51.31 111.088 179.087 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . 0.492 ' HA3' HG21 ' A' ' 158' ' ' VAL . . . 61.9 47.64 88.81 Favored Glycine 0 C--N 1.348 1.203 0 O-C-N 124.065 0.509 . . . . 43.45 112.989 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 69.5 m -71.99 87.44 1.04 Allowed 'General case' 0 CA--C 1.546 0.826 0 CA-C-O 121.502 0.667 . . . . 74.32 109.857 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 171.5 27.72 0.02 OUTLIER Glycine 0 C--N 1.336 0.561 0 CA-C-N 114.612 -1.176 . . . . 62.31 110.632 -178.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -105.47 107.13 2.76 Favored Glycine 0 C--N 1.354 1.557 0 N-CA-C 111.361 -0.696 . . . . 74.32 111.361 178.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 29.1 m -65.92 106.08 1.48 Allowed 'General case' 0 C--N 1.35 0.61 0 C-N-CA 123.562 0.745 . . . . 72.43 110.483 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -160.74 -135.19 1.78 Allowed Glycine 0 C--N 1.339 0.71 0 CA-C-N 116.081 -0.509 . . . . 73.31 111.845 -178.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.444 ' O ' ' HA2' ' A' ' 172' ' ' GLY . . . 71.22 -85.33 0.41 Allowed Glycine 0 C--N 1.336 0.557 0 CA-C-O 119.612 -0.549 . . . . 71.33 112.153 -177.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 79.0 p 47.6 40.39 11.57 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 125.129 1.372 . . . . 71.22 110.933 -174.174 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 158.53 -133.66 3.53 Favored Glycine 0 C--N 1.336 0.563 0 N-CA-C 109.333 -1.507 . . . . 52.42 109.333 -171.613 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -96.35 120.35 36.49 Favored 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 108.566 -0.901 . . . . 73.0 108.566 178.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.464 ' HB3' ' HE ' ' A' ' 120' ' ' ARG . 5.9 m-20 -79.39 121.19 24.84 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.545 -0.539 . . . . 71.1 109.545 174.21 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.499 HD12 ' HA2' ' A' ' 165' ' ' GLY . 12.3 mt -100.76 132.45 46.16 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 107.601 -1.259 . . . . 71.31 107.601 167.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.464 ' HE ' ' HB3' ' A' ' 118' ' ' ASP . 21.4 mmt85 -127.84 133.49 49.38 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 107.851 -1.166 . . . . 72.44 107.851 -177.255 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -154.01 145.3 22.97 Favored 'General case' 0 N--CA 1.47 0.552 0 O-C-N 123.441 0.463 . . . . 50.25 109.756 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.672 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 41.3 mt-10 -112.09 148.36 34.1 Favored 'General case' 0 C--O 1.246 0.885 0 C-N-CA 123.59 0.756 . . . . 75.43 109.721 174.557 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.653 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.7 pt? -145.88 130.04 8.68 Favored Pre-proline 0 C--O 1.222 -0.376 0 CA-C-N 115.443 -0.799 . . . . 61.21 111.065 -176.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.18 117.49 4.28 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 121.819 1.679 . . . . 74.21 110.152 163.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.472 ' HB3' HD23 ' A' ' 180' ' ' LEU . 21.3 tp -110.59 139.8 45.5 Favored 'General case' 0 C--O 1.233 0.202 0 C-N-CA 123.624 0.77 . . . . 63.22 109.237 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.613 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 4.7 m -76.63 149.33 36.54 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 109.015 -0.735 . . . . 74.05 109.015 170.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.403 HD11 ' O ' ' A' ' 183' ' ' HIS . 44.4 mt -57.06 -44.58 83.18 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 122.267 1.032 . . . . 64.2 109.868 177.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -57.26 -37.7 72.75 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 113.383 -1.735 . . . . 63.52 111.439 176.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.613 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 42.1 mm-40 -77.58 -27.36 51.36 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 122.644 0.378 . . . . 74.24 111.758 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.503 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -58.75 -36.32 74.16 Favored 'General case' 0 C--O 1.243 0.741 0 C-N-CA 123.203 0.601 . . . . 64.43 111.446 167.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.415 ' CZ ' ' HB3' ' A' ' 216' ' ' GLU . 70.9 t80 -74.0 -51.84 14.67 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.151 -0.931 . . . . 73.44 112.427 171.15 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 34.3 m80 -63.83 -49.15 73.96 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 123.358 0.411 . . . . 73.55 112.04 -167.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 48.44 52.76 18.25 Favored Glycine 0 CA--C 1.534 1.28 0 O-C-N 124.118 0.886 . . . . 51.34 114.125 178.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -102.67 -168.61 26.45 Favored Glycine 0 C--N 1.347 1.139 0 CA-C-O 120.044 -0.309 . . . . 64.22 112.481 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.425 ' HB3' ' OG ' ' A' ' 146' ' ' SER . 2.1 mp0 -77.36 113.97 15.69 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 109.556 -0.535 . . . . 64.41 109.556 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.438 ' HG2' HD21 ' A' ' 98' ' ' LEU . 2.4 mpt_? -124.36 150.61 45.33 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 124.106 0.963 . . . . 60.12 108.681 173.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.8 p -76.35 129.74 36.89 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.093 0 CA-C-O 121.256 0.551 . . . . 72.42 111.266 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.527 HG21 HD21 ' A' ' 174' ' ' LEU . 7.9 p -111.27 141.0 27.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 C-N-CA 124.66 1.184 . . . . 71.43 108.81 170.577 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -125.72 100.68 6.53 Favored 'General case' 0 C--O 1.238 0.498 0 N-CA-C 107.819 -1.178 . . . . 74.22 107.819 178.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.7 m -123.84 108.03 19.97 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 C-N-CA 124.288 1.035 . . . . 41.45 110.436 -175.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 66.19 25.29 10.68 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 124.633 1.173 . . . . 55.24 111.766 179.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.83 4.96 78.41 Favored Glycine 0 C--N 1.353 1.482 0 CA-C-N 116.035 -0.53 . . . . 65.35 112.909 -176.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 30.9 tpt180 -94.02 115.41 27.74 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 108.687 -0.857 . . . . 71.4 108.687 177.158 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 75.3 ttt180 -97.74 115.58 28.28 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 108.729 -0.841 . . . . 71.23 108.729 177.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.432 HG11 ' SD ' ' A' ' 164' ' ' MET . 16.1 t -130.51 154.59 40.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 108.059 -1.089 . . . . 74.35 108.059 173.748 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.425 ' OG ' ' HB3' ' A' ' 135' ' ' GLU . 48.3 t -92.19 109.0 20.36 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.289 -1.004 . . . . 55.44 108.289 171.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 9.9 p -97.77 129.6 47.71 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 C-N-CA 123.702 0.801 . . . . 73.43 109.743 -178.613 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 29.1 ttt180 -107.96 97.47 7.17 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 107.719 -1.215 . . . . 72.41 107.719 173.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.555 ' HB ' HD13 ' A' ' 159' ' ' ILE . 26.1 pt -78.51 141.4 60.82 Favored Pre-proline 0 CA--C 1.552 1.053 0 N-CA-C 109.286 -0.635 . . . . 70.01 109.286 177.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -70.06 134.19 26.76 Favored 'Trans proline' 0 C--N 1.372 1.78 0 C-N-CA 122.299 1.999 . . . . 74.23 112.526 -173.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -54.31 138.85 73.38 Favored 'Trans proline' 0 C--N 1.371 1.752 0 C-N-CA 123.121 2.547 . . . . 73.13 112.02 168.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 105.78 36.93 2.67 Favored Glycine 0 N--CA 1.463 0.493 0 N-CA-C 111.589 -0.604 . . . . 52.35 111.589 -173.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.608 HG21 HD11 ' A' ' 159' ' ' ILE . 2.4 p -112.71 155.93 13.83 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.251 0 N-CA-C 109.099 -0.704 . . . . 62.35 109.099 -177.194 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.431 ' HD2' ' O ' ' A' ' 188' ' ' LEU . 38.7 mtp180 -142.38 173.16 11.78 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 125.177 1.391 . . . . 73.03 110.742 -168.46 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.4 tp10 -58.39 121.1 10.02 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 123.758 0.823 . . . . 74.41 110.997 174.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 81.25 7.68 88.13 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-N 116.252 -0.431 . . . . 33.31 113.48 -178.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.436 ' HB3' HG23 ' A' ' 153' ' ' VAL . 38.6 t -77.8 125.55 29.51 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 109.45 -0.574 . . . . 74.01 109.45 179.134 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.542 HG12 HD22 ' A' ' 175' ' ' LEU . 8.5 t -98.5 120.26 47.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.518 0 CA-C-N 114.609 -1.178 . . . . 72.12 108.75 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.608 HD11 HG21 ' A' ' 153' ' ' VAL . 49.1 mt -107.21 120.43 58.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.92 0.888 . . . . 71.43 111.136 -172.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 25.8 ttm180 -92.58 114.13 26.6 Favored 'General case' 0 N--CA 1.468 0.458 0 C-N-CA 123.2 0.6 . . . . 73.11 111.068 177.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -113.46 96.07 38.55 Favored Pre-proline 0 CA--C 1.559 1.313 0 N-CA-C 109.279 -0.637 . . . . 73.52 109.279 173.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -62.24 148.66 92.84 Favored 'Trans proline' 0 C--N 1.388 2.609 0 C-N-CA 123.646 2.898 . . . . 74.13 113.588 -177.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 85.5 -12.85 57.88 Favored Glycine 0 C--N 1.349 1.272 0 O-C-N 123.813 0.696 . . . . 75.23 113.34 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.432 ' SD ' HG11 ' A' ' 145' ' ' VAL . 36.4 mmm -92.33 -28.58 16.85 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.411 1.084 . . . . 62.34 111.912 -170.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . 0.499 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . -82.64 -94.76 0.55 Allowed Glycine 0 C--N 1.344 1.025 0 N-CA-C 111.158 -0.777 . . . . 61.24 111.158 176.276 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.529 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -59.12 98.63 0.11 Allowed Glycine 0 C--N 1.345 1.042 0 C-N-CA 123.625 0.631 . . . . 45.22 112.894 172.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 8.7 mm-40 -75.97 104.93 6.74 Favored 'General case' 0 C--O 1.241 0.649 0 C-N-CA 124.296 1.038 . . . . 62.32 108.645 177.087 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 164.57 -163.18 36.05 Favored Glycine 0 C--N 1.338 0.65 0 O-C-N 123.314 0.384 . . . . 64.1 112.335 -179.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.446 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 60.8 t30 -74.76 -46.27 5.24 Favored Pre-proline 0 CA--C 1.558 1.274 0 CA-C-O 118.2 -0.905 . . . . 74.44 111.261 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.446 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 16.4 Cg_exo -70.39 106.23 1.74 Allowed 'Trans proline' 0 C--N 1.39 2.742 0 C-N-CA 121.527 1.485 . . . . 74.2 109.849 167.438 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.28 123.02 9.54 Favored 'Trans proline' 0 C--N 1.375 1.927 0 C-N-CA 121.985 1.79 . . . . 75.03 111.307 -171.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.529 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -105.34 152.18 17.22 Favored Glycine 0 CA--C 1.504 -0.652 0 N-CA-C 109.806 -1.317 . . . . 64.33 109.806 171.516 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -112.96 168.81 9.39 Favored 'General case' 0 C--O 1.241 0.628 0 CA-C-O 121.503 0.668 . . . . 71.51 110.488 -173.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.527 HD21 HG21 ' A' ' 138' ' ' VAL . 12.4 tp -118.62 115.39 24.44 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 107.722 -1.214 . . . . 73.12 107.722 175.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.542 HD22 HG12 ' A' ' 158' ' ' VAL . 53.6 mt -88.38 100.22 12.86 Favored 'General case' 0 C--O 1.241 0.653 0 O-C-N 123.958 0.786 . . . . 74.43 110.305 177.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 81.5 mt -88.29 102.99 15.39 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.013 -0.994 . . . . 71.12 110.57 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.672 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 48.2 t -86.66 104.81 14.28 Favored 'Isoleucine or valine' 0 C--O 1.241 0.605 0 N-CA-C 108.307 -0.998 . . . . 52.34 108.307 173.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.469 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 9.6 m -82.04 150.82 4.33 Favored 'Isoleucine or valine' 0 C--O 1.245 0.821 0 CA-C-O 121.325 0.583 . . . . 64.11 110.838 -177.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 24.0 mmm-85 -126.99 97.11 4.83 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 107.242 -1.392 . . . . 72.35 107.242 -175.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.472 HD23 ' HB3' ' A' ' 125' ' ' LEU . 46.1 mt -66.4 147.09 53.8 Favored 'General case' 0 C--O 1.242 0.683 0 CA-C-O 120.536 0.208 . . . . 61.42 110.656 -176.449 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.411 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 37.6 mt -54.8 152.19 13.72 Favored Pre-proline 0 CA--C 1.556 1.19 0 O-C-N 124.09 0.869 . . . . 73.45 111.829 -173.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -58.29 -8.7 5.43 Favored 'Trans proline' 0 C--N 1.383 2.376 0 C-N-CA 123.377 2.718 . . . . 64.11 113.363 172.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.403 ' O ' HD11 ' A' ' 127' ' ' LEU . 6.3 t60 -93.59 107.97 30.65 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 124.79 1.236 . . . . 72.24 108.614 168.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -99.52 163.69 0.55 Allowed 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 123.314 2.676 . . . . 71.44 112.427 165.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -156.64 -45.67 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 N-CA-C 109.02 -0.733 . . . . 61.41 109.02 168.604 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.462 ' CE2' HD13 ' A' ' 193' ' ' LEU . 5.6 m-85 -100.66 122.54 43.49 Favored 'General case' 0 C--O 1.238 0.454 0 C-N-CA 123.585 0.754 . . . . 72.42 110.699 -177.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 12.0 mtp180 -99.75 108.72 21.11 Favored 'General case' 0 C--O 1.237 0.441 0 C-N-CA 124.612 1.165 . . . . 72.41 108.624 170.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.431 ' O ' ' HD2' ' A' ' 154' ' ' ARG . 60.2 tp -84.54 110.67 18.87 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.932 -0.766 . . . . 73.35 108.932 170.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 24.0 mm-40 -104.11 97.05 7.07 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 107.325 -1.361 . . . . 62.22 107.325 172.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 67.64 -89.06 0.18 Allowed Glycine 0 CA--C 1.531 1.044 0 O-C-N 123.757 0.66 . . . . 71.5 112.807 -175.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . 0.405 HE22 ' HB3' ' A' ' 244' ' ' ALA . 50.3 tt0 -120.74 -18.12 7.78 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 125.103 1.361 . . . . 73.03 109.779 -176.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.422 ' O ' HD12 ' A' ' 188' ' ' LEU . 44.5 m-20 -96.07 160.04 14.65 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.382 1.073 . . . . 74.55 111.383 -173.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.585 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 96.3 mt -119.21 154.97 32.54 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 124.202 1.001 . . . . 63.43 112.298 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 74.0 m-85 -139.0 120.72 15.28 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 106.248 -1.76 . . . . 73.44 106.248 170.2 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . 0.465 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -141.7 140.06 33.07 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 108.178 -1.045 . . . . 64.43 108.178 176.667 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 19.1 m -77.15 129.98 36.71 Favored 'General case' 0 CA--C 1.539 0.548 0 O-C-N 123.347 0.405 . . . . 65.15 110.323 -175.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.422 HD13 ' HB2' ' A' ' 212' ' ' ALA . 51.2 tp -114.42 111.79 21.99 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 123.951 0.9 . . . . 73.12 108.785 176.694 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -101.64 107.73 19.06 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.127 -0.694 . . . . 72.12 109.127 178.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . 0.521 HG11 HG11 ' A' ' 223' ' ' VAL . 5.9 m -108.52 145.69 32.1 Favored Pre-proline 0 N--CA 1.478 0.963 0 C-N-CA 123.755 0.822 . . . . 43.12 109.472 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -70.83 149.67 60.45 Favored 'Trans proline' 0 C--N 1.366 1.481 0 C-N-CA 121.699 1.599 . . . . 73.03 110.664 173.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . 0.422 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -56.11 -43.53 99.29 Favored Pre-proline 0 CA--C 1.561 1.389 0 CA-C-O 118.374 -0.822 . . . . 71.32 113.112 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -46.21 -51.51 8.52 Favored 'Trans proline' 0 C--N 1.394 2.952 0 C-N-CA 122.921 2.414 . . . . 73.42 114.274 169.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 5.7 mt -69.15 -38.57 78.21 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 C-N-CA 122.335 0.254 . . . . 74.14 111.117 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.18 -41.55 88.75 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.239 0.616 . . . . 73.0 112.234 -179.193 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 33.1 m -82.84 -38.64 15.0 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 CA-C-N 115.891 -0.595 . . . . 71.12 111.53 -174.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.6 m -77.0 -24.79 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 CA-C-O 120.82 0.343 . . . . 73.3 110.849 177.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 76.68 52.84 5.71 Favored Glycine 0 C--N 1.346 1.112 0 CA-C-N 115.376 -0.829 . . . . 70.22 112.366 -175.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.42 -160.35 27.51 Favored Glycine 0 C--N 1.359 1.817 0 N-CA-C 112.123 -0.391 . . . . 54.31 112.123 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 21.2 ptmt -119.91 142.9 48.28 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 123.023 0.529 . . . . 72.34 109.727 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . 0.403 HG21 HG12 ' A' ' 199' ' ' VAL . 75.6 t -128.7 135.11 63.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 C-N-CA 124.351 1.06 . . . . 71.32 108.631 177.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . 0.607 ' HG2' ' HG2' ' A' ' 220' ' ' GLU . 99.3 mtt180 -77.95 112.56 14.97 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 109.198 -0.668 . . . . 75.55 109.198 171.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.422 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -99.14 129.27 45.38 Favored 'General case' 0 C--O 1.242 0.686 0 N-CA-C 108.436 -0.949 . . . . 64.4 108.436 175.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . 0.413 ' SD ' ' N ' ' A' ' 214' ' ' THR . 1.3 tpp -69.72 130.29 41.93 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.837 -0.62 . . . . 63.03 109.79 175.054 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.497 HG21 HG13 ' A' ' 219' ' ' VAL . 7.7 t -134.07 163.67 29.06 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.507 1.123 . . . . 75.43 110.142 173.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 79.4 mt -71.68 -8.87 56.79 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 124.004 0.922 . . . . 72.35 113.183 -172.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . 0.415 ' HB3' ' CZ ' ' A' ' 131' ' ' PHE . 10.3 pt-20 -97.39 -18.34 19.16 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.433 0.693 . . . . 71.11 111.767 173.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.74 -146.36 15.74 Favored Glycine 0 C--N 1.349 1.253 0 CA-C-O 119.556 -0.58 . . . . 53.4 112.181 -176.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -91.17 131.15 1.42 Allowed 'Trans proline' 0 CA--C 1.559 1.736 0 C-N-CA 122.796 2.331 . . . . 72.3 112.777 170.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . 0.497 HG13 HG21 ' A' ' 214' ' ' THR . 20.5 m -110.13 147.25 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 108.996 -0.742 . . . . 72.44 108.996 163.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . 0.607 ' HG2' ' HG2' ' A' ' 211' ' ' ARG . 42.8 mt-10 -114.37 104.33 11.96 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 108.781 -0.822 . . . . 73.12 108.781 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.42 HG23 HD21 ' A' ' 235' ' ' LEU . 2.8 p -95.68 120.25 44.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 124.033 0.933 . . . . 74.44 110.373 -177.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.12 103.57 12.65 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 107.689 -1.226 . . . . 42.22 107.689 173.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.521 HG11 HG11 ' A' ' 199' ' ' VAL . 14.6 m -65.96 143.89 98.61 Favored Pre-proline 0 CA--C 1.553 1.059 0 C-N-CA 123.229 0.612 . . . . 74.13 110.168 -179.014 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -55.58 138.79 81.71 Favored 'Trans proline' 0 C--N 1.376 1.994 0 C-N-CA 122.625 2.216 . . . . 52.41 112.209 176.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.11 122.34 11.42 Favored 'Trans proline' 0 C--N 1.369 1.624 0 C-N-CA 122.181 1.921 . . . . 63.1 110.129 172.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . 0.479 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 96.0 mtt180 63.39 41.25 7.77 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 124.418 1.074 . . . . 71.23 110.996 -175.591 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.4 t -65.15 168.89 6.13 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 122.858 0.463 . . . . 51.23 111.009 177.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . 0.466 ' H ' ' HD3' ' A' ' 231' ' ' ARG . 26.2 mp0 -118.09 146.72 43.92 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 123.889 0.876 . . . . 74.41 109.165 -176.15 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -75.02 135.91 41.25 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.745 -0.835 . . . . 41.32 108.745 173.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 106.11 -7.91 41.36 Favored Glycine 0 C--N 1.34 0.762 0 N-CA-C 112.153 -0.379 . . . . 75.34 112.153 -175.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . 0.466 ' HD3' ' H ' ' A' ' 228' ' ' GLN . 62.0 mtp180 -79.92 160.99 25.79 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.284 0.634 . . . . 75.12 111.079 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.464 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 10.5 mptt -119.05 112.91 20.15 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 124.065 0.946 . . . . 62.44 108.503 176.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . 0.497 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 39.6 mt -89.69 110.08 21.0 Favored 'General case' 0 C--N 1.358 0.958 0 N-CA-C 108.868 -0.79 . . . . 72.35 108.868 -178.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . 0.407 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 41.4 ttp180 -83.81 102.51 12.38 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 114.923 -1.035 . . . . 64.52 111.046 -169.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.42 HD21 HG23 ' A' ' 221' ' ' VAL . 26.5 mt -95.74 98.01 10.13 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 108.513 -0.921 . . . . 74.31 108.513 174.171 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . 0.436 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 26.7 mtpp -80.79 143.87 32.53 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.96 0.41 . . . . 71.14 111.316 -174.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 75.94 24.12 70.21 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.148 -0.933 . . . . 74.24 111.809 -174.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 48.4 mmtm -128.94 10.25 5.91 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 124.366 1.066 . . . . 74.2 110.442 177.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -84.67 -158.21 28.34 Favored Glycine 0 C--N 1.359 1.838 0 O-C-N 123.13 0.269 . . . . 44.14 113.052 175.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.543 ' CD1' HD21 ' A' ' 193' ' ' LEU . 10.5 m-85 -98.02 166.14 14.02 Favored Pre-proline 0 N--CA 1.48 1.044 0 C-N-CA 123.131 0.573 . . . . 63.51 110.565 172.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -61.01 160.45 25.82 Favored 'Trans proline' 0 C--N 1.384 2.409 0 C-N-CA 122.829 2.353 . . . . 71.35 112.113 172.201 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 175.76 -171.21 44.29 Favored Glycine 0 CA--C 1.527 0.791 0 CA-C-N 116.147 -0.479 . . . . 73.32 113.515 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -57.31 -38.73 93.92 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.975 3.116 . . . . 60.05 113.29 -179.155 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . 0.405 ' HB3' HE22 ' A' ' 191' ' ' GLN . . . -92.33 21.84 4.94 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 123.389 0.676 . . . . 71.32 111.937 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 91.66 -102.66 2.95 Favored Glycine 0 C--N 1.347 1.194 0 N-CA-C 111.746 -0.541 . . . . 45.41 111.746 178.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 51.6 ttt180 -121.52 140.02 52.74 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 122.933 0.493 . . . . 73.12 109.675 174.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -81.06 -157.2 16.4 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 124.014 0.821 . . . . 71.33 113.076 -179.039 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . 0.436 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 3.5 p30 -146.62 154.25 41.27 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 123.032 0.533 . . . . 71.41 110.722 -174.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.585 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 26.2 tp -98.58 128.27 44.83 Favored 'General case' 0 C--O 1.22 -0.468 0 C-N-CA 124.338 1.055 . . . . 62.5 110.384 -174.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . 0.464 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 63.1 m-85 -102.63 107.43 18.34 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 123.57 0.748 . . . . 73.22 109.505 173.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.497 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 77.2 mt -87.07 111.11 20.58 Favored 'General case' 0 C--O 1.233 0.233 0 C-N-CA 123.701 0.8 . . . . 74.34 112.52 178.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.41 ' HG2' ' HE3' ' A' ' 232' ' ' LYS . 1.6 tm-20 -80.42 90.37 5.63 Favored 'General case' 0 CA--C 1.552 1.025 0 N-CA-C 108.457 -0.942 . . . . 73.54 108.457 -176.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.407 ' O ' ' HD2' ' A' ' 254' ' ' ARG . 46.0 t -53.29 128.34 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.253 0 C-N-CA 125.991 1.716 . . . . 74.15 112.882 -177.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . 0.407 ' HD2' ' O ' ' A' ' 253' ' ' VAL . 23.5 mmm180 -126.8 98.57 5.41 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 107.255 -1.387 . . . . 74.22 107.255 173.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.422 HG23 ' HA ' ' A' ' 201' ' ' ALA . 63.6 mt -76.53 102.43 3.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 108.861 -0.792 . . . . 74.12 108.861 177.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 8.9 t . . . . . 0 C--O 1.253 1.263 0 C-N-CA 124.357 1.063 . . . . 55.31 110.173 -171.424 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.822 0 N-CA-C 109.421 -0.585 . . . . 41.23 109.421 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.74 -54.38 11.98 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 123.537 0.735 . . . . 62.31 111.175 -175.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.605 HD21 ' HG3' ' A' ' 136' ' ' ARG . 0.2 OUTLIER -139.79 -49.91 0.48 Allowed 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 115.782 -0.645 . . . . 71.44 110.913 -177.991 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.646 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 43.9 t -58.04 119.82 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 C-N-CA 122.988 0.515 . . . . 42.13 111.238 177.576 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -67.22 -71.4 0.2 Allowed 'General case' 0 C--O 1.238 0.485 0 O-C-N 124.275 0.984 . . . . 72.2 109.31 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.0 m80 -168.0 176.12 6.33 Favored 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 124.665 1.186 . . . . 72.33 109.757 -178.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 99.5 t -61.38 136.51 24.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.025 0 C-N-CA 124.094 0.958 . . . . 73.22 110.47 171.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 42.6 p -68.11 110.79 4.13 Favored 'General case' 0 CA--C 1.551 0.992 0 N-CA-C 109.122 -0.696 . . . . 75.1 109.122 170.231 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 13.7 p -65.55 116.6 6.97 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.83 0.852 . . . . 75.1 110.046 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 87.76 40.48 6.71 Favored Glycine 0 C--N 1.345 1.043 0 N-CA-C 110.955 -0.858 . . . . 70.3 110.955 -169.424 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 25.9 p -62.35 111.57 2.06 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 124.063 0.945 . . . . 74.02 111.321 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -146.94 -170.3 15.19 Favored Glycine 0 C--N 1.345 1.061 0 CA-C-N 116.338 -0.392 . . . . 70.05 112.855 -176.073 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 131.61 -61.4 0.66 Allowed Glycine 0 C--N 1.346 1.113 0 N-CA-C 111.591 -0.604 . . . . 33.03 111.591 178.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 25.8 t -168.88 -175.21 2.3 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 124.187 0.995 . . . . 70.31 109.196 -175.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -77.77 161.94 50.04 Favored Glycine 0 CA--C 1.53 0.98 0 N-CA-C 111.833 -0.507 . . . . 61.53 111.833 172.473 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -115.97 -63.6 0.36 Allowed Glycine 0 N--CA 1.473 1.159 0 N-CA-C 111.745 -0.542 . . . . 73.12 111.745 178.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 23.7 t -70.79 -175.46 1.1 Allowed 'General case' 0 CA--C 1.558 1.269 0 C-N-CA 123.726 0.811 . . . . 75.23 110.866 178.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -57.84 -38.68 89.54 Favored Glycine 0 C--N 1.355 1.621 0 N-CA-C 113.853 0.301 . . . . 75.31 113.853 -177.424 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 174.25 -57.49 0.13 Allowed Glycine 0 C--N 1.34 0.798 0 N-CA-C 110.457 -1.057 . . . . 72.24 110.457 178.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 16.6 p -83.14 137.35 34.11 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 123.911 0.884 . . . . 71.1 110.152 174.571 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 96.07 129.64 6.07 Favored Glycine 0 C--N 1.345 1.073 0 N-CA-C 110.559 -1.017 . . . . 63.11 110.559 -174.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 17.3 ptp180 -72.72 145.31 47.23 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 117.161 0.481 . . . . 74.31 111.057 -173.464 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -87.51 149.96 24.05 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 108.686 -0.857 . . . . 53.43 108.686 165.462 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.491 HD21 ' HB ' ' A' ' 140' ' ' VAL . 44.5 tp -128.79 134.98 48.56 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 107.759 -1.2 . . . . 72.33 107.759 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.425 ' HD3' ' HB2' ' A' ' 175' ' ' LEU . 9.8 mmt85 -115.43 134.97 54.59 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 109.438 -0.579 . . . . 73.41 109.438 -178.017 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -150.6 154.54 37.7 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 123.329 0.652 . . . . 72.31 109.38 173.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -119.78 151.35 38.94 Favored 'General case' 0 C--O 1.245 0.851 0 C-N-CA 123.134 0.574 . . . . 72.42 110.169 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.646 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.4 pt? -144.95 143.13 19.72 Favored Pre-proline 0 N--CA 1.471 0.59 0 CA-C-N 115.424 -0.807 . . . . 74.13 111.286 -178.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.43 113.95 3.87 Favored 'Trans proline' 0 C--N 1.37 1.68 0 C-N-CA 121.377 1.384 . . . . 55.55 109.119 160.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.518 HD22 HG11 ' A' ' 178' ' ' VAL . 20.0 tp -104.97 148.44 26.72 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 108.463 -0.94 . . . . 74.13 108.463 178.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.678 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 4.1 m -82.15 157.54 23.99 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 109.919 -0.401 . . . . 63.21 109.919 175.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.456 HD23 ' HB3' ' A' ' 180' ' ' LEU . 77.5 mt -59.16 -48.68 80.72 Favored 'General case' 0 N--CA 1.482 1.145 0 CA-C-O 122.342 1.068 . . . . 64.32 109.529 172.331 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.53 -34.46 64.7 Favored 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 113.621 -1.627 . . . . 74.41 111.963 174.693 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.459 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 17.0 mm-40 -85.63 -17.69 35.39 Favored 'General case' 0 N--CA 1.481 1.083 0 C-N-CA 123.398 0.679 . . . . 71.45 112.416 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.728 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -58.23 -43.41 87.75 Favored 'General case' 0 C--O 1.249 1.05 0 CA-C-O 121.382 0.611 . . . . 61.21 109.697 163.155 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -71.32 -60.31 2.3 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 114.842 -1.072 . . . . 74.14 111.62 174.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -69.05 -47.16 66.04 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 123.588 0.755 . . . . 71.43 112.252 -169.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 71.76 -86.25 0.45 Allowed Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.816 -0.914 . . . . 74.23 110.816 -170.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.0 -179.57 51.3 Favored Glycine 0 C--N 1.345 1.08 0 N-CA-C 114.528 0.571 . . . . 70.34 114.528 174.244 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 14.8 mp0 -98.61 115.27 28.27 Favored 'General case' 0 N--CA 1.471 0.584 0 N-CA-C 107.301 -1.37 . . . . 71.2 107.301 175.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.605 ' HG3' HD21 ' A' ' 98' ' ' LEU . 39.3 mmt-85 -132.15 138.51 48.07 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.711 1.204 . . . . 71.35 108.287 -173.278 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.409 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 27.8 m -73.61 123.01 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 121.343 0.592 . . . . 52.11 111.295 -176.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 13.4 p -105.43 141.36 20.94 Favored 'Isoleucine or valine' 0 C--O 1.252 1.23 0 C-N-CA 125.092 1.357 . . . . 73.34 110.195 178.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 13.2 tp10 -120.29 103.36 9.17 Favored 'General case' 0 C--O 1.243 0.75 0 C-N-CA 124.033 0.933 . . . . 74.02 109.001 174.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.51 HG21 HD22 ' A' ' 174' ' ' LEU . 2.9 m -143.87 123.56 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 123.939 0.896 . . . . 70.2 110.693 -173.189 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.03 19.9 11.95 Favored 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 124.322 1.049 . . . . 62.0 112.137 173.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 83.62 17.5 65.93 Favored Glycine 0 C--N 1.347 1.161 0 CA-C-N 116.366 -0.379 . . . . 73.01 112.345 -177.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.2 mmm180 -108.12 118.17 36.04 Favored 'General case' 0 C--N 1.35 0.596 0 N-CA-C 108.317 -0.994 . . . . 71.31 108.317 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 49.9 ttt180 -94.94 108.2 20.25 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 108.406 -0.961 . . . . 64.34 108.406 173.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 72.2 t -135.82 146.74 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 108.674 -0.861 . . . . 54.22 108.674 -178.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 67.0 p -90.17 107.63 19.25 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.563 -1.273 . . . . 73.1 107.563 167.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.9 p -97.68 140.92 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-O 121.322 0.582 . . . . 73.44 111.012 -172.513 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 14.4 ttp180 -104.13 103.39 13.17 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 107.741 -1.207 . . . . 75.11 107.741 177.241 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.44 ' HB ' HD13 ' A' ' 159' ' ' ILE . 36.5 pt -92.1 112.78 56.67 Favored Pre-proline 0 CA--C 1.555 1.137 0 N-CA-C 109.553 -0.536 . . . . 74.24 109.553 179.067 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.526 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 96.2 Cg_exo -47.82 131.01 20.1 Favored 'Trans proline' 0 C--N 1.39 2.727 0 C-N-CA 123.947 3.098 . . . . 70.14 114.676 -173.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.526 ' HD3' ' HA ' ' A' ' 150' ' ' PRO . 23.2 Cg_exo -67.19 135.52 37.44 Favored 'Trans proline' 0 C--N 1.379 2.162 0 C-N-CA 123.472 2.781 . . . . 71.34 112.269 -177.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.652 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 120.51 41.88 0.52 Allowed Glycine 0 C--N 1.349 1.272 0 N-CA-C 111.908 -0.477 . . . . 54.32 111.908 -175.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.728 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.6 p -115.33 162.89 13.08 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.533 0 C-N-CA 123.915 0.886 . . . . 63.11 109.76 -173.17 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 43.9 mtp180 -143.26 168.99 18.49 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 125.228 1.411 . . . . 65.41 110.09 -170.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -54.94 120.59 7.1 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.759 0.824 . . . . 75.2 111.022 170.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.87 3.65 90.39 Favored Glycine 0 C--N 1.349 1.288 0 O-C-N 123.647 0.592 . . . . 70.54 113.903 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 40.3 t -81.99 131.89 35.25 Favored 'General case' 0 C--O 1.248 0.983 0 N-CA-C 109.303 -0.628 . . . . 60.44 109.303 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 9.0 p -97.42 135.74 30.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.986 0 CA-C-N 115.103 -0.953 . . . . 71.13 109.24 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.486 HD11 HG21 ' A' ' 153' ' ' VAL . 28.1 mt -112.61 123.07 67.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 123.9 0.88 . . . . 74.02 110.707 -175.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.426 HH21 HD11 ' A' ' 175' ' ' LEU . 35.3 ttm180 -92.53 118.84 31.4 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 117.924 0.329 . . . . 72.23 110.26 174.504 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.465 HG22 ' HB3' ' A' ' 174' ' ' LEU . 4.5 m -113.0 125.65 29.47 Favored Pre-proline 0 CA--C 1.551 1.0 0 N-CA-C 108.004 -1.109 . . . . 75.23 108.004 171.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -79.26 148.72 21.46 Favored 'Trans proline' 0 C--N 1.367 1.532 0 C-N-CA 122.132 1.888 . . . . 63.3 113.081 -174.185 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 74.37 23.24 76.13 Favored Glycine 0 CA--C 1.53 0.982 0 N-CA-C 115.141 0.816 . . . . 73.25 115.141 173.057 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 50.7 tpp -102.91 -45.92 4.83 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 117.811 0.806 . . . . 70.44 110.7 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -74.57 -88.21 0.22 Allowed Glycine 0 C--N 1.349 1.299 0 CA-C-N 116.093 -0.503 . . . . 74.33 112.52 -177.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.655 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -58.71 99.36 0.12 Allowed Glycine 0 C--N 1.347 1.165 0 C-N-CA 123.567 0.603 . . . . 25.11 112.536 173.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.4 mm-40 -87.31 104.31 16.29 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 123.785 0.834 . . . . 63.41 109.105 178.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 156.38 -164.44 32.48 Favored Glycine 0 C--N 1.339 0.723 0 N-CA-C 111.472 -0.651 . . . . 73.15 111.472 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -60.38 -45.25 97.46 Favored Pre-proline 0 CA--C 1.561 1.368 0 CA-C-O 118.178 -0.915 . . . . 74.45 112.014 177.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -74.81 106.71 2.32 Favored 'Trans proline' 0 C--N 1.39 2.728 0 C-N-CA 121.885 1.724 . . . . 75.14 110.341 168.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -77.56 126.07 8.0 Favored 'Trans proline' 0 C--N 1.375 1.954 0 C-N-CA 121.494 1.463 . . . . 62.41 111.015 -175.042 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.655 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -108.68 168.29 13.47 Favored Glycine 0 N--CA 1.462 0.369 0 N-CA-C 111.185 -0.766 . . . . 54.44 111.185 175.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -118.92 169.88 9.5 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 123.61 0.764 . . . . 63.43 111.656 -165.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.51 HD22 HG21 ' A' ' 140' ' ' VAL . 37.0 tp -124.62 116.47 22.46 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-N 114.608 -1.178 . . . . 62.42 108.234 169.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.426 HD11 HH21 ' A' ' 160' ' ' ARG . 41.3 mt -92.19 100.93 13.45 Favored 'General case' 0 C--O 1.243 0.76 0 CA-C-N 114.248 -1.342 . . . . 62.41 109.868 175.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 85.2 mt -90.85 107.39 19.16 Favored 'General case' 0 CA--C 1.538 0.494 0 CA-C-N 114.462 -1.245 . . . . 74.33 111.177 178.454 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 34.9 t -86.67 106.11 15.51 Favored 'Isoleucine or valine' 0 C--O 1.249 1.05 0 N-CA-C 108.459 -0.941 . . . . 71.32 108.459 175.466 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.518 HG11 HD22 ' A' ' 125' ' ' LEU . 19.0 m -81.57 149.77 4.77 Favored 'Isoleucine or valine' 0 C--O 1.24 0.6 0 CA-C-O 121.811 0.815 . . . . 72.42 112.203 -179.268 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 25.0 mmm-85 -123.75 105.66 9.86 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 107.38 -1.341 . . . . 64.32 107.38 174.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.456 ' HB3' HD23 ' A' ' 127' ' ' LEU . 30.2 mt -67.73 142.66 56.21 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 118.191 0.45 . . . . 74.42 111.186 -178.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.678 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 41.3 mt -55.22 142.35 58.61 Favored Pre-proline 0 CA--C 1.555 1.153 0 O-C-N 124.029 0.831 . . . . 62.42 111.791 -175.051 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.31 63.98 7.86 Favored 'Trans proline' 0 C--N 1.378 2.105 0 C-N-CA 123.389 2.726 . . . . 64.54 113.113 -177.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 3.7 p80 -149.61 50.18 0.75 Allowed Pre-proline 0 CA--C 1.564 1.5 0 C-N-CA 124.043 0.937 . . . . 63.0 108.84 169.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -62.63 122.97 11.52 Favored 'Trans proline' 0 C--N 1.385 2.459 0 C-N-CA 121.814 1.676 . . . . 75.42 111.808 -166.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.3 p -122.54 -42.57 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 N-CA-C 107.894 -1.15 . . . . 71.45 107.894 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -101.1 123.45 45.27 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.765 -1.107 . . . . 71.52 109.09 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 91.5 mtm180 -119.0 119.71 35.09 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.606 1.162 . . . . 71.45 108.085 -179.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 66.1 tp -105.0 139.02 40.31 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.848 0.859 . . . . 72.43 110.936 -174.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 -134.53 108.03 7.86 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 124.415 1.086 . . . . 72.55 108.104 164.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 73.16 -82.48 0.65 Allowed Glycine 0 C--N 1.35 1.332 0 O-C-N 123.529 0.518 . . . . 64.14 112.914 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -134.84 -15.64 2.03 Favored 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 123.772 0.829 . . . . 72.21 110.748 177.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 52.9 m-20 -91.0 143.78 26.35 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.345 0.658 . . . . 62.35 112.396 -174.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.57 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 87.3 mt -112.7 161.21 17.12 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 125.112 1.365 . . . . 71.03 111.215 -174.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -141.0 121.83 14.41 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 107.325 -1.361 . . . . 73.53 107.325 174.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . 0.455 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -148.96 136.23 20.12 Favored 'General case' 0 N--CA 1.468 0.453 0 N-CA-C 108.891 -0.781 . . . . 65.42 108.891 -178.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . 0.541 ' HA ' ' HB2' ' A' ' 252' ' ' GLU . 12.1 m -81.28 123.14 28.25 Favored 'General case' 0 CA--C 1.542 0.665 0 O-C-N 123.478 0.486 . . . . 70.13 110.616 -175.678 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.508 HD22 HD13 ' A' ' 251' ' ' LEU . 48.2 tp -108.71 113.28 26.11 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.825 0.85 . . . . 73.31 109.484 -179.699 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -87.23 113.11 22.68 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 108.43 -0.952 . . . . 65.25 108.43 172.097 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 4.2 p -118.37 124.9 28.22 Favored Pre-proline 0 CA--C 1.551 1.005 0 C-N-CA 124.035 0.934 . . . . 71.21 109.347 178.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -61.73 146.27 96.79 Favored 'Trans proline' 0 C--N 1.371 1.715 0 C-N-CA 122.507 2.138 . . . . 74.33 112.287 175.558 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . 0.407 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -54.55 -42.98 97.49 Favored Pre-proline 0 CA--C 1.56 1.338 0 CA-C-O 117.346 -1.311 . . . . 64.34 113.965 -176.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . 0.407 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 7.1 Cg_endo -48.84 -47.6 20.68 Favored 'Trans proline' 0 C--N 1.402 3.344 0 C-N-CA 122.647 2.231 . . . . 65.3 112.821 172.189 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 15.7 mt -70.01 -38.15 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 122.725 0.41 . . . . 71.34 110.843 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.2 -41.47 98.39 Favored 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 123.307 0.643 . . . . 72.31 111.778 -177.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.7 m -80.21 -40.07 19.75 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 CA-C-N 116.108 -0.496 . . . . 65.33 111.715 -176.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.0 m -79.88 -24.02 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 CA-C-N 117.842 0.292 . . . . 74.42 111.194 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.504 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 73.22 61.38 3.46 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.855 -0.611 . . . . 72.33 112.317 -174.477 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.55 -142.22 9.77 Favored Glycine 0 C--N 1.356 1.672 0 N-CA-C 111.799 -0.52 . . . . 71.03 111.799 -178.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -131.36 144.78 51.48 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 123.812 0.845 . . . . 74.04 110.216 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 11.8 m -134.35 169.77 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 124.508 1.123 . . . . 75.11 109.171 175.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . 0.517 ' HD3' ' H ' ' A' ' 211' ' ' ARG . 0.0 OUTLIER -104.03 133.7 48.54 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.536 -0.756 . . . . 72.45 109.079 176.163 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -117.81 114.87 23.91 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 108.597 -0.89 . . . . 72.11 108.597 172.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 3.9 tpt -70.56 105.13 3.0 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.966 -0.561 . . . . 55.43 109.687 177.311 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 5.8 t -115.69 169.37 9.25 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.486 0.714 . . . . 74.3 111.255 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 46.4 mt -75.4 -3.06 31.5 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.254 1.022 . . . . 73.33 112.535 -170.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -106.1 -6.27 18.77 Favored 'General case' 0 N--CA 1.484 1.234 0 C-N-CA 124.029 0.931 . . . . 74.24 111.566 175.218 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 116.62 155.99 10.54 Favored Glycine 0 C--N 1.348 1.214 0 CA-C-O 118.583 -1.12 . . . . 60.22 111.634 -175.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -59.76 126.91 21.79 Favored 'Trans proline' 0 C--N 1.379 2.184 0 C-N-CA 123.096 2.531 . . . . 61.23 113.078 -168.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 35.1 m -108.47 166.49 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 C-N-CA 123.296 0.639 . . . . 71.23 110.184 -179.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -113.22 113.26 25.08 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 108.11 -1.07 . . . . 72.13 108.11 -177.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.504 HG22 HD11 ' A' ' 235' ' ' LEU . 5.2 t -95.92 115.99 36.53 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-N 115.664 -0.698 . . . . 61.42 109.303 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -85.61 101.25 12.55 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.585 -1.265 . . . . 74.12 107.585 170.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.504 HG23 ' HA2' ' A' ' 207' ' ' GLY . 9.0 m -74.71 146.56 83.38 Favored Pre-proline 0 CA--C 1.559 1.323 0 N-CA-C 109.509 -0.552 . . . . 53.41 109.509 -176.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -60.79 136.18 64.72 Favored 'Trans proline' 0 C--N 1.376 2.021 0 C-N-CA 122.769 2.312 . . . . 71.44 112.027 177.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_exo -54.88 122.57 11.89 Favored 'Trans proline' 0 C--N 1.377 2.037 0 C-N-CA 122.244 1.963 . . . . 63.51 110.572 169.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 68.6 mtm180 62.57 49.99 3.74 Favored 'General case' 0 CA--C 1.551 1.002 0 O-C-N 124.333 1.021 . . . . 74.44 110.576 -177.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.5 t -72.87 170.21 15.19 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.007 0.523 . . . . 51.43 110.52 177.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . 0.633 ' H ' ' HD2' ' A' ' 231' ' ' ARG . 2.0 mp0 -121.35 147.05 46.21 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.269 0.628 . . . . 71.5 109.987 -178.424 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -76.34 123.3 25.74 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.209 1.004 . . . . 44.33 109.483 175.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 113.91 -10.65 22.98 Favored Glycine 0 N--CA 1.472 1.085 0 N-CA-C 111.924 -0.47 . . . . 55.01 111.924 -171.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . 0.633 ' HD2' ' H ' ' A' ' 228' ' ' GLN . 20.9 mtt180 -69.98 161.61 29.7 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.516 0.726 . . . . 64.23 111.402 173.042 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.431 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.3 mptp? -119.99 111.3 17.74 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 107.825 -1.176 . . . . 73.22 107.825 176.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . 0.554 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 60.0 mt -85.63 107.51 17.57 Favored 'General case' 0 C--N 1.356 0.868 0 N-CA-C 108.613 -0.884 . . . . 73.34 108.613 -178.349 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 38.4 ttm180 -84.4 105.92 15.6 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.248 -0.887 . . . . 70.22 109.993 -171.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.581 ' HB3' ' HG3' ' A' ' 238' ' ' LYS . 58.2 mt -98.07 99.13 10.37 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 108.652 -0.87 . . . . 74.14 108.652 172.586 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -75.88 144.64 41.05 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 122.489 0.316 . . . . 64.12 111.159 -177.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 72.92 28.13 67.43 Favored Glycine 0 C--N 1.353 1.481 0 O-C-N 123.755 0.659 . . . . 64.31 113.042 -175.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . 0.581 ' HG3' ' HB3' ' A' ' 235' ' ' LEU . 4.1 mmtm -119.8 -10.59 9.5 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 124.138 0.975 . . . . 71.52 111.512 -178.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . 0.425 ' O ' ' HD2' ' A' ' 246' ' ' ARG . . . -81.93 -154.01 12.51 Favored Glycine 0 C--N 1.339 0.719 0 O-C-N 123.414 0.446 . . . . 63.35 113.279 -179.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.652 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 6.1 m-85 -94.68 158.69 34.93 Favored Pre-proline 0 CA--C 1.548 0.867 0 C-N-CA 123.576 0.75 . . . . 75.5 109.811 177.033 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.66 129.32 26.64 Favored 'Trans proline' 0 C--N 1.387 2.556 0 C-N-CA 123.361 2.707 . . . . 75.55 113.482 -178.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -158.18 -169.09 21.34 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.626 -0.716 . . . . 44.52 112.278 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.35 -17.99 59.3 Favored 'Trans proline' 0 C--N 1.376 2.025 0 C-N-CA 123.133 2.555 . . . . 65.54 113.414 -177.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -98.42 21.23 11.4 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 123.868 0.867 . . . . 65.4 111.233 178.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 88.74 -82.97 1.48 Allowed Glycine 0 C--N 1.347 1.176 0 N-CA-C 110.122 -1.191 . . . . 43.1 110.122 -174.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.425 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 22.5 mtm180 -127.09 158.77 36.12 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 107.324 -1.362 . . . . 71.43 107.324 165.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.08 -156.96 4.76 Favored Glycine 0 C--N 1.344 1.002 0 O-C-N 123.483 0.489 . . . . 64.41 114.142 -174.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 35.0 m-20 -117.8 151.15 37.9 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 108.871 -0.788 . . . . 72.44 108.871 -176.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.57 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 18.3 tp -105.19 114.57 28.83 Favored 'General case' 0 CA--C 1.531 0.233 0 N-CA-C 108.71 -0.848 . . . . 73.04 108.71 171.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -96.18 106.86 19.11 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 123.109 0.564 . . . . 74.41 109.984 175.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.554 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 73.4 mt -88.0 120.96 29.85 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 124.162 0.985 . . . . 52.51 112.789 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.541 ' HB2' ' HA ' ' A' ' 196' ' ' THR . 26.0 mt-10 -79.11 91.3 4.9 Favored 'General case' 0 C--O 1.24 0.574 0 C-N-CA 123.774 0.83 . . . . 74.25 109.279 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 48.0 t -52.37 114.81 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.655 1.182 . . . . 64.54 112.108 178.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 49.7 mmm-85 -117.09 93.68 4.28 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 106.933 -1.506 . . . . 62.35 106.933 173.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 72.2 mt -74.55 110.73 9.33 Favored 'Isoleucine or valine' 0 C--N 1.343 0.31 0 N-CA-C 108.274 -1.01 . . . . 60.11 108.274 177.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 4.5 t . . . . . 0 CA--C 1.557 1.226 0 C-N-CA 123.982 0.913 . . . . 74.31 109.539 -177.205 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.229 0 N-CA-C 110.361 -0.237 . . . . 74.12 110.361 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -62.42 -32.33 73.16 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.49 0.716 . . . . 75.42 111.36 178.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.451 ' HB2' ' HB3' ' A' ' 136' ' ' ARG . 1.2 tm? -112.43 111.02 21.57 Favored 'General case' 0 C--O 1.24 0.578 0 N-CA-C 106.685 -1.598 . . . . 62.03 106.685 169.345 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.413 ' O ' ' HB3' ' A' ' 123' ' ' LEU . 86.0 t -68.3 134.82 29.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 N-CA-C 108.84 -0.8 . . . . 74.34 108.84 177.334 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -150.25 56.45 0.94 Allowed 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 107.999 -1.111 . . . . 64.21 107.999 176.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -65.7 109.4 2.41 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-N 113.995 -1.457 . . . . 71.33 108.659 176.623 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 39.8 t -59.55 121.77 8.05 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.765 0 O-C-N 124.287 0.992 . . . . 73.43 109.384 -178.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.9 t -151.21 149.73 29.76 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 123.896 0.878 . . . . 74.3 109.487 -173.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.5 m -95.81 67.5 2.75 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.019 -0.734 . . . . 72.21 109.019 177.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -92.66 160.22 25.29 Favored Glycine 0 C--N 1.347 1.178 0 CA-C-N 115.052 -0.977 . . . . 73.41 113.954 -172.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 17.4 m -94.0 162.45 13.88 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 124.053 0.941 . . . . 65.53 111.608 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 99.13 116.8 3.82 Favored Glycine 0 C--N 1.349 1.277 0 N-CA-C 111.551 -0.62 . . . . 12.35 111.551 177.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -115.65 164.1 12.23 Favored Glycine 0 C--N 1.346 1.089 0 CA-C-N 116.952 0.376 . . . . 73.31 112.694 -176.141 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 34.9 t -91.36 -43.27 9.86 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.821 0.848 . . . . 72.22 109.543 175.047 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 141.8 -91.77 0.18 Allowed Glycine 0 C--O 1.239 0.434 0 CA-C-N 115.105 -0.952 . . . . 51.04 110.876 -177.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 60.11 -150.18 40.64 Favored Glycine 0 C--N 1.35 1.342 0 O-C-N 124.158 0.564 . . . . 72.04 112.846 179.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 24.5 p -175.96 135.87 0.29 Allowed 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.295 1.038 . . . . 74.53 109.237 172.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 70.17 -152.12 50.72 Favored Glycine 0 CA--C 1.531 1.034 0 O-C-N 123.659 0.599 . . . . 75.41 113.106 177.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 168.85 177.43 39.7 Favored Glycine 0 C--O 1.24 0.506 0 N-CA-C 110.502 -1.039 . . . . 74.35 110.502 -177.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . 0.419 ' HB3' ' HA2' ' A' ' 172' ' ' GLY . 34.6 t -137.31 98.44 3.72 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 117.5 0.65 . . . . 43.21 110.335 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 63.5 -124.19 30.88 Favored Glycine 0 C--N 1.346 1.094 0 CA-C-N 115.295 -0.866 . . . . 53.2 112.848 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -79.22 119.41 22.26 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 122.718 0.407 . . . . 73.55 109.963 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -92.72 133.72 35.74 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 108.472 -0.936 . . . . 62.01 108.472 172.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -96.05 144.48 26.28 Favored 'General case' 0 CA--C 1.544 0.722 0 N-CA-C 107.015 -1.476 . . . . 73.1 107.015 178.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -130.59 129.36 42.67 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 108.108 -1.071 . . . . 73.01 108.108 176.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -150.79 150.23 30.72 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-N 115.75 -0.659 . . . . 62.42 109.571 -179.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -120.24 148.0 44.24 Favored 'General case' 0 C--O 1.245 0.84 0 N-CA-C 109.11 -0.7 . . . . 74.13 109.11 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.413 ' HB3' ' O ' ' A' ' 99' ' ' VAL . 1.3 pt? -145.32 147.58 34.44 Favored Pre-proline 0 N--CA 1.467 0.404 0 C-N-CA 122.8 0.44 . . . . 52.22 111.76 179.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_endo -78.04 114.21 3.55 Favored 'Trans proline' 0 C--N 1.366 1.448 0 C-N-CA 121.751 1.634 . . . . 72.12 109.935 159.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.475 HD22 HG11 ' A' ' 178' ' ' VAL . 34.7 tp -106.75 157.24 17.88 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 108.791 -0.818 . . . . 72.1 108.791 177.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.693 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 14.4 m -89.36 151.69 21.93 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 122.99 0.516 . . . . 75.04 110.344 177.519 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.583 HD23 ' HB3' ' A' ' 180' ' ' LEU . 68.9 mt -58.1 -50.57 73.01 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.725 0.81 . . . . 52.33 109.389 174.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -53.78 -39.07 65.11 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 113.95 -1.477 . . . . 72.42 111.673 178.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.518 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 28.4 mm-40 -86.06 -18.07 33.45 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 122.999 0.52 . . . . 73.23 111.269 -176.484 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.653 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -64.41 -36.93 85.77 Favored 'General case' 0 C--O 1.242 0.673 0 C-N-CA 123.447 0.699 . . . . 70.01 109.886 167.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.458 ' HA ' ' HE1' ' A' ' 240' ' ' PHE . 27.6 t80 -71.94 -55.92 6.61 Favored 'General case' 0 CA--C 1.551 0.982 0 CA-C-N 114.999 -1.001 . . . . 61.12 110.574 172.053 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -67.97 -44.89 75.65 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 112.24 0.459 . . . . 72.12 112.24 -171.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.81 -111.62 4.27 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 111.275 -0.73 . . . . 70.23 111.275 -173.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.41 -175.87 54.54 Favored Glycine 0 C--N 1.347 1.163 0 N-CA-C 114.232 0.453 . . . . 44.22 114.232 171.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.425 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 2.0 mp0 -87.4 143.96 26.98 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 109.283 -0.636 . . . . 62.33 109.283 178.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.451 ' HB3' ' HB2' ' A' ' 98' ' ' LEU . 0.6 OUTLIER -156.79 147.84 21.98 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 109.546 -0.539 . . . . 74.22 109.546 -178.268 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 32.1 m -82.14 125.38 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 CA-C-O 121.51 0.671 . . . . 73.12 111.206 -174.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 41.1 t -120.7 144.77 28.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 C-N-CA 125.035 1.334 . . . . 73.3 109.442 -176.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -126.15 97.79 5.22 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.041 0.536 . . . . 62.12 109.584 169.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.0 m -107.54 132.62 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 N-CA-C 108.922 -0.77 . . . . 73.22 108.922 173.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.46 23.02 13.35 Favored 'General case' 0 CA--C 1.554 1.118 0 C-N-CA 123.964 0.905 . . . . 64.23 111.694 -176.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.23 0.07 88.67 Favored Glycine 0 C--N 1.357 1.703 0 CA-C-N 116.038 -0.528 . . . . 44.21 113.468 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -103.34 123.27 46.48 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.696 0.798 . . . . 61.12 110.036 -175.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 40.2 ttp-105 -88.2 105.93 17.86 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.344 0.658 . . . . 71.2 110.797 -174.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 38.5 t -124.42 134.41 66.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.351 1.061 . . . . 53.43 108.828 178.021 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 37.2 m -83.81 120.9 26.61 Favored 'General case' 0 CA--C 1.546 0.803 0 N-CA-C 109.682 -0.488 . . . . 73.3 109.682 176.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 8.1 p -99.77 148.73 6.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 123.317 0.647 . . . . 73.42 110.687 -178.387 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.3 ttt85 -110.02 96.39 6.2 Favored 'General case' 0 C--O 1.237 0.43 0 N-CA-C 107.324 -1.361 . . . . 72.04 107.324 160.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.476 ' HB ' HD13 ' A' ' 159' ' ' ILE . 37.9 pt -78.05 125.98 84.44 Favored Pre-proline 0 C--O 1.243 0.724 0 N-CA-C 108.617 -0.883 . . . . 62.31 108.617 173.144 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.415 ' HD2' HG23 ' A' ' 159' ' ' ILE . 97.7 Cg_exo -48.68 127.18 15.89 Favored 'Trans proline' 0 C--N 1.384 2.406 0 C-N-CA 123.04 2.494 . . . . 61.41 113.37 -178.266 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.553 ' HB2' ' HZ ' ' A' ' 240' ' ' PHE . 57.1 Cg_endo -69.36 143.85 54.16 Favored 'Trans proline' 0 C--N 1.376 2.007 0 C-N-CA 122.251 1.967 . . . . 72.35 110.355 175.02 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.44 27.37 5.56 Favored Glycine 0 C--N 1.337 0.586 0 N-CA-C 110.927 -0.869 . . . . 53.15 110.927 -171.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.653 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.2 p -93.67 157.32 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 N-CA-C 108.168 -1.049 . . . . 71.05 108.168 -176.603 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 37.4 mtp180 -147.11 169.23 19.72 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 124.141 0.976 . . . . 75.41 109.751 -166.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -51.99 123.86 11.42 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.539 0.736 . . . . 32.55 111.624 174.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 85.55 -7.64 75.56 Favored Glycine 0 C--N 1.349 1.302 0 CA-C-O 119.419 -0.656 . . . . 32.02 114.111 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.4 m -69.53 122.64 19.44 Favored 'General case' 0 C--N 1.351 0.633 0 CA-C-N 117.336 0.568 . . . . 54.34 110.553 -178.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.412 HG12 HD22 ' A' ' 175' ' ' LEU . 10.5 t -98.93 123.17 51.39 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 N-CA-C 108.486 -0.931 . . . . 72.44 108.486 179.302 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.531 HD11 HG21 ' A' ' 153' ' ' VAL . 43.5 mt -102.49 115.69 44.85 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.593 0 C-N-CA 123.926 0.89 . . . . 72.22 110.537 -169.075 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.41 ' HG3' ' HB2' ' A' ' 173' ' ' ASP . 30.3 ttm180 -89.69 115.86 27.38 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.07 0.548 . . . . 65.23 110.493 175.237 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 173' ' ' ASP . 15.0 m -119.16 116.11 34.12 Favored Pre-proline 0 CA--C 1.555 1.172 0 C-N-CA 123.363 0.665 . . . . 74.34 109.578 176.32 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 11.2 Cg_exo -72.47 148.51 48.41 Favored 'Trans proline' 0 C--N 1.368 1.594 0 C-N-CA 122.479 2.119 . . . . 64.04 111.998 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.65 18.27 28.36 Favored Glycine 0 C--N 1.341 0.825 0 N-CA-C 115.673 1.029 . . . . 73.2 115.673 172.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.413 ' HE3' HG23 ' A' ' 147' ' ' VAL . 54.2 mtt -121.6 -57.45 1.82 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 118.449 1.125 . . . . 33.5 112.128 176.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -61.36 -88.79 0.03 OUTLIER Glycine 0 C--N 1.35 1.329 0 O-C-N 123.372 0.42 . . . . 73.11 113.047 -174.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.622 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -68.99 92.93 0.31 Allowed Glycine 0 C--N 1.338 0.648 0 O-C-N 123.648 0.264 . . . . 33.24 112.631 176.047 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.0 mm-40 -92.2 128.97 38.25 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 123.182 0.593 . . . . 75.14 109.733 171.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 174.82 -59.65 0.12 Allowed Glycine 0 C--N 1.337 0.626 0 N-CA-C 110.945 -0.862 . . . . 61.32 110.945 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.403 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 3.2 t30 -162.62 -51.63 0.01 OUTLIER Pre-proline 0 CA--C 1.561 1.401 0 C-N-CA 124.402 1.081 . . . . 54.51 109.498 176.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.428 ' HA ' ' HD3' ' A' ' 171' ' ' PRO . 94.8 Cg_endo -81.44 122.76 4.15 Favored 'Trans proline' 0 C--N 1.395 2.997 0 C-N-CA 121.775 1.65 . . . . 34.42 111.089 171.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 170' ' ' PRO . 34.2 Cg_exo -61.81 121.91 10.21 Favored 'Trans proline' 0 C--N 1.378 2.116 0 C-N-CA 122.627 2.218 . . . . 74.21 112.167 -176.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.622 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -95.41 159.21 22.44 Favored Glycine 0 C--N 1.348 1.212 0 O-C-N 123.385 0.428 . . . . 73.1 112.406 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.447 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 9.4 p-10 -96.46 151.54 19.47 Favored 'General case' 0 C--O 1.237 0.439 0 C-N-CA 123.012 0.525 . . . . 74.42 112.036 -167.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 11.2 tp -113.88 124.27 51.8 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 107.472 -1.307 . . . . 72.33 107.472 163.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.412 HD22 HG12 ' A' ' 158' ' ' VAL . 37.3 mt -99.28 100.63 11.74 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 124.583 1.153 . . . . 72.24 110.098 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 93.0 mt -95.8 102.74 14.57 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.93 0.892 . . . . 72.14 110.917 177.339 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 6.5 p -86.16 111.91 21.9 Favored 'Isoleucine or valine' 0 C--O 1.244 0.81 0 CA-C-O 121.635 0.731 . . . . 62.43 109.209 172.388 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.475 HG11 HD22 ' A' ' 125' ' ' LEU . 6.2 m -86.98 149.35 4.14 Favored 'Isoleucine or valine' 0 C--O 1.241 0.607 0 CA-C-N 115.638 -0.71 . . . . 65.21 111.49 -178.365 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -124.31 104.57 8.87 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 106.914 -1.513 . . . . 73.34 106.914 176.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.583 ' HB3' HD23 ' A' ' 127' ' ' LEU . 32.4 mt -68.09 143.36 55.5 Favored 'General case' 0 CA--C 1.54 0.59 0 O-C-N 123.098 0.249 . . . . 71.21 111.243 -175.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.693 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 54.8 mt -53.86 147.83 22.42 Favored Pre-proline 0 CA--C 1.553 1.063 0 C-N-CA 123.852 0.861 . . . . 72.13 111.661 -173.265 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.19 37.24 0.62 Allowed 'Trans proline' 0 C--N 1.368 1.557 0 C-N-CA 123.32 2.68 . . . . 71.24 114.394 -175.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -121.06 65.55 13.93 Favored Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 123.544 0.738 . . . . 65.51 109.371 170.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -68.28 123.7 10.87 Favored 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 121.485 1.456 . . . . 74.22 111.231 -169.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.7 p -134.61 -38.81 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 N-CA-C 108.499 -0.926 . . . . 74.24 108.499 178.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.429 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 5.5 m-85 -114.82 141.92 47.24 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 121.902 0.858 . . . . 72.35 112.259 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.536 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 43.8 mtt85 -128.54 154.0 46.62 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 113.472 -1.695 . . . . 73.2 106.838 171.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.467 HD13 HD23 ' A' ' 193' ' ' LEU . 42.5 tp -132.7 138.41 47.25 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 109.051 -0.722 . . . . 72.24 109.051 179.534 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.4 tp10 -142.32 117.69 10.22 Favored 'General case' 0 C--O 1.241 0.645 0 N-CA-C 109.101 -0.703 . . . . 73.45 109.101 173.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 68.16 -86.82 0.18 Allowed Glycine 0 C--N 1.349 1.279 0 O-C-N 123.864 0.727 . . . . 62.23 112.986 -177.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 4.5 pm0 -135.41 -14.85 1.94 Allowed 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 124.25 1.02 . . . . 74.31 111.206 -174.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -111.19 156.42 21.45 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-O 121.16 0.505 . . . . 74.12 111.36 -174.075 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.467 HD23 HD13 ' A' ' 188' ' ' LEU . 79.5 mt -109.09 170.78 7.83 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.334 1.054 . . . . 64.13 109.593 -168.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . 0.536 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 71.4 m-85 -142.45 122.58 13.75 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 107.51 -1.293 . . . . 74.34 107.51 177.502 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . 0.474 ' HB3' HD23 ' A' ' 251' ' ' LEU . . . -134.99 152.45 51.75 Favored 'General case' 0 CA--C 1.508 -0.657 0 N-CA-C 109.522 -0.547 . . . . 54.13 109.522 177.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 4.9 m -98.77 119.09 36.93 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 108.969 -0.752 . . . . 75.24 108.969 177.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.487 HD22 HD13 ' A' ' 251' ' ' LEU . 61.4 tp -105.31 111.84 24.73 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.347 1.059 . . . . 71.13 109.716 -174.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -94.43 104.85 16.81 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 109.333 -0.617 . . . . 74.51 109.333 176.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . 0.567 HG11 HG11 ' A' ' 223' ' ' VAL . 14.6 m -101.52 140.87 21.6 Favored Pre-proline 0 N--CA 1.476 0.825 0 N-CA-C 109.378 -0.601 . . . . 71.21 109.378 177.036 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.19 151.21 84.13 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 121.999 1.799 . . . . 73.21 110.986 171.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -56.69 -44.95 99.97 Favored Pre-proline 0 CA--C 1.546 0.791 0 CA-C-O 118.327 -0.844 . . . . 54.33 113.051 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . 0.421 ' O ' HG22 ' A' ' 206' ' ' VAL . 69.7 Cg_exo -46.69 -55.64 3.64 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 122.484 2.123 . . . . 64.42 113.495 170.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.2 mt -65.57 -37.25 79.56 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 122.736 0.414 . . . . 73.55 111.613 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -56.27 -58.33 8.43 Favored 'General case' 0 CA--C 1.547 0.828 0 CA-C-O 121.261 0.553 . . . . 72.53 111.087 178.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.6 m -69.79 -40.06 78.62 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.969 0 CA-C-N 115.212 -0.904 . . . . 72.15 112.461 -173.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 202' ' ' PRO . 18.3 m -78.17 -27.0 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 122.259 0.224 . . . . 74.12 110.977 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.548 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 77.52 63.66 2.2 Favored Glycine 0 C--N 1.341 0.835 0 CA-C-N 115.919 -0.582 . . . . 42.15 113.171 -176.4 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -91.89 -147.12 19.82 Favored Glycine 0 C--N 1.354 1.578 0 N-CA-C 111.694 -0.563 . . . . 33.35 111.694 177.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -138.18 135.5 35.7 Favored 'General case' 0 C--O 1.24 0.593 0 C-N-CA 123.154 0.582 . . . . 71.22 110.462 178.051 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 61.3 t -120.68 134.64 63.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.131 0.972 . . . . 70.23 108.964 -179.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.68 114.81 17.92 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.502 -0.555 . . . . 74.33 109.502 171.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.63 146.0 28.3 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 108.71 -0.848 . . . . 64.35 108.71 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 55.4 mmm -83.81 148.59 26.92 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 110.13 -0.322 . . . . 62.44 110.13 174.411 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.429 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 9.3 t -140.03 167.59 21.77 Favored 'General case' 0 C--O 1.242 0.691 0 C-N-CA 124.0 0.92 . . . . 72.54 109.873 173.581 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 63.7 mt -74.31 -0.56 17.46 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 123.882 0.873 . . . . 74.11 112.138 -173.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.65 -4.07 9.78 Favored 'General case' 0 N--CA 1.485 1.292 0 N-CA-C 112.747 0.647 . . . . 74.23 112.747 176.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 153.89 -160.74 29.55 Favored Glycine 0 N--CA 1.478 1.465 0 CA-C-O 119.679 -0.512 . . . . 62.41 112.859 178.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -94.26 132.54 0.71 Allowed 'Trans proline' 0 CA--C 1.559 1.726 0 C-N-CA 123.473 2.782 . . . . 43.15 112.596 168.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 34.3 m -111.38 151.97 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.64 0.776 . . . . 73.44 110.32 173.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -114.58 115.14 26.69 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-O 121.139 0.495 . . . . 73.44 110.099 171.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.528 ' HB ' HD11 ' A' ' 235' ' ' LEU . 2.6 p -104.66 121.44 56.48 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 123.359 0.664 . . . . 74.34 110.968 179.408 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.98 105.62 15.0 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 109.22 -0.659 . . . . 75.52 109.22 173.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.567 HG11 HG11 ' A' ' 199' ' ' VAL . 11.0 m -71.2 135.61 84.65 Favored Pre-proline 0 CA--C 1.556 1.189 0 N-CA-C 108.839 -0.8 . . . . 72.32 108.839 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . 0.427 ' HB2' HH12 ' A' ' 231' ' ' ARG . 31.5 Cg_exo -61.28 144.12 98.52 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 122.373 2.048 . . . . 64.23 112.581 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -51.24 128.35 25.04 Favored 'Trans proline' 0 C--N 1.38 2.222 0 C-N-CA 122.904 2.403 . . . . 74.43 112.046 173.008 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 42.1 mtp180 67.87 60.98 0.43 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 125.032 1.333 . . . . 75.12 110.369 -175.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -85.3 139.62 31.46 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 114.852 -1.067 . . . . 72.22 111.29 178.355 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 23.1 mp0 -112.2 158.84 19.19 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 123.768 0.827 . . . . 62.15 109.392 176.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -71.07 140.47 50.71 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 116.013 -0.54 . . . . 43.44 109.673 174.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 96.97 -3.7 62.5 Favored Glycine 0 CA--C 1.521 0.443 0 CA-C-O 119.448 -0.64 . . . . 52.12 112.996 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . 0.427 HH12 ' HB2' ' A' ' 224' ' ' PRO . 90.1 mtt180 -69.41 156.11 39.37 Favored 'General case' 0 N--CA 1.478 0.972 0 CA-C-N 117.649 0.724 . . . . 75.44 110.733 172.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 13.2 mptt -125.44 123.23 38.81 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 123.404 0.682 . . . . 74.4 109.726 177.31 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 46.6 mt -112.6 109.98 19.87 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 108.554 -0.906 . . . . 71.12 108.554 -175.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . 0.444 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 57.3 ttp85 -99.23 104.31 16.24 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 116.072 -0.513 . . . . 61.21 111.145 -168.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.528 HD11 ' HB ' ' A' ' 221' ' ' VAL . 37.0 mt -89.9 100.52 13.32 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 124.091 0.956 . . . . 71.31 110.145 -176.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . 0.424 ' HE2' ' HB3' ' A' ' 236' ' ' LYS . 42.4 mtpt -66.37 151.53 46.94 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 116.378 -0.374 . . . . 71.03 111.534 177.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.65 20.2 73.76 Favored Glycine 0 C--N 1.348 1.203 0 CA-C-N 115.325 -0.852 . . . . 52.11 112.845 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.0 mmtt -137.59 16.44 2.92 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.801 0.84 . . . . 73.31 111.266 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -99.11 -160.72 29.42 Favored Glycine 0 C--N 1.347 1.161 0 O-C-N 123.654 0.596 . . . . 72.15 112.038 170.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.553 ' HZ ' ' HB2' ' A' ' 151' ' ' PRO . 13.3 t80 -83.43 127.14 69.56 Favored Pre-proline 0 CA--C 1.552 1.043 0 CA-C-N 116.74 0.27 . . . . 55.44 110.945 -176.531 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . 0.567 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 13.5 Cg_exo -70.87 126.33 12.47 Favored 'Trans proline' 0 C--N 1.376 1.979 0 C-N-CA 122.269 1.979 . . . . 72.42 111.732 173.474 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -158.69 -146.13 4.45 Favored Glycine 0 CA--C 1.534 1.219 0 CA-C-O 119.149 -0.806 . . . . 50.03 112.583 -176.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -65.38 -24.54 57.25 Favored 'Trans proline' 0 C--N 1.376 2.01 0 C-N-CA 123.375 2.717 . . . . 62.21 112.866 -177.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.45 22.54 3.9 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 124.041 0.937 . . . . 70.24 111.113 178.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 81.18 -98.63 1.87 Allowed Glycine 0 C--N 1.345 1.042 0 N-CA-C 110.469 -1.053 . . . . 53.41 110.469 -176.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.567 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 23.2 ttm180 -128.62 146.53 50.83 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 109.146 -0.687 . . . . 74.25 109.146 166.148 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -85.61 -155.34 24.99 Favored Glycine 0 C--O 1.253 1.338 0 O-C-N 123.694 0.621 . . . . 41.12 112.424 175.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -140.27 160.52 39.78 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.835 0.854 . . . . 51.54 109.961 -174.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.444 ' O ' ' HA ' ' A' ' 234' ' ' ARG . 15.6 tp -99.51 122.39 42.51 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 123.919 0.887 . . . . 74.41 110.329 178.1 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -101.57 104.47 15.35 Favored 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 108.433 -0.951 . . . . 72.31 108.433 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.548 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 74.5 mt -85.72 149.93 24.95 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.987 0.915 . . . . 53.41 112.328 -178.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -114.47 96.01 5.55 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.539 -0.912 . . . . 70.51 108.539 176.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 69.1 t -52.15 125.82 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 123.582 0.753 . . . . 72.24 111.683 176.776 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 27.3 mmm-85 -136.17 101.5 4.72 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 125.257 1.423 . . . . 74.1 107.259 179.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 65.1 mt -80.97 125.39 39.45 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 CA-C-N 116.342 -0.39 . . . . 75.55 110.053 -175.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 10.0 t . . . . . 0 CA--C 1.55 0.966 0 C-N-CA 124.402 1.081 . . . . 72.55 109.653 -179.766 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.192 0 N-CA-C 110.22 -0.289 . . . . 74.43 110.22 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -157.35 -71.91 0.1 Allowed 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 123.033 0.533 . . . . 73.11 110.09 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.658 ' HB2' ' HG2' ' A' ' 136' ' ' ARG . 22.0 tp -80.58 -50.45 9.97 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.294 -0.632 . . . . 74.2 109.294 177.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.429 ' HA ' ' CB ' ' A' ' 123' ' ' LEU . 12.5 p -65.48 137.06 25.65 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 115.345 -0.843 . . . . 63.41 110.042 172.245 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -82.82 -50.14 8.96 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.215 -0.661 . . . . 62.55 109.215 174.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 49.0 p-80 -170.16 163.97 9.11 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 114.896 -1.047 . . . . 71.41 109.964 -175.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 1.8 p -95.38 162.09 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.086 0 N-CA-C 109.642 -0.503 . . . . 71.32 109.642 174.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 71.7 p -140.16 -176.66 4.68 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 124.792 1.237 . . . . 75.34 109.362 -171.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 44.7 t -75.75 166.41 23.58 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 124.05 0.94 . . . . 42.14 112.251 -175.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -94.4 174.64 33.83 Favored Glycine 0 C--N 1.353 1.481 0 CA-C-N 115.513 -0.767 . . . . 64.43 112.103 176.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 34.9 t -75.64 167.62 21.55 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 124.139 0.976 . . . . 54.22 111.839 -174.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -109.38 132.67 11.19 Favored Glycine 0 C--N 1.344 1.003 0 CA-C-N 115.721 -0.672 . . . . 71.53 111.748 -179.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.79 47.99 23.63 Favored Glycine 0 C--N 1.348 1.233 0 O-C-N 123.964 0.449 . . . . 53.34 112.582 179.466 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 21.1 m -76.17 76.89 2.99 Favored 'General case' 0 CA--C 1.554 1.098 0 C-N-CA 123.608 0.763 . . . . 75.05 110.367 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -87.29 -60.67 1.63 Allowed Glycine 0 C--N 1.348 1.243 0 CA-C-N 115.628 -0.715 . . . . 71.15 113.016 -176.54 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -85.63 56.78 4.9 Favored Glycine 0 C--N 1.344 1.022 0 N-CA-C 112.039 -0.424 . . . . 70.21 112.039 -179.52 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 35.3 p -160.86 138.38 9.29 Favored 'General case' 0 C--O 1.239 0.55 0 C-N-CA 124.425 1.09 . . . . 71.33 108.612 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -134.91 172.09 22.14 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 111.266 -0.734 . . . . 63.2 111.266 178.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 162.64 -159.1 31.39 Favored Glycine 0 C--N 1.336 0.58 0 N-CA-C 111.967 -0.453 . . . . 62.35 111.967 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 17.3 m -89.33 14.34 11.37 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 123.973 0.909 . . . . 75.11 112.443 -175.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 146.33 -142.46 10.51 Favored Glycine 0 C--N 1.35 1.36 0 N-CA-C 112.328 -0.309 . . . . 74.43 112.328 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.33 138.63 41.91 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 124.479 1.112 . . . . 64.23 110.487 -174.44 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.627 ' HB3' ' HB2' ' A' ' 167' ' ' GLN . 6.7 p-10 -70.36 146.56 50.38 Favored 'General case' 0 N--CA 1.486 1.361 0 CA-C-O 120.886 0.374 . . . . 70.34 110.418 170.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 31.6 tp -122.64 146.2 47.67 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 107.662 -1.236 . . . . 74.35 107.662 -170.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 64.6 ttt-85 -141.72 143.87 33.76 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.737 -0.838 . . . . 72.44 108.737 -176.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.442 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -149.06 118.81 7.03 Favored 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 109.079 -0.711 . . . . 73.25 109.079 175.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -94.03 139.38 31.02 Favored 'General case' 0 C--O 1.247 0.959 0 N-CA-C 109.305 -0.628 . . . . 74.42 109.305 174.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.474 HD12 ' HG ' ' A' ' 98' ' ' LEU . 1.8 pt? -144.87 132.37 10.37 Favored Pre-proline 0 CA--C 1.541 0.622 0 C-N-CA 123.099 0.56 . . . . 73.34 111.41 -166.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_exo -68.82 115.08 3.77 Favored 'Trans proline' 0 C--N 1.375 1.973 0 C-N-CA 122.654 2.236 . . . . 74.25 112.194 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.443 ' HB3' HD23 ' A' ' 180' ' ' LEU . 16.9 tp -109.2 166.84 10.55 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.512 1.125 . . . . 73.35 108.202 174.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.561 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 25.9 m -103.32 156.64 17.59 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 109.671 -0.492 . . . . 72.02 109.671 173.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.5 HD23 ' HB3' ' A' ' 180' ' ' LEU . 87.5 mt -56.02 -50.5 70.74 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-O 121.671 0.748 . . . . 64.14 110.069 171.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -57.48 -34.18 68.77 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 114.517 -1.22 . . . . 71.13 111.987 176.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.537 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 31.3 mm-40 -74.12 -31.49 62.79 Favored 'General case' 0 N--CA 1.482 1.169 0 C-N-CA 123.171 0.588 . . . . 74.41 111.56 176.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.444 ' HB1' ' O ' ' A' ' 153' ' ' VAL . . . -59.33 -37.91 79.02 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.442 0.697 . . . . 70.24 111.471 169.511 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.556 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 46.8 t80 -71.61 -47.73 52.7 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 115.79 -0.641 . . . . 75.51 112.174 173.16 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 31.8 m80 -63.09 -53.71 49.39 Favored 'General case' 0 N--CA 1.483 1.187 0 O-C-N 123.702 0.626 . . . . 64.44 111.004 -173.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 59.41 149.76 0.01 OUTLIER Glycine 0 CA--C 1.537 1.431 0 CA-C-N 115.772 -0.649 . . . . 74.51 113.297 -168.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 170.37 -179.06 42.74 Favored Glycine 0 CA--C 1.505 -0.551 0 C-N-CA 119.968 -1.11 . . . . 52.53 114.666 177.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -89.78 138.36 31.55 Favored 'General case' 0 C--O 1.24 0.596 0 CA-C-N 113.445 -1.377 . . . . 75.13 107.886 177.153 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.658 ' HG2' ' HB2' ' A' ' 98' ' ' LEU . 19.7 tpp180 -154.05 158.19 40.16 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 108.622 -0.881 . . . . 53.55 108.622 178.347 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.4 p -80.14 126.16 39.29 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.21 0 CA-C-O 121.544 0.687 . . . . 70.33 111.689 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 8.9 p -107.71 123.24 62.96 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 C-N-CA 124.732 1.213 . . . . 73.51 108.883 171.293 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -118.94 98.73 6.33 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 108.508 -0.923 . . . . 72.44 108.508 177.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.416 HG21 HD22 ' A' ' 174' ' ' LEU . 14.3 m -122.69 134.73 65.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 124.245 1.018 . . . . 73.34 109.785 -176.007 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 59.21 29.79 19.42 Favored 'General case' 0 CA--C 1.551 1.012 0 C-N-CA 124.18 0.992 . . . . 71.3 110.38 -173.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.28 6.39 79.91 Favored Glycine 0 C--N 1.358 1.797 0 CA-C-N 115.364 -0.835 . . . . 62.13 113.806 -177.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -99.31 115.08 28.35 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 109.103 -0.703 . . . . 73.53 109.103 -176.267 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 38.0 ttm180 -95.41 116.04 28.25 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 123.709 0.803 . . . . 65.43 110.144 -175.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.675 HG21 ' SD ' ' A' ' 164' ' ' MET . 7.5 m -142.79 156.99 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.893 0 C-N-CA 125.368 1.467 . . . . 74.24 108.539 176.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 38.9 t -88.37 127.02 35.48 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 109.864 -0.421 . . . . 60.52 109.864 174.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.7 p -99.91 144.88 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 123.699 0.8 . . . . 65.0 109.567 171.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.6 ttt180 -109.43 116.22 31.41 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.593 -0.891 . . . . 74.03 108.593 168.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.435 HG22 HG21 ' A' ' 159' ' ' ILE . 35.1 pt -121.1 132.04 24.31 Favored Pre-proline 0 CA--C 1.549 0.927 0 N-CA-C 108.93 -0.767 . . . . 72.3 108.93 171.189 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -76.45 166.61 27.13 Favored 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 122.8 2.333 . . . . 73.13 113.531 -170.327 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -68.89 154.62 70.65 Favored 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.109 1.873 . . . . 65.41 110.468 165.126 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 90.41 44.35 4.66 Favored Glycine 0 C--O 1.239 0.44 0 N-CA-C 111.548 -0.621 . . . . 73.12 111.548 -173.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.444 ' O ' ' HB1' ' A' ' 130' ' ' ALA . 2.7 p -116.3 156.26 17.52 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.102 0 N-CA-C 108.197 -1.038 . . . . 75.15 108.197 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 57.2 mtp180 -138.76 166.17 25.1 Favored 'General case' 0 N--CA 1.491 1.596 0 C-N-CA 123.967 0.907 . . . . 72.03 110.916 -164.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -57.97 127.55 32.61 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 122.957 0.503 . . . . 54.51 110.823 170.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 77.19 6.67 86.45 Favored Glycine 0 C--N 1.349 1.261 0 O-C-N 123.717 0.636 . . . . 51.32 113.379 -178.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 41.2 t -69.56 122.45 19.09 Favored 'General case' 0 C--N 1.358 0.953 0 C-N-CA 122.942 0.497 . . . . 61.13 109.7 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.443 HG22 HD22 ' A' ' 175' ' ' LEU . 7.3 p -103.01 119.94 52.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 O-C-N 124.475 1.109 . . . . 65.13 109.608 -176.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.435 HG21 HG22 ' A' ' 149' ' ' ILE . 17.6 mt -115.74 116.82 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 123.864 0.865 . . . . 70.15 109.86 -173.115 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.407 ' HA ' HD23 ' A' ' 175' ' ' LEU . 44.1 ttp180 -75.8 120.3 20.97 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-N 118.36 0.527 . . . . 75.03 110.141 175.758 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.651 ' HB ' ' HB3' ' A' ' 174' ' ' LEU . 84.2 t -112.16 113.88 51.42 Favored Pre-proline 0 CA--C 1.552 1.027 0 C-N-CA 124.249 1.019 . . . . 72.4 109.636 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -76.95 157.4 34.61 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.664 2.242 . . . . 70.32 113.233 178.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . 0.626 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . 105.76 -25.94 22.63 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 115.365 0.906 . . . . 70.04 115.365 173.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.675 ' SD ' HG21 ' A' ' 145' ' ' VAL . 4.1 mpp? -111.0 -45.89 3.4 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-N 118.893 1.347 . . . . 63.01 112.431 -175.001 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -76.47 -165.88 21.99 Favored Glycine 0 C--N 1.343 0.936 0 C-N-CA 121.441 -0.409 . . . . 61.42 112.624 179.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -111.85 -66.45 0.51 Allowed Glycine 0 C--N 1.339 0.727 0 N-CA-C 112.14 -0.384 . . . . 63.31 112.14 178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.627 ' HB2' ' HB3' ' A' ' 118' ' ' ASP . 11.8 mm-40 -58.7 175.38 0.26 Allowed 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 124.917 1.287 . . . . 64.01 113.1 -177.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 129.11 -174.68 19.12 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 115.341 -0.845 . . . . 74.22 112.013 171.327 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -80.79 -46.11 1.24 Allowed Pre-proline 0 CA--C 1.56 1.346 0 N-CA-C 109.496 -0.557 . . . . 75.11 109.496 169.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -89.2 163.87 5.67 Favored 'Trans proline' 0 C--N 1.388 2.623 0 C-N-CA 121.561 1.508 . . . . 62.42 110.263 162.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -63.22 124.94 14.74 Favored 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 121.481 1.454 . . . . 65.43 110.241 169.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.626 ' HA3' ' H ' ' A' ' 163' ' ' GLY . . . 103.91 119.97 4.7 Favored Glycine 0 C--N 1.34 0.778 0 N-CA-C 112.301 -0.319 . . . . 60.31 112.301 -176.329 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -134.6 107.5 7.53 Favored 'General case' 0 C--N 1.333 -0.141 0 C-N-CA 124.524 1.129 . . . . 72.31 108.153 172.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.651 ' HB3' ' HB ' ' A' ' 161' ' ' VAL . 27.4 tp -121.33 105.89 10.95 Favored 'General case' 0 C--O 1.226 -0.132 0 N-CA-C 107.2 -1.407 . . . . 75.22 107.2 168.003 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.443 HD22 HG22 ' A' ' 158' ' ' VAL . 59.8 mt -84.76 99.39 10.83 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.017 -0.538 . . . . 62.43 110.483 -176.015 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.442 ' HA ' ' O ' ' A' ' 121' ' ' ALA . 59.8 mt -84.35 102.81 13.0 Favored 'General case' 0 C--N 1.344 0.351 0 CA-C-N 115.569 -0.741 . . . . 74.44 109.393 176.101 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.7 t -95.98 95.05 4.54 Favored 'Isoleucine or valine' 0 C--O 1.242 0.665 0 CA-C-N 114.61 -1.177 . . . . 74.24 107.962 179.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.41 HG21 HG22 ' A' ' 153' ' ' VAL . 5.6 m -75.3 147.63 8.14 Favored 'Isoleucine or valine' 0 C--O 1.245 0.831 0 CA-C-O 121.521 0.676 . . . . 75.24 110.898 -171.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -121.35 94.93 4.49 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 108.119 -1.067 . . . . 71.3 108.119 -176.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.5 ' HB3' HD23 ' A' ' 127' ' ' LEU . 50.1 mt -67.34 147.12 53.36 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 110.269 -0.271 . . . . 73.12 110.269 -176.343 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.561 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 20.3 mt -56.59 123.41 56.95 Favored Pre-proline 0 CA--C 1.552 1.054 0 CA-C-O 119.307 -0.378 . . . . 73.13 110.362 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 17.2 Cg_exo -66.82 85.27 0.3 Allowed 'Trans proline' 0 C--N 1.379 2.143 0 C-N-CA 123.508 2.805 . . . . 75.21 113.356 -172.423 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -162.44 77.25 2.01 Favored Pre-proline 0 CA--C 1.558 1.281 0 N-CA-C 108.094 -1.076 . . . . 71.05 108.094 171.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -63.33 123.46 12.17 Favored 'Trans proline' 0 C--N 1.377 2.031 0 C-N-CA 122.002 1.801 . . . . 74.22 111.924 -171.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.8 p -134.56 -46.78 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 N-CA-C 107.517 -1.29 . . . . 62.2 107.517 174.135 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.54 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 4.3 m-85 -103.55 123.77 47.55 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.22 -0.9 . . . . 72.45 110.61 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 15.0 mtm180 -120.82 104.75 10.11 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 106.905 -1.517 . . . . 74.11 106.905 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.46 HD13 ' HD1' ' A' ' 240' ' ' PHE . 44.3 tp -83.6 138.55 33.31 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 108.996 -0.742 . . . . 55.34 108.996 174.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -141.59 104.93 4.65 Favored 'General case' 0 C--O 1.243 0.747 0 N-CA-C 107.393 -1.336 . . . . 71.34 107.393 176.273 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 74.84 -88.17 0.76 Allowed Glycine 0 C--N 1.348 1.221 0 CA-C-N 115.738 -0.665 . . . . 53.44 111.654 -174.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -136.59 -6.36 1.96 Allowed 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 123.625 0.77 . . . . 71.1 110.854 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -98.53 149.55 22.62 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.369 0.668 . . . . 71.24 111.202 -177.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.601 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.7 mt -109.58 151.17 27.16 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.486 1.114 . . . . 74.54 109.207 -177.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -140.41 120.17 13.42 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 107.372 -1.344 . . . . 73.41 107.372 178.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -143.24 140.66 30.78 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.742 0.817 . . . . 63.42 108.939 -177.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 20.5 m -83.39 127.98 34.13 Favored 'General case' 0 CA--C 1.543 0.676 0 CA-C-O 121.194 0.521 . . . . 60.13 110.208 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . . . . . . . . . 65.1 tp -112.3 120.66 42.5 Favored 'General case' 0 C--O 1.22 -0.479 0 C-N-CA 125.216 1.406 . . . . 74.21 108.941 176.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -99.35 123.08 43.33 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.402 -0.962 . . . . 74.32 108.402 170.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 4.6 m -110.2 147.78 36.99 Favored Pre-proline 0 C--O 1.245 0.849 0 C-N-CA 123.039 0.536 . . . . 74.41 109.883 -177.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -60.22 134.1 53.7 Favored 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 122.367 2.045 . . . . 72.14 110.877 168.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -53.96 -43.35 96.57 Favored Pre-proline 0 CA--C 1.564 1.493 0 C-N-CA 124.325 1.05 . . . . 71.4 113.541 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_exo -55.13 -46.48 32.71 Favored 'Trans proline' 0 C--N 1.395 3.024 0 C-N-CA 122.473 2.116 . . . . 73.34 112.97 171.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 7.1 mt -63.28 -38.24 81.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 123.344 0.657 . . . . 71.42 111.072 178.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.91 -43.62 98.29 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 123.099 0.56 . . . . 64.55 111.889 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . 0.515 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 35.8 m -80.81 -38.96 17.59 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 CA-C-N 116.154 -0.476 . . . . 65.3 112.178 -175.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.0 m -79.53 -35.78 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 CA-C-N 118.12 0.418 . . . . 53.33 110.573 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 89.81 80.02 1.34 Allowed Glycine 0 C--N 1.348 1.22 0 CA-C-N 115.613 -0.721 . . . . 75.01 112.229 -175.11 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -117.54 -160.42 11.71 Favored Glycine 0 C--N 1.357 1.732 0 N-CA-C 112.164 -0.374 . . . . 42.25 112.164 175.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 10.5 mtmp? -115.98 137.44 52.11 Favored 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 123.47 0.708 . . . . 73.45 110.373 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 28.2 t -118.82 152.06 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 C-N-CA 124.745 1.218 . . . . 55.15 108.749 176.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -81.13 119.2 23.27 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 108.434 -0.95 . . . . 71.44 108.434 171.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -102.16 122.94 45.12 Favored 'General case' 0 C--O 1.239 0.511 0 N-CA-C 108.125 -1.065 . . . . 55.21 108.125 175.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 54.7 mmm -77.21 113.4 14.92 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.193 0.52 . . . . 64.11 110.288 178.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.54 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 9.1 t -109.83 167.96 9.77 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-N 114.692 -1.14 . . . . 62.04 109.766 171.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . 0.412 HD13 ' O ' ' A' ' 127' ' ' LEU . 72.1 mt -71.12 -7.5 47.0 Favored 'General case' 0 CA--C 1.546 0.821 0 CA-C-N 114.701 -1.136 . . . . 73.24 111.735 178.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -90.57 -19.79 23.34 Favored 'General case' 0 CA--C 1.558 1.26 0 C-N-CA 124.211 1.004 . . . . 73.33 110.951 172.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 137.24 -154.36 22.33 Favored Glycine 0 C--N 1.347 1.163 0 N-CA-C 110.901 -0.88 . . . . 31.11 110.901 -174.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -89.19 129.06 1.92 Allowed 'Trans proline' 0 CA--C 1.55 1.295 0 C-N-CA 122.649 2.232 . . . . 61.32 111.923 170.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.0 m -109.82 167.91 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 123.775 0.83 . . . . 74.32 111.197 174.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 15.8 mm-40 -105.69 115.79 30.85 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 123.598 0.759 . . . . 62.31 109.906 177.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 2.7 p -116.55 125.44 73.54 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 C-N-CA 123.974 0.91 . . . . 71.31 109.566 174.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -92.31 121.83 34.18 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.124 -0.695 . . . . 34.24 109.124 175.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 10.0 m -81.7 145.43 54.33 Favored Pre-proline 0 CA--C 1.553 1.06 0 N-CA-C 108.989 -0.745 . . . . 43.04 108.989 177.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -61.99 141.92 90.94 Favored 'Trans proline' 0 C--N 1.371 1.713 0 C-N-CA 122.13 1.887 . . . . 65.33 111.914 173.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -60.04 122.21 11.03 Favored 'Trans proline' 0 C--N 1.368 1.592 0 C-N-CA 122.784 2.322 . . . . 75.54 112.257 174.358 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . 0.515 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 62.3 mtp180 65.85 39.33 4.7 Favored 'General case' 0 N--CA 1.482 1.172 0 C-N-CA 124.732 1.213 . . . . 73.3 111.427 -176.294 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 7.1 t -70.9 174.41 6.17 Favored 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 122.941 0.496 . . . . 75.13 111.272 -179.098 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.2 mp0 -123.55 143.65 50.07 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 123.859 0.863 . . . . 73.32 109.54 -176.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.08 123.28 21.18 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.785 0.834 . . . . 63.31 110.098 175.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 112.87 12.24 12.88 Favored Glycine 0 C--N 1.34 0.788 0 CA-C-N 116.244 -0.434 . . . . 73.41 112.605 -176.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 84.8 mtt180 -91.17 154.51 19.28 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 109.292 -0.633 . . . . 74.01 109.292 167.601 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.404 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.1 OUTLIER -104.27 111.45 24.08 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 123.615 0.766 . . . . 71.52 109.03 172.568 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . 0.475 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 67.8 mt -87.63 104.78 16.84 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 108.333 -0.988 . . . . 73.34 108.333 -177.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 40.5 ttm105 -76.58 110.39 11.1 Favored 'General case' 0 CA--C 1.538 0.481 0 CA-C-N 115.313 -0.858 . . . . 54.21 111.755 -172.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.454 HD12 HD23 ' A' ' 249' ' ' LEU . 20.9 mt -91.97 106.12 18.21 Favored 'General case' 0 C--O 1.239 0.551 0 N-CA-C 107.897 -1.149 . . . . 71.22 107.897 169.338 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 93.3 mttt -66.57 132.89 49.18 Favored 'General case' 0 CA--C 1.538 0.506 0 CA-C-N 114.578 -1.192 . . . . 75.24 111.828 -167.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 79.91 -1.11 80.61 Favored Glycine 0 C--N 1.348 1.228 0 O-C-N 123.834 0.709 . . . . 54.23 114.649 173.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.1 mmtt -84.57 -3.78 58.63 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.496 0.554 . . . . 71.41 112.496 -176.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.91 -179.31 48.92 Favored Glycine 0 C--N 1.346 1.136 0 N-CA-C 112.446 -0.262 . . . . 71.24 112.446 174.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.556 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 73.9 m-85 -86.38 155.86 56.93 Favored Pre-proline 0 N--CA 1.476 0.847 0 C-N-CA 123.197 0.599 . . . . 75.32 112.296 -173.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -60.97 140.5 90.5 Favored 'Trans proline' 0 C--N 1.384 2.444 0 C-N-CA 122.778 2.318 . . . . 73.25 112.772 178.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -150.82 -162.01 10.37 Favored Glycine 0 CA--C 1.533 1.179 0 N-CA-C 110.458 -1.057 . . . . 72.13 110.458 175.044 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -69.7 -20.68 34.81 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.803 2.335 . . . . 63.22 113.043 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.79 3.18 55.33 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.673 0.789 . . . . 73.12 112.083 -175.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 114.37 -105.97 1.62 Allowed Glycine 0 C--N 1.35 1.314 0 N-CA-C 110.619 -0.993 . . . . 64.31 110.619 -176.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 50.6 mtm-85 -126.58 152.28 46.82 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 108.045 -1.095 . . . . 74.3 108.045 167.395 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -78.03 -158.28 10.79 Favored Glycine 0 C--N 1.343 0.936 0 O-C-N 123.362 0.414 . . . . 72.21 112.152 174.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 38.6 m-20 -136.65 170.1 16.62 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 109.323 -0.621 . . . . 62.34 109.323 -175.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.601 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 23.9 tp -103.27 124.44 48.64 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.202 -0.666 . . . . 75.21 109.202 171.35 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . 0.404 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 48.3 m-85 -107.89 104.35 13.81 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.293 0.637 . . . . 62.11 109.405 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.475 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 85.2 mt -89.11 113.75 24.93 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.802 0.841 . . . . 71.11 112.414 -178.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -78.85 91.66 4.78 Favored 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 108.777 -0.823 . . . . 72.4 108.777 176.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.1 p -54.11 130.98 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.353 1.061 . . . . 74.14 111.066 176.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 13.2 mmt180 -131.02 99.01 4.75 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 125.12 1.368 . . . . 72.02 107.548 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 63.5 mt -76.58 124.76 35.48 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 C-N-CA 123.822 0.849 . . . . 72.35 109.269 -175.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 9.4 t . . . . . 0 C--O 1.25 1.086 0 C-N-CA 123.552 0.741 . . . . 72.5 109.781 -175.62 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.454 ' HB1' HG13 ' A' ' 99' ' ' VAL . . . . . . . . 0 N--CA 1.484 1.238 0 N-CA-C 109.959 -0.385 . . . . 50.55 109.959 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -149.25 -84.77 0.09 Allowed 'General case' 0 N--CA 1.48 1.06 0 C-N-CA 122.508 0.323 . . . . 73.43 110.71 -179.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.54 HD22 HD12 ' A' ' 123' ' ' LEU . 0.0 OUTLIER -82.9 -24.21 33.23 Favored 'General case' 0 N--CA 1.484 1.226 0 CA-C-O 121.254 0.549 . . . . 61.11 110.108 178.237 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.558 ' HA ' ' HB2' ' A' ' 123' ' ' LEU . 11.4 p -84.08 143.46 11.77 Favored 'Isoleucine or valine' 0 C--O 1.236 0.389 0 C-N-CA 124.702 1.201 . . . . 72.42 110.624 171.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -77.82 -87.07 0.05 Allowed 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 108.439 -0.949 . . . . 72.22 108.439 169.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.4 m80 -168.78 179.54 4.16 Favored 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 125.026 1.33 . . . . 74.12 109.72 177.461 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 93.4 t -62.23 140.16 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 C-N-CA 123.654 0.782 . . . . 61.44 111.146 178.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 37.4 p -66.57 110.21 3.09 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 123.163 0.585 . . . . 73.21 109.443 172.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 48.0 t -58.2 98.55 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 124.745 1.218 . . . . 50.4 112.109 -175.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -173.35 -175.19 40.93 Favored Glycine 0 C--N 1.342 0.867 0 CA-C-N 115.764 -0.653 . . . . 51.43 111.592 178.415 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 32.2 p -77.65 -66.13 0.88 Allowed 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.335 0.654 . . . . 72.25 109.793 177.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -161.5 154.16 25.08 Favored Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.665 -0.574 . . . . 72.44 111.665 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -109.76 -89.48 1.99 Allowed Glycine 0 C--N 1.345 1.035 0 C-N-CA 123.335 0.493 . . . . 75.11 112.478 -177.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 13.0 t -154.1 34.76 0.43 Allowed 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 121.403 0.62 . . . . 73.02 110.105 -174.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -79.95 156.12 39.66 Favored Glycine 0 C--N 1.342 0.912 0 CA-C-N 115.62 -0.718 . . . . 74.52 112.656 176.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 101.74 43.36 2.13 Favored Glycine 0 C--N 1.338 0.675 0 C-N-CA 123.642 0.639 . . . . 74.51 113.15 176.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 39.6 m -76.01 110.34 10.4 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 122.721 0.408 . . . . 53.52 110.386 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 77.75 -73.28 2.11 Favored Glycine 0 C--N 1.344 1.021 0 N-CA-C 110.676 -0.97 . . . . 61.03 110.676 -174.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.554 ' HA3' ' HG2' ' A' ' 171' ' ' PRO . . . -76.97 98.45 1.32 Allowed Glycine 0 C--N 1.344 0.994 0 N-CA-C 110.645 -0.982 . . . . 75.3 110.645 170.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 14.3 p -76.13 92.8 3.26 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 123.4 0.68 . . . . 65.32 110.87 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -127.24 -177.08 14.71 Favored Glycine 0 C--N 1.342 0.878 0 CA-C-N 115.268 -0.878 . . . . 71.01 111.071 172.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.577 ' HB3' ' HA2' ' A' ' 166' ' ' GLY . 20.0 tpp180 -63.1 124.64 21.65 Favored 'General case' 0 C--O 1.248 1.006 0 C-N-CA 122.9 0.48 . . . . 73.52 110.921 -176.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -61.24 125.33 23.35 Favored 'General case' 0 CA--C 1.538 0.51 0 CA-C-N 114.361 -1.29 . . . . 70.0 110.576 171.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.551 HD12 ' HA2' ' A' ' 165' ' ' GLY . 12.4 mt -125.59 142.46 51.5 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 107.26 -1.385 . . . . 74.04 107.26 160.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.6 ' HG2' ' HB2' ' A' ' 175' ' ' LEU . 41.0 mtm180 -141.91 145.78 34.97 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 107.694 -1.224 . . . . 64.33 107.694 178.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -151.46 118.42 5.85 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 108.516 -0.92 . . . . 71.24 108.516 175.379 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -88.85 132.45 34.66 Favored 'General case' 0 C--O 1.24 0.594 0 N-CA-C 108.086 -1.079 . . . . 52.23 108.086 173.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.558 ' HB2' ' HA ' ' A' ' 99' ' ' VAL . 2.2 pt? -142.71 146.65 39.0 Favored Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 122.778 0.431 . . . . 72.51 111.683 -168.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -75.97 121.6 6.3 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.689 2.259 . . . . 62.41 111.182 173.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.441 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 14.2 tp -120.16 168.94 10.7 Favored 'General case' 0 CA--C 1.534 0.335 0 C-N-CA 124.216 1.006 . . . . 65.44 108.793 174.69 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.628 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 11.5 m -107.06 155.98 19.25 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.136 0.574 . . . . 74.12 109.776 174.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 80.5 mt -50.49 -52.41 38.57 Favored 'General case' 0 N--CA 1.487 1.41 0 C-N-CA 124.127 0.971 . . . . 65.24 110.216 173.29 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.552 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -54.91 -39.52 68.89 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 113.506 -1.679 . . . . 71.44 112.103 177.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.628 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 16.0 mm-40 -76.88 -26.31 54.06 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 123.099 0.56 . . . . 72.15 112.107 -176.354 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.539 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -61.12 -44.56 97.16 Favored 'General case' 0 C--O 1.252 1.219 0 CA-C-O 121.62 0.724 . . . . 72.3 111.129 169.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -67.69 -46.31 72.65 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 114.029 -1.441 . . . . 72.21 112.747 176.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.2 m80 -69.2 -47.43 64.86 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 122.775 0.43 . . . . 73.5 110.759 -176.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.69 -148.24 50.99 Favored Glycine 0 C--N 1.344 1.022 0 N-CA-C 111.229 -0.749 . . . . 72.23 111.229 -169.533 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 117.26 172.72 16.21 Favored Glycine 0 N--CA 1.472 1.039 0 CA-C-N 117.224 0.512 . . . . 24.11 113.471 172.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 13.7 mp0 -90.11 114.42 26.34 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 107.744 -1.206 . . . . 61.13 107.744 179.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 4.9 mmp_? -116.75 163.19 16.51 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 123.855 0.862 . . . . 73.51 110.306 -177.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.6 p -88.48 124.07 41.24 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 CA-C-O 121.241 0.543 . . . . 65.04 110.241 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.408 ' HA ' HG11 ' A' ' 99' ' ' VAL . 12.0 p -114.24 145.87 19.5 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.694 0 C-N-CA 123.816 0.846 . . . . 64.44 109.962 178.463 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -125.91 109.06 12.05 Favored 'General case' 0 C--O 1.242 0.682 0 N-CA-C 108.668 -0.864 . . . . 74.45 108.668 174.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.9 m -130.43 117.52 39.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 123.678 0.791 . . . . 73.24 111.068 -176.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.05 23.39 13.79 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.835 1.254 . . . . 63.51 112.257 176.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.12 12.71 57.25 Favored Glycine 0 C--N 1.343 0.944 0 CA-C-O 120.032 -0.315 . . . . 51.11 112.995 -178.309 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.1 mpt_? -103.3 116.87 33.27 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.203 -0.665 . . . . 74.42 109.203 177.169 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 62.5 ttp85 -94.32 105.17 17.15 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 108.14 -1.059 . . . . 74.42 108.14 172.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 8.9 m -142.11 157.07 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 C-N-CA 124.338 1.055 . . . . 52.12 109.575 -175.15 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 54.3 p -90.94 120.08 31.66 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 122.889 0.476 . . . . 63.54 110.217 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.22 141.35 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.348 0.659 . . . . 34.44 109.425 177.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -107.04 103.42 12.83 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 108.298 -1.001 . . . . 63.41 108.298 174.45 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.439 ' HB ' HD13 ' A' ' 159' ' ' ILE . 37.8 pt -106.98 107.27 60.22 Favored Pre-proline 0 CA--C 1.548 0.873 0 N-CA-C 108.677 -0.861 . . . . 72.42 108.677 170.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.96 162.08 43.11 Favored 'Trans proline' 0 C--N 1.38 2.235 0 C-N-CA 122.972 2.448 . . . . 71.11 113.389 -171.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -59.85 114.77 2.22 Favored 'Trans proline' 0 C--N 1.376 2.017 0 C-N-CA 122.482 2.121 . . . . 73.44 110.448 169.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.42 ' HA2' ' CD2' ' A' ' 240' ' ' PHE . . . 140.62 61.35 0.04 OUTLIER Glycine 0 C--N 1.341 0.811 0 N-CA-C 111.811 -0.515 . . . . 71.12 111.811 -173.724 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.568 HG21 HD11 ' A' ' 159' ' ' ILE . 3.2 p -150.9 163.14 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.301 0 C-N-CA 122.505 0.322 . . . . 74.43 110.162 -178.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 44.8 mtp180 -146.8 177.02 9.43 Favored 'General case' 0 N--CA 1.484 1.234 0 C-N-CA 124.987 1.315 . . . . 75.42 110.113 -171.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.2 tp10 -51.72 118.2 3.22 Favored 'General case' 0 CA--C 1.546 0.8 0 C-N-CA 125.053 1.341 . . . . 71.14 111.51 170.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 79.0 1.28 84.91 Favored Glycine 0 C--N 1.351 1.373 0 CA-C-O 119.382 -0.677 . . . . 73.51 113.866 176.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 61.4 m -73.78 136.49 43.59 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-N 117.352 0.576 . . . . 63.34 110.953 -176.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.446 HG12 HD22 ' A' ' 175' ' ' LEU . 13.2 t -101.06 122.97 53.77 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-N 114.646 -1.161 . . . . 53.42 108.894 -174.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.568 HD11 HG21 ' A' ' 153' ' ' VAL . 16.6 mt -106.4 107.35 22.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 N-CA-C 109.035 -0.728 . . . . 74.21 109.035 -175.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.507 ' HA ' HD23 ' A' ' 175' ' ' LEU . 58.4 ttt-85 -81.7 109.13 15.83 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 110.03 -0.359 . . . . 63.5 110.03 176.202 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.444 HG22 ' O ' ' A' ' 174' ' ' LEU . 19.5 m -101.72 97.81 8.56 Favored Pre-proline 0 CA--C 1.559 1.319 0 N-CA-C 108.647 -0.872 . . . . 72.41 108.647 172.069 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -74.55 155.98 45.07 Favored 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 123.053 2.502 . . . . 50.41 113.189 -176.49 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 73.27 24.73 74.78 Favored Glycine 0 C--N 1.345 1.076 0 CA-C-N 115.488 -0.778 . . . . 72.51 112.586 -178.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.405 ' HG2' HG23 ' A' ' 161' ' ' VAL . 6.7 tpt -125.68 -56.89 1.47 Allowed 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 124.01 0.924 . . . . 74.35 111.573 -166.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . 0.551 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . -70.43 -79.96 0.32 Allowed Glycine 0 C--N 1.353 1.491 0 O-C-N 123.725 0.641 . . . . 61.45 112.14 -175.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.577 ' HA2' ' HB3' ' A' ' 117' ' ' ARG . . . -60.5 116.96 9.96 Favored Glycine 0 C--N 1.338 0.69 0 O-C-N 123.98 0.459 . . . . 50.42 113.688 169.493 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.6 mm-40 -81.51 146.57 30.12 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 124.049 0.94 . . . . 73.14 109.846 177.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 118.3 -177.63 16.55 Favored Glycine 0 N--CA 1.465 0.577 0 CA-C-N 116.536 -0.302 . . . . 44.51 112.478 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -65.16 -43.51 66.29 Favored Pre-proline 0 CA--C 1.554 1.114 0 CA-C-O 118.367 -0.825 . . . . 75.25 112.183 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.43 118.69 5.77 Favored 'Trans proline' 0 C--N 1.393 2.891 0 C-N-CA 121.424 1.416 . . . . 55.41 110.157 167.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.554 ' HG2' ' HA3' ' A' ' 114' ' ' GLY . 62.6 Cg_endo -73.8 125.2 9.78 Favored 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 121.731 1.621 . . . . 50.4 112.539 -175.087 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.521 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -98.87 178.69 31.05 Favored Glycine 0 C--O 1.222 -0.625 0 N-CA-C 110.565 -1.014 . . . . 52.14 110.565 166.67 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -146.56 157.14 43.68 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 118.12 0.96 . . . . 71.51 111.259 -171.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.444 ' O ' HG22 ' A' ' 161' ' ' VAL . 27.0 tp -114.57 115.59 27.42 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 114.655 -1.157 . . . . 72.44 108.684 176.297 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.6 ' HB2' ' HG2' ' A' ' 120' ' ' ARG . 93.8 mt -90.35 99.46 12.48 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.297 1.039 . . . . 63.11 110.254 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.422 HD12 HG21 ' A' ' 149' ' ' ILE . 45.6 mt -87.07 104.59 16.48 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 122.81 0.444 . . . . 72.15 110.51 175.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 42.5 t -89.39 95.78 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 107.803 -1.184 . . . . 72.42 107.803 176.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.441 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 8.1 m -82.08 144.11 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 109.769 -0.456 . . . . 74.4 109.769 -174.695 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 5.2 mmm180 -122.28 105.55 10.31 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 106.118 -1.808 . . . . 64.52 106.118 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 36.6 mt -69.61 147.88 50.11 Favored 'General case' 0 N--CA 1.473 0.706 0 O-C-N 123.373 0.421 . . . . 65.21 111.175 -172.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.472 HD12 HG23 ' A' ' 126' ' ' THR . 36.5 mt -55.73 121.04 36.95 Favored Pre-proline 0 C--N 1.357 0.905 0 O-C-N 123.641 0.588 . . . . 73.54 109.748 177.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -65.98 88.02 0.24 Allowed 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 122.969 2.446 . . . . 61.13 112.306 -178.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 13.3 p80 -156.99 62.9 2.88 Favored Pre-proline 0 CA--C 1.55 0.958 0 N-CA-C 107.794 -1.187 . . . . 74.1 107.794 169.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -56.14 122.06 11.1 Favored 'Trans proline' 0 C--N 1.382 2.339 0 C-N-CA 122.089 1.859 . . . . 74.24 112.639 -170.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.83 -45.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 N-CA-C 107.704 -1.221 . . . . 61.51 107.704 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.435 ' CE2' HD13 ' A' ' 193' ' ' LEU . 4.9 m-85 -107.41 131.98 53.68 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 123.93 0.892 . . . . 72.41 110.384 178.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 69.0 mtp180 -117.81 131.12 56.61 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.765 1.226 . . . . 74.41 108.635 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.406 HD12 ' O ' ' A' ' 192' ' ' ASP . 58.6 tp -109.9 130.84 55.48 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 121.004 0.43 . . . . 64.2 110.182 177.267 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -129.87 101.79 6.02 Favored 'General case' 0 C--O 1.24 0.572 0 N-CA-C 107.417 -1.327 . . . . 63.53 107.417 172.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 69.67 -82.65 0.29 Allowed Glycine 0 CA--C 1.53 1.008 0 O-C-N 123.793 0.683 . . . . 62.11 112.607 -176.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . 0.417 HE22 ' HB3' ' A' ' 244' ' ' ALA . 49.8 tt0 -134.2 -22.18 1.79 Allowed 'General case' 0 CA--C 1.552 1.053 0 C-N-CA 124.733 1.213 . . . . 73.03 109.554 -177.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.406 ' O ' HD12 ' A' ' 188' ' ' LEU . 41.3 m-20 -81.41 149.73 28.69 Favored 'General case' 0 C--N 1.358 0.967 0 C-N-CA 123.809 0.844 . . . . 72.43 111.385 -178.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.535 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.8 mt -109.58 155.04 21.92 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 124.639 1.176 . . . . 51.1 110.491 174.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -140.02 119.02 12.6 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 105.605 -1.998 . . . . 74.31 105.605 172.34 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -135.5 134.41 39.49 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 109.184 -0.672 . . . . 71.4 109.184 -178.235 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . 0.437 ' HA ' ' HB3' ' A' ' 252' ' ' GLU . 24.0 m -70.91 123.64 22.49 Favored 'General case' 0 CA--C 1.541 0.612 0 O-C-N 123.654 0.596 . . . . 73.2 110.064 -179.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.466 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 61.3 tp -105.95 111.34 23.95 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 108.767 -0.827 . . . . 71.34 108.767 -178.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -85.04 116.74 23.6 Favored 'General case' 0 CA--C 1.535 0.401 0 N-CA-C 108.492 -0.929 . . . . 55.44 108.492 176.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 2.2 m -122.86 141.64 35.95 Favored Pre-proline 0 N--CA 1.479 0.986 0 N-CA-C 108.996 -0.742 . . . . 50.33 108.996 177.592 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -72.7 147.1 44.44 Favored 'Trans proline' 0 C--N 1.366 1.485 0 C-N-CA 121.539 1.493 . . . . 63.42 110.521 169.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -58.31 -40.97 86.87 Favored Pre-proline 0 CA--C 1.558 1.26 0 C-N-CA 123.689 0.796 . . . . 62.32 112.419 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -45.68 -54.84 4.07 Favored 'Trans proline' 0 C--N 1.392 2.844 0 C-N-CA 122.524 2.15 . . . . 43.41 114.164 167.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 11.7 mt -65.58 -36.29 77.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 C-N-CA 122.237 0.215 . . . . 75.13 111.429 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.53 -44.27 93.23 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.16 0.584 . . . . 31.24 111.944 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.7 m -80.16 -41.15 20.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.725 0 CA-C-N 116.063 -0.517 . . . . 53.34 111.569 -176.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.3 m -78.88 -21.18 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 122.549 0.34 . . . . 74.04 111.148 -178.649 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.516 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 71.2 65.32 2.48 Favored Glycine 0 C--N 1.342 0.885 0 CA-C-N 115.764 -0.653 . . . . 74.32 112.439 -176.484 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -93.85 -155.55 31.87 Favored Glycine 0 C--N 1.353 1.505 0 CA-C-N 116.94 0.37 . . . . 65.4 112.535 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.22 134.87 54.62 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 124.326 1.05 . . . . 61.01 108.438 178.332 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 46.6 t -117.97 125.77 74.42 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 124.078 0.951 . . . . 64.43 108.593 -178.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -79.6 109.14 13.71 Favored 'General case' 0 CA--C 1.542 0.659 0 N-CA-C 109.137 -0.69 . . . . 64.54 109.137 177.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.95 129.92 48.35 Favored 'General case' 0 C--O 1.238 0.483 0 C-N-CA 123.417 0.687 . . . . 70.1 109.148 179.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.2 116.75 18.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.004 -0.544 . . . . 70.5 109.899 174.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.41 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.9 t -109.67 163.56 13.36 Favored 'General case' 0 C--O 1.242 0.685 0 O-C-N 123.901 0.75 . . . . 74.43 109.402 172.09 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . 0.552 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 90.2 mt -71.53 -2.58 17.37 Favored 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 115.507 -0.77 . . . . 63.33 112.61 -172.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -112.26 -11.72 13.69 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.565 0.746 . . . . 63.11 112.111 175.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 153.71 -156.34 26.73 Favored Glycine 0 C--N 1.349 1.267 0 CA-C-O 119.546 -0.585 . . . . 61.32 112.799 -179.047 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -94.28 133.53 0.76 Allowed 'Trans proline' 0 CA--C 1.556 1.592 0 C-N-CA 123.001 2.467 . . . . 74.14 112.846 174.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 27.1 m -114.56 157.5 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 123.585 0.754 . . . . 73.34 109.639 170.351 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -114.47 113.9 25.09 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 108.999 -0.741 . . . . 72.22 108.999 177.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.477 HG22 HD11 ' A' ' 235' ' ' LEU . 6.3 t -95.79 117.19 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 C-N-CA 123.99 0.916 . . . . 75.04 110.026 -177.328 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -83.99 100.57 11.14 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 108.977 -0.749 . . . . 74.21 108.977 176.101 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.516 HG23 ' HA2' ' A' ' 207' ' ' GLY . 20.0 m -79.43 137.45 55.65 Favored Pre-proline 0 CA--C 1.551 1.019 0 N-CA-C 109.415 -0.587 . . . . 54.14 109.415 179.415 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -63.31 144.9 92.39 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.537 2.158 . . . . 61.32 112.498 176.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -55.77 120.41 8.2 Favored 'Trans proline' 0 C--N 1.381 2.258 0 C-N-CA 123.081 2.521 . . . . 43.42 112.043 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 67.3 mtt180 64.76 54.61 1.34 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.382 1.073 . . . . 64.41 110.388 -175.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.3 t -75.49 167.36 22.04 Favored 'General case' 0 CA--C 1.545 0.781 0 CA-C-N 115.372 -0.831 . . . . 71.31 109.159 173.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -128.15 146.28 50.76 Favored 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 123.217 0.607 . . . . 74.12 109.614 -177.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -68.13 127.9 34.6 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 115.318 -0.855 . . . . 74.35 109.27 175.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.29 0.31 23.69 Favored Glycine 0 N--CA 1.471 1.032 0 CA-C-O 119.497 -0.613 . . . . 62.42 112.841 -173.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 25.0 mtp180 -84.4 154.89 22.55 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 117.414 0.607 . . . . 73.15 109.865 170.025 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.658 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.0 OUTLIER -120.59 101.67 7.91 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 108.497 -0.927 . . . . 75.12 108.497 176.269 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 37.2 mt -83.37 113.98 21.11 Favored 'General case' 0 C--N 1.352 0.686 0 N-CA-C 108.964 -0.754 . . . . 73.12 108.964 -173.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 -87.24 106.68 18.07 Favored 'General case' 0 C--O 1.239 0.507 0 C-N-CA 123.782 0.833 . . . . 75.32 110.839 -167.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.477 HD11 HG22 ' A' ' 221' ' ' VAL . 15.7 mt -94.06 104.28 16.32 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 108.112 -1.07 . . . . 75.15 108.112 174.091 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -74.65 141.47 44.61 Favored 'General case' 0 C--O 1.242 0.683 0 CA-C-N 115.763 -0.653 . . . . 73.13 112.025 -170.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 66.59 32.99 83.16 Favored Glycine 0 C--N 1.349 1.271 0 O-C-N 124.12 0.888 . . . . 71.22 113.253 178.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 41.1 mmtm -116.13 -2.68 12.15 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.663 0.785 . . . . 74.21 111.166 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . 0.449 ' O ' ' HD2' ' A' ' 246' ' ' ARG . . . -82.03 -156.16 17.28 Favored Glycine 0 C--N 1.347 1.177 0 O-C-N 123.657 0.598 . . . . 61.33 114.181 -178.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.42 ' CD2' ' HA2' ' A' ' 152' ' ' GLY . 35.0 m-85 -88.34 160.29 45.64 Favored Pre-proline 0 N--CA 1.482 1.159 0 C-N-CA 123.204 0.601 . . . . 52.24 110.56 176.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -57.09 152.5 44.15 Favored 'Trans proline' 0 C--N 1.382 2.313 0 C-N-CA 123.031 2.487 . . . . 71.51 113.971 178.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 176.94 -167.71 39.2 Favored Glycine 0 C--N 1.341 0.853 0 CA-C-N 115.27 -0.877 . . . . 74.34 112.11 176.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.27 -15.3 35.15 Favored 'Trans proline' 0 C--N 1.382 2.291 0 C-N-CA 122.983 2.456 . . . . 71.13 112.619 -176.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . 0.417 ' HB3' HE22 ' A' ' 191' ' ' GLN . . . -96.77 24.12 6.39 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.175 0.99 . . . . 54.34 110.692 174.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 77.8 -89.62 1.06 Allowed Glycine 0 C--N 1.345 1.063 0 N-CA-C 110.943 -0.863 . . . . 70.41 110.943 -175.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.449 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 23.1 mtm180 -128.09 155.89 43.67 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 108.728 -0.841 . . . . 75.14 108.728 169.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -70.9 -160.78 3.72 Favored Glycine 0 C--N 1.348 1.231 0 O-C-N 123.727 0.642 . . . . 60.14 114.397 -176.25 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -129.21 138.33 51.64 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 122.888 0.475 . . . . 74.52 109.772 -173.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.535 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 30.6 tp -97.27 115.96 28.59 Favored 'General case' 0 C--O 1.214 -0.788 0 C-N-CA 123.624 0.77 . . . . 75.1 110.017 -178.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . 0.658 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 97.3 m-85 -101.65 106.95 18.06 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 123.497 0.719 . . . . 73.0 109.356 179.1 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.5 ' HA ' ' O ' ' A' ' 195' ' ' ALA . 78.3 mt -87.08 118.72 26.65 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 115.372 -0.831 . . . . 72.23 113.115 -175.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.437 ' HB3' ' HA ' ' A' ' 196' ' ' THR . 10.5 tp10 -79.76 91.71 5.34 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 108.578 -0.897 . . . . 74.21 108.578 -178.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 59.7 t -52.5 118.38 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 123.99 0.916 . . . . 74.03 110.875 177.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 30.7 mmm180 -123.48 94.79 4.35 Favored 'General case' 0 C--O 1.24 0.569 0 C-N-CA 124.635 1.174 . . . . 74.11 107.95 176.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 63.4 mt -76.62 114.25 16.69 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 115.716 -0.674 . . . . 55.22 109.299 177.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 6.4 t . . . . . 0 C--O 1.248 1.014 0 C-N-CA 124.619 1.168 . . . . 62.41 108.944 -179.559 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.072 0 N-CA-C 109.406 -0.59 . . . . 43.14 109.406 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -63.1 -63.77 1.1 Allowed 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 123.622 0.769 . . . . 72.52 110.467 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.7 tp -128.46 149.03 50.75 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.599 -1.26 . . . . 64.24 107.599 160.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.561 ' HB ' ' HB3' ' A' ' 123' ' ' LEU 0.269 2.4 p 36.57 -95.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 C-N-CA 126.337 1.855 . . . . 74.31 113.713 176.956 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.46 ' H ' HG13 ' A' ' 99' ' ' VAL . . . 57.31 8.32 0.57 Allowed 'General case' 0 N--CA 1.493 1.683 0 C-N-CA 124.963 1.305 . . . . 62.25 113.14 -176.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 35.7 t-80 -103.81 71.91 1.08 Allowed 'General case' 0 C--O 1.243 0.756 0 N-CA-C 107.374 -1.343 . . . . 74.11 107.374 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 104' ' ' SER . 81.0 t -72.53 137.18 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 CA-C-N 114.375 -1.284 . . . . 34.54 109.702 -179.031 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 72.2 p -79.97 14.49 1.79 Allowed 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 124.504 1.122 . . . . 72.42 112.724 -173.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.426 ' H ' HG12 ' A' ' 102' ' ' VAL . 28.6 m 65.2 12.61 8.15 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 124.879 1.272 . . . . 71.53 111.877 -174.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -113.74 150.63 18.53 Favored Glycine 0 C--N 1.349 1.294 0 CA-C-N 115.953 -0.567 . . . . 75.02 112.499 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 34.8 t -163.97 97.86 0.84 Allowed 'General case' 0 C--O 1.247 0.925 0 C-N-CA 124.286 1.034 . . . . 64.4 108.971 178.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -86.32 -162.85 37.45 Favored Glycine 0 C--N 1.344 0.995 0 CA-C-N 116.675 -0.238 . . . . 75.23 113.07 -175.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -113.61 93.58 0.67 Allowed Glycine 0 C--N 1.34 0.795 0 N-CA-C 110.983 -0.847 . . . . 62.22 110.983 178.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.635 ' HB2' ' HB3' ' A' ' 118' ' ' ASP . 38.2 t -57.53 112.7 1.51 Allowed 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 124.705 1.202 . . . . 71.34 111.419 177.472 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -136.48 -128.62 2.73 Favored Glycine 0 C--N 1.338 0.657 0 N-CA-C 110.695 -0.962 . . . . 72.25 110.695 178.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 68.08 -83.82 0.17 Allowed Glycine 0 C--N 1.354 1.54 0 C-N-CA 123.107 0.384 . . . . 73.22 112.491 175.095 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 30.5 t -144.02 99.33 3.37 Favored 'General case' 0 C--O 1.242 0.671 0 N-CA-C 108.525 -0.917 . . . . 74.42 108.525 172.493 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 88.93 141.53 8.14 Favored Glycine 0 CA--C 1.527 0.806 0 CA-C-N 115.744 -0.662 . . . . 73.51 112.234 178.081 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 121.64 -84.5 0.37 Allowed Glycine 0 C--O 1.238 0.378 0 N-CA-C 110.339 -1.105 . . . . 70.04 110.339 -176.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 76.0 p 44.74 61.98 2.25 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 125.296 1.438 . . . . 64.04 110.998 -173.172 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.99 -176.24 45.81 Favored Glycine 0 N--CA 1.461 0.3 0 CA-C-N 114.076 -1.42 . . . . 75.02 110.168 -178.523 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 5.4 ptm180 -75.46 120.39 20.83 Favored 'General case' 0 C--O 1.247 0.937 0 CA-C-N 117.851 0.826 . . . . 75.05 109.957 179.374 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.635 ' HB3' ' HB2' ' A' ' 109' ' ' SER . 4.3 p30 -81.26 135.35 35.72 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 106.811 -1.552 . . . . 71.14 106.811 162.296 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 1.3 tt -99.83 143.34 30.17 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 106.427 -1.694 . . . . 71.51 106.427 177.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 12.7 tpp85 -119.0 125.23 48.9 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 118.778 0.717 . . . . 72.53 110.591 -173.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -147.85 149.95 33.25 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.341 0.656 . . . . 71.34 109.794 178.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.664 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 41.8 mt-10 -127.83 149.4 50.29 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.52 0.728 . . . . 71.43 109.418 -179.074 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.561 ' HB3' ' HB ' ' A' ' 99' ' ' VAL . 1.5 pt? -143.93 147.1 36.93 Favored Pre-proline 0 N--CA 1.474 0.741 0 O-C-N 123.505 0.503 . . . . 63.51 111.323 -176.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -76.79 113.93 3.74 Favored 'Trans proline' 0 C--N 1.371 1.738 0 C-N-CA 121.426 1.418 . . . . 73.44 109.688 162.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.464 HD22 HG11 ' A' ' 178' ' ' VAL . 18.6 tp -108.28 158.8 17.15 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.758 0.823 . . . . 45.44 108.839 178.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.57 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 6.9 m -95.52 156.26 16.4 Favored 'General case' 0 CA--C 1.544 0.744 0 C-N-CA 123.397 0.679 . . . . 71.33 109.191 175.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 82.0 mt -58.34 -49.33 77.58 Favored 'General case' 0 N--CA 1.488 1.436 0 CA-C-O 122.348 1.071 . . . . 62.14 109.455 174.302 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -57.01 -38.16 72.7 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 113.276 -1.784 . . . . 74.14 111.475 177.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 31.5 mm-40 -80.02 -21.16 43.86 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.231 0.612 . . . . 72.22 112.469 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.539 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -61.63 -40.33 94.47 Favored 'General case' 0 C--O 1.256 1.417 0 CA-C-O 121.665 0.745 . . . . 42.31 110.696 167.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.491 ' HA ' ' CE1' ' A' ' 240' ' ' PHE . 69.0 t80 -70.31 -48.35 56.98 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 113.964 -1.471 . . . . 74.44 112.774 172.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -71.55 -47.32 55.78 Favored 'General case' 0 N--CA 1.485 1.277 0 N-CA-C 112.067 0.395 . . . . 74.01 112.067 -172.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.32 -115.89 8.19 Favored Glycine 0 CA--C 1.533 1.204 0 N-CA-C 111.121 -0.791 . . . . 52.13 111.121 -175.643 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.8 174.55 39.71 Favored Glycine 0 C--N 1.346 1.124 0 N-CA-C 115.175 0.83 . . . . 54.44 115.175 167.613 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -87.61 118.26 26.98 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.346 1.059 . . . . 62.42 108.221 178.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -130.44 138.88 50.53 Favored 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 124.368 1.067 . . . . 74.43 108.543 -176.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 7.2 p -83.12 139.93 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 N-CA-C 108.697 -0.853 . . . . 74.2 108.697 174.16 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.446 HG21 HG13 ' A' ' 99' ' ' VAL . 7.1 p -143.04 153.09 16.89 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 C-N-CA 124.011 0.924 . . . . 74.53 109.324 -178.275 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -116.38 100.27 7.77 Favored 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 107.782 -1.192 . . . . 73.2 107.782 170.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 9.0 t -103.65 111.54 33.72 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 N-CA-C 108.753 -0.832 . . . . 71.34 108.753 -172.037 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.93 26.0 15.33 Favored 'General case' 0 N--CA 1.479 1.017 0 O-C-N 124.493 1.121 . . . . 72.43 111.658 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 91.75 13.63 57.77 Favored Glycine 0 C--N 1.355 1.585 0 CA-C-N 115.807 -0.633 . . . . 74.4 113.315 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 25.8 ttt180 -116.7 116.23 27.13 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 122.986 0.514 . . . . 72.23 110.134 177.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -87.5 114.09 23.8 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 122.838 0.455 . . . . 62.15 110.196 -178.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.6 p -148.13 152.79 12.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 C-N-CA 124.835 1.254 . . . . 72.02 109.089 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 43.7 m -82.86 122.19 27.91 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 122.835 0.454 . . . . 75.13 110.258 175.15 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.414 HG22 HG23 ' A' ' 149' ' ' ILE . 13.7 p -98.59 123.99 51.48 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 C-N-CA 123.646 0.778 . . . . 75.03 109.594 175.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 30.9 ttt85 -108.05 98.25 7.84 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 107.849 -1.167 . . . . 74.41 107.849 174.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.414 HG23 HG22 ' A' ' 147' ' ' VAL . 35.3 pt -96.32 131.4 28.64 Favored Pre-proline 0 N--CA 1.479 0.984 0 N-CA-C 109.673 -0.492 . . . . 75.32 109.673 178.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.404 ' HA ' ' HD3' ' A' ' 151' ' ' PRO . 58.2 Cg_endo -67.71 145.32 69.04 Favored 'Trans proline' 0 C--N 1.375 1.94 0 C-N-CA 122.852 2.368 . . . . 73.44 112.982 -174.154 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.475 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 32.1 Cg_exo -63.68 125.12 14.85 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 123.045 2.497 . . . . 74.33 110.596 171.186 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 131.44 41.25 0.21 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 111.827 -0.509 . . . . 50.31 111.827 -173.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.539 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -118.58 154.21 20.77 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 N-CA-C 108.775 -0.824 . . . . 74.32 108.775 -177.484 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 40.9 mtp180 -144.66 166.85 24.01 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 124.943 1.297 . . . . 72.25 109.055 -165.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -52.75 123.18 10.65 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 123.61 0.764 . . . . 60.14 111.943 176.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 80.62 -4.61 68.17 Favored Glycine 0 C--N 1.348 1.202 0 CA-C-N 115.896 -0.593 . . . . 64.13 113.629 179.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 32.4 t -68.82 127.52 33.38 Favored 'General case' 0 C--O 1.248 1.016 0 C-N-CA 123.665 0.786 . . . . 61.1 110.134 -176.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.515 HG12 HD22 ' A' ' 175' ' ' LEU . 8.7 t -97.89 119.46 45.94 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-N 114.303 -1.317 . . . . 63.4 108.627 -176.449 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.483 HD11 HG21 ' A' ' 153' ' ' VAL . 17.2 mt -102.94 117.07 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 123.664 0.786 . . . . 75.4 110.054 -170.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 22.3 ttm180 -84.02 117.39 23.37 Favored 'General case' 0 C--O 1.239 0.512 0 C-N-CA 123.53 0.732 . . . . 64.22 110.414 172.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 17.4 m -112.84 101.39 53.02 Favored Pre-proline 0 CA--C 1.559 1.29 0 N-CA-C 108.293 -1.003 . . . . 70.54 108.293 169.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -64.92 149.66 89.2 Favored 'Trans proline' 0 C--N 1.384 2.407 0 C-N-CA 123.55 2.833 . . . . 60.44 113.428 -172.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 71.3 24.2 77.22 Favored Glycine 0 C--N 1.348 1.216 0 O-C-N 123.594 0.559 . . . . 62.43 113.795 175.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 2.9 tpt -100.52 -51.86 3.5 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.149 0.98 . . . . 64.42 109.998 -177.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -82.84 -89.16 0.7 Allowed Glycine 0 C--N 1.351 1.391 0 CA-C-N 115.403 -0.817 . . . . 71.32 112.092 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -65.36 91.76 0.13 Allowed Glycine 0 C--N 1.354 1.538 0 C-N-CA 123.04 0.352 . . . . 41.12 113.15 179.472 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.1 mm-40 -70.26 146.1 50.87 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 123.289 0.636 . . . . 64.24 111.145 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 123.25 -168.07 15.47 Favored Glycine 0 N--CA 1.476 1.361 0 CA-C-O 119.733 -0.482 . . . . 74.13 112.874 176.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.411 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 93.0 m-20 -53.25 -47.62 95.36 Favored Pre-proline 0 CA--C 1.567 1.624 0 C-N-CA 124.062 0.945 . . . . 73.45 112.69 -178.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.411 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 2.0 Cg_endo -85.08 113.44 1.51 Allowed 'Trans proline' 0 C--N 1.388 2.614 0 C-N-CA 122.572 2.181 . . . . 72.42 110.355 168.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_endo -80.35 123.7 5.05 Favored 'Trans proline' 0 C--N 1.371 1.725 0 C-N-CA 121.745 1.63 . . . . 55.2 112.507 -175.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -100.6 150.5 18.82 Favored Glycine 0 C--N 1.342 0.866 0 N-CA-C 108.988 -1.645 . . . . 61.31 108.988 174.193 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -113.09 -179.89 3.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 118.049 0.924 . . . . 74.23 111.498 -164.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 15.6 tp -121.98 128.63 51.69 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 107.82 -1.178 . . . . 71.53 107.82 167.3 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.515 HD22 HG12 ' A' ' 158' ' ' VAL . 76.6 mt -99.76 101.99 13.31 Favored 'General case' 0 C--O 1.243 0.746 0 C-N-CA 125.085 1.354 . . . . 75.4 110.28 178.342 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 86.4 mt -91.28 109.46 20.73 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 123.612 0.765 . . . . 74.4 111.114 175.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.664 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 21.5 t -90.2 105.22 16.0 Favored 'Isoleucine or valine' 0 C--O 1.247 0.938 0 N-CA-C 108.115 -1.068 . . . . 71.11 108.115 173.286 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.464 HG11 HD22 ' A' ' 125' ' ' LEU . 6.1 m -82.4 151.34 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 CA-C-O 121.223 0.535 . . . . 60.24 111.615 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 38.2 mmt180 -124.07 98.95 6.01 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 107.67 -1.233 . . . . 71.25 107.67 176.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 57.5 mt -67.46 144.64 55.61 Favored 'General case' 0 C--O 1.241 0.628 0 O-C-N 123.139 0.274 . . . . 72.04 110.685 -178.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.57 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 44.1 mt -59.83 147.03 80.11 Favored Pre-proline 0 CA--C 1.558 1.284 0 O-C-N 124.366 1.041 . . . . 52.15 110.967 -176.436 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -75.46 58.09 5.06 Favored 'Trans proline' 0 C--N 1.375 1.96 0 C-N-CA 123.991 3.127 . . . . 73.44 113.845 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -142.28 51.82 2.17 Favored Pre-proline 0 CA--C 1.562 1.434 0 C-N-CA 123.035 0.534 . . . . 54.04 109.831 171.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -64.21 123.56 12.05 Favored 'Trans proline' 0 C--N 1.388 2.632 0 C-N-CA 122.43 2.087 . . . . 61.31 111.905 -168.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -128.22 -37.49 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 123.81 0.844 . . . . 74.52 109.363 -177.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.435 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 6.0 m-85 -107.39 124.37 49.74 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 114.814 -1.085 . . . . 73.02 110.338 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.652 ' HB3' ' HB2' ' A' ' 194' ' ' TYR . 19.6 tpp180 -105.02 139.08 40.24 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 106.934 -1.506 . . . . 63.51 106.934 172.073 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 51.1 tp -123.41 122.62 38.74 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 122.897 0.479 . . . . 63.14 109.86 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -144.9 127.86 16.47 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 122.39 0.276 . . . . 74.13 110.322 169.16 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 63.94 33.83 88.28 Favored Glycine 0 C--N 1.356 1.648 0 O-C-N 123.91 0.756 . . . . 75.25 114.246 177.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 73.96 -5.24 2.08 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 125.714 1.606 . . . . 73.25 112.659 -175.567 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -93.33 149.98 20.82 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.479 0.711 . . . . 73.01 109.579 178.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.646 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 93.1 mt -108.92 163.57 13.17 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 124.281 1.033 . . . . 70.21 109.94 -176.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . 0.652 ' HB2' ' HB3' ' A' ' 187' ' ' ARG . 85.1 m-85 -143.38 121.52 12.18 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 106.803 -1.554 . . . . 74.51 106.803 178.01 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -147.25 164.32 33.58 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 123.444 0.697 . . . . 75.54 109.921 -176.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 17.5 m -106.2 125.45 51.01 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.51 -0.768 . . . . 62.0 109.17 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.56 HD22 HD13 ' A' ' 251' ' ' LEU . 65.5 tp -112.44 115.65 29.03 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.541 0.736 . . . . 73.04 109.631 177.419 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -78.7 131.03 36.46 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 108.138 -1.06 . . . . 65.44 108.138 169.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 255' ' ' ILE . 90.9 t -129.78 121.15 19.86 Favored Pre-proline 0 N--CA 1.474 0.728 0 N-CA-C 107.682 -1.229 . . . . 72.14 107.682 178.626 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -65.83 147.66 85.57 Favored 'Trans proline' 0 C--N 1.369 1.657 0 C-N-CA 122.143 1.895 . . . . 74.13 110.888 176.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . 0.445 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -53.5 -42.5 92.24 Favored Pre-proline 0 N--CA 1.48 1.065 0 C-N-CA 124.483 1.113 . . . . 65.11 113.569 -177.323 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . 0.445 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 10.8 Cg_endo -52.42 -51.29 11.46 Favored 'Trans proline' 0 C--N 1.397 3.107 0 C-N-CA 122.144 1.896 . . . . 74.11 112.64 172.219 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 7.0 mt -66.49 -37.11 78.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 123.211 0.604 . . . . 72.21 111.641 -179.065 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.3 -42.97 99.11 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 122.926 0.49 . . . . 52.24 111.929 -178.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.2 m -82.62 -35.59 12.73 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.87 0 CA-C-N 115.931 -0.577 . . . . 73.55 111.987 -175.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 12.4 m -87.23 -18.92 8.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 CA-C-N 118.043 0.383 . . . . 74.22 111.658 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.408 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 77.87 55.04 4.28 Favored Glycine 0 C--N 1.344 1.022 0 CA-C-N 115.857 -0.61 . . . . 75.24 113.218 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -84.87 -169.66 46.17 Favored Glycine 0 C--N 1.349 1.252 0 CA-C-O 121.783 0.657 . . . . 71.11 112.585 -177.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . 0.432 ' HD2' ' N ' ' A' ' 209' ' ' LYS . 0.0 OUTLIER -115.61 120.18 38.58 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 107.771 -1.196 . . . . 63.53 107.771 -173.667 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . 0.442 HG11 HG22 ' A' ' 199' ' ' VAL . 7.3 p -124.42 144.07 35.57 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.796 0 C-N-CA 124.37 1.068 . . . . 44.21 109.343 -178.304 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.22 138.06 34.74 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.297 -0.631 . . . . 72.13 109.297 176.134 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -107.69 131.56 54.28 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 108.446 -0.946 . . . . 63.5 108.446 169.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.49 104.55 9.16 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.988 -1.116 . . . . 72.33 107.988 179.375 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.447 HG23 ' H ' ' A' ' 216' ' ' GLU . 14.8 t -112.41 168.15 9.87 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.161 0.584 . . . . 63.1 110.543 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 65.2 mt -70.03 -7.3 39.93 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 123.562 0.745 . . . . 71.23 111.788 -179.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . 0.447 ' H ' HG23 ' A' ' 214' ' ' THR . 42.6 tt0 -97.28 -18.07 19.42 Favored 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.679 1.192 . . . . 70.32 111.382 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 133.06 -147.83 19.11 Favored Glycine 0 N--CA 1.475 1.284 0 CA-C-O 119.188 -0.784 . . . . 64.15 111.82 -178.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -85.84 126.73 2.98 Favored 'Trans proline' 0 CA--C 1.559 1.757 0 C-N-CA 122.878 2.386 . . . . 53.42 112.021 172.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 26.1 m -109.68 156.1 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 122.918 0.487 . . . . 63.35 110.944 172.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 24.9 mm-40 -95.09 109.89 21.89 Favored 'General case' 0 C--O 1.238 0.475 0 C-N-CA 123.572 0.749 . . . . 72.12 109.827 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.566 HG22 HD11 ' A' ' 235' ' ' LEU . 8.7 t -104.25 117.52 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.663 0.785 . . . . 65.55 109.057 172.525 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -98.62 102.42 14.15 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 108.279 -1.008 . . . . 71.34 108.279 174.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.408 HG23 ' HA2' ' A' ' 207' ' ' GLY . 11.9 m -75.97 143.52 74.35 Favored Pre-proline 0 CA--C 1.551 1.011 0 N-CA-C 109.638 -0.504 . . . . 75.33 109.638 -176.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -64.46 140.68 70.62 Favored 'Trans proline' 0 C--N 1.368 1.587 0 C-N-CA 122.777 2.318 . . . . 63.13 112.34 174.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.9 129.38 34.63 Favored 'Trans proline' 0 C--N 1.376 1.992 0 C-N-CA 122.713 2.275 . . . . 53.31 111.337 171.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 64.3 mtm180 65.85 34.89 6.98 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 125.116 1.367 . . . . 73.33 110.988 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 5.7 t -66.64 164.55 16.6 Favored 'General case' 0 CA--C 1.549 0.919 0 N-CA-C 109.938 -0.393 . . . . 74.12 109.938 176.548 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -120.46 150.95 40.0 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.731 0.813 . . . . 75.52 109.697 -176.019 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -68.28 141.92 55.72 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.13 0.972 . . . . 54.21 110.727 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 91.11 -3.83 80.64 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-O 119.467 -0.629 . . . . 72.41 112.542 -176.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 41.1 mtp180 -72.01 161.3 31.12 Favored 'General case' 0 C--N 1.362 1.125 0 CA-C-O 122.16 0.981 . . . . 74.22 110.64 177.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . . . . . . . . . 1.6 mppt? -107.62 107.73 18.67 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 113.892 -1.503 . . . . 53.54 108.043 -173.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . 0.447 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 45.9 mt -100.38 98.31 8.96 Favored 'General case' 0 C--N 1.349 0.576 0 N-CA-C 107.328 -1.36 . . . . 63.24 107.328 175.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . 0.498 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 20.0 ttm180 -100.92 115.86 31.43 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.154 0.502 . . . . 74.12 110.698 -171.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.566 HD11 HG22 ' A' ' 221' ' ' VAL . 23.4 mt -96.06 117.75 31.3 Favored 'General case' 0 C--O 1.241 0.631 0 C-N-CA 124.159 0.983 . . . . 62.32 109.508 -176.02 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 49.8 mtmt -72.46 133.66 44.95 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.597 0.759 . . . . 74.21 111.151 -175.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 70.69 33.81 66.82 Favored Glycine 0 C--N 1.345 1.03 0 O-C-N 124.214 0.946 . . . . 62.02 112.954 176.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 72.7 mmtt -123.17 5.49 9.19 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.246 0.618 . . . . 72.13 111.958 178.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -85.51 -147.94 10.18 Favored Glycine 0 C--N 1.35 1.328 0 O-C-N 123.532 0.52 . . . . 71.25 112.952 177.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.491 ' CE1' ' HA ' ' A' ' 131' ' ' PHE . 16.2 m-85 -95.95 145.18 29.1 Favored Pre-proline 0 N--CA 1.478 0.931 0 C-N-CA 123.05 0.54 . . . . 71.04 111.589 173.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.72 156.53 39.82 Favored 'Trans proline' 0 C--N 1.375 1.968 0 C-N-CA 123.308 2.672 . . . . 72.34 112.468 173.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 173.92 -163.17 34.09 Favored Glycine 0 CA--C 1.535 1.335 0 CA-C-N 115.317 -0.856 . . . . 63.2 111.921 177.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.43 -16.49 43.31 Favored 'Trans proline' 0 C--N 1.379 2.179 0 C-N-CA 123.274 2.649 . . . . 41.02 112.912 -175.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -97.1 22.62 8.27 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.794 0.837 . . . . 63.05 111.222 177.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 79.93 -138.31 19.88 Favored Glycine 0 C--N 1.352 1.441 0 N-CA-C 110.699 -0.961 . . . . 51.31 110.699 -174.222 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 56.4 ttt180 -110.53 142.19 42.65 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 117.509 0.654 . . . . 72.03 109.648 171.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -77.76 -158.24 10.24 Favored Glycine 0 C--N 1.342 0.903 0 O-C-N 123.684 0.615 . . . . 43.33 112.945 177.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -128.52 170.58 13.02 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.803 0.841 . . . . 54.31 109.746 -172.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.646 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 15.7 tp -111.79 113.66 26.15 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.784 0.834 . . . . 72.42 109.806 171.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . 0.493 ' HB3' ' O ' ' A' ' 193' ' ' LEU . 2.9 t80 -88.42 108.06 19.18 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 107.567 -1.272 . . . . 74.14 107.567 174.202 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.56 HD13 HD22 ' A' ' 197' ' ' LEU . 52.3 mt -91.16 145.42 24.69 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 123.522 0.729 . . . . 73.34 110.744 170.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -107.63 101.95 11.23 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 107.161 -1.422 . . . . 75.24 107.161 167.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.3 p -62.38 128.25 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 CA-C-O 121.326 0.584 . . . . 72.34 110.115 177.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 9.9 mmm180 -125.72 94.33 4.09 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 107.195 -1.409 . . . . 75.14 107.195 -177.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 199' ' ' VAL . 67.2 mt -76.55 139.89 18.09 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 CA-C-N 115.364 -0.835 . . . . 64.34 110.379 -173.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.5 t . . . . . 0 CA--C 1.554 1.108 0 C-N-CA 123.781 0.832 . . . . 53.52 109.244 -175.429 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.173 0 N-CA-C 110.349 -0.241 . . . . 72.23 110.349 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -99.81 -68.19 0.82 Allowed 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 122.736 0.415 . . . . 73.22 110.809 179.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.6 tp -120.52 62.78 0.85 Allowed 'General case' 0 N--CA 1.48 1.025 0 CA-C-O 121.523 0.678 . . . . 74.23 110.237 -173.181 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 12.9 p 176.86 146.32 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-N 114.218 -1.356 . . . . 73.34 109.282 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -88.08 -78.53 0.32 Allowed 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 108.37 -0.974 . . . . 71.42 108.37 167.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 10.3 m170 -159.32 165.42 33.42 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 124.163 0.985 . . . . 64.3 109.92 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 84.2 t -64.02 136.35 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 O-C-N 124.052 0.845 . . . . 71.4 109.637 174.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 32.6 p -67.69 86.84 0.21 Allowed 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 123.716 0.806 . . . . 75.43 109.363 173.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.1 m -68.25 140.02 56.01 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.879 -1.055 . . . . 74.41 111.733 -171.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 134.07 155.81 7.7 Favored Glycine 0 C--N 1.345 1.061 0 O-C-N 123.736 0.647 . . . . 63.31 111.809 176.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 19.0 t -74.35 97.28 3.0 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.171 -0.677 . . . . 74.42 109.171 176.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 157.26 -172.15 34.68 Favored Glycine 0 C--N 1.342 0.884 0 CA-C-N 115.417 -0.811 . . . . 61.41 111.476 -176.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.14 143.3 5.9 Favored Glycine 0 C--N 1.342 0.898 0 CA-C-O 120.125 -0.264 . . . . 74.21 112.543 179.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 41.5 m -78.55 80.51 4.93 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 123.428 0.691 . . . . 41.43 109.842 177.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -177.88 150.59 10.03 Favored Glycine 0 C--N 1.343 0.946 0 CA-C-N 115.558 -0.746 . . . . 61.42 111.497 178.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 88.47 122.57 1.94 Allowed Glycine 0 C--N 1.343 0.949 0 O-C-N 123.64 0.259 . . . . 60.01 113.303 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 62.4 m -149.97 115.51 5.52 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 123.323 0.649 . . . . 74.43 109.944 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 63.88 -124.9 31.64 Favored Glycine 0 C--N 1.353 1.486 0 O-C-N 123.913 0.758 . . . . 70.34 113.327 175.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -75.95 75.5 1.5 Allowed Glycine 0 C--N 1.346 1.122 0 N-CA-C 111.939 -0.465 . . . . 72.4 111.939 177.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 56.3 m -146.44 138.05 24.64 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.19 0.996 . . . . 62.24 109.261 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -75.75 157.72 49.29 Favored Glycine 0 C--N 1.351 1.361 0 CA-C-O 119.436 -0.647 . . . . 70.43 111.727 175.272 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 72.8 mtp180 -61.95 114.51 3.42 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 122.694 0.398 . . . . 71.44 111.118 -177.066 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -91.14 150.3 21.44 Favored 'General case' 0 C--O 1.241 0.65 0 N-CA-C 108.878 -0.786 . . . . 73.23 108.878 175.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 30.3 mt -96.4 156.22 16.43 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 123.469 0.708 . . . . 70.22 109.19 -178.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -137.2 146.28 44.68 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.519 -1.289 . . . . 74.0 107.519 174.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -158.36 136.82 10.98 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 123.528 0.731 . . . . 71.32 109.787 -178.042 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -100.97 142.62 32.19 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.485 0.714 . . . . 54.01 109.718 -178.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -146.45 143.09 18.25 Favored Pre-proline 0 CA--C 1.552 1.049 0 C-N-CA 123.077 0.551 . . . . 71.23 110.565 174.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_exo -77.4 118.26 4.57 Favored 'Trans proline' 0 C--N 1.376 2.004 0 C-N-CA 122.97 2.447 . . . . 72.35 111.327 172.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.427 ' HG ' ' HB2' ' A' ' 129' ' ' GLU . 14.8 tp -108.62 155.59 20.51 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 123.75 0.82 . . . . 72.14 109.678 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.606 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 20.7 m -93.56 157.48 16.17 Favored 'General case' 0 CA--C 1.55 0.945 0 N-CA-C 109.363 -0.606 . . . . 55.23 109.363 174.235 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.479 HD11 ' O ' ' A' ' 183' ' ' HIS . 32.6 mt -58.22 -48.18 81.16 Favored 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 123.944 0.898 . . . . 33.44 110.382 178.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -54.25 -36.49 63.62 Favored 'General case' 0 C--O 1.218 -0.584 0 CA-C-N 113.796 -1.547 . . . . 61.44 110.736 176.371 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.606 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 7.5 mm-40 -79.6 -23.04 42.95 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.48 0.712 . . . . 74.14 111.411 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.792 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -63.0 -36.32 83.16 Favored 'General case' 0 C--O 1.244 0.793 0 CA-C-O 121.42 0.628 . . . . 72.2 110.304 167.334 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.415 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 26.8 t80 -81.31 -33.54 32.51 Favored 'General case' 0 CA--C 1.554 1.097 0 CA-C-N 114.709 -1.132 . . . . 75.22 111.972 176.11 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . 0.474 ' HB2' ' HA ' ' A' ' 129' ' ' GLU . 24.6 m80 -84.13 -40.96 17.58 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 112.631 0.604 . . . . 63.53 112.631 -173.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 72.16 -129.55 15.23 Favored Glycine 0 CA--C 1.536 1.389 0 N-CA-C 110.834 -0.907 . . . . 74.11 110.834 -166.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 134.97 140.2 4.19 Favored Glycine 0 N--CA 1.477 1.401 0 CA-C-N 117.805 0.802 . . . . 61.12 114.145 169.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -86.54 113.6 22.59 Favored 'General case' 0 C--N 1.357 0.91 0 N-CA-C 108.486 -0.931 . . . . 61.23 108.486 167.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -141.81 170.11 16.32 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.901 1.281 . . . . 71.32 108.314 175.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.498 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 14.7 p -95.18 143.3 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 118.639 0.654 . . . . 61.22 111.276 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 12.2 p -114.94 138.24 45.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 C-N-CA 123.833 0.853 . . . . 64.4 109.553 172.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -125.51 105.12 8.81 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 108.678 -0.86 . . . . 63.24 108.678 173.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.2 m -129.59 133.72 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.882 0 C-N-CA 124.187 0.995 . . . . 63.12 110.042 -177.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 62.96 22.82 13.67 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 124.534 1.134 . . . . 73.44 111.313 -176.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.64 -6.7 79.6 Favored Glycine 0 C--N 1.354 1.538 0 CA-C-N 115.734 -0.666 . . . . 74.51 113.124 -176.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 53.4 ttt85 -94.81 119.67 33.77 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 123.632 0.773 . . . . 62.43 110.396 -175.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 20.6 ttp180 -105.07 109.63 21.69 Favored 'General case' 0 CA--C 1.552 1.024 0 C-N-CA 123.998 0.919 . . . . 62.23 110.797 -174.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 13.7 m -133.24 155.54 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 C-N-CA 124.708 1.203 . . . . 52.44 108.795 174.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.498 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 60.1 p -76.8 126.8 31.59 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 118.235 0.471 . . . . 55.41 110.684 -179.567 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.94 120.35 48.14 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.741 0 CA-C-O 121.827 0.822 . . . . 73.1 110.48 176.164 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 49.8 ttt180 -109.13 95.13 5.43 Favored 'General case' 0 C--O 1.243 0.745 0 N-CA-C 108.74 -0.837 . . . . 73.21 108.74 176.313 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 28.4 pt -93.66 119.78 66.8 Favored Pre-proline 0 CA--C 1.547 0.852 0 N-CA-C 107.913 -1.143 . . . . 72.13 107.913 171.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -76.64 163.17 32.08 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.352 2.035 . . . . 74.11 112.507 -177.403 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -54.76 142.68 73.17 Favored 'Trans proline' 0 C--N 1.375 1.963 0 C-N-CA 123.005 2.47 . . . . 72.34 112.372 171.188 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 108.66 38.31 1.92 Allowed Glycine 0 C--N 1.339 0.721 0 CA-C-N 116.773 -0.194 . . . . 72.33 113.037 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.792 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -108.66 163.07 6.23 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.359 0 N-CA-C 108.7 -0.852 . . . . 53.43 108.7 177.005 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.528 ' HB2' ' HB2' ' A' ' 157' ' ' SER . 25.1 mtp-105 -141.8 164.28 30.63 Favored 'General case' 0 N--CA 1.492 1.635 0 C-N-CA 123.963 0.905 . . . . 72.13 111.071 -165.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.1 tp10 -54.53 116.72 2.82 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.444 1.098 . . . . 71.1 111.226 165.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 82.27 4.68 90.11 Favored Glycine 0 C--N 1.357 1.706 0 CA-C-N 116.04 -0.527 . . . . 70.34 113.166 178.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.528 ' HB2' ' HB2' ' A' ' 154' ' ' ARG . 30.1 t -79.21 124.2 28.13 Favored 'General case' 0 C--O 1.25 1.11 0 N-CA-C 109.026 -0.731 . . . . 74.1 109.026 -179.686 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.44 HG12 HD22 ' A' ' 175' ' ' LEU . 20.0 t -99.05 120.68 48.71 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 CA-C-N 114.298 -1.319 . . . . 72.4 107.886 -177.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.434 HD11 HG21 ' A' ' 153' ' ' VAL . 13.0 mt -101.86 122.01 53.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 C-N-CA 123.533 0.733 . . . . 54.32 110.15 -168.697 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 74.2 ttt180 -86.31 103.25 14.72 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 123.317 0.647 . . . . 74.34 109.908 177.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.449 HG22 ' O ' ' A' ' 174' ' ' LEU . 16.4 m -107.59 104.92 54.65 Favored Pre-proline 0 CA--C 1.564 1.5 0 C-N-CA 122.608 0.363 . . . . 74.11 110.027 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -67.41 140.69 53.47 Favored 'Trans proline' 0 C--N 1.375 1.954 0 C-N-CA 122.82 2.346 . . . . 70.33 113.332 -173.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 105.04 -9.97 47.32 Favored Glycine 0 C--N 1.349 1.282 0 N-CA-C 114.868 0.707 . . . . 61.44 114.868 170.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.4 mpt? -81.9 -61.35 1.94 Allowed 'General case' 0 N--CA 1.482 1.135 0 CA-C-N 117.815 0.807 . . . . 73.41 110.157 176.096 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -87.8 171.41 41.16 Favored Glycine 0 C--N 1.345 1.073 0 CA-C-N 115.345 -0.843 . . . . 74.35 111.785 176.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 60.72 51.52 58.14 Favored Glycine 0 C--N 1.343 0.965 0 O-C-N 124.238 0.611 . . . . 52.12 112.611 176.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.6 mm-40 -76.56 104.88 7.3 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 120.982 0.42 . . . . 62.33 110.434 -176.505 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -176.93 -146.2 6.02 Favored Glycine 0 C--N 1.335 0.487 0 N-CA-C 110.572 -1.011 . . . . 51.31 110.572 -178.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.411 ' HB2' ' HD3' ' A' ' 170' ' ' PRO . 17.7 m120 -73.06 -46.28 8.25 Favored Pre-proline 0 CA--C 1.56 1.35 0 CA-C-O 118.7 -0.667 . . . . 63.02 111.033 176.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.411 ' HD3' ' HB2' ' A' ' 169' ' ' ASN . 95.1 Cg_endo -94.58 107.42 0.14 Allowed 'Trans proline' 0 C--N 1.393 2.871 0 C-N-CA 122.284 1.989 . . . . 61.14 111.573 167.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -65.34 127.84 19.07 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 122.585 2.19 . . . . 63.22 111.683 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -80.97 -132.26 1.2 Allowed Glycine 0 C--N 1.34 0.764 0 N-CA-C 111.498 -0.641 . . . . 62.12 111.498 175.177 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -163.81 177.79 8.35 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.205 0.526 . . . . 71.42 110.885 -175.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.449 ' O ' HG22 ' A' ' 161' ' ' VAL . 15.0 tp -129.32 122.57 29.83 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 108.571 -0.9 . . . . 62.24 108.571 173.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.44 HD22 HG12 ' A' ' 158' ' ' VAL . 49.8 mt -88.11 99.41 12.17 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.139 -0.937 . . . . 64.34 110.927 179.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 74.9 mt -87.44 105.34 17.22 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 123.011 0.524 . . . . 64.42 110.748 175.429 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 16.8 t -85.49 104.45 13.37 Favored 'Isoleucine or valine' 0 C--O 1.242 0.697 0 N-CA-C 108.23 -1.026 . . . . 73.12 108.23 174.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.423 HG21 HG22 ' A' ' 153' ' ' VAL . 25.3 m -83.95 144.79 9.25 Favored 'Isoleucine or valine' 0 C--O 1.251 1.136 0 CA-C-O 121.481 0.657 . . . . 74.11 110.367 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 13.5 mmm180 -118.53 99.3 6.72 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 107.068 -1.456 . . . . 73.01 107.068 -178.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.421 HD23 ' HB3' ' A' ' 125' ' ' LEU . 29.5 mt -67.56 146.1 54.24 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 118.314 0.507 . . . . 73.41 110.303 177.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.438 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 73.1 mt -55.27 154.51 11.06 Favored Pre-proline 0 CA--C 1.553 1.063 0 O-C-N 124.489 1.118 . . . . 72.24 112.839 -170.337 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.403 ' O ' ' HD3' ' A' ' 184' ' ' PRO . 55.5 Cg_endo -66.81 0.38 3.72 Favored 'Trans proline' 0 C--N 1.381 2.287 0 C-N-CA 123.081 2.52 . . . . 62.2 112.808 171.231 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.479 ' O ' HD11 ' A' ' 127' ' ' LEU . 14.7 t60 -95.55 99.21 4.41 Favored Pre-proline 0 CA--C 1.541 0.611 0 C-N-CA 124.974 1.31 . . . . 72.43 107.582 162.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 182' ' ' PRO . 44.4 Cg_endo -103.64 123.67 0.07 OUTLIER 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 123.135 2.557 . . . . 64.33 112.413 168.607 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -120.68 -43.58 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 107.74 -1.207 . . . . 63.44 107.74 171.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -113.64 126.31 55.12 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 114.674 -1.148 . . . . 62.42 110.144 176.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 36.5 ttp85 -119.41 127.04 52.74 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 108.51 -0.922 . . . . 71.44 108.51 172.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.427 HD12 ' O ' ' A' ' 192' ' ' ASP . 56.0 tp -90.18 132.53 35.42 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 108.359 -0.978 . . . . 63.15 108.359 170.461 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 15.3 tp10 -144.48 130.1 19.07 Favored 'General case' 0 C--O 1.241 0.642 0 N-CA-C 109.621 -0.511 . . . . 74.12 109.621 173.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 70.95 -75.78 0.59 Allowed Glycine 0 C--N 1.35 1.346 0 O-C-N 124.003 0.814 . . . . 63.52 111.871 -175.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . 0.497 ' HB2' ' O ' ' A' ' 240' ' ' PHE . 3.7 pt20 -157.6 -10.49 0.08 Allowed 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 124.118 0.967 . . . . 60.43 110.846 174.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.427 ' O ' HD12 ' A' ' 188' ' ' LEU . 80.3 m-20 -96.31 162.96 13.28 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 123.014 0.526 . . . . 62.12 110.942 -175.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.478 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.2 mt -106.9 155.91 19.25 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 107.704 -1.221 . . . . 73.15 107.704 -178.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -137.15 121.8 18.53 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 108.642 -0.873 . . . . 70.1 108.642 -175.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . 0.479 ' HB3' HD23 ' A' ' 251' ' ' LEU . . . -142.63 162.12 36.29 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.697 0.799 . . . . 65.3 110.221 -178.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . 0.519 ' HA ' ' HB3' ' A' ' 252' ' ' GLU . 36.0 m -109.08 119.37 39.34 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 109.018 -0.734 . . . . 71.15 109.018 174.794 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.534 HD22 HD13 ' A' ' 251' ' ' LEU . 55.1 tp -106.84 110.13 22.21 Favored 'General case' 0 N--CA 1.466 0.361 0 N-CA-C 109.17 -0.678 . . . . 53.35 109.17 178.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -89.83 127.56 36.0 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 107.804 -1.184 . . . . 62.32 107.804 172.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . 0.507 HG12 HG11 ' A' ' 210' ' ' VAL . 15.4 m -119.99 139.83 28.87 Favored Pre-proline 0 C--O 1.244 0.78 0 N-CA-C 109.097 -0.705 . . . . 64.33 109.097 -178.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -60.05 143.99 99.51 Favored 'Trans proline' 0 C--N 1.367 1.522 0 C-N-CA 122.073 1.849 . . . . 52.21 111.085 174.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -53.44 -45.69 98.41 Favored Pre-proline 0 CA--C 1.555 1.165 0 CA-C-O 118.359 -0.829 . . . . 75.13 113.046 177.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -55.62 -42.33 68.8 Favored 'Trans proline' 0 C--N 1.39 2.755 0 C-N-CA 122.106 1.871 . . . . 63.15 113.261 172.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 4.0 mt -65.84 -43.6 93.12 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.022 0 C-N-CA 122.63 0.372 . . . . 72.54 111.256 176.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -58.56 -44.72 89.79 Favored 'General case' 0 N--CA 1.468 0.468 0 C-N-CA 123.057 0.543 . . . . 74.11 111.451 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 33.4 m -77.39 -40.28 28.83 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 CA-C-N 115.745 -0.661 . . . . 74.33 112.081 -175.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.0 m -81.13 -20.72 11.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 CA-C-N 119.1 0.863 . . . . 63.24 111.188 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.592 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 80.09 48.45 6.48 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-N 115.985 -0.552 . . . . 73.32 112.179 -175.837 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.27 -174.0 49.41 Favored Glycine 0 C--N 1.351 1.375 0 CA-C-O 121.37 0.428 . . . . 42.54 112.945 -177.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 222' ' ' ALA . 20.5 pttm -114.17 134.71 54.72 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.385 1.074 . . . . 74.31 109.797 -176.106 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . 0.507 HG11 HG12 ' A' ' 199' ' ' VAL . 7.6 p -133.71 157.23 42.13 Favored 'Isoleucine or valine' 0 C--O 1.241 0.608 0 C-N-CA 124.552 1.141 . . . . 75.24 108.494 -175.317 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 59.2 mmt-85 -91.55 128.93 37.57 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 109.489 -0.56 . . . . 72.44 109.489 178.033 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -102.72 122.09 43.76 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 108.643 -0.873 . . . . 71.24 108.643 171.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 5.6 tpt -74.04 104.66 4.95 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.732 0.813 . . . . 74.3 109.574 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 10.1 t -110.82 170.76 7.88 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 123.452 0.701 . . . . 65.31 110.623 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 62.4 mt -73.89 -2.2 22.83 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 124.022 0.929 . . . . 73.14 112.481 -175.233 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -114.82 -0.22 13.57 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 123.743 0.817 . . . . 70.35 112.17 174.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 133.25 -154.15 21.08 Favored Glycine 0 N--CA 1.48 1.597 0 CA-C-O 119.269 -0.74 . . . . 73.22 112.818 177.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -89.9 134.12 2.18 Favored 'Trans proline' 0 CA--C 1.554 1.49 0 C-N-CA 122.92 2.413 . . . . 74.11 112.259 172.083 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.1 m -113.79 158.15 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.224 0 CA-C-O 121.014 0.435 . . . . 73.11 111.74 175.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 18.6 mm-40 -96.75 104.54 16.54 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 114.966 -1.015 . . . . 63.25 108.429 -177.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.448 ' HB ' HD11 ' A' ' 235' ' ' LEU . 2.8 p -118.84 113.51 41.84 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 CA-C-O 121.437 0.637 . . . . 74.44 109.928 177.461 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . 0.444 ' HA ' ' HA ' ' A' ' 209' ' ' LYS . . . -97.28 118.69 34.3 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 108.759 -0.83 . . . . 73.01 108.759 178.061 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.592 HG23 ' HA2' ' A' ' 207' ' ' GLY . 18.2 m -72.96 148.04 88.96 Favored Pre-proline 0 CA--C 1.555 1.152 0 N-CA-C 109.523 -0.547 . . . . 75.14 109.523 176.029 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.0 151.98 73.31 Favored 'Trans proline' 0 CA--C 1.559 1.753 0 C-N-CA 122.173 1.915 . . . . 74.01 112.019 173.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -52.07 119.68 6.09 Favored 'Trans proline' 0 C--N 1.383 2.365 0 C-N-CA 123.646 2.898 . . . . 75.51 112.801 177.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . 0.479 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 48.6 mtm180 54.34 58.11 5.25 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 124.488 1.115 . . . . 71.5 110.668 -174.612 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 10.7 t -66.22 169.29 7.33 Favored 'General case' 0 CA--C 1.545 0.761 0 CA-C-N 115.539 -0.755 . . . . 54.15 109.506 173.079 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 26.8 mp0 -121.33 144.13 48.81 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 123.035 0.534 . . . . 52.4 109.83 -175.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -67.2 119.67 12.48 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-N 115.212 -0.904 . . . . 63.02 108.822 173.505 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.33 -12.06 19.26 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-O 119.65 -0.528 . . . . 60.23 112.315 -174.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 58.2 mtp180 -74.14 160.9 30.58 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 117.2 0.5 . . . . 73.41 110.604 174.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.403 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.3 mppt? -128.55 120.57 26.97 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 122.77 0.428 . . . . 74.1 110.676 -175.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . 0.493 HD11 HG12 ' A' ' 223' ' ' VAL . 59.6 mt -97.59 112.88 24.56 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 108.697 -0.853 . . . . 73.54 108.697 -178.248 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . 0.53 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 39.5 ttt85 -98.6 104.61 16.67 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 116.014 -0.539 . . . . 72.24 110.015 -172.211 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.516 HD12 HD23 ' A' ' 249' ' ' LEU . 27.3 mt -91.63 107.2 19.04 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.671 0.788 . . . . 62.13 109.156 -177.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 6.8 mtpm? -77.25 144.1 38.45 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 112.273 0.471 . . . . 71.51 112.273 -173.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 85.38 35.92 11.45 Favored Glycine 0 C--N 1.349 1.266 0 O-C-N 123.769 0.668 . . . . 74.22 112.323 -177.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 34.9 mmtm -125.61 -41.16 2.02 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 122.86 0.464 . . . . 72.11 112.184 -176.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -83.85 -178.04 51.69 Favored Glycine 0 C--N 1.337 0.62 0 C-N-CA 121.609 -0.329 . . . . 54.12 112.28 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.497 ' O ' ' HB2' ' A' ' 191' ' ' GLN . 72.5 m-85 -94.93 157.91 35.88 Favored Pre-proline 0 N--CA 1.476 0.846 0 C-N-CA 123.307 0.643 . . . . 74.43 111.77 -174.122 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_exo -52.42 150.48 20.5 Favored 'Trans proline' 0 C--N 1.381 2.283 0 C-N-CA 123.254 2.636 . . . . 52.43 114.002 175.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 179.01 -159.54 24.5 Favored Glycine 0 CA--C 1.535 1.293 0 CA-C-O 119.516 -0.602 . . . . 71.5 113.099 -176.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -62.92 -34.34 71.85 Favored 'Trans proline' 0 C--N 1.375 1.925 0 C-N-CA 123.925 3.083 . . . . 72.52 114.217 -171.163 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.89 22.81 4.0 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.342 0.657 . . . . 73.01 111.289 178.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.97 -96.56 2.14 Favored Glycine 0 C--N 1.347 1.191 0 N-CA-C 111.192 -0.763 . . . . 63.43 111.192 179.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 42.1 ttt-85 -115.65 144.69 43.55 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 123.558 0.743 . . . . 75.43 109.09 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -80.26 168.99 52.37 Favored Glycine 0 C--O 1.253 1.297 0 O-C-N 123.604 0.565 . . . . 62.44 112.899 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 55.4 m-20 -139.57 171.97 13.48 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.342 1.057 . . . . 74.53 108.915 -173.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.53 ' O ' ' HA ' ' A' ' 234' ' ' ARG . 15.5 tp -98.44 128.92 45.02 Favored 'General case' 0 C--O 1.21 -0.974 0 C-N-CA 123.101 0.56 . . . . 71.43 109.761 177.129 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 53.8 t80 -111.47 102.62 10.97 Favored 'General case' 0 CA--C 1.551 1.01 0 N-CA-C 107.49 -1.3 . . . . 71.22 107.49 -178.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.534 HD13 HD22 ' A' ' 197' ' ' LEU . 90.3 mt -87.54 150.61 23.61 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.996 0.919 . . . . 51.31 112.688 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.519 ' HB3' ' HA ' ' A' ' 196' ' ' THR . 14.0 tp10 -105.62 98.09 7.83 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 123.494 0.717 . . . . 72.32 109.314 173.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 80.3 t -56.98 112.5 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 123.205 0.602 . . . . 53.12 111.019 174.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 49.3 mmm-85 -119.07 96.06 5.07 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 125.033 1.333 . . . . 75.15 108.069 177.149 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 58.8 mt -75.5 128.18 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 N-CA-C 109.561 -0.533 . . . . 41.33 109.561 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.249 1.028 0 C-N-CA 124.574 1.15 . . . . 64.4 107.911 -176.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 110.653 -0.128 . . . . 73.41 110.653 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -156.19 -53.53 0.08 Allowed 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 122.936 0.495 . . . . 64.1 110.67 179.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.622 ' HB2' ' HB3' ' A' ' 136' ' ' ARG . 33.4 tp -83.31 -74.89 0.34 Allowed 'General case' 0 N--CA 1.476 0.868 0 N-CA-C 109.379 -0.6 . . . . 75.43 109.379 -179.521 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 24.0 t -89.6 150.93 3.57 Favored 'Isoleucine or valine' 0 C--O 1.239 0.502 0 C-N-CA 124.454 1.102 . . . . 72.02 109.14 172.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -77.23 -51.06 11.57 Favored 'General case' 0 CA--C 1.54 0.579 0 O-C-N 123.713 0.633 . . . . 64.21 109.484 175.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 46.5 p-80 -179.2 177.13 0.8 Allowed 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 124.864 1.266 . . . . 71.24 109.535 -175.126 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.524 HG11 HD12 ' A' ' 119' ' ' LEU . 29.5 m -78.51 155.12 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 C-N-CA 122.683 0.393 . . . . 72.33 111.366 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 9.0 t -131.96 51.25 2.16 Favored 'General case' 0 CA--C 1.546 0.799 0 CA-C-O 122.402 1.096 . . . . 71.42 109.226 179.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 30.2 t -73.74 97.3 2.68 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 114.806 -1.088 . . . . 60.41 109.785 178.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -139.67 -115.3 1.25 Allowed Glycine 0 C--N 1.343 0.931 0 N-CA-C 110.545 -1.022 . . . . 33.15 110.545 178.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 61.4 m -79.27 177.74 8.6 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 117.331 0.566 . . . . 55.34 110.3 172.352 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 78.13 54.07 4.58 Favored Glycine 0 C--N 1.346 1.096 0 N-CA-C 110.849 -0.9 . . . . 62.13 110.849 -171.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 98.65 167.95 31.05 Favored Glycine 0 C--N 1.346 1.108 0 CA-C-N 115.19 -0.505 . . . . 55.23 112.206 -176.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 52.3 p -86.53 -22.32 26.41 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 123.579 0.751 . . . . 71.32 111.173 177.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 86.57 66.72 1.37 Allowed Glycine 0 C--N 1.352 1.441 0 N-CA-C 110.154 -1.178 . . . . 34.23 110.154 -172.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -162.01 64.32 0.26 Allowed Glycine 0 C--N 1.336 0.552 0 N-CA-C 110.934 -0.867 . . . . 65.44 110.934 -176.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 31.0 t -55.35 -30.72 60.82 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.565 1.146 . . . . 64.44 111.966 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 81.3 -13.31 34.11 Favored Glycine 0 C--N 1.35 1.319 0 N-CA-C 114.678 0.631 . . . . 34.14 114.678 171.438 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -94.1 0.75 66.87 Favored Glycine 0 C--N 1.352 1.438 0 CA-C-N 117.438 0.619 . . . . 54.43 113.092 -176.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 70.5 p -141.51 -165.23 1.94 Allowed 'General case' 0 C--O 1.243 0.746 0 C-N-CA 124.04 0.936 . . . . 72.44 109.158 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -72.78 -115.89 0.06 OUTLIER Glycine 0 C--N 1.349 1.255 0 N-CA-C 110.537 -1.025 . . . . 44.15 110.537 169.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 65.4 mtt85 -91.57 118.12 30.33 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 117.892 0.846 . . . . 62.35 109.102 168.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -87.6 128.34 35.27 Favored 'General case' 0 C--O 1.241 0.655 0 N-CA-C 108.452 -0.944 . . . . 72.14 108.452 171.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.524 HD12 HG11 ' A' ' 102' ' ' VAL . 4.5 mm? -96.19 159.69 14.82 Favored 'General case' 0 N--CA 1.464 0.25 0 C-N-CA 124.129 0.972 . . . . 73.31 109.418 176.008 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 23.1 ptt180 -141.95 121.12 12.99 Favored 'General case' 0 C--O 1.241 0.649 0 N-CA-C 109.322 -0.622 . . . . 65.53 109.322 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -145.69 129.43 17.17 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 124.232 1.013 . . . . 65.11 109.446 -173.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.742 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 43.5 mt-10 -105.05 138.54 41.09 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 123.721 0.808 . . . . 62.33 109.228 178.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.476 HD21 HG12 ' A' ' 178' ' ' VAL . 1.8 pt? -135.64 141.52 37.47 Favored Pre-proline 0 N--CA 1.474 0.747 0 N-CA-C 110.033 -0.358 . . . . 61.34 110.033 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -73.38 113.27 3.73 Favored 'Trans proline' 0 C--N 1.368 1.586 0 C-N-CA 122.217 1.944 . . . . 64.44 109.924 171.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.547 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 11.9 tp -122.67 147.73 46.11 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 106.27 -1.752 . . . . 74.33 106.27 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 8.9 t -107.24 172.95 6.54 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 119.455 1.025 . . . . 74.1 110.491 175.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.5 ' O ' HD13 ' A' ' 215' ' ' LEU . 31.4 mt -55.38 -46.17 76.52 Favored 'General case' 0 N--CA 1.47 0.533 0 O-C-N 124.561 1.163 . . . . 71.12 109.949 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -51.66 -40.79 60.66 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 113.969 -1.469 . . . . 72.12 111.263 177.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.503 ' HB2' ' HG ' ' A' ' 125' ' ' LEU . 22.8 mm-40 -83.31 -24.02 32.33 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.195 0.598 . . . . 73.11 111.193 -178.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.432 ' HA ' ' CG1' ' A' ' 153' ' ' VAL . . . -59.78 -32.97 71.1 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 123.117 0.567 . . . . 72.5 111.645 167.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 69.3 t80 -77.72 -53.53 7.43 Favored 'General case' 0 C--N 1.351 0.636 0 CA-C-N 116.167 -0.47 . . . . 72.45 111.062 171.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -60.36 -45.85 92.04 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 123.552 0.532 . . . . 72.32 111.728 -172.137 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 59.53 -125.28 38.91 Favored Glycine 0 C--N 1.349 1.257 0 O-C-N 123.881 0.738 . . . . 65.51 111.378 -178.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.01 169.83 29.66 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 114.009 0.364 . . . . 42.4 114.009 166.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.417 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.6 mp0 -88.08 126.82 35.31 Favored 'General case' 0 C--O 1.239 0.552 0 N-CA-C 107.443 -1.318 . . . . 62.42 107.443 172.38 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.622 ' HB3' ' HB2' ' A' ' 98' ' ' LEU . 6.6 tpt180 -154.83 134.0 12.42 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 108.87 -0.789 . . . . 71.12 108.87 -177.221 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.673 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 10.9 p -74.75 143.38 13.47 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 C-N-CA 123.103 0.561 . . . . 62.25 112.477 -168.287 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.429 HG12 ' HB3' ' A' ' 98' ' ' LEU . 5.0 m -128.66 161.56 37.35 Favored 'Isoleucine or valine' 0 C--O 1.247 0.956 0 C-N-CA 124.458 1.103 . . . . 62.31 110.258 178.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 46.4 mm-40 -111.09 111.32 22.34 Favored 'General case' 0 C--O 1.238 0.499 0 C-N-CA 123.954 0.902 . . . . 71.54 109.419 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.461 HG21 HD22 ' A' ' 174' ' ' LEU . 45.2 t -138.27 119.89 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 123.503 0.721 . . . . 73.04 110.628 178.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 64.05 21.78 12.7 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 124.785 1.234 . . . . 63.13 112.94 171.105 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.19 14.12 77.49 Favored Glycine 0 C--N 1.349 1.251 0 CA-C-N 116.702 -0.226 . . . . 65.32 112.729 -176.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? -110.78 118.5 36.31 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.422 1.089 . . . . 74.02 108.152 176.019 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 54.2 ttp180 -87.1 106.33 17.79 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 107.694 -1.224 . . . . 73.32 107.694 174.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 8.1 m -136.01 135.78 50.13 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.314 0 C-N-CA 123.541 0.737 . . . . 72.42 110.429 -172.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.673 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 35.9 t -83.51 128.28 34.39 Favored 'General case' 0 C--O 1.241 0.616 0 C-N-CA 123.371 0.668 . . . . 71.21 109.679 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.557 HG13 HG11 ' A' ' 161' ' ' VAL . 99.0 t -99.65 125.98 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 123.577 0.751 . . . . 65.05 110.469 177.482 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . 0.417 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 74.4 ttt180 -99.08 104.23 16.22 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 123.844 0.857 . . . . 74.03 109.483 172.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.574 HG22 HG21 ' A' ' 159' ' ' ILE . 28.3 pt -107.54 118.11 54.14 Favored Pre-proline 0 CA--C 1.55 0.969 0 N-CA-C 108.598 -0.89 . . . . 72.51 108.598 169.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -67.09 152.15 80.48 Favored 'Trans proline' 0 C--N 1.379 2.14 0 C-N-CA 122.668 2.245 . . . . 71.44 113.107 -175.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_exo -49.2 113.7 1.02 Allowed 'Trans proline' 0 C--N 1.371 1.744 0 C-N-CA 123.609 2.873 . . . . 73.43 112.662 170.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 129.94 65.37 0.1 Allowed Glycine 0 C--N 1.342 0.911 0 CA-C-N 116.319 -0.401 . . . . 71.04 112.208 177.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.5 HG21 HD11 ' A' ' 159' ' ' ILE . 3.9 p -129.72 159.96 41.22 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.51 0 C-N-CA 123.15 0.58 . . . . 53.14 109.529 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 29.9 mtp-105 -136.79 168.31 19.78 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 123.8 0.84 . . . . 72.44 111.292 -164.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -57.1 121.64 10.52 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.403 1.081 . . . . 73.44 111.333 171.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.62 9.9 86.66 Favored Glycine 0 C--N 1.35 1.339 0 O-C-N 123.832 0.708 . . . . 71.43 113.21 178.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 30.3 t -73.39 122.89 22.79 Favored 'General case' 0 C--N 1.356 0.881 0 C-N-CA 123.165 0.586 . . . . 42.44 109.468 -177.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.556 HG12 HD22 ' A' ' 175' ' ' LEU . 11.3 t -99.46 116.25 42.19 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 O-C-N 124.399 1.062 . . . . 50.12 108.485 -178.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.574 HG21 HG22 ' A' ' 149' ' ' ILE . 18.1 mt -107.66 113.42 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 123.665 0.786 . . . . 73.54 110.247 -170.79 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 26.8 ttm180 -89.59 113.28 24.69 Favored 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 123.346 0.658 . . . . 63.12 110.878 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.557 HG11 HG13 ' A' ' 147' ' ' VAL . 22.5 m -109.48 99.48 37.34 Favored Pre-proline 0 CA--C 1.564 1.51 0 N-CA-C 109.603 -0.517 . . . . 55.35 109.603 176.333 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -69.62 150.31 68.87 Favored 'Trans proline' 0 C--N 1.377 2.058 0 C-N-CA 123.298 2.665 . . . . 74.3 113.501 -172.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.32 10.37 86.26 Favored Glycine 0 C--N 1.344 1.005 0 CA-C-N 115.383 -0.826 . . . . 75.12 113.656 176.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 58.4 mtp -114.82 -20.48 10.58 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.365 0.666 . . . . 71.24 112.419 -173.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -86.81 -104.38 0.81 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.755 -0.469 . . . . 32.45 112.067 177.061 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.43 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -65.92 105.56 1.3 Allowed Glycine 0 C--N 1.349 1.281 0 N-CA-C 111.46 -0.656 . . . . 75.31 111.46 176.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.6 mm-40 -79.0 134.39 36.79 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.512 0.725 . . . . 72.05 110.332 -176.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 145.25 -164.13 28.02 Favored Glycine 0 C--N 1.341 0.809 0 CA-C-N 115.967 -0.56 . . . . 72.12 111.854 -176.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -67.08 -52.46 30.63 Favored Pre-proline 0 CA--C 1.565 1.546 0 CA-C-O 118.015 -0.993 . . . . 42.34 110.316 -178.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -75.33 106.27 2.24 Favored 'Trans proline' 0 C--N 1.396 3.041 0 CA-C-N 121.375 1.527 . . . . 62.52 110.229 170.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.45 124.81 9.66 Favored 'Trans proline' 0 C--N 1.372 1.799 0 C-N-CA 121.343 1.362 . . . . 73.23 111.56 -171.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.43 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -90.98 160.23 27.17 Favored Glycine 0 C--N 1.334 0.46 0 N-CA-C 110.063 -1.215 . . . . 52.41 110.063 170.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -120.03 176.95 5.18 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.012 0.525 . . . . 74.35 110.446 -174.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.461 HD22 HG21 ' A' ' 140' ' ' VAL . 19.5 tp -128.06 115.95 19.25 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 115.34 -0.846 . . . . 70.54 109.304 172.424 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.556 HD22 HG12 ' A' ' 158' ' ' VAL . 88.9 mt -87.87 105.69 17.6 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 125.164 1.386 . . . . 74.22 110.852 179.28 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 36.6 mt -95.91 108.06 20.39 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 123.079 0.551 . . . . 73.31 111.037 177.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.742 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 19.7 t -90.78 99.9 10.32 Favored 'Isoleucine or valine' 0 C--O 1.242 0.71 0 N-CA-C 107.957 -1.127 . . . . 75.13 107.957 174.054 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.476 HG12 HD21 ' A' ' 123' ' ' LEU . 4.3 m -82.21 141.48 14.97 Favored 'Isoleucine or valine' 0 C--O 1.245 0.833 0 N-CA-C 109.054 -0.721 . . . . 75.33 109.054 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 16.1 mmm-85 -119.54 104.98 10.78 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.669 -1.234 . . . . 74.24 107.669 -175.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.547 ' HA ' ' O ' ' A' ' 125' ' ' LEU . 61.2 mt -68.87 147.43 51.71 Favored 'General case' 0 CA--C 1.545 0.763 0 O-C-N 123.506 0.504 . . . . 75.31 111.009 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.465 ' HB2' ' HB3' ' A' ' 183' ' ' HIS . 27.7 mt -63.64 168.78 4.96 Favored Pre-proline 0 CA--C 1.56 1.33 0 C-N-CA 124.07 0.948 . . . . 71.42 111.098 -174.361 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -75.76 43.01 1.02 Allowed 'Trans proline' 0 C--N 1.381 2.243 0 C-N-CA 122.885 2.39 . . . . 71.45 111.601 162.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.465 ' HB3' ' HB2' ' A' ' 181' ' ' LEU . 8.2 t60 -125.27 95.48 41.23 Favored Pre-proline 0 CA--C 1.532 0.281 0 N-CA-C 105.88 -1.896 . . . . 73.45 105.88 -178.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -100.75 123.76 0.11 Allowed 'Trans proline' 0 CA--C 1.554 1.525 0 C-N-CA 122.636 2.224 . . . . 63.5 113.052 176.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.437 HG12 HD12 ' A' ' 127' ' ' LEU . 4.1 p -144.75 -42.04 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 N-CA-C 108.855 -0.794 . . . . 71.13 108.855 175.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.429 ' H ' HD13 ' A' ' 127' ' ' LEU . 3.8 m-85 -126.96 154.93 43.91 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.387 1.075 . . . . 73.24 110.208 174.443 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 18.6 ttp85 -156.25 142.8 18.55 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 123.221 0.608 . . . . 63.14 109.564 178.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.468 HD13 ' HD1' ' A' ' 240' ' ' PHE . 56.6 tp -104.63 140.61 37.78 Favored 'General case' 0 N--CA 1.476 0.828 0 C-N-CA 123.762 0.825 . . . . 73.1 110.27 178.186 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -139.64 111.49 7.35 Favored 'General case' 0 C--O 1.246 0.877 0 N-CA-C 107.191 -1.411 . . . . 61.31 107.191 168.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 74.66 -80.93 0.88 Allowed Glycine 0 C--N 1.347 1.171 0 O-C-N 123.558 0.536 . . . . 64.2 112.611 177.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . 0.428 ' HB3' ' HA3' ' A' ' 242' ' ' GLY . 9.3 pt20 -138.39 -23.04 1.0 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 124.068 0.947 . . . . 53.23 110.168 176.302 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.439 ' O ' HD12 ' A' ' 188' ' ' LEU . 0.6 OUTLIER -89.6 157.59 17.98 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 123.832 0.853 . . . . 64.25 110.884 -173.046 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.575 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.7 mt -108.62 166.88 10.46 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 124.75 1.22 . . . . 73.33 109.508 -177.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -142.78 122.1 13.07 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 107.135 -1.432 . . . . 74.33 107.135 -178.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -148.19 152.18 36.8 Favored 'General case' 0 CA--C 1.518 -0.285 0 C-N-CA 123.823 0.849 . . . . 63.12 110.459 -174.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 7.4 m -100.94 120.87 40.8 Favored 'General case' 0 CA--C 1.541 0.604 0 O-C-N 124.025 0.828 . . . . 74.41 109.389 176.294 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.53 HD22 HD13 ' A' ' 251' ' ' LEU . 66.0 tp -107.53 111.89 24.37 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.839 0.856 . . . . 74.13 109.467 -179.346 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -95.28 119.14 33.27 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.399 0.68 . . . . 75.41 109.259 176.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . 0.527 HG11 HG11 ' A' ' 223' ' ' VAL . 6.0 m -122.99 139.97 32.53 Favored Pre-proline 0 N--CA 1.475 0.8 0 C-N-CA 123.37 0.668 . . . . 73.23 109.267 -178.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_exo -59.31 144.37 99.42 Favored 'Trans proline' 0 C--N 1.372 1.793 0 C-N-CA 122.745 2.297 . . . . 63.34 111.81 171.411 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . 0.401 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -55.67 -44.63 99.76 Favored Pre-proline 0 CA--C 1.554 1.12 0 CA-C-O 117.963 -1.018 . . . . 53.51 111.991 177.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -48.61 -51.3 10.58 Favored 'Trans proline' 0 C--N 1.399 3.232 0 C-N-CA 122.537 2.158 . . . . 61.41 112.865 169.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 4.3 mt -62.44 -38.84 82.33 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.078 0 C-N-CA 123.202 0.601 . . . . 72.24 111.03 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.45 -44.41 96.47 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.17 0.588 . . . . 61.05 112.06 -178.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.3 m -78.55 -39.39 23.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-N 116.004 -0.543 . . . . 64.15 111.426 -174.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.1 m -82.9 -20.8 9.37 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 122.434 0.294 . . . . 71.22 111.284 -179.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.432 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 72.6 68.16 1.66 Allowed Glycine 0 C--N 1.343 0.932 0 N-CA-C 111.324 -0.711 . . . . 60.54 111.324 -175.531 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -92.87 -164.49 37.85 Favored Glycine 0 C--N 1.352 1.472 0 N-CA-C 111.482 -0.647 . . . . 74.11 111.482 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -115.11 139.17 50.12 Favored 'General case' 0 C--O 1.241 0.647 0 C-N-CA 123.554 0.742 . . . . 73.32 109.146 -178.05 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . 0.544 HG23 HG13 ' A' ' 221' ' ' VAL . 6.6 m -134.39 149.22 29.77 Favored 'Isoleucine or valine' 0 C--O 1.24 0.589 0 C-N-CA 123.876 0.87 . . . . 63.13 109.073 177.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . 0.483 ' H ' ' HD2' ' A' ' 211' ' ' ARG . 0.2 OUTLIER -104.87 125.9 51.38 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 108.116 -1.068 . . . . 74.11 108.116 174.874 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.48 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -99.89 129.2 45.95 Favored 'General case' 0 C--O 1.245 0.843 0 N-CA-C 108.792 -0.818 . . . . 44.33 108.792 -175.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 6.1 tpt -71.47 102.6 2.71 Favored 'General case' 0 CA--C 1.537 0.452 0 O-C-N 124.198 0.936 . . . . 73.21 109.4 -178.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.495 HG21 HG13 ' A' ' 219' ' ' VAL . 10.0 t -110.95 166.75 10.78 Favored 'General case' 0 C--O 1.238 0.451 0 CA-C-O 121.62 0.724 . . . . 72.33 110.694 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . 0.5 HD13 ' O ' ' A' ' 127' ' ' LEU . 25.9 mt -66.59 -19.04 65.68 Favored 'General case' 0 CA--C 1.545 0.765 0 CA-C-N 114.634 -1.166 . . . . 73.51 110.88 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -87.48 -21.7 25.35 Favored 'General case' 0 CA--C 1.558 1.263 0 C-N-CA 125.609 1.564 . . . . 63.12 111.797 -179.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 139.39 -146.91 18.71 Favored Glycine 0 C--N 1.352 1.431 0 CA-C-O 119.157 -0.802 . . . . 71.42 111.583 -169.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -93.51 133.79 0.94 Allowed 'Trans proline' 0 CA--C 1.557 1.666 0 C-N-CA 122.373 2.049 . . . . 61.3 112.276 165.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . 0.495 HG13 HG21 ' A' ' 214' ' ' THR . 16.5 m -108.97 143.25 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 C-N-CA 122.934 0.494 . . . . 63.31 110.453 171.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -91.37 108.9 20.21 Favored 'General case' 0 CA--C 1.542 0.649 0 CA-C-O 121.524 0.678 . . . . 73.55 109.598 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.544 HG13 HG23 ' A' ' 210' ' ' VAL . 2.6 p -119.19 127.15 75.85 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.761 0 C-N-CA 123.55 0.74 . . . . 72.1 110.557 173.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -96.88 120.21 36.79 Favored 'General case' 0 C--O 1.238 0.453 0 C-N-CA 123.982 0.913 . . . . 71.31 109.215 177.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.527 HG11 HG11 ' A' ' 199' ' ' VAL . 11.5 m -82.65 141.85 45.26 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 109.631 -0.507 . . . . 63.14 109.631 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -63.74 141.07 77.37 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 122.752 2.302 . . . . 74.12 112.202 175.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_exo -62.12 125.31 16.13 Favored 'Trans proline' 0 C--N 1.37 1.693 0 C-N-CA 122.513 2.142 . . . . 73.31 111.076 173.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 56.6 mtm180 64.77 50.21 2.08 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 124.951 1.407 . . . . 74.01 109.993 -172.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.0 t -79.5 169.7 17.66 Favored 'General case' 0 CA--C 1.546 0.804 0 CA-C-N 115.862 -0.608 . . . . 54.31 109.619 172.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . 0.595 ' H ' ' HD3' ' A' ' 231' ' ' ARG . 26.3 mp0 -125.04 142.09 51.71 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 123.808 0.843 . . . . 73.35 109.373 -172.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.66 119.39 13.83 Favored 'General case' 0 C--N 1.348 0.515 0 C-N-CA 123.469 0.708 . . . . 74.43 109.221 175.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.75 -7.08 22.17 Favored Glycine 0 C--N 1.34 0.793 0 CA-C-N 116.156 -0.475 . . . . 73.51 111.999 -171.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . 0.595 ' HD3' ' H ' ' A' ' 228' ' ' GLN . 75.2 mtp180 -81.94 160.94 23.24 Favored 'General case' 0 C--N 1.354 0.761 0 C-N-CA 122.766 0.426 . . . . 73.1 110.416 173.479 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.448 ' HG2' ' CE1' ' A' ' 250' ' ' TYR . 2.7 mppt? -122.23 135.59 54.78 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.267 0.627 . . . . 74.41 110.35 -175.727 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 61.8 mt -112.19 104.74 12.95 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 107.697 -1.223 . . . . 61.11 107.697 175.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . 0.548 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 50.3 ttt180 -94.14 109.04 20.84 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 115.682 -0.69 . . . . 74.13 109.622 -173.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.497 HD12 HD23 ' A' ' 249' ' ' LEU . 18.5 mt -85.95 128.11 34.77 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 122.838 0.455 . . . . 73.23 110.219 -175.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 50.0 mtmt -71.04 122.14 19.5 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 124.449 1.1 . . . . 71.45 111.762 -167.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.58 16.98 70.37 Favored Glycine 0 C--N 1.351 1.385 0 O-C-N 123.793 0.683 . . . . 55.11 114.02 172.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -94.9 7.28 46.51 Favored 'General case' 0 N--CA 1.48 1.049 0 N-CA-C 112.49 0.552 . . . . 70.11 112.49 -174.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -95.62 -170.84 35.9 Favored Glycine 0 C--N 1.34 0.789 0 O-C-N 123.553 0.533 . . . . 62.2 112.347 175.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.468 ' HD1' HD13 ' A' ' 188' ' ' LEU . 60.3 m-85 -85.95 159.88 53.57 Favored Pre-proline 0 CA--C 1.544 0.733 0 C-N-CA 123.578 0.751 . . . . 74.13 111.107 -176.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -52.97 127.94 26.94 Favored 'Trans proline' 0 C--N 1.391 2.812 0 C-N-CA 122.713 2.276 . . . . 71.4 112.221 176.693 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . 0.428 ' HA3' ' HB3' ' A' ' 191' ' ' GLN . . . -157.0 -164.36 13.49 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-O 119.03 -0.872 . . . . 74.34 111.945 -177.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -58.39 -30.34 91.02 Favored 'Trans proline' 0 C--N 1.373 1.821 0 C-N-CA 123.569 2.846 . . . . 75.31 114.153 -173.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -93.61 22.97 4.96 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 123.428 0.691 . . . . 71.11 111.329 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 87.87 -73.92 2.26 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 110.104 -1.198 . . . . 74.31 110.104 -174.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 50.0 mtm180 -127.02 162.52 25.82 Favored 'General case' 0 N--CA 1.477 0.89 0 C-N-CA 124.16 0.984 . . . . 73.44 108.674 167.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -89.38 -156.86 32.34 Favored Glycine 0 C--N 1.342 0.876 0 O-C-N 123.671 0.607 . . . . 72.03 112.398 176.476 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -135.86 171.59 14.24 Favored 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 109.182 -0.673 . . . . 72.41 109.182 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.575 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 12.8 tp -106.81 117.4 33.96 Favored 'General case' 0 C--O 1.213 -0.848 0 C-N-CA 123.268 0.627 . . . . 43.33 111.171 176.11 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . 0.478 ' HB3' ' O ' ' A' ' 193' ' ' LEU . 1.9 t80 -89.68 103.98 16.58 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 107.979 -1.119 . . . . 73.52 107.979 173.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.53 HD13 HD22 ' A' ' 197' ' ' LEU . 76.2 mt -88.77 148.03 24.15 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 123.261 0.625 . . . . 74.15 110.921 172.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -109.34 97.49 7.07 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 108.768 -0.827 . . . . 74.32 108.768 175.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 57.3 t -53.68 113.94 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 123.28 0.632 . . . . 45.51 110.802 173.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 27.7 mmt85 -123.64 94.3 4.2 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 107.185 -1.413 . . . . 73.42 107.185 178.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.401 HG23 ' HA ' ' A' ' 201' ' ' ALA . 76.6 mt -77.82 114.76 18.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 123.718 0.807 . . . . 65.24 110.318 -176.551 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 4.2 t . . . . . 0 CA--C 1.562 1.428 0 C-N-CA 123.633 0.773 . . . . 63.54 109.527 176.051 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.53 ' HB2' ' HG2' ' A' ' 139' ' ' GLU . . . . . . . . 0 N--CA 1.481 1.121 0 N-CA-C 110.343 -0.243 . . . . 73.24 110.343 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -82.14 -61.54 1.88 Allowed 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 123.42 0.688 . . . . 73.21 111.348 -174.092 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.463 HD21 HD13 ' A' ' 125' ' ' LEU . 30.5 tp -83.82 -55.43 4.26 Favored 'General case' 0 C--O 1.241 0.658 0 C-N-CA 122.882 0.473 . . . . 63.35 111.121 -170.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.447 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 14.8 p -67.3 120.62 14.94 Favored 'Isoleucine or valine' 0 C--N 1.36 1.051 0 CA-C-O 121.54 0.686 . . . . 64.13 110.26 175.462 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -85.67 -60.71 1.94 Allowed 'General case' 0 C--O 1.24 0.564 0 CA-C-N 114.933 -1.031 . . . . 62.1 110.456 -175.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 26.6 t-80 -165.94 157.81 14.22 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 115.793 -0.64 . . . . 75.53 111.217 -171.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 25.9 t -64.42 145.14 14.08 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 125.148 1.379 . . . . 63.42 111.028 175.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.669 HG22 ' HG3' ' A' ' 122' ' ' GLU . 41.6 p -63.66 -45.99 87.65 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 123.517 0.727 . . . . 74.32 111.377 177.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 46.0 t -99.74 -75.71 0.56 Allowed 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 123.95 0.9 . . . . 40.53 109.887 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 160.4 -60.59 0.3 Allowed Glycine 0 C--N 1.345 1.047 0 N-CA-C 110.385 -1.086 . . . . 60.33 110.385 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 57.6 p -89.27 70.27 8.21 Favored 'General case' 0 CA--C 1.551 0.981 0 C-N-CA 123.687 0.795 . . . . 71.52 110.21 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.444 ' O ' HD23 ' A' ' 119' ' ' LEU . . . 85.63 -81.97 1.7 Allowed Glycine 0 C--N 1.347 1.17 0 CA-C-N 115.696 -0.683 . . . . 52.14 111.443 -176.242 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 162.39 156.71 8.59 Favored Glycine 0 C--O 1.243 0.659 0 CA-C-O 119.589 -0.561 . . . . 74.12 111.834 179.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 40.9 m -57.09 109.75 0.71 Allowed 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 123.499 0.72 . . . . 74.2 111.582 -176.068 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -67.69 135.58 30.89 Favored Glycine 0 C--N 1.343 0.955 0 CA-C-N 115.386 -0.825 . . . . 45.45 112.709 -177.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 140.24 38.76 0.09 OUTLIER Glycine 0 C--N 1.335 0.519 0 N-CA-C 111.842 -0.503 . . . . 73.14 111.842 -179.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 35.3 t -158.08 -61.69 0.08 Allowed 'General case' 0 CA--C 1.541 0.631 0 N-CA-C 109.519 -0.548 . . . . 64.24 109.519 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -70.63 -54.28 10.52 Favored Glycine 0 C--N 1.344 1.024 0 CA-C-N 115.708 -0.678 . . . . 73.33 112.809 -178.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.71 -49.78 3.9 Favored Glycine 0 C--N 1.343 0.947 0 N-CA-C 114.183 0.433 . . . . 61.14 114.183 172.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.2 t -74.94 119.92 19.78 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 122.86 0.464 . . . . 51.15 110.312 -176.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 62.54 -132.68 44.54 Favored Glycine 0 C--N 1.352 1.468 0 O-C-N 123.846 0.716 . . . . 74.11 111.849 -177.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.634 ' H ' ' HA3' ' A' ' 166' ' ' GLY . 4.4 tpm_? -90.53 122.53 33.44 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 123.165 0.586 . . . . 70.21 109.558 168.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -60.58 109.26 0.98 Allowed 'General case' 0 C--O 1.243 0.746 0 N-CA-C 108.061 -1.088 . . . . 41.4 108.061 165.373 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.598 HD21 HG11 ' A' ' 140' ' ' VAL . 0.5 OUTLIER -95.77 135.88 36.9 Favored 'General case' 0 C--N 1.345 0.402 0 N-CA-C 106.283 -1.747 . . . . 52.21 106.283 175.015 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 56.7 mtp180 -142.65 126.52 17.17 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 108.304 -0.998 . . . . 74.02 108.304 -175.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -148.78 133.27 17.65 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.335 0.654 . . . . 73.42 110.157 -178.465 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.669 ' HG3' HG22 ' A' ' 103' ' ' THR . 44.8 mt-10 -92.89 144.99 24.72 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 122.929 0.491 . . . . 62.41 109.993 173.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.447 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.7 pt? -146.68 132.18 9.23 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-N 115.365 -0.834 . . . . 70.41 110.533 -177.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -72.09 114.96 4.13 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 121.814 1.676 . . . . 75.31 111.221 175.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.463 HD13 HD21 ' A' ' 98' ' ' LEU . 22.0 tp -108.93 167.26 10.22 Favored 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.539 1.136 . . . . 65.54 108.065 176.334 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.497 HG23 HD12 ' A' ' 181' ' ' LEU . 7.8 m -103.46 159.8 15.27 Favored 'General case' 0 N--CA 1.476 0.865 0 O-C-N 121.624 -0.672 . . . . 63.33 109.513 171.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.555 HD23 ' HB3' ' A' ' 180' ' ' LEU . 81.2 mt -52.12 -52.77 49.5 Favored 'General case' 0 N--CA 1.479 0.994 0 CA-C-O 121.311 0.577 . . . . 51.3 109.625 169.441 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.574 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.7 mp0 -55.64 -39.74 71.26 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-N 114.588 -1.187 . . . . 71.14 112.146 177.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -77.7 -21.17 52.4 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 122.765 0.426 . . . . 64.54 111.845 -178.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.489 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -68.55 -36.08 78.3 Favored 'General case' 0 C--O 1.248 0.99 0 C-N-CA 123.628 0.771 . . . . 71.43 110.64 168.531 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.483 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 69.2 t80 -64.44 -49.05 73.0 Favored 'General case' 0 C--N 1.346 0.448 0 CA-C-N 115.232 -0.894 . . . . 75.1 110.537 170.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -72.94 -28.82 62.67 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 112.855 0.687 . . . . 70.43 112.855 -173.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 67.3 -96.18 0.32 Allowed Glycine 0 C--N 1.351 1.376 0 N-CA-C 111.415 -0.674 . . . . 53.53 111.415 -174.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.38 150.55 25.46 Favored Glycine 0 C--N 1.349 1.29 0 N-CA-C 114.78 0.672 . . . . 71.04 114.78 167.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -85.59 125.57 33.22 Favored 'General case' 0 N--CA 1.473 0.684 0 N-CA-C 108.116 -1.068 . . . . 61.42 108.116 169.633 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 21.9 mmt180 -129.22 152.66 48.55 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 124.255 1.022 . . . . 63.42 108.742 -168.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 22.3 m -85.24 127.11 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.212 0 N-CA-C 110.053 -0.351 . . . . 72.21 110.053 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 85.7 t -123.73 122.78 65.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 123.086 0.554 . . . . 70.33 109.884 175.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . 0.53 ' HG2' ' HB2' ' A' ' 96' ' ' ALA . 11.7 pt-20 -124.8 96.53 4.91 Favored 'General case' 0 N--CA 1.476 0.87 0 CA-C-O 121.99 0.9 . . . . 61.02 109.24 172.063 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.598 HG11 HD21 ' A' ' 119' ' ' LEU . 74.0 t -130.59 133.11 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 123.786 0.834 . . . . 71.54 109.64 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.33 28.35 17.84 Favored 'General case' 0 N--CA 1.484 1.236 0 C-N-CA 124.621 1.168 . . . . 60.1 111.157 -178.639 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.12 -9.3 66.98 Favored Glycine 0 C--N 1.35 1.321 0 CA-C-N 115.548 -0.751 . . . . 62.03 113.447 -177.603 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 3.2 tpp180 -91.08 115.67 28.19 Favored 'General case' 0 C--N 1.344 0.339 0 N-CA-C 109.424 -0.584 . . . . 74.24 109.424 -176.143 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 59.0 ttp180 -103.72 111.4 23.88 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 108.636 -0.875 . . . . 74.14 108.636 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.5 p -145.89 141.86 21.74 Favored 'Isoleucine or valine' 0 C--O 1.243 0.731 0 C-N-CA 125.011 1.324 . . . . 71.43 108.325 178.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 32.4 p -77.69 134.14 38.19 Favored 'General case' 0 CA--C 1.536 0.437 0 CA-C-N 116.384 -0.371 . . . . 74.24 110.016 178.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 9.0 p -98.74 136.11 31.03 Favored 'Isoleucine or valine' 0 C--N 1.341 0.2 0 N-CA-C 109.126 -0.694 . . . . 72.45 109.126 175.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.1 ttt85 -108.19 95.45 5.68 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 107.559 -1.275 . . . . 75.33 107.559 168.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.446 ' HB ' HD13 ' A' ' 159' ' ' ILE . 36.5 pt -87.03 113.62 54.46 Favored Pre-proline 0 CA--C 1.552 1.021 0 N-CA-C 107.777 -1.194 . . . . 52.21 107.777 171.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -61.45 137.41 69.64 Favored 'Trans proline' 0 C--N 1.381 2.251 0 C-N-CA 122.683 2.255 . . . . 70.12 112.85 -173.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.426 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 83.7 Cg_exo -50.62 120.07 5.98 Favored 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 123.281 2.654 . . . . 74.32 112.132 172.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 126.03 52.57 0.16 Allowed Glycine 0 C--N 1.341 0.826 0 N-CA-C 110.861 -0.896 . . . . 63.21 110.861 -174.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.574 HG21 HD11 ' A' ' 159' ' ' ILE . 1.9 p -126.05 161.87 30.71 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.197 0 C-N-CA 123.94 0.896 . . . . 71.13 109.247 -176.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 63.1 mtp180 -140.94 165.9 26.26 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 124.869 1.267 . . . . 73.23 111.576 -165.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -57.12 122.85 13.38 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.948 0.899 . . . . 71.11 110.008 169.118 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.86 7.88 86.44 Favored Glycine 0 C--N 1.343 0.931 0 CA-C-O 119.4 -0.667 . . . . 64.3 113.824 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 46.5 t -78.77 123.33 27.08 Favored 'General case' 0 C--O 1.244 0.794 0 N-CA-C 109.415 -0.587 . . . . 60.51 109.415 177.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.412 HG22 HD22 ' A' ' 175' ' ' LEU . 7.6 p -100.49 120.78 50.42 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.126 0 CA-C-N 115.063 -0.971 . . . . 74.35 109.569 -179.233 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.574 HD11 HG21 ' A' ' 153' ' ' VAL . 20.1 mt -106.73 116.82 51.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.963 0.905 . . . . 72.25 110.32 -167.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.482 ' HG3' ' HB2' ' A' ' 173' ' ' ASP . 29.6 ttm180 -89.3 113.12 24.35 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.653 0.781 . . . . 72.13 111.245 -179.305 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 18.4 m -115.41 103.27 54.3 Favored Pre-proline 0 CA--C 1.561 1.374 0 CA-C-O 121.498 0.666 . . . . 75.4 110.581 178.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -65.5 145.65 83.04 Favored 'Trans proline' 0 C--N 1.381 2.258 0 C-N-CA 122.716 2.278 . . . . 75.22 112.992 -177.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 94.07 -23.25 32.22 Favored Glycine 0 C--N 1.345 1.03 0 CA-C-N 115.742 -0.663 . . . . 64.31 113.962 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.481 ' HB3' ' HE2' ' A' ' 164' ' ' MET . 68.8 mtp -95.13 -23.66 17.2 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 112.927 0.714 . . . . 63.01 112.927 -169.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -78.18 -112.82 0.19 Allowed Glycine 0 C--N 1.346 1.105 0 N-CA-C 113.8 0.28 . . . . 61.11 113.8 -177.274 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.634 ' HA3' ' H ' ' A' ' 117' ' ' ARG . . . -68.97 105.66 1.55 Allowed Glycine 0 C--N 1.341 0.853 0 C-N-CA 122.836 0.255 . . . . 73.23 112.828 178.087 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 9.0 mm-40 -68.2 151.44 46.96 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.354 0.662 . . . . 62.31 110.578 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 138.32 -169.61 24.2 Favored Glycine 0 N--CA 1.466 0.688 0 CA-C-N 115.798 -0.637 . . . . 43.34 111.772 -176.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 41.1 t30 -64.58 -49.21 71.79 Favored Pre-proline 0 CA--C 1.553 1.07 0 CA-C-O 117.696 -1.145 . . . . 72.31 111.239 177.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -78.72 104.46 1.81 Allowed 'Trans proline' 0 C--N 1.396 3.047 0 C-N-CA 121.596 1.531 . . . . 71.44 110.525 168.139 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -65.9 125.24 13.87 Favored 'Trans proline' 0 C--N 1.381 2.28 0 C-N-CA 122.285 1.99 . . . . 74.31 111.544 -174.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.442 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -84.96 166.73 41.17 Favored Glycine 0 CA--C 1.509 -0.331 0 CA-C-N 116.169 -0.469 . . . . 44.41 111.946 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.482 ' HB2' ' HG3' ' A' ' 160' ' ' ARG . 8.2 p-10 -116.77 145.65 43.36 Favored 'General case' 0 C--O 1.245 0.824 0 C-N-CA 123.846 0.859 . . . . 64.21 109.28 -177.443 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.424 HD13 HD22 ' A' ' 119' ' ' LEU . 17.7 tp -106.39 122.37 46.12 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.824 -1.176 . . . . 42.42 107.824 176.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.412 HD22 HG22 ' A' ' 158' ' ' VAL . 77.1 mt -98.8 98.91 9.96 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 125.279 1.432 . . . . 74.13 110.282 -177.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 52.8 mt -92.57 107.39 19.18 Favored 'General case' 0 N--CA 1.464 0.256 0 C-N-CA 123.411 0.684 . . . . 74.34 111.405 178.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.648 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 34.7 t -88.66 104.22 14.57 Favored 'Isoleucine or valine' 0 C--O 1.245 0.836 0 N-CA-C 108.465 -0.939 . . . . 74.42 108.465 173.551 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 9.7 m -82.0 147.59 5.99 Favored 'Isoleucine or valine' 0 C--O 1.242 0.686 0 CA-C-O 121.499 0.666 . . . . 72.05 110.318 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 24.3 mmm-85 -120.63 96.32 5.08 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 107.418 -1.327 . . . . 61.34 107.418 -179.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.555 ' HB3' HD23 ' A' ' 127' ' ' LEU . 31.0 mt -69.26 136.53 52.07 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 122.626 0.371 . . . . 73.13 110.368 -174.677 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.497 HD12 HG23 ' A' ' 126' ' ' THR . 53.7 mt -53.67 125.49 46.0 Favored Pre-proline 0 CA--C 1.554 1.122 0 CA-C-O 118.543 -0.742 . . . . 74.24 110.319 -177.189 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 24.0 Cg_exo -64.18 85.23 0.15 Allowed 'Trans proline' 0 C--N 1.379 2.139 0 C-N-CA 123.109 2.539 . . . . 74.13 113.471 -174.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.2 p80 -154.23 54.82 1.15 Allowed Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 123.758 0.823 . . . . 74.35 109.054 171.147 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -61.21 122.92 11.87 Favored 'Trans proline' 0 C--N 1.381 2.273 0 C-N-CA 122.54 2.16 . . . . 72.4 112.143 -165.055 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.29 -44.57 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 N-CA-C 107.824 -1.176 . . . . 70.11 107.824 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.456 ' HE2' HD13 ' A' ' 193' ' ' LEU . 3.6 m-85 -104.81 123.75 48.22 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.209 -0.905 . . . . 63.3 109.353 176.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.507 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 4.3 mmm180 -115.68 150.94 35.97 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 106.082 -1.821 . . . . 64.31 106.082 178.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.439 HD12 ' O ' ' A' ' 192' ' ' ASP . 63.9 tp -130.76 132.02 45.06 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 122.833 0.453 . . . . 64.52 109.832 -176.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -143.5 116.76 9.0 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 108.417 -0.957 . . . . 73.21 108.417 168.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 55.42 52.85 44.93 Favored Glycine 0 C--N 1.355 1.584 0 O-C-N 123.953 0.783 . . . . 60.22 114.04 176.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . 0.401 ' OE1' ' HD2' ' A' ' 243' ' ' PRO . 38.5 mt-30 72.5 -5.94 1.71 Allowed 'General case' 0 N--CA 1.496 1.866 0 C-N-CA 125.024 1.329 . . . . 72.13 113.168 177.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.439 ' O ' HD12 ' A' ' 188' ' ' LEU . 23.1 t70 -98.98 145.09 27.42 Favored 'General case' 0 C--N 1.348 0.503 0 N-CA-C 109.483 -0.562 . . . . 64.5 109.483 -176.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.606 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 86.7 mt -105.72 152.97 22.5 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.691 0.796 . . . . 71.1 109.232 -174.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . 0.507 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 98.3 m-85 -140.84 120.82 13.63 Favored 'General case' 0 C--O 1.223 -0.308 0 N-CA-C 107.649 -1.241 . . . . 75.12 107.649 -174.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -147.47 169.46 19.5 Favored 'General case' 0 C--O 1.24 0.595 0 C-N-CA 123.637 0.775 . . . . 74.44 110.287 -175.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 16.6 m -116.25 126.99 54.35 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.757 -0.656 . . . . 73.3 109.447 175.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.407 HD22 HD13 ' A' ' 251' ' ' LEU . 67.0 tp -107.39 119.46 39.46 Favored 'General case' 0 C--O 1.214 -0.804 0 C-N-CA 124.47 1.108 . . . . 71.52 108.696 176.071 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -97.31 136.79 37.29 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.257 -1.016 . . . . 62.3 108.257 167.439 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . 0.571 HG12 HG11 ' A' ' 210' ' ' VAL . 13.3 m -130.26 142.82 46.78 Favored Pre-proline 0 N--CA 1.476 0.833 0 N-CA-C 109.1 -0.704 . . . . 73.43 109.1 179.235 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -61.94 140.06 82.85 Favored 'Trans proline' 0 C--N 1.372 1.79 0 C-N-CA 121.942 1.761 . . . . 64.3 110.772 172.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . 0.416 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -52.78 -42.2 88.24 Favored Pre-proline 0 CA--C 1.558 1.263 0 CA-C-O 117.542 -1.218 . . . . 54.5 113.041 178.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . 0.48 ' O ' HG22 ' A' ' 206' ' ' VAL . 8.8 Cg_endo -49.78 -52.69 8.37 Favored 'Trans proline' 0 C--N 1.408 3.671 0 C-N-CA 122.851 2.367 . . . . 72.35 112.267 169.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 3.4 mt -60.98 -41.66 89.94 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 122.836 0.454 . . . . 74.51 111.271 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.49 -42.53 98.55 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.163 0.585 . . . . 51.43 112.187 -175.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 28.1 m -81.2 -35.51 14.25 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 CA-C-N 115.959 -0.564 . . . . 75.21 111.894 -173.06 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.48 HG22 ' O ' ' A' ' 202' ' ' PRO . 20.8 m -88.0 -19.21 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 O-C-N 122.118 -0.364 . . . . 74.04 111.635 178.614 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.415 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 76.37 66.67 1.81 Allowed Glycine 0 C--N 1.342 0.894 0 O-C-N 123.484 0.49 . . . . 75.33 112.181 -177.449 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.02 -168.45 42.89 Favored Glycine 0 C--N 1.348 1.203 0 N-CA-C 111.854 -0.498 . . . . 73.33 111.854 175.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -125.79 119.34 27.63 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 107.997 -1.112 . . . . 64.34 107.997 -179.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . 0.571 HG11 HG12 ' A' ' 199' ' ' VAL . 7.9 p -116.43 147.88 19.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.547 0 C-N-CA 124.143 0.977 . . . . 61.44 109.439 -174.1 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -76.24 123.66 26.25 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 116.026 -0.534 . . . . 73.42 109.579 172.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.13 130.14 47.15 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 108.052 -1.092 . . . . 72.03 108.052 173.179 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 56.3 mmm -76.55 141.01 41.32 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.131 0.491 . . . . 64.34 110.776 178.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.429 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 5.7 t -143.68 166.91 23.53 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-N 114.563 -1.199 . . . . 73.35 110.159 177.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . 0.574 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 65.1 mt -66.51 -19.84 65.88 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 124.306 1.042 . . . . 52.34 110.953 176.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -82.97 -18.25 40.61 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 124.859 1.263 . . . . 75.01 111.022 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 134.26 -147.49 19.11 Favored Glycine 0 C--N 1.352 1.433 0 N-CA-C 111.226 -0.75 . . . . 72.1 111.226 -174.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -93.11 129.37 0.76 Allowed 'Trans proline' 0 CA--C 1.56 1.787 0 C-N-CA 122.432 2.088 . . . . 62.43 112.775 165.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.7 m -109.15 166.71 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 C-N-CA 123.595 0.758 . . . . 73.12 109.56 169.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -113.94 116.47 29.3 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 109.867 -0.42 . . . . 74.51 109.867 178.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.4 p -108.78 136.82 43.38 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.681 0 C-N-CA 123.459 0.704 . . . . 71.24 110.175 173.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -95.12 115.73 27.81 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 124.025 0.93 . . . . 41.03 109.491 176.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.453 HG11 HG11 ' A' ' 199' ' ' VAL . 14.2 m -82.06 142.05 47.57 Favored Pre-proline 0 CA--C 1.548 0.893 0 N-CA-C 109.376 -0.601 . . . . 55.22 109.376 176.16 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_exo -61.0 141.12 93.47 Favored 'Trans proline' 0 C--N 1.368 1.558 0 C-N-CA 122.451 2.1 . . . . 75.12 112.746 172.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_exo -56.4 119.79 7.23 Favored 'Trans proline' 0 C--N 1.373 1.833 0 C-N-CA 122.588 2.192 . . . . 74.45 111.783 169.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 53.7 mtm180 60.75 51.64 4.75 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.676 1.19 . . . . 74.45 110.759 -174.082 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . 0.473 ' OG1' ' HD2' ' A' ' 231' ' ' ARG . 12.1 t -73.17 172.68 10.64 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-N 114.955 -1.02 . . . . 73.11 110.257 174.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -126.49 141.81 51.75 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 123.149 0.58 . . . . 74.34 109.455 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . 0.466 ' HB2' ' H ' ' A' ' 255' ' ' ILE . . . -63.96 119.69 10.56 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.759 0.824 . . . . 64.31 109.836 175.112 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.98 4.78 20.75 Favored Glycine 0 C--O 1.241 0.57 0 C-N-CA 123.69 0.662 . . . . 33.41 112.314 -176.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . 0.473 ' HD2' ' OG1' ' A' ' 227' ' ' THR . 92.3 mtt180 -79.54 159.01 27.06 Favored 'General case' 0 C--N 1.358 0.942 0 CA-C-O 121.707 0.765 . . . . 73.0 109.551 170.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.474 ' HG3' ' HE2' ' A' ' 250' ' ' TYR . 10.1 mptt -108.34 99.13 8.57 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 114.32 -1.309 . . . . 74.11 108.452 -176.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . 0.448 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 62.6 mt -90.11 96.48 10.69 Favored 'General case' 0 C--N 1.349 0.545 0 N-CA-C 106.231 -1.766 . . . . 64.42 106.231 176.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . 0.495 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 39.1 ttp180 -96.11 101.36 13.01 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 114.915 -1.039 . . . . 71.01 110.015 -167.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.508 HD12 HD23 ' A' ' 249' ' ' LEU . 43.3 mt -81.08 105.92 12.67 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.934 0.894 . . . . 73.02 108.806 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt -74.61 144.18 44.02 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.171 0.588 . . . . 74.41 112.267 -171.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 71.11 19.99 77.65 Favored Glycine 0 C--N 1.349 1.275 0 O-C-N 123.764 0.665 . . . . 52.02 113.934 178.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 1.4 mmmp? -106.65 -12.43 15.56 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.792 0.437 . . . . 71.43 111.173 -179.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.17 -175.51 49.82 Favored Glycine 0 C--N 1.348 1.217 0 O-C-N 123.409 0.443 . . . . 72.31 112.138 173.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.483 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 87.5 m-85 -77.4 149.26 78.5 Favored Pre-proline 0 N--CA 1.475 0.809 0 N-CA-C 112.252 0.464 . . . . 74.04 112.252 -172.027 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . 0.595 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 53.3 Cg_endo -65.52 160.58 42.28 Favored 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 122.838 2.359 . . . . 55.51 113.562 -175.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 164.7 -151.74 20.97 Favored Glycine 0 C--N 1.346 1.097 0 CA-C-O 118.929 -0.928 . . . . 33.52 112.044 -178.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . 0.401 ' HD2' ' OE1' ' A' ' 191' ' ' GLN . 37.6 Cg_endo -61.33 -32.53 89.77 Favored 'Trans proline' 0 C--N 1.377 2.047 0 C-N-CA 123.264 2.643 . . . . 72.23 113.198 -176.513 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -84.52 18.63 2.22 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 123.485 0.714 . . . . 63.12 111.77 178.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 78.77 -78.12 1.7 Allowed Glycine 0 C--N 1.347 1.175 0 N-CA-C 110.039 -1.224 . . . . 65.34 110.039 -172.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.595 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 62.2 mtm180 -128.47 169.51 14.24 Favored 'General case' 0 N--CA 1.469 0.494 0 C-N-CA 124.081 0.953 . . . . 64.03 108.579 166.245 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -82.78 -163.66 34.07 Favored Glycine 0 C--N 1.337 0.626 0 N-CA-C 111.697 -0.561 . . . . 41.11 111.697 172.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -130.78 170.73 13.98 Favored 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 109.238 -0.653 . . . . 72.43 109.238 -178.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.606 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 17.5 tp -115.87 120.65 39.9 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.868 0.867 . . . . 73.31 110.663 175.365 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . 0.474 ' HE2' ' HG3' ' A' ' 232' ' ' LYS . 10.7 t80 -89.31 107.93 19.34 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.613 1.165 . . . . 75.15 108.693 175.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.448 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 87.8 mt -94.14 117.86 30.71 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.904 -0.406 . . . . 72.04 109.904 167.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -88.29 93.56 9.55 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 107.327 -1.36 . . . . 74.52 107.327 171.412 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 3.3 p -60.05 133.82 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 O-C-N 123.725 0.641 . . . . 51.43 110.645 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 48.6 mmm-85 -135.26 102.01 5.03 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 125.049 1.34 . . . . 73.15 107.529 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.466 ' H ' ' HB2' ' A' ' 229' ' ' ALA . 63.0 mt -76.54 116.93 20.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.359 -0.837 . . . . 70.05 109.768 -175.089 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.0 t . . . . . 0 CA--C 1.553 1.087 0 C-N-CA 124.829 1.252 . . . . 70.32 109.214 -178.635 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.155 0 N-CA-C 110.121 -0.325 . . . . 64.21 110.121 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.416 ' HB3' ' HB3' ' A' ' 136' ' ' ARG . . . -106.47 -18.86 13.85 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 123.006 0.523 . . . . 74.33 112.277 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.474 HD23 ' H ' ' A' ' 99' ' ' VAL . 2.0 pt? -140.27 -50.2 0.47 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 117.529 0.15 . . . . 74.31 111.084 178.078 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.711 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 13.6 p -64.45 146.7 12.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 C-N-CA 123.584 0.754 . . . . 72.12 111.894 -179.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.462 ' HB2' ' HD3' ' A' ' 124' ' ' PRO . . . -83.22 -58.35 2.88 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 109.479 -0.563 . . . . 62.05 109.479 173.16 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 40.0 t-80 -175.59 159.58 2.38 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 123.697 0.799 . . . . 73.43 109.857 -175.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -66.44 136.68 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 123.346 0.658 . . . . 71.21 110.277 171.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 12.6 t -127.95 154.73 45.25 Favored 'General case' 0 CA--C 1.543 0.708 0 N-CA-C 109.308 -0.627 . . . . 72.53 109.308 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 28.6 m -89.55 95.07 10.11 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 123.186 0.594 . . . . 75.13 109.789 -175.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . 0.563 ' HA3' ' HG3' ' A' ' 120' ' ' ARG . . . -92.77 -176.22 41.26 Favored Glycine 0 C--N 1.348 1.244 0 CA-C-N 116.483 -0.326 . . . . 61.32 113.172 -177.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 23.3 m -72.6 113.27 9.45 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 123.064 0.546 . . . . 73.05 110.693 -179.399 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -64.59 129.0 36.09 Favored Glycine 0 C--N 1.346 1.095 0 N-CA-C 110.821 -0.912 . . . . 74.22 110.821 170.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -73.37 75.39 1.0 Allowed Glycine 0 C--N 1.349 1.305 0 CA-C-N 117.011 0.406 . . . . 51.12 113.363 -177.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 37.2 t -77.43 -54.37 6.52 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 123.768 0.827 . . . . 73.42 109.402 -179.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -92.77 4.64 75.85 Favored Glycine 0 C--N 1.346 1.129 0 CA-C-N 115.585 -0.734 . . . . 35.35 111.929 171.568 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -80.82 154.4 35.71 Favored Glycine 0 C--N 1.351 1.388 0 C-N-CA 123.286 0.47 . . . . 52.52 112.035 177.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 15.5 m -75.83 103.43 5.91 Favored 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 123.264 0.625 . . . . 71.22 109.511 177.206 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 127.63 165.24 11.83 Favored Glycine 0 C--N 1.344 1.012 0 N-CA-C 112.182 -0.367 . . . . 74.32 112.182 -177.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 154.09 7.34 0.09 OUTLIER Glycine 0 N--CA 1.473 1.137 0 CA-C-O 120.058 -0.301 . . . . 54.51 113.08 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 47.2 t -71.59 -50.41 31.17 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.712 0.805 . . . . 74.12 109.958 177.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -96.61 148.27 18.94 Favored Glycine 0 C--N 1.34 0.795 0 N-CA-C 110.968 -0.853 . . . . 74.02 110.968 173.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 43.3 ttm105 -65.77 127.9 33.83 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.514 0.726 . . . . 74.14 111.428 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -72.47 147.34 46.17 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.535 0.734 . . . . 72.35 110.034 172.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.505 HD12 HD13 ' A' ' 174' ' ' LEU . 0.2 OUTLIER -138.16 137.41 37.61 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 106.392 -1.707 . . . . 73.52 106.392 177.46 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.563 ' HG3' ' HA3' ' A' ' 105' ' ' GLY . 19.4 mmt85 -125.58 138.59 53.95 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 109.065 -0.717 . . . . 73.22 109.065 -178.57 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 176' ' ' LEU . . . -159.11 126.74 4.91 Favored 'General case' 0 CA--C 1.536 0.417 0 O-C-N 123.703 0.627 . . . . 51.23 109.447 175.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -105.73 150.55 25.41 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 109.607 -0.516 . . . . 65.14 109.607 175.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.711 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.4 pt? -145.87 147.08 31.13 Favored Pre-proline 0 N--CA 1.473 0.72 0 C-N-CA 123.033 0.533 . . . . 72.41 111.925 -170.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.462 ' HD3' ' HB2' ' A' ' 100' ' ' ALA . 91.5 Cg_endo -81.76 113.41 2.51 Favored 'Trans proline' 0 C--N 1.376 1.993 0 C-N-CA 121.769 1.646 . . . . 74.22 111.082 171.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.429 ' HB3' HD23 ' A' ' 180' ' ' LEU . 19.2 tp -111.06 167.71 10.05 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.043 -1.095 . . . . 63.31 108.043 175.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.566 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 8.8 m -101.09 155.07 18.21 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 109.922 -0.399 . . . . 61.12 109.922 174.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.436 HD23 ' HB3' ' A' ' 180' ' ' LEU . 85.6 mt -51.96 -51.93 53.75 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 122.304 1.049 . . . . 72.31 109.766 171.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -56.83 -40.14 75.5 Favored 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 113.386 -1.734 . . . . 74.14 111.735 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.411 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 23.8 mm-40 -79.87 -18.27 51.13 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 123.358 0.663 . . . . 73.32 112.195 -179.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.671 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -63.25 -41.57 99.09 Favored 'General case' 0 C--O 1.249 1.036 0 C-N-CA 122.863 0.465 . . . . 74.02 110.583 165.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -67.93 -54.45 18.6 Favored 'General case' 0 C--N 1.354 0.787 0 CA-C-N 115.664 -0.698 . . . . 74.31 110.932 172.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.5 m80 -69.88 -30.03 67.39 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 123.941 0.776 . . . . 72.24 112.158 -170.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 65.08 -149.34 51.71 Favored Glycine 0 C--N 1.346 1.124 0 N-CA-C 111.334 -0.706 . . . . 70.21 111.334 -171.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 136.92 136.94 3.57 Favored Glycine 0 C--N 1.346 1.095 0 CA-C-N 116.73 0.265 . . . . 71.1 112.673 170.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -80.21 127.0 31.83 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.408 0.683 . . . . 75.23 109.191 174.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.416 ' HB3' ' HB3' ' A' ' 97' ' ' ALA . 8.2 mpt_? -136.26 168.13 19.99 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.527 0.731 . . . . 73.13 109.101 177.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 6.5 p -85.85 129.61 37.78 Favored 'Isoleucine or valine' 0 C--O 1.246 0.878 0 CA-C-O 121.311 0.577 . . . . 52.51 110.66 174.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.493 HG21 HD21 ' A' ' 174' ' ' LEU . 14.6 p -98.65 142.33 14.9 Favored 'Isoleucine or valine' 0 C--O 1.242 0.704 0 C-N-CA 124.215 1.006 . . . . 71.11 109.43 175.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . 0.457 ' H ' HG11 ' A' ' 99' ' ' VAL . 42.7 mm-40 -121.76 100.68 7.13 Favored 'General case' 0 C--O 1.24 0.563 0 C-N-CA 124.61 1.164 . . . . 42.2 108.142 179.042 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.2 m -124.05 107.53 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.79 0 C-N-CA 123.352 0.661 . . . . 72.43 111.063 -176.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.87 24.24 11.29 Favored 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 124.747 1.219 . . . . 54.21 111.909 176.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 91.12 3.49 69.9 Favored Glycine 0 C--N 1.346 1.116 0 CA-C-N 116.031 -0.531 . . . . 73.3 113.371 -177.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 64.0 mtp85 -95.98 119.62 34.81 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.024 -0.732 . . . . 72.22 109.024 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 33.9 ttt85 -98.82 116.63 31.49 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.483 0.713 . . . . 72.42 109.952 -178.213 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 46.3 t -136.53 145.53 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.778 0.831 . . . . 73.13 108.918 179.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 21.2 m -79.03 110.99 14.78 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 109.072 -0.714 . . . . 74.4 109.072 171.08 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.0 p -98.28 137.41 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 CA-C-O 121.762 0.791 . . . . 74.34 110.597 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 77.6 ttt180 -103.82 117.78 35.16 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 114.485 -1.234 . . . . 73.22 108.342 175.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 33.4 pt -122.86 127.0 25.89 Favored Pre-proline 0 N--CA 1.477 0.919 0 N-CA-C 109.01 -0.737 . . . . 74.41 109.01 169.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -81.86 159.97 18.63 Favored 'Trans proline' 0 C--N 1.375 1.959 0 C-N-CA 122.909 2.406 . . . . 73.24 114.523 -167.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -68.1 114.92 3.57 Favored 'Trans proline' 0 C--N 1.381 2.289 0 C-N-CA 123.331 2.687 . . . . 41.24 110.618 174.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.621 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 133.9 49.7 0.08 OUTLIER Glycine 0 N--CA 1.469 0.844 0 N-CA-C 111.299 -0.72 . . . . 45.24 111.299 -173.712 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.671 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.4 p -125.99 165.61 23.56 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.403 0 N-CA-C 108.35 -0.981 . . . . 62.45 108.35 -176.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 51.3 mtp180 -145.69 166.7 25.07 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 124.519 1.127 . . . . 72.43 110.375 -165.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -55.49 123.89 15.43 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 124.005 0.922 . . . . 75.11 111.112 169.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.75 5.42 74.31 Favored Glycine 0 C--N 1.35 1.337 0 O-C-N 123.752 0.657 . . . . 55.15 113.601 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 31.2 t -73.45 126.01 29.23 Favored 'General case' 0 C--O 1.243 0.715 0 N-CA-C 109.828 -0.434 . . . . 72.1 109.828 -177.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.442 HG22 HD22 ' A' ' 175' ' ' LEU . 7.4 p -99.43 120.05 48.26 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 CA-C-N 114.756 -1.111 . . . . 73.41 109.911 -174.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.448 HD11 HG21 ' A' ' 153' ' ' VAL . 24.9 mt -106.95 115.53 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 124.004 0.922 . . . . 62.42 110.081 -171.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.494 ' HA ' HD23 ' A' ' 175' ' ' LEU . 69.3 ttt180 -83.53 119.1 24.28 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.504 0.722 . . . . 73.23 111.024 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.655 HG23 ' HG3' ' A' ' 164' ' ' MET . 16.6 m -124.37 104.76 31.38 Favored Pre-proline 0 CA--C 1.571 1.77 0 CA-C-O 120.764 0.316 . . . . 71.33 110.209 174.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.17 156.59 64.42 Favored 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.865 2.376 . . . . 73.41 113.7 -178.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.56 23.15 65.55 Favored Glycine 0 C--N 1.348 1.247 0 CA-C-N 115.336 -0.847 . . . . 55.42 113.808 176.472 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.655 ' HG3' HG23 ' A' ' 161' ' ' VAL . 16.4 mmt -106.81 -62.08 1.45 Allowed 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.079 0.952 . . . . 72.41 111.271 178.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -65.56 -74.48 0.5 Allowed Glycine 0 C--N 1.354 1.539 0 N-CA-C 111.591 -0.603 . . . . 40.55 111.591 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.779 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -72.67 116.41 5.69 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 111.803 -0.519 . . . . 72.32 111.803 166.635 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.3 mm-40 -88.94 158.7 17.96 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 124.258 1.023 . . . . 54.15 110.916 177.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 76.8 -123.9 6.83 Favored Glycine 0 C--N 1.342 0.907 0 CA-C-N 115.502 -0.772 . . . . 75.11 113.378 172.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -76.22 -48.9 3.25 Favored Pre-proline 0 CA--C 1.551 0.99 0 CA-C-O 117.76 -1.114 . . . . 75.41 112.006 -173.391 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -79.3 105.2 1.86 Allowed 'Trans proline' 0 C--N 1.393 2.881 0 C-N-CA 121.683 1.589 . . . . 74.14 110.809 172.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -77.57 125.09 7.36 Favored 'Trans proline' 0 C--N 1.379 2.159 0 C-N-CA 122.104 1.869 . . . . 75.21 110.653 -175.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.779 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -110.08 148.41 17.4 Favored Glycine 0 CA--C 1.503 -0.693 0 N-CA-C 111.334 -0.706 . . . . 52.12 111.334 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 -109.0 130.54 55.48 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 123.215 0.606 . . . . 75.25 109.53 -165.017 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.505 HD13 HD12 ' A' ' 119' ' ' LEU . 17.4 tp -100.6 115.12 29.42 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 107.145 -1.428 . . . . 73.22 107.145 173.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.497 ' HB2' ' HD3' ' A' ' 120' ' ' ARG . 65.0 mt -92.23 100.73 13.28 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-N 114.46 -1.246 . . . . 63.45 109.794 -179.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.414 ' HA ' ' O ' ' A' ' 121' ' ' ALA . 83.2 mt -86.63 102.49 14.23 Favored 'General case' 0 C--N 1.346 0.418 0 CA-C-N 114.773 -1.103 . . . . 73.11 110.061 176.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 47.2 t -90.0 99.4 9.4 Favored 'Isoleucine or valine' 0 C--O 1.243 0.714 0 N-CA-C 108.397 -0.964 . . . . 65.54 108.397 176.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 4.9 m -79.49 148.12 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 N-CA-C 109.493 -0.558 . . . . 75.34 109.493 -177.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 40.0 mmm-85 -126.63 99.2 5.69 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 105.85 -1.908 . . . . 72.3 105.85 -175.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.436 ' HB3' HD23 ' A' ' 127' ' ' LEU . 38.2 mt -68.65 148.34 50.58 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 122.339 0.256 . . . . 71.04 110.954 -173.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.566 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 39.1 mt -55.76 130.52 72.01 Favored Pre-proline 0 CA--C 1.552 1.04 0 CA-C-O 118.844 -0.598 . . . . 72.04 110.737 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -67.91 84.47 0.42 Allowed 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 123.279 2.653 . . . . 74.22 112.079 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 8.6 p80 -154.58 50.62 0.55 Allowed Pre-proline 0 CA--C 1.558 1.274 0 N-CA-C 107.87 -1.159 . . . . 72.12 107.87 169.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -62.69 126.42 18.21 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 122.713 2.275 . . . . 62.33 112.261 -163.525 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -137.74 -45.1 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 108.686 -0.857 . . . . 72.43 108.686 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.426 ' CD2' HD13 ' A' ' 193' ' ' LEU . 6.5 m-85 -103.82 123.61 47.42 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.932 0.893 . . . . 74.21 110.269 -177.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.601 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 92.3 mtt180 -119.15 109.18 15.58 Favored 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 124.623 1.169 . . . . 75.1 107.887 -176.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.503 HD22 ' CD2' ' A' ' 240' ' ' PHE . 62.0 tp -85.09 142.56 29.45 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 122.659 0.383 . . . . 73.3 110.378 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -142.45 115.61 8.88 Favored 'General case' 0 C--O 1.243 0.736 0 N-CA-C 107.782 -1.192 . . . . 71.4 107.782 164.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 67.46 -95.37 0.31 Allowed Glycine 0 C--N 1.346 1.139 0 CA-C-N 115.725 -0.67 . . . . 44.25 111.514 -173.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 -123.84 -23.27 4.7 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.034 0.934 . . . . 72.42 110.247 177.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -93.83 153.34 18.33 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.411 0.624 . . . . 74.11 111.038 -171.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.621 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 73.6 mt -113.36 167.08 10.87 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.198 -0.91 . . . . 54.12 112.581 -170.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . 0.601 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 97.4 m-85 -135.28 121.57 20.32 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 105.873 -1.899 . . . . 74.51 105.873 172.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' A' ' 251' ' ' LEU . . . -152.75 140.1 19.56 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 108.573 -0.899 . . . . 64.44 108.573 176.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.02 141.71 40.21 Favored 'General case' 0 C--N 1.325 -0.46 0 O-C-N 123.566 0.541 . . . . 73.4 110.128 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.548 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 57.5 tp -110.03 113.73 26.67 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.027 -0.988 . . . . 72.35 109.07 179.29 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -85.71 101.9 13.16 Favored 'General case' 0 C--O 1.24 0.566 0 N-CA-C 108.149 -1.056 . . . . 62.22 108.149 176.228 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . 0.435 HG11 HG13 ' A' ' 253' ' ' VAL . 4.3 p -116.82 127.44 26.72 Favored Pre-proline 0 CA--C 1.548 0.881 0 N-CA-C 109.332 -0.618 . . . . 63.11 109.332 -178.237 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_exo -58.71 144.71 97.71 Favored 'Trans proline' 0 C--N 1.379 2.169 0 C-N-CA 122.461 2.107 . . . . 51.24 111.948 172.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -54.49 -42.93 97.07 Favored Pre-proline 0 CA--C 1.564 1.506 0 CA-C-O 118.106 -0.949 . . . . 42.52 112.117 175.174 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_exo -46.12 -53.24 6.07 Favored 'Trans proline' 0 C--N 1.397 3.106 0 C-N-CA 122.684 2.256 . . . . 62.31 114.126 167.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . 0.472 HG22 HG21 ' A' ' 223' ' ' VAL . 12.8 mt -65.96 -37.02 78.89 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 O-C-N 123.169 0.293 . . . . 43.42 110.923 -178.111 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -63.13 -43.86 97.23 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 123.306 0.642 . . . . 43.51 111.599 -177.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 32.6 m -76.79 -37.97 28.9 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 115.951 -0.568 . . . . 55.43 111.262 -176.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.4 m -83.44 -23.87 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 N-CA-C 111.763 0.283 . . . . 43.42 111.763 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.462 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 72.19 64.05 2.77 Favored Glycine 0 C--N 1.341 0.84 0 CA-C-N 116.227 -0.442 . . . . 71.12 112.183 -172.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -94.53 -154.19 30.78 Favored Glycine 0 C--N 1.355 1.625 0 CA-C-O 121.428 0.46 . . . . 52.32 112.378 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 14.7 mmmm -121.76 128.97 52.33 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 123.781 0.832 . . . . 74.32 109.104 -174.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 39.5 t -116.18 129.98 71.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 N-CA-C 108.91 -0.774 . . . . 75.03 108.91 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -78.24 106.09 9.91 Favored 'General case' 0 CA--C 1.537 0.46 0 N-CA-C 107.861 -1.163 . . . . 75.41 107.861 168.064 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -98.83 133.42 43.15 Favored 'General case' 0 C--N 1.343 0.31 0 C-N-CA 123.822 0.849 . . . . 64.42 108.922 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -74.94 144.24 43.32 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 122.651 0.38 . . . . 71.23 110.402 173.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.41 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 7.5 t -148.27 167.43 25.16 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 124.353 1.061 . . . . 72.41 109.77 172.471 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . 0.407 HD13 ' O ' ' A' ' 127' ' ' LEU . 45.8 mt -71.58 -15.12 62.26 Favored 'General case' 0 CA--C 1.552 1.046 0 CA-C-N 115.178 -0.919 . . . . 74.21 110.796 176.363 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -80.73 -20.73 42.16 Favored 'General case' 0 CA--C 1.564 1.503 0 C-N-CA 124.747 1.219 . . . . 71.51 109.888 174.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 135.03 -151.26 20.4 Favored Glycine 0 C--N 1.361 1.932 0 CA-C-O 119.628 -0.54 . . . . 33.42 112.41 -177.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -91.84 124.54 0.78 Allowed 'Trans proline' 0 C--N 1.368 1.591 0 C-N-CA 123.33 2.687 . . . . 70.1 111.807 170.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . 0.408 HG11 ' HD3' ' A' ' 238' ' ' LYS . 22.7 m -116.98 160.71 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 C-N-CA 123.604 0.762 . . . . 51.32 110.771 179.389 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -115.28 110.39 19.35 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 109.001 -0.74 . . . . 61.44 109.001 178.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.553 HG23 HD21 ' A' ' 235' ' ' LEU . 5.9 p -97.09 138.29 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 123.37 0.668 . . . . 70.45 110.512 177.082 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -93.81 111.7 23.44 Favored 'General case' 0 C--O 1.239 0.533 0 C-N-CA 123.698 0.799 . . . . 73.21 109.009 173.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.472 HG21 HG22 ' A' ' 203' ' ' ILE . 13.8 m -86.47 140.66 34.0 Favored Pre-proline 0 CA--C 1.55 0.964 0 N-CA-C 108.91 -0.774 . . . . 43.15 108.91 177.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -62.12 143.38 94.62 Favored 'Trans proline' 0 CA--C 1.56 1.818 0 C-N-CA 122.501 2.134 . . . . 74.52 112.318 177.594 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.9 123.76 12.47 Favored 'Trans proline' 0 C--N 1.378 2.104 0 C-N-CA 122.408 2.072 . . . . 71.41 110.669 174.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 44.2 mtm105 64.07 48.88 2.87 Favored 'General case' 0 N--CA 1.475 0.824 0 O-C-N 124.233 0.958 . . . . 72.53 110.343 -173.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . 0.454 HG23 HD11 ' A' ' 255' ' ' ILE . 11.8 t -71.16 170.63 12.55 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.319 0.58 . . . . 65.21 111.103 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.9 mp0 -121.91 139.39 53.71 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.221 1.008 . . . . 73.01 108.574 -176.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -76.62 127.69 33.28 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.288 0.635 . . . . 75.41 109.94 179.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.38 -4.71 23.36 Favored Glycine 0 C--N 1.339 0.746 0 N-CA-C 111.512 -0.635 . . . . 51.44 111.512 -173.077 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . 0.428 ' O ' ' HA ' ' A' ' 252' ' ' GLU . 60.6 mtt-85 -71.51 160.1 33.32 Favored 'General case' 0 C--N 1.36 1.042 0 C-N-CA 122.917 0.487 . . . . 63.25 110.762 173.669 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.445 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 0.1 OUTLIER -123.43 100.43 6.82 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.088 0.955 . . . . 61.44 108.774 179.69 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . 0.428 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 86.3 mt -84.89 104.85 15.2 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 108.92 -0.77 . . . . 55.11 108.92 -176.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 14.6 ttp180 -82.31 101.95 10.89 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 114.784 -1.098 . . . . 74.12 110.367 -171.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.553 HD21 HG23 ' A' ' 221' ' ' VAL . 48.9 mt -89.62 101.61 14.3 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 115.131 -0.94 . . . . 64.3 108.555 171.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 47.0 mtpt -73.06 149.15 43.41 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.354 0.662 . . . . 74.13 110.574 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 67.72 28.88 73.48 Favored Glycine 0 C--N 1.345 1.05 0 O-C-N 123.369 0.418 . . . . 74.55 113.413 -178.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . 0.523 ' HG3' ' HB3' ' A' ' 235' ' ' LEU . 0.0 OUTLIER -127.55 -8.38 5.69 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 124.165 0.986 . . . . 70.24 111.145 -176.973 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . 0.434 ' HA2' ' CD1' ' A' ' 193' ' ' LEU . . . -84.71 -163.97 37.42 Favored Glycine 0 C--N 1.344 0.977 0 CA-C-N 115.919 -0.582 . . . . 63.54 113.174 176.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.621 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 1.5 m-85 -85.99 158.88 55.39 Favored Pre-proline 0 N--CA 1.48 1.053 0 N-CA-C 109.341 -0.615 . . . . 72.24 109.341 179.014 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -47.53 129.55 16.83 Favored 'Trans proline' 0 C--N 1.382 2.32 0 C-N-CA 123.077 2.518 . . . . 70.13 113.598 174.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -165.34 -162.8 17.3 Favored Glycine 0 CA--C 1.535 1.282 0 CA-C-O 118.986 -0.897 . . . . 44.32 112.203 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_exo -47.05 -41.1 26.55 Favored 'Trans proline' 0 C--N 1.377 2.06 0 C-N-CA 124.616 3.544 . . . . 71.41 115.378 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -87.47 21.0 2.63 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 123.965 0.906 . . . . 24.12 112.145 -177.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.15 -81.82 1.5 Allowed Glycine 0 C--N 1.346 1.102 0 N-CA-C 110.568 -1.013 . . . . 65.2 110.568 -173.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -113.2 135.41 53.85 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.624 -1.25 . . . . 53.43 107.624 169.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.48 -157.21 5.28 Favored Glycine 0 C--N 1.345 1.045 0 N-CA-C 115.152 0.821 . . . . 73.3 115.152 -169.165 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -111.27 164.58 12.74 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 123.155 0.582 . . . . 75.42 110.374 -175.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.621 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 20.0 tp -128.04 116.26 19.75 Favored 'General case' 0 C--O 1.218 -0.602 0 C-N-CA 124.644 1.178 . . . . 73.22 109.342 169.421 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . 0.445 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 10.6 m-85 -97.46 107.36 19.86 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 109.243 -0.651 . . . . 70.12 109.243 175.298 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.548 ' HB3' ' HB2' ' A' ' 197' ' ' LEU . 85.8 mt -86.58 115.4 24.04 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 124.004 0.922 . . . . 74.54 112.042 178.236 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.428 ' HA ' ' O ' ' A' ' 231' ' ' ARG . 36.4 tt0 -77.74 93.91 4.37 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 108.348 -0.982 . . . . 63.34 108.348 175.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.435 HG13 HG11 ' A' ' 199' ' ' VAL . 91.9 t -48.71 116.49 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 C-N-CA 124.705 1.202 . . . . 73.21 111.286 176.738 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 26.5 mmm180 -120.75 94.8 4.47 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 107.416 -1.328 . . . . 75.22 107.416 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.454 HD11 HG23 ' A' ' 227' ' ' THR . 60.3 mt -77.69 106.98 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 CA-C-N 115.379 -0.828 . . . . 74.2 109.366 -178.02 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 CA--C 1.552 1.034 0 C-N-CA 124.034 0.934 . . . . 62.33 108.942 -179.701 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.417 ' HB1' ' O ' ' A' ' 99' ' ' VAL . . . . . . . . 0 N--CA 1.477 0.878 0 N-CA-C 109.671 -0.492 . . . . 71.32 109.671 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.539 ' HB3' ' HB3' ' A' ' 136' ' ' ARG . . . -84.66 -67.08 0.82 Allowed 'General case' 0 CA--C 1.546 0.79 0 O-C-N 123.384 0.427 . . . . 71.04 110.497 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -100.69 -37.63 8.66 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 122.776 0.43 . . . . 74.22 111.289 174.673 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.417 ' O ' ' HB1' ' A' ' 96' ' ' ALA . 7.4 p -61.15 125.25 17.03 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.647 0 O-C-N 123.79 0.681 . . . . 64.52 110.946 -175.22 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -74.25 -75.92 0.15 Allowed 'General case' 0 C--N 1.346 0.427 0 N-CA-C 108.483 -0.932 . . . . 72.03 108.483 174.191 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -162.91 153.23 16.34 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 124.866 1.266 . . . . 72.41 108.416 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 8.4 p -67.74 121.03 16.13 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.916 0 CA-C-O 121.063 0.459 . . . . 45.02 109.798 172.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.574 HG21 ' HG3' ' A' ' 122' ' ' GLU . 11.4 t -96.46 -27.88 14.68 Favored 'General case' 0 CA--C 1.549 0.906 0 C-N-CA 123.699 0.799 . . . . 54.01 111.86 -174.066 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.403 ' HB2' ' HB3' ' A' ' 120' ' ' ARG . 42.3 m -149.9 173.14 14.12 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 123.935 0.894 . . . . 72.55 109.821 -177.061 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -169.96 62.48 0.18 Allowed Glycine 0 C--N 1.338 0.67 0 N-CA-C 111.057 -0.817 . . . . 74.31 111.057 177.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 32.7 t -148.72 119.52 7.57 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.272 0.629 . . . . 74.43 109.606 -174.32 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.76 75.13 2.29 Favored Glycine 0 C--N 1.348 1.239 0 O-C-N 123.439 0.462 . . . . 44.04 112.868 -177.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -83.81 167.64 44.44 Favored Glycine 0 C--N 1.342 0.894 0 N-CA-C 112.167 -0.373 . . . . 61.03 112.167 175.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 28.4 m 61.74 35.41 16.86 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 123.581 0.752 . . . . 73.43 110.683 -173.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -70.38 -33.0 68.14 Favored Glycine 0 C--N 1.351 1.379 0 CA-C-N 114.921 -1.036 . . . . 75.13 112.03 175.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 66.68 -96.71 0.31 Allowed Glycine 0 C--N 1.349 1.25 0 O-C-N 123.621 0.248 . . . . 74.32 113.653 173.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 39.3 p -70.37 -30.05 66.87 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 124.011 0.924 . . . . 43.51 111.397 -177.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -164.27 -126.02 0.8 Allowed Glycine 0 C--N 1.338 0.651 0 N-CA-C 111.015 -0.834 . . . . 54.51 111.015 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 171.96 146.64 5.4 Favored Glycine 0 C--N 1.339 0.748 0 N-CA-C 111.29 -0.724 . . . . 55.31 111.29 177.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 62.6 p -100.19 -170.28 1.85 Allowed 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 123.766 0.826 . . . . 73.45 110.817 -176.726 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -55.34 122.68 27.28 Favored Glycine 0 C--N 1.361 1.952 0 N-CA-C 110.568 -1.013 . . . . 72.21 110.568 170.257 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 40.4 ttm180 -61.72 131.22 49.21 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.011 0.524 . . . . 75.44 111.875 -167.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -77.1 152.33 35.03 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 115.228 -0.896 . . . . 44.44 111.442 -178.132 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.687 HD12 ' HA2' ' A' ' 165' ' ' GLY . 24.5 mt -94.36 155.26 17.07 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 106.681 -1.6 . . . . 70.24 106.681 159.284 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.556 ' HE ' HD12 ' A' ' 175' ' ' LEU . 29.6 ttm180 -144.47 114.66 7.47 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 109.66 -0.496 . . . . 74.43 109.66 -174.147 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -126.8 126.46 43.42 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 123.523 0.729 . . . . 54.34 110.195 -177.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.574 ' HG3' HG21 ' A' ' 103' ' ' THR . 24.4 mt-10 -92.09 136.74 32.93 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 108.505 -0.924 . . . . 72.15 108.505 169.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -145.13 147.26 33.72 Favored Pre-proline 0 N--CA 1.468 0.44 0 C-N-CA 123.191 0.596 . . . . 44.03 110.578 -170.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.86 154.48 67.3 Favored 'Trans proline' 0 C--N 1.369 1.617 0 C-N-CA 121.877 1.718 . . . . 71.53 111.646 170.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 22.2 tp -149.5 150.34 32.15 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 123.811 0.844 . . . . 64.11 109.067 174.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.584 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 69.2 m -84.59 151.98 24.16 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 123.326 0.651 . . . . 72.42 109.487 172.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.52 HD11 ' O ' ' A' ' 183' ' ' HIS . 45.1 mt -58.19 -48.05 81.53 Favored 'General case' 0 N--CA 1.483 1.194 0 CA-C-O 121.881 0.848 . . . . 74.44 110.204 176.236 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.627 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.7 mp0 -57.88 -31.79 67.06 Favored 'General case' 0 N--CA 1.484 1.259 0 CA-C-N 114.328 -1.306 . . . . 63.45 111.97 178.06 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 38.0 mm-40 -88.95 -16.69 31.17 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 112.109 0.411 . . . . 63.14 112.109 178.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.727 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -63.26 -31.65 72.85 Favored 'General case' 0 C--O 1.25 1.12 0 CA-C-O 121.168 0.508 . . . . 55.13 110.152 162.853 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.558 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 17.1 t80 -71.87 -60.37 2.27 Favored 'General case' 0 C--N 1.351 0.642 0 CA-C-N 115.326 -0.852 . . . . 74.3 110.877 168.238 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -71.89 -28.62 63.64 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 113.605 0.965 . . . . 60.2 113.605 -168.233 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 74.09 -87.46 0.68 Allowed Glycine 0 CA--C 1.532 1.123 0 N-CA-C 110.738 -0.945 . . . . 63.51 110.738 -167.628 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 84.01 126.65 1.34 Allowed Glycine 0 C--N 1.352 1.449 0 C-N-CA 122.844 0.259 . . . . 42.32 113.129 174.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.43 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.7 mp0 -78.28 114.56 17.28 Favored 'General case' 0 C--N 1.345 0.392 0 N-CA-C 108.431 -0.952 . . . . 74.2 108.431 176.509 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.539 ' HB3' ' HB3' ' A' ' 97' ' ' ALA . 7.3 mpt_? -131.36 153.38 49.7 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 123.084 0.554 . . . . 73.11 109.884 176.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 14.7 p -72.89 140.9 17.13 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.083 0 C-N-CA 123.308 0.643 . . . . 63.32 111.779 -173.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.43 HG22 HG23 ' A' ' 140' ' ' VAL . 7.9 p -136.43 124.57 35.15 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 C-N-CA 125.239 1.416 . . . . 73.12 108.553 -179.425 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -116.57 96.44 5.51 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 107.358 -1.349 . . . . 71.15 107.358 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.558 HG12 HD13 ' A' ' 119' ' ' LEU . 90.0 t -130.73 131.49 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 122.992 0.517 . . . . 73.44 109.714 -178.531 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.02 30.08 19.6 Favored 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 124.962 1.305 . . . . 64.03 112.021 -179.278 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 92.07 -1.15 73.47 Favored Glycine 0 C--N 1.344 1.025 0 CA-C-N 115.336 -0.847 . . . . 60.13 114.137 173.741 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.84 119.15 38.64 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-N 118.284 1.042 . . . . 64.42 110.691 -179.312 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 63.2 ttp85 -92.66 106.66 18.6 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.139 0.975 . . . . 73.42 108.489 172.076 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 61.7 t -133.5 149.77 31.45 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 108.238 -1.023 . . . . 74.31 108.238 178.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 34.9 p -81.02 120.97 25.47 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 109.132 -0.692 . . . . 73.31 109.132 172.597 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.4 p -96.83 131.12 44.37 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 CA-C-O 121.19 0.519 . . . . 61.43 110.647 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . 0.43 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 40.6 ttp180 -104.28 102.06 11.76 Favored 'General case' 0 C--O 1.238 0.487 0 N-CA-C 107.746 -1.205 . . . . 74.52 107.746 175.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.63 ' HB ' HD13 ' A' ' 159' ' ' ILE . 30.8 pt -91.96 130.82 37.07 Favored Pre-proline 0 CA--C 1.549 0.941 0 N-CA-C 108.965 -0.754 . . . . 73.33 108.965 176.226 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -63.63 135.99 51.82 Favored 'Trans proline' 0 C--N 1.383 2.37 0 C-N-CA 122.88 2.387 . . . . 73.34 112.847 -171.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_exo -54.49 141.59 72.88 Favored 'Trans proline' 0 C--N 1.379 2.159 0 C-N-CA 123.427 2.751 . . . . 71.33 112.381 169.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 104.18 24.66 7.45 Favored Glycine 0 C--N 1.338 0.675 0 N-CA-C 111.645 -0.582 . . . . 70.41 111.645 -176.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.727 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.4 p -95.06 158.74 2.93 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.917 0 N-CA-C 108.504 -0.924 . . . . 54.4 108.504 -177.268 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.484 ' HA ' HD11 ' A' ' 180' ' ' LEU . 27.0 mtm180 -149.62 176.15 10.91 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 124.426 1.09 . . . . 74.52 110.135 -170.621 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -52.93 124.86 15.3 Favored 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 124.017 0.927 . . . . 62.52 111.744 173.148 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 74.85 10.03 83.44 Favored Glycine 0 C--N 1.347 1.182 0 O-C-N 123.534 0.521 . . . . 72.54 113.809 177.36 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.419 ' HB3' HG23 ' A' ' 153' ' ' VAL . 33.0 t -76.97 122.35 24.77 Favored 'General case' 0 C--O 1.246 0.879 0 N-CA-C 109.391 -0.596 . . . . 74.33 109.391 179.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.476 HG22 HD22 ' A' ' 175' ' ' LEU . 7.1 p -94.14 121.88 45.14 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.964 0 C-N-CA 123.77 0.828 . . . . 71.52 109.689 -179.335 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.63 HD13 ' HB ' ' A' ' 149' ' ' ILE . 46.3 mt -110.52 118.16 56.51 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 124.273 1.029 . . . . 72.34 109.999 -172.475 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 60.0 ttp85 -95.78 109.96 22.19 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 122.863 0.465 . . . . 74.31 110.408 -178.169 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 10.7 m -109.48 101.57 46.44 Favored Pre-proline 0 CA--C 1.569 1.7 0 C-N-CA 122.933 0.493 . . . . 62.34 110.125 -178.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . 0.45 ' HA ' ' HB3' ' A' ' 173' ' ' ASP . 33.2 Cg_exo -64.1 147.61 91.48 Favored 'Trans proline' 0 C--N 1.384 2.403 0 C-N-CA 123.554 2.836 . . . . 45.21 114.314 -172.675 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 83.18 5.08 89.36 Favored Glycine 0 C--N 1.348 1.249 0 CA-C-N 115.058 -0.974 . . . . 64.21 114.447 175.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 46.9 tpp -96.43 -36.14 10.92 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.092 0.557 . . . . 73.52 110.95 -177.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . 0.687 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . -83.45 -105.96 0.52 Allowed Glycine 0 C--N 1.349 1.26 0 CA-C-N 115.635 -0.711 . . . . 53.25 114.3 -175.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.483 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -64.67 93.99 0.16 Allowed Glycine 0 C--N 1.348 1.247 0 C-N-CA 123.351 0.501 . . . . 40.51 113.125 179.24 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 10.5 mm-40 -67.79 117.28 9.47 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 123.662 0.785 . . . . 72.34 110.173 178.014 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 165.11 -172.06 40.64 Favored Glycine 0 C--N 1.34 0.773 0 O-C-N 123.601 0.563 . . . . 72.24 112.983 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -61.5 -40.4 70.84 Favored Pre-proline 0 CA--C 1.56 1.343 0 C-N-CA 123.739 0.816 . . . . 75.13 111.867 174.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -82.01 104.52 1.41 Allowed 'Trans proline' 0 C--N 1.393 2.918 0 C-N-CA 122.064 1.843 . . . . 73.03 109.73 162.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -71.74 125.29 10.95 Favored 'Trans proline' 0 C--N 1.379 2.172 0 C-N-CA 121.937 1.758 . . . . 61.01 111.77 -174.448 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.483 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -101.09 160.42 18.6 Favored Glycine 0 C--N 1.34 0.763 0 N-CA-C 111.075 -0.81 . . . . 62.35 111.075 176.837 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.45 ' HB3' ' HA ' ' A' ' 162' ' ' PRO . 0.9 OUTLIER -124.94 179.59 4.96 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 123.696 0.798 . . . . 74.25 110.966 -167.021 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . . . . . . . . . 21.2 tp -127.74 118.91 24.66 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.146 0.578 . . . . 75.24 109.686 175.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.556 HD12 ' HE ' ' A' ' 120' ' ' ARG . 86.0 mt -86.19 99.32 11.45 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 124.608 1.163 . . . . 63.12 110.391 177.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 76.5 mt -89.82 102.61 15.31 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.704 0.802 . . . . 64.2 110.576 174.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.453 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 29.3 t -90.9 102.79 13.79 Favored 'Isoleucine or valine' 0 C--O 1.244 0.777 0 N-CA-C 108.313 -0.995 . . . . 63.02 108.313 175.597 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 5.5 m -79.75 150.47 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 CA-C-O 121.65 0.738 . . . . 74.22 111.479 -173.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 19.6 mmt85 -122.26 98.47 5.95 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 114.482 -1.235 . . . . 73.24 107.811 -178.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.484 HD11 ' HA ' ' A' ' 154' ' ' ARG . 21.5 mt -68.34 151.49 46.81 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.207 0.603 . . . . 63.31 112.443 -177.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.584 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 60.6 mt -53.69 138.58 51.95 Favored Pre-proline 0 CA--C 1.559 1.322 0 O-C-N 124.091 0.869 . . . . 74.0 111.324 -179.304 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -57.32 -13.08 11.94 Favored 'Trans proline' 0 C--N 1.383 2.375 0 C-N-CA 124.239 3.293 . . . . 74.12 115.584 -173.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.52 ' O ' HD11 ' A' ' 127' ' ' LEU . 1.0 OUTLIER -87.52 114.33 58.3 Favored Pre-proline 0 CA--C 1.548 0.889 0 N-CA-C 108.708 -0.849 . . . . 75.14 108.708 173.247 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -92.62 126.67 0.75 Allowed 'Trans proline' 0 C--N 1.377 2.066 0 C-N-CA 122.568 2.179 . . . . 74.01 112.287 173.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.9 p -127.29 -41.8 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 N-CA-C 109.565 -0.531 . . . . 53.14 109.565 174.302 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.454 ' HE2' HD13 ' A' ' 193' ' ' LEU . 6.5 m-85 -107.52 125.2 50.98 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 115.896 -0.593 . . . . 74.31 110.691 -178.074 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.578 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 6.2 mpt_? -112.38 103.97 12.11 Favored 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 107.237 -1.394 . . . . 51.53 107.237 175.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 42.1 tp -92.72 136.51 33.17 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.115 0.566 . . . . 71.14 109.8 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -143.68 134.05 24.64 Favored 'General case' 0 C--O 1.241 0.657 0 N-CA-C 109.225 -0.657 . . . . 75.35 109.225 165.586 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 68.28 -81.88 0.2 Allowed Glycine 0 C--N 1.352 1.426 0 O-C-N 123.913 0.758 . . . . 71.22 113.087 -178.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 24.1 pt20 -144.34 -17.57 0.56 Allowed 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 123.645 0.778 . . . . 50.44 110.755 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -109.86 158.27 18.35 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-O 121.269 0.557 . . . . 70.53 111.683 -170.049 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.468 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 77.4 mt -111.34 163.38 14.04 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.005 1.322 . . . . 73.31 111.779 -168.67 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . 0.578 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 82.5 m-85 -139.52 124.16 18.37 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 114.563 -1.199 . . . . 63.14 108.516 170.032 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . 0.425 ' HB3' HD11 ' A' ' 249' ' ' LEU . . . -135.84 171.43 14.47 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 122.836 0.454 . . . . 44.55 110.157 175.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 7.8 m -102.48 134.42 45.84 Favored 'General case' 0 CA--C 1.544 0.712 0 N-CA-C 109.389 -0.597 . . . . 71.31 109.389 178.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.603 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 42.7 tp -109.98 114.09 27.34 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.382 1.073 . . . . 60.52 110.133 -177.384 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -94.11 103.71 15.75 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.414 0.686 . . . . 74.01 109.746 177.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . 0.63 HG12 HG11 ' A' ' 210' ' ' VAL . 3.5 m -113.2 142.44 27.42 Favored Pre-proline 0 N--CA 1.479 1.012 0 C-N-CA 122.981 0.513 . . . . 73.12 109.668 176.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -68.96 155.49 68.33 Favored 'Trans proline' 0 C--N 1.365 1.439 0 C-N-CA 122.33 2.02 . . . . 74.11 111.38 167.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . 0.407 ' N ' ' HD2' ' A' ' 202' ' ' PRO . . . -60.04 -45.85 98.02 Favored Pre-proline 0 N--CA 1.479 0.979 0 CA-C-O 118.737 -0.649 . . . . 73.21 112.215 177.518 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . 0.463 ' O ' HG22 ' A' ' 206' ' ' VAL . 9.8 Cg_endo -49.77 -45.76 30.49 Favored 'Trans proline' 0 C--N 1.391 2.781 0 C-N-CA 122.568 2.179 . . . . 12.33 113.348 171.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . 0.484 ' HA ' ' HA3' ' A' ' 207' ' ' GLY . 3.5 mt -67.64 -43.94 86.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 O-C-N 121.967 -0.458 . . . . 72.51 111.569 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -52.51 -43.96 65.42 Favored 'General case' 0 CA--C 1.538 0.489 0 O-C-N 124.446 1.091 . . . . 51.21 111.177 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . 0.621 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 28.8 m -88.91 -58.46 3.46 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.262 0 N-CA-C 113.015 0.746 . . . . 64.34 113.015 -176.555 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.533 HG13 HG23 ' A' ' 205' ' ' VAL . 18.6 m -104.43 -25.28 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 113.328 0.862 . . . . 70.55 113.328 -172.124 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.484 ' HA3' ' HA ' ' A' ' 203' ' ' ILE . . . -74.96 -70.82 1.21 Allowed Glycine 0 C--N 1.346 1.123 0 C-N-CA 121.565 -0.35 . . . . 62.21 112.289 -168.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 92.15 -2.06 74.6 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-O 119.2 -0.778 . . . . 74.34 114.131 170.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 40.8 mtmt -139.33 138.93 37.09 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 108.352 -0.981 . . . . 73.1 108.352 178.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . 0.63 HG11 HG12 ' A' ' 199' ' ' VAL . 7.3 p -160.58 145.98 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 C-N-CA 123.897 0.879 . . . . 72.43 108.71 -178.771 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . 0.456 ' HA ' ' HA ' ' A' ' 220' ' ' GLU . 69.0 mtt180 -93.56 123.88 37.17 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 122.759 0.424 . . . . 74.24 109.951 177.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.477 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -101.18 165.02 11.51 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 124.237 1.015 . . . . 50.51 109.146 173.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 66.2 mmm -103.34 146.75 28.0 Favored 'General case' 0 C--O 1.239 0.551 0 CA-C-O 121.162 0.506 . . . . 73.2 110.419 175.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.433 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.3 t -138.6 169.08 18.43 Favored 'General case' 0 C--O 1.238 0.467 0 CA-C-N 114.726 -1.125 . . . . 64.23 109.709 173.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . 0.627 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 81.9 mt -70.92 -3.3 18.53 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 114.844 -1.071 . . . . 54.41 113.223 -174.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 1.8 pp20? -121.0 -1.45 9.85 Favored 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.274 0.629 . . . . 73.1 112.52 178.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.16 -158.51 27.71 Favored Glycine 0 N--CA 1.475 1.278 0 CA-C-O 119.719 -0.489 . . . . 44.25 113.443 176.043 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -90.76 129.47 1.43 Allowed 'Trans proline' 0 C--N 1.367 1.52 0 C-N-CA 123.223 2.616 . . . . 62.22 112.412 174.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 31.5 m -109.66 151.43 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 C-N-CA 123.819 0.848 . . . . 71.31 109.434 171.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 211' ' ' ARG . 32.9 tt0 -114.58 114.62 25.97 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.647 -0.501 . . . . 64.32 109.647 173.055 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.466 HG23 HD21 ' A' ' 235' ' ' LEU . 4.5 p -100.56 144.32 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 C-N-CA 124.703 1.201 . . . . 61.21 110.744 178.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -95.96 113.02 24.6 Favored 'General case' 0 C--O 1.24 0.561 0 N-CA-C 109.159 -0.682 . . . . 73.34 109.159 173.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.53 HG11 HG11 ' A' ' 199' ' ' VAL . 14.1 m -84.53 138.6 38.4 Favored Pre-proline 0 N--CA 1.481 1.097 0 N-CA-C 108.86 -0.792 . . . . 74.33 108.86 176.36 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -54.3 140.68 72.51 Favored 'Trans proline' 0 C--N 1.379 2.136 0 C-N-CA 122.625 2.217 . . . . 72.53 112.622 177.283 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -54.17 112.74 1.07 Allowed 'Trans proline' 0 C--N 1.379 2.181 0 C-N-CA 122.881 2.388 . . . . 75.13 111.282 174.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . 0.621 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 60.6 mtp180 63.27 58.43 1.4 Allowed 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 124.531 1.133 . . . . 74.52 110.634 -171.164 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.8 t -71.15 171.82 10.31 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.334 -0.848 . . . . 65.44 110.431 175.22 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.5 mp0 -121.18 146.35 46.87 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.711 0.804 . . . . 73.34 109.225 -175.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -72.52 113.73 9.87 Favored 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 123.218 0.607 . . . . 65.22 110.292 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.6 4.88 19.23 Favored Glycine 0 C--N 1.339 0.712 0 CA-C-N 115.73 -0.668 . . . . 72.21 112.399 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 61.3 mtp180 -76.17 153.25 36.32 Favored 'General case' 0 N--CA 1.477 0.918 0 CA-C-N 117.345 0.573 . . . . 73.44 109.962 172.092 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 0.2 OUTLIER -111.71 119.27 38.08 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 123.727 0.811 . . . . 60.34 108.934 -179.746 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 70.2 mt -106.02 114.49 28.66 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 122.85 0.46 . . . . 74.03 109.827 -178.022 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . 0.589 ' HG3' ' HB3' ' A' ' 248' ' ' ASP . 39.7 ttp180 -82.48 104.22 12.61 Favored 'General case' 0 CA--C 1.547 0.851 0 C-N-CA 124.863 1.265 . . . . 74.41 111.354 -171.23 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.498 ' HB2' ' HB3' ' A' ' 249' ' ' LEU . 38.2 mt -89.48 97.63 11.3 Favored 'General case' 0 C--O 1.239 0.531 0 C-N-CA 123.231 0.612 . . . . 71.04 109.594 172.618 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 5.9 mtpm? -72.81 134.95 45.12 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 114.766 -1.106 . . . . 63.53 110.119 -178.323 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 85.26 24.65 43.02 Favored Glycine 0 C--N 1.34 0.77 0 O-C-N 123.493 0.496 . . . . 73.15 113.247 178.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -124.52 -6.88 7.5 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 123.223 0.609 . . . . 75.43 112.353 176.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -85.32 -161.67 34.74 Favored Glycine 0 C--N 1.345 1.082 0 O-C-N 123.53 0.518 . . . . 34.53 112.506 175.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.558 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 92.2 m-85 -97.24 147.0 32.32 Favored Pre-proline 0 N--CA 1.481 1.082 0 C-N-CA 123.524 0.729 . . . . 75.25 111.282 175.434 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.43 132.52 33.75 Favored 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 122.257 1.971 . . . . 64.42 111.315 171.452 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -156.83 -148.64 5.15 Favored Glycine 0 CA--C 1.532 1.152 0 CA-C-O 119.01 -0.883 . . . . 71.32 111.595 -176.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -51.63 -53.96 6.15 Favored 'Trans proline' 0 C--N 1.377 2.055 0 C-N-CA 123.953 3.102 . . . . 63.44 114.999 -177.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -83.67 -24.46 31.32 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 122.608 0.363 . . . . 72.2 111.778 -177.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 141.86 -155.4 25.4 Favored Glycine 0 N--CA 1.47 0.92 0 N-CA-C 110.091 -1.204 . . . . 32.25 110.091 -177.088 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 22.1 ttm180 -65.13 134.73 54.39 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 118.511 1.155 . . . . 73.13 109.351 171.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -75.05 -170.85 27.49 Favored Glycine 0 C--O 1.249 1.052 0 CA-C-O 121.974 0.763 . . . . 60.43 114.686 -170.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . 0.589 ' HB3' ' HG3' ' A' ' 234' ' ' ARG . 12.1 m-20 -129.33 136.9 50.61 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 114.268 -0.966 . . . . 74.42 109.565 -169.555 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.498 ' HB3' ' HB2' ' A' ' 235' ' ' LEU . 20.7 tp -97.01 111.74 23.82 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.889 -0.411 . . . . 74.13 109.889 179.559 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -91.85 106.63 18.61 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.222 0.534 . . . . 74.12 109.813 177.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.603 ' HB3' ' HB2' ' A' ' 197' ' ' LEU . 85.9 mt -87.53 120.01 28.41 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 124.245 1.018 . . . . 62.4 112.379 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -80.61 93.86 6.2 Favored 'General case' 0 CA--C 1.539 0.535 0 N-CA-C 108.093 -1.077 . . . . 65.41 108.093 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.402 HG22 HD23 ' A' ' 197' ' ' LEU . 60.3 t -48.96 123.68 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.561 1.144 . . . . 65.03 111.184 175.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 38.5 mmm-85 -128.69 100.94 5.92 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 107.219 -1.4 . . . . 70.12 107.219 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 56.5 mt -83.34 117.84 29.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 115.149 -0.932 . . . . 63.5 110.05 -177.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.8 t . . . . . 0 CA--C 1.556 1.187 0 C-N-CA 124.23 1.012 . . . . 65.23 108.603 174.53 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 109.968 -0.382 . . . . 64.54 109.968 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -177.48 -68.85 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.944 0 C-N-CA 124.839 1.255 . . . . 71.33 107.971 176.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.667 HD22 ' HG3' ' A' ' 136' ' ' ARG . 20.4 tp -92.46 -55.14 3.51 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 115.488 -0.778 . . . . 53.02 110.236 -176.797 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.583 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 10.0 p -60.76 126.79 19.26 Favored 'Isoleucine or valine' 0 C--N 1.36 1.063 0 O-C-N 123.465 0.478 . . . . 72.3 111.025 175.579 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -83.31 -65.9 0.95 Allowed 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.493 -0.776 . . . . 62.42 109.699 -179.104 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -150.13 147.45 27.77 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 114.987 -1.006 . . . . 74.1 110.258 -169.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 92.9 t -78.81 124.59 37.4 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 N-CA-C 109.259 -0.645 . . . . 74.31 109.259 169.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 70.1 p -76.53 93.4 3.55 Favored 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 123.359 0.664 . . . . 64.31 109.471 176.042 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.7 m -72.72 86.15 1.22 Allowed 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 123.52 0.728 . . . . 63.02 109.226 178.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -154.56 120.3 1.01 Allowed Glycine 0 C--N 1.34 0.788 0 CA-C-N 115.027 -0.988 . . . . 62.34 110.779 -177.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 39.8 t -73.04 161.69 30.36 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 123.609 0.763 . . . . 74.43 111.994 -174.173 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -122.23 57.14 0.63 Allowed Glycine 0 C--N 1.338 0.691 0 CA-C-N 114.888 -1.051 . . . . 72.52 110.647 175.337 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -68.39 -21.86 74.47 Favored Glycine 0 C--N 1.354 1.578 0 O-C-N 124.02 0.482 . . . . 74.44 113.791 -179.076 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 19.4 m -63.09 90.79 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.024 0 C-N-CA 123.796 0.839 . . . . 65.2 110.551 177.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 158.04 -42.33 0.51 Allowed Glycine 0 C--N 1.338 0.659 0 CA-C-N 115.483 -0.78 . . . . 45.33 111.23 -175.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 85.47 -48.92 4.1 Favored Glycine 0 C--N 1.354 1.571 0 C-N-CA 122.78 0.229 . . . . 72.11 112.543 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 36.7 m -71.19 108.2 4.58 Favored 'General case' 0 CA--C 1.553 1.089 0 C-N-CA 124.006 0.923 . . . . 75.2 110.407 177.209 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -140.65 178.78 19.77 Favored Glycine 0 C--N 1.343 0.925 0 N-CA-C 111.417 -0.673 . . . . 52.41 111.417 176.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -133.39 -173.02 13.12 Favored Glycine 0 C--N 1.346 1.109 0 CA-C-N 117.235 0.518 . . . . 43.21 113.432 -178.332 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 15.9 m -65.1 -56.18 14.48 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 124.22 1.008 . . . . 72.11 111.162 -178.683 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -83.14 117.59 4.45 Favored Glycine 0 C--N 1.344 1.01 0 N-CA-C 111.588 -0.605 . . . . 73.11 111.588 176.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 27.7 ptt180 -73.29 154.39 40.17 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 123.452 0.701 . . . . 73.21 112.337 -177.065 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.682 ' HB2' ' HB2' ' A' ' 167' ' ' GLN . 16.2 t70 -72.27 133.61 45.14 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 108.591 -0.892 . . . . 74.5 108.591 170.119 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 28.6 tp -101.61 142.07 33.53 Favored 'General case' 0 C--O 1.22 -0.453 0 N-CA-C 107.356 -1.35 . . . . 72.33 107.356 -178.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 37.3 ttp-105 -143.28 132.93 23.73 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 108.513 -0.921 . . . . 71.54 108.513 -178.091 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -144.75 138.41 27.16 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 123.953 0.901 . . . . 73.22 109.052 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -103.26 148.98 25.15 Favored 'General case' 0 C--O 1.252 1.191 0 CA-C-O 120.935 0.398 . . . . 72.15 110.101 176.344 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.583 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.6 pt? -146.95 130.93 8.44 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.674 -0.694 . . . . 73.24 111.967 -170.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -67.97 120.64 7.63 Favored 'Trans proline' 0 C--N 1.378 2.084 0 C-N-CA 122.49 2.127 . . . . 72.25 111.477 174.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 18.0 tp -120.42 152.79 37.45 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.542 1.137 . . . . 64.45 109.165 179.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.474 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 22.4 m -86.25 155.41 20.7 Favored 'General case' 0 CA--C 1.551 0.993 0 N-CA-C 109.365 -0.606 . . . . 54.21 109.365 172.009 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.433 HD11 ' O ' ' A' ' 183' ' ' HIS . 28.6 mt -55.34 -49.23 72.76 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-O 121.923 0.868 . . . . 70.24 109.934 175.113 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.607 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.3 mp0 -55.96 -35.44 66.69 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 113.943 -1.48 . . . . 64.35 111.544 177.665 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.474 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 35.7 mm-40 -83.11 -19.57 36.5 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 122.993 0.517 . . . . 73.33 112.077 -179.474 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.59 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -65.27 -31.66 72.92 Favored 'General case' 0 C--O 1.246 0.919 0 CA-C-O 121.169 0.509 . . . . 72.44 110.162 165.502 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.443 ' HA ' ' CE1' ' A' ' 240' ' ' PHE . 6.6 t80 -77.28 -47.36 20.29 Favored 'General case' 0 CA--C 1.546 0.789 0 CA-C-N 115.366 -0.834 . . . . 71.51 112.279 170.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -76.75 -30.19 56.46 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 112.54 0.57 . . . . 75.43 112.54 -171.224 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 67.92 -107.08 1.91 Allowed Glycine 0 CA--C 1.533 1.218 0 N-CA-C 111.564 -0.614 . . . . 4.34 111.564 -173.31 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.33 162.43 36.39 Favored Glycine 0 C--N 1.353 1.496 0 N-CA-C 114.904 0.722 . . . . 63.14 114.904 168.621 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.457 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 1.6 mp0 -96.03 114.17 25.86 Favored 'General case' 0 C--N 1.357 0.917 0 N-CA-C 108.856 -0.794 . . . . 75.21 108.856 179.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.667 ' HG3' HD22 ' A' ' 98' ' ' LEU . 4.6 mmp_? -130.37 139.25 50.66 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.836 0.854 . . . . 51.34 109.372 -174.78 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 17.9 m -74.55 128.23 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 CA-C-O 121.638 0.732 . . . . 75.4 111.614 -172.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.439 HG13 HG11 ' A' ' 99' ' ' VAL . 21.7 t -119.87 129.65 75.16 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 C-N-CA 125.292 1.437 . . . . 75.22 109.168 -177.531 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -121.8 97.74 5.63 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 108.746 -0.835 . . . . 73.32 108.746 177.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.461 HG21 HD22 ' A' ' 174' ' ' LEU . 27.9 m -137.82 142.87 35.02 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.885 0 C-N-CA 125.09 1.356 . . . . 72.04 108.336 -177.304 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 65.55 19.2 11.47 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 124.081 0.953 . . . . 72.01 112.665 176.48 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 75.08 22.87 75.82 Favored Glycine 0 C--N 1.352 1.463 0 CA-C-N 116.393 -0.367 . . . . 64.3 112.359 -174.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 29.2 mmt180 -120.79 135.65 55.1 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.366 1.067 . . . . 75.31 108.861 -178.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 41.1 ttt180 -111.41 106.24 15.09 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.005 -0.739 . . . . 74.22 109.005 175.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 29.2 t -132.59 126.89 55.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 N-CA-C 108.461 -0.94 . . . . 64.14 108.461 -178.33 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 72.6 p -71.53 122.87 21.24 Favored 'General case' 0 CA--C 1.54 0.592 0 N-CA-C 109.084 -0.71 . . . . 55.21 109.084 171.651 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 7.3 p -96.79 140.72 16.84 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 109.769 -0.456 . . . . 73.33 109.769 -177.742 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 54.9 ttp180 -109.35 99.96 9.13 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 107.395 -1.335 . . . . 70.13 107.395 171.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.522 ' HB ' HD13 ' A' ' 159' ' ' ILE . 35.8 pt -89.27 127.53 54.8 Favored Pre-proline 0 CA--C 1.55 0.953 0 N-CA-C 108.467 -0.938 . . . . 72.23 108.467 175.128 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.09 135.86 33.2 Favored 'Trans proline' 0 C--N 1.376 2.008 0 C-N-CA 122.477 2.118 . . . . 42.25 113.061 -173.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_exo -46.25 119.92 3.37 Favored 'Trans proline' 0 C--N 1.376 2.012 0 C-N-CA 123.937 3.091 . . . . 73.45 112.75 167.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 123.48 58.17 0.19 Allowed Glycine 0 N--CA 1.465 0.625 0 N-CA-C 110.635 -0.986 . . . . 74.5 110.635 -175.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.59 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.0 p -134.17 161.48 40.7 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.319 0 C-N-CA 123.698 0.799 . . . . 73.11 109.397 -178.162 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 14.5 mtp180 -141.35 170.94 14.78 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 126.05 1.74 . . . . 71.02 109.747 -169.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.9 tp10 -55.24 126.54 25.33 Favored 'General case' 0 CA--C 1.551 1.015 0 CA-C-N 116.027 -0.533 . . . . 71.35 110.695 164.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.38 2.7 74.97 Favored Glycine 0 C--N 1.346 1.126 0 CA-C-O 119.781 -0.455 . . . . 60.13 113.891 179.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 42.1 t -77.76 130.96 37.39 Favored 'General case' 0 C--O 1.247 0.932 0 N-CA-C 109.677 -0.49 . . . . 61.25 109.677 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.488 HG12 HD22 ' A' ' 175' ' ' LEU . 15.3 t -106.78 121.52 59.62 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 CA-C-N 114.743 -1.117 . . . . 75.02 109.275 -168.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.528 HD11 HG21 ' A' ' 153' ' ' VAL . 23.6 mt -109.73 113.93 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 123.65 0.78 . . . . 74.55 110.686 -171.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 48.6 ttm-85 -83.19 119.42 24.52 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.22 0.608 . . . . 71.01 110.119 177.036 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 173' ' ' ASP . 5.1 m -123.94 132.14 24.28 Favored Pre-proline 0 N--CA 1.481 1.106 0 C-N-CA 123.138 0.575 . . . . 65.34 109.822 -178.362 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.92 157.26 43.22 Favored 'Trans proline' 0 C--N 1.374 1.899 0 C-N-CA 122.54 2.16 . . . . 73.34 113.889 -175.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 78.52 24.14 63.56 Favored Glycine 0 C--N 1.35 1.31 0 CA-C-N 115.128 -0.942 . . . . 45.21 115.389 171.564 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.4 ' SD ' HD23 ' A' ' 174' ' ' LEU . 62.3 mtt -124.66 -61.09 1.34 Allowed 'General case' 0 N--CA 1.493 1.708 0 CA-C-N 119.075 1.437 . . . . 53.31 112.919 -179.137 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -86.43 -115.88 0.95 Allowed Glycine 0 N--CA 1.481 1.693 0 C-N-CA 121.699 -0.286 . . . . 75.12 113.605 -176.223 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -154.08 -58.73 0.01 OUTLIER Glycine 0 C--N 1.35 1.306 0 CA-C-O 119.749 -0.473 . . . . 72.33 112.412 174.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.682 ' HB2' ' HB2' ' A' ' 118' ' ' ASP . 13.1 mm-40 -72.42 150.68 43.14 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 112.047 0.388 . . . . 72.15 112.047 -177.043 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 148.2 -153.33 25.2 Favored Glycine 0 C--N 1.348 1.214 0 CA-C-N 114.854 -1.066 . . . . 73.31 111.461 177.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -88.15 -45.82 0.47 Allowed Pre-proline 0 CA--C 1.562 1.44 0 CA-C-O 118.858 -0.591 . . . . 74.22 110.098 172.465 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -90.54 165.87 4.24 Favored 'Trans proline' 0 C--N 1.386 2.51 0 C-N-CA 122.155 1.903 . . . . 70.33 112.014 165.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -68.28 126.33 14.16 Favored 'Trans proline' 0 C--N 1.373 1.858 0 C-N-CA 122.067 1.845 . . . . 70.11 111.031 170.048 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . 85.11 109.28 0.67 Allowed Glycine 0 C--O 1.22 -0.757 0 CA-C-O 119.22 -0.767 . . . . 72.21 112.762 178.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.509 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 47.3 m-20 -144.98 134.52 23.24 Favored 'General case' 0 N--CA 1.481 1.119 0 CA-C-N 117.899 0.849 . . . . 72.52 111.489 172.398 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.461 HD22 HG21 ' A' ' 140' ' ' VAL . 28.1 tp -112.16 126.6 55.38 Favored 'General case' 0 C--N 1.347 0.477 0 N-CA-C 108.459 -0.941 . . . . 70.51 108.459 171.082 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.488 HD22 HG12 ' A' ' 158' ' ' VAL . 29.9 mt -93.99 100.73 12.82 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.539 1.135 . . . . 73.52 110.163 176.661 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 62.9 mt -87.11 104.45 16.36 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 123.532 0.733 . . . . 74.13 111.272 176.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 23.4 t -90.08 100.3 10.77 Favored 'Isoleucine or valine' 0 C--O 1.243 0.748 0 N-CA-C 108.101 -1.074 . . . . 65.21 108.101 175.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 3.2 m -78.25 149.88 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-O 121.624 0.726 . . . . 74.11 111.32 -174.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 33.0 mmt180 -119.22 95.29 4.74 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.497 -1.229 . . . . 73.54 107.963 -177.321 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 39.6 mt -67.99 147.91 51.77 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 110.192 -0.299 . . . . 55.33 110.192 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.402 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 47.5 mt -54.2 146.83 29.15 Favored Pre-proline 0 CA--C 1.562 1.415 0 C-N-CA 124.111 0.964 . . . . 73.33 111.417 -174.33 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -61.51 77.11 0.09 OUTLIER 'Trans proline' 0 C--N 1.379 2.173 0 C-N-CA 123.176 2.584 . . . . 73.03 111.447 171.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.433 ' O ' HD11 ' A' ' 127' ' ' LEU . 8.2 t60 170.78 87.69 0.04 OUTLIER Pre-proline 0 CA--C 1.547 0.859 0 C-N-CA 126.242 1.817 . . . . 70.13 107.287 -166.671 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -98.76 125.27 0.17 Allowed 'Trans proline' 0 CA--C 1.564 1.994 0 C-N-CA 123.316 2.678 . . . . 74.43 113.188 172.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -122.64 -42.0 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.632 -0.668 . . . . 71.43 109.413 174.146 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 4.7 m-85 -98.08 128.36 44.56 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.19 -0.914 . . . . 71.45 110.304 -178.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 10.4 mtt180 -112.63 103.98 12.04 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 106.218 -1.771 . . . . 72.41 106.218 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.428 HD12 ' O ' ' A' ' 192' ' ' ASP . 42.7 tp -81.44 110.84 17.24 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-O 121.259 0.552 . . . . 74.22 109.576 176.585 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -99.11 99.49 10.5 Favored 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 106.393 -1.706 . . . . 61.24 106.393 171.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 62.7 -94.9 0.11 Allowed Glycine 0 C--N 1.349 1.294 0 O-C-N 124.018 0.823 . . . . 65.4 113.352 179.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . 0.542 HE22 ' HB3' ' A' ' 244' ' ' ALA . 8.7 pt20 -108.46 -19.2 13.53 Favored 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 123.742 0.817 . . . . 51.23 110.849 178.042 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.428 ' O ' HD12 ' A' ' 188' ' ' LEU . 29.0 m-20 -97.0 155.03 16.95 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 123.876 0.87 . . . . 72.1 111.63 -172.541 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.455 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 82.6 mt -109.53 154.33 22.86 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 124.206 1.003 . . . . 74.45 109.484 -177.55 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -137.17 121.83 18.55 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 107.502 -1.296 . . . . 74.25 107.502 171.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -134.03 141.51 47.24 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 108.632 -0.877 . . . . 53.11 108.632 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 3.5 m -82.3 122.46 27.98 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 109.747 -0.464 . . . . 65.12 109.747 -178.706 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.446 HD13 ' HB2' ' A' ' 212' ' ' ALA . 57.2 tp -107.75 112.2 24.76 Favored 'General case' 0 C--O 1.216 -0.69 0 C-N-CA 124.335 1.054 . . . . 64.52 109.116 -178.706 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -93.52 108.23 19.96 Favored 'General case' 0 N--CA 1.474 0.755 0 CA-C-O 121.338 0.59 . . . . 72.22 109.617 177.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . 0.48 HG22 HG21 ' A' ' 210' ' ' VAL . 65.2 t -101.37 126.0 35.93 Favored Pre-proline 0 N--CA 1.474 0.74 0 C-N-CA 124.148 0.979 . . . . 61.43 109.344 -176.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_exo -57.18 139.29 89.59 Favored 'Trans proline' 0 C--N 1.369 1.622 0 C-N-CA 122.624 2.216 . . . . 62.21 111.503 171.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -55.31 -41.83 92.79 Favored Pre-proline 0 N--CA 1.482 1.136 0 N-CA-C 113.673 0.99 . . . . 74.32 113.673 179.76 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo -47.58 -52.91 7.25 Favored 'Trans proline' 0 C--N 1.386 2.519 0 C-N-CA 122.166 1.911 . . . . 73.15 113.621 168.013 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . 0.53 HG21 HG13 ' A' ' 210' ' ' VAL . 9.3 mt -67.73 -33.33 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 C-N-CA 123.035 0.534 . . . . 64.34 111.689 -179.502 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -68.39 -42.24 79.34 Favored 'General case' 0 C--O 1.245 0.861 0 C-N-CA 123.122 0.569 . . . . 52.12 111.855 -177.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.2 m -77.44 -40.78 29.14 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 CA-C-N 115.729 -0.669 . . . . 65.44 110.968 -177.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.1 m -79.16 -30.38 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 CA-C-O 120.841 0.353 . . . . 75.22 111.437 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.512 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 79.87 67.37 1.58 Allowed Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.683 -0.689 . . . . 74.14 112.513 -175.323 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -97.92 -148.99 24.56 Favored Glycine 0 C--N 1.35 1.347 0 CA-C-N 116.688 0.244 . . . . 43.0 112.546 176.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . 0.676 ' HD3' ' HB2' ' A' ' 220' ' ' GLU . 4.7 ttmp? -125.54 131.44 52.77 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.517 0.727 . . . . 74.21 109.081 -178.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . 0.53 HG13 HG21 ' A' ' 203' ' ' ILE . 5.7 m -120.87 135.76 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.357 -0.979 . . . . 74.52 108.357 172.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . 0.533 ' HD3' ' HB2' ' A' ' 218' ' ' PRO . 35.0 ttm105 -96.26 117.15 30.2 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 121.279 0.561 . . . . 74.33 109.699 178.766 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.446 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -99.78 155.4 17.66 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 124.027 0.931 . . . . 75.24 109.681 178.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 58.1 mmm -92.4 128.21 38.17 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 109.82 -0.437 . . . . 54.23 109.82 172.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.0 t -114.42 173.01 6.67 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-N 115.277 -0.874 . . . . 65.24 109.172 167.357 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . 0.607 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 73.1 mt -75.28 -2.99 30.72 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-N 115.449 -0.796 . . . . 75.52 112.614 -172.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.65 7.76 11.12 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 123.541 0.736 . . . . 72.22 112.122 179.219 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 137.01 -161.16 25.11 Favored Glycine 0 N--CA 1.476 1.362 0 CA-C-O 119.817 -0.435 . . . . 44.1 112.91 178.143 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . 0.533 ' HB2' ' HD3' ' A' ' 211' ' ' ARG . 98.5 Cg_endo -94.35 125.17 0.45 Allowed 'Trans proline' 0 C--N 1.37 1.681 0 C-N-CA 123.499 2.799 . . . . 60.23 112.763 176.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.7 m -108.85 146.28 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 123.322 0.649 . . . . 71.53 110.52 175.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . 0.676 ' HB2' ' HD3' ' A' ' 209' ' ' LYS . 9.9 pt-20 -113.73 104.66 12.43 Favored 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 108.996 -0.742 . . . . 75.11 108.996 -177.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.5 p -97.61 135.54 31.65 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 CA-C-N 115.656 -0.702 . . . . 70.52 110.832 -179.084 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -93.93 117.63 30.37 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-N 115.269 -0.878 . . . . 63.54 109.418 176.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.512 HG23 ' HA2' ' A' ' 207' ' ' GLY . 21.4 m -84.22 140.06 39.34 Favored Pre-proline 0 CA--C 1.553 1.096 0 N-CA-C 109.615 -0.513 . . . . 72.54 109.615 176.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_exo -64.37 144.23 85.13 Favored 'Trans proline' 0 C--N 1.378 2.081 0 C-N-CA 122.583 2.189 . . . . 42.24 112.065 173.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -56.52 126.89 23.77 Favored 'Trans proline' 0 C--N 1.371 1.73 0 C-N-CA 122.746 2.297 . . . . 74.13 111.76 171.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 50.9 mtt180 65.64 44.28 3.02 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 124.445 1.098 . . . . 74.42 110.592 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 5.5 t -77.43 168.84 19.35 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 122.874 0.469 . . . . 45.44 110.046 177.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -130.72 152.06 50.48 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 122.893 0.477 . . . . 71.22 109.782 -178.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.61 134.06 48.32 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.752 0.821 . . . . 74.14 111.166 178.454 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.2 -8.11 20.91 Favored Glycine 0 C--N 1.341 0.854 0 CA-C-O 119.562 -0.576 . . . . 73.44 112.755 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -78.84 159.31 27.88 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-N 117.45 0.625 . . . . 73.45 109.483 175.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.561 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 12.9 mptt -118.57 102.6 9.01 Favored 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 123.748 0.819 . . . . 74.04 109.37 177.41 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . 0.433 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 83.3 mt -78.92 104.61 9.67 Favored 'General case' 0 C--N 1.355 0.805 0 N-CA-C 108.463 -0.94 . . . . 74.35 108.463 -176.116 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 22.3 ttp85 -79.65 121.49 25.36 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 115.261 -0.881 . . . . 71.43 110.446 -169.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 34.4 mt -105.94 120.09 40.87 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.733 0.813 . . . . 64.2 109.93 175.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -70.55 128.32 35.74 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 124.327 1.051 . . . . 63.12 112.237 -169.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 81.56 7.48 88.13 Favored Glycine 0 C--N 1.349 1.267 0 O-C-N 123.718 0.636 . . . . 74.52 114.453 171.579 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 38.2 mmtm -85.16 -23.33 28.42 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 117.192 0.496 . . . . 63.22 112.237 -178.141 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -81.62 173.74 53.97 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 111.861 -0.495 . . . . 75.34 111.861 176.229 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.443 ' CE1' ' HA ' ' A' ' 131' ' ' PHE . 88.2 m-85 -81.15 150.82 68.96 Favored Pre-proline 0 N--CA 1.477 0.894 0 N-CA-C 112.739 0.644 . . . . 73.21 112.739 -172.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -55.61 132.15 50.37 Favored 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.066 2.511 . . . . 75.54 111.226 170.151 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -160.81 -150.8 6.0 Favored Glycine 0 CA--C 1.532 1.154 0 CA-C-O 119.595 -0.558 . . . . 62.0 112.05 -174.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -65.77 -27.56 52.02 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 123.168 2.579 . . . . 72.34 113.287 -174.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . 0.542 ' HB3' HE22 ' A' ' 191' ' ' GLN . . . -109.51 21.79 16.57 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 123.667 0.787 . . . . 64.14 111.052 179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.08 -151.6 33.61 Favored Glycine 0 C--N 1.347 1.171 0 N-CA-C 110.489 -1.045 . . . . 72.52 110.489 -170.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -61.83 138.9 58.39 Favored 'General case' 0 N--CA 1.477 0.924 0 CA-C-N 117.979 0.889 . . . . 73.45 110.162 174.124 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -78.54 -158.87 12.57 Favored Glycine 0 C--O 1.247 0.94 0 CA-C-N 115.969 -0.56 . . . . 33.13 112.146 172.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 -144.35 156.02 44.05 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.011 0.524 . . . . 75.52 109.938 -173.167 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.455 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 20.6 tp -97.67 109.84 22.52 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.462 0.649 . . . . 72.01 110.039 179.037 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . 0.561 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 97.5 m-85 -91.33 106.96 18.87 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-N 115.108 -0.951 . . . . 72.4 109.942 176.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.442 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 72.5 mt -89.25 112.76 23.89 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 123.939 0.895 . . . . 74.43 112.486 -179.289 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -78.62 91.37 4.61 Favored 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.945 -0.761 . . . . 74.42 108.945 178.259 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.1 p -55.54 125.9 11.64 Favored 'Isoleucine or valine' 0 C--N 1.353 0.732 0 CA-C-N 115.043 -0.98 . . . . 74.15 110.324 175.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 44.8 mmm-85 -131.15 109.83 10.73 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 106.536 -1.653 . . . . 74.31 106.536 175.587 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 66.3 mt -83.67 121.21 36.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.454 0 CA-C-N 115.966 -0.561 . . . . 62.35 111.799 -171.212 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 21.5 m . . . . . 0 CA--C 1.558 1.284 0 C-N-CA 124.586 1.154 . . . . 51.13 108.992 175.158 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.533 ' HB1' ' O ' ' A' ' 99' ' ' VAL . . . . . . . . 0 N--CA 1.477 0.909 0 N-CA-C 109.788 -0.449 . . . . 64.45 109.788 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.16 -79.08 0.13 Allowed 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 122.693 0.397 . . . . 55.24 110.836 -176.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.514 ' HB3' HD12 ' A' ' 123' ' ' LEU . 86.5 mt -91.17 -56.4 3.17 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.437 0.695 . . . . 73.42 109.543 -178.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.533 ' O ' ' HB1' ' A' ' 96' ' ' ALA . 6.4 t -82.9 119.64 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 115.092 -0.958 . . . . 55.44 109.468 178.641 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -75.35 -51.43 13.19 Favored 'General case' 0 N--CA 1.478 0.936 0 O-C-N 124.352 1.032 . . . . 71.51 110.579 177.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -165.79 178.15 6.75 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 125.094 1.358 . . . . 74.42 109.338 -172.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.497 HG12 ' HB2' ' A' ' 121' ' ' ALA . 19.0 m -92.04 156.39 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 112.151 0.426 . . . . 51.45 112.151 179.43 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 60.9 p -72.89 -53.59 10.95 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-N 115.11 -0.95 . . . . 71.42 109.268 172.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.5 t -171.33 151.7 3.16 Favored 'General case' 0 C--O 1.245 0.864 0 CA-C-N 114.572 -1.195 . . . . 74.2 109.364 177.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -93.89 161.2 24.54 Favored Glycine 0 CA--C 1.529 0.908 0 CA-C-N 116.003 -0.544 . . . . 33.14 112.039 173.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . 0.688 ' HB2' ' HB2' ' A' ' 118' ' ' ASP . 41.0 m -131.14 169.64 15.62 Favored 'General case' 0 N--CA 1.476 0.825 0 C-N-CA 124.015 0.926 . . . . 72.31 108.654 173.152 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -171.39 111.49 0.4 Allowed Glycine 0 C--N 1.34 0.782 0 N-CA-C 112.11 -0.396 . . . . 63.3 112.11 -175.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -85.32 98.63 2.27 Favored Glycine 0 C--N 1.34 0.78 0 N-CA-C 111.869 -0.492 . . . . 30.3 111.869 -178.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.0 m -57.56 -34.08 68.81 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 123.694 0.797 . . . . 72.21 111.441 176.511 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -148.19 168.24 28.95 Favored Glycine 0 C--N 1.338 0.644 0 CA-C-N 114.75 -1.114 . . . . 72.22 110.724 172.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 83.72 -59.46 4.96 Favored Glycine 0 C--N 1.344 1.001 0 N-CA-C 111.375 -0.69 . . . . 62.21 111.375 -174.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 33.2 t -72.83 113.86 10.33 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 123.138 0.575 . . . . 64.11 110.683 178.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -115.5 -14.28 8.28 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-N 116.194 -0.457 . . . . 74.11 112.896 178.341 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -83.96 -52.39 3.67 Favored Glycine 0 C--N 1.351 1.39 0 CA-C-N 116.695 0.248 . . . . 62.34 112.767 -177.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 44.9 m -107.85 141.6 39.19 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 123.673 0.789 . . . . 65.42 109.746 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -78.02 -93.43 0.27 Allowed Glycine 0 C--N 1.347 1.173 0 N-CA-C 111.644 -0.582 . . . . 74.12 111.644 177.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.574 ' HB2' ' HA3' ' A' ' 166' ' ' GLY . 9.9 mpt_? -96.33 122.37 39.14 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 108.39 -0.967 . . . . 62.25 108.39 168.436 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.688 ' HB2' ' HB2' ' A' ' 106' ' ' SER . 5.9 m-20 -73.36 147.92 43.91 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 108.667 -0.864 . . . . 63.24 108.667 173.759 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.502 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 14.1 tp -131.63 131.48 43.24 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 107.42 -1.326 . . . . 74.13 107.42 179.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.711 ' HG3' ' HB2' ' A' ' 175' ' ' LEU . 0.0 OUTLIER -134.41 133.93 41.09 Favored 'General case' 0 N--CA 1.482 1.135 0 N-CA-C 109.173 -0.677 . . . . 73.43 109.173 -177.172 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.497 ' HB2' HG12 ' A' ' 102' ' ' VAL . . . -146.46 164.17 33.33 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 124.079 0.952 . . . . 53.23 110.479 -176.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.644 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 46.3 mt-10 -126.42 151.01 48.29 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.079 0.951 . . . . 75.5 108.685 173.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.514 HD12 ' HB3' ' A' ' 98' ' ' LEU . 1.4 pt? -145.88 135.3 11.44 Favored Pre-proline 0 N--CA 1.477 0.897 0 C-N-CA 122.967 0.507 . . . . 55.35 110.171 -178.187 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -71.21 113.08 3.48 Favored 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 121.648 1.566 . . . . 64.32 109.583 167.675 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.459 HD22 HG11 ' A' ' 178' ' ' VAL . 17.2 tp -108.29 157.81 18.03 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 108.264 -1.013 . . . . 74.01 108.264 178.385 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.521 HG23 HD12 ' A' ' 181' ' ' LEU . 3.4 m -95.41 161.0 14.26 Favored 'General case' 0 CA--C 1.544 0.736 0 N-CA-C 109.4 -0.593 . . . . 72.44 109.4 173.629 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.47 HD23 ' HB3' ' A' ' 180' ' ' LEU . 67.7 mt -61.33 -46.17 91.36 Favored 'General case' 0 N--CA 1.476 0.836 0 CA-C-O 121.42 0.629 . . . . 72.32 110.104 175.674 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -60.15 -34.83 74.11 Favored 'General case' 0 N--CA 1.484 1.252 0 CA-C-N 114.636 -1.165 . . . . 73.11 111.871 176.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -72.94 -33.57 66.01 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 123.308 0.643 . . . . 72.13 110.472 177.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.491 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -62.68 -36.68 83.68 Favored 'General case' 0 C--O 1.246 0.891 0 C-N-CA 123.955 0.902 . . . . 72.01 111.883 171.347 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.5 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 31.7 t80 -66.87 -61.28 2.03 Favored 'General case' 0 N--CA 1.472 0.671 0 O-C-N 123.961 0.788 . . . . 72.11 111.72 175.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 40.7 m80 -77.68 -26.32 50.16 Favored 'General case' 0 N--CA 1.478 0.926 0 CA-C-N 115.54 -0.754 . . . . 74.5 112.645 -170.088 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 62.68 -121.72 25.87 Favored Glycine 0 C--N 1.349 1.295 0 O-C-N 123.374 0.421 . . . . 53.43 112.281 -175.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 89.59 172.63 45.52 Favored Glycine 0 C--N 1.345 1.059 0 N-CA-C 114.288 0.475 . . . . 75.43 114.288 173.53 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 23.4 mp0 -84.17 136.66 33.88 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 123.512 0.725 . . . . 62.42 109.392 176.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.32 148.12 30.05 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 106.947 -1.501 . . . . 74.53 106.947 170.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 34.7 m -77.41 127.68 38.19 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-O 121.786 0.803 . . . . 70.0 111.643 -173.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.495 HG23 ' HB ' ' A' ' 99' ' ' VAL . 6.7 p -97.54 128.36 48.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.905 -1.146 . . . . 51.44 107.905 170.524 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . 0.445 ' HA ' ' O ' ' A' ' 143' ' ' ARG . 42.4 tt0 -123.27 95.06 4.45 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 107.908 -1.145 . . . . 75.25 107.908 -179.6 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.479 ' O ' ' HG2' ' A' ' 143' ' ' ARG . 15.3 m -136.92 138.16 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 124.714 1.206 . . . . 72.4 108.653 -173.418 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.86 20.41 10.63 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 123.741 0.816 . . . . 64.23 111.864 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 85.55 1.73 87.52 Favored Glycine 0 C--N 1.349 1.274 0 CA-C-O 119.549 -0.584 . . . . 45.44 113.754 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.479 ' HG2' ' O ' ' A' ' 140' ' ' VAL . 8.5 ptm180 -99.98 127.21 46.22 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 118.066 0.933 . . . . 72.34 109.253 176.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -114.16 113.77 25.14 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 124.073 0.949 . . . . 74.11 108.645 178.032 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 4.1 p -148.71 146.39 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 123.456 0.702 . . . . 75.33 109.912 -178.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 19.7 m -70.03 112.95 6.78 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.025 0.53 . . . . 75.25 110.931 178.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 14.2 p -98.99 137.31 26.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.042 0.537 . . . . 54.33 110.021 175.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 59.1 ttp180 -104.75 122.76 46.38 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 107.455 -1.313 . . . . 75.4 107.455 171.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.621 ' HB ' HD13 ' A' ' 159' ' ' ILE . 28.0 pt -107.46 127.47 27.78 Favored Pre-proline 0 CA--C 1.552 1.024 0 N-CA-C 108.172 -1.047 . . . . 72.43 108.172 172.393 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -53.61 130.85 40.84 Favored 'Trans proline' 0 C--N 1.387 2.594 0 C-N-CA 123.29 2.66 . . . . 64.02 113.914 -171.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -59.81 109.96 0.67 Allowed 'Trans proline' 0 C--N 1.378 2.085 0 C-N-CA 122.486 2.124 . . . . 62.51 109.952 170.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.423 ' HA2' ' CD2' ' A' ' 240' ' ' PHE . . . 139.19 28.48 0.23 Allowed Glycine 0 N--CA 1.468 0.776 0 CA-C-N 116.291 -0.413 . . . . 43.0 112.306 -169.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.556 HG21 HD11 ' A' ' 159' ' ' ILE . 2.1 p -104.94 157.36 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.269 0 N-CA-C 109.815 -0.439 . . . . 74.23 109.815 -173.607 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -139.64 163.95 31.2 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 124.951 1.301 . . . . 74.13 110.635 -165.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 20.3 tp10 -47.32 117.9 1.95 Allowed 'General case' 0 CA--C 1.549 0.927 0 C-N-CA 124.479 1.112 . . . . 64.23 112.779 169.506 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.83 7.58 86.25 Favored Glycine 0 C--N 1.353 1.514 0 CA-C-N 115.573 -0.74 . . . . 62.32 113.978 178.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 33.6 t -76.55 129.51 36.57 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 117.311 0.556 . . . . 74.1 109.861 -178.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.431 HG22 HD22 ' A' ' 175' ' ' LEU . 7.1 p -96.56 131.43 43.35 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.093 0 CA-C-N 115.363 -0.835 . . . . 70.34 109.758 -177.391 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.621 HD13 ' HB ' ' A' ' 149' ' ' ILE . 23.1 mt -116.98 115.8 50.08 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 123.675 0.79 . . . . 74.13 110.693 -173.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 18.1 ttm180 -86.78 117.76 25.74 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.059 0.544 . . . . 72.53 110.369 -179.184 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.431 ' HA ' ' HD3' ' A' ' 162' ' ' PRO . 9.0 m -120.29 107.19 39.57 Favored Pre-proline 0 CA--C 1.563 1.446 0 N-CA-C 109.621 -0.511 . . . . 74.45 109.621 178.054 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 7.9 Cg_exo -72.41 152.87 55.38 Favored 'Trans proline' 0 C--N 1.376 2.014 0 C-N-CA 123.105 2.537 . . . . 71.51 112.834 -174.282 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 72.36 24.7 75.9 Favored Glycine 0 C--N 1.35 1.339 0 O-C-N 123.61 0.569 . . . . 52.32 113.126 179.019 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 48.7 tpp -111.08 -37.53 5.32 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.101 0.56 . . . . 55.53 110.6 -178.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -76.72 -140.0 1.05 Allowed Glycine 0 CA--C 1.532 1.151 0 CA-C-N 116.106 -0.497 . . . . 63.3 113.467 174.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.574 ' HA3' ' HB2' ' A' ' 117' ' ' ARG . . . -68.07 111.53 4.09 Favored Glycine 0 C--N 1.344 0.977 0 C-N-CA 122.945 0.307 . . . . 63.23 113.453 -176.026 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.576 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -88.09 163.1 16.4 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 123.761 0.825 . . . . 70.13 110.767 176.805 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 156.79 -78.25 0.19 Allowed Glycine 0 C--N 1.338 0.678 0 N-CA-C 109.587 -1.405 . . . . 54.24 109.587 179.354 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -135.89 -57.1 0.02 OUTLIER Pre-proline 0 CA--C 1.562 1.431 0 CA-C-O 118.427 -0.797 . . . . 72.35 109.713 170.265 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.44 ' HA ' ' HD3' ' A' ' 171' ' ' PRO . 69.2 Cg_endo -76.48 111.75 3.32 Favored 'Trans proline' 0 C--N 1.39 2.752 0 CA-C-N 121.327 1.51 . . . . 74.43 110.302 167.02 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 170' ' ' PRO . 4.6 Cg_exo -74.7 126.39 10.13 Favored 'Trans proline' 0 C--N 1.372 1.785 0 C-N-CA 122.228 1.952 . . . . 64.23 110.995 -176.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -76.12 151.6 40.7 Favored Glycine 0 C--N 1.336 0.579 0 N-CA-C 111.796 -0.522 . . . . 54.32 111.796 174.203 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -103.72 172.74 6.64 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 123.761 0.825 . . . . 74.21 109.154 178.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.502 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 37.5 tp -129.85 114.37 15.82 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 109.336 -0.616 . . . . 75.3 109.336 170.464 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.711 ' HB2' ' HG3' ' A' ' 120' ' ' ARG . 32.4 mt -85.56 102.39 13.49 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 114.903 -1.044 . . . . 75.2 110.837 176.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.44 ' HB2' ' HB ' ' A' ' 159' ' ' ILE . 79.0 mt -91.59 102.55 15.2 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 124.087 0.955 . . . . 60.01 111.71 179.137 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.644 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 43.3 t -86.48 103.83 13.29 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 N-CA-C 108.678 -0.86 . . . . 75.24 108.678 174.115 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.459 HG11 HD22 ' A' ' 125' ' ' LEU . 9.4 m -80.01 151.97 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-O 121.683 0.754 . . . . 71.31 112.124 -177.755 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 7.0 mmm180 -124.69 97.44 5.29 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 125.404 1.482 . . . . 73.31 107.598 178.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.47 ' HB3' HD23 ' A' ' 127' ' ' LEU . 54.9 mt -67.15 134.18 51.27 Favored 'General case' 0 CA--C 1.546 0.793 0 O-C-N 123.156 0.285 . . . . 65.2 110.902 -178.47 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.521 HD12 HG23 ' A' ' 126' ' ' THR . 37.1 mt -55.1 146.49 39.44 Favored Pre-proline 0 C--N 1.364 1.222 0 C-N-CA 124.197 0.999 . . . . 74.15 111.379 -174.505 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_exo -70.13 79.07 1.08 Allowed 'Trans proline' 0 C--N 1.376 2.0 0 C-N-CA 123.196 2.597 . . . . 74.24 113.043 -176.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 7.9 p80 -161.31 57.71 0.86 Allowed Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 124.152 0.981 . . . . 74.01 109.457 173.322 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -66.5 122.52 9.97 Favored 'Trans proline' 0 C--N 1.376 2.009 0 C-N-CA 121.976 1.784 . . . . 54.3 112.019 -168.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.459 ' O ' ' HA ' ' A' ' 195' ' ' ALA . 2.9 p -134.92 -41.07 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 C-N-CA 123.364 0.666 . . . . 74.42 109.322 179.387 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.451 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 8.8 m-85 -109.89 124.36 51.23 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 122.917 0.487 . . . . 74.02 110.925 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.45 114.79 25.51 Favored 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.069 1.348 . . . . 71.42 107.824 175.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 54.9 tp -86.43 144.78 27.13 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 122.897 0.479 . . . . 74.53 110.441 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -142.98 99.87 3.54 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 106.073 -1.825 . . . . 51.1 106.073 177.311 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 65.26 -88.6 0.1 OUTLIER Glycine 0 C--N 1.344 1.003 0 N-CA-C 112.088 -0.405 . . . . 41.2 112.088 -172.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -130.66 -10.69 3.97 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 123.92 0.888 . . . . 72.1 110.58 175.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -85.87 150.41 24.55 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.71 0.804 . . . . 72.01 111.489 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.653 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 95.9 mt -114.91 161.12 18.7 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 124.25 1.02 . . . . 75.02 111.588 -177.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . 0.467 ' HA ' ' O ' ' A' ' 250' ' ' TYR . 89.1 m-85 -140.89 118.41 11.54 Favored 'General case' 0 C--O 1.233 0.227 0 N-CA-C 107.091 -1.448 . . . . 75.01 107.091 173.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . 0.472 ' HB3' HD11 ' A' ' 249' ' ' LEU . . . -141.23 128.7 21.27 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.82 -0.437 . . . . 71.45 109.82 -176.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 14.2 m -76.8 114.92 16.1 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-O 121.163 0.506 . . . . 72.45 110.915 -173.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.526 HD22 HD13 ' A' ' 251' ' ' LEU . 69.3 tp -106.58 113.06 26.34 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 124.329 1.052 . . . . 73.22 109.689 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -84.51 129.49 34.85 Favored 'General case' 0 C--O 1.242 0.701 0 N-CA-C 109.061 -0.718 . . . . 73.12 109.061 169.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 12.1 m -125.84 141.78 40.33 Favored Pre-proline 0 N--CA 1.48 1.042 0 N-CA-C 108.25 -1.019 . . . . 75.12 108.25 176.238 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -64.67 141.17 71.45 Favored 'Trans proline' 0 C--N 1.368 1.553 0 C-N-CA 121.693 1.595 . . . . 74.5 110.698 170.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . 0.412 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -55.83 -41.86 93.1 Favored Pre-proline 0 CA--C 1.558 1.288 0 C-N-CA 123.878 0.871 . . . . 72.55 113.308 -178.312 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . 0.425 ' O ' HG22 ' A' ' 206' ' ' VAL . 83.1 Cg_exo -49.04 -47.77 20.56 Favored 'Trans proline' 0 C--N 1.39 2.744 0 C-N-CA 122.434 2.09 . . . . 61.24 114.081 169.101 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . 0.482 ' HA ' ' HA3' ' A' ' 207' ' ' GLY . 5.6 mt -66.46 -44.37 90.51 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 CA-C-N 117.822 0.283 . . . . 73.31 111.252 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -50.69 -43.85 57.78 Favored 'General case' 0 CA--C 1.538 0.514 0 O-C-N 124.546 1.154 . . . . 60.42 111.51 -178.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . 0.644 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 29.6 m -89.34 -59.61 2.74 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.404 0 N-CA-C 113.226 0.824 . . . . 63.43 113.226 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.425 HG22 ' O ' ' A' ' 202' ' ' PRO . 27.3 m -102.39 -24.61 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 N-CA-C 113.537 0.94 . . . . 71.43 113.537 -171.797 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.482 ' HA3' ' HA ' ' A' ' 203' ' ' ILE . . . -75.0 -76.01 0.78 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 121.181 -0.533 . . . . 61.0 111.993 -173.411 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 94.69 -0.36 65.05 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-O 119.155 -0.803 . . . . 75.42 114.02 172.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . 0.462 ' O ' HD13 ' A' ' 203' ' ' ILE . 48.6 mtmt -138.11 132.89 32.71 Favored 'General case' 0 N--CA 1.481 1.082 0 CA-C-N 118.165 0.982 . . . . 62.45 108.838 178.553 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 7.7 p -153.65 141.64 13.44 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 C-N-CA 124.124 0.97 . . . . 63.35 108.758 -174.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 16.6 ptp180 -77.5 148.92 35.06 Favored 'General case' 0 CA--C 1.547 0.864 0 N-CA-C 110.172 -0.307 . . . . 74.51 110.172 175.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.454 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -140.1 159.86 41.24 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.33 0.652 . . . . 63.33 109.82 174.342 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -106.28 143.7 34.03 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-N 115.599 -0.728 . . . . 65.42 110.702 179.259 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.451 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 8.9 t -133.4 165.43 24.86 Favored 'General case' 0 C--O 1.24 0.566 0 C-N-CA 124.102 0.961 . . . . 64.41 109.489 171.292 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 81.4 mt -64.44 -14.82 58.89 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.268 1.027 . . . . 72.51 111.789 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -95.86 -21.39 18.11 Favored 'General case' 0 CA--C 1.558 1.281 0 C-N-CA 123.443 0.697 . . . . 53.4 111.787 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 148.13 -151.66 23.84 Favored Glycine 0 N--CA 1.478 1.438 0 CA-C-O 119.26 -0.744 . . . . 54.12 112.67 -176.405 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -91.76 133.26 1.37 Allowed 'Trans proline' 0 CA--C 1.559 1.752 0 C-N-CA 123.115 2.543 . . . . 35.35 113.695 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 36.0 m -114.89 159.36 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 123.939 0.896 . . . . 61.44 110.495 171.565 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -114.08 113.43 24.72 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 123.859 0.863 . . . . 71.54 109.069 175.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.462 HG22 HD11 ' A' ' 235' ' ' LEU . 20.5 t -95.14 126.24 47.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 123.661 0.785 . . . . 75.42 109.548 -178.615 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -106.5 99.44 9.02 Favored 'General case' 0 C--O 1.24 0.582 0 N-CA-C 107.003 -1.481 . . . . 64.42 107.003 173.311 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.516 HG12 HD13 ' A' ' 233' ' ' LEU . 3.3 m -79.09 132.23 64.06 Favored Pre-proline 0 CA--C 1.553 1.065 0 N-CA-C 108.031 -1.1 . . . . 55.24 108.031 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -56.37 129.61 35.69 Favored 'Trans proline' 0 C--N 1.375 1.956 0 C-N-CA 122.133 1.889 . . . . 74.11 111.665 176.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -42.35 124.27 3.05 Favored 'Trans proline' 0 C--N 1.385 2.462 0 C-N-CA 124.69 3.593 . . . . 62.15 114.361 -173.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . 0.644 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 52.8 mtm180 64.09 73.44 0.43 Allowed 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 124.333 1.053 . . . . 75.3 111.046 -173.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . 0.465 HG23 HD11 ' A' ' 255' ' ' ILE . 8.2 t -88.59 171.99 9.63 Favored 'General case' 0 N--CA 1.478 0.935 0 C-N-CA 123.647 0.779 . . . . 73.23 110.457 175.446 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -127.9 140.2 52.15 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 123.741 0.816 . . . . 62.11 109.249 -178.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.53 128.8 37.78 Favored 'General case' 0 N--CA 1.472 0.662 0 C-N-CA 123.228 0.611 . . . . 43.44 109.863 177.594 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.24 -4.07 22.05 Favored Glycine 0 C--N 1.339 0.729 0 O-C-N 123.342 0.401 . . . . 50.01 113.276 -170.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . 0.425 ' O ' HG12 ' A' ' 253' ' ' VAL . 69.5 mtp180 -93.59 162.48 13.94 Favored 'General case' 0 N--CA 1.477 0.902 0 CA-C-N 117.39 0.595 . . . . 71.42 111.553 -179.776 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.798 ' HB3' ' HB3' ' A' ' 250' ' ' TYR . 3.2 mptp? -118.35 104.6 10.89 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 108.946 -0.761 . . . . 72.24 108.946 -176.679 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . 0.548 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 23.4 mt -84.42 115.33 22.48 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.52 0.728 . . . . 62.2 109.898 -172.227 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 58.5 ttt180 -86.67 110.21 19.71 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 123.497 0.719 . . . . 71.22 111.631 -170.476 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.543 HD12 HD23 ' A' ' 249' ' ' LEU . 15.5 mt -99.95 104.0 15.59 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.024 -1.102 . . . . 73.34 108.024 170.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 56.0 mttp -74.66 138.86 43.15 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.942 0.497 . . . . 52.32 111.712 -171.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . 0.441 ' O ' ' HD3' ' A' ' 246' ' ' ARG . . . 80.05 6.84 88.98 Favored Glycine 0 C--N 1.348 1.243 0 O-C-N 123.903 0.752 . . . . 63.42 113.486 178.207 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 33.5 mmtp -106.96 8.59 30.58 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-N 117.263 0.532 . . . . 72.4 111.831 179.092 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -97.35 -178.5 34.2 Favored Glycine 0 C--N 1.344 1.023 0 O-C-N 123.481 0.488 . . . . 60.44 112.03 170.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.562 ' CE1' HD21 ' A' ' 193' ' ' LEU . 25.7 m-85 -76.28 163.1 68.51 Favored Pre-proline 0 CA--C 1.549 0.93 0 C-N-CA 124.257 1.023 . . . . 74.13 112.588 -174.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -52.47 129.05 30.21 Favored 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 123.248 2.632 . . . . 75.11 112.804 173.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -156.33 -162.26 11.31 Favored Glycine 0 CA--C 1.532 1.094 0 CA-C-O 119.091 -0.838 . . . . 75.34 112.043 -179.33 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -61.39 -30.98 88.14 Favored 'Trans proline' 0 C--N 1.377 2.047 0 C-N-CA 123.465 2.777 . . . . 73.51 112.916 -175.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -90.95 22.13 3.82 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.961 0.905 . . . . 74.23 111.438 179.473 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 82.27 -70.82 3.08 Favored Glycine 0 C--N 1.35 1.307 0 N-CA-C 111.104 -0.798 . . . . 73.11 111.104 -175.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.441 ' HD3' ' O ' ' A' ' 237' ' ' GLY . 78.2 mtt180 -116.32 161.47 18.97 Favored 'General case' 0 C--O 1.243 0.749 0 C-N-CA 124.459 1.103 . . . . 75.31 108.578 172.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -96.13 -158.3 31.93 Favored Glycine 0 C--O 1.243 0.704 0 CA-C-N 115.699 -0.682 . . . . 54.03 112.308 177.38 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -132.35 155.63 48.07 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 109.641 -0.504 . . . . 65.41 109.641 -175.671 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.653 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 14.3 tp -103.25 129.02 50.1 Favored 'General case' 0 C--O 1.214 -0.812 0 C-N-CA 123.648 0.779 . . . . 71.12 109.12 171.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . 0.798 ' HB3' ' HB3' ' A' ' 232' ' ' LYS . 92.7 m-85 -115.36 107.64 15.48 Favored 'General case' 0 N--CA 1.477 0.906 0 N-CA-C 108.907 -0.775 . . . . 74.21 108.907 176.693 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.548 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 42.1 mt -87.5 126.15 34.74 Favored 'General case' 0 C--N 1.332 -0.16 0 C-N-CA 123.568 0.747 . . . . 72.42 111.876 -173.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -78.91 90.84 4.74 Favored 'General case' 0 C--O 1.238 0.467 0 N-CA-C 107.366 -1.346 . . . . 75.12 107.366 176.03 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.425 HG12 ' O ' ' A' ' 231' ' ' ARG . 2.8 p -63.29 124.12 17.35 Favored 'Isoleucine or valine' 0 C--O 1.239 0.55 0 CA-C-O 121.802 0.81 . . . . 73.22 110.472 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 29.7 mmm180 -124.25 95.34 4.51 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 107.574 -1.269 . . . . 72.55 107.574 -178.527 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.465 HD11 HG23 ' A' ' 227' ' ' THR . 69.1 mt -75.83 107.14 6.34 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 115.204 -0.907 . . . . 50.03 109.394 -177.725 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.2 t . . . . . 0 CA--C 1.549 0.928 0 C-N-CA 124.539 1.136 . . . . 72.5 109.139 -179.317 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.378 0 N-CA-C 110.403 -0.221 . . . . 63.2 110.403 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -117.15 -77.89 0.57 Allowed 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 122.998 0.519 . . . . 74.11 109.917 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.643 ' HG ' ' HG2' ' A' ' 136' ' ' ARG . 68.2 mt -85.38 -57.08 3.21 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 122.694 0.398 . . . . 75.51 110.449 177.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.451 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 11.8 p -56.28 134.62 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 O-C-N 123.858 0.724 . . . . 61.31 111.531 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.96 -60.73 2.19 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 108.746 -0.835 . . . . 53.13 108.746 174.661 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 31.2 m80 -162.94 159.48 23.66 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 124.98 1.312 . . . . 64.13 108.82 -177.635 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.477 ' HA ' ' HB2' ' A' ' 121' ' ' ALA . 13.0 p -78.0 127.7 38.44 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.007 0 CA-C-O 121.025 0.44 . . . . 62.55 110.451 178.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.471 HG23 ' HA ' ' A' ' 121' ' ' ALA . 43.8 p -82.57 150.4 26.92 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.537 0.735 . . . . 62.44 110.474 -179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 29.1 t -68.02 145.69 54.25 Favored 'General case' 0 CA--C 1.551 0.99 0 C-N-CA 123.402 0.681 . . . . 52.0 109.51 175.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . 0.505 ' HA3' ' HD2' ' A' ' 120' ' ' ARG . . . -151.85 131.73 3.54 Favored Glycine 0 C--N 1.344 1.019 0 C-N-CA 121.457 -0.401 . . . . 65.12 113.038 -174.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 35.1 p -63.58 147.86 50.36 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.867 0.867 . . . . 75.45 111.144 178.319 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 171.38 -30.45 0.12 Allowed Glycine 0 C--N 1.342 0.881 0 CA-C-N 115.974 -0.557 . . . . 71.4 112.258 -177.381 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.56 -165.63 26.14 Favored Glycine 0 C--N 1.346 1.09 0 C-N-CA 123.19 0.424 . . . . 34.53 112.738 177.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.501 ' HA ' ' HB3' ' A' ' 115' ' ' SER . 69.8 p -132.62 121.65 23.51 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 123.509 0.724 . . . . 70.13 110.109 178.398 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -65.6 -38.83 95.05 Favored Glycine 0 C--N 1.355 1.591 0 O-C-N 123.661 0.601 . . . . 75.21 111.683 174.346 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -97.43 -158.74 30.85 Favored Glycine 0 C--N 1.352 1.44 0 N-CA-C 111.425 -0.67 . . . . 75.1 111.425 169.324 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 25.7 m -75.97 -33.74 59.78 Favored 'General case' 0 N--CA 1.479 0.986 0 C-N-CA 123.713 0.805 . . . . 72.14 110.869 174.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -149.25 -32.39 0.05 OUTLIER Glycine 0 C--N 1.343 0.938 0 N-CA-C 111.144 -0.782 . . . . 60.51 111.144 179.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -66.92 88.4 0.14 Allowed Glycine 0 C--N 1.353 1.508 0 N-CA-C 111.424 -0.67 . . . . 54.14 111.424 172.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . 0.501 ' HB3' ' HA ' ' A' ' 109' ' ' SER . 19.5 p -112.79 124.92 53.67 Favored 'General case' 0 C--O 1.238 0.487 0 C-N-CA 123.907 0.883 . . . . 62.44 109.22 179.316 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -81.88 66.17 3.9 Favored Glycine 0 C--N 1.344 1.019 0 N-CA-C 110.72 -0.952 . . . . 64.43 110.72 172.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 11.7 mmm180 -71.65 147.72 47.22 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 124.107 0.963 . . . . 72.41 110.746 -177.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -72.97 150.47 42.46 Favored 'General case' 0 C--O 1.243 0.741 0 N-CA-C 107.734 -1.21 . . . . 64.35 107.734 170.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.517 HD13 HG23 ' A' ' 140' ' ' VAL . 39.7 mt -95.04 139.02 31.98 Favored 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 107.402 -1.332 . . . . 74.24 107.402 -176.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.505 ' HD2' ' HA3' ' A' ' 105' ' ' GLY . 17.8 ptp180 -146.3 135.8 23.03 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.379 -0.971 . . . . 61.5 108.379 178.403 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.477 ' HB2' ' HA ' ' A' ' 102' ' ' VAL . . . -156.95 139.2 14.67 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.189 -0.671 . . . . 75.53 109.189 -171.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -96.7 148.02 23.31 Favored 'General case' 0 C--O 1.244 0.764 0 N-CA-C 109.38 -0.6 . . . . 62.34 109.38 173.422 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.627 HD12 ' HB3' ' A' ' 98' ' ' LEU . 1.6 pt? -144.12 132.18 10.84 Favored Pre-proline 0 N--CA 1.473 0.71 0 CA-C-N 115.991 -0.55 . . . . 61.42 110.83 -171.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -68.5 117.2 4.82 Favored 'Trans proline' 0 C--N 1.374 1.895 0 C-N-CA 121.963 1.775 . . . . 75.52 110.932 174.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.473 HD22 HG11 ' A' ' 178' ' ' VAL . 16.0 tp -119.8 150.56 40.22 Favored 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 108.828 -0.804 . . . . 62.31 108.828 178.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.498 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 10.5 m -89.16 158.28 17.97 Favored 'General case' 0 CA--C 1.547 0.854 0 N-CA-C 109.31 -0.626 . . . . 65.34 109.31 175.345 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.474 HD11 ' O ' ' A' ' 183' ' ' HIS . 55.9 mt -54.56 -51.32 65.6 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 123.886 0.875 . . . . 74.21 111.062 177.317 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.436 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 2.1 mp0 -55.67 -37.59 68.5 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 114.325 -1.307 . . . . 74.34 111.024 176.834 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.498 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 10.3 mm-40 -79.18 -18.12 53.64 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.557 0.743 . . . . 64.31 111.313 -177.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.678 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -66.12 -42.37 89.27 Favored 'General case' 0 C--O 1.252 1.221 0 CA-C-O 121.004 0.43 . . . . 72.03 110.951 165.785 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -65.02 -48.88 72.32 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 115.824 -0.626 . . . . 73.31 111.318 172.507 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.6 m80 -73.82 -48.07 34.02 Favored 'General case' 0 N--CA 1.481 1.116 0 O-C-N 123.773 0.671 . . . . 70.03 111.839 -171.444 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 58.51 -109.54 2.03 Favored Glycine 0 CA--C 1.533 1.176 0 N-CA-C 111.351 -0.7 . . . . 72.51 111.351 -172.199 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.21 -162.89 50.13 Favored Glycine 0 C--N 1.346 1.106 0 N-CA-C 114.983 0.753 . . . . 73.33 114.983 166.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 -79.06 135.97 37.03 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 124.424 1.09 . . . . 73.42 110.989 -174.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.643 ' HG2' ' HG ' ' A' ' 98' ' ' LEU . 13.8 tpt180 -156.86 167.97 28.87 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.137 0.975 . . . . 72.12 109.215 175.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.0 p -110.25 136.72 45.36 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 CA-C-O 121.148 0.499 . . . . 72.34 110.613 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 15.5 m -121.23 137.81 53.69 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 C-N-CA 124.011 0.925 . . . . 71.44 108.864 172.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -126.47 98.44 5.42 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-O 121.894 0.854 . . . . 63.51 109.228 171.368 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.517 HG23 HD13 ' A' ' 119' ' ' LEU . 10.6 m -130.24 139.41 51.47 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 124.517 1.127 . . . . 63.2 108.63 -179.161 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.54 24.77 14.17 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 124.256 1.023 . . . . 74.42 111.465 -176.234 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.11 -3.9 74.18 Favored Glycine 0 C--N 1.351 1.406 0 CA-C-N 115.809 -0.632 . . . . 71.03 113.038 -177.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 31.1 mmm180 -97.17 116.37 29.26 Favored 'General case' 0 C--N 1.346 0.456 0 C-N-CA 123.409 0.684 . . . . 75.11 109.425 -176.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 44.1 ttm180 -101.45 106.12 17.21 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 108.598 -0.89 . . . . 73.55 108.598 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 38.5 t -127.74 142.85 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 C-N-CA 124.025 0.93 . . . . 43.42 109.223 -177.311 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 9.6 p -77.28 114.5 16.17 Favored 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 123.28 0.632 . . . . 62.51 110.041 175.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.8 p -98.88 136.43 29.93 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 C-N-CA 123.808 0.843 . . . . 72.15 110.345 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 59.6 ttp180 -111.2 95.44 5.53 Favored 'General case' 0 C--O 1.242 0.705 0 N-CA-C 108.227 -1.027 . . . . 72.34 108.227 168.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.413 ' HB ' HD13 ' A' ' 159' ' ' ILE . 34.9 pt -82.48 128.5 66.62 Favored Pre-proline 0 CA--C 1.548 0.872 0 N-CA-C 108.492 -0.929 . . . . 71.33 108.492 175.067 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -68.98 147.19 67.35 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.41 2.073 . . . . 74.31 113.059 -168.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -64.32 111.91 1.76 Allowed 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 122.362 2.041 . . . . 72.01 110.636 172.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.771 ' HA2' ' HD2' ' A' ' 240' ' ' PHE . . . 142.23 30.45 0.13 Allowed Glycine 0 C--N 1.354 1.578 0 C-N-CA 121.435 -0.412 . . . . 74.32 114.051 -174.632 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.678 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.0 p -106.26 164.57 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.569 1.683 0 C-N-CA 123.506 0.722 . . . . 73.22 109.891 -176.166 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 52.9 mtm-85 -144.56 167.19 23.1 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 125.106 1.363 . . . . 71.43 108.979 -172.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . 0.453 ' HB2' ' HB2' ' A' ' 180' ' ' LEU . 13.3 tp10 -54.82 122.48 10.86 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 123.329 0.651 . . . . 75.42 110.14 168.218 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 89.12 -11.6 68.94 Favored Glycine 0 C--N 1.344 0.983 0 CA-C-O 119.632 -0.538 . . . . 75.22 113.395 179.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 35.0 t -70.86 129.53 39.31 Favored 'General case' 0 C--O 1.245 0.863 0 CA-C-N 117.206 0.503 . . . . 71.2 109.756 -178.015 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.546 HG12 HD22 ' A' ' 175' ' ' LEU . 18.6 t -104.01 119.37 52.64 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 CA-C-N 114.386 -1.279 . . . . 53.22 109.073 -173.068 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.516 HD11 HG21 ' A' ' 153' ' ' VAL . 23.4 mt -103.13 117.45 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 C-N-CA 123.803 0.841 . . . . 71.42 110.023 -171.095 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 55.9 ttt85 -90.52 111.64 23.01 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 123.686 0.794 . . . . 63.32 110.226 -178.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.3 m -120.31 102.37 45.79 Favored Pre-proline 0 CA--C 1.568 1.665 0 C-N-CA 122.618 0.367 . . . . 60.23 110.611 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -63.56 150.99 87.11 Favored 'Trans proline' 0 C--N 1.375 1.93 0 C-N-CA 122.938 2.425 . . . . 62.22 113.175 -177.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 106.11 -26.11 21.57 Favored Glycine 0 CA--C 1.535 1.329 0 CA-C-O 119.038 -0.868 . . . . 72.44 114.777 177.024 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.9 mpt? -81.24 -55.15 4.92 Favored 'General case' 0 N--CA 1.494 1.736 0 CA-C-N 118.674 1.237 . . . . 65.05 111.23 -178.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -70.61 -179.51 27.98 Favored Glycine 0 C--N 1.348 1.219 0 CA-C-N 115.993 -0.549 . . . . 74.01 113.755 -177.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -95.59 -50.46 1.99 Allowed Glycine 0 C--N 1.343 0.96 0 CA-C-O 119.487 -0.618 . . . . 41.42 113.578 -177.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.559 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -38.4 127.44 1.41 Allowed 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 115.66 1.726 . . . . 70.22 115.66 -161.981 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 91.35 165.88 40.04 Favored Glycine 0 C--N 1.353 1.513 0 O-C-N 124.42 1.075 . . . . 61.13 111.944 -178.101 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -65.8 -43.38 59.24 Favored Pre-proline 0 CA--C 1.559 1.324 0 CA-C-O 118.682 -0.675 . . . . 75.42 110.326 173.644 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -67.46 143.5 63.49 Favored 'Trans proline' 0 C--N 1.388 2.648 0 C-N-CA 121.25 1.3 . . . . 73.34 110.248 161.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -64.34 126.81 17.72 Favored 'Trans proline' 0 C--N 1.371 1.741 0 C-N-CA 122.007 1.805 . . . . 74.52 111.489 -176.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -65.49 -171.54 3.38 Favored Glycine 0 C--N 1.346 1.106 0 CA-C-N 115.866 -0.606 . . . . 63.01 113.943 -177.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 10.5 p-10 -108.58 172.9 6.57 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 123.828 0.851 . . . . 54.14 112.129 -168.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 19.2 tp -120.41 116.76 26.11 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 114.44 -1.255 . . . . 70.25 107.867 172.205 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.546 HD22 HG12 ' A' ' 158' ' ' VAL . 65.3 mt -88.11 100.03 12.64 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 123.982 0.913 . . . . 74.13 110.901 177.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 70.8 mt -91.46 104.9 17.36 Favored 'General case' 0 CA--C 1.544 0.727 0 C-N-CA 123.222 0.609 . . . . 72.41 111.044 176.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.407 HG22 HG13 ' A' ' 158' ' ' VAL . 12.4 t -91.58 101.11 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 108.399 -0.963 . . . . 70.23 108.399 177.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.473 HG11 HD22 ' A' ' 125' ' ' LEU . 3.7 m -76.84 150.12 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 CA-C-O 121.612 0.72 . . . . 64.01 112.16 -172.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 42.8 mmt180 -116.18 91.55 3.63 Favored 'General case' 0 C--O 1.238 0.448 0 C-N-CA 125.352 1.461 . . . . 75.45 107.686 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.453 ' HB2' ' HB2' ' A' ' 155' ' ' GLU . 21.3 mt -69.9 148.77 48.58 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 120.716 0.293 . . . . 72.45 110.28 175.431 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 69.1 mt -54.74 144.41 45.8 Favored Pre-proline 0 CA--C 1.556 1.195 0 C-N-CA 123.927 0.891 . . . . 65.45 112.131 -175.319 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.462 ' O ' ' HD3' ' A' ' 184' ' ' PRO . 23.9 Cg_exo -65.62 1.4 2.21 Favored 'Trans proline' 0 C--N 1.385 2.474 0 C-N-CA 123.529 2.819 . . . . 61.34 113.347 175.52 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.474 ' O ' HD11 ' A' ' 127' ' ' LEU . 8.4 t60 -91.36 98.31 1.7 Allowed Pre-proline 0 CA--C 1.549 0.93 0 N-CA-C 107.546 -1.279 . . . . 71.1 107.546 159.34 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 182' ' ' PRO . 60.6 Cg_endo -102.16 124.7 0.09 OUTLIER 'Trans proline' 0 C--N 1.37 1.665 0 C-N-CA 122.913 2.408 . . . . 72.44 111.729 168.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.5 p -114.28 -42.2 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 CA-C-O 121.348 0.594 . . . . 73.15 109.728 177.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.482 ' HD2' HD22 ' A' ' 193' ' ' LEU . 5.5 m-85 -101.54 125.44 48.19 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 115.562 -0.745 . . . . 74.4 109.96 -177.384 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 37.2 ttp-105 -98.74 111.98 24.19 Favored 'General case' 0 C--O 1.243 0.758 0 N-CA-C 107.167 -1.419 . . . . 63.42 107.167 169.597 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 54.2 tp -83.45 116.99 22.77 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 108.443 -0.947 . . . . 62.25 108.443 172.482 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -126.76 99.21 5.67 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 124.488 1.115 . . . . 63.5 108.253 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 55.87 56.49 23.65 Favored Glycine 0 C--N 1.353 1.475 0 CA-C-O 119.504 -0.609 . . . . 62.22 113.76 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 69.13 -6.16 0.96 Allowed 'General case' 0 N--CA 1.504 2.25 0 C-N-CA 125.281 1.432 . . . . 63.32 113.15 -179.339 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -97.82 150.12 21.61 Favored 'General case' 0 C--N 1.35 0.616 0 C-N-CA 124.864 1.266 . . . . 74.02 108.756 -178.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.595 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 94.9 mt -111.43 148.98 31.92 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 121.616 0.722 . . . . 64.0 112.418 -176.246 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -132.96 121.33 22.64 Favored 'General case' 0 C--O 1.238 0.475 0 CA-C-N 114.062 -1.427 . . . . 75.44 107.728 171.182 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -132.9 170.51 15.22 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 124.294 1.038 . . . . 55.52 109.071 177.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 54.9 m -109.96 133.38 53.24 Favored 'General case' 0 CA--C 1.537 0.449 0 N-CA-C 109.034 -0.728 . . . . 73.15 109.034 172.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . . . . . . . . . 52.5 tp -112.51 112.11 23.42 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 108.466 -0.938 . . . . 71.23 108.466 175.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -90.77 102.46 15.22 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 108.824 -0.806 . . . . 64.44 108.824 175.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . 0.402 HG21 HG11 ' A' ' 223' ' ' VAL . 7.7 p -109.3 131.88 21.59 Favored Pre-proline 0 CA--C 1.548 0.882 0 CA-C-N 114.98 -1.009 . . . . 72.21 109.291 -176.508 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -56.32 145.34 78.57 Favored 'Trans proline' 0 C--N 1.373 1.847 0 C-N-CA 122.785 2.323 . . . . 74.01 113.181 174.051 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . 0.463 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -54.73 -45.86 99.52 Favored Pre-proline 0 CA--C 1.563 1.465 0 C-N-CA 124.112 0.965 . . . . 74.54 113.4 176.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . 0.42 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 26.0 Cg_endo -58.76 -44.18 38.25 Favored 'Trans proline' 0 C--N 1.392 2.826 0 C-N-CA 122.014 1.809 . . . . 72.55 111.941 175.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.5 mt -63.68 -37.62 80.13 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 C-N-CA 123.105 0.562 . . . . 61.24 110.931 178.788 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -61.89 -46.76 87.97 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.436 0.695 . . . . 75.24 112.011 -177.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 35.3 m -77.08 -36.91 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 N-CA-C 112.235 0.457 . . . . 71.11 112.235 -177.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m -80.57 -25.24 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 CA-C-O 120.838 0.351 . . . . 74.01 110.978 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.498 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 72.93 69.4 1.4 Allowed Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.421 -0.809 . . . . 62.32 112.244 -173.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -96.08 -149.17 25.28 Favored Glycine 0 C--N 1.352 1.452 0 CA-C-O 121.312 0.395 . . . . 55.22 113.117 -178.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 53.1 tttp -125.82 125.93 43.69 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 124.845 1.258 . . . . 73.03 108.792 -172.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . 0.506 HG23 HG13 ' A' ' 221' ' ' VAL . 11.4 m -130.5 163.2 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 C-N-CA 124.203 1.001 . . . . 64.02 108.598 173.474 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 39.0 ptt85 -104.57 148.16 26.82 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 109.665 -0.495 . . . . 74.34 109.665 176.08 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -120.45 135.23 55.12 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 108.852 -0.795 . . . . 62.1 108.852 174.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 5.0 tpt -87.02 107.57 18.48 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 108.906 -0.776 . . . . 74.3 108.906 178.368 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.44 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 14.6 t -110.33 168.62 9.31 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 121.075 0.464 . . . . 71.51 109.78 174.287 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . 0.436 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 61.9 mt -74.55 -9.91 59.03 Favored 'General case' 0 CA--C 1.542 0.653 0 CA-C-N 115.667 -0.697 . . . . 64.32 112.519 -173.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -86.36 -21.75 27.03 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.598 0.759 . . . . 73.05 110.625 173.429 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 139.96 -169.73 24.57 Favored Glycine 0 C--N 1.345 1.032 0 N-CA-C 111.281 -0.728 . . . . 74.31 111.281 -173.645 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -76.01 126.85 9.6 Favored 'Trans proline' 0 C--N 1.363 1.336 0 C-N-CA 122.42 2.08 . . . . 65.13 112.015 176.049 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 33.4 m -110.25 163.53 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.083 0 C-N-CA 123.549 0.74 . . . . 74.34 109.268 171.592 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -114.04 127.24 55.85 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.41 -0.589 . . . . 74.23 109.41 174.48 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.541 ' HB ' HD11 ' A' ' 235' ' ' LEU . 3.2 p -120.76 118.44 56.44 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 C-N-CA 123.818 0.847 . . . . 64.25 110.007 175.194 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.37 113.5 24.81 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 108.24 -1.022 . . . . 70.41 108.24 174.338 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.498 HG23 ' HA2' ' A' ' 207' ' ' GLY . 10.4 m -73.31 139.71 78.96 Favored Pre-proline 0 CA--C 1.553 1.096 0 N-CA-C 108.751 -0.833 . . . . 71.15 108.751 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -74.52 145.39 33.37 Favored 'Trans proline' 0 CA--C 1.557 1.674 0 C-N-CA 122.143 1.895 . . . . 53.42 111.309 178.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_exo -54.32 130.36 39.43 Favored 'Trans proline' 0 C--N 1.38 2.235 0 C-N-CA 123.325 2.683 . . . . 73.22 113.247 -179.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 61.69 61.28 1.47 Allowed 'General case' 0 N--CA 1.477 0.892 0 O-C-N 124.639 1.212 . . . . 73.33 111.201 -176.212 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.9 t -87.81 172.04 9.94 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 109.56 -0.533 . . . . 72.22 109.56 172.37 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . 0.547 HE21 ' HD2' ' A' ' 231' ' ' ARG . 1.9 mp0 -130.66 153.25 49.15 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 108.72 -0.845 . . . . 65.22 108.72 -178.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -72.36 139.69 48.02 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 122.779 0.432 . . . . 74.32 110.028 176.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 101.75 -6.84 55.01 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 116.052 -0.522 . . . . 70.11 112.395 -178.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . 0.547 ' HD2' HE21 ' A' ' 228' ' ' GLN . 58.6 mtp180 -82.48 160.72 22.6 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.006 0.522 . . . . 71.02 110.251 179.081 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.481 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 11.9 mptt -118.3 116.97 27.85 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.828 0.851 . . . . 60.35 109.73 -178.293 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 73.6 mt -92.0 107.42 19.2 Favored 'General case' 0 C--O 1.24 0.603 0 N-CA-C 107.265 -1.383 . . . . 72.43 107.265 175.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . 0.446 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 66.5 ttt180 -88.56 103.14 15.62 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 115.362 -0.835 . . . . 75.11 110.313 -166.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.541 HD11 ' HB ' ' A' ' 221' ' ' VAL . 33.3 mt -93.28 97.58 10.71 Favored 'General case' 0 C--N 1.348 0.508 0 N-CA-C 108.706 -0.85 . . . . 62.4 108.706 178.076 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . 0.57 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 10.3 mtmp? -81.38 144.38 31.48 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.332 -0.849 . . . . 44.51 111.525 -172.524 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 76.46 18.39 79.16 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.499 -0.773 . . . . 75.41 112.817 -172.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 73.1 mmtt -121.05 7.11 10.3 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.278 0.631 . . . . 71.33 111.934 -178.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . 0.411 ' HA2' ' CD1' ' A' ' 193' ' ' LEU . . . -92.22 -169.44 40.73 Favored Glycine 0 C--N 1.338 0.681 0 O-C-N 123.578 0.549 . . . . 53.22 112.131 174.679 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.771 ' HD2' ' HA2' ' A' ' 152' ' ' GLY . 3.9 m-85 -76.77 144.23 72.64 Favored Pre-proline 0 CA--C 1.547 0.849 0 C-N-CA 122.302 0.241 . . . . 71.2 110.614 -175.634 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.89 127.73 21.22 Favored 'Trans proline' 0 C--N 1.377 2.055 0 C-N-CA 122.885 2.39 . . . . 62.1 111.646 176.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -164.36 -154.09 7.71 Favored Glycine 0 CA--C 1.537 1.458 0 CA-C-O 119.448 -0.64 . . . . 71.3 113.298 -174.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -60.67 -24.28 78.17 Favored 'Trans proline' 0 C--N 1.379 2.166 0 C-N-CA 124.263 3.309 . . . . 72.44 114.164 -178.111 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.0 23.01 5.21 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 123.453 0.701 . . . . 74.32 111.461 176.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 74.33 -78.54 0.97 Allowed Glycine 0 C--N 1.348 1.206 0 N-CA-C 110.938 -0.865 . . . . 73.02 110.938 -173.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 12.8 ttt85 -129.65 141.74 50.86 Favored 'General case' 0 CA--C 1.546 0.8 0 N-CA-C 108.348 -0.982 . . . . 72.24 108.348 172.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -74.74 -156.78 5.28 Favored Glycine 0 N--CA 1.475 1.252 0 N-CA-C 113.805 0.282 . . . . 74.22 113.805 -178.032 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . 0.57 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 0.7 OUTLIER -148.44 156.46 42.51 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 123.125 0.57 . . . . 65.22 111.281 179.39 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.595 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 28.5 tp -110.42 133.63 53.09 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 124.73 1.212 . . . . 74.02 111.196 -172.137 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -106.21 107.2 18.09 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 124.147 0.979 . . . . 72.32 109.402 174.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.481 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 84.8 mt -87.56 115.57 25.08 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 123.1 0.56 . . . . 73.11 111.839 176.546 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -79.89 93.74 5.72 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 108.472 -0.936 . . . . 74.32 108.472 179.056 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 59.6 t -48.18 121.0 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.553 1.141 . . . . 40.05 110.659 174.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 25.6 mmm180 -128.9 95.45 4.09 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.194 -1.41 . . . . 74.14 107.194 177.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.463 HG23 ' HA ' ' A' ' 201' ' ' ALA . 66.5 mt -75.32 120.38 24.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-N 114.898 -1.046 . . . . 73.22 109.407 -176.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.556 1.189 0 C-N-CA 123.637 0.775 . . . . 74.14 109.315 -173.697 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.076 0 N-CA-C 109.827 -0.435 . . . . 74.22 109.827 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -160.78 -64.44 0.06 Allowed 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 122.808 0.443 . . . . 63.45 110.409 -177.459 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.53 HD23 HH11 ' A' ' 136' ' ' ARG . 55.1 tp -81.47 -52.15 7.55 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 123.236 0.614 . . . . 61.25 109.928 -178.281 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.568 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 8.1 p -87.54 158.81 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 C-N-CA 123.216 0.606 . . . . 64.53 110.093 168.598 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -88.82 -89.62 0.14 Allowed 'General case' 0 CA--C 1.549 0.939 0 C-N-CA 123.278 0.631 . . . . 62.32 109.896 170.241 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 40.9 m80 -160.74 176.52 11.41 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 125.106 1.363 . . . . 72.21 108.915 -174.443 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 9.1 p -68.68 125.62 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 CA-C-O 121.224 0.535 . . . . 74.31 110.557 178.186 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 81.9 p -71.23 107.35 4.19 Favored 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 124.122 0.969 . . . . 65.35 109.826 175.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 43.0 t -73.56 82.73 1.51 Allowed 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.404 0.681 . . . . 72.13 110.216 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -165.33 136.81 4.37 Favored Glycine 0 C--N 1.342 0.907 0 N-CA-C 111.407 -0.677 . . . . 75.13 111.407 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 50.6 m -70.56 141.58 51.84 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 123.839 0.856 . . . . 72.41 111.305 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -137.31 111.47 0.84 Allowed Glycine 0 C--N 1.346 1.117 0 N-CA-C 111.897 -0.481 . . . . 74.5 111.897 -175.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.89 58.2 3.66 Favored Glycine 0 C--N 1.346 1.12 0 C-N-CA 123.134 0.397 . . . . 43.41 112.596 -178.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 25.8 m -79.65 90.1 5.16 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 123.528 0.731 . . . . 43.11 109.858 179.018 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 80.0 -73.95 2.37 Favored Glycine 0 C--N 1.346 1.134 0 CA-C-N 115.46 -0.791 . . . . 45.2 111.709 -177.237 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 64.31 19.07 63.81 Favored Glycine 0 C--N 1.351 1.402 0 O-C-N 123.861 0.389 . . . . 51.24 113.892 179.229 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 18.0 p -69.8 109.03 4.2 Favored 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 123.61 0.764 . . . . 74.42 110.904 -177.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.84 -115.18 4.44 Favored Glycine 0 C--N 1.348 1.245 0 CA-C-N 115.932 -0.576 . . . . 73.5 112.233 -177.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -161.68 153.84 24.67 Favored Glycine 0 C--N 1.342 0.89 0 N-CA-C 112.343 -0.303 . . . . 72.2 112.343 -179.369 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 60.4 m -149.29 178.74 8.5 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 124.699 1.2 . . . . 73.34 109.627 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -63.46 149.93 49.82 Favored Glycine 0 C--N 1.353 1.474 0 N-CA-C 111.729 -0.549 . . . . 43.22 111.729 173.384 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.501 ' HB3' ' HA3' ' A' ' 166' ' ' GLY . 59.6 ttt180 -59.85 120.58 9.85 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.881 0.872 . . . . 72.34 111.176 -174.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -88.12 147.73 24.78 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-O 121.518 0.675 . . . . 62.41 110.603 -179.459 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.532 HD12 ' HA2' ' A' ' 165' ' ' GLY . 14.5 mt -104.53 155.11 19.1 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.179 -1.415 . . . . 72.43 107.179 162.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 10.8 ttm180 -145.11 118.26 8.89 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 108.87 -0.789 . . . . 73.35 108.87 -175.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.412 ' HB3' HD23 ' A' ' 176' ' ' LEU . . . -141.37 141.61 33.8 Favored 'General case' 0 N--CA 1.471 0.61 0 C-N-CA 123.702 0.801 . . . . 61.32 109.724 -176.577 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.709 ' HG2' ' HB ' ' A' ' 177' ' ' VAL . 39.4 mt-10 -116.95 149.82 39.55 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.066 0.546 . . . . 73.04 110.811 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.568 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.6 pt? -145.85 144.89 23.29 Favored Pre-proline 0 N--CA 1.471 0.599 0 CA-C-N 115.392 -0.822 . . . . 72.23 110.873 -179.44 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -77.55 115.3 3.86 Favored 'Trans proline' 0 C--N 1.371 1.739 0 C-N-CA 121.825 1.683 . . . . 63.14 110.711 168.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.554 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 15.7 tp -107.37 154.1 21.8 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.532 0.733 . . . . 65.55 109.407 179.36 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.573 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 11.5 m -87.74 160.97 17.86 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.137 0.575 . . . . 65.52 109.527 175.455 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.504 HD13 HG12 ' A' ' 185' ' ' VAL . 30.2 mt -63.07 -48.96 76.42 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 123.884 0.874 . . . . 65.51 110.562 178.58 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -57.28 -31.59 65.76 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 114.777 -1.101 . . . . 72.5 110.937 176.621 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.573 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 8.8 mm-40 -83.82 -23.99 31.17 Favored 'General case' 0 C--O 1.212 -0.869 0 C-N-CA 122.996 0.519 . . . . 73.45 111.054 -179.091 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.7 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -60.62 -35.21 75.6 Favored 'General case' 0 C--O 1.248 1.015 0 CA-C-O 121.804 0.811 . . . . 70.51 110.3 165.536 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.526 ' HA ' ' CZ ' ' A' ' 240' ' ' PHE . 55.3 t80 -72.03 -47.42 51.9 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.419 -1.264 . . . . 71.21 111.82 172.213 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 38.3 m80 -83.96 -16.82 42.71 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 113.283 0.846 . . . . 70.1 113.283 -171.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 89.75 -117.72 5.06 Favored Glycine 0 CA--C 1.535 1.326 0 N-CA-C 111.987 -0.445 . . . . 43.54 111.987 -170.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 148.91 94.01 0.12 Allowed Glycine 0 C--N 1.353 1.488 0 CA-C-N 117.828 0.814 . . . . 73.44 113.571 175.12 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -85.21 123.06 30.28 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 123.273 0.629 . . . . 63.35 109.397 175.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.577 ' NH2' HD13 ' A' ' 176' ' ' LEU . 16.9 ptt-85 -148.65 168.45 22.81 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.204 0.602 . . . . 53.35 111.526 -170.157 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 23.1 m -89.84 106.23 16.93 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.992 0 CA-C-N 115.022 -0.99 . . . . 75.43 108.624 169.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.552 HG21 HD21 ' A' ' 174' ' ' LEU . 7.4 p -98.89 123.1 51.3 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 C-N-CA 123.153 0.581 . . . . 61.14 109.789 -179.38 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -119.03 98.73 6.32 Favored 'General case' 0 C--O 1.241 0.614 0 C-N-CA 124.256 1.023 . . . . 73.41 109.186 -178.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.433 HG21 HD22 ' A' ' 174' ' ' LEU . 8.6 m -131.8 121.45 47.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 124.457 1.103 . . . . 70.53 109.919 -173.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.25 22.84 13.55 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 124.533 1.133 . . . . 73.12 111.954 -178.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 88.8 2.39 78.64 Favored Glycine 0 C--N 1.345 1.067 0 CA-C-O 119.815 -0.436 . . . . 72.13 113.388 -177.17 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -92.8 113.92 26.33 Favored 'General case' 0 C--N 1.348 0.515 0 N-CA-C 108.625 -0.88 . . . . 74.41 108.625 175.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 59.9 ttp180 -106.22 110.85 23.22 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 108.116 -1.068 . . . . 62.22 108.116 176.1 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 5.7 m -141.38 155.72 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 124.52 1.128 . . . . 74.14 109.078 -177.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 47.4 t -87.21 115.5 24.65 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.128 -0.693 . . . . 65.22 109.128 177.312 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.2 p -99.33 136.66 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-O 121.095 0.474 . . . . 52.22 110.718 179.167 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 55.5 ttp180 -110.29 98.76 7.92 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 107.743 -1.206 . . . . 74.22 107.743 172.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.473 HD13 HH12 ' A' ' 136' ' ' ARG . 28.9 pt -89.88 131.24 39.99 Favored Pre-proline 0 N--CA 1.475 0.809 0 N-CA-C 108.684 -0.858 . . . . 73.33 108.684 177.27 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -72.01 157.7 53.98 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.45 2.1 . . . . 72.33 112.828 -172.1 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -68.5 148.17 72.39 Favored 'Trans proline' 0 C--N 1.375 1.959 0 C-N-CA 122.283 1.988 . . . . 74.12 111.356 172.204 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 100.04 41.49 2.83 Favored Glycine 0 C--N 1.34 0.786 0 N-CA-C 110.988 -0.845 . . . . 65.13 110.988 -176.504 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.7 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -111.37 160.74 10.47 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.267 0 N-CA-C 108.265 -1.013 . . . . 72.43 108.265 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.401 ' HD3' ' HB3' ' A' ' 188' ' ' LEU . 74.8 mtm180 -148.47 176.74 10.05 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 123.909 0.884 . . . . 72.01 111.735 -166.118 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.1 tp10 -55.61 115.74 2.51 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 114.214 -1.357 . . . . 50.22 111.072 170.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 75.89 10.22 85.06 Favored Glycine 0 C--N 1.345 1.053 0 O-C-N 123.601 0.563 . . . . 34.52 113.683 178.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 37.5 t -75.13 125.97 30.05 Favored 'General case' 0 C--O 1.245 0.819 0 C-N-CA 122.97 0.508 . . . . 71.05 109.906 -178.797 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.446 HG12 HD22 ' A' ' 175' ' ' LEU . 21.2 t -95.83 121.57 46.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 C-N-CA 124.719 1.208 . . . . 74.45 109.457 -175.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.538 HD11 HG21 ' A' ' 153' ' ' VAL . 27.3 mt -107.28 111.21 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 123.46 0.704 . . . . 51.42 109.634 -174.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 25.1 ttp180 -84.83 117.76 24.07 Favored 'General case' 0 CA--C 1.538 0.493 0 O-C-N 123.655 0.597 . . . . 63.32 109.989 179.192 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.5 m -114.86 96.47 44.67 Favored Pre-proline 0 CA--C 1.561 1.394 0 CA-C-O 121.431 0.634 . . . . 71.24 109.419 175.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -63.22 136.61 56.68 Favored 'Trans proline' 0 C--N 1.379 2.153 0 C-N-CA 123.391 2.727 . . . . 72.54 113.224 -175.616 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 97.59 -17.14 59.43 Favored Glycine 0 C--N 1.345 1.064 0 N-CA-C 114.39 0.516 . . . . 43.33 114.39 174.51 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 10.4 mtm -100.69 -6.29 25.31 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 117.718 0.759 . . . . 65.1 112.187 -174.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . 0.532 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . -88.33 -115.19 1.25 Allowed Glycine 0 C--N 1.351 1.391 0 N-CA-C 111.813 -0.515 . . . . 75.52 111.813 175.285 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.501 ' HA3' ' HB3' ' A' ' 117' ' ' ARG . . . -67.71 129.91 27.85 Favored Glycine 0 C--N 1.347 1.169 0 N-CA-C 112.012 -0.435 . . . . 73.22 112.012 178.373 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.0 mm-40 -89.65 154.18 20.16 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.477 0.711 . . . . 61.23 110.986 -177.745 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 137.68 -166.89 24.98 Favored Glycine 0 N--CA 1.472 1.041 0 N-CA-C 111.788 -0.525 . . . . 72.23 111.788 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -71.51 -42.18 10.73 Favored Pre-proline 0 CA--C 1.56 1.361 0 CA-C-O 118.331 -0.843 . . . . 65.15 110.805 174.085 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -69.57 116.26 4.46 Favored 'Trans proline' 0 C--N 1.394 2.953 0 C-N-CA 122.015 1.81 . . . . 61.13 110.401 164.32 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -71.08 125.08 11.11 Favored 'Trans proline' 0 C--N 1.375 1.957 0 C-N-CA 121.546 1.497 . . . . 74.43 111.688 177.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . . . . . . . . . . . -98.63 151.93 19.64 Favored Glycine 0 N--CA 1.452 -0.294 0 N-CA-C 110.123 -1.191 . . . . 74.12 110.123 171.039 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -116.49 167.83 10.71 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 124.422 1.089 . . . . 74.44 109.751 -173.598 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.552 HD21 HG21 ' A' ' 138' ' ' VAL . 11.8 tp -120.22 129.64 54.17 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.167 -1.049 . . . . 62.1 108.167 176.479 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.446 HD22 HG12 ' A' ' 158' ' ' VAL . 83.1 mt -103.79 98.6 8.43 Favored 'General case' 0 C--O 1.233 0.212 0 C-N-CA 124.345 1.058 . . . . 54.05 109.636 -175.39 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.577 HD13 ' NH2' ' A' ' 136' ' ' ARG . 45.4 mt -92.88 101.23 13.59 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.357 -0.838 . . . . 70.11 109.649 178.827 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.709 ' HB ' ' HG2' ' A' ' 122' ' ' GLU . 25.5 t -90.71 107.65 18.78 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 N-CA-C 108.422 -0.955 . . . . 71.12 108.422 179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.554 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 3.2 m -87.43 148.93 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 109.463 -0.569 . . . . 61.34 109.463 -177.733 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 10.0 mmm-85 -123.51 104.17 8.9 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 107.466 -1.309 . . . . 74.22 107.466 -174.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 27.4 mt -69.15 151.55 46.22 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-O 121.213 0.53 . . . . 64.21 111.3 -178.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 52.9 mt -54.56 150.7 16.59 Favored Pre-proline 0 CA--C 1.561 1.397 0 CA-C-N 114.608 -1.178 . . . . 72.11 112.383 -177.172 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -61.1 -8.05 9.26 Favored 'Trans proline' 0 C--N 1.385 2.489 0 C-N-CA 123.144 2.562 . . . . 74.02 113.459 177.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.472 ' O ' HD11 ' A' ' 127' ' ' LEU . 5.2 t60 -93.44 104.83 13.53 Favored Pre-proline 0 CA--C 1.544 0.743 0 C-N-CA 124.436 1.094 . . . . 72.32 108.726 164.011 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -101.16 128.82 0.13 Allowed 'Trans proline' 0 CA--C 1.559 1.746 0 C-N-CA 123.379 2.72 . . . . 61.32 112.486 165.69 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.504 HG12 HD13 ' A' ' 127' ' ' LEU . 2.6 p -113.85 -46.21 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 122.899 0.48 . . . . 74.04 109.998 172.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -98.98 122.68 42.55 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.031 0.443 . . . . 74.31 110.774 -174.195 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.63 ' HB3' ' HB2' ' A' ' 194' ' ' TYR . 28.7 ttm180 -97.88 109.13 21.94 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 107.6 -1.259 . . . . 75.21 107.6 170.536 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.401 ' HB3' ' HD3' ' A' ' 154' ' ' ARG . 50.1 tp -89.56 112.62 23.87 Favored 'General case' 0 CA--C 1.543 0.702 0 N-CA-C 108.597 -0.89 . . . . 61.13 108.597 173.515 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -108.97 102.13 11.16 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 108.291 -1.003 . . . . 74.4 108.291 176.162 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 72.16 -87.41 0.49 Allowed Glycine 0 C--N 1.347 1.166 0 O-C-N 123.704 0.627 . . . . 71.4 111.765 -174.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 5.0 pm0 -134.01 -4.94 2.75 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 124.17 0.988 . . . . 73.33 110.574 178.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 56.5 m-20 -93.66 151.4 19.68 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.598 0.759 . . . . 71.45 111.198 -177.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.425 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 88.8 mt -107.44 147.07 30.9 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 124.372 1.069 . . . . 72.3 109.429 -178.493 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . 0.63 ' HB2' ' HB3' ' A' ' 187' ' ' ARG . 89.4 m-85 -133.46 121.07 21.69 Favored 'General case' 0 C--O 1.232 0.182 0 N-CA-C 107.389 -1.337 . . . . 75.31 107.389 175.233 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -134.76 170.88 15.16 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 123.916 0.886 . . . . 73.43 108.892 178.126 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 87.1 m -109.55 124.2 50.71 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.64 -0.709 . . . . 52.04 109.288 175.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.417 ' HB2' ' HB3' ' A' ' 251' ' ' LEU . 57.6 tp -107.06 111.75 24.36 Favored 'General case' 0 C--O 1.225 -0.201 0 C-N-CA 124.154 0.982 . . . . 74.52 109.106 177.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -87.45 125.53 34.34 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 107.758 -1.201 . . . . 75.13 107.758 172.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . 0.495 HG12 HG21 ' A' ' 210' ' ' VAL . 15.4 m -120.15 135.19 24.23 Favored Pre-proline 0 N--CA 1.475 0.82 0 N-CA-C 108.901 -0.777 . . . . 75.23 108.901 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -57.69 140.21 92.79 Favored 'Trans proline' 0 C--N 1.367 1.549 0 C-N-CA 122.314 2.01 . . . . 65.25 111.624 169.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -50.24 -44.21 80.33 Favored Pre-proline 0 CA--C 1.567 1.621 0 CA-C-O 118.057 -0.973 . . . . 63.33 113.069 179.384 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo -47.59 -52.61 7.75 Favored 'Trans proline' 0 C--N 1.404 3.485 0 C-N-CA 122.816 2.344 . . . . 74.31 112.754 168.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 11.8 mt -68.34 -33.4 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 C-N-CA 123.079 0.552 . . . . 70.41 111.7 -176.316 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -59.61 -47.97 83.51 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.329 0.651 . . . . 74.04 110.863 178.227 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . 0.457 ' HA ' ' HA ' ' A' ' 226' ' ' ARG . 32.8 m -81.78 -35.57 13.66 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.898 0 CA-C-N 115.695 -0.684 . . . . 51.43 112.362 -174.587 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 14.2 m -84.61 -22.97 7.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 CA-C-N 118.24 0.473 . . . . 64.25 111.245 -179.039 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 71.7 56.7 6.42 Favored Glycine 0 C--N 1.343 0.939 0 CA-C-N 115.823 -0.626 . . . . 72.02 112.31 -174.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -84.75 -152.96 17.98 Favored Glycine 0 C--N 1.355 1.624 0 N-CA-C 111.979 -0.449 . . . . 72.12 111.979 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -111.79 140.54 46.34 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 109.106 -0.702 . . . . 71.22 109.106 177.29 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . 0.495 HG21 HG12 ' A' ' 199' ' ' VAL . 41.1 t -125.66 149.47 30.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 108.066 -1.087 . . . . 63.2 108.066 168.635 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . 0.435 ' HD2' ' HG2' ' A' ' 220' ' ' GLU . 0.2 OUTLIER -90.06 125.27 35.35 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 108.268 -1.012 . . . . 74.41 108.268 166.946 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -100.43 129.11 46.35 Favored 'General case' 0 C--O 1.248 0.999 0 N-CA-C 108.59 -0.893 . . . . 64.35 108.59 178.537 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 4.2 tpt -76.25 105.16 7.14 Favored 'General case' 0 CA--C 1.537 0.471 0 O-C-N 123.697 0.623 . . . . 62.32 109.435 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 9.2 t -117.26 169.68 9.28 Favored 'General case' 0 C--O 1.24 0.553 0 C-N-CA 123.418 0.687 . . . . 71.01 110.524 177.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 63.3 mt -76.1 -5.6 47.31 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 123.957 0.903 . . . . 55.35 111.423 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -88.12 -20.38 25.73 Favored 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 124.077 0.951 . . . . 73.34 110.348 172.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 130.64 -149.87 19.15 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-O 119.073 -0.848 . . . . 65.02 111.108 -174.26 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -86.83 120.38 1.67 Allowed 'Trans proline' 0 CA--C 1.553 1.428 0 C-N-CA 122.211 1.941 . . . . 73.41 111.604 169.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 20.0 m -108.24 155.39 9.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 108.968 -0.753 . . . . 63.21 108.968 173.59 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . 0.435 ' HG2' ' HD2' ' A' ' 211' ' ' ARG . 33.4 mt-10 -109.46 107.36 17.47 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 108.788 -0.819 . . . . 72.14 108.788 -175.305 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 4.2 p -96.38 132.54 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 C-N-CA 123.739 0.816 . . . . 63.42 110.342 177.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -90.69 105.41 17.8 Favored 'General case' 0 C--O 1.24 0.588 0 C-N-CA 123.648 0.779 . . . . 42.3 108.961 173.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 97.3 t -67.11 133.51 93.63 Favored Pre-proline 0 CA--C 1.557 1.24 0 C-N-CA 124.038 0.935 . . . . 62.2 110.063 177.578 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_exo -65.04 140.69 66.88 Favored 'Trans proline' 0 C--N 1.379 2.144 0 C-N-CA 122.89 2.393 . . . . 75.42 111.539 172.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -58.98 124.41 15.63 Favored 'Trans proline' 0 C--N 1.376 2.008 0 C-N-CA 122.724 2.283 . . . . 75.24 111.418 178.147 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . 0.457 ' HA ' ' HA ' ' A' ' 205' ' ' VAL . 85.3 mtm180 60.41 76.74 0.35 Allowed 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 124.423 1.089 . . . . 74.03 110.865 -177.533 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 7.5 t -103.71 173.81 6.14 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 123.365 0.666 . . . . 71.31 109.594 174.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -131.44 155.53 47.18 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 123.655 0.782 . . . . 65.42 109.019 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -69.11 130.23 42.12 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.297 0.639 . . . . 74.12 110.279 177.191 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.03 -11.5 22.48 Favored Glycine 0 C--N 1.337 0.588 0 C-N-CA 123.505 0.574 . . . . 64.33 112.129 -176.087 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 73.3 mtp180 -81.7 155.58 25.48 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 122.818 0.447 . . . . 74.11 110.481 178.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.505 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 0.5 OUTLIER -118.53 125.29 49.55 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.776 0.83 . . . . 74.44 109.762 -179.115 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 28.1 mt -100.79 111.55 23.79 Favored 'General case' 0 C--N 1.353 0.759 0 N-CA-C 108.127 -1.064 . . . . 73.02 108.127 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . 0.428 ' HG3' ' HB3' ' A' ' 248' ' ' ASP . 57.4 ttm-85 -82.91 105.4 13.88 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.9 0.88 . . . . 70.11 110.894 -170.268 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.534 HD12 HD23 ' A' ' 249' ' ' LEU . 30.0 mt -87.03 97.46 10.73 Favored 'General case' 0 C--O 1.241 0.656 0 N-CA-C 107.782 -1.192 . . . . 62.13 107.782 171.103 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 89.8 mttt -71.76 138.2 48.25 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 114.831 -1.077 . . . . 71.03 111.634 -169.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 75.89 4.08 76.05 Favored Glycine 0 C--N 1.348 1.238 0 O-C-N 123.801 0.688 . . . . 63.4 113.991 177.219 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . 0.604 ' HE2' ' HA ' ' A' ' 238' ' ' LYS . 9.6 mmpt? -94.17 -3.13 51.47 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.253 0.621 . . . . 73.13 111.955 -177.484 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -86.27 -170.68 47.2 Favored Glycine 0 C--N 1.343 0.967 0 N-CA-C 111.941 -0.463 . . . . 53.51 111.941 171.236 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.526 ' CZ ' ' HA ' ' A' ' 131' ' ' PHE . 97.3 m-85 -83.6 154.9 65.68 Favored Pre-proline 0 N--CA 1.477 0.917 0 C-N-CA 122.822 0.449 . . . . 61.04 111.687 -177.148 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . 0.474 ' HA ' ' O ' ' A' ' 245' ' ' GLY . 26.3 Cg_exo -64.5 127.05 18.06 Favored 'Trans proline' 0 C--N 1.375 1.962 0 C-N-CA 122.144 1.896 . . . . 54.43 110.468 166.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -165.22 -156.9 9.4 Favored Glycine 0 C--N 1.342 0.916 0 CA-C-O 119.219 -0.767 . . . . 75.24 112.329 -177.063 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -59.43 -10.78 11.83 Favored 'Trans proline' 0 N--CA 1.504 2.14 0 C-N-CA 124.017 3.145 . . . . 73.52 115.257 -178.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -109.49 19.14 19.62 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.287 0.635 . . . . 43.22 111.06 176.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 241' ' ' PRO . . . 77.45 -76.49 1.68 Allowed Glycine 0 C--N 1.345 1.067 0 N-CA-C 110.993 -0.843 . . . . 63.34 110.993 -173.34 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 55.5 mtm180 -123.77 155.88 37.1 Favored 'General case' 0 N--CA 1.476 0.875 0 N-CA-C 107.801 -1.185 . . . . 75.12 107.801 170.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -90.74 -177.89 43.85 Favored Glycine 0 C--N 1.338 0.682 0 O-C-N 123.34 0.4 . . . . 50.12 113.245 176.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . 0.428 ' HB3' ' HG3' ' A' ' 234' ' ' ARG . 60.9 m-20 -136.01 142.5 44.48 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.82 0.848 . . . . 70.34 109.189 -175.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.534 HD23 HD12 ' A' ' 235' ' ' LEU . 19.3 tp -97.53 112.97 24.6 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 109.346 -0.613 . . . . 62.24 109.346 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -90.29 105.86 18.1 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 108.754 -0.832 . . . . 75.02 108.754 176.509 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.505 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 93.6 mt -87.92 110.77 20.8 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.376 0.67 . . . . 52.23 112.01 176.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -79.06 92.98 5.06 Favored 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 109.117 -0.697 . . . . 75.25 109.117 -178.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 70.6 t -48.04 117.66 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 C-N-CA 124.911 1.284 . . . . 75.15 110.997 173.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 26.3 mmm180 -128.98 101.24 5.97 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 106.435 -1.691 . . . . 72.44 106.435 174.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 60.4 mt -77.17 117.51 22.24 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 CA-C-N 115.582 -0.735 . . . . 75.44 110.94 -172.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 3.3 t . . . . . 0 CA--C 1.559 1.326 0 C-N-CA 124.092 0.957 . . . . 72.21 109.211 177.725 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.403 ' HB2' ' H ' ' A' ' 139' ' ' GLU . . . . . . . . 0 N--CA 1.471 0.578 0 N-CA-C 108.742 -0.836 . . . . 74.32 108.742 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.74 -54.34 6.2 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 123.213 0.605 . . . . 61.51 111.531 -171.468 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.625 ' HG ' ' HG2' ' A' ' 136' ' ' ARG . 89.0 mt -82.86 -71.93 0.47 Allowed 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 109.844 -0.428 . . . . 61.12 109.844 177.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.472 ' HB ' HG23 ' A' ' 138' ' ' VAL . 30.0 t -58.89 131.13 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 C-N-CA 123.574 0.749 . . . . 50.55 111.798 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -70.67 -52.52 20.6 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.322 -0.853 . . . . 73.45 109.732 176.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -179.96 174.99 0.85 Allowed 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.556 1.142 . . . . 75.35 109.266 -178.124 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 88.7 t -65.19 132.16 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 N-CA-C 108.762 -0.829 . . . . 72.21 108.762 171.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.431 HG23 ' HA ' ' A' ' 121' ' ' ALA . 24.5 p -63.48 90.61 0.05 OUTLIER 'General case' 0 CA--C 1.547 0.842 0 CA-C-O 121.557 0.694 . . . . 71.11 110.962 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.0 p -76.57 91.67 3.41 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 114.741 -1.118 . . . . 43.3 109.154 176.621 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -172.37 159.7 30.73 Favored Glycine 0 C--N 1.339 0.696 0 CA-C-N 115.265 -0.88 . . . . 44.45 112.132 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 49.8 m -121.93 142.75 49.96 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.045 0.938 . . . . 60.32 109.285 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 178.39 -114.3 0.45 Allowed Glycine 0 C--N 1.339 0.716 0 N-CA-C 111.584 -0.606 . . . . 30.11 111.584 -179.309 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -107.73 107.94 2.67 Favored Glycine 0 C--N 1.341 0.814 0 N-CA-C 112.12 -0.392 . . . . 73.21 112.12 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 42.6 p -75.25 158.78 32.39 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 123.269 0.627 . . . . 64.55 110.135 175.157 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -68.41 149.82 50.22 Favored Glycine 0 C--N 1.342 0.868 0 O-C-N 123.196 0.31 . . . . 72.44 112.441 176.736 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -88.01 17.34 47.07 Favored Glycine 0 C--N 1.344 0.982 0 CA-C-O 119.975 -0.347 . . . . 50.24 113.076 178.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 41.3 t -84.0 -71.13 0.52 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.816 0.846 . . . . 75.53 109.599 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 65.68 -97.89 0.31 Allowed Glycine 0 C--N 1.351 1.393 0 O-C-N 123.475 0.485 . . . . 62.53 112.317 -178.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 71.74 -169.59 50.16 Favored Glycine 0 C--N 1.35 1.31 0 O-C-N 123.72 0.306 . . . . 62.21 112.782 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 25.2 m -77.59 147.27 35.75 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 123.223 0.609 . . . . 54.11 109.463 173.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 91.87 139.23 8.56 Favored Glycine 0 C--N 1.347 1.174 0 N-CA-C 112.032 -0.427 . . . . 50.41 112.032 -178.684 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 2.2 tmm_? -76.59 118.85 19.66 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.379 -0.6 . . . . 75.42 109.379 -176.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -89.1 146.23 24.95 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 123.717 0.807 . . . . 73.31 110.816 -179.062 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.49 HD22 HD13 ' A' ' 174' ' ' LEU . 4.9 tt -136.89 149.07 47.43 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 106.611 -1.626 . . . . 53.41 106.611 -179.312 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.435 ' N ' HD23 ' A' ' 119' ' ' LEU . 0.1 OUTLIER -138.11 148.69 45.23 Favored 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 119.335 0.97 . . . . 71.24 110.351 179.533 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.431 ' HA ' HG23 ' A' ' 103' ' ' THR . . . -156.89 163.26 39.37 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.525 1.13 . . . . 71.23 108.709 -177.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -126.45 151.56 47.59 Favored 'General case' 0 C--O 1.248 0.99 0 CA-C-O 121.063 0.459 . . . . 73.02 110.224 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.473 HD12 ' HB3' ' A' ' 98' ' ' LEU . 1.6 pt? -140.41 135.02 15.65 Favored Pre-proline 0 N--CA 1.468 0.451 0 CA-C-N 115.681 -0.691 . . . . 73.34 111.593 -174.6 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -66.09 114.55 3.05 Favored 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 121.781 1.654 . . . . 72.25 110.351 161.152 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.461 HD22 HG11 ' A' ' 178' ' ' VAL . 16.1 tp -115.48 166.29 12.05 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.313 1.045 . . . . 71.55 108.222 175.443 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 17.6 m -108.74 161.53 15.02 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.208 0.603 . . . . 70.12 109.46 174.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.491 HD11 ' O ' ' A' ' 183' ' ' HIS . 30.8 mt -55.97 -51.94 65.94 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.808 0.843 . . . . 61.13 109.7 173.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.574 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.9 mp0 -57.36 -38.38 74.07 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 114.408 -1.269 . . . . 72.4 111.667 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -76.83 -21.86 54.42 Favored 'General case' 0 N--CA 1.479 1.025 0 C-N-CA 123.362 0.665 . . . . 70.21 111.672 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.624 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -71.85 -25.82 62.12 Favored 'General case' 0 C--O 1.249 1.073 0 C-N-CA 123.704 0.802 . . . . 51.44 110.94 170.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.521 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 36.9 t80 -82.39 -47.39 12.36 Favored 'General case' 0 C--N 1.35 0.602 0 CA-C-N 115.477 -0.783 . . . . 75.25 111.736 171.601 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -74.32 -47.46 34.43 Favored 'General case' 0 N--CA 1.478 0.933 0 O-C-N 123.237 0.335 . . . . 74.43 111.338 -172.093 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.16 -153.09 52.63 Favored Glycine 0 CA--C 1.533 1.159 0 N-CA-C 111.183 -0.767 . . . . 74.24 111.183 -168.441 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 119.46 -175.96 15.96 Favored Glycine 0 C--N 1.343 0.953 0 N-CA-C 114.379 0.511 . . . . 51.14 114.379 171.149 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.619 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 1.7 mp0 -90.74 136.28 33.17 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.993 0.917 . . . . 65.34 109.372 -177.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.625 ' HG2' ' HG ' ' A' ' 98' ' ' LEU . 0.2 OUTLIER -153.11 150.89 29.57 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 110.375 -0.231 . . . . 75.2 110.375 176.059 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 25.3 m -75.87 136.82 24.03 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 123.251 0.62 . . . . 70.13 111.836 -173.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.472 HG23 ' HB ' ' A' ' 99' ' ' VAL . 5.8 p -142.86 135.9 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.925 0 C-N-CA 124.212 1.005 . . . . 72.25 111.297 178.158 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . 0.403 ' H ' ' HB2' ' A' ' 96' ' ' ALA . 1.4 mp0 -100.37 98.39 9.04 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 109.483 -0.562 . . . . 75.42 109.483 169.597 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 4.0 m -108.36 124.87 65.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 N-CA-C 108.895 -0.78 . . . . 72.33 108.895 171.61 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 63.09 21.83 13.09 Favored 'General case' 0 N--CA 1.481 1.115 0 C-N-CA 124.324 1.05 . . . . 61.51 111.436 -174.086 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.28 -1.78 86.38 Favored Glycine 0 C--N 1.356 1.656 0 CA-C-N 115.835 -0.62 . . . . 61.42 113.238 -178.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.3 mmt85 -94.3 117.11 29.62 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 123.207 0.603 . . . . 72.02 109.905 -178.295 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 43.1 ttm180 -84.9 115.94 23.05 Favored 'General case' 0 C--N 1.352 0.705 0 N-CA-C 109.756 -0.461 . . . . 73.42 109.756 175.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 12.2 m -136.68 155.27 33.37 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 C-N-CA 125.136 1.375 . . . . 74.33 108.708 177.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 60.8 p -86.81 114.98 23.93 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 109.139 -0.689 . . . . 73.52 109.139 174.134 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.0 p -96.15 124.67 48.96 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 CA-C-O 121.172 0.51 . . . . 71.1 109.924 176.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . 0.619 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 13.7 ttp180 -99.03 104.94 17.01 Favored 'General case' 0 C--O 1.244 0.799 0 N-CA-C 108.841 -0.8 . . . . 71.03 108.841 175.511 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 32.7 pt -95.63 131.3 29.71 Favored Pre-proline 0 CA--C 1.548 0.878 0 N-CA-C 108.737 -0.838 . . . . 72.21 108.737 174.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -71.39 146.1 49.57 Favored 'Trans proline' 0 C--N 1.371 1.728 0 C-N-CA 122.554 2.169 . . . . 63.21 112.923 -174.697 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.64 142.5 89.84 Favored 'Trans proline' 0 C--N 1.378 2.108 0 C-N-CA 122.881 2.387 . . . . 75.13 111.425 172.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.71 52.39 0.75 Allowed Glycine 0 C--N 1.339 0.709 0 N-CA-C 110.7 -0.96 . . . . 53.55 110.7 -173.246 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.624 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.3 p -130.65 162.12 39.26 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 108.165 -1.05 . . . . 72.01 108.165 179.581 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.6 ' HA ' HD11 ' A' ' 180' ' ' LEU . 0.0 OUTLIER -162.37 173.67 13.81 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 124.925 1.29 . . . . 73.35 110.379 -179.352 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.4 tp10 -47.3 118.38 2.15 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 124.601 1.16 . . . . 70.24 112.711 -176.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 100.5 -24.86 30.47 Favored Glycine 0 C--N 1.349 1.296 0 CA-C-O 119.153 -0.804 . . . . 53.2 113.562 178.797 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.56 ' HB2' HG23 ' A' ' 153' ' ' VAL . 43.6 m -60.09 125.7 24.68 Favored 'General case' 0 C--O 1.248 0.998 0 C-N-CA 123.34 0.656 . . . . 63.21 111.127 -174.493 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.532 HG22 HD22 ' A' ' 175' ' ' LEU . 14.8 p -100.57 123.21 53.37 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.095 0 CA-C-N 114.801 -1.091 . . . . 64.1 109.071 -179.027 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.424 HD11 HG21 ' A' ' 153' ' ' VAL . 25.9 mt -105.38 112.97 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.329 1.052 . . . . 64.41 109.545 -170.166 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 34.6 ttt-85 -92.75 105.32 17.48 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 122.822 0.449 . . . . 74.23 110.256 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.426 HG22 ' HB3' ' A' ' 174' ' ' LEU . 10.5 m -97.79 112.38 61.41 Favored Pre-proline 0 CA--C 1.561 1.396 0 N-CA-C 108.072 -1.084 . . . . 72.35 108.072 176.209 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 161' ' ' VAL . 7.6 Cg_exo -73.65 156.22 49.26 Favored 'Trans proline' 0 C--N 1.374 1.875 0 C-N-CA 123.132 2.555 . . . . 75.21 113.213 -171.598 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 66.09 24.44 71.79 Favored Glycine 0 C--N 1.347 1.188 0 O-C-N 123.715 0.635 . . . . 52.54 114.14 177.367 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.6 tpt -101.8 -63.21 1.17 Allowed 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.293 0.637 . . . . 74.41 111.288 -170.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -68.48 -62.8 3.89 Favored Glycine 0 C--N 1.353 1.514 0 N-CA-C 111.412 -0.675 . . . . 51.14 111.412 178.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.602 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -69.72 99.77 0.7 Allowed Glycine 0 C--N 1.341 0.822 0 CA-C-N 115.121 -0.54 . . . . 62.3 111.87 173.048 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -89.25 169.51 11.38 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.579 0.752 . . . . 75.5 110.56 176.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 89.57 -143.28 17.13 Favored Glycine 0 C--O 1.242 0.622 0 N-CA-C 111.344 -0.703 . . . . 44.45 111.344 -174.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 29.5 p-10 -92.23 -13.56 0.19 Allowed Pre-proline 0 CA--C 1.563 1.453 0 N-CA-C 114.8 1.407 . . . . 54.03 114.8 175.447 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -91.53 101.75 0.23 Allowed 'Trans proline' 0 C--N 1.398 3.145 0 CA-C-N 123.099 2.142 . . . . 71.33 110.997 165.714 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -73.22 126.72 11.33 Favored 'Trans proline' 0 C--N 1.371 1.749 0 C-N-CA 122.421 2.081 . . . . 72.05 112.108 -176.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.602 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -99.89 -137.09 9.64 Favored Glycine 0 C--N 1.342 0.916 0 N-CA-C 111.156 -0.778 . . . . 71.33 111.156 176.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -167.38 165.55 14.92 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 117.377 0.588 . . . . 75.14 111.245 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.49 HD13 HD22 ' A' ' 119' ' ' LEU . 35.5 tp -124.98 122.63 37.86 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 114.822 -1.081 . . . . 70.33 108.191 166.844 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.532 HD22 HG22 ' A' ' 158' ' ' VAL . 30.2 mt -95.17 101.42 13.16 Favored 'General case' 0 CA--C 1.534 0.328 0 C-N-CA 124.542 1.137 . . . . 52.42 110.188 178.535 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 56.5 mt -93.5 105.42 17.47 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.56 0.744 . . . . 72.04 111.653 178.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 15.4 t -88.66 108.36 18.77 Favored 'Isoleucine or valine' 0 C--O 1.246 0.876 0 N-CA-C 108.977 -0.749 . . . . 60.04 108.977 176.286 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.461 HG11 HD22 ' A' ' 125' ' ' LEU . 25.5 m -77.69 148.3 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 N-CA-C 112.991 0.738 . . . . 62.42 112.991 -176.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 37.5 mmt180 -124.08 96.89 5.11 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 113.91 -1.495 . . . . 71.04 107.613 175.321 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.6 HD11 ' HA ' ' A' ' 154' ' ' ARG . 35.1 mt -69.09 147.74 51.02 Favored 'General case' 0 C--O 1.241 0.624 0 O-C-N 123.132 0.27 . . . . 63.34 110.725 -179.246 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.413 ' HA ' ' HD3' ' A' ' 182' ' ' PRO . 40.8 mt -54.13 128.55 57.51 Favored Pre-proline 0 CA--C 1.551 0.988 0 O-C-N 124.354 1.034 . . . . 54.11 110.055 177.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 181' ' ' LEU . 31.7 Cg_exo -60.27 82.04 0.07 OUTLIER 'Trans proline' 0 C--N 1.377 2.034 0 C-N-CA 123.792 2.994 . . . . 65.32 113.563 -176.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.491 ' O ' HD11 ' A' ' 127' ' ' LEU . 2.3 p80 -170.05 109.08 0.45 Allowed Pre-proline 0 CA--C 1.551 0.986 0 N-CA-C 106.652 -1.61 . . . . 71.22 106.652 171.521 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -89.52 127.31 1.63 Allowed 'Trans proline' 0 C--N 1.36 1.159 0 C-N-CA 122.096 1.864 . . . . 64.11 112.622 178.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 5.2 p -137.21 -47.78 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 109.515 -0.55 . . . . 64.12 109.515 168.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -109.84 123.55 49.76 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-O 121.436 0.636 . . . . 72.1 111.731 -176.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.478 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 0.1 OUTLIER -113.47 162.5 16.06 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.672 1.589 . . . . 71.4 109.351 -179.461 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.437 HD12 ' O ' ' A' ' 192' ' ' ASP . 43.2 tp -130.49 136.71 49.25 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 123.665 0.786 . . . . 64.31 109.958 179.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.476 ' HB3' ' CE1' ' A' ' 194' ' ' TYR . 10.0 tp10 -142.07 109.94 5.82 Favored 'General case' 0 C--O 1.242 0.683 0 C-N-CA 124.184 0.994 . . . . 73.32 108.345 176.147 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 72.22 -83.33 0.53 Allowed Glycine 0 C--N 1.347 1.153 0 N-CA-C 111.447 -0.661 . . . . 64.4 111.447 -174.468 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . 0.539 ' NE2' ' HB3' ' A' ' 244' ' ' ALA . 29.7 pt20 -141.74 -8.26 0.95 Allowed 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.85 0.86 . . . . 72.23 110.017 178.206 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.437 ' O ' HD12 ' A' ' 188' ' ' LEU . 17.1 m-20 -93.88 156.35 16.69 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.447 0.699 . . . . 75.21 111.169 -171.406 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.469 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 90.4 mt -104.59 150.89 24.26 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 124.816 1.246 . . . . 53.41 108.913 -177.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . 0.478 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 77.4 m-85 -138.26 128.39 25.75 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 107.167 -1.42 . . . . 72.4 107.167 -177.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -154.18 171.27 19.44 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 123.842 0.857 . . . . 62.34 109.197 -176.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 14.6 m -120.41 135.28 55.09 Favored 'General case' 0 C--O 1.238 0.5 0 N-CA-C 108.867 -0.79 . . . . 74.11 108.867 176.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.558 HD23 HD12 ' A' ' 233' ' ' LEU . 70.1 tp -123.63 114.18 19.66 Favored 'General case' 0 C--O 1.217 -0.62 0 C-N-CA 124.112 0.965 . . . . 63.31 109.542 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -84.78 119.78 25.69 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 108.266 -1.012 . . . . 75.52 108.266 171.032 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 84.2 t -110.22 126.4 29.02 Favored Pre-proline 0 N--CA 1.469 0.486 0 N-CA-C 108.632 -0.877 . . . . 72.01 108.632 -178.543 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -54.56 133.33 56.2 Favored 'Trans proline' 0 C--N 1.375 1.958 0 C-N-CA 122.767 2.311 . . . . 64.51 110.903 172.4 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -51.68 -45.37 91.52 Favored Pre-proline 0 CA--C 1.556 1.191 0 C-N-CA 124.568 1.147 . . . . 71.21 113.685 -175.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -53.41 -45.53 40.35 Favored 'Trans proline' 0 C--N 1.39 2.751 0 C-N-CA 121.841 1.694 . . . . 74.23 113.666 173.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . 0.437 HG21 HG13 ' A' ' 210' ' ' VAL . 8.7 mt -67.62 -37.71 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.08 0 C-N-CA 122.386 0.274 . . . . 75.15 111.276 178.437 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -67.19 -34.53 77.7 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 122.977 0.511 . . . . 42.32 112.319 -176.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.3 m -83.77 -39.17 14.74 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 CA-C-N 116.159 -0.473 . . . . 54.22 111.052 -177.593 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m -82.68 -24.81 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-N 118.12 0.418 . . . . 72.03 110.939 179.676 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 79.02 67.54 1.58 Allowed Glycine 0 C--N 1.341 0.813 0 CA-C-N 116.084 -0.507 . . . . 72.51 112.493 -177.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -101.46 -147.23 19.95 Favored Glycine 0 C--N 1.35 1.31 0 CA-C-N 116.854 0.327 . . . . 64.24 112.337 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 59.1 pttt -127.64 138.19 52.76 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 124.319 1.048 . . . . 64.51 109.43 -177.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . 0.437 HG13 HG21 ' A' ' 203' ' ' ILE . 17.9 m -126.28 143.74 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.117 0.967 . . . . 73.34 109.179 175.31 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 10.0 mpt_? -85.36 107.16 17.23 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 108.958 -0.756 . . . . 63.04 108.958 174.253 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . . . . . . . . . . . -101.6 117.59 35.22 Favored 'General case' 0 CA--C 1.517 -0.31 0 N-CA-C 107.62 -1.252 . . . . 64.24 107.62 174.39 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . 0.504 ' HA ' ' HA ' ' A' ' 218' ' ' PRO . 1.2 ppp? -79.38 138.23 37.59 Favored 'General case' 0 C--O 1.243 0.754 0 N-CA-C 109.29 -0.633 . . . . 74.22 109.29 179.003 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.527 HG23 ' HG2' ' A' ' 216' ' ' GLU . 4.5 t -128.9 174.95 9.04 Favored 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 124.155 0.982 . . . . 73.24 108.805 177.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . 0.574 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 73.9 mt -72.99 -3.34 25.46 Favored 'General case' 0 CA--C 1.549 0.929 0 N-CA-C 113.613 0.968 . . . . 70.32 113.613 -169.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . 0.527 ' HG2' HG23 ' A' ' 214' ' ' THR . 14.3 pt-20 -104.8 -4.62 22.07 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 123.806 0.842 . . . . 53.12 111.183 175.487 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 129.28 -174.09 19.35 Favored Glycine 0 C--N 1.344 0.982 0 N-CA-C 110.686 -0.966 . . . . 63.23 110.686 -172.073 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . 0.504 ' HA ' ' HA ' ' A' ' 213' ' ' MET . 2.2 Cg_endo -81.84 133.38 7.96 Favored 'Trans proline' 0 CA--C 1.55 1.283 0 C-N-CA 122.52 2.147 . . . . 65.22 112.13 179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 34.5 m -110.27 165.15 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.076 0 C-N-CA 123.077 0.551 . . . . 74.11 111.915 171.371 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -111.41 113.03 25.19 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 124.058 0.943 . . . . 74.23 109.011 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.567 HG22 HD11 ' A' ' 235' ' ' LEU . 21.8 t -97.19 117.65 42.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 C-N-CA 123.439 0.696 . . . . 72.2 110.36 178.731 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -87.57 105.53 17.39 Favored 'General case' 0 C--O 1.239 0.519 0 N-CA-C 107.442 -1.318 . . . . 64.04 107.442 171.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 6.2 m -80.95 142.38 51.96 Favored Pre-proline 0 CA--C 1.553 1.085 0 N-CA-C 109.383 -0.599 . . . . 54.1 109.383 -177.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -62.62 144.28 93.98 Favored 'Trans proline' 0 C--N 1.371 1.725 0 C-N-CA 123.003 2.469 . . . . 54.15 112.977 177.022 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.04 122.99 10.94 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.411 2.074 . . . . 73.3 111.306 174.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 73.5 mtt180 67.99 36.38 3.39 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.693 1.197 . . . . 65.45 110.822 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . 0.509 HG23 HD11 ' A' ' 255' ' ' ILE . 9.3 t -67.53 172.06 5.49 Favored 'General case' 0 CA--C 1.551 1.017 0 CA-C-N 115.865 -0.607 . . . . 64.41 110.86 -178.585 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 27.2 mp0 -117.51 138.03 52.16 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.645 0.778 . . . . 60.44 109.623 -174.314 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -66.66 114.64 5.73 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.365 0.666 . . . . 54.13 110.046 176.317 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.79 3.71 19.86 Favored Glycine 0 C--N 1.336 0.549 0 CA-C-N 115.897 -0.592 . . . . 70.11 112.251 -176.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . 0.414 ' O ' HG12 ' A' ' 253' ' ' VAL . 57.3 mtp180 -78.39 161.83 26.87 Favored 'General case' 0 C--O 1.243 0.725 0 CA-C-O 121.684 0.754 . . . . 64.23 110.838 173.129 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.429 ' HD2' ' N ' ' A' ' 232' ' ' LYS . 0.1 OUTLIER -99.96 100.7 11.64 Favored 'General case' 0 C--O 1.24 0.565 0 CA-C-N 114.235 -1.348 . . . . 74.01 108.367 -178.447 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 251' ' ' LEU . 33.3 mt -84.53 97.71 9.72 Favored 'General case' 0 C--N 1.351 0.646 0 N-CA-C 105.217 -2.142 . . . . 74.43 105.217 173.826 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . 0.469 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 51.6 ttp85 -96.13 103.64 15.54 Favored 'General case' 0 C--O 1.24 0.593 0 CA-C-N 114.781 -1.099 . . . . 72.5 109.437 -165.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.585 HD12 HD23 ' A' ' 249' ' ' LEU . 20.2 mt -85.02 97.83 10.06 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 107.589 -1.263 . . . . 75.21 107.589 177.664 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 10.4 mtmp? -69.43 135.97 50.96 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 114.639 -1.164 . . . . 71.11 111.479 -169.67 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 80.17 13.82 81.39 Favored Glycine 0 C--N 1.347 1.194 0 O-C-N 123.577 0.548 . . . . 32.31 113.354 177.395 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . 0.676 ' HE2' ' HA ' ' A' ' 238' ' ' LYS . 9.3 mmpt? -96.98 -18.79 19.21 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 122.877 0.471 . . . . 71.45 112.222 -178.318 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . 0.466 ' HA2' ' HG ' ' A' ' 193' ' ' LEU . . . -82.75 169.64 49.02 Favored Glycine 0 C--N 1.338 0.689 0 N-CA-C 112.028 -0.429 . . . . 63.04 112.028 176.688 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.521 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 98.0 m-85 -66.06 154.91 88.69 Favored Pre-proline 0 N--CA 1.479 0.994 0 C-N-CA 123.45 0.7 . . . . 74.22 111.933 -172.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -66.55 128.13 18.55 Favored 'Trans proline' 0 C--N 1.367 1.524 0 C-N-CA 121.948 1.765 . . . . 64.35 110.289 165.163 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -151.5 -159.02 8.65 Favored Glycine 0 N--CA 1.465 0.632 0 CA-C-O 119.714 -0.492 . . . . 65.3 112.732 -178.591 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -65.95 -13.02 37.92 Favored 'Trans proline' 0 C--N 1.373 1.851 0 C-N-CA 123.375 2.716 . . . . 65.41 114.324 -170.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . 0.539 ' HB3' ' NE2' ' A' ' 191' ' ' GLN . . . -116.9 25.03 10.81 Favored 'General case' 0 N--CA 1.482 1.126 0 C-N-CA 122.86 0.464 . . . . 62.43 110.684 178.767 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 102.87 -101.92 2.17 Favored Glycine 0 C--N 1.348 1.206 0 CA-C-O 119.764 -0.465 . . . . 62.1 112.149 174.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 9.5 ttm180 -124.43 155.31 39.09 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 108.573 -0.899 . . . . 74.33 108.573 173.092 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -94.74 -173.48 38.01 Favored Glycine 0 C--N 1.335 0.511 0 CA-C-O 121.271 0.373 . . . . 54.13 113.114 -177.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -135.95 168.06 20.04 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 108.062 -1.088 . . . . 70.22 108.062 -177.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.585 HD23 HD12 ' A' ' 235' ' ' LEU . 16.7 tp -104.96 124.16 49.03 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 122.786 0.434 . . . . 71.12 110.366 173.037 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . 0.433 ' HB3' ' HA ' ' A' ' 194' ' ' TYR . 11.6 t80 -89.3 108.53 19.68 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 124.62 1.168 . . . . 74.32 108.077 171.232 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 233' ' ' LEU . 65.7 mt -96.89 120.83 37.97 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.793 -0.447 . . . . 70.11 109.793 164.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -83.55 94.41 8.05 Favored 'General case' 0 C--O 1.237 0.41 0 N-CA-C 108.012 -1.107 . . . . 72.32 108.012 168.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 231' ' ' ARG . 2.3 p -59.48 126.9 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 CA-C-O 121.291 0.567 . . . . 71.21 110.203 177.513 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 10.2 mmm180 -127.19 94.74 4.09 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 107.299 -1.371 . . . . 75.12 107.299 -177.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.509 HD11 HG23 ' A' ' 227' ' ' THR . 64.6 mt -74.77 120.04 23.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 115.193 -0.912 . . . . 73.1 109.74 -172.54 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 1.4 t . . . . . 0 CA--C 1.557 1.214 0 C-N-CA 125.161 1.384 . . . . 73.4 108.506 -174.129 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.955 0 N-CA-C 110.17 -0.307 . . . . 52.3 110.17 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.513 ' HB1' HG13 ' A' ' 137' ' ' VAL . . . -73.41 -98.25 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.078 0 C-N-CA 124.049 0.94 . . . . 74.15 109.867 174.032 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.531 HD11 HD13 ' A' ' 149' ' ' ILE . 0.9 OUTLIER -124.79 49.18 1.87 Allowed 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 107.038 -1.468 . . . . 72.11 107.038 170.153 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.507 HG23 ' HB1' ' A' ' 121' ' ' ALA . 2.9 p -173.88 131.39 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-N 113.72 -1.582 . . . . 61.53 109.006 -176.12 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.482 ' HB2' ' HD3' ' A' ' 124' ' ' PRO . . . -94.09 -46.85 6.94 Favored 'General case' 0 N--CA 1.472 0.625 0 C-N-CA 123.264 0.626 . . . . 62.25 110.072 174.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 2.1 p80 -163.45 151.72 13.59 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 115.653 -0.703 . . . . 62.22 111.18 -178.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 93.5 t -73.79 126.57 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.021 0.929 . . . . 64.0 109.168 175.009 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 10.1 t -128.88 83.45 2.15 Favored 'General case' 0 CA--C 1.547 0.838 0 CA-C-O 122.357 1.075 . . . . 62.21 110.127 -178.277 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.2 t -64.6 -32.95 74.82 Favored 'General case' 0 CA--C 1.547 0.828 0 CA-C-N 115.571 -0.741 . . . . 72.2 110.259 175.55 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 74.86 -82.46 0.85 Allowed Glycine 0 C--N 1.356 1.644 0 CA-C-N 115.586 -0.734 . . . . 50.3 112.181 179.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 88.5 p -165.64 164.04 19.15 Favored 'General case' 0 C--O 1.246 0.909 0 C-N-CA 124.222 1.009 . . . . 74.32 109.544 175.297 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -80.12 147.4 28.84 Favored Glycine 0 C--N 1.339 0.701 0 CA-C-N 115.761 -0.654 . . . . 62.13 111.678 175.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.48 137.16 4.09 Favored Glycine 0 C--N 1.338 0.688 0 N-CA-C 111.767 -0.533 . . . . 33.43 111.767 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 25.5 t -86.57 81.4 8.28 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 123.028 0.531 . . . . 53.52 109.861 178.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -72.25 -28.49 68.01 Favored Glycine 0 C--N 1.345 1.058 0 CA-C-N 115.432 -0.804 . . . . 61.41 112.518 176.16 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -175.61 -140.95 3.58 Favored Glycine 0 C--N 1.342 0.882 0 N-CA-C 110.684 -0.966 . . . . 74.12 110.684 177.446 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 67.0 m -99.55 113.82 26.46 Favored 'General case' 0 C--O 1.241 0.65 0 N-CA-C 108.945 -0.761 . . . . 62.14 108.945 173.018 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -87.28 53.24 4.4 Favored Glycine 0 C--N 1.349 1.253 0 N-CA-C 111.751 -0.54 . . . . 72.04 111.751 179.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.67 80.38 1.19 Allowed Glycine 0 C--N 1.349 1.298 0 N-CA-C 111.799 -0.52 . . . . 31.3 111.799 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 21.2 t -158.01 -169.48 2.83 Favored 'General case' 0 C--O 1.243 0.724 0 C-N-CA 123.859 0.863 . . . . 72.02 109.024 -174.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -74.98 -165.38 14.32 Favored Glycine 0 C--N 1.344 1.027 0 N-CA-C 111.748 -0.541 . . . . 43.31 111.748 167.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 -61.59 121.9 13.92 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 122.762 0.425 . . . . 65.44 110.73 176.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -69.58 133.62 47.84 Favored 'General case' 0 N--CA 1.472 0.638 0 O-C-N 124.58 1.175 . . . . 54.04 109.299 172.125 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.461 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 33.4 tp -136.35 121.33 18.8 Favored 'General case' 0 C--O 1.215 -0.755 0 N-CA-C 106.595 -1.631 . . . . 72.2 106.595 -175.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -121.34 131.88 54.45 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.603 -0.517 . . . . 73.33 109.603 -171.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.507 ' HB1' HG23 ' A' ' 99' ' ' VAL . . . -153.12 146.81 25.14 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.294 0.637 . . . . 65.11 109.701 -177.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -126.16 152.98 45.25 Favored 'General case' 0 C--O 1.244 0.768 0 CA-C-O 121.081 0.467 . . . . 54.21 110.49 177.062 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -145.5 148.58 37.6 Favored Pre-proline 0 N--CA 1.471 0.583 0 CA-C-N 114.933 -1.031 . . . . 71.13 110.362 -177.119 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.482 ' HD3' ' HB2' ' A' ' 100' ' ' ALA . 4.0 Cg_exo -73.86 115.31 4.28 Favored 'Trans proline' 0 C--N 1.37 1.695 0 C-N-CA 121.561 1.507 . . . . 73.23 110.151 167.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' A' ' 180' ' ' LEU . 23.8 tp -105.84 148.47 27.52 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 108.378 -0.971 . . . . 74.02 108.378 175.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.765 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 24.7 m -76.38 147.23 38.18 Favored 'General case' 0 CA--C 1.547 0.853 0 N-CA-C 109.963 -0.384 . . . . 51.53 109.963 173.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.532 HD23 ' HB3' ' A' ' 180' ' ' LEU . 96.6 mt -52.73 -51.42 60.57 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 121.822 0.82 . . . . 65.22 110.48 172.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.594 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -55.76 -28.83 58.01 Favored 'General case' 0 CA--C 1.551 1.003 0 CA-C-N 113.947 -1.479 . . . . 61.33 112.451 177.211 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.68 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 22.1 mm-40 -86.24 -21.44 27.41 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 118.18 0.446 . . . . 73.3 111.679 178.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.655 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -61.13 -34.67 75.36 Favored 'General case' 0 C--O 1.239 0.546 0 CA-C-O 121.268 0.556 . . . . 72.34 110.059 164.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.639 ' HA ' ' HZ ' ' A' ' 240' ' ' PHE . 57.8 t80 -76.42 -50.84 13.1 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 114.823 -1.08 . . . . 71.41 112.887 172.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -75.27 -49.21 19.97 Favored 'General case' 0 N--CA 1.486 1.33 0 C-N-CA 122.338 0.255 . . . . 63.25 111.651 -170.364 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 66.15 -161.61 44.33 Favored Glycine 0 CA--C 1.535 1.331 0 CA-C-O 119.905 -0.386 . . . . 71.54 112.153 -173.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 128.63 -169.66 20.08 Favored Glycine 0 N--CA 1.476 1.305 0 CA-C-N 117.307 0.554 . . . . 52.32 114.272 171.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -94.61 121.34 36.07 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 124.156 0.982 . . . . 72.3 108.592 -178.129 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 4.6 mmp_? -130.66 167.32 18.96 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.759 0.823 . . . . 53.41 108.977 172.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.513 HG13 ' HB1' ' A' ' 97' ' ' ALA . 13.0 p -90.53 142.14 13.37 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 108.736 -0.839 . . . . 70.31 108.736 179.152 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.479 HG22 HG23 ' A' ' 140' ' ' VAL . 8.8 p -131.05 136.59 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.75 0 N-CA-C 108.863 -0.792 . . . . 71.53 108.863 177.522 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . 0.459 ' HA ' ' O ' ' A' ' 143' ' ' ARG . 36.6 tt0 -126.6 97.83 5.17 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.854 -0.425 . . . . 63.21 109.854 172.483 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.479 HG23 HG22 ' A' ' 138' ' ' VAL . 22.9 t -122.13 138.26 52.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 108.208 -1.034 . . . . 65.24 108.208 174.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 64.52 21.58 12.48 Favored 'General case' 0 N--CA 1.482 1.136 0 C-N-CA 124.712 1.205 . . . . 70.13 111.341 -176.61 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.59 13.71 82.9 Favored Glycine 0 C--N 1.352 1.452 0 CA-C-N 116.056 -0.52 . . . . 64.22 113.631 -179.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.459 ' O ' ' HA ' ' A' ' 139' ' ' GLU . 72.5 mtt180 -108.71 117.67 34.79 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.29 0.636 . . . . 74.34 109.468 179.217 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 21.7 ttm180 -105.35 105.35 15.35 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 109.842 -0.429 . . . . 72.53 109.842 -176.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 61.1 t -129.92 141.98 45.01 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.53 1.132 . . . . 63.53 108.291 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.427 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 72.0 p -72.2 111.12 7.14 Favored 'General case' 0 CA--C 1.546 0.817 0 N-CA-C 109.022 -0.733 . . . . 74.44 109.022 174.212 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 12.2 p -96.82 147.4 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 C-N-CA 123.884 0.874 . . . . 72.24 109.327 -179.245 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -109.03 127.45 54.11 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 107.888 -1.152 . . . . 71.32 107.888 171.281 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.531 HD13 HD11 ' A' ' 98' ' ' LEU . 38.1 pt -120.62 124.73 27.45 Favored Pre-proline 0 CA--C 1.547 0.858 0 N-CA-C 107.873 -1.158 . . . . 71.42 107.873 170.016 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_endo -72.13 153.5 57.12 Favored 'Trans proline' 0 C--N 1.373 1.847 0 C-N-CA 122.346 2.031 . . . . 71.12 113.021 -173.061 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -65.59 147.68 86.63 Favored 'Trans proline' 0 C--N 1.373 1.852 0 C-N-CA 122.282 1.988 . . . . 62.43 111.428 170.041 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 101.42 53.38 1.0 Allowed Glycine 0 C--N 1.335 0.521 0 N-CA-C 110.123 -1.191 . . . . 75.11 110.123 -171.502 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.655 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -128.49 161.04 38.02 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.299 0 N-CA-C 108.191 -1.041 . . . . 51.32 108.191 -179.459 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -146.16 171.39 15.0 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 124.206 1.002 . . . . 43.02 110.502 -165.562 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 15.5 tp10 -56.59 125.74 23.54 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 123.416 0.686 . . . . 73.22 110.426 169.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.83 -6.0 56.21 Favored Glycine 0 C--N 1.347 1.151 0 CA-C-O 119.362 -0.688 . . . . 63.1 113.921 179.73 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 47.8 t -67.06 129.11 38.82 Favored 'General case' 0 C--N 1.359 0.987 0 C-N-CA 123.404 0.682 . . . . 75.41 109.548 -178.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.469 HG12 HD22 ' A' ' 175' ' ' LEU . 13.7 t -104.98 118.25 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 O-C-N 124.83 1.331 . . . . 74.11 109.102 -171.218 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.457 HD11 HG21 ' A' ' 153' ' ' VAL . 28.1 mt -104.51 111.31 33.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 123.878 0.871 . . . . 74.42 109.71 -171.311 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 54.9 ttt180 -81.35 117.89 22.2 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.573 0.749 . . . . 70.44 110.643 177.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.641 HG22 ' HB3' ' A' ' 174' ' ' LEU . 2.9 m -118.04 117.14 35.51 Favored Pre-proline 0 CA--C 1.557 1.224 0 N-CA-C 109.093 -0.706 . . . . 73.3 109.093 170.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -81.26 149.69 17.2 Favored 'Trans proline' 0 C--N 1.377 2.042 0 C-N-CA 122.473 2.116 . . . . 73.04 112.663 -177.538 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 82.1 24.71 54.26 Favored Glycine 0 C--N 1.349 1.286 0 CA-C-N 115.925 -0.579 . . . . 75.13 113.649 177.383 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 54.9 tpp -109.8 -57.68 2.15 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.545 0.738 . . . . 71.32 110.68 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -70.12 -82.87 0.2 Allowed Glycine 0 C--N 1.356 1.657 0 N-CA-C 111.665 -0.574 . . . . 60.3 111.665 -179.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.742 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -63.91 113.45 5.89 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 112.329 -0.308 . . . . 52.01 112.329 166.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -87.74 172.16 9.88 Favored 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 124.189 0.995 . . . . 73.12 109.899 171.26 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 92.82 -135.77 12.83 Favored Glycine 0 C--N 1.342 0.864 0 N-CA-C 112.019 -0.433 . . . . 41.13 112.019 179.18 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 62.4 m-80 -81.15 -48.86 1.05 Allowed Pre-proline 0 CA--C 1.556 1.189 0 CA-C-O 117.68 -1.152 . . . . 71.13 111.779 177.052 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -71.02 113.61 3.63 Favored 'Trans proline' 0 C--N 1.399 3.193 0 C-N-CA 121.871 1.714 . . . . 60.43 111.546 176.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -74.85 125.97 9.76 Favored 'Trans proline' 0 C--N 1.381 2.244 0 C-N-CA 121.989 1.793 . . . . 54.22 111.52 -178.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.742 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -94.67 144.89 17.43 Favored Glycine 0 C--N 1.338 0.658 0 N-CA-C 112.096 -0.402 . . . . 74.03 112.096 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . 0.412 ' HA ' ' O ' ' A' ' 161' ' ' VAL . 63.9 m-20 -106.39 116.47 31.99 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 123.035 0.534 . . . . 74.12 110.207 -169.561 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.641 ' HB3' HG22 ' A' ' 161' ' ' VAL . 47.3 tp -89.85 109.68 20.66 Favored 'General case' 0 C--O 1.235 0.338 0 N-CA-C 107.36 -1.348 . . . . 44.23 107.36 171.428 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.469 HD22 HG12 ' A' ' 158' ' ' VAL . 70.0 mt -89.88 98.91 12.04 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.085 1.354 . . . . 62.33 109.538 -179.416 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 84.0 mt -90.22 102.86 15.58 Favored 'General case' 0 C--O 1.232 0.173 0 C-N-CA 124.075 0.95 . . . . 71.02 110.876 179.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 35.1 t -86.91 105.25 14.82 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 N-CA-C 108.161 -1.051 . . . . 62.54 108.161 175.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 7.8 m -83.48 148.99 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 CA-C-O 121.551 0.691 . . . . 51.51 111.336 -178.388 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . 0.445 ' HB2' ' HA ' ' A' ' 124' ' ' PRO . 35.3 mmt180 -119.04 100.15 7.17 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 107.236 -1.394 . . . . 74.13 107.236 -178.492 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.532 ' HB3' HD23 ' A' ' 127' ' ' LEU . 41.7 mt -67.47 145.86 54.56 Favored 'General case' 0 C--O 1.239 0.514 0 O-C-N 122.938 0.149 . . . . 72.45 110.771 -176.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.765 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 26.5 mt -55.98 138.92 71.76 Favored Pre-proline 0 CA--C 1.548 0.897 0 O-C-N 123.603 0.564 . . . . 71.3 111.211 -177.034 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.8 67.55 4.79 Favored 'Trans proline' 0 C--N 1.377 2.036 0 C-N-CA 123.368 2.712 . . . . 73.25 113.668 -174.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 8.8 p80 -155.47 82.3 3.84 Favored Pre-proline 0 CA--C 1.557 1.247 0 N-CA-C 108.18 -1.044 . . . . 52.01 108.18 172.055 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -62.88 126.16 17.51 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 121.726 1.617 . . . . 72.33 111.548 -175.085 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.8 p -136.75 -48.14 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 108.103 -1.073 . . . . 74.4 108.103 174.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.494 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 4.2 m-85 -113.16 137.16 51.88 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.759 0.824 . . . . 64.43 110.554 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.572 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 2.7 mpt_? -125.09 154.39 41.46 Favored 'General case' 0 CA--C 1.537 0.446 0 N-CA-C 106.836 -1.542 . . . . 74.02 106.836 175.626 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . . . . . . . . . 48.4 tp -134.43 137.9 44.37 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.305 -0.628 . . . . 71.02 109.305 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -142.07 115.89 9.23 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 107.592 -1.262 . . . . 71.1 107.592 169.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 66.71 -95.48 0.27 Allowed Glycine 0 C--N 1.346 1.13 0 O-C-N 123.779 0.674 . . . . 61.33 111.918 -175.282 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . 0.434 ' OE1' ' HD2' ' A' ' 243' ' ' PRO . 1.9 mp0 -120.63 -19.51 7.42 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.673 0.789 . . . . 71.41 110.267 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -83.03 144.01 30.23 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.438 0.695 . . . . 64.02 112.005 -171.421 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.512 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 92.6 mt -106.64 155.72 19.36 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 124.917 1.287 . . . . 74.24 108.239 177.379 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . 0.572 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 73.9 m-85 -139.9 121.84 15.59 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 107.117 -1.438 . . . . 74.34 107.117 -179.083 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -139.9 141.87 36.52 Favored 'General case' 0 CA--C 1.51 -0.58 0 N-CA-C 109.342 -0.614 . . . . 74.24 109.342 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 25.7 m -91.35 118.07 30.21 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 108.779 -0.823 . . . . 70.12 108.779 178.512 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.478 HD13 ' HB2' ' A' ' 212' ' ' ALA . 65.0 tp -105.94 113.3 26.76 Favored 'General case' 0 N--CA 1.469 0.481 0 C-N-CA 123.714 0.805 . . . . 71.1 109.357 -178.154 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . 0.402 ' HA ' ' O ' ' A' ' 254' ' ' ARG . 14.5 p-10 -89.54 111.55 22.49 Favored 'General case' 0 C--O 1.244 0.776 0 N-CA-C 108.879 -0.786 . . . . 61.54 108.879 172.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . . . . . . . . . 60.5 t -97.44 119.18 63.38 Favored Pre-proline 0 CA--C 1.536 0.414 0 N-CA-C 108.269 -1.011 . . . . 62.52 108.269 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -56.52 135.13 68.62 Favored 'Trans proline' 0 C--N 1.371 1.731 0 C-N-CA 122.439 2.093 . . . . 70.33 110.95 176.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -50.33 -43.86 79.99 Favored Pre-proline 0 CA--C 1.564 1.482 0 C-N-CA 124.803 1.241 . . . . 53.21 113.519 -174.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . 0.447 ' O ' HG22 ' A' ' 206' ' ' VAL . 92.1 Cg_exo -49.35 -54.7 5.04 Favored 'Trans proline' 0 C--N 1.397 3.094 0 C-N-CA 122.395 2.064 . . . . 73.03 113.075 169.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 12.6 mt -66.03 -35.65 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 C-N-CA 122.6 0.36 . . . . 74.33 110.956 -178.328 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -58.27 -44.13 88.26 Favored 'General case' 0 N--CA 1.464 0.26 0 C-N-CA 123.503 0.721 . . . . 72.12 110.885 -178.07 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 31.5 m -89.75 -57.69 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.157 0 N-CA-C 112.701 0.63 . . . . 63.43 112.701 -177.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.447 HG22 ' O ' ' A' ' 202' ' ' PRO . 33.2 m -94.86 -27.01 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 118.768 0.713 . . . . 51.44 112.388 -173.299 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -86.53 -146.89 10.24 Favored Glycine 0 C--N 1.342 0.906 0 N-CA-C 112.29 -0.324 . . . . 64.4 112.29 -171.183 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . 169.05 10.4 0.02 OUTLIER Glycine 0 C--N 1.339 0.732 0 CA-C-O 118.933 -0.926 . . . . 73.21 115.184 -179.222 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 53.5 mttp -138.48 119.42 14.33 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 118.255 1.027 . . . . 64.13 108.538 -179.206 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 6.2 p -140.54 137.05 36.31 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 108.054 -1.091 . . . . 73.21 108.054 177.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . 0.406 ' N ' ' HD2' ' A' ' 211' ' ' ARG . 7.6 mpt_? -98.56 126.88 44.28 Favored 'General case' 0 C--O 1.24 0.555 0 N-CA-C 108.672 -0.862 . . . . 70.54 108.672 -177.187 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.478 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -102.2 138.42 39.16 Favored 'General case' 0 C--O 1.244 0.808 0 C-N-CA 123.537 0.735 . . . . 70.53 110.076 -176.102 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 3.0 tpt -74.69 109.18 7.96 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-N 115.379 -0.828 . . . . 70.24 109.378 175.026 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.494 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 8.8 t -111.61 166.81 10.84 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 123.011 0.524 . . . . 61.54 110.162 174.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . 0.594 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 64.6 mt -72.38 -5.53 37.09 Favored 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 123.8 0.84 . . . . 74.45 111.86 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -96.16 -20.61 18.48 Favored 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 124.405 1.082 . . . . 73.25 111.126 177.121 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 136.41 -146.41 18.37 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 119.211 -0.772 . . . . 43.25 111.298 -171.239 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -86.06 127.78 3.07 Favored 'Trans proline' 0 CA--C 1.556 1.618 0 C-N-CA 122.541 2.16 . . . . 71.22 112.729 170.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . 0.452 HG13 HG21 ' A' ' 214' ' ' THR . 17.2 m -109.34 150.9 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 N-CA-C 108.974 -0.75 . . . . 61.34 108.974 164.801 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -111.35 108.76 18.46 Favored 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 107.874 -1.158 . . . . 72.24 107.874 178.048 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 2.8 p -104.43 133.81 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.644 0 C-N-CA 123.187 0.595 . . . . 73.51 110.31 177.225 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.19 125.57 35.12 Favored 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 115.625 -0.716 . . . . 74.54 109.779 177.457 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.458 HG12 HD11 ' A' ' 233' ' ' LEU . 28.1 m -97.4 141.12 22.54 Favored Pre-proline 0 N--CA 1.479 1.018 0 N-CA-C 108.485 -0.931 . . . . 73.44 108.485 173.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -60.62 139.89 88.24 Favored 'Trans proline' 0 C--N 1.37 1.698 0 C-N-CA 122.171 1.914 . . . . 71.1 111.971 176.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -53.31 112.39 0.92 Allowed 'Trans proline' 0 C--N 1.381 2.253 0 C-N-CA 122.629 2.219 . . . . 75.23 110.781 172.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 70.2 mtp180 66.13 72.4 0.39 Allowed 'General case' 0 CA--C 1.548 0.884 0 O-C-N 124.597 1.186 . . . . 74.41 110.428 -164.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 12.1 t -81.6 173.87 11.95 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 123.638 0.775 . . . . 72.4 109.299 169.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . 0.464 HE21 ' HD2' ' A' ' 231' ' ' ARG . 2.2 mp0 -132.24 147.38 52.41 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 123.814 0.846 . . . . 64.25 109.302 -176.437 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.08 117.6 11.86 Favored 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 123.316 0.647 . . . . 72.24 109.583 174.496 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 114.25 3.16 22.97 Favored Glycine 0 C--N 1.344 1.023 0 CA-C-N 116.133 -0.485 . . . . 40.34 113.108 -174.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . 0.464 ' HD2' HE21 ' A' ' 228' ' ' GLN . 19.2 mtp-105 -83.63 160.65 21.33 Favored 'General case' 0 N--CA 1.479 1.015 0 CA-C-N 117.286 0.543 . . . . 75.12 111.223 175.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -116.05 120.83 40.36 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.549 1.139 . . . . 74.25 109.523 -176.224 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . 0.458 HD11 HG12 ' A' ' 223' ' ' VAL . 33.1 mt -110.54 100.02 8.91 Favored 'General case' 0 C--O 1.237 0.416 0 N-CA-C 107.2 -1.407 . . . . 70.12 107.2 174.548 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . 0.444 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 44.4 ttp180 -95.65 104.13 16.04 Favored 'General case' 0 CA--C 1.542 0.636 0 CA-C-N 115.566 -0.743 . . . . 62.13 109.859 -170.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.492 HD12 HD23 ' A' ' 249' ' ' LEU . 16.5 mt -81.04 119.07 23.06 Favored 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 123.17 0.588 . . . . 72.13 110.131 -177.118 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 34.2 mtmm -66.65 120.67 13.85 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 125.085 1.354 . . . . 72.12 112.514 -168.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 65.84 33.95 87.27 Favored Glycine 0 C--N 1.351 1.405 0 O-C-N 123.983 0.802 . . . . 63.14 114.053 170.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 28.5 mmtp -116.01 2.11 13.4 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 123.474 0.71 . . . . 73.51 111.635 179.104 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -88.72 -177.58 46.66 Favored Glycine 0 C--N 1.345 1.082 0 N-CA-C 111.434 -0.666 . . . . 65.21 111.434 167.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.639 ' HZ ' ' HA ' ' A' ' 131' ' ' PHE . 95.2 m-85 -74.68 151.82 87.04 Favored Pre-proline 0 N--CA 1.479 1.016 0 C-N-CA 122.545 0.338 . . . . 73.54 111.119 -177.141 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -77.58 165.68 26.77 Favored 'Trans proline' 0 C--N 1.372 1.788 0 C-N-CA 122.036 1.824 . . . . 73.32 111.631 178.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 161.07 -157.39 28.92 Favored Glycine 0 CA--C 1.528 0.876 0 CA-C-O 119.545 -0.586 . . . . 63.04 113.106 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . 0.434 ' HD2' ' OE1' ' A' ' 191' ' ' GLN . 77.1 Cg_exo -54.35 -23.24 29.83 Favored 'Trans proline' 0 C--N 1.375 1.945 0 C-N-CA 124.174 3.249 . . . . 60.44 114.315 175.582 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -90.42 19.42 5.24 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 123.362 0.665 . . . . 63.11 111.484 176.233 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 71.26 -94.18 0.54 Allowed Glycine 0 C--N 1.352 1.452 0 N-CA-C 110.893 -0.883 . . . . 74.43 110.893 -174.568 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . . . . . . . . . 69.7 mtt180 -119.7 146.2 45.82 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 124.7 1.2 . . . . 72.53 107.847 166.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -80.44 -173.16 46.12 Favored Glycine 0 C--O 1.24 0.483 0 O-C-N 123.766 0.666 . . . . 73.1 111.751 173.021 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -137.94 163.05 32.46 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 123.278 0.631 . . . . 70.04 109.327 -176.37 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.512 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 18.3 tp -99.63 109.58 22.07 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 109.46 -0.57 . . . . 71.05 109.46 172.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -87.86 105.42 17.4 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 107.083 -1.451 . . . . 71.1 107.083 175.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.422 HD22 ' HB2' ' A' ' 197' ' ' LEU . 78.4 mt -87.49 145.98 26.01 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 123.02 0.528 . . . . 75.45 111.575 172.678 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -110.83 98.18 7.39 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 107.924 -1.139 . . . . 71.31 107.924 174.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 61.3 t -56.94 126.56 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 123.227 0.611 . . . . 73.42 110.737 176.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . 0.402 ' O ' ' HA ' ' A' ' 198' ' ' ASP . 23.2 mmt180 -132.86 97.11 3.95 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 106.968 -1.493 . . . . 53.11 106.968 178.339 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 62.4 mt -74.59 122.57 28.28 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 N-CA-C 109.274 -0.639 . . . . 61.05 109.274 -177.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.3 t . . . . . 0 CA--C 1.565 1.525 0 C-N-CA 124.719 1.207 . . . . 63.5 108.779 -177.392 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.241 0 CA-C-O 120.455 0.169 . . . . 75.33 110.976 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -79.11 -41.44 28.62 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 116.292 -0.413 . . . . 54.53 111.202 -179.012 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 14.8 mt -97.79 -78.77 0.48 Allowed 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 122.952 0.501 . . . . 73.41 111.082 174.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.784 ' HA ' ' HB3' ' A' ' 123' ' ' LEU . 24.6 m -58.62 159.16 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 N-CA-C 114.252 1.205 . . . . 71.43 114.252 -173.796 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -108.08 -43.2 4.46 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 113.428 -1.714 . . . . 74.54 109.127 178.053 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 2.9 p80 -177.9 169.74 1.97 Allowed 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 124.08 0.952 . . . . 73.23 110.445 -178.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 85.7 t -64.98 116.33 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 108.287 -1.005 . . . . 73.43 108.287 166.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.52 ' HB ' ' HB2' ' A' ' 122' ' ' GLU . 10.2 t -71.13 -46.28 61.94 Favored 'General case' 0 N--CA 1.473 0.695 0 O-C-N 123.381 0.426 . . . . 75.12 111.539 -174.109 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 32.7 t -167.89 102.27 0.47 Allowed 'General case' 0 C--O 1.238 0.452 0 N-CA-C 108.721 -0.844 . . . . 72.11 108.721 -174.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -81.54 68.33 3.48 Favored Glycine 0 C--N 1.341 0.861 0 N-CA-C 111.907 -0.477 . . . . 50.11 111.907 178.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 59.2 p -82.99 22.21 0.97 Allowed 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 124.051 0.94 . . . . 64.45 111.375 -178.253 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 78.65 -79.5 1.54 Allowed Glycine 0 C--N 1.347 1.169 0 N-CA-C 110.428 -1.069 . . . . 65.11 110.428 -170.188 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 124.77 -154.6 18.17 Favored Glycine 0 C--N 1.34 0.777 0 C-N-CA 123.299 0.476 . . . . 22.23 111.989 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 31.1 t -90.78 -57.19 2.9 Favored 'General case' 0 C--O 1.241 0.656 0 C-N-CA 123.903 0.881 . . . . 43.2 109.64 -177.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 73.7 -160.85 53.81 Favored Glycine 0 C--N 1.345 1.057 0 CA-C-N 115.779 -0.646 . . . . 63.03 112.137 -175.142 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 176.65 -158.58 24.77 Favored Glycine 0 C--N 1.341 0.809 0 C-N-CA 121.584 -0.341 . . . . 62.42 113.423 -179.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 43.9 t -122.91 -65.06 1.13 Allowed 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 124.608 1.163 . . . . 74.34 108.539 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -86.42 76.67 2.1 Favored Glycine 0 C--N 1.344 1.0 0 N-CA-C 110.779 -0.929 . . . . 63.34 110.779 175.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.18 173.27 30.04 Favored Glycine 0 C--N 1.339 0.742 0 N-CA-C 111.435 -0.666 . . . . 62.23 111.435 -170.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 49.4 m 59.29 84.0 0.12 Allowed 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 124.507 1.123 . . . . 64.22 111.777 -179.59 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -73.67 -105.1 0.08 OUTLIER Glycine 0 C--N 1.342 0.897 0 CA-C-N 115.374 -0.83 . . . . 71.33 111.107 171.374 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.91 123.26 39.43 Favored 'General case' 0 CA--C 1.542 0.659 0 N-CA-C 108.953 -0.758 . . . . 74.33 108.953 172.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -70.47 130.52 42.1 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.642 -0.873 . . . . 64.32 108.642 174.37 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 50.3 tp -108.18 127.06 53.49 Favored 'General case' 0 C--O 1.217 -0.638 0 N-CA-C 106.994 -1.484 . . . . 74.33 106.994 173.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 45.3 mtp85 -120.76 108.95 14.58 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.621 -0.511 . . . . 75.54 109.621 -170.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -130.69 139.55 50.32 Favored 'General case' 0 N--CA 1.478 0.944 0 C-N-CA 123.436 0.694 . . . . 33.24 110.578 -174.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . 0.52 ' HB2' ' HB ' ' A' ' 103' ' ' THR . 34.8 tt0 -104.38 146.53 28.7 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.266 0.626 . . . . 74.34 110.294 178.436 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.784 ' HB3' ' HA ' ' A' ' 99' ' ' VAL . 1.8 pt? -145.7 146.32 28.79 Favored Pre-proline 0 N--CA 1.467 0.415 0 C-N-CA 124.077 0.951 . . . . 64.32 110.379 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -78.36 121.91 5.42 Favored 'Trans proline' 0 C--N 1.366 1.457 0 C-N-CA 121.977 1.785 . . . . 73.11 110.581 167.539 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.529 ' HB2' ' HB ' ' A' ' 178' ' ' VAL . 14.2 tp -111.86 162.04 15.72 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.582 0.753 . . . . 71.13 109.218 175.161 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 19.5 m -101.86 158.03 16.42 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 109.174 -0.676 . . . . 75.02 109.174 175.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.477 HD23 ' HB3' ' A' ' 180' ' ' LEU . 65.1 mt -55.81 -52.19 64.87 Favored 'General case' 0 N--CA 1.486 1.352 0 CA-C-O 121.717 0.77 . . . . 63.43 111.248 179.06 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.414 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 10.9 mp0 -54.26 -33.24 58.1 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 114.495 -1.23 . . . . 65.2 111.708 175.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 20.4 mm-40 -85.96 -18.61 32.16 Favored 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 123.306 0.642 . . . . 73.25 111.98 -176.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.681 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -60.23 -41.34 92.9 Favored 'General case' 0 C--O 1.247 0.947 0 CA-C-O 121.805 0.812 . . . . 72.42 110.41 162.345 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.465 ' HA ' ' CE2' ' A' ' 240' ' ' PHE . 66.1 t80 -73.15 -43.2 61.91 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 114.365 -1.289 . . . . 72.4 112.812 175.003 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.8 m80 -83.94 -49.25 9.16 Favored 'General case' 0 N--CA 1.493 1.692 0 N-CA-C 112.439 0.533 . . . . 71.13 112.439 -172.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 69.06 -110.61 3.46 Favored Glycine 0 CA--C 1.531 1.063 0 N-CA-C 111.412 -0.675 . . . . 52.33 111.412 -173.597 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 90.0 172.99 45.13 Favored Glycine 0 C--N 1.35 1.318 0 C-N-CA 123.079 0.371 . . . . 61.14 113.923 168.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.63 ' HG3' ' HB2' ' A' ' 148' ' ' ARG . 2.1 mp0 -86.34 125.72 33.83 Favored 'General case' 0 C--N 1.351 0.671 0 N-CA-C 108.975 -0.75 . . . . 71.54 108.975 178.071 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 33.2 ttt85 -156.15 138.05 14.41 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 108.139 -1.06 . . . . 73.34 108.139 175.434 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.705 ' HA ' ' HA ' ' A' ' 146' ' ' SER . 12.6 p -72.51 142.64 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 112.85 0.685 . . . . 73.03 112.85 -167.327 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 34.6 m -124.26 152.39 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 124.262 1.025 . . . . 75.35 109.781 174.121 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -124.5 104.31 8.66 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 107.179 -1.415 . . . . 63.13 107.179 171.14 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 7.1 p -150.9 139.12 14.43 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.965 0 C-N-CA 123.593 0.757 . . . . 54.54 109.885 -176.368 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 61.17 20.56 11.07 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 125.26 1.424 . . . . 74.43 112.768 -176.504 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.19 26.65 57.33 Favored Glycine 0 C--N 1.346 1.085 0 CA-C-N 116.538 -0.301 . . . . 54.41 112.385 -176.057 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.3 mmt180 -127.16 117.57 22.63 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.61 0.764 . . . . 64.21 110.277 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 43.1 ttp180 -98.5 104.57 16.62 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 108.321 -0.992 . . . . 72.13 108.321 173.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 2.2 m -146.81 137.47 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 123.672 0.789 . . . . 53.43 109.853 -177.197 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.705 ' HA ' ' HA ' ' A' ' 137' ' ' VAL . 35.7 p -73.34 118.19 15.99 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.413 0.685 . . . . 64.12 110.146 177.173 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 10.9 p -100.08 139.07 22.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 122.933 0.493 . . . . 64.02 110.129 -178.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . 0.63 ' HB2' ' HG3' ' A' ' 135' ' ' GLU . 24.8 ttp180 -106.9 106.47 17.01 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 108.344 -0.984 . . . . 75.23 108.344 173.585 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.465 ' HB ' HD13 ' A' ' 159' ' ' ILE . 34.2 pt -96.73 128.33 36.29 Favored Pre-proline 0 CA--C 1.546 0.794 0 N-CA-C 107.828 -1.175 . . . . 73.42 107.828 175.084 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -71.14 151.35 61.12 Favored 'Trans proline' 0 C--N 1.373 1.822 0 C-N-CA 122.331 2.021 . . . . 71.43 113.59 -167.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.422 ' HB3' ' O ' ' A' ' 131' ' ' PHE . 43.4 Cg_exo -60.54 110.52 0.82 Allowed 'Trans proline' 0 C--N 1.378 2.105 0 C-N-CA 122.779 2.319 . . . . 70.41 109.939 169.755 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 131.37 59.64 0.09 OUTLIER Glycine 0 C--N 1.341 0.811 0 N-CA-C 111.01 -0.836 . . . . 73.45 111.01 -170.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.681 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.7 p -140.24 162.82 24.26 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.203 0 N-CA-C 108.453 -0.943 . . . . 60.31 108.453 177.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.545 ' HD2' ' HB3' ' A' ' 188' ' ' LEU . 38.5 mtp180 -146.67 176.52 9.79 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 124.405 1.082 . . . . 72.44 110.869 -171.006 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 -56.74 117.81 4.27 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 124.537 1.135 . . . . 75.42 111.694 173.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 78.24 7.75 87.67 Favored Glycine 0 C--N 1.342 0.869 0 CA-C-N 115.372 -0.831 . . . . 72.52 113.645 179.128 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 33.8 t -78.76 136.32 37.35 Favored 'General case' 0 C--N 1.35 0.599 0 CA-C-O 121.145 0.498 . . . . 53.15 109.799 -178.105 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.435 HG12 HD22 ' A' ' 175' ' ' LEU . 8.2 t -103.47 119.29 51.81 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 CA-C-N 114.531 -1.213 . . . . 74.44 109.329 -172.099 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.578 HD11 HG21 ' A' ' 153' ' ' VAL . 26.4 mt -103.05 115.55 45.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.811 0.844 . . . . 75.12 110.417 -171.214 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 32.2 ttt85 -85.06 107.32 17.1 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.603 0.761 . . . . 62.05 109.813 177.098 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.452 HG22 ' O ' ' A' ' 174' ' ' LEU . 25.4 m -112.88 111.59 51.01 Favored Pre-proline 0 CA--C 1.56 1.356 0 C-N-CA 122.648 0.379 . . . . 64.3 110.404 178.119 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -65.97 148.74 86.17 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 123.286 2.657 . . . . 71.14 114.01 -173.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 70.75 23.9 77.44 Favored Glycine 0 C--N 1.352 1.433 0 CA-C-N 116.025 -0.534 . . . . 42.52 114.218 173.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 52.9 mmm -120.16 -30.64 4.6 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.876 0.87 . . . . 75.2 111.554 -172.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -83.87 -98.74 0.59 Allowed Glycine 0 C--N 1.346 1.104 0 O-C-N 123.146 0.279 . . . . 73.43 113.069 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.504 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -67.24 98.69 0.46 Allowed Glycine 0 C--N 1.346 1.128 0 N-CA-C 111.777 -0.529 . . . . 52.14 111.777 177.741 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . . . . . . . . . 11.5 mm-40 -78.3 106.17 10.03 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 123.83 0.852 . . . . 75.33 110.301 -178.104 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 170.24 -158.57 30.59 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 116.096 -0.502 . . . . 72.43 112.012 178.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.485 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 25.0 t-20 -66.27 -47.54 60.16 Favored Pre-proline 0 CA--C 1.563 1.443 0 CA-C-O 118.307 -0.854 . . . . 70.44 111.65 -175.764 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.485 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 3.0 Cg_exo -77.42 112.55 3.38 Favored 'Trans proline' 0 C--N 1.387 2.588 0 C-N-CA 122.119 1.879 . . . . 74.41 110.414 165.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.32 122.55 9.82 Favored 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 121.871 1.714 . . . . 75.33 111.698 -176.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.504 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -97.65 150.12 19.4 Favored Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.788 -0.925 . . . . 75.04 110.788 175.014 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -106.88 160.05 15.79 Favored 'General case' 0 C--O 1.238 0.45 0 C-N-CA 123.622 0.769 . . . . 51.32 109.691 -178.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.452 ' O ' HG22 ' A' ' 161' ' ' VAL . 13.8 tp -115.04 114.7 25.72 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 108.204 -1.035 . . . . 64.43 108.204 -179.713 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.435 HD22 HG12 ' A' ' 158' ' ' VAL . 57.0 mt -84.72 101.69 12.4 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.673 1.189 . . . . 74.31 111.237 176.381 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.422 ' HB3' HD21 ' A' ' 123' ' ' LEU . 42.5 mt -90.93 105.65 17.97 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 114.95 -1.023 . . . . 74.31 111.32 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 27.3 t -85.55 99.67 7.77 Favored 'Isoleucine or valine' 0 C--O 1.242 0.685 0 N-CA-C 107.959 -1.126 . . . . 44.41 107.959 172.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.529 ' HB ' ' HB2' ' A' ' 125' ' ' LEU . 17.4 m -82.25 148.88 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 121.216 0.531 . . . . 71.15 110.235 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 39.4 mmm-85 -121.2 103.95 9.38 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 107.798 -1.186 . . . . 65.41 107.798 178.329 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.477 ' HB3' HD23 ' A' ' 127' ' ' LEU . 30.6 mt -67.97 149.08 50.19 Favored 'General case' 0 C--O 1.242 0.667 0 N-CA-C 109.256 -0.646 . . . . 45.12 109.256 177.339 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 40.2 mt -53.85 137.56 54.79 Favored Pre-proline 0 CA--C 1.552 1.045 0 O-C-N 123.674 0.609 . . . . 74.14 110.311 -178.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -58.78 -5.13 2.35 Favored 'Trans proline' 0 C--N 1.378 2.119 0 C-N-CA 123.141 2.56 . . . . 61.13 114.073 -177.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.456 ' O ' HD11 ' A' ' 127' ' ' LEU . 6.2 t60 -83.72 107.76 11.36 Favored Pre-proline 0 CA--C 1.548 0.893 0 C-N-CA 124.654 1.182 . . . . 72.42 108.526 162.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -96.67 163.48 1.12 Allowed 'Trans proline' 0 C--N 1.369 1.631 0 C-N-CA 122.916 2.411 . . . . 74.45 111.922 168.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.66 -42.98 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 122.999 0.52 . . . . 72.2 109.769 169.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.503 ' CZ ' ' HA ' ' A' ' 214' ' ' THR . 5.6 m-85 -101.92 123.97 46.74 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 115.783 -0.644 . . . . 70.45 110.795 -176.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -109.64 123.38 49.38 Favored 'General case' 0 C--O 1.238 0.449 0 C-N-CA 125.136 1.375 . . . . 73.3 108.092 179.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.545 ' HB3' ' HD2' ' A' ' 154' ' ' ARG . 22.4 tp -95.58 113.11 24.73 Favored 'General case' 0 CA--C 1.547 0.85 0 CA-C-O 121.445 0.641 . . . . 60.24 111.174 -173.158 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -83.93 170.37 14.08 Favored 'General case' 0 CA--C 1.555 1.166 0 C-N-CA 125.533 1.533 . . . . 72.04 107.826 162.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . -42.77 86.74 0.01 OUTLIER Glycine 0 C--N 1.362 2.004 0 CA-C-N 118.761 0.71 . . . . 53.53 114.357 175.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 67.18 -4.82 0.78 Allowed 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 127.658 2.383 . . . . 64.23 113.554 -175.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.503 ' O ' HD12 ' A' ' 188' ' ' LEU . 27.2 t70 -105.52 156.13 18.52 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 124.899 1.28 . . . . 64.44 109.989 -174.463 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.536 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 78.4 mt -113.62 157.7 21.78 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 124.047 0.939 . . . . 72.11 112.177 -172.686 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . . . . . . . . . 46.8 m-85 -139.61 122.25 16.33 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 114.419 -1.264 . . . . 74.03 108.378 174.164 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -142.61 171.1 14.51 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 124.144 0.978 . . . . 62.5 109.504 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 16.2 m -109.41 128.43 55.13 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 109.779 -0.452 . . . . 74.23 109.779 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.476 HD22 HD13 ' A' ' 251' ' ' LEU . 62.3 tp -114.75 115.0 26.35 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.222 1.009 . . . . 61.25 109.713 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . 0.436 ' HA ' ' HB2' ' A' ' 254' ' ' ARG . 10.3 m-20 -99.68 106.35 18.27 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.655 -0.498 . . . . 72.05 109.655 178.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . 0.496 HG12 HG21 ' A' ' 210' ' ' VAL . 6.4 m -107.72 147.36 35.23 Favored Pre-proline 0 N--CA 1.481 1.097 0 C-N-CA 123.232 0.613 . . . . 74.22 109.563 178.179 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.32 148.8 55.87 Favored 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 122.149 1.899 . . . . 64.2 110.565 167.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . . . . . . . . . . . -54.14 -44.38 98.4 Favored Pre-proline 0 CA--C 1.56 1.346 0 CA-C-O 117.468 -1.253 . . . . 61.42 112.893 176.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -43.66 -52.98 4.78 Favored 'Trans proline' 0 C--N 1.403 3.396 0 C-N-CA 123.029 2.486 . . . . 75.45 113.895 171.032 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . 0.522 HG21 HG13 ' A' ' 210' ' ' VAL . 6.3 mt -71.05 -38.06 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 CA-C-N 116.62 -0.263 . . . . 63.22 110.781 -177.639 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -61.01 -38.71 87.05 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 123.321 0.648 . . . . 65.34 112.078 -178.211 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 34.8 m -84.45 -38.44 13.62 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 CA-C-N 116.173 -0.467 . . . . 65.03 111.759 -176.318 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.1 m -78.2 -27.51 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 CA-C-N 118.121 0.418 . . . . 60.12 111.201 179.408 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . 0.456 ' HA2' HG23 ' A' ' 223' ' ' VAL . . . 79.56 53.52 4.32 Favored Glycine 0 C--N 1.339 0.72 0 CA-C-N 115.554 -0.748 . . . . 73.25 112.849 -175.773 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -82.8 -152.6 11.53 Favored Glycine 0 C--N 1.354 1.555 0 N-CA-C 111.762 -0.535 . . . . 75.23 111.762 178.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 57.9 mttp -125.27 139.13 53.98 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 123.371 0.668 . . . . 74.44 109.842 176.265 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . 0.522 HG13 HG21 ' A' ' 203' ' ' ILE . 13.6 m -123.71 134.63 65.9 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 CA-C-N 114.737 -1.119 . . . . 70.04 108.322 173.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 39.7 ttp-105 -81.64 113.48 19.68 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 108.835 -0.802 . . . . 72.2 108.835 175.564 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.42 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -101.19 165.6 11.21 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.374 -0.973 . . . . 65.21 108.374 175.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 1.9 mtp -106.4 154.14 21.23 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.593 0.711 . . . . 74.31 110.762 173.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.503 ' HA ' ' CZ ' ' A' ' 186' ' ' PHE . 9.8 t -144.53 173.38 11.86 Favored 'General case' 0 C--O 1.242 0.705 0 CA-C-N 113.641 -1.618 . . . . 61.14 108.365 171.715 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . 0.414 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 49.9 mt -73.7 -10.53 59.78 Favored 'General case' 0 CA--C 1.553 1.069 0 CA-C-N 115.946 -0.57 . . . . 74.01 111.092 -179.723 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . 0.407 ' H ' HG23 ' A' ' 214' ' ' THR . 35.1 tt0 -86.87 -18.98 29.59 Favored 'General case' 0 CA--C 1.551 1.011 0 C-N-CA 124.58 1.152 . . . . 54.02 110.819 173.697 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 134.26 -157.91 23.12 Favored Glycine 0 C--N 1.353 1.48 0 CA-C-O 119.53 -0.595 . . . . 61.12 111.786 -176.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -84.4 130.96 4.7 Favored 'Trans proline' 0 C--N 1.366 1.46 0 C-N-CA 122.5 2.134 . . . . 74.31 112.227 175.481 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 35.1 m -113.08 161.9 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 C-N-CA 124.22 1.008 . . . . 74.31 111.292 178.219 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -106.25 121.23 43.78 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 108.627 -0.879 . . . . 70.25 108.627 173.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 20.2 t -103.26 115.45 45.25 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 109.312 -0.625 . . . . 72.43 109.312 176.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -84.59 100.66 11.56 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 107.689 -1.226 . . . . 74.11 107.689 170.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.456 HG23 ' HA2' ' A' ' 207' ' ' GLY . 12.3 m -76.26 141.1 69.89 Favored Pre-proline 0 CA--C 1.549 0.913 0 N-CA-C 108.927 -0.768 . . . . 71.34 108.927 -178.653 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_exo -64.46 136.02 48.68 Favored 'Trans proline' 0 C--N 1.367 1.531 0 C-N-CA 122.622 2.215 . . . . 62.32 112.092 177.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -58.34 117.6 4.34 Favored 'Trans proline' 0 C--N 1.371 1.716 0 C-N-CA 122.611 2.207 . . . . 61.1 111.23 174.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 64.96 51.74 1.68 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 124.636 1.174 . . . . 73.42 110.826 -175.449 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 11.6 t -77.61 172.35 13.52 Favored 'General case' 0 CA--C 1.545 0.788 0 CA-C-N 115.248 -0.887 . . . . 74.52 109.555 170.556 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 28.1 mp0 -122.5 145.46 48.29 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 123.398 0.679 . . . . 74.4 110.036 -174.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.57 121.86 18.65 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.734 -0.839 . . . . 75.5 108.734 172.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 115.69 -7.7 19.87 Favored Glycine 0 N--CA 1.469 0.893 0 CA-C-N 116.087 -0.506 . . . . 52.54 112.324 -171.279 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . . . . . . . . . 70.5 mtp180 -83.28 160.1 21.79 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 122.842 0.457 . . . . 62.42 110.347 173.319 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 3.4 mppt? -125.13 113.4 17.66 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.966 0.906 . . . . 73.11 109.527 177.443 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 38.3 mt -89.89 125.71 35.45 Favored 'General case' 0 C--N 1.354 0.802 0 N-CA-C 108.451 -0.944 . . . . 53.43 108.451 -177.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . 0.51 ' HA ' ' O ' ' A' ' 249' ' ' LEU . 37.2 ttp180 -106.26 112.17 25.07 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-O 121.056 0.455 . . . . 63.44 111.22 -168.781 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.472 HD12 HD23 ' A' ' 249' ' ' LEU . 44.7 mt -86.61 127.12 34.9 Favored 'General case' 0 C--O 1.241 0.649 0 CA-C-N 115.347 -0.842 . . . . 73.3 110.11 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 35.1 mtmm -70.18 124.64 24.62 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 124.763 1.225 . . . . 73.31 111.809 -172.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 70.8 13.92 72.43 Favored Glycine 0 C--N 1.348 1.216 0 N-CA-C 114.954 0.742 . . . . 74.33 114.954 170.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . . . . . . . . . 39.4 mmtm -87.74 -9.96 52.5 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.226 0.61 . . . . 70.03 111.982 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -87.6 179.57 47.66 Favored Glycine 0 C--N 1.342 0.896 0 O-C-N 123.407 0.442 . . . . 70.13 112.799 177.08 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.465 ' CE2' ' HA ' ' A' ' 131' ' ' PHE . 14.4 m-85 -69.07 144.45 95.48 Favored Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 123.565 0.746 . . . . 75.44 110.99 -177.154 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 23.0 Cg_exo -66.65 130.35 23.25 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.632 2.222 . . . . 70.24 112.304 172.411 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -161.21 -151.53 6.29 Favored Glycine 0 CA--C 1.538 1.507 0 CA-C-O 119.271 -0.738 . . . . 72.12 111.99 178.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -56.18 -23.62 46.02 Favored 'Trans proline' 0 C--N 1.377 2.048 0 C-N-CA 123.996 3.131 . . . . 65.32 115.865 -174.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -101.15 22.6 12.09 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 123.298 0.639 . . . . 71.52 111.586 -179.397 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.16 -93.31 1.82 Allowed Glycine 0 C--N 1.341 0.846 0 N-CA-C 110.075 -1.21 . . . . 72.24 110.075 -172.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.468 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 46.6 mtm180 -122.14 153.68 38.41 Favored 'General case' 0 N--CA 1.478 0.935 0 N-CA-C 108.484 -0.932 . . . . 74.21 108.484 170.218 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -84.61 -162.46 34.94 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.789 -0.641 . . . . 41.11 112.186 178.365 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 42.7 m-20 -138.95 173.65 11.35 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.424 0.689 . . . . 71.13 109.853 -173.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.536 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 16.6 tp -119.82 115.85 24.68 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.397 0.679 . . . . 72.42 111.583 176.2 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . 0.425 ' CZ ' ' HD3' ' A' ' 234' ' ' ARG . 20.5 m-85 -88.95 107.44 19.02 Favored 'General case' 0 N--CA 1.48 1.051 0 C-N-CA 123.561 0.744 . . . . 72.51 109.997 171.259 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.573 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 38.2 mt -89.93 118.72 29.7 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 125.041 1.336 . . . . 74.34 112.178 176.081 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -77.57 96.56 4.81 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 108.965 -0.754 . . . . 73.2 108.965 178.261 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 45.2 t -49.85 115.1 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 124.201 1.001 . . . . 52.14 111.354 173.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . 0.436 ' HB2' ' HA ' ' A' ' 198' ' ' ASP . 30.5 mmm180 -118.21 93.2 4.04 Favored 'General case' 0 C--O 1.235 0.34 0 N-CA-C 106.905 -1.517 . . . . 75.35 106.905 174.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 71.2 mt -76.48 122.94 31.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 N-CA-C 109.216 -0.661 . . . . 75.04 109.216 176.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.557 1.244 0 CA-C-O 117.446 -1.264 . . . . 64.21 107.941 -178.597 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.205 0 N-CA-C 110.071 -0.344 . . . . 63.33 110.071 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.521 ' HB1' HG13 ' A' ' 137' ' ' VAL . . . -59.39 -70.1 0.17 Allowed 'General case' 0 N--CA 1.479 0.975 0 C-N-CA 124.295 1.038 . . . . 54.34 109.663 175.43 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.459 HD13 ' HG3' ' A' ' 136' ' ' ARG . 60.7 tp -127.85 -64.3 0.97 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 105.994 -1.854 . . . . 74.4 105.994 156.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.406 HG22 ' H ' ' A' ' 101' ' ' HIS . 12.4 p -107.26 154.99 8.07 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 C-N-CA 124.445 1.098 . . . . 71.43 109.306 165.636 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -141.57 1.93 1.58 Allowed 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 124.366 1.066 . . . . 75.1 110.518 173.318 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . 0.406 ' H ' HG22 ' A' ' 99' ' ' VAL . 9.2 t-80 -109.06 103.33 12.33 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 124.898 1.279 . . . . 72.14 109.545 -177.772 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 82.6 t -83.98 136.21 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.832 0 N-CA-C 108.597 -0.89 . . . . 61.52 108.597 173.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 43.1 p -83.15 134.81 34.97 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.459 0.704 . . . . 71.3 111.912 -172.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.5 m -84.3 -20.39 32.19 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 124.0 0.92 . . . . 54.44 109.991 167.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -150.55 -124.75 1.23 Allowed Glycine 0 CA--C 1.532 1.142 0 N-CA-C 109.68 -1.368 . . . . 55.04 109.68 178.431 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 60.8 p 39.5 -84.55 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 126.148 1.779 . . . . 71.23 114.367 177.009 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.466 ' O ' ' HD3' ' A' ' 120' ' ' ARG . . . -62.14 133.15 45.87 Favored Glycine 0 C--N 1.354 1.553 0 O-C-N 123.397 0.436 . . . . 71.5 112.991 -176.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 179.12 155.84 15.85 Favored Glycine 0 C--N 1.342 0.873 0 N-CA-C 112.138 -0.385 . . . . 74.31 112.138 -177.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 59.1 m -146.47 147.33 31.09 Favored 'General case' 0 C--O 1.242 0.685 0 C-N-CA 123.727 0.811 . . . . 75.54 109.919 179.243 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -120.08 -176.98 15.99 Favored Glycine 0 C--N 1.346 1.088 0 CA-C-N 116.294 -0.412 . . . . 71.24 112.429 -179.681 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 89.56 -45.95 3.14 Favored Glycine 0 C--N 1.345 1.053 0 CA-C-O 120.205 -0.22 . . . . 55.31 113.114 176.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 38.0 t -78.07 -36.42 48.28 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.1 0.56 . . . . 53.51 111.126 -179.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 82.85 6.97 87.92 Favored Glycine 0 C--N 1.346 1.126 0 CA-C-N 115.729 -0.669 . . . . 62.23 113.022 -175.67 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.59 -59.94 4.9 Favored Glycine 0 C--N 1.354 1.573 0 C-N-CA 123.184 0.421 . . . . 65.42 113.105 -178.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.0 m 72.49 -72.46 0.11 Allowed 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 125.76 1.624 . . . . 73.33 110.704 -178.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -86.2 176.88 48.88 Favored Glycine 0 C--N 1.347 1.15 0 N-CA-C 110.125 -1.19 . . . . 74.4 110.125 165.618 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 42.1 mtm180 -64.41 117.5 7.37 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 117.689 0.744 . . . . 54.45 110.183 177.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -92.84 107.61 19.35 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 108.69 -0.856 . . . . 71.41 108.69 175.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.437 ' O ' ' HA ' ' A' ' 174' ' ' LEU . 2.5 tt -94.36 138.61 32.12 Favored 'General case' 0 C--O 1.215 -0.722 0 N-CA-C 105.993 -1.854 . . . . 64.04 105.993 179.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.466 ' HD3' ' O ' ' A' ' 107' ' ' GLY . 92.2 mtt180 -128.49 139.91 52.09 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 109.586 -0.524 . . . . 72.23 109.586 -169.747 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.402 ' HB1' HG21 ' A' ' 99' ' ' VAL . . . -153.83 149.77 27.73 Favored 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 123.889 0.876 . . . . 70.41 110.313 -177.041 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 72.6 tt0 -127.75 135.29 49.93 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.536 1.134 . . . . 74.05 109.375 -174.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -140.84 142.41 28.04 Favored Pre-proline 0 N--CA 1.478 0.973 0 C-N-CA 122.785 0.434 . . . . 72.35 110.865 -175.149 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_exo -73.6 113.34 3.76 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 121.889 1.726 . . . . 73.42 109.851 166.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.451 HD22 HG11 ' A' ' 178' ' ' VAL . 17.9 tp -109.54 165.79 11.39 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.299 1.039 . . . . 70.25 108.932 179.401 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.592 ' HA ' ' HG ' ' A' ' 181' ' ' LEU . 8.6 m -95.39 156.6 16.25 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.23 0.612 . . . . 44.0 109.903 176.266 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.669 HD23 ' HB3' ' A' ' 180' ' ' LEU . 51.9 mt -56.7 -50.35 72.43 Favored 'General case' 0 N--CA 1.487 1.405 0 CA-C-O 122.21 1.005 . . . . 71.54 109.353 174.083 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.483 ' HA ' ' HB3' ' A' ' 215' ' ' LEU . 1.8 mp0 -58.51 -38.07 76.93 Favored 'General case' 0 CA--C 1.546 0.813 0 CA-C-N 113.614 -1.63 . . . . 61.14 111.802 178.823 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.404 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 12.0 mm-40 -77.94 -23.25 48.61 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 122.844 0.458 . . . . 73.22 111.831 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.642 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -66.23 -32.0 73.16 Favored 'General case' 0 C--O 1.252 1.201 0 CA-C-O 121.712 0.768 . . . . 63.43 111.156 168.505 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.468 ' HA ' ' CE2' ' A' ' 240' ' ' PHE . 36.9 t80 -75.73 -47.92 24.03 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 114.746 -1.115 . . . . 73.31 111.892 172.798 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -75.23 -48.17 24.7 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 122.59 0.356 . . . . 71.34 111.626 -170.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 63.58 -130.14 40.03 Favored Glycine 0 CA--C 1.532 1.124 0 O-C-N 123.666 0.604 . . . . 42.23 111.861 -175.204 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 94.76 -172.94 31.67 Favored Glycine 0 C--N 1.35 1.332 0 N-CA-C 114.245 0.458 . . . . 35.51 114.245 171.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . . . . . . . . . 7.6 mp0 -88.93 125.96 35.18 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.152 0.981 . . . . 53.12 109.965 -176.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . 0.459 ' HG3' HD13 ' A' ' 98' ' ' LEU . 33.3 mmt180 -137.78 168.49 19.57 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 124.883 1.273 . . . . 72.24 108.325 171.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.521 HG13 ' HB1' ' A' ' 97' ' ' ALA . 6.0 p -90.23 144.79 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 108.676 -0.861 . . . . 71.12 108.676 178.092 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 144' ' ' ARG . 7.8 p -134.23 138.2 50.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 123.249 0.62 . . . . 74.34 109.457 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -124.69 106.15 9.86 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 108.14 -1.059 . . . . 75.21 108.14 169.185 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.5 m -125.09 117.81 51.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 C-N-CA 124.461 1.105 . . . . 72.05 109.592 -178.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . 0.416 ' HB3' HD11 ' A' ' 119' ' ' LEU . . . 64.43 20.47 12.17 Favored 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 124.598 1.159 . . . . 73.23 111.771 179.579 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 93.69 -6.9 74.23 Favored Glycine 0 C--N 1.357 1.704 0 O-C-N 123.225 0.328 . . . . 73.02 113.478 -178.302 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 6.3 tpm_? -91.6 117.41 29.71 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 108.92 -0.77 . . . . 65.35 108.92 176.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.401 ' HA ' ' O ' ' A' ' 138' ' ' VAL . 52.5 ttp180 -99.66 122.07 42.14 Favored 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 123.583 0.753 . . . . 75.34 109.516 179.181 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 19.0 t -133.19 156.99 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.056 0 N-CA-C 108.3 -1.0 . . . . 74.54 108.3 176.148 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 24.3 p -85.35 113.71 21.87 Favored 'General case' 0 CA--C 1.547 0.838 0 N-CA-C 108.325 -0.991 . . . . 75.25 108.325 165.511 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 7.2 p -98.02 123.52 50.54 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 CA-C-O 121.641 0.734 . . . . 72.42 111.402 -176.259 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -97.94 104.77 16.83 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 107.76 -1.2 . . . . 74.23 107.76 167.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 38.7 pt -97.32 103.63 16.61 Favored Pre-proline 0 CA--C 1.55 0.967 0 N-CA-C 108.154 -1.054 . . . . 51.41 108.154 167.19 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -61.09 151.21 80.16 Favored 'Trans proline' 0 C--N 1.383 2.366 0 C-N-CA 122.613 2.209 . . . . 74.32 112.788 -178.116 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -49.28 151.37 6.62 Favored 'Trans proline' 0 C--N 1.378 2.081 0 C-N-CA 123.829 3.019 . . . . 71.54 114.153 176.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 108.73 23.36 6.55 Favored Glycine 0 N--CA 1.478 1.438 0 C-N-CA 121.465 -0.398 . . . . 51.51 113.238 174.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.642 HG13 ' HA ' ' A' ' 130' ' ' ALA . 2.5 p -99.65 162.84 2.95 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.192 0 N-CA-C 107.831 -1.174 . . . . 71.41 107.831 179.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.601 ' HA ' HD11 ' A' ' 180' ' ' LEU . 0.0 OUTLIER -158.87 177.69 10.88 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.618 1.167 . . . . 74.11 111.91 -172.02 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 17.3 tp10 -51.58 115.5 1.65 Allowed 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 124.76 1.224 . . . . 72.32 111.722 178.09 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 80.68 10.43 85.18 Favored Glycine 0 C--N 1.356 1.64 0 CA-C-N 115.775 -0.648 . . . . 54.34 113.591 177.652 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.4 t -85.77 123.76 31.51 Favored 'General case' 0 C--O 1.245 0.822 0 C-N-CA 123.097 0.559 . . . . 73.41 109.58 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 3.4 t -99.6 122.4 51.38 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 124.129 0.972 . . . . 72.21 108.659 -176.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.627 HD11 HG21 ' A' ' 153' ' ' VAL . 13.5 mt -103.11 119.68 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 124.046 0.938 . . . . 74.42 109.33 -169.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 34.3 ttt180 -97.43 103.67 15.63 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 122.693 0.397 . . . . 65.54 110.361 -177.115 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 12.1 m -102.39 118.91 57.75 Favored Pre-proline 0 CA--C 1.559 1.293 0 N-CA-C 109.451 -0.574 . . . . 53.13 109.451 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -74.47 152.25 43.36 Favored 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.635 2.224 . . . . 64.34 113.684 -173.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 79.74 24.48 60.19 Favored Glycine 0 C--N 1.349 1.267 0 N-CA-C 115.0 0.76 . . . . 61.52 115.0 168.147 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 39.6 mtt -105.18 -62.91 1.29 Allowed 'General case' 0 N--CA 1.488 1.465 0 CA-C-N 118.285 1.042 . . . . 74.22 112.093 176.061 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . . . . . . . . . . . -62.42 -87.01 0.04 OUTLIER Glycine 0 C--N 1.349 1.294 0 CA-C-N 115.933 -0.576 . . . . 41.14 112.937 -177.295 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.705 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -68.25 90.44 0.23 Allowed Glycine 0 C--N 1.339 0.732 0 C-N-CA 122.91 0.29 . . . . 53.41 112.949 176.71 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.633 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -83.52 104.84 13.97 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 109.245 -0.65 . . . . 71.31 109.245 175.461 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 171.03 -154.53 22.85 Favored Glycine 0 C--N 1.342 0.875 0 N-CA-C 110.984 -0.846 . . . . 15.22 110.984 -175.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . 0.456 ' HB3' ' HD3' ' A' ' 170' ' ' PRO . 6.5 t30 -69.28 -48.72 25.63 Favored Pre-proline 0 CA--C 1.562 1.427 0 CA-C-O 118.431 -0.795 . . . . 62.43 110.999 176.454 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.456 ' HD3' ' HB3' ' A' ' 169' ' ' ASN . 5.1 Cg_exo -76.89 113.31 3.61 Favored 'Trans proline' 0 C--N 1.392 2.82 0 C-N-CA 121.818 1.679 . . . . 70.33 110.276 169.16 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 12.3 Cg_exo -70.81 125.93 12.1 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.274 1.983 . . . . 74.3 110.966 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.705 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -101.78 153.3 18.74 Favored Glycine 0 CA--C 1.502 -0.773 0 N-CA-C 110.621 -0.992 . . . . 71.22 110.621 174.634 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -112.69 178.59 4.24 Favored 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 123.473 0.709 . . . . 74.41 111.511 -168.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.437 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 34.9 tp -130.16 112.92 13.86 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 114.579 -1.191 . . . . 74.1 108.615 168.419 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . . . . . . . . . 72.9 mt -85.09 100.86 11.98 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.138 1.375 . . . . 44.25 111.238 177.118 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 70.7 mt -95.38 101.64 13.38 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 122.69 0.396 . . . . 55.04 110.666 174.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 2.5 p -87.03 108.65 18.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 N-CA-C 109.158 -0.682 . . . . 62.25 109.158 172.576 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.451 HG11 HD22 ' A' ' 125' ' ' LEU . 4.0 m -87.35 149.37 4.11 Favored 'Isoleucine or valine' 0 C--O 1.245 0.851 0 CA-C-N 115.946 -0.57 . . . . 74.12 110.665 -177.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 13.1 mmm-85 -124.97 101.31 6.99 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 107.491 -1.299 . . . . 64.13 107.491 -178.521 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.669 ' HB3' HD23 ' A' ' 127' ' ' LEU . 25.3 mt -69.46 148.61 49.3 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 112.082 0.401 . . . . 61.31 112.082 -172.115 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.592 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 39.8 mt -57.5 138.25 81.57 Favored Pre-proline 0 CA--C 1.559 1.295 0 C-N-CA 123.283 0.633 . . . . 73.03 110.752 179.488 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.44 83.79 1.0 Allowed 'Trans proline' 0 C--N 1.374 1.875 0 C-N-CA 123.188 2.592 . . . . 63.11 112.584 -177.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -165.19 54.03 0.34 Allowed Pre-proline 0 CA--C 1.559 1.306 0 C-N-CA 124.12 0.968 . . . . 73.43 109.314 170.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.61 124.4 15.71 Favored 'Trans proline' 0 C--N 1.389 2.668 0 C-N-CA 122.627 2.218 . . . . 63.32 112.723 -169.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.4 p -130.84 -44.42 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 C-N-CA 124.182 0.993 . . . . 75.41 109.561 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . 0.41 ' CE1' ' HA ' ' A' ' 214' ' ' THR . 6.4 m-85 -105.01 120.29 41.11 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.218 0.532 . . . . 73.31 111.347 -176.048 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.705 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 23.5 mtp180 -104.17 162.7 12.95 Favored 'General case' 0 N--CA 1.467 0.425 0 C-N-CA 124.18 0.992 . . . . 75.42 109.337 173.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.418 HD12 ' O ' ' A' ' 192' ' ' ASP . 57.2 tp -132.42 127.53 35.56 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 123.493 0.717 . . . . 64.04 109.743 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -139.52 102.52 4.48 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 125.034 1.333 . . . . 73.2 108.122 176.637 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 56.59 58.41 14.53 Favored Glycine 0 C--N 1.353 1.479 0 O-C-N 123.951 0.782 . . . . 75.34 114.04 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . 0.568 ' NE2' ' HD2' ' A' ' 243' ' ' PRO . 52.6 mt-30 74.09 -15.81 0.57 Allowed 'General case' 0 N--CA 1.505 2.322 0 C-N-CA 125.407 1.483 . . . . 70.12 112.305 179.141 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.418 ' O ' HD12 ' A' ' 188' ' ' LEU . 9.7 t0 -97.41 152.44 18.95 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.333 1.053 . . . . 65.21 108.362 -175.358 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.4 ' HB2' ' HA ' ' A' ' 249' ' ' LEU . 78.4 mt -110.33 168.47 9.42 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 122.024 0.916 . . . . 61.54 111.512 -173.187 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . 0.705 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 35.6 m-85 -134.14 132.29 39.68 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 114.085 -1.416 . . . . 55.43 108.062 171.182 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . 0.436 ' HB3' HD11 ' A' ' 249' ' ' LEU . . . -154.02 168.28 26.95 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.909 0.884 . . . . 43.11 109.308 174.18 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 35.5 m -105.75 128.51 53.74 Favored 'General case' 0 CA--C 1.54 0.583 0 CA-C-N 115.702 -0.681 . . . . 71.24 109.672 178.428 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.512 HD13 ' HB2' ' A' ' 212' ' ' ALA . 59.9 tp -107.76 113.65 27.05 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.733 -0.84 . . . . 75.23 108.733 173.382 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 37.8 t70 -94.9 119.82 34.08 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.373 -0.973 . . . . 72.43 108.373 175.496 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . 0.461 HG11 HG23 ' A' ' 253' ' ' VAL . 7.5 p -134.52 134.77 22.68 Favored Pre-proline 0 N--CA 1.479 1.018 0 C-N-CA 124.284 1.033 . . . . 64.42 109.37 -173.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.58 149.14 91.05 Favored 'Trans proline' 0 C--N 1.372 1.782 0 C-N-CA 122.715 2.277 . . . . 63.3 113.092 175.693 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . 0.492 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -60.75 -43.19 91.16 Favored Pre-proline 0 N--CA 1.478 0.972 0 N-CA-C 113.171 0.804 . . . . 75.53 113.171 176.445 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . 0.422 ' HD2' ' N ' ' A' ' 201' ' ' ALA . 10.6 Cg_endo -53.73 -44.36 49.84 Favored 'Trans proline' 0 C--N 1.392 2.854 0 C-N-CA 121.759 1.639 . . . . 74.32 112.294 172.025 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . . . . . . . . . 10.7 mt -67.44 -36.22 75.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 C-N-CA 122.821 0.449 . . . . 73.53 111.189 177.618 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -64.57 -41.42 96.3 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 123.201 0.6 . . . . 73.22 111.802 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . . . . . . . . . 33.7 m -79.89 -42.28 22.14 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 CA-C-N 116.003 -0.544 . . . . 72.34 111.362 -177.017 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 10.1 m -80.1 -20.02 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 122.471 0.308 . . . . 71.21 111.054 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . 68.92 65.92 2.45 Favored Glycine 0 C--N 1.343 0.962 0 CA-C-N 115.687 -0.688 . . . . 51.43 112.461 -176.26 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . . . . . . . . . . . -90.83 -145.92 15.4 Favored Glycine 0 C--N 1.357 1.7 0 N-CA-C 111.233 -0.747 . . . . 63.1 111.233 175.316 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . . . . . . . . . 24.4 pttm -133.0 149.82 52.2 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 122.853 0.461 . . . . 71.51 109.88 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . . . . . . . . . 2.8 m -145.09 134.37 18.04 Favored 'Isoleucine or valine' 0 C--O 1.239 0.528 0 N-CA-C 107.539 -1.282 . . . . 73.02 107.539 176.246 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 31.7 ptt180 -79.43 137.77 37.38 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 109.472 -0.566 . . . . 62.12 109.472 176.038 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.512 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -108.19 134.65 50.75 Favored 'General case' 0 C--O 1.245 0.845 0 C-N-CA 123.311 0.644 . . . . 74.45 109.408 174.218 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 4.8 tpt -75.85 106.26 7.33 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 108.837 -0.801 . . . . 74.22 108.837 173.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . 0.41 ' HA ' ' CE1' ' A' ' 186' ' ' PHE . 11.2 t -110.68 165.85 11.49 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 109.703 -0.48 . . . . 64.31 109.703 174.553 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . 0.483 ' HB3' ' HA ' ' A' ' 128' ' ' GLU . 59.7 mt -69.69 -17.7 63.5 Favored 'General case' 0 CA--C 1.551 0.99 0 CA-C-N 115.686 -0.688 . . . . 61.02 111.162 178.348 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -79.21 -19.42 50.83 Favored 'General case' 0 CA--C 1.556 1.209 0 C-N-CA 123.934 0.894 . . . . 50.41 110.948 174.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 131.77 -148.53 19.06 Favored Glycine 0 C--N 1.346 1.088 0 N-CA-C 111.378 -0.689 . . . . 70.33 111.378 -176.079 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -85.86 126.85 2.99 Favored 'Trans proline' 0 CA--C 1.557 1.64 0 C-N-CA 122.376 2.05 . . . . 74.42 112.473 172.118 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . 0.525 HG11 ' HD2' ' A' ' 238' ' ' LYS . 34.9 m -111.56 155.47 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 N-CA-C 109.132 -0.692 . . . . 71.22 109.132 169.575 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -114.36 111.8 22.04 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.944 -0.761 . . . . 72.44 108.944 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.458 HG22 HD11 ' A' ' 235' ' ' LEU . 8.5 t -96.27 115.75 36.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.381 0 C-N-CA 123.593 0.757 . . . . 71.22 109.704 -178.594 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -89.59 101.28 13.97 Favored 'General case' 0 C--O 1.239 0.529 0 N-CA-C 106.673 -1.603 . . . . 54.23 106.673 174.256 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 19.0 m -75.21 141.47 74.13 Favored Pre-proline 0 CA--C 1.551 1.018 0 C-N-CA 122.546 0.338 . . . . 74.04 110.546 -173.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -60.07 133.27 49.15 Favored 'Trans proline' 0 C--N 1.378 2.092 0 C-N-CA 122.679 2.253 . . . . 42.24 111.828 176.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -56.0 124.57 16.58 Favored 'Trans proline' 0 C--N 1.377 2.077 0 C-N-CA 122.692 2.261 . . . . 71.41 110.92 173.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 60.58 51.98 4.8 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 124.593 1.157 . . . . 72.34 110.77 -173.271 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . . . . . . . . . 6.2 t -78.61 165.77 23.3 Favored 'General case' 0 CA--C 1.544 0.741 0 N-CA-C 109.229 -0.656 . . . . 73.43 109.229 170.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . 0.43 ' H ' ' HD3' ' A' ' 231' ' ' ARG . 25.7 mp0 -119.51 147.32 44.58 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 108.707 -0.849 . . . . 72.15 108.707 -174.628 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -70.01 143.62 52.51 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.554 0.742 . . . . 74.12 110.844 178.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 89.46 0.04 80.03 Favored Glycine 0 C--N 1.343 0.966 0 O-C-N 123.442 0.464 . . . . 34.0 113.342 -179.065 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . 0.462 ' O ' HG12 ' A' ' 253' ' ' VAL . 80.8 mtp180 -80.26 163.48 23.95 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-N 117.455 0.627 . . . . 74.43 109.855 174.426 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.465 ' HA ' ' O ' ' A' ' 251' ' ' LEU . 2.8 mptp? -112.97 107.31 15.81 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 108.69 -0.856 . . . . 75.34 108.69 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 56.9 mt -85.2 116.34 23.5 Favored 'General case' 0 C--N 1.355 0.824 0 N-CA-C 107.92 -1.141 . . . . 75.2 107.92 178.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 19.6 ttm-85 -95.79 114.76 26.53 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 124.097 0.959 . . . . 74.25 109.433 -164.229 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.458 HD11 HG22 ' A' ' 221' ' ' VAL . 25.0 mt -106.77 106.07 16.41 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.081 0.552 . . . . 73.3 109.698 176.573 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . 0.56 ' HA ' ' HB3' ' A' ' 248' ' ' ASP . 44.8 mttp -62.7 148.98 44.91 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 123.651 0.781 . . . . 55.24 111.718 176.539 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.51 35.44 81.41 Favored Glycine 0 C--N 1.355 1.636 0 O-C-N 123.971 0.794 . . . . 64.22 113.228 176.009 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . 0.525 ' HD2' HG11 ' A' ' 219' ' ' VAL . 15.9 mmtm -123.82 -23.08 4.75 Favored 'General case' 0 N--CA 1.484 1.27 0 C-N-CA 123.774 0.83 . . . . 62.02 112.116 -176.159 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . . . . . . . . . . . -81.38 -155.66 14.05 Favored Glycine 0 C--N 1.341 0.844 0 O-C-N 123.592 0.557 . . . . 74.04 112.68 178.203 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.468 ' CE2' ' HA ' ' A' ' 131' ' ' PHE . 75.3 m-85 -96.26 143.68 26.54 Favored Pre-proline 0 N--CA 1.474 0.754 0 O-C-N 122.346 -0.502 . . . . 71.03 111.802 178.186 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . 0.581 ' HA ' ' HA ' ' A' ' 246' ' ' ARG . 27.9 Cg_exo -62.22 168.21 9.71 Favored 'Trans proline' 0 C--N 1.378 2.095 0 C-N-CA 123.245 2.63 . . . . 72.13 112.868 176.684 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . 163.22 -159.08 31.58 Favored Glycine 0 CA--C 1.534 1.226 0 CA-C-O 119.586 -0.564 . . . . 60.35 112.959 -177.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . 0.568 ' HD2' ' NE2' ' A' ' 191' ' ' GLN . 39.8 Cg_exo -60.44 -24.04 76.73 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 123.768 2.979 . . . . 74.24 113.363 177.601 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -91.44 18.56 7.08 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.668 0.787 . . . . 74.32 111.507 178.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.34 -98.84 1.79 Allowed Glycine 0 C--N 1.349 1.266 0 N-CA-C 110.746 -0.942 . . . . 64.14 110.746 -174.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.581 ' HA ' ' HA ' ' A' ' 241' ' ' PRO . 51.9 ttt180 -129.32 149.69 51.0 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.362 0.665 . . . . 75.53 109.845 166.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -75.31 -171.21 28.99 Favored Glycine 0 C--N 1.348 1.234 0 O-C-N 123.592 0.558 . . . . 50.23 112.882 176.387 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . 0.56 ' HB3' ' HA ' ' A' ' 236' ' ' LYS . 1.6 p-10 -145.16 169.56 17.93 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 123.89 0.876 . . . . 72.01 110.526 -174.307 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.436 HD11 ' HB3' ' A' ' 195' ' ' ALA . 22.9 tp -110.61 126.39 54.41 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 124.121 0.968 . . . . 72.24 112.095 -171.075 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . . . . . . . . . 15.1 m-85 -88.84 107.06 18.78 Favored 'General case' 0 C--N 1.357 0.918 0 C-N-CA 123.7 0.8 . . . . 71.24 109.308 168.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.465 ' O ' ' HA ' ' A' ' 232' ' ' LYS . 73.5 mt -88.57 121.93 31.48 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 123.783 0.833 . . . . 73.1 111.628 171.325 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -82.35 92.83 7.05 Favored 'General case' 0 C--O 1.235 0.313 0 N-CA-C 108.032 -1.099 . . . . 64.12 108.032 174.351 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.462 HG12 ' O ' ' A' ' 231' ' ' ARG . 2.4 p -58.61 114.29 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 C-N-CA 123.395 0.678 . . . . 45.14 110.484 177.586 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 21.3 mmm-85 -116.08 95.2 4.98 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 107.802 -1.184 . . . . 61.33 107.802 -177.759 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.492 HG23 ' HA ' ' A' ' 201' ' ' ALA . 75.2 mt -76.03 102.57 3.05 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 114.991 -1.004 . . . . 72.44 110.41 -174.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 CA--C 1.564 1.512 0 C-N-CA 124.337 1.055 . . . . 71.35 109.258 175.985 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.816 0 N-CA-C 110.171 -0.307 . . . . 52.41 110.171 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -63.87 -56.81 12.58 Favored 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 108.503 -0.925 . . . . 65.3 108.503 171.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.46 ' HA ' HD13 ' A' ' 123' ' ' LEU . 3.5 mm? -85.49 84.64 7.56 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-N 114.248 -1.342 . . . . 74.22 107.402 169.076 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.446 HG13 ' H ' ' A' ' 101' ' ' HIS . 7.1 p -60.1 -27.94 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 C-N-CA 123.092 0.557 . . . . 74.1 111.391 -178.485 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . 64.86 35.85 8.21 Favored 'General case' 0 C--N 1.355 0.818 0 O-C-N 124.541 1.151 . . . . 74.23 110.905 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . 0.446 ' H ' HG13 ' A' ' 99' ' ' VAL . 66.5 t-80 -75.35 91.07 2.68 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 114.755 -1.112 . . . . 75.04 108.088 178.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 46.3 t -57.2 145.72 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 C-N-CA 124.582 1.153 . . . . 75.43 111.297 -173.391 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 13.5 t -134.53 153.1 52.12 Favored 'General case' 0 C--O 1.242 0.665 0 C-N-CA 123.172 0.589 . . . . 63.43 109.836 177.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 44.7 m -137.8 111.16 7.96 Favored 'General case' 0 C--O 1.24 0.576 0 C-N-CA 124.149 0.98 . . . . 63.23 108.394 177.269 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 157.67 153.01 6.54 Favored Glycine 0 C--N 1.342 0.869 0 N-CA-C 111.704 -0.558 . . . . 70.32 111.704 -178.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 20.2 m -75.42 96.67 3.48 Favored 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 123.313 0.645 . . . . 72.44 109.691 -179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -142.9 62.18 0.51 Allowed Glycine 0 C--N 1.343 0.969 0 N-CA-C 111.281 -0.728 . . . . 33.4 111.281 -179.048 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.05 118.72 0.53 Allowed Glycine 0 C--N 1.339 0.748 0 N-CA-C 110.818 -0.913 . . . . 74.4 110.818 -177.404 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 21.3 m -65.32 97.86 0.3 Allowed 'General case' 0 CA--C 1.546 0.824 0 C-N-CA 123.595 0.758 . . . . 72.14 110.555 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -87.33 -90.29 1.03 Allowed Glycine 0 C--N 1.346 1.09 0 CA-C-N 116.047 -0.524 . . . . 73.33 112.492 -178.589 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 119.82 -149.47 17.84 Favored Glycine 0 C--N 1.348 1.24 0 N-CA-C 111.453 -0.659 . . . . 51.45 111.453 -176.877 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 35.5 p -71.41 95.99 1.42 Allowed 'General case' 0 CA--C 1.551 0.988 0 C-N-CA 123.304 0.642 . . . . 73.52 110.045 176.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . -177.63 82.1 0.07 OUTLIER Glycine 0 C--N 1.348 1.206 0 CA-C-N 116.04 -0.527 . . . . 70.54 112.072 -179.24 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -138.31 -86.76 0.16 Allowed Glycine 0 C--N 1.342 0.899 0 N-CA-C 111.345 -0.702 . . . . 73.1 111.345 176.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.1 t 66.27 -70.54 0.1 Allowed 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 125.48 1.512 . . . . 74.1 111.543 179.03 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -88.65 169.56 37.38 Favored Glycine 0 C--N 1.342 0.889 0 N-CA-C 111.104 -0.798 . . . . 73.01 111.104 167.675 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 53.2 ttp180 -57.51 125.84 24.69 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 122.912 0.485 . . . . 63.32 110.479 174.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -73.62 141.28 46.55 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.098 0.559 . . . . 64.0 110.158 177.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.542 HD12 ' HA2' ' A' ' 165' ' ' GLY . 11.6 mt -124.05 151.41 43.83 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 108.129 -1.063 . . . . 45.31 108.129 168.524 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . 0.515 ' HG2' ' HB2' ' A' ' 175' ' ' LEU . 17.3 mtp180 -142.6 151.01 41.07 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.571 0.748 . . . . 73.35 109.376 177.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.497 ' HB3' HD23 ' A' ' 176' ' ' LEU . . . -151.63 120.11 6.44 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 123.615 0.766 . . . . 54.31 109.412 177.003 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' GLU . . . . . . . . . . . . . 37.8 mm-40 -84.05 143.18 29.91 Favored 'General case' 0 C--O 1.242 0.708 0 N-CA-C 109.111 -0.699 . . . . 73.34 109.111 175.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.46 HD13 ' HA ' ' A' ' 98' ' ' LEU . 0.7 OUTLIER -145.21 145.25 26.06 Favored Pre-proline 0 N--CA 1.475 0.781 0 C-N-CA 122.38 0.272 . . . . 74.2 110.923 174.707 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_endo -81.64 114.51 2.69 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 121.864 1.709 . . . . 63.5 110.638 165.173 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 15.1 tp -106.79 138.8 42.29 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 123.863 0.865 . . . . 73.4 109.354 -178.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.751 ' HB ' ' HG2' ' A' ' 129' ' ' GLU . 20.8 m -78.78 158.76 28.15 Favored 'General case' 0 CA--C 1.548 0.901 0 N-CA-C 109.605 -0.517 . . . . 55.23 109.605 172.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.418 HD11 ' O ' ' A' ' 183' ' ' HIS . 31.6 mt -61.52 -47.11 87.09 Favored 'General case' 0 N--CA 1.483 1.177 0 CA-C-O 121.909 0.861 . . . . 61.34 110.004 178.287 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -56.81 -32.76 66.03 Favored 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 114.12 -1.4 . . . . 65.32 111.172 175.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.751 ' HG2' ' HB ' ' A' ' 126' ' ' THR . 29.6 mm-40 -76.97 -32.08 57.0 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 122.977 0.511 . . . . 73.24 111.385 178.514 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.533 ' HA ' HG13 ' A' ' 153' ' ' VAL . . . -55.6 -35.1 65.46 Favored 'General case' 0 C--O 1.245 0.824 0 C-N-CA 122.999 0.519 . . . . 63.0 111.564 167.326 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.561 ' HA ' ' HE2' ' A' ' 240' ' ' PHE . 69.2 t80 -75.17 -47.62 27.55 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.447 -0.797 . . . . 72.51 112.877 171.306 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -68.95 -48.51 63.02 Favored 'General case' 0 N--CA 1.485 1.306 0 N-CA-C 112.115 0.413 . . . . 53.04 112.115 -170.092 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 57.52 -122.14 28.17 Favored Glycine 0 CA--C 1.534 1.272 0 O-C-N 123.869 0.731 . . . . 74.22 111.984 -172.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 78.27 -173.67 55.14 Favored Glycine 0 C--N 1.35 1.32 0 N-CA-C 114.358 0.503 . . . . 53.3 114.358 168.491 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' GLU . . . . . 0.532 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 1.3 mp0 -83.38 112.12 19.63 Favored 'General case' 0 C--N 1.356 0.856 0 N-CA-C 109.56 -0.533 . . . . 53.2 109.56 -178.552 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' ARG . . . . . . . . . . . . . 10.3 mmm180 -123.07 156.47 34.84 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.291 1.036 . . . . 71.22 108.462 178.194 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 35.1 m -77.05 133.32 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 C-N-CA 122.46 0.304 . . . . 71.5 111.356 -176.718 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 144' ' ' ARG . 38.6 t -125.13 134.05 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.685 1.194 . . . . 73.21 108.798 172.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -125.67 97.17 5.05 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.058 0.943 . . . . 74.32 109.366 171.637 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 53.2 t -122.84 122.31 65.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 C-N-CA 123.548 0.739 . . . . 50.14 109.803 178.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . 60.56 28.41 18.09 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 124.93 1.292 . . . . 60.21 112.381 175.558 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 98.37 -13.61 62.84 Favored Glycine 0 C--N 1.349 1.294 0 CA-C-N 116.107 -0.497 . . . . 53.2 113.594 178.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.98 118.0 30.35 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 117.508 0.654 . . . . 73.24 110.569 -179.716 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 138' ' ' VAL . 38.0 ttp180 -95.49 106.15 18.2 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 124.499 1.12 . . . . 61.33 108.41 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.9 t -128.33 131.21 69.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.19 0.996 . . . . 73.11 109.491 -179.197 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 70.0 m -72.25 115.19 11.2 Favored 'General case' 0 C--O 1.242 0.677 0 N-CA-C 108.635 -0.876 . . . . 34.02 108.635 170.699 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 135' ' ' GLU . 7.1 p -96.81 143.67 11.93 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 123.044 0.538 . . . . 65.42 110.295 -178.637 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' ARG . . . . . . . . . . . . . 31.2 ttm180 -107.89 100.26 9.64 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 107.585 -1.265 . . . . 72.13 107.585 171.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.409 ' HB ' HD13 ' A' ' 159' ' ' ILE . 27.7 pt -92.91 130.91 34.8 Favored Pre-proline 0 CA--C 1.548 0.881 0 N-CA-C 108.393 -0.966 . . . . 51.23 108.393 172.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -66.7 131.04 24.79 Favored 'Trans proline' 0 C--N 1.376 2.002 0 C-N-CA 122.617 2.211 . . . . 54.14 113.121 -172.164 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_exo -53.02 117.61 3.93 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.303 2.669 . . . . 75.3 111.824 167.037 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 124.46 54.26 0.18 Allowed Glycine 0 CA--C 1.506 -0.489 0 N-CA-C 110.758 -0.937 . . . . 71.42 110.758 -173.683 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.533 HG13 ' HA ' ' A' ' 130' ' ' ALA . 3.1 p -126.85 156.62 38.11 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.301 0 C-N-CA 123.456 0.703 . . . . 64.44 109.542 -175.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 55.4 mtp180 -138.26 176.09 9.0 Favored 'General case' 0 N--CA 1.491 1.599 0 C-N-CA 124.61 1.164 . . . . 74.53 111.284 -168.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -55.55 121.56 9.32 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 124.272 1.029 . . . . 74.33 111.04 171.367 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . 76.14 7.86 84.8 Favored Glycine 0 C--N 1.348 1.204 0 O-C-N 123.589 0.556 . . . . 64.23 113.842 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 70.8 m -72.37 126.32 29.55 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 117.287 0.543 . . . . 61.25 109.818 176.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.461 HG12 HD22 ' A' ' 175' ' ' LEU . 32.7 t -100.47 123.03 53.13 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-N 114.045 -1.434 . . . . 64.31 108.265 -175.313 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.453 ' HB ' ' HB2' ' A' ' 176' ' ' LEU . 25.4 mt -110.57 118.6 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 123.414 0.686 . . . . 72.33 110.153 -172.452 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 33.2 ttm-85 -85.12 130.29 34.64 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.663 0.785 . . . . 72.12 110.619 179.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.621 HG22 ' HB3' ' A' ' 174' ' ' LEU . 4.2 m -124.49 125.96 25.52 Favored Pre-proline 0 CA--C 1.551 0.984 0 N-CA-C 108.691 -0.855 . . . . 64.33 108.691 166.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -76.34 147.17 28.81 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 122.614 2.209 . . . . 71.02 113.424 -173.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' GLY . . . . . . . . . . . . . . . 70.62 24.89 76.52 Favored Glycine 0 C--N 1.351 1.415 0 CA-C-N 115.733 -0.667 . . . . 52.04 114.348 170.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 44.3 tpp -104.99 -37.64 6.89 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.152 0.581 . . . . 74.33 109.904 177.205 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' GLY . . . . . 0.542 ' HA2' HD12 ' A' ' 119' ' ' LEU . . . -75.71 -99.3 0.13 Allowed Glycine 0 C--N 1.347 1.167 0 CA-C-N 115.483 -0.781 . . . . 32.54 112.942 -177.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.67 ' H ' ' HA3' ' A' ' 172' ' ' GLY . . . -62.1 100.99 0.33 Allowed Glycine 0 C--N 1.346 1.105 0 C-N-CA 123.596 0.617 . . . . 53.02 112.346 173.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' GLN . . . . . 0.546 ' HA ' HE21 ' A' ' 167' ' ' GLN . 0.0 OUTLIER -84.78 105.29 15.45 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 108.597 -0.89 . . . . 74.41 108.597 178.503 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 165.52 -157.56 30.07 Favored Glycine 0 C--O 1.243 0.685 0 N-CA-C 111.065 -0.814 . . . . 73.21 111.065 -177.557 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -65.15 -48.87 68.8 Favored Pre-proline 0 CA--C 1.561 1.379 0 CA-C-O 118.128 -0.939 . . . . 73.04 111.28 176.795 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -80.42 106.17 1.83 Allowed 'Trans proline' 0 C--N 1.394 2.972 0 C-N-CA 122.299 1.999 . . . . 65.41 110.115 169.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.5 126.83 8.55 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.185 1.923 . . . . 63.23 110.425 -177.257 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' GLY . . . . . 0.67 ' HA3' ' H ' ' A' ' 166' ' ' GLY . . . -95.5 172.66 30.4 Favored Glycine 0 C--O 1.237 0.338 0 N-CA-C 110.768 -0.933 . . . . 65.13 110.768 173.091 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' ASP . . . . . . . . . . . . . 14.3 m-20 -120.22 159.48 24.85 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 123.447 0.699 . . . . 71.55 110.689 -170.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' LEU . . . . . 0.621 ' HB3' HG22 ' A' ' 161' ' ' VAL . 43.1 tp -109.74 120.43 42.46 Favored 'General case' 0 C--O 1.242 0.698 0 N-CA-C 107.092 -1.447 . . . . 74.32 107.092 169.519 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' LEU . . . . . 0.515 ' HB2' ' HG2' ' A' ' 120' ' ' ARG . 52.5 mt -100.36 100.29 11.06 Favored 'General case' 0 C--O 1.241 0.616 0 O-C-N 124.495 1.122 . . . . 51.41 109.326 -178.003 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.497 HD23 ' HB3' ' A' ' 121' ' ' ALA . 26.7 mt -86.92 101.28 13.25 Favored 'General case' 0 C--O 1.237 0.424 0 CA-C-N 114.562 -1.199 . . . . 63.04 109.098 -179.394 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 23.1 t -93.47 105.98 17.46 Favored 'Isoleucine or valine' 0 C--O 1.244 0.812 0 N-CA-C 108.451 -0.944 . . . . 70.13 108.451 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.448 HG21 HG22 ' A' ' 153' ' ' VAL . 13.7 m -82.44 147.95 5.62 Favored 'Isoleucine or valine' 0 C--O 1.241 0.643 0 CA-C-N 115.593 -0.73 . . . . 73.15 110.271 -178.435 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 17.0 mmt180 -123.72 105.53 9.77 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 107.675 -1.231 . . . . 64.35 107.675 178.665 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 33.9 mt -67.22 148.81 51.27 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 117.725 0.239 . . . . 73.23 110.381 179.521 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.544 ' HG ' ' HA ' ' A' ' 126' ' ' THR . 29.5 mt -57.46 157.44 13.33 Favored Pre-proline 0 CA--C 1.556 1.179 0 C-N-CA 123.78 0.832 . . . . 74.2 112.486 -171.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -57.19 -12.79 10.83 Favored 'Trans proline' 0 C--N 1.386 2.524 0 C-N-CA 123.019 2.48 . . . . 43.42 113.336 174.136 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.418 ' O ' HD11 ' A' ' 127' ' ' LEU . 28.3 t60 -99.09 101.12 11.52 Favored Pre-proline 0 CA--C 1.545 0.763 0 C-N-CA 124.364 1.066 . . . . 63.24 108.528 166.235 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -102.44 128.41 0.1 Allowed 'Trans proline' 0 CA--C 1.557 1.665 0 C-N-CA 123.387 2.725 . . . . 51.54 112.396 162.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 2.9 p -116.93 -44.82 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 N-CA-C 109.135 -0.691 . . . . 63.4 109.135 172.138 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 186' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -100.28 123.84 45.0 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.576 -0.738 . . . . 70.35 111.438 -177.054 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 187' ' ' ARG . . . . . 0.706 ' HB2' ' HB2' ' A' ' 194' ' ' TYR . 80.2 mtt180 -109.46 160.85 15.87 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-N 114.084 -1.416 . . . . 72.04 108.118 175.42 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 188' ' ' LEU . . . . . 0.559 HD13 ' HD1' ' A' ' 240' ' ' PHE . 51.7 tp -130.78 142.64 50.41 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 108.913 -0.773 . . . . 61.03 108.913 178.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -140.85 99.95 3.72 Favored 'General case' 0 C--O 1.242 0.697 0 N-CA-C 107.411 -1.329 . . . . 74.21 107.411 175.168 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . 70.18 -78.64 0.42 Allowed Glycine 0 CA--C 1.531 1.047 0 O-C-N 123.881 0.738 . . . . 73.43 112.216 -175.325 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 191' ' ' GLN . . . . . 0.441 HE22 ' HD2' ' A' ' 243' ' ' PRO . 7.6 tt0 -138.34 -14.38 1.31 Allowed 'General case' 0 CA--C 1.558 1.26 0 C-N-CA 123.866 0.867 . . . . 74.23 110.448 -176.503 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.503 ' O ' HD12 ' A' ' 188' ' ' LEU . 9.2 m-20 -86.16 153.86 21.75 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 124.177 0.991 . . . . 72.52 112.103 -178.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 193' ' ' LEU . . . . . 0.514 ' HG ' ' HA2' ' A' ' 239' ' ' GLY . 85.0 mt -107.35 160.76 15.38 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 124.264 1.026 . . . . 72.25 108.519 175.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 194' ' ' TYR . . . . . 0.706 ' HB2' ' HB2' ' A' ' 187' ' ' ARG . 64.7 m-85 -136.63 121.55 18.79 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.584 -1.265 . . . . 54.33 107.584 177.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 195' ' ' ALA . . . . . . . . . . . . . . . -144.14 148.29 34.86 Favored 'General case' 0 C--O 1.239 0.542 0 O-C-N 124.308 1.005 . . . . 42.32 109.197 179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 196' ' ' THR . . . . . . . . . . . . . 49.4 m -88.37 127.18 35.49 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.258 -0.883 . . . . 70.32 109.165 173.15 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 197' ' ' LEU . . . . . 0.497 HD22 HD13 ' A' ' 251' ' ' LEU . 66.3 tp -105.9 110.5 22.81 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 108.215 -1.031 . . . . 73.2 108.215 178.101 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 198' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -92.35 112.02 23.81 Favored 'General case' 0 C--O 1.24 0.568 0 N-CA-C 108.71 -0.848 . . . . 74.23 108.71 178.061 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 199' ' ' VAL . . . . . 0.428 HG21 HG21 ' A' ' 223' ' ' VAL . 2.8 p -119.51 127.22 26.56 Favored Pre-proline 0 CA--C 1.546 0.821 0 C-N-CA 124.023 0.929 . . . . 75.22 108.946 -177.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 200' ' ' PRO . . . . . 0.448 ' HD2' HD12 ' A' ' 203' ' ' ILE . 51.7 Cg_exo -56.65 142.28 91.03 Favored 'Trans proline' 0 C--N 1.376 2.02 0 C-N-CA 122.729 2.286 . . . . 73.24 111.786 174.285 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 201' ' ' ALA . . . . . 0.468 ' HA ' HG23 ' A' ' 255' ' ' ILE . . . -55.8 -42.48 96.31 Favored Pre-proline 0 CA--C 1.557 1.222 0 CA-C-O 118.252 -0.88 . . . . 74.31 112.478 176.627 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 202' ' ' PRO . . . . . 0.51 ' O ' HG22 ' A' ' 206' ' ' VAL . 63.3 Cg_exo -46.75 -55.35 3.9 Favored 'Trans proline' 0 C--N 1.394 2.967 0 C-N-CA 122.972 2.448 . . . . 75.02 114.005 167.022 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 203' ' ' ILE . . . . . 0.454 HG23 ' H ' ' A' ' 208' ' ' GLY . 21.1 mt -61.7 -41.7 91.48 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 122.907 0.483 . . . . 75.1 111.122 -179.503 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 204' ' ' ALA . . . . . . . . . . . . . . . -62.36 -35.39 78.98 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 115.063 -0.971 . . . . 71.52 111.832 -175.564 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 205' ' ' VAL . . . . . 0.589 HG23 HG13 ' A' ' 206' ' ' VAL . 25.9 m -89.35 -55.52 6.21 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 N-CA-C 112.798 0.666 . . . . 71.42 112.798 178.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.589 HG13 HG23 ' A' ' 205' ' ' VAL . 18.4 m -95.13 -38.3 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 CA-C-N 118.337 0.517 . . . . 74.5 112.074 -171.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 207' ' ' GLY . . . . . . . . . . . . . . . -91.17 -115.93 1.95 Allowed Glycine 0 C--N 1.34 0.765 0 CA-C-N 116.606 -0.27 . . . . 74.44 112.657 -164.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 208' ' ' GLY . . . . . 0.454 ' H ' HG23 ' A' ' 203' ' ' ILE . . . 142.36 14.31 0.37 Allowed Glycine 0 C--N 1.335 0.521 0 CA-C-O 119.655 -0.525 . . . . 72.52 113.732 177.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 209' ' ' LYS . . . . . 0.444 ' O ' HD13 ' A' ' 203' ' ' ILE . 15.4 tppt? -117.51 118.22 31.59 Favored 'General case' 0 C--N 1.349 0.553 0 CA-C-N 117.762 0.781 . . . . 70.44 109.453 -173.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 210' ' ' VAL . . . . . 0.426 HG23 ' HB ' ' A' ' 221' ' ' VAL . 2.9 m -145.34 146.21 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.831 0 N-CA-C 108.596 -0.89 . . . . 72.23 108.596 170.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 211' ' ' ARG . . . . . . . . . . . . . 56.4 mtm-85 -107.16 124.31 49.52 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.648 -0.871 . . . . 70.05 108.648 174.253 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 212' ' ' ALA . . . . . 0.471 ' HB2' HD13 ' A' ' 197' ' ' LEU . . . -103.09 137.91 40.64 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.298 0.639 . . . . 33.1 109.559 178.185 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 213' ' ' MET . . . . . . . . . . . . . 44.1 mmm -82.98 119.91 25.04 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 122.37 0.268 . . . . 70.43 110.489 174.506 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 214' ' ' THR . . . . . . . . . . . . . 3.5 t -118.04 169.88 9.3 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.411 1.085 . . . . 71.2 109.816 171.026 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 215' ' ' LEU . . . . . . . . . . . . . 83.1 mt -73.96 -10.48 59.68 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 123.735 0.814 . . . . 73.55 112.688 -172.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 216' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -93.87 -13.33 27.33 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.602 0.761 . . . . 62.33 111.366 175.041 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 217' ' ' GLY . . . . . . . . . . . . . . . 140.16 -157.87 25.64 Favored Glycine 0 C--N 1.347 1.183 0 CA-C-O 119.521 -0.599 . . . . 35.34 111.611 -177.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 218' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -85.59 135.83 5.18 Favored 'Trans proline' 0 CA--C 1.551 1.343 0 C-N-CA 122.469 2.113 . . . . 62.31 112.244 172.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 219' ' ' VAL . . . . . . . . . . . . . 29.9 m -113.08 159.92 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 C-N-CA 123.38 0.672 . . . . 64.13 110.26 168.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 220' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -111.35 109.59 19.66 Favored 'General case' 0 C--O 1.238 0.496 0 N-CA-C 107.669 -1.234 . . . . 73.33 107.669 179.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.517 HG22 HD11 ' A' ' 235' ' ' LEU . 12.7 t -96.16 125.24 49.07 Favored 'Isoleucine or valine' 0 C--O 1.243 0.754 0 C-N-CA 123.535 0.734 . . . . 70.23 109.582 177.471 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 222' ' ' ALA . . . . . . . . . . . . . . . -88.67 103.59 16.07 Favored 'General case' 0 C--O 1.24 0.598 0 N-CA-C 108.767 -0.827 . . . . 63.44 108.767 170.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.428 HG21 HG21 ' A' ' 199' ' ' VAL . 17.0 m -80.04 136.01 54.43 Favored Pre-proline 0 N--CA 1.477 0.887 0 N-CA-C 107.879 -1.156 . . . . 74.41 107.879 172.068 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 224' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -61.47 129.44 28.13 Favored 'Trans proline' 0 CA--C 1.555 1.543 0 C-N-CA 122.0 1.8 . . . . 74.44 111.83 176.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 225' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -52.02 128.42 26.87 Favored 'Trans proline' 0 C--N 1.372 1.791 0 C-N-CA 122.655 2.236 . . . . 74.42 111.993 172.051 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 226' ' ' ARG . . . . . . . . . . . . . 17.5 mtp180 65.31 42.61 3.84 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 125.252 1.421 . . . . 73.31 111.949 -173.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 227' ' ' THR . . . . . 0.507 HG23 HD11 ' A' ' 255' ' ' ILE . 8.5 t -78.36 177.45 8.46 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.115 0.566 . . . . 62.23 110.462 174.584 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . 0.583 HE21 ' HD2' ' A' ' 231' ' ' ARG . 1.8 mp0 -126.85 154.08 44.83 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 123.412 0.685 . . . . 64.32 109.371 -178.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 229' ' ' ALA . . . . . . . . . . . . . . . -71.61 149.43 45.61 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.236 0.614 . . . . 72.45 110.572 176.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . 88.25 -4.13 85.42 Favored Glycine 0 CA--C 1.527 0.807 0 CA-C-O 119.705 -0.497 . . . . 52.51 112.853 -178.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 231' ' ' ARG . . . . . 0.583 ' HD2' HE21 ' A' ' 228' ' ' GLN . 83.3 mtp180 -77.88 162.34 26.92 Favored 'General case' 0 C--N 1.36 1.063 0 CA-C-O 121.224 0.535 . . . . 75.22 111.153 177.641 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 232' ' ' LYS . . . . . 0.497 ' HG2' ' CZ ' ' A' ' 250' ' ' TYR . 10.6 mptt -118.35 122.06 41.92 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.89 0.876 . . . . 73.5 110.311 -173.302 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 233' ' ' LEU . . . . . . . . . . . . . 64.4 mt -110.54 117.33 33.24 Favored 'General case' 0 C--N 1.348 0.506 0 N-CA-C 107.784 -1.191 . . . . 74.31 107.784 173.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 234' ' ' ARG . . . . . . . . . . . . . 44.1 ttp180 -112.78 111.44 22.22 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 109.29 -0.633 . . . . 63.5 109.29 -168.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.517 HD11 HG22 ' A' ' 221' ' ' VAL . 14.7 mt -96.8 120.84 37.89 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 123.581 0.752 . . . . 74.04 109.82 -174.212 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 236' ' ' LYS . . . . . . . . . . . . . 51.1 mttp -71.14 147.04 48.78 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.256 0.622 . . . . 72.04 112.32 -177.514 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 237' ' ' GLY . . . . . . . . . . . . . . . 68.73 15.81 69.28 Favored Glycine 0 C--N 1.352 1.453 0 O-C-N 124.054 0.846 . . . . 55.34 114.401 173.486 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 238' ' ' LYS . . . . . 0.442 ' HG3' ' HB2' ' A' ' 235' ' ' LEU . 1.3 mmpm? -101.35 -17.43 16.52 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 123.548 0.739 . . . . 74.35 111.708 -175.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 239' ' ' GLY . . . . . 0.514 ' HA2' ' HG ' ' A' ' 193' ' ' LEU . . . -74.97 -148.13 1.66 Allowed Glycine 0 C--N 1.346 1.084 0 O-C-N 123.847 0.717 . . . . 63.44 113.709 -176.679 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 240' ' ' PHE . . . . . 0.561 ' HE2' ' HA ' ' A' ' 131' ' ' PHE . 39.9 m-85 -97.32 155.53 37.26 Favored Pre-proline 0 N--CA 1.475 0.786 0 CA-C-O 119.158 -0.448 . . . . 70.21 111.576 174.557 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 241' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -55.12 146.92 56.65 Favored 'Trans proline' 0 C--N 1.385 2.466 0 C-N-CA 122.906 2.404 . . . . 64.4 112.751 179.495 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 242' ' ' GLY . . . . . . . . . . . . . . . -178.98 -165.71 33.78 Favored Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.669 -0.696 . . . . 72.42 112.15 -178.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 243' ' ' PRO . . . . . 0.441 ' HD2' HE22 ' A' ' 191' ' ' GLN . 46.1 Cg_exo -58.05 -27.6 80.19 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.375 2.717 . . . . 65.22 114.49 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 244' ' ' ALA . . . . . . . . . . . . . . . -94.07 22.82 5.44 Favored 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 123.556 0.742 . . . . 44.22 111.718 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.13 -86.01 1.56 Allowed Glycine 0 C--N 1.348 1.218 0 N-CA-C 110.097 -1.201 . . . . 54.14 110.097 -174.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 246' ' ' ARG . . . . . 0.484 ' HD2' ' O ' ' A' ' 239' ' ' GLY . 18.6 mtm180 -126.94 164.54 21.24 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 108.355 -0.98 . . . . 55.32 108.355 163.238 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 247' ' ' GLY . . . . . . . . . . . . . . . -77.85 -153.87 6.5 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.541 -0.754 . . . . 55.51 113.71 -177.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 248' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -120.5 164.5 16.33 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.154 0.581 . . . . 62.51 110.262 -177.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 249' ' ' LEU . . . . . 0.5 ' HA ' ' HB2' ' A' ' 193' ' ' LEU . 15.8 tp -109.98 111.15 22.37 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 124.037 0.935 . . . . 61.24 108.913 168.293 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 250' ' ' TYR . . . . . 0.497 ' CZ ' ' HG2' ' A' ' 232' ' ' LYS . 17.9 t80 -90.68 104.57 17.14 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 107.914 -1.143 . . . . 75.31 107.914 178.528 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 251' ' ' LEU . . . . . 0.497 HD13 HD22 ' A' ' 197' ' ' LEU . 63.7 mt -89.19 148.8 23.43 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.292 1.037 . . . . 63.03 111.583 179.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -110.14 97.12 6.68 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 107.922 -1.14 . . . . 65.23 107.922 173.145 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 60.2 t -52.24 117.09 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 123.663 0.785 . . . . 62.22 110.104 174.531 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 254' ' ' ARG . . . . . . . . . . . . . 12.8 mmm180 -124.73 93.12 3.81 Favored 'General case' 0 C--O 1.238 0.463 0 N-CA-C 107.708 -1.219 . . . . 73.22 107.708 178.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.507 HD11 HG23 ' A' ' 227' ' ' THR . 60.1 mt -75.64 104.82 4.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-N 115.103 -0.953 . . . . 73.44 109.267 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.554 1.116 0 C-N-CA 124.047 0.939 . . . . 75.03 109.728 -178.001 . . . . . . . . 0 0 . 1 stop_ save_